<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Plast Reconstr Surg Glob Open</journal-id><journal-id journal-id-type="iso-abbrev">Plast Reconstr Surg Glob Open</journal-id><journal-id journal-id-type="pmc-domain-id">2522</journal-id><journal-id journal-id-type="pmc-domain">prsgo</journal-id><journal-id journal-id-type="publisher-id">GOX</journal-id><journal-title-group><journal-title>Plastic and Reconstructive Surgery Global Open</journal-title></journal-title-group><issn pub-type="epub">2169-7574</issn><publisher><publisher-name>Wolters Kluwer Health</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12494053</article-id><article-id pub-id-type="pmcid-ver">PMC12494053.1</article-id><article-id pub-id-type="pmcaid">12494053</article-id><article-id pub-id-type="pmcaiid">12494053</article-id><article-id pub-id-type="pmid">41050965</article-id><article-id pub-id-type="doi">10.1097/GOX.0000000000007191</article-id><article-id pub-id-type="publisher-id">GOX-D-25-00317</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Reconstructive</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Brain Drain for Brain Gain: Potential Applications of Robotic-assisted Lymphatic Microsurgery in the Management of Neurological Disorders</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Watson</surname><given-names initials="JA">Jennifer A.</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Knoedler</surname><given-names initials="S">Samuel</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>von Reibnitz</surname><given-names initials="D">Donata</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zurfluh</surname><given-names initials="CE">Carmen E.</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Imholz</surname><given-names initials="C">Carlotta</given-names></name><degrees>MMed</degrees><xref rid="aff1" ref-type="aff">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Esposito</surname><given-names initials="G">Giuseppe</given-names></name><degrees>MD, PhD</degrees><xref rid="aff2" ref-type="aff">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schreiner</surname><given-names initials="SJ">Simon J.</given-names></name><degrees>MD</degrees><xref rid="aff3" ref-type="aff">&#8225;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gousopoulos</surname><given-names initials="E">Epameinondas</given-names></name><degrees>MD, PhD</degrees><xref rid="aff1" ref-type="aff">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cai</surname><given-names initials="A">Aijia</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kollarik</surname><given-names initials="S">Sedef</given-names></name><degrees>PhD</degrees><xref rid="aff1" ref-type="aff">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Giovanoli</surname><given-names initials="P">Pietro</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">*</xref><xref rid="aff4" ref-type="aff">&#167;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Baumann</surname><given-names initials="C">Christian</given-names></name><degrees>MD</degrees><xref rid="aff3" ref-type="aff">&#8225;</xref><xref rid="aff4" ref-type="aff">&#167;</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Lindenblatt</surname><given-names initials="N">Nicole</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">*</xref><xref rid="aff4" ref-type="aff">&#167;</xref></contrib><aff id="aff1">From the <label>*</label>Department of Plastic Surgery and Hand Surgery, University Hospital Zurich, Zurich, Switzerland</aff><aff id="aff2"><label>&#8224;</label>Department of Neurosurgery, University Hospital Zurich, Zurich, Switzerland</aff><aff id="aff3"><label>&#8225;</label>Department of Neurology, University Hospital Zurich, Zurich, Switzerland</aff><aff id="aff4"><label>&#167;</label>Faculty of Medicine, University of Zurich, Zurich, Switzerland.</aff></contrib-group><author-notes><corresp id="c1">Nicole Lindenblatt, MD, Department of Plastic Surgery and Hand Surgery, University Hospital Zurich, R&#228;mistrasse 100, 8091 Z&#252;rich, Switzerland, E-mail: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="nicole.lindenblatt@usz.ch">nicole.lindenblatt@usz.ch</email></corresp></author-notes><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>03</day><month>10</month><year>2025</year></pub-date><volume>13</volume><issue>10</issue><issue-id pub-id-type="pmc-issue-id">498115</issue-id><elocation-id>e7191</elocation-id><history><date date-type="received"><day>29</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>19</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-06 15:25:14.893"><day>06</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of The American Society of Plastic Surgeons.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License 4.0 (CCBY)</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="gox-13-e7191.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="gox-13-e7191.pdf"/><abstract><sec><title>Background:</title><p>The central nervous system (CNS) was long believed to be devoid of lymphatic drainage. However, the discovery of the glymphatic system and meningeal lymphatics has revolutionized our understanding of cerebrospinal fluid homeostasis and neuroimmune interactions. The glymphatic system facilitates perivascular cerebrospinal fluid&#8211;interstitial fluid exchange and promotes neurotoxic waste clearance, whereas meningeal lymphatics serve as conduits between the CNS and peripheral lymphatic circulation. Dysfunction in these lymphatic efflux pathways has been implicated in the pathogenesis of neurological disorders such as Alzheimer disease, Parkinson disease, traumatic brain injury, and intracranial hemorrhage, where impaired waste removal contributes to protein aggregation, neuroinflammation, and hence, disease onset and progression.</p></sec><sec><title>Methods:</title><p>Recent preliminary evidence suggests that surgical modulation of lymphatic drainage may offer novel therapeutic avenues for these disorders, with lymphatic microsurgery, particularly deep cervical lymphovenous anastomosis (LVA), proposed as an innovative procedure to enhance CNS lymphatic outflow. The first case reports in Alzheimer disease patients demonstrated not only the operative feasibility of LVA but also postoperative cognitive improvements. Despite these promising findings, systematic (pre)clinical studies remain scarce, calling for further research.</p></sec><sec><title>Results:</title><p>This article examined the role of the brain lymphatic system in neurological disorders and discussed the potential of lymphatic microsurgery as a novel therapeutic intervention. We also highlight ongoing clinical trials and potential future innovations, including surgical robotic assistance, and report on 2 cases of deep neck LVA for central lymphatic disorders.</p></sec><sec><title>Conclusions:</title><p>By combining neurolymphatic research with surgical advances, LVAs have the potential to redefine therapeutic paradigms in CNS disorder management.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta><custom-meta><meta-name>COUNTRY</meta-name><meta-value>SWITZERLAND</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text position="float" orientation="portrait"><sec><title>Takeaways</title><p><bold>Question:</bold> How does cerebral lymphatic drainage dysfunction contribute to neurological disorders, and can lymphatic microsurgery play a role in reconstructing lymphatic flow?</p><p><bold>Findings:</bold> Emerging preclinical evidence suggests that deep cervical lymphovenous anastomoses may enhance brain waste clearance. Robotic-assisted lymphatic reconstruction may aid in advancing the field in the future.</p><p><bold>Meaning:</bold> Enhancing CNS lymphatic drainage via lymphatic microsurgery represents a promising therapeutic avenue for the treatment of neurodegenerative diseases.</p></sec></boxed-text><sec sec-type="intro"><title>INTRODUCTION</title><p>The interplay between the central nervous system (CNS) and the lymphatic system has long been poorly understood. Historically, the brain was thought to be immune-privileged, lacking conventional lymphatic drainage. Histological evidence of lymphatic vessels could not be identified in the brain parenchyma, in part because of postmortem changes in the tissue. The blood-brain barrier was believed to prevent the diffusion of molecular and cellular components. However, the discovery of functional meningeal lymphatic vessels and the glymphatic system has redefined our understanding of CNS fluid dynamics, implicating lymphatic function in neurological health and disease.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> The glymphatic system, a perivascular network facilitating cerebrospinal fluid (CSF) and interstitial fluid (ISF) exchange, is postulated to play a key role in neurotoxic waste clearance, with meningeal lymphatics serving as conduits linking the CNS and peripheral lymphatic circulation.<sup><xref rid="R2" ref-type="bibr">2</xref></sup> These findings have sparked interest in the contribution of lymphatic dysfunction to the pathogenesis and etiology of neurological disorders.<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R3" ref-type="bibr">3</xref>&#8211;<xref rid="R5" ref-type="bibr">5</xref></sup></p><p>The notion of &#8220;brain drain&#8221; via microsurgical optimization of cerebral lymphatic outflow may herald a new era in CNS disorder therapy; as reflected in the article&#8217;s title, this concept proposes that promoting lymphatic clearance from the brain (&#8220;drain&#8221;) could result in functional neurological improvement (&#8220;gain&#8221;).<sup><xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R7" ref-type="bibr">7</xref></sup> Deep cervical lymphovenous anastomoses (LVAs), connecting deep cervical lymphatic vessels to veins, could enhance toxic protein aggregate clearance, reduce neuroinflammation, and influence the trajectory of neurological disorders.<sup><xref rid="R7" ref-type="bibr">7</xref>&#8211;<xref rid="R9" ref-type="bibr">9</xref></sup> This article investigates whether lymphatic microsurgery&#8212;specifically deep cervical LVA&#8212;can serve as a novel therapeutic strategy for enhancing CNS lymphatic clearance in neurological disorders, with a particular focus on the role of robotic-assisted techniques in enabling the precision, feasibility, and broader clinical translation of this emerging approach.</p></sec><sec><title>LYMPHATIC DRAINAGE SYSTEM OF THE BRAIN</title><sec><title>Glymphatic System</title><p>For a long time, the brain&#8217;s toxic metabolite removal was assumed to rely solely on intracellular degradation and slow diffusion across the blood-brain barrier.<sup><xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R10" ref-type="bibr">10</xref></sup> However, recent discoveries have identified a previously unrecognized fluid clearance pathway&#8212;the glymphatic system&#8212;enabling rapid and efficient exchange between CSF and ISF.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> Coined by the neuroscientist Nedergaard, &#8220;glymphatic&#8221; reflects the system&#8217;s dependence on glial cells, particularly astrocytes, and its functional similarity to the peripheral lymphatic system.<sup><xref rid="R2" ref-type="bibr">2</xref></sup></p><p>Approximately 200&#8201;mL of CSF circulates within the brain, with complete turnover occurring roughly 4 times daily.<sup><xref rid="R11" ref-type="bibr">11</xref></sup> Although some is quickly reabsorbed into the bloodstream upon reaching the subarachnoid space, another portion flows along leptomeningeal perivascular spaces (Virchow&#8211;Robin spaces) lined by astrocyte endfeet that facilitate rapid fluid movement.<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref></sup> Arterial pulsations, vasomotor tone, and inspiratory pressure fluctuations potentially modulate these perivascular spaces, circulating CSF into the brain.<sup><xref rid="R12" ref-type="bibr">12</xref>,<xref rid="R13" ref-type="bibr">13</xref></sup> Astrocytic endfeet surround the blood vessels entering the brain and are populated with water-selective aquaporin-4 (AQP4) channels, which enable rapid water molecule movement.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> As CSF flows through the interstitial compartment, it collects metabolic waste products, such as beta-amyloid (A&#946;), tau proteins, and other neurotoxic substances. Sleep plays a critical role in this machinery, facilitating the brain&#8217;s nightly clearance of toxic metabolites.<sup><xref rid="R14" ref-type="bibr">14</xref></sup> The link between sleep and clearance was first demonstrated in live mice by Xie et al,<sup><xref rid="R15" ref-type="bibr">15</xref></sup> who reported a 60% increase in interstitial space during sleep accompanied by an increase in glymphatic flow and A&#946; clearance.</p></sec><sec><title>Meningeal Lymphatics</title><p>Predominantly situated in the dura mater along the dural sinuses and the skull base, the meningeal lymphatic vessels provide a direct route for CSF drainage from the intracranial glymphatic to the peripheral lymphatic system. The meningeal lymphatic network seems to be located near the eyes, following a path above the olfactory bulb before settling alongside the sinuses and cranial nerves, and ultimately, exiting the cranium through foramina along with their respective structures. The meningeal lymphatic network is made up of narrower vessels.<sup><xref rid="R10" ref-type="bibr">10</xref></sup> These vessels collect CSF along with its solute components, including metabolic waste products and immune cells, after the fluid has circulated along the glymphatic pathway from the subarachnoid space via arachnoid granulations. Following the intracerebroventricular injection of fluorescent tracer dye into anesthetized adult mice, Louveau et al<sup><xref rid="R10" ref-type="bibr">10</xref></sup> validated the functional capability of the meningeal lymphatic vessels to transport CSF and their topographic alignment along the superior sagittal sinus. Draining CSF into the peripheral lymphatic system, the meningeal lymphatics facilitate the clearance of potentially harmful proteins and metabolic waste from the CNS.</p></sec><sec><title>Cervical Lymph Nodes</title><p>Cervical lymph nodes (cLNs) represent the final checkpoint in the brain lymphatic clearance pathway, acting as an interface between waste originating from the CNS and the peripheral immune system (Fig. <xref rid="F1" ref-type="fig">1</xref>). Distributed throughout the neck, cLNs receive lymphatic drainage not only from the head and neck but also specifically from the meningeal lymphatics.<sup><xref rid="R16" ref-type="bibr">16</xref></sup> Louveau et al<sup><xref rid="R10" ref-type="bibr">10</xref></sup> measured a substantial increase in the number of meningeal T cells when dissecting cLNs, indicating an inability of T cells to drain from meningeal spaces once this anatomical connection has been compromised. The cerebral lymphatic efflux pathway is impaired with aging and neurodegeneration<sup><xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R18" ref-type="bibr">18</xref></sup>; cLNs remove metabolic debris and neurotoxic proteins while initiating appropriate immune responses to CNS-derived solutes such as oligomeric &#945;-synuclein and A&#946;.<sup><xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R19" ref-type="bibr">19</xref>,<xref rid="R20" ref-type="bibr">20</xref></sup> Interestingly, a recent study in mice highlighted a circadian component to this drainage process. Although glymphatic activity and influx are increased during sleep, especially deep sleep, CSF drainage to the cLNs is higher during wakefulness.<sup><xref rid="R14" ref-type="bibr">14</xref></sup></p><fig position="float" id="F1" orientation="portrait"><label>Fig. 1.</label><caption><p>The glymphatic and meningeal lymphatic pathways in central nervous system clearance. Facilitated by astrocytic aquaporin-4 (AQP4) water channels, CSF enters the brain parenchyma, mixes with ISF, and facilitates metabolic waste clearance.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gox-13-e7191-g001.jpg"/></fig></sec></sec><sec><title>BRAIN LYMPHATIC IMPAIRMENT AND PATHOGENESIS OF NEUROLOGICAL DISORDERS</title><p>Neurological disorders pose a major burden for patients and the healthcare system. Recent research highlights the potential role of impaired lymphatic clearance in their pathogenesis, suggesting that disruptions in the brain&#8217;s waste removal systems may contribute to the accumulation of neurotoxic proteins and the progression of chronic inflammation.<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R21" ref-type="bibr">21</xref>&#8211;<xref rid="R30" ref-type="bibr">30</xref></sup></p><sec><title>Alzheimer Disease</title><p>Alzheimer disease (AD) is a neurodegenerative disease characterized by extracellular A&#946; plaques and intracellular neurofibrillary tangles of hyperphosphorylated tau protein.<sup><xref rid="R31" ref-type="bibr">31</xref></sup> Impaired lymphatic clearance could significantly contribute to the accumulation of these neurotoxic proteins, triggering the chronic neuroinflammation observed in AD. In the healthy brain, extracellular A&#946; is eliminated via multiple pathways to prevent downstream effects of A&#946; accumulation in the brain.<sup><xref rid="R32" ref-type="bibr">32</xref></sup> The glymphatic system drives the convective movement of CSF through perivascular spaces, facilitating exchange with ISF and the removal of soluble A&#946;. Once in the CSF, A&#946; is transported out of the cranium through meningeal lymphatic vessels, which, ultimately, drain into the deep cLNs and the systemic circulation.<sup><xref rid="R20" ref-type="bibr">20</xref></sup></p><p>Recent research revealed that the glymphatic system may be compromised in AD.<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R21" ref-type="bibr">21</xref>&#8211;<xref rid="R25" ref-type="bibr">25</xref></sup> Iliff et al<sup><xref rid="R1" ref-type="bibr">1</xref></sup> proposed that the glymphatic system removes A&#946; from the brain via an AQP4-dependent ISF flow. They demonstrated that the clearance rate of radiolabeled A&#946; in AQP4-deficient mice was reduced by more than 50% compared with wild-type controls, which might result in the formation of extracellular A&#946; aggregates and disease progression in AD.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> Further studies using AD murine models have shown that glymphatic transport is markedly suppressed in aged animals, leading to significant A&#946; deposition, cerebral amyloid angiopathy, and astrocytic atrophy. Notably, reductions in glymphatic clearance were observed even before the appearance of substantial amyloid plaques in younger mice, suggesting that early impairment of this clearance mechanism may serve as a biomarker for AD.<sup><xref rid="R23" ref-type="bibr">23</xref>,<xref rid="R24" ref-type="bibr">24</xref></sup> Human studies have also reported impaired glymphatic function in AD.<sup><xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R17" ref-type="bibr">17</xref></sup> These findings resonate with pathological examinations showing a high prevalence of A&#946; in human lymph nodes, with the highest concentrations in the cervical region.<sup><xref rid="R20" ref-type="bibr">20</xref></sup> These data are consistent with a model of A&#946; drainage to cLNs in humans, although direct evidence on dysfunction of lymphatic clearance in human AD is lacking at this point.</p></sec><sec><title>Parkinson Disease</title><p>Parkinson disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra and the pathological aggregation of misfolded proteins such as &#945;&#8208;synuclein.<sup><xref rid="R33" ref-type="bibr">33</xref></sup> Preclinical evidence indicates that the glymphatic system may be impaired in PD.<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R26" ref-type="bibr">26</xref>&#8211;<xref rid="R28" ref-type="bibr">28</xref></sup> Zou et al<sup><xref rid="R34" ref-type="bibr">34</xref></sup> showed that ligating the deep cLNs in A53T mice expressing mutant human &#945;&#8208;synuclein led to perivascular clustering of &#945;&#8208;synuclein and disrupted AQP4 polarization in the substantia nigra. This resulted in an increased buildup of &#945;&#8208;synuclein, activation of glial cells, heightened inflammation, loss of dopaminergic neurons, and motor deficits, pointing to the involvement of compromised lymphatic clearance in PD pathology.<sup><xref rid="R27" ref-type="bibr">27</xref>,<xref rid="R34" ref-type="bibr">34</xref></sup> Zhang et al<sup><xref rid="R5" ref-type="bibr">5</xref></sup> demonstrated that deletion of the AQP4 gene resulted in reduced clearance of injected &#945;&#8208;synuclein in mice. Finally, non-REM sleep enhancement in murine PD models reduced &#945;&#8208;synuclein accumulation, which was associated with increased recruitment of AQP4 to perivascular sites, further corroborating the role of increased glymphatic function.</p><p>Importantly, clinical studies, particularly with neuroimaging data, have also reported impaired neurolymphatic function in PD.<sup><xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R26" ref-type="bibr">26</xref>,<xref rid="R28" ref-type="bibr">28</xref></sup> Shen et al<sup><xref rid="R4" ref-type="bibr">4</xref></sup> showed significantly lower diffusion tensor image analysis along the perivascular space scores&#8212;a proxy for glymphatic function&#8212;in 76 PD patients compared with a control group. Consistent with the concept of sleep-dependent clearance, a recent study linked impaired deep sleep to magnetic resonance imaging&#8211;visible perivascular spaces, another imaging marker of glymphatic dysfunction, in PD patients.<sup><xref rid="R35" ref-type="bibr">35</xref></sup></p></sec><sec><title>Traumatic Brain Injury</title><p>Li et al<sup><xref rid="R29" ref-type="bibr">29</xref></sup> investigated the impact of mild traumatic brain injury (TBI) on the glymphatic system in a rat model. Ten weeks postinjury, contrast-enhanced magnetic resonance imaging revealed significantly reduced clearance rates of a contrast agent and prolonged clearance times in TBI-affected animals compared with healthy controls, indicative of glymphatic dysfunction. These findings were supported by Christensen et al,<sup><xref rid="R36" ref-type="bibr">36</xref></sup> who examined glymphatic alterations in a TBI rat model. Clinical trials substantiate these preclinical findings: in a cohort study of 58 patients with mild TBI, Yang et al<sup><xref rid="R30" ref-type="bibr">30</xref></sup> reported significantly lower diffusion tensor image analysis along the perivascular space scores compared with 34 healthy controls.</p></sec><sec><title>Intracranial Hemorrhage</title><p>Liu et al<sup><xref rid="R37" ref-type="bibr">37</xref></sup> investigated the role of AQP4 in hematoma clearance following intracerebral hemorrhage in rat and murine models, respectively, under conditions of regulated AQP4 expression. In their study, dysregulated AQP4 expression was associated with glymphatic dysfunction, neurological impairment, and increased hematoma volume.</p></sec></sec><sec><title>LYMPHATIC MICROSURGERY AS A THERAPEUTIC AVENUE</title><sec><title>Clinical Data</title><p>Traditionally, the treatment of the aforementioned neurological conditions has primarily relied on pharmacological approaches. However, the discovery of a mechanical drainage component in their etiopathogenesis has drawn attention toward lymphatic microsurgical interventions, particularly cervical LVA.<sup><xref rid="R38" ref-type="bibr">38</xref></sup> This surgery connects lymphatic vessels and venous structures, thereby bypassing obstructed or dysfunctional lymphatic pathways. Previous studies have demonstrated the technical feasibility and effectiveness of LVA in treating both upper and lower limb lymphedema.<sup><xref rid="R39" ref-type="bibr">39</xref>&#8211;<xref rid="R41" ref-type="bibr">41</xref></sup> By enhancing lymphatic fluid flow from the CNS, LVA may alleviate glymphatic dysfunction, reduce protein aggregation, and potentially slow or reverse neurodegeneration.</p><p>In 2022, Lu et al<sup><xref rid="R9" ref-type="bibr">9</xref></sup> published the first clinical case report on deep cervical LVA for the treatment of cognitive dysfunction. It was also reported that Dr. Xie had successfully performed 50 cases of such cervical LVA reconstructions in AD patients, with an average follow-up of 9 months. More recently, Li et al<sup><xref rid="R8" ref-type="bibr">8</xref></sup> published another case report describing a supermicrosurgical technique to restore cerebral lymphatic drainage in a patient with AD. The aim of this approach was to enhance the clearance of proteins such as A&#946; and tau from the brain&#8217;s lymphatic system into the cervical lymphatics, thereby reducing toxic protein accumulation in the brain.</p><p>Although the pioneering work from China has laid a strong foundation, extensive preclinical studies and well-designed clinical trials are warranted. Several trials are underway to explore lymphatic supermicrosurgery in neurological disorders. Multiple prospective clinical trials investigating the effect of cervical LVAs in AD have been registered (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06448442">NCT06448442</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06448975">NCT06448975</ext-link>, ChiCTR2500095309, ChiCTR2400093030 [AD and type 2 diabetes], ChiCTR2400089883, ChiCTR2400094603, and ChiCTR2400084617).</p><p>Yang et al<sup><xref rid="R7" ref-type="bibr">7</xref></sup> have extrapolated the preliminary yet promising findings from the field of AD to hypothesize that deep cervical LVA could also be leveraged for PD treatment. To date, however, there are no known clinical case reports in which cervical LVA has been performed for the treatment of PD. Likewise, despite the aforementioned etiopathogenetic links between neurolymphatic impairment and further CNS disorders, including TBI or intracerebral hemorrhage, no human studies or clinical cases involving LVA have been documented in these contexts. A prospective study has been launched investigating cervical LVAs in patients with PD (ChiCTR2400091857). To our knowledge, no studies have yet been planned/registered on the surgical treatment of other neurological disorders via lymphatic microsurgery.</p><p>Numerous ongoing investigations in this field highlight the growing research momentum while emphasizing the pressing need for high-quality empirical data. A thorough preoperative assessment of the patient&#8217;s lymphatic function would, therefore, be essential to determine patient eligibility for the procedure. Histological evidence of lymphatic vessels could not be identified in the brain parenchyma, in part because of postmortem changes in the tissue. The blood-brain barrier was believed to prevent the diffusion of molecular and cellular components. Further research with objective, high-quality outcome studies remains indispensable to investigate both the safety and efficacy of LVA for the treatment of neurological disorders. Special consideration should be given to ethical concerns when planning clinical studies involving patients with neurodegenerative diseases or debilitating cranial injury, as these individuals represent a vulnerable patient population. Beyond the general ethical obligations inherent to surgical innovation, the application of lymphatic microsurgery in neurological disorders poses specific challenges. Informed consent must be carefully tailored to account for potential cognitive impairment, and surrogate decision-making may be necessary in select cases. Transparent communication of the experimental nature of the intervention, as well as the lack of large-scale efficacy data, is essential to avoid therapeutic misconception. Furthermore, equitable access to such advanced surgical options&#8212;including those involving costly robotic assistance&#8212;must be proactively addressed to prevent widening disparities in neurological care.</p></sec><sec><title>Robotic-assisted Lymphatic Microsurgery</title><p>Given the small diameter of many lymphatic vessels (&lt;0.5&#8201;mm), LVAs require high-magnification microscopes and specialized microsurgical instrumentation. The use of robotic systems, such as the MUSA robot (MicroSure B.V., Son, The Netherlands) and the Symani Surgical System (Medical Microinstruments [MMI], Jacksonville, FL), is well established in the surgical treatment of lymphedema and central lymphatic lesions.<sup><xref rid="R42" ref-type="bibr">42</xref>&#8211;<xref rid="R46" ref-type="bibr">46</xref></sup> Our team documented the first-in-human use of a microsurgical robotic system for central lymphatic reconstruction in 2023.<sup><xref rid="R47" ref-type="bibr">47</xref></sup> Since then, we have successfully treated patients presenting with thoracic duct lesions or thrombotic occlusions via LVA in the deep neck, further solidifying our expertise in this fast-evolving field (Fig. <xref rid="F2" ref-type="fig">2</xref>).<sup><xref rid="R48" ref-type="bibr">48</xref>&#8211;<xref rid="R50" ref-type="bibr">50</xref></sup> (<xref rid="video1" ref-type="other">See Video [online]</xref>, which displays an 8-month-old patient who had a history of severe bilateral chylothorax and protein-losing enteropathy due to thrombotic occlusion at the left venous angle. Robotic-assisted end-to-end anastomosis of the thoracic duct (0.9&#8201;mm) with a branch of the left external jugular vein was performed in the deep neck.)</p><fig position="float" id="F2" orientation="portrait"><label>Fig. 2.</label><caption><p>Deep cervical LVAs. A, Thoracic duct in the deep left neck (0.9-mm diameter) of a 6-month-old child with severe central lymphatic flow disorder with chylothorax, chylaskos, protein-losing enteropathy, and head and neck lymphedema. B, (1) LVA of thoracic duct anterograde end-to-side to collateral external jugular vein, (2) LVA of thoracic duct retrograde end-to-end to collateral vein, and (3) multiple LVAs of deep lymphatic collectors draining the head in the left neck.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gox-13-e7191-g002.jpg"/></fig><p>
<fig id="video1" position="anchor" orientation="portrait"><label>Video 1.</label><caption><title>The 8-month-old patient had a history of severe bilateral chylothorax, protein-losing enteropathy due a thrombotic occlusion at the left venous angle. Robotic-assisted end-to-end anastomosis of the thoracic duct (0.9 mm) and a branch of the left external jugular vein was performed in the deep neck. Reproduced under a CCBY-NC-ND license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), the figure legend has been modified.50</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="gox-13-e7191-s001.mp4" mimetype="video" mime-subtype="mp4" position="float" orientation="portrait"><object-id pub-id-type="other" content-type="media-stream-id">GOX.0000000000007191video1.mp4</object-id><object-id pub-id-type="other" content-type="media-source">Kaltura</object-id></media></fig>
</p><p>Recently, we shared our experience with 100 (super-)microsurgical anastomoses in both peripheral and central lymphatic reconstruction performed with robotic Symani assistance.<sup><xref rid="R51" ref-type="bibr">51</xref></sup> Postoperatively, no anastomosis-related complications were observed, all anastomoses remained patent, and most patients reported postoperative improvement. These promising findings on robotic-assisted LVA are echoed on a global level.<sup><xref rid="R52" ref-type="bibr">52</xref></sup> Accordingly, the scientific community increasingly recognizes the potential benefits of robotic surgical systems with possible applications extending to cervical LVAs. Robotic systems provide better access to deep anatomical planes and small structures, facilitating precise dissection and suturing.<sup><xref rid="R53" ref-type="bibr">53</xref></sup> The integration of wristed robotic arms improves the range of motion compared with conventional microsurgical procedures.<sup><xref rid="R53" ref-type="bibr">53</xref>&#8211;<xref rid="R55" ref-type="bibr">55</xref></sup> Motion scaling and tremor elimination are crucial in improving surgical accuracy by filtering out unintended hand tremors and translating the surgeon&#8217;s movements with greater accuracy.<sup><xref rid="R53" ref-type="bibr">53</xref>,<xref rid="R54" ref-type="bibr">54</xref></sup> Conventional microsurgery typically requires surgeons to maintain a prolonged static posture, negatively affecting performance over time.<sup><xref rid="R56" ref-type="bibr">56</xref>,<xref rid="R57" ref-type="bibr">57</xref></sup> Robotic platforms offer ergonomically optimized working environments, potentially minimizing fatigue and physical strain and enhancing long-term surgical accuracy.<sup><xref rid="R56" ref-type="bibr">56</xref>,<xref rid="R57" ref-type="bibr">57</xref></sup> Finally, the use of robotic platforms may offer improved visualization through advanced imaging technologies.<sup><xref rid="R53" ref-type="bibr">53</xref></sup> High-definition 3-dimensional magnification, combined with augmented reality overlays and digital enhancements, allows for superior differentiation of tissue planes and microvascular structures.<sup><xref rid="R58" ref-type="bibr">58</xref></sup></p><p>Despite its immense potential, several challenges must be overcome before robotic-assisted lymphatic supermicrosurgery can be widely adopted and integrated into the future surgical treatment of neurological disorders via cervical LVA. The acquisition and maintenance costs of robotic systems remain high, yet increasing acceptance and technological dissemination could lower costs over time.<sup><xref rid="R53" ref-type="bibr">53</xref>,<xref rid="R59" ref-type="bibr">59</xref></sup> In addition, the effective and safe use of robotic platforms in lymphatic surgery requires specialized training. Surgeons must complete structured educational programs to develop proficiency in robotic-assisted procedures.<sup><xref rid="R60" ref-type="bibr">60</xref></sup> However, it is important to note that, although initial operative times may be longer, the steep learning curve leads to significant improvements in efficiency.<sup><xref rid="R61" ref-type="bibr">61</xref></sup> The rigidity of robotic arms can limit the range of motion and flexibility and restrict access to certain surgical sites. Accordingly, careful preoperative planning and the establishment of optimal access routes are essential for successful procedure execution. Our experience suggests that surgeons can adapt to the missing sensory feedback in robotic systems, as the force required to manipulate the robotic system is perceived as equivalent to that needed for conventional microsurgical instruments.<sup><xref rid="R45" ref-type="bibr">45</xref></sup></p><p>The convergence of these 2 emerging fields&#8212;robotic supermicrosurgery and lymphatic reconstruction for the management of neurological disorders&#8212;holds immense potential for advancing treatment strategies and redefining therapeutic paradigms. Robotic assistance enables greater precision in manipulating delicate lymphatic structures, improving the efficacy of lymphatic reconstruction not only in the extremities but also potentially in the cervical region. In this context, it is also worth noting that if surgical intervention on the glymphatic system were ever to be performed, the use of robotic assistance would be practically mandatory due to its minuscule size of less than 100 &#181;m.<sup><xref rid="R62" ref-type="bibr">62</xref></sup> Further research is essential to bridge these disciplines and their synergistic advantages into clinically meaningful outcomes.</p></sec></sec><sec sec-type="conclusions"><title>CONCLUSIONS</title><p>The discovery of the brain&#8217;s lymphatic system has revolutionized our understanding of CSF homeostasis and neuroimmune regulation, providing novel insights into the pathophysiology of neurological disorders. Impaired glymphatic and meningeal lymphatic drainage is increasingly recognized as a major factor in the accumulation of neurotoxic proteins, neuroinflammation, and progressive neuronal dysfunction. In this context, lymphatic supermicrosurgery&#8212;particularly deep cervical LVA&#8212;has emerged as a promising intervention to enhance CNS lymphatic clearance and facilitate the removal of toxic waste products from the brain. Early clinical reports suggested that LVA is not only technically feasible but may also improve cognitive function in select patients with AD.</p><p>Despite these encouraging preliminary findings, thorough scientific validation remains imperative. The available evidence is limited to case reports, and further clinical studies are needed to elucidate the precise mechanistic impact of LVA on CNS fluid dynamics and its long(er)-term therapeutic potential. Future research should also focus on refining patient selection criteria, maximizing surgical safety&#8212;potentially incorporating robotic-assisted microsurgery&#8212;and exploring synergistic therapeutic strategies, including pharmacological modulation of lymphatic function. Given the nascent stage of this field, this article synthesizes early clinical insights with emerging experimental evidence and distinguishes between hypothesis and data, aiming to provide a structured, scientifically grounded framework for future investigation. To minimize potential bias and avoid overinterpretation, we have contextualized subjective observations and highlighted the need for robust, controlled, and objective studies moving forward. Ultimately, widespread clinical adoption will depend on the generation of high-quality, objective evidence from well-designed trials. However, unlocking the full potential of lymphatic supermicrosurgery is not merely a surgical challenge but a watershed moment in redefining brain health itself. If successful, LVA could herald a new era&#8212;one in which restoring the brain&#8217;s intrinsic clearance mechanisms becomes a cornerstone of neurological disorder therapy, offering hope where there are currently few options.</p></sec><sec sec-type="COI-statement"><title>DISCLOSURE</title><p>Dr. Lindenblatt acts as a consultant and scientific advisor for Medical Microinstruments (MMI). The other authors have no financial interest to declare in relation to the content of this article.</p></sec><sec sec-type="subjects"><title>PATIENT CONSENT</title><p>All patients have given written permission to publish the intraoperative images and signed the hospital&#8217;s general consent form.</p></sec></body><back><fn-group><fn fn-type="other"><p>Published online 3 October 2025.</p></fn><fn fn-type="financial-disclosure"><p>
<italic toggle="yes">Disclosure statements are at the end of this article, following the correspondence information.</italic>
</p></fn><fn fn-type="other"><p>Related Digital Media are available in the full-text version of the article on <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.PRSGlobalOpen.com" ext-link-type="uri">www.PRSGlobalOpen.com</ext-link>.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iliff</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Liao</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta.</article-title><source>Sci Transl Med</source>. <year>2012</year>;<volume>4</volume>:<fpage>147ra111</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.3003748</pub-id><pub-id pub-id-type="pmcid">PMC3551275</pub-id><pub-id pub-id-type="pmid">22896675</pub-id></mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hablitz</surname><given-names>LM</given-names></name><name name-style="western"><surname>Nedergaard</surname><given-names>M</given-names></name></person-group>. <article-title>The glymphatic system.</article-title><source>Curr Biol</source>. <year>2021</year>;<volume>31</volume>:<fpage>R1371</fpage>&#8211;<lpage>R1375</lpage>.<pub-id pub-id-type="pmid">34699796</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cub.2021.08.026</pub-id></mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Glymphatic system impairment in Alzheimer&#8217;s disease: associations with perivascular space volume and cognitive function.</article-title><source>Eur Radiol</source>. <year>2024</year>;<volume>34</volume>:<fpage>1314</fpage>&#8211;<lpage>1323</lpage>.<pub-id pub-id-type="pmid">37610441</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00330-023-10122-3</pub-id></mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>T</given-names></name><name name-style="western"><surname>Yue</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ba</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Diffusion along perivascular spaces as marker for impairment of glymphatic system in Parkinson&#8217;s disease.</article-title><source>NPJ Parkinsons Dis</source>. <year>2022</year>;<volume>8</volume>:<fpage>174</fpage>.<pub-id pub-id-type="pmid">36543809</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41531-022-00437-1</pub-id><pub-id pub-id-type="pmcid">PMC9772196</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>He</surname><given-names>XZ</given-names></name><etal/></person-group>. <article-title>Interaction between the glymphatic system and alpha-synuclein in Parkinson&#8217;s disease.</article-title><source>Mol Neurobiol</source>. <year>2023</year>;<volume>60</volume>:<fpage>2209</fpage>&#8211;<lpage>2222</lpage>.<pub-id pub-id-type="pmid">36637746</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12035-023-03212-2</pub-id></mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>Q</given-names></name><name name-style="western"><surname>Louveau</surname><given-names>A</given-names></name><name name-style="western"><surname>Pandey</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Rewiring the brain: the next frontier in supermicrosurgery.</article-title><source>Plast Reconstr Surg</source>. <year>2024</year>;<volume>153</volume>:<fpage>494e</fpage>&#8211;<lpage>495e</lpage>.<pub-id pub-id-type="pmid">37467388</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/PRS.0000000000010933</pub-id></mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>G</given-names></name><name name-style="western"><surname>Yang</surname><given-names>G</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Deep cervical lymphovenous bypass for Parkinson&#8217;s disease: a hypothesis.</article-title><source>Med Hypotheses</source>. <year>2025</year>;<volume>195</volume>:<fpage>111559</fpage>.</mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Promising outcomes 5 weeks after a surgical cervical shunting procedure to unclog cerebral lymphatic systems in a patient with Alzheimer&#8217;s disease.</article-title><source>Gen Psychiatr</source>. <year>2024</year>;<volume>37</volume>:<fpage>e101641</fpage>.<pub-id pub-id-type="pmid">39816183</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gpsych-2024-101641</pub-id><pub-id pub-id-type="pmcid">PMC11733982</pub-id></mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>H</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Q</given-names></name></person-group>. <article-title>Preliminary observation of deep cervical lymphatic-venous anastomosis under off-eyepiece 3D microscope to treat an elderly patient with cognitive impairment.</article-title><source>Chin J Microsurg</source>. <year>2022</year>;<volume>6</volume>:<fpage>570</fpage>&#8211;<lpage>574</lpage>.</mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Louveau</surname><given-names>A</given-names></name><name name-style="western"><surname>Smirnov</surname><given-names>I</given-names></name><name name-style="western"><surname>Keyes</surname><given-names>TJ</given-names></name><etal/></person-group>. <article-title>Structural and functional features of central nervous system lymphatic vessels.</article-title><source>Nature</source>. <year>2015</year>;<volume>523</volume>:<fpage>337</fpage>&#8211;<lpage>341</lpage>.<pub-id pub-id-type="pmid">26030524</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature14432</pub-id><pub-id pub-id-type="pmcid">PMC4506234</pub-id></mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jessen</surname><given-names>NA</given-names></name><name name-style="western"><surname>Munk</surname><given-names>AS</given-names></name><name name-style="western"><surname>Lundgaard</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>The glymphatic system: a beginner&#8217;s guide.</article-title><source>Neurochem Res</source>. <year>2015</year>;<volume>40</volume>:<fpage>2583</fpage>&#8211;<lpage>2599</lpage>.<pub-id pub-id-type="pmid">25947369</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11064-015-1581-6</pub-id><pub-id pub-id-type="pmcid">PMC4636982</pub-id></mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iliff</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Zeppenfeld</surname><given-names>DM</given-names></name><etal/></person-group>. <article-title>Cerebral arterial pulsation drives paravascular CSF-interstitial fluid exchange in the murine brain.</article-title><source>J Neurosci</source>. <year>2013</year>;<volume>33</volume>:<fpage>18190</fpage>&#8211;<lpage>18199</lpage>.<pub-id pub-id-type="pmid">24227727</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.1592-13.2013</pub-id><pub-id pub-id-type="pmcid">PMC3866416</pub-id></mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bohr</surname><given-names>T</given-names></name><name name-style="western"><surname>Hjorth</surname><given-names>PG</given-names></name><name name-style="western"><surname>Holst</surname><given-names>SC</given-names></name><etal/></person-group>. <article-title>The glymphatic system: current understanding and modeling.</article-title><source>iScience</source>. <year>2022</year>;<volume>25</volume>:<fpage>104987</fpage>.<pub-id pub-id-type="pmid">36093063</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.isci.2022.104987</pub-id><pub-id pub-id-type="pmcid">PMC9460186</pub-id></mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hablitz</surname><given-names>LM</given-names></name><name name-style="western"><surname>Pla</surname><given-names>V</given-names></name><name name-style="western"><surname>Giannetto</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Circadian control of brain glymphatic and lymphatic fluid flow.</article-title><source>Nat Commun</source>. <year>2020</year>;<volume>11</volume>:<fpage>4411</fpage>.<pub-id pub-id-type="pmid">32879313</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-18115-2</pub-id><pub-id pub-id-type="pmcid">PMC7468152</pub-id></mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>L</given-names></name><name name-style="western"><surname>Kang</surname><given-names>H</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Q</given-names></name><etal/></person-group>. <article-title>Sleep drives metabolite clearance from the adult brain.</article-title><source>Science</source>. <year>2013</year>;<volume>342</volume>:<fpage>373</fpage>&#8211;<lpage>377</lpage>.<pub-id pub-id-type="pmid">24136970</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1241224</pub-id><pub-id pub-id-type="pmcid">PMC3880190</pub-id></mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Licastro</surname><given-names>E</given-names></name><name name-style="western"><surname>Pignataro</surname><given-names>G</given-names></name><name name-style="western"><surname>Iliff</surname><given-names>JJ</given-names></name><etal/></person-group>. <article-title>Glymphatic and lymphatic communication with systemic responses during physiological and pathological conditions in the central nervous system.</article-title><source>Commun Biol</source>. <year>2024</year>;<volume>7</volume>:<fpage>229</fpage>.<pub-id pub-id-type="pmid">38402351</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s42003-024-05911-5</pub-id><pub-id pub-id-type="pmcid">PMC10894274</pub-id></mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Diwani</surname><given-names>A</given-names></name><name name-style="western"><surname>Provine</surname><given-names>NM</given-names></name><name name-style="western"><surname>Murchison</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Neurodegenerative fluid biomarkers are enriched in human cervical lymph nodes.</article-title><source>Brain</source>. <year>2025</year>;<volume>148</volume>:<fpage>394</fpage>&#8211;<lpage>400</lpage>.<pub-id pub-id-type="pmid">39432679</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awae329</pub-id><pub-id pub-id-type="pmcid">PMC11788199</pub-id></mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Deep cervical lymph node ligation aggravates AD-like pathology of APP/PS1 mice.</article-title><source>Brain Pathol</source>. <year>2019</year>;<volume>29</volume>:<fpage>176</fpage>&#8211;<lpage>192</lpage>.<pub-id pub-id-type="pmid">30192999</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bpa.12656</pub-id><pub-id pub-id-type="pmcid">PMC8028636</pub-id></mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>The cervical lymph node contributes to peripheral inflammation related to Parkinson&#8217;s disease.</article-title><source>J Neuroinflammation</source>. <year>2023</year>;<volume>20</volume>:<fpage>93</fpage>.<pub-id pub-id-type="pmid">37038192</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-023-02770-5</pub-id><pub-id pub-id-type="pmcid">PMC10088204</pub-id></mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nauen</surname><given-names>DW</given-names></name><name name-style="western"><surname>Troncoso</surname><given-names>JC</given-names></name></person-group>. <article-title>Amyloid-beta is present in human lymph nodes and greatly enriched in those of the cervical region.</article-title><source>Alzheimers Dement</source>. <year>2022</year>;<volume>18</volume>:<fpage>205</fpage>&#8211;<lpage>210</lpage>.<pub-id pub-id-type="pmid">34057798</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12385</pub-id></mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iliff</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Plog</surname><given-names>BA</given-names></name><etal/></person-group>. <article-title>Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury.</article-title><source>J Neurosci</source>. <year>2014</year>;<volume>34</volume>:<fpage>16180</fpage>&#8211;<lpage>16193</lpage>.<pub-id pub-id-type="pmid">25471560</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.3020-14.2014</pub-id><pub-id pub-id-type="pmcid">PMC4252540</pub-id></mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>Q</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Transport of beta-amyloid from brain to eye causes retinal degeneration in Alzheimer&#8217;s disease.</article-title><source>J Exp Med</source>. <year>2024</year>;<volume>221</volume>:<fpage>e20240386</fpage>.<pub-id pub-id-type="pmid">39316084</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20240386</pub-id><pub-id pub-id-type="pmcid">PMC11448872</pub-id></mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>W</given-names></name><name name-style="western"><surname>Achariyar</surname><given-names>TM</given-names></name><name name-style="western"><surname>Li</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Suppression of glymphatic fluid transport in a mouse model of Alzheimer&#8217;s disease.</article-title><source>Neurobiol Dis</source>. <year>2016</year>;<volume>93</volume>:<fpage>215</fpage>&#8211;<lpage>225</lpage>.<pub-id pub-id-type="pmid">27234656</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nbd.2016.05.015</pub-id><pub-id pub-id-type="pmcid">PMC4980916</pub-id></mixed-citation></ref><ref id="R24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>N</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Deletion of aquaporin-4 in APP/PS1 mice exacerbates brain Abeta accumulation and memory deficits.</article-title><source>Mol Neurodegener</source>. <year>2015</year>;<volume>10</volume>:<fpage>58</fpage>.<pub-id pub-id-type="pmid">26526066</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-015-0056-1</pub-id><pub-id pub-id-type="pmcid">PMC4631089</pub-id></mixed-citation></ref><ref id="R25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>W</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Aquaporin-4 mediates astrocyte response to beta-amyloid.</article-title><source>Mol Cell Neurosci</source>. <year>2012</year>;<volume>49</volume>:<fpage>406</fpage>&#8211;<lpage>414</lpage>.<pub-id pub-id-type="pmid">22365952</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mcn.2012.02.002</pub-id></mixed-citation></ref><ref id="R26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>XB</given-names></name><name name-style="western"><surname>Wang</surname><given-names>XX</given-names></name><name name-style="western"><surname>Xia</surname><given-names>DH</given-names></name><etal/></person-group>. <article-title>Impaired meningeal lymphatic drainage in patients with idiopathic Parkinson&#8217;s disease.</article-title><source>Nat Med</source>. <year>2021</year>;<volume>27</volume>:<fpage>411</fpage>&#8211;<lpage>418</lpage>.<pub-id pub-id-type="pmid">33462448</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-020-01198-1</pub-id></mixed-citation></ref><ref id="R27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Zong</surname><given-names>S</given-names></name><name name-style="western"><surname>Cui</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>The effects of microglia-associated neuroinflammation on Alzheimer&#8217;s disease.</article-title><source>Front Immunol</source>. <year>2023</year>;<volume>14</volume>:<fpage>1117172</fpage>.<pub-id pub-id-type="pmid">36911732</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2023.1117172</pub-id><pub-id pub-id-type="pmcid">PMC9992739</pub-id></mixed-citation></ref><ref id="R28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>C</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X</given-names></name><name name-style="western"><surname>Guan</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Glymphatic system dysfunction and risk of clinical milestones in patients with Parkinson disease.</article-title><source>Eur J Neurol</source>. <year>2024</year>;<volume>31</volume>:<fpage>e16521</fpage>.<pub-id pub-id-type="pmid">39425566</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ene.16521</pub-id><pub-id pub-id-type="pmcid">PMC11554988</pub-id></mixed-citation></ref><ref id="R29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Chopp</surname><given-names>M</given-names></name><name name-style="western"><surname>Ding</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>MRI detection of impairment of glymphatic function in rat after mild traumatic brain injury.</article-title><source>Brain Res</source>. <year>2020</year>;<volume>1747</volume>:<fpage>147062</fpage>.<pub-id pub-id-type="pmid">32818526</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.brainres.2020.147062</pub-id><pub-id pub-id-type="pmcid">PMC9419050</pub-id></mixed-citation></ref><ref id="R30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>DX</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yu</surname><given-names>MM</given-names></name><etal/></person-group>. <article-title>Associations of MRI-derived glymphatic system impairment with global white matter damage and cognitive impairment in mild traumatic brain injury: a DTI-ALPS study.</article-title><source>J Magn Reson Imaging</source>. <year>2024</year>;<volume>59</volume>:<fpage>639</fpage>&#8211;<lpage>647</lpage>.<pub-id pub-id-type="pmid">37276070</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jmri.28797</pub-id></mixed-citation></ref><ref id="R31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knopman</surname><given-names>DS</given-names></name><name name-style="western"><surname>Amieva</surname><given-names>H</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>RC</given-names></name><etal/></person-group>. <article-title>Alzheimer disease.</article-title><source>Nat Rev Dis Primers</source>. <year>2021</year>;<volume>7</volume>:<fpage>33</fpage>.<pub-id pub-id-type="pmid">33986301</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41572-021-00269-y</pub-id><pub-id pub-id-type="pmcid">PMC8574196</pub-id></mixed-citation></ref><ref id="R32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mawuenyega</surname><given-names>KG</given-names></name><name name-style="western"><surname>Sigurdson</surname><given-names>W</given-names></name><name name-style="western"><surname>Ovod</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Decreased clearance of CNS beta-amyloid in Alzheimer&#8217;s disease.</article-title><source>Science</source>. <year>2010</year>;<volume>330</volume>:<fpage>1774</fpage>.<pub-id pub-id-type="pmid">21148344</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1197623</pub-id><pub-id pub-id-type="pmcid">PMC3073454</pub-id></mixed-citation></ref><ref id="R33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balestrino</surname><given-names>R</given-names></name><name name-style="western"><surname>Schapira</surname><given-names>AHV</given-names></name></person-group>. <article-title>Parkinson disease.</article-title><source>Eur J Neurol</source>. <year>2020</year>;<volume>27</volume>:<fpage>27</fpage>&#8211;<lpage>42</lpage>.<pub-id pub-id-type="pmid">31631455</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ene.14108</pub-id></mixed-citation></ref><ref id="R34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zou</surname><given-names>W</given-names></name><name name-style="western"><surname>Pu</surname><given-names>T</given-names></name><name name-style="western"><surname>Feng</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Blocking meningeal lymphatic drainage aggravates Parkinson&#8217;s disease-like pathology in mice overexpressing mutated alpha-synuclein.</article-title><source>Transl Neurodegener</source>. <year>2019</year>;<volume>8</volume>:<fpage>7</fpage>.<pub-id pub-id-type="pmid">30867902</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40035-019-0147-y</pub-id><pub-id pub-id-type="pmcid">PMC6396507</pub-id></mixed-citation></ref><ref id="R35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meinhold</surname><given-names>L</given-names></name><name name-style="western"><surname>Gennari</surname><given-names>AG</given-names></name><name name-style="western"><surname>Baumann-Vogel</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>T2 MRI visible perivascular spaces in Parkinson&#8217;s disease: clinical significance and association with polysomnography measured sleep.</article-title><source>Sleep</source>. <year>2025</year>;<volume>48</volume>:<fpage>zsae233</fpage>.<pub-id pub-id-type="pmid">39377177</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/sleep/zsae233</pub-id><pub-id pub-id-type="pmcid">PMC11725513</pub-id></mixed-citation></ref><ref id="R36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Christensen</surname><given-names>J</given-names></name><name name-style="western"><surname>Wright</surname><given-names>DK</given-names></name><name name-style="western"><surname>Yamakawa</surname><given-names>GR</given-names></name><etal/></person-group>. <article-title>Repetitive mild traumatic brain injury alters glymphatic clearance rates in limbic structures of adolescent female rats.</article-title><source>Sci Rep</source>. <year>2020</year>;<volume>10</volume>:<fpage>6254</fpage>.<pub-id pub-id-type="pmid">32277097</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-020-63022-7</pub-id><pub-id pub-id-type="pmcid">PMC7148360</pub-id></mixed-citation></ref><ref id="R37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>E</given-names></name><name name-style="western"><surname>Peng</surname><given-names>X</given-names></name><name name-style="western"><surname>Ma</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>The involvement of aquaporin-4 in the interstitial fluid drainage impairment following subarachnoid hemorrhage.</article-title><source>Front Aging Neurosci</source>. <year>2020</year>;<volume>12</volume>:<fpage>611494</fpage>.<pub-id pub-id-type="pmid">33574749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2020.611494</pub-id><pub-id pub-id-type="pmcid">PMC7870692</pub-id></mixed-citation></ref><ref id="R38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Formolo</surname><given-names>DA</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name><name name-style="western"><surname>Lin</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Leveraging the glymphatic and meningeal lymphatic systems as therapeutic strategies in Alzheimer&#8217;s disease: an updated overview of nonpharmacological therapies.</article-title><source>Mol Neurodegener</source>. <year>2023</year>;<volume>18</volume>:<fpage>26</fpage>.<pub-id pub-id-type="pmid">37081555</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-023-00618-3</pub-id><pub-id pub-id-type="pmcid">PMC10116684</pub-id></mixed-citation></ref><ref id="R39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grunherz</surname><given-names>L</given-names></name><name name-style="western"><surname>Barbon</surname><given-names>C</given-names></name><name name-style="western"><surname>Gousopoulos</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>PROMs after lymphatic reconstructive surgery: is there a correlation between volume reduction and quality of life?</article-title><source>Plast Reconstr Surg Glob Open</source>. <year>2023</year>;<volume>11</volume>:<fpage>e5020</fpage>.<pub-id pub-id-type="pmid">37250829</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/GOX.0000000000005020</pub-id><pub-id pub-id-type="pmcid">PMC10219699</pub-id></mixed-citation></ref><ref id="R40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwon</surname><given-names>JG</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jang</surname><given-names>MY</given-names></name><etal/></person-group>. <article-title>The quality of life after lymphaticovenous anastomosis in 118 lower limb lymphedema patients.</article-title><source>Arch Plast Surg</source>. <year>2023</year>;<volume>50</volume>:<fpage>514</fpage>&#8211;<lpage>522</lpage>.<pub-id pub-id-type="pmid">37808336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/a-2117-4478</pub-id><pub-id pub-id-type="pmcid">PMC10556310</pub-id></mixed-citation></ref><ref id="R41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>M</given-names></name><name name-style="western"><surname>Pike</surname><given-names>C</given-names></name><name name-style="western"><surname>Humphreys</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Impact and outcomes after lymphaticovenous anastomosis for 150 cases of lymphoedema followed up over 24 months.</article-title><source>J Plast Reconstr Aesthet Surg</source>. <year>2023</year>;<volume>85</volume>:<fpage>104</fpage>&#8211;<lpage>113</lpage>.<pub-id pub-id-type="pmid">37473641</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bjps.2023.06.068</pub-id></mixed-citation></ref><ref id="R42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carlotta</surname><given-names>I</given-names></name><name name-style="western"><surname>Lisanne</surname><given-names>G</given-names></name><name name-style="western"><surname>Nicole</surname><given-names>L</given-names></name></person-group>. <article-title>Systematic review of robotic-assisted peripheral and central lymphatic surgery.</article-title><source>J Surg Oncol</source>. <year>2024</year>;<volume>131</volume>:<fpage>62</fpage>&#8211;<lpage>71</lpage>.<pub-id pub-id-type="pmid">39257236</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jso.27866</pub-id><pub-id pub-id-type="pmcid">PMC11874190</pub-id></mixed-citation></ref><ref id="R43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Engstrom</surname><given-names>O</given-names></name><name name-style="western"><surname>Mani</surname><given-names>M</given-names></name></person-group>. <article-title>Surgical treatments of lymphedema&#8212;a literature review on robot-assisted lymphovenous anastomosis (LVA).</article-title><source>Gland Surg</source>. <year>2024</year>;<volume>13</volume>:<fpage>1066</fpage>&#8211;<lpage>1075</lpage>.<pub-id pub-id-type="pmid">39015714</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/gs-24-22</pub-id><pub-id pub-id-type="pmcid">PMC11247599</pub-id></mixed-citation></ref><ref id="R44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gr&#252;nherz</surname><given-names>L</given-names></name><name name-style="western"><surname>von Reibnitz</surname><given-names>D</given-names></name><name name-style="western"><surname>Lindenblatt</surname><given-names>N</given-names></name></person-group>. <article-title>Robotisch-assistierte Lymphchirurgie [Robotic-assisted lymphatic surgery].</article-title><source>Handchir Mikrochir Plast Chir</source>. <year>2024</year>;<volume>56</volume>:<fpage>122</fpage>&#8211;<lpage>127</lpage>.<pub-id pub-id-type="pmid">38670085</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/a-2254-7045</pub-id></mixed-citation></ref><ref id="R45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lindenblatt</surname><given-names>N</given-names></name><name name-style="western"><surname>Gr&#252;nherz</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Early experience using a new robotic microsurgical system for lymphatic surgery.</article-title><source>Plast Reconstr Surg Glob Open</source>. <year>2022</year>;<volume>10</volume>:<fpage>e4013</fpage>.<pub-id pub-id-type="pmid">35028251</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/GOX.0000000000004013</pub-id><pub-id pub-id-type="pmcid">PMC8747501</pub-id></mixed-citation></ref><ref id="R46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>K&#246;nneker</surname><given-names>S</given-names></name><name name-style="western"><surname>Watson</surname><given-names>JA</given-names></name><name name-style="western"><surname>Weinzierl</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Advances in reconstructive robotic microsurgery in the extremity.</article-title><source>J Craniofac Surg</source>. <year>2024</year>;<volume>36</volume>:<fpage>354</fpage>&#8211;<lpage>357</lpage>.<pub-id pub-id-type="pmid">39283079</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/SCS.0000000000010622</pub-id></mixed-citation></ref><ref id="R47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gr&#252;nherz</surname><given-names>L</given-names></name><name name-style="western"><surname>Weinzierl</surname><given-names>A</given-names></name><name name-style="western"><surname>Puippe</surname><given-names>GD</given-names></name><etal/></person-group>. <article-title>First-in-human use of a microsurgical robotic system for central lymphatic reconstruction.</article-title><source>Plast Reconstr Surg Glob Open</source>. <year>2023</year>;<volume>11</volume>:<fpage>e5484</fpage>.<pub-id pub-id-type="pmid">38115836</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/GOX.0000000000005484</pub-id><pub-id pub-id-type="pmcid">PMC10730044</pub-id></mixed-citation></ref><ref id="R48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weinzierl</surname><given-names>A</given-names></name><name name-style="western"><surname>Gr&#252;nherz</surname><given-names>L</given-names></name><name name-style="western"><surname>Puippe</surname><given-names>GD</given-names></name><etal/></person-group>. <article-title>Microsurgical central lymphatic reconstruction&#8212;the role of thoracic duct lymphovenous anastomoses at different anatomical levels.</article-title><source>Front Surg</source>. <year>2024</year>;<volume>11</volume>:<fpage>1415010</fpage>.<pub-id pub-id-type="pmid">38826811</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fsurg.2024.1415010</pub-id><pub-id pub-id-type="pmcid">PMC11140048</pub-id></mixed-citation></ref><ref id="R49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lisanne</surname><given-names>G</given-names></name><name name-style="western"><surname>Nicole</surname><given-names>L</given-names></name></person-group>. <article-title>Central lymphatic surgery.</article-title><source>Plast Aesthet Res</source>. <year>2023</year>;<volume>10</volume>:<fpage>20</fpage>.</mixed-citation></ref><ref id="R50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gr&#252;nherz</surname><given-names>L</given-names></name><name name-style="western"><surname>Weinzierl</surname><given-names>A</given-names></name><name name-style="western"><surname>Gutschow</surname><given-names>CA</given-names></name><etal/></person-group>. <article-title>Robotic-assisted lymphovenous anastomosis of the central lymphatic system.</article-title><source>Plast Reconstr Surg Glob Open</source>. <year>2024</year>;<volume>12</volume>:<fpage>e6164</fpage>.<pub-id pub-id-type="pmid">39286611</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/GOX.0000000000006164</pub-id><pub-id pub-id-type="pmcid">PMC11404956</pub-id></mixed-citation></ref><ref id="R51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>von Reibnitz</surname><given-names>D</given-names></name><name name-style="western"><surname>Weinzierl</surname><given-names>A</given-names></name><name name-style="western"><surname>Barbon</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>100 anastomoses: a two-year single-center experience with robotic-assisted micro- and supermicrosurgery for lymphatic reconstruction.</article-title><source>J Robot Surg</source>. <year>2024</year>;<volume>18</volume>:<fpage>164</fpage>.<pub-id pub-id-type="pmid">38581589</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11701-024-01937-3</pub-id><pub-id pub-id-type="pmcid">PMC10998780</pub-id></mixed-citation></ref><ref id="R52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Mulken</surname><given-names>TJM</given-names></name><name name-style="western"><surname>Wolfs</surname><given-names>J</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>SS</given-names></name><etal/></person-group>. <article-title>One-year outcomes of the first human trial on robot-assisted lymphaticovenous anastomosis for breast cancer-related lymphedema.</article-title><source>Plast Reconstr Surg</source>. <year>2022</year>;<volume>149</volume>:<fpage>151</fpage>&#8211;<lpage>161</lpage>.<pub-id pub-id-type="pmid">34936615</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/PRS.0000000000008670</pub-id></mixed-citation></ref><ref id="R53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weinzierl</surname><given-names>A</given-names></name><name name-style="western"><surname>Barbon</surname><given-names>C</given-names></name><name name-style="western"><surname>Gousopoulos</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Benefits of robotic-assisted lymphatic microsurgery in deep anatomical planes.</article-title><source>JPRAS Open</source>. <year>2023</year>;<volume>37</volume>:<fpage>145</fpage>&#8211;<lpage>154</lpage>.<pub-id pub-id-type="pmid">37546233</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpra.2023.07.001</pub-id><pub-id pub-id-type="pmcid">PMC10403710</pub-id></mixed-citation></ref><ref id="R54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moorthy</surname><given-names>K</given-names></name><name name-style="western"><surname>Munz</surname><given-names>Y</given-names></name><name name-style="western"><surname>Dosis</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Dexterity enhancement with robotic surgery.</article-title><source>Surg Endosc</source>. <year>2004</year>;<volume>18</volume>:<fpage>790</fpage>&#8211;<lpage>795</lpage>.<pub-id pub-id-type="pmid">15216862</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00464-003-8922-2</pub-id></mixed-citation></ref><ref id="R55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gr&#252;nherz</surname><given-names>L</given-names></name><name name-style="western"><surname>Gousopoulos</surname><given-names>E</given-names></name><name name-style="western"><surname>Barbon</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Robotik in der plastischen Chirurgie [Robotics in plastic surgery].</article-title><source>Chirurgie (Heidelb)</source>. <year>2023</year>;<volume>94</volume>:<fpage>325</fpage>&#8211;<lpage>329</lpage>.<pub-id pub-id-type="pmid">36625922</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00104-022-01790-w</pub-id><pub-id pub-id-type="pmcid">PMC10042931</pub-id></mixed-citation></ref><ref id="R56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Randell</surname><given-names>R</given-names></name><name name-style="western"><surname>Alvarado</surname><given-names>N</given-names></name><name name-style="western"><surname>Honey</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Impact of robotic surgery on decision making: perspectives of surgical teams.</article-title><source>AMIA Annu Symp Proc</source>. <year>2015</year>;<volume>2015</volume>:<fpage>1057</fpage>&#8211;<lpage>1066</lpage>.<pub-id pub-id-type="pmid">26958244</pub-id><pub-id pub-id-type="pmcid">PMC4765621</pub-id></mixed-citation></ref><ref id="R57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Catchpole</surname><given-names>K</given-names></name><name name-style="western"><surname>Bisantz</surname><given-names>A</given-names></name><name name-style="western"><surname>Hallbeck</surname><given-names>MS</given-names></name><etal/></person-group>. <article-title>Human factors in robotic assisted surgery: lessons from studies &#8220;in the Wild&#8221;.</article-title><source>Appl Ergon</source>. <year>2019</year>;<volume>78</volume>:<fpage>270</fpage>&#8211;<lpage>276</lpage>.<pub-id pub-id-type="pmid">29478667</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apergo.2018.02.011</pub-id><pub-id pub-id-type="pmcid">PMC6105731</pub-id></mixed-citation></ref><ref id="R58"><label>58.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Wessling</surname><given-names>B</given-names></name></person-group>. <article-title>Symani Surgical System takes the surgeon out of the operating area.</article-title><comment>Available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.therobotreport.com/symani-surgical-system-takes-the-surgeon-out-of-the-operating-area/" ext-link-type="uri">https://www.therobotreport.com/symani-surgical-system-takes-the-surgeon-out-of-the-operating-area/</ext-link>. Accessed February 8, 2025</comment>.</mixed-citation></ref><ref id="R59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hinrichs-Krapels</surname><given-names>S</given-names></name><name name-style="western"><surname>Ditewig</surname><given-names>B</given-names></name><name name-style="western"><surname>Boulding</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Purchasing high-cost medical devices and equipment in hospitals: a systematic review.</article-title><source>BMJ Open</source>. <year>2022</year>;<volume>12</volume>:<fpage>e057516</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjopen-2021-057516</pub-id><pub-id pub-id-type="pmcid">PMC9438058</pub-id><pub-id pub-id-type="pmid">36581959</pub-id></mixed-citation></ref><ref id="R60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sridhar</surname><given-names>AN</given-names></name><name name-style="western"><surname>Briggs</surname><given-names>TP</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>JD</given-names></name><etal/></person-group>. <article-title>Training in robotic surgery&#8212;an overview.</article-title><source>Curr Urol Rep</source>. <year>2017</year>;<volume>18</volume>:<fpage>58</fpage>.<pub-id pub-id-type="pmid">28647793</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11934-017-0710-y</pub-id><pub-id pub-id-type="pmcid">PMC5486586</pub-id></mixed-citation></ref><ref id="R61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barbon</surname><given-names>C</given-names></name><name name-style="western"><surname>Grunherz</surname><given-names>L</given-names></name><name name-style="western"><surname>Uyulmaz</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Exploring the learning curve of a new robotic microsurgical system for microsurgery.</article-title><source>JPRAS Open</source>. <year>2022</year>;<volume>34</volume>:<fpage>126</fpage>&#8211;<lpage>133</lpage>.<pub-id pub-id-type="pmid">36304073</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpra.2022.09.002</pub-id><pub-id pub-id-type="pmcid">PMC9593278</pub-id></mixed-citation></ref><ref id="R62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ringstad</surname><given-names>G</given-names></name><name name-style="western"><surname>Eide</surname><given-names>PK</given-names></name></person-group>. <article-title>Glymphatic-lymphatic coupling: assessment of the evidence from magnetic resonance imaging of humans.</article-title><source>Cell Mol Life Sci</source>. <year>2024</year>;<volume>81</volume>:<fpage>131</fpage>.<pub-id pub-id-type="pmid">38472405</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00018-024-05141-2</pub-id><pub-id pub-id-type="pmcid">PMC10933166</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Brain</journal-id><journal-id journal-id-type="iso-abbrev">Brain</journal-id><journal-id journal-id-type="pmc-domain-id">719</journal-id><journal-id journal-id-type="pmc-domain">brain</journal-id><journal-id journal-id-type="publisher-id">brainj</journal-id><journal-title-group><journal-title>Brain</journal-title></journal-title-group><issn pub-type="ppub">0006-8950</issn><issn pub-type="epub">1460-2156</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12493056</article-id><article-id pub-id-type="pmcid-ver">PMC12493056.1</article-id><article-id pub-id-type="pmcaid">12493056</article-id><article-id pub-id-type="pmcaiid">12493056</article-id><article-id pub-id-type="pmid">40279515</article-id><article-id pub-id-type="doi">10.1093/brain/awaf156</article-id><article-id pub-id-type="publisher-id">awaf156</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00310</subject><subject>AcademicSubjects/SCI01870</subject></subj-group><subj-group subj-group-type="category-oup-series"><subject>Editor's Choice</subject></subj-group></article-categories><title-group><article-title>Neuropsychiatric symptoms and progression to pathologically confirmed Alzheimer&#8217;s disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Sharif</surname><given-names initials="SF">Sergio F</given-names></name><aff>
<institution>Cumming School of Medicine, University of Calgary</institution>, <addr-line>Calgary, AB</addr-line>, <country country="CA">Canada</country> T2N 1N4</aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7065-1963</contrib-id><name name-style="western"><surname>Guan</surname><given-names initials="DX">Dylan X</given-names></name><aff>
<institution>Cumming School of Medicine, University of Calgary</institution>, <addr-line>Calgary, AB</addr-line>, <country country="CA">Canada</country> T2N 1N4</aff><aff>
<institution>Hotchkiss Brain Institute, University of Calgary</institution>, <addr-line>Calgary, AB</addr-line>, <country country="CA">Canada</country> T2N 4Z6</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bodnar</surname><given-names initials="TS">Tamara S</given-names></name><aff>
<institution>Department of Biological Sciences, University of Calgary</institution>, <addr-line>Calgary, AB</addr-line>, <country country="CA">Canada</country> T2N 1N4</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Joseph</surname><given-names initials="JT">Jeffery T</given-names></name><aff>
<institution>Hotchkiss Brain Institute, University of Calgary</institution>, <addr-line>Calgary, AB</addr-line>, <country country="CA">Canada</country> T2N 4Z6</aff><aff>
<institution>Department of Pathology and Laboratory Medicine, University of Calgary</institution>, <addr-line>Calgary, AB</addr-line>, <country country="CA">Canada</country> T2N 4Z6</aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3930-4354</contrib-id><name name-style="western"><surname>Zetterberg</surname><given-names initials="H">Henrik</given-names></name><aff>
<institution>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg</institution>, <addr-line>M&#246;lndal 431 39</addr-line>, <country country="SE">Sweden</country></aff><aff>
<institution>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital</institution>, <addr-line>M&#246;lndal 431 39</addr-line>, <country country="SE">Sweden</country></aff><aff>
<institution>Department of Neurodegenerative Disease, UCL Institute of Neurology</institution>, <addr-line>London WC1N 3BG</addr-line>, <country country="GB">UK</country></aff><aff>
<institution>UK Dementia Research Institute at UCL</institution>, <addr-line>London NW1 3BT</addr-line>, <country country="GB">UK</country></aff><aff>
<institution>Hong Kong Center for Neurodegenerative Diseases</institution>, <addr-line>Clear Water Bay, Hong Kong</addr-line>, <country country="CN">China</country></aff><aff>
<institution>Wisconsin Alzheimer&#8217;s Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison</institution>, <addr-line>Madison, WI 53792</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Smith</surname><given-names initials="EE">Eric E</given-names></name><aff>
<institution>Hotchkiss Brain Institute, University of Calgary</institution>, <addr-line>Calgary, AB</addr-line>, <country country="CA">Canada</country> T2N 4Z6</aff><aff>
<institution>Department of Community Health Sciences, University of Calgary</institution>, <addr-line>Calgary, AB</addr-line>, <country country="CA">Canada</country> T2N 4Z6</aff><aff>
<institution>Department of Clinical Neurosciences, University of Calgary</institution>, <addr-line>Calgary, AB</addr-line>, <country country="CA">Canada</country> T2N 4Z6</aff></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5529-3731</contrib-id><name name-style="western"><surname>Ismail</surname><given-names initials="Z">Zahinoor</given-names></name><aff>
<institution>Hotchkiss Brain Institute, University of Calgary</institution>, <addr-line>Calgary, AB</addr-line>, <country country="CA">Canada</country> T2N 4Z6</aff><aff>
<institution>Department of Pathology and Laboratory Medicine, University of Calgary</institution>, <addr-line>Calgary, AB</addr-line>, <country country="CA">Canada</country> T2N 4Z6</aff><aff>
<institution>Department of Community Health Sciences, University of Calgary</institution>, <addr-line>Calgary, AB</addr-line>, <country country="CA">Canada</country> T2N 4Z6</aff><aff>
<institution>Department of Clinical Neurosciences, University of Calgary</institution>, <addr-line>Calgary, AB</addr-line>, <country country="CA">Canada</country> T2N 4Z6</aff><aff>
<institution>O&#8217;Brien Institute for Public Health, University of Calgary</institution>, <addr-line>Calgary, AB</addr-line>, <country country="CA">Canada</country> T2N 4Z6</aff><aff>
<institution>Department of Psychiatry, University of Calgary</institution>, <addr-line>Calgary, AB</addr-line>, <country country="CA">Canada</country> T2N 4Z6</aff><aff>
<institution>Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter</institution>, <addr-line>Exeter EX1 2HZ</addr-line>, <country country="GB">UK</country></aff><xref rid="awaf156-cor1" ref-type="corresp"/></contrib></contrib-group><author-notes><corresp id="awaf156-cor1">Correspondence to: Zahinoor Ismail Hotchkiss Brain Institute, University of Calgary, 3280 Hospital Drive NW, Calgary, AB, Canada T2N 4Z6 E-mail: <email>ismailz@ucalgary.ca</email></corresp></author-notes><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><pub-date pub-type="epub" iso-8601-date="2025-04-25"><day>25</day><month>4</month><year>2025</year></pub-date><volume>148</volume><issue>10</issue><issue-id pub-id-type="pmc-issue-id">498255</issue-id><fpage>3694</fpage><lpage>3704</lpage><history><date date-type="received"><day>14</day><month>11</month><year>2024</year></date><date date-type="rev-recd"><day>25</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>21</day><month>3</month><year>2025</year></date><date date-type="corrected-typeset"><day>09</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>25</day><month>04</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-04 10:26:05.627"><day>04</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025. Published by Oxford University Press on behalf of the Guarantors of Brain.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="awaf156.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="awaf156.pdf"/><abstract><title>Abstract</title><p>Whether or not neuropsychiatric symptoms (NPS) in advance of dementia are associated with Alzheimer&#8217;s disease (AD) and/or other neurodegenerative dementias remains to be determined. The mild behavioural impairment (MBI) construct selects persons with NPS that are later-life emergent and persistent to identify a high-risk group for cognitive decline and incident dementia. Here, in older adults without dementia at baseline, we examined whether post-mortem AD and other neurodegenerative pathologies were associated with MBI in the 5 years before death.</p><p>National Alzheimer&#8217;s Coordinating Center study autopsy participants (<italic toggle="yes">n</italic> = 1016, 82.6 years of age, 48.7% female, 60% normal cognition) were included in the analyses. Using the Neuropsychiatric Inventory-Questionnaire, MBI+ status was operationalized as NPS persistence at more than two-thirds of pre-dementia study visits; otherwise, status was non-MBI NPS. The presence of AD, Lewy body disease (LBD) and transactive response DNA-binding protein 43 neuropathological changes was determined using published guidelines. Adjusted multinomial logistic regressions modelled pathology&#8211;NPS status associations. Adjusted Cox proportional hazards regressions modelled hazard for AD dementia at each NPS status level, including interaction terms with cognitive status and each co-pathology.</p><p>AD+ individuals (51.4%) were 88.4% more likely to be MBI+ &#8764;5 years prior than AD&#8722; individuals [odds ratio: 1.88, 95% confidence interval (CI): 1.29&#8211;2.75, <italic toggle="yes">P</italic> &lt; 0.01]; however, the likelihood of having non-MBI NPS was not different (odds ratio: 1.22, CI: 0.90&#8211;1.66, <italic toggle="yes">P</italic> = 0.20). No significant associations were seen for LBD pathology, even among AD+ participants. There were no significant differences in the levels of LBD or transactive response DNA-binding protein 43 in those with MBI in comparison to no MBI. Among MBI progressors to dementia (<italic toggle="yes">n</italic> = 106), 33.0% were solely AD+, 18.9% were mixed AD+ and LBD+, and 11.3% had all three pathologies. For all those with MBI (including dementia non-progressors), of persons with LBD, 83.4% were comorbid with AD. In the survival analysis, MBI+ individuals had a 2.03-fold greater progression rate to AD dementia than those without NPS (CI: 1.60&#8211;2.57, <italic toggle="yes">P</italic> &lt; 0.01). The progression rate was higher in mild cognitive impairment , but the effect of MBI on progression was greater in normal cognition (hazard ratio: 3.05, CI: 1.37&#8211;6.80, <italic toggle="yes">P</italic> &lt; 0.01) versus mild cognitive impairment (hazard ratio: 1.93, CI: 1.51&#8211;2.47, <italic toggle="yes">P</italic> &lt; 0.01). Limbic LBD appeared also to moderate the association between MBI and incident AD (limbic LBD+ hazard ratio: 4.64, CI: 2.05&#8211;10.50, <italic toggle="yes">P</italic> &lt; 0.001; limbic LBD&#8722; hazard ratio: 1.87, CI: 1.46&#8211;2.40, <italic toggle="yes">P</italic> &lt; 0.001).</p><p>Antecedent MBI was strongly associated with AD pathology but not with other neurodegenerative dementias. Inclusion of MBI in research and clinical frameworks for dementia might aid in identification of early stages of neurodegenerative disease, which might be helpful for selecting patients for treatment with AD-modifying drugs.</p></abstract><abstract abstract-type="teaser"><p>Psychiatric symptoms emerging later in life may be early signs of neurodegenerative disease. Sharif <italic toggle="yes">et al.</italic> show that older adults who met criteria for mild behavioural impairment progressed more rapidly to Alzheimer&#8217;s disease dementia, and were enriched for Alzheimer&#8217;s disease pathology at autopsy.</p></abstract><kwd-group><kwd>mild behavioural impairment</kwd><kwd>dementia</kwd><kwd>TDP-43</kwd><kwd>neuropsychiatry</kwd><kwd>neuropathology</kwd><kwd>cognitive decline</kwd></kwd-group><funding-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Alberta Innovates</institution><institution-id institution-id-type="DOI">10.13039/501100009192</institution-id></institution-wrap></funding-source></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Gordie Howe CARES</institution></institution-wrap></funding-source></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>UK National Institute for Health and Care Research Exeter Biomedical Research Centre</institution></institution-wrap></funding-source></award-group></funding-group><counts><page-count count="11"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="awaf156-s1"><title>Introduction</title><p>Alzheimer&#8217;s disease (AD) is the most common cause of dementia, with neuropathological assessment serving as the gold standard for diagnosis.<sup><xref rid="awaf156-B1" ref-type="bibr">1</xref></sup> Recent evidence points to neuropsychiatric symptoms (NPS) as potential preclinical/prodromal aspects of AD dementia.<sup><xref rid="awaf156-B2" ref-type="bibr">2-9</xref></sup> However, it is unclear whether inclusion of NPS in staging of individuals along the AD continuum is of benefit.<sup><xref rid="awaf156-B10" ref-type="bibr">10</xref>,<xref rid="awaf156-B11" ref-type="bibr">11</xref></sup> Whether specific NPS have distinct pathological substrates or are common across multiple diseases also remains uncertain.<sup><xref rid="awaf156-B10" ref-type="bibr">10</xref>,<xref rid="awaf156-B12" ref-type="bibr">12</xref>,<xref rid="awaf156-B13" ref-type="bibr">13</xref></sup> Without consideration of the natural history of symptoms, research on NPS might fail to distinguish between long-standing behaviours or personality differences related to psychiatric disorders and later-life-onset psychiatric symptoms that are prodromal to neurodegenerative disease.<sup><xref rid="awaf156-B4" ref-type="bibr">4</xref>,<xref rid="awaf156-B14" ref-type="bibr">14</xref>,<xref rid="awaf156-B15" ref-type="bibr">15</xref></sup></p><p>To address this issue, the Neuropsychiatric Syndromes Professional Interest Area of the Alzheimer&#8217;s Association International Society to Advance Alzheimer's Research and Treatment developed the mild behavioural impairment (MBI) construct. The MBI syndromic criteria were created to incorporate NPS better into dementia risk assessment, leveraging the higher risk associated with NPS that emerge <italic toggle="yes">de novo</italic> in later life and that persist for &#8805;6 months.<sup><xref rid="awaf156-B2" ref-type="bibr">2</xref></sup> This construct has shed light on the utility of NPS meeting MBI criteria for prognosticating cognitive decline and incident dementia. Studies of MBI have demonstrated: (i) poorer cognitive performance and faster cognitive decline; (ii) greater progression rates from normal cognition (NC) and subjective cognitive decline to mild cognitive impairment (MCI); and (iii) greater progression rates from MCI to dementia, with lower reversion rates from MCI to NC, relative to non-MBI comparator groups.<sup><xref rid="awaf156-B16" ref-type="bibr">16-22</xref></sup></p><p>MBI has demonstrated associations with many AD markers.<sup><xref rid="awaf156-B23" ref-type="bibr">23-27</xref></sup> Furthermore, in line with the National Institute on Aging&#8211;Alzheimer&#8217;s Association (NIA-AA) Amyloid-Tau-Neurodegeneration (ATN) Research Framework for AD,<sup><xref rid="awaf156-B28" ref-type="bibr">28</xref></sup> several studies have demonstrated associations between MBI and biomarkers related to the AD framework, such as amyloid-&#946; and tau, in addition to the AD-associated <italic toggle="yes">APOE</italic> &#603;4 allele.<sup><xref rid="awaf156-B25" ref-type="bibr">25</xref>,<xref rid="awaf156-B29" ref-type="bibr">29-34</xref></sup> Thus, current evidence suggests that of persons with NPS, MBI criteria select for a subset who are at high risk for cognitive decline and incident dementia and who might already be on the AD continuum.</p><p>With respect to non-AD pathologies, a study in cognitively unimpaired participants found an association between an approximation of MBI and greater progression rate to clinically diagnosed and neuropathologically confirmed AD, although co-pathologies were not reported.<sup><xref rid="awaf156-B23" ref-type="bibr">23</xref></sup> A growing body of evidence points to the additive and synergistic effect of multiple pathologies in the development of dementia symptoms.<sup><xref rid="awaf156-B12" ref-type="bibr">12</xref>,<xref rid="awaf156-B35" ref-type="bibr">35-37</xref></sup> However, more research is needed, especially regarding the differential influence of Lewy body disease (LBD) and/or transactive response DNA-binding protein 43 (TDP-43) pathology on NPS presentations in those with AD. Furthermore, data with preclinical and prodromal behavioural symptoms are sparse. Owing to the potential diagnostic and prognostic utility of MBI, additional gold standard neuropathological assessments are required, using current approaches to operationalizing MBI and incorporating additional pathologies in the modelling.</p><p>Here, we examined the links between AD, post-mortem co-pathologies and MBI. Specifically, we tested whether AD neuropathological change (ADNC), LBD pathology and/or TDP-43 inclusions were associated with a greater likelihood of preceding MBI, in the 5 years before death. We also tested whether baseline MBI was predictive of a greater progression rate to AD dementia, the potential moderation of cognitive status and/or co-pathology for incident AD dementia, and whether there were group differences in participant pathological profiles. We hypothesized that those with MBI would progress more rapidly to neuropathologically confirmed AD, thus identifying a group enriched for AD pathology post-mortem.</p></sec><sec sec-type="materials|methods" id="awaf156-s2"><title>Materials and methods</title><sec id="awaf156-s2.1"><title>Source population</title><p>Data were obtained from the National Alzheimer&#8217;s Coordinating Center (NACC) database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://naccdata.org" ext-link-type="uri">https://naccdata.org</ext-link>), with a May 2022 data freeze. NACC was established by the National Institute on Aging and consists of multiple institute-funded Alzheimer&#8217;s Disease Research Centers recruiting and collecting data on participants with cognitive functions ranging from normal to dementia. The NACC Uniform Data Set is a large longitudinal dataset including demographic and standardized clinical data collected approximately annually. All test centres administered standardized forms, and informed consent was collected from all participants and their informants. All protocols were approved by the University of Washington institute review board. Detailed information on the cohort and neuropsychological battery of tests included in the Uniform Data Set are described elsewhere.<sup><xref rid="awaf156-B38" ref-type="bibr">38-40</xref></sup> Data from the NACC Neuropathology Data Set were collected according to a standardized Neuropathology Form and Coding Guidebook. In 2014, the Neuropathology Form version 10 was revised to NIA-AA guidelines,<sup><xref rid="awaf156-B41" ref-type="bibr">41</xref></sup> including updated classification of ADNC and incorporation of a wider range of neuropathological variables.<sup><xref rid="awaf156-B42" ref-type="bibr">42</xref></sup> Since the time of these analyses, a newer dataset has been released; however, the data-collection methods have not changed substantially.</p></sec><sec id="awaf156-s2.2"><title>Participants</title><p>All participants (<italic toggle="yes">n</italic> = 1016) were in NACC and had data available in the Neuropathology Data Set with form version 10 or later.</p><p>
<xref rid="awaf156-F1" ref-type="fig">Figure 1</xref> outlines the participant inclusion and exclusion criteria. To distinguish between later-life, <italic toggle="yes">de novo</italic> NPS with symptomatology attributable to longstanding neurological and/or psychiatric conditions, participants with a history of chronic and/or recurrent psychiatric disorders (e.g. depression, schizophrenia, bipolar disorder) and neurodevelopmental/neurological disorders (e.g. Down&#8217;s syndrome, autism, Huntington&#8217;s disease) were excluded. All available participant NPS data were used from pre-dementia visits. To maximize sample size, individuals with both NC and MCI were included (all analyses controlled for cognitive status).</p><fig position="float" id="awaf156-F1" fig-type="figure" orientation="portrait"><label>Figure 1</label><caption><p>
<bold>Flow diagram for participant inclusion and exclusion criteria.</bold> ADNC = Alzheimer's disease neuropathologic change; NACC = National Alzheimer&#8217;s Coordinating Center; NPI-Q = Neuropsychiatric Inventory-Questionnaire.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="awaf156f1.jpg"/></fig></sec><sec id="awaf156-s2.3"><title>Neuropsychiatric symptom status</title><p>NPS severity was derived from the Neuropsychiatric Inventory-Questionnaire (NPI-Q)<sup><xref rid="awaf156-B43" ref-type="bibr">43</xref></sup> using a published algorithm,<sup><xref rid="awaf156-B44" ref-type="bibr">44</xref>,<xref rid="awaf156-B45" ref-type="bibr">45</xref></sup> mapping 10 items onto the following five domains of MBI: (i) decreased motivation (apathy/indifference); (ii) emotional dysregulation (depression/dysphoria, anxiety, elation/euphoria); (iii) impulse dyscontrol (agitation/aggression, irritability/lability, aberrant motor behaviour); (iv) social inappropriateness (disinhibition); and (v) abnormal perception or thoughts (delusions and hallucinations). MBI domain scores were calculated by summing the scores of each corresponding NPI-Q domain item. MBI+ status was determined based on the most recently validated operational definition of MBI,<sup><xref rid="awaf156-B46" ref-type="bibr">46</xref></sup> with symptom persistence operationalized by the presence of NPS at more than two-thirds of study visits preceding either onset of dementia or death (whichever occurred first) and <italic toggle="yes">de novo</italic> symptom emergence determined by the absence of any previous psychiatric conditions. If NPS did not meet MBI criteria (i.e. impersistent NPS and/or occurring in the context of a previous psychiatric diagnosis), status was non-MBI NPS, and if no NPS were present, status was no NPS.</p></sec><sec id="awaf156-s2.4"><title>Neuropathology</title><p>Participant pathology was derived from the Neuropathological Data Set, dichotomized by the presence/absence of each proteinopathy (AD, LBD and TDP-43). AD pathology was scored using the semi-quantitative ABC criteria, which account for Thal staging (criterion A), Braak staging (criterion B) and Consortium to Establish a Registry for Alzheimer&#8217;s Disease (CERAD) staging (criterion C). These criteria are then used to rate the likelihood of ADNC, resulting in a scale described as &#8216;Not&#8217;, &#8216;Low&#8217;, &#8216;Intermediate&#8217; or &#8216;High&#8217;. AD status was derived using the NIA-AA recommendations for AD neuropathological assessment, with scores of &#8216;Intermediate&#8217; or &#8216;High&#8217; probability ADNC conferring AD+ status.<sup><xref rid="awaf156-B41" ref-type="bibr">41</xref></sup> For LBD pathology, participants were dichotomized based on the presence/absence of alpha-synuclein immunoreactivity anywhere in the brain. LBD pathology was assessed following a modified DLB Consortium classification<sup><xref rid="awaf156-B47" ref-type="bibr">47</xref></sup>: brainstem-predominant, limbic (transitional), neocortical (diffuse), amygdala-predominant or olfactory bulb LBD. For TDP-43 pathology, participants were dichotomized based on the presence/absence of TDP-43-immunoreactive inclusions in any of the following regions: spinal cord, amygdala, hippocampus, entorhinal/inferior temporal cortex or neocortex.</p></sec><sec id="awaf156-s2.5"><title>Statistical analysis</title><p>Following a case&#8211;control approach, a multinomial logistic regression was used to model the association between the presence of each pathology at autopsy (predictor) and NPS status out to 5 years before death (outcome), controlling for the presence of co-pathologies. To examine the potentially differing contributions of co-pathologies to MBI in AD+ individuals, another multinomial logistic regression was run between each co-pathology (i.e. LBD, TDP-43) as a predictor and NPS status as the outcome. The same model was run in AD&#8722; individuals to test for any associations between co-pathologies in those with low levels of ADNC. All models adjusted for age, sex, education, cognitive status (NC versus MCI), time to death, and <italic toggle="yes">APOE</italic> &#603;4 carrier status.</p><p>To determine whether MBI was associated with a greater progression rate to AD dementia (clinical diagnosis of dementia, AD+ at autopsy), Cox proportional hazards regression modelled the association between baseline NPS status and incident AD dementia within 5 years. NPS and/or cognitive status were time-varying covariates. All models adjusted for age, sex, education, cognitive status, time to death, and <italic toggle="yes">APOE</italic> &#603;4 carrier status, with interaction term NPS &#215; Cognitive status (i.e. NC versus MCI).</p><p>In an exploratory analysis, the proportion of participant pathologies was tabulated and stratified by NPS status. An adjusted multinomial logistic regression modelling baseline NPS status (predictor) and each combination of pathologies (outcome) was also used, with the no pathology group (i.e. AD&#8722;, LBD&#8722;, TDP&#8722;) serving as the reference. The model was adjusted for age, sex, education, cognitive status, time to death, and <italic toggle="yes">APOE</italic> &#603;4 carrier status.</p><p>In a further exploratory analysis, interactions between NPS and proteinopathy status (i.e. LBD and TDP-43 pathology) were examined in a Cox proportional hazards model for baseline NPS status and AD dementia within 5 years, adjusted for age, sex, education, cognitive status, time to death, and <italic toggle="yes">APOE</italic> &#603;4 carrier status. To explore region-specific associations for LBD pathology further, the same analyses were repeated with an LBD variable stratified by the different regions reported for immunoreactivity [i.e. brainstem-predominant, limbic (transitional), neocortical (diffuse), amygdala-predominant or olfactory bulb].</p><p>Statistical analyses were performed in R v.4.3.0 using the <italic toggle="yes">survival</italic> package v.3.5-5 for Cox proportional hazards regression models and <italic toggle="yes">ggplot2</italic> v.3.4.2 and <italic toggle="yes">survminer</italic> v.0.4.9 packages for Kaplan&#8211;Meier curves and forest plots of hazard ratio. Assumptions for proportional hazards were assessed using the cox.zph() function from the survival package. Multinomial models were run using the <italic toggle="yes">nnet</italic> package v.7.3-18. Statistical significance was considered at a <italic toggle="yes">P</italic>-value of &lt;0.05.</p></sec></sec><sec sec-type="results" id="awaf156-s3"><title>Results</title><sec id="awaf156-s3.1"><title>Descriptive statistics</title><p>The demographics of participants are summarized in <xref rid="awaf156-T1" ref-type="table">Table 1</xref>. The proportion of pathologies, stratified by NPS status, are summarized in <xref rid="awaf156-F2" ref-type="fig">Fig. 2</xref> and <xref rid="awaf156-T2" ref-type="table">Table 2</xref>. Among those who progressed to dementia, NPS were assessed annually over an average of 2.72 &#177; 1.39 visits before the onset of dementia. Among those with MBI (<italic toggle="yes">n</italic> = 195), 33.8% were solely AD+, 15.4% were mixed AD+/LBD+, and 7.7% had AD, LBD and TDP-43 pathology. In the non-MBI NPS group, 29.5% were AD+, whereas 12.5% were AD+/LBD+, and 6.6% were AD+/LBD+/TDP+. For those with MBI, of persons with LBD, 83.4% were comorbid with AD. For non-MBI NPS, 64.8% had comorbid AD, and for no NPS it was 59.3%. Among those with MBI who progressed to dementia (<italic toggle="yes">n</italic> = 106), 33.0% were solely AD+, 18.9% were mixed AD+/LBD+, and 11.3% had AD, LBD and TDP-43 pathology. In the non-MBI NPS group (<italic toggle="yes">n</italic> = 125), 33.6% were AD+, whereas 16.8% were AD+/LBD+, and 11.2% were AD+/LBD+/TDP+.</p><fig position="float" id="awaf156-F2" fig-type="figure" orientation="portrait"><label>Figure 2</label><caption><p>
<bold>Proportions of participants with AD, LBD and TDP-43 pathology, by NPS status.</bold> AD = Alzheimer&#8217;s disease; LBD = Lewy body; MBI = mild behavioural impairment; NPS = neuropsychiatric symptoms.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="awaf156f2.jpg"/></fig><table-wrap position="float" id="awaf156-T1" orientation="portrait"><label>Table 1</label><caption><p>Participant characteristics, stratified by NPS status</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">No NPS (<italic toggle="yes">n</italic> = 533)</th><th align="center" rowspan="1" colspan="1">Non-MBI NPS(<italic toggle="yes">n</italic> = 288)</th><th align="center" rowspan="1" colspan="1">MBI+ (<italic toggle="yes">n</italic> = 195)</th><th align="center" rowspan="1" colspan="1">Total(<italic toggle="yes">n</italic> = 1016)</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P-</italic>value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age</td><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">&lt;0.001<sup><xref rid="tblfn2" ref-type="table-fn">a</xref></sup></td></tr><tr><td rowspan="1" colspan="1">Mean (SD)</td><td rowspan="1" colspan="1">83.932 (8.365)</td><td rowspan="1" colspan="1">81.309 (8.775)</td><td rowspan="1" colspan="1">81.077 (10.058)</td><td rowspan="1" colspan="1">82.641 (8.924)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
<bold>Sex</bold>
</td><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">0.014<sup><xref rid="tblfn3" ref-type="table-fn">b</xref></sup></td></tr><tr><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">255 (47.8%)</td><td rowspan="1" colspan="1">149 (51.7%)</td><td rowspan="1" colspan="1">117 (60.0%)</td><td rowspan="1" colspan="1">521 (51.3%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">278 (52.2%)</td><td rowspan="1" colspan="1">139 (48.3%)</td><td rowspan="1" colspan="1">78 (40.0%)</td><td rowspan="1" colspan="1">495 (48.7%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
<bold>Education</bold>
</td><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">0.222<sup><xref rid="tblfn2" ref-type="table-fn">a</xref></sup></td></tr><tr><td rowspan="1" colspan="1">Mean (SD)</td><td rowspan="1" colspan="1">16.131 (2.996)</td><td rowspan="1" colspan="1">15.878 (2.860)</td><td rowspan="1" colspan="1">15.738 (3.049)</td><td rowspan="1" colspan="1">15.984 (2.970)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
<bold>Cognitive Status</bold>
</td><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">&lt;0.001<sup><xref rid="tblfn3" ref-type="table-fn">b</xref></sup></td></tr><tr><td rowspan="1" colspan="1">NC</td><td rowspan="1" colspan="1">384 (72.0%)</td><td rowspan="1" colspan="1">161 (55.9%)</td><td rowspan="1" colspan="1">60 (30.8%)</td><td rowspan="1" colspan="1">605 (59.5%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">MCI</td><td rowspan="1" colspan="1">149 (28.0%)</td><td rowspan="1" colspan="1">127 (44.1%)</td><td rowspan="1" colspan="1">135 (69.2%)</td><td rowspan="1" colspan="1">411 (40.5%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
<bold>AD status</bold>
</td><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">&lt;0.001<sup><xref rid="tblfn3" ref-type="table-fn">b</xref></sup></td></tr><tr><td rowspan="1" colspan="1">AD&#8722;</td><td rowspan="1" colspan="1">286 (53.7%)</td><td rowspan="1" colspan="1">138 (47.9%)</td><td rowspan="1" colspan="1">70 (35.9%)</td><td rowspan="1" colspan="1">494 (48.6%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">AD+</td><td rowspan="1" colspan="1">247 (46.3%)</td><td rowspan="1" colspan="1">150 (52.1%)</td><td rowspan="1" colspan="1">125 (64.1%)</td><td rowspan="1" colspan="1">522 (51.4%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
<bold>LBD status</bold>
</td><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">0.608<sup><xref rid="tblfn3" ref-type="table-fn">b</xref></sup></td></tr><tr><td rowspan="1" colspan="1">LBD&#8722;</td><td rowspan="1" colspan="1">393 (73.7%)</td><td rowspan="1" colspan="1">203 (70.5%)</td><td rowspan="1" colspan="1">141 (72.3%)</td><td rowspan="1" colspan="1">737 (72.5%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">LBD+</td><td rowspan="1" colspan="1">140 (26.3%)</td><td rowspan="1" colspan="1">85 (29.5%)</td><td rowspan="1" colspan="1">54 (27.7%)</td><td rowspan="1" colspan="1">279 (27.5%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
<bold>TDP-43 status</bold>
</td><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">0.236<sup><xref rid="tblfn3" ref-type="table-fn">b</xref></sup></td></tr><tr><td rowspan="1" colspan="1">TDP-43&#8722;</td><td rowspan="1" colspan="1">447 (83.9%)</td><td rowspan="1" colspan="1">236 (81.9%)</td><td rowspan="1" colspan="1">153 (78.5%)</td><td rowspan="1" colspan="1">836 (82.3%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">TDP-43+</td><td rowspan="1" colspan="1">86 (16.1%)</td><td rowspan="1" colspan="1">52 (18.1%)</td><td rowspan="1" colspan="1">42 (21.5%)</td><td rowspan="1" colspan="1">180 (17.7%)</td><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><p>AD+/&#8722; = Alzheimer&#8217;s disease present/absent; LBD+/&#8722; = Lewy body disease present/absent; MBI = mild behavioural impairment; MCI = mild cognitive impairment; NC = normal cognition; NPS = neuropsychiatric symptoms; SD = standard deviation; TDP-43+/&#8722; = transactive response DNA-binding protein 43 present/absent.</p></fn><fn id="tblfn2"><p>
<sup>a</sup>Linear model ANOVA.</p></fn><fn id="tblfn3"><p>
<sup>b</sup>Pearson&#8217;s &#967;<sup>2</sup> test.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="awaf156-T2" orientation="portrait"><label>Table 2</label><caption><p>Descriptive table of participant pathologies, stratified by NPS status</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Pathological profile</th><th align="center" rowspan="1" colspan="1">No NPS(<italic toggle="yes">n</italic> = 533)</th><th align="center" rowspan="1" colspan="1">Non-MBI NPS(<italic toggle="yes">n</italic> = 288)</th><th align="center" rowspan="1" colspan="1">MBI+ (<italic toggle="yes">n</italic> = 195)</th><th align="center" rowspan="1" colspan="1">Total(<italic toggle="yes">n</italic> = 1016)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">AD&#8722;LBD&#8722;TDP&#8722;</td><td rowspan="1" colspan="1">198 (37.1%)</td><td rowspan="1" colspan="1">90 (31.2%)</td><td rowspan="1" colspan="1">50 (25.6%)</td><td rowspan="1" colspan="1">338 (33.3%)</td></tr><tr><td rowspan="1" colspan="1">AD+</td><td rowspan="1" colspan="1">143 (26.8%)</td><td rowspan="1" colspan="1">85 (29.5%)</td><td rowspan="1" colspan="1">66 (33.8%)</td><td rowspan="1" colspan="1">294 (28.9%)</td></tr><tr><td rowspan="1" colspan="1">TDP+</td><td rowspan="1" colspan="1">31 (5.8%)</td><td rowspan="1" colspan="1">18 (6.2%)</td><td rowspan="1" colspan="1">11 (5.6%)</td><td rowspan="1" colspan="1">60 (5.9%)</td></tr><tr><td rowspan="1" colspan="1">LBD+</td><td rowspan="1" colspan="1">44 (8.3%)</td><td rowspan="1" colspan="1">25 (8.7%)</td><td rowspan="1" colspan="1">7 (3.6%)</td><td rowspan="1" colspan="1">76 (7.5%)</td></tr><tr><td rowspan="1" colspan="1">LBD+TDP+</td><td rowspan="1" colspan="1">13 (2.4%)</td><td rowspan="1" colspan="1">5 (1.7%)</td><td rowspan="1" colspan="1">2 (1.0%)</td><td rowspan="1" colspan="1">20 (2.0%)</td></tr><tr><td rowspan="1" colspan="1">AD+TDP+</td><td rowspan="1" colspan="1">21 (3.9%)</td><td rowspan="1" colspan="1">10 (3.5%)</td><td rowspan="1" colspan="1">14 (7.2%)</td><td rowspan="1" colspan="1">45 (4.4%)</td></tr><tr><td rowspan="1" colspan="1">AD+LBD+</td><td rowspan="1" colspan="1">62 (11.6%)</td><td rowspan="1" colspan="1">36 (12.5%)</td><td rowspan="1" colspan="1">30 (15.4%)</td><td rowspan="1" colspan="1">128 (12.6%)</td></tr><tr><td rowspan="1" colspan="1">AD+LBD+TDP+</td><td rowspan="1" colspan="1">21 (3.9%)</td><td rowspan="1" colspan="1">19 (6.6%)</td><td rowspan="1" colspan="1">15 (7.7%)</td><td rowspan="1" colspan="1">55 (5.4%)</td></tr></tbody></table><table-wrap-foot><fn id="tblfn5"><p>AD+/&#8722; = Alzheimer&#8217;s disease present/absent; LBD+/&#8722; = Lewy body disease present/absent; MBI = mild behavioural impairment; NPS = neuropsychiatric symptoms; TDP-43+/&#8722; = transactive response DNA-binding protein 43 present/absent.</p></fn></table-wrap-foot></table-wrap></sec><sec id="awaf156-s3.2"><title>Case&#8211;control analysis</title><p>In comparison to AD&#8722; individuals, AD+ individuals were 88% more likely to have MBI+ status in the 5 years preceding death [odds ratio: 1.88, 95% confidence interval (CI): 1.29&#8211;2.75, <italic toggle="yes">P</italic> &lt; 0.001], but not more likely to have non-MBI NPS status (odds ratio: 1.22, CI: 0.90&#8211;1.66, <italic toggle="yes">P</italic> = 0.20). Neither LBD nor TDP-43 pathology was associated with a greater likelihood of having either MBI or non-MBI NPS in advance of dementia. In the sub-analysis of AD+ individuals, neither LBD nor TDP-43 co-pathologies showed any associations with NPS status; the same held true among AD&#8722; individuals.</p></sec><sec id="awaf156-s3.3"><title>Survival analysis</title><p>Survival analysis revealed that MBI+ individuals had a 2.03-fold greater progression rate to AD dementia than those with no NPS (CI: 1.60&#8211;2.57, <italic toggle="yes">P</italic> &lt; 0.001). Those with non-MBI NPS did not progress to the outcome any faster than the reference group (<xref rid="awaf156-F3" ref-type="fig">Fig. 3</xref> and <xref rid="awaf156-T3" ref-type="table">Table 3</xref>). For the interaction analysis, cognitive status did not moderate the relationship between MBI and AD dementia (<italic toggle="yes">P</italic> = 0.284), but the effect of MBI on progression was greater in NC (hazard ratio: 3.05, CI: 1.37&#8211;6.80, <italic toggle="yes">P</italic> = 0.006) versus MCI participants (hazard ratio: 1.93, CI: 1.51&#8211;2.47, <italic toggle="yes">P</italic> &lt; 0.001).</p><fig position="float" id="awaf156-F3" fig-type="figure" orientation="portrait"><label>Figure 3</label><caption><p>
<bold>Kaplan&#8211;Meier curve for 5-year progression to AD dementia, stratified by NPS status and results of Cox proportional hazards regression for progression to AD dementia.</bold> All models adjusted for age, sex, education, cognitive status, time to death and <italic toggle="yes">APOE</italic> &#603;4 carrier status. AD = Alzheimer&#8217;s disease; <italic toggle="yes">APOE</italic> = apolipoprotein E; MBI = mild behavioural impairment; NPS= neuropsychiatric symptoms. See also <xref rid="awaf156-T3" ref-type="table">Table 3</xref>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="awaf156f3.jpg"/></fig><table-wrap position="float" id="awaf156-T3" orientation="portrait"><label>Table 3</label><caption><p>Results of Cox proportional hazards regression for progression to AD dementia</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Characteristic</th><th align="center" rowspan="2" colspan="1">Subgroup</th><th align="center" rowspan="2" colspan="1">
<italic toggle="yes">n</italic>
</th><th align="center" rowspan="2" colspan="1">Hazard ratio</th><th align="center" colspan="2" rowspan="1">95% CI</th><th align="center" rowspan="2" colspan="1">
<italic toggle="yes">P</italic>-value</th></tr><tr><th align="left" rowspan="1" colspan="1">Lower</th><th align="center" rowspan="1" colspan="1">Upper</th></tr></thead><tbody><tr><td rowspan="2" colspan="1">NPS group</td><td rowspan="1" colspan="1">Non-MBI NPS</td><td rowspan="1" colspan="1">1126</td><td rowspan="1" colspan="1">1.027</td><td rowspan="1" colspan="1">0.800</td><td rowspan="1" colspan="1">1.319</td><td rowspan="1" colspan="1">0.8348</td></tr><tr><td rowspan="1" colspan="1">MBI</td><td rowspan="1" colspan="1">572</td><td rowspan="1" colspan="1">2.027</td><td rowspan="1" colspan="1">1.599</td><td rowspan="1" colspan="1">2.569</td><td rowspan="1" colspan="1">&lt;0.001<xref rid="tblfn9" ref-type="table-fn">*</xref></td></tr><tr><td rowspan="1" colspan="1">Cognitive status</td><td rowspan="1" colspan="1">MCI</td><td rowspan="1" colspan="1">1418</td><td rowspan="1" colspan="1">14.908</td><td rowspan="1" colspan="1">10.617</td><td rowspan="1" colspan="1">20.933</td><td rowspan="1" colspan="1">&lt;0.001<xref rid="tblfn9" ref-type="table-fn">*</xref></td></tr><tr><td rowspan="1" colspan="1">Age of death</td><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">4515</td><td rowspan="1" colspan="1">0.965</td><td rowspan="1" colspan="1">0.954</td><td rowspan="1" colspan="1">0.976</td><td rowspan="1" colspan="1">&lt;0.001<xref rid="tblfn9" ref-type="table-fn">*</xref></td></tr><tr><td rowspan="1" colspan="1">Sex</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">2244</td><td rowspan="1" colspan="1">1.081</td><td rowspan="1" colspan="1">0.885</td><td rowspan="1" colspan="1">1.321</td><td rowspan="1" colspan="1">0.444</td></tr><tr><td rowspan="1" colspan="1">Education</td><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">4515</td><td rowspan="1" colspan="1">0.982</td><td rowspan="1" colspan="1">0.948</td><td rowspan="1" colspan="1">1.017</td><td rowspan="1" colspan="1">0.3106</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">APOE</italic> &#603;4 allele</td><td rowspan="1" colspan="1">Carrier</td><td rowspan="1" colspan="1">1642</td><td rowspan="1" colspan="1">1.715</td><td rowspan="1" colspan="1">1.400</td><td rowspan="1" colspan="1">2.101</td><td rowspan="1" colspan="1">&lt;0.001<xref rid="tblfn9" ref-type="table-fn">*</xref></td></tr></tbody></table><table-wrap-foot><fn id="tblfn6"><p>Number of events: 413; global <italic toggle="yes">P</italic>-value (log-rank): 5.7915 &#215; 10<sup>&#8722;155</sup>. Akaike information criterion: 4929.89; Concordance Index: 0.85. Hazards ratios calculated for subgroups with discrete categories used the following reference groups as comparators: no NPS (NPS group); MCI (cognitive status); female (sex); non-carrier (APOE &#603;4 allele). AD = Alzheimer&#8217;s disease; CI = confidence interval; MBI = mild behavioural impairment; MCI = mild cognitive impairment; NC = normal cognition; NPS = neuropsychiatric symptoms; TDP-43 = transactive response DNA-binding protein 43.</p></fn><fn id="tblfn9"><p>
<sup>*</sup>
<italic toggle="yes">P</italic> &lt; 0.05.</p></fn></table-wrap-foot></table-wrap></sec><sec id="awaf156-s3.4"><title>Exploratory analyses</title><p>In the first exploratory analysis (<xref rid="awaf156-T4" ref-type="table">Table 4</xref>), MBI tended to associate with post-mortem AD pathology, whether in isolation or with TDP-43/LBD co-pathology. With the exception of the AD+, LBD+, TDP+ outcome, non-MBI NPS was not associated with a higher likelihood of any pathological profile.</p><table-wrap position="float" id="awaf156-T4" orientation="portrait"><label>Table 4</label><caption><p>Exploratory analysis of baseline NPS status (predictor) with post-mortem pathologies (outcome)</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">NPS status</th><th align="center" rowspan="1" colspan="1">AD+ (<italic toggle="yes">n</italic> = 294)</th><th align="center" rowspan="1" colspan="1">LBD+ (<italic toggle="yes">n</italic> = 76)</th><th align="center" rowspan="1" colspan="1">TDP-43+ (<italic toggle="yes">n</italic> = 60)</th><th align="center" rowspan="1" colspan="1">AD+TDP-43+ (<italic toggle="yes">n</italic> = 45)</th><th align="center" rowspan="1" colspan="1">AD+LBD+ (<italic toggle="yes">n</italic> = 128)</th><th align="center" rowspan="1" colspan="1">LBD+TDP-43+ (<italic toggle="yes">n</italic> = 20)</th><th align="center" rowspan="1" colspan="1">AD+LBD+TDP-43+ (<italic toggle="yes">n</italic> = 55)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">No NPS (reference)</td><td rowspan="1" colspan="1">1.00</td><td rowspan="1" colspan="1">1.00</td><td rowspan="1" colspan="1">1.00</td><td rowspan="1" colspan="1">1.00</td><td rowspan="1" colspan="1">1.00</td><td rowspan="1" colspan="1">1.00</td><td rowspan="1" colspan="1">1.00</td></tr><tr><td rowspan="1" colspan="1">Non-MBI NPS</td><td rowspan="1" colspan="1">1.285 (0.195)</td><td rowspan="1" colspan="1">1.185 (0.290)</td><td rowspan="1" colspan="1">1.044 (0.335)</td><td rowspan="1" colspan="1">1.072 (0.414)</td><td rowspan="1" colspan="1">1.066 (0.256)</td><td rowspan="1" colspan="1">0.845 (0.557)</td><td rowspan="1" colspan="1">1.930<xref rid="tblfn12" ref-type="table-fn">*</xref> (0.355)</td></tr><tr><td rowspan="1" colspan="1">MBI+</td><td rowspan="1" colspan="1">1.565<xref rid="tblfn12" ref-type="table-fn">*</xref> (0.238)</td><td rowspan="1" colspan="1">0.535 (0.457)</td><td rowspan="1" colspan="1">0.847 (0.418)</td><td rowspan="1" colspan="1">2.183<xref rid="tblfn12" ref-type="table-fn">*</xref> (0.411)</td><td rowspan="1" colspan="1">1.214 (0.297)</td><td rowspan="1" colspan="1">0.518 (0.806)</td><td rowspan="1" colspan="1">2.021<xref rid="tblfn12" ref-type="table-fn">*</xref> (0.402)</td></tr></tbody></table><table-wrap-foot><fn id="tblfn10"><p>Results are presented as odds ratios (standard error) for each NPS status relative to the no-NPS group, and were determined using a multinomial logistic regression with no pathologies (i.e. AD&#8722;, LBD&#8722;, TDP&#8722;) as the reference group was run adjusting for age, sex, education, cognitive status (MCI versus NC), time to death and <italic toggle="yes">APOE</italic> &#603;4 carrier status. AD+ = Alzheimer&#8217;s disease present; LBD+ = Lewy body disease present; MBI+ = mild behavioural impairment present; MCI = mild cognitive impairment; NC = normal cognition; NPS = neuropsychiatric symptoms; TDP-43+ = transactive response DNA-binding protein 43 present.</p></fn><fn id="tblfn12"><p>
<sup>*</sup>
<italic toggle="yes">P</italic> &lt; 0.1.</p></fn></table-wrap-foot></table-wrap><p>The results of the second exploratory analysis revealed that the presence of limbic LBD significantly moderated the association between MBI and AD dementia within 5 years (<italic toggle="yes">P</italic> = 0.0319). For participants with limbic LBD, being MBI+ was associated with a 4.64-fold greater progression rate to AD dementia (hazard ratio: 4.64, CI: 2.05&#8211;10.50, <italic toggle="yes">P</italic> &lt; 0.001); whereas for the MBI+ group without limbic LBD, there was a 1.87-fold progression rate (hazard ratio: 1.87, CI: 1.46&#8211;2.40, <italic toggle="yes">P</italic> &lt; 0.001). No other regional LBD pathology, nor TPD-43 status, had any associations. Kaplan&#8211;Meier curves for each stratum are visualized in <xref rid="awaf156-F4" ref-type="fig">Fig. 4</xref>.</p><fig position="float" id="awaf156-F4" fig-type="figure" orientation="portrait"><label>Figure 4</label><caption><p>
<bold>Kaplan&#8211;Meier curve for 5-year progression to AD dementia, stratified by NPS status and presence/absence of proteinopathies.</bold> LBD/TDP+ participants had a greater rate of incident AD dementia, although the differences were not significant from negative participants. When LBD pathology was stratified by regional presence, a significant moderation was seen for limbic LBDs. Note that participant strata between LBD and TDP groups are not mutually exclusive. AD = Alzheimer&#8217;s disease; LBD = Lewy body disease; MBI = mild behavioural impairment; NPS = neuropsychiatric symptoms; TDP-43 = transactive response DNA-binding protein 43.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="awaf156f4.jpg"/></fig></sec></sec><sec sec-type="discussion" id="awaf156-s4"><title>Discussion</title><p>In this study, we examined the relationship between three common dementia-linked pathologies and NPS status in the 5 years preceding death. In this sample of older adults, dementia-free at baseline, we found that post-mortem AD pathology, but not LBD or TDP-43 co-pathology, had a greater likelihood of being MBI+ up to 5 years before death versus comparator NPS groups. In comparison to those without NPS, MBI+ participants progressed to AD dementia twice as fast. Limbic LBDs, but no other co-pathology, appeared to moderate the progression rate to AD dementia in those with MBI.</p><p>In line with the NIA-AA ATN framework, various lines of evidence have linked MBI with core AD pathology, whether at NIA-AA disease Stage 2 (encompassing NC and subjective cognitive decline) or Stage 3 (MCI). The studies exploring MBI versus conventionally identified psychiatric symptomatology, no MBI or no NPS have consistently found greater associations with AD for the NPS that are later-life emergent and persistent, i.e. MBI. Operationalizing MBI with these core criteria has face validity, given that 30% of persons who develop AD will develop NPS prior to cognitive impairment<sup><xref rid="awaf156-B5" ref-type="bibr">5</xref></sup> and that persistent NPS (versus transient or reactive symptoms) increase specificity that the identified NPS do indeed represent neurodegenerative disease rather than a reaction to life stressors, change or other psychiatric syndromes.<sup><xref rid="awaf156-B20" ref-type="bibr">20</xref>,<xref rid="awaf156-B48" ref-type="bibr">48</xref>,<xref rid="awaf156-B49" ref-type="bibr">49</xref></sup> These multi-modal MBI studies have found differences in CSF amyloid-&#946;,<sup><xref rid="awaf156-B29" ref-type="bibr">29</xref></sup> plasma amyloid-&#946;,<sup><xref rid="awaf156-B21" ref-type="bibr">21</xref></sup> &#946;-amyloid PET,<sup><xref rid="awaf156-B27" ref-type="bibr">27</xref></sup> plasma p-tau181,<sup><xref rid="awaf156-B25" ref-type="bibr">25</xref></sup> tau PET,<sup><xref rid="awaf156-B30" ref-type="bibr">30</xref>,<xref rid="awaf156-B50" ref-type="bibr">50</xref></sup> neuropathology<sup><xref rid="awaf156-B23" ref-type="bibr">23</xref></sup> and both imaging and biofluid markers of neurodegeneration.<sup><xref rid="awaf156-B31" ref-type="bibr">31</xref>,<xref rid="awaf156-B32" ref-type="bibr">32</xref></sup></p><p>A longstanding question in dementia research is whether NPS have specific pathological substrates or are common across multiple diseases.<sup><xref rid="awaf156-B10" ref-type="bibr">10</xref>,<xref rid="awaf156-B12" ref-type="bibr">12</xref>,<xref rid="awaf156-B13" ref-type="bibr">13</xref></sup> However, here and previously, it has been shown that when NPS are operationalized following MBI criteria, an AD-specific association is observed; a further consideration that requires substantial study concerns the potential contribution of vascular pathology.<sup><xref rid="awaf156-B23" ref-type="bibr">23-25</xref></sup> This, alongside other common neuropathologies, such as tau, would help to elucidate whether certain NPS are disease-specific manifestations, and conversely, whether any given combination of disease processes is associated with a unique NPS profile.</p><p>The results of the case&#8211;control analysis showed that autopsy-confirmed AD was associated with a greater likelihood of having MBI in 5 years before death, but not non-MBI NPS. There were no associations seen for any co-pathology with MBI or non-MBI NPS. These findings suggest that development of MBI might be a specific marker for AD over other pathologies. Furthermore, the co-pathology sub-analysis among AD+ individuals reinforces these findings, demonstrating that having concomitant LBD and TDP-43 pathology does not increase the likelihood of having MBI or even any NPS. Although some studies point to the additive effect of LBD pathology on symptomatology in patients with ADNC, emerging literature suggests that behavioural symptoms might correlate better with AD rather than LBD pathology,<sup><xref rid="awaf156-B36" ref-type="bibr">36</xref>,<xref rid="awaf156-B51" ref-type="bibr">51</xref></sup> with the likely exception of hallucinations.<sup><xref rid="awaf156-B52" ref-type="bibr">52</xref>,<xref rid="awaf156-B53" ref-type="bibr">53</xref></sup> This might be attributable to the diffuse neuroanatomical involvement of AD rather than the comparatively narrow distribution of early-stage LBD pathology. Comorbid TDP-43 pathology has been shown to contribute to greater cognitive decline, but our results and previous work fail to demonstrate a similar link to NPS.<sup><xref rid="awaf156-B12" ref-type="bibr">12</xref>,<xref rid="awaf156-B54" ref-type="bibr">54</xref></sup> Despite the high prevalence of co-pathologies in AD, the lack of any additional association between LBD or TDP-43 and MBI suggests that in individuals at risk of AD dementia, NPS as operationalized by MBI criteria might be a more specific correlate of ADNC. A potential explanation for this finding might relate to symptom fluctuations in dementia with Lewy bodies (DLB), such that NPS are less stable than in AD.<sup><xref rid="awaf156-B35" ref-type="bibr">35</xref></sup> These differences in stability might underscore the specificity of MBI for AD in multiple studies, given that symptom persistence is a cardinal MBI criterion conferring substantially greater specificity. Thus, NPS identified as MBI might represent an important manifestation of AD proteinopathy. However, in other datasets, MBI has been linked to Parkinson&#8217;s disease, also a synucleinopathy.<sup><xref rid="awaf156-B55" ref-type="bibr">55</xref>,<xref rid="awaf156-B56" ref-type="bibr">56</xref></sup> Nonetheless, further study is required to address this novel finding.</p><p>Our finding from the sub-analysis is notable. In AD&#8722; individuals (&#8216;No&#8217; or &#8216;Low&#8217; ADNC scores), neither TDP-43 nor LBD pathology was associated with MBI, in contrast to previous studies, suggesting that the link between co-pathologies and NPS is stronger in those earlier in the AD course.<sup><xref rid="awaf156-B12" ref-type="bibr">12</xref></sup> The similar trend we observed in AD+ individuals has been reported before in studies examining either concomitant LBD or TDP-43 pathology.<sup><xref rid="awaf156-B12" ref-type="bibr">12</xref>,<xref rid="awaf156-B51" ref-type="bibr">51</xref>,<xref rid="awaf156-B54" ref-type="bibr">54</xref></sup> Our results also build on another study showing that greater ADNC was linked to further NPS, but this study did not examine whether comorbid TDP-43 (associated with greater ADNC) had any further associations.<sup><xref rid="awaf156-B57" ref-type="bibr">57</xref></sup></p><p>Earlier research highlights NPS as having an independent association with AD pathology; specifically, neurofibrillary tangle burden.<sup><xref rid="awaf156-B58" ref-type="bibr">58-60</xref></sup> One study showed that NACC dementia participants with psychosis were often misdiagnosed with DLB, reflecting a potential misattribution of NPS to LBD-related dementias when NPS were likely to be a manifestation of AD.<sup><xref rid="awaf156-B52" ref-type="bibr">52</xref></sup> In another longitudinal study among dementia progressors with symptoms captured by MBI domain of psychosis (NPS more often ascribed to the DLB prodrome), 66.7% had clinician-diagnosed AD, in comparison to 10.0% for DLB and 0% for behavioural-variant frontotemporal dementia.<sup><xref rid="awaf156-B24" ref-type="bibr">24</xref></sup> In a similar study of participants showing symptoms from the MBI domain of apathy, 80.9% of dementia progressors had AD, 5.0% DLB and 4.3% behavioural-variant frontotemporal dementia. Finally, in a comparable study of MBI affective symptoms, 85.5% of progressors had AD, 3.7% DLB and 2.5% behavioural-variant frontotemporal dementia.<sup><xref rid="awaf156-B61" ref-type="bibr">61</xref></sup> Here, we demonstrate a comparable trend with neuropathological findings.</p><p>In comparison to the overall prevalence of each proteinopathy, a greater proportion of those with MBI were AD+ and had approximately equivalent levels of LBD and TDP-43 positivity. Among MBI+ individuals, the largest proportion had only AD pathology, in comparison to the other groups, where the largest category was no pathology. Interestingly, there was an ordinal relationship between post-mortem pathology and NPS status, wherein those with no NPS had the largest proportion of no pathology, followed by the non-MBI NPS group, and least of all, the MBI group, supporting the notion of MBI as being an AD-related phenomenon. Overall, these results suggest that those with MBI are often AD+, yet other pathologies are not any more prevalent in those with MBI. A larger proportion of those with MBI had multiple pathologies, potentially reflective of shared aetiological mechanisms between proteinopathies and/or as a consequence of a greater vulnerability to age-associated neuropathology.<sup><xref rid="awaf156-B62" ref-type="bibr">62</xref>,<xref rid="awaf156-B63" ref-type="bibr">63</xref></sup></p><p>The survival analysis highlighted the utility of MBI as a prognostic marker for AD dementia. As we have shown, AD pathology, but not other pathologies, is linked to a greater likelihood of MBI before death. The results here suggest that in advance of dementia, MBI is associated with a more rapid progression to AD dementia. Importantly, neither these models nor the case&#8211;control ones showed any associations with non-MBI NPS. Thus, NPS on their own might not be a robust marker for AD, but when operationalized with MBI criteria, these symptoms become informative of AD risk. Although cognitive status was not a significant modifier of progression to dementia, the greater hazard ratio for incident dementia seen in the NC group is noteworthy. In previous studies, similar results have been found,<sup><xref rid="awaf156-B24" ref-type="bibr">24</xref>,<xref rid="awaf156-B61" ref-type="bibr">61</xref>,<xref rid="awaf156-B64" ref-type="bibr">64</xref></sup> demonstrating the relevance of behavioural symptoms in dementia prognostication, especially when no cognitive changes are observed. In such cases, a primarily behavioural presentation might not trigger a dementia work-up in clinic, instead leading to the misdiagnosis of a psychiatric prodrome to dementia as a psychiatric condition.<sup><xref rid="awaf156-B2" ref-type="bibr">2</xref>,<xref rid="awaf156-B4" ref-type="bibr">4</xref>,<xref rid="awaf156-B15" ref-type="bibr">15</xref></sup> Building on the NIA-AA neuropathological guidelines, which state that in those with cognitive impairment, the presence of intermediate or high ADNC is an &#8216;adequate explanation&#8217; of symptoms,<sup><xref rid="awaf156-B41" ref-type="bibr">41</xref></sup> our results suggest that ADNC should also be considered as a primary contributor to MBI symptoms. Failure to acknowledge NPS as a part of a dementia prodrome has negative consequences both for those receiving inappropriate treatment for a misdiagnosed psychiatric condition and for early AD dementia detection and treatment trials relying solely on cognitive changes to select at-risk groups.<sup><xref rid="awaf156-B65" ref-type="bibr">65</xref></sup> With MBI, a subset of individuals can be selected from those showing NPS and identified for having a greater likelihood of progression to AD dementia.</p><p>With the diagnosis of dementia commonly being made in older age, an individual might have a primary pathology considered to be the main contributor to symptoms and yet potentially also harbour several other disease- and age-associated co-pathologies.<sup><xref rid="awaf156-B66" ref-type="bibr">66</xref></sup> In a clinicopathological study among community-dwelling participants, a majority of those who received a clinician diagnosis of dementia had more than one pathology identified at autopsy.<sup><xref rid="awaf156-B67" ref-type="bibr">67</xref></sup> With the advent of disease-modifying therapeutics directed at specific proteinopathies, failure to consider the presence of comorbid pathology might explain why a treatment does not appear to have clinical benefit.<sup><xref rid="awaf156-B63" ref-type="bibr">63</xref>,<xref rid="awaf156-B68" ref-type="bibr">68</xref></sup> In the current treatment paradigm, clinicians should know the underlying pathological profile of a patient&#8217;s symptomatology and use that information to guide treatment. Thus, it is important to determine whether preclinical/prodromal AD is attributable to AD pathology or caused by the presence of co-pathologies recapitulating behavioural symptoms (e.g. TDP-43 in behavioural-variant frontotemporal dementia).<sup><xref rid="awaf156-B3" ref-type="bibr">3</xref>,<xref rid="awaf156-B12" ref-type="bibr">12</xref></sup> If MBI is indeed specific to AD neuropathology, as our work suggests, then its implementation in clinical trials and practice would be of great aid in enriching target treatment groups with AD.<sup><xref rid="awaf156-B3" ref-type="bibr">3</xref></sup></p><p>Our study has a number of important limitations. For NPS measurement, we relied on the NPI-Q to capture symptomatology, implementing a published algorithm to operationalize MBI. However, the NPI-Q was developed for measurement of NPS in dementia and might lack sensitivity for detection of more subtle preclinical symptomatology or symptoms not overtly associated with dementia. To improve specificity, we included the stipulation of symptom persistence at more than two-thirds of visits, a validated approach to improve specificity.<sup><xref rid="awaf156-B46" ref-type="bibr">46</xref></sup> Additionally, the reliance of NPI-Q on informant reports poses a minor limitation, given its validation for use in dementia, in addition to the role of informant characteristics on accuracy of NPS reporting.<sup><xref rid="awaf156-B69" ref-type="bibr">69</xref></sup> Another shortcoming with our study was how we operationalized pathology; dichotomizing participants fails to account for the progressive nature of neurodegenerative disease. To address this, we conducted further analyses by stratifying participants by differential regional presence of LBDs but found no associations with higher likelihood of having NPS before death. Furthermore, we did not examine the associations of MBI symptom domains with any outcomes; these limitations all represent future directions for further research. Finally, NACC participants are not completely representative of the general clinical population owing to the referral/volunteer-based design of the study and geographical challenges in attending ADRCs. Future studies representative of a diverse clinical population are needed to shed further light on the value of the MBI construct.</p></sec><sec id="awaf156-s5"><title>Conclusion</title><p>Taken together, these results add to the evidence pointing towards NPS as a core feature of preclinical and prodromal AD. In addition to changes in cognition, research and clinical frameworks should account for behavioural change in the staging of AD. In the 2018 NIA-AA framework, for clinical staging MBI is included in Stage 2. Our results, and others, support keeping new-onset persistent behavioural symptoms in the revised NIA-AA clinical framework. Furthermore, the inclusion of MBI in Stage 3 AD should also be considered, given the diagnostic and prognostic importance of later-life emergent NPS in MCI.</p></sec></body><back><ack id="ack1"><title>Acknowledgements</title><p>The NACC database is funded by NIA/NIH Grant U24 AG072122. NACC data are contributed by the NIA-funded ADRCs: P30 AG062429 (PI James Brewer, MD, PhD), P30 AG066468 (PI Oscar Lopez, MD), P30 AG062421 (PI Bradley Hyman, MD, PhD), P30 AG066509 (PI Thomas Grabowski, MD), P30 AG066514 (PI Mary Sano, PhD), P30 AG066530 (PI Helena Chui, MD), P30 AG066507 (PI Marilyn Albert, PhD), P30 AG066444 (PI John Morris, MD), P30 AG066518 (PI Jeffrey Kaye, MD), P30 AG066512 (PI Thomas Wisniewski, MD), P30 AG066462 (PI Scott Small, MD), P30 AG072979 (PI David Wolk, MD), P30 AG072972 (PI Charles DeCarli, MD), P30 AG072976 (PI Andrew Saykin, PsyD), P30 AG072975 (PI David Bennett, MD), P30 AG072978 (PI Neil Kowall, MD), P30 AG072977 (PI Robert Vassar, PhD), P30 AG066519 (PI Frank LaFerla, PhD), P30 AG062677 (PI Ronald Petersen, MD, PhD), P30 AG079280 (PI Eric Reiman, MD), P30 AG062422 (PI Gil Rabinovici, MD), P30 AG066511 (PI Allan Levey, MD, PhD), P30 AG072946 (PI Linda Van Eldik, PhD), P30 AG062715 (PI Sanjay Asthana, MD, FRCP), P30 AG072973 (PI Russell Swerdlow, MD), P30 AG066506 (PI Todd Golde, MD, PhD), P30 AG066508 (PI Stephen Strittmatter, MD, PhD), P30 AG066515 (PI Victor Henderson, MD, MS), P30 AG072947 (PI Suzanne Craft, PhD), P30 AG072931 (PI Henry Paulson, MD, PhD), P30 AG066546 (PI Sudha Seshadri, MD), P20 AG068024 (PI Erik Roberson, MD, PhD), P20 AG068053 (PI Justin Miller, PhD), P20 AG068077 (PI Gary Rosenberg, MD), P20 AG068082 (PI Angela Jefferson, PhD), P30 AG072958 (PI Heather Whitson, MD) and P30 AG072959 (PI James Leverenz, MD).</p></ack><sec sec-type="data-availability" id="awaf156-s6"><title>Data availability</title><p>All NACC data are freely available to researchers.</p></sec><sec id="awaf156-s7"><title>Funding</title><p>S.F.S. received a summer studentship from Alberta Innovates. D.X.G. is supported by the Hotchkiss Brain Institute at University of Calgary, Killam Trust, Alzheimer Society of Canada, Canadian Institutes of Health Research, and Vascular Training Platform. Z.I. is supported by Gordie Howe CARES and UK National Institute for Health and Care Research Exeter Biomedical Research Centre. H.Z. is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356, #2022-01018 and #2019-02397), the European Union&#8217;s Horizon Europe research and innovation programme under grant agreement no. 101053962, and Swedish State Support for Clinical Research (#ALFGBG-71320).</p></sec><sec sec-type="COI-statement" id="awaf156-s8"><title>Competing interests</title><p>H.Z. has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk and Roche and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). E.E.S. reported consulting (unpaid) for Alnylam Pharmaceuticals and Eli Lilly and an advisory board (unpaid) for Eisai. Z.I. has served as an advisor/consultant to CADTH, Eisai, Lilly, Lundbeck/Otsuka, Novo Nordisk and Roche. All other authors report no competing interests.</p></sec><ref-list id="ref1"><title>References</title><ref id="awaf156-B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>DeTure</surname> &#160;<given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Dickson</surname> &#160;<given-names>DW</given-names></string-name></person-group>. <article-title>The neuropathological diagnosis of Alzheimer&#8217;s disease</article-title>. <source>Mol Neurodegener</source>. <year>2019</year>;<volume>14</volume>(<issue>1</issue>):<fpage>32</fpage>.<pub-id pub-id-type="pmid">31375134</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-019-0333-5</pub-id><pub-id pub-id-type="pmcid">PMC6679484</pub-id></mixed-citation></ref><ref id="awaf156-B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ismail</surname> &#160;<given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname> &#160;<given-names>EE</given-names></string-name>, <string-name name-style="western"><surname>Geda</surname> &#160;<given-names>Y</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment</article-title>. <source>Alzheimers Dement</source>. <year>2016</year>;<volume>12</volume>(<issue>2</issue>):<fpage>195</fpage>&#8211;<lpage>202</lpage>.<pub-id pub-id-type="pmid">26096665</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2015.05.017</pub-id><pub-id pub-id-type="pmcid">PMC4684483</pub-id></mixed-citation></ref><ref id="awaf156-B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Creese</surname> &#160;<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Ismail</surname> &#160;<given-names>Z</given-names></string-name></person-group>. <article-title>Mild behavioral impairment: Measurement and clinical correlates of a novel marker of preclinical Alzheimer&#8217;s disease</article-title>. <source>Alzheimers Res Ther</source>. <year>2022</year>;<volume>14</volume>(<issue>1</issue>):<fpage>2</fpage>.<pub-id pub-id-type="pmid">34986891</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-021-00949-7</pub-id><pub-id pub-id-type="pmcid">PMC8734161</pub-id></mixed-citation></ref><ref id="awaf156-B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Woolley</surname> &#160;<given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Khan</surname> &#160;<given-names>BK</given-names></string-name>, <string-name name-style="western"><surname>Murthy</surname> &#160;<given-names>NK</given-names></string-name>, <string-name name-style="western"><surname>Miller</surname> &#160;<given-names>BL</given-names></string-name>, <string-name name-style="western"><surname>Rankin</surname> &#160;<given-names>KP</given-names></string-name></person-group>. <article-title>The diagnostic challenge of psychiatric symptoms in neurodegenerative disease: Rates of and risk factors for prior psychiatric diagnosis in patients with early neurodegenerative disease</article-title>. <source>J Clin Psychiatry</source>. <year>2011</year>;<volume>72</volume>(<issue>2</issue>):<fpage>126</fpage>&#8211;<lpage>33</lpage>.<pub-id pub-id-type="pmid">21382304</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4088/JCP.10m06382oli</pub-id><pub-id pub-id-type="pmcid">PMC3076589</pub-id></mixed-citation></ref><ref id="awaf156-B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wise</surname> &#160;<given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Rosenberg</surname> &#160;<given-names>PB</given-names></string-name>, <string-name name-style="western"><surname>Lyketsos</surname> &#160;<given-names>CG</given-names></string-name>, <string-name name-style="western"><surname>Leoutsakos</surname> &#160;<given-names>J-M</given-names></string-name></person-group>. <article-title>Time course of neuropsychiatric symptoms and cognitive diagnosis in National Alzheimer&#8217;s Coordinating Centers volunteers</article-title>. <source>Alzheimers Dement (Amst)</source>. <year>2019</year>;<volume>11</volume>:<fpage>333</fpage>&#8211;<lpage>339</lpage>.<pub-id pub-id-type="pmid">31024987</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.dadm.2019.02.006</pub-id><pub-id pub-id-type="pmcid">PMC6476801</pub-id></mixed-citation></ref><ref id="awaf156-B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Soto</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rosenberg</surname> &#160;<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Ballard</surname> &#160;<given-names>C</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>CTAD task force paper: Neuropsychiatric symptoms in AD: Clinical trials targeting mild behavioral impairment: A report from the international CTAD task force</article-title>. <source>J Prev Alzheimers Dis</source>. <year>2024</year>;<volume>11</volume>(<issue>1</issue>):<fpage>56</fpage>&#8211;<lpage>64</lpage>.<pub-id pub-id-type="pmid">38230717</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14283/jpad.2023.125</pub-id></mixed-citation></ref><ref id="awaf156-B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ghahremani</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname> &#160;<given-names>EE</given-names></string-name>, <string-name name-style="western"><surname>Ismail</surname> &#160;<given-names>Z</given-names></string-name></person-group>. <article-title>Improving dementia prognostication in cognitively normal older adults: Conventional versus novel approaches to modelling risk associated with neuropsychiatric symptoms</article-title>. <source>Br J Psychiatry</source>. <year>2025</year>;<volume>226</volume>(<issue>3</issue>):<fpage>129</fpage>&#8211;<lpage>136</lpage>.<pub-id pub-id-type="pmid">39679452</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1192/bjp.2024.136</pub-id></mixed-citation></ref><ref id="awaf156-B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Guan</surname> &#160;<given-names>DX</given-names></string-name>, <string-name name-style="western"><surname>Rehman</surname> &#160;<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Nathan</surname> &#160;<given-names>S</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Neuropsychiatric symptoms: Risk factor or disease marker? A study of structural imaging biomarkers of Alzheimer&#8217;s disease and incident cognitive decline</article-title>. <source>Hum Brain Mapp</source>. <year>2024</year>;<volume>45</volume>(<issue>13</issue>):<fpage>e70016</fpage>.<pub-id pub-id-type="pmid">39254167</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hbm.70016</pub-id><pub-id pub-id-type="pmcid">PMC11386326</pub-id></mixed-citation></ref><ref id="awaf156-B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gonzalez-Bautista</surname> &#160;<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Momm&#233;ja</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>de Maul&#233;on</surname> &#160;<given-names>A</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Mild behavioral impairment domains are longitudinally associated with pTAU and metabolic biomarkers in dementia-free older adults</article-title>. <source>Alzheimers Dement</source>. <year>2024</year>;<volume>20</volume>(<issue>7</issue>):<fpage>4692</fpage>&#8211;<lpage>4701</lpage>.<pub-id pub-id-type="pmid">38877658</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13902</pub-id><pub-id pub-id-type="pmcid">PMC11247706</pub-id></mixed-citation></ref><ref id="awaf156-B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Assal</surname> &#160;<given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Cummings</surname> &#160;<given-names>JL</given-names></string-name></person-group>. <article-title>Neuropsychiatric symptoms in the dementias</article-title>. <source>Curr Opin Neurol</source>. <year>2002</year>;<volume>15</volume>(<issue>4</issue>):<fpage>445</fpage>&#8211;<lpage>450</lpage>.<pub-id pub-id-type="pmid">12151841</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00019052-200208000-00007</pub-id></mixed-citation></ref><ref id="awaf156-B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Petersen</surname> &#160;<given-names>RC</given-names></string-name>, <string-name name-style="western"><surname>Wiste</surname> &#160;<given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>Weigand</surname> &#160;<given-names>SD</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>NIA-AA Alzheimer&#8217;s disease framework: Clinical characterization of stages</article-title>. <source>Ann Neurol</source>. <year>2021</year>;<volume>89</volume>(<issue>6</issue>):<fpage>1145</fpage>&#8211;<lpage>1156</lpage>.<pub-id pub-id-type="pmid">33772866</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.26071</pub-id><pub-id pub-id-type="pmcid">PMC8131266</pub-id></mixed-citation></ref><ref id="awaf156-B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bayram</surname> &#160;<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Shan</surname> &#160;<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Cummings</surname> &#160;<given-names>JL</given-names></string-name></person-group>. <article-title>Associations between comorbid TDP-43, Lewy body pathology, and neuropsychiatric symptoms in Alzheimer&#8217;s disease</article-title>. <source>J Alzheimers Dis</source>. <year>2019</year>;<volume>69</volume>:<fpage>953</fpage>&#8211;<lpage>961</lpage>.<pub-id pub-id-type="pmid">31127776</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-181285</pub-id><pub-id pub-id-type="pmcid">PMC6597983</pub-id></mixed-citation></ref><ref id="awaf156-B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lyketsos</surname> &#160;<given-names>CG</given-names></string-name>, <string-name name-style="western"><surname>Carrillo</surname> &#160;<given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Ryan</surname> &#160;<given-names>JM</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Neuropsychiatric symptoms in Alzheimer&#8217;s disease</article-title>. <source>Alzheimers Dement</source>. <year>2011</year>;<volume>7</volume>(<issue>5</issue>):<fpage>532</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">21889116</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2011.05.2410</pub-id><pub-id pub-id-type="pmcid">PMC3299979</pub-id></mixed-citation></ref><ref id="awaf156-B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cieslak</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname> &#160;<given-names>EE</given-names></string-name>, <string-name name-style="western"><surname>Lysack</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ismail</surname> &#160;<given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Mortby</surname> &#160;<given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Ismail</surname> &#160;<given-names>Z</given-names></string-name></person-group>. <article-title>Case series of mild behavioral impairment: Toward an understanding of the early stages of neurodegenerative diseases affecting behavior and cognition</article-title>. <source>Int Psychogeriatr</source>. <year>2018</year>;<volume>30</volume>(<issue>2</issue>):<fpage>273</fpage>&#8211;<lpage>280</lpage>.<pub-id pub-id-type="pmid">29017626</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S1041610217001855</pub-id></mixed-citation></ref><ref id="awaf156-B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Matsuoka</surname> &#160;<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Ismail</surname> &#160;<given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Narumoto</surname> &#160;<given-names>J</given-names></string-name></person-group>. <article-title>Prevalence of mild behavioral impairment and risk of dementia in a psychiatric outpatient clinic</article-title>. <source>J Alzheimers Dis</source>. <year>2019</year>;<volume>70</volume>(<issue>2</issue>):<fpage>505</fpage>&#8211;<lpage>513</lpage>.<pub-id pub-id-type="pmid">31177229</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-190278</pub-id><pub-id pub-id-type="pmcid">PMC6700628</pub-id></mixed-citation></ref><ref id="awaf156-B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hu</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Patten</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Charlton</surname> &#160;<given-names>A</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Validating the mild behavioral impairment checklist in a cognitive clinic: Comparisons with the neuropsychiatric inventory questionnaire</article-title>. <source>J Geriatr Psychiatry Neurol</source>. <year>2023</year>;<volume>36</volume>(<issue>2</issue>):<fpage>107</fpage>&#8211;<lpage>120</lpage>.<pub-id pub-id-type="pmid">35430902</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/08919887221093353</pub-id><pub-id pub-id-type="pmcid">PMC9941652</pub-id></mixed-citation></ref><ref id="awaf156-B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ismail</surname> &#160;<given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>McGirr</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gill</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Forkert</surname> &#160;<given-names>ND</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname> &#160;<given-names>EE</given-names></string-name></person-group>. <article-title>Mild behavioral impairment and subjective cognitive decline predict cognitive and functional decline</article-title>. <source>J Alzheimers Dis</source>. <year>2021</year>;<volume>80</volume>(<issue>1</issue>):<fpage>459</fpage>&#8211;<lpage>469</lpage>.<pub-id pub-id-type="pmid">33554909</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-201184</pub-id><pub-id pub-id-type="pmcid">PMC8075401</pub-id></mixed-citation></ref><ref id="awaf156-B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kan</surname> &#160;<given-names>CN</given-names></string-name>, <string-name name-style="western"><surname>Cano</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname> &#160;<given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Ismail</surname> &#160;<given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname> &#160;<given-names>CL-H</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname> &#160;<given-names>X</given-names></string-name></person-group>. <article-title>Prevalence, clinical correlates, cognitive trajectories, and dementia risk associated with mild behavioral impairment in Asians</article-title>. <source>J Clin Psychiatry</source>. <year>2022</year>;<volume>83</volume>(<issue>3</issue>):<fpage>40123</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.4088/JCP.21m14105</pub-id><pub-id pub-id-type="pmid">36036661</pub-id></mixed-citation></ref><ref id="awaf156-B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kassam</surname> &#160;<given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Nosheny</surname> &#160;<given-names>RL</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Cognitive profile of people with mild behavioral impairment in Brain Health Registry participants</article-title>. <source>Int Psychogeriatr</source>. <year>2023</year>;<volume>35</volume>(<issue>11</issue>):<fpage>643</fpage>&#8211;<lpage>652</lpage>.<pub-id pub-id-type="pmid">35130991</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S1041610221002878</pub-id><pub-id pub-id-type="pmcid">PMC10063171</pub-id></mixed-citation></ref><ref id="awaf156-B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>McGirr</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Nathan</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ghahremani</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gill</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname> &#160;<given-names>EE</given-names></string-name>, <string-name name-style="western"><surname>Ismail</surname> &#160;<given-names>Z</given-names></string-name></person-group>. <article-title>Progression to dementia or reversion to normal cognition in mild cognitive impairment as a function of late onset neuropsychiatric symptoms</article-title>. <source>Neurology</source>. <year>2022</year>;<volume>98</volume>(<issue>21</issue>):<fpage>e2132</fpage>&#8211;<lpage>2139</lpage>.<pub-id pub-id-type="pmid">35351783</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000200256</pub-id><pub-id pub-id-type="pmcid">PMC9169943</pub-id></mixed-citation></ref><ref id="awaf156-B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Miao</surname> &#160;<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname> &#160;<given-names>H-Y</given-names></string-name>, <string-name name-style="western"><surname>Gill</surname> &#160;<given-names>S</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Plasma &#946;-amyloid in mild behavioural impairment&#8212;Neuropsychiatric symptoms on the Alzheimer&#8217;s continuum</article-title>. <source>J Geriatr Psychiatry Neurol</source>. <year>2022</year>;<volume>35</volume>(<issue>3</issue>):<fpage>434</fpage>&#8211;<lpage>441</lpage>.<pub-id pub-id-type="pmid">34036829</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/08919887211016068</pub-id></mixed-citation></ref><ref id="awaf156-B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wolfova</surname> &#160;<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Creese</surname> &#160;<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Aarsland</surname> &#160;<given-names>D</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Gender/sex differences in the association of mild behavioral impairment with cognitive aging</article-title>. <source>J Alzheimers Dis</source>. <year>2022</year>;<volume>88</volume>(<issue>1</issue>):<fpage>345</fpage>&#8211;<lpage>355</lpage>.<pub-id pub-id-type="pmid">35599483</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-220040</pub-id></mixed-citation></ref><ref id="awaf156-B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ruthirakuhan</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ismail</surname> &#160;<given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Herrmann</surname> &#160;<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Gallagher</surname> &#160;<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Lanct&#244;t</surname> &#160;<given-names>KL</given-names></string-name></person-group>. <article-title>Mild behavioral impairment is associated with progression to Alzheimer&#8217;s disease: A clinicopathological study</article-title>. <source>Alzheimers Dement</source>. <year>2022</year>;<volume>18</volume>(1<issue>1</issue>):<fpage>2199</fpage>&#8211;<lpage>2208</lpage>.<pub-id pub-id-type="pmid">35103400</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12519</pub-id><pub-id pub-id-type="pmcid">PMC9339594</pub-id></mixed-citation></ref><ref id="awaf156-B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ismail</surname> &#160;<given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Ghahremani</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Amlish Munir</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Fischer</surname> &#160;<given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname> &#160;<given-names>EE</given-names></string-name>, <string-name name-style="western"><surname>Creese</surname> &#160;<given-names>B</given-names></string-name></person-group>. <article-title>A longitudinal study of late-life psychosis and incident dementia and the potential effects of race and cognition</article-title>. <source>Nat Mental Health</source>. <year>2023</year>;<volume>1</volume>(<issue>4</issue>):<fpage>273</fpage>&#8211;<lpage>283</lpage>.</mixed-citation></ref><ref id="awaf156-B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ghahremani</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname> &#160;<given-names>H-Y</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Plasma phosphorylated tau at threonine 181 and neuropsychiatric symptoms in preclinical and prodromal Alzheimer disease</article-title>. <source>Neurology</source>. <year>2023</year>;<volume>100</volume>(<issue>7</issue>):<fpage>e683</fpage>.<pub-id pub-id-type="pmid">36323521</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000201517</pub-id><pub-id pub-id-type="pmcid">PMC9969916</pub-id></mixed-citation></ref><ref id="awaf156-B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Johansson</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Stomrud</surname> &#160;<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Insel</surname> &#160;<given-names>PS</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer&#8217;s disease</article-title>. <source>Transl Psychiatry</source>. <year>2021</year>;<volume>11</volume>(<issue>1</issue>):<fpage>76</fpage>.<pub-id pub-id-type="pmid">33500386</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41398-021-01206-z</pub-id><pub-id pub-id-type="pmcid">PMC7838407</pub-id></mixed-citation></ref><ref id="awaf156-B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lussier</surname> &#160;<given-names>FZ</given-names></string-name>, <string-name name-style="western"><surname>Pascoal</surname> &#160;<given-names>TA</given-names></string-name>, <string-name name-style="western"><surname>Chamoun</surname> &#160;<given-names>M</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Mild behavioral impairment is associated with &#946;-amyloid but not tau or neurodegeneration in cognitively intact elderly individuals</article-title>. <source>Alzheimers Dement</source>. <year>2020</year>;<volume>16</volume>(<issue>1</issue>):<fpage>192</fpage>&#8211;<lpage>199</lpage>.<pub-id pub-id-type="pmid">31914223</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12007</pub-id><pub-id pub-id-type="pmcid">PMC7041633</pub-id></mixed-citation></ref><ref id="awaf156-B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jack</surname> &#160;<given-names>CR</given-names> &#160;<suffix>Jr</suffix></string-name>, <string-name name-style="western"><surname>Bennett</surname> &#160;<given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Blennow</surname> &#160;<given-names>K</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>NIA-AA research framework: Toward a biological definition of Alzheimer&#8217;s disease</article-title>. <source>Alzheimers Dement</source>. <year>2018</year>;<volume>14</volume>(<issue>4</issue>):<fpage>535</fpage>&#8211;<lpage>562</lpage>.<pub-id pub-id-type="pmid">29653606</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2018.02.018</pub-id><pub-id pub-id-type="pmcid">PMC5958625</pub-id></mixed-citation></ref><ref id="awaf156-B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ismail</surname> &#160;<given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Leon</surname> &#160;<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Creese</surname> &#160;<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Ballard</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Robert</surname> &#160;<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname> &#160;<given-names>EE</given-names></string-name></person-group>. <article-title>Optimizing detection of Alzheimer&#8217;s disease in mild cognitive impairment: a 4-year biomarker study of mild behavioral impairment in ADNI and MEMENTO</article-title>. <source>Mol Neurodegener</source>. <year>2023</year>;<volume>18</volume>(<issue>1</issue>):<fpage>50</fpage>.<pub-id pub-id-type="pmid">37516848</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-023-00631-6</pub-id><pub-id pub-id-type="pmcid">PMC10386685</pub-id></mixed-citation></ref><ref id="awaf156-B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Johansson</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Stomrud</surname> &#160;<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Insel</surname> &#160;<given-names>PS</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer&#8217;s disease</article-title>. <source>Transl Psychiatry</source>. <year>2021</year>;<volume>11</volume>(<issue>1</issue>):<fpage>76</fpage>.<pub-id pub-id-type="pmid">33500386</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41398-021-01206-z</pub-id><pub-id pub-id-type="pmcid">PMC7838407</pub-id></mixed-citation></ref><ref id="awaf156-B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Matuskova</surname> &#160;<given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Ismail</surname> &#160;<given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Nikolai</surname> &#160;<given-names>T</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Mild behavioral impairment is associated with atrophy of entorhinal cortex and hippocampus in a memory clinic cohort</article-title>. <source>Front Aging Neurosci</source>. <year>2021</year>;<volume>13</volume>:<fpage>643271</fpage>.<pub-id pub-id-type="pmid">34108874</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2021.643271</pub-id><pub-id pub-id-type="pmcid">PMC8180573</pub-id></mixed-citation></ref><ref id="awaf156-B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Naude</surname> &#160;<given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Gill</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname> &#160;<given-names>S</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Plasma neurofilament light: A marker of neurodegeneration in mild behavioral impairment</article-title>. <source>J Alzheimers Dis</source>. <year>2020</year>;<volume>76</volume>:<fpage>1017</fpage>&#8211;<lpage>1027</lpage>.<pub-id pub-id-type="pmid">32597801</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-200011</pub-id><pub-id pub-id-type="pmcid">PMC7504997</pub-id></mixed-citation></ref><ref id="awaf156-B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Andrews</surname> &#160;<given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Ismail</surname> &#160;<given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Anstey</surname> &#160;<given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Mortby</surname> &#160;<given-names>M</given-names></string-name></person-group>. <article-title>Association of Alzheimer&#8217;s genetic loci with mild behavioral impairment</article-title>. <source>Am J Med Genet B Neuropsychiatr Genet</source>. <year>2018</year>;<volume>177</volume>(<issue>8</issue>):<fpage>727</fpage>&#8211;<lpage>735</lpage>.<pub-id pub-id-type="pmid">30378268</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ajmg.b.32684</pub-id></mixed-citation></ref><ref id="awaf156-B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Creese</surname> &#160;<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Arathimos</surname> &#160;<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Brooker</surname> &#160;<given-names>H</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Genetic risk for Alzheimer&#8217;s disease, cognition, and mild behavioral impairment in healthy older adults</article-title>. <source>Alzheimers Dement (Amst)</source>. <year>2021</year>;<volume>13</volume>(<issue>1</issue>):<fpage>e12164</fpage>.<pub-id pub-id-type="pmid">33748395</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dad2.12164</pub-id><pub-id pub-id-type="pmcid">PMC7968121</pub-id></mixed-citation></ref><ref id="awaf156-B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vik-Mo</surname> &#160;<given-names>AO</given-names></string-name>, <string-name name-style="western"><surname>Giil</surname> &#160;<given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Borda</surname> &#160;<given-names>MG</given-names></string-name>, <string-name name-style="western"><surname>Ballard</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Aarsland</surname> &#160;<given-names>D</given-names></string-name></person-group>. <article-title>The individual course of neuropsychiatric symptoms in people with Alzheimer&#8217;s and Lewy body dementia: 12-year longitudinal cohort study</article-title>. <source>Br J Psychiatry</source>. <year>2020</year>;<volume>216</volume>(<issue>1</issue>):<fpage>43</fpage>&#8211;<lpage>48</lpage>.<pub-id pub-id-type="pmid">31506117</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1192/bjp.2019.195</pub-id></mixed-citation></ref><ref id="awaf156-B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gibson</surname> &#160;<given-names>LL</given-names></string-name>, <string-name name-style="western"><surname>Grinberg</surname> &#160;<given-names>LT</given-names></string-name>, <string-name name-style="western"><surname>Ffytche</surname> &#160;<given-names>D</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Neuropathological correlates of neuropsychiatric symptoms in dementia</article-title>. <source>Alzheimers Dement</source>. <year>2023</year>;<volume>19</volume>(<issue>4</issue>):<fpage>1372</fpage>&#8211;<lpage>1382</lpage>.<pub-id pub-id-type="pmid">36150075</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12765</pub-id><pub-id pub-id-type="pmcid">PMC10033459</pub-id></mixed-citation></ref><ref id="awaf156-B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gauthreaux</surname> &#160;<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Mock</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Teylan</surname> &#160;<given-names>MA</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Symptomatic profile and cognitive performance in autopsy-confirmed limbic-predominant age-related TDP-43 encephalopathy with comorbid Alzheimer disease</article-title>. <source>J Neuropathol Exp Neurol</source>. <year>2022</year>;<volume>81</volume>(<issue>12</issue>):<fpage>975</fpage>&#8211;<lpage>987</lpage>.<pub-id pub-id-type="pmid">36264254</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnen/nlac093</pub-id><pub-id pub-id-type="pmcid">PMC9677237</pub-id></mixed-citation></ref><ref id="awaf156-B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Weintraub</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Salmon</surname> &#160;<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Mercaldo</surname> &#160;<given-names>N</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>The Alzheimer&#8217;s disease centers&#8217; Uniform Data Set (UDS): the neuropsychologic test battery</article-title>. <source>Alzheimer Dis Assoc Disord</source>. <year>2009</year>;<volume>23</volume>(<issue>2</issue>):<fpage>91</fpage>&#8211;<lpage>101</lpage>.<pub-id pub-id-type="pmid">19474567</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/WAD.0b013e318191c7dd</pub-id><pub-id pub-id-type="pmcid">PMC2743984</pub-id></mixed-citation></ref><ref id="awaf156-B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Morris</surname> &#160;<given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Weintraub</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Chui</surname> &#160;<given-names>HC</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>The Uniform Data Set (UDS): Clinical and cognitive variables and descriptive data from Alzheimer disease centers</article-title>. <source>Alzheimer Dis Assoc Disord</source>. <year>2006</year>;<volume>20</volume>(<issue>4</issue>):<fpage>210</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">17132964</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.wad.0000213865.09806.92</pub-id></mixed-citation></ref><ref id="awaf156-B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Beekly</surname> &#160;<given-names>DL</given-names></string-name>, <string-name name-style="western"><surname>Ramos</surname> &#160;<given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname> &#160;<given-names>WW</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>The National Alzheimer&#8217;s Coordinating Center (NACC) database: the Uniform Data Set</article-title>. <source>Alzheimer Dis Assoc Disord</source>. <year>2007</year>;<volume>21</volume>(<issue>3</issue>):<fpage>249</fpage>&#8211;<lpage>58</lpage>.<pub-id pub-id-type="pmid">17804958</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/WAD.0b013e318142774e</pub-id></mixed-citation></ref><ref id="awaf156-B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Montine</surname> &#160;<given-names>TJ</given-names></string-name>, <string-name name-style="western"><surname>Phelps</surname> &#160;<given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Beach</surname> &#160;<given-names>TG</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>National Institute on Aging&#8211;Alzheimer&#8217;s Association guidelines for the neuropathologic assessment of Alzheimer&#8217;s disease: A practical approach</article-title>. <source>Acta Neuropathol</source>. <year>2012</year>;<volume>123</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="pmid">22101365</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-011-0910-3</pub-id><pub-id pub-id-type="pmcid">PMC3268003</pub-id></mixed-citation></ref><ref id="awaf156-B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Besser</surname> &#160;<given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Kukull</surname> &#160;<given-names>WA</given-names></string-name>, <string-name name-style="western"><surname>Teylan</surname> &#160;<given-names>MA</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>The revised national Alzheimer&#8217;s Coordinating Center&#8217;s Neuropathology form&#8212;Available data and new analyses</article-title>. <source>J Neuropathol Exp Neurol</source>. <year>2018</year>;<volume>77</volume>(<issue>8</issue>):<fpage>717</fpage>&#8211;<lpage>726</lpage>.<pub-id pub-id-type="pmid">29945202</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnen/nly049</pub-id><pub-id pub-id-type="pmcid">PMC6044344</pub-id></mixed-citation></ref><ref id="awaf156-B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cummings</surname> &#160;<given-names>J</given-names></string-name></person-group>. <article-title>The neuropsychiatric inventory: Development and applications</article-title>. <source>J Geriatr Psychiatry Neurol</source>. <year>2020</year>;<volume>33</volume>(<issue>2</issue>):<fpage>73</fpage>&#8211;<lpage>84</lpage>.<pub-id pub-id-type="pmid">32013737</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0891988719882102</pub-id><pub-id pub-id-type="pmcid">PMC8505128</pub-id></mixed-citation></ref><ref id="awaf156-B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sheikh</surname> &#160;<given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Ismail</surname> &#160;<given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Mortby</surname> &#160;<given-names>ME</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Prevalence of mild behavioral impairment in mild cognitive impairment and subjective cognitive decline, and its association with caregiver burden</article-title>. <source>Int Psychogeriatr</source>. <year>2018</year>;<volume>30</volume>(<issue>2</issue>):<fpage>233</fpage>&#8211;<lpage>244</lpage>.<pub-id pub-id-type="pmid">28879833</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S104161021700151X</pub-id></mixed-citation></ref><ref id="awaf156-B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mortby</surname> &#160;<given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Ismail</surname> &#160;<given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Anstey</surname> &#160;<given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Mortby</surname> &#160;<given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Ismail</surname> &#160;<given-names>Z</given-names></string-name></person-group>. <article-title>Prevalence estimates of mild behavioral impairment in a population-based sample of pre-dementia states and cognitively healthy older adults</article-title>. <source>Int Psychogeriatr</source>. <year>2018</year>;<volume>30</volume>(<issue>2</issue>):<fpage>221</fpage>&#8211;<lpage>232</lpage>.<pub-id pub-id-type="pmid">28931446</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S1041610217001909</pub-id></mixed-citation></ref><ref id="awaf156-B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Guan</surname> &#160;<given-names>DX</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname> &#160;<given-names>EE</given-names></string-name>, <string-name name-style="western"><surname>Pike</surname> &#160;<given-names>GB</given-names></string-name>, <string-name name-style="western"><surname>Ismail</surname> &#160;<given-names>Z</given-names></string-name></person-group>. <article-title>Persistence of neuropsychiatric symptoms and dementia prognostication: A comparison of three operational case definitions of mild behavioral impairment</article-title>. <source>Alzheimers Dement (Amst)</source>. <year>2023</year>;<volume>15</volume>(<issue>4</issue>):<fpage>e12483</fpage>.<pub-id pub-id-type="pmid">37786862</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dad2.12483</pub-id><pub-id pub-id-type="pmcid">PMC10541800</pub-id></mixed-citation></ref><ref id="awaf156-B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>McKeith</surname> &#160;<given-names>IG</given-names></string-name>, <string-name name-style="western"><surname>Dickson</surname> &#160;<given-names>DW</given-names></string-name>, <string-name name-style="western"><surname>Lowe</surname> &#160;<given-names>J</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium</article-title>. <source>Neurology</source>. <year>2005</year>;<volume>65</volume>(<issue>12</issue>):<fpage>1863</fpage>&#8211;<lpage>1872</lpage>.<pub-id pub-id-type="pmid">16237129</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/01.wnl.0000187889.17253.b1</pub-id></mixed-citation></ref><ref id="awaf156-B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gill</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mouches</surname> &#160;<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname> &#160;<given-names>S</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Using machine learning to predict dementia from neuropsychiatric symptom and neuroimaging data</article-title>. <source>J Alzheimers Dis</source>. <year>2020</year>;<volume>75</volume>(<issue>1</issue>):<fpage>277</fpage>&#8211;<lpage>288</lpage>.<pub-id pub-id-type="pmid">32250302</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-191169</pub-id><pub-id pub-id-type="pmcid">PMC7306896</pub-id></mixed-citation></ref><ref id="awaf156-B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Matsuoka</surname> &#160;<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Ueno</surname> &#160;<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ismail</surname> &#160;<given-names>Z</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Neural correlates of mild behavioral impairment: A functional brain connectivity study using resting-state functional magnetic resonance imaging</article-title>. <source>J Alzheimers Dis</source>. <year>2021</year>;<volume>83</volume>(<issue>3</issue>):<fpage>1221</fpage>&#8211;<lpage>1231</lpage>.<pub-id pub-id-type="pmid">34420972</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-210628</pub-id><pub-id pub-id-type="pmcid">PMC8543254</pub-id></mixed-citation></ref><ref id="awaf156-B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Naude</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Leon</surname> &#160;<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname> &#160;<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Ismail</surname> &#160;<given-names>Z</given-names></string-name></person-group>. <article-title>Tau-PET in early cortical Alzheimer brain regions in relation to mild behavioral impairment in older adults with either normal cognition or mild cognitive impairment</article-title>. <source>Neurobiol Aging</source>. <year>2024</year>;<volume>138</volume>:<fpage>19</fpage>&#8211;<lpage>27</lpage>.<pub-id pub-id-type="pmid">38490074</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2024.02.006</pub-id></mixed-citation></ref><ref id="awaf156-B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Stern</surname> &#160;<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Jacobs</surname> &#160;<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Goldman</surname> &#160;<given-names>J</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>An investigation of clinical correlates of Lewy bodies in autopsy-proven Alzheimer disease</article-title>. <source>Arch Neurol</source>. <year>2001</year>;<volume>58</volume>(<issue>3</issue>):<fpage>460</fpage>&#8211;<lpage>465</lpage>.<pub-id pub-id-type="pmid">11255450</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archneur.58.3.460</pub-id></mixed-citation></ref><ref id="awaf156-B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fischer</surname> &#160;<given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Qian</surname> &#160;<given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Schweizer</surname> &#160;<given-names>TA</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Determining the impact of psychosis on rates of false-positive and false-negative diagnosis in Alzheimer&#8217;s disease</article-title>. <source>Alzheimers Dement (N Y)</source>. <year>2017</year>;<volume>3</volume>(<issue>3</issue>):<fpage>385</fpage>&#8211;<lpage>392</lpage>.<pub-id pub-id-type="pmid">29067344</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trci.2017.06.001</pub-id><pub-id pub-id-type="pmcid">PMC5651446</pub-id></mixed-citation></ref><ref id="awaf156-B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fischer</surname> &#160;<given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Qian</surname> &#160;<given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Schweizer</surname> &#160;<given-names>TA</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Lewy bodies, vascular risk factors, and subcortical arteriosclerotic leukoencephalopathy, but not Alzheimer pathology, are associated with development of psychosis in Alzheimer&#8217;s disease</article-title>. <source>J Alzheimers Dis</source>. <year>2016</year>;<volume>50</volume>(<issue>1</issue>):<fpage>283</fpage>&#8211;<lpage>295</lpage>.<pub-id pub-id-type="pmid">26682680</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-150606</pub-id><pub-id pub-id-type="pmcid">PMC4844451</pub-id></mixed-citation></ref><ref id="awaf156-B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname> &#160;<given-names>KY</given-names></string-name>, <string-name name-style="western"><surname>Reeves</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>McAleese</surname> &#160;<given-names>KE</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Neuropsychiatric symptoms in limbic-predominant age-related TDP-43 encephalopathy and Alzheimer&#8217;s disease</article-title>. <source>Brain</source>. <year>2020</year>;<volume>143</volume>(<issue>12</issue>):<fpage>3842</fpage>&#8211;<lpage>3849</lpage>.<pub-id pub-id-type="pmid">33188391</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awaa315</pub-id><pub-id pub-id-type="pmcid">PMC7805786</pub-id></mixed-citation></ref><ref id="awaf156-B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yoon</surname> &#160;<given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Ismail</surname> &#160;<given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Hanganu</surname> &#160;<given-names>A</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Mild behavioral impairment is linked to worse cognition and brain atrophy in Parkinson&#8217;s disease</article-title>. <source>Neurology</source>. <year>2019</year>;<volume>93</volume>(<issue>8</issue>):<fpage>e766</fpage>&#8211;<lpage>e777</lpage>.<pub-id pub-id-type="pmid">31320470</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000007968</pub-id><pub-id pub-id-type="pmcid">PMC6711660</pub-id></mixed-citation></ref><ref id="awaf156-B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lang</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Yoon</surname> &#160;<given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Kibreab</surname> &#160;<given-names>M</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Mild behavioral impairment in Parkinson&#8217;s disease is associated with altered corticostriatal connectivity</article-title>. <source>Neuroimage Clin</source>. <year>2020</year>;<volume>26</volume>:<fpage>102252</fpage>.<pub-id pub-id-type="pmid">32279019</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nicl.2020.102252</pub-id><pub-id pub-id-type="pmcid">PMC7152681</pub-id></mixed-citation></ref><ref id="awaf156-B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sennik</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Schweizer</surname> &#160;<given-names>TA</given-names></string-name>, <string-name name-style="western"><surname>Fischer</surname> &#160;<given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Munoz</surname> &#160;<given-names>DG</given-names></string-name></person-group>. <article-title>Risk factors and pathological substrates associated with agitation/aggression in Alzheimer&#8217;s disease: A preliminary study using NACC data</article-title>. <source>J Alzheimers Dis</source>. <year>2017</year>;<volume>55</volume>:<fpage>1519</fpage>&#8211;<lpage>1528</lpage>.<pub-id pub-id-type="pmid">27911311</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-160780</pub-id><pub-id pub-id-type="pmcid">PMC5607738</pub-id></mixed-citation></ref><ref id="awaf156-B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Farber</surname> &#160;<given-names>NB</given-names></string-name>, <string-name name-style="western"><surname>Rubin</surname> &#160;<given-names>EH</given-names></string-name>, <string-name name-style="western"><surname>Newcomer</surname> &#160;<given-names>JW</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Increased neocortical neurofibrillary tangle density in subjects with Alzheimer disease and psychosis</article-title>. <source>Arch Gen Psychiatry</source>. <year>2000</year>;<volume>57</volume>(<issue>12</issue>):<fpage>1165</fpage>&#8211;<lpage>1173</lpage>.<pub-id pub-id-type="pmid">11115331</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archpsyc.57.12.1165</pub-id></mixed-citation></ref><ref id="awaf156-B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Marshall</surname> &#160;<given-names>GA</given-names></string-name>, <string-name name-style="western"><surname>Fairbanks</surname> &#160;<given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Tekin</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Vinters</surname> &#160;<given-names>HV</given-names></string-name>, <string-name name-style="western"><surname>Cummings</surname> &#160;<given-names>JL</given-names></string-name></person-group>. <article-title>Neuropathologic correlates of apathy in Alzheimer&#8217;s disease</article-title>. <source>Dement Geriatr Cogn Disord</source>. <year>2006</year>;<volume>21</volume>(<issue>3</issue>):<fpage>144</fpage>&#8211;<lpage>147</lpage>.<pub-id pub-id-type="pmid">16391476</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000090674</pub-id></mixed-citation></ref><ref id="awaf156-B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lanct&#244;t</surname> &#160;<given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Amatniek</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ancoli-Israel</surname> &#160;<given-names>S</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Neuropsychiatric signs and symptoms of Alzheimer&#8217;s disease: New treatment paradigms</article-title>. <source>Alzheimers Dement (N Y)</source>. <year>2017</year>;<volume>3</volume>(<issue>3</issue>):<fpage>440</fpage>&#8211;<lpage>449</lpage>.<pub-id pub-id-type="pmid">29067350</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trci.2017.07.001</pub-id><pub-id pub-id-type="pmcid">PMC5651439</pub-id></mixed-citation></ref><ref id="awaf156-B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ebrahim</surname> &#160;<given-names>IM</given-names></string-name>, <string-name name-style="western"><surname>Ghahremani</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Camicioli</surname> &#160;<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname> &#160;<given-names>EE</given-names></string-name>, <string-name name-style="western"><surname>Ismail</surname> &#160;<given-names>Z</given-names></string-name></person-group>. <article-title>Effects of race, baseline cognition, and APOE on the association of affective dysregulation with incident dementia: A longitudinal study of dementia-free older adults</article-title>. <source>J Affect Disord</source>. <year>2023</year>;<volume>332</volume>:<fpage>9</fpage>&#8211;<lpage>18</lpage>.<pub-id pub-id-type="pmid">36997127</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jad.2023.03.074</pub-id></mixed-citation></ref><ref id="awaf156-B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>McAleese</surname> &#160;<given-names>KE</given-names></string-name>, <string-name name-style="western"><surname>Walker</surname> &#160;<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Erskine</surname> &#160;<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Thomas</surname> &#160;<given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>McKeith</surname> &#160;<given-names>IG</given-names></string-name>, <string-name name-style="western"><surname>Attems</surname> &#160;<given-names>J</given-names></string-name></person-group>. <article-title>TDP-43 pathology in Alzheimer&#8217;s disease, dementia with Lewy bodies and ageing</article-title>. <source>Brain Pathol</source>. <year>2017</year>;<volume>27</volume>(<issue>4</issue>):<fpage>472</fpage>&#8211;<lpage>479</lpage>.<pub-id pub-id-type="pmid">27495267</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bpa.12424</pub-id><pub-id pub-id-type="pmcid">PMC8029292</pub-id></mixed-citation></ref><ref id="awaf156-B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Robinson</surname> &#160;<given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname> &#160;<given-names>EB</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname> &#160;<given-names>SX</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated</article-title>. <source>Brain</source>. <year>2018</year>;<volume>141</volume>(<issue>7</issue>):<fpage>2181</fpage>&#8211;<lpage>2193</lpage>.<pub-id pub-id-type="pmid">29878075</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awy146</pub-id><pub-id pub-id-type="pmcid">PMC6022546</pub-id></mixed-citation></ref><ref id="awaf156-B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vellone</surname> &#160;<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ghahremani</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Goodarzi</surname> &#160;<given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Forkert</surname> &#160;<given-names>ND</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname> &#160;<given-names>EE</given-names></string-name>, <string-name name-style="western"><surname>Ismail</surname> &#160;<given-names>Z</given-names></string-name></person-group>. <article-title>Apathy and APOE in mild behavioral impairment, and risk for incident dementia</article-title>. <source>Alzheimers Dement (N Y)</source>. <year>2022</year>;<volume>8</volume>(<issue>1</issue>):<fpage>e12370</fpage>.<pub-id pub-id-type="pmid">36544988</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/trc2.12370</pub-id><pub-id pub-id-type="pmcid">PMC9763783</pub-id></mixed-citation></ref><ref id="awaf156-B65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>McGirr</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Nathan</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ghahremani</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gill</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname> &#160;<given-names>EE</given-names></string-name>, <string-name name-style="western"><surname>Ismail</surname> &#160;<given-names>Z</given-names></string-name></person-group>. <article-title>Progression to dementia or reversion to normal cognition in mild cognitive impairment as a function of late-onset neuropsychiatric symptoms</article-title>. <source>Neurology</source>. <year>2022</year>;<volume>98</volume>(<issue>21</issue>):<fpage>e2132</fpage>&#8211;<lpage>e2139</lpage>.<pub-id pub-id-type="pmid">35351783</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000200256</pub-id><pub-id pub-id-type="pmcid">PMC9169943</pub-id></mixed-citation></ref><ref id="awaf156-B66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rabinovici</surname> &#160;<given-names>GD</given-names></string-name>, <string-name name-style="western"><surname>Carrillo</surname> &#160;<given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Forman</surname> &#160;<given-names>M</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Multiple comorbid neuropathologies in the setting of Alzheimer&#8217;s disease neuropathology and implications for drug development</article-title>. <source>Alzheimers Dement (N Y)</source>. <year>2017</year>;<volume>3</volume>(<issue>1</issue>):<fpage>83</fpage>&#8211;<lpage>91</lpage>.<pub-id pub-id-type="pmid">29067320</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trci.2016.09.002</pub-id><pub-id pub-id-type="pmcid">PMC5651346</pub-id></mixed-citation></ref><ref id="awaf156-B67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schneider</surname> &#160;<given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Arvanitakis</surname> &#160;<given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Bang</surname> &#160;<given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Bennett</surname> &#160;<given-names>DA</given-names></string-name></person-group>. <article-title>Mixed brain pathologies account for most dementia cases in community-dwelling older persons</article-title>. <source>Neurology</source>. <year>2007</year>;<volume>69</volume>(<issue>24</issue>):<fpage>2197</fpage>&#8211;<lpage>204</lpage>.<pub-id pub-id-type="pmid">17568013</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/01.wnl.0000271090.28148.24</pub-id></mixed-citation></ref><ref id="awaf156-B68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hendrix</surname> &#160;<given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Bateman</surname> &#160;<given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Brashear</surname> &#160;<given-names>HR</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Challenges, solutions, and recommendations for Alzheimer&#8217;s disease combination therapy</article-title>. <source>Alzheimers Dement</source>. <year>2016</year>;<volume>12</volume>(<issue>5</issue>):<fpage>623</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="pmid">27017906</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2016.02.007</pub-id></mixed-citation></ref><ref id="awaf156-B69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Guan</surname> &#160;<given-names>DX</given-names></string-name>, <string-name name-style="western"><surname>Mudalige</surname> &#160;<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Munro</surname> &#160;<given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Nosheny</surname> &#160;<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname> &#160;<given-names>EE</given-names></string-name>, <string-name name-style="western"><surname>Ismail</surname> &#160;<given-names>Z</given-names></string-name></person-group>. <article-title>The effect of study partner characteristics on the reporting of neuropsychiatric symptoms across the neurocognitive spectrum</article-title>. <source>Int Psychogeriatr</source>. <year>2024</year>;<volume>36</volume>(<issue>8</issue>):<fpage>675</fpage>&#8211;<lpage>688</lpage>.<pub-id pub-id-type="pmid">39291399</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S1041610224000590</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Dement Geriatr Cogn Disord</journal-id><journal-id journal-id-type="iso-abbrev">Dement Geriatr Cogn Disord</journal-id><journal-id journal-id-type="pmc-domain-id">2985</journal-id><journal-id journal-id-type="pmc-domain">kargersd</journal-id><journal-id journal-id-type="publisher-id">DEM</journal-id><journal-title-group><journal-title>Dementia and Geriatric Cognitive Disorders</journal-title></journal-title-group><issn pub-type="ppub">1420-8008</issn><issn pub-type="epub">1421-9824</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Karger Author's Choice</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12500249</article-id><article-id pub-id-type="pmcid-ver">PMC12500249.1</article-id><article-id pub-id-type="pmcaid">12500249</article-id><article-id pub-id-type="pmcaiid">12500249</article-id><article-id pub-id-type="pmid">39999809</article-id><article-id pub-id-type="doi">10.1159/000544801</article-id><article-id pub-id-type="publisher-id">544801</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Deciphering Perspectives: A European Survey on Clinical Decision Support Tools for Dementia and Alzheimer&#8217;s Disease</article-title><alt-title alt-title-type="short">A European Survey on Clinical Decision Support Tools</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="relnr" authenticated="false">2776279</contrib-id><name name-style="western"><surname>Umoh</surname><given-names initials="I">Ini</given-names></name><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="relnr" authenticated="false">2776280</contrib-id><name name-style="western"><surname>Xia</surname><given-names initials="X">Xin</given-names></name><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="relnr" authenticated="false">2776281</contrib-id><name name-style="western"><surname>Winblad</surname><given-names initials="B">Bengt</given-names></name><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>c</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="relnr" authenticated="false">2776282</contrib-id><name name-style="western"><surname>Aye</surname><given-names initials="S">Sandar</given-names></name><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="relnr" authenticated="false">2776283</contrib-id><name name-style="western"><surname>Aho</surname><given-names initials="E">Emil</given-names></name><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="relnr" authenticated="false">2776284</contrib-id><name name-style="western"><surname>Rhodius-Meester</surname><given-names initials="HFM">Hanneke F.M.</given-names></name><xref rid="aff4" ref-type="aff">
<sup>d</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>e</sup>
</xref><xref rid="aff6" ref-type="aff">
<sup>f</sup>
</xref><xref rid="aff7" ref-type="aff">
<sup>g</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="relnr" authenticated="false">2776285</contrib-id><name name-style="western"><surname>J&#246;nsson</surname><given-names initials="L">Linus</given-names></name><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><aff id="aff1">
<label>a</label>Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, <city>Solna</city>, <country>Sweden</country></aff><aff id="aff2">
<label>b</label>Division of Neurogeriatrics, Department of NVS, Karolinska Institutet, <city>Solna</city>, <country>Sweden</country></aff><aff id="aff3">
<label>c</label>Theme Inflammation and Aging, Karolinska University Hospital, <city>Huddinge</city>, <country>Sweden</country></aff><aff id="aff4">
<label>d</label>Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, De Boelelaan, <city>Amsterdam</city>, <country>The Netherlands</country></aff><aff id="aff5">
<label>e</label>Amsterdam Neuroscience, Neurodegeneration, <city>Amsterdam</city>, <country>The Netherlands</country></aff><aff id="aff6">
<label>f</label>Department of Internal Medicine, Geriatric Medicine Section, Vrije Universiteit Amsterdam, Amsterdam UMC, <city>Amsterdam</city>, <country>The Netherlands</country></aff><aff id="aff7">
<label>g</label>Department of Geriatric Medicine, The Memory Clinic, Oslo University Hospital, <city>Oslo</city>, <country>Norway</country></aff></contrib-group><author-notes><corresp id="cor1">Correspondence to: Ini Umoh, <email>umohini.iu@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>25</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>10</month><year>2025</year></pub-date><volume>54</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">498431</issue-id><fpage>284</fpage><lpage>293</lpage><history><date date-type="received"><day>16</day><month>7</month><year>2024</year></date><date date-type="accepted"><day>4</day><month>2</month><year>2025</year></date><date date-type="subscription-year"><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>25</day><month>02</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>07</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-07 16:25:59.750"><day>07</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Author(s). Published by S. Karger AG, Basel</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This article is licensed under the Creative Commons Attribution 4.0 International License (CC BY) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.karger.com/Services/OpenAccessLicense">http://www.karger.com/Services/OpenAccessLicense</ext-link>). Usage, derivative works and distribution are permitted provided that proper credit is given to the author and the original publisher.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="dem-2025-0054-0005-544801.pdf"/><abstract><title>Abstract</title><sec><title>Introduction</title><p>Technological advancements like digital monitoring tools, disease-modifying therapies, and artificial intelligence have been shown to improve the clinical management of neurocognitive diseases like Alzheimer&#8217;s disease (AD). To enhance implementation in daily practice, users&#8217; input is essential in the technology development process. This study aimed to determine clinician&#8217;s perspective of clinical decision support systems (CDSS) in the management of dementia and AD.</p></sec><sec><title>Method</title><p>A survey was conducted targeting clinicians practicing in the field of dementia across Europe. A sixty-five-item digital questionnaire was administered, and opinions were inquired across the domains of diagnosis, disease-modifying therapy, and prognosis, including factors that affect tool implementation and utilization.</p></sec><sec><title>Results</title><p>Eighty-four clinicians (including specialist physicians, psychologists, and nurses) responded to this survey, and more than 50% had no knowledge or experience with CDSS. Most of the respondents reported the ability to predict the likelihood of AD as the most important diagnostic function. It was surprising to find the middling responses for the ability to predict amyloid positivity. The majority indicated assessment of treatment eligibility for disease-modifying therapy as vital, and the ability to predict cognitive and functional decline as the most important prognostic functions. Data accuracy and ease of use were noted as most necessary to facilitate CDSS adoption and implementation.</p></sec><sec><title>Conclusion</title><p>Findings from this study contribute to the future development of CDSS in this field, especially regarding the approval and imminent use of disease-modifying therapies, a comprehensive tool that is precise and user friendly would improve clinical decisions and efficiency.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>Clinical decision support system</kwd><kwd>Alzheimer&#8217;s disease</kwd><kwd>Dementia</kwd><kwd>Clinician perspective</kwd></kwd-group><funding-group><funding-statement>This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101112145. The JU receives support from the European Union&#8217;s Horizon Europe research and innovation programme, Combinostics Oy and Bioarctic AB. &#8220;The funder had no role in the design, data collection, data analysis, and reporting of this study.&#8221; H.R. is recipient of the Memorabel Dementia Fellowship 2021 (ZonMw project no. 10510022110004) and Alzheimer Nederland InterACT grant (project no. WE.08-2022-06).</funding-statement></funding-group><counts><fig-count count="5"/><table-count count="1"/><ref-count count="34"/><page-count count="10"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>accessibilitySummary</meta-name><meta-value>WCAG 2.1 Level AA</meta-value></custom-meta><custom-meta><meta-name>accessibility-pdf-ua-compliance</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="introduction" id="s1"><title>Introduction</title><p>The burden of neurocognitive diseases like Alzheimer&#8217;s disease (AD), pose significant challenges to public health and healthcare systems. And an increase in life expectancy has contributed to the shrinking workforce [<xref rid="B1" ref-type="bibr">1</xref>&#8211;<xref rid="B5" ref-type="bibr">5</xref>]. One of the existing challenges in managing this problem is obtaining timely and accurate diagnosis. This is in addition to the unavailability of personalized treatment. Hence, there is a need for targeted interventions and healthcare strategies to address the growing burden of these conditions.</p><p>Scientific advancements in the areas of diagnosis and treatment have been made for AD management, which spread across various domains of clinical management. For diagnosis, PredictND integrates biomarkers to support differential diagnosis of neurocognitive diseases [<xref rid="B6" ref-type="bibr">6</xref>], while ADappt tool facilitates risk calculation of AD [<xref rid="B7" ref-type="bibr">7</xref>]. Also, a combination of machine learning with neuroimaging has been demonstrated to enhance the diagnostic accuracy of neurodegenerative disorders [<xref rid="B8" ref-type="bibr">8</xref>&#8211;<xref rid="B11" ref-type="bibr">11</xref>]. Following diagnosis, another essential yet challenging domain in clinical management is communication amongst patients and care partners, which can influence patient outcomes. A personalized diagnostic report has been designed to solve this challenge and promote clear communication [<xref rid="B12" ref-type="bibr">12</xref>]. For the treatment of AD, majority of available therapies have been found to temporarily alleviate symptoms; and slow down AD progression by targeting brain amyloid deposits [<xref rid="B13" ref-type="bibr">13</xref>]. This initiated the development of several disease modifying therapies (DMTs) [<xref rid="B13" ref-type="bibr">13</xref>&#8211;<xref rid="B15" ref-type="bibr">15</xref>], and Donanemab has recently been approved by the US Food and Drug Administration for the treatment of early AD [<xref rid="B16" ref-type="bibr">16</xref>]. There is a push for earlier diagnosis because of new DMT that require initiation in early disease stages.</p><p>Despite the advances mentioned, challenges like effective diagnosis persist, and AI can bridge that gap. A proposed solution is use of clinical decision support tools [<xref rid="B17" ref-type="bibr">17</xref>&#8211;<xref rid="B19" ref-type="bibr">19</xref>] to assist disease management. The potential of decision support tools in streamlining clinical processes and improving overall efficiency has been highlighted [<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B21" ref-type="bibr">21</xref>]. Aside from the core functionalities, tool implementation in clinical practice should also be considered.</p><p>Different factors have been reported to influence the acceptance and adoption of digital clinical decision support systems (CDSSs) in healthcare facilities. The human, organization, and technology (HOT) fit framework [<xref rid="B22" ref-type="bibr">22</xref>] aids in the assessment of factors that affect adoption and implementation of healthcare tools like CDSS. Perceived usefulness and trust in the knowledge base of the tools [<xref rid="B23" ref-type="bibr">23</xref>] have been purported as contributory reasons for utilization. Clinicians&#8217; views of the system align with their acceptance [<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>]. Consequently, they influence the redesign of the system to fit their workflows. Few studies [<xref rid="B26" ref-type="bibr">26</xref>&#8211;<xref rid="B28" ref-type="bibr">28</xref>] have assessed healthcare providers&#8217; opinions on the decision support tools within this field. However, functions regarding DMT were not explored.</p><p>In a new Innovative Health Initiative project, PROMINENT, we are developing a platform for precision medicine specifically targeting the diagnosis and treatment of neurocognitive diseases and their comorbidities [<xref rid="B29" ref-type="bibr">29</xref>]. To create a relevant and practical platform, inputs from the intended users will inform the development. Hence, this study aimed to determine clinician&#8217;s perspective of CDSS in the management of dementia and AD across Europe. The survey was designed to answer two research questions: (1) What are the required functionalities in a CDSS for the management of dementia and AD from a clinician&#8217;s perspective? With a specific focus on DMT, (2) What factors impact the uptake and use of a CDSS?</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2-1"><title>Study Design</title><p>This was a cross-sectional survey conducted from June 2023 to September 2023. The study was carried out within various healthcare facilities across Europe.</p></sec><sec id="s2-2"><title>Participant Selection</title><p>Participants were invited from the European Alzheimer&#8217;s Disease Consortium, which comprises 65 member centers. We targeted clinicians with field expertise, including neurologists, psychiatrists, and geriatricians. The selection rationale for these participants was to ensure that survey captured practical insights into real-world clinical needs and reflect the diversity in practices across Europe. Invitations were sent via institutional email lists containing the link to the survey. All participants were informed about the study&#8217;s purpose and confidentiality, and they provided digital informed consents.</p></sec><sec id="s2-3"><title>Questionnaire Development</title><p>The questionnaire used in our survey was adapted from a previous study [<xref rid="B26" ref-type="bibr">26</xref>], which evaluated the views of medical professionals on the use of computer tools in memory clinics. We expanded on the previous study questionnaire by including questions about experience with current CDSS and adding a section for DMT and treatment functionalities required from the new CDSS. The questionnaire was created using the Research Electronic Data Capture (REDCap) web application and designed in English. There were four main sections. The first section captured basic demographic information of the study participants including age, country of practice, profession, and type of healthcare practice. The second section explored knowledge and experience with CDSS, using a sliding scale format for this exploration. The third section explored the potential usefulness of CDSS functions across the domains of diagnosis, treatment decisions &#8211; DMT, prognosis and communication with patients or care partners. Some examples of questions included were the potential usefulness of CDSS in predicting the likelihood of the patient having AD, assessing eligibility for DMT. A Likert-scale format was employed for this section. Participants rated their responses on a scale from 1 &#8220;not useful&#8221; to 5 &#8220;very useful.&#8221; The final section had a set of 12 questions to gather opinions on HOT factors that impact CDSS implementation in a healthcare setting. These questions helped us understand the barriers and facilitators related to CDSS adoption. The domains captured were system quality, information quality, system use, and environment. These were also asked using a five-level Likert scale ranging from &#8220;not important&#8221; to &#8220;very important.&#8221; The entire questionnaire form can be found in supplementary material A (for all online suppl. material, see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10.1159/000544801" ext-link-type="doi">https://doi.org/10.1159/000544801</ext-link>).</p></sec><sec id="s2-4"><title>Data Collection</title><p>We administered the questionnaire digitally using the REDCap platform, which facilitated secure data collection and management. Participants accessed the survey via personalized links, and reminders were sent periodically to enhance response rates. Responses were collected anonymously, and data were stored in a secure environment at Karolinska Institutet.</p></sec><sec id="s2-5"><title>Data Analysis</title><p>There were no mandatory questions in the questionnaire; this was done to encourage willing and honest responses. Therefore, there were item missing responses. This was addressed during the data cleaning process, by excluding incomplete responses that had no influence on study outcomes. We also excluded respondents with no experience in the field of dementia. Following the exclusion, 84 questionnaires were eligible for analysis. Participant characteristics and survey outcomes were analyzed on Microsoft Excel using descriptive summaries.</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><sec id="s3-1"><title>Demography of Respondents</title><p>At least one participant was anticipated from each of the 65 member centers, and we received 117 responses. A filtration criterion was applied during data cleaning. These filter criteria excluded respondents that had no clinical experience in the field of dementia or AD, missing or no response about CDSS and drop-outs.</p><p>
<xref rid="F1" ref-type="fig">Figure 1</xref> depicts the geographical distribution of survey respondents. A total of 15% did not state their country of practice. Respondents were distributed across 18 countries in Europe. Amongst those that indicated their country of practice, the top three most represented countries were the Netherlands, Norway, and Spain with a share of 20%, 18%, and 8%, respectively. The United Kingdom, Belgium, France, Finland, Sweden, Portugal had similar representation ranging from 2 to 4%.</p><fig position="float" id="F1" orientation="portrait"><label>Fig. 1.</label><caption><p>Regional distribution of survey respondents across European countries. The map illustrates the percentage distribution of survey responses in different European countries. The percentages represent the proportion of respondents (<italic toggle="yes">n</italic> = 84) from each country. Countries that participated in the survey are shaded in varying intensities, with darker shades corresponding to higher proportions of responses. Countries with no representation are left unshaded.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="dem-2025-0054-0005-544801_F01.jpg"/></fig><p>A total of 77% (<italic toggle="yes">N</italic> = 63) survey respondents were specialist physicians including neurologists, geriatricians, and psychiatrists. Over half of the specialist physicians had more than 10 years of clinical experience. A total of 13% respondents were psychologists, and nearly half of them had 3&#8211;5 years of relevant clinical experience. The remaining 10% comprised nurses, research physicians, and trainee physicians. More than half of the respondent category had no previous knowledge or experience with CDSS.</p><p>
<xref rid="T1" ref-type="table">Table 1</xref> contains descriptive information on the baseline characteristics. Participants were mostly in the 30&#8211;59-year age group. With regard to their primary workplace, 63% worked at tertiary referral centers or university clinics, 31% at specialist memory clinics, and the remaining distributed across community care centers and nursing homes.</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1.</label><caption><p>Baseline demographic and professional characteristics of respondents</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Characteristics</th><th rowspan="1" colspan="1">Specialist physician, <italic toggle="yes">n</italic> = 63</th><th rowspan="1" colspan="1">Psychologist, <italic toggle="yes">n</italic> = 11</th><th rowspan="1" colspan="1">Others, <italic toggle="yes">n</italic> = 10</th></tr></thead><tbody><tr><td colspan="4" rowspan="1">Sex</td></tr><tr><td rowspan="1" colspan="1">&#8195;Proportion of female, %</td><td rowspan="1" colspan="1">46</td><td rowspan="1" colspan="1">72.7</td><td rowspan="1" colspan="1">62.5</td></tr><tr><td rowspan="1" colspan="1">&#8195;Proportion of male, %</td><td rowspan="1" colspan="1">54</td><td rowspan="1" colspan="1">27.3</td><td rowspan="1" colspan="1">37.5</td></tr><tr><td colspan="4" rowspan="1">Age</td></tr><tr><td rowspan="1" colspan="1">&#8195;Proportion of &lt;30 years, %</td><td rowspan="1" colspan="1">&#8211;</td><td rowspan="1" colspan="1">36.4</td><td rowspan="1" colspan="1">25</td></tr><tr><td rowspan="1" colspan="1">&#8195;Proportion of 30&#8211;39 years, %</td><td rowspan="1" colspan="1">22.2</td><td rowspan="1" colspan="1">27.3</td><td rowspan="1" colspan="1">62.5</td></tr><tr><td rowspan="1" colspan="1">&#8195;Proportion of 40&#8211;49 years, %</td><td rowspan="1" colspan="1">36.5</td><td rowspan="1" colspan="1">9.1</td><td rowspan="1" colspan="1">&#8211;</td></tr><tr><td rowspan="1" colspan="1">&#8195;Proportion of 50&#8211;59 years, %</td><td rowspan="1" colspan="1">22.2</td><td rowspan="1" colspan="1">18.2</td><td rowspan="1" colspan="1">12.5</td></tr><tr><td rowspan="1" colspan="1">&#8195;Proportion of &gt;60 years, %</td><td rowspan="1" colspan="1">19.1</td><td rowspan="1" colspan="1">9.1</td><td rowspan="1" colspan="1">&#8211;</td></tr><tr><td colspan="4" rowspan="1">Length of clinical experience with dementia</td></tr><tr><td rowspan="1" colspan="1">&#8195;0&#8211;2 years, %</td><td rowspan="1" colspan="1">3.2</td><td rowspan="1" colspan="1">9.1</td><td rowspan="1" colspan="1">&#8211;</td></tr><tr><td rowspan="1" colspan="1">&#8195;3&#8211;5 years, %</td><td rowspan="1" colspan="1">19.4</td><td rowspan="1" colspan="1">45.5</td><td rowspan="1" colspan="1">62.5</td></tr><tr><td rowspan="1" colspan="1">&#8195;6&#8211;10 years, %</td><td rowspan="1" colspan="1">17.7</td><td rowspan="1" colspan="1">9.1</td><td rowspan="1" colspan="1">25</td></tr><tr><td rowspan="1" colspan="1">&#8195;&gt;10 years, %</td><td rowspan="1" colspan="1">59.7</td><td rowspan="1" colspan="1">36.4</td><td rowspan="1" colspan="1">12.5</td></tr></tbody></table></table-wrap></sec><sec id="s3-2"><title>Required Functionalities for a Future CDSS</title><sec id="s3-2-1"><title>Diagnosis</title><p>Of the 84 respondents who answered this survey, 63 respondents answered the section on future diagnostic functionalities for the system. Majority (90%) indicated that predicting the likelihood of the patient having AD was the most vital function. This was followed by predicting differential diagnosis and identifying patients for screening, reported by about 70%. The least required function as claimed by a little over half of them was predicting amyloid positivity. <xref rid="F2" ref-type="fig">Figure 2</xref> shows more details on the responses.</p><fig position="float" id="F2" orientation="portrait"><label>Fig. 2.</label><caption><p>Perceived usefulness of CDSS diagnostic functionalities. The bar chart demonstrates the respondents (<italic toggle="yes">n</italic> = 63) perceptions of the usefulness of CDSS across six diagnostic functions in dementia and AD management. Respondents rated each functionality using a Likert scale. Response distributions are displayed as percentages and differentiated using a color-coded scheme.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="dem-2025-0054-0005-544801_F02.jpg"/></fig></sec><sec id="s3-2-2"><title>Treatment Decisions in the Context of DMT</title><p>Over three-quarter (79%) of the respondents indicated ability to assess treatment eligibility as most useful. While identifying contraindications to DMT (72%) and predicting response to treatment (70%) had a great degree of usefulness. The least required functions in this category were predicting effects on quality of life and predicting effects on institutionalization. <xref rid="F3" ref-type="fig">Figure 3</xref> displays the responses of this section.</p><fig position="float" id="F3" orientation="portrait"><label>Fig. 3.</label><caption><p>Perceived usefulness of CDSS for DMT decisions. The bar chart illustrates the perceptions of respondents (<italic toggle="yes">n</italic> = 58) regarding the usefulness of CDSS across eight distinct DMT functions. Each bar is segmented to represent the proportion of responses for each category on the Likert scale, with color coding employed to differentiate the categories.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="dem-2025-0054-0005-544801_F03.jpg"/></fig></sec><sec id="s3-2-3"><title>Prognosis</title><p>This section received 64 responses from the total number of participants. Two functions &#8211; predicting future cognitive decline and future functional decline were deemed the most useful by 69% of respondents, followed by predicting the ability to drive a car by 61% of respondents. Predicting mortality was considered the least useful by 47% of respondents in this domain. <xref rid="F4" ref-type="fig">Figure 4</xref> illustrates the responses of this section.</p><fig position="float" id="F4" orientation="portrait"><label>Fig. 4.</label><caption><p>Perceived usefulness of CDSS prognostic functionalities. Respondents (<italic toggle="yes">n</italic> = 64) rated six different prognostic factors in dementia and AD management, on a 5-point Likert scale ranging from &#8220;Very useful&#8221; to &#8220;Not useful.&#8221; The stacked bar chart illustrates the percentage distribution of responses. Color coding used to indicate Likert-scale categories.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="dem-2025-0054-0005-544801_F04.jpg"/></fig></sec></sec><sec id="s3-3"><title>Influencing Factors for Implementation and Utilization</title><p>We received 58 responses in this section. Using HOT fit framework, information quality dimension had the highest frequency of importance, with 90% of the respondent&#8217;s indicating accuracy/validity of output as the most important facilitator/barrier. A total of 79% stated that documentation and evidence of the CDSS were important. User friendliness was a significant facilitator, highlighted by 88% of respondents, closely followed by integration with electronic health records system with 87% of respondents. The least important factors were system customizability (64%) and colleagues experience with system (51%). <xref rid="F5" ref-type="fig">Figure 5</xref> contains all the descriptions of this section.</p><fig position="float" id="F5" orientation="portrait"><label>Fig. 5.</label><caption><p>Perceived importance of CDSS implementation factors in healthcare settings. Respondents (<italic toggle="yes">n</italic> = 58) rated twelve different implementation factors on a 5-point Likert scale ranging from &#8220;Very important&#8221; to &#8220;Not important.&#8221; Results are presented as horizontal stacked bar charts showing the percentage distribution of responses for each factor. The bars are also color coded according to scale categories.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="dem-2025-0054-0005-544801_F05.jpg"/></fig></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>This survey explored the perspectives of clinicians on required functionalities for a CDSS. Most significant findings for diagnostic functions were the ability to predict the likelihood of AD and differential diagnosis. Predicting amyloid positivity as the least required function was a surprising finding, considering the significance of amyloid positivity in management of AD. Plausible explanations for this finding may be the reliance on established diagnostic tools to assess amyloid positivity, or some participants like psychologists, who are not directly involved with diagnosis may not be familiar with the relevance of this marker. This could have resulted in underestimating its utility as an essential functionality. For treatment domain, assessing eligibility for treatment and identifying contraindications to DMT had the most responses, while predicting future cognitive and functional decline were the most useful prognostic functions.</p><p>Our study findings add to the expectation of a CDSS in the context of DMT. The ability to identify eligible patients for this therapy drives clinical efficiency, since not all patients with AD may be suitable for this intervention [<xref rid="B15" ref-type="bibr">15</xref>]. In addition, predicting how patients are likely to respond to this therapy can help tailor treatment plans that could lead to improved patient outcomes. Adverse events like infusion-related reactions, cerebral microhemorrhages [<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B15" ref-type="bibr">15</xref>] have been associated with DMT, justifying the predictive function of experiencing these events. Amongst the least prioritized functionalities were effects on cost of care and institutionalization. One possible explanation for this finding is that the clinicians are not directly responsible for them. Or perhaps the cost of care is difficult to forecast due to other contributory factors.</p><p>According to the survey, user friendliness, accuracy of output, and integration with existing health records significantly influence implementation. Limited familiarity with CDSS may raise concerns about disruptions to established workflows and confidence in its utility. Addressing this issue may require organizational changes like tailored training programs to improve user proficiency. Also, clinical leadership could assist with the transition, by communicating the tool benefits in relation to patient outcomes and other organizational goals. This may increase confidence and tool acceptance. Additionally, integrating CDSS within clinical settings could depend on its interoperability with existing health records and compatibility with other health information technology. Technical barriers such as lack of standardized data formats, difference in protocols and policies, and varying level of system security are some of the potential issues that could impact integration. Customizing the CDSS to align with the data and governance standards of the settings could be a potential solution.</p><p>Various studies have demonstrated the effectiveness of decision support systems and machine learning techniques in the management of dementia [<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>]. A previous European survey on functionalities and implementation of a computer tool in clinics reported the preference of these tools for diagnostic, prognostic, and communication [<xref rid="B26" ref-type="bibr">26</xref>]. Within the same study, technical and user ability were cited as essential implementation factors, although setting was limited to memory clinics. Our study adds on to this survey by expanding on CDSS functionalities to incorporate DMT, and providing specific requirements of each functionality. A systematic review [<xref rid="B32" ref-type="bibr">32</xref>] on implementation success factors found information and system quality factors like ease of use and compatibility with existing health records as high contributory factors, which was similar to our study findings. Furthermore, technological factors have also been demonstrated to affect implementation in primary care setting [<xref rid="B33" ref-type="bibr">33</xref>]. In hospitals, practical usability, trust in output, and fit with workflows influenced utilization of CDSS [<xref rid="B34" ref-type="bibr">34</xref>].</p><p>This study exhibited several strengths. First, the participant heterogeneity in terms of their specialization, healthcare setting, and countries broadened the perspective of the findings. Diversity in the respondent pool ensured that survey results captured several viewpoints, which enhanced result transferability to other settings. Second, knowledge from this survey would be translated to real-world settings, as the survey was directly linked to the design and development of a future CDSS.</p><p>Conversely, there were a couple of limitations. First of all, the questionnaire mostly comprised of technological implementation factors, with reduced spotlight on human and organizational factors. This restricted the consideration of potential insights that could hinder tool adoption and integration. Furthermore, selection bias may have been introduced during data analysis, while mitigating the issue of incomplete data, as responses could have skewed towards more informed clinicians. Finally, participants were selected purposively from a clinical group, which limited the sample size and representation of some countries. Therefore, findings may not fully capture the perspectives of all potential users of the tool, which could affect the generalizability of the findings. However, there was at least one survey respondent from each cardinal geographic regions, which provided sufficient diversity to achieve the survey objectives.</p><p>Future studies could improve response rate and inclusion of underrepresented countries by increasing their sample area and sampling approach to ensure a more balanced representation. Also, broader participation could be promoted by utilizing multi-lingual questionnaires.</p></sec><sec sec-type="conclusion" id="s5"><title>Conclusion</title><p>The study provides guidance for the development and implementation of future clinical decision support tools in the management of dementia and AD. Although experiences with CDSS are still limited, considering the needs and preferences of the clinicians, can help facilitate adoption and integration into workflows. This approach, coupled with the insights gained from the study, can assist the development of clinical support tools that are practical and useful in a real-world setting.</p></sec><sec sec-type="statement of ethics" id="s6"><title>Statement of Ethics</title><p>Participants signed a digital informed consent prior to data collection. This consent was embedded in the digital questionnaire, and those who withheld consent did not complete the questionnaire. All data were collected anonymously. Personal data such as your name, email address or date of birth were not obtained. Data were kept confidential and results only presented at group level. Additionally, data will be retained for 5 years and stored in a secure IT environment at the Karolinska Institutet. As no sensitive data were collected or processed, the study did not require ethics review according to Swedish research ethics legislation.</p></sec><sec sec-type="COI-statement" id="s7"><title>Conflict of Interest Statement</title><p>This study was funded by the European Union, the private members, and those contributing partners of the IHI JU. Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them. Bengt Winblad was a member of the journal&#8217;s Editorial Board at the time of submission.</p></sec><sec sec-type="funding sources" id="s8"><title>Funding Sources</title><p>This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101112145. The JU receives support from the European Union&#8217;s Horizon Europe research and innovation programme, Combinostics Oy and Bioarctic AB. &#8220;The funder had no role in the design, data collection, data analysis, and reporting of this study.&#8221; H.R. is recipient of the Memorabel Dementia Fellowship 2021 (ZonMw project no. 10510022110004) and Alzheimer Nederland InterACT grant (project no. WE.08-2022-06).</p></sec><sec sec-type="author contributions" id="s9"><title>Author Contributions</title><p>L.J.: conceptualization, validation, and writing &#8211; review; I.U.: data analysis, writing &#8211; original draft, review, and editing; X.X., B.W., S.A., H.F.M.R.-M., and E.A.: writing &#8211; review. All authors read and approved the final manuscript.</p></sec></body><back><sec sec-type="data-availability" id="s18"><title>Data Availability Statement</title><p>The dataset is not publicly available because individual privacy could be compromised; however, it can be made available from the corresponding author on reasonable request.</p></sec><sec sec-type="supplementary-material" id="s26"><label>Supplementary Material</label><supplementary-material id="SD1" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Supplementary_material-Suppl.1-s1.pdf" id="d67e648" position="anchor" orientation="portrait"/></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bacigalupo</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Mayer</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Lacorte</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Di Pucchio</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Marzolini</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Canevelli</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>A systematic review and meta-analysis on the prevalence of dementia in Europe: estimates from the highest-quality studies adopting the DSM IV diagnostic criteria</article-title>. <source>J Alzheimers Dis</source>. <year>2018</year>;<volume>66</volume>(<issue>4</issue>):<fpage>1471</fpage>&#8211;<lpage>81</lpage>.<pub-id pub-id-type="pmid">30412486</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-180416</pub-id><pub-id pub-id-type="pmcid">PMC6294583</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Niu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>&#193;lvarez-&#193;lvarez</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Guill&#233;n-Grima</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Aguinaga-Ontoso</surname><given-names>I</given-names></string-name></person-group>. <article-title>Prevalence and incidence of Alzheimer&#8217;s disease in Europe: a meta-analysis</article-title>. <source>Neurolog&#237;a</source>. <year>2017</year>;<volume>32</volume>(<issue>8</issue>):<fpage>523</fpage>&#8211;<lpage>32</lpage>.<pub-id pub-id-type="pmid">27130306</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nrl.2016.02.016</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tahami Monfared</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Byrnes</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>White</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></string-name></person-group>. <article-title>Alzheimer&#8217;s disease: epidemiology and clinical progression</article-title>. <source>Neurol Ther</source>. <year>2022</year>;<volume>11</volume>(<issue>2</issue>):<fpage>553</fpage>&#8211;<lpage>69</lpage>.<pub-id pub-id-type="pmid">35286590</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40120-022-00338-8</pub-id><pub-id pub-id-type="pmcid">PMC9095793</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ogawa</surname><given-names>S</given-names></string-name></person-group>. <article-title>Nutritional management of older adults with cognitive decline and dementia</article-title>. <source>Geriatr Gerontol Int</source>. <year>2014</year>;<volume>14</volume>(<issue>Suppl 2</issue>):<fpage>17</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="pmid">24650061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ggi.12252</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Takizawa</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Thompson</surname><given-names>PL</given-names></string-name>, <string-name name-style="western"><surname>van Walsem</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Faure</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Maier</surname><given-names>WC</given-names></string-name></person-group>. <article-title>Epidemiological and economic burden of alzheimer&#8217;s disease: a systematic literature review of data across Europe and the United States of America</article-title>. <source>J Alzheimers Dis</source>. <year>2015</year>;<volume>43</volume>(<issue>4</issue>):<fpage>1271</fpage>&#8211;<lpage>84</lpage>.<pub-id pub-id-type="pmid">25159675</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-141134</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bruun</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Frederiksen</surname><given-names>KS</given-names></string-name>, <string-name name-style="western"><surname>Rhodius-Meester</surname><given-names>HFM</given-names></string-name>, <string-name name-style="western"><surname>Baroni</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gjerum</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Koikkalainen</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Impact of a clinical decision support tool on dementia diagnostics in memory clinics: the PredictND validation study</article-title>. <source>Curr Alzheimer Res</source>. <year>2019</year>;<volume>16</volume>(<issue>2</issue>):<fpage>91</fpage>&#8211;<lpage>101</lpage>.<pub-id pub-id-type="pmid">30605060</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1567205016666190103152425</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>van Maurik</surname><given-names>IS</given-names></string-name>, <string-name name-style="western"><surname>Visser</surname><given-names>LN</given-names></string-name>, <string-name name-style="western"><surname>Pel-Littel</surname><given-names>RE</given-names></string-name>, <string-name name-style="western"><surname>van Buchem</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Zwan</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Kunneman</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>Development and usability of ADappt: web-based tool to support clinicians, patients, and caregivers in the diagnosis of mild cognitive impairment and alzheimer disease</article-title>. <source>JMIR Form Res</source>. <year>2019</year>;<volume>3</volume>(<issue>3</issue>):<fpage>e13417</fpage>.<pub-id pub-id-type="pmid">31287061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2196/13417</pub-id><pub-id pub-id-type="pmcid">PMC6643768</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Borchert</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Azevedo</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Badhwar</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bernal</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Betts</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bruffaerts</surname><given-names>R</given-names></string-name>, <etal/></person-group>. <article-title>Artificial intelligence for diagnostic and prognostic neuroimaging in dementia: a systematic review</article-title>. <source>Alzheimers Dement</source>. <year>2023</year>;<volume>19</volume>(<issue>12</issue>):<fpage>5885</fpage>&#8211;<lpage>904</lpage>.<pub-id pub-id-type="pmid">37563912</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13412</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Battineni</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Chintalapudi</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Hossain</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Losco</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Ruocco</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Sagaro</surname><given-names>GG</given-names></string-name>, <etal/></person-group>. <article-title>Artificial intelligence models in the diagnosis of adult-onset dementia disorders: a review</article-title>. <source>Bioengineering</source>. <year>2022</year>;<volume>9</volume>(<issue>8</issue>):<fpage>370</fpage>.<pub-id pub-id-type="pmid">36004895</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/bioengineering9080370</pub-id><pub-id pub-id-type="pmcid">PMC9405227</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Farooq</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Anwar</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Awais</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Alnowami</surname><given-names>M</given-names></string-name></person-group>. <article-title>Artificial intelligence based smart diagnosis of alzheimer&#8217;s disease and mild cognitive impairment</article-title>. <source>2017 international smart cities conference (ISC2)</source><publisher-name>IEEE</publisher-name>; <year>2017</year>. p. <fpage>1</fpage>&#8211;<lpage>4</lpage>.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Battista</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Salvatore</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Berlingeri</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Cerasa</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Castiglioni</surname><given-names>I</given-names></string-name></person-group>. <article-title>Artificial intelligence and neuropsychological measures: the case of Alzheimer&#8217;s disease</article-title>. <source>Neurosci Biobehav Rev</source>. <year>2020</year>;<volume>114</volume>:<fpage>211</fpage>&#8211;<lpage>28</lpage>.<pub-id pub-id-type="pmid">32437744</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neubiorev.2020.04.026</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>van Gils</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Visser</surname><given-names>LNC</given-names></string-name>, <string-name name-style="western"><surname>Hendriksen</surname><given-names>HMA</given-names></string-name>, <string-name name-style="western"><surname>Georges</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>van der Flier</surname><given-names>WM</given-names></string-name>, <string-name name-style="western"><surname>Rhodius&#8208;Meester</surname><given-names>HFM</given-names></string-name></person-group>. <article-title>Development and design of a diagnostic report to support communication in dementia: Co&#8208;creation with patients and care partners</article-title>. <source>Alzheimers Dement</source>. <year>2022</year>;<volume>14</volume>(<issue>1</issue>):<fpage>e12333</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dad2.12333</pub-id><pub-id pub-id-type="pmcid">PMC9446898</pub-id><pub-id pub-id-type="pmid">36092691</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>van Dyck</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Swanson</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Aisen</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Bateman</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Gee</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>Lecanemab in early alzheimer&#8217;s disease</article-title>. <source>N Engl J Med</source>. <year>2023</year>;<volume>388</volume>(<issue>1</issue>):<fpage>9</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="pmid">36449413</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2212948</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Budd Haeberlein</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Aisen</surname><given-names>PS</given-names></string-name>, <string-name name-style="western"><surname>Barkhof</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Chalkias</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Cohen</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Two randomized phase 3 studies of aducanumab in early alzheimer&#8217;s disease</article-title>. <source>J Prev Alzheimers Dis</source>. <year>2022</year>;<volume>9</volume>(<issue>2</issue>):<fpage>197</fpage>&#8211;<lpage>210</lpage>.<pub-id pub-id-type="pmid">35542991</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14283/jpad.2022.30</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mintun</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Lo</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Duggan Evans</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wessels</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Ardayfio</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Andersen</surname><given-names>SW</given-names></string-name>, <etal/></person-group>. <article-title>Donanemab in early alzheimer&#8217;s disease</article-title>. <source>N Engl J Med</source>. <year>2021</year>;<volume>384</volume>(<issue>18</issue>):<fpage>1691</fpage>&#8211;<lpage>704</lpage>.<pub-id pub-id-type="pmid">33720637</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2100708</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="other">Donanemab Approved for Treatment of Early Alzheimer&#8217;s | alz.org Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.alz.org/alzheimers-dementia/treatments/donanemab" ext-link-type="uri">https://www.alz.org/alzheimers-dementia/treatments/donanemab</ext-link></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pc</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sherimon</surname><given-names>VSPP</given-names></string-name>, <string-name name-style="western"><surname>Sp</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Nair</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Mathew</surname><given-names>R</given-names></string-name></person-group>. <article-title>A systematic review of clinical decision support systems in alzheimer&#8217;s disease domain</article-title>. <source>Int J Onl Eng</source>. <year>2021</year>;<volume>17</volume>(<issue>08</issue>):<fpage>74</fpage>&#8211;<lpage>90</lpage>.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Carvalho</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Christina</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Saade</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Conci</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Seixas</surname><given-names>FL</given-names></string-name>, <string-name name-style="western"><surname>Laks</surname><given-names>J</given-names></string-name></person-group>. <article-title>A clinical decision support system for aiding diagnosis of Alzheimer&#8217;s disease and related disorders in mobile devices</article-title>. <source>2017 IEEE international conference on communications (ICC)</source><publisher-name>IEEE</publisher-name>; <year>2017</year>. p. <fpage>1</fpage>&#8211;<lpage>6</lpage>.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lindgren</surname><given-names>H</given-names></string-name></person-group>. <article-title>Towards personalized decision support in the dementia domain based on clinical practice guidelines</article-title>. <source>User Model User-adapt Interact</source>. <year>2011</year>;<volume>21</volume>(<issue>4&#8211;5</issue>):<fpage>377</fpage>&#8211;<lpage>406</lpage>.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chinner</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Blane</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lancaster</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hinds</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Koychev</surname><given-names>I</given-names></string-name></person-group>. <article-title>Digital technologies for the assessment of cognition: a clinical review</article-title>. <source>Evid Based Ment Health</source>. <year>2018</year>;<volume>21</volume>(<issue>2</issue>):<fpage>67</fpage>&#8211;<lpage>71</lpage>.<pub-id pub-id-type="pmid">29678927</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/eb-2018-102890</pub-id><pub-id pub-id-type="pmcid">PMC10270380</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Staffaroni</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Taylor</surname>, <given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Boxer</surname>, <given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Possin</surname>, <given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Tsoy</surname><given-names>E</given-names></string-name></person-group>. <article-title>Digital Cognitive Assessments for Dementia: digital assessments may enhance the efficiency of evaluations in neurology and other clinics</article-title>. <source>Pract Neurol</source>. <year>2020</year>;<volume>2020</volume>;<fpage>24</fpage>&#8211;<lpage>45</lpage>.<pub-id pub-id-type="pmcid">PMC8078574</pub-id><pub-id pub-id-type="pmid">33927583</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yusof</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Kuljis</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Papazafeiropoulou</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Stergioulas</surname><given-names>LK</given-names></string-name></person-group>. <article-title>An evaluation framework for Health Information Systems: human, organization and technology-fit factors (HOT-fit)</article-title>. <source>Int J Med Inform</source>. <year>2008</year>;<volume>77</volume>(<issue>6</issue>):<fpage>386</fpage>&#8211;<lpage>98</lpage>.<pub-id pub-id-type="pmid">17964851</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijmedinf.2007.08.011</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shibl</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Lawley</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Debuse</surname><given-names>J</given-names></string-name></person-group>. <article-title>Factors influencing decision support system acceptance</article-title>. <source>Decis Support Syst</source>. <year>2013</year>;<volume>54</volume>(<issue>2</issue>):<fpage>953</fpage>&#8211;<lpage>61</lpage>.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zheng</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Padman</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Johnson</surname><given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Diamond</surname><given-names>HS</given-names></string-name></person-group>. <article-title>Understanding technology adoption in clinical care: clinician adoption behavior of a point-of-care reminder system</article-title>. <source>Int J Med Inform</source>. <year>2005</year>;<volume>74</volume>(<issue>7&#8211;8</issue>):<fpage>535</fpage>&#8211;<lpage>43</lpage>.<pub-id pub-id-type="pmid">16043083</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijmedinf.2005.03.007</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Politi</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Adsul</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Kuzemchak</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Zeuner</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Frosch</surname><given-names>DL</given-names></string-name></person-group>. <article-title>Clinicians&#8217; perceptions of digital vs. paper&#8208;based decision support interventions</article-title>. <source>J Eval Clin Pract</source>. <year>2015</year>;<volume>21</volume>(<issue>2</issue>):<fpage>175</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">25318648</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jep.12269</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>van Gils</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Visser</surname><given-names>LN</given-names></string-name>, <string-name name-style="western"><surname>Hendriksen</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Georges</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Muller</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bouwman</surname><given-names>FH</given-names></string-name>, <etal/></person-group>. <article-title>Assessing the views of professionals, patients, and care partners concerning the use of computer tools in memory clinics: international survey study</article-title>. <source>JMIR Form Res</source>. <year>2021</year>;<volume>5</volume>(<issue>12</issue>):<fpage>e31053</fpage>.<pub-id pub-id-type="pmid">34870612</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2196/31053</pub-id><pub-id pub-id-type="pmcid">PMC8686488</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ford</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Edelman</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Somers</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Shrewsbury</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Lopez Levy</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>van Marwijk</surname><given-names>H</given-names></string-name>, <etal/></person-group>. <article-title>Barriers and facilitators to the adoption of electronic clinical decision support systems: a qualitative interview study with UK general practitioners</article-title>. <source>BMC Med Inform Decis Mak</source>. <year>2021</year>;<volume>21</volume>(<issue>1</issue>):<fpage>193</fpage>.<pub-id pub-id-type="pmid">34154580</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12911-021-01557-z</pub-id><pub-id pub-id-type="pmcid">PMC8215812</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>van Gils</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Rhodius-Meester</surname><given-names>HFM</given-names></string-name>, <string-name name-style="western"><surname>Handgraaf</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Hendriksen</surname><given-names>HMA</given-names></string-name>, <string-name name-style="western"><surname>van Strien</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Schoonenboom</surname><given-names>N</given-names></string-name>, <etal/></person-group>. <article-title>Use of a digital tool to support the diagnostic process in memory clinics&#8211;a usability study</article-title>. <source>Alzheimers Res Ther</source>. <year>2024</year>;<volume>16</volume>(<issue>1</issue>):<fpage>75</fpage>.<pub-id pub-id-type="pmid">38589933</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-024-01433-8</pub-id><pub-id pub-id-type="pmcid">PMC11003066</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tate</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Su&#225;rez-Calvet</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ekelund</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Eriksson</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Eriksdotter</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Van Der Flier</surname><given-names>WM</given-names></string-name>, <etal/></person-group>. <article-title>Precision medicine in neurodegeneration: the IHI-PROMINENT project</article-title>. <source>Front Neurol</source>. <year>2023</year>;<volume>14</volume>:<fpage>1175922</fpage>.<pub-id pub-id-type="pmid">37602259</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2023.1175922</pub-id><pub-id pub-id-type="pmcid">PMC10433183</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rhodius-Meester</surname><given-names>HFM</given-names></string-name>, <string-name name-style="western"><surname>van Maurik</surname><given-names>IS</given-names></string-name>, <string-name name-style="western"><surname>Koikkalainen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Tolonen</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Frederiksen</surname><given-names>KS</given-names></string-name>, <string-name name-style="western"><surname>Hasselbalch</surname><given-names>SG</given-names></string-name>, <etal/></person-group>. <article-title>Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy</article-title>. <source>PLoS One</source>. <year>2020</year>;<volume>15</volume>(<issue>1</issue>):<fpage>e0226784</fpage>.<pub-id pub-id-type="pmid">31940390</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0226784</pub-id><pub-id pub-id-type="pmcid">PMC6961870</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Simonsen</surname><given-names>AH</given-names></string-name>, <string-name name-style="western"><surname>Mattila</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hejl</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Garde</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>van Gils</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Thomsen</surname><given-names>C</given-names></string-name>, <etal/></person-group>. <article-title>Application of the PredictAD decision support tool to a Danish cohort of patients with alzheimer&#8217;s disease and other dementias</article-title>. <source>Dement Geriatr Cogn Disord</source>. <year>2014</year>;<volume>37</volume>(<issue>3&#8211;4</issue>):<fpage>207</fpage>&#8211;<lpage>13</lpage>.<pub-id pub-id-type="pmid">24193095</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000354372</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kilsdonk</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Peute</surname><given-names>LW</given-names></string-name>, <string-name name-style="western"><surname>Jaspers</surname><given-names>MWM</given-names></string-name></person-group>. <article-title>Factors influencing implementation success of guideline-based clinical decision support systems: a systematic review and gaps analysis</article-title>. <source>Int J Med Inform</source>. <year>2017</year>;<volume>98</volume>:<fpage>56</fpage>&#8211;<lpage>64</lpage>.<pub-id pub-id-type="pmid">28034413</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijmedinf.2016.12.001</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Meunier</surname><given-names>PY</given-names></string-name>, <string-name name-style="western"><surname>Raynaud</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Guimaraes</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Gueyffier</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Letrilliart</surname><given-names>L</given-names></string-name></person-group>. <article-title>Barriers and facilitators to the use of clinical decision support systems in primary care: a mixed-methods systematic review</article-title>. <source>Ann Fam Med</source>. <year>2023</year>;<volume>21</volume>(<issue>1</issue>):<fpage>57</fpage>&#8211;<lpage>69</lpage>.<pub-id pub-id-type="pmid">36690490</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1370/afm.2908</pub-id><pub-id pub-id-type="pmcid">PMC9870646</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Abell</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Naicker</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Rodwell</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Donovan</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Tariq</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Baysari</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>Identifying barriers and facilitators to successful implementation of computerized clinical decision support systems in hospitals: a NASSS framework-informed scoping review</article-title>. <source>Implement Sci</source>. <year>2023</year>;<volume>18</volume>(<issue>1</issue>):<fpage>32</fpage>.<pub-id pub-id-type="pmid">37495997</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13012-023-01287-y</pub-id><pub-id pub-id-type="pmcid">PMC10373265</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Radiol Imaging Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Radiol Imaging Cancer</journal-id><journal-id journal-id-type="pmc-domain-id">4010</journal-id><journal-id journal-id-type="pmc-domain">radimgcan</journal-id><journal-id journal-id-type="publisher-id">imaging-cancer</journal-id><journal-title-group><journal-title>Radiology: Imaging Cancer</journal-title></journal-title-group><issn pub-type="epub">2638-616X</issn><publisher><publisher-name>Radiological Society of North America</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12492422</article-id><article-id pub-id-type="pmcid-ver">PMC12492422.1</article-id><article-id pub-id-type="pmcaid">12492422</article-id><article-id pub-id-type="pmcaiid">12492422</article-id><article-id pub-id-type="pmid">41002286</article-id><article-id pub-id-type="doi">10.1148/rycan.250049</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Technical Development</subject><subj-group><subject>Clinical Research</subject></subj-group></subj-group><subj-group subj-group-type="subject"><compound-subject><compound-subject-part content-type="code">MR</compound-subject-part><compound-subject-part content-type="text">Magnetic Resonance
Imaging</compound-subject-part></compound-subject><compound-subject><compound-subject-part content-type="code">NR</compound-subject-part><compound-subject-part content-type="text">Neuroradiology</compound-subject-part></compound-subject><compound-subject><compound-subject-part content-type="code">OI</compound-subject-part><compound-subject-part content-type="text">Oncologic
Imaging</compound-subject-part></compound-subject></subj-group></article-categories><title-group><article-title>Multiparametric Dynamic Contrast Imaging for Voxelwise Quantitative
Assessment of Brain Tumors</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0001-7995-4119</contrib-id><name name-style="western"><surname>Chen</surname><given-names initials="Y">Yang</given-names></name><degrees>MS</degrees><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-7478-6534</contrib-id><name name-style="western"><surname>Xiao</surname><given-names initials="J">Jiayu</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cen</surname><given-names initials="S">Steven</given-names></name><degrees>PhD</degrees><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hu</surname><given-names initials="Z">Zhehao</given-names></name><degrees>PhD</degrees><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="J">Junzhou</given-names></name><degrees>PhD</degrees><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shiroishi</surname><given-names initials="MS">Mark S.</given-names></name><degrees>MD</degrees><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chow</surname><given-names initials="FE">Frances E.</given-names></name><degrees>MD</degrees><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ye</surname><given-names initials="JC">Jason C.</given-names></name><degrees>MD</degrees><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-2380-8921</contrib-id><name name-style="western"><surname>Tran</surname><given-names initials="DD">David D.</given-names></name><degrees>MD</degrees><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hurth</surname><given-names initials="K">Kyle</given-names></name><degrees>MD, PhD</degrees><xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-5821-902X</contrib-id><name name-style="western"><surname>Zada</surname><given-names initials="G">Gabriel</given-names></name><degrees>MD</degrees><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-5509-5199</contrib-id><name name-style="western"><surname>Lee</surname><given-names initials="HL">Hsu-Lei</given-names></name><degrees>PhD</degrees><xref rid="aff8" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-9334-8684</contrib-id><name name-style="western"><surname>Christodoulou</surname><given-names initials="AG">Anthony G.</given-names></name><degrees>PhD</degrees><xref rid="aff9" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-8560-8231</contrib-id><name name-style="western"><surname>Li</surname><given-names initials="D">Debiao</given-names></name><degrees>PhD</degrees><xref rid="aff8" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chang</surname><given-names initials="E">Eric</given-names></name><degrees>MD</degrees><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-2693-0260</contrib-id><name name-style="western"><surname>Fan</surname><given-names initials="Z">Zhaoyang</given-names></name><degrees>PhD</degrees><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Zhaoyang.Fan@med.usc.edu">Zhaoyang.Fan@med.usc.edu</email></contrib><aff id="aff1"><sup>1</sup>Department of Radiology, Keck School of Medicine,
University of Southern California, 2250 Alcazar St, CSC Rm 104, Los Angeles, CA
90033</aff><aff id="aff2"><sup>2</sup>Department of Biomedical Engineering, University of
Southern California, Los Angeles, Calif</aff><aff id="aff3"><sup>3</sup>Department of Radiation Oncology, Keck School of
Medicine, University of Southern California, Los Angeles, Calif</aff><aff id="aff4"><sup>4</sup>Department of Radiology, Los Angeles General Medical
Center, Los Angeles, Calif</aff><aff id="aff5"><sup>5</sup>Department of Neurology, Keck School of Medicine,
University of Southern California, Los Angeles, Calif</aff><aff id="aff6"><sup>6</sup>Department of Neurological Surgery, Keck School of
Medicine, University of Southern California, Los Angeles, Calif</aff><aff id="aff7"><sup>7</sup>Department of Clinical Pathology, Keck School of
Medicine, University of Southern California, Los Angeles, Calif</aff><aff id="aff8"><sup>8</sup>Biomedical Imaging Research Institute, Cedars-Sinai
Medical Center, Los Angeles, Calif</aff><aff id="aff9"><sup>9</sup>Department of Radiological Sciences, University of
California, Los Angeles, Los Angeles, Calif</aff></contrib-group><author-notes><corresp id="cor1"><bold>Address correspondence to:</bold> Z.F. (email: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Zhaoyang.Fan@med.usc.edu">Zhaoyang.Fan@med.usc.edu</email>).</corresp><fn fn-type="con"><p><bold>Author contributions:</bold> Guarantors of integrity of entire study,
<bold>Y.C., J.C.Y., Z.F.</bold>; study concepts/study design or data
acquisition or data analysis/interpretation, all authors; manuscript
drafting or manuscript revision for important intellectual content, all
authors; approval of final version of submitted manuscript, all authors;
agrees to ensure any questions related to the work are appropriately
resolved, all authors; literature research, <bold>Y.C., J.X., Z.H., J.C.,
F.E.C., A.G.C., D.L., Z.F.</bold>; clinical studies, <bold>Y.C., J.X.,
Z.H., J.C., M.S.S., F.E.C., K.H., G.Z., H.L.L., D.L., Z.F.</bold>;
statistical analysis, <bold>Y.C., S.C., Z.H., Z.F.</bold>; and manuscript
editing, <bold>Y.C., J.X., S.C., Z.H., M.S.S., F.E.C., J.C.Y., D.D.T., K.H.,
G.Z., A.G.C., D.L., E.C., Z.F.</bold></p></fn><fn fn-type="COI-statement"><p><bold>Disclosures of conflicts of interest: </bold><bold>Y.C.</bold> No relevant relationships. <bold>J.X.</bold> No relevant
relationships. <bold>S.C.</bold> No relevant relationships.
<bold>Z.H.</bold> No relevant relationships. <bold>J.C.</bold> No
relevant relationships. <bold>M.S.S.</bold> No relevant relationships.
<bold>F.E.C.</bold> No relevant relationships. <bold>J.C.Y.</bold>
Consulting fees from Cardinal Health, paid to author; travel support
(flight, hotel) from VisionRT for the annual Surface Guided Radiation
Therapy (SGRT) symposium; member of the Los Angeles Radiological Society
executive board (unpaid).<bold> D.D.T.</bold> Research grants from Novocure,
Monteris, Merck, Novartis, Sarepta, and Lacerta; research funding from
Northwest Bio and Stemline; honoraria from Novocure and Monteris for
consultant work; support from Novocure for attending meetings and/or travel.
<bold>K.H.</bold> No relevant relationships. <bold>G.Z.</bold> No
relevant relationships. <bold>H.L.L.</bold> No relevant relationships.
<bold>A.G.C.</bold> Grants to author&#8217;s institution from the
National Institutes of Health (NIH R01 EB028146, NIH R01 HL127153, NIH R01
EB032801, and NIH R01 HL156818) and Siemens Medical Solutions USA
(CLMA179688); Siemens Healthineers booked travel on author&#8217;s behalf
to meet for research; co-inventor for pending patents "Systems and methods
for MR multitasking-based dynamic imaging for cerebrovascular evaluations,"
U.S. patent pending 18/001,998, PCT patent pending PCT/US2021/037695,
Canadian patent pending 3185606A, and European patent pending 21825185.8A;
treasurer for the Society for Magnetic Resonance Angiography (unpaid
scientific society executive position).<bold> D.L.</bold> No relevant
relationships. <bold>E.C.</bold> No relevant relationships.
<bold>Z.F.</bold> Patent planned, issued, or pending for "Systems and
methods for MR multitasking-based dynamic imaging for cerebrovascular
evaluation," US20230225628A1.</p></fn></author-notes><pub-date pub-type="epub"><day>26</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><volume>7</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">498250</issue-id><elocation-id>e250049</elocation-id><history><date date-type="received"><day>30</day><month>1</month><year>2025</year></date><date date-type="rev-request"><day>17</day><month>3</month><year>2025</year></date><date date-type="rev-recd"><day>5</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>13</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>26</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-04 10:26:05.627"><day>04</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 by the Radiological Society of North America,
Inc.</copyright-statement><copyright-year>2025</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="rycan.250049.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="rycan.250049.pdf"/><abstract><sec><title>Purpose</title><p>To develop a multiparametric dynamic contrast imaging (mpDYCI) technique
that enables simultaneous quantification of brain tissue perfusion,
microvasculature permeability, transmembrane water efflux, and
susceptibility and can be integrated into the routine brain tumor
imaging protocol for voxelwise multifaceted quantitative brain tumor
assessment.</p></sec><sec><title>Materials and Methods</title><p>In this prospective study conducted from March 2023 to April 2024, the
mpDYCI technique was evaluated. The mpDYCI technique builds on an MR
Multitasking&#8211;based dynamic T1 and T2* mapping method and
incorporates several technical optimizations in pulse sequence, image
reconstruction, T1/T2* quantification, and quantitative metric
estimation to achieve robust whole-brain multiparametric quantification.
The intersession repeatability and accuracy of mpDYCI metrics were
assessed, using intraclass correlation coefficient (ICC), through
digital phantom and in vivo experiments involving healthy individuals
and individuals with brain tumors. The feasibility of integrating mpDYCI
into the routine brain imaging protocol and its clinical utilities based
on complementary information from intrinsically coregistered multiple
quantitative metrics were also explored.</p></sec><sec><title>Results</title><p>In vivo experiments were performed in six healthy participants (mean age,
33 years; range, 27&#8211;48 years; three female) and 55 participants
with brain tumors (mean age, 56 years; range, 24&#8211;81 years; 36
female). Quantitative metrics derived from mpDYCI demonstrated good to
excellent repeatability (ICC &#8805; 0.80) and excellent agreement with
reference standards (range, 6.86%&#8211;15.21% percentage error or ICC
&#8805; 0.93). Histogram analysis, voxel clustering, and histologic
validation confirmed the capability of mpDYCI to capture the
intratumoral heterogeneity. Low voxelwise correlations between each pair
of mpDYCI metrics (correlation coefficient &#8804; 0.33 except for one
pair) suggested that each metric provides complementary information.
Furthermore, mpDYCI exhibited the potential to help differentiate
treatment-related effects from true tumor progression in brain
metastases.</p></sec><sec><title>Conclusion</title><p>With a single 7.5-minute scan and single-dose contrast media injection,
mpDYCI can simultaneously quantify perfusion, permeability, water
efflux, and susceptibility, thereby enabling comprehensive voxelwise
characterization of brain tumors.</p><p><bold>Keywords:</bold> MR Perfusion, CNS, Brain/Brain Stem, Tumor Immune
Microenvironment, Reconstruction Algorithms, MR&#8211;Dynamic Contrast
Enhanced, MR Imaging, Brain Tumor Heterogeneity, Multiparametric MR
Imaging, Dynamic Contrast-enhanced MRI, Dynamic Susceptibility Contrast
MRI, Quantitative Susceptibility Mapping</p><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.rsna.org/doi/suppl/10.1148/rycan.250049" specific-use="inline-supplementary-material">
<italic toggle="yes">Supplemental material is available for this
article.</italic>
</ext-link>
</p><p>&#169; RSNA, 2025</p></sec></abstract><kwd-group><kwd>MR Perfusion</kwd><kwd>CNS</kwd><kwd>Brain/Brain Stem</kwd><kwd>Tumor Immune Microenvironment</kwd><kwd>Reconstruction Algorithms</kwd><kwd>MR&#8211;Dynamic Contrast Enhanced</kwd><kwd>MR Imaging</kwd><kwd>Brain Tumor Heterogeneity</kwd><kwd>Multiparametric MR Imaging</kwd><kwd>Dynamic Contrast-enhanced MRI</kwd><kwd>Dynamic Susceptibility Contrast MRI</kwd><kwd>Quantitative Susceptibility Mapping</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Neurosci</journal-id><journal-id journal-id-type="iso-abbrev">Front Neurosci</journal-id><journal-id journal-id-type="pmc-domain-id">670</journal-id><journal-id journal-id-type="pmc-domain">frontneurosci</journal-id><journal-id journal-id-type="publisher-id">Front. Neurosci.</journal-id><journal-title-group><journal-title>Frontiers in Neuroscience</journal-title></journal-title-group><issn pub-type="ppub">1662-4548</issn><issn pub-type="epub">1662-453X</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12498287</article-id><article-id pub-id-type="pmcid-ver">PMC12498287.1</article-id><article-id pub-id-type="pmcaid">12498287</article-id><article-id pub-id-type="pmcaiid">12498287</article-id><article-id pub-id-type="pmid">41059095</article-id><article-id pub-id-type="doi">10.3389/fnins.2025.1650937</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Neuroscience</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Altered brain structural covariance networks of the thalamic subfields in right chronic capsular stroke</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name name-style="western"><surname>Guo</surname><given-names initials="J">Jun</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="c003" ref-type="corresp">
<sup>*</sup>
</xref><xref rid="fn1001" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2575475/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Zhang</surname><given-names initials="H">Hongchuan</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fn1001" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="J">Jingchun</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/789603/overview"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="C">Caihong</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1445880/overview"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cao</surname><given-names initials="C">Chen</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cheng</surname><given-names initials="J">Jingliang</given-names></name><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/935240/overview"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Yu</surname><given-names initials="C">Chunshui</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="c002" ref-type="corresp">
<sup>*</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Qin</surname><given-names initials="W">Wen</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="c001" ref-type="corresp">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/214402/overview"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Radiology, Tianjin Huanhu Hospital, Huanhu Hospital Affiliated to Tianjin Medical University and Tianjin University HuanHu Hospital</institution>, <addr-line>Tianjin</addr-line>, <country>China</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Radiology, Yijishan Hospital of Wannan Medical College</institution>, <addr-line>Wuhu</addr-line>, <country>China</country></aff><aff id="aff3"><sup>3</sup><institution>Department of Radiology, Tianjin Key Lab of Functional Imaging, Tianjin Institute of Radiology and State Key Laboratory of Experimental Hematology, Tianjin Medical University General Hospital</institution>, <addr-line>Tianjin</addr-line>, <country>China</country></aff><aff id="aff4"><sup>4</sup><institution>Department of Magnetic Resonance Imaging, The Fifth Affiliated Hospital of Zhengzhou University</institution>, <addr-line>Zhengzhou</addr-line>, <country>China</country></aff><aff id="aff5"><sup>5</sup><institution>Department of Magnetic Resonance Imaging, The First Affiliated Hospital of Zhengzhou University</institution>, <addr-line>Zhengzhou</addr-line>, <country>China</country></aff><author-notes><fn fn-type="edited-by" id="fn0004"><p>Edited by: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/844/overview" ext-link-type="uri">Francisco Clasca</ext-link>, Aut&#243;noma de Madrid University, Spain</p></fn><fn fn-type="edited-by" id="fn0005"><p>Reviewed by: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/499723/overview" ext-link-type="uri">Shinsuke Hidese</ext-link>, Teikyo University, Japan</p><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/777951/overview" ext-link-type="uri">Alaka Acharya</ext-link>, Harbin Institute of Technology, China</p></fn><corresp id="c001">*Correspondence: Wen Qin, <email>wayne.wenqin@gmail.com</email></corresp><corresp id="c002">Chunshui Yu, <email>chunshuiyu@tmu.edu.cn</email></corresp><corresp id="c003">Jun Guo, <email>junguomr@163.com</email></corresp><fn fn-type="equal" id="fn1001"><p><sup>&#8224;</sup>These authors have contributed equally to this work</p></fn></author-notes><pub-date pub-type="epub"><day>26</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>19</volume><issue-id pub-id-type="pmc-issue-id">480891</issue-id><elocation-id>1650937</elocation-id><history><date date-type="received"><day>20</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>16</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>26</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>07</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 09:25:15.110"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 Guo, Zhang, Liu, Wang, Cao, Cheng, Yu and Qin.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Guo, Zhang, Liu, Wang, Cao, Cheng, Yu and Qin</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fnins-19-1650937.pdf"/><abstract><sec id="sec1"><title>Background</title><p>The thalamus, along with its component nuclei, possesses extensive connections with various brain regions and is engaged in diverse functions. However, it is unknown whether the gray matter volume (GMV) covariance networks of thalamic subfields are selectively affected in chronic capsular stroke.</p></sec><sec id="sec2"><title>Methods</title><p>We recruited 45 patients with chronic right capsular strokes (CS) and 93 normal controls (NC) from three centers. The thalamus was segmented into 25 subfields using FreeSurfer (v7.1.1). A general linear model was applied to investigate intergroup differences in the GMV covariance network of each thalamic subfield with each voxel of the entire brain between CS and NC, correcting for confounders such as age, gender, total intracranial volume (TIV), and scanners (voxel-wise <italic toggle="yes">p</italic>&#8239;&lt;&#8239;0.001, cluster-wise FWE corrected <italic toggle="yes">p</italic>&#8239;&lt;&#8239;0.05).</p></sec><sec id="sec3"><title>Results</title><p>Our findings revealed that all 25 ipsilesional thalamic subfields in CS were atrophied (<italic toggle="yes">p</italic>&#8239;&lt;&#8239;0.05, FDR correction). Among these, 16 ipsilesional thalamic subfields (including AV, LD, LP, VLa, VLp, VPL, VM, CeM, CL, MDm, LGN, PuM, PuI, CM, Pf, and Pt) exhibited significantly subfield-specific increased GMV covariance connectivity with the anterior orbital gyrus, superior occipital gyrus, calcarine, anterior cingulate cortex, precentral gyrus, and other regions. Additionally, although none of the contralesional thalamic subfields demonstrated regional GMV changes, 3/25 showed subfield-specific increased GMV covariance connectivity with the ipsilesional anterior orbital gyrus and subcortex.</p></sec><sec id="sec4"><title>Conclusion</title><p>The GMV covariance networks of thalamic subfields are selectively involved in patients with chronic capsular stroke, which affect not only the ipsilesional thalamic subfields but also the contralesional ones.</p></sec></abstract><kwd-group><kwd>capsular stroke</kwd><kwd>gray matter volume</kwd><kwd>network Remoding</kwd><kwd>structural covariance network</kwd><kwd>thalamus subfield</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research and/or publication of this article. This work was supported by the Sponsored by Tianjin Health Research Project [Grant No. TJWJ2025MS029 (JG)], National Natural Science Foundation of China [82472052 (WQ), 81971599 (WQ), 82430063 (CY), 82030053 (CY), 82572169 (JL)], Tianjin Natural Science Foundation [19JCYBJC25100 (WQ), 21JCYBJC00520 (JG), 24JCYBJC00970 (JL), and TEDA-UCB Science Innovation Award (WQ)].</funding-statement></funding-group><counts><fig-count count="5"/><table-count count="1"/><equation-count count="1"/><ref-count count="58"/><page-count count="12"/><word-count count="8078"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Brain Imaging Methods</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec5"><title>Introduction</title><p>The human thalamus is a brain structure composed of numerous highly specific nuclear groups. Different thalamic nuclei have diverse functions (such as processing speed, attention, and executive functions) and are connected to different regions of the cerebral cortex, there is great interest in the neuroimaging community to study their volume, shape, and connectivity (<xref rid="ref10" ref-type="bibr">Corona et al., 2020</xref>; <xref rid="ref20" ref-type="bibr">Iglesias et al., 2018</xref>). The thalamus and basal ganglia collectively constitute a vital component of the cortico-striato-thalamo-cortical (CSTC) circuit. The anatomical vulnerability of the lenticulostriate arteries makes capsular infarction the predominant type of ischemic stroke, which usually involves the integrity of the CSTC circuit (<xref rid="ref17" ref-type="bibr">Herrero et al., 2002</xref>; <xref rid="ref51" ref-type="bibr">Yan et al., 2022</xref>). In such instances, the thalamus typically experiences secondary degenerative alterations, which not only compromise its structural integrity but also significantly modify its functional state, potentially resulting in motor and cognitive impairments (<xref rid="ref21" ref-type="bibr">Ilves et al., 2022</xref>; <xref rid="ref43" ref-type="bibr">Steiner et al., 2022</xref>). For example, some studies have shown that capsular stroke (CS) can lead to frontal dysfunction or memory impairment (<xref rid="ref34" ref-type="bibr">Pantoni et al., 2001</xref>). The symptoms of frontal dysfunction are thought to be caused by disrupted connections between the thalamus and the frontal cortex (<xref rid="ref4" ref-type="bibr">Biesbroek et al., 2017</xref>; <xref rid="ref45" ref-type="bibr">Tatemichi et al., 1992</xref>; <xref rid="ref56" ref-type="bibr">Zhang et al., 2021</xref>). This phenomenon may be ascribed to secondary degeneration of the thalamus, and this process is not confined solely to the ipsilesional thalamus, with the potential for involvement of the contralateral thalamus as well (<xref rid="ref5" ref-type="bibr">Carey et al., 2011</xref>; <xref rid="ref6" ref-type="bibr">Carmichael et al., 2004</xref>; <xref rid="ref53" ref-type="bibr">Yassi et al., 2015</xref>).</p><p>While capsular strokes impact the adjacent thalamus, research often treats the thalamus as a single unit (<xref rid="ref30" ref-type="bibr">Liu et al., 2019</xref>). However, the thalamus is highly heterogeneous, with distinct subfields differing in anatomical structure and function (<xref rid="ref3" ref-type="bibr">Beloozerova and Marlinski, 2020</xref>; <xref rid="ref26" ref-type="bibr">Lambert et al., 2017</xref>; <xref rid="ref27" ref-type="bibr">Li et al., 2023</xref>). Each subfield has unique connections to the cortex, mediating specific functions. For example, the ventral lateral anterior (VLa) nucleus, part of the motor thalamus, connects with the substantia nigra and prefrontal cortex and functions as motor planning and learning (<xref rid="ref25" ref-type="bibr">Kumar et al., 2014</xref>); The mediodorsal (MD) nucleus connects with the medial temporal and dorsolateral prefrontal cortex, and pallidum, and is involved in working memory and sensorimotor integration (<xref rid="ref26" ref-type="bibr">Lambert et al., 2017</xref>). Critically, the integrity of the thalamocortical connection between the MD and dorsolateral prefrontal cortex is crucial for motor recovery post-stroke (<xref rid="ref8" ref-type="bibr">Choi et al., 2020</xref>). Given this functional divisions of the thalamic subfields within the cortico-striato-thalamo-cortical (CSTC) circuit (<xref rid="ref15" ref-type="bibr">Haber and McFarland, 2002</xref>; <xref rid="ref31" ref-type="bibr">Mair et al., 2022</xref>), analyzing the entire thalamus&#8217;s volume obscures the specific cognitive and sensorimotor deficits caused by stroke.</p><p>Structural covariance network (SCN) is a valuable metric for investigating the brain&#8217;s topological organization, as it reflects the coordinated development and synchronous impact of interconnected regions (<xref rid="ref29" ref-type="bibr">Liu et al., 2023</xref>; <xref rid="ref55" ref-type="bibr">Zhang et al., 2025</xref>; <xref rid="ref57" ref-type="bibr">Zielinski et al., 2010</xref>). This SCN is closely linked to cognitive abilities (<xref rid="ref24" ref-type="bibr">Khundrakpam et al., 2017</xref>), genetic variant (<xref rid="ref49" ref-type="bibr">Wen et al., 2023</xref>) and expression (<xref rid="ref38" ref-type="bibr">Romero-Garcia et al., 2018</xref>) and neuropsychiatric disorders including stroke (<xref rid="ref29" ref-type="bibr">Liu et al., 2023</xref>; <xref rid="ref55" ref-type="bibr">Zhang et al., 2025</xref>). Therefore, examining both thalamic subfieldal structure and the structural covariance between thalamic subfields and remote cortical areas can improve our ability to identify the specific circuits disrupted by capsular stroke. This, in turn, may provide avenues for targeted rehabilitation.</p><p>In this context, we hypothesized that gray matter volume (GMV) covariance patterns in thalamic subfields would be selectively altered in patients with chronic capsular stroke. To test this hypothesis, we enrolled 45 patients with right internal capsule stroke and 93 healthy controls. We investigated whether the GMV covariance of thalamic subfields differed significantly between the two groups. Furthermore, we explored the potential associations between GMV covariance in these thalamic subfields and clinical behavior. This study aims to enhance our understanding of the GMV covariance alterations pattern of different thalamic subfields caused by capsular stroke and its subsequent functional consequences.</p></sec><sec sec-type="methods" id="sec6"><title>Methods</title><sec id="sec7"><title>Subjects</title><p>The MRI data were acquired from three hospitals using three scanners. All enrolled patients had to meet the following criteria: firstly, it must be a first-time ischemic stroke and exhibited motor dysfuncion at stroke onset; secondly, the lesion involved the right internal capsule and was a single lesion; furthermore, the time interval between stroke onset and enrollment should exceed 6 months; In addition, right-handedness before the stroke. The exclusion criteria for subjects include: firstly, patients with a clinical history or confirmed recurrent stroke through imaging examination; <bold>t</bold>he second is the presence of other intracranial abnormalities, such as tumors, vascular malformations, etc.; thirdly, histories of other mental illnesses or drug dependence; Fourth, left-handedness before stroke. Finally, 45 patients with chronic right CS and 93 normal controls (NC) were enrolled for the research. The demographic data of participants are described in <xref rid="tab1" ref-type="table">Table 1</xref>.</p><table-wrap position="float" id="tab1" orientation="portrait"><label>Table 1</label><caption><p>Demographic and clinical information pertaining to patients with stroke and normal controls.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Variables</th><th align="center" valign="top" rowspan="1" colspan="1">Capsular stroke</th><th align="center" valign="top" rowspan="1" colspan="1">Normal controls</th><th align="center" valign="top" rowspan="1" colspan="1">Statistics</th><th align="center" valign="top" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-value</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age (year)</td><td align="center" valign="middle" rowspan="1" colspan="1">55.51&#8239;&#177;&#8239;7.31</td><td align="center" valign="middle" rowspan="1" colspan="1">55.53&#8239;&#177;&#8239;7.43</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">t&#8239;=</italic> 0.012</td><td align="center" valign="middle" rowspan="1" colspan="1">0.990</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gender (male/female)</td><td align="center" valign="top" rowspan="1" colspan="1">27/18</td><td align="center" valign="top" rowspan="1" colspan="1">50/43</td><td align="center" valign="top" rowspan="1" colspan="1"><italic toggle="yes">&#967;2</italic> =&#8239;0.478</td><td align="center" valign="top" rowspan="1" colspan="1">0.489</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FMA total</td><td align="center" valign="top" rowspan="1" colspan="1">100 (82.5, 100)</td><td align="center" valign="top" rowspan="1" colspan="1">100 (100, 100)</td><td align="center" valign="top" rowspan="1" colspan="1">Z&#8239;=&#8239;&#8722;7.097</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RAVLT-SR</td><td align="center" valign="middle" rowspan="1" colspan="1">42.778&#8239;&#177;&#8239;10.396</td><td align="center" valign="top" rowspan="1" colspan="1">49.527&#8239;&#177;&#8239;8.305</td><td align="center" valign="top" rowspan="1" colspan="1"><italic toggle="yes">t</italic> =&#8239;&#8722;3.807</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RAVLT-LR</td><td align="center" valign="top" rowspan="1" colspan="1">11 (9, 12)</td><td align="center" valign="top" rowspan="1" colspan="1">12 (10, 14)</td><td align="center" valign="top" rowspan="1" colspan="1"><italic toggle="yes">Z&#8239;=</italic> &#8722;2.25</td><td align="center" valign="top" rowspan="1" colspan="1">0.024</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">N_ACC</td><td align="center" valign="top" rowspan="1" colspan="1">0.90 (0.87, 0.95)</td><td align="center" valign="top" rowspan="1" colspan="1">0.93 (0.88, 0.95)</td><td align="center" valign="top" rowspan="1" colspan="1"><italic toggle="yes">Z</italic> =&#8239;&#8722;1.082</td><td align="center" valign="top" rowspan="1" colspan="1">0.279</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">N_RT</td><td align="center" valign="top" rowspan="1" colspan="1">805.15 (726.42, 1003.88)</td><td align="center" valign="top" rowspan="1" colspan="1">758.16 (666.18, 914.14)</td><td align="center" valign="top" rowspan="1" colspan="1"><italic toggle="yes">Z</italic> =&#8239;1.617</td><td align="center" valign="top" rowspan="1" colspan="1">0.106</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">S_ACC</td><td align="center" valign="top" rowspan="1" colspan="1">0.92 (0.85, 0.95)</td><td align="center" valign="top" rowspan="1" colspan="1">0.92(0.89, 0.95)</td><td align="center" valign="top" rowspan="1" colspan="1"><italic toggle="yes">Z</italic> =&#8239;&#8722;1.164</td><td align="center" valign="top" rowspan="1" colspan="1">0.245</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">S_RT</td><td align="center" valign="top" rowspan="1" colspan="1">849.72 (738.52, 1030.49)</td><td align="center" valign="top" rowspan="1" colspan="1">794.86 (690.30, 929.56)</td><td align="center" valign="top" rowspan="1" colspan="1"><italic toggle="yes">Z</italic> =&#8239;1.580</td><td align="center" valign="top" rowspan="1" colspan="1">0.114</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lesion volume at chronic stage (mL)</td><td align="center" valign="top" rowspan="1" colspan="1">243.796&#8239;&#177;&#8239;50.248</td><td align="center" valign="top" rowspan="1" colspan="1">/</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">/</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">/</td></tr></tbody></table><table-wrap-foot><p>Continuous variables are presented as mean&#8239;&#177;&#8239;SD for normally distributed data, or as median (interquartile range) for non-normally distributed data. FMA, Fugl-Meyer assessment; N_RT, reaction time of number 1-back test; N_ACC, accuracy of number 1-back test; S_RT, reaction time of spatial 1-back test; S_ACC, accuracy of Spatial 1-back test; SD, standard deviation.</p></table-wrap-foot></table-wrap><p>The experimental protocol was approved by the ethics committee of Tianjin Medical University General Hospital (IRB2015-092-02), Tianjin Huanhu Hospital (JinHuan 2022-103), and the first affiliated hospital of zhengzhou university (2018-KY-03), and written informed consent was obtained from all participants prior to enrolment.</p></sec><sec id="sec8"><title>Clinical behavioral assessment</title><p>All participants underwent behavioral assessments about motor and recognition functions. Fugl-Meyer assessment (FMA) was used to evaluate motor function of stroke patients. Rey Auditory Verbal Learning Test (RAVLT) used to assess verbal learning and memory, including short-term and long-term memory (<xref rid="ref9001" ref-type="bibr">Hochstenbach et al. 1998</xref>). The working memory (WM) test included number 1-back and spatial 1-back tasks. E-Prime software, developed by Psychology Software Tools in Pittsburgh, PA, USA, was utilized to measure the accuracy (ACC) and response time (RT) of the participants. The 1-back task is a continuous processing model that effectively evaluates WM function and is widely employed in neuroscience research. The detailed clinical data are described in <xref rid="tab1" ref-type="table">Table 1</xref>.</p></sec><sec id="sec9"><title>Structutral MR images acquisition</title><p>High-resolution structural MRI images were acquired using 3.0&#8239;T MR scanners at three hospitals, including two GE Healthcare Discovery MR750 scanners and one Siemens Magnetom TrioTim scanner. For MR750, a brain volume (BRAVO) sequence was applied with the following parameters: Repetition Time (TR)/Echo Time (TE)/Inversion Time (TI)&#8239;=&#8239;8.14/3.17/450&#8239;ms, flip angle&#8239;=&#8239;12&#176;, field of view (FOV)&#8239;=&#8239;256&#8239;mm&#8239;&#215;&#8239;256&#8239;mm, matrix&#8239;=&#8239;256&#8239;&#215;&#8239;256, thickness&#8239;=&#8239;1&#8239;mm, slices&#8239;=&#8239;188, voxel size&#8239;=&#8239;1&#8239;mm&#8239;&#215;&#8239;1&#8239;mm&#8239;&#215;&#8239;1&#8239;mm; for TrioTim, a magnetization prepared rapid acquisition gradient echo (MPRAGE) sequence was used: TR/TE/TI&#8239;=&#8239;2000/2.26/900&#8239;ms, flip angle&#8239;=&#8239;9&#176;, FOV&#8239;=&#8239;256&#8239;mm&#8239;&#215;&#8239;232&#8239;mm, matrix&#8239;=&#8239;256&#8239;&#215;&#8239;232, thickness&#8239;=&#8239;1&#8239;mm, and slices&#8239;=&#8239;192, resulting in a 1&#8239;mm isotropic voxel.</p></sec><sec id="sec10"><title>Segmentation of thalamic subfields</title><p>Thalamic subfields were segmented using FreeSurfer software v7.1.1.<xref rid="fn0001" ref-type="fn"><sup>1</sup></xref> The thalamic subfields module in FreeSurfer was used to perform automated segmentation of the thalamus, based on probabilistic atlases derived from histological data. This segmentation used each subject&#8217;s high-resolution T1 structural images and was processed with a Bayesian algorithm through the recon-all pipeline. This approach successfully segmented the thalamus into 25 distinct subfields per hemisphere (<xref rid="ref20" ref-type="bibr">Iglesias et al., 2018</xref>; <xref rid="ref32" ref-type="bibr">Manmatharayan et al., 2023</xref>). Each subfield was automatically labeled, and its volume was extracted. The total volume of the bilateral thalamus and the total intracranial volume were also derived. <xref rid="fig1" ref-type="fig">Figure 1</xref> illustrates the thalamic subfield segmentations for a representative healthy control subject.</p><fig position="float" id="fig1" orientation="portrait"><label>Figure 1</label><caption><p>Schematic overview of the thalamic subfield segmentations for one NC subject. L: left, R: right.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnins-19-1650937-g001.jpg"><alt-text content-type="machine-generated">Illustration of thalamic nuclei, showing anterior, lateral, ventral, intralaminar, posterior, and medial regions in distinct colors. Labels and color codes identify various regions like AV, CeM, CL, and others. MRI images on the right display the corresponding anatomical sections for comparison.</alt-text></graphic></fig></sec><sec id="sec11"><title>Voxel-based morphometry of the whole brain</title><p>High-resolution structural MRI images were further preprocessed using a VBM pipeline with the CAT12.7 (r1742) toolbox<xref rid="fn0002" ref-type="fn"><sup>2</sup></xref> integrated within SPM12<xref rid="fn0003" ref-type="fn"><sup>3</sup></xref> in MATLAB 2016b to derive gray matter volume (GMV). Key steps included: (1) bias-field correction to ensure image singal uniformity; (2) tissue segmentation to distinguish between gray matter, white matter, and cerebrospinal fluid; (3) normalization to MNI space using the DARTEL algorithm for standardization across subjects; (4) resampling to a resolution of 1.5&#8239;&#215;&#8239;1.5&#8239;&#215;&#8239;1.5&#8239;mm; and (5) smoothing of gray matter maps using a 6&#8239;mm FWHM Gaussian kernel to enhance the signal-to-noise ratio and minimize local variations.</p></sec><sec id="sec12"><title>The stroke lesion probability map calculation</title><p>First, an experienced neuroradiologist used MRIcron software to precisely identify and manually delineate each stroke patient&#8217;s lesion on the original T1-weighted images, creating a customized lesion mask for each patient. Second, these T1-weighted images were spatially normalized to MNI space. The lesion masks were then co-registered to MNI space using the normalization parameters. Finally, a group-level lesion probability map was generated by combining all lesion masks in MNI space and dividing by the number of patients. The stroke lesion probability map is shown in <xref rid="fig2" ref-type="fig">Figure 2</xref>.</p><fig position="float" id="fig2" orientation="portrait"><label>Figure 2</label><caption><p>Probability maps of capsular stroke lesions. Color bar represents the lesion probability across patients.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnins-19-1650937-g002.jpg"><alt-text content-type="machine-generated">Three views of a brain scan showing highlighted areas in red and orange along the ventricular region. The intensity scale on the right ranges from five to twenty-five.</alt-text></graphic></fig></sec><sec id="sec13"><title>Statistical analyses</title><sec id="sec14"><title>Demography and clinical statistics</title><p>One-sample Kolmogorov Smirnov test was used to evaluate the distribution of continuous data. Two-sample <italic toggle="yes">t</italic>-test (normal distribution) or the Mann&#8211;Whitney U test (non-normal distribution) were used to compare inter-group differences for continuous variables. Chi-square test was used for categorical variables including gender (<italic toggle="yes">p</italic>&#8239;&lt;&#8239;0.05).</p></sec><sec id="sec15"><title>Inter-group differences in SCN between thalamic subfields and each brain voxel</title><p>To estimate and compare the GMV covariance connectivity (SCN) between CS and NC, a general linear model (GLM) implemented in SPM12 was used with the <xref rid="EQ1" ref-type="disp-formula">Equation 1</xref>:</p><disp-formula id="EQ1"><label>(1)</label><mml:math id="M1" overflow="scroll"><mml:mtable columnalign="left" displaystyle="true"><mml:mtr><mml:mtd><mml:mi mathvariant="italic">GMV</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mi>&#946;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>&#8727;</mml:mo><mml:mtext mathvariant="italic">Labe</mml:mtext><mml:msub><mml:mi>l</mml:mi><mml:mi mathvariant="italic">cs</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#946;</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>&#8727;</mml:mo><mml:mtext mathvariant="italic">Labe</mml:mtext><mml:msub><mml:mi>l</mml:mi><mml:mi mathvariant="italic">nc</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#946;</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mo>&#8727;</mml:mo><mml:mtext mathvariant="italic">SubfieldVolum</mml:mtext><mml:msub><mml:mi>e</mml:mi><mml:mi mathvariant="italic">cs</mml:mi></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo>+</mml:mo><mml:msub><mml:mi>&#946;</mml:mi><mml:mn>4</mml:mn></mml:msub><mml:mo>&#8727;</mml:mo><mml:mtext mathvariant="italic">SubfieldVolum</mml:mtext><mml:msub><mml:mi>e</mml:mi><mml:mi mathvariant="italic">nc</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mo>&#8721;</mml:mo><mml:msub><mml:mi>&#946;</mml:mi><mml:mi>x</mml:mi></mml:msub><mml:mo>&#8727;</mml:mo><mml:mtext mathvariant="italic">Confounders</mml:mtext><mml:mo>+</mml:mo><mml:mi>&#949;</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula><p>Where <inline-formula>
<mml:math id="M2" overflow="scroll"><mml:mtext mathvariant="italic">Label</mml:mtext></mml:math>
</inline-formula> represents the group identifier, such that <inline-formula>
<mml:math id="M3" overflow="scroll"><mml:msub><mml:mi>&#946;</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:math>
</inline-formula> and <inline-formula>
<mml:math id="M4" overflow="scroll"><mml:msub><mml:mi>&#946;</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:math>
</inline-formula> represents the mean GMV for CS and NC group, respectively. <inline-formula>
<mml:math id="M5" overflow="scroll"><mml:mtext mathvariant="italic">SubfieldVolume</mml:mtext></mml:math>
</inline-formula> represents the <italic toggle="yes">z</italic>-scored volume of a thalamic subfield, and its coefficients (<inline-formula>
<mml:math id="M6" overflow="scroll"><mml:msub><mml:mi>&#946;</mml:mi><mml:mn>3</mml:mn></mml:msub></mml:math>
</inline-formula> and <inline-formula>
<mml:math id="M7" overflow="scroll"><mml:msub><mml:mi>&#946;</mml:mi><mml:mn>4</mml:mn></mml:msub></mml:math>
</inline-formula>) represent the covariance connectivity between the volume of this thalamic subfield and each voxel in the whole brain for the CS and NC groups, respectively. Age, gender, scanner type, and total intracranial volume (TIV) were included in the model as covariates. A <italic toggle="yes">t</italic>-test was used to compare differences in covariance connectivity (contrast: [<inline-formula>
<mml:math id="M8" overflow="scroll"><mml:msub><mml:mi>&#946;</mml:mi><mml:mn>3</mml:mn></mml:msub></mml:math>
</inline-formula> - <inline-formula>
<mml:math id="M9" overflow="scroll"><mml:msub><mml:mi>&#946;</mml:mi><mml:mn>4</mml:mn></mml:msub></mml:math>
</inline-formula>]) between the CS and NC groups, with a voxel-wise threshold of <italic toggle="yes">p</italic>&#8239;&lt;&#8239;0.001 and cluster-wise correction for multiple comparisons at <italic toggle="yes">p</italic>&#8239;&lt;&#8239;0.05 using the family-wise error (FWE) method. We also carried the same analysis on the whole thalamus to compare the sensitivity of the SCN changes detected by whole thalamus analysis and those by thalamic subfields ways. For all voxel-wise statistics, voxels falling within the stroke lesion of any patients were excluded.</p></sec><sec id="sec16"><title>ROI extraction and <italic toggle="yes">post-hoc</italic> statistics</title><p>To identify the specific patterns of covariance connectivity disruption within thalamic subfields in CS, we extracted the mean GMV values from cortical and subcortical regions showing altered covariance with these thalamic subfields. Key steps included: (1) generating a binary mask from the statistical map for each thalamic subfield, preserving voxels showing significant between-group differences in SCN; (2) creating a union mask by combining the binary masks of all thalamic subfields; (3) identifying overlapping voxels between the union mask and each region defined by the Automated Anatomical Labeling 3 (AAL3) atlas (<xref rid="ref37" ref-type="bibr">Rolls et al., 2020</xref>), and calculating the overlapping ratio between the intersecting voxels and each AAL3 region; (4) identifying target regions of interest (ROIs) based on a criterion that the overlapping ratio exceeded 10%; and (5) for each subject, extracting the average GMV within each selected target ROI. Subsequently, a ROI-based general linear model (GLM) analysis was conducted the <italic toggle="yes">post-hoc</italic> analysis with the same model as <xref rid="EQ1" ref-type="disp-formula">Equation 1</xref> (<italic toggle="yes">p</italic> &lt;&#8239;0.05, Bonferroni correction).</p></sec><sec id="sec17"><title>Inter-group differences in regional GMV of thalamic subfields</title><p>Intergroup differences in regional GMV of thalamic subfields were also compared using GLM model, with group as the main effect, controlling for confouders such as age, gender, scanner type, and total intracranial volume (TIV) [<italic toggle="yes">p</italic>&#8239;&lt;&#8239;0.05, false discovery rate (FDR) correction].</p></sec><sec id="sec18"><title>Correlation between alterated GMV covariance connectivity and clinical metrics in CS patients</title><p>A Spearman partial correlation analysis was used to test the association between clinical features (RAVLT_SR, RAVLT_LR, N_ACC, N_RT, S_ACC, S_RT and FMA) and thalamic SCN, controlling for the effects of age, gender, and scanners and the clinical features (<italic toggle="yes">p</italic>&#8239;&lt;&#8239;0.05, FDR correction).</p></sec></sec></sec><sec sec-type="results" id="sec19"><title>Result</title><sec id="sec20"><title>Demographic and clinical information</title><p>The characteristics of the subjects were shown in <xref rid="tab1" ref-type="table">Table 1</xref>. There were no significant differences in age (two-sample <italic toggle="yes">t</italic>-test, <italic toggle="yes">t</italic> =&#8239;0.012, <italic toggle="yes">p</italic> =&#8239;0.990) and gender (<italic toggle="yes">&#967;</italic><sup>2</sup> =&#8239;0.478, <italic toggle="yes">p</italic> =&#8239;0.489) between the CS and NC. A preponderance of stroke patients demonstrate a substantial recovery in their motor function [FMA quantile&#8239;=&#8239;(82.5, 100)]. In comparison to the NC group, the RAVLT-SR scores in the CS group exhibited a significant decrease (<italic toggle="yes">t</italic> =&#8239;3.807, <italic toggle="yes">p</italic> &lt;&#8239;0.001). However, no inter-group differences were observed for the RAVLT-LR scores (<italic toggle="yes">Z</italic> =&#8239;&#8722;2.25, <italic toggle="yes">p</italic> =&#8239;0.024), reaction time of number 1-back (<italic toggle="yes">Z</italic> =&#8239;&#8722;1.617, <italic toggle="yes">p</italic> =&#8239;0.106), spatial 1-back task (<italic toggle="yes">Z</italic> =&#8239;&#8722;1.580, <italic toggle="yes">p</italic> =&#8239;0.114), number 1-back (<italic toggle="yes">Z</italic> =&#8239;&#8722;1.082, <italic toggle="yes">p</italic> =&#8239;0.279) and spatial 1-back (Z&#8239;=&#8239;&#8722;1.164, <italic toggle="yes">p</italic> =&#8239;0.245) tasks. There were significant differences in volume of TIV and WM between the CS and NC, and no significant difference in volume of GM and CSF between the two groups (<xref rid="SM1" ref-type="supplementary-material">Supplementary Figure 1</xref>).</p></sec><sec id="sec21"><title>Inter-group SCN difference of thalamic subfields</title><p>Voxel-wise GLM analysis revealed significant changed SCN between either one of the thalamic subfields and widespread of brain regions (<xref rid="fig3" ref-type="fig">Figure 3A</xref>), including the bilateral orbitofrontal cortex (OFC), bilateral dorsal and ventral visual cortex, ipsilesional thalamus, ipsilesional caudate, ipsilesional striatum, bilateral the anterior cingulate cortex (ACC), and so on. In contrast, increased SCN was only shown between the ipsilesional ventral visual cortex and the whole thalamus (<xref rid="fig3" ref-type="fig">Figure 3B</xref>) (<italic toggle="yes">p</italic>&#8239;&lt;&#8239;0.05, cluster-wise FWE correction).</p><fig position="float" id="fig3" orientation="portrait"><label>Figure 3</label><caption><p>Different masks showthe notable GMV covariance results: thalamic subfields (<bold>A</bold>, red) and entire thalamus (<bold>B</bold>, green).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnins-19-1650937-g003.jpg"><alt-text content-type="machine-generated">MRI brain scans displaying areas of activation. Section A shows multiple regions highlighted in red across various slices, indicating areas of interest or activity. Section B shows fewer green-highlighted areas in different slices, suggesting different regions of activation. The images are labeled with "L" for left and "R" for right.</alt-text></graphic></fig><p>We observed notably increased SCN for 16/25 ipsilesional thalamic subfields, including AV, LD, LP, VLa, VLp, VPL, VM, CeM, CL, MDm, LGN, PuM, PuI, CM, Pf and Pt (<xref rid="fig4" ref-type="fig">Figure 4A</xref>). Besides, we found 3/25 contralesional thalamic subfields showing increased SCN with the ipsilesional OFC, thalamus and striatum (<xref rid="fig5" ref-type="fig">Figure 5A</xref>).</p><fig position="float" id="fig4" orientation="portrait"><label>Figure 4</label><caption><p>Brain regions with increased SCN in only ipsilesional thalamic subfields. Panel <bold>(A)</bold> Pshows the brain regions with changed SCN in each thalamic subfield. Color bar represents the T-values. <bold>(B)</bold> GMV covariance dot-line graph of the 13 thalamic subfields. The T-value of dot-line graph indicating inter-group differences in the covariance of GMV.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnins-19-1650937-g004.jpg"><alt-text content-type="machine-generated">MRI images and graphs illustrate various subfields of the ipsilesional thalamus. Subfields like VPL, VLa, and VM are highlighted in yellow, indicating specific areas of activity. On the right, graphs display T values for each subfield over different conditions or time points, using colored lines to differentiate subfields like Right_VPL, Right_VM, etc. A color scale ranges from red to yellow, representing intensity levels from 0 to 6.</alt-text></graphic></fig><fig position="float" id="fig5" orientation="portrait"><label>Figure 5</label><caption><p>Brain regions with increased SCN in bilateral thalamic subfields. Panel <bold>(A)</bold> shows the brain regions with changed SCN in each thalamic subfield. Color bar represents the T-values. <bold>(B)</bold> GMV covariance dot-line graph of the six thalamic subfields. The T-value of dot-line graph indicating inter-group differences in the covariance of GMV.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnins-19-1650937-g005.jpg"><alt-text content-type="machine-generated">Brain scan images and graphs showing ipsilesional and contralesional thalamus subregions CM, Pt, and Pf. The left side presents highlighted brain areas in yellow and red. The right side displays line graphs for right CM, left CM, right Pt, left Pt, right Pf, and left Pf T-values, with horizontal axes labeled with brain region codes. A color scale indicates intensity levels.</alt-text></graphic></fig></sec><sec id="sec22"><title>Subfield-specific SCN change patterns of CS patients</title><p>Based on the ROIs defined in the methods section, we selected 19 specific target regions. Dot-line graphs were created to illustrate the subfield-specific amplitudes of SCN changes (T-values) between each thalamic subregion and the 19 selected ROIs in CS patients (<xref rid="fig4" ref-type="fig">Figures 4B</xref>, <xref rid="fig5" ref-type="fig">5B</xref>). Specifically, the ipsilesional SOG exhibited strengthened SCN with the ipsilesional VPL, VM, AV, VLa, LGN, and VLp, while the contralesional SOG showed strengthened SCN with the ipsilesional VPL and VM. The ipsilesional OFC demonstrated strengthened SCN with the ipsilesional VPL, VM, PuM, PuI, and CL. The ipsilesional ACC displayed strengthened SCN with the VPL. The ipsilesional medial thalamus showed strengthened SCN with the VPL, AV, LP, CL, and Cem, and the ipsilesional sensorimotor cortex (SMC) exhibited strengthened SCN with the ipsilesional LD and MDm.</p></sec><sec id="sec23"><title>Subfields of thalamus GMV analysis</title><p>ROI-wise GLM analysis revealed a significant reduction in GMV across all 25 ipsilesional thalamic subfields in CS patients (<xref rid="SM1" ref-type="supplementary-material">Supplementary Figure 2</xref>) (<italic toggle="yes">p</italic> &lt;&#8239;0.05, FDR correction). In contrast, no statistically significant GMV differences were observed in the contralesional thalamic subfields (<xref rid="SM1" ref-type="supplementary-material">Supplementary Figure 3</xref>) (<italic toggle="yes">p</italic> &gt;&#8239;0.05, FDR correction).</p></sec><sec id="sec24"><title>Association between the GMV covariance and clinical information</title><p>Spearman partial correlation analysis did not reveal any significant associations between thalamic SCN and clinical metrics after multiple comparison corrections (<italic toggle="yes">p</italic> &gt;&#8239;0.05, FDR correction). However, using a looser threshold (<italic toggle="yes">p</italic> &lt;&#8239;0.05, uncorrected), we found that spatial 1-back accuracy showed the highest number of weak associations with thalamic SCN in both ipsilesional (<italic toggle="yes">N</italic> =&#8239;19) and contralesional (<italic toggle="yes">N</italic> =&#8239;16) subfields in CS patients, followed by short-term memory performance on the RAVLT (<italic toggle="yes">N</italic> =&#8239;8 for ipsilesional, <italic toggle="yes">N</italic> =&#8239;16 for contralesional) (<xref rid="SM1" ref-type="supplementary-material">Supplementary Figure 4</xref>). On a subfield level, the ipsilesional L_Sg exhibited the highest number of weak associations (<italic toggle="yes">N</italic> =&#8239;6) with the clinical metrics, followed by the ipsilesional MGN (<italic toggle="yes">N</italic> =&#8239;5) (One L_Sg and one MGN were, respectively, associated with FMA). Additionally, the contralesional MGN, LD, and Pt also showed several weak associations (<italic toggle="yes">N</italic> =&#8239;4 for each subfield) with clinical metrics (<xref rid="SM1" ref-type="supplementary-material">Supplementary Figure 5</xref> and <xref rid="SM1" ref-type="supplementary-material">Supplementary Tables 1&#8211;13</xref>). We also found that S_ACC showed the highest number of weak associations with thalamic SCN in right thalamic subfields (<italic toggle="yes">N</italic> =&#8239;15), in NC group, followed by N_ACC (<italic toggle="yes">N</italic> =&#8239;14). Additionally, some subfields of the left thalamus SCN also showed weak correlation with working memory (<xref rid="SM1" ref-type="supplementary-material">Supplementary Figure 6</xref>). On a subfield level, the right MGN exhibited the highest number of weak associations (<italic toggle="yes">N</italic> =&#8239;5) with the cognication metrics, followed by the right LGN, PuI, VLp (<italic toggle="yes">N</italic> =&#8239;4) (<xref rid="SM1" ref-type="supplementary-material">Supplementary Figure 7</xref>). The correlation between the right thalamic SCN and RAVLT_LR, N_ACC, N_RT, S_ACC, and S_RT also showed weak positive or negative associations between the CS and NC groups (<xref rid="SM1" ref-type="supplementary-material">Supplementary Figure 8</xref>). The correlation between the left thalamic SCN and RAVLT_LR also showed weak positive associations between the CS and NC groups (<xref rid="SM1" ref-type="supplementary-material">Supplementary Figure 9</xref>).</p></sec></sec><sec sec-type="discussion" id="sec25"><title>Discussion</title><p>This study systematically investigates alterations in thalamic subfield structural covariance networks (SCNs) in patients with chronic right capsular stroke (CS), providing novel insights into thalamocortical reorganization mechanisms underlying post-stroke recovery. Utilizing high-resolution thalamic segmentation, we identified three key findings: (1) Subfield-level SCN mapping demonstrates superior sensitivity in detecting network-specific disruptions compared to conventional whole-thalamus approaches; (2) The GMV covariance networks of thalamic subfields are selectively involved in patients with chronic capsular stroke; and (3) contralesional thalamic subfields exhibit adaptive SCN remodeling despite preserved gray matter volume. These findings challenge the traditional whole-thalamus analytical framework and establish the critical role of subfield-specific network reorganization in stroke recovery, offering novel spatial-resolution perspectives for understanding neural plasticity, thereby enhancing our comprehension of the distinct functions played by thalamic subfields in the pathological course of CS.</p><p>The thalamus comprises functionally differentiated subfields, with distinct nuclei mediating specialized neural processes (<xref rid="ref10" ref-type="bibr">Corona et al., 2020</xref>; <xref rid="ref20" ref-type="bibr">Iglesias et al., 2018</xref>). The fundamental limitation of whole-thalamus analyses stems from the forced homogenization of inherently heterogeneous structures (<xref rid="ref54" ref-type="bibr">Yuan et al., 2015</xref>), which obscures subfield-level functional antagonism or complementary patterns through artificial neutralization. While this simplification reduces analytical complexity, it critically compromises the understanding of fine-grained thalamic functional architecture and the pathophysiological mechanisms underlying thalamic-related disorder (<xref rid="ref1" ref-type="bibr">Antonucci et al., 2021</xref>; <xref rid="ref28" ref-type="bibr">Lin et al., 2018</xref>; <xref rid="ref33" ref-type="bibr">McKenna et al., 2023</xref>; <xref rid="ref52" ref-type="bibr">Yang et al., 2023</xref>). The high-resolution thalamic segmentation framework proposed by <xref rid="ref20" ref-type="bibr">Iglesias et al. (2018)</xref> enables subfield-level structural covariance network (SCN) analysis, substantially enhancing our capacity to detect post-stroke thalamocortical network pathology. In our study, the whole-thalamus analysis identified only ipsilesional ventral visual cortex-thalamus SCN enhancement (<xref rid="fig3" ref-type="fig">Figure. 3B</xref>). In contrast, subfield-specific analysis revealed significant GMV covariance alterations in 16/25 ipsilesional and 3/25 contralesional thalamic subfields (<xref rid="fig4" ref-type="fig">Figures 4A</xref>, <xref rid="fig5" ref-type="fig">5A</xref>), demonstrating the superior sensitivity of subfield-level approaches&#8212;consistent with prior studies showing that subfield decomposition uncovers otherwise hidden network changes (<xref rid="ref11" ref-type="bibr">d'Ambrosio et al., 2017</xref>; <xref rid="ref47" ref-type="bibr">Tung et al., 2022</xref>). Analogous methodology in schizophrenia research highlights the value of subfieldal decomposition&#8212;amygdala subfield analysis reveals more extensive GMV covariance abnormalities and distinct subfieldal engagement patterns, advancing understanding of limbic pathophysiology (<xref rid="ref7" ref-type="bibr">Chang et al., 2024</xref>). These convergent findings underscore the critical advantage of subfield-level paradigms in elucidating network-level neuropathology.</p><p>While the thalamus does not receive direct vascular supply from the middle cerebral artery (MCA), accumulating evidence suggests that MCA infarction may induce secondary microstructural damage to the ipsilesional thalamus through remote degenerative mechanisms (<xref rid="ref18" ref-type="bibr">Herve et al., 2005</xref>; <xref rid="ref30" ref-type="bibr">Liu et al., 2019</xref>). Our findings extend these observations by demonstrating significant volumetric reduction of the ipsilesional thalamus in chronic capsular stroke patients, consistent with the thalamic atrophy patterns reported in prior studies (<xref rid="ref30" ref-type="bibr">Liu et al., 2019</xref>; <xref rid="ref48" ref-type="bibr">Wang et al., 2019</xref>). Through high-resolution thalamic parcellation into 25 distinct subfields, we further revealed that this volume loss occurred diffusely across all thalamic subfields compared to healthy controls. This whole thalamic degeneration pattern implies that secondary thalamic damage following capsular stroke may involve more extensive disconnection mechanisms than previously recognized (<xref rid="ref18" ref-type="bibr">Herve et al., 2005</xref>; <xref rid="ref30" ref-type="bibr">Liu et al., 2019</xref>; <xref rid="ref48" ref-type="bibr">Wang et al., 2019</xref>), potentially disrupting both corticothalamic and thalamostriatal pathways (<xref rid="ref14" ref-type="bibr">Haber and Calzavara, 2009</xref>; <xref rid="ref26" ref-type="bibr">Lambert et al., 2017</xref>). The specific vulnerability of thalamic nuclei to retrograde degeneration might stem from their pivotal role as multimodal integration hubs within distributed cortical&#8211;subcortical networks (<xref rid="ref19" ref-type="bibr">Hwang et al., 2017</xref>; <xref rid="ref41" ref-type="bibr">Sherman, 2016</xref>; <xref rid="ref46" ref-type="bibr">Tu et al., 2023</xref>).</p><p>Despite this widespread atrophy of thalamic subfields, SCN enhancements were selective: 16 ipsilesional subfields (e.g., VPL, VM, PuM) showed increased covariance with specific cortical regions, suggesting that structural covariance remodeling is not a random response but a targeted adaptation to preserve critical functions. We speculated that this may be related to the location of the lesions (<xref rid="ref13" ref-type="bibr">Guo et al., 2019</xref>; <xref rid="ref22" ref-type="bibr">Jiang et al., 2017</xref>; <xref rid="ref48" ref-type="bibr">Wang et al., 2019</xref>). We observed that different thalamic subfields could demonstrate covariation with the same cerebral cortex.</p><p>For instance, ipsilesional thalamic subfields (VPL, VM, AV, VLa, LGN, and VLp) exhibited strengthened SCN with the superior occipital gyrus (SOG)&#8212;a region central to visual processing and spatial attention (<xref rid="ref16" ref-type="bibr">Hageter et al., 2023</xref>; <xref rid="ref36" ref-type="bibr">Reinhold et al., 2023</xref>). These subfields are key nodes in somatosensory, cognitive, visual, and motor pathways (<xref rid="ref9" ref-type="bibr">Choi et al., 2022</xref>; <xref rid="ref26" ref-type="bibr">Lambert et al., 2017</xref>), their enhanced covariance with the SOG likely reflects cross-modal compensation: as ascending sensory pathways are disrupted by capsular lesions (<xref rid="ref17" ref-type="bibr">Herrero et al., 2002</xref>), residual connections between thalamic subfields and the SOG may be reinforced to maintain visual-somatosensory integration. Similarly, the ipsilesional OFCant also exhibited increased SCN with several thalamic subregions, such as VPL, VM, PuM, PuI, CM, and Pt. As research conducted by <xref rid="ref2" ref-type="bibr">Bechara et al. (2000)</xref> has demonstrated, the OFC plays a vital role in decision-making and emotional regulation. This pattern suggests adaptive remodeling of thalamocortical loops supporting cognitive-emotional functions, consistent with prior findings that thalamo-cortical connectivity preserves affective stability post-stroke (<xref rid="ref43" ref-type="bibr">Steiner et al., 2022</xref>). Furthermore, the strengthened SCN between the ipsilesional sensorimotor cortex (SMC) and the ipsilesional LD and MDm is also notable. According to previous studies, the MDm are associated with motor control and integration of sensory and motor information (<xref rid="ref8" ref-type="bibr">Choi et al., 2020</xref>; <xref rid="ref44" ref-type="bibr">Stockert et al., 2023</xref>).</p><p>In striking contrast to the ipsilesional thalamus, contralesional subfields showed no significant volume changes but exhibited enhanced SCN in 3/25 subfields&#8212;specifically with the ipsilesional OFCant, thalamus, and striatum. This dissociation between structural volume and covariance dynamics highlights a unique form of neural plasticity: the contralesional thalamus, though structurally intact, reorganizes its network connections to compensate for ipsilesional deficits. This pattern is best explained by the &#8220;diaschisis&#8221; effect&#8212;a phenomenon where focal brain lesions induce functional or structural changes in remote, interconnected regions (<xref rid="ref6" ref-type="bibr">Carmichael et al., 2004</xref>; <xref rid="ref39" ref-type="bibr">Seitz et al., 1999</xref>). Previous study (<xref rid="ref53" ref-type="bibr">Yassi et al., 2015</xref>) demonstrated that contralesional thalamic microstructure is altered post-stroke, linked to functional disconnection of ipsilateral cortical regions; our findings extend this by showing that such changes manifest as enhanced structural covariance with the ipsilateral OFCant. Specifically, the contralesional thalamus may leverage interhemispheric projections (e.g., via the corpus callosum) to assume a &#8220;relay&#8221; role: as direct pathways from the ipsilesional thalamus to OFCant are damaged, contralesional subfields strengthen indirect connections to sustain critical cognitive-emotional functions. This is supported by <xref rid="ref12" ref-type="bibr">Dermon and Barbas (1994)</xref> who identified robust contralateral thalamic projections to orbital cortices in non-human primates, providing an anatomical substrate for such cross-hemispheric compensation.</p><p>Previous animal studies have demonstrated that the majority of thalamic nuclei project into one or more well-defined cortical areas (<xref rid="ref23" ref-type="bibr">Jones, 1990</xref>; <xref rid="ref50" ref-type="bibr">Wise et al., 1996</xref>). The connection between the thalamus and the cortex is not a simple one-to-one relationship; rather, multiple cortical regions receive input from a single thalamic nucleus and transmit information back to different thalamic nuclei (<xref rid="ref35" ref-type="bibr">Percheron et al., 1996</xref>). Hwang&#8217;s research also reveals significant functional connections between each nucleus and a minimum of three or more functional networks, and numerous cortical functional networks also demonstrate robust functional connections with multiple thalamic nuclei (<xref rid="ref19" ref-type="bibr">Hwang et al., 2017</xref>). In our study, we found that some thalamic subfields exhibited increased GMV covariance with different cortical regions, which not only belonged to different functional networks, but also spanned to the contralesional hemisphere. For example, the strengthened SCN between the ipsilesional VPL and VM and bilateral SOG and ipsilesional OFCant. This may be the fact that thalamic nuclei play important roles in various cortical systems, and there seems to be overlapping patterns of connections among certain nuclei (<xref rid="ref42" ref-type="bibr">Sherman and Usrey, 2024</xref>; <xref rid="ref54" ref-type="bibr">Yuan et al., 2015</xref>). This overlap results in heterogeneity in the functional characteristics of individual nuclei, further compounding the complexity of thalamic nuclei functional representations (<xref rid="ref40" ref-type="bibr">Sherman, 2007</xref>, <xref rid="ref41" ref-type="bibr">2016</xref>). Overall, these findings highlight the differential vulnerability and plasticity of thalamocortical circuits at the subfield level, providing valuable insights into the neural mechanisms underlying the observed structural changes.</p><p>In this study, after applying multiple comparison corrections, no significant correlation was identified between altered GMV covariance and clinical metrics in CS patients and the NC group&#8212;likely due to limited clinical variability: CS patients exhibited generally good functional recovery and mild symptoms, while NC group had no cognitive impairments, and this reduces the range of clinical measures needed to detect strong correlations. However, adopting a less stringent threshold (<italic toggle="yes">p</italic> &lt;&#8239;0.05, uncorrected) revealed several intriguing yet weak associations. In CS patients, S_ACC showed the highest number of these weak associations with thalamic SCN: 19 in ipsilesional thalamic subfields and 16 in contralesional subfields, followed by RAVLT_SR with 8 associations in ipsilesional subfields and 16 in contralesional ones. This asymmetry reflects stroke-induced reliance on the ipsilesional thalamus for spatial working memory, while contralesional subfields contribute more to verbal memory. At the subfield level, the ipsilesional L_Sg was the top node (<italic toggle="yes">N</italic> =&#8239;6), followed by the ipsilesional MGN (<italic toggle="yes">N</italic> =&#8239;5), while the contralesional MGN, LD, and Pt each had 4 associations&#8212;indicating that CS patients rely disproportionately on ipsilesional subfields to sustain cognitive function, with contralesional subfields playing a secondary compensatory role. The NC group exhibited S_ACC had the weak associations with right thalamic SCN (<italic toggle="yes">N</italic> =&#8239;15), followed by N_ACC (<italic toggle="yes">N</italic> =&#8239;14), with left thalamic subfields also showing weak working memory links. Unlike CS group, NCs exhibited a right-weighted but non-lateralized pattern. Additional, the NC group also shared weak associations with CS patients for key metrics (e.g., right thalamic SCN with RAVLT_LR, working memory indices; left thalamic SCN with RAVLT_LR), indicating preserved fundamental thalamic-cognitive links. These cross-group findings collectively suggest that while no associations reached strict statistical significance, certain cognitive measures (especially spatial working memory) exhibit subtle relationships with specific thalamic subfields in both groups. The nuanced pattern of weak associations highlights the complexity of the relationship between thalamic subfields GMV covariance and behavior in CS patients, underscoring the need for more refined analytical approaches to fully elucidate these interactions. Future studies should explore potential confounding factors and consider longitudinal designs to better understand the temporal dynamics of these associations.</p></sec><sec id="sec26"><title>Limitation</title><p>Several limitations of our study should be considered. First, our patient cohort exhibits high homogeneity, characterized by nearly complete motor recovery (median FMA&#8239;=&#8239;100, interquartile range [82.5, 100]) and mild cognitive deficits. This is likely due to practical barriers in recruiting chronic stroke patients with moderate-to-severe deficits, who often cannot complete MRI scans or standardized assessments. The low variability in clinical measures weakened our ability to detect associations with SCN changes, as statistical power for correlation analyses depends on sufficient range in both variables. Furthermore, this sample bias limits generalizability: our findings may specifically reflect SCN remodeling in well-recovered chronic capsular stroke, rather than the broader stroke population (including those with persistent motor/cognitive impairments). Thus, our results should be interpreted with caution and validated in cohorts encompassing diverse recovery outcomes. Second, this is a cross-sectional study, which constraining its capacity to monitor the temporal variations in the covariance patterns of GMV across thalamic subfields. Longitudinal studies are crucial for observing the volume changes in thalamic subfields in stroke patients, as well as the progression of covariance between these subfields and cortical structures. Moreover, they are also essential for establishing clearer causal relationships between thalamic subfield structural covariance patterns and clinical outcomes. Additional validation in cohorts encompassing greater symptom severity heterogeneity is warranted to confirm these findings. Finally, our current research focuses on the structural covariance characteristics of thalamic subfields, but the study of the causal relationship with the structural covariance of the cerebral cortex is still shallow. In the future, we will deepen the research on the causal structural covariance of thalamic subfields to more accurately reveal the mechanism of its structural covariance with the cerebral cortex after stroke. This is crucial for understanding the interaction between them and the impact of stroke.</p></sec><sec sec-type="conclusions" id="sec27"><title>Conclusion</title><p>In conclusion, our research investigated the SCN of thalamic subfields in patients with capsular stroke for the first time. The GMV covariance networks of thalamic subfields, which are selectively involved in patients with chronic capsular stroke, affect not only the ipsilesional thalamic subfields but also the contralesional ones. These subfield-specific SCN disruptions likely reflect neurodegenerative cascades and compensatory plasticity mechanisms post-stroke, with implications for both motor and cognitive functional reorganization. Future research should prioritize longitudinal designs to delineate dynamic GMV covariance patterns across thalamic subfields and validate their clinical translatability as biomarkers of post-stroke.</p></sec></body><back><fn-group><fn id="fn0001"><p>
<sup>1</sup>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://surfer.nmr.mgh.harvard.edu/" ext-link-type="uri">https://surfer.nmr.mgh.harvard.edu/</ext-link>
</p></fn><fn id="fn0002"><p>
<sup>2</sup>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.neuro.uni-jena.de/cat/" ext-link-type="uri">http://www.neuro.uni-jena.de/cat/</ext-link>
</p></fn><fn id="fn0003"><p>
<sup>3</sup>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.fil.ion.ucl.ac.uk/spm/software/spm12/" ext-link-type="uri">http://www.fil.ion.ucl.ac.uk/spm/software/spm12/</ext-link>
</p></fn></fn-group><sec sec-type="data-availability" id="sec28"><title>Data availability statement</title><p>The original contributions presented in the study are included in the article/<xref rid="SM1" ref-type="supplementary-material">Supplementary material</xref>, further inquiries can be directed to the corresponding authors.</p></sec><sec sec-type="ethics-statement" id="sec29"><title>Ethics statement</title><p>The studies involving humans were approved by Tianjin Medical University General Hospital (IRB2015-092-02), Tianjin Huanhu Hospital (JinHuan 2022-103), and the first affiliated hospital of Zhengzhou University (2018-KY-03). The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.</p></sec><sec sec-type="author-contributions" id="sec30"><title>Author contributions</title><p>JG: Writing &#8211; original draft, Resources, Methodology, Investigation, Writing &#8211; review &amp; editing. HZ: Resources, Writing &#8211; review &amp; editing, Methodology, Investigation. JL: Resources, Methodology, Data curation, Investigation, Writing &#8211; review &amp; editing. CW: Resources, Methodology, Writing &#8211; review &amp; editing, Data curation, Investigation. CC: Investigation, Writing &#8211; review &amp; editing, Formal analysis, Methodology, Resources. JC: Investigation, Supervision, Writing &#8211; review &amp; editing, Resources. CY: Methodology, Writing &#8211; review &amp; editing, Supervision, Resources, Project administration. WQ: Project administration, Methodology, Writing &#8211; review &amp; editing, Supervision, Investigation.</p></sec><sec sec-type="COI-statement" id="sec32"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="sec33"><title>Generative AI statement</title><p>The authors declare that no Gen AI was used in the creation of this manuscript.</p><p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p></sec><sec sec-type="disclaimer" id="sec34"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec sec-type="supplementary-material" id="sec35"><title>Supplementary material</title><p>The Supplementary material for this article can be found online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.frontiersin.org/articles/10.3389/fnins.2025.1650937/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fnins.2025.1650937/full#supplementary-material</ext-link></p><supplementary-material id="SM1" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Data_Sheet_1.docx" position="float" orientation="portrait"/></supplementary-material></sec><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Antonucci</surname><given-names>L. A.</given-names></name><name name-style="western"><surname>Penzel</surname><given-names>N.</given-names></name><name name-style="western"><surname>Pigoni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dominke</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kambeitz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pergola</surname><given-names>G.</given-names></name></person-group> (<year>2021</year>). <article-title>Flexible and specific contributions of thalamic subdivisions to human cognition</article-title>. <source>Neurosci. Biobehav. Rev.</source><volume>124</volume>, <fpage>35</fpage>&#8211;<lpage>53</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neubiorev.2021.01.014</pub-id>, PMID: <pub-id pub-id-type="pmid">33497787</pub-id></mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bechara</surname><given-names>A.</given-names></name><name name-style="western"><surname>Damasio</surname><given-names>H.</given-names></name><name name-style="western"><surname>Damasio</surname><given-names>A.</given-names></name></person-group> (<year>2000</year>). <article-title>Emotion, decision making and the orbitofrontal cortex</article-title>. <source>Cereb. Cortex</source><volume>10</volume>, <fpage>295</fpage>&#8211;<lpage>307</lpage>. doi: <pub-id pub-id-type="doi">10.1093/cercor/10.3.295</pub-id><pub-id pub-id-type="pmid">10731224</pub-id></mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beloozerova</surname><given-names>I. N.</given-names></name><name name-style="western"><surname>Marlinski</surname><given-names>V.</given-names></name></person-group> (<year>2020</year>). <article-title>Contribution of the ventrolateral thalamus to the locomotion-related activity of motor cortex</article-title>. <source>J. Neurophysiol.</source><volume>124</volume>, <fpage>1480</fpage>&#8211;<lpage>1504</lpage>. doi: <pub-id pub-id-type="doi">10.1152/jn.00253.2020</pub-id>, PMID: <pub-id pub-id-type="pmid">32783584</pub-id><pub-id pub-id-type="pmcid">PMC7701357</pub-id></mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Biesbroek</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>N. A.</given-names></name><name name-style="western"><surname>Biessels</surname><given-names>G. J.</given-names></name></person-group> (<year>2017</year>). <article-title>Lesion location and cognitive impact of cerebral small vessel disease</article-title>. <source>Portland Press</source><volume>131</volume>, <fpage>715</fpage>&#8211;<lpage>728</lpage>. doi: <pub-id pub-id-type="doi">10.1042/CS20160452</pub-id><pub-id pub-id-type="pmid">28385827</pub-id></mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carey</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Abbott</surname><given-names>D. F.</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Puce</surname><given-names>A.</given-names></name><name name-style="western"><surname>Seitz</surname><given-names>R. J.</given-names></name><name name-style="western"><surname>Donnan</surname><given-names>G. A.</given-names></name></person-group> (<year>2011</year>). <article-title>Relationship between touch impairment and brain activation after lesions of subcortical and cortical somatosensory regions</article-title>. <source>Neurorehabil. Neural Repair</source><volume>25</volume>, <fpage>443</fpage>&#8211;<lpage>457</lpage>. doi: <pub-id pub-id-type="doi">10.1177/1545968310395777</pub-id>, PMID: <pub-id pub-id-type="pmid">21382887</pub-id></mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carmichael</surname><given-names>S. T.</given-names></name><name name-style="western"><surname>Tatsukawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Katsman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tsuyuguchi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kornblum</surname><given-names>H. I.</given-names></name></person-group> (<year>2004</year>). <article-title>Evolution of diaschisis in a focal stroke model</article-title>. <source>Stroke</source><volume>35</volume>, <fpage>758</fpage>&#8211;<lpage>763</lpage>. doi: <pub-id pub-id-type="doi">10.1161/01.Str.0000117235.11156.55</pub-id><pub-id pub-id-type="pmid">14963280</pub-id></mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>H.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Selective disrupted gray matter volume covariance of amygdala subregions in schizophrenia</article-title>. <source>Front. Psych.</source><volume>15</volume>, 1&#8211;14. doi: <pub-id pub-id-type="doi">10.3389/fpsyt.2024.1349989</pub-id>, PMID: <pub-id pub-id-type="pmid">38742128</pub-id><pub-id pub-id-type="pmcid">PMC11090100</pub-id></mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>K. T.</given-names></name><name name-style="western"><surname>Kwak</surname><given-names>S. G.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>M. C.</given-names></name></person-group> (<year>2020</year>). <article-title>Does injury of the thalamocortical connection between the mediodorsal nucleus of the thalamus and the dorsolateral prefrontal cortex affect motor recovery after cerebral infarct?</article-title><source>Acta Neurol. Belg.</source><volume>121</volume>, <fpage>921</fpage>&#8211;<lpage>926</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s13760-020-01309-2</pub-id><pub-id pub-id-type="pmid">32107716</pub-id></mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>E. Y.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>L.</given-names></name><name name-style="western"><surname>Su</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Radovan</surname><given-names>M. T.</given-names></name><name name-style="western"><surname>Tourdias</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>T.</given-names></name></person-group> (<year>2022</year>). <article-title>Thalamic nuclei atrophy at high and heterogenous rates during cognitively unimpaired human aging</article-title>. <source>NeuroImage</source><volume>262</volume>:<fpage>119584</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuroimage.2022.119584</pub-id><pub-id pub-id-type="pmid">36007822</pub-id><pub-id pub-id-type="pmcid">PMC9787236</pub-id></mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corona</surname><given-names>V.</given-names></name><name name-style="western"><surname>Lellmann</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nestor</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sch&#246;nlieb</surname><given-names>C. B.</given-names></name><name name-style="western"><surname>Acosta-Cabronero</surname><given-names>J.</given-names></name></person-group> (<year>2020</year>). <article-title>A multi-contrast MRI approach to thalamus segmentation</article-title>. <source>Hum. Brain Mapp.</source><volume>41</volume>, <fpage>2104</fpage>&#8211;<lpage>2120</lpage>. doi: <pub-id pub-id-type="doi">10.1002/hbm.24933</pub-id>, PMID: <pub-id pub-id-type="pmid">31957926</pub-id><pub-id pub-id-type="pmcid">PMC7267924</pub-id></mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>d'Ambrosio</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hidalgo de la Cruz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Valsasina</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pagani</surname><given-names>E.</given-names></name><name name-style="western"><surname>Colombo</surname><given-names>B.</given-names></name></person-group> (<year>2017</year>). <article-title>Structural connectivity-defined thalamic subregions have different functional connectivity abnormalities in multiple sclerosis patients: implications for clinical correlations</article-title>. <source>Hum. Brain Mapp.</source><volume>38</volume>, <fpage>6005</fpage>&#8211;<lpage>6018</lpage>. doi: <pub-id pub-id-type="doi">10.1002/hbm.23805</pub-id>, PMID: <pub-id pub-id-type="pmid">28881433</pub-id><pub-id pub-id-type="pmcid">PMC6866737</pub-id></mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dermon</surname><given-names>C. R.</given-names></name><name name-style="western"><surname>Barbas</surname><given-names>H.</given-names></name></person-group> (<year>1994</year>). <article-title>Contralateral thalamic projections predominantly reach transitional cortices in the rhesus monkey</article-title>. <source>J. Comp. Neurol.</source><volume>344</volume>, <fpage>508</fpage>&#8211;<lpage>531</lpage>. doi: <pub-id pub-id-type="doi">10.1002/cne.903440403</pub-id><pub-id pub-id-type="pmid">7523458</pub-id></mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Han</surname><given-names>T.</given-names></name></person-group> (<year>2019</year>). <article-title>Differential involvement of rubral branches in chronic capsular and pontine stroke</article-title>. <source>NeuroImage Clin</source><volume>24</volume>:<fpage>102090</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.nicl.2019.102090</pub-id><pub-id pub-id-type="pmid">31835285</pub-id><pub-id pub-id-type="pmcid">PMC6911903</pub-id></mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haber</surname><given-names>S. N.</given-names></name><name name-style="western"><surname>Calzavara</surname><given-names>R.</given-names></name></person-group> (<year>2009</year>). <article-title>The cortico-basal ganglia integrative network: the role of the thalamus</article-title>. <source>Brain Res. Bull.</source><volume>78</volume>, <fpage>69</fpage>&#8211;<lpage>74</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.brainresbull.2008.09.013</pub-id>, PMID: <pub-id pub-id-type="pmid">18950692</pub-id><pub-id pub-id-type="pmcid">PMC4459637</pub-id></mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haber</surname><given-names>S. N.</given-names></name><name name-style="western"><surname>McFarland</surname><given-names>N. R.</given-names></name></person-group> (<year>2002</year>). <article-title>Thalamic relay nuclei of the basal ganglia form both reciprocal and nonreciprocal cortical connections, linking multiple frontal cortical areas</article-title>. <source>J. Neurosci.</source><volume>22</volume>, <fpage>8117</fpage>&#8211;<lpage>8132</lpage>. doi: <pub-id pub-id-type="doi">10.1523/JNEUROSCI.22-18-08117.2002</pub-id><pub-id pub-id-type="pmid">12223566</pub-id><pub-id pub-id-type="pmcid">PMC6758100</pub-id></mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hageter</surname><given-names>J.</given-names></name><name name-style="western"><surname>Starkey</surname><given-names>J.</given-names></name><name name-style="western"><surname>Horstick</surname><given-names>E. J.</given-names></name></person-group> (<year>2023</year>). <article-title>Thalamic regulation of a visual critical period and motor behavior</article-title>. <source>Cell Rep.</source><volume>42</volume>:<fpage>112287</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.celrep.2023.112287</pub-id>, PMID: <pub-id pub-id-type="pmid">36952349</pub-id><pub-id pub-id-type="pmcid">PMC10514242</pub-id></mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herrero</surname><given-names>M. T.</given-names></name><name name-style="western"><surname>Barcia</surname><given-names>C.</given-names></name><name name-style="western"><surname>Navarro</surname><given-names>J. M.</given-names></name></person-group> (<year>2002</year>). <article-title>Functional anatomy of thalamus and basal ganglia</article-title>. <source>Childs Nerv. Syst.</source><volume>18</volume>, <fpage>386</fpage>&#8211;<lpage>404</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00381-002-0604-1</pub-id><pub-id pub-id-type="pmid">12192499</pub-id></mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herve</surname><given-names>D.</given-names></name><name name-style="western"><surname>Molko</surname><given-names>N.</given-names></name><name name-style="western"><surname>Pappata</surname><given-names>S.</given-names></name><name name-style="western"><surname>Buffon</surname><given-names>F.</given-names></name><name name-style="western"><surname>LeBihan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bousser</surname><given-names>M. G.</given-names></name><etal/></person-group>. (<year>2005</year>). <article-title>Longitudinal thalamic diffusion changes after middle cerebral artery infarcts</article-title>. <source>J. Neurol. Neurosurg. Psychiatry</source><volume>76</volume>, <fpage>200</fpage>&#8211;<lpage>205</lpage>. doi: <pub-id pub-id-type="doi">10.1136/jnnp.2004.041012</pub-id>, PMID: <pub-id pub-id-type="pmid">15654032</pub-id><pub-id pub-id-type="pmcid">PMC1739509</pub-id></mixed-citation></ref><ref id="ref9001"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hochstenbach</surname><given-names>J.</given-names></name><name name-style="western"><surname>van Spaendonck</surname><given-names>K. P.</given-names></name><name name-style="western"><surname>Cools</surname><given-names>A. R.</given-names></name><name name-style="western"><surname>Horstink</surname><given-names>M. W.</given-names></name><name name-style="western"><surname>Mulder</surname><given-names>T.</given-names></name></person-group> (<year>1998</year>). <article-title>Cognitive deficits following stroke in the basal ganglia</article-title>. <source>Clin Rehabil.</source><volume>12</volume>:<fpage>514</fpage>&#8211;20. doi: <pub-id pub-id-type="doi">10.1191/026921598666870672</pub-id>, PMID: <pub-id pub-id-type="pmid">9869255</pub-id></mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hwang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bertolero</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W. B.</given-names></name><name name-style="western"><surname>D'Esposito</surname><given-names>M.</given-names></name></person-group> (<year>2017</year>). <article-title>The human thalamus is an integrative hub for functional brain networks</article-title>. <source>J. Neurosci.</source><volume>37</volume>, <fpage>5594</fpage>&#8211;<lpage>5607</lpage>. doi: <pub-id pub-id-type="doi">10.1523/jneurosci.0067-17.2017</pub-id>, PMID: <pub-id pub-id-type="pmid">28450543</pub-id><pub-id pub-id-type="pmcid">PMC5469300</pub-id></mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iglesias</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Insausti</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lerma-Usabiaga</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bocchetta</surname><given-names>M.</given-names></name><name name-style="western"><surname>Van Leemput</surname><given-names>K.</given-names></name><name name-style="western"><surname>Greve</surname><given-names>D. N.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>A probabilistic atlas of the human thalamic nuclei combining ex vivo MRI and histology</article-title>. <source>NeuroImage</source><volume>183</volume>, <fpage>314</fpage>&#8211;<lpage>326</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuroimage.2018.08.012</pub-id><pub-id pub-id-type="pmid">30121337</pub-id><pub-id pub-id-type="pmcid">PMC6215335</pub-id></mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ilves</surname><given-names>N.</given-names></name><name name-style="western"><surname>L&#245;o</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ilves</surname><given-names>N.</given-names></name><name name-style="western"><surname>Laugesaar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Loorits</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kool</surname><given-names>P.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Ipsilesional volume loss of basal ganglia and thalamus is associated with poor hand function after ischemic perinatal stroke</article-title>. <source>BMC Neurol.</source><volume>23</volume>. doi: <pub-id pub-id-type="doi">10.1186/s12883-022-02550-3</pub-id><pub-id pub-id-type="pmcid">PMC8753896</pub-id><pub-id pub-id-type="pmid">35022000</pub-id></mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Han</surname><given-names>T.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Structural alterations in chronic capsular versus pontine stroke</article-title>. <source>Radiology</source><volume>285</volume>, <fpage>214</fpage>&#8211;<lpage>222</lpage>. doi: <pub-id pub-id-type="doi">10.1148/radiol.2017161055</pub-id><pub-id pub-id-type="pmid">28777703</pub-id></mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>E. G.</given-names></name></person-group> (<year>1990</year>). <article-title>Correlation and revised nomenclature of ventral nuclei in the thalamus of human and monkey</article-title>. <source>Stereotact. Funct. Neurosurg.</source><volume>54-55</volume>, <fpage>1</fpage>&#8211;<lpage>20</lpage>. doi: <pub-id pub-id-type="doi">10.1159/000100184</pub-id>, PMID: <pub-id pub-id-type="pmid">2127858</pub-id></mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khundrakpam</surname><given-names>B. S.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Reid</surname><given-names>A.</given-names></name><name name-style="western"><surname>Karama</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chouinard-Decorte</surname><given-names>F.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Imaging structural covariance in the development of intelligence</article-title>. <source>NeuroImage</source><volume>144</volume>, <fpage>227</fpage>&#8211;<lpage>240</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuroimage.2016.08.041</pub-id><pub-id pub-id-type="pmid">27554529</pub-id></mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Grodd</surname><given-names>W.</given-names></name></person-group> (<year>2014</year>). <article-title>Direct diffusion-based parcellation of the human thalamus</article-title>. <source>Brain Struct. Funct.</source><volume>220</volume>, <fpage>1619</fpage>&#8211;<lpage>1635</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00429-014-0748-2</pub-id><pub-id pub-id-type="pmid">24659254</pub-id></mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lambert</surname><given-names>C.</given-names></name><name name-style="western"><surname>Simon</surname><given-names>H.</given-names></name><name name-style="western"><surname>Colman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Barrick</surname><given-names>T. R.</given-names></name></person-group> (<year>2017</year>). <article-title>Defining thalamic nuclei and topographic connectivity gradients in vivo</article-title>. <source>NeuroImage</source><volume>158</volume>, <fpage>466</fpage>&#8211;<lpage>479</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuroimage.2016.08.028</pub-id><pub-id pub-id-type="pmid">27639355</pub-id></mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jacob</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Norris</surname><given-names>D. G.</given-names></name><name name-style="western"><surname>Marques</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Chamberland</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Dissociable contributions of thalamic-subregions to cognitive impairment in small vessel disease</article-title>. <source>Stroke</source><volume>54</volume>, <fpage>1367</fpage>&#8211;<lpage>1376</lpage>. doi: <pub-id pub-id-type="doi">10.1161/STROKEAHA.122.041687</pub-id><pub-id pub-id-type="pmid">36912138</pub-id><pub-id pub-id-type="pmcid">PMC10121245</pub-id></mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zivadinov</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hagemeier</surname><given-names>J.</given-names></name><name name-style="western"><surname>Weinstock-Guttman</surname><given-names>B.</given-names></name><name name-style="western"><surname>Vaughn</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gandhi</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Altered nuclei-specific thalamic functional connectivity patterns in multiple sclerosis and their associations with fatigue and cognition</article-title>. <source>Mult. Scler.</source><volume>25</volume>, <fpage>1243</fpage>&#8211;<lpage>1254</lpage>. doi: <pub-id pub-id-type="doi">10.1177/1352458518788218</pub-id><pub-id pub-id-type="pmid">30004291</pub-id></mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Structural covariances of prefrontal subregions selectively associate with dopamine-related gene coexpression and schizophrenia</article-title>. <source>Cereb. Cortex</source><volume>33</volume>, <fpage>8035</fpage>&#8211;<lpage>8045</lpage>. doi: <pub-id pub-id-type="doi">10.1093/cercor/bhad096</pub-id><pub-id pub-id-type="pmid">36935097</pub-id></mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Dang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>S.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>N.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Regional shape abnormalities in thalamus and verbal memory impairment after subcortical infarction</article-title>. <source>Neurorehabil. Neural Repair</source><volume>33</volume>, <fpage>476</fpage>&#8211;<lpage>485</lpage>. doi: <pub-id pub-id-type="doi">10.1177/1545968319846121</pub-id><pub-id pub-id-type="pmid">31081462</pub-id></mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mair</surname><given-names>R. G.</given-names></name><name name-style="western"><surname>Francoeur</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Krell</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>B. M.</given-names></name></person-group> (<year>2022</year>). <article-title>Where actions meet outcomes: medial prefrontal cortex, central thalamus, and the basal ganglia</article-title>. <source>Front. Behav. Neurosci.</source><volume>16</volume>:<fpage>928610</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnbeh.2022.928610</pub-id>, PMID: <pub-id pub-id-type="pmid">35864847</pub-id><pub-id pub-id-type="pmcid">PMC9294389</pub-id></mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manmatharayan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kogan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Matias</surname><given-names>C.</given-names></name><name name-style="western"><surname>Syed</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shelley</surname><given-names>I.</given-names></name><name name-style="western"><surname>Chinni</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Automated subfield volumetric analysis of amygdala, hippocampus, and thalamic nuclei in mesial temporal lobe epilepsy</article-title>. <source>World Neurosurg. X</source><volume>19</volume>:<fpage>100212</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.wnsx.2023.100212</pub-id>, PMID: <pub-id pub-id-type="pmid">37304157</pub-id><pub-id pub-id-type="pmcid">PMC10250154</pub-id></mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McKenna</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Lope</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bede</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>E. L.</given-names></name></person-group> (<year>2023</year>). <article-title>Thalamic pathology in frontotemporal dementia: predilection for specific nuclei, phenotype-specific signatures, clinical correlates, and practical relevance</article-title>. <source>Brain Behav.</source><volume>13</volume>:<fpage>e2881</fpage>. doi: <pub-id pub-id-type="doi">10.1002/brb3.2881</pub-id>, PMID: <pub-id pub-id-type="pmid">36609810</pub-id><pub-id pub-id-type="pmcid">PMC9927864</pub-id></mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pantoni</surname><given-names>L.</given-names></name><name name-style="western"><surname>Romanelli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Piccini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sarti</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nencini</surname><given-names>P.</given-names></name><name name-style="western"><surname>Inzitari</surname><given-names>D.</given-names></name></person-group> (<year>2001</year>). <article-title>Abulia and cognitive impairment in two patients with capsular genu infact.pdf</article-title>. <source>Acta Neurol. Scand.</source><volume>104</volume>, <fpage>185</fpage>&#8211;<lpage>190</lpage>. doi: <pub-id pub-id-type="doi">10.1034/J.1600-0404.2001.00370.X</pub-id><pub-id pub-id-type="pmid">11551242</pub-id></mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Percheron</surname><given-names>G.</given-names></name><name name-style="western"><surname>Talbi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yelnik</surname><given-names>J.</given-names></name><name name-style="western"><surname>F&#233;nelon</surname><given-names>G.</given-names></name></person-group> (<year>1996</year>). <article-title>Sagittal cytoarchitectonic maps of the <italic toggle="yes">Macaca mulatta</italic> thalamus with a revised nomenclature of the motor-related nuclei validated by observations on their connectivity</article-title>. <source>Brain Res. Rev.</source><volume>22</volume>, <fpage>93</fpage>&#8211;<lpage>181</lpage>. doi: <pub-id pub-id-type="doi">10.1002/cne.902620303</pub-id>8883918
</mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reinhold</surname><given-names>K.</given-names></name><name name-style="western"><surname>Resulaj</surname><given-names>A.</given-names></name><name name-style="western"><surname>Scanziani</surname><given-names>M.</given-names></name></person-group> (<year>2023</year>). <article-title>Brain state-dependent modulation of thalamic visual processing by Cortico-thalamic feedback</article-title>. <source>J. Neurosci.</source><volume>43</volume>, <fpage>1540</fpage>&#8211;<lpage>1554</lpage>. doi: <pub-id pub-id-type="doi">10.1523/jneurosci.2124-21.2022</pub-id>, PMID: <pub-id pub-id-type="pmid">36653192</pub-id><pub-id pub-id-type="pmcid">PMC10008059</pub-id></mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rolls</surname><given-names>E. T.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C. C.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C. P.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Joliot</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>Automated anatomical labelling atlas 3</article-title>. <source>NeuroImage</source><volume>206</volume>:<fpage>116189</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuroimage.2019.116189</pub-id>, PMID: <pub-id pub-id-type="pmid">31521825</pub-id></mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Romero-Garcia</surname><given-names>R.</given-names></name><name name-style="western"><surname>Whitaker</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>Vasa</surname><given-names>F.</given-names></name><name name-style="western"><surname>Seidlitz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shinn</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fonagy</surname><given-names>P.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Structural covariance networks are coupled to expression of genes enriched in supragranular layers of the human cortex</article-title>. <source>NeuroImage</source><volume>171</volume>, <fpage>256</fpage>&#8211;<lpage>267</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuroimage.2017.12.060</pub-id><pub-id pub-id-type="pmid">29274746</pub-id><pub-id pub-id-type="pmcid">PMC5883331</pub-id></mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seitz</surname><given-names>R. J.</given-names></name><name name-style="western"><surname>N.</surname><given-names>A.</given-names></name><name name-style="western"><surname>Knorr</surname><given-names>U.</given-names></name><name name-style="western"><surname>Binkofski</surname><given-names>F.</given-names></name><name name-style="western"><surname>Herzog</surname><given-names>H.</given-names></name><name name-style="western"><surname>Freund</surname><given-names>H. J</given-names></name></person-group>. (<year>1999</year>). <article-title>The role of diaschisis in stroke recovery</article-title>. <source>Stroke</source><volume>30</volume>, <fpage>1844</fpage>&#8211;<lpage>1850</lpage>. doi: <pub-id pub-id-type="doi">10.1161/01.str.30.9.1844</pub-id><pub-id pub-id-type="pmid">10471434</pub-id></mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sherman</surname><given-names>S. M.</given-names></name></person-group> (<year>2007</year>). <article-title>The thalamus is more than just a relay</article-title>. <source>Curr. Opin. Neurobiol.</source><volume>17</volume>, <fpage>417</fpage>&#8211;<lpage>422</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.conb.2007.07.003</pub-id>, PMID: <pub-id pub-id-type="pmid">17707635</pub-id><pub-id pub-id-type="pmcid">PMC2753250</pub-id></mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sherman</surname><given-names>S. M.</given-names></name></person-group> (<year>2016</year>). <article-title>Thalamus plays a central role in ongoing cortical functioning</article-title>. <source>Nat. Neurosci.</source><volume>19</volume>, <fpage>533</fpage>&#8211;<lpage>541</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nn.4269</pub-id>, PMID: <pub-id pub-id-type="pmid">27021938</pub-id></mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sherman</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Usrey</surname><given-names>W. M.</given-names></name></person-group> (<year>2024</year>). <article-title>Transthalamic pathways for cortical function</article-title>. <source>J. Neurosci.</source><volume>44</volume>:<fpage>e0909242024</fpage>. doi: <pub-id pub-id-type="doi">10.1523/jneurosci.0909-24.2024</pub-id>, PMID: <pub-id pub-id-type="pmid">39197951</pub-id><pub-id pub-id-type="pmcid">PMC11358609</pub-id></mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steiner</surname><given-names>L.</given-names></name><name name-style="western"><surname>Federspiel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Slavova</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wiest</surname><given-names>R.</given-names></name><name name-style="western"><surname>Grunt</surname><given-names>S.</given-names></name><name name-style="western"><surname>Steinlin</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Cognitive outcome is related to functional thalamo-cortical connectivity after paediatric stroke</article-title>. <source>Brain Commun.</source><volume>4</volume>:<fpage>fcac110</fpage>. doi: <pub-id pub-id-type="doi">10.1093/braincomms/fcac110</pub-id>, PMID: <pub-id pub-id-type="pmid">35611308</pub-id><pub-id pub-id-type="pmcid">PMC9122536</pub-id></mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stockert</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hormig-Rauber</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wawrzyniak</surname><given-names>M.</given-names></name><name name-style="western"><surname>Klingbeil</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>H. R.</given-names></name><name name-style="western"><surname>Pirlich</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Involvement of thalamocortical networks in patients with poststroke thalamic aphasia</article-title>. <source>Neurology</source><volume>100</volume>, <fpage>e485</fpage>&#8211;<lpage>e496</lpage>. doi: <pub-id pub-id-type="doi">10.1212/wnl.0000000000201488</pub-id><pub-id pub-id-type="pmid">36302664</pub-id><pub-id pub-id-type="pmcid">PMC9931083</pub-id></mixed-citation></ref><ref id="ref45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tatemichi</surname><given-names>T. K.</given-names></name><name name-style="western"><surname>Desmond</surname><given-names>D. W.</given-names></name><name name-style="western"><surname>Prohovnik</surname><given-names>I.</given-names></name><name name-style="western"><surname>Cross</surname><given-names>D. T.</given-names></name><name name-style="western"><surname>Gropen</surname><given-names>T. I.</given-names></name><name name-style="western"><surname>Mohr</surname><given-names>J. P.</given-names></name><etal/></person-group>. (<year>1992</year>). <article-title>Confusion and memory loss from capsular genu infarction: a thalamocortical disconnection syndrome?</article-title><source>Neurology</source><volume>42</volume>, <fpage>1966</fpage>&#8211;<lpage>1979</lpage>. doi: <pub-id pub-id-type="doi">10.1212/wnl.42.10.1966</pub-id>, PMID: <pub-id pub-id-type="pmid">1407580</pub-id></mixed-citation></ref><ref id="ref46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tu</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Millar</surname><given-names>P. R.</given-names></name><name name-style="western"><surname>Strain</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Eck</surname><given-names>A.</given-names></name><name name-style="western"><surname>Adeyemo</surname><given-names>B.</given-names></name><name name-style="western"><surname>Daniels</surname><given-names>A.</given-names></name></person-group> (<year>2023</year>). <article-title>Increasing hub disruption parallels dementia severity in autosomal dominant Alzheimer disease</article-title>. <source>bioRxiv</source><volume>10</volume>:<fpage>564633</fpage>. doi: <pub-id pub-id-type="doi">10.1101/2023.10.29.564633</pub-id><pub-id pub-id-type="pmcid">PMC11674321</pub-id><pub-id pub-id-type="pmid">39735502</pub-id></mixed-citation></ref><ref id="ref47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tung</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>S.-Y.</given-names></name><name name-style="western"><surname>Lan</surname><given-names>T.-H.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y.-Y.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>S.-J.</given-names></name></person-group> (<year>2022</year>). <article-title>Characterization of hippocampal-thalamic-cortical morphometric reorganization in temporal lobe epilepsy</article-title>. <source>Front. Neurol.</source><volume>12</volume>:<fpage>810186</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fneur.2021.810186</pub-id>, PMID: <pub-id pub-id-type="pmid">35222230</pub-id><pub-id pub-id-type="pmcid">PMC8866816</pub-id></mixed-citation></ref><ref id="ref48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Miao</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>S.</given-names></name></person-group> (<year>2019</year>). <article-title>Structural covariance in subcortical stroke patients measured by automated MRI-based volumetry</article-title>. <source>Neuroimage Clin.</source><volume>22</volume>:<fpage>101682</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.nicl.2019.101682</pub-id><pub-id pub-id-type="pmid">30710874</pub-id><pub-id pub-id-type="pmcid">PMC6357849</pub-id></mixed-citation></ref><ref id="ref49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nasrallah</surname><given-names>I. M.</given-names></name><name name-style="western"><surname>Abdulkadir</surname><given-names>A.</given-names></name><name name-style="western"><surname>Satterthwaite</surname><given-names>T. D.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Erus</surname><given-names>G.</given-names></name></person-group> (<year>2023</year>). <article-title>Genomic loci influence patterns of structural covariance in the human brain</article-title>. <source>Proc. Natl. Acad. Sci. USA</source><volume>120</volume>:<fpage>e2300842120</fpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.2300842120</pub-id><pub-id pub-id-type="pmid">38127979</pub-id><pub-id pub-id-type="pmcid">PMC10756284</pub-id></mixed-citation></ref><ref id="ref50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wise</surname><given-names>S. P.</given-names></name><name name-style="western"><surname>Murray</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Gerfen</surname><given-names>C. R.</given-names></name></person-group> (<year>1996</year>). <article-title>The frontal cortex-basal ganglia system in primates</article-title>. <source>Crit. Rev. Neurobiol.</source><volume>10</volume>, <fpage>317</fpage>&#8211;<lpage>356</lpage>. doi: <pub-id pub-id-type="doi">10.1615/critrevneurobiol.v10.i3-4.30</pub-id>, PMID: <pub-id pub-id-type="pmid">8978985</pub-id></mixed-citation></ref><ref id="ref51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>T.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>D.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Abnormalities of cortical morphology and structural covariance network in patients with subacute basal ganglia stroke</article-title>. <source>Acad. Radiol.</source><volume>29</volume>, <fpage>S157</fpage>&#8211;<lpage>S165</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.acra.2021.08.011</pub-id><pub-id pub-id-type="pmid">34556428</pub-id></mixed-citation></ref><ref id="ref52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Altered dynamic functional connectivity of the thalamus subregions in patients with schizophrenia</article-title>. <source>J. Psychiatr. Res.</source><volume>167</volume>, <fpage>86</fpage>&#8211;<lpage>92</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jpsychires.2023.09.021</pub-id><pub-id pub-id-type="pmid">37862908</pub-id></mixed-citation></ref><ref id="ref53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yassi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Malpas</surname><given-names>C. B.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>B. C. V.</given-names></name><name name-style="western"><surname>Moffat</surname><given-names>B.</given-names></name><name name-style="western"><surname>Steward</surname><given-names>C.</given-names></name><name name-style="western"><surname>Parsons</surname><given-names>M. W.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>Contralesional thalamic surface atrophy and functional disconnection 3 months after ischemic stroke</article-title>. <source>Cerebrovasc. Dis.</source><volume>39</volume>, <fpage>232</fpage>&#8211;<lpage>241</lpage>. doi: <pub-id pub-id-type="doi">10.1159/000381105</pub-id><pub-id pub-id-type="pmid">25823493</pub-id></mixed-citation></ref><ref id="ref54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Di</surname><given-names>X.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>P. A.</given-names></name><name name-style="western"><surname>Gohel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>Y.-H.</given-names></name><name name-style="western"><surname>Biswal</surname><given-names>B. B.</given-names></name></person-group> (<year>2015</year>). <article-title>Functional topography of the thalamocortical system in human</article-title>. <source>Brain Struct. Funct.</source><volume>221</volume>, <fpage>1971</fpage>&#8211;<lpage>1984</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00429-015-1018-7</pub-id><pub-id pub-id-type="pmid">25924563</pub-id><pub-id pub-id-type="pmcid">PMC6363530</pub-id></mixed-citation></ref><ref id="ref55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>H.</given-names></name><name name-style="western"><surname>Han</surname><given-names>T.</given-names></name><etal/></person-group>. (<year>2025</year>). <article-title>Reorganization of cortical individualized differential structural covariance network is associated with regional morphometric changes in chronic subcortical stroke</article-title>. <source>NeuroImage Clin.</source> doi: <pub-id pub-id-type="doi">10.1016/j.nicl.2025.103735</pub-id><pub-id pub-id-type="pmcid">PMC11787593</pub-id><pub-id pub-id-type="pmid">39827521</pub-id></mixed-citation></ref><ref id="ref56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Cerebral perfusion mediated by thalamo-cortical functional connectivity in non-dominant thalamus affects naming ability in aphasia</article-title>. <source>Hum. Brain Mapp.</source><volume>43</volume>, <fpage>940</fpage>&#8211;<lpage>954</lpage>. doi: <pub-id pub-id-type="doi">10.1002/hbm.25696</pub-id><pub-id pub-id-type="pmid">34698418</pub-id><pub-id pub-id-type="pmcid">PMC8764486</pub-id></mixed-citation></ref><ref id="ref57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zielinski</surname><given-names>B. A.</given-names></name><name name-style="western"><surname>Gennatas</surname><given-names>E. D.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Seeley</surname><given-names>W. W.</given-names></name></person-group> (<year>2010</year>). <article-title>Network-level structural covariance in the developing brain</article-title>. <source>Proc. Natl. Acad. Sci. USA</source><volume>107</volume>, <fpage>18191</fpage>&#8211;<lpage>18196</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1003109107</pub-id>, PMID: <pub-id pub-id-type="pmid">20921389</pub-id><pub-id pub-id-type="pmcid">PMC2964249</pub-id></mixed-citation></ref></ref-list><glossary><def-list><title>Glossary</title><def-item><term>ACCsup</term><def><p>supra callosal part of Anterior Cingulate Cortex</p></def></def-item><def-item><term>AV</term><def><p>anteroventral</p></def></def-item><def-item><term>CAL</term><def><p>calcarine</p></def></def-item><def-item><term>CAU</term><def><p>caudate</p></def></def-item><def-item><term>CeM</term><def><p>central medical</p></def></def-item><def-item><term>CL</term><def><p>central lateral</p></def></def-item><def-item><term>CM</term><def><p>centromedian</p></def></def-item><def-item><term>FWE</term><def><p>family-wise error</p></def></def-item><def-item><term>IFGorb</term><def><p>IFG pars orbitalis</p></def></def-item><def-item><term>LD</term><def><p>laterodorsal</p></def></def-item><def-item><term>LGN</term><def><p>lateral geniculate</p></def></def-item><def-item><term>LING</term><def><p>lingual</p></def></def-item><def-item><term>LP</term><def><p>lateral posterior</p></def></def-item><def-item><term>L-Sg</term><def><p>limitans (suprageniculate)</p></def></def-item><def-item><term>MDl</term><def><p>mediodorsal lateral</p></def></def-item><def-item><term>MDm</term><def><p>mediodorsal media</p></def></def-item><def-item><term>MCC</term><def><p>cingulate_mid</p></def></def-item><def-item><term>MGN</term><def><p>medial geniculate</p></def></def-item><def-item><term>MVre</term><def><p>reuniens (medial ventral)</p></def></def-item><def-item><term>N_ACC</term><def><p>number 1-back accuracy rate</p></def></def-item><def-item><term>N_RT</term><def><p>number 1-back response time</p></def></def-item><def-item><term>OFCant</term><def><p>anterior orbital gyrus</p></def></def-item><def-item><term>OFCpost</term><def><p>posterior orbital gyrus</p></def></def-item><def-item><term>PAL</term><def><p>pallidum</p></def></def-item><def-item><term>PC</term><def><p>paracentral</p></def></def-item><def-item><term>PCL</term><def><p>paracentral_lobule</p></def></def-item><def-item><term>Pf</term><def><p>parafascicular</p></def></def-item><def-item><term>PreCG</term><def><p>precentral gyrus;</p></def></def-item><def-item><term>Pt</term><def><p>paratenial</p></def></def-item><def-item><term>PuA</term><def><p>pulvinar anterior</p></def></def-item><def-item><term>PuI</term><def><p>pulvinar inferior</p></def></def-item><def-item><term>PuL</term><def><p>Pulvinar lateral</p></def></def-item><def-item><term>PuM</term><def><p>pulvinar medial</p></def></def-item><def-item><term>PUT</term><def><p>putamen</p></def></def-item><def-item><term>S_ACC</term><def><p>spatial 1-back accuracy rate</p></def></def-item><def-item><term>S_RT</term><def><p>spatial 1-back response time</p></def></def-item><def-item><term>SOG</term><def><p>superior occipital gyrus</p></def></def-item><def-item><term>VA</term><def><p>ventral anterior</p></def></def-item><def-item><term>VAmc</term><def><p>ventral anterior magnocellular</p></def></def-item><def-item><term>VLa</term><def><p>ventral lateral anterior</p></def></def-item><def-item><term>VLp</term><def><p>ventral lateral posterior</p></def></def-item><def-item><term>VM</term><def><p>ventromedial</p></def></def-item><def-item><term>VPL</term><def><p>ventral posterolateral</p></def></def-item><def-item><term>L</term><def><p>left</p></def></def-item><def-item><term>R</term><def><p>right</p></def></def-item></def-list></glossary></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Neuroinflammation</journal-id><journal-id journal-id-type="iso-abbrev">J Neuroinflammation</journal-id><journal-id journal-id-type="pmc-domain-id">249</journal-id><journal-id journal-id-type="pmc-domain">jneuro</journal-id><journal-title-group><journal-title>Journal of Neuroinflammation</journal-title></journal-title-group><issn pub-type="epub">1742-2094</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12497346</article-id><article-id pub-id-type="pmcid-ver">PMC12497346.1</article-id><article-id pub-id-type="pmcaid">12497346</article-id><article-id pub-id-type="pmcaiid">12497346</article-id><article-id pub-id-type="pmid">41046290</article-id><article-id pub-id-type="doi">10.1186/s12974-025-03561-w</article-id><article-id pub-id-type="publisher-id">3561</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>NLRP3 inflammasome and hearing loss: from mechanisms to therapies</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Murillo-Cuesta</surname><given-names initials="S">Silvia</given-names></name><address><email>silvia.murillo@csic.es</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Seoane</surname><given-names initials="E">Elena</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cervantes</surname><given-names initials="B">Blanca</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zubeldia</surname><given-names initials="JM">Jose Manuel</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Varela-Nieto</surname><given-names initials="I">Isabel</given-names></name><address><email>i.varela.nieto@csic.es</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00ha1f767</institution-id><institution-id institution-id-type="GRID">grid.466793.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 1803 1972</institution-id><institution>Instituto de Investigaciones Biom&#233;dicas Sols-Morreale (CSIC-UAM), </institution></institution-wrap>Madrid, Espa&#241;a </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01ygm5w19</institution-id><institution-id institution-id-type="GRID">grid.452372.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1791 1185</institution-id><institution>Centro de Investigaci&#243;n Biom&#233;dica en Red en Enfermedades Raras (CIBERER), </institution></institution-wrap>Madrid, Espa&#241;a </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01s1q0w69</institution-id><institution-id institution-id-type="GRID">grid.81821.32</institution-id><institution-id institution-id-type="ISNI">0000 0000 8970 9163</institution-id><institution>Instituto de Investigaci&#243;n Sanitaria del Hospital La Paz (IdiPAZ), </institution></institution-wrap>Madrid, Espa&#241;a </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0111es613</institution-id><institution-id institution-id-type="GRID">grid.410526.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 0277 7938</institution-id><institution>Allergy Service, </institution><institution>Hospital General Universitario Gregorio Mara&#241;&#243;n, </institution></institution-wrap>Madrid, Spain </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0111es613</institution-id><institution-id institution-id-type="GRID">grid.410526.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 0277 7938</institution-id><institution>Gregorio Mara&#241;&#243;n Health Research Institute (IiSGM), </institution></institution-wrap>Madrid, Spain </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02p0gd045</institution-id><institution-id institution-id-type="GRID">grid.4795.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 2157 7667</institution-id><institution>Dept. of Medicine, </institution><institution>Complutense University School of Medicine, </institution></institution-wrap>Madrid, Spain </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02p6gmn22</institution-id><institution-id institution-id-type="GRID">grid.441511.4</institution-id><institution>Escuela de Medicina, </institution><institution>Universidad An&#225;huac Puebla, </institution></institution-wrap>Puebla, M&#233;xico </aff></contrib-group><pub-date pub-type="epub"><day>4</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>22</volume><issue-id pub-id-type="pmc-issue-id">478515</issue-id><elocation-id>225</elocation-id><history><date date-type="received"><day>10</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>15</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>04</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>06</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-06 10:25:23.720"><day>06</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="12974_2025_Article_3561.pdf"/><abstract id="Abs1"><p id="Par1">The NLRP3 inflammasome, a key component of the innate immune system, has emerged as a central mediator of inflammation-driven sensorineural hearing loss (SNHL). This review synthesizes current evidence on its involvement across a wide spectrum of auditory pathologies, including genetic syndromes such as CAPS and autosomal dominant deafness (DFNA) 34, as well as noise-induced, age-related, drug-induced, and viral hearing loss. Dysregulated activation of NLRP3 in the cochlea leads to the release of proinflammatory cytokines (IL-1B and IL-18) and pyroptotic cell death, contributing to irreversible cochlear damage. </p><p id="Par2">Experimental studies have demonstrated that pharmacological inhibition of NLRP3 via agents such as MCC950, oridonin and tranylcypromine can preserve auditory function. Gain-of-function mutations in the NLRP3 gene are frequently associated with both syndromic and nonsyndromic hearing loss, and animal models expressing these mutations replicate cochlear inflammation and hearing deficits, validating their pathogenic role. Clinically, IL-1B signaling blockers such as anakinra and canakinumab have shown efficacy in CAPS patients, stabilizing or improving hearing outcomes. Emerging selective NLRP3 inhibitors, including dapansutrilo and MCC950, are progressing through early-phase clinical trials. Additionally, natural compounds such as piceatannol and oridonin have demonstrated otoprotective effects in preclinical models of noise- and drug-induced hearing loss. </p><p id="Par3">Collectively, these findings position the NLRP3 inflammasome as a promising therapeutic target for SNHL. Future translational research should focus on validating NLRP3-targeting compounds in human trials, identifying biomarkers for early diagnosis, and exploring combination therapies that integrate anti-inflammatory, antioxidant, and regenerative strategies. Targeting NLRP3 may ultimately redefine treatment paradigms for preventing or halting progressive hearing loss.</p><sec><title>Graphical Abstract</title><p id="Par4">
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="MO1" orientation="portrait" xlink:href="12974_2025_3561_Figa_HTML.jpg"/>
</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Autoinflammatory diseases</kwd><kwd>Cryopyrin-associated periodic syndromes</kwd><kwd>Deafness</kwd><kwd>IL-1 receptor</kwd><kwd>Pyroptosis</kwd><kwd>Rare diseases</kwd></kwd-group><funding-group><award-group><funding-source><institution>MICIU/AEI</institution></funding-source><award-id>PID2023-147347OB-I00 THEARPY</award-id><award-id>PID2023-147347OB-I00 THEARPY</award-id><principal-award-recipient><name name-style="western"><surname>Murillo-Cuesta</surname><given-names>Silvia</given-names></name><name name-style="western"><surname>Varela-Nieto</surname><given-names>Isabel</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>CIBERER ISCiii</institution></funding-source><award-id>CIBERER ISCiii, RP24P5AC761-ACCI23-19-761 SENSORARE</award-id><award-id>CIBERER ISCiii, RP24P5AC761-ACCI23-19-761 SENSORARE</award-id><principal-award-recipient><name name-style="western"><surname>Murillo-Cuesta</surname><given-names>Silvia</given-names></name><name name-style="western"><surname>Varela-Nieto</surname><given-names>Isabel</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Fundaci&#243;n Familia Alonso</institution></funding-source><award-id>FFA2024</award-id><principal-award-recipient><name name-style="western"><surname>Seoane</surname><given-names>Elena</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>ISCIII</institution></funding-source><award-id>PI21/01325</award-id><principal-award-recipient><name name-style="western"><surname>Seoane</surname><given-names>Elena</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par23">Inflammasomes are multiprotein complexes that assemble and activate in the cell cytoplasm in response to a variety of noxious signals, leading to cytokine release, which is the first step of the host defense response. The dysregulation of inflammasomes, mostly NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3), has been traditionally associated with autoinflammatory syndromes, but in recent years, many studies have associated this structure with many other human diseases, including cardiovascular (stroke and atherosclerosis), allergic (asthma and urticaria) and neurodegenerative (Parkinson and Alzheimer) diseases, diabetes and cancer [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Therefore, NLRP3 has emerged as a potential target for therapeutic intervention. The only FDA-approved medications for treating NLRP3-related diseases are inhibitors of interleukin-1beta (IL-1B) signaling, such as IL-1B (canakinumab and rilonacept) and IL-1R1 (anakinra) blockers (Drugs@FDA, accessed July 2025). Several other NLRP3 inflammasome inhibition strategies are currently under investigation, some of which have already entered clinical trials [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par24">The NLRP3 inflammasome also seems to play an important role in the pathogenesis of different types of hearing loss, including chronic otitis media, rare genetic syndromic and nonsyndromic deafness, noise- or ototoxic-induced hearing impairment, presbycusis and tumor-induced hearing loss in vestibular schwannoma [<xref ref-type="bibr" rid="CR4">4</xref>]. However, the precise mechanisms of NLRP3 inflammasome activation and their effects have not yet been clearly determined.</p><p id="Par25">Here, we review the relationship between the NLRP3 inflammasome and hearing loss, summarize some of the relevant experimental results reported in recent years, and introduce promising NLRP3 inhibitors with potential use for clinical treatment.</p></sec><sec id="Sec2"><title>NLRP3 inflammasome and the cochlea</title><p id="Par26">The NLRP3 inflammasome is a cytosolic protein complex that acts as an intracellular innate immune sensor and is composed of three basic elements: a pattern recognition receptor (NLRP3), an adaptor protein (apoptosis-associated speck-like protein containing a CARD, ASC), and an effector protease (caspase-1) [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par27">NLRP3 inflammasome formation occurs in two steps: priming and activation. During priming, the detection of pathogen- and damage-associated molecular patterns (PAMPs and DAMPs) by different receptors (TLR, NOD2, IL1R1 or TNFR) results in the transcriptional upregulation of NLRP3 and proinflammatory cytokines. Inactivated NLRP3 remains as a monomer or oligomer and localizes to membranes. The activation stage occurs when NLRP3 recognizes a secondary damaging stimulus and then recruits ASC monomers, forming a filamentous structure (called a speck), upon which caspase-1 is activated. Activated caspase 1 processes the procytokines IL-1B and IL-18 into their proinflammatory forms and gasdermin D, which induces pore formation in the plasma membrane and ultimately cell death via pyroptosis. IL-1B and IL-18 exit the cell through these pores and bind to their receptors (IL-1R1 and IL-18-R1/IL-18-RAP, respectively) on surrounding cells, eliciting downstream inflammatory responses, including the production of other inflammatory mediators, such as IL-6 (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Although NLRP3 is expressed mainly in immune system cells (macrophages, neutrophils and lymphocytes), other cell types, including neurons, microglia, osteoblasts, and dendritic or epithelial cells, are also able to produce NLRP3 inflammasome components. Most of these cells are present in the mouse cochlea; therefore, <italic toggle="yes">Nlrp3</italic>, <italic toggle="yes">Pycard</italic> (encoding ASC), <italic toggle="yes">Casp1</italic> and <italic toggle="yes">Il1b</italic> mRNAs have been detected via RT&#8210;qPCR [<xref ref-type="bibr" rid="CR5">5</xref>]. NLRP3 is present mostly in resident macrophages at the stria vascularis and basilar membrane and is activated by classical stimuli, such as lipopolysaccharide (LPS) and ATP, leading to IL-1B secretion [<xref ref-type="bibr" rid="CR5">5</xref>]. Single-cell RNA-seq studies of human and mouse inner ears show that <italic toggle="yes">Nlrp3</italic> is not highly expressed in sensory hair cells [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Other authors have detected NLRP3 immunostaining in the spiral ganglion neurons of the mouse cochlea [<xref ref-type="bibr" rid="CR8">8</xref>], which could be responsible for the spiral ganglion neuron death caused by pyroptosis observed in cytomegalovirus-induced hearing loss [<xref ref-type="bibr" rid="CR9">9</xref>]. <italic toggle="yes">Nlrp3</italic> expression has also been confirmed in supporting cells by RNA-seq studies and validated by immunofluorescence [<xref ref-type="bibr" rid="CR10">10</xref>]. Finally, increased expression of NLRP3, caspase-1, IL-1B, and gasdermin D (GSDMD) has been confirmed in the marginal cells of the stria vascularis in vitro [<xref ref-type="bibr" rid="CR11">11</xref>]. In summary, NLRP3, together with other inflammasome components, is expressed in different cochlear cell types and constitutes a potential initiator of inflammatory responses in the hearing organ</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="12974_2025_3561_Fig1_HTML.jpg"/></fig></p><p id="Par28">The activation of the NLRP3 inflammasome follows a two-signal model. First, a priming signal (PAMPs like LPS or DAMPs such as TNF-&#945;) activates pattern recognition receptors (like TLRs), leading to NF-&#954;B activation. This transcription factor upregulates the expression of pro-IL-1B, pro-IL-18, and NLRP3. Next, a second activation signal (potassium efflux, reactive oxygen species, mitochondrial damage, or lysosomal rupture) induce NLRP3 oligomerization, allowing it to recruit the adaptor protein ASC, which in turn binds pro-caspase-1. The assembled inflammasome catalyzes the cleavage of pro-caspase-1 into its active form, enabling the processing of pro-cytokines into their mature form, and the cleavage of GSDMD, whose N-terminal fragment forms pores in the cell membrane, leading to pyroptotic cell death. Abbreviations: ASC, apoptosis-associated speck-like protein containing a CARD; CARD, caspase activation and recruitment domain; DAMPs, damage-associated molecular patterns; GSDMD, gasdermin D; GSDMD-N, gasdermin D N-terminal; IL-1B, interleukin-1B; IL-18, interleukin-18; mtDNA, mitochondrial DNA; NACHT, an acronym from NAIP, CIITA, HET-E and TP1; NF- &#954;B, nuclear factor kappa-light-chain-enhancer of activated B cells; NLRP3, NLR family pyrin domain-containing 3; NOD-2, nucleotide-binding oligomerization domain-containing protein 2; LPS, lipopolysaccharide; LRR, leucine-rich repeat; PAMPs, pathogen-associated molecular patterns; PYD, pyrin domain; ROS, reactive oxygen species; TNF, tumor necrosis factor; TNFR, tumor necrosis factor receptor; TLR, toll-like receptor.</p></sec><sec id="Sec3"><title>NLRP3 and hearing loss</title><p id="Par29">Sensorineural hearing loss (SNHL) affects approximately 1.5 billion people globally. Approximately 430 million of these patients require rehabilitation services for disabling hearing loss [<xref ref-type="bibr" rid="CR12">12</xref>]. SNHL is caused mainly by dysfunction of the inner ear due to aging, exposure to ototoxic drugs or noise, or mutations in nuclear or mitochondrial genes. However, it is idiopathic in some patients. Although the inner ear was previously thought of as an immune-privileged organ, inflammation&#8212;along with oxidative stress&#8212;is considered a central pathogenic mechanism of hearing loss [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>].</p><p id="Par30">The activation of the NLRP3 inflammasome constitutes a physiological host defense response to danger signals. However, dysregulated inflammasome activity can lead to excessive inflammation, causing substantial damage, especially in those tissues, such as the cochlea, with scarce regenerative capacity. There is increasing evidence that inflammasome activation is associated with hearing loss. Thus, gain-of-function <italic toggle="yes">NLRP3</italic> mutations in autoinflammatory diseases are commonly associated with hearing loss. Furthermore, the increase in the cochlear uptake of gadolinium, measured as an increased intensity of the MRI signal, indicates barrier leakage and is normalized by anakinra therapy. The induction of the NLRP3 inflammasome has also been confirmed in experimental models of noise-induced hearing loss [<xref ref-type="bibr" rid="CR15">15</xref>], ototoxicity induced by aminoglycoside antibiotics [<xref ref-type="bibr" rid="CR16">16</xref>] or platin-derived chemotherapeutics [<xref ref-type="bibr" rid="CR11">11</xref>]. In addition, hearing loss can occur due to cytomegalovirus infection during pregnancy [<xref ref-type="bibr" rid="CR17">17</xref>].</p><sec id="Sec4"><title>Hearing loss in cryopyrin-associated periodic syndrome</title><p id="Par31">Abnormal hyperactivation of the inflammasome and excessive production of IL-1B are the causes of a spectrum of autosomal dominant systemic autoinflammatory diseases called cryopyrin-associated periodic syndrome (CAPS), which include (in order of severity) familial cold autoinflammatory syndrome (FCAS), Muckle&#8211;Wells syndrome (MWS), and chronic infantile neurological, cutaneous and articular (CINCA) syndrome. These diseases have an estimated world prevalence of 2.7&#8211;5.5 per 1 million people [<xref ref-type="bibr" rid="CR18">18</xref>] and are considered ultrarare diseases (ORPHA:208650). However, considering that many patients are diagnosed very late or not at all, its prevalence is likely greater.</p><p id="Par32">The typical inflammatory symptoms observed in CAPS include fever, headache or fatigue, and local symptoms in the skin, joints, muscles, eyes, cochlea and central nervous system [<xref ref-type="bibr" rid="CR19">19</xref>]. The correct diagnosis and immediate initiation of therapy with IL-1B inhibitors are mandatory in most patients to achieve a reversal of daily symptoms and prevent possible life-threatening sequelae [<xref ref-type="bibr" rid="CR18">18</xref>].</p><p id="Par33">FCAS was first described in 1940 in a five-generation family exhibiting recurrent episodes of urticarial-like rash, limb pain and fever following cold exposure [<xref ref-type="bibr" rid="CR20">20</xref>]. Over the next few decades, similar cases with &#8220;cold hypersensitivity&#8221; were reported and finally classified as FCAS to differentiate this inherited disorder from the more common acquired cold urticaria. In addition to urticaria rash and a burning sensation triggered by exposure to cold, fever, malaise, conjunctivitis, abdominal discomfort and polyarthralgias are very common, whereas amyloidosis and deafness are uncommon or absent.</p><p id="Par34">MWS presents similar symptoms (fever, rash, arthralgia, conjunctivitis, amyloidosis) and sensorineural deafness. The first report of the auditory phenotype in MWS was in 2012, when a single-center MWS cohort (19 patients aged 3&#8211;72 years, belonging to four families with three different mutations in <italic toggle="yes">NLRP3</italic>) was explored with pure tone audiograms, vestibular testing, and tinnitus questionnaires: 89% of them presented bilateral SNHL, which started at high frequencies and led to profound deafness in the most severe cases, and nearly half of the adults reported intermittent or permanent tinnitus [<xref ref-type="bibr" rid="CR21">21</xref>]. Another study with additional cohorts of MWS patients reported a high percentage (67&#8211;92%) of hearing loss [<xref ref-type="bibr" rid="CR22">22</xref>&#8211;<xref ref-type="bibr" rid="CR24">24</xref>].</p><p id="Par35">CINCA, also called neonatal-onset multisystem inflammatory disease (NOMID), was identified in 1987 [<xref ref-type="bibr" rid="CR25">25</xref>] and represents the most severe phenotype of CAPS, with very early-onset skin rash, arthropathy and severe central nervous system symptoms, including chronic aseptic meningitis, which may lead to brain atrophy and severe intellectual disability [<xref ref-type="bibr" rid="CR26">26</xref>]. Hearing loss is also a common symptom that occurs within the first years of life. Early anti-IL1B treatment is the standard therapy, reducing the risk of developing major complications.</p><p id="Par36">CAPS is caused by single heterozygous germline or somatic gain-of-function mutations in the human <italic toggle="yes">NLRP3</italic> gene. The Infevers database (available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://infevers.umai-montpellier.fr/">https://infevers.umai-montpellier.fr/</ext-link>, accessed June 17, 2025) currently lists 303 sequence variants of the <italic toggle="yes">NLRP3</italic> gene associated with autoinflammatory diseases, mostly substitutions affecting exon 4 (formerly named exon 3) [<xref ref-type="bibr" rid="CR27">27</xref>], with pathogenic mutations typically located in the NACHT domain of the NLRP3 protein [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. Among them, 19 variants were specifically associated with CAPS (5 likely pathogenic, 3 variants of uncertain significance).</p><p id="Par37">Genotype&#8210;phenotype correlations are important for identifying predictive disease severity markers. Similarly, the Eurofever Registry analyzed 136 CAPS patients carrying <italic toggle="yes">NLRP3</italic> variants and concluded that skin rash, musculoskeletal involvement and fever were the most prevalent features, with neurological symptoms and hearing loss present in 40% and 42% of the patients, respectively [<xref ref-type="bibr" rid="CR30">30</xref>]. Heterozygous germline mutations were found in 98% of the patients, and only 3 patients were mutation-negative despite complete <italic toggle="yes">NLRP3</italic> gene screening. Thirty-one different <italic toggle="yes">NLRP3</italic> gene mutations were detected, with 7 accounting for 78% of the patients, and 24 rare variants in 21% of the patients were significantly associated with early disease onset (&lt; 6 mo), neurological complications or hearing loss. Specifically, rare variants linked to hearing loss included the T348M, V198M, E311K and A439V alleles. In addition, other variants, including R918Q, Y861C and Y861H and S595N, have been associated with atypical CAPS syndrome, with hearing loss as the primary presentation [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>].</p><p id="Par38">Although CAPS patients frequently suffer from sensorineural hearing loss, it remains unclear whether <italic toggle="yes">NLRP3</italic> mutation is the primary cause of cochlear autoinflammation, which may be the sole manifestation in some CAPS rare cases (DFNA34), or if systemic inflammation contributes to the development of progressive hearing loss. This fact may have an impact on treatment decisions. Notably, there is a window of opportunity to treat patients with anti-IL-1B, and younger patients are most likely to respond. Consequently, it is important to know the characteristics of CAPS for the early diagnosis of associated hearing loss, and mutation analysis of <italic toggle="yes">NLRP3</italic> will lead to a definite diagnosis [<xref ref-type="bibr" rid="CR31">31</xref>].</p><p id="Par39">In addition to CAPS, classical autoinflammatory diseases are characterized by apparently unprovoked inflammation without high-titer autoantibodies or antigen-specific T cells. These manifestations usually include neurological manifestations, such as meningitis, hearing loss, and other nonneurological manifestations. Among the genes involved in these diseases are those encoding <italic toggle="yes">MEFV</italic> (Mediterranean fever), <italic toggle="yes">TNFR</italic> (TNF receptor-associated periodic syndrome) or <italic toggle="yes">MKV</italic> (hyperimmunoglobulinemia syndrome). <italic toggle="yes">NLRP3</italic> mutations have also been identified. Thus, Salsano and coworkers demonstrated a novel <italic toggle="yes">NLRP3</italic> mutation (p.I288M) and a previously described MEFV mutation (p.R761H) in a patient with a chronic disease characterized by meningitis, osteomyelitis, leukoencephalopathy and progressive hearing loss, along with increased inflammatory markers. Patients respond to tocilizumab (an anti-IL-6 receptor monoclonal antibody) but not to anakinra (a recombinant IL-1R antagonist); therefore, IL-6 hypersecretion is the likely pathogenic mechanism [<xref ref-type="bibr" rid="CR32">32</xref>].</p></sec><sec id="Sec5"><title>Nonsyndromic genetic hearing loss</title><p id="Par40">
<italic toggle="yes">NLRP3</italic> gene mutations are the cause of autosomal dominant autoinflammatory disorders, mostly CAPS, which include (syndromic) hearing loss. However, hearing loss has also been found to be the sole manifestation of these diseases, leading to a misdiagnosis of nonsyndromic deafness [<xref ref-type="bibr" rid="CR33">33</xref>].</p><p id="Par41">A variety of targeted NGS panels have been developed in recent years for genetic screening of nonsyndromic deafness, but they do not usually include typical syndromic deafness genes, such as <italic toggle="yes">NLRP3</italic>. Thus, Chen and colleagues conducted genetic screening via targeted next-generation sequencing (NGS) panels in a family with dominant inheritance initially diagnosed with nonsyndromic deafness. No pathogenic variants were found in any of the 72 known genes associated with nonsyndromic hearing loss. However, subsequent whole-exome sequencing identified a heterozygous p.E313K variant in the <italic toggle="yes">NLRP3</italic> gene. Follow-up clinical evaluation revealed that 6 out of 9 affected family members presented subtle inflammatory signs that had previously gone unnoticed [<xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par42">Similarly, Nakanishi et al. identified a missense mutation, p.Arg918Gln, of the <italic toggle="yes">NLRP3</italic> gene associated with autosomal-dominant nonsyndromic SNHL in two unrelated families [<xref ref-type="bibr" rid="CR5">5</xref>]. The affected subjects presented an atypical CAPS phenotype, with the sole symptom being a bilateral slowly progressive SNHL with an onset in the late 2nd to 4th decade of life that initially affects high frequencies, which can be improved or stabilized by anti-IL-1 therapy [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR34">34</xref>].</p><p id="Par43">In a recent study, 110 families with autosomal dominant hearing loss were tested with a custom panel of 237 hearing loss genes, and the <italic toggle="yes">NLRP3</italic> c.1872 C &gt;G, p.Ser624Arg mutation was identified in one family [<xref ref-type="bibr" rid="CR35">35</xref>]. ELISA and bioluminescence assays in peripheral blood mononuclear cells from these patients revealed that this novel gain-of-function mutation led to increased activity of caspase-1 and subsequent oversecretion of proinflammatory IL-1B [<xref ref-type="bibr" rid="CR35">35</xref>]. Clinical reanalysis of the affected individuals, together with serological evidence of inflammation and pathological cochlear enhancement on magnetic resonance images, guided the diagnosis of atypical NLRP3 autoinflammatory disorder. In summary, genetic analysis in patients with nonsyndromic hearing loss should include genes causing these atypical forms to allow timely and effective treatment with IL-1 receptor antagonists.</p></sec><sec id="Sec6"><title>Nonhereditary congenital hearing loss</title><p id="Par44">
<italic toggle="yes">Congenital cytomegalovirus infection.</italic> It is the most common fetal viral infection and the leading nongenetic cause of SNHL in children, contributing to 25% of the cases under 4 years of age [<xref ref-type="bibr" rid="CR36">36</xref>]. Cytomegalovirus infection induces a direct cytopathic effect in spiral ganglion neurons and a cochlear inflammatory response. A study with an experimental model of cytomegalovirus infection-associated hearing loss in newborn mice established that cytomegalovirus induced inflammasome-associated factors in spiral ganglion neurons and increased the content of reactive oxygen species [<xref ref-type="bibr" rid="CR17">17</xref>]. More recently, cytomegalovirus has been shown to induce spiral ganglion neuron (SGN) death via both apoptosis and pyroptosis, with simultaneous activation of the p53/JNK and NLRP3/caspase-1 signaling pathways, respectively, due to the activity of the mixed lineage kinase family (MLK1/2/3), and the MLK inhibitor URMC-099 can prevent cytomegalovirus-induced SGN death and hearing loss [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par45">
<italic toggle="yes">Bilirubin ototoxicity.</italic> An increase in bilirubin levels in newborns can cause toxic effects on the auditory system, leading to hearing loss. Unconjugated bilirubin (UCB) can activate inflammatory mediators such as IL-18 and TNF, although the mechanism at the molecular and cellular levels remains unclear. Ex vivo organotypic cochlear cultures exposed to UCB presented demyelinated nerve fibers and a decreased size of spiral ganglion neurons, along with increased levels of NLRP3, cleaved caspase-1 and GSDMD. In addition, the application of pyroptosis inhibitors reduces the levels of the aforementioned proteins, ASC and IL-18, suggesting that the NLRP3 signaling pathway could be involved in UCB-induced ototoxicity [<xref ref-type="bibr" rid="CR37">37</xref>].</p></sec><sec id="Sec7"><title>Drug ototoxicity</title><p id="Par46">
<italic toggle="yes">Cisplatin-induced deafness.</italic> Hearing loss is a serious secondary effect observed after antitumoral treatment with cisplatin, affecting 40&#8211;80% of adults and over 50% of children treated with this drug [<xref ref-type="bibr" rid="CR38">38</xref>]. Cisplatin cytotoxicity is generally mediated through DNA crosslinking and reactive oxygen species production. The high susceptibility of the cochlea to cisplatin damage is due, in part, to long-term retention of cisplatin in the stria vascularis, where it induces an inflammatory response and marginal cell damage [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>].</p><p id="Par47">A recent in vitro study confirmed that in response to cisplatin, marginal cells exhibit increased expression of NLRP3, caspase-1, IL-1B, and GSDMD, along with the formation of cell membrane pores. This situation was reversed by downregulation of NLRP3 by small interfering RNA, suggesting that NLRP3 inflammasome activation may mediate cisplatin-induced marginal cell inflammation and pyroptosis in the cochlear stria vascularis [<xref ref-type="bibr" rid="CR11">11</xref>].</p><p id="Par48">Additional mechanisms linking cisplatin ototoxicity to NLRP3 inflammasome activation have been described. First, cisplatin significantly decreased the levels of POU4F3, a transcription factor encoded by a well-known dominant nonsyndromic deafness pathogenic gene (DFNA15). Recently, Pou4f3 mutations were shown to promote cochlear hair cell pyroptosis by activating the NLRP3/caspase-3/GSDME pathway. Therefore, <italic toggle="yes">Pou4f3</italic> knockdown via shRNA can be combined with cisplatin treatment to induce pyroptosis in cochlear hair cells through the NLRP3/caspase-3/GSDME pathway [<xref ref-type="bibr" rid="CR41">41</xref>]. Second, a retrospective cohort study with patients receiving cisplatin chemotherapy with or without concomitant antidepressive treatment revealed that the risk of ototoxicity was lower in the group treated with the selective serotonin reuptake inhibitors fluoxetine or fluvoxamine, which have been shown to inhibit the NLRP3 inflammasome [<xref ref-type="bibr" rid="CR42">42</xref>]. In summary, the NLRP3 inflammasome plays a pivotal role in mediating cisplatin-induced ototoxicity through different mechanisms.</p><p id="Par49">
<italic toggle="yes">Aminoglycoside ototoxicity.</italic> Several antibiotics can induce hearing loss in children and adults, and the accumulation of oxygen radicals and inflammation in the inner ear are considered central pathological mechanisms. A recent study investigating whether the NLRP3 inflammasome is involved in aminoglycoside-related hearing loss revealed that mice treated with kanamycin plus furosemide presented increased levels of NLRP3 and increased levels of activated caspase-1, IL-1B, IL-18, and GSDMD-N and that oridonin treatment reversed this situation [<xref ref-type="bibr" rid="CR16">16</xref>]. Furthermore, another study demonstrated that pharmacological inhibition of NLRP3 via MCC950, as well as genetic deletion of <italic toggle="yes">NLRP3</italic>, significantly protected against SGN degeneration in patients with aminoglycoside-induced hearing loss [<xref ref-type="bibr" rid="CR43">43</xref>].</p></sec><sec id="Sec8"><title>Noise-induced hearing loss (NIHL)</title><p id="Par50">Exposure to acute high-intensity noise can severely damage cochlear structures and induce the activation of DAMPs, which are recognized by innate immune receptors, triggering an inflammatory response [<xref ref-type="bibr" rid="CR44">44</xref>]. Recent studies have confirmed increases in the levels of NLRP3, cleaved caspase-1, IL-1B, and IL-18 in the cochleae of minipigs and in mice exposed to 120 dB SPL noise, suggesting that the activation of the NLRP3 inflammasome constitutes a central pathogenic mechanism in NIHL [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. Moreover, the use of anakinra or oridonin has been proven to be effective in protecting mice from NIHL by facilitating inflammasome complex assembly [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>].</p><p id="Par51">Chronic exposure to moderate levels of noise also affects the inner ear and reorganizes central auditory pathways, although the role of NLRP3 remains to be elucidated. In a study from Feng and collaborators, C57BL/6J mice were exposed to long-term 70 dB SPL white noise, aggravating the concomitant age-related hearing impairment typical of this strain [<xref ref-type="bibr" rid="CR47">47</xref>]. They reported that cochlear ribbon synapses were the primary site of inner ear injury caused by chronic noise exposure. These authors confirmed by western blotting the presence of a significant increase in the levels of NLRP3, caspase-1 and IL-1B in P3 mouse cochlear explants exposed to NMDA and kainate to mimic noise-induced excitotoxic damage. These results indicate that NLRP3 inflammasome is an important mechanisms underlying auditory nerve fiber damage after noise [<xref ref-type="bibr" rid="CR47">47</xref>].</p></sec><sec id="Sec9"><title>Age-related hearing loss (ARHL)</title><p id="Par52">ARHL, or presbyacusis, is a progressive loss of hearing sensitivity predominantly associated with hair cell and SGN degeneration in the inner ear. Oxidative stress and a chronic low-level inflammatory response are frequently found in aging cochleae. Although inflammasomes are likely responsible for the accumulation of reactive species in immune cells, whether they are involved in the development of ARHL is still unknown. A study in mice demonstrated via RT&#8210;qPCR, western blotting and ELISA that the levels of activated NLRP3, caspase 1, IL-1B and IL-18 were significantly greater in the inner ears of aged mice than in those of young mice [<xref ref-type="bibr" rid="CR48">48</xref>].</p></sec><sec id="Sec10"><title>Meniere&#8217;s disease</title><p id="Par53">Meniere&#8217;s disease is an inner ear disorder characterized by severe vertigo episodes and hearing loss. The causes and precise pathological mechanisms remain undefined, although alterations in immune responses have been proposed. Recently, downregulation of serum/glucocorticoid-inducible kinase 1 (SGK1) was shown to be associated with activation of the NLRP3 inflammasome in vestibular resident macrophage-like cells from Meniere&#8217;s disease patients [<xref ref-type="bibr" rid="CR49">49</xref>]. Moreover, <italic toggle="yes">Sgk</italic><sup><italic toggle="yes">&#8722;/&#8722;</italic></sup> mice that received LPS presented severe audiovestibular symptoms, increased inflammasome activation and endolymphatic hydrops, which were ameliorated by blocking NLRP3. Pharmacological inhibition of SGK 1 also increases disease severity in vivo. SGK1 phosphorylates the NLRP3 PYD domain, which acts as a physiological inhibitor of NLRP3 inflammasome activation to maintain inner ear immune homeostasis. SGK1 depletion enhances the NLRP3 inflammasome and IL-1B production, potentially leading to damage to inner ear hair cells and the vestibular nerve. Thus, SGK1 inhibition could offer an alternative to current treatments based on corticosteroid administration [<xref ref-type="bibr" rid="CR50">50</xref>].</p></sec><sec id="Sec11"><title>Vestibular Schwannoma</title><p id="Par54">Vestibular schwannomas arise from neoplastic Schwann cells of the vestibular nerve and constitute the fourth most common type of intracranial tumor, often causing SNHL and tinnitus [<xref ref-type="bibr" rid="CR51">51</xref>]. There was no correlation between tumor size and the grade of hearing loss, suggesting that vestibular schwannoma-associated SNHL is due not only to mechanical compression of the auditory nerve but also to differences in the intrinsic biology of these tumors. Previous research has reported an abnormal upregulation of inflammatory pathways in these tumors and a correlation between poor hearing and a robust inflammatory response in vestibular schwannoma patients. A meta-analysis of a large vestibular schwannoma microarray dataset by Sagers and collaborators identified the NLRP3 inflammasome as a candidate, which was further validated in human vestibular schwannoma tissue via RT&#8210;qPCR and immunohistochemistry [<xref ref-type="bibr" rid="CR52">52</xref>]. In addition, the authors reported an association between the overexpression of NLRP3 inflammasome components in vestibular schwannoma and a high degree of hearing loss. Therefore, the inhibition of the NLRP3 inflammasome in vestibular schwannoma could contribute to preserving hearing.</p></sec></sec><sec id="Sec12"><title>Auditory function in Nlrp3 mutant mice</title><p id="Par55">The pathogenesis of hearing loss due to inflammasome activation remains incompletely understood. Therefore, animal models are still necessary to obtain key information. According to the Mouse Genome Informatics database, 47 <italic toggle="yes">Nlrp</italic>3 mutant alleles were generated, 18 by classical gene targeting, 18 by endonucleases and 13 induced chemically (URL: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.informatics.jax.org">http://www.informatics.jax.org</ext-link>, accessed June, 2025). Most of them are knockouts (null or conditional), but others incorporate humanized sequences or include mutations found in the <italic toggle="yes">NLRP3</italic> gene in patients suffering from autoinflammatory disorders (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>).</p><p id="Par56">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p><italic toggle="yes">Nlrp3</italic> mutant alleles</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Mutant allele</th><th align="left" colspan="1" rowspan="1">Mutation details</th><th align="left" colspan="1" rowspan="1">Abnormal phenotype</th><th align="left" colspan="1" rowspan="1">Human disease</th><th align="left" colspan="1" rowspan="1">Reference</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"><p>
<italic toggle="yes">Nlrp3</italic>
<sup><italic toggle="yes">tm1Hhf</italic></sup></p><p>NLR family, pyrin domain containing 3; targeted mutation 1, Hal M Hoffman</p><p><italic toggle="yes">(Nlrp3</italic>
<sup><italic toggle="yes">A350VneoR</italic></sup><italic toggle="yes">)</italic></p></td><td align="left" colspan="1" rowspan="1">Modeling the A352V human mutation linked to Muckle-Wells syndrome (MWS), A floxed neomycin resistance cassette was inserted in reverse orientation into intron 2, upstream of the mutated exon. Upon Cre-mediated recombination, the cassette is excised, allowing expression of the mutant allele.</td><td align="left" colspan="1" rowspan="1">digestive/alimentary, growth/size/body, hematopoietic, homeostasis, immune, integument, mortality/aging, renal/urinary</td><td align="left" colspan="1" rowspan="1">MWS</td><td align="left" colspan="1" rowspan="1"> [<xref ref-type="bibr" rid="CR53">53</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>
<italic toggle="yes">Nlrp3</italic>
<sup>tm2Hhf</sup>
</p><p>NLR family, pyrin domain containing 3; targeted mutation 2, Hal M Hoffman</p><p><italic toggle="yes">(Nlrp3</italic>
<sup><italic toggle="yes">L351PneoR</italic></sup><italic toggle="yes">)</italic></p></td><td align="left" colspan="1" rowspan="1">Modeling the human L353P mutation associated with familial cold autoinflammatory syndrome (FCAS). A floxed neomycin resistance cassette was inserted in reverse orientation into intron 2, upstream of the mutant exon. Upon Cre recombinase expression, the cassette is excised, allowing expression of the mutant allele.</td><td align="left" colspan="1" rowspan="1">hematopoietic, immune, mortality/aging</td><td align="left" colspan="1" rowspan="1">FCAS</td><td align="left" colspan="1" rowspan="1"> [<xref ref-type="bibr" rid="CR53">53</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"><p><italic toggle="yes">Nlrp3</italic>
<sup><italic toggle="yes">tm1Smoc</italic></sup></p><p>NLR family, pyrin domain containing 3; targeted mutation 1, Shanghai Model Organisms Center</p><p><italic toggle="yes">(Nlrp3</italic>
<sup><italic toggle="yes">tm(LSL&#8722;A350V)Smoc</italic></sup>
<italic toggle="yes">)</italic></p></td><td align="left" colspan="1" rowspan="1">This allele carries a A350V conditional mutation of the gene</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Shanghai Model Organisms Center,</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>
<italic toggle="yes">Nlrp3</italic>
<sup><italic toggle="yes">tm1Wstr</italic></sup>
</p><p>NLR family, pyrin domain containing 3; targeted mutation 1, Warren Strober</p><p>
<italic toggle="yes">(Nlrp3</italic>
<sup><italic toggle="yes">R258W</italic></sup>
<italic toggle="yes">)</italic>
</p></td><td align="left" colspan="1" rowspan="1">To model the human R260W <italic toggle="yes">NLRP3</italic> mutation linked to Muckle-Wells syndrome (MWS), mice were engineered with the equivalent R258W mutation. A neomycin resistance cassette flanked by FRT sites and a pair of loxP sites were inserted around exon 3. When Cre recombinase is expressed, exon 3 is deleted, resulting in a frameshift mutation that creates a null allele.</td><td align="left" colspan="1" rowspan="1">growth/size/body, hematopoietic, immune, integument, liver/biliary, mortality/aging, reproductive</td><td align="left" colspan="1" rowspan="1">MWS</td><td align="left" colspan="1" rowspan="1"> [<xref ref-type="bibr" rid="CR54">54</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>
<italic toggle="yes">Nlrp</italic>3<sup>tm3.1Hhf</sup></p><p>NLR family, pyrin domain containing 3; targeted mutation 3.1, Hal M Hoffman</p><p>(D301N NLRP3, NOMID)</p></td><td align="left" colspan="1" rowspan="1">To model the D301N mutation associated with CAPS, researchers introduced a point mutation into exon 3 of the mouse <italic toggle="yes">Nlrp3</italic> gene, corresponding to human residue 303. A neomycin resistance cassette flanked by loxP sites was inserted in reverse orientation into intron 2. After Cre recombinase excised the cassette, the mutant allele was expressed.</td><td align="left" colspan="1" rowspan="1">cellular, growth/size/body, hematopoietic, homeostasis, immune, limbs/digits/tail, mortality/aging, nervous system, skeleton</td><td align="left" colspan="1" rowspan="1">CINCA</td><td align="left" colspan="1" rowspan="1"> [<xref ref-type="bibr" rid="CR55">55</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>
<italic toggle="yes">Nlrp3</italic>
<sup>tm3.1(NLRP3*)Bhk</sup>
</p><p>NLR family, pyrin domain containing 3; targeted mutation 3.1, Beverly H Koller</p><p>D305N</p></td><td align="left" colspan="1" rowspan="1">Humanized mouse model generated by replacing the mouse <italic toggle="yes">Nlrp3</italic> gene with a human variant carrying the CAPS-associated p.Asp303Asn mutation. A vector containing the human gene and a mutated loxP site was introduced into Nlrp3 &lt; sup &gt; tm1Bhk&lt;/sup &gt;embryonic stem cells, where the original locus had been replaced by a neomycin cassette flanked by FRT sites. After Flp recombination removed the cassette, Cre recombinase enabled targeted insertion of the mutant human gene at the endogenous locus, restoring gene expression.</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">CAPS</td><td align="left" colspan="1" rowspan="1"> [<xref ref-type="bibr" rid="CR56">56</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>
<italic toggle="yes">Nlrp3</italic>_c.2750 G &gt;A</p><p>EM:15,753</p></td><td align="left" colspan="1" rowspan="1">Mice generated by CRISPRCas9 edition, carrying a specific point mutation in the <italic toggle="yes">NLRP3</italic> gene, where at DNA position 2750 a guanine (G) is replaced by an adenine (A) resulting in a missense variant, An equivalent missense mutation, p.Arg918Gln (c.2753G &gt;A) causes autosomal-dominant sensorineural hearing loss DFNA34 in two unrelated families single-nucleotide variant has been identified in patients</td><td align="left" colspan="1" rowspan="1">Ongoing</td><td align="left" colspan="1" rowspan="1">DFNA34</td><td align="left" colspan="1" rowspan="1"> [<xref ref-type="bibr" rid="CR5">5</xref>]</td></tr></tbody></table></table-wrap>
</p><p id="Par57">Table&#160;<xref rid="Tab1" ref-type="table">1</xref>. Nonexhaustive list of <italic toggle="yes">Nlrp3</italic> mouse mutant alleles generated, including pathogenic human <italic toggle="yes">NLRP3</italic> variants identified in CAPS patients. Source: Mouse Genome Informatics Database and INFRAFRONTIER/EMMA repository. Accessed June 2025.</p><p id="Par58">The first knockout avatar mice expressing <italic toggle="yes">Nlrp3</italic> gain-of-function mutations identified in MWS (A352V, R258W) and FCAS (L353P) patients presented with systemic inflammation, poor growth, and increased mortality rates before weaning; therefore, these mice did not survive to an age when hearing evaluation was possible [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]. Similarly, a mouse expressing the D301N <italic toggle="yes">NLRP3</italic> mutation (the ortholog of D303N in human <italic toggle="yes">NLRP3</italic>, which causes CINCA) was subsequently generated. These mice exhibit neutrophilia and high levels of serum inflammatory mediators, along with abnormalities in postnatal skeletal growth and bone remodeling, analogous to those observed in CINCA patients. They also exhibit growth retardation and lower body weight and usually die by 2&#8211;3 weeks of age [<xref ref-type="bibr" rid="CR55">55</xref>].</p><p id="Par59">In 2016, Snouwaert and collaborators generated a mouse mutant carrying a D305N SNP in the <italic toggle="yes">Nlrp3</italic> gene (autoinflammatory disease-associated <italic toggle="yes">NLRP3</italic> D303N SNP). These mice present a normal appearance at birth and early growth, surviving beyond weaning. Later, they develop systemic inflammatory symptoms, including splenomegaly, with a marked increase in myeloid cells in the spleen, blepharitis, and meningeal inflammation. Arthritic changes became apparent within the first 3 months of life and progressed as the mice aged, along with osteoporosis and kyphosis. Nevertheless, no evidence of hearing loss was detected [<xref ref-type="bibr" rid="CR56">56</xref>].</p><p id="Par60">In 2022, Kim and collaborators bred <italic toggle="yes">Nlrp3</italic><sup><italic toggle="yes">D301NneoR</italic></sup> mice [<xref ref-type="bibr" rid="CR55">55</xref>] (available at The Jackson Laboratory, Jax #017971) with a <italic toggle="yes">Gfi1-Cre</italic> knock-in mouse line for the activation of this conditional mutant <italic toggle="yes">NLRP3</italic> in the cochlea and hematopoietic cells, bypassing preweaning mortality [<xref ref-type="bibr" rid="CR57">57</xref>]. This novel mouse model exhibited severe to profound hearing loss at postnatal day 20 and cochlear inflammation detected by MRI, along with the overexpression of mutant NLRP3 in the spiral prominence, inner and outer sulcus regions, organ of Corti, and SGN. The cochleae of these mice at P12 presented a disorganized organ of Corti and a collapsed Nuel&#8217;s space. They also show varying degrees of inflammation with lymphocytic infiltration in the brain, kidney, and liver [<xref ref-type="bibr" rid="CR57">57</xref>]. A similar <italic toggle="yes">Nlrp3</italic><sup><italic toggle="yes">D301NneoR/Flox</italic></sup>
<italic toggle="yes">Cx3cr1</italic><sup><italic toggle="yes">CreER7+</italic></sup> mouse model with conditional expression of the <italic toggle="yes">Nlrp3</italic> D301N mutation in CX3CR1-positive cells (macrophage and microglia) was generated by Ma and collaborators. Compared with control mice, these mice presented more severe cochlear inflammation, inflammasome activation and hearing loss after LPS injection. These symptoms are reduced by the administration of the NLRP3 inhibitor MCC950 [<xref ref-type="bibr" rid="CR58">58</xref>]. These mouse lines model human autoinflammatory hearing loss and could be valuable tools for elucidating the underlying pathogenic mechanism of inflammasome activation-mediated hearing loss. Similarly, our group recently generated a CRISPR-Cas9 mouse mutant that reproduces the missense mutation c.2753G &gt;A (p.Arg918Gln) of <italic toggle="yes">NLRP3</italic>, which causes the nonsyndromic autosomal-dominant sensorineural hearing loss DFN34 [<xref ref-type="bibr" rid="CR5">5</xref>].</p></sec><sec id="Sec13"><title>NLRP3 inflammasome inhibitors as drugs for hearing loss treatment</title><p id="Par61">FDA and/or EMA-approved inhibitors of IL-1B signaling, such as anakinra, canakinumab or rilonacept, are the first-line therapeutic options available for CAPS and other anti-inflammatory diseases [<xref ref-type="bibr" rid="CR18">18</xref>]; therefore, they can benefit patients with associated hearing loss.</p><p id="Par62">Anakinra (Kineret<sup>&#174;</sup>) is a modified version of the human IL-1R antagonist protein that competitively inhibits the binding of IL-1&#160;A and IL-1B to the IL-1R1 receptor, thereby reducing inflammation and tissue damage. It is produced in <italic toggle="yes">E. coli</italic> via recombinant DNA technology and is commonly used to treat CAPS via subcutaneous injection.</p><p id="Par63">A recent study revealed its potential to treat human hearing loss in select cases of NLRP3-related autoinflammatory disorders. Thus, a significant improvement in hearing after anakinra therapy was observed in 17 families diagnosed with either CAPS or DFNA34, although the <italic toggle="yes">NLRP3</italic> genotype, hearing status at diagnosis and cochlear radiological findings were prognostic factors for the final hearing status after treatment [<xref ref-type="bibr" rid="CR59">59</xref>]. For patients suffering severe deafness not responsive to anakinra, cochlear implantation could be the last option for hearing rehabilitation. Although not generally indicated for patients with autoinflammatory diseases, recent successful outcomes have been reported for cochlear implants in CINCA, MWS and DFNA34 patients [<xref ref-type="bibr" rid="CR60">60</xref>].</p><p id="Par64">Anakinra has been shown to partially alleviate the degree of hearing impairment in a NIHL mouse model, suggesting that inhibiting NLRP3 and downstream signaling pathways may constitute a new strategy for the clinical treatment of this condition.</p><p id="Par65">Canakinumab (Ilaris<sup>&#174;</sup>) is a fully human monoclonal IgG1 anti-IL-1B antibody that provides selective and prolonged IL-1B blockade and a rapid (within hours), complete and sustained response in most CAPS patients, without any consistent pattern of side effects. Long-term follow-up trials have demonstrated the sustained efficacy, safety and tolerability of canakinumab [<xref ref-type="bibr" rid="CR61">61</xref>]; therefore, it was approved by the FDA for FCAS and MWS and by the EMA for the treatment of all three CAPS phenotypes. With respect to SNHL, the efficacy of canakinumab is variable, as reported in an MWS family, where only the younger member showed auditory improvement, highlighting the importance of early intervention [<xref ref-type="bibr" rid="CR62">62</xref>].</p><p id="Par66">Gevokizumab is an experimental (not yet approved) monoclonal antibody that selectively neutralizes IL-1B and has been explored as a potential treatment for autoimmune inner ear diseases resistant to corticosteroids in a phase 2 clinical study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01950312">NCT01950312</ext-link>), with no updated results [<xref ref-type="bibr" rid="CR63">63</xref>]. Similarly, rilonacept (Arcalyst<sup>&#174;</sup>) is a soluble IL-1R that blocks IL-1 A and IL-1B signaling and has not yet been widely established for SNHL treatment. An early phase 1 proof-of-concept clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02828033">NCT02828033</ext-link>) was initiated in 2017 to explore rilonacept in patients with autoimmune SNHL, but no results have been reported to date [<xref ref-type="bibr" rid="CR63">63</xref>].</p><p id="Par67">The majority of current knowledge on the role of NLRP3 in hearing loss stems from animal studies; therefore, several therapeutic strategies specifically targeting NLRP3 itself have been tested preclinically and are progressing toward clinical translation.</p><p id="Par68">Piceatannol [(E)&#8722;4-(3,5-dihydroxystyryl) benzene-1,2-diol] is a natural analog of resveratrol that has been shown to have immunomodulatory and anti-inflammatory effects, among other activities. A recent study investigated its effect in ARHL models both in vitro and in vivo. Thus, HEI-OC-1 cells exposed to LPS to simulate the aging inflammatory environment presented increased expression of NLRP3, caspase-11 and GSDMD, whereas treatment with PCT reduced inflammation-associated protein expression and pyroptosis, improving cell survival. In vivo experiments revealed that PCT protects mice from ARHL and reduces inner hair cell and spiral ganglion neuron loss. These results suggest a protective role for PCT against ARHL, possibly through the caspase-11-GSDMD pathway [<xref ref-type="bibr" rid="CR64">64</xref>].</p><p id="Par69">Oridonin is a traditional medicinal product with anti-inflammatory properties that has been recently reported to protect mice from NIHL. Li et al. confirmed that oridonin acts by blocking the interaction between NLRP3 and NEK7 (NLRP3 never in mitosis gene A-related kinase 7) and therefore inflammasome complex assembly, which inhibits the downstream inflammasome. Another factor regulated by oridonin that could explain the otoprotective effect after noise exposure is IL-1R type 2 (IL-1R2). AAV-mediated overexpression of IL-1R2 in the inner ear significantly reduces NIHL and ribbon synapse lesions by blocking cytokine storms; similarly, oridonin induces IL-1R2 expression in spiral ganglion neurons and hair cells.</p><p id="Par70">Oridonin has also shown efficacy in treating aminoglycoside ototoxicity, reducing kanamycin-related hearing loss by inhibiting NLRP3 inflammasome activation and caspase-1/GSDMD-related hair cell pyroptosis. These findings demonstrate that pyroptosis, as well as apoptosis, may be involved in kanamycin-induced hearing loss and that the NLRP3 inflammasome could be a new target for treating aminoglycoside ototoxicity [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par71">MCC950 [{N-[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl) carbamoyl]&#8722;4-(2-hydroxypropan-2-yl)furan-2-sulfonamide}] is a chemically characterized NLRP3 inhibitor that has been shown to be effective in different inflammatory models, such as CAPS and gout.</p><p id="Par72">With respect to hearing loss, Ma and colleagues reported that MCC950 significantly alleviated systemic LPS-induced hearing loss and the inflammatory phenotype in mutant mice expressing the pathological <italic toggle="yes">NLRP3</italic> variant D301N in cochlea-resident CX3CR1 macrophages.</p><p id="Par73">Dapansutrilo (OLT1177, [3-(methylsulfonyl)propanenitrile]) is a selective NLRP3 inflammasome inhibitor that is currently under investigation for various inflammatory conditions, including gout and cardiovascular disease. It is gaining attention for its potential to modulate IL-1B-driven inflammation and is currently being evaluated in phase I and II clinical trials [<xref ref-type="bibr" rid="CR63">63</xref>].</p><p id="Par74">Finally, tranylcypromine, a monoamine oxidase inhibitor traditionally used as an antidepressant, has been recently proposed to have otoprotective effects in a mouse model of NIHL via different mechanisms, including blockade of NLRP3 inflammasome signaling [<xref ref-type="bibr" rid="CR65">65</xref>]. Table <xref rid="Tab2" ref-type="table">2</xref> summarizes key therapeutic interventions for NLRP3-related SNHL, their mechanisms, indications, and clinical development stages.</p><p id="Par75">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Treatments for NLRP3 autoinflammatory disorders</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Name</th><th align="left" colspan="1" rowspan="1">Mechanism of Action</th><th align="left" colspan="1" rowspan="1">Indication</th><th align="left" colspan="1" rowspan="1">Current Status</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Anakinra</td><td align="left" colspan="1" rowspan="1">IL-1R antagonist that blocks IL-1B signaling, reducing downstream inflammation</td><td align="left" colspan="1" rowspan="1">Autoinflammatory CAPS-related sensorineural hearing loss; mitigates Noise-induced hearing loss in animals</td><td align="left" colspan="1" rowspan="1">Approved (FDA/EMA) therapy for CAPS</td></tr><tr><td align="left" colspan="1" rowspan="1">Canakinumab</td><td align="left" colspan="1" rowspan="1">Monoclonal antibody that neutralizes IL-1B to prevent inflammasome-mediated inflammation</td><td align="left" colspan="1" rowspan="1">CAPS-related sensorineural hearing loss (e.g., MWS, NOMID)</td><td align="left" colspan="1" rowspan="1">Approved (FDA/EMA)</td></tr><tr><td align="left" colspan="1" rowspan="1">Rilonacept</td><td align="left" colspan="1" rowspan="1">Decoy receptor fusion protein for IL-1B and IL-1&#160;A</td><td align="left" colspan="1" rowspan="1">NLRP3-associated autoinflammatory hearing loss</td><td align="left" colspan="1" rowspan="1">Approved (FDA)</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Cochlear</p><p>Implant</p></td><td align="left" colspan="1" rowspan="1">Bypasses damaged cochlear cells with direct electrical stimulation of the auditory nerve</td><td align="left" colspan="1" rowspan="1">Severe sensorineural hearing loss in CAPS/DFNA34 unresponsive to drugs</td><td align="left" colspan="1" rowspan="1">Standard clinical medical device for SNHL</td></tr><tr><td align="left" colspan="1" rowspan="1">Piceatannol</td><td align="left" colspan="1" rowspan="1">Polyphenol (resveratrol analog) that reduces NLRP3, caspase-11, and GSDMD; inhibits pyroptosis</td><td align="left" colspan="1" rowspan="1">Age-related hearing loss</td><td align="left" colspan="1" rowspan="1">Preclinical</td></tr><tr><td align="left" colspan="1" rowspan="1">Oridonin</td><td align="left" colspan="1" rowspan="1">Blocks NLRP3&#8211;NEK7 interaction and IL-1B release</td><td align="left" colspan="1" rowspan="1">Noise-induced and aminoglycoside-induced hearing loss</td><td align="left" colspan="1" rowspan="1">Preclinical</td></tr><tr><td align="left" colspan="1" rowspan="1">MCC950</td><td align="left" colspan="1" rowspan="1">Selective small-molecule NLRP3 inhibitor</td><td align="left" colspan="1" rowspan="1">Inflammation-driven sensorineural hearing loss (e.g., CAPS models)</td><td align="left" colspan="1" rowspan="1">Preclinical</td></tr><tr><td align="left" colspan="1" rowspan="1">Tranylcypromine</td><td align="left" colspan="1" rowspan="1">LSD1 inhibitor that upregulates SESN2, activates autophagy, and suppresses NLRP3</td><td align="left" colspan="1" rowspan="1">Noise-induced hearing loss</td><td align="left" colspan="1" rowspan="1">Preclinical (drug repurposing)</td></tr><tr><td align="left" colspan="1" rowspan="1">Dapansutrilo (OLT1177)</td><td align="left" colspan="1" rowspan="1">Oral selective NLRP3 inhibitor; demonstrated reduction of IL-1B/IL-18 in preclinical models; well-tolerated in Phase 1 trials</td><td align="left" colspan="1" rowspan="1">Inflammation-related sensorineural hearing loss</td><td align="left" colspan="1" rowspan="1">Early clinical development (Phase 1 completed; Phase 2 ongoing in gout and heart failure)</td></tr></tbody></table></table-wrap>
</p><p id="Par76">Table&#160;<xref rid="Tab2" ref-type="table">2</xref>. List of therapeutic approaches used to treat NLRP3 autoinflammatory disorders. Sources: ClinicalTrials.gov and Euclinicaltrials.eu, accessed June 2025.</p></sec><sec id="Sec14"><title>Conclusions</title><p id="Par77">The growing body of evidence reviewed here firmly establishes the NLRP3 inflammasome as a pivotal player in the pathogenesis of sensorineural hearing loss across multiple etiologies. From inherited autoinflammatory syndromes to noise exposure, aging and ototoxic insults, NLRP3 activation is consistently correlated with increased cochlear inflammation, pyroptotic cell death and hearing loss. Genetic studies further implicate <italic toggle="yes">NLRP3</italic> variants in both syndromic and nonsyndromic progressive hearing loss. These studies also revealed a spectrum of disease phenotypes responsive to IL-1B inhibition. While IL-1R1 receptor antagonists and monoclonal antibodies remain the basis of clinical therapy for CAPS-related deafness, the development of direct NLRP3 inhibitors, some of which are already in early clinical stages, offers a promising horizon for broader applications. Advances in animal modeling, drug screening and molecular imaging are expected to deepen our understanding of the role of NLRP3 in hearing receptors.</p><p id="Par78">Future research should prioritize translational efforts to validate NLRP3-targeting compounds in human trials, explore biomarkers for early diagnosis, and investigate combination therapies that integrate anti-inflammatory, antioxidant and regenerative strategies. Ultimately, targeting the NLRP3 inflammasome may redefine therapeutic paradigms for preventing or halting irreversible hearing loss.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ARHL</term><def><p id="Par5">Age-related hearing loss</p></def></def-item><def-item><term>ASC</term><def><p id="Par6">Apoptosis-associated speck-like protein containing a CARD</p></def></def-item><def-item><term>CAPS</term><def><p id="Par7">Cryopyrin-associated Periodic Syndromes</p></def></def-item><def-item><term>CINCA</term><def><p id="Par8">Chronic infantile neurological, cutaneous and articular</p></def></def-item><def-item><term>DAMP</term><def><p id="Par9">Damage-associated molecular pattern</p></def></def-item><def-item><term>DFNA</term><def><p id="Par10">Autosomal dominant nonsyndromic deafness</p></def></def-item><def-item><term>FCAS</term><def><p id="Par11">Familial cold autoinflammatory syndrome</p></def></def-item><def-item><term>GSDM</term><def><p id="Par12">Gasdermin</p></def></def-item><def-item><term>HEI-OC1</term><def><p id="Par13">House Ear Institute Organ of Corti-1 cell line</p></def></def-item><def-item><term>IL-1B</term><def><p id="Par14">Interleukin 1 beta</p></def></def-item><def-item><term>IL-1R</term><def><p id="Par15">Interleukin 1 beta receptor</p></def></def-item><def-item><term>IL-18</term><def><p id="Par16">Interleukin 18</p></def></def-item><def-item><term>LPS</term><def><p id="Par17">Lipopolysaccharide</p></def></def-item><def-item><term>MWS</term><def><p id="Par18">Muckle&#8211;Wells syndrome</p></def></def-item><def-item><term>NLRP3</term><def><p id="Par19">NOD-, LRR- and pyrin domain-containing protein 3</p></def></def-item><def-item><term>PAMPs</term><def><p id="Par20">Pathogen-associated molecular patterns</p></def></def-item><def-item><term>SGN</term><def><p id="Par21">Spiral ganglion neuron</p></def></def-item><def-item><term>SNHL</term><def><p id="Par22">Sensorineural Hearing Loss</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#8217;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We are thankful for the support of the Comunidad de Madrid MINA-CM P2022-BMD-7236 Consortium and the MICIU/AEI RED2022-134511-T REDInflama network. We also thank Miguel &#193;ngel S&#225;nchez V&#225;zquez for the help with the illustrations.</p></ack><notes notes-type="author-contribution"><title>Authors&#8217; contributions</title><p>SMC, IVN, JMZ: writing and editing of the original manuscript; ES, BC: revision of the original manuscript; BC and IVN: design and conceptualization of the figures.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was funded by CIBERER Grant &#8220;ACCI 2023: Nuevas estrategias terap&#233;uticas para el tratamiento de enfermedades raras neurosensoriales (SensoRare)&#8221; to SM; MICIU/AEI Grant PID2023&#8211;147347OB-I00 to SM and IVN; ISCIII Grant PI21/01325; and Fundaci&#243;n Familia Alonso Grant FFA2024 to ESR. SM holds a CIBERER senior researcher contract.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par79">Not applicable.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par80">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par81">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>R</given-names></name><name name-style="western"><surname>Qi</surname><given-names>X</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Q</given-names></name><name name-style="western"><surname>Niu</surname><given-names>L</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D</given-names></name><etal/></person-group><article-title>The role of NLRP3 inflammasome in aging and age-related diseases</article-title><source>Immun Ageing</source><year>2024</year><volume>21</volume><fpage>14</fpage><pub-id pub-id-type="doi">10.1186/s12979-023-00395-z</pub-id><pub-id pub-id-type="pmid">38317229</pub-id><pub-id pub-id-type="pmcid">PMC10840156</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Liang R, Qi X, Cai Q, Niu L, Huang X, Zhang D, et al. The role of NLRP3 inflammasome in aging and age-related diseases. Immun Ageing. 2024;21:14.<pub-id pub-id-type="pmid">38317229</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12979-023-00395-z</pub-id><pub-id pub-id-type="pmcid">PMC10840156</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>H-F</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y-C</given-names></name><name name-style="western"><surname>Hu</surname><given-names>T-Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>D-H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X-J</given-names></name><name name-style="western"><surname>Luo</surname><given-names>D-D</given-names></name><etal/></person-group><article-title>Unraveling the role of NLRP3 inflammasome in allergic inflammation: implications for novel therapies</article-title><source>Front Immunol</source><year>2024</year><volume>15</volume><fpage>1435892</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2024.1435892</pub-id><pub-id pub-id-type="pmid">39131161</pub-id><pub-id pub-id-type="pmcid">PMC11310156</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Lu H-F, Zhou Y-C, Hu T-Y, Yang D-H, Wang X-J, Luo D-D, et al. Unraveling the role of NLRP3 inflammasome in allergic inflammation: implications for novel therapies. Front Immunol. 2024;15:1435892.<pub-id pub-id-type="pmid">39131161</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2024.1435892</pub-id><pub-id pub-id-type="pmcid">PMC11310156</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blevins</surname><given-names>HM</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Biby</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name></person-group><article-title>The NLRP3 inflammasome pathway: A review of mechanisms and inhibitors for the treatment of inflammatory diseases</article-title><source>Front Aging Neurosci</source><year>2022</year><volume>14</volume><fpage>879021</fpage><pub-id pub-id-type="doi">10.3389/fnagi.2022.879021</pub-id><pub-id pub-id-type="pmid">35754962</pub-id><pub-id pub-id-type="pmcid">PMC9226403</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Blevins HM, Xu Y, Biby S, Zhang S. The NLRP3 inflammasome pathway: A review of mechanisms and inhibitors for the treatment of inflammatory diseases. Front Aging Neurosci. 2022;14:879021.<pub-id pub-id-type="pmid">35754962</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2022.879021</pub-id><pub-id pub-id-type="pmcid">PMC9226403</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gregory</surname><given-names>GE</given-names></name><name name-style="western"><surname>Munro</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Couper</surname><given-names>KN</given-names></name><name name-style="western"><surname>Pathmanaban</surname><given-names>ON</given-names></name><name name-style="western"><surname>Brough</surname><given-names>D</given-names></name></person-group><article-title>The NLRP3 inflammasome as a target for sensorineural hearing loss</article-title><source>Clin Immunol</source><year>2023</year><volume>249</volume><fpage>109287</fpage><pub-id pub-id-type="doi">10.1016/j.clim.2023.109287</pub-id><pub-id pub-id-type="pmid">36907540</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Gregory GE, Munro KJ, Couper KN, Pathmanaban ON, Brough D. The NLRP3 inflammasome as a target for sensorineural hearing loss. Clin Immunol. 2023;249:109287.<pub-id pub-id-type="pmid">36907540</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clim.2023.109287</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakanishi</surname><given-names>H</given-names></name><name name-style="western"><surname>Kawashima</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kurima</surname><given-names>K</given-names></name><name name-style="western"><surname>Chae</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Ross</surname><given-names>AM</given-names></name><name name-style="western"><surname>Pinto-Patarroyo</surname><given-names>G</given-names></name><etal/></person-group><article-title>NLRP3 mutation and cochlear autoinflammation cause syndromic and nonsyndromic hearing loss DFNA34 responsive to Anakinra therapy</article-title><source>Proc Natl Acad Sci U S A</source><year>2017</year><volume>114</volume><fpage>E7766</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1073/pnas.1702946114</pub-id><pub-id pub-id-type="pmid">28847925</pub-id><pub-id pub-id-type="pmcid">PMC5604003</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Nakanishi H, Kawashima Y, Kurima K, Chae JJ, Ross AM, Pinto-Patarroyo G, et al. NLRP3 mutation and cochlear autoinflammation cause syndromic and nonsyndromic hearing loss DFNA34 responsive to Anakinra therapy. Proc Natl Acad Sci U S A. 2017;114:E7766&#8211;75.<pub-id pub-id-type="pmid">28847925</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1702946114</pub-id><pub-id pub-id-type="pmcid">PMC5604003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">Tang F, Chen X, Jia L, Li H, Li J, Yuan W. Differential Gene Expression Patterns Between Apical and Basal Inner Hair Cells Revealed by RNA-Seq. Front Mol Neurosci [Internet]. 2020 [cited 2025 Aug 26];12. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.frontiersin.org/journals/molecular-neuroscience/articles/">https://www.frontiersin.org/journals/molecular-neuroscience/articles/</ext-link>10.3389/fnmol.2019.00332/full<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnmol.2019.00332</pub-id><pub-id pub-id-type="pmcid">PMC6985465</pub-id><pub-id pub-id-type="pmid">32038162</pub-id></mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">Xu Z, Tu S, Pass C, Zhang Y, Liu H, Diers J et al. Profiling mouse cochlear cell maturation using 10&#215; Genomics single-cell transcriptomics. Front Cell Neurosci [Internet]. 2022 [cited 2025 Aug 26];16. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.frontiersin.org/journals/cellular-neuroscience/articles/">https://www.frontiersin.org/journals/cellular-neuroscience/articles/</ext-link>10.3389/fncel.2022.962106/full<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fncel.2022.962106</pub-id><pub-id pub-id-type="pmcid">PMC9434313</pub-id><pub-id pub-id-type="pmid">36060279</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>P</given-names></name><name name-style="western"><surname>He</surname><given-names>L</given-names></name><name name-style="western"><surname>Pang</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Yang</surname><given-names>T</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H</given-names></name></person-group><article-title>NLRP3 is expressed in the spiral ganglion neurons and associated with both syndromic and nonsyndromic sensorineural deafness</article-title><source>Neural Plast</source><year>2016</year><volume>2016</volume><fpage>3018132</fpage><pub-id pub-id-type="doi">10.1155/2016/3018132</pub-id><pub-id pub-id-type="pmid">27965898</pub-id><pub-id pub-id-type="pmcid">PMC5124661</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Chen P, He L, Pang X, Wang X, Yang T, Wu H. NLRP3 is expressed in the spiral ganglion neurons and associated with both syndromic and nonsyndromic sensorineural deafness. Neural Plast. 2016;2016:3018132.<pub-id pub-id-type="pmid">27965898</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2016/3018132</pub-id><pub-id pub-id-type="pmcid">PMC5124661</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Guo</surname><given-names>M</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Murine cytomegalovirus employs the mixed lineage kinases family to regulate the spiral ganglion neuron cell death and hearing loss</article-title><source>Neurosci Lett</source><year>2023</year><volume>793</volume><fpage>136990</fpage><pub-id pub-id-type="doi">10.1016/j.neulet.2022.136990</pub-id><pub-id pub-id-type="pmid">36455693</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Li M, Guo M, Xu Y, Wu L, Chen M, Dong Y, et al. Murine cytomegalovirus employs the mixed lineage kinases family to regulate the spiral ganglion neuron cell death and hearing loss. Neurosci Lett. 2023;793:136990.<pub-id pub-id-type="pmid">36455693</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neulet.2022.136990</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoa</surname><given-names>M</given-names></name><name name-style="western"><surname>Olszewski</surname><given-names>R</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Taukulis</surname><given-names>I</given-names></name><name name-style="western"><surname>Gu</surname><given-names>S</given-names></name><name name-style="western"><surname>DeTorres</surname><given-names>A</given-names></name><etal/></person-group><article-title>Characterizing adult cochlear supporting cell transcriptional diversity using Single-Cell RNA-Seq: validation in the adult mouse and translational implications for the adult human cochlea</article-title><source>Front Mol Neurosci</source><year>2020</year><volume>13</volume><fpage>13</fpage><pub-id pub-id-type="doi">10.3389/fnmol.2020.00013</pub-id><pub-id pub-id-type="pmid">32116546</pub-id><pub-id pub-id-type="pmcid">PMC7012811</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Hoa M, Olszewski R, Li X, Taukulis I, Gu S, DeTorres A, et al. Characterizing adult cochlear supporting cell transcriptional diversity using Single-Cell RNA-Seq: validation in the adult mouse and translational implications for the adult human cochlea. Front Mol Neurosci. 2020;13:13.<pub-id pub-id-type="pmid">32116546</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnmol.2020.00013</pub-id><pub-id pub-id-type="pmcid">PMC7012811</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>W</given-names></name><name name-style="western"><surname>Zong</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>P</given-names></name><name name-style="western"><surname>Wei</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>E</given-names></name><name name-style="western"><surname>Ming</surname><given-names>R</given-names></name><etal/></person-group><article-title>Cochlear marginal cell pyroptosis is induced by cisplatin via NLRP3 inflammasome activation</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>823439</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.823439</pub-id><pub-id pub-id-type="pmid">35529876</pub-id><pub-id pub-id-type="pmcid">PMC9067579</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Yu W, Zong S, Zhou P, Wei J, Wang E, Ming R, et al. Cochlear marginal cell pyroptosis is induced by cisplatin via NLRP3 inflammasome activation. Front Immunol. 2022;13:823439.<pub-id pub-id-type="pmid">35529876</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.823439</pub-id><pub-id pub-id-type="pmcid">PMC9067579</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chadha</surname><given-names>S</given-names></name><name name-style="western"><surname>Kamenov</surname><given-names>K</given-names></name><name name-style="western"><surname>Cieza</surname><given-names>A</given-names></name></person-group><article-title>The world report on hearing, 2021</article-title><source>Bull World Health Organ</source><year>2021</year><volume>99</volume><fpage>242</fpage><lpage>A242</lpage><pub-id pub-id-type="doi">10.2471/BLT.21.285643</pub-id><pub-id pub-id-type="pmid">33953438</pub-id><pub-id pub-id-type="pmcid">PMC8085630</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Chadha S, Kamenov K, Cieza A. The world report on hearing, 2021. Bull World Health Organ. 2021;99:242&#8211;A242.<pub-id pub-id-type="pmid">33953438</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2471/BLT.21.285643</pub-id><pub-id pub-id-type="pmcid">PMC8085630</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Celaya AM, S&#225;nchez-P&#233;rez I, Berm&#250;dez-Mu&#241;oz JM, Rodr&#237;guez-de la Rosa L, Pintado-Berninches L, Perona R et al. Deficit of mitogen-activated protein kinase phosphatase 1 (DUSP1) accelerates progressive hearing loss. Elife. 2019;8:e39159. 10.7554/eLife.39159.<pub-id pub-id-type="doi" assigning-authority="pmc">10.7554/eLife.39159</pub-id><pub-id pub-id-type="pmcid">PMC6464786</pub-id><pub-id pub-id-type="pmid">30938680</pub-id></mixed-citation></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berm&#250;dez-Mu&#241;oz</surname><given-names>JM</given-names></name><name name-style="western"><surname>Celaya</surname><given-names>AM</given-names></name><name name-style="western"><surname>Hijazo-Pechero</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Serrano</surname><given-names>M</given-names></name><name name-style="western"><surname>Varela-Nieto</surname><given-names>I</given-names></name></person-group><article-title>G6PD overexpression protects from oxidative stress and age-related hearing loss</article-title><source>Aging Cell</source><year>2020</year><volume>19</volume><fpage>e13275</fpage><pub-id pub-id-type="doi">10.1111/acel.13275</pub-id><pub-id pub-id-type="pmid">33222382</pub-id><pub-id pub-id-type="pmcid">PMC7744953</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Berm&#250;dez-Mu&#241;oz JM, Celaya AM, Hijazo-Pechero S, Wang J, Serrano M, Varela-Nieto I. G6PD overexpression protects from oxidative stress and age-related hearing loss. Aging Cell. 2020;19:e13275.<pub-id pub-id-type="pmid">33222382</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/acel.13275</pub-id><pub-id pub-id-type="pmcid">PMC7744953</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sai</surname><given-names>N</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y-Y</given-names></name><name name-style="western"><surname>Ma</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Q-Q</given-names></name><name name-style="western"><surname>Guo</surname><given-names>W-W</given-names></name><etal/></person-group><article-title>Involvement of NLRP3-inflammasome pathway in noise-induced hearing loss</article-title><source>Neural Regen Res</source><year>2022</year><volume>17</volume><fpage>2750</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.4103/1673-5374.339499</pub-id><pub-id pub-id-type="pmid">35662224</pub-id><pub-id pub-id-type="pmcid">PMC9165387</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Sai N, Yang Y-Y, Ma L, Liu D, Jiang Q-Q, Guo W-W, et al. Involvement of NLRP3-inflammasome pathway in noise-induced hearing loss. Neural Regen Res. 2022;17:2750&#8211;4.<pub-id pub-id-type="pmid">35662224</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/1673-5374.339499</pub-id><pub-id pub-id-type="pmcid">PMC9165387</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>L</given-names></name><etal/></person-group><article-title>Oridonin alleviates kanamycin-related hearing loss by inhibiting NLRP3/caspase-1/gasdermin D-induced inflammasome activation and hair cell pyroptosis</article-title><source>Mol Immunol</source><year>2022</year><volume>149</volume><fpage>66</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2022.06.006</pub-id><pub-id pub-id-type="pmid">35749835</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Wu L, Chen M, Li M, Wang Y, Li Y, Zheng L, et al. Oridonin alleviates kanamycin-related hearing loss by inhibiting NLRP3/caspase-1/gasdermin D-induced inflammasome activation and hair cell pyroptosis. Mol Immunol. 2022;149:66&#8211;76.<pub-id pub-id-type="pmid">35749835</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molimm.2022.06.006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhuang</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Shi</surname><given-names>X</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><name name-style="western"><surname>Xu</surname><given-names>B</given-names></name><etal/></person-group><article-title>MCMV triggers ROS/NLRP3-associated inflammasome activation in the inner ear of mice and cultured spiral ganglion neurons, contributing to sensorineural hearing loss</article-title><source>Int J Mol Med</source><year>2018</year><volume>41</volume><fpage>3448</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">29512778</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ijmm.2018.3539</pub-id><pub-id pub-id-type="pmcid">PMC5881649</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Zhuang W, Wang C, Shi X, Qiu S, Zhang S, Xu B, et al. MCMV triggers ROS/NLRP3-associated inflammasome activation in the inner ear of mice and cultured spiral ganglion neurons, contributing to sensorineural hearing loss. Int J Mol Med. 2018;41:3448&#8211;56.<pub-id pub-id-type="pmid">29512778</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ijmm.2018.3539</pub-id><pub-id pub-id-type="pmcid">PMC5881649</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Welzel</surname><given-names>T</given-names></name><name name-style="western"><surname>Kuemmerle-Deschner</surname><given-names>JB</given-names></name></person-group><article-title>Diagnosis and management of the Cryopyrin-Associated periodic syndromes (CAPS): what do we know today?</article-title><source>J Clin Med</source><year>2021</year><volume>10</volume><fpage>128</fpage><pub-id pub-id-type="doi">10.3390/jcm10010128</pub-id><pub-id pub-id-type="pmid">33401496</pub-id><pub-id pub-id-type="pmcid">PMC7794776</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Welzel T, Kuemmerle-Deschner JB. Diagnosis and management of the Cryopyrin-Associated periodic syndromes (CAPS): what do we know today? J Clin Med. 2021;10:128.<pub-id pub-id-type="pmid">33401496</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm10010128</pub-id><pub-id pub-id-type="pmcid">PMC7794776</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuemmerle-Deschner</surname><given-names>JB</given-names></name></person-group><article-title>CAPS&#8211;pathogenesis, presentation and treatment of an autoinflammatory disease</article-title><source>Semin Immunopathol</source><year>2015</year><volume>37</volume><fpage>377</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1007/s00281-015-0491-7</pub-id><pub-id pub-id-type="pmid">25963520</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Kuemmerle-Deschner JB. CAPS&#8211;pathogenesis, presentation and treatment of an autoinflammatory disease. Semin Immunopathol. 2015;37:377&#8211;85.<pub-id pub-id-type="pmid">25963520</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00281-015-0491-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Kile RL. A case of cold urticaria with an unusual family history. JAMA. 1940;114:1067&#8211;8. 10.1001/jama.1940.62810120003010b.</mixed-citation></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koitschev</surname><given-names>A</given-names></name><name name-style="western"><surname>Gramlich</surname><given-names>K</given-names></name><name name-style="western"><surname>Hansmann</surname><given-names>S</given-names></name><name name-style="western"><surname>Benseler</surname><given-names>S</given-names></name><name name-style="western"><surname>Plontke</surname><given-names>SK</given-names></name><name name-style="western"><surname>Koitschev</surname><given-names>C</given-names></name><etal/></person-group><article-title>Progressive Familial hearing loss in Muckle-Wells syndrome</article-title><source>Acta Otolaryngol</source><year>2012</year><volume>132</volume><fpage>756</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.3109/00016489.2012.656321</pub-id><pub-id pub-id-type="pmid">22497426</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Koitschev A, Gramlich K, Hansmann S, Benseler S, Plontke SK, Koitschev C, et al. Progressive Familial hearing loss in Muckle-Wells syndrome. Acta Otolaryngol. 2012;132:756&#8211;62.<pub-id pub-id-type="pmid">22497426</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/00016489.2012.656321</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuemmerle-Deschner</surname><given-names>JB</given-names></name><name name-style="western"><surname>Koitschev</surname><given-names>A</given-names></name><name name-style="western"><surname>Tyrrell</surname><given-names>PN</given-names></name><name name-style="western"><surname>Plontke</surname><given-names>SK</given-names></name><name name-style="western"><surname>Deschner</surname><given-names>N</given-names></name><name name-style="western"><surname>Hansmann</surname><given-names>S</given-names></name><etal/></person-group><article-title>Early detection of sensorineural hearing loss in Muckle-Wells-syndrome</article-title><source>Pediatr Rheumatol Online J</source><year>2015</year><volume>13</volume><fpage>43</fpage><pub-id pub-id-type="doi">10.1186/s12969-015-0041-9</pub-id><pub-id pub-id-type="pmid">26531310</pub-id><pub-id pub-id-type="pmcid">PMC4632838</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Kuemmerle-Deschner JB, Koitschev A, Tyrrell PN, Plontke SK, Deschner N, Hansmann S, et al. Early detection of sensorineural hearing loss in Muckle-Wells-syndrome. Pediatr Rheumatol Online J. 2015;13:43.<pub-id pub-id-type="pmid">26531310</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12969-015-0041-9</pub-id><pub-id pub-id-type="pmcid">PMC4632838</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuemmerle-Deschner</surname><given-names>JB</given-names></name><name name-style="western"><surname>Koitschev</surname><given-names>A</given-names></name><name name-style="western"><surname>Ummenhofer</surname><given-names>K</given-names></name><name name-style="western"><surname>Hansmann</surname><given-names>S</given-names></name><name name-style="western"><surname>Plontke</surname><given-names>SK</given-names></name><name name-style="western"><surname>Koitschev</surname><given-names>C</given-names></name><etal/></person-group><article-title>Hearing loss in Muckle-Wells syndrome</article-title><source>Arthritis Rheum</source><year>2013</year><volume>65</volume><fpage>824</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1002/art.37810</pub-id><pub-id pub-id-type="pmid">23440695</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Kuemmerle-Deschner JB, Koitschev A, Ummenhofer K, Hansmann S, Plontke SK, Koitschev C, et al. Hearing loss in Muckle-Wells syndrome. Arthritis Rheum. 2013;65:824&#8211;31.<pub-id pub-id-type="pmid">23440695</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/art.37810</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuemmerle-Deschner</surname><given-names>JB</given-names></name><name name-style="western"><surname>Lohse</surname><given-names>P</given-names></name><name name-style="western"><surname>Koetter</surname><given-names>I</given-names></name><name name-style="western"><surname>Dannecker</surname><given-names>GE</given-names></name><name name-style="western"><surname>Reess</surname><given-names>F</given-names></name><name name-style="western"><surname>Ummenhofer</surname><given-names>K</given-names></name><etal/></person-group><article-title>NLRP3 E311K mutation in a large family with Muckle-Wells syndrome&#8211;description of a heterogeneous phenotype and response to treatment</article-title><source>Arthritis Res Ther</source><year>2011</year><volume>13</volume><fpage>R196</fpage><pub-id pub-id-type="doi">10.1186/ar3526</pub-id><pub-id pub-id-type="pmid">22146561</pub-id><pub-id pub-id-type="pmcid">PMC3334646</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Kuemmerle-Deschner JB, Lohse P, Koetter I, Dannecker GE, Reess F, Ummenhofer K, et al. NLRP3 E311K mutation in a large family with Muckle-Wells syndrome&#8211;description of a heterogeneous phenotype and response to treatment. Arthritis Res Ther. 2011;13:R196.<pub-id pub-id-type="pmid">22146561</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/ar3526</pub-id><pub-id pub-id-type="pmcid">PMC3334646</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prieur</surname><given-names>AM</given-names></name><name name-style="western"><surname>Griscelli</surname><given-names>C</given-names></name><name name-style="western"><surname>Lampert</surname><given-names>F</given-names></name><name name-style="western"><surname>Truckenbrodt</surname><given-names>H</given-names></name><name name-style="western"><surname>Guggenheim</surname><given-names>MA</given-names></name><name name-style="western"><surname>Lovell</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>A chronic, infantile, neurological, cutaneous and articular (CINCA) syndrome. A specific entity analysed in 30 patients</article-title><source>Scand J Rheumatol Suppl</source><year>1987</year><volume>66</volume><fpage>57</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.3109/03009748709102523</pub-id><pub-id pub-id-type="pmid">3482735</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Prieur AM, Griscelli C, Lampert F, Truckenbrodt H, Guggenheim MA, Lovell DJ, et al. A chronic, infantile, neurological, cutaneous and articular (CINCA) syndrome. A specific entity analysed in 30 patients. Scand J Rheumatol Suppl. 1987;66:57&#8211;68.<pub-id pub-id-type="pmid">3482735</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/03009748709102523</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finetti</surname><given-names>M</given-names></name><name name-style="western"><surname>Omenetti</surname><given-names>A</given-names></name><name name-style="western"><surname>Federici</surname><given-names>S</given-names></name><name name-style="western"><surname>Caorsi</surname><given-names>R</given-names></name><name name-style="western"><surname>Gattorno</surname><given-names>M</given-names></name></person-group><article-title>Chronic infantile neurological cutaneous and articular (CINCA) syndrome: a review</article-title><source>Orphanet J Rare Dis</source><year>2016</year><volume>11</volume><fpage>167</fpage><pub-id pub-id-type="doi">10.1186/s13023-016-0542-8</pub-id><pub-id pub-id-type="pmid">27927236</pub-id><pub-id pub-id-type="pmcid">PMC5142346</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Finetti M, Omenetti A, Federici S, Caorsi R, Gattorno M. Chronic infantile neurological cutaneous and articular (CINCA) syndrome: a review. Orphanet J Rare Dis. 2016;11:167.<pub-id pub-id-type="pmid">27927236</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13023-016-0542-8</pub-id><pub-id pub-id-type="pmcid">PMC5142346</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Conforti-Andreoni</surname><given-names>C</given-names></name><name name-style="western"><surname>Ricciardi-Castagnoli</surname><given-names>P</given-names></name><name name-style="western"><surname>Mortellaro</surname><given-names>A</given-names></name></person-group><article-title>The inflammasomes in health and disease: from genetics to molecular mechanisms of autoinflammation and beyond</article-title><source>Cell Mol Immunol</source><year>2011</year><volume>8</volume><fpage>135</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1038/cmi.2010.81</pub-id><pub-id pub-id-type="pmid">21258359</pub-id><pub-id pub-id-type="pmcid">PMC4003142</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Conforti-Andreoni C, Ricciardi-Castagnoli P, Mortellaro A. The inflammasomes in health and disease: from genetics to molecular mechanisms of autoinflammation and beyond. Cell Mol Immunol. 2011;8:135&#8211;45.<pub-id pub-id-type="pmid">21258359</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/cmi.2010.81</pub-id><pub-id pub-id-type="pmcid">PMC4003142</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fayand</surname><given-names>A</given-names></name><name name-style="western"><surname>Cescato</surname><given-names>M</given-names></name><name name-style="western"><surname>Le Corre</surname><given-names>L</given-names></name><name name-style="western"><surname>Terr&#233;</surname><given-names>A</given-names></name><name name-style="western"><surname>Wacheux</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>YYJ</given-names></name><etal/></person-group><article-title>Pathogenic variants in the NLRP3 LRR domain at position 861 are responsible for a boost-dependent atypical CAPS phenotype</article-title><source>J Allergy Clin Immunol</source><year>2023</year><volume>152</volume><fpage>1303</fpage><lpage>e13111</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2023.07.006</pub-id><pub-id pub-id-type="pmid">37506976</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Fayand A, Cescato M, Le Corre L, Terr&#233; A, Wacheux M, Zhu YYJ, et al. Pathogenic variants in the NLRP3 LRR domain at position 861 are responsible for a boost-dependent atypical CAPS phenotype. J Allergy Clin Immunol. 2023;152:1303&#8211;e13111.<pub-id pub-id-type="pmid">37506976</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaci.2023.07.006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Birk-Bachar</surname><given-names>M</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>H</given-names></name><name name-style="western"><surname>Sofrin-Drucker</surname><given-names>E</given-names></name><name name-style="western"><surname>Kropach-Gilad</surname><given-names>N</given-names></name><name name-style="western"><surname>Orenstein</surname><given-names>N</given-names></name><name name-style="western"><surname>Lidzbarsky</surname><given-names>G</given-names></name><etal/></person-group><article-title>Discovery of a novel missense variant in NLRP3 causing atypical Cryopyrin-Associated periodic syndromes with hearing loss as the primary Presentation, responsive to Anti-Interleukin-1 therapy</article-title><source>Arthritis Rheumatol</source><year>2024</year><volume>76</volume><fpage>444</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1002/art.42721</pub-id><pub-id pub-id-type="pmid">37738164</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Birk-Bachar M, Cohen H, Sofrin-Drucker E, Kropach-Gilad N, Orenstein N, Lidzbarsky G, et al. Discovery of a novel missense variant in NLRP3 causing atypical Cryopyrin-Associated periodic syndromes with hearing loss as the primary Presentation, responsive to Anti-Interleukin-1 therapy. Arthritis Rheumatol. 2024;76:444&#8211;54.<pub-id pub-id-type="pmid">37738164</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/art.42721</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levy</surname><given-names>R</given-names></name><name name-style="western"><surname>G&#233;rard</surname><given-names>L</given-names></name><name name-style="western"><surname>Kuemmerle-Deschner</surname><given-names>J</given-names></name><name name-style="western"><surname>Lachmann</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Kon&#233;-Paut</surname><given-names>I</given-names></name><name name-style="western"><surname>Cantarini</surname><given-names>L</given-names></name><etal/></person-group><article-title>Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever registry</article-title><source>Ann Rheum Dis</source><year>2015</year><volume>74</volume><fpage>2043</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2013-204991</pub-id><pub-id pub-id-type="pmid">25038238</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Levy R, G&#233;rard L, Kuemmerle-Deschner J, Lachmann HJ, Kon&#233;-Paut I, Cantarini L, et al. Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever registry. Ann Rheum Dis. 2015;74:2043&#8211;9.<pub-id pub-id-type="pmid">25038238</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/annrheumdis-2013-204991</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="other">Nakanishi H, Yamada S, Kita J, Shinmura D, Hosokawa K, Sahara S et al. Auditory and Vestibular Characteristics of NLRP3 Inflammasome Related Autoinflammatory Disorders: Monogenic Hearing Loss Can Be Improved by Anti-interleukin-1 Therapy. Frontiers in Neurology [Internet]. 2022 [cited 2023 Mar 9];13. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/">https://www.frontiersin.org/articles/</ext-link>10.3389/fneur.2022.865763<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2022.865763</pub-id><pub-id pub-id-type="pmcid">PMC9099043</pub-id><pub-id pub-id-type="pmid">35572943</pub-id></mixed-citation></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salsano</surname><given-names>E</given-names></name><name name-style="western"><surname>Rizzo</surname><given-names>A</given-names></name><name name-style="western"><surname>Bedini</surname><given-names>G</given-names></name><name name-style="western"><surname>Bernard</surname><given-names>L</given-names></name><name name-style="western"><surname>Dall&#8217;olio</surname><given-names>V</given-names></name><name name-style="western"><surname>Volorio</surname><given-names>S</given-names></name><etal/></person-group><article-title>An autoinflammatory neurological disease due to Interleukin 6 hypersecretion</article-title><source>J Neuroinflammation</source><year>2013</year><volume>10</volume><fpage>29</fpage><pub-id pub-id-type="doi">10.1186/1742-2094-10-29</pub-id><pub-id pub-id-type="pmid">23432807</pub-id><pub-id pub-id-type="pmcid">PMC3601972</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Salsano E, Rizzo A, Bedini G, Bernard L, Dall&#8217;olio V, Volorio S, et al. An autoinflammatory neurological disease due to Interleukin 6 hypersecretion. J Neuroinflammation. 2013;10:29.<pub-id pub-id-type="pmid">23432807</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1742-2094-10-29</pub-id><pub-id pub-id-type="pmcid">PMC3601972</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakanishi</surname><given-names>H</given-names></name><name name-style="western"><surname>Prakash</surname><given-names>P</given-names></name><name name-style="western"><surname>Ito</surname><given-names>T</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Brewer</surname><given-names>CC</given-names></name><name name-style="western"><surname>Harrow</surname><given-names>D</given-names></name><etal/></person-group><article-title>Genetic hearing loss associated with autoinflammation</article-title><source>Front Neurol</source><year>2020</year><volume>11</volume><fpage>141</fpage><pub-id pub-id-type="doi">10.3389/fneur.2020.00141</pub-id><pub-id pub-id-type="pmid">32194497</pub-id><pub-id pub-id-type="pmcid">PMC7066252</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Nakanishi H, Prakash P, Ito T, Kim HJ, Brewer CC, Harrow D, et al. Genetic hearing loss associated with autoinflammation. Front Neurol. 2020;11:141.<pub-id pub-id-type="pmid">32194497</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2020.00141</pub-id><pub-id pub-id-type="pmcid">PMC7066252</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakanishi</surname><given-names>H</given-names></name><name name-style="western"><surname>Kawashima</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kurima</surname><given-names>K</given-names></name><name name-style="western"><surname>Muskett</surname><given-names>JA</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Brewer</surname><given-names>CC</given-names></name><etal/></person-group><article-title>Gradual symmetric progression of DFNA34 hearing loss caused by an NLRP3 mutation and cochlear autoinflammation</article-title><source>Otol Neurotol</source><year>2018</year><volume>39</volume><fpage>e181</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1097/MAO.0000000000001715</pub-id><pub-id pub-id-type="pmid">29342053</pub-id><pub-id pub-id-type="pmcid">PMC5807171</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Nakanishi H, Kawashima Y, Kurima K, Muskett JA, Kim HJ, Brewer CC, et al. Gradual symmetric progression of DFNA34 hearing loss caused by an NLRP3 mutation and cochlear autoinflammation. Otol Neurotol. 2018;39:e181&#8211;5.<pub-id pub-id-type="pmid">29342053</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MAO.0000000000001715</pub-id><pub-id pub-id-type="pmcid">PMC5807171</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ozi&#281;b&#322;o</surname><given-names>D</given-names></name><name name-style="western"><surname>Leja</surname><given-names>ML</given-names></name><name name-style="western"><surname>Jeznach</surname><given-names>A</given-names></name><name name-style="western"><surname>Orzechowska</surname><given-names>M</given-names></name><name name-style="western"><surname>Skirecki</surname><given-names>T</given-names></name><name name-style="western"><surname>Wi&#281;sik-Szewczyk</surname><given-names>E</given-names></name><etal/></person-group><article-title>Hearing loss as the main clinical presentation in NLRP3-Associated autoinflammatory disease</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>904632</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.904632</pub-id><pub-id pub-id-type="pmid">35720340</pub-id><pub-id pub-id-type="pmcid">PMC9204589</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Ozi&#281;b&#322;o D, Leja ML, Jeznach A, Orzechowska M, Skirecki T, Wi&#281;sik-Szewczyk E, et al. Hearing loss as the main clinical presentation in NLRP3-Associated autoinflammatory disease. Front Immunol. 2022;13:904632.<pub-id pub-id-type="pmid">35720340</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.904632</pub-id><pub-id pub-id-type="pmcid">PMC9204589</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>S</given-names></name><name name-style="western"><surname>Maheshwari</surname><given-names>A</given-names></name><name name-style="western"><surname>Boppana</surname><given-names>S</given-names></name></person-group><article-title>CMV-induced hearing loss</article-title><source>Newborn (Clarksville)</source><year>2023</year><volume>2</volume><fpage>249</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">38348106</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5005/jp-journals-11002-0081</pub-id><pub-id pub-id-type="pmcid">PMC10860330</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Singh S, Maheshwari A, Boppana S. CMV-induced hearing loss. Newborn (Clarksville). 2023;2:249&#8211;62.<pub-id pub-id-type="pmid">38348106</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5005/jp-journals-11002-0081</pub-id><pub-id pub-id-type="pmcid">PMC10860330</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>S</given-names></name><name name-style="western"><surname>Yu</surname><given-names>S</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H</given-names></name><name name-style="western"><surname>Yao</surname><given-names>G</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>F</given-names></name><etal/></person-group><article-title>The pyroptosis mechanism of ototoxicity caused by unconjugated bilirubin in neonatal hyperbilirubinemia</article-title><source>Biomed Pharmacother</source><year>2023</year><volume>165</volume><fpage>115162</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2023.115162</pub-id><pub-id pub-id-type="pmid">37467648</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Sun S, Yu S, Yu H, Yao G, Guo X, Zhao F, et al. The pyroptosis mechanism of ototoxicity caused by unconjugated bilirubin in neonatal hyperbilirubinemia. Biomed Pharmacother. 2023;165:115162.<pub-id pub-id-type="pmid">37467648</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2023.115162</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moke</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Luo</surname><given-names>C</given-names></name><name name-style="western"><surname>Millstein</surname><given-names>J</given-names></name><name name-style="western"><surname>Knight</surname><given-names>KR</given-names></name><name name-style="western"><surname>Rassekh</surname><given-names>SR</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>B</given-names></name><etal/></person-group><article-title>Prevalence and risk factors for cisplatin-induced hearing loss in children, adolescents, and young adults: a multi-institutional North American cohort study</article-title><source>Lancet Child Adolesc Health</source><year>2021</year><volume>5</volume><fpage>274</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/S2352-4642(21)00020-1</pub-id><pub-id pub-id-type="pmid">33581749</pub-id><pub-id pub-id-type="pmcid">PMC9059427</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Moke DJ, Luo C, Millstein J, Knight KR, Rassekh SR, Brooks B, et al. Prevalence and risk factors for cisplatin-induced hearing loss in children, adolescents, and young adults: a multi-institutional North American cohort study. Lancet Child Adolesc Health. 2021;5:274&#8211;83.<pub-id pub-id-type="pmid">33581749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2352-4642(21)00020-1</pub-id><pub-id pub-id-type="pmcid">PMC9059427</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Breglio</surname><given-names>AM</given-names></name><name name-style="western"><surname>Rusheen</surname><given-names>AE</given-names></name><name name-style="western"><surname>Shide</surname><given-names>ED</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>KA</given-names></name><name name-style="western"><surname>Spielbauer</surname><given-names>KK</given-names></name><name name-style="western"><surname>McLachlin</surname><given-names>KM</given-names></name><etal/></person-group><article-title>Cisplatin is retained in the cochlea indefinitely following chemotherapy</article-title><source>Nat Commun</source><year>2017</year><volume>8</volume><fpage>1654</fpage><pub-id pub-id-type="doi">10.1038/s41467-017-01837-1</pub-id><pub-id pub-id-type="pmid">29162831</pub-id><pub-id pub-id-type="pmcid">PMC5698400</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Breglio AM, Rusheen AE, Shide ED, Fernandez KA, Spielbauer KK, McLachlin KM, et al. Cisplatin is retained in the cochlea indefinitely following chemotherapy. Nat Commun. 2017;8:1654.<pub-id pub-id-type="pmid">29162831</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-017-01837-1</pub-id><pub-id pub-id-type="pmcid">PMC5698400</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murillo-Cuesta</surname><given-names>S</given-names></name><name name-style="western"><surname>Celaya</surname><given-names>AM</given-names></name><name name-style="western"><surname>Cervantes</surname><given-names>B</given-names></name><name name-style="western"><surname>Berm&#250;dez-Mu&#241;oz</surname><given-names>JM</given-names></name><name name-style="western"><surname>Rodr&#237;guez-de la Rosa</surname><given-names>L</given-names></name><name name-style="western"><surname>Contreras</surname><given-names>J</given-names></name><etal/></person-group><article-title>Therapeutic efficiency of the APAF-1 antagonist LPT99 in a rat model of cisplatin-induced hearing loss</article-title><source>Clin Transl Med</source><year>2021</year><volume>11</volume><fpage>e363</fpage><pub-id pub-id-type="doi">10.1002/ctm2.363</pub-id><pub-id pub-id-type="pmid">33931965</pub-id><pub-id pub-id-type="pmcid">PMC8021538</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Murillo-Cuesta S, Celaya AM, Cervantes B, Berm&#250;dez-Mu&#241;oz JM, Rodr&#237;guez-de la Rosa L, Contreras J, et al. Therapeutic efficiency of the APAF-1 antagonist LPT99 in a rat model of cisplatin-induced hearing loss. Clin Transl Med. 2021;11:e363.<pub-id pub-id-type="pmid">33931965</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ctm2.363</pub-id><pub-id pub-id-type="pmcid">PMC8021538</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>R</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K</given-names></name><name name-style="western"><surname>Luo</surname><given-names>W</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H</given-names></name></person-group><article-title>Knockdown and mutation of Pou4f3 gene mutation promotes pyroptosis of cochleae in cisplatin-induced deafness mice by NLRP3/caspase-3/GSDME pathway</article-title><source>Toxicology</source><year>2022</year><volume>482</volume><fpage>153368</fpage><pub-id pub-id-type="doi">10.1016/j.tox.2022.153368</pub-id><pub-id pub-id-type="pmid">36341876</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Yu R, Wang K, Luo W, Jiang H. Knockdown and mutation of Pou4f3 gene mutation promotes pyroptosis of cochleae in cisplatin-induced deafness mice by NLRP3/caspase-3/GSDME pathway. Toxicology. 2022;482:153368.<pub-id pub-id-type="pmid">36341876</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tox.2022.153368</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Magagnoli</surname><given-names>J</given-names></name><name name-style="western"><surname>Cummings</surname><given-names>TH</given-names></name><name name-style="western"><surname>Hardin</surname><given-names>JW</given-names></name><name name-style="western"><surname>Sutton</surname><given-names>SS</given-names></name><name name-style="western"><surname>Ambati</surname><given-names>J</given-names></name></person-group><article-title>Fluoxetine, fluvoxamine, and hearing loss or tinnitus after cisplatin treatment: A retrospective cohort study</article-title><source>J Investig Med</source><year>2024</year><volume>72</volume><fpage>579</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1177/10815589241247796</pub-id><pub-id pub-id-type="pmid">38597272</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Magagnoli J, Cummings TH, Hardin JW, Sutton SS, Ambati J. Fluoxetine, fluvoxamine, and hearing loss or tinnitus after cisplatin treatment: A retrospective cohort study. J Investig Med. 2024;72:579&#8211;86.<pub-id pub-id-type="pmid">38597272</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/10815589241247796</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Mao</surname><given-names>S</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Inhibition of the NLRP3 inflammasome attenuates spiral ganglion neuron degeneration in aminoglycoside-induced hearing loss</article-title><source>Neural Regen Res</source><year>2025</year><volume>20</volume><fpage>3025</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.4103/NRR.NRR-D-23-01879</pub-id><pub-id pub-id-type="pmid">39610108</pub-id><pub-id pub-id-type="pmcid">PMC11826467</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Fang J, Li Z, Wang P, Zhang X, Mao S, Li Y, et al. Inhibition of the NLRP3 inflammasome attenuates spiral ganglion neuron degeneration in aminoglycoside-induced hearing loss. Neural Regen Res. 2025;20:3025&#8211;39.<pub-id pub-id-type="pmid">39610108</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/NRR.NRR-D-23-01879</pub-id><pub-id pub-id-type="pmcid">PMC11826467</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frye</surname><given-names>MD</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>AF</given-names></name><name name-style="western"><surname>Kurabi</surname><given-names>A</given-names></name></person-group><article-title>Inflammation associated with noise-induced hearing loss</article-title><source>J Acoust Soc Am</source><year>2019</year><volume>146</volume><fpage>4020</fpage><pub-id pub-id-type="doi">10.1121/1.5132545</pub-id><pub-id pub-id-type="pmid">31795714</pub-id><pub-id pub-id-type="pmcid">PMC7480080</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Frye MD, Ryan AF, Kurabi A. Inflammation associated with noise-induced hearing loss. J Acoust Soc Am. 2019;146:4020.<pub-id pub-id-type="pmid">31795714</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1121/1.5132545</pub-id><pub-id pub-id-type="pmcid">PMC7480080</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>W</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><etal/></person-group><article-title>Oridonin ameliorates noise-induced hearing loss by blocking NLRP3 - NEK7 mediated inflammasome activation</article-title><source>Int Immunopharmacol</source><year>2021</year><volume>95</volume><fpage>107576</fpage><pub-id pub-id-type="doi">10.1016/j.intimp.2021.107576</pub-id><pub-id pub-id-type="pmid">33770730</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Li M, Zhang Y, Qiu S, Zhuang W, Jiang W, Wang C, et al. Oridonin ameliorates noise-induced hearing loss by blocking NLRP3 - NEK7 mediated inflammasome activation. Int Immunopharmacol. 2021;95:107576.<pub-id pub-id-type="pmid">33770730</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.intimp.2021.107576</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>M-B</given-names></name><name name-style="western"><surname>Li</surname><given-names>M-H</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L-Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R</given-names></name><name name-style="western"><surname>Long</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Oridonin employs Interleukin 1 receptor type 2 to treat noise-induced hearing loss by blocking inner ear inflammation</article-title><source>Biochem Pharmacol</source><year>2023</year><volume>210</volume><fpage>115457</fpage><pub-id pub-id-type="doi">10.1016/j.bcp.2023.115457</pub-id><pub-id pub-id-type="pmid">36806583</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Chen M-B, Li M-H, Wu L-Y, Wang R, Long X, Zhang L, et al. Oridonin employs Interleukin 1 receptor type 2 to treat noise-induced hearing loss by blocking inner ear inflammation. Biochem Pharmacol. 2023;210:115457.<pub-id pub-id-type="pmid">36806583</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bcp.2023.115457</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>S</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name><name name-style="western"><surname>Hui</surname><given-names>L</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Du</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>W</given-names></name><etal/></person-group><article-title>Long-term exposure to low-intensity environmental noise aggravates age-related hearing loss via disruption of cochlear ribbon synapses</article-title><source>Am J Transl Res</source><year>2020</year><volume>12</volume><fpage>3674</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">32774726</pub-id><pub-id pub-id-type="pmcid">PMC7407738</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Feng S, Yang L, Hui L, Luo Y, Du Z, Xiong W, et al. Long-term exposure to low-intensity environmental noise aggravates age-related hearing loss via disruption of cochlear ribbon synapses. Am J Transl Res. 2020;12:3674&#8211;87.<pub-id pub-id-type="pmid">32774726</pub-id><pub-id pub-id-type="pmcid">PMC7407738</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>X</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>W</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>N</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><etal/></person-group><article-title>NLRP3-inflammasomes are triggered by age-related hearing loss in the inner ear of mice</article-title><source>Am J Transl Res</source><year>2017</year><volume>9</volume><fpage>5611</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">29312513</pub-id><pub-id pub-id-type="pmcid">PMC5752911</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Shi X, Qiu S, Zhuang W, Yuan N, Wang C, Zhang S, et al. NLRP3-inflammasomes are triggered by age-related hearing loss in the inner ear of mice. Am J Transl Res. 2017;9:5611&#8211;8.<pub-id pub-id-type="pmid">29312513</pub-id><pub-id pub-id-type="pmcid">PMC5752911</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>D-G</given-names></name><name name-style="western"><surname>Yu</surname><given-names>W-Q</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J-H</given-names></name><name name-style="western"><surname>Kong</surname><given-names>L-G</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y-D</given-names></name><etal/></person-group><article-title>Serum/glucocorticoid-inducible kinase 1 deficiency induces NLRP3 inflammasome activation and autoinflammation of macrophages in a murine endolymphatic hydrops model</article-title><source>Nat Commun</source><year>2023</year><volume>14</volume><fpage>1249</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-36949-4</pub-id><pub-id pub-id-type="pmid">36872329</pub-id><pub-id pub-id-type="pmcid">PMC9986248</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Zhang D-G, Yu W-Q, Liu J-H, Kong L-G, Zhang N, Song Y-D, et al. Serum/glucocorticoid-inducible kinase 1 deficiency induces NLRP3 inflammasome activation and autoinflammation of macrophages in a murine endolymphatic hydrops model. Nat Commun. 2023;14:1249.<pub-id pub-id-type="pmid">36872329</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-36949-4</pub-id><pub-id pub-id-type="pmcid">PMC9986248</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murillo-Cuesta</surname><given-names>S</given-names></name><name name-style="western"><surname>Lara</surname><given-names>E</given-names></name><name name-style="western"><surname>Berm&#250;dez-Mu&#241;oz</surname><given-names>JM</given-names></name><name name-style="western"><surname>Torres-Campos</surname><given-names>E</given-names></name><name name-style="western"><surname>Rodr&#237;guez-de la Rosa</surname><given-names>L</given-names></name><name name-style="western"><surname>L&#243;pez-Larrubia</surname><given-names>P</given-names></name><etal/></person-group><article-title>Protection of lipopolysaccharide-induced otic injury by a single dose administration of a novel dexamethasone formulation</article-title><source>Translational Med Commun</source><year>2023</year><volume>8</volume><fpage>23</fpage><pub-id pub-id-type="doi">10.1186/s41231-023-00156-6</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Murillo-Cuesta S, Lara E, Berm&#250;dez-Mu&#241;oz JM, Torres-Campos E, Rodr&#237;guez-de la Rosa L, L&#243;pez-Larrubia P, et al. Protection of lipopolysaccharide-induced otic injury by a single dose administration of a novel dexamethasone formulation. Translational Med Commun. 2023;8:23.</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruiz-Garc&#237;a</surname><given-names>C</given-names></name><name name-style="western"><surname>Lassaletta</surname><given-names>L</given-names></name><name name-style="western"><surname>L&#243;pez-Larrubia</surname><given-names>P</given-names></name><name name-style="western"><surname>Varela-Nieto</surname><given-names>I</given-names></name><name name-style="western"><surname>Murillo-Cuesta</surname><given-names>S</given-names></name></person-group><article-title>Tumors of the nervous system and hearing loss: beyond vestibular schwannomas</article-title><source>Hear Res</source><year>2024</year><volume>447</volume><fpage>109012</fpage><pub-id pub-id-type="doi">10.1016/j.heares.2024.109012</pub-id><pub-id pub-id-type="pmid">38703433</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Ruiz-Garc&#237;a C, Lassaletta L, L&#243;pez-Larrubia P, Varela-Nieto I, Murillo-Cuesta S. Tumors of the nervous system and hearing loss: beyond vestibular schwannomas. Hear Res. 2024;447:109012.<pub-id pub-id-type="pmid">38703433</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.heares.2024.109012</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sagers</surname><given-names>JE</given-names></name><name name-style="western"><surname>Sahin</surname><given-names>MI</given-names></name><name name-style="western"><surname>Moon</surname><given-names>I</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>SG</given-names></name><name name-style="western"><surname>Stemmer-Rachamimov</surname><given-names>A</given-names></name><name name-style="western"><surname>Brenner</surname><given-names>GJ</given-names></name><etal/></person-group><article-title>NLRP3 inflammasome activation in human vestibular schwannoma: implications for tumor-induced hearing loss</article-title><source>Hear Res</source><year>2019</year><volume>381</volume><fpage>107770</fpage><pub-id pub-id-type="doi">10.1016/j.heares.2019.07.007</pub-id><pub-id pub-id-type="pmid">31430634</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Sagers JE, Sahin MI, Moon I, Ahmed SG, Stemmer-Rachamimov A, Brenner GJ, et al. NLRP3 inflammasome activation in human vestibular schwannoma: implications for tumor-induced hearing loss. Hear Res. 2019;381:107770.<pub-id pub-id-type="pmid">31430634</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.heares.2019.07.007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brydges</surname><given-names>SD</given-names></name><name name-style="western"><surname>Mueller</surname><given-names>JL</given-names></name><name name-style="western"><surname>McGeough</surname><given-names>MD</given-names></name><name name-style="western"><surname>Pena</surname><given-names>CA</given-names></name><name name-style="western"><surname>Misaghi</surname><given-names>A</given-names></name><name name-style="western"><surname>Gandhi</surname><given-names>C</given-names></name><etal/></person-group><article-title>Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity</article-title><source>Immunity</source><year>2009</year><volume>30</volume><fpage>875</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2009.05.005</pub-id><pub-id pub-id-type="pmid">19501000</pub-id><pub-id pub-id-type="pmcid">PMC2759865</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Brydges SD, Mueller JL, McGeough MD, Pena CA, Misaghi A, Gandhi C, et al. Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity. Immunity. 2009;30:875&#8211;87.<pub-id pub-id-type="pmid">19501000</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2009.05.005</pub-id><pub-id pub-id-type="pmcid">PMC2759865</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meng</surname><given-names>G</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F</given-names></name><name name-style="western"><surname>Fuss</surname><given-names>I</given-names></name><name name-style="western"><surname>Kitani</surname><given-names>A</given-names></name><name name-style="western"><surname>Strober</surname><given-names>W</given-names></name></person-group><article-title>A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses</article-title><source>Immunity</source><year>2009</year><volume>30</volume><fpage>860</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2009.04.012</pub-id><pub-id pub-id-type="pmid">19501001</pub-id><pub-id pub-id-type="pmcid">PMC2764254</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Meng G, Zhang F, Fuss I, Kitani A, Strober W. A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses. Immunity. 2009;30:860&#8211;74.<pub-id pub-id-type="pmid">19501001</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2009.04.012</pub-id><pub-id pub-id-type="pmcid">PMC2764254</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonar</surname><given-names>SL</given-names></name><name name-style="western"><surname>Brydges</surname><given-names>SD</given-names></name><name name-style="western"><surname>Mueller</surname><given-names>JL</given-names></name><name name-style="western"><surname>McGeough</surname><given-names>MD</given-names></name><name name-style="western"><surname>Pena</surname><given-names>C</given-names></name><name name-style="western"><surname>Chen</surname><given-names>D</given-names></name><etal/></person-group><article-title>Constitutively activated NLRP3 inflammasome causes inflammation and abnormal skeletal development in mice</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><fpage>e35979</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0035979</pub-id><pub-id pub-id-type="pmid">22558291</pub-id><pub-id pub-id-type="pmcid">PMC3338787</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Bonar SL, Brydges SD, Mueller JL, McGeough MD, Pena C, Chen D, et al. Constitutively activated NLRP3 inflammasome causes inflammation and abnormal skeletal development in mice. PLoS ONE. 2012;7:e35979.<pub-id pub-id-type="pmid">22558291</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0035979</pub-id><pub-id pub-id-type="pmcid">PMC3338787</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Snouwaert</surname><given-names>JN</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>M</given-names></name><name name-style="western"><surname>Repenning</surname><given-names>PW</given-names></name><name name-style="western"><surname>Dye</surname><given-names>R</given-names></name><name name-style="western"><surname>Livingston</surname><given-names>EW</given-names></name><name name-style="western"><surname>Kovarova</surname><given-names>M</given-names></name><etal/></person-group><article-title>An NLRP3 mutation causes arthropathy and osteoporosis in humanized mice</article-title><source>Cell Rep</source><year>2016</year><volume>17</volume><fpage>3077</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.11.052</pub-id><pub-id pub-id-type="pmid">27974218</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Snouwaert JN, Nguyen M, Repenning PW, Dye R, Livingston EW, Kovarova M, et al. An NLRP3 mutation causes arthropathy and osteoporosis in humanized mice. Cell Rep. 2016;17:3077&#8211;88.<pub-id pub-id-type="pmid">27974218</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2016.11.052</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S-Y</given-names></name><name name-style="western"><surname>Kim</surname><given-names>MY</given-names></name><name name-style="western"><surname>Park</surname><given-names>K</given-names></name><name name-style="western"><surname>Han</surname><given-names>JH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Auditory phenotype and histopathologic findings of a mutant Nlrp3 expression mouse model</article-title><source>Front Neurol</source><year>2022</year><volume>13</volume><fpage>890256</fpage><pub-id pub-id-type="doi">10.3389/fneur.2022.890256</pub-id><pub-id pub-id-type="pmid">35812087</pub-id><pub-id pub-id-type="pmcid">PMC9263128</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Kim Y, Lee S-Y, Kim MY, Park K, Han JH, Kim JH, et al. Auditory phenotype and histopathologic findings of a mutant Nlrp3 expression mouse model. Front Neurol. 2022;13:890256.<pub-id pub-id-type="pmid">35812087</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2022.890256</pub-id><pub-id pub-id-type="pmcid">PMC9263128</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>J-H</given-names></name><name name-style="western"><surname>Lee</surname><given-names>E</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>S-H</given-names></name><name name-style="western"><surname>Min</surname><given-names>H</given-names></name><name name-style="western"><surname>Oh</surname><given-names>JH</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>I</given-names></name><etal/></person-group><article-title>Therapeutic effect of NLRP3 Inhibition on hearing loss induced by systemic inflammation in a CAPS-associated mouse model</article-title><source>EBioMedicine</source><year>2022</year><volume>82</volume><fpage>104184</fpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2022.104184</pub-id><pub-id pub-id-type="pmid">35870427</pub-id><pub-id pub-id-type="pmcid">PMC9307460</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Ma J-H, Lee E, Yoon S-H, Min H, Oh JH, Hwang I, et al. Therapeutic effect of NLRP3 Inhibition on hearing loss induced by systemic inflammation in a CAPS-associated mouse model. EBioMedicine. 2022;82:104184.<pub-id pub-id-type="pmid">35870427</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ebiom.2022.104184</pub-id><pub-id pub-id-type="pmcid">PMC9307460</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Kim</surname><given-names>YH</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S</given-names></name><name name-style="western"><surname>Han</surname><given-names>JH</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S-Y</given-names></name><name name-style="western"><surname>Seong</surname><given-names>J</given-names></name><etal/></person-group><article-title>Otological aspects of NLRP3-related autoinflammatory disorder focusing on the responsiveness to Anakinra</article-title><source>Rheumatology (Oxford)</source><year>2021</year><volume>60</volume><fpage>1523</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/keaa511</pub-id><pub-id pub-id-type="pmid">33020839</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Kim BJ, Kim YH, Lee S, Han JH, Lee S-Y, Seong J, et al. Otological aspects of NLRP3-related autoinflammatory disorder focusing on the responsiveness to Anakinra. Rheumatology (Oxford). 2021;60:1523&#8211;32.<pub-id pub-id-type="pmid">33020839</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/rheumatology/keaa511</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Kim</surname><given-names>YH</given-names></name><name name-style="western"><surname>Han</surname><given-names>JH</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S-Y</given-names></name><name name-style="western"><surname>Carandang</surname><given-names>M</given-names></name><name name-style="western"><surname>Lee</surname><given-names>D-H</given-names></name><etal/></person-group><article-title>Outcome of cochlear implantation in NLRP3-related autoinflammatory inner ear disorders</article-title><source>Otol Neurotol</source><year>2021</year><volume>42</volume><fpage>e168</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1097/MAO.0000000000002933</pub-id><pub-id pub-id-type="pmid">33156237</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Kim BJ, Kim YH, Han JH, Lee S-Y, Carandang M, Lee D-H, et al. Outcome of cochlear implantation in NLRP3-related autoinflammatory inner ear disorders. Otol Neurotol. 2021;42:e168&#8211;71.<pub-id pub-id-type="pmid">33156237</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MAO.0000000000002933</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuemmerle-Deschner</surname><given-names>JB</given-names></name><name name-style="western"><surname>Haug</surname><given-names>I</given-names></name></person-group><article-title>Canakinumab in patients with cryopyrin-associated periodic syndrome: an update for clinicians</article-title><source>Ther Adv Musculoskelet Dis</source><year>2013</year><volume>5</volume><fpage>315</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1177/1759720X13502629</pub-id><pub-id pub-id-type="pmid">24294305</pub-id><pub-id pub-id-type="pmcid">PMC3836377</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Kuemmerle-Deschner JB, Haug I. Canakinumab in patients with cryopyrin-associated periodic syndrome: an update for clinicians. Ther Adv Musculoskelet Dis. 2013;5:315&#8211;29.<pub-id pub-id-type="pmid">24294305</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1759720X13502629</pub-id><pub-id pub-id-type="pmcid">PMC3836377</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iida</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wakiguchi</surname><given-names>H</given-names></name><name name-style="western"><surname>Okazaki</surname><given-names>F</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>T</given-names></name><name name-style="western"><surname>Yasudo</surname><given-names>H</given-names></name><name name-style="western"><surname>Kubo</surname><given-names>M</given-names></name><etal/></person-group><article-title>Early Canakinumab therapy for the sensorineural deafness in a family with Muckle-Wells syndrome due to a novel mutation of NLRP3 gene</article-title><source>Clin Rheumatol</source><year>2019</year><volume>38</volume><fpage>943</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1007/s10067-018-4331-8</pub-id><pub-id pub-id-type="pmid">30338413</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Iida Y, Wakiguchi H, Okazaki F, Nakamura T, Yasudo H, Kubo M, et al. Early Canakinumab therapy for the sensorineural deafness in a family with Muckle-Wells syndrome due to a novel mutation of NLRP3 gene. Clin Rheumatol. 2019;38:943&#8211;8.<pub-id pub-id-type="pmid">30338413</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10067-018-4331-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dinarello</surname><given-names>CA</given-names></name></person-group><article-title>Treatment of inflammatory diseases with IL-1 Blockade</article-title><source>Curr Otorhinolaryngol Rep</source><year>2018</year><volume>6</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1007/s40136-018-0181-9</pub-id><pub-id pub-id-type="pmid">33133777</pub-id><pub-id pub-id-type="pmcid">PMC7597638</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Dinarello CA. Treatment of inflammatory diseases with IL-1 Blockade. Curr Otorhinolaryngol Rep. 2018;6:1&#8211;14.<pub-id pub-id-type="pmid">33133777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40136-018-0181-9</pub-id><pub-id pub-id-type="pmcid">PMC7597638</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>T</given-names></name><name name-style="western"><surname>Qian</surname><given-names>W</given-names></name><etal/></person-group><article-title>Piceatannol protects against age-related hearing loss by inhibiting cellular pyroptosis and inflammation through regulated Caspase11-GSDMD pathway</article-title><source>Biomed Pharmacother</source><year>2023</year><volume>163</volume><fpage>114704</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2023.114704</pub-id><pub-id pub-id-type="pmid">37100013</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Yang X, Wu Y, Zhang M, Zhang L, Zhao T, Qian W, et al. Piceatannol protects against age-related hearing loss by inhibiting cellular pyroptosis and inflammation through regulated Caspase11-GSDMD pathway. Biomed Pharmacother. 2023;163:114704.<pub-id pub-id-type="pmid">37100013</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2023.114704</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Guo</surname><given-names>W</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>S</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L</given-names></name><etal/></person-group><article-title>Tranylcypromine upregulates sestrin 2 expression to ameliorate NLRP3-related noise-induced hearing loss</article-title><source>Neural Regeneration Res</source><year>2025</year><volume>20</volume><fpage>1483</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.4103/NRR.NRR-D-24-00130</pub-id><pub-id pub-id-type="pmcid">PMC11624888</pub-id><pub-id pub-id-type="pmid">39075914</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Chen X, Chen Z, Li M, Guo W, Yuan S, Xu L, et al. Tranylcypromine upregulates sestrin 2 expression to ameliorate NLRP3-related noise-induced hearing loss. Neural Regeneration Res. 2025;20:1483&#8211;94.<pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/NRR.NRR-D-24-00130</pub-id><pub-id pub-id-type="pmcid">PMC11624888</pub-id><pub-id pub-id-type="pmid">39075914</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="article-commentary" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Alzheimers Dis</journal-id><journal-id journal-id-type="iso-abbrev">J Alzheimers Dis</journal-id><journal-id journal-id-type="pmc-domain-id">464</journal-id><journal-id journal-id-type="pmc-domain">sageopen</journal-id><journal-id journal-id-type="publisher-id">ALZ</journal-id><journal-title-group><journal-title>Journal of Alzheimer's Disease</journal-title></journal-title-group><issn pub-type="ppub">1387-2877</issn><issn pub-type="epub">1875-8908</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Sage Choice</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12495099</article-id><article-id pub-id-type="pmcid-ver">PMC12495099.1</article-id><article-id pub-id-type="pmcaid">12495099</article-id><article-id pub-id-type="pmcaiid">12495099</article-id><article-id pub-id-type="pmid">40808585</article-id><article-id pub-id-type="doi">10.1177/13872877251366671</article-id><article-id pub-id-type="publisher-id">10.1177_13872877251366671</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Commentaries</subject></subj-group></article-categories><title-group><article-title>Is early-phase amyloid PET ready for use as neurodegeneration marker?</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3518-436X</contrib-id><name name-style="western"><surname>Boccalini</surname><given-names initials="C">Cecilia</given-names></name><xref rid="aff1-13872877251366671" ref-type="aff">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2422-698X</contrib-id><name name-style="western"><surname>Garibotto</surname><given-names initials="V">Valentina</given-names></name><xref rid="aff1-13872877251366671" ref-type="aff">1</xref><xref rid="aff2-13872877251366671" ref-type="aff">2</xref><xref rid="aff3-13872877251366671" ref-type="aff">3</xref><xref rid="corresp1-13872877251366671" ref-type="corresp"/></contrib></contrib-group><aff id="aff1-13872877251366671">
<label>1</label>Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTlab), Geneva University Neurocenter and Faculty of Medicine, University of Geneva, Geneva, Switzerland</aff><aff id="aff2-13872877251366671">
<label>2</label>Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospitals, Geneva, Switzerland</aff><aff id="aff3-13872877251366671">
<label>3</label>CIBM Center for Biomedical Imaging, Geneva, Switzerland</aff><author-notes><corresp id="corresp1-13872877251366671">Valentina Garibotto, Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTlab), Geneva University Neurocenter and Faculty of Medicine, University of Geneva, Geneva, Switzerland. 
Email: <email>valentina.garibotto@hug.ch</email></corresp></author-notes><pub-date pub-type="epub"><day>14</day><month>8</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><volume>107</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">498304</issue-id><fpage>1411</fpage><lpage>1414</lpage><history><date date-type="received"><day>15</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>12</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>04</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>05</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-05 00:26:29.067"><day>05</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder content-type="sage">SAGE Publications</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the Creative Commons Attribution 4.0 License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="10.1177_13872877251366671.pdf"/><abstract><p>Alzheimer's disease is marked by accumulation of amyloid-&#946; (A&#946;) and abnormal tau, associated with subsequent neurodegeneration. Validated markers of neurodegeneration include brain glucose metabolism, perfusion and atrophy. Dual-phase amyloid PET imaging allows to assess both A&#946; buildup and perfusion changes through a single tracer injection. Increasing evidence supports the comparability of early-phase amyloid PET scans and glucose metabolism changes assessed by <sup>18</sup>F-FDG PET at group and individual levels, regardless of the amyloid tracers and the disease, emphasizing the added value of dual-phase amyloid PET imaging protocols for clinical and research settings.</p></abstract><kwd-group><kwd>Alzheimer's disease</kwd><kwd>dementia</kwd><kwd>imaging</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>typesetter</meta-name><meta-value>ts19</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Amyloid PET, which assesses brain amyloid deposition, and <sup>18</sup>F-fluorodeoxyglucose (<sup>18</sup>F-FDG) PET, which assesses glucose metabolism, provide valuable and complementary information for the diagnosis of Alzheimer's disease (AD) and other neurodegenerative diseases.<sup>
<xref rid="bibr1-13872877251366671" ref-type="bibr">1</xref>
</sup> Extensive research indicates that integrating multiple biomarkers&#8212;whether PET-based or not&#8212;enhances diagnostic precision.<sup>
<xref rid="bibr2-13872877251366671" ref-type="bibr">2</xref>
</sup> While a recent set of diagnostic criteria proposes that a positive amyloid status, assessed by amyloid PET or fluid biomarkers, could be necessary and sufficient for AD diagnosis,<sup>
<xref rid="bibr3-13872877251366671" ref-type="bibr">3</xref>
</sup>
<sup>18</sup>F-FDG PET as measure of neurodegeneration adds important steps in terms of disease staging, clinical outcomes and presence of other pathologies.<sup>
<xref rid="bibr4-13872877251366671" ref-type="bibr">4</xref>
</sup>
<sup>18</sup>F-FDG PET also allows assessment of the extent and location of hypometabolism specific for neurodegenerative diseases other than AD, helping in differential diagnosis and giving insight about heterogeneity.<sup>
<xref rid="bibr2-13872877251366671" ref-type="bibr">2</xref>
</sup> The importance of this additional information is well consolidated in the recent intersocietal recommendations for a biomarker-based diagnosis of neurocognitive disorders, which gives a prominent role to <sup>18</sup>F-FDG PET.<sup>
<xref rid="bibr2-13872877251366671" ref-type="bibr">2</xref>
</sup></p><p>Dual-phase protocol for amyloid PET data acquisition has proven to be able to evaluate brain amyloidosis and neurodegeneration at the same time, adding to the reference late acquisition a short acquisition of the tracer distribution immediately after injection. The optimal early time frame has been usually investigated based on the best within- or inter-subject correlation with <sup>18</sup>F-FDG PET, achieving the best association with a 5- to 10-min acquisition with some tracer-related differences.<sup><xref rid="bibr5-13872877251366671" ref-type="bibr">5</xref><xref rid="bibr6-13872877251366671" ref-type="bibr"/>&#8211;<xref rid="bibr7-13872877251366671" ref-type="bibr">7</xref></sup> In this way, dual-phase protocol provides a perfusion measure very close to metabolism through the early-phase scan because of the high lipophilicity of the tracers<sup><xref rid="bibr8-13872877251366671" ref-type="bibr">8</xref>,<xref rid="bibr9-13872877251366671" ref-type="bibr">9</xref></sup> and the neurovascular coupling for which cerebral perfusion is strongly related to metabolic consumption in aging and dementia conditions.<sup><xref rid="bibr10-13872877251366671" ref-type="bibr">10</xref>,<xref rid="bibr11-13872877251366671" ref-type="bibr">11</xref></sup> Using different amyloid tracers, early-phase amyloid PET has demonstrated strong concordance with <sup>18</sup>F-FDG PET uptake at the group level, supporting its potential as a surrogate marker for neuronal dysfunction in AD and non-AD.<sup><xref rid="bibr5-13872877251366671" ref-type="bibr">5</xref><xref rid="bibr6-13872877251366671" ref-type="bibr"/>&#8211;<xref rid="bibr7-13872877251366671" ref-type="bibr">7</xref>,<xref rid="bibr12-13872877251366671" ref-type="bibr">12</xref><xref rid="bibr13-13872877251366671" ref-type="bibr"/><xref rid="bibr14-13872877251366671" ref-type="bibr"/><xref rid="bibr15-13872877251366671" ref-type="bibr"/><xref rid="bibr16-13872877251366671" ref-type="bibr"/><xref rid="bibr17-13872877251366671" ref-type="bibr"/><xref rid="bibr18-13872877251366671" ref-type="bibr"/><xref rid="bibr19-13872877251366671" ref-type="bibr"/>&#8211;<xref rid="bibr20-13872877251366671" ref-type="bibr">20</xref></sup> Some differences in underlying biological mechanisms and regional uptakes between the two modalities have been recognized without impacting on the overall good concordance. For instance, <sup>18</sup>F-FDG-PET has a slow and steady uptake, while blood flow has a high extraction in the first passage, which is however tracer-specific. <sup>18</sup>F-FDG-PET is associated with active cellular uptake, likely involving glial cells, which may not be observed in perfusion examinations.<sup><xref rid="bibr21-13872877251366671" ref-type="bibr">21</xref>,<xref rid="bibr22-13872877251366671" ref-type="bibr">22</xref></sup> Regarding regional differences between the two modalities, low cerebellar metabolism was found on <sup>18</sup>F-FDG-PET and higher medial temporal perfusion and perfusion in the thalamus and the brainstem in early-phase amyloid PET.<sup>
<xref rid="bibr23-13872877251366671" ref-type="bibr">23</xref>
</sup></p><p>The applicability of dual-phase amyloid PET at single-subject level has been first demonstrated using <sup>18</sup>F-Florbetapir and <sup>18</sup>F-Flutemetamol tracers, showing a comparable distribution of perfusion to metabolism and a comparable ability in excluding the presence of neurodegeneration.<sup>
<xref rid="bibr24-13872877251366671" ref-type="bibr">24</xref>
</sup> In line with the strong relationship between hypometabolism and cognitive performance,<sup>
<xref rid="bibr4-13872877251366671" ref-type="bibr">4</xref>
</sup> perfusion also showed a comparable good correlation with Mini-Mental State Examination scores.<sup>
<xref rid="bibr24-13872877251366671" ref-type="bibr">24</xref>
</sup> Lojo-Ram&#237;rez and colleagues confirmed the applicability of dual-phase amyloid-PET at single-subject level also using <sup>18</sup>F-Florbetaben.<sup>
<xref rid="bibr25-13872877251366671" ref-type="bibr">25</xref>
</sup> They further supported the robustness of early-phase <sup>18</sup>F-Florbetaben PET as a surrogate biomarker for neurodegeneration, independent of amyloid and clinical status. Indeed, the hypoperfusion patterns found by single-subject voxel-wise t-maps identified neurodegenerative patterns similar to those seen in <sup>18</sup>F-FDG PET, allowing neuroimaging experts to have the same rating for two image modalities and supporting clinical translation.<sup>
<xref rid="bibr25-13872877251366671" ref-type="bibr">25</xref>
</sup> An important added value of this additional measure of neurodegeneration is the ability to assess, in amyloid positive cases, the presence of neurodegeneration that allows linking the underlying pathology with the presence of clinical signs and symptoms, while in amyloid negative cases the presence or absence of specific hypoperfusion patterns can provide elements supporting alternative degenerative or non-degenerative etiologies.<sup>
<xref rid="bibr19-13872877251366671" ref-type="bibr">19</xref>
</sup></p><p>The sample included in the study by Lojo-Ramirez et al.<sup>
<xref rid="bibr25-13872877251366671" ref-type="bibr">25</xref>
</sup> evaluated mainly prodromal and dementia patients, leaving open the question about the suitability of early-phase PET for individuals in preclinical phases, such as subjective cognitive decline, when brain metabolic changes can be already present<sup>
<xref rid="bibr26-13872877251366671" ref-type="bibr">26</xref>
</sup> and <sup>18</sup>F-FDG PET might be more accurate.<sup>
<xref rid="bibr24-13872877251366671" ref-type="bibr">24</xref>
</sup> In this framework, the sensitivity of early-phase amyloid PET to predict clinical progression in a specific preclinical population needs to be addressed.</p><p>Other open issues still need to be considered. Semi-quantification is strongly recommended in conjunction with visual reading by several clinical consensus, the official recommendations by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the European Association of Nuclear Medicine (EANM), to perform high-quality reads of <sup>18</sup>F-FDG-PET in the clinical setting and freeware and commercial software are available on different methods for <sup>18</sup>F-FDG-PET. Among semi-quantification methods, voxel-based single-subject analysis has been suggested in common practice guidelines for supporting visual interpretation of brain <sup>18</sup>F-FDG-PET,<sup><xref rid="bibr27-13872877251366671" ref-type="bibr">27</xref>,<xref rid="bibr28-13872877251366671" ref-type="bibr">28</xref></sup> and a comparable approach is likewise desirable for perfusion imaging. However, a healthy control (HC) dataset is essential for achieving strong performance in voxel-wise analyses and methods for early-phase images are less developed compared to those for <sup>18</sup>F-FDG-PET. The use of <sup>18</sup>F-FDG-PET HC datasets for the analysis of early-phase images has been tested but is suboptimal given the systematic differences in regional uptakes of the tracers. Although artificial intelligence strategies have been tested to correct these systematic differences,<sup>
<xref rid="bibr29-13872877251366671" ref-type="bibr">29</xref>
</sup> public datasets of normal controls for early-phase imaging are desirable, largely encouraged and in development by the European Association of Nuclear Medicine (EANM). In this view, formal training of physicians in the field would also be necessary for perfusion PET scans.<sup>
<xref rid="bibr27-13872877251366671" ref-type="bibr">27</xref>
</sup> Moreover, it is important to consider that perfusion images as well as <sup>18</sup>F-FDG-PET can suffer from biases in the presence of severe atrophy and cerebral vascular disease.<sup><xref rid="bibr11-13872877251366671" ref-type="bibr">11</xref>,<xref rid="bibr24-13872877251366671" ref-type="bibr">24</xref></sup> Thus, structural images acquired in combination with PET or close to it are crucial for adequate image interpretation. In addition, blood glucose level limits <sup>18</sup>F-FDG uptake in the brain and thus its use in diabetic patients,<sup>
<xref rid="bibr30-13872877251366671" ref-type="bibr">30</xref>
</sup> and its effect on early-phase amyloid scanning, which is expected to be lower, should be explored.</p><p>Lastly, the lack of reimbursement for amyloid PET can represent a limit for its wide clinical implementation for some countries that needs to be taken into account.</p><p>Overall, the possibility of acquiring information about amyloidosis and neurodegeneration with a single tracer injection offered by dual-phase PET protocol represents a clear advantage in terms of radiation exposure and potentially in terms of costs. Multiple studies at group and individual levels support the readiness of dual-phase amyloid PET to be included in routine clinical practice, and emerging evidence is also paving the way toward achieving similar results for the early-phase imaging of tau PET.<sup><xref rid="bibr31-13872877251366671" ref-type="bibr">31</xref><xref rid="bibr32-13872877251366671" ref-type="bibr"/><xref rid="bibr33-13872877251366671" ref-type="bibr"/>&#8211;<xref rid="bibr34-13872877251366671" ref-type="bibr">34</xref></sup></p></body><back><ack><title>Acknowledgements</title><p>The authors have no acknowledgments to report.</p></ack><fn-group><fn fn-type="other"><p><bold>ORCID iDs:</bold> Cecilia Boccalini <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0002-3518-436X" ext-link-type="uri">https://orcid.org/0000-0002-3518-436X</ext-link></p><p>Valentina Garibotto <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0003-2422-698X" ext-link-type="uri">https://orcid.org/0000-0003-2422-698X</ext-link></p></fn><fn fn-type="other"><p><bold>Author contributions:</bold>
<bold>Cecilia Boccalini:</bold> Conceptualization; Investigation; Writing &#8211; original draft.</p><p><bold>Valentina Garibotto:</bold> Conceptualization; Investigation; Resources; Supervision; Validation; Writing &#8211; review &amp; editing.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Competitive research projects have been funded by: H2020 (projects n. 667375), Innovative Medicines Initiative (IMI contract n. 115736 and 115952), IMI2, Swiss National Science Foundation ((projects 320030_169876, 320030_185028, and 320030_220099), VELUX Foundation, and the Schmidheiny foundation.</p></fn><fn fn-type="COI-statement"><p>The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: VG received research support and speaker fees through her institution from GE Healthcare, Siemens Healthineers, and Novartis.</p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-13872877251366671"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ch&#233;telat</surname><given-names>G</given-names></name><name name-style="western"><surname>Arbizu</surname><given-names>J</given-names></name><name name-style="western"><surname>Barthel</surname><given-names>H</given-names></name></person-group>, <etal>et al.</etal><article-title>Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer&#8217;s disease and other dementias</article-title>. <source>Lancet Neurol</source><year>2020</year>; <volume>19</volume>: <fpage>951</fpage>&#8211;<lpage>962</lpage>.<pub-id pub-id-type="pmid">33098804</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(20)30314-8</pub-id></mixed-citation></ref><ref id="bibr2-13872877251366671"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frisoni</surname><given-names>GB</given-names></name><name name-style="western"><surname>Festari</surname><given-names>C</given-names></name><name name-style="western"><surname>Massa</surname><given-names>F</given-names></name></person-group>, <etal>et al.</etal><article-title>European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders</article-title>. <source>Lancet Neurol</source><year>2024</year>; <volume>23</volume>: <fpage>302</fpage>&#8211;<lpage>312</lpage>.<pub-id pub-id-type="pmid">38365381</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(23)00447-7</pub-id></mixed-citation></ref><ref id="bibr3-13872877251366671"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Andrews</surname><given-names>JS</given-names></name><name name-style="western"><surname>Beach</surname><given-names>TG</given-names></name></person-group>, <etal>et al.</etal><article-title>Revised criteria for diagnosis and staging of Alzheimer&#8217;s disease: Alzheimer&#8217;s association workgroup</article-title>. <source>Alzheimers Dement</source><year>2024</year>; <volume>20</volume>: <fpage>5143</fpage>&#8211;<lpage>5169</lpage>.<pub-id pub-id-type="pmid">38934362</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13859</pub-id><pub-id pub-id-type="pmcid">PMC11350039</pub-id></mixed-citation></ref><ref id="bibr4-13872877251366671"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boccalini</surname><given-names>C</given-names></name><name name-style="western"><surname>Ribaldi</surname><given-names>F</given-names></name><name name-style="western"><surname>Hristovska</surname><given-names>I</given-names></name></person-group>, <etal>et al.</etal><article-title>The impact of tau deposition and hypometabolism on cognitive impairment and longitudinal cognitive decline</article-title>. <source>Alzheimers Dement</source><year>2024</year>; <volume>20</volume>: <fpage>221</fpage>&#8211;<lpage>233</lpage>.<pub-id pub-id-type="pmid">37555516</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13355</pub-id><pub-id pub-id-type="pmcid">PMC10916991</pub-id></mixed-citation></ref><ref id="bibr5-13872877251366671"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsiao</surname><given-names>IT</given-names></name><name name-style="western"><surname>Huang</surname><given-names>CC</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>CJ</given-names></name></person-group>, <etal>et al.</etal><article-title>Correlation of early-phase 18F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies</article-title>. <source>Eur J Nucl Med Mol Imaging</source><year>2012</year>; <volume>39</volume>: <fpage>613</fpage>&#8211;<lpage>620</lpage>.<pub-id pub-id-type="pmid">22270508</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-011-2051-2</pub-id></mixed-citation></ref><ref id="bibr6-13872877251366671"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vanhoutte</surname><given-names>M</given-names></name><name name-style="western"><surname>Landeau</surname><given-names>B</given-names></name><name name-style="western"><surname>Sherif</surname><given-names>S</given-names></name></person-group>, <etal>et al.</etal><article-title>Evaluation of the early-phase [18F]AV45 PET as an optimal surrogate of [18F]FDG PET in ageing and Alzheimer&#8217;s clinical syndrome</article-title>. <source>Neuroimage Clin</source><year>2021</year>; <volume>31</volume>: <fpage>102750</fpage>.<pub-id pub-id-type="pmid">34247116</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nicl.2021.102750</pub-id><pub-id pub-id-type="pmcid">PMC8274342</pub-id></mixed-citation></ref><ref id="bibr7-13872877251366671"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ottoy</surname><given-names>J</given-names></name><name name-style="western"><surname>Verhaeghe</surname><given-names>J</given-names></name><name name-style="western"><surname>Niemantsverdriet</surname><given-names>E</given-names></name></person-group>, <etal>et al.</etal><article-title>18F-FDG PET, the early phases and the delivery rate of 18F-AV45 PET as proxies of cerebral blood flow in Alzheimer&#8217;s disease: validation against 15O-H2O PET</article-title>. <source>Alzheimers Dement</source><year>2019</year>; <volume>15</volume>: <fpage>1172</fpage>&#8211;<lpage>1182</lpage>.<pub-id pub-id-type="pmid">31405824</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2019.05.010</pub-id></mixed-citation></ref><ref id="bibr8-13872877251366671"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gjedde</surname><given-names>A</given-names></name><name name-style="western"><surname>Aanerud</surname><given-names>J</given-names></name><name name-style="western"><surname>Braendgaard</surname><given-names>H</given-names></name></person-group>, <etal>et al.</etal><article-title>Blood-brain transfer of Pittsburgh compound B in humans</article-title>. <source>Front Aging Neurosci</source><year>2013</year>; <volume>5</volume>: <fpage>70</fpage>.<pub-id pub-id-type="pmid">24223554</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2013.00070</pub-id><pub-id pub-id-type="pmcid">PMC3819578</pub-id></mixed-citation></ref><ref id="bibr9-13872877251366671"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garibotto</surname><given-names>V</given-names></name><name name-style="western"><surname>Morbelli</surname><given-names>S</given-names></name><name name-style="western"><surname>Pagani</surname><given-names>M</given-names></name></person-group>. <article-title>Dual-phase amyloid PET: hitting two birds with one stone</article-title>. <source>Eur J Nucl Med Mol Imaging</source><year>2016</year>; <volume>43</volume>: <fpage>1300</fpage>&#8211;<lpage>1303</lpage>.<pub-id pub-id-type="pmid">27221519</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-016-3426-1</pub-id></mixed-citation></ref><ref id="bibr10-13872877251366671"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jueptner</surname><given-names>M</given-names></name><name name-style="western"><surname>Weiller</surname><given-names>C</given-names></name></person-group>. <article-title>Does measurement of regional cerebral blood flow reflect synaptic activity?&#8212;Implications for PET and fMRI</article-title>. <source>Neuroimage</source><year>1995</year>; <volume>2</volume>: <fpage>148</fpage>&#8211;<lpage>156</lpage>.<pub-id pub-id-type="pmid">9343597</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/nimg.1995.1017</pub-id></mixed-citation></ref><ref id="bibr11-13872877251366671"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silverman</surname><given-names>DHS</given-names></name></person-group>. <article-title>Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging</article-title>. <source>J Nucl Med</source><year>2004</year>; <volume>45</volume>: <fpage>594</fpage>&#8211;<lpage>607</lpage>.<pub-id pub-id-type="pmid">15073255</pub-id></mixed-citation></ref><ref id="bibr12-13872877251366671"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forsberg</surname><given-names>A</given-names></name><name name-style="western"><surname>Engler</surname><given-names>H</given-names></name><name name-style="western"><surname>Blomquist</surname><given-names>G</given-names></name></person-group>, <etal>et al.</etal><article-title>The use of PIB-PET as a dual pathological and functional biomarker in AD</article-title>. <source>Biochim Biophys Acta</source><year>2012</year>; <volume>1822</volume>: <fpage>380</fpage>&#8211;<lpage>385</lpage>.<pub-id pub-id-type="pmid">22115832</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbadis.2011.11.006</pub-id></mixed-citation></ref><ref id="bibr13-13872877251366671"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodriguez-Vieitez</surname><given-names>E</given-names></name><name name-style="western"><surname>Carter</surname><given-names>SF</given-names></name><name name-style="western"><surname>Chiotis</surname><given-names>K</given-names></name></person-group>, <etal>et al.</etal><article-title>Comparison of early-phase 11C-deuterium-L-deprenyl and 11C-Pittsburgh compound B PET for assessing brain perfusion in Alzheimer disease</article-title>. <source>J Nucl Med</source><year>2016</year>; <volume>57</volume>: <fpage>1071</fpage>&#8211;<lpage>1077</lpage>.<pub-id pub-id-type="pmid">26912447</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.115.168732</pub-id></mixed-citation></ref><ref id="bibr14-13872877251366671"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tiepolt</surname><given-names>S</given-names></name><name name-style="western"><surname>Hesse</surname><given-names>S</given-names></name><name name-style="western"><surname>Patt</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Early [18F]florbetaben and [11C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer&#8217;s disease</article-title>. <source>Eur J Nucl Med Mol Imaging</source><year>2016</year>; <volume>43</volume>: <fpage>1700</fpage>&#8211;<lpage>1709</lpage>.<pub-id pub-id-type="pmid">27026271</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-016-3353-1</pub-id></mixed-citation></ref><ref id="bibr15-13872877251366671"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seiffert</surname><given-names>AP</given-names></name><name name-style="western"><surname>G&#243;mez-Grande</surname><given-names>A</given-names></name><name name-style="western"><surname>Villarejo-Galende</surname><given-names>A</given-names></name></person-group>, <etal>et al.</etal><article-title>High correlation of static first-minute-frame (fmf) pet imaging after18f-labeled amyloid tracer injection with [18f]fdg pet imaging</article-title>. <source>Sensors</source><year>2021</year>; <volume>21</volume>: <fpage>5182</fpage>.<pub-id pub-id-type="pmid">34372416</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/s21155182</pub-id><pub-id pub-id-type="pmcid">PMC8348394</pub-id></mixed-citation></ref><ref id="bibr16-13872877251366671"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meyer</surname><given-names>PT</given-names></name><name name-style="western"><surname>Hellwig</surname><given-names>S</given-names></name><name name-style="western"><surname>Amtage</surname><given-names>F</given-names></name></person-group>, <etal>et al.</etal><article-title>Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and11C-labeled Pittsburgh compound B</article-title>. <source>J Nucl Med</source><year>2011</year>; <volume>52</volume>: <fpage>393</fpage>&#8211;<lpage>400</lpage>.<pub-id pub-id-type="pmid">21321269</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.110.083683</pub-id></mixed-citation></ref><ref id="bibr17-13872877251366671"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rostomian</surname><given-names>AH</given-names></name><name name-style="western"><surname>Madison</surname><given-names>C</given-names></name><name name-style="western"><surname>Rabinovici</surname><given-names>GD</given-names></name></person-group>, <etal>et al.</etal><article-title>Early 11C-PIB frames and 18F-FDG PET measures are comparable: a study validated in a cohort of AD and FTLD patients</article-title>. <source>J Nucl Med</source><year>2011</year>; <volume>52</volume>: <fpage>173</fpage>&#8211;<lpage>179</lpage>.<pub-id pub-id-type="pmid">21233181</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.110.082057</pub-id><pub-id pub-id-type="pmcid">PMC3166243</pub-id></mixed-citation></ref><ref id="bibr18-13872877251366671"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodriguez-Vieitez</surname><given-names>E</given-names></name><name name-style="western"><surname>Leuzy</surname><given-names>A</given-names></name><name name-style="western"><surname>Chiotis</surname><given-names>K</given-names></name></person-group>, <etal>et al.</etal><article-title>Comparability of [18F]THK5317 and [11C]PIB blood flow proxy images with [18F]FDG positron emission tomography in Alzheimer&#8217;s disease</article-title>. <source>J Cereb Blood Flow Metab</source><year>2017</year>; <volume>37</volume>: <fpage>740</fpage>&#8211;<lpage>749</lpage>.<pub-id pub-id-type="pmid">27107028</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0271678X16645593</pub-id><pub-id pub-id-type="pmcid">PMC5381463</pub-id></mixed-citation></ref><ref id="bibr19-13872877251366671"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daerr</surname><given-names>S</given-names></name><name name-style="western"><surname>Brendel</surname><given-names>M</given-names></name><name name-style="western"><surname>Zach</surname><given-names>C</given-names></name></person-group>, <etal>et al.</etal><article-title>Evaluation of early-phase [18F]-florbetaben PET acquisition in clinical routine cases</article-title>. <source>Neuroimage Clin</source><year>2017</year>; <volume>14</volume>: <fpage>77</fpage>&#8211;<lpage>86</lpage>.<pub-id pub-id-type="pmid">28138429</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nicl.2016.10.005</pub-id><pub-id pub-id-type="pmcid">PMC5257027</pub-id></mixed-citation></ref><ref id="bibr20-13872877251366671"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peretti</surname><given-names>DE</given-names></name><name name-style="western"><surname>Garc&#237;a</surname><given-names>DV</given-names></name><name name-style="western"><surname>Reesink</surname><given-names>FE</given-names></name></person-group>, <etal>et al.</etal><article-title>Relative cerebral flow from dynamic PIB scans as an alternative for FDG scans in Alzheimer&#8217;s disease PET studies</article-title>. <source>PLoS One</source><year>2019</year>; <volume>14</volume>: <comment>e0211000</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0211000</pub-id><pub-id pub-id-type="pmcid">PMC6336325</pub-id><pub-id pub-id-type="pmid">30653612</pub-id></mixed-citation></ref><ref id="bibr21-13872877251366671"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ch&#233;telat</surname><given-names>G</given-names></name><name name-style="western"><surname>Arbizu</surname><given-names>J</given-names></name><name name-style="western"><surname>Barthel</surname><given-names>H</given-names></name></person-group>, <etal>et al.</etal><article-title>Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer&#8217;s disease and other dementias</article-title>. <source>Lancet Neurol</source><year>2020</year>; <volume>19</volume>: <fpage>951</fpage>&#8211;<lpage>962</lpage>.<pub-id pub-id-type="pmid">33098804</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(20)30314-8</pub-id></mixed-citation></ref><ref id="bibr22-13872877251366671"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zimmer</surname><given-names>ER</given-names></name><name name-style="western"><surname>Parent</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Souza</surname><given-names>DG</given-names></name></person-group>, <etal>et al.</etal><article-title>[18f]FDG PET signal is driven by astroglial glutamate transport</article-title>. <source>Nat Neurosci</source><year>2017</year>; <volume>20</volume>: <fpage>393</fpage>&#8211;<lpage>395</lpage>.<pub-id pub-id-type="pmid">28135241</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nn.4492</pub-id><pub-id pub-id-type="pmcid">PMC5378483</pub-id></mixed-citation></ref><ref id="bibr23-13872877251366671"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carneiro</surname><given-names>CdG</given-names></name><name name-style="western"><surname>Faria</surname><given-names>DdP</given-names></name><name name-style="western"><surname>Coutinho</surname><given-names>AM</given-names></name></person-group>, <etal>et al.</etal><article-title>Evaluation of 10-min post-injection 11C-PiB PET and its correlation with 18F-FDG PET in older adults who are cognitively healthy, mildly impaired, or with probable Alzheimer&#8217;s disease</article-title>. <source>Brazilian J Psychiatry</source><year>2022</year>; <volume>44</volume>: <fpage>495</fpage>&#8211;<lpage>506</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.47626/1516-4446-2021-2374</pub-id><pub-id pub-id-type="pmcid">PMC9561831</pub-id><pub-id pub-id-type="pmid">36420910</pub-id></mixed-citation></ref><ref id="bibr24-13872877251366671"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boccalini</surname><given-names>C</given-names></name><name name-style="western"><surname>Peretti</surname><given-names>DE</given-names></name><name name-style="western"><surname>Ribaldi</surname><given-names>F</given-names></name></person-group>, <etal>et al.</etal><article-title>Early-phase 18 F-Florbetapir and 18 F-Flutemetamol images as proxies of brain metabolism in a memory clinic setting</article-title>. <source>J Nucl Med</source><year>2022</year>; <volume>64</volume>: <fpage>266</fpage>&#8211;<lpage>273</lpage>.<pub-id pub-id-type="pmid">35863896</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.122.264256</pub-id><pub-id pub-id-type="pmcid">PMC9902851</pub-id></mixed-citation></ref><ref id="bibr25-13872877251366671"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lojo-Ram&#237;rez</surname><given-names>JA</given-names></name><name name-style="western"><surname>Fern&#225;ndez-Rodr&#237;guez</surname><given-names>P</given-names></name><name name-style="western"><surname>Guerra-G&#243;mez</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Evaluation of early-phase F-Florbetaben PET as a surrogate biomarker of neurodegeneration: in-depth comparison with 18 F-FDG PET at group and single patient level</article-title>. <source>J Alzheimers Dis</source><year>2025</year>; <volume>106</volume>: <fpage>304</fpage>&#8211;<lpage>316</lpage>.<pub-id pub-id-type="pmid">40340729</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/13872877251340380</pub-id><pub-id pub-id-type="pmcid">PMC12231879</pub-id></mixed-citation></ref><ref id="bibr26-13872877251366671"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tondo</surname><given-names>G</given-names></name><name name-style="western"><surname>Boccalini</surname><given-names>C</given-names></name><name name-style="western"><surname>Vanoli</surname><given-names>EG</given-names></name></person-group>, <etal>et al.</etal><article-title>Brain metabolism and amyloid load in individuals with subjective cognitive decline or pre&#8211;mild cognitive impairment</article-title>. <source>Neurology</source><year>2022</year>; <volume>99</volume>: <comment>e258</comment>&#8211;<lpage>e269</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000200351</pub-id><pub-id pub-id-type="pmcid">PMC9302934</pub-id><pub-id pub-id-type="pmid">35487700</pub-id></mixed-citation></ref><ref id="bibr27-13872877251366671"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arbizu</surname><given-names>J</given-names></name><name name-style="western"><surname>Morbelli</surname><given-names>S</given-names></name><name name-style="western"><surname>Minoshima</surname><given-names>S</given-names></name></person-group>, <etal>et al.</etal><article-title>SNMMI Procedure standard/EANM practice guideline for brain [18F]FDG PET imaging, version 2.0</article-title>. <source>J Nucl Med</source><year>2025</year>; <volume>66</volume>: <comment>S45</comment>&#8211;<lpage>S60</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.124.268754</pub-id><pub-id pub-id-type="pmid">39419552</pub-id></mixed-citation></ref><ref id="bibr28-13872877251366671"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guedj</surname><given-names>E</given-names></name><name name-style="western"><surname>Varrone</surname><given-names>A</given-names></name><name name-style="western"><surname>Boellaard</surname><given-names>R</given-names></name></person-group>, <etal>et al.</etal><article-title>EANM Procedure guidelines for brain PET imaging using [18F]FDG, version 3</article-title>. <source>Eur J Nucl Med Mol Imaging</source><year>2022</year>; <volume>49</volume>: <fpage>632</fpage>&#8211;<lpage>651</lpage>.<pub-id pub-id-type="pmid">34882261</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-021-05603-w</pub-id><pub-id pub-id-type="pmcid">PMC8803744</pub-id></mixed-citation></ref><ref id="bibr29-13872877251366671"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanaat</surname><given-names>A</given-names></name><name name-style="western"><surname>Boccalini</surname><given-names>C</given-names></name><name name-style="western"><surname>Mathoux</surname><given-names>G</given-names></name></person-group>, <etal>et al.</etal><article-title>A deep learning model for generating [18F]FDG PET images from early-phase [18F]Florbetapir and [18F]Flutemetamol PET images</article-title>. <source>Eur J Nucl Med Mol Imaging</source><year>2024</year>; <volume>51</volume>: <fpage>3518</fpage>&#8211;<lpage>3531</lpage>.<pub-id pub-id-type="pmid">38861183</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-024-06755-1</pub-id><pub-id pub-id-type="pmcid">PMC11445334</pub-id></mixed-citation></ref><ref id="bibr30-13872877251366671"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Apostolova</surname><given-names>I</given-names></name><name name-style="western"><surname>Lange</surname><given-names>C</given-names></name><name name-style="western"><surname>Suppa</surname><given-names>P</given-names></name></person-group>, <etal>et al.</etal><article-title>Impact of plasma glucose level on the pattern of brain FDG uptake and the predictive power of FDG PET in mild cognitive impairment</article-title>. <source>Eur J Nucl Med Mol Imaging</source><year>2018</year>; <volume>45</volume>: <fpage>1417</fpage>&#8211;<lpage>1422</lpage>.<pub-id pub-id-type="pmid">29502311</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-018-3985-4</pub-id></mixed-citation></ref><ref id="bibr31-13872877251366671"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boccalini</surname><given-names>C</given-names></name><name name-style="western"><surname>Peretti</surname><given-names>DE</given-names></name><name name-style="western"><surname>Mathoux</surname><given-names>G</given-names></name></person-group>, <etal>et al.</etal><article-title>Early-phase 18F-Flortaucipir tau-PET as a proxy of brain metabolism in Alzheimer's disease: a comparison with 18F-FDG-PET and early-phase amyloid-PET</article-title>. <source>Eur J Nucl Med Mol Imaging</source><year>2025</year>; <volume>52</volume>: <fpage>1958</fpage>&#8211;<lpage>1969</lpage>.<pub-id pub-id-type="pmid">39849149</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-024-07063-4</pub-id><pub-id pub-id-type="pmcid">PMC12014785</pub-id></mixed-citation></ref><ref id="bibr32-13872877251366671"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>V&#246;lter</surname><given-names>F</given-names></name><name name-style="western"><surname>Beyer</surname><given-names>L</given-names></name><name name-style="western"><surname>Eckenweber</surname><given-names>F</given-names></name></person-group>, <etal>et al.</etal><article-title>Assessment of perfusion deficit with early phases of [18F]PI-2620 tau-PET versus [18F]flutemetamol-amyloid-PET recordings</article-title>. <source>Eur J Nucl Med Mol Imaging</source><year>2022</year>; <volume>50</volume>: <fpage>1384</fpage>&#8211;<lpage>1394</lpage>.<pub-id pub-id-type="pmid">36572740</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-022-06087-y</pub-id><pub-id pub-id-type="pmcid">PMC10027797</pub-id></mixed-citation></ref><ref id="bibr33-13872877251366671"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beyer</surname><given-names>L</given-names></name><name name-style="western"><surname>Nitschmann</surname><given-names>A</given-names></name><name name-style="western"><surname>Barthel</surname><given-names>H</given-names></name></person-group>, <etal>et al.</etal><article-title>Early-phase [18F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury</article-title>. <source>Eur J Nucl Med Mol Imaging</source><year>2020</year>; <volume>47</volume>: <fpage>2911</fpage>&#8211;<lpage>2922</lpage>.<pub-id pub-id-type="pmid">32318783</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-020-04788-w</pub-id><pub-id pub-id-type="pmcid">PMC7567714</pub-id></mixed-citation></ref><ref id="bibr34-13872877251366671"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hammes</surname><given-names>J</given-names></name><name name-style="western"><surname>Leuwer</surname><given-names>I</given-names></name><name name-style="western"><surname>Bischof</surname><given-names>GN</given-names></name></person-group>, <etal>et al.</etal><article-title>Multimodal correlation of dynamic [18F]-AV-1451 perfusion PET and neuronal hypometabolism in [18F]-FDG PET</article-title>. <source>Eur J Nucl Med Mol Imaging</source><year>2017</year>; <volume>44</volume>: <fpage>2249</fpage>&#8211;<lpage>2256</lpage>.<pub-id pub-id-type="pmid">29026951</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-017-3840-z</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Neuroinflammation</journal-id><journal-id journal-id-type="iso-abbrev">J Neuroinflammation</journal-id><journal-id journal-id-type="pmc-domain-id">249</journal-id><journal-id journal-id-type="pmc-domain">jneuro</journal-id><journal-title-group><journal-title>Journal of Neuroinflammation</journal-title></journal-title-group><issn pub-type="epub">1742-2094</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12492836</article-id><article-id pub-id-type="pmcid-ver">PMC12492836.1</article-id><article-id pub-id-type="pmcaid">12492836</article-id><article-id pub-id-type="pmcaiid">12492836</article-id><article-id pub-id-type="pmid">41039597</article-id><article-id pub-id-type="doi">10.1186/s12974-025-03546-9</article-id><article-id pub-id-type="publisher-id">3546</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Microglial glycolytic reprogramming in alzheimer&#8217;s disease: association with impaired phagocytic function and altered vascular proximity</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Lu</surname><given-names initials="N">Ning</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Jin</surname><given-names initials="Z">Zhongman</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="N">Nian</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhu</surname><given-names initials="C">Caiyun</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Wei</surname><given-names initials="H">Hui</given-names></name><address><email>hui.wei@ibms.pumc.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Xu</surname><given-names initials="Q">Qi</given-names></name><address><email>xuqi@pumc.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02drdmm93</institution-id><institution-id institution-id-type="GRID">grid.506261.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 0706 7839</institution-id><institution>State Key Laboratory of Common Mechanism Research for Major Disease, School of Basic Medicine Peking Union Medical College, </institution><institution>Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, </institution></institution-wrap>Beijing, 100005 China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02drdmm93</institution-id><institution-id institution-id-type="GRID">grid.506261.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 0706 7839</institution-id><institution>Neuroscience Center, </institution><institution>Chinese Academy of Medical Sciences, </institution></institution-wrap>Beijing, 100005 China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02drdmm93</institution-id><institution-id institution-id-type="GRID">grid.506261.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 0706 7839</institution-id><institution>Department of General Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, </institution><institution>Chinese Academy of Medical Sciences and Peking Union Medical College, </institution></institution-wrap>Beijing, China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02drdmm93</institution-id><institution-id institution-id-type="GRID">grid.506261.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 0706 7839</institution-id><institution>4+4 Medical Doctor Program, </institution><institution>Chinese Academy of Medical Sciences &amp; Peking Union Medical College, </institution></institution-wrap>Beijing, 100005 China </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>22</volume><issue-id pub-id-type="pmc-issue-id">478515</issue-id><elocation-id>223</elocation-id><history><date date-type="received"><day>22</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>22</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-04 10:26:05.627"><day>04</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="12974_2025_Article_3546.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Alzheimer&#8217;s disease (AD) is characterized by chronic neuroinflammation alongside amyloid-beta plaque and phosphorylated tau (p-Tau) tangle accumulation. Microglia, as resident immune cells, undergo glycolytic reprogramming that may exacerbate inflammation and impede toxic protein clearance. Specifically, the glycolytic enzyme pyruvate kinase M2 (PKM2) drives proinflammatory microglial phenotypes linked to neurodegeneration. This study investigates how PKM2-mediated microglial glycolytic reprogramming and inflammatory responses alongside A&#946;/p-Tau clearance in human AD brains.</p></sec><sec><title>Methods and results</title><p id="Par2">Hippocampal-entorhinal cortex (HP-EC) tissues from 8 AD patients and 8 matched controls underwent multiplex immunohistochemistry and high-resolution spatial analysis. PKM2<sup>+</sup>Iba1<sup>+</sup> microglia density significantly increased in AD versus controls (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), predominantly displaying a disease-associated microglial (HAM-like) phenotype (ABCA7<sup>+</sup>) with concurrent lipid-droplet accumulation (PLIN3<sup>+</sup>; LDAM phenotype). Spatially, glycolytic PKM2<sup>+</sup>Iba1<sup>+</sup> microglia accumulated near A&#946; plaques, p-Tau tangles, and cerebral vasculature. Notably, their distribution around plaques/tau showed anomalous increasing density with distance (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), suggesting impaired chemotaxis. Perivascular localization lacked clear chemotactic gradients. Functionally, overall phagocytic activity (CD68<sup>+</sup>) decreased significantly in AD (<italic toggle="yes">p</italic>&#8201;=&#8201;0.001), primarily attributed to PKM2&#8211; subsets, whereas PKM2<sup>+</sup>Iba1<sup>+</sup> microglia exhibited pronounced phagocytic exhaustion (PLIN2<sup>+</sup>; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), consistent around both A&#946; and p-Tau lesions (all <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001).</p></sec><sec><title>Conclusion</title><p id="Par3">Our study establishes that microglial glycolytic reprogramming via PKM2 promotes a proinflammatory HAM-like phenotype, phagocytic exhaustion, and peri-pathological accumulation with aggregates and cerebral vessels. Targeting glycolytic pathways represents a viable therapeutic strategy for alleviating microglial dysfunction and neuroinflammation in AD.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12974-025-03546-9.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Microglia</kwd><kwd>Alzheimer&#8217;s disease</kwd><kwd>Glycolysis</kwd><kwd>PKM2</kwd><kwd>Neuroinflammation</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100012166</institution-id><institution>National Key Research and Development Program of China</institution></institution-wrap></funding-source><award-id>2020YFA0804502</award-id><principal-award-recipient><name name-style="western"><surname>Zhu</surname><given-names>Caiyun</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>STI2030-Major Projects</institution></funding-source><award-id>2021ZD0200600</award-id><principal-award-recipient><name name-style="western"><surname>Wei</surname><given-names>Hui</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>CAMS Innovation Fund for Medical Sciences</institution></funding-source><award-id>2021-I2M-1-020</award-id><principal-award-recipient><name name-style="western"><surname>Xu</surname><given-names>Qi</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>National High Level Hospital Clinical Research Funding</institution></funding-source><award-id>2022-PUMCH-D-002</award-id><principal-award-recipient><name name-style="western"><surname>Xu</surname><given-names>Qi</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par22">Alzheimer&#8217;s disease (AD) is the most common neurodegenerative disorder and is characterized by extracellular amyloid-&#946; (A&#946;) plaques and intracellular phosphorylated-tau (p-Tau) neurofibrillary tangles that drive synaptic loss, neuronal death, and cognitive decline &#8203; [<xref ref-type="bibr" rid="CR1">1</xref>]. Accumulating evidence indicates that chronic neuroinflammation significantly contributes to AD progression. Reactive microglia, the resident immune cells of the central nervous system, physically associated with A&#946; plaques in both AD patients and experimental models &#8203; [<xref ref-type="bibr" rid="CR2">2</xref>]. Activated microglia release proinflammatory cytokines and neurotoxic factors that can exacerbate synaptic dysfunction and neuronal injury &#8203; [<xref ref-type="bibr" rid="CR3">3</xref>]. Indeed, microglial activation represents an established early event in AD pathogenesis, and genome-wide association studies have identified multiple AD risk genes (e.g., <italic toggle="yes">TREM2</italic>, <italic toggle="yes">CR1</italic>, <italic toggle="yes">CD33</italic>) functionally linked to microglial activity&#8203; [<xref ref-type="bibr" rid="CR4">4</xref>&#8211;<xref ref-type="bibr" rid="CR6">6</xref>]. Collectively, these findings implicate microglia-mediated neuroinflammation as a critical component of AD pathophysiology.</p><p id="Par23">Microglial activation involves dynamic metabolic reprogramming, a process intrinsically linked to inflammatory phenotypes. Under homeostatic conditions, microglia primarily utilize oxidative phosphorylation for energy production &#8203; [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Upon pathogenic stimulation, however, microglia undergo a &#8203;&#8203;Warburg-like metabolic shift&#8203;&#8203; toward aerobic glycolysis. This transition facilitates rapid ATP generation and biosynthetic precursor synthesis to support immune effector functions [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>], mirroring metabolic changes observed in peripherally activated macrophages. Notably, while acute glycolysis may enhance microglial responses, sustained glycolysis proves detrimental. Microglia in AD models (e.g., APP/PS1 mice) exhibit heightened glycolytic flux with reduced phagocytic capacity and impaired migration &#8203; [<xref ref-type="bibr" rid="CR11">11</xref>]. Excess lactate, a byproduct of glycolysis, further amplifies proinflammatory cytokines (TNF-&#945;, IL-6, IL-1&#946;) release from microglia &#8203; [<xref ref-type="bibr" rid="CR11">11</xref>]. Consistent with these findings, pharmacological inhibition of glycolysis attenuates neuroinflammation in rodent AD models &#8203; [<xref ref-type="bibr" rid="CR12">12</xref>]. Thus, microglial glycolytic reprogramming may potentiate neuroinflammatory damage in AD&#8203;.</p><p id="Par24">Pyruvate kinase M2 (PKM2) has serves as a pivotal regulator bridging cellular metabolism and inflammation. PKM2 is an isoenzyme of pyruvate kinase that is preferentially expressed in proliferating or activated cells, nuclear-translocated dimeric PKM2 acts as a coactivator for transcription factors such as hypoxia-inducible factor 1&#945; (HIF-1&#945;), thereby promoting inflammatory gene expression [<xref ref-type="bibr" rid="CR13">13</xref>]. This mechanism, initially characterized in macrophages and cancer cells, underpins the metabolic&#8211;functional shift observed during immune activation&#8203; [<xref ref-type="bibr" rid="CR13">13</xref>&#8211;<xref ref-type="bibr" rid="CR15">15</xref>]. In the context of AD, accumulating evidence implicates PKM2-driven metabolic alterations in microglial dysfunction. Recent studies demonstrate upregulated glycolytic enzymes (including PKM2) and elevated glucose uptake in AD model microglia &#8203; [<xref ref-type="bibr" rid="CR12">12</xref>]. Notably, disruption of PKM2 activity exerts protective effects. For example, microglia-specific <italic toggle="yes">Pkm2</italic> ablation in 5&#215;FAD mice reduces lactate overproduction, restores homeostatic functions, and improves cognitive performance&#8203; [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Pharmacological PKM2 inhibition attenuates microglial activation and A&#946; pathology in AD models, supporting a causal role for PKM2-mediated glycolysis in driving neuroinflammation [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par25">Despite these advances, the mechanistic links between microglial metabolic reprogramming and AD pathogenesis remain incompletely defined. Moreover, it remains unclear whether findings from AD mouse models accurately reflect microglial metabolic states and functions in human AD patients. Thus, there is a need to clarify how dysregulated glycolysis and enzymes, such as PKM2 influence microglial behaviour and neurodegeneration in AD. Building on this evidence, the present study aimed to determine the association between PKM2-driven glycolytic reprogramming and neuroinflammatory damage in human AD, and elucidate spatial-functional relationships of glycolytic microglia in AD pathology. By elucidating these mechanisms, we sought to inform the development of metabolism-based therapeutic approaches for AD.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Tissue acquisition and fixation</title><p id="Par26">In this study, 16 postmortem human hippocampus&#8210;entorhinal cortex (HP&#8210;EC) tissue samples were obtained from the National Human Brain Bank for Developmental and Functional Research (NHBBDF) at the Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences. Informed consent was obtained from each participant, ensuring that the use of these brain samples adhered strictly to the NHBBDF guidelines and the Declaration of Helsinki (Approval number: 2022125) [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. All brain samples were evaluated by the NHBBDF following the ABC score for the level of AD neuropathologic change [<xref ref-type="bibr" rid="CR19">19</xref>]. The diagnosis of AD was based solely on neuropathological assessment after autopsy rather than clinical diagnoses prior to death. All HP&#8210;EC samples were dissected by experienced anatomists within 9&#160;h of death to minimize postmortem degradation. Immediately after dissection, the tissue was immersion-fixed in 4% paraformaldehyde (PFA) (Solarbio, China, Cat#: P110) to preserve morphology and antigenicity. The tissues were subsequently dehydrated using a graded ethanol series, cleared in xylene, and infiltrated with molten paraffin before being embedded in paraffin. Tissue sections of 4&#160;&#956;m thickness were cut with a paraffin slicer (Leica, Germany, Cat#: RM2235).</p></sec><sec id="Sec4"><title>Multiplex immunohistochemistry (mIHC) staining</title><p id="Par27">Multiplex immunohistochemistry (mIHC) was performed via the TSA-based method (AlphaTSA<sup>&#174;</sup> Multiplex IHC Kit, Alpha X Biotechnology, Beijing, China; Cat#: AXT37100031). Three tissue sections from each subject were used for mIHC staining, with each section stained using one distinct marker panel (Panel 1, 2, and 3). These three mIHC panels included the following cell biomarkers and extracellular proteins: Iba1, PKM2, TMEM119, ABCA7, PLIN3, CD31, p-Tau, A&#946;, CD68, and PLIN2 (Supplementary Table 1). The sections were deparaffinized and rehydrated through standard methods and were incubated in sodium citrate buffer (pH 6.0) at 95&#160;&#176;C for 10&#160;min for antigen retrieval. Hydrogen peroxide and blocking solution were used to reduce nonspecific binding. The sections were incubated with primary antibodies overnight at 4&#160;&#176;C. The samples were then incubated with secondary antibodies for 10&#160;min at 37&#160;&#176;C. Each marker was visualized sequentially using fluorescent dyes, and antigen stripping was performed between rounds of staining. After all the markers were sequentially detected, DAPI was used to counterstain the nuclei. Finally, the slides were rinsed with water and coverslipped with antifade mounting medium.</p></sec><sec id="Sec5"><title>Whole-slide imaging</title><p id="Par28">The stained slides were scanned at high resolution using a Zeiss Axioscan 7 slide scanner (Carl Zeiss, Oberkochen, Germany) with a 20&#215; objective lens, using a 14-bit depth per channel for a high dynamic range. The resulting digital image files encompassed the entire HP&#8210;EC section and were used for subsequent analysis.</p></sec><sec id="Sec6"><title>Image analysis</title><p id="Par29">HP&#8210;EC subregions were manually annotated on each digital slide image with reference to a standard brain atlas (Allen Brain Atlas) [<xref ref-type="bibr" rid="CR20">20</xref>], including the entorhinal cortex (EC), subiculum (SUB), hippocampus (CA1, CA2, CA3, CA4), and dentate gyrus (DG) (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>c). Quantitative image analysis was then performed using HALO<sup>&#174;</sup> image analysis software (v.3.6, Indica Labs, Albuquerque, NM, USA). The Highplex FL module (v.4.1.2) was used to identify cells and quantify marker expression across all fluorescence channels, and the Object Colocalization module (v.2.1) was used to measure noncell structures and colocalization of markers within individual cells. The fluorescence intensity thresholds for positive staining were determined for each marker by a board-certified neuropathologist blinded to the clinical diagnosis, ensuring objective and consistent scoring. The optimized analysis was applied uniformly to all cases, and the software provided counts of marker-positive cells and coexpression events within each annotated subregion. These quantitative data were exported for statistical analysis. Notably, the HALO<sup>&#174;</sup> software separately identifies cell nuclei and cytoplasm. If two markers co-localize within the same cell, regardless of whether they are localized in the nucleus or cytoplasm, the HALO<sup>&#174;</sup> software labels this cell accordingly.</p></sec><sec id="Sec7"><title>Statistical analysis and data visualization</title><p id="Par30">Statistical analyses were performed using GraphPad Prism 10 (GraphPad Software, San Diego, CA, USA). Group differences between AD and control (CTL) samples were assessed with two-tailed t tests. Paired t tests were used for matched comparisons, and unpaired t tests were used for independent group comparisons (with Welch&#8217;s correction applied if variances were unequal). The Shapiro-Wilk test was conducted to evaluate the normality of data distribution prior to performing parametric tests. For outcomes involving repeated measures (e.g., measurements across multiple HP&#8210;EC regions per case), linear mixed-effects models were employed to account for within-subject variability. Unless specifically noted as regional analyses, statistical comparisons were based on averaged values per patient (each patient contributed three independent slides). A <italic toggle="yes">p</italic> value&#8201;&lt;&#8201;0.05 was considered statistically significant. <italic toggle="yes">P</italic> values are reported to three decimal places, with values smaller than 0.001 reported as <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001. Graphs were generated using custom R (v.4.4.3) code.</p></sec></sec><sec id="Sec8"><title>Results</title><p id="Par31">In this study, we analysed HP&#8210;EC tissue from 8 AD patients (mean age: 86.5 years, 5 males, 3 females, ABC score: middle to high AD neuropathologic change) and 8 age- and sex-matched CTL subjects (mean age: 78.8 years, 5 males, 3 females, ABC score: no to low AD neuropathologic change) (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>; Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>a). Representative annotations of brain sections are shown in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>c. In the AD group, there were significantly more A&#946; plaques and p-Tau aggregates than in the CTL group (A&#946; plaques: <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, Shapiro-Wilk normality test, CTL <italic toggle="yes">p</italic>&#8201;=&#8201;0.338, AD <italic toggle="yes">p</italic>&#8201;=&#8201;0.522, Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>d; p-Tau: <italic toggle="yes">p</italic>&#8201;=&#8201;0.002, Shapiro-Wilk normality test, CTL <italic toggle="yes">p</italic>&#8201;=&#8201;0.541, AD <italic toggle="yes">p</italic>&#8201;=&#8201;0.929, Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>e), indicating robust evaluation of ABC scores. Multiplex immunohistochemical staining was performed using the following two panels: Panel 1, which included Iba1 (microglia), PKM2 (glycolytic enzyme), ABCA7 (Human AD microglia marker, HAM), TMEM119 (homeostatic signature), and PLIN3 (Lipid droplet accumulating microglia marker, LDAM) (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>f); Panel 2, which included Iba1, PKM2, CD31 (endothelial cells), p-Tau, and A&#946; (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>g); and Panel 3, which included Iba1, PKM2, CD68 (phagocytosis marker), PLIN2 (phagocytic exhaustion), p-Tau, and A&#946; (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>h).</p><p id="Par32">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Basic information of patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">ID</th><th align="left" colspan="1" rowspan="1">Sex</th><th align="left" colspan="1" rowspan="1">Age (years)</th><th align="left" colspan="1" rowspan="1">Cause of Death</th><th align="left" colspan="1" rowspan="1">Medical history related to nervous system</th><th align="left" colspan="1" rowspan="1">Postmortem autopsy time (hours)</th><th align="left" colspan="2" rowspan="1">ABC score</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">F</td><td align="left" colspan="1" rowspan="1">67</td><td align="left" colspan="1" rowspan="1">Liver cancer</td><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1">2.0</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="A0B1C0">A0B1C0</ext-link></td><td align="left" colspan="1" rowspan="1">No</td></tr><tr><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">M</td><td align="left" colspan="1" rowspan="1">76</td><td align="left" colspan="1" rowspan="1">Colon cancer</td><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1">5.2</td><td align="left" colspan="1" rowspan="1">A3B3C2</td><td align="left" colspan="1" rowspan="1">High</td></tr><tr><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">F</td><td align="left" colspan="1" rowspan="1">90</td><td align="left" colspan="1" rowspan="1">Oesophageal cancer</td><td align="left" colspan="1" rowspan="1">Encephalic angioma</td><td align="left" colspan="1" rowspan="1">3.5</td><td align="left" colspan="1" rowspan="1">A1B1C0</td><td align="left" colspan="1" rowspan="1">Low</td></tr><tr><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">M</td><td align="left" colspan="1" rowspan="1">93</td><td align="left" colspan="1" rowspan="1">Sudden cardiac death</td><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1">5.0</td><td align="left" colspan="1" rowspan="1">A3B2C2</td><td align="left" colspan="1" rowspan="1">Middle</td></tr><tr><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">M</td><td align="left" colspan="1" rowspan="1">86</td><td align="left" colspan="1" rowspan="1">Sudden cardiac death</td><td align="left" colspan="1" rowspan="1">Cerebral infarction</td><td align="left" colspan="1" rowspan="1">3.5</td><td align="left" colspan="1" rowspan="1">A3B2C2</td><td align="left" colspan="1" rowspan="1">Middle</td></tr><tr><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">M</td><td align="left" colspan="1" rowspan="1">79</td><td align="left" colspan="1" rowspan="1">Diabetes mellitus</td><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1">3.5</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="A0B2C0">A0B2C0</ext-link></td><td align="left" colspan="1" rowspan="1">No</td></tr><tr><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">M</td><td align="left" colspan="1" rowspan="1">93</td><td align="left" colspan="1" rowspan="1">Respiratory failure</td><td align="left" colspan="1" rowspan="1">Cerebrovascular disease</td><td align="left" colspan="1" rowspan="1">4.2</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="A0B2C0">A0B2C0</ext-link></td><td align="left" colspan="1" rowspan="1">No</td></tr><tr><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">F</td><td align="left" colspan="1" rowspan="1">88</td><td align="left" colspan="1" rowspan="1">Heart attack</td><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1">3.5</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="A0B2C0">A0B2C0</ext-link></td><td align="left" colspan="1" rowspan="1">No</td></tr><tr><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">M</td><td align="left" colspan="1" rowspan="1">70</td><td align="left" colspan="1" rowspan="1">Cardiac failure</td><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1">5.5</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="A0B1C0">A0B1C0</ext-link></td><td align="left" colspan="1" rowspan="1">No</td></tr><tr><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">F</td><td align="left" colspan="1" rowspan="1">83</td><td align="left" colspan="1" rowspan="1">Pulmonary infection</td><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1">6.5</td><td align="left" colspan="1" rowspan="1">A2B2C1</td><td align="left" colspan="1" rowspan="1">Middle</td></tr><tr><td align="left" colspan="1" rowspan="1">11</td><td align="left" colspan="1" rowspan="1">F</td><td align="left" colspan="1" rowspan="1">85</td><td align="left" colspan="1" rowspan="1">Respiratory failure</td><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1">8.5</td><td align="left" colspan="1" rowspan="1">A1B2C2</td><td align="left" colspan="1" rowspan="1">Middle</td></tr><tr><td align="left" colspan="1" rowspan="1">12</td><td align="left" colspan="1" rowspan="1">M</td><td align="left" colspan="1" rowspan="1">91</td><td align="left" colspan="1" rowspan="1">Respiratory failure</td><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1">4.7</td><td align="left" colspan="1" rowspan="1">A3B3C2</td><td align="left" colspan="1" rowspan="1">High</td></tr><tr><td align="left" colspan="1" rowspan="1">13</td><td align="left" colspan="1" rowspan="1">F</td><td align="left" colspan="1" rowspan="1">84</td><td align="left" colspan="1" rowspan="1">Bacterial pneumonia</td><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1">2.4</td><td align="left" colspan="1" rowspan="1">A2B2C2</td><td align="left" colspan="1" rowspan="1">Middle</td></tr><tr><td align="left" colspan="1" rowspan="1">14</td><td align="left" colspan="1" rowspan="1">M</td><td align="left" colspan="1" rowspan="1">94</td><td align="left" colspan="1" rowspan="1">Cardiac failure</td><td align="left" colspan="1" rowspan="1">Dementia</td><td align="left" colspan="1" rowspan="1">4.5</td><td align="left" colspan="1" rowspan="1">A3B3C2</td><td align="left" colspan="1" rowspan="1">High</td></tr><tr><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">M</td><td align="left" colspan="1" rowspan="1">72</td><td align="left" colspan="1" rowspan="1">Bacterial pneumonia</td><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1">2.5</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="A0B1C0">A0B1C0</ext-link></td><td align="left" colspan="1" rowspan="1">No</td></tr><tr><td align="left" colspan="1" rowspan="1">16</td><td align="left" colspan="1" rowspan="1">M</td><td align="left" colspan="1" rowspan="1">72</td><td align="left" colspan="1" rowspan="1">Infectious shock</td><td align="left" colspan="1" rowspan="1">Cerebral infarction, Cerebral haemorrhage</td><td align="left" colspan="1" rowspan="1">4.2</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="A0B1C0">A0B1C0</ext-link></td><td align="left" colspan="1" rowspan="1">No</td></tr></tbody></table></table-wrap>
</p><p id="Par33">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Study overview.&#160;(<bold>a</bold>) Age and sex composition of the AD (<italic toggle="yes">n</italic>&#8201;=&#8201;8) and control (<italic toggle="yes">n</italic>&#8201;=&#8201;8) groups.&#160;(<bold>b</bold>) Schematic of the experimental workflow from tissue processing to imaging and analysis.&#160;(<bold>c</bold>) An example of annotations in brain slides.&#160;(<bold>d</bold>) Quantitative analysis of total A&#946; plaque counts in AD patients and CTLs.&#160;(<bold>e</bold>) Quantitative analysis of total p-Tau counts in AD patients and CTLs.&#160;(<bold>f</bold>) Example merged mIHC images from Panel (1) DAPI (blue, f<sub>1</sub>), Iba1 (green, f<sub>2</sub>), PKM2 (red, f<sub>3</sub>), ABCA7 (orange, f<sub>4</sub>), PLIN3 (white, f<sub>5</sub>), and TMEM119 (cyan, f<sub>6</sub>). Scale bars&#8201;=&#8201;50&#160;&#956;m.&#160;(<bold>g</bold>) Example merged mIHC images from Panel (2) DAPI (blue, g<sub>1</sub>), Iba1 (cyan, g<sub>2</sub>), PKM2 (orange, g<sub>3</sub>), p-Tau (cyan, g<sub>4</sub>), CD31 (red, g<sub>5</sub>), and A&#946; (white, g<sub>6</sub>). Scale bars&#8201;=&#8201;50&#160;&#956;m.&#160;(<bold>h</bold>) Example merged mIHC images from Panel (3) DAPI (blue, h<sub>1</sub>), Iba1 (cyan, h<sub>2</sub>), PKM2 (red, h<sub>3</sub>), CD68 (orange, h<sub>4</sub>), PLIN2 (white, h<sub>5</sub>), p-Tau (cyan, h<sub>6</sub>), and A&#946; (magenta, h<sub>7</sub>). Scale bars&#8201;=&#8201;50&#160;&#956;m.&#160;All the data are presented as the means&#8201;&#177;&#8201;SEMs, and unpaired t tests were performed (**<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01 and ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e964" position="float" orientation="portrait" xlink:href="12974_2025_3546_Fig1_HTML.jpg"/></fig>
</p><sec id="Sec9"><title>PKM2<sup>+</sup>Iba1<sup>+</sup> microglia predominantly exhibit a disease-associated phenotype in AD brains</title><p id="Par34">To further understand the heterogeneity of glycolytically active microglia in AD, we compared the proportion of distinct PKM2<sup>+</sup> microglial subpopulations between AD patients and CTL individuals. Specifically, we examined homeostatic microglia (TMEM119<sup>+</sup>), HAM-like microglia (ABCA7<sup>+</sup>), and LDAM (PLIN3<sup>+</sup>).</p><p id="Par35">Representative mIHC images demonstrated clear colocalization of PKM2<sup>+</sup>Iba1<sup>+</sup> microglia with the HAM-like marker ABCA7 in AD brain samples, confirming a robust presence of HAM-like microglia expressing PKM2 (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>a). Conversely, colocalization of PKM2<sup>+</sup>Iba1<sup>+</sup> microglia with the homeostatic marker TMEM119 was relatively infrequent in AD samples, reflecting a reduction in the homeostatic microglial population (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>a). LDAM (PLIN3<sup>+</sup>) were also identified among PKM2<sup>+</sup>Iba1<sup>+</sup> microglia, showing a modest presence (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>a). In control samples, colocalization of PKM2<sup>+</sup>Iba1<sup>+</sup> microglia with ABCA7, TMEM119, and PLIN3 appeared balanced without clear predominance, indicating a mixed microglial state with lower glycolytic activation compared to AD samples (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>b). These findings collectively highlight a shift toward disease-associated glycolytic microglial phenotypes in AD.</p><p id="Par36">Quantitative analyses were performed to determine the proportion differences among these PKM2&#8314;Iba1&#8314; microglial subtypes. Overall, PKM2&#8314;Iba1&#8314; glycolytic microglia were significantly increased in AD compared to control brains (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; Shapiro-Wilk normality test, CTL <italic toggle="yes">p</italic>&#8201;=&#8201;0.914, AD <italic toggle="yes">p</italic>&#8201;=&#8201;0.516; Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>c). Among PKM2<sup>+</sup>Iba1<sup>+</sup> microglia, HAM-like (ABCA7<sup>+</sup>PKM2<sup>+</sup>Iba1<sup>+</sup>) microglia represented the predominant subtype (68.1%), followed by LDAM (PLIN3<sup>+</sup>PKM2<sup>+</sup>Iba1<sup>+</sup>) microglia (13.7%), and homeostatic (TMEM119<sup>+</sup>PKM2<sup>+</sup>Iba1<sup>+</sup>) microglia (2.5%; Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>d). HAM-like (ABCA7<sup>+</sup>PKM2<sup>+</sup>Iba1<sup>+</sup>) microglia exhibited significantly greater proportions compared with LDAM (PLIN3<sup>+</sup>PKM2<sup>+</sup>Iba1<sup>+</sup>) microglia (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) and homeostatic (TMEM119<sup>+</sup>PKM2<sup>+</sup>Iba1<sup>+</sup>) microglia (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). LDAM (PLIN3<sup>+</sup>PKM2<sup>+</sup>Iba1<sup>+</sup> microglia) also showed a slightly higher proportion compared to homeostatic TMEM119<sup>+</sup>PKM2<sup>+</sup>Iba1<sup>+</sup> microglia (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; Shapiro-Wilk normality test, ABCA7 <italic toggle="yes">p</italic>&#8201;=&#8201;0.735, PLIN3 <italic toggle="yes">p</italic>&#8201;=&#8201;0.283, TMEM119 <italic toggle="yes">p</italic>&#8201;=&#8201;0.056; Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>d). These results indicate a clear hierarchical distribution among glycolytic microglial subtypes, with HAM-like microglia representing the major glycolytic phenotype.</p><p id="Par37">When comparing AD to CTL groups, HAM-like ABCA7<sup>+</sup>PKM2<sup>+</sup>Iba1<sup>+</sup> microglia were significantly increased in AD patients (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; Shapiro-Wilk normality test, CTL <italic toggle="yes">p</italic>&#8201;=&#8201;0.312, AD <italic toggle="yes">p</italic>&#8201;=&#8201;0.854), further emphasizing the shift toward disease-associated glycolytic activation (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>e). LDAM PLIN3<sup>+</sup>PKM2<sup>+</sup>Iba1<sup>+</sup> microglia showed a slight yet statistically significant increase in the AD group (<italic toggle="yes">p</italic>&#8201;=&#8201;0.003; Shapiro-Wilk normality test, CTL <italic toggle="yes">p</italic>&#8201;=&#8201;0.107, AD <italic toggle="yes">p</italic>&#8201;=&#8201;0.873), suggesting a mild but meaningful alteration in lipid metabolism within glycolytic microglia (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>g). In contrast, homeostatic TMEM119<sup>+</sup>PKM2<sup>+</sup>Iba1<sup>+</sup> microglia had no significant difference in the AD group compared to controls (<italic toggle="yes">p</italic>&#8201;=&#8201;0.140, Shapiro-Wilk normality test, CTL <italic toggle="yes">p</italic>&#8201;=&#8201;0.052, AD <italic toggle="yes">p</italic>&#8201;=&#8201;0.455), reflecting that the homeostatic phenotype is rarely associated with glycolytic PKM2<sup>+</sup>Iba1<sup>+</sup> microglia, thus remaining relatively unchanged in the AD glycolytic context (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>i).</p><p id="Par38">Regional analyses across HP-EC consistently validated these findings, demonstrating significant increases in HAM-like ABCA7<sup>+</sup>PKM2<sup>+</sup>Iba1<sup>+</sup> microglia across all examined regions (all <italic toggle="yes">p</italic>s&#8201;&lt;&#8201;0.05; all Shapiro&#8211;Wilk normality test <italic toggle="yes">p</italic>s&#8201;&gt;&#8201;0.05; Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>f). Similarly, LDAM PLIN3<sup>+</sup>PKM2<sup>+</sup>Iba1<sup>+</sup> microglia were significantly elevated in most regions, with the exceptions of CA2 (<italic toggle="yes">p</italic>&#8201;=&#8201;0.080) and CA3 (<italic toggle="yes">p</italic>&#8201;=&#8201;0.252; other regions, <italic toggle="yes">p</italic>s&#8201;&lt;&#8201;0.05; all Shapiro&#8211;Wilk normality test <italic toggle="yes">p</italic>s&#8201;&gt;&#8201;0.05; Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>h). Conversely, homeostatic TMEM119<sup>+</sup>PKM2<sup>+</sup>Iba1<sup>+</sup> microglia exhibited no significant regional differences between AD and controls (all <italic toggle="yes">p</italic>s&#8201;&gt;&#8201;0.05; all Shapiro&#8211;Wilk normality test <italic toggle="yes">p</italic>s&#8201;&gt;&#8201;0.05; Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>j). These regional patterns collectively indicate that the shift towards HAM-like and LDAM phenotypes broadly occurs across areas particularly vulnerable to AD pathology.</p><p id="Par39">These results collectively indicate that glycolytic reprogramming of microglia in AD is strongly linked to specific functional states, characterized by increased proportions of disease-associated HAM-like and LDAM phenotypes, accompanied by a concurrent reduction in homeostatic microglial populations.</p><p id="Par40">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Glycolytic microglia in AD exhibit a disease-associated phenotype in AD brains.&#160;(<bold>a</bold>-<bold>b</bold>) Representative mIHC images illustrating colocalization of PKM2<sup>+</sup>Iba1<sup>+</sup> cells with ABCA7, PLIN3, and TMEM119 in the AD (<bold>a</bold>) and CTL (<bold>b</bold>) groups. Images a<sub>1</sub> and b<sub>1</sub> show the merged mIHC images. Images a<sub>2</sub>&#8211;a<sub>6</sub> and b<sub>2</sub>&#8211;b<sub>6</sub> display single-channel images corresponding to a<sub>1</sub>, including DAPI (blue, a<sub>2</sub> and b<sub>2</sub>), Iba1 (green, a<sub>3</sub> and b<sub>3</sub>), PKM2 (red, a<sub>4</sub> and b<sub>4</sub>), ABCA7 (orange, a<sub>5</sub> and b<sub>5</sub>), PLIN3 (white, a<sub>6</sub> and b<sub>6</sub>), and TMEM119 (cyan, a<sub>7</sub> and b<sub>7</sub>). Images a<sub>8</sub> and b<sub>8</sub> represent the original fluorescence channels for Iba1, PKM2, ABCA7, and DAPI, with arrows highlighting ABCA7<sup>+</sup>PKM2<sup>+</sup>Iba1<sup>+</sup> cells. Images a<sub>9</sub> and b<sub>9</sub> illustrate the corresponding segmentation masks for a<sub>8</sub> and b<sub>8</sub>. Images a<sub>10</sub> and b<sub>10</sub> show original fluorescence channels for Iba1, PKM2, PLIN3, and DAPI, with arrows indicating PLIN3<sup>+</sup>PKM2<sup>+</sup>Iba1<sup>+</sup> cells. Images a<sub>11</sub> and b<sub>11</sub> present the corresponding masks for a<sub>10</sub> and b<sub>10</sub>. Images a<sub>12</sub> and b<sub>12</sub> display original fluorescence channels for Iba1, PKM2, TMEM119, and DAPI. Images a<sub>13</sub> and b<sub>13</sub> show the corresponding masks for a<sub>12</sub> and b<sub>12</sub>. Scale bars&#8201;=&#8201;50&#160;&#956;m.&#160;(<bold>c</bold>) Proportions of PKM2<sup>+</sup>Iba1<sup>+</sup> cells within Iba1<sup>+</sup> microglial population.&#160;(<bold>d</bold>) Comparison of ABCA7<sup>+</sup>PKM2<sup>+</sup>Iba1<sup>+</sup>, PLIN3<sup>+</sup>PKM2<sup>+</sup>Iba1<sup>+</sup>, and TMEM119<sup>+</sup>PKM2<sup>+</sup>Iba1<sup>+</sup> proportions within Iba1<sup>+</sup> microglial population.&#160;(<bold>e</bold>) Abundance of ABCA7<sup>+</sup>PKM2<sup>+</sup>Iba1<sup>+</sup> microglia in AD vs. CTL brains.&#160;(<bold>f</bold>) Regional comparison of ABCA7<sup>+</sup>PKM2<sup>+</sup>Iba1<sup>+</sup> microglia across HP&#8210;EC in AD vs. CTL brains.&#160;(<bold>g</bold>) Abundance of PLIN3<sup>+</sup>PKM2<sup>+</sup>Iba1<sup>+</sup> microglia in AD vs. CTL brains.&#160;(<bold>h</bold>) Regional comparison of PLIN3<sup>+</sup>PKM2<sup>+</sup>Iba1<sup>+</sup> microglia across HP&#8210;EC in AD vs. CTL brains.&#160;(<bold>i</bold>)&#160;Abundance of TMEM119<sup>+</sup>PKM2<sup>+</sup>Iba1<sup>+</sup> microglia in AD vs. CTL brains.&#160;(<bold>j</bold>) Regional comparison of TMEM119<sup>+</sup>PKM2<sup>+</sup>Iba1<sup>+</sup> microglia across HP&#8210;EC in AD vs. CTL brains.&#160;All the data are presented as the means&#8201;&#177;&#8201;SEMs, and unpaired t tests were performed (*<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01, ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, and ns: no significant difference)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1455" position="float" orientation="portrait" xlink:href="12974_2025_3546_Fig2_HTML.jpg"/></fig>
</p></sec><sec id="Sec10"><title>Glycolytic microglia exhibit increased numbers and altered spatial distribution around A&#946; plaques in AD brains</title><p id="Par41">To investigate the spatial relationship between glycolytically active microglia and A&#946; plaques in AD, we defined the region within a 50&#160;&#956;m radius from the center of A&#946; plaques as &#8220;plaque-associated&#8221; or &#8220;periplaque.&#8221; (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). Representative mIHC images demonstrated the proximity of PKM2<sup>+</sup>Iba1<sup>+</sup> microglia to A&#946; plaques in AD patients compared to CTL (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>a&#8211;b, image a<sub>1</sub> and b<sub>1</sub>). Segmentation masks and spatial distance analyses revealed a distinct localization pattern, with PKM2<sup>+</sup>Iba1<sup>+</sup> microglia positioned near A&#946; plaques but not closely engaged or actively surrounding these plaques (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>a-b, image a<sub>2</sub> and b<sub>2</sub>).</p><p id="Par42">The spatial association between PKM2<sup>+</sup>Iba1<sup>+</sup> microglia and A&#946; plaques was also examined. The proportion of PKM2<sup>+</sup>Iba1<sup>+</sup> microglia among plaque-associated microglia was significantly greater in AD brains than in control brains (<italic toggle="yes">p</italic>&#8201;=&#8201;0.002, Shapiro-Wilk normality test, CTL <italic toggle="yes">p</italic>&#8201;=&#8201;0.256, AD <italic toggle="yes">p</italic>&#8201;=&#8201;0.139, Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>c), suggesting preferential recruitment of glycolytic microglia to A&#946; deposits.</p><p id="Par43">To assess the specific spatial relationship between PKM2<sup>+</sup>Iba1<sup>+</sup> microglia and A&#946; plaques, we performed spatial modelling of PKM2<sup>+</sup>Iba1<sup>+</sup> microglial cell counts relative to their distance from A&#946; plaques (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>d). In AD brains, the number of glycolytic microglia increased progressively with increasing distance from plaque centres (<italic toggle="yes">&#946;</italic>&#8201;=&#8201;7.79, <italic toggle="yes">R</italic><sup>2</sup>&#8201;=&#8201;0.324, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), yet this accumulation was not associated with a corresponding reduction in plaque load. Importantly, the slope of the microglial distribution with distance differed significantly between groups (interaction term: <italic toggle="yes">&#946;</italic> = &#8722;7.824, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), suggesting altered spatial dynamics in AD, which may reflect inefficient targeting or impaired phagocytic function. Region-specific analyses revealed that the altered spatial distribution of PKM2&#8314;Iba1&#8314; microglia differed significantly between AD and control groups, with notable differences observed in the EC (<italic toggle="yes">p</italic>&#8201;=&#8201;0.015), SUB (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), CA1 (<italic toggle="yes">p</italic>&#8201;=&#8201;0.002), CA2 (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), CA3 (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), and DG (<italic toggle="yes">p</italic>&#8201;=&#8201;0.005) regions (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>e).</p><p id="Par44">These results indicate that glycolytically active microglia exhibit enhanced accumulation around A&#946; plaques in AD brains, with a characteristic spatial distribution pattern significantly distinct from controls.</p><p id="Par45">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Glycolytic microglia show increased numbers and altered spatial distribution around A&#946; in patients with AD.&#160;(<bold>a</bold>-<bold>b</bold>) Representative images from human HP&#8210;EC sections showing PKM2<sup>+</sup>Iba1<sup>+</sup> microglia in relation to A&#946; plaques in the AD (<bold>a</bold>) and CTL (b) groups. Image a<sub>1</sub> and b<sub>1</sub> depicts the merged mIHC image, with arrows highlighting PKM2<sup>+</sup>Iba1<sup>+</sup> microglia. Image a<sub>2</sub> and b<sub>2</sub> presents the corresponding mask, with concentric circles showing the distance to A&#946; plaque (white) and highlighting PKM2<sup>+</sup>Iba1<sup>+</sup> (magenta) and PKM2<sup>&#8211;</sup>Iba1<sup>+</sup> (cyan) cell masks. Images a<sub>3</sub>&#8211;a<sub>6</sub> and b<sub>3</sub>&#8211;b<sub>6</sub> show the single-channel images derived from a<sub>1</sub> and b<sub>1</sub>, including DAPI (blue, a<sub>3</sub> and b<sub>3</sub>), Iba1 (green, a<sub>4</sub> and b<sub>4</sub>), PKM2 (orange, a<sub>5</sub> and b<sub>5</sub>), and A&#946; (white, a<sub>6</sub> and b<sub>6</sub>). Scale bars&#8201;=&#8201;50&#160;&#956;m.&#160;(<bold>c</bold>) Proportion of PKM2<sup>+</sup>Iba1<sup>+</sup> cells among plaque-associated Iba1<sup>+</sup> microglia in AD vs. CTL brains.&#160;(<bold>d</bold>) PKM2<sup>+</sup>Iba1<sup>+</sup> microglia&#8211;plaque spatial relationships in AD vs. CTL brains.&#160;(<bold>e</bold>) Region&#8211;specific analysis of PKM2<sup>+</sup>Iba1<sup>+</sup> microglia&#8211;plaque spatial relationships across HP&#8210;EC in AD vs. CTL brains.&#160;All the data are presented as the means&#8201;&#177;&#8201;SEMs, and unpaired t tests, fixed-effects and mixed-effects models were performed (*<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01, ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, and ns: no significant difference)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1674" position="float" orientation="portrait" xlink:href="12974_2025_3546_Fig3_HTML.jpg"/></fig>
</p><sec id="Sec11"><title>Glycolytic microglia show altered Spatial distribution and increased numbers around p-Tau aggregates in AD brains</title><p id="Par46">To investigate the spatial relationship between glycolytically active microglia and p-Tau aggregates in AD, we defined regions within a 50&#160;&#956;m radius from the center of p-Tau aggregates as &#8220;aggregate-associated&#8221; or &#8220;peri-aggregate&#8221; areas (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>). Representative mIHC images revealed that PKM2<sup>+</sup>Iba1<sup>+</sup> microglia localized near p-Tau aggregates but rarely directly engaged these structures in AD compared to CTL (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>a-b, image a<sub>1</sub> and b<sub>1</sub>). Segmentation masks and spatial distance analyses revealed that PKM2<sup>+</sup>Iba1<sup>+</sup> microglia accumulated peripherally around p-Tau aggregates without evidence of effective clearance or engulfment activity (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>a&#8211;b, image a<sub>2</sub> and b<sub>2</sub>).</p><p id="Par47">Quantitative analysis revealed that the proportion of PKM2<sup>+</sup>Iba1<sup>+</sup> microglia among aggregate-associated Iba1<sup>+</sup> microglia was significantly greater in patients with AD than in controls (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, Shapiro-Wilk normality test, CTL <italic toggle="yes">p</italic>&#8201;=&#8201;0.726, AD <italic toggle="yes">p</italic>&#8201;=&#8201;0.326, Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>c), suggesting that glycolytic microglia are actively recruited towards regions of tau pathology.</p><p id="Par48">Spatial modeling further clarified this relationship by showing that, in AD brains, the number of PKM2<sup>+</sup>Iba1<sup>+</sup> microglia increased significantly with distance from p-Tau sites (<italic toggle="yes">&#946;</italic>&#8201;=&#8201;13.14, <italic toggle="yes">R</italic><sup>2</sup>&#8201;=&#8201;0.175, <italic toggle="yes">p</italic>&#8201;=&#8201;0.014; Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>d), whereas no such pattern was detected in control brains (<italic toggle="yes">p</italic>&#8201;=&#8201;0.054). Importantly, a significant interaction between disease status and distance (interaction term: <italic toggle="yes">&#946;</italic> = &#8722;12.33, <italic toggle="yes">p</italic>&#8201;=&#8201;0.014) indicated that the spatial distribution patterns of microglia around tau aggregates were significantly altered in AD patients. Region-specific analyses confirmed the disrupted microglial&#8211;p-Tau interaction in multiple brain areas (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>e). Significant interaction effects were observed in the EC (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), SUB (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), CA1 (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), CA2 (<italic toggle="yes">p</italic>&#8201;=&#8201;0.013), CA4 (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), and DG (<italic toggle="yes">p</italic>&#8201;=&#8201;0.004) regions, suggesting pronounced spatial uncoupling of microglial positioning and p-Tau in these regions. In contrast, no significant differences were found in the CA3 (<italic toggle="yes">p</italic>&#8201;=&#8201;0.375) region.</p><p id="Par49">These findings highlight that glycolytic microglia exhibit increased recruitment and distinct altered spatial distributions relative to p-Tau aggregates in AD brains, suggesting a specific spatial reorganization of microglia in response to tau-related neuropathology.</p><p id="Par50">
<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Glycolytic microglia show altered spatial distribution and increased numbers around p-Tau in patients with AD.&#160;(<bold>a</bold>-<bold>b</bold>) Representative images from human HP&#8210;EC sections showing PKM2<sup>+</sup>Iba1<sup>+</sup> microglia in relation to p-Tau aggregates in the AD (<bold>a</bold>) and CTL (<bold>b</bold>) groups. Image a<sub>1</sub> and b<sub>1</sub> depicts the merged mIHC image, with arrows highlighting PKM2<sup>+</sup>Iba1<sup>+</sup> microglia. Image a<sub>2</sub> and b<sub>2</sub> presents the corresponding mask, with concentric circles showing the distance to p-Tau aggregates (blue) and highlighting PKM2<sup>+</sup>Iba1<sup>+</sup> (magenta) and PKM2<sup>&#8211;</sup>Iba1<sup>+</sup> (cyan) cell masks. Images a<sub>3</sub>&#8211;a<sub>6</sub> and b<sub>3</sub>&#8211;b<sub>6</sub> show the single-channel images derived from a<sub>1</sub> and b<sub>1</sub>, including DAPI (blue, a<sub>3</sub> and b<sub>3</sub>), Iba1 (green, a<sub>4</sub> and b<sub>4</sub>), PKM2 (orange, a<sub>5</sub> and b<sub>5</sub>), and p-Tau (cyan, a<sub>6</sub> and b<sub>6</sub>). Scale bars&#8201;=&#8201;50&#160;&#956;m.&#160;(<bold>c</bold>) Proportion of PKM2<sup>+</sup>Iba1<sup>+</sup> cells among aggregate-associated Iba1<sup>+</sup> microglia in AD vs. CTL brains.&#160;(<bold>d</bold>) PKM2<sup>+</sup>Iba1<sup>+</sup> microglia&#8211;aggregate spatial relationships in AD vs. CTL brains.&#160;(<bold>e</bold>) Region&#8211;specific analysis of PKM2<sup>+</sup>Iba1<sup>+</sup> microglia&#8211;aggregate spatial relationships across HP&#8210;EC in AD vs. CTL brains.&#160;All the data are presented as the means&#8201;&#177;&#8201;SEMs, and unpaired t tests, fixed-effects and mixed-effects models were performed (*<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01, ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, and ns: no significant difference)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1895" position="float" orientation="portrait" xlink:href="12974_2025_3546_Fig4_HTML.jpg"/></fig>
</p></sec></sec><sec id="Sec12"><title>Glycolytic microglia exhibit increased numbers and Preferential localization near cerebral blood vessels in AD brains</title><p id="Par51">We next examined the spatial relationship between glycolytic microglia and cerebral blood vessels in patients with AD by analysing PKM2<sup>+</sup>Iba1<sup>+</sup> microglia in relation to endothelial cells (CD31<sup>+</sup>) (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>). We defined the area within a radius of 50&#160;&#956;m from the vessel (CD31<sup>+</sup> endothelial cells) as the &#8220;perivascular&#8221; region.</p><p id="Par52">Representative mIHC images revealed the accumulation of PKM2<sup>+</sup>Iba1<sup>+</sup> microglia near cerebral vessels, as indicated by merged images and spatial segmentation analyses (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>a&#8211;b, images a<sub>1</sub>&#8211;a<sub>2</sub> and b<sub>1</sub>&#8211;b<sub>2</sub>). Compared with those in control brains, the proportion of PKM2<sup>+</sup>Iba1<sup>+</sup> microglia within perivascular regions was significantly higher in AD brains than in CTL brains (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; Shapiro-Wilk normality test, CTL <italic toggle="yes">p</italic>&#8201;=&#8201;0.808, AD <italic toggle="yes">p</italic>&#8201;=&#8201;0.227, Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>c), indicating increased accumulation of glycolytic microglia around cerebral blood vessels in AD. Furthermore, PKM2<sup>+</sup>Iba1<sup>+</sup> microglia in AD brains were significantly closer to blood vessels (<italic toggle="yes">p</italic>&#8201;=&#8201;0.013, Shapiro-Wilk normality test, CTL <italic toggle="yes">p</italic>&#8201;=&#8201;0.430, AD <italic toggle="yes">p</italic>&#8201;=&#8201;0.116, Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>d), indicating enhanced perivascular accumulation of glycolytic microglia in the diseased state.</p><p id="Par53">To further investigate this spatial relationship, we analysed the distribution of PKM2<sup>+</sup>Iba1<sup>+</sup> microglia across increasing distance intervals from CD31<sup>+</sup> structures (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>d). Although AD brains consistently showed greater numbers of PKM2<sup>+</sup>Iba1<sup>+</sup> microglia at all distances compared to CTL brains, no significant linear relationship between distance and microglial density was observed within either group (AD: <italic toggle="yes">p</italic>&#8201;=&#8201;0.269, CTL: <italic toggle="yes">p</italic>&#8201;=&#8201;0.286), and the interaction term between distance and disease status was also nonsignificant (<italic toggle="yes">p</italic>&#8201;=&#8201;0.151). The lack of a significant linear relationship, despite increased proximity and numbers, suggests that glycolytic microglia preferentially localize near cerebral vessels in AD without exhibiting a strictly linear chemotactic gradient. Region-specific modelling further confirmed that none of the annotations analysed showed significant interactions between distance and disease group (all <italic toggle="yes">p</italic>s&#8201;&gt;&#8201;0.05). This pattern may imply the involvement of more complex mechanisms beyond simple directional chemotaxis, such as localized microenvironmental factors or vessel-associated signaling.</p><p id="Par54">Collectively, these observations indicate that glycolytically active microglia in AD brains exhibit both increased numbers and enhanced proximity to cerebral blood vessels. Although the spatial distribution does not follow a simple linear gradient, the consistent preferential localization near vessels across brain regions underscores a prominent perivascular accumulation pattern, reflecting altered microglial&#8211;vascular interactions that could be crucial in AD pathogenesis.</p><p id="Par55">
<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Glycolytic microglia show increased numbers and preferential localization near cerebral blood vessels in patients with AD.&#160;(<bold>a</bold>-<bold>b</bold>) Representative images from human HP&#8210;EC sections showing PKM2<sup>+</sup>Iba1<sup>+</sup> microglia in relation to blood vessels in the AD (<bold>a</bold>) and CTL (<bold>b</bold>) groups. Image a<sub>1</sub> and b<sub>1</sub> depicts the merged mIHC image, with arrows highlighting PKM2<sup>+</sup>Iba1<sup>+</sup> microglia. Image a<sub>2</sub> and b<sub>2</sub> presents the corresponding mask, with concentric circles showing the distance to blood vessels (red) and highlighting PKM2<sup>+</sup>Iba1<sup>+</sup> (magenta) and PKM2<sup>&#8211;</sup>Iba1<sup>+</sup> (cyan) cell masks. Images a<sub>3</sub>&#8211;a<sub>6</sub> and b<sub>3</sub>&#8211;b<sub>6</sub> show the single-channel images derived from a<sub>1</sub> and b<sub>1</sub>, including DAPI (blue, a<sub>3</sub> and b<sub>3</sub>), Iba1 (green, a<sub>4</sub> and b<sub>4</sub>), PKM2 (orange, a<sub>5</sub> and b<sub>5</sub>), and CD31 (red, a<sub>6</sub> and b<sub>6</sub>). Scale bars&#8201;=&#8201;50&#160;&#956;m.&#160;(<bold>c</bold>) Proportion of PKM2<sup>+</sup>Iba1<sup>+</sup> cells among endothelia-associated Iba1<sup>+</sup> microglia in AD vs. CTL brains.&#160;(<bold>d</bold>) Quantification of the average distance between PKM2<sup>+</sup>Iba1<sup>+</sup> microglia and the nearest blood vessel in AD vs. CTL brains.&#160;(<bold>e</bold>) PKM2<sup>+</sup>Iba1<sup>+</sup> microglia&#8211;endothelial spatial relationships in AD vs. CTL brains.&#160;(<bold>f</bold>) Region&#8211;specific analysis of PKM2<sup>+</sup>Iba1<sup>+</sup> microglia&#8211;endothelial spatial relationships across HP&#8210;EC in AD vs. CTL brains.&#160;All the data are presented as the means&#8201;&#177;&#8201;SEMs, and unpaired t tests, fixed-effects and mixed-effects models were performed (*<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01, ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, and ns: no significant difference)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e2113" position="float" orientation="portrait" xlink:href="12974_2025_3546_Fig5_HTML.jpg"/></fig>
</p></sec><sec id="Sec13"><title>Impaired phagocytic activity of glycolytic microglia in AD</title><p id="Par56">To further investigate microglial phagocytic function abnormalities in AD, we utilized mIHC with Panel 3, including markers Iba1 (general microglia marker), PKM2 (glycolytic enzyme marker), CD68 (marker for active phagocytosis), PLIN2 (marker for phagocytic exhaustion), and pathological structures (p-Tau and A&#946;). Our goal was to determine whether impaired microglial phagocytosis observed in AD is specifically associated with glycolytic metabolic changes.</p><p id="Par57">Representative mIHC images revealed clear colocalization patterns among the selected markers. In AD brain samples, Iba1<sup>+</sup> microglia exhibited visibly reduced CD68 expression, indicative of lower active phagocytosis, particularly within PKM2<sup>&#8211;</sup> populations; and increased PLIN2 expression, indicating higher phagocytic exhaustion, particularly within PKM2&#8314; populations (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>a&#8211;h). Segmentation masks confirmed the precise localization and differential distribution of these markers around pathological aggregates (p-Tau and A&#946;), demonstrating pronounced differences between AD and CTL groups.</p><p id="Par58">Quantitative analysis showed that the overall proportion of CD68&#8314;Iba1&#8314; microglia among total Iba1&#8314; microglia was significantly lower in AD brains compared to CTL (<italic toggle="yes">p</italic>&#8201;=&#8201;0.001, Shapiro-Wilk normality test, CTL <italic toggle="yes">p</italic>&#8201;=&#8201;0.774, AD <italic toggle="yes">p</italic>&#8201;=&#8201;0.762; Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>i<sub>1</sub>), clearly indicating reduced overall phagocytic capacity in AD. However, within the glycolytic (PKM2&#8314;Iba1<sup>+</sup>) microglial subgroup, there was no significant difference in active phagocytosis (CD68<sup>+</sup>PKM2&#8314;Iba1<sup>+</sup>) proportions between AD and CTL (<italic toggle="yes">p</italic>&#8201;=&#8201;0.342; Shapiro-Wilk normality test, CTL <italic toggle="yes">p</italic>&#8201;=&#8201;0.214, AD <italic toggle="yes">p</italic>&#8201;=&#8201;0.225; Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>i<sub>2</sub>). In contrast, among the non-glycolytic (PKM2&#8315; Iba1<sup>+</sup>) microglial subgroup, the active phagocytic (CD68<sup>+</sup>PKM2<sup>&#8211;</sup>Iba1<sup>+</sup>) proportion was significantly lower in AD brains compared to CTL (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; Shapiro-Wilk normality test, CTL <italic toggle="yes">p</italic>&#8201;=&#8201;0.557, AD <italic toggle="yes">p</italic>&#8201;=&#8201;0.109; Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>i<sub>3</sub>). This result indicates that the observed overall decline in phagocytic activity in AD brains is predominantly observed in PKM2&#8315; microglial populations, suggesting that PKM2 expression is not closely related to active phagocytic function.</p><p id="Par59">In parallel, we observed a significant increase in the proportion of PLIN2&#8314;Iba1&#8314; microglia in AD brains compared to CTLs (<italic toggle="yes">p</italic>&#8201;=&#8201;0.002, Shapiro-Wilk normality test, CTL <italic toggle="yes">p</italic>&#8201;=&#8201;0.658, AD <italic toggle="yes">p</italic>&#8201;=&#8201;0.787; Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>i<sub>4</sub>), indicating enhanced phagocytic exhaustion in AD pathology. Notably, the proportion of PLIN2&#8314;PKM2&#8314;Iba1&#8314; microglia was significantly higher in AD compared to CTL (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; Shapiro-Wilk normality test, CTL <italic toggle="yes">p</italic>&#8201;=&#8201;0.245, AD <italic toggle="yes">p</italic>&#8201;=&#8201;0.518; Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>i<sub>5</sub>), whereas no significant difference was observed in PLIN2&#8314;PKM2&#8315;Iba1&#8314; proportions between groups (<italic toggle="yes">p</italic>&#8201;=&#8201;0.986; Shapiro-Wilk normality test, CTL <italic toggle="yes">p</italic>&#8201;=&#8201;0.845, AD <italic toggle="yes">p</italic>&#8201;=&#8201;0.404; Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>i<sub>6</sub>). These results clearly suggest that increased phagocytic exhaustion in AD brains specifically related to the glycolytic state of microglia.</p><p id="Par60">Further analysis within defined periplaque regions (within 50&#160;&#956;m of p-Tau and A&#946; aggregates) showed consistent patterns: AD brains exhibited significantly decreased proportions of active phagocytic (CD68&#8314;Iba1&#8314;) microglia and significantly increased proportions of phagocytically exhausted (PLIN2&#8314;Iba1&#8314;) microglia compared to CTL around both A&#946; (Fig. 6k<sub>1</sub> &amp; 6k<sub>4</sub>) and p-Tau aggregates (Fig. 6j<sub>1</sub> &amp; 6j<sub>4</sub>; <italic toggle="yes">p</italic>s&#8201;&lt;&#8201;0.001, Shapiro-Wilk normality test <italic toggle="yes">p</italic>&#8201;&gt;&#8201;0.05). Notably, glycolytic (PKM2&#8314;Iba1<sup>+</sup>) microglia specifically showed a pronounced increase in phagocytic exhaustion (PLIN2&#8314;PKM2&#8314;Iba1&#8314;, <italic toggle="yes">p</italic>s&#8201;&lt;&#8201;0.001, Shapiro-Wilk normality test <italic toggle="yes">p</italic>&#8201;&gt;&#8201;0.05; Fig. 6j<sub>5</sub> &amp; 6k<sub>5</sub>) but no significant difference in active phagocytosis (CD68<sup>+</sup>PKM2&#8314;Iba1<sup>+</sup>) in AD versus CTL (<italic toggle="yes">p</italic>s&#8201;&gt;&#8201;0.05, Shapiro-Wilk normality test <italic toggle="yes">p</italic>&#8201;&gt;&#8201;0.05; Fig. 6j<sub>2</sub> &amp; 6k<sub>2</sub>). In contrast, non-glycolytic (PKM2&#8315;Iba1<sup>+</sup>) microglia showed significantly decreased active phagocytosis (CD68<sup>+</sup>PKM2<sup>&#8211;</sup>Iba1<sup>+</sup>) around pathological aggregates (<italic toggle="yes">p</italic>s&#8201;&lt;&#8201;0.001, Shapiro-Wilk normality test <italic toggle="yes">p</italic>&#8201;&#8805;&#8201;0.05; Fig. 6j<sub>3</sub> &amp; 6k<sub>3</sub>), but no significant different in phagocytic exhaustion (PLIN2<sup>+</sup>PKM2<sup>&#8211;</sup>Iba1<sup>+</sup>) in AD compared to CTL (<italic toggle="yes">p</italic>s&#8201;&gt;&#8201;0.001, Shapiro-Wilk normality test&#8201;&gt;&#8201;0.05; Fig. 6j<sub>6</sub> &amp; 6k<sub>6</sub>). These results reinforced the conclusion that impaired phagocytosis in AD pathology is broadly related to microglial changes rather than specifically confined to PKM2&#8314;Iba1<sup>+</sup> cells.</p><p id="Par61">Collectively, these results indicate significant overall impairment in microglial phagocytic function and increased phagocytic exhaustion in AD brains. Critically, glycolytic microglia (PKM2&#8314;Iba1<sup>+</sup>) are specifically associated with increased exhaustion but not with reduced active phagocytosis, suggesting that the glycolytic state of microglia relates specifically to phagocytic exhaustion rather than to active phagocytic capability.</p><p id="Par62">
<fig id="Fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><p>Glycolytic microglia show impaired phagocytic function pattern in AD patients.&#160;(<bold>a</bold>-<bold>h</bold>) Representative images from human HP&#8210;EC sections showing phagocytic function pattern of PKM2<sup>+</sup>Iba1<sup>+</sup> microglia around A&#946; and p-Tau in the AD (<bold>a</bold>-<bold>d</bold>) and CTL (<bold>e</bold>-<bold>h</bold>) groups. Image a<sub>1</sub>&#8211;h<sub>1</sub> depicts the merged mIHC image, with arrows highlighting PLIN2<sup>+</sup>PKM2<sup>+</sup>Iba1<sup>+</sup> and CD68<sup>+</sup>PKM2<sup>&#8211;</sup>Iba1<sup>+</sup> microglia. Image a<sub>2</sub>&#8211;h<sub>2</sub> presents the corresponding mask, with a circle showing 50&#160;&#956;m to A&#946; (magenta) and p-Tau (cyan) and highlighting CD68<sup>&#8211;</sup>PKM2<sup>+</sup>Iba1<sup>+</sup> (red), CD68<sup>+</sup>PKM2<sup>&#8211;</sup>Iba1<sup>+</sup> (orange), PLIN2<sup>+</sup>PKM2<sup>+</sup>Iba1<sup>+</sup> (white), and PLIN2<sup>&#8211;</sup>PKM2<sup>&#8211;</sup>Iba1<sup>+</sup> (green) cell masks. Rest images show the single-channel images derived from a<sub>1</sub>&#8211;h<sub>1</sub>, including DAPI (blue, a<sub>3</sub>&#8211;h<sub>3</sub>), Iba1 (green, a<sub>4</sub>&#8211;h<sub>4</sub>), PKM2 (red, a<sub>5</sub>&#8211;h<sub>5</sub>), CD68 (orange, a<sub>6</sub> and b<sub>6</sub>, e<sub>6</sub> and f<sub>6</sub>), PLIN2 (white, c<sub>6</sub> and d<sub>6</sub>, g<sub>6</sub> and h<sub>6</sub>), A&#946; (magenta, a<sub>6</sub> and c<sub>6</sub>, e<sub>6</sub> and g<sub>6</sub>), and p-Tau (cyan, b<sub>6</sub> and d<sub>6</sub>, f<sub>6</sub> and h<sub>6</sub>). Scale bars&#8201;=&#8201;50&#160;&#956;m.&#160;(i-k) Quantitive comparison of phagocytic function of microglia in the whole sections (<bold>i</bold>), around A&#946; plaques (<bold>j</bold>), and around p-Tau aggregates (<bold>k</bold>) in AD vs. CTL brains. Image i<sub>1</sub>&#8211;k<sub>1</sub> compared CD68<sup>+</sup>Iba1<sup>+</sup> cells among Iba1<sup>+</sup> microglia. Image i<sub>2</sub>&#8211;k<sub>2</sub> compared CD68<sup>+</sup>PKM2<sup>+</sup>Iba1<sup>+</sup> cells among PKM2<sup>+</sup>Iba1<sup>+</sup> glycolytic microglia. Image i<sub>3</sub>&#8211;k<sub>3</sub> compared CD68<sup>+</sup>PKM2<sup>&#8211;</sup>Iba1<sup>+</sup> cells among PKM2<sup>&#8211;</sup>Iba1<sup>+</sup> microglia. Image i<sub>4</sub>&#8211;k<sub>4</sub> compared PLIN2<sup>+</sup>Iba1<sup>+</sup> cells among Iba1<sup>+</sup> microglia. Image i<sub>5</sub>&#8211;k<sub>5</sub> compared PLIN2<sup>+</sup>PKM2<sup>+</sup>Iba1<sup>+</sup> cells among PKM2<sup>+</sup>Iba1<sup>+</sup> glycolytic microglia. Image i<sub>6</sub>&#8211;k<sub>6</sub> compared PLIN2<sup>+</sup>PKM2<sup>&#8211;</sup>Iba1<sup>+</sup> cells among PKM2<sup>&#8211;</sup>Iba1<sup>+</sup> microglia.&#160;All the data are presented as the means&#8201;&#177;&#8201;SEMs, and unpaired t tests were performed (**<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01, ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, and ns: no significant difference)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e2549" position="float" orientation="portrait" xlink:href="12974_2025_3546_Fig6_HTML.jpg"/></fig>
</p></sec></sec><sec id="Sec14"><title>Discussion</title><p id="Par63">In this study, we demonstrate a clear association between microglial glycolytic reprogramming, highlighted by elevated PKM2 expression, and functional and phenotypic abnormalities in AD. Our data reveal that glycolytic PKM2&#8314;Iba1&#8314; microglia in AD brains predominantly adopted a disease-associated phenotype characterized by elevated ABCA7 expression (HAM-like) and concurrent lipid droplet accumulation (PLIN3<sup>+</sup>; LDAM phenotype). Spatially, PKM2<sup>+</sup>Iba1<sup>+</sup> microglia preferentially localize near A&#946; plaques, p-Tau aggregates, and cerebral blood vessels. Importantly, although these PKM2<sup>+</sup> cells retain active phagocytic capability, they exhibit marked signs of phagocytic exhaustion rather than phagocytic activation. Conversely, the decline in active phagocytosis observed in AD brains predominantly affects PKM2&#8315; microglial populations. These findings illustrate a complex relationship between microglial glycolytic metabolism, spatial localization, and phagocytic functionality in AD.</p><p id="Par64">In our AD samples, glycolytically active microglia (PKM2&#8314;Iba1<sup>+</sup>) predominantly adopted a HAM-like phenotype characterized by elevated ABCA7 expression. This phenotypic shift aligns with established markers of human AD-associated microglial states, which exhibit enhanced inflammatory signatures and impaired phagocytic functions [<xref ref-type="bibr" rid="CR21">21</xref>&#8211;<xref ref-type="bibr" rid="CR23">23</xref>]. Upregulation of PKM2, a key glycolytic enzyme, may sustain microglial inflammation by stabilizing pro-inflammatory signaling cascades or inflammasome activation, potentially reinforcing the HAM-like state [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. Such glycolytically driven inflammatory microglia could contribute to chronic neuroinflammation and hinder clearance of pathological aggregates, possibly exacerbating AD progression [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Therefore, our findings highlight glycolytic metabolism as a potential factor linking microglial inflammatory phenotypes to the development and persistence of AD pathology.</p><p id="Par65">Spatially, PKM2&#8314;Iba1<sup>+</sup> microglia exhibited preferential accumulation around A&#946; plaques and p-Tau aggregates. Unexpectedly, their density increased rather than decreased with distance from these pathological cores. This inverse spatial distribution suggests abnormal or impaired chemotactic responses, possibly reflecting disruptions in microglial migration signals or local inhibitory cues [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. Potential underlying mechanisms include chronic metabolic stress from sustained glycolysis, persistent inflammatory signaling in the plaque microenvironment, or direct repulsive signals emanating from dense protein aggregates [<xref ref-type="bibr" rid="CR28">28</xref>&#8211;<xref ref-type="bibr" rid="CR30">30</xref>]. These observations align with ultrastructural evidence of dystrophic microglia near plaques in human AD tissues [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>].</p><p id="Par66">Another critical observation is the preferential perivascular localization of PKM2&#8314;Iba1<sup>+</sup> microglia in AD brains. Glycolytically reprogrammed microglia accumulated significantly closer to cerebral blood vessels compared to controls, yet without forming clear chemotactic gradients. This pattern implies complex mechanisms beyond directional migration, such as blood-brain barrier disruption, cerebral amyloid angiopathy (CAA), or localized inflammatory signaling [<xref ref-type="bibr" rid="CR33">33</xref>&#8211;<xref ref-type="bibr" rid="CR35">35</xref>]. Prior studies support these interpretations, demonstrating that microglial accumulation near impaired vessels is associated with blood&#8211;brain barrier (BBB) damage and chronic inflammation [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. Such perivascular clustering may exacerbate vascular dysfunction and impede perivascular amyloid clearance, underscoring neurovascular interactions as a critical component of AD pathogenesis [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR38">38</xref>].</p><p id="Par67">Functionally, our data suggest that microglial glycolysis (PKM2<sup>+</sup>Iba1<sup>+</sup>) specifically correlates with phagocytic exhaustion rather than active phagocytosis. Notably, while overall active phagocytic activity declined in AD brains, this decline occurred predominantly within the PKM2&#8315; subset, whereas PKM2&#8314; cells maintained their phagocytic proportions but became severely exhausted, accumulating lipid droplets. This result underscores a metabolic division of labor: glycolytically reprogrammed microglia maintain continuous debris uptake but fail to process ingested materials effectively, transitioning into a lipid-overloaded, dysfunctional state (analogous to LDAM) [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. In contrast, non-glycolytic cells become functionally hypoactive, suggesting they may be metabolically or functionally suppressed by chronic inflammation or insufficient energy metabolism [<xref ref-type="bibr" rid="CR41">41</xref>&#8211;<xref ref-type="bibr" rid="CR43">43</xref>]. Recent studies align with our observations, showing glycolytic microglia exhibit impaired lysosomal degradation capacity and chronic lipid accumulation in aging and AD models [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR44">44</xref>].</p><p id="Par68">Our findings have notable clinical and therapeutic implications. Given that PKM2&#8314;Iba1<sup>+</sup> glycolytic microglia primarily experience phagocytic exhaustion, therapeutic modulation of microglial metabolism emerges as an attractive strategy. Targeting glycolytic pathways, specifically PKM2, may reprogram microglial metabolic profiles, alleviate exhaustion, and restore debris clearance capacity [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. Pharmacological agents that stabilize PKM2 tetramers, reducing nuclear translocation and inflammatory gene activation, could shift microglia toward more effective clearance functions [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. Moreover, therapeutic interventions enhancing microglial oxidative metabolism, lysosomal function, or anti-inflammatory polarization may mitigate exhaustion and improve pathological aggregate removal [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]. Agents targeting the TREM2 pathway or inflammasome activity represent promising adjunct strategies that may further recalibrate microglial activity and metabolic balance [<xref ref-type="bibr" rid="CR48">48</xref>&#8211;<xref ref-type="bibr" rid="CR50">50</xref>].</p><p id="Par69">Several limitations warrant consideration. First, our 2D immunohistochemistry approach might not fully capture the detailed spatial relationships between metabolically reprogrammed microglia and pathological structures (plaques and tangles). Future studies employing advanced 3D tissue clearing methods could further clarify these spatial dynamics. Second, while our findings suggest significant metabolic reprogramming in microglia, we could not directly identify specific metabolic pathways or key metabolites altered in these cells. Single-cell and spatial metabolomics would further elucidate these precise metabolic shifts. Additionally, our findings illustrate a complex relationship between microglial glycolytic metabolism, spatial localization, and phagocytic functionality in AD, but do not allow us to infer causality regarding impaired clearance of pathological aggregates. To address this limitation, future studies should use animal models and targeted interventions to clarify the causal links between microglial metabolism and AD progression. Finally, technical limitations related to multiplex immunostaining, cross-sectional design, and human brain sample heterogeneity are inherent but common in postmortem human studies; thus, further validation in larger cohorts and experimental models would enhance the generalizability of our findings.</p><p id="Par70">Future studies should adopt advanced 3D imaging technologies and tissue-clearing approaches to precisely characterize microglial interactions with AD pathology. Moreover, applying single-cell and spatial metabolomics could uncover critical metabolic pathways underlying microglial reprogramming. Longitudinal investigations in appropriate animal models, coupled with targeted metabolic and transcriptomic interventions, will be valuable to clarify the causative relationships between microglial metabolism, functional alterations, and Alzheimer&#8217;s disease progression. Additionally, investigations specifically designed to elucidate sex-related differences in microglial metabolism and functional responses may provide important insights into the biological underpinnings of sex-specific vulnerability to Alzheimer&#8217;s disease.</p></sec><sec id="Sec15"><title>Conclusion</title><p id="Par71">In conclusion, our study reveals a clear association between microglial metabolic reprogramming and functional abnormalities in AD, highlighting glycolytic PKM2&#8314;Iba1<sup>+</sup> microglia as central components of disease-associated microglial responses. These metabolically altered microglia preferentially adopt a HAM-like inflammatory phenotype, displaying pronounced phagocytic exhaustion rather than active phagocytosis. Spatially, PKM2&#8314;Iba1<sup>+</sup> microglia cluster near pathological aggregates and cerebral blood vessels, suggesting their close engagement in AD pathogenesis, yet exhibit abnormal distribution patterns indicative of compromised migration or interaction capabilities. Collectively, our findings suggest that glycolytic metabolism, marked by PKM2 upregulation, may sustain microglial inflammation and dysfunction, potentially contributing to AD pathology and neurodegeneration. These insights advance our understanding of microglial immunometabolism in AD, highlighting metabolic pathways as promising therapeutic targets for restoring microglial homeostasis, alleviating chronic inflammation, and ultimately providing novel approaches for mitigating cognitive decline in AD.</p></sec><sec id="Sec16" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12974_2025_3546_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Material 1.</p></caption></media></supplementary-material>
</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AD</term><def><p id="Par4">Alzheimer&#8217;s disease</p></def></def-item><def-item><term>A&#946;</term><def><p id="Par5">Amyloid-&#946;</p></def></def-item><def-item><term>p-Tau</term><def><p id="Par6">Phosphorylated-tau</p></def></def-item><def-item><term>PKM2</term><def><p id="Par7">Pyruvate kinase M2</p></def></def-item><def-item><term>HIF-1&#945;</term><def><p id="Par8">Hypoxia-inducible factor 1&#945;</p></def></def-item><def-item><term>HP&#8210;EC</term><def><p id="Par9">Hippocampus&#8210;entorhinal cortex</p></def></def-item><def-item><term>NHBBDF</term><def><p id="Par10">National Human Brain Bank for Developmental and Functional Research</p></def></def-item><def-item><term>PFA</term><def><p id="Par11">Paraformaldehyde</p></def></def-item><def-item><term>mIHC</term><def><p id="Par12">Multiplex immunohistochemistry</p></def></def-item><def-item><term>Iba1</term><def><p id="Par13">Ionized calcium-binding adapter molecule 1</p></def></def-item><def-item><term>ABCA7</term><def><p id="Par14">ATP Binding Cassette Subfamily A Member 7</p></def></def-item><def-item><term>TMEM119</term><def><p id="Par15">Transmembrane Protein 119</p></def></def-item><def-item><term>PLIN3</term><def><p id="Par16">Perilipin-3</p></def></def-item><def-item><term>PLIN2</term><def><p id="Par17">Perilipin-2</p></def></def-item><def-item><term>EC</term><def><p id="Par18">Entorhinal cortex</p></def></def-item><def-item><term>SUB</term><def><p id="Par19">Subiculum</p></def></def-item><def-item><term>DG</term><def><p id="Par20">Dentate gyrus</p></def></def-item><def-item><term>CTL</term><def><p id="Par21">Healthy control</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#8217;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Ning Lu and Zhongman Jin contributed equally to this work.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This work was supported by State Key Laboratory of Common Mechanism Research of Major Diseases Platform. We thank Ran Zhang, Jie Kong, and Xiaolin Yu for providing technical support. The human brain samples used in this article are from NHBBDF at the Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences. We sincerely thank the staff of NHBBDF for their invaluable contributions. We also appreciate the neuropathologist for assisting with the determination of fluorescence intensity thresholds for mIHC image analysis.</p></ack><notes notes-type="author-contribution"><title>Authors&#8217; contributions</title><p>N. Lu and Q.X. conceived and designed the study. N. Lu and Z.J. conducted experiments, performed data analysis, prepared figures, and drafted the manuscript. N. Lu, Z.J., N. Liu, C.Z., and H.W. contributed to sample preparation, immunohistochemical staining, and assisted in data interpretation. Q.X. and H.W. supervised the study, provided critical revisions, and finalized the manuscript. Funding acquisition and resources were provided by Q.X., H.W., and C.Z. All authors have read and approved the final version of the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by grants from the STI2030-Major Projects (2021ZD0200600, 2021ZD0202001), the National Key Research and Development Program of China (2020YFA0804502), the CAMS Innovation Fund for Medical Sciences (2021-I2M-1-020), and the National High Level Hospital Clinical Research Funding (2022-PUMCH-D-002).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The original contributions presented in the study are included in the article. Other data that support the findings are available from the corresponding author upon reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par72">The research protocol was approved by the Institutional Review Board of the Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, China (Approval Number: 2022125).</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par73">All authors have consented for the publication of manuscript.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par74">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heneka</surname><given-names>MT</given-names></name><etal/></person-group><article-title>Neuroinflammation in alzheimer&#8217;s disease</article-title><source>Lancet Neurol</source><year>2015</year><volume>14</volume><issue>4</issue><fpage>388</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(15)70016-5</pub-id><pub-id pub-id-type="pmid">25792098</pub-id><pub-id pub-id-type="pmcid">PMC5909703</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Heneka MT, et al. Neuroinflammation in alzheimer&#8217;s disease. Lancet Neurol. 2015;14(4):388&#8211;405.<pub-id pub-id-type="pmid">25792098</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(15)70016-5</pub-id><pub-id pub-id-type="pmcid">PMC5909703</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hansen</surname><given-names>DV</given-names></name><name name-style="western"><surname>Hanson</surname><given-names>JE</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>M</given-names></name></person-group><article-title>Microglia in alzheimer&#8217;s disease</article-title><source>J Cell Biol</source><year>2018</year><volume>217</volume><issue>2</issue><fpage>459</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1083/jcb.201709069</pub-id><pub-id pub-id-type="pmid">29196460</pub-id><pub-id pub-id-type="pmcid">PMC5800817</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Hansen DV, Hanson JE, Sheng M. Microglia in alzheimer&#8217;s disease. J Cell Biol. 2018;217(2):459&#8211;72.<pub-id pub-id-type="pmid">29196460</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1083/jcb.201709069</pub-id><pub-id pub-id-type="pmcid">PMC5800817</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Colonna</surname><given-names>M</given-names></name><name name-style="western"><surname>Butovsky</surname><given-names>O</given-names></name></person-group><article-title>Microglia function in the central nervous system during health and neurodegeneration</article-title><source>Annu Rev Immunol</source><year>2017</year><volume>35</volume><fpage>441</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-051116-052358</pub-id><pub-id pub-id-type="pmid">28226226</pub-id><pub-id pub-id-type="pmcid">PMC8167938</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Colonna M, Butovsky O. Microglia function in the central nervous system during health and neurodegeneration. Annu Rev Immunol. 2017;35:441&#8211;68.<pub-id pub-id-type="pmid">28226226</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-immunol-051116-052358</pub-id><pub-id pub-id-type="pmcid">PMC8167938</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guerreiro</surname><given-names>R</given-names></name><etal/></person-group><article-title>TREM2 variants in alzheimer&#8217;s disease</article-title><source>N Engl J Med</source><year>2013</year><volume>368</volume><issue>2</issue><fpage>117</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1211851</pub-id><pub-id pub-id-type="pmid">23150934</pub-id><pub-id pub-id-type="pmcid">PMC3631573</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Guerreiro R, et al. TREM2 variants in alzheimer&#8217;s disease. N Engl J Med. 2013;368(2):117&#8211;27.<pub-id pub-id-type="pmid">23150934</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1211851</pub-id><pub-id pub-id-type="pmcid">PMC3631573</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Griciuc</surname><given-names>A</given-names></name><etal/></person-group><article-title>Alzheimer&#8217;s disease risk gene CD33 inhibits microglial uptake of amyloid beta</article-title><source>Neuron</source><year>2013</year><volume>78</volume><issue>4</issue><fpage>631</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2013.04.014</pub-id><pub-id pub-id-type="pmid">23623698</pub-id><pub-id pub-id-type="pmcid">PMC3706457</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Griciuc A, et al. Alzheimer&#8217;s disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron. 2013;78(4):631&#8211;43.<pub-id pub-id-type="pmid">23623698</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2013.04.014</pub-id><pub-id pub-id-type="pmcid">PMC3706457</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lambert</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for alzheimer&#8217;s disease</article-title><source>Nat Genet</source><year>2013</year><volume>45</volume><issue>12</issue><fpage>1452</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1038/ng.2802</pub-id><pub-id pub-id-type="pmid">24162737</pub-id><pub-id pub-id-type="pmcid">PMC3896259</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Lambert JC, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for alzheimer&#8217;s disease. Nat Genet. 2013;45(12):1452&#8211;8.<pub-id pub-id-type="pmid">24162737</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.2802</pub-id><pub-id pub-id-type="pmcid">PMC3896259</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lauro</surname><given-names>C</given-names></name><name name-style="western"><surname>Limatola</surname><given-names>C</given-names></name></person-group><article-title>Metabolic reprograming of microglia in the regulation of the innate inflammatory response</article-title><source>Front Immunol</source><year>2020</year><volume>11</volume><fpage>493</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.00493</pub-id><pub-id pub-id-type="pmid">32265936</pub-id><pub-id pub-id-type="pmcid">PMC7099404</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Lauro C, Limatola C. Metabolic reprograming of microglia in the regulation of the innate inflammatory response. Front Immunol. 2020;11:493.<pub-id pub-id-type="pmid">32265936</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2020.00493</pub-id><pub-id pub-id-type="pmcid">PMC7099404</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sadeghdoust</surname><given-names>M</given-names></name><name name-style="western"><surname>Das</surname><given-names>A</given-names></name><name name-style="western"><surname>Kaushik</surname><given-names>DK</given-names></name></person-group><article-title>Fueling neurodegeneration: metabolic insights into microglia functions</article-title><source>J Neuroinflammation</source><year>2024</year><volume>21</volume><issue>1</issue><fpage>300</fpage><pub-id pub-id-type="doi">10.1186/s12974-024-03296-0</pub-id><pub-id pub-id-type="pmid">39551788</pub-id><pub-id pub-id-type="pmcid">PMC11571669</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Sadeghdoust M, Das A, Kaushik DK. Fueling neurodegeneration: metabolic insights into microglia functions. J Neuroinflammation. 2024;21(1):300.<pub-id pub-id-type="pmid">39551788</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-024-03296-0</pub-id><pub-id pub-id-type="pmcid">PMC11571669</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baik</surname><given-names>SH</given-names></name><etal/></person-group><article-title>A breakdown in metabolic reprogramming causes microglia dysfunction in alzheimer&#8217;s disease</article-title><source>Cell Metab</source><year>2019</year><volume>30</volume><issue>3</issue><fpage>493</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2019.06.005</pub-id><pub-id pub-id-type="pmid">31257151</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Baik SH, et al. A breakdown in metabolic reprogramming causes microglia dysfunction in alzheimer&#8217;s disease. Cell Metab. 2019;30(3):493&#8211;507. .e6.<pub-id pub-id-type="pmid">31257151</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2019.06.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sangineto</surname><given-names>M</given-names></name><etal/></person-group><article-title>Metabolic reprogramming in inflammatory microglia indicates a potential way of targeting inflammation in alzheimer&#8217;s disease</article-title><source>Redox Biol</source><year>2023</year><volume>66</volume><fpage>102846</fpage><pub-id pub-id-type="doi">10.1016/j.redox.2023.102846</pub-id><pub-id pub-id-type="pmid">37586250</pub-id><pub-id pub-id-type="pmcid">PMC10457454</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Sangineto M, et al. Metabolic reprogramming in inflammatory microglia indicates a potential way of targeting inflammation in alzheimer&#8217;s disease. Redox Biol. 2023;66:102846.<pub-id pub-id-type="pmid">37586250</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.redox.2023.102846</pub-id><pub-id pub-id-type="pmcid">PMC10457454</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>RY</given-names></name><etal/></person-group><article-title>Positive feedback regulation of microglial glucose metabolism by histone H4 lysine 12 lactylation in alzheimer&#8217;s disease</article-title><source>Cell Metab</source><year>2022</year><volume>34</volume><issue>4</issue><fpage>634</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2022.02.013</pub-id><pub-id pub-id-type="pmid">35303422</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Pan RY, et al. Positive feedback regulation of microglial glucose metabolism by histone H4 lysine 12 lactylation in alzheimer&#8217;s disease. Cell Metab. 2022;34(4):634&#8211;48. .e6.<pub-id pub-id-type="pmid">35303422</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2022.02.013</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lepiarz-Raba</surname><given-names>I</given-names></name><etal/></person-group><article-title>Metabolic regulation of microglial phagocytosis: implications for alzheimer&#8217;s disease therapeutics</article-title><source>Transl Neurodegener</source><year>2023</year><volume>12</volume><issue>1</issue><fpage>48</fpage><pub-id pub-id-type="doi">10.1186/s40035-023-00382-w</pub-id><pub-id pub-id-type="pmid">37908010</pub-id><pub-id pub-id-type="pmcid">PMC10617244</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Lepiarz-Raba I, et al. Metabolic regulation of microglial phagocytosis: implications for alzheimer&#8217;s disease therapeutics. Transl Neurodegener. 2023;12(1):48.<pub-id pub-id-type="pmid">37908010</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40035-023-00382-w</pub-id><pub-id pub-id-type="pmcid">PMC10617244</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palsson-McDermott</surname><given-names>EM</given-names></name><etal/></person-group><article-title>Pyruvate kinase M2 regulates Hif-1&#945; activity and IL-1&#946; induction and is a critical determinant of the Warburg effect in LPS-activated macrophages</article-title><source>Cell Metab</source><year>2015</year><volume>21</volume><issue>1</issue><fpage>65</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2014.12.005</pub-id><pub-id pub-id-type="pmid">25565206</pub-id><pub-id pub-id-type="pmcid">PMC5198835</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Palsson-McDermott EM, et al. Pyruvate kinase M2 regulates Hif-1&#945; activity and IL-1&#946; induction and is a critical determinant of the Warburg effect in LPS-activated macrophages. Cell Metab. 2015;21(1):65&#8211;80.<pub-id pub-id-type="pmid">25565206</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2014.12.005</pub-id><pub-id pub-id-type="pmcid">PMC5198835</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toller-Kawahisa</surname><given-names>JE</given-names></name><etal/></person-group><article-title>Metabolic reprogramming of macrophages by PKM2 promotes IL-10 production via adenosine</article-title><source>Cell Rep</source><year>2025</year><volume>44</volume><issue>1</issue><fpage>115172</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2024.115172</pub-id><pub-id pub-id-type="pmid">39772395</pub-id><pub-id pub-id-type="pmcid">PMC11781862</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Toller-Kawahisa JE, et al. Metabolic reprogramming of macrophages by PKM2 promotes IL-10 production via adenosine. Cell Rep. 2025;44(1):115172.<pub-id pub-id-type="pmid">39772395</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2024.115172</pub-id><pub-id pub-id-type="pmcid">PMC11781862</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>PKM2, function and expression and regulation</article-title><source>Cell Biosci</source><year>2019</year><volume>9</volume><fpage>52</fpage><pub-id pub-id-type="doi">10.1186/s13578-019-0317-8</pub-id><pub-id pub-id-type="pmid">31391918</pub-id><pub-id pub-id-type="pmcid">PMC6595688</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Zhang Z, et al. PKM2, function and expression and regulation. Cell Biosci. 2019;9:52.<pub-id pub-id-type="pmid">31391918</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13578-019-0317-8</pub-id><pub-id pub-id-type="pmcid">PMC6595688</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>L</given-names></name><etal/></person-group><article-title>Pyruvate kinase isoform M2 impairs cognition in systemic lupus erythematosus by promoting microglial synaptic pruning via the &#946;-catenin signaling pathway</article-title><source>J Neuroinflammation</source><year>2021</year><volume>18</volume><issue>1</issue><fpage>229</fpage><pub-id pub-id-type="doi">10.1186/s12974-021-02279-9</pub-id><pub-id pub-id-type="pmid">34645459</pub-id><pub-id pub-id-type="pmcid">PMC8513209</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Lu L, et al. Pyruvate kinase isoform M2 impairs cognition in systemic lupus erythematosus by promoting microglial synaptic pruning via the &#946;-catenin signaling pathway. J Neuroinflammation. 2021;18(1):229.<pub-id pub-id-type="pmid">34645459</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-021-02279-9</pub-id><pub-id pub-id-type="pmcid">PMC8513209</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>World Medical Association</surname></name></person-group><article-title>Declaration of helsinki: ethical principles for medical research involving human subjects</article-title><source>JAMA</source><year>2013</year><volume>310</volume><issue>20</issue><fpage>2191</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1001/jama.2013.281053</pub-id><pub-id pub-id-type="pmid">24141714</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">World Medical Association. Declaration of helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191&#8211;4.<pub-id pub-id-type="pmid">24141714</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2013.281053</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>W</given-names></name><etal/></person-group><article-title>Standardized operational protocol for human brain banking in China</article-title><source>Neurosci Bull</source><year>2019</year><volume>35</volume><issue>2</issue><fpage>270</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1007/s12264-018-0306-7</pub-id><pub-id pub-id-type="pmid">30411305</pub-id><pub-id pub-id-type="pmcid">PMC6426885</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Qiu W, et al. Standardized operational protocol for human brain banking in China. Neurosci Bull. 2019;35(2):270&#8211;6.<pub-id pub-id-type="pmid">30411305</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12264-018-0306-7</pub-id><pub-id pub-id-type="pmcid">PMC6426885</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montine</surname><given-names>TJ</given-names></name><etal/></person-group><article-title>National Institute on Aging-Alzheimer&#8217;s association guidelines for the neuropathologic assessment of alzheimer&#8217;s disease: a practical approach</article-title><source>Acta Neuropathol</source><year>2012</year><volume>123</volume><issue>1</issue><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1007/s00401-011-0910-3</pub-id><pub-id pub-id-type="pmid">22101365</pub-id><pub-id pub-id-type="pmcid">PMC3268003</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Montine TJ, et al. National Institute on Aging-Alzheimer&#8217;s association guidelines for the neuropathologic assessment of alzheimer&#8217;s disease: a practical approach. Acta Neuropathol. 2012;123(1):1&#8211;11.<pub-id pub-id-type="pmid">22101365</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-011-0910-3</pub-id><pub-id pub-id-type="pmcid">PMC3268003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>SL</given-names></name><etal/></person-group><article-title>Comprehensive cellular-resolution atlas of the adult human brain</article-title><source>J Comp Neurol</source><year>2016</year><volume>524</volume><issue>16</issue><fpage>3127</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.1002/cne.24080</pub-id><pub-id pub-id-type="pmid">27418273</pub-id><pub-id pub-id-type="pmcid">PMC5054943</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Ding SL, et al. Comprehensive cellular-resolution atlas of the adult human brain. J Comp Neurol. 2016;524(16):3127&#8211;481.<pub-id pub-id-type="pmid">27418273</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cne.24080</pub-id><pub-id pub-id-type="pmcid">PMC5054943</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paolicelli</surname><given-names>RC</given-names></name><etal/></person-group><article-title>Microglia States and nomenclature: A field at its crossroads</article-title><source>Neuron</source><year>2022</year><volume>110</volume><issue>21</issue><fpage>3458</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2022.10.020</pub-id><pub-id pub-id-type="pmid">36327895</pub-id><pub-id pub-id-type="pmcid">PMC9999291</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Paolicelli RC, et al. Microglia States and nomenclature: A field at its crossroads. Neuron. 2022;110(21):3458&#8211;83.<pub-id pub-id-type="pmid">36327895</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2022.10.020</pub-id><pub-id pub-id-type="pmcid">PMC9999291</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prater</surname><given-names>KE</given-names></name><etal/></person-group><article-title>Human microglia show unique transcriptional changes in alzheimer&#8217;s disease</article-title><source>Nat Aging</source><year>2023</year><volume>3</volume><issue>7</issue><fpage>894</fpage><lpage>907</lpage><pub-id pub-id-type="doi">10.1038/s43587-023-00424-y</pub-id><pub-id pub-id-type="pmid">37248328</pub-id><pub-id pub-id-type="pmcid">PMC10353942</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Prater KE, et al. Human microglia show unique transcriptional changes in alzheimer&#8217;s disease. Nat Aging. 2023;3(7):894&#8211;907.<pub-id pub-id-type="pmid">37248328</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43587-023-00424-y</pub-id><pub-id pub-id-type="pmcid">PMC10353942</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aikawa</surname><given-names>T</given-names></name><etal/></person-group><article-title>ABCA7 haplodeficiency disturbs microglial immune responses in the mouse brain</article-title><source>Proc Natl Acad Sci U S A</source><year>2019</year><volume>116</volume><issue>47</issue><fpage>23790</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1073/pnas.1908529116</pub-id><pub-id pub-id-type="pmid">31690660</pub-id><pub-id pub-id-type="pmcid">PMC6876254</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Aikawa T, et al. ABCA7 haplodeficiency disturbs microglial immune responses in the mouse brain. Proc Natl Acad Sci U S A. 2019;116(47):23790&#8211;6.<pub-id pub-id-type="pmid">31690660</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1908529116</pub-id><pub-id pub-id-type="pmcid">PMC6876254</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>M</given-names></name><etal/></person-group><article-title>PKM2-dependent Glycolysis promotes NLRP3 and AIM2 inflammasome activation</article-title><source>Nat Commun</source><year>2016</year><volume>7</volume><fpage>13280</fpage><pub-id pub-id-type="doi">10.1038/ncomms13280</pub-id><pub-id pub-id-type="pmid">27779186</pub-id><pub-id pub-id-type="pmcid">PMC5093342</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Xie M, et al. PKM2-dependent Glycolysis promotes NLRP3 and AIM2 inflammasome activation. Nat Commun. 2016;7:13280.<pub-id pub-id-type="pmid">27779186</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms13280</pub-id><pub-id pub-id-type="pmcid">PMC5093342</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>PKM2-mediated metabolic reprogramming of microglia in neuroinflammation</article-title><source>Cell Death Discov</source><year>2025</year><volume>11</volume><issue>1</issue><fpage>149</fpage><pub-id pub-id-type="doi">10.1038/s41420-025-02453-5</pub-id><pub-id pub-id-type="pmid">40189596</pub-id><pub-id pub-id-type="pmcid">PMC11973174</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Zhang Q, et al. PKM2-mediated metabolic reprogramming of microglia in neuroinflammation. Cell Death Discov. 2025;11(1):149.<pub-id pub-id-type="pmid">40189596</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41420-025-02453-5</pub-id><pub-id pub-id-type="pmcid">PMC11973174</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balig&#225;cs</surname><given-names>N</given-names></name><etal/></person-group><article-title>Homeostatic microglia initially seed and activated microglia later reshape amyloid plaques in alzheimer&#8217;s disease</article-title><source>Nat Commun</source><year>2024</year><volume>15</volume><issue>1</issue><fpage>10634</fpage><pub-id pub-id-type="doi">10.1038/s41467-024-54779-w</pub-id><pub-id pub-id-type="pmid">39639016</pub-id><pub-id pub-id-type="pmcid">PMC11621353</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Balig&#225;cs N, et al. Homeostatic microglia initially seed and activated microglia later reshape amyloid plaques in alzheimer&#8217;s disease. Nat Commun. 2024;15(1):10634.<pub-id pub-id-type="pmid">39639016</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-024-54779-w</pub-id><pub-id pub-id-type="pmcid">PMC11621353</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsering</surname><given-names>W</given-names></name><etal/></person-group><article-title>Preferential clustering of microglia and astrocytes around neuritic plaques during progression of alzheimer&#8217;s disease neuropathological changes</article-title><source>J Neurochem</source><year>2025</year><volume>169</volume><issue>1</issue><fpage>e16275</fpage><pub-id pub-id-type="doi">10.1111/jnc.16275</pub-id><pub-id pub-id-type="pmid">39655787</pub-id><pub-id pub-id-type="pmcid">PMC11629606</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Tsering W, et al. Preferential clustering of microglia and astrocytes around neuritic plaques during progression of alzheimer&#8217;s disease neuropathological changes. J Neurochem. 2025;169(1):e16275.<pub-id pub-id-type="pmid">39655787</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jnc.16275</pub-id><pub-id pub-id-type="pmcid">PMC11629606</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lau</surname><given-names>SF</given-names></name><etal/></person-group><article-title>The VCAM1-ApoE pathway directs microglial chemotaxis and alleviates alzheimer&#8217;s disease pathology</article-title><source>Nat Aging</source><year>2023</year><volume>3</volume><issue>10</issue><fpage>1219</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1038/s43587-023-00491-1</pub-id><pub-id pub-id-type="pmid">37735240</pub-id><pub-id pub-id-type="pmcid">PMC10570140</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Lau SF, et al. The VCAM1-ApoE pathway directs microglial chemotaxis and alleviates alzheimer&#8217;s disease pathology. Nat Aging. 2023;3(10):1219&#8211;36.<pub-id pub-id-type="pmid">37735240</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43587-023-00491-1</pub-id><pub-id pub-id-type="pmcid">PMC10570140</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Microglia use TAM receptors to detect and engulf amyloid &#946; plaques</article-title><source>Nat Immunol</source><year>2021</year><volume>22</volume><issue>5</issue><fpage>586</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1038/s41590-021-00913-5</pub-id><pub-id pub-id-type="pmid">33859405</pub-id><pub-id pub-id-type="pmcid">PMC8102389</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Huang Y, et al. Microglia use TAM receptors to detect and engulf amyloid &#946; plaques. Nat Immunol. 2021;22(5):586&#8211;94.<pub-id pub-id-type="pmid">33859405</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41590-021-00913-5</pub-id><pub-id pub-id-type="pmcid">PMC8102389</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miao</surname><given-names>J</given-names></name><etal/></person-group><article-title>Microglial metabolic reprogramming: emerging insights and therapeutic strategies in neurodegenerative diseases</article-title><source>Cell Mol Neurobiol</source><year>2023</year><volume>43</volume><issue>7</issue><fpage>3191</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1007/s10571-023-01376-y</pub-id><pub-id pub-id-type="pmid">37341833</pub-id><pub-id pub-id-type="pmcid">PMC11410021</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Miao J, et al. Microglial metabolic reprogramming: emerging insights and therapeutic strategies in neurodegenerative diseases. Cell Mol Neurobiol. 2023;43(7):3191&#8211;210.<pub-id pub-id-type="pmid">37341833</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10571-023-01376-y</pub-id><pub-id pub-id-type="pmcid">PMC11410021</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shahidehpour</surname><given-names>RK</given-names></name><etal/></person-group><article-title>Exploring the link between dystrophic microglia and the spread of alzheimer&#8217;s neuropathology</article-title><source>Brain</source><year>2025</year><volume>148</volume><issue>1</issue><fpage>89</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1093/brain/awae258</pub-id><pub-id pub-id-type="pmid">39101580</pub-id><pub-id pub-id-type="pmcid">PMC11706277</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Shahidehpour RK, et al. Exploring the link between dystrophic microglia and the spread of alzheimer&#8217;s neuropathology. Brain. 2025;148(1):89&#8211;101.<pub-id pub-id-type="pmid">39101580</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awae258</pub-id><pub-id pub-id-type="pmcid">PMC11706277</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>St-Pierre</surname><given-names>MK</given-names></name><etal/></person-group><article-title>Ultrastructural characterization of dark microglia during aging in a mouse model of alzheimer&#8217;s disease pathology and in human post-mortem brain samples</article-title><source>J Neuroinflammation</source><year>2022</year><volume>19</volume><issue>1</issue><fpage>235</fpage><pub-id pub-id-type="doi">10.1186/s12974-022-02595-8</pub-id><pub-id pub-id-type="pmid">36167544</pub-id><pub-id pub-id-type="pmcid">PMC9513936</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">St-Pierre MK, et al. Ultrastructural characterization of dark microglia during aging in a mouse model of alzheimer&#8217;s disease pathology and in human post-mortem brain samples. J Neuroinflammation. 2022;19(1):235.<pub-id pub-id-type="pmid">36167544</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-022-02595-8</pub-id><pub-id pub-id-type="pmcid">PMC9513936</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kozberg</surname><given-names>MG</given-names></name><etal/></person-group><article-title>Blood-brain barrier leakage and perivascular inflammation in cerebral amyloid angiopathy</article-title><source>Brain Commun</source><year>2022</year><volume>4</volume><issue>5</issue><fpage>fcac245</fpage><pub-id pub-id-type="doi">10.1093/braincomms/fcac245</pub-id><pub-id pub-id-type="pmid">36267331</pub-id><pub-id pub-id-type="pmcid">PMC9576155</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Kozberg MG, et al. Blood-brain barrier leakage and perivascular inflammation in cerebral amyloid angiopathy. Brain Commun. 2022;4(5):fcac245.<pub-id pub-id-type="pmid">36267331</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/braincomms/fcac245</pub-id><pub-id pub-id-type="pmcid">PMC9576155</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Munsterman</surname><given-names>D</given-names></name><etal/></person-group><article-title>Cerebral amyloid angiopathy and the immune system</article-title><source>Alzheimers Dement</source><year>2024</year><volume>20</volume><issue>7</issue><fpage>4999</fpage><lpage>5008</lpage><pub-id pub-id-type="doi">10.1002/alz.13826</pub-id><pub-id pub-id-type="pmid">38881491</pub-id><pub-id pub-id-type="pmcid">PMC11247707</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Munsterman D, et al. Cerebral amyloid angiopathy and the immune system. Alzheimers Dement. 2024;20(7):4999&#8211;5008.<pub-id pub-id-type="pmid">38881491</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13826</pub-id><pub-id pub-id-type="pmcid">PMC11247707</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="other">Alkhalifa AE et al. Blood-Brain Barrier Breakdown in Alzheimer&#8217;s Disease: Mechanisms and Targeted Strategies. Int J Mol Sci, 2023. 24(22).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms242216288</pub-id><pub-id pub-id-type="pmcid">PMC10671257</pub-id><pub-id pub-id-type="pmid">38003477</pub-id></mixed-citation></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Schepper</surname><given-names>S</given-names></name><etal/></person-group><article-title>Perivascular cells induce microglial phagocytic States and synaptic engulfment via SPP1 in mouse models of alzheimer&#8217;s disease</article-title><source>Nat Neurosci</source><year>2023</year><volume>26</volume><issue>3</issue><fpage>406</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1038/s41593-023-01257-z</pub-id><pub-id pub-id-type="pmid">36747024</pub-id><pub-id pub-id-type="pmcid">PMC9991912</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">De Schepper S, et al. Perivascular cells induce microglial phagocytic States and synaptic engulfment via SPP1 in mouse models of alzheimer&#8217;s disease. Nat Neurosci. 2023;26(3):406&#8211;15.<pub-id pub-id-type="pmid">36747024</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41593-023-01257-z</pub-id><pub-id pub-id-type="pmcid">PMC9991912</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mayer</surname><given-names>MG</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>T</given-names></name></person-group><article-title>Microglia at the blood brain barrier in health and disease</article-title><source>Front Cell Neurosci</source><year>2024</year><volume>18</volume><fpage>1360195</fpage><pub-id pub-id-type="doi">10.3389/fncel.2024.1360195</pub-id><pub-id pub-id-type="pmid">38550920</pub-id><pub-id pub-id-type="pmcid">PMC10976855</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Mayer MG, Fischer T. Microglia at the blood brain barrier in health and disease. Front Cell Neurosci. 2024;18:1360195.<pub-id pub-id-type="pmid">38550920</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fncel.2024.1360195</pub-id><pub-id pub-id-type="pmcid">PMC10976855</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonnar</surname><given-names>O</given-names></name><name name-style="western"><surname>Eyre</surname><given-names>B</given-names></name><name name-style="western"><surname>van Veluw</surname><given-names>SJ</given-names></name></person-group><article-title>Perivascular brain clearance as a therapeutic target in cerebral amyloid angiopathy and alzheimer&#8217;s disease</article-title><source>Neurotherapeutics</source><year>2025</year><volume>22</volume><issue>3</issue><fpage>e00535</fpage><pub-id pub-id-type="doi">10.1016/j.neurot.2025.e00535</pub-id><pub-id pub-id-type="pmid">39890534</pub-id><pub-id pub-id-type="pmcid">PMC12047398</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Bonnar O, Eyre B, van Veluw SJ. Perivascular brain clearance as a therapeutic target in cerebral amyloid angiopathy and alzheimer&#8217;s disease. Neurotherapeutics. 2025;22(3):e00535.<pub-id pub-id-type="pmid">39890534</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurot.2025.e00535</pub-id><pub-id pub-id-type="pmcid">PMC12047398</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marschallinger</surname><given-names>J</given-names></name><etal/></person-group><article-title>Lipid-droplet-accumulating microglia represent a dysfunctional and Proinflammatory state in the aging brain</article-title><source>Nat Neurosci</source><year>2020</year><volume>23</volume><issue>2</issue><fpage>194</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1038/s41593-019-0566-1</pub-id><pub-id pub-id-type="pmid">31959936</pub-id><pub-id pub-id-type="pmcid">PMC7595134</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Marschallinger J, et al. Lipid-droplet-accumulating microglia represent a dysfunctional and Proinflammatory state in the aging brain. Nat Neurosci. 2020;23(2):194&#8211;208.<pub-id pub-id-type="pmid">31959936</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41593-019-0566-1</pub-id><pub-id pub-id-type="pmcid">PMC7595134</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J</given-names></name><etal/></person-group><article-title>Microglial REV-ERB&#945; regulates inflammation and lipid droplet formation to drive tauopathy in male mice</article-title><source>Nat Commun</source><year>2023</year><volume>14</volume><issue>1</issue><fpage>5197</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-40927-1</pub-id><pub-id pub-id-type="pmid">37626048</pub-id><pub-id pub-id-type="pmcid">PMC10457319</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Lee J, et al. Microglial REV-ERB&#945; regulates inflammation and lipid droplet formation to drive tauopathy in male mice. Nat Commun. 2023;14(1):5197.<pub-id pub-id-type="pmid">37626048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-40927-1</pub-id><pub-id pub-id-type="pmcid">PMC10457319</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heneka</surname><given-names>MT</given-names></name><etal/></person-group><article-title>Neuroinflammation in alzheimer disease</article-title><source>Nat Rev Immunol</source><year>2025</year><volume>25</volume><issue>5</issue><fpage>321</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1038/s41577-024-01104-7</pub-id><pub-id pub-id-type="pmid">39653749</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Heneka MT, et al. Neuroinflammation in alzheimer disease. Nat Rev Immunol. 2025;25(5):321&#8211;52.<pub-id pub-id-type="pmid">39653749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-024-01104-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fairley</surname><given-names>LH</given-names></name><etal/></person-group><article-title>Mitochondrial control of microglial phagocytosis by the translocator protein and hexokinase 2 in alzheimer&#8217;s disease</article-title><source>Proc Natl Acad Sci U S A</source><year>2023</year><volume>120</volume><issue>8</issue><fpage>e2209177120</fpage><pub-id pub-id-type="doi">10.1073/pnas.2209177120</pub-id><pub-id pub-id-type="pmid">36787364</pub-id><pub-id pub-id-type="pmcid">PMC9974442</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Fairley LH, et al. Mitochondrial control of microglial phagocytosis by the translocator protein and hexokinase 2 in alzheimer&#8217;s disease. Proc Natl Acad Sci U S A. 2023;120(8):e2209177120.<pub-id pub-id-type="pmid">36787364</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2209177120</pub-id><pub-id pub-id-type="pmcid">PMC9974442</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jung</surname><given-names>ES</given-names></name><name name-style="western"><surname>Choi</surname><given-names>H</given-names></name><name name-style="western"><surname>Mook-Jung</surname><given-names>I</given-names></name></person-group><article-title>Decoding microglial immunometabolism: a new frontier in alzheimer&#8217;s disease research</article-title><source>Mol Neurodegener</source><year>2025</year><volume>20</volume><issue>1</issue><fpage>37</fpage><pub-id pub-id-type="doi">10.1186/s13024-025-00825-0</pub-id><pub-id pub-id-type="pmid">40149001</pub-id><pub-id pub-id-type="pmcid">PMC11948825</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Jung ES, Choi H, Mook-Jung I. Decoding microglial immunometabolism: a new frontier in alzheimer&#8217;s disease research. Mol Neurodegener. 2025;20(1):37.<pub-id pub-id-type="pmid">40149001</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-025-00825-0</pub-id><pub-id pub-id-type="pmcid">PMC11948825</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Reducing microglial lipid load enhances &#946; amyloid phagocytosis in an alzheimer&#8217;s disease mouse model</article-title><source>Sci Adv</source><year>2025</year><volume>11</volume><issue>6</issue><fpage>eadq6038</fpage><pub-id pub-id-type="doi">10.1126/sciadv.adq6038</pub-id><pub-id pub-id-type="pmid">39908361</pub-id><pub-id pub-id-type="pmcid">PMC11797491</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Wu X, et al. Reducing microglial lipid load enhances &#946; amyloid phagocytosis in an alzheimer&#8217;s disease mouse model. Sci Adv. 2025;11(6):eadq6038.<pub-id pub-id-type="pmid">39908361</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.adq6038</pub-id><pub-id pub-id-type="pmcid">PMC11797491</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>J</given-names></name><etal/></person-group><article-title>TRPV1 sustains microglial metabolic reprogramming in alzheimer&#8217;s disease</article-title><source>EMBO Rep</source><year>2021</year><volume>22</volume><issue>6</issue><fpage>e52013</fpage><pub-id pub-id-type="doi">10.15252/embr.202052013</pub-id><pub-id pub-id-type="pmid">33998138</pub-id><pub-id pub-id-type="pmcid">PMC8183394</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Lu J, et al. TRPV1 sustains microglial metabolic reprogramming in alzheimer&#8217;s disease. EMBO Rep. 2021;22(6):e52013.<pub-id pub-id-type="pmid">33998138</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/embr.202052013</pub-id><pub-id pub-id-type="pmcid">PMC8183394</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>X</given-names></name><etal/></person-group><article-title>TEPP-46 inhibits Glycolysis to promote M2 polarization of microglia after ischemic stroke</article-title><source>Int Immunopharmacol</source><year>2025</year><volume>149</volume><fpage>114148</fpage><pub-id pub-id-type="doi">10.1016/j.intimp.2025.114148</pub-id><pub-id pub-id-type="pmid">39904037</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Xia X, et al. TEPP-46 inhibits Glycolysis to promote M2 polarization of microglia after ischemic stroke. Int Immunopharmacol. 2025;149:114148.<pub-id pub-id-type="pmid">39904037</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.intimp.2025.114148</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>P</given-names></name><etal/></person-group><article-title>A tetravalent TREM2 agonistic antibody reduced amyloid pathology in a mouse model of alzheimer&#8217;s disease</article-title><source>Sci Transl Med</source><year>2022</year><volume>14</volume><issue>661</issue><fpage>eabq0095</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.abq0095</pub-id><pub-id pub-id-type="pmid">36070367</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Zhao P, et al. A tetravalent TREM2 agonistic antibody reduced amyloid pathology in a mouse model of alzheimer&#8217;s disease. Sci Transl Med. 2022;14(661):eabq0095.<pub-id pub-id-type="pmid">36070367</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.abq0095</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Lengerich</surname><given-names>B</given-names></name><etal/></person-group><article-title>A TREM2-activating antibody with a blood-brain barrier transport vehicle enhances microglial metabolism in alzheimer&#8217;s disease models</article-title><source>Nat Neurosci</source><year>2023</year><volume>26</volume><issue>3</issue><fpage>416</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">36635496</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41593-022-01240-0</pub-id><pub-id pub-id-type="pmcid">PMC9991924</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">van Lengerich B, et al. A TREM2-activating antibody with a blood-brain barrier transport vehicle enhances microglial metabolism in alzheimer&#8217;s disease models. Nat Neurosci. 2023;26(3):416&#8211;29.<pub-id pub-id-type="pmid">36635496</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41593-022-01240-0</pub-id><pub-id pub-id-type="pmcid">PMC9991924</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kraller</surname><given-names>M</given-names></name><etal/></person-group><article-title>Novel fully human high-affinity anti-TREM2 antibody shows efficacy in clinically relevant alzheimer&#180;s mouse model</article-title><source>Alzheimers Res Ther</source><year>2025</year><volume>17</volume><issue>1</issue><fpage>114</fpage><pub-id pub-id-type="doi">10.1186/s13195-025-01759-x</pub-id><pub-id pub-id-type="pmid">40405265</pub-id><pub-id pub-id-type="pmcid">PMC12096560</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Kraller M, et al. Novel fully human high-affinity anti-TREM2 antibody shows efficacy in clinically relevant alzheimer&#180;s mouse model. Alzheimers Res Ther. 2025;17(1):114.<pub-id pub-id-type="pmid">40405265</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-025-01759-x</pub-id><pub-id pub-id-type="pmcid">PMC12096560</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McManus</surname><given-names>RM</given-names></name><etal/></person-group><article-title>NLRP3-mediated Glutaminolysis controls microglial phagocytosis to promote alzheimer&#8217;s disease progression</article-title><source>Immunity</source><year>2025</year><volume>58</volume><issue>2</issue><fpage>326</fpage><lpage>e34311</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2025.01.007</pub-id><pub-id pub-id-type="pmid">39904338</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">McManus RM, et al. NLRP3-mediated Glutaminolysis controls microglial phagocytosis to promote alzheimer&#8217;s disease progression. Immunity. 2025;58(2):326&#8211;e34311.<pub-id pub-id-type="pmid">39904338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2025.01.007</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cell Mol Neurobiol</journal-id><journal-id journal-id-type="iso-abbrev">Cell Mol Neurobiol</journal-id><journal-id journal-id-type="pmc-domain-id">4635</journal-id><journal-id journal-id-type="pmc-domain">cmneuro</journal-id><journal-title-group><journal-title>Cellular and Molecular Neurobiology</journal-title></journal-title-group><issn pub-type="ppub">0272-4340</issn><issn pub-type="epub">1573-6830</issn><publisher><publisher-name>Springer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12494529</article-id><article-id pub-id-type="pmcid-ver">PMC12494529.1</article-id><article-id pub-id-type="pmcaid">12494529</article-id><article-id pub-id-type="pmcaiid">12494529</article-id><article-id pub-id-type="pmid">41042431</article-id><article-id pub-id-type="doi">10.1007/s10571-025-01601-w</article-id><article-id pub-id-type="publisher-id">1601</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Paper</subject></subj-group></article-categories><title-group><article-title>Uncovering Necroptosis in Alzheimer&#8217;s Disease: A Systematic Review of Evidence Across Experimental Models</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0009-0001-7098-1620</contrib-id><name name-style="western"><surname>Shah</surname><given-names initials="N">Nishi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-5404-2607</contrib-id><name name-style="western"><surname>Natesan</surname><given-names initials="G">Gopal</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-4608-2745</contrib-id><name name-style="western"><surname>Gupta</surname><given-names initials="R">Richa</given-names></name><address><email>richa.gupta@nirmauni.ac.in</email><email>richa1771@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05qkq7x38</institution-id><institution-id institution-id-type="GRID">grid.412204.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 1792 2351</institution-id><institution>Department of Pharmacology, Institute of Pharmacy, </institution><institution>Nirma University, </institution></institution-wrap>Sarkhej-Gandhinagar Hwy, Gota, Ahmedabad, Gujarat 382481 India </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05qkq7x38</institution-id><institution-id institution-id-type="GRID">grid.412204.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 1792 2351</institution-id><institution>Department of Pharmaceutical Chemistry, Institute of Pharmacy, </institution><institution>Nirma University, </institution></institution-wrap>Sarkhej-Gandhinagar Hwy, Gota, Ahmedabad, Gujarat 382481 India </aff></contrib-group><pub-date pub-type="epub"><day>3</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2025</year></pub-date><volume>45</volume><issue-id pub-id-type="pmc-issue-id">484138</issue-id><elocation-id>83</elocation-id><history><date date-type="received"><day>12</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>13</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>05</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-05 00:26:29.067"><day>05</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="10571_2025_Article_1601.pdf"/><abstract id="Abs1"><p id="Par1">Alzheimer's disease (AD), one of the most challenging neurodegenerative disorders, with high prevalence worldwide, is characterized by progressive cognitive decline and accumulation of amyloid-&#946; plaques and neurofibrillary tau tangles. Despite significant research, the limited efficacy of current treatments underscores the critical need to identify novel pathogenic mechanisms and therapeutic targets. Necroptosis, a regulated and highly inflammatory form of programmed cell death, has emerged as one of the key contributors to AD pathogenesis. This systematic review comprises 25 high-quality in vivo, in vitro, and autopsy studies, published between 2015 and 2025, extracted from PubMed, Scopus, and Science Direct databases. The keywords include "necroptosis", "RIPK1", "RIPK3", "MLKL", "pMLKL", "necroptosis inhibitors", "Alzheimer&#8217;s disease", and "neurodegeneration". The review summarizes the multiple molecular mechanisms, including TNF-&#945;/TNFR1 signaling, TRIF-mediated RIPK3 activation, and RHIM-dependent MLKL phosphorylation, associated with necroptosis in the pathogenesis of AD. All the studies converge on necroptosis as a central pathogenic pathway linking key molecular and cellular abnormalities observed in AD. The accumulated evidence strongly supports prioritizing the development of brain-penetrant necroptosis inhibitors and clinical validation of associated biomarkers. These insights signal a significant shift in AD therapeutics, moving from symptomatic treatment to mechanistically targeted interventions that can alter disease progression.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Alzheimer&#8217;s disease</kwd><kwd>Necroptosis</kwd><kwd>Programmed cell death</kwd><kwd>Amyloid-&#946;</kwd><kwd>RIPK1</kwd><kwd>RIPK3</kwd><kwd>MLKL</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Science+Business Media, LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Alzheimer&#8217;s disease, the most prevalent form of dementia, represents a growing global public health challenge with significant medical, social, and economic implications. Clinically, AD is characterized by a progressive deterioration in memory, cognition, language, and functional capacity, with early manifestations often including subtle symptoms such as forgetfulness, impaired judgment, and difficulties with planning or spatial orientation (Al-Kuraishy et al. <xref ref-type="bibr" rid="CR2">2025a</xref>; Livingston et al. <xref ref-type="bibr" rid="CR52">2024</xref>). More than 55 million individuals globally are living with dementia, with AD accounting for approximately 60&#8211;70% of cases (Gustavsson et al. <xref ref-type="bibr" rid="CR34">2023</xref>; Zhang et al. <xref ref-type="bibr" rid="CR98">2025</xref>). This figure is projected to rise to 78 million by 2030 and 139 million by 2050, driven largely by aging populations, particularly in low and middle-income countries, where over 60% of individuals with dementia currently reside (Chen et al. <xref ref-type="bibr" rid="CR16">2024a</xref>, <xref ref-type="bibr" rid="CR18">b</xref>; Thapa et al. <xref ref-type="bibr" rid="CR84">2024</xref>). The economic burden of AD is equally substantial, with global costs expected to surpass $1 trillion annually by 2050, much of which stems from informal caregiving (Mahboob et al. <xref ref-type="bibr" rid="CR54">2024</xref>). In the United States, approximately 6.9 million adults aged 65&#160;years and older were living with AD in 2024, a number anticipated to rise to 13.8 million by 2060 in the absence of effective preventive or disease-modifying therapies (Conic et al. <xref ref-type="bibr" rid="CR22">2025</xref>). Additionally, AD ranks as the fifth leading cause of death among older adults in the U.S., accounting for more than 119,000 deaths in 2021, a 141% increase since 2000 (Mobaderi et al. <xref ref-type="bibr" rid="CR59">2024</xref>).These statistics underscore the urgent need for the broad implementation of preventive strategies to mitigate the growing human and economic toll of Alzheimer&#8217;s disease.</p><p id="Par3">The pathophysiological landscape of AD is governed by a multifactorial interplay of molecular and cellular disruptions that collectively lead to progressive neurodegeneration (Jiang et al. <xref ref-type="bibr" rid="CR40">2025a</xref>, <xref ref-type="bibr" rid="CR41">b</xref>). One of the earliest and most salient features is the deposition of extracellular beta-amyloid (A&#946;) plaques, which are the product of the aberrant cleavage of amyloid precursor protein (APP) by &#946;-secretase (BACE1) and &#947;-secretase (Al-Kuraishy et al. <xref ref-type="bibr" rid="CR3">2025b</xref>, <xref ref-type="bibr" rid="CR4">c</xref>). These neurotoxic aggregates disrupt synaptic function, trigger innate immune responses, and set off a cascade of chronic neuroinflammation (Azargoonjahromi <xref ref-type="bibr" rid="CR7">2024</xref>). Neuroinflammation further amplifies this degenerative cascade. Initially, a protective mechanism, sustained activation of microglia and astrocytes in the presence of A&#946; and tau aggregates, results in the persistent release of pro-inflammatory mediators such as tumor necrosis factor-&#945;, interleukin-1, and interleukin-6, which contribute to neuronal damage and synaptic loss (Dias et al. <xref ref-type="bibr" rid="CR25">2025</xref>). Hyperphosphorylated tau, another major pathological hallmark, dissociates from microtubules and forms intracellular neurofibrillary tangles (NFTs), disrupting axonal transport and cytoskeletal stability (Abubakar et al. <xref ref-type="bibr" rid="CR1">2025</xref>; Alsubaie et al. <xref ref-type="bibr" rid="CR5">2022</xref>; Jiang et al. <xref ref-type="bibr" rid="CR40">2025a</xref>, <xref ref-type="bibr" rid="CR41">b</xref>). The spread of pathological tau through prion-like mechanisms further exacerbates neuronal damage and is closely associated with the progression of cognitive decline (Pandey et al. <xref ref-type="bibr" rid="CR69">2025</xref>). Moreover, oxidative stress and mitochondrial dysfunction also play pivotal roles in the disease progression. Mitochondrial dysfunction fails to meet the high-energy demands of neurons, rendering them increasingly susceptible to apoptotic and necrotic processes (Singh and Dilawari <xref ref-type="bibr" rid="CR80">2025</xref>). In addition to mitochondrial failure, dysregulation of calcium homeostasis, endoplasmic reticulum stress, and defective autophagy-lysosomal pathways contribute to neuronal injury in AD (Angst et al. <xref ref-type="bibr" rid="CR6">2025</xref>). Genetic influences further modulate the risk and onset of the&#160;disease. Mutations in APP, presenilin 1&#160;(PSEN1), and presenilin 2 (PSEN2) are associated with early onset familial AD, which accounts for approximately 10% and is characterized by excessive A&#946; production, while the apolipoprotein &#949;4 (APOE &#949;4) allele remains the most significant genetic risk factor for late-onset AD, accounting for about 90% of cases, which is primarily linked to impaired A&#946; clearance and is strongly associated with aging (Al-Kuraishy et al. <xref ref-type="bibr" rid="CR3">2025b</xref>; Nan et al. <xref ref-type="bibr" rid="CR65">2025</xref>). Besides genetic factors, environmental and lifestyle factors such as exposure to neurotoxicants, poor diet, physical inactivity, and disrupted sleep patterns also influence disease susceptibility and progression. The initiation of complex pathological processes in Alzheimer&#8217;s disease often precedes clinical symptoms by years or even decades, emphasizing the critical need for early detection and therapeutic strategies that effectively target the molecular drivers of disease progression (Wo&#378;niak et al. <xref ref-type="bibr" rid="CR91">2024</xref>).</p><p id="Par4">Neuronal cell death is a hallmark feature of AD, and for many years, this degeneration was predominantly attributed to classical mechanisms of cell death, namely, apoptosis and necrosis (Homma et al. <xref ref-type="bibr" rid="CR37">2024</xref>). Apoptosis, a genetically programmed and energy-dependent process, plays a critical role in maintaining cellular homeostasis by eliminating damaged or dysfunctional cells in a highly controlled and non-inflammatory manner (Ekundayo et al. <xref ref-type="bibr" rid="CR28">2024</xref>). Morphologically, it is characterized by cell shrinkage, chromatin condensation, DNA fragmentation, and membrane blebbing, ultimately resulting in phagocytic clearance without triggering an immune response (Guo et al. <xref ref-type="bibr" rid="CR33">2024</xref>). In contrast, necrosis represents an uncontrolled, passive form of cell death usually induced by severe cellular stress or injury, such as oxidative damage, excitotoxicity, or energy failure (Zhang and Niu <xref ref-type="bibr" rid="CR99">2024</xref>). Necrotic cells typically undergo rapid swelling, membrane rupture, and subsequent release of intracellular contents into the surrounding tissue, provoking a robust inflammatory response (Homma et al. <xref ref-type="bibr" rid="CR37">2024</xref>). While both mechanisms have been observed in AD, they fail to fully explain the complex patterns of neuronal loss and neuroinflammation characteristic of the disease. Consequently, recent research has shifted toward exploring newly identified, regulated forms of programmed cell death, including necroptosis, ferroptosis, pyroptosis, parthanatos, oxeiptosis, cuproptosis, and alkaliptosis (Yao Chen et al. <xref ref-type="bibr" rid="CR16">2024a</xref>, <xref ref-type="bibr" rid="CR18">b</xref>).</p><p id="Par5">Among these, necroptosis, a programmed cell death, is typically characterized by both necroptosis and apoptosis, and is triggered when apoptotic pathways are blocked, which leads to the activation of key molecules involved in necroptosis, is RIPK1, RIPK3, and MLKL (Yuan and Ofengeim <xref ref-type="bibr" rid="CR95">2024</xref>). In contrast to apoptosis, which does not start an immune response, necroptosis is linked to disruption of plasma membranes and consequent release of damage-associated molecular patterns like ATP, HMGB1, and mitochondrial DNA, leading to a robust inflammatory response (Nakano et al. <xref ref-type="bibr" rid="CR64">2022</xref>). The process starts with the help of death receptors like TNF, Fas, and TLRs. When these receptors are activated and apoptosis is inhibited, generally due to caspase-8 blockage, RIPK1 interacts with RIPK3 to form the necrosome, which further activates MLKL, leading to cell membrane disruption and necroptotic cell death (Seo et al. <xref ref-type="bibr" rid="CR78">2021</xref>). Necroptosis has also been implicated in various diseases like ischemic stroke, myocardial infarction, inflammatory bowel disease, retinal degeneration, infectious diseases, and certain cancers, where it amplifies tissue damage through uncontrolled inflammation (Dai et al. <xref ref-type="bibr" rid="CR23">2021</xref>). Emerging evidence has also implicated necroptosis in the progression of multiple neurodegenerative diseases such as AD, Parkinson&#8217;s disease, Amyotrophic lateral sclerosis, and Multiple sclerosis, causing neuronal damage and death (Thadathil et al. <xref ref-type="bibr" rid="CR83">2021</xref>). These results collectively implicate necroptosis as a key contributor to neuronal death and neuroinflammation in various neurological disorders.</p><p id="Par6">In AD, increasing evidence supports a role for necroptosis in neuronal death and neuroinflammation. Elevated levels of RIPK1, RIPK3, and phosphorylated MLKL have been identified in postmortem AD brains, linking necroptosis with disease severity (Zhang et al. <xref ref-type="bibr" rid="CR100">2023</xref>). Amyloid-&#946; and tau aggregates appear to trigger this pathway via oxidative stress, mitochondrial dysfunction, and microglial activation, while DAMP release sustains microglial activation in a vicious inflammatory cycle (Choi et al. <xref ref-type="bibr" rid="CR21">2023</xref>). Emerging research illuminates how necroptosis is intricately linked with key AD pathologies amyloid&#8209;&#946; aggregation, tau hyperphosphorylation, oxidative stress, and neuroinflammation, though these interactions remain under&#8209;explored. A&#946; oligomers (A&#946;o), rather than insoluble fibrils, have been shown to activate necroptosis via TNF-&#945;/TNFR1 signaling in microglia, triggering RIPK1/RIPK3/MLKL activation in neurons (Salvadores et al. <xref ref-type="bibr" rid="CR76">2022</xref>). Intriguingly, the RIPK1&#8211;RIPK3 necrosome itself forms amyloid-like fibril structures that enhance cell surface expression of APP processing products (sA&#946;PP&#946;), promoting further A&#946; plaque formation (Zhang et al. <xref ref-type="bibr" rid="CR100">2023</xref>). Hyperphosphorylated tau is also a direct activator of necroptosis. Studies in AD mouse models and cell culture reveal that pTau induces RIPK1/RIPK3/MLKL activation and concurrently stimulates NF-&#954;B-driven pro-inflammatory cytokine production, which further amplifies microglial activation and neuronal damage (Zhang et al. <xref ref-type="bibr" rid="CR100">2023</xref>). Further, oxidative stress and mitochondrial dysfunction both contribute to and are amplified by necroptosis. Mitochondrial damage induced by necroptosis raises ROS levels, reinforcing mitochondrial dysfunction and promoting neuron vulnerability. Elevated ROS may also facilitate RIPK1 activation by damaging redox-sensitive inhibitory pathways (Richard and Mousa <xref ref-type="bibr" rid="CR74">2022</xref>). Moreover, necroptosis actively drives neuroinflammation. DAMPs released during necroptotic neuronal death (e.g., HMGB1, ATP) activate microglia toward a pro-inflammatory M1 phenotype (Kaur et al. <xref ref-type="bibr" rid="CR43">2023</xref>). In AD models, inhibition of RIPK1 signaling reduces M1 microglial markers and inflammatory cytokines, promoting microglial phenotypic shift toward the anti-inflammatory, A&#946;-clearing M2 state (Zhang et al. <xref ref-type="bibr" rid="CR100">2023</xref>). Thus, inhibition of necroptosis offers a promising therapeutic approach, with antagonists such as necrostatin-1 and RIPK1 inhibitors currently being explored for their neuroprotective effects (Kang et al. <xref ref-type="bibr" rid="CR42">2025</xref>). Understanding these interactions in an integrated manner would not only deepen insight into AD pathogenesis but also enhance the precision of targeted therapies (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>Schematic Representation of the Role of Necroptosis in Alzheimer&#8217;s Disease</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="10571_2025_1601_Fig1_HTML.jpg"/></fig></p><p id="Par7">Figure <xref rid="Fig1" ref-type="fig">1</xref>&#160;depicts the role of necroptosis in Alzheimer&#8217;s disease pathogenesis. It illustrates how core AD pathologies like amyloid-beta plaques, tau protein, and microglial activation converge to activate RIPK1, RIPK3, and MLKL, initiating necroptosis. This regulated cell death further drives a vicious cycle of neurodegeneration, contributing to inflammation, oxidative stress, blood&#8211;brain barrier disruption, synaptic loss, mitochondrial dysfunction, and increased hyperphosphorylated tau, culminating in widespread neuronal death. This systematic review&#160;examines the growing evidences and&#160;emerging role of necroptosis in the pathogenesis of AD. The review compiles findings from both preclinical and clinical studies that establish links between necroptosis and hallmark AD pathologies, including amyloid-&#946; accumulation, tau hyperphosphorylation, microglial activation, and blood&#8211;brain barrier disruption. It further explores the initiation and execution of the necroptotic pathway, different pathway involves in necroptosis leading to neurodegeneration, detailing the role of MLKL as the final executor of cell death, and examining how necroptosis contributes to AD-related neurodegeneration. Additionally, the review discusses current efforts to modulate necroptosis through pharmacological agents and genetic interventions, as well as their clinical development status. Despite growing interest in necroptosis as a neurodegenerative mechanism, a comprehensive synthesis of evidence linking this pathway specifically to AD is still lacking. By consolidating these insights across experimental models and human data, the review aims to clarify the mechanistic underpinnings of necroptosis in AD and various translational potential as a therapeutic target. By addressing those gap, this review contributes to a deeper understanding of neurodegeneration and helps guide future research and therapeutic innovation.</p></sec><sec id="Sec2"><title>Methodology</title><sec id="Sec3"><title>Search Strategy and Databases</title><p id="Par9">A comprehensive literature search was conducted across multiple electronic databases, including PubMed, Scopus, and Science Direct, to identify relevant studies on necroptosis assessment in AD. The search included publications from January 2015 to April 2025 and limited to articles published in the English language. The search strategy incorporated a combination of Medical Subject Headings (MeSH) and free-text keywords such as: "necroptosis", "RIPK1", "RIPK3", "MLKL", "pMLKL", "necroptosis inhibitors", "Alzheimer&#8217;s disease", "neurodegeneration", "tau pathology", and "A&#946; deposition". Boolean operators (AND, OR) were used to combine terms effectively.</p><p id="Par10">The study selection was restricted to original research and review articles that addressed the role of necroptosis in AD. To ensure thoroughness, gray literature was also reviewed using sources such as Google Scholar, individual journal websites, and manual searches of reference lists to retrieve additional relevant articles and clarify ambiguous data. This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews (PRISMA). The process of study selection, including identification, screening, eligibility, and inclusion, is depicted in the PRISMA flow diagram below (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2" position="float" orientation="portrait"><label>Fig.&#160;2</label><caption><p>PRISMA Analysis</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="10571_2025_1601_Fig2_HTML.jpg"/></fig></p><p id="Par11">The inclusion and exclusion criteria for the study are as</p><p id="Par12">Inclusion criteria:<list list-type="bullet"><list-item><p id="Par13">Original research and review articles&#160;covering&#160;in vitro,&#160;in vivo,&#160;ex vivo, or clinical studies.</p></list-item><list-item><p id="Par14">Examination or discussion of necroptosis markers, including RIPK1, RIPK3, MLKL, or phosphorylated MLKL.</p></list-item><list-item><p id="Par15">Articles published between 2015 and 2025.</p></list-item><list-item><p id="Par16">Peer-reviewed publications in English&#160;(or with an available English translation).</p></list-item><list-item><p id="Par17">Studies analyzing necroptosis in association with AD pathologies, including A&#946; deposition, tau phosphorylation, or neuroinflammation.</p></list-item></list></p><p id="Par18">Exclusion criteria:<list list-type="bullet"><list-item><p id="Par19">Editorials, commentaries, or letters lacking original data or in-depth analysis.</p></list-item><list-item><p id="Par20">Research omitting necroptosis markers (RIPK1, RIPK3, MLKL, or pMLKL).</p></list-item><list-item><p id="Par21">Publications outside the 2015&#8211;2025 timeframe.</p></list-item><list-item><p id="Par22">Non-English articles without an official translation.</p></list-item></list></p></sec><sec id="Sec4"><title>Study Selection Process</title><p id="Par23">The study selection process began with a careful review of all identified article titles. Initial exclusions were made for duplicate entries across the three primary databases (PubMed, Scopus, and ScienceDirect) as well as articles that failed to meet the predefined eligibility criteria. These included studies published outside the 2015&#8211;2025 timeframe, those not focused on necroptosis or AD, and publications in languages other than English. Following duplicate removal, the remaining articles underwent abstract screening to assess their relevance based on inclusion criteria. Priority was given to studies examining necroptosis markers (RIPK1, RIPK3, MLKL) and their association with AD pathology, including neuroinflammation, tau hyperphosphorylation, and amyloid-beta accumulation. Articles that did not meet these criteria were excluded from further analysis.</p><p id="Par24">The final stage of the review involved a detailed full-text assessment of the remaining articles. Each study&#8217;s methodology was critically examined to determine its relevance and appropriateness for evaluating necroptosis in AD. A total of 25 rigorously selected studies were included in the synthesis, all of which explored key necroptotic markers and their contribution to AD pathogenesis. Although the review process was comprehensive, certain limitations remain. Restricting the search to English language publications may have introduced language bias, potentially omitting relevant non-English studies. Additionally, significant heterogeneity in study designs and inconsistencies in methodological reporting limited the feasibility of conducting a quantitative synthesis. Nevertheless, the study selection process, as illustrated in the PRISMA flow diagram&#160;(Fig. <xref rid="Fig2" ref-type="fig">2</xref>), was carried out with strict adherence to predefined inclusion criteria, ensuring that only methodologically robust and scientifically relevant research contributed to our understanding of necroptosis in AD.</p></sec><sec id="Sec5"><title>Necroptosis: Mechanisms and Key Molecular Players</title><sec id="Sec6"><title>Key Players of Necroptosis</title><p id="Par25">Necroptosis is closely regulated by a group of signaling proteins, of which RIPK1, RIPK3, and MLKL are the key components of necroptotic machinery (Seo et al. <xref ref-type="bibr" rid="CR78">2021</xref>). RIPK1 is a pleiotropic protein that functions as an essential molecular switch between cell survival, apoptosis, and necroptosis. Structurally, RIPK1 has both a kinase domain and a RIP homotypic interaction motif (RHIM), allowing it to bind to other RHIM-containing proteins (Du and Wang <xref ref-type="bibr" rid="CR26">2024</xref>). In necroptotic situations, for example, when caspase-8 is inhibited, RIPK1 changes from survival promotion to necroptosis initiation (Orning and Lien <xref ref-type="bibr" rid="CR68">2021</xref>). This transition occurs by binding and recruiting RIPK3, creating the necrosome, a signaling platform needed for the downstream activation of the pathway. The kinase activity of RIPK1 plays an indispensable role in initiating necroptosis by mediating the phosphorylation of RIPK3, which in turn promotes its oligomerization and autophosphorylation (Seo et al. <xref ref-type="bibr" rid="CR78">2021</xref>).</p><p id="Par26">RIPK3 is a serine/threonine kinase that serves as a key mediator of necroptosis. Upon necrosome formation, RIPK3 becomes activated and phosphorylates MLKL, the terminal effector of necroptosis (Morgan and Kim <xref ref-type="bibr" rid="CR61">2022</xref>). Apart from its kinase activity, RIPK3 also contributes as a signaling center through its interaction with metabolic enzymes and regulation of inflammatory responses (Riebeling et al. <xref ref-type="bibr" rid="CR75">2022</xref>). Activation of RIPK3 not only activates and enhances cell membrane breakdown via MLKL but also increases cytokine production, associating necroptosis with inflammation (Ermine et al. <xref ref-type="bibr" rid="CR30">2022</xref>). So, RIPK3&#8217;s function is particularly important in regulating the balance between pathological and protective inflammation, and its dysregulation is more and more linked with a variety of neurodegenerative and inflammatory diseases (Ke et al. <xref ref-type="bibr" rid="CR44">2023</xref>).</p><p id="Par27">MLKL, the final effector of necroptosis, is a pseudokinase that consists of a four-helical bundle domain, a brace region, and a kinase-like domain (Chen et al. <xref ref-type="bibr" rid="CR14">2022a</xref>, <xref ref-type="bibr" rid="CR15">b</xref>, <xref ref-type="bibr" rid="CR17">c</xref>, <xref ref-type="bibr" rid="CR19">d</xref>). Upon phosphorylation of RIPK3, MLKL undergoes conformational rearrangements that permit its oligomerization and subsequent translocation to the plasma membrane (Liccardi and Annibaldi <xref ref-type="bibr" rid="CR50">2023</xref>). At the membrane, MLKL disrupts cellular homeostasis by compromising membrane integrity, inducing ionic imbalance, promoting cell swelling, and ultimately causing membrane rupture (Chen et al. <xref ref-type="bibr" rid="CR13">2019</xref>). This membrane rupture leads to the passive release of DAMPs from the lysed cells, which in turn provokes a strong immune response, reinforcing the dual role of necroptosis as both a form of cell death and a contributor to sustained inflammation (M&#225;zl&#243; et al. <xref ref-type="bibr" rid="CR57">2022</xref>).</p></sec><sec id="Sec7"><title>Mechanistic of Necroptosis</title><p id="Par28">Several forms of signaling pathways by which necroptosis is activated, each of which involves different receptor-ligand interactions and molecular adaptors, but all converging on a central axis involving RIPK1, RIPK3, and MLKL. These include pathways mediated by TNF-&#945;, TRAIL, Toll-like receptors (TLR3/4), Interferons (IFNs), Z-DNA-binding protein 1 (ZBP1/DAI), and the cGAS-STING axis. Figure&#160;<xref rid="Fig3" ref-type="fig">3</xref> represents the various mechanistic pathways of necroptosis activation.<fig id="Fig3" position="float" orientation="portrait"><label>Fig.&#160;3</label><caption><p>Different pathogenetic mechanisms of Necroptosis Signaling and key molecules involved</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="10571_2025_1601_Fig3_HTML.jpg"/></fig></p><p id="Par29">Figure illustrates diverse signaling pathways initiating necroptosis, a regulated form of cell death. Highlighting the key receptor-ligand interactions via TNFR, Fas, TRAIL-R1/2, TLR4, and ZBP1, and their downstream adaptors like RIPK1 and TRIF. The pathways converge on RIPK3 and MLKL activation, leading to necrosome formation and MLKL oligomerization. Ultimately, disruption of the cell membrane, releases damage-associated molecular patterns, resulting the inflammatory necroptotic&#160;cell&#160;death.</p></sec></sec><sec id="Sec8"><title>TNF-&#945; Mediated Necroptosis Pathway</title><p id="Par30">The tumor necrosis factor receptor pathway is activated mainly by TNF-&#945;, which binds to its respective receptors, TNFR1 and TNFR2, and a signaling cascade is initiated that decides the fate of the cell survival, apoptosis, or necroptosis (Sharma et al. <xref ref-type="bibr" rid="CR79">2021</xref>). On binding with TNF-&#945;, it leads to the trimerization of the receptor and formation of Complex I. This receptor-bound signaling complex is made up of TNFR1-associated death domain protein (TRADD), receptor-interacting protein kinase 1(RIPK1), TNF-receptor-associated factor 2 (TRAF2), and E3 ubiquitin ligases such as cellular inhibitor of apoptosis proteins (cIAP1/2), in addition to the linear ubiquitin chain assembly complex&#160;(Manohar <xref ref-type="bibr" rid="CR56">2024</xref>). Ubiquitination of RIPK1, specifically by K63 ubiquitination by cIAP1/2, increases the activation of TAK1 through TA<xref rid="Tab2" ref-type="table">B2</xref>/TAB3, leading to NF-&#954;B and MAPK activation, which is responsible for the induction of pro-inflammatory and pro-survival genes (Huang et al. <xref ref-type="bibr" rid="CR38">2025</xref>). In addition, LUBAC complex enhances NF-&#954;B signaling through M1-type linear ubiquitination of RPK1 and TNFR1, thus increasing inflammatory responses by recruiting the IKK complex (IKK&#945;, IKK&#946;, and NEMO/IKK&#947;). In general, regulation of RIPK1 is via phosphorylation by TAK1, IKK&#945;/&#946;, MK2, and TBK1, which is responsible for inhibiting excessive cellular death (Duan et al. <xref ref-type="bibr" rid="CR27">2022</xref>; Sasaki and Iwai <xref ref-type="bibr" rid="CR77">2023</xref>).</p><p id="Par31">If conditions are conducive to cell death, deubiquitination of RIPK1 by CYLD (cylindromatosis) results in Complex I destabilization and the generation of Complex IIa, which consists of TRADD, FADD (Fas-associated death domain protein), RIPK1, and pro-caspase-8 (Engin <xref ref-type="bibr" rid="CR29">2021</xref>). Caspase-8 activation triggers apoptosis. But if caspase-8 activity is inhibited, RIPK1 binds to RIPK3 via their RHIM (RIP homotypic interaction motif) domains, resulting in the assembly of Complex IIb (the necrosome) (Orning and Lien <xref ref-type="bibr" rid="CR68">2021</xref>). Within this complex, RIPK1 is auto-phosphorylated (Ser14/15, Ser20, Ser161/166) and associates with RIPK3 through their RHIM domains, resulting in RIPK3 phosphorylation and activation (Ser227). Activated RIPK3 phosphorylates MLKL(Thr357/Ser358), resulting in oligomerization of MLKL and translocation to the plasma membrane, where it disrupts the membrane integrity, resulting in ion influx, cell swelling, and rupture (Chaouhan et al. <xref ref-type="bibr" rid="CR12">2022</xref>). This results in the release of damage-associated molecular patterns (DAMPs) such as ATP, HMGB1, and mitochondrial DNA, activating immune cells and propagating inflammation (Klegeris <xref ref-type="bibr" rid="CR46">2021</xref>). Although RIPK1 is an important regulator of TNF-&#945;-induced necroptosis, necroptosis also proceeds independently of RIPK1 through TLR3/TLR4 activation and viral infection, where RHIM-containing proteins such as TRIF and ZBP1 directly activate RIPK3 (Udawatte and Rothman <xref ref-type="bibr" rid="CR87">2021</xref>).</p></sec><sec id="Sec9"><title>TNF-Related Apoptosis-Inducing Ligand (TRAIL) Pathway</title><p id="Par32">The TRAIL pathway works similarly but is induced through the binding of TRAIL to death receptors (DR4 and DR5), which are members of the TNFR superfamily (Moriwaki et al. <xref ref-type="bibr" rid="CR62">2021</xref>). TRAIL binding causes DR4/DR5 trimerization, subsequent recruitment of FADD and pro-caspase-8, and formation of the death-inducing signaling complex (DISC). Under healthy circumstances, caspase-8 is activated and cleaves downstream caspases, initiating apoptosis. But if caspase-8 is blocked, TRAIL signaling can change direction to necroptosis (Pimentel et al. <xref ref-type="bibr" rid="CR73">2023</xref>). Further, RIPK1 and RIPK3 comprise the necrosome, with phosphorylation of MLKL resulting in the execution of necroptotic cell death. Nevertheless, resistance mechanisms, including caspase-8 inhibition or FLIP (FLICE-like inhibitory protein) expression, may redirect TRAIL signaling toward necroptosis rather than apoptosis (Engin <xref ref-type="bibr" rid="CR29">2021</xref>).</p></sec><sec id="Sec10"><title>Toll-Like Receptors (TLRs) Mediated Necroptosis Pathway</title><p id="Par33">Aside from TNF signaling, Toll-like receptors are also essential in necroptosis, especially TLR3 and TLR4 (Wicherska-Paw&#322;owska et al. <xref ref-type="bibr" rid="CR90">2021</xref>). These receptors are pattern recognition receptors (PRRs), recognizing microbial components like viral RNA (TLR3) and bacterial lipopolysaccharides (TLR4) (Li and Wu <xref ref-type="bibr" rid="CR49">2021</xref>). These receptors, upon binding to their ligands, bring in the adaptor proteins to facilitate immune signaling, such as Toll/IL-1 receptor (TIR) domain-containing adaptors. TLR3 signals solely through the TIR-domain-containing adaptor-inducing interferon-&#946;/TIR-domain-containing adapter molecule-1 (TRIF/TICAM-1) adaptor, while TLR4 can use both TRIF and MyD88 (Manik et al. <xref ref-type="bibr" rid="CR55">2025</xref>). Necroptosis occurs in TLR-mediated signaling when caspase-8 activity is suppressed. For example, LPS-induced necroptosis in human macrophages happens when caspase-8 inhibition hinders apoptosis, initiating RIPK3-dependent MLKL activation. (Kim et al. <xref ref-type="bibr" rid="CR45">2022</xref>). Similarly, synthetic dsRNA analog poly (I: C) triggers apoptosis in Jurkat cells upon combination with IFN-&#947;, but when caspase-8 or FADD is absent, necroptosis is triggered instead (Molyer Yildirir <xref ref-type="bibr" rid="CR60">2024</xref>). These suggest that TLR3 and TLR4 pathways can start necroptosis, although precise regulatory mechanisms remain under investigation.</p></sec><sec id="Sec11"><title>Interferon (IFN)-Induced Necroptosis</title><p id="Par34">Interferons are also known to induce necroptosis by distinct signaling pathways. IFN-induced necroptosis is dependent on Janus Kinase-1 (JAK1) and signal transducer and activator of transcription 1 (STAT1)-mediated transcription, which enables the assembly of a RIPK1-RIPK3 complex (Liu et al. <xref ref-type="bibr" rid="CR51">2024</xref>). The results underscore the intricate crosstalk among various receptors and cellular sensors in the control of necroptotic cell death. While each of the death receptors, TLRs, and IFN receptors participates in the initiation of necroptosis, it is via distinctive interactions that involve RHIM domain-containing proteins, including RIPK1, RIPK3, TRIF, and ZBP1 (Peng <xref ref-type="bibr" rid="CR72">2024</xref>).</p></sec><sec id="Sec12"><title>ZBP1/DAI-Induced Necroptosis</title><p id="Par35">Z-DNA-binding protein 1 (ZBP1) or DNA-dependent activator of IFN-regulatory factors (DAI) is another mechanism that triggers necroptosis. ZBP1 is a cytoplasmic receptor of double-stranded nucleic acids and is a critical component of viral immunity and necroptosis control (Chen et al. <xref ref-type="bibr" rid="CR14">2022a</xref>, <xref ref-type="bibr" rid="CR15">b</xref>, <xref ref-type="bibr" rid="CR17">c</xref>, <xref ref-type="bibr" rid="CR19">d</xref>). In contrast to TNF and TLR pathways, which are dependent on extracellular ligand-receptor interactions, ZBP1 binds to cytoplasmic nucleic acids, specifically Z-form DNA and RNA, commonly linked to viral replication (Zhan et al. <xref ref-type="bibr" rid="CR97">2024</xref>). In response to viral or endogenous Z-form nucleic acid recognition, ZBP1 oligomerizes, which allows it to directly recruit RIPK3 by its RHIM domain-containing regions. In cases where caspase-8 is inhibited or deficient, ZBp1-mediated necroptosis occurs as RIPK3 phosphorylates MLKL and induces membrane disruption and inflammatory cell death (Mishra et al. <xref ref-type="bibr" rid="CR58">2025</xref>). Most viruses contain caspase-8 inhibitors within their genome, promoting cell death toward necroptosis as an alternative cell death mechanism to counteract viral immune evasion.</p></sec><sec id="Sec13"><title>cGAS-STING Pathway Mediated Necroptosis</title><p id="Par36">The cGAS-STING pathway is important in necroptosis as it senses cytosolic DNA and activates downstream signaling, resulting in regulated necrotic cell death. When double-stranded DNA derived from pathogens, dying cells, or mitochondrial leakage enters the cytoplasm, it is sensed by cyclic GMP-AMP synthase (cGAS) (Zheng et al. <xref ref-type="bibr" rid="CR101">2023</xref>). This activation leads to the synthesis of cyclic GMP-AMP (cGAMP), a second messenger that binds to STING (stimulator of interferon genes), a transmembrane protein located on the endoplasmic reticulum (ER) (Su et al. <xref ref-type="bibr" rid="CR81">2022</xref>). Activated STING is subject to conformational changes and translocates to the Golgi apparatus, recruiting TANK-binding kinase 1 (TBK1) there. TBK1 phosphorylates interferon regulatory factors (IRF3), which initiates the production of type I interferons (IFN-&#945;/&#946;) and pro-inflammatory cytokines. Further, STING directly binds to RIPK3, an essential necroptotic kinase, resulting in its autophosphorylation and activation. Activated RIPK3 phosphorylates MLKL, which oligomerizes and moves to the plasma membrane, resulting in membrane disruption, ion influx, and eventual cell rupture (Yuhan Chen et al. <xref ref-type="bibr" rid="CR20">2025</xref>). It reinforces inflammation by releasing DAMPs, propagating further immune responses.</p><p id="Par37">Ultimately, necroptosis is a highly regulated, immune-driven form of cell death that integrates multiple pathways, including TNF, TLR, IFN, ZBP1, and cGAS-STING, to maintain host defense and eliminate infected or damaged cells. However, its dysregulation contributes to inflammatory and neurodegenerative diseases, highlighting the delicate balance between protective immunity and pathological cell loss. Understanding the precise molecular mechanisms governing necroptosis will be crucial for developing targeted therapies to modulate its effects in disease contexts. A summary of all the mechanisms is included in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table&#160;1</label><caption><p>Summary of mechanisms of necroptosis signaling</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Pathway</th><th align="left" colspan="1" rowspan="1">Initiating Ligand</th><th align="left" colspan="1" rowspan="1">Key Receptor/Sensors</th><th align="left" colspan="1" rowspan="1">Adaptor/Signaling&#160;Molecules</th><th align="left" colspan="1" rowspan="1">Necrosome Components</th><th align="left" colspan="1" rowspan="1">Downstream effects</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">TNF-&#945; pathway</td><td align="left" colspan="1" rowspan="1">Tumor Necrosis Factor-&#945; (TNF-&#945;)</td><td align="left" colspan="1" rowspan="1">TNFR1, TNFR2</td><td align="left" colspan="1" rowspan="1">TRADD, RIPK1, TRAF2, cIAP1/2, LUBAC, TAK1, IKK&#945;/&#946;, NF-&#954;B</td><td align="left" colspan="1" rowspan="1">RIPK1, RIPK3, MLKL (if caspase-8 inhibited)</td><td align="left" colspan="1" rowspan="1">Cell membrane rupture, DAMPs release (ATP, HMGB1, mtDNA), inflammation</td></tr><tr><td align="left" colspan="1" rowspan="1">TRAIL pathway</td><td align="left" colspan="1" rowspan="1">TNF-related apoptosis-inducing ligand</td><td align="left" colspan="1" rowspan="1">DR4, DR5 (TNFR superfamily)</td><td align="left" colspan="1" rowspan="1">FADD, pro-caspase-8</td><td align="left" colspan="1" rowspan="1">RIPK1, RIPK3, MLKL (if caspase-8 inhibited or FLIP expressed)</td><td align="left" colspan="1" rowspan="1">Membrane disruption, necroptotic death</td></tr><tr><td align="left" colspan="1" rowspan="1">TLR pathway</td><td align="left" colspan="1" rowspan="1">PAMPs (e.g., LPS, dsRNA)</td><td align="left" colspan="1" rowspan="1">TLR3, TLR4</td><td align="left" colspan="1" rowspan="1">TRIF (for TLR3/4), MyD88 (for TLR4), FADD</td><td align="left" colspan="1" rowspan="1">RIPK3, MLKL (if caspase-8 or FADD is deficient)</td><td align="left" colspan="1" rowspan="1">Inflammatory necroptosis, DAMPs release</td></tr><tr><td align="left" colspan="1" rowspan="1">IFN pathway</td><td align="left" colspan="1" rowspan="1">Type I Interferons (IFN-&#945;, IFN-&#946;)</td><td align="left" colspan="1" rowspan="1">IFN receptors</td><td align="left" colspan="1" rowspan="1">JAK1, STAT1</td><td align="left" colspan="1" rowspan="1">RIPK1, RIPK3, MLKL</td><td align="left" colspan="1" rowspan="1">Regulated necroptosis via transcriptional induction of RIP kinases</td></tr><tr><td align="left" colspan="1" rowspan="1">ZBP1 pathway</td><td align="left" colspan="1" rowspan="1">Z-form DNA/RNA (viral/endogenous)</td><td align="left" colspan="1" rowspan="1">Cytosolic nucleic acid sensor ZBP1</td><td align="left" colspan="1" rowspan="1">ZBP1 (directly senses Z-DNA/Z-RNA)</td><td align="left" colspan="1" rowspan="1">RIPK3, MLKL (if caspase-8 is deficient)</td><td align="left" colspan="1" rowspan="1">Membrane rupture and inflammatory death during viral infection</td></tr><tr><td align="left" colspan="1" rowspan="1">cGAS-STING pathway</td><td align="left" colspan="1" rowspan="1">Cytosolic dsDNA (mitochondrial/pathogen-derived)</td><td align="left" colspan="1" rowspan="1">Cytosolic DNA sensor cGAS, receptor STING</td><td align="left" colspan="1" rowspan="1">cGAS&#8201;&#8594;&#8201;cGAMP&#8201;&#8594;&#8201;STING&#8201;&#8594;&#8201;TBK1&#8201;&#8594;&#8201;IRF3, STING directly binds RIPK3</td><td align="left" colspan="1" rowspan="1">RIPK3, MLKL</td><td align="left" colspan="1" rowspan="1">MLKL activation, membrane rupture, DAMPs release, type I IFN production, inflammation</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec14"><title>Evidence of Necroptosis in AD</title><p id="Par38">Several cellular, animal, and human models have given robust evidence in favor of necroptosis. Strong evidence from human studies has unequivocally placed necroptosis as a pathological contributor in AD.</p><sec id="Sec15"><title>Postmortem Brain Tissue Studies</title><p id="Par39">A key study by Caccamo et al. (<xref ref-type="bibr" rid="CR11">2017</xref>) examined postmortem brain tissues of AD patients and reported elevated expression of RIPK1, RIPK3, MLKL, and pMLKL, particularly in the hippocampus and entorhinal cortex, which are the most affected areas commonly associated with cognitive decline in AD. Their findings suggested that necroptosis activation could serve as a key pathological feature of AD progression (Caccamo et al. <xref ref-type="bibr" rid="CR11">2017</xref>). Additionally, in the study by Koper et al. (<xref ref-type="bibr" rid="CR48">2022</xref>), the researchers examined how Limbic-predominant age-related TDP-43 encephalopathy with neurocognitive impairment (LATE-NC) exacerbates GVD-mediated necroptosis in AD. They found that in human postmortem brain tissue from AD patients with LATE-NC, there were significantly higher levels of pMLKL-positive GVD lesions, alongside increased tau pathology and neuronal loss, particularly in the hippocampus. This suggests that LATE-NC intensifies necroptosis, worsening neuronal damage and cognitive decline in AD (Koper et al. <xref ref-type="bibr" rid="CR48">2022</xref>). Furthermore, in postmortem brain tissue from late-onset AD patients, Degterev et al. (<xref ref-type="bibr" rid="CR24">2019</xref>) observed elevated RIPK1 expression at both mRNA and protein levels. This increase correlated with lower brain weight and advanced Braak stages. Additionally, RIPK1-regulated genes like Ch25h were upregulated in vulnerable brain regions, linking necroptosis and lipid metabolism to AD progression (Degterev et al. <xref ref-type="bibr" rid="CR24">2019</xref>). In addition, in postmortem brain samples from AD patients, Koper et al. (<xref ref-type="bibr" rid="CR47">2024</xref>) observed increased pMLKL and activated RIPK1 expression in neurons from the hippocampus and cortex, confirming that necroptosis is also active in human AD pathology. These human findings strongly aligned with the in vivo data using a mouse model, supporting necroptosis as a conserved and targetable mechanism of neuronal death in AD (Koper et al. <xref ref-type="bibr" rid="CR47">2024</xref>). Another study by Verheijen et al. (<xref ref-type="bibr" rid="CR88">2022</xref>) utilized iPSC-derived cortical neurons to investigate sporadic AD (sAD) and its relation to environmental factors. The authors compared transcriptomic changes in sAD iPSC-derived neurons to postmortem brain samples. They found similar alterations in AD-related processes, with iPSC-derived neurons revealing more differentially expressed genes. Exposure to Alzheimerogens like copper and fipronil sulfone affected genes related to lipid metabolism and immune responses, supporting the involvement of inflammation and potentially necroptosis in AD (Verheijen et al. <xref ref-type="bibr" rid="CR88">2022</xref>). Furthermore, another notable study by Park et al. (<xref ref-type="bibr" rid="CR71">2021</xref>) demonstrated that diminished O-GlcNAcylation enhances RIPK3 activity in AD brains. They further identified that O-GlcNAc modification at serine 350 normally inhibits RIPK3 activity. Loss of this modification promotes MLKL phosphorylation, triggering necroptotic neuronal death, and restoration of O-GlcNAcylation suppresses necroptosis, whereas it shows protective action for neurons. So, this study links metabolic dysfunction to necroptosis in AD (Park et al. <xref ref-type="bibr" rid="CR71">2021</xref>). Additionally, Jayaraman et al. (<xref ref-type="bibr" rid="CR39">2021</xref>) investigated the role of necroptosis in AD. They found that the TNF receptor 1 (TNFR1) signaling pathway is upregulated in neurons within the hippocampus of AD patients. This upregulation leads to the activation of RIPK1 and MLKL, key components of the necroptotic pathway. Additionally, the study observed a downregulation of components of the endosomal sorting complex required for transport III (ESCRT-III), which are crucial for membrane repair. This imbalance contributes to plasma membrane rupture, a hallmark of necroptosis, thereby promoting neuronal loss in AD (Jayaraman et al. <xref ref-type="bibr" rid="CR39">2021</xref>).</p></sec><sec id="Sec16"><title>In Vivo Studies</title><p id="Par40">To support human findings, Caccamo et al. (<xref ref-type="bibr" rid="CR11">2017</xref>) employed two well-established transgenic mouse models of Alzheimer&#8217;s disease: APP/PS1 and 5xFAD mice, both of which harbor human familial AD mutations in the APP and PSEN1 genes. These were compared with age- and sex-matched non-transgenic (NonTg) littermate controls. They assessed necroptotic activation by quantifying RIPK1, MLKL, and pMLKL levels. While APP/PS1 mice did not show significant necroptotic marker elevation at 12&#160;months, 5xFAD mice at 11&#160;months exhibited markedly increased levels of RIPK1, MLKL, and pMLKL compared to controls, correlating with prominent neuronal loss. To test the functional role of necroptosis, they overexpressed a constitutively active MLKL variant (caMLKL) via AAV delivery into APP/PS1 and NonTg mice, creating four experimental groups: APP/PS1-GFP, APP/PS1-MLKL, NonTg-GFP, and NonTg-MLKL. Behavioral analysis using the Morris Water Maze revealed that APP/PS1-MLKL mice performed significantly worse than other groups, particularly in spatial memory retention and learning, despite no changes in A&#946; or tau pathology. NeuN staining further confirmed that caMLKL induced greater neuronal loss in APP/PS1 mice than in NonTg mice, highlighting that APP/PS1 brains are more susceptible to necroptosis. These comparisons established that necroptosis exacerbates neurodegeneration and cognitive impairment in an AD context and that its activation is a driving mechanism of neuronal death (Caccamo et al. <xref ref-type="bibr" rid="CR11">2017</xref>). Further, another study by Degterev et al. (<xref ref-type="bibr" rid="CR24">2019</xref>) used 11-month-old 5xFAD and APP/PS1 transgenic mice to examine the necroptotic activity. Western blot analysis revealed significantly increased expression of RIPK1, MLKL, and pMLKL in the 5xFAD mice, but not in age-matched APP/PS1 mice. To evaluate functional outcomes, 5xFAD mice were treated with Necrostatin-1&#160;s (Nec-1&#160;s) at 10&#160;mg/kg intraperitoneally and 0.5&#160;mg/mL in drinking water for 21&#160;days. This treatment reduced neuronal death, evidenced by fewer Fluoro-Jade-positive neurons, and lowered pMLKL/MLKL ratios, suggesting inhibition of necroptosis. These results confirmed that RIPK1-dependent necroptosis drives neurodegeneration in the 5xFAD model, while also revealing that RIPK1 modulates genes related to disease-associated microglia like Cst7, Csf1, and Clec7a (Degterev et al. <xref ref-type="bibr" rid="CR24">2019</xref>). Further, Koper et al. (<xref ref-type="bibr" rid="CR47">2024</xref>) investigated necroptosis in Alzheimer&#8217;s disease using APP/PS1 transgenic mice and TauP301S mice, both of which model amyloid and tau pathologies, respectively. The researchers found elevated levels of pMLKL, indicating active necroptosis in vulnerable brain regions. Genetic deletion of MLKL or pharmacological inhibition using the RIPK1 inhibitor Necrostatin-1&#160;s rescued neuronal loss and restored cognitive function in both models. These findings provided robust in vivo evidence that necroptosis contributes to neurodegeneration in AD and that its inhibition can be neuroprotective (Koper et al. <xref ref-type="bibr" rid="CR47">2024</xref>). In another study, in an A&#946;&#8321;&#8331;&#8324;&#8322;-injected mouse model of Alzheimer&#8217;s disease, Tu et al. (<xref ref-type="bibr" rid="CR86">2020</xref>) demonstrated that treatment with EGb761 (a standardized Ginkgo biloba extract) significantly ameliorated necroptotic signaling. Mice treated with EGb761 exhibited reduced expression of RIP1, RIP3, and MLKL, as well as improved mitochondrial membrane potential and decreased ROS generation in hippocampal tissue. These findings indicated that EGb761 mitigates necroptosis by modulating RIP1-mediated mitochondrial dysfunction and oxidative stress (Tu et al. <xref ref-type="bibr" rid="CR86">2020</xref>). Furthermore, the study by Ma et al. (<xref ref-type="bibr" rid="CR53">2021</xref>) primarily focused on in vivo models using young and aged SAMP8 mice. The researchers investigated the effects of Cornel Iridoid Glycoside (CIG) on AD-like pathologies and necroptosis through the RIPK1/MLKL pathway in these mice. The study focused entirely on in vivo experimentation, confirming that CIG alleviates AD-like pathology by suppressing the RIPK1/MLKL axis involved in necroptosis (Ma et al. <xref ref-type="bibr" rid="CR53">2021</xref>). Similarly, Pang et al. (<xref ref-type="bibr" rid="CR70">2022</xref>) developed a novel App<sup>NL&#8722;G&#8722;F</sup> knock-in rat model carrying three familial AD mutations with a humanized A&#946; sequence. Unlike mice, these rats showed AD-like A&#946; plaques, tau pathology, synaptic loss, cognitive deficits, and importantly, activation of necroptosis marked by increased RIPK1, RIPK3, and pMLKL in the hippocampus. This model uniquely mimics human AD neurodegeneration and necroptosis, making it a valuable tool for drug discovery (Pang et al. <xref ref-type="bibr" rid="CR70">2022</xref>). In line with this, Jayaraman et al. (<xref ref-type="bibr" rid="CR39">2021</xref>) in their in vivo model, used APP/PS1 transgenic mice and observed that increased TNF-&#945; levels in the hippocampus triggered neuroinflammation, which was associated with necroptosis. Specifically, they found that necroptotic cell death was prominent in the hippocampal neurons of AD mice, and that blocking TNF-&#945; signaling helped reduce the neuroinflammatory response and necroptosis. This suggests significant role of TNF-&#945; in mediating necroptosis in AD and highlights the potential of targeting this pathway for therapeutic intervention in AD (Jayaraman et al. <xref ref-type="bibr" rid="CR39">2021</xref>). Moreover, in vivo experiments with APP/PS1 transgenic mice, Salvadores et al. (<xref ref-type="bibr" rid="CR76">2022</xref>) found that inhibition of RIPK1 using Nec-1 reduced microglial activation and neuroinflammation. This intervention led to a decrease in A&#946;-induced neurodegeneration, highlighting the potential for RIPK1 as a therapeutic target in AD (Salvadores et al. <xref ref-type="bibr" rid="CR76">2022</xref>). The study by Yang et al. (<xref ref-type="bibr" rid="CR93">2017</xref>) explored the role of necroptosis in AD using APP/PS1 transgenic mice as an in vivo model. They found that Necrostatin-1, a specific RIPK1 inhibitor, alleviated cognitive impairment and reduced amyloid-beta plaques and tau abnormalities in the mice. This suggests that inhibiting necroptosis can help mitigate the cognitive and pathological features of AD (Yang et al. <xref ref-type="bibr" rid="CR93">2017</xref>). Another study by Naderi et al. (<xref ref-type="bibr" rid="CR63">2024</xref>) used an in vivo rat model to examine the effects of A&#946;25&#8201;&#8722;&#8201;35-induced neurotoxicity in AD. The rats were treated with Necrostatin-1, a specific inhibitor of necroptosis, to investigate its neuroprotective potential. The researchers focused on the dentate gyrus (DG) granule cells, where they observed that A&#946;25&#8201;&#8722;&#8201;35 caused significant electrophysiological changes, including a reduction in neuronal excitability and a decrease in voltage-gated calcium channel (Ca<sup>2+</sup>) currents. However, administration of Nec-1 nearly restored the normal excitability and Ca<sup>2+</sup> currents in these neurons. This suggests that necroptosis plays a critical role in A&#946;25&#8201;&#8722;&#8201;35-induced neurotoxicity, and inhibiting necroptosis could potentially protect against the electrophysiological alterations associated with AD (Naderi et al. <xref ref-type="bibr" rid="CR63">2024</xref>). In support of this, Zou et al. (<xref ref-type="bibr" rid="CR104">2020</xref>), using APP/PS1 AD mouse models, the authors found that venous and capillary cerebral endothelial cells (ECs) were particularly vulnerable to necroptosis, with activation of RIPK1, RIPK3, and MLKL. A reduction in mNat1 (murine N-acetyltransferase 1) expression in these ECs sensitized them to necroptosis. Restoring mNat1 expression in AD mice reduced necroptosis, improved blood&#8211;brain barrier integrity, and alleviated cognitive dysfunction. This study emphasizes the role of endothelial necroptosis in AD and the potential therapeutic benefit of targeting mNat1 (Zou et al. <xref ref-type="bibr" rid="CR104">2020</xref>).</p></sec><sec id="Sec17"><title>In Vivo Studies: Chemically Induced Models</title><p id="Par41">Zhang and Niu (<xref ref-type="bibr" rid="CR99">2024</xref>) in their studies using AD animal models induced by Al, observed similar results. Al exposure led to increased necroptosis in the brains of these animals, reflected by upregulated expression of necroptosis-related proteins. Administration of Nec-1 in these animals also reduced necroptosis and attenuated neuronal loss. Compared to apoptosis and autophagy inhibitors, Nec-1 showed more prominent effects in reducing cell death and protecting against Al-induced neurodegeneration, highlighting the significance of necroptosis as the dominant cell death pathway in AD associated with aluminum exposure (Zhang and Niu <xref ref-type="bibr" rid="CR99">2024</xref>). Other chemically induced models support this as well. Additionally, He et al. (<xref ref-type="bibr" rid="CR35">2021</xref>) investigated the neuroprotective effects of Qiangji Decoction (QJD) in a D-galactose-induced mouse model mimicking aging-related AD. Chronic D-gal exposure caused cognitive impairment, hippocampal neurodegeneration, and neuroinflammation, accompanied by suppressed AMPK/SIRT1 signaling and activated NF-&#954;B pathways. QJD treatment significantly improved learning and memory, reduced neuronal apoptosis, and downregulated pro-inflammatory markers (He et al. <xref ref-type="bibr" rid="CR35">2021</xref>). In a study by Nasseri et al. (<xref ref-type="bibr" rid="CR67">2020</xref>), intracerebroventricular (ICV) injection of streptozotocin (STZ) in rats was used to model sporadic AD. This model induced cognitive deficits and hippocampal neuroinflammation, mimicking AD-like pathology. Notably, there was a significant upregulation of necrosome components RIP1, RIP3, and TNF-&#945;, indicating activation of necroptosis in the hippocampus. Treatment with Apelin-13, a neuroprotective peptide, for 15&#160;days post-STZ injection, led to marked reductions in these necroptotic markers and improved learning and memory in the Morris Water Maze (Nasseri et al. <xref ref-type="bibr" rid="CR67">2020</xref>). Lastly, in a study by Gao et al. (<xref ref-type="bibr" rid="CR31">2022</xref>), necroptosis was identified as a key contributor to cognitive decline in a zebrafish model of AD induced by aluminum trichloride. Aluminum exposure led to memory deficits, reduced acetylcholine levels, and increased AD-related gene and protein expression. Treatment with Necrostatin-1, a necroptosis inhibitor targeting RIPK1, significantly improved learning and memory, restored acetylcholine levels, and altered necroptosis-related gene expression. These results suggest that necroptosis plays a crucial role in aluminum-induced AD pathology and that Nec-1 holds promise as a therapeutic agent (Gao et al. <xref ref-type="bibr" rid="CR31">2022</xref>).</p></sec><sec id="Sec18"><title>In Vitro Studies</title><p id="Par42">Cell culture studies have yielded detailed mechanistic insights into necroptosis. In SH-SY5Y neuroblastoma cells exposed to A&#946;&#8321;&#8331;&#8324;&#8322;, Tu et al. (<xref ref-type="bibr" rid="CR86">2020</xref>) observed that EGb761 pretreatment suppressed cell death by attenuating RIP1 expression, preserving mitochondrial function, and lowering intracellular ROS levels. This effect was comparable to that of the RIP1 inhibitor Necrostatin-1, suggesting that EGb761 protects neuronal cells via a RIP1-dependent mechanism of necroptosis inhibition (Tu et al. <xref ref-type="bibr" rid="CR86">2020</xref>). Additionally, in the study by Salvadores et al. (<xref ref-type="bibr" rid="CR76">2022</xref>), in vitro experiments using primary microglial cultures demonstrated that A&#946; oligomers activated microglia, leading to necroptosis via the RIPK1/RIPK3/MLKL signaling pathway. This activation triggered the release of pro-inflammatory cytokines, contributing to neurodegeneration in AD (Salvadores et al. <xref ref-type="bibr" rid="CR76">2022</xref>). Furthermore, in vitro model, using primary neuronal cultures, Yang et al. (<xref ref-type="bibr" rid="CR93">2017</xref>) showed that Nec-1 prevented A&#946;-induced neuronal damage by inhibiting necroptosis. This further supports that necroptosis inhibition could be a potential therapeutic strategy for AD, particularly in protecting neurons from A&#946; toxicity. (Yang et al. <xref ref-type="bibr" rid="CR93">2017</xref>). Jayaraman et al. (<xref ref-type="bibr" rid="CR39">2021</xref>) in their in vitro model, used primary hippocampal neuronal cultures and exposed them to TNF-&#945; and A&#946; oligomers to mimic the neuroinflammatory environment of AD. They observed that TNF-&#945; stimulation led to increased necroptosis in the neuronal cultures, which was also mitigated by blocking TNF receptor signaling. This provided further evidence that TNF-mediated neuroinflammation contributes to necroptosis in AD neurons, supporting the potential for TNF-&#945; inhibitors as therapeutic agents in AD (Jayaraman et al. <xref ref-type="bibr" rid="CR39">2021</xref>). Another study by Yuan et al. (<xref ref-type="bibr" rid="CR96">2020</xref>) explored the neuroprotective role of DHA in A&#946;25-35-induced necroptosis in THP-1 monocytes. DHA pretreatment inhibited necroptotic markers (RIPK1, RIPK3, MLKL) and pro-inflammatory cytokines (TNF-&#945;, IL-1&#946;, IL-6), and blocked ERK1/2 activation. Co-treatment with DHA and Nec-1 synergistically suppressed RIPK3, indicating DHA acts via the RIPK1/RIPK3 pathway. Additionally, DHA restored A&#946;-impaired monocyte migration, highlighting its therapeutic potential in AD-related necroptosis (Yuan et al. <xref ref-type="bibr" rid="CR96">2020</xref>). Finally, Naseri et al. (<xref ref-type="bibr" rid="CR66">2022</xref>) investigated the neuroprotective effects of ghrelin in an amyloid-&#946;<sub>1-42</sub> (A&#946;<sub>1-42</sub>)-induced rat model of AD. The study found that ghrelin improved memory performance and reduced the expression of pro-apoptotic proteins (Bax), necroptotic proteins (RIP1K and RIP3K), and the Bax/Bcl-2 ratio. Ghrelin also promoted autophagy by increasing Beclin-1 expression. The results suggest that ghrelin inhibits apoptosis and necroptosis while promoting autophagy, offering potential therapeutic benefits for AD (Naseri et al. <xref ref-type="bibr" rid="CR66">2022</xref>).</p></sec><sec id="Sec19"><title>In Vivo and In Vitro -&#160;Combined Model</title><p id="Par43">Bansal et al. (<xref ref-type="bibr" rid="CR10">2025</xref>) explored the impact of A&#946; on neuronal dysfunction in AD using the APP knock-in mouse model App<sup>NL&#8722;G&#8722;F/NL&#8722;G&#8722;F</sup> (APP KI), which shows robust A&#946; neuropathology. Utilizing both in vitro neuron-glia cocultures and in vivo brain tissue analyses, the author demonstrated that A&#946; accumulation causes early disruption of the nuclear pore complex. This was evidenced by decreased expression of nucleoporins such as NUP98 and NUP107, along with impaired nucleocytoplasmic transport occurring even before the appearance of A&#946; plaques. The disruption led to abnormal trafficking of proteins across the nuclear envelope and reduced levels of key transport proteins like importin-&#946;1 and RanGAP1. Notably, the application of oligomeric A&#946; alone was sufficient to induce these changes, while inhibiting A&#946; production with a &#947;-secretase blocker partially restored nuclear integrity. Furthermore, neurons with compromised NPCs became more susceptible to TNF-&#945;&#8211;triggered necroptosis, showing elevated activation of necroptotic markers RIPK3 and MLKL. Intervention through nuclear transport blockade or RIPK1 inhibition significantly reduced this cell death, suggesting that NPC impairment is an early and actionable event in A&#946;-driven neurodegeneration in AD (Bansal et al. <xref ref-type="bibr" rid="CR10">2025</xref>). In another study by Chong Xu et al. (<xref ref-type="bibr" rid="CR92">2021</xref>), the investigation of the intricate relationship between inflammation, necroptosis, and autophagy in the development of AD was conducted. Increased expression of necroptotic markers, such as phosphorylated RIPK1, RIPK3, and MLKL, was detected in both postmortem brain tissues of AD patients and APP/PS1 transgenic mouse models. These findings indicated enhanced activation of the necroptotic pathway. Additionally, experiments using primary cortical neurons exposed to TNF-&#945; in vitro confirmed that TNF-&#945; could induce necroptotic neuronal death via the RIPK1-RIPK3-MLKL signaling cascade. The study further revealed that RIPK1 interacts with p62/sequestosome 1(SQSTM1), which acts as a scaffold protein to facilitate necroptosis signaling. Importantly, the study identified a key regulatory role for UV Radiation Resistance Associated Gene (UVRAG), a protein involved in autophagy, in suppressing necroptosis. Under normal conditions, UVRAG interacts with the RIPK1-p62 complex to promote the degradation of RIPK1 through autophagy, thereby limiting necroptotic signaling, but in the context of AD, the expression of UVRAG was found to be significantly reduced. This reduction leads to impaired degradation of RIPK1, resulting in its accumulation and prolonged activation of necroptosis, which in turn contributes to neuronal loss (Xu et al. <xref ref-type="bibr" rid="CR92">2021</xref>).</p></sec><sec id="Sec20"><title>Human Xenograft Model</title><p id="Par44">In a groundbreaking study, Balusu et al. (<xref ref-type="bibr" rid="CR9">2023</xref>) explored the role of the long noncoding RNA MEG3 in AD using an innovative human Rag2<sup>&#8722;/&#8722;/</sup>App<sup>NL&#8722;G&#8722;F</sup> knock-in mouse, which is immunodeficient and carries three familial AD mutations. This setup allowed the human neurons to integrate into the mouse brain and be exposed to an AD-like pathological environment. Over time, the transplanted human neurons exhibited hallmark AD features, including phosphorylated tau (AT8-positive), granulovacuolar degeneration, and neuronal loss, while neurons transplanted into control mice did not show such alterations. Transcriptomic profiling of these xenografted human neurons revealed that MEG3 was among the most significantly upregulated genes in neurons exposed to the AD brain microenvironment. To confirm a functional role for MEG3, the researchers overexpressed MEG3 in human neurons in vitro, which led to robust activation of the necroptotic pathway, specifically marked by the activation of RIPK1, RIPK3, and MLKL. Conversely, knockdown of MEG3 in the xenografted human neurons prevented necroptosis, reduced neuronal loss, and improved cell survival within the AD mouse brain. Additionally, postmortem human AD brain samples revealed elevated MEG3 expression and colocalization with necroptosis markers, indicating that this mechanism is not only present in the model but also clinically relevant in human AD pathology. This study is pivotal as it establishes MEG3 as a human-specific driver of necroptosis in AD and underscores the utility of human neuron xenografts for uncovering disease mechanisms that are not observable in rodent neurons (Balusu et al. <xref ref-type="bibr" rid="CR9">2023</xref>).</p></sec><sec id="Sec21"><title><italic toggle="yes">In Silico</italic> Model</title><p id="Par45">The article by Chen et al. (<xref ref-type="bibr" rid="CR14">2022a</xref>, <xref ref-type="bibr" rid="CR15">b</xref>, <xref ref-type="bibr" rid="CR17">c</xref>, <xref ref-type="bibr" rid="CR19">d</xref>) investigates the role of exercise in preventing necroptosis, a regulated form of cell death, in AD (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). The study proposes that exercise may modulate exosomal miRNAs, particularly miR-215-5p, which can inhibit necroptosis-related genes like IDH1, BCL2L11, and SIRT1. The authors constructed a risk prediction model for AD using necroptosis-related genes and lncRNAs, achieving a high predictive power (AUC&#8201;=&#8201;0.979). Through SCENIC analysis, key transcriptional regulators, CEBPB and GATA6, were identified as essential for the upregulation of miR-215-5p in skeletal muscle during exercise. These findings suggest that exercise can influence miRNA levels in circulating exosomes, which in turn prevent necroptosis and delay AD onset (Chen et al. <xref ref-type="bibr" rid="CR14">2022a</xref>, <xref ref-type="bibr" rid="CR15">b</xref>, <xref ref-type="bibr" rid="CR17">c</xref>, <xref ref-type="bibr" rid="CR19">d</xref>).<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table&#160;2</label><caption><p>Summary of evidence studies of necroptosis in AD</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Model</th><th align="left" colspan="1" rowspan="1">Species/source</th><th align="left" colspan="1" rowspan="1">Intervention</th><th align="left" colspan="1" rowspan="1">Markers Assessed</th><th align="left" colspan="1" rowspan="1">Key Takeaways</th><th align="left" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Human (Postmortem Study)</td><td align="left" colspan="1" rowspan="1">AD brain tissue</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">pRIPK1, pMLKL</td><td align="left" colspan="1" rowspan="1">Increased necroptotic markers in neurodegeneration-prone areas</td><td align="left" colspan="1" rowspan="1">Caccamo et al. (<xref ref-type="bibr" rid="CR11">2017</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Human (Postmortem Study)</td><td align="left" colspan="1" rowspan="1">AD&#8201;+&#8201;LATE-NC brain tissue</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">pMLKL</td><td align="left" colspan="1" rowspan="1">pMLKL was increased in GVD, correlated with tau and neuron loss</td><td align="left" colspan="1" rowspan="1">Koper et al. (<xref ref-type="bibr" rid="CR48">2022</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Human (Transcriptomic)</td><td align="left" colspan="1" rowspan="1">Transcriptomics and Human brain tissue</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">RIPK1, Ch25h</td><td align="left" colspan="1" rowspan="1">RIPK1 and lipid-related genes (e.g., Ch25h) were upregulated in AD brains</td><td align="left" colspan="1" rowspan="1">Degterev et al. (<xref ref-type="bibr" rid="CR24">2019</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Human (Postmortem Study)</td><td align="left" colspan="1" rowspan="1">Cortex &amp; hippocampus of the AD brain</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">pMLKL, RIPK1</td><td align="left" colspan="1" rowspan="1">Elevated pMLKL and RIPK1 in AD neurons; necroptosis linked with neurodegeneration</td><td align="left" colspan="1" rowspan="1">Koper et al. (<xref ref-type="bibr" rid="CR47">2024</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">In vitro (Human iPSC)</td><td align="left" colspan="1" rowspan="1">iPSC-derived human neurons</td><td align="left" colspan="1" rowspan="1">Nec-1, MLKL inhibitors</td><td align="left" colspan="1" rowspan="1">MLKL, RIPK3</td><td align="left" colspan="1" rowspan="1">Necroptotic activation reversed by RIPK1 and MLKL inhibition</td><td align="left" colspan="1" rowspan="1">Verheijen et al. (<xref ref-type="bibr" rid="CR88">2022</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Human (Postmortem Study)</td><td align="left" colspan="1" rowspan="1">Human brain tissue analysis</td><td align="left" colspan="1" rowspan="1">O-GlcNAc modulation</td><td align="left" colspan="1" rowspan="1">RIPK3, MLKL, O-GlcNAc</td><td align="left" colspan="1" rowspan="1">Reduced O-GlcNAcylation activated RIPK3/MLKL; restoration blocked necroptosis</td><td align="left" colspan="1" rowspan="1">Park et al. (<xref ref-type="bibr" rid="CR71">2021</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Human (Postmortem Study)</td><td align="left" colspan="1" rowspan="1">Human cortex</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">RIPK1, MLKL</td><td align="left" colspan="1" rowspan="1">RIPK1-MLKL upregulated, ESCRT-III repair system downregulated</td><td align="left" colspan="1" rowspan="1">Jayaraman et al. (<xref ref-type="bibr" rid="CR39">2021</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">Xenograft</td><td align="left" colspan="1" rowspan="1">Human neurons in App<sup>NL&#8722;G&#8722;F</sup> mice</td><td align="left" colspan="1" rowspan="1">lncRNA MEG3 overexpression</td><td align="left" colspan="1" rowspan="1">RIPK1, RIPK3, MLKL</td><td align="left" colspan="1" rowspan="1">MEG3 induced necroptosis via RIPK1/RIPK3/MLKL</td><td align="left" colspan="1" rowspan="1">Balusu et al. (<xref ref-type="bibr" rid="CR9">2023</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">In vivo transgenic mice</td><td align="left" colspan="1" rowspan="1">5xFAD, APP/PS1 Mice</td><td align="left" colspan="1" rowspan="1">MLKL overexpression</td><td align="left" colspan="1" rowspan="1">MLKL, RIPK1</td><td align="left" colspan="1" rowspan="1">Overexpression of MLKL worsened memory and increased necroptosis and neuronal loss</td><td align="left" colspan="1" rowspan="1">Caccamo et al. (<xref ref-type="bibr" rid="CR11">2017</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">In vivo transgenic mice</td><td align="left" colspan="1" rowspan="1">APP/PS1, 5xFAD mice</td><td align="left" colspan="1" rowspan="1">Nec-1s</td><td align="left" colspan="1" rowspan="1">RIPK1</td><td align="left" colspan="1" rowspan="1">RIPK1 inhibition reduced A&#946; pathology, restored microglial function, and improved synaptic health</td><td align="left" colspan="1" rowspan="1">Degterev et al. (<xref ref-type="bibr" rid="CR24">2019</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">In vivo Transgenic mice</td><td align="left" colspan="1" rowspan="1">APP/PS1, TauP301S mice</td><td align="left" colspan="1" rowspan="1">MLKL knockout, Nec-1s</td><td align="left" colspan="1" rowspan="1">RIPK1, pMLKL</td><td align="left" colspan="1" rowspan="1">MLKL KO and Nec-1&#160;s reduced necroptosis, improved memory, and neuronal survival</td><td align="left" colspan="1" rowspan="1">Koper et al. (<xref ref-type="bibr" rid="CR47">2024</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">In vivo mouse model (Chemically Induced)</td><td align="left" colspan="1" rowspan="1">A&#946;1&#8211;42-injected mice</td><td align="left" colspan="1" rowspan="1">EGb761 (Ginkgo biloba extract)</td><td align="left" colspan="1" rowspan="1">RIPK1, RIPK3, MLKL</td><td align="left" colspan="1" rowspan="1">Reduced necroptosis and oxidative stress; improved mitochondrial function and memory</td><td align="left" colspan="1" rowspan="1">Tu et al. (<xref ref-type="bibr" rid="CR86">2020</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">In vivo (aged mice)</td><td align="left" colspan="1" rowspan="1">SAMP8 mice</td><td align="left" colspan="1" rowspan="1">Cornel Iridoid Glycoside (CIG)</td><td align="left" colspan="1" rowspan="1">RIPK1, RIPK3, MLKL</td><td align="left" colspan="1" rowspan="1">CIG lowered necroptosis markers and enhanced memory</td><td align="left" colspan="1" rowspan="1">Ma et al. (<xref ref-type="bibr" rid="CR53">2021</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">In vivo transgenic mice</td><td align="left" colspan="1" rowspan="1">APP/PS1 mice</td><td align="left" colspan="1" rowspan="1">Anti-TNF therapy</td><td align="left" colspan="1" rowspan="1">RIPK1, MLKL</td><td align="left" colspan="1" rowspan="1">TNF-&#945; induced necroptosis via RIPK1/MLKL; anti-TNF therapy reduced necroptosis and restored membrane repair capacity</td><td align="left" colspan="1" rowspan="1">Jayaraman et al. (<xref ref-type="bibr" rid="CR39">2021</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">In vivo Transgenic Mice</td><td align="left" colspan="1" rowspan="1">APPxTAU Mice</td><td align="left" colspan="1" rowspan="1">Nec-1</td><td align="left" colspan="1" rowspan="1">RIPK1, pMLKL</td><td align="left" colspan="1" rowspan="1">Nec-1 reduced microgliosis and neuronal damage</td><td align="left" colspan="1" rowspan="1">Salvadores et al. (<xref ref-type="bibr" rid="CR76">2022</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">In vivo Transgenic Mice</td><td align="left" colspan="1" rowspan="1">APP/PS1 mice</td><td align="left" colspan="1" rowspan="1">Nec-1</td><td align="left" colspan="1" rowspan="1">RIPK1, A&#946;, Tau</td><td align="left" colspan="1" rowspan="1">Nec-1 restored memory, reduced A&#946; and tau burden</td><td align="left" colspan="1" rowspan="1">Yang et al. (<xref ref-type="bibr" rid="CR93">2017</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">In vivo Transgenic mice</td><td align="left" colspan="1" rowspan="1">APP/PS1 mice</td><td align="left" colspan="1" rowspan="1">mNat1 restoration</td><td align="left" colspan="1" rowspan="1">RIPK1, mNat1</td><td align="left" colspan="1" rowspan="1">Loss of mNat1 triggered RIPK-mediated endothelial necroptosis, and restoration reversed changes</td><td align="left" colspan="1" rowspan="1">Zou et al. (<xref ref-type="bibr" rid="CR104">2020</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">In vivo Chemically Induced</td><td align="left" colspan="1" rowspan="1">AlCl&#8323;-treated cortical neurons</td><td align="left" colspan="1" rowspan="1">Nec-1</td><td align="left" colspan="1" rowspan="1">RIPK1, RIPK3</td><td align="left" colspan="1" rowspan="1">Al increased necroptosis markers (RIPK1/RIPK3); Nec-1 reduced necroptosis and neuronal loss more effectively than autophagy or apoptosis inhibitors</td><td align="left" colspan="1" rowspan="1">Zhang and Niu (<xref ref-type="bibr" rid="CR99">2024</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">In vivo Chemically Induced</td><td align="left" colspan="1" rowspan="1">D-galactose-induced mice</td><td align="left" colspan="1" rowspan="1">Qiangji Decoction (QJD)</td><td align="left" colspan="1" rowspan="1">NF-&#954;B, AMPK, SIRT1</td><td align="left" colspan="1" rowspan="1">Improved memory, reduced apoptosis, neuroinflammation, restored AMPK/SIRT1, and suppressed NF-&#954;B</td><td align="left" colspan="1" rowspan="1">He et al. (<xref ref-type="bibr" rid="CR35">2021</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">In vivo Chemically Induced</td><td align="left" colspan="1" rowspan="1">STZ-ICV-injected rats</td><td align="left" colspan="1" rowspan="1">Apelin-13</td><td align="left" colspan="1" rowspan="1">RIPK1, RIPK3, TNF-&#945;</td><td align="left" colspan="1" rowspan="1">Apelin-13 reversed necroptosis and improved memory</td><td align="left" colspan="1" rowspan="1">Nasseri et al. (<xref ref-type="bibr" rid="CR67">2020</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">In vivo transgenic rats</td><td align="left" colspan="1" rowspan="1">A&#946;25&#8211;35-injected rats</td><td align="left" colspan="1" rowspan="1">Nec-1</td><td align="left" colspan="1" rowspan="1">Ca<sup>2</sup>&#8314; current, excitability</td><td align="left" colspan="1" rowspan="1">Nec-1 normalized disrupted neuronal excitability and calcium current</td><td align="left" colspan="1" rowspan="1">Naderi et al. (<xref ref-type="bibr" rid="CR63">2024</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">In vivo Transgenic rats</td><td align="left" colspan="1" rowspan="1">APP<sup>NL&#8722;G&#8722;F</sup> Rats</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">RIPK1, RIPK3, pMLKL</td><td align="left" colspan="1" rowspan="1">Demonstrated necroptosis pathway upregulation; model validated for AD necroptosis studies</td><td align="left" colspan="1" rowspan="1">Pang et al. (<xref ref-type="bibr" rid="CR70">2022</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">In vivo Chemically Induced</td><td align="left" colspan="1" rowspan="1">AlCl&#8323;-induced zebrafish</td><td align="left" colspan="1" rowspan="1">Nec-1</td><td align="left" colspan="1" rowspan="1">RIPK1, RIPK3, MLKL</td><td align="left" colspan="1" rowspan="1">AlCl&#8323; impaired cognition and ACh; Nec-1 restored memory and reduced necroptosis gene expression</td><td align="left" colspan="1" rowspan="1">Gao et al. (<xref ref-type="bibr" rid="CR31">2022</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">In vivo &amp; In vitro (Transgenic mice)</td><td align="left" colspan="1" rowspan="1">APP knock-in mouse model App<sup>NL&#8722;G&#8722;F/NL&#8722;G&#8722;F</sup></td><td align="left" colspan="1" rowspan="1">&#947;-secretase inhibitor (DAPT), Nec-1s, nuclear transport blockers</td><td align="left" colspan="1" rowspan="1">RIPK1, RIPK3, MLKL, NUP98, NUP107</td><td align="left" colspan="1" rowspan="1">A&#946; disrupted NPC function, impaired nucleocytoplasmic transport, and sensitized neurons to TNF-&#945;&#8211;induced necroptosis; Nec-1&#160;s and DAPT restored integrity</td><td align="left" colspan="1" rowspan="1">Bansal et al. (<xref ref-type="bibr" rid="CR10">2025</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">In vivo &amp; In vitro (Transgenic mice)</td><td align="left" colspan="1" rowspan="1">APP/PS1 mice and primary neurons</td><td align="left" colspan="1" rowspan="1">RIPK1-p62-UVRAG interaction</td><td align="left" colspan="1" rowspan="1">RIPK1, p62, UVRAG</td><td align="left" colspan="1" rowspan="1">Necroptosis is linked with impaired autophagy through RIPK1 interactions</td><td align="left" colspan="1" rowspan="1">Xu et al. (<xref ref-type="bibr" rid="CR92">2021</xref>)</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="Sec22"><title>Potential Therapeutic Approach Targeting Necroptosis in AD</title><p id="Par46">The therapeutic targeting of necroptosis in AD represents a promising disease-modifying approach due to the involvement of this pathway in neurodegeneration and neuroinflammation. One of the most investigated targets is RIPK1, a kinase that acts at the top of the necroptosis cascade and also regulates inflammation. Pharmacological inhibition of RIPK1 using molecules such as Necrostatin-1 and its more stable and selective analogue Nec-1s (7-Cl-O-Nec-1) has shown protective effects in multiple neurodegeneration models (Yuan et al. <xref ref-type="bibr" rid="CR94">2019</xref>). These inhibitors prevent the activation of downstream necroptotic mediators and simultaneously reduce the production of inflammatory cytokines by microglia. To overcome the limitations of early RIPK1 inhibitors, such as poor pharmacokinetics and limited brain penetration, novel compounds like GSK2982772 and DNL747 (SAR443060) have been developed (Chen et al. <xref ref-type="bibr" rid="CR14">2022a</xref>, <xref ref-type="bibr" rid="CR15">b</xref>, <xref ref-type="bibr" rid="CR17">c</xref>, <xref ref-type="bibr" rid="CR19">d</xref>). Notably, DNL747 was optimized for CNS penetration and has progressed into early phase clinical trials for neuroinflammatory and neurodegenerative conditions, including ALS and AD (Hincelin&#8208;Mery et al. <xref ref-type="bibr" rid="CR36">2024</xref>). Although DNL747 showed acceptable safety in Phase 1 trials, its clinical development was halted due to insufficient target engagement, highlighting the complexity of translating RIPK1 inhibition into effective CNS therapies. Nonetheless, continued optimization of RIPK1 inhibitors with improved BBB permeability and isoform selectivity remains a high priority (Vissers et al. <xref ref-type="bibr" rid="CR89">2022</xref>). Inhibiting RIPK1 could therefore mitigate both neuronal death and neuroinflammatory cascades that exacerbate synaptic dysfunction (Gong et al. <xref ref-type="bibr" rid="CR32">2024</xref>).</p><p id="Par47">Further downstream, RIPK3 serves as a key kinase responsible for phosphorylating MLKL, the executioner protein of necroptosis; thus, targeting RIPK3 can effectively interrupt the progression of the necroptotic pathway. Experimental inhibitors like GSK&#8217;843, GSK&#8217;872, and HS-1371 have demonstrated RIPK3-specific inhibition, reducing neuronal death and glial activation in preclinical models (Zhou et al. <xref ref-type="bibr" rid="CR102">2019</xref>, <xref ref-type="bibr" rid="CR103">2024</xref>). While these inhibitors are still largely in experimental stages, they offer a strategic advantage by selectively blocking the necroptotic execution phase without disrupting other cellular processes. Unlike RIPK1, which also regulates apoptosis and inflammation, targeting RIPK3 may offer greater pathway specificity, but this comes at the cost of limited versatility in modulating upstream inflammatory responses.</p><p id="Par48">At the terminal end of the pathway, MLKL oligomerization and translocation to the plasma membrane are essential for membrane disruption and cell lysis, and release of DAMPs, leading to neuroinflammation. Preventing this step could halt necroptosis even after upstream activation. Although specific MLKL inhibitors are still under development, small molecules such as necrosulfonamide (NSA) have been shown to bind human MLKL and inhibit its oligomerization and membrane insertion (Tang and Zhuang <xref ref-type="bibr" rid="CR82">2024</xref>). However, NSA is species-specific and nonfunctional in rodent models, limiting its utility in preclinical studies. Development of brain-penetrant, cross-species MLKL inhibitors remains an unmet need, though targeting MLKL is mechanistically attractive for preventing DAMP-induced inflammation and preserving cellular integrity.</p><p id="Par49">Importantly, cell-type-specific roles of necroptosis are increasingly recognized in AD. Microglial necroptosis may exacerbate synaptic pruning and contribute to neuronal loss via cytokine-mediated toxicity, while astrocytic and neuronal necroptosis directly drive structural brain damage (Balestri et al. <xref ref-type="bibr" rid="CR8">2024</xref>). As such, timing and targeting strategies should be carefully refined. Early intervention, before widespread neuronal loss, could be critical for maximizing therapeutic benefit. Moreover, combining necroptosis inhibitors with conventional anti-amyloid or anti-tau therapies may produce synergistic effects by addressing multiple facets of AD pathology simultaneously (Tondo et al. <xref ref-type="bibr" rid="CR85">2024</xref>). This combinatorial approach could help overcome the limited efficacy of current monotherapies and improve patient outcomes. Thus, the modulation of necroptosis offers not only a mechanistically grounded therapeutic strategy but also the potential for personalized treatment approaches in AD.</p></sec></sec><sec id="Sec23"><title>Conclusion and Future Directions</title><p id="Par50">This systematic review consolidates the evidence identifying necroptosis as a mechanistically significant contributor to AD pathogenesis. Elevated expression and activation of the necroptotic mediators, i.e., RIPK1, RIPK3, and MLKL, have been consistently demonstrated across human postmortem tissues, iPSC-derived neurons, transgenic models, chemically induced models, and in vitro assays. These findings underscore necroptosis as an upstream and regulated driver of neurodegeneration, integrally associated with key pathological features of AD, including amyloid-beta deposition, tau hyperphosphorylation, synaptic loss, and chronic neuroinflammation. Preclinical studies employing pharmacological inhibitors of RIPK1 (e.g., Necrostatin-1, Nec-1&#160;s) and MLKL (e.g., necrosulfonamide) have demonstrated encouraging results, including the preservation of neuronal viability, reduced neuroinflammation, and partial restoration of cognitive function. These findings suggest that targeting necroptosis may offer a novel therapeutic strategy that addresses both neuronal death and inflammatory cascades, potentially complementing or surpassing mono-targeted symptomatic treatments.</p><p id="Par51">Despite these promising advances, the translation of necroptosis inhibition into clinical therapies remains in its early stages and faces several critical challenges. The development of brain-penetrant, isoform-selective, and metabolically stable inhibitors for RIPK1, RIPK3, or MLKL is a prerequisite for human application. Equally vital is the thorough assessment of their safety, pharmacokinetics, and clinical efficacy in well-controlled trials. Parallel efforts should also focus on the identification and longitudinal validation of necroptosis-associated biomarkers, such as phosphorylated MLKL or RIPK3, in cerebrospinal fluid and plasma, as studies have detected elevated levels of pMLKL in the CSF of AD patients, which suggests its potential as a diagnostic indicator but also as a predictor of therapeutic response and disease progression. Understanding the temporal dynamics of necroptosis activation across different stages of AD is also imperative. Early stage intervention may yield maximal therapeutic benefits by preventing irreversible neuronal damage and AD. Moreover, exploring the complex intersection between necroptosis and other regulated cell death pathways, including apoptosis, ferroptosis, and pyroptosis, may also uncover novel nodes of convergence and provide a rationale for combinatorial therapeutic strategies. Additionally, research into the genetic, epigenetic, and transcriptomic regulation of necroptotic machinery could enhance our understanding of individual susceptibility to AD and aid in tailoring personalized therapeutic approaches.</p><p id="Par52">In conclusion, necroptosis represents a biologically robust and increasingly validated pathway contributing to AD pathology. While its therapeutic targeting holds considerable evidence, substantial preclinical and clinical validation is required to establish its role as a disease-modifying intervention. Continued research into the regulation, modulation, and translational application of necroptosis could mark a transformative step forward in the development of effective interventions for AD, shifting the focus from symptomatic relief to mechanistic disease reversal and neuronal preservation.</p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author Contributions</title><p>All authors contributed to the review article. The idea for the article was provided by Dr Richa Gupta. The manuscript preparation, data collection, and analysis were performed by Nishi Shah, Richa Gupta, and Gopal Natesan. The first draft of the manuscript was written by Nishi Shah and Richa Gupta, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.</p></notes><notes notes-type="data-availability"><title>Data Availability</title><p>No datasets were generated or analyzed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par53">The authors have no relevant financial or non-financial interests to disclose. <bold>Generative AI in Scientific Writing</bold> AI assistance was utilized solely for grammatical corrections in the preparation of this manuscript.</p></notes><notes id="FPar2"><title>Ethical approval</title><p id="Par54">This is a review article and has confirmed that no ethical approval is required.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abubakar</surname><given-names>M</given-names></name><name name-style="western"><surname>Giri</surname><given-names>A</given-names></name><name name-style="western"><surname>Goel</surname><given-names>F</given-names></name><name name-style="western"><surname>Khan</surname><given-names>M</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>J</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>D</given-names></name><name name-style="western"><surname>Kaushik</surname><given-names>M</given-names></name><name name-style="western"><surname>Rai</surname><given-names>SN</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>N</given-names></name></person-group><article-title>Diabetes, Alzheimer's disease risk factors, and the cafeteria diet: a comprehensive review</article-title><source>Curr Neuropharmacol</source><year>2025</year><pub-id pub-id-type="doi">10.2174/011570159x384737250626094315</pub-id><pub-id pub-id-type="pmid">40635220</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Abubakar M, Giri A, Goel F, Khan M, Gupta J, Kumar D, Kaushik M, Rai SN, Kumar N (2025) Diabetes, Alzheimer&#8217;s disease risk factors, and the cafeteria diet: a comprehensive review. Curr Neuropharmacol. 10.2174/011570159x384737250626094315<pub-id pub-id-type="pmid">40635220</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/011570159X384737250626094315</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Kuraishy</surname><given-names>HM</given-names></name><name name-style="western"><surname>Al-Maiahy</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Sulaiman</surname><given-names>GM</given-names></name><name name-style="western"><surname>Mohammed</surname><given-names>HA</given-names></name><name name-style="western"><surname>Albuhadily</surname><given-names>AK</given-names></name><name name-style="western"><surname>Al-Gareeb</surname><given-names>AI</given-names></name><name name-style="western"><surname>Abomughaid</surname><given-names>MM</given-names></name></person-group><article-title>The potential role of aryl hydrocarbon receptor in Alzheimer's disease: protective or detrimental</article-title><source>Ageing Res Rev</source><year>2025</year><pub-id pub-id-type="doi">10.1016/j.arr.2025.102810</pub-id><pub-id pub-id-type="pmid">40553978</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Al-Kuraishy HM, Al-Maiahy TJ, Sulaiman GM, Mohammed HA, Albuhadily AK, Al-Gareeb AI, Abomughaid MM (2025a) The potential role of aryl hydrocarbon receptor in Alzheimer&#8217;s disease: protective or detrimental. Ageing Res Rev. 10.1016/j.arr.2025.102810<pub-id pub-id-type="pmid">40553978</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2025.102810</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Kuraishy</surname><given-names>HM</given-names></name><name name-style="western"><surname>Sulaiman</surname><given-names>GM</given-names></name><name name-style="western"><surname>Mohammed</surname><given-names>HA</given-names></name><name name-style="western"><surname>Mohammed</surname><given-names>SG</given-names></name><name name-style="western"><surname>Al-Gareeb</surname><given-names>AI</given-names></name><name name-style="western"><surname>Albuhadily</surname><given-names>AK</given-names></name><name name-style="western"><surname>Dawood</surname><given-names>RA</given-names></name><name name-style="western"><surname>Al Ali</surname><given-names>A</given-names></name><name name-style="western"><surname>Abu-Alghayth</surname><given-names>MH</given-names></name></person-group><article-title>Amyloid-&#946; and heart failure in Alzheimer&#8217;s disease: the new vistas</article-title><source>Front Med</source><year>2025</year><volume>12</volume><fpage>1494101</fpage><pub-id pub-id-type="doi">10.3389/fmed.2025.1494101</pub-id><pub-id pub-id-type="pmcid">PMC11832649</pub-id><pub-id pub-id-type="pmid">39967593</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Al-Kuraishy HM, Sulaiman GM, Mohammed HA, Mohammed SG, Al-Gareeb AI, Albuhadily AK, Dawood RA, Al Ali A, Abu-Alghayth MH (2025b) Amyloid-&#946; and heart failure in Alzheimer&#8217;s disease: the new vistas. Front Med 12:1494101. 10.3389/fmed.2025.1494101<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmed.2025.1494101</pub-id><pub-id pub-id-type="pmcid">PMC11832649</pub-id><pub-id pub-id-type="pmid">39967593</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Kuraishy</surname><given-names>HM</given-names></name><name name-style="western"><surname>Sulaiman</surname><given-names>GM</given-names></name><name name-style="western"><surname>Mohammed</surname><given-names>HA</given-names></name><name name-style="western"><surname>Dawood</surname><given-names>RA</given-names></name><name name-style="western"><surname>Albuhadily</surname><given-names>AK</given-names></name><name name-style="western"><surname>Al-Gareeb</surname><given-names>AI</given-names></name><name name-style="western"><surname>Abomughaid</surname><given-names>MM</given-names></name><name name-style="western"><surname>Klionsky</surname><given-names>DJ</given-names></name></person-group><article-title>Alterations in the processing of platelet APP (Amyloid beta precursor protein) in Alzheimer disease: the possible nexus</article-title><source>Neuropsychopharmacology Reports</source><year>2025</year><volume>45</volume><issue>1</issue><fpage>e12525</fpage><pub-id pub-id-type="doi">10.1002/npr2.12525</pub-id><pub-id pub-id-type="pmid">39757022</pub-id><pub-id pub-id-type="pmcid">PMC11702489</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Al-Kuraishy HM, Sulaiman GM, Mohammed HA, Dawood RA, Albuhadily AK, Al-Gareeb AI, Abomughaid MM, Klionsky DJ (2025c) Alterations in the processing of platelet APP (Amyloid beta precursor protein) in Alzheimer disease: the possible nexus. Neuropsychopharmacology Reports 45(1):e12525. 10.1002/npr2.12525<pub-id pub-id-type="pmid">39757022</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/npr2.12525</pub-id><pub-id pub-id-type="pmcid">PMC11702489</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alsubaie</surname><given-names>N</given-names></name><name name-style="western"><surname>Al-Kuraishy</surname><given-names>HM</given-names></name><name name-style="western"><surname>Al-Gareeb</surname><given-names>AI</given-names></name><name name-style="western"><surname>Alharbi</surname><given-names>B</given-names></name><name name-style="western"><surname>De Waard</surname><given-names>M</given-names></name><name name-style="western"><surname>Sabatier</surname><given-names>J-M</given-names></name><name name-style="western"><surname>Saad</surname><given-names>HM</given-names></name><name name-style="western"><surname>Batiha</surname><given-names>GE-S</given-names></name></person-group><article-title>Statins use in Alzheimer disease: bane or boon from frantic search and narrative review</article-title><source>Brain Sci</source><year>2022</year><volume>12</volume><issue>10</issue><fpage>1290</fpage><pub-id pub-id-type="doi">10.3390/brainsci12101290</pub-id><pub-id pub-id-type="pmid">36291224</pub-id><pub-id pub-id-type="pmcid">PMC9599431</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Alsubaie N, Al-Kuraishy HM, Al-Gareeb AI, Alharbi B, De Waard M, Sabatier J-M, Saad HM, Batiha GE-S (2022) Statins use in Alzheimer disease: bane or boon from frantic search and narrative review. Brain Sci 12(10):1290. 10.3390/brainsci12101290<pub-id pub-id-type="pmid">36291224</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/brainsci12101290</pub-id><pub-id pub-id-type="pmcid">PMC9599431</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Angst</surname><given-names>G</given-names></name><name name-style="western"><surname>Jia</surname><given-names>N</given-names></name><name name-style="western"><surname>Esqueda</surname><given-names>LET</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name></person-group><article-title>Autophagy in alzheimer disease pathogenesis and its therapeutic values</article-title><source>Autophagy Reports</source><year>2025</year><volume>4</volume><issue>1</issue><fpage>2471677</fpage><pub-id pub-id-type="doi">10.1080/27694127.2025.2471677</pub-id><pub-id pub-id-type="pmid">40395993</pub-id><pub-id pub-id-type="pmcid">PMC12064067</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Angst G, Jia N, Esqueda LET, Fan Y, Cai Q, Wang C (2025) Autophagy in alzheimer disease pathogenesis and its therapeutic values. Autophagy Reports 4(1):2471677. 10.1080/27694127.2025.2471677<pub-id pub-id-type="pmid">40395993</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/27694127.2025.2471677</pub-id><pub-id pub-id-type="pmcid">PMC12064067</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Azargoonjahromi</surname><given-names>A</given-names></name></person-group><article-title>The duality of amyloid-&#946;: its role in normal and Alzheimer&#8217;s disease states</article-title><source>Mol Brain</source><year>2024</year><volume>17</volume><issue>1</issue><fpage>44</fpage><pub-id pub-id-type="doi">10.1186/s13041-024-01118-1</pub-id><pub-id pub-id-type="pmid">39020435</pub-id><pub-id pub-id-type="pmcid">PMC11256416</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Azargoonjahromi A (2024) The duality of amyloid-&#946;: its role in normal and Alzheimer&#8217;s disease states. Mol Brain 17(1):44. 10.1186/s13041-024-01118-1<pub-id pub-id-type="pmid">39020435</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13041-024-01118-1</pub-id><pub-id pub-id-type="pmcid">PMC11256416</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balestri</surname><given-names>W</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>R</given-names></name><name name-style="western"><surname>da Silva</surname><given-names>VA</given-names></name><name name-style="western"><surname>Bobotis</surname><given-names>BC</given-names></name><name name-style="western"><surname>Curle</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Kothakota</surname><given-names>V</given-names></name><name name-style="western"><surname>Kalantarnia</surname><given-names>F</given-names></name><name name-style="western"><surname>Hangad</surname><given-names>MV</given-names></name><name name-style="western"><surname>Hoorfar</surname><given-names>M</given-names></name><name name-style="western"><surname>Jones</surname><given-names>JL</given-names></name></person-group><article-title>Modeling the neuroimmune system in Alzheimer&#8217;s and Parkinson&#8217;s diseases</article-title><source>J Neuroinflamm</source><year>2024</year><volume>21</volume><issue>1</issue><fpage>32</fpage><pub-id pub-id-type="doi">10.1186/s12974-024-03024-8</pub-id><pub-id pub-id-type="pmcid">PMC10807115</pub-id><pub-id pub-id-type="pmid">38263227</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Balestri W, Sharma R, da Silva VA, Bobotis BC, Curle AJ, Kothakota V, Kalantarnia F, Hangad MV, Hoorfar M, Jones JL (2024) Modeling the neuroimmune system in Alzheimer&#8217;s and Parkinson&#8217;s diseases. J Neuroinflamm 21(1):32. 10.1186/s12974-024-03024-8<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-024-03024-8</pub-id><pub-id pub-id-type="pmcid">PMC10807115</pub-id><pub-id pub-id-type="pmid">38263227</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balusu</surname><given-names>S</given-names></name><name name-style="western"><surname>Horr&#233;</surname><given-names>K</given-names></name><name name-style="western"><surname>Thrupp</surname><given-names>N</given-names></name><name name-style="western"><surname>Craessaerts</surname><given-names>K</given-names></name><name name-style="western"><surname>Snellinx</surname><given-names>A</given-names></name><name name-style="western"><surname>Serneels</surname><given-names>L</given-names></name><name name-style="western"><surname>T&#8217;Syen</surname><given-names>D</given-names></name><name name-style="western"><surname>Chrysidou</surname><given-names>I</given-names></name><name name-style="western"><surname>Arranz</surname><given-names>AM</given-names></name><name name-style="western"><surname>Sierksma</surname><given-names>A</given-names></name></person-group><article-title>MEG3 activates necroptosis in human neuron xenografts modeling Alzheimer&#8217;s disease</article-title><source>Science</source><year>2023</year><volume>381</volume><issue>6663</issue><fpage>1176</fpage><lpage>1182</lpage><pub-id pub-id-type="doi">10.1126/science.abp9556</pub-id><pub-id pub-id-type="pmid">37708272</pub-id><pub-id pub-id-type="pmcid">PMC7615236</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Balusu S, Horr&#233; K, Thrupp N, Craessaerts K, Snellinx A, Serneels L, T&#8217;Syen D, Chrysidou I, Arranz AM, Sierksma A (2023) MEG3 activates necroptosis in human neuron xenografts modeling Alzheimer&#8217;s disease. Science 381(6663):1176&#8211;1182. 10.1126/science.abp9556<pub-id pub-id-type="pmid">37708272</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abp9556</pub-id><pub-id pub-id-type="pmcid">PMC7615236</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bansal</surname><given-names>VA</given-names></name><name name-style="western"><surname>Tan</surname><given-names>JM</given-names></name><name name-style="western"><surname>Soon</surname><given-names>HR</given-names></name><name name-style="western"><surname>Zainolabidin</surname><given-names>N</given-names></name><name name-style="western"><surname>Saido</surname><given-names>T</given-names></name><name name-style="western"><surname>Ch'ng</surname><given-names>TH</given-names></name></person-group><article-title>A&#946;-driven nuclear pore complex dysfunction alters activation of necroptosis proteins in a mouse model of Alzheimer&#8217;s disease</article-title><source>Elife</source><year>2025</year><volume>13</volume><fpage>RP92069</fpage><pub-id pub-id-type="doi">10.7554/eLife.92069.3</pub-id><pub-id pub-id-type="pmid">40132021</pub-id><pub-id pub-id-type="pmcid">PMC11936419</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Bansal VA, Tan JM, Soon HR, Zainolabidin N, Saido T, Ch&#8217;ng TH (2025) A&#946;-driven nuclear pore complex dysfunction alters activation of necroptosis proteins in a mouse model of Alzheimer&#8217;s disease. Elife 13:RP92069. 10.7554/eLife.92069.3<pub-id pub-id-type="pmid">40132021</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7554/eLife.92069</pub-id><pub-id pub-id-type="pmcid">PMC11936419</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caccamo</surname><given-names>A</given-names></name><name name-style="western"><surname>Branca</surname><given-names>C</given-names></name><name name-style="western"><surname>Piras</surname><given-names>IS</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>E</given-names></name><name name-style="western"><surname>Huentelman</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Liang</surname><given-names>WS</given-names></name><name name-style="western"><surname>Readhead</surname><given-names>B</given-names></name><name name-style="western"><surname>Dudley</surname><given-names>JT</given-names></name><name name-style="western"><surname>Spangenberg</surname><given-names>EE</given-names></name><name name-style="western"><surname>Green</surname><given-names>KN</given-names></name></person-group><article-title>Necroptosis activation in Alzheimer's disease</article-title><source>Nat Neurosci</source><year>2017</year><volume>20</volume><issue>9</issue><fpage>1236</fpage><lpage>1246</lpage><pub-id pub-id-type="doi">10.1038/nn.4608</pub-id><pub-id pub-id-type="pmid">28758999</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Caccamo A, Branca C, Piras IS, Ferreira E, Huentelman MJ, Liang WS, Readhead B, Dudley JT, Spangenberg EE, Green KN (2017) Necroptosis activation in Alzheimer&#8217;s disease. Nat Neurosci 20(9):1236&#8211;1246. 10.1038/nn.4608<pub-id pub-id-type="pmid">28758999</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nn.4608</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaouhan</surname><given-names>HS</given-names></name><name name-style="western"><surname>Vinod</surname><given-names>C</given-names></name><name name-style="western"><surname>Mahapatra</surname><given-names>N</given-names></name><name name-style="western"><surname>Yu</surname><given-names>S-H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>I-K</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K-B</given-names></name><name name-style="western"><surname>Yu</surname><given-names>T-M</given-names></name><name name-style="western"><surname>Li</surname><given-names>C-Y</given-names></name></person-group><article-title>Necroptosis: a pathogenic negotiator in human diseases</article-title><source>Int J Mol Sci</source><year>2022</year><volume>23</volume><issue>21</issue><fpage>12714</fpage><pub-id pub-id-type="doi">10.3390/ijms232112714</pub-id><pub-id pub-id-type="pmid">36361505</pub-id><pub-id pub-id-type="pmcid">PMC9655262</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Chaouhan HS, Vinod C, Mahapatra N, Yu S-H, Wang I-K, Chen K-B, Yu T-M, Li C-Y (2022) Necroptosis: a pathogenic negotiator in human diseases. Int J Mol Sci 23(21):12714. 10.3390/ijms232112714<pub-id pub-id-type="pmid">36361505</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms232112714</pub-id><pub-id pub-id-type="pmcid">PMC9655262</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Kos</surname><given-names>R</given-names></name><name name-style="western"><surname>Garssen</surname><given-names>J</given-names></name><name name-style="western"><surname>Redegeld</surname><given-names>F</given-names></name></person-group><article-title>Molecular insights into the mechanism of necroptosis: the necrosome as a potential therapeutic target</article-title><source>Cells</source><year>2019</year><volume>8</volume><issue>12</issue><fpage>1486</fpage><pub-id pub-id-type="doi">10.3390/cells8121486</pub-id><pub-id pub-id-type="pmid">31766571</pub-id><pub-id pub-id-type="pmcid">PMC6952807</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Chen J, Kos R, Garssen J, Redegeld F (2019) Molecular insights into the mechanism of necroptosis: the necrosome as a potential therapeutic target. Cells 8(12):1486. 10.3390/cells8121486<pub-id pub-id-type="pmid">31766571</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells8121486</pub-id><pub-id pub-id-type="pmcid">PMC6952807</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Blokhuis</surname><given-names>B</given-names></name><name name-style="western"><surname>Ruijtenbeek</surname><given-names>R</given-names></name><name name-style="western"><surname>Garssen</surname><given-names>J</given-names></name><name name-style="western"><surname>Redegeld</surname><given-names>F</given-names></name></person-group><article-title>Cell death triggers induce MLKL cleavage in multiple myeloma cells, which may promote cell death</article-title><source>Front Oncol</source><year>2022</year><volume>12</volume><fpage>907036</fpage><pub-id pub-id-type="doi">10.3389/fonc.2022.907036</pub-id><pub-id pub-id-type="pmid">35965541</pub-id><pub-id pub-id-type="pmcid">PMC9369655</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Chen J, Wang S, Blokhuis B, Ruijtenbeek R, Garssen J, Redegeld F (2022a) Cell death triggers induce MLKL cleavage in multiple myeloma cells, which may promote cell death. Front Oncol 12:907036. 10.3389/fonc.2022.907036<pub-id pub-id-type="pmid">35965541</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2022.907036</pub-id><pub-id pub-id-type="pmcid">PMC9369655</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Ou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><name name-style="western"><surname>Yu</surname><given-names>D</given-names></name><name name-style="western"><surname>Song</surname><given-names>Z</given-names></name><name name-style="western"><surname>Niu</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J</given-names></name></person-group><article-title>Advances in RIPK1 kinase inhibitors</article-title><source>Front Pharmacol</source><year>2022</year><volume>13</volume><fpage>976435</fpage><pub-id pub-id-type="doi">10.3389/fphar.2022.976435</pub-id><pub-id pub-id-type="pmid">36249746</pub-id><pub-id pub-id-type="pmcid">PMC9554302</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Chen L, Zhang X, Ou Y, Liu M, Yu D, Song Z, Niu L, Zhang L, Shi J (2022b) Advances in RIPK1 kinase inhibitors. Front Pharmacol 13:976435. 10.3389/fphar.2022.976435<pub-id pub-id-type="pmid">36249746</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2022.976435</pub-id><pub-id pub-id-type="pmcid">PMC9554302</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Nandi</surname><given-names>A</given-names></name><name name-style="western"><surname>Counts</surname><given-names>N</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>L</given-names></name><name name-style="western"><surname>Prettner</surname><given-names>K</given-names></name><name name-style="western"><surname>Kuhn</surname><given-names>M</given-names></name><name name-style="western"><surname>Seligman</surname><given-names>B</given-names></name><name name-style="western"><surname>Tortorice</surname><given-names>D</given-names></name><name name-style="western"><surname>Vigo</surname><given-names>DJTLGH</given-names></name></person-group><article-title>The global macroeconomic burden of Alzheimer's disease and other dementias: estimates and projections for 152 countries or territories</article-title><source>Lancet Glob Health</source><year>2024</year><volume>12</volume><issue>9</issue><fpage>e1534</fpage><lpage>e1543</lpage><pub-id pub-id-type="doi">10.1016/s2214-109x(24)00264-x</pub-id><pub-id pub-id-type="pmid">39151988</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Chen S, Cao Z, Nandi A, Counts N, Jiao L, Prettner K, Kuhn M, Seligman B, Tortorice D, Vigo DJTLGH (2024a) The global macroeconomic burden of Alzheimer&#8217;s disease and other dementias: estimates and projections for 152 countries or territories. Lancet Glob Health 12(9):e1534&#8211;e1543. 10.1016/s2214-109x(24)00264-x<pub-id pub-id-type="pmid">39151988</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2214-109X(24)00264-X</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>X-Y</given-names></name><name name-style="western"><surname>Dai</surname><given-names>Y-H</given-names></name><name name-style="western"><surname>Wan</surname><given-names>X-X</given-names></name><name name-style="western"><surname>Hu</surname><given-names>X-M</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>W-J</given-names></name><name name-style="western"><surname>Ban</surname><given-names>X-X</given-names></name><name name-style="western"><surname>Wan</surname><given-names>H</given-names></name><name name-style="western"><surname>Huang</surname><given-names>K</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>K</given-names></name></person-group><article-title>ZBP1-mediated necroptosis: mechanisms and therapeutic implications</article-title><source>Molecules</source><year>2022</year><volume>28</volume><issue>1</issue><fpage>52</fpage><pub-id pub-id-type="doi">10.3390/molecules28010052</pub-id><pub-id pub-id-type="pmid">36615244</pub-id><pub-id pub-id-type="pmcid">PMC9822119</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Chen X-Y, Dai Y-H, Wan X-X, Hu X-M, Zhao W-J, Ban X-X, Wan H, Huang K, Zhang Q, Xiong K (2022c) ZBP1-mediated necroptosis: mechanisms and therapeutic implications. Molecules 28(1):52. 10.3390/molecules28010052<pub-id pub-id-type="pmid">36615244</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules28010052</pub-id><pub-id pub-id-type="pmcid">PMC9822119</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S-B</given-names></name></person-group><article-title>Research progress on morphology and mechanism of programmed cell death</article-title><source>Cell Death Dis</source><year>2024</year><volume>15</volume><issue>5</issue><fpage>327</fpage><pub-id pub-id-type="doi">10.1038/s41419-024-06712-8</pub-id><pub-id pub-id-type="pmid">38729953</pub-id><pub-id pub-id-type="pmcid">PMC11087523</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Chen Y, Li X, Yang M, Liu S-B (2024) Research progress on morphology and mechanism of programmed cell death. Cell Death Dis 15(5):327<pub-id pub-id-type="pmid">38729953</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-024-06712-8</pub-id><pub-id pub-id-type="pmcid">PMC11087523</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Z</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J</given-names></name><name name-style="western"><surname>Qi</surname><given-names>B</given-names></name><name name-style="western"><surname>Kang</surname><given-names>X</given-names></name><name name-style="western"><surname>Ying</surname><given-names>C</given-names></name><name name-style="western"><surname>Guo</surname><given-names>C</given-names></name><name name-style="western"><surname>Yao</surname><given-names>M</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name></person-group><article-title>Potential mechanism underlying exercise upregulated circulating blood exosome miR-215-5p to prevent necroptosis of neuronal cells and a model for early diagnosis of alzheimer&#8217;s disease</article-title><source>Front Aging Neurosci</source><year>2022</year><volume>14</volume><fpage>860364</fpage><pub-id pub-id-type="doi">10.3389/fnagi.2022.860364</pub-id><pub-id pub-id-type="pmid">35615585</pub-id><pub-id pub-id-type="pmcid">PMC9126031</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Chen Y, Sun Y, Luo Z, Lin J, Qi B, Kang X, Ying C, Guo C, Yao M, Chen X (2022d) Potential mechanism underlying exercise upregulated circulating blood exosome miR-215-5p to prevent necroptosis of neuronal cells and a model for early diagnosis of alzheimer&#8217;s disease. Front Aging Neurosci 14:860364. 10.3389/fnagi.2022.860364<pub-id pub-id-type="pmid">35615585</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2022.860364</pub-id><pub-id pub-id-type="pmcid">PMC9126031</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yue</surname><given-names>S</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L</given-names></name><name name-style="western"><surname>Cao</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Deng</surname><given-names>A</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Du</surname><given-names>J</given-names></name></person-group><article-title>Regulation and function of the cGAS-STING pathway: mechanisms, post-translational modifications, and therapeutic potential in immunotherapy</article-title><source>Drug Des Dev Ther</source><year>2025</year><pub-id pub-id-type="doi">10.1016/j.cytogfr.2022.09.003</pub-id><pub-id pub-id-type="pmcid">PMC11911240</pub-id><pub-id pub-id-type="pmid">40098909</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Chen Y, Yue S, Yu L, Cao J, Liu Y, Deng A, Lu Y, Yang J, Li H, Du J (2025) Regulation and function of the cGAS-STING pathway: mechanisms, post-translational modifications, and therapeutic potential in immunotherapy. Drug Des Dev Ther. 10.1016/j.cytogfr.2022.09.003<pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/DDDT.S501773</pub-id><pub-id pub-id-type="pmcid">PMC11911240</pub-id><pub-id pub-id-type="pmid">40098909</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>S-B</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>S</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J-H</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>N-H</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J-H</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S-H</given-names></name></person-group><article-title>The molecular mechanisms of neuroinflammation in Alzheimer&#8217;s disease, the consequence of neural cell death</article-title><source>Int J Mol Sci</source><year>2023</year><volume>24</volume><issue>14</issue><fpage>11757</fpage><pub-id pub-id-type="doi">10.3390/ijms241411757</pub-id><pub-id pub-id-type="pmid">37511515</pub-id><pub-id pub-id-type="pmcid">PMC10380735</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Choi S-B, Kwon S, Kim J-H, Ahn N-H, Lee J-H, Yang S-H (2023) The molecular mechanisms of neuroinflammation in Alzheimer&#8217;s disease, the consequence of neural cell death. Int J Mol Sci 24(14):11757. 10.3390/ijms241411757<pub-id pub-id-type="pmid">37511515</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms241411757</pub-id><pub-id pub-id-type="pmcid">PMC10380735</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Conic</surname><given-names>JZ</given-names></name><name name-style="western"><surname>Chetty</surname><given-names>A</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Marsh</surname><given-names>A</given-names></name><name name-style="western"><surname>Barry</surname><given-names>S</given-names></name><name name-style="western"><surname>Pattabhi</surname><given-names>R</given-names></name><name name-style="western"><surname>Reske</surname><given-names>T</given-names></name><name name-style="western"><surname>Aguilar</surname><given-names>E</given-names></name><name name-style="western"><surname>Ali</surname><given-names>L</given-names></name></person-group><article-title>Effect of steroids on the progression of Alzheimer's dementia: a retrospective chart review</article-title><source>Aging Med</source><year>2025</year><volume>8</volume><issue>1</issue><fpage>e70004</fpage><pub-id pub-id-type="doi">10.1002/agm2.70004</pub-id><pub-id pub-id-type="pmcid">PMC11833297</pub-id><pub-id pub-id-type="pmid">39968005</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Conic JZ, Chetty A, Chen L, Marsh A, Barry S, Pattabhi R, Reske T, Aguilar E, Ali L (2025) Effect of steroids on the progression of Alzheimer&#8217;s dementia: a retrospective chart review. Aging Med 8(1):e70004. 10.1002/agm2.70004<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/agm2.70004</pub-id><pub-id pub-id-type="pmcid">PMC11833297</pub-id><pub-id pub-id-type="pmid">39968005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dai</surname><given-names>W</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>J</given-names></name><name name-style="western"><surname>Leng</surname><given-names>X</given-names></name><name name-style="western"><surname>Hu</surname><given-names>X</given-names></name><name name-style="western"><surname>Ao</surname><given-names>Y</given-names></name></person-group><article-title>The potential role of necroptosis in clinical diseases</article-title><source>Int J Mol Med</source><year>2021</year><volume>47</volume><issue>5</issue><fpage>89</fpage><pub-id pub-id-type="doi">10.3892/ijmm.2021.4922</pub-id><pub-id pub-id-type="pmid">33786617</pub-id><pub-id pub-id-type="pmcid">PMC8012024</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Dai W, Cheng J, Leng X, Hu X, Ao Y (2021) The potential role of necroptosis in clinical diseases. Int J Mol Med 47(5):89. 10.3892/ijmm.2021.4922<pub-id pub-id-type="pmid">33786617</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ijmm.2021.4922</pub-id><pub-id pub-id-type="pmcid">PMC8012024</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Degterev</surname><given-names>A</given-names></name><name name-style="western"><surname>Ofengeim</surname><given-names>D</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>J</given-names></name></person-group><article-title>Targeting RIPK1 for the treatment of human diseases</article-title><source>Proc Natl Acad Sci USA</source><year>2019</year><volume>116</volume><issue>20</issue><fpage>9714</fpage><lpage>9722</lpage><pub-id pub-id-type="doi">10.1073/pnas.1901179116</pub-id><pub-id pub-id-type="pmid">31048504</pub-id><pub-id pub-id-type="pmcid">PMC6525537</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Degterev A, Ofengeim D, Yuan J (2019) Targeting RIPK1 for the treatment of human diseases. Proc Natl Acad Sci USA 116(20):9714&#8211;9722. 10.1073/pnas.1901179116<pub-id pub-id-type="pmid">31048504</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1901179116</pub-id><pub-id pub-id-type="pmcid">PMC6525537</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dias</surname><given-names>D</given-names></name><name name-style="western"><surname>Portugal</surname><given-names>CC</given-names></name><name name-style="western"><surname>Relvas</surname><given-names>J</given-names></name><name name-style="western"><surname>Socodato</surname><given-names>R</given-names></name></person-group><article-title>From genetics to neuroinflammation: the impact of ApoE4 on microglial function in Alzheimer&#8217;s disease</article-title><source>Cells</source><year>2025</year><volume>14</volume><issue>4</issue><fpage>243</fpage><pub-id pub-id-type="doi">10.3390/cells14040243</pub-id><pub-id pub-id-type="pmid">39996715</pub-id><pub-id pub-id-type="pmcid">PMC11853365</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Dias D, Portugal CC, Relvas J, Socodato R (2025) From genetics to neuroinflammation: the impact of ApoE4 on microglial function in Alzheimer&#8217;s disease. Cells 14(4):243. 10.3390/cells14040243<pub-id pub-id-type="pmid">39996715</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells14040243</pub-id><pub-id pub-id-type="pmcid">PMC11853365</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name></person-group><article-title>Regulation of RIPK1 phosphorylation: implications for inflammation, cell death, and therapeutic interventions</article-title><source>Biomedicines</source><year>2024</year><volume>12</volume><issue>7</issue><fpage>1525</fpage><pub-id pub-id-type="doi">10.3390/biomedicines12071525</pub-id><pub-id pub-id-type="pmid">39062098</pub-id><pub-id pub-id-type="pmcid">PMC11275223</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Du J, Wang Z (2024) Regulation of RIPK1 phosphorylation: implications for inflammation, cell death, and therapeutic interventions. Biomedicines 12(7):1525. 10.3390/biomedicines12071525<pub-id pub-id-type="pmid">39062098</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biomedicines12071525</pub-id><pub-id pub-id-type="pmcid">PMC11275223</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duan</surname><given-names>Y-W</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S-X</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q-Y</given-names></name><name name-style="western"><surname>Zang</surname><given-names>Y</given-names></name></person-group><article-title>Neuroimmune mechanisms underlying neuropathic pain: the potential role of TNF-&#945;-necroptosis pathway</article-title><source>Int J Mol Sci</source><year>2022</year><volume>23</volume><issue>13</issue><fpage>7191</fpage><pub-id pub-id-type="doi">10.3390/ijms23137191</pub-id><pub-id pub-id-type="pmid">35806192</pub-id><pub-id pub-id-type="pmcid">PMC9266916</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Duan Y-W, Chen S-X, Li Q-Y, Zang Y (2022) Neuroimmune mechanisms underlying neuropathic pain: the potential role of TNF-&#945;-necroptosis pathway. Int J Mol Sci 23(13):7191. 10.3390/ijms23137191<pub-id pub-id-type="pmid">35806192</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms23137191</pub-id><pub-id pub-id-type="pmcid">PMC9266916</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ekundayo</surname><given-names>BE</given-names></name><name name-style="western"><surname>Obafemi</surname><given-names>TO</given-names></name><name name-style="western"><surname>Adewale</surname><given-names>OB</given-names></name><name name-style="western"><surname>Obafemi</surname><given-names>BA</given-names></name><name name-style="western"><surname>Oyinloye</surname><given-names>BE</given-names></name><name name-style="western"><surname>Ekundayo</surname><given-names>SK</given-names></name></person-group><article-title>Oxidative stress, endoplasmic reticulum stress and apoptosis in the pathology of Alzheimer&#8217;s disease</article-title><source>Cell Biochem Biophys</source><year>2024</year><volume>82</volume><issue>2</issue><fpage>457</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1007/s12013-024-01248-2</pub-id><pub-id pub-id-type="pmid">38472715</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Ekundayo BE, Obafemi TO, Adewale OB, Obafemi BA, Oyinloye BE, Ekundayo SK (2024) Oxidative stress, endoplasmic reticulum stress and apoptosis in the pathology of Alzheimer&#8217;s disease. Cell Biochem Biophys 82(2):457&#8211;477. 10.1007/s12013-024-01248-2<pub-id pub-id-type="pmid">38472715</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12013-024-01248-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Engin</surname><given-names>A</given-names></name></person-group><article-title>Protein kinase-mediated decision between the life and death</article-title><source>Advances Exp Med Biol</source><year>2021</year><pub-id pub-id-type="doi">10.1007/978-3-030-49844-3_1</pub-id><pub-id pub-id-type="pmid">33539010</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Engin A (2021) Protein kinase-mediated decision between the life and death. Advances Exp Med Biol. 10.1007/978-3-030-49844-3_1<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-3-030-49844-3_1</pub-id><pub-id pub-id-type="pmid">33539010</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ermine</surname><given-names>K</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name></person-group><article-title>Role of receptor interacting protein (RIP) kinases in cancer</article-title><source>Genes Dis</source><year>2022</year><volume>9</volume><issue>6</issue><fpage>1579</fpage><lpage>1593</lpage><pub-id pub-id-type="doi">10.1016/j.gendis.2021.10.007</pub-id><pub-id pub-id-type="pmid">36157481</pub-id><pub-id pub-id-type="pmcid">PMC9485196</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Ermine K, Yu J, Zhang L (2022) Role of receptor interacting protein (RIP) kinases in cancer. Genes Dis 9(6):1579&#8211;1593. 10.1016/j.gendis.2021.10.007<pub-id pub-id-type="pmid">36157481</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.gendis.2021.10.007</pub-id><pub-id pub-id-type="pmcid">PMC9485196</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Shang</surname><given-names>N</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Fan</surname><given-names>R</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>T</given-names></name><name name-style="western"><surname>Niu</surname><given-names>Q</given-names></name></person-group><article-title>Necrostatin-1 relieves learning and memory deficits in a zebrafish model of Alzheimer&#8217;s disease induced by aluminum</article-title><source>Neurotoxicol Res</source><year>2022</year><volume>40</volume><issue>1</issue><fpage>198</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1007/s12640-021-00463-6</pub-id><pub-id pub-id-type="pmid">34982355</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Gao X, Zhang P, Chen J, Zhang L, Shang N, Chen J, Fan R, Wang Y, Huang T, Niu Q (2022) Necrostatin-1 relieves learning and memory deficits in a zebrafish model of Alzheimer&#8217;s disease induced by aluminum. Neurotoxicol Res 40(1):198&#8211;214. 10.1007/s12640-021-00463-6<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12640-021-00463-6</pub-id><pub-id pub-id-type="pmid">34982355</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gong</surname><given-names>Q</given-names></name><name name-style="western"><surname>Ali</surname><given-names>T</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gao</surname><given-names>R</given-names></name><name name-style="western"><surname>Mou</surname><given-names>S</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C</given-names></name><name name-style="western"><surname>Li</surname><given-names>A</given-names></name><name name-style="western"><surname>Li</surname><given-names>T</given-names></name><name name-style="western"><surname>Hao</surname><given-names>LL</given-names></name></person-group><article-title>RIPK1 inhibition mitigates neuroinflammation and rescues depressive-like behaviors in a mouse model of LPS-induced depression</article-title><source>Cell Commun Signal</source><year>2024</year><volume>22</volume><issue>1</issue><fpage>427</fpage><pub-id pub-id-type="doi">10.1186/s12964-024-01796-3</pub-id><pub-id pub-id-type="pmid">39223674</pub-id><pub-id pub-id-type="pmcid">PMC11367892</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Gong Q, Ali T, Hu Y, Gao R, Mou S, Luo Y, Yang C, Li A, Li T, Hao LL (2024) RIPK1 inhibition mitigates neuroinflammation and rescues depressive-like behaviors in a mouse model of LPS-induced depression. Cell Commun Signal 22(1):427. 10.1186/s12964-024-01796-3<pub-id pub-id-type="pmid">39223674</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12964-024-01796-3</pub-id><pub-id pub-id-type="pmcid">PMC11367892</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W-T</given-names></name><name name-style="western"><surname>Mai</surname><given-names>F-Y</given-names></name><name name-style="western"><surname>Liang</surname><given-names>J-R</given-names></name><name name-style="western"><surname>Luo</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>M-C</given-names></name><name name-style="western"><surname>Yu</surname><given-names>D-D</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y-L</given-names></name><name name-style="western"><surname>Li</surname><given-names>C-G</given-names></name></person-group><article-title>Unravelling oncosis: morphological and molecular insights into a unique cell death pathway</article-title><source>Front Immunol</source><year>2024</year><volume>15</volume><fpage>1450998</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2024.1450998</pub-id><pub-id pub-id-type="pmid">39281670</pub-id><pub-id pub-id-type="pmcid">PMC11393741</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Guo J, Yang W-T, Mai F-Y, Liang J-R, Luo J, Zhou M-C, Yu D-D, Wang Y-L, Li C-G (2024) Unravelling oncosis: morphological and molecular insights into a unique cell death pathway. Front Immunol 15:1450998. 10.3389/fimmu.2024.1450998<pub-id pub-id-type="pmid">39281670</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2024.1450998</pub-id><pub-id pub-id-type="pmcid">PMC11393741</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gustavsson</surname><given-names>A</given-names></name><name name-style="western"><surname>Norton</surname><given-names>N</given-names></name><name name-style="western"><surname>Fast</surname><given-names>T</given-names></name><name name-style="western"><surname>Fr&#246;lich</surname><given-names>L</given-names></name><name name-style="western"><surname>Georges</surname><given-names>J</given-names></name><name name-style="western"><surname>Holzapfel</surname><given-names>D</given-names></name><name name-style="western"><surname>Kirabali</surname><given-names>T</given-names></name><name name-style="western"><surname>Krolak-Salmon</surname><given-names>P</given-names></name><name name-style="western"><surname>Rossini</surname><given-names>PM</given-names></name><name name-style="western"><surname>Ferretti</surname><given-names>MT</given-names></name></person-group><article-title>Global estimates on the number of persons across the Alzheimer's disease continuum</article-title><source>Alzheimer's Dementia</source><year>2023</year><volume>19</volume><issue>2</issue><fpage>658</fpage><lpage>670</lpage><pub-id pub-id-type="doi">10.1002/alz.12694</pub-id><pub-id pub-id-type="pmid">35652476</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Gustavsson A, Norton N, Fast T, Fr&#246;lich L, Georges J, Holzapfel D, Kirabali T, Krolak-Salmon P, Rossini PM, Ferretti MT (2023) Global estimates on the number of persons across the Alzheimer&#8217;s disease continuum. Alzheimer&#8217;s Dementia 19(2):658&#8211;670. 10.1002/alz.12694<pub-id pub-id-type="pmid">35652476</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12694</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>L-L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y-C</given-names></name><name name-style="western"><surname>Ai</surname><given-names>Y-T</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Gu</surname><given-names>S-M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P</given-names></name><name name-style="western"><surname>Long</surname><given-names>Q-H</given-names></name><name name-style="western"><surname>Hu</surname><given-names>H</given-names></name></person-group><article-title>Qiangji decoction alleviates neurodegenerative changes and hippocampal neuron apoptosis induced by D-Galactose via regulating AMPK/SIRT1/NF-&#954;B signaling pathway</article-title><source>Front Pharmacol</source><year>2021</year><volume>12</volume><fpage>735812</fpage><pub-id pub-id-type="doi">10.3389/fphar.2021.735812</pub-id><pub-id pub-id-type="pmid">34630111</pub-id><pub-id pub-id-type="pmcid">PMC8495211</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">He L-L, Wang Y-C, Ai Y-T, Wang L, Gu S-M, Wang P, Long Q-H, Hu H (2021) Qiangji decoction alleviates neurodegenerative changes and hippocampal neuron apoptosis induced by D-Galactose via regulating AMPK/SIRT1/NF-&#954;B signaling pathway. Front Pharmacol 12:735812. 10.3389/fphar.2021.735812<pub-id pub-id-type="pmid">34630111</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2021.735812</pub-id><pub-id pub-id-type="pmcid">PMC8495211</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hincelin-Mery</surname><given-names>A</given-names></name><name name-style="western"><surname>Nicolas</surname><given-names>X</given-names></name><name name-style="western"><surname>Cantalloube</surname><given-names>C</given-names></name><name name-style="western"><surname>Pomponio</surname><given-names>R</given-names></name><name name-style="western"><surname>Lewanczyk</surname><given-names>P</given-names></name><name name-style="western"><surname>Benamor</surname><given-names>M</given-names></name><name name-style="western"><surname>Ofengeim</surname><given-names>D</given-names></name><name name-style="western"><surname>Krupka</surname><given-names>E</given-names></name><name name-style="western"><surname>Hsiao-Nakamoto</surname><given-names>J</given-names></name><name name-style="western"><surname>Eastenson</surname><given-names>A</given-names></name></person-group><article-title>Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants</article-title><source>Clin Transl Sci</source><year>2024</year><volume>17</volume><issue>1</issue><fpage>e13690</fpage><pub-id pub-id-type="doi">10.1111/cts.13690</pub-id><pub-id pub-id-type="pmid">38010108</pub-id><pub-id pub-id-type="pmcid">PMC10772668</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Hincelin-Mery A, Nicolas X, Cantalloube C, Pomponio R, Lewanczyk P, Benamor M, Ofengeim D, Krupka E, Hsiao-Nakamoto J, Eastenson A (2024) Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants. Clin Transl Sci 17(1):e13690. 10.1111/cts.13690<pub-id pub-id-type="pmid">38010108</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cts.13690</pub-id><pub-id pub-id-type="pmcid">PMC10772668</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Homma</surname><given-names>H</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>H</given-names></name><name name-style="western"><surname>Fujita</surname><given-names>K</given-names></name><name name-style="western"><surname>Okazawa</surname><given-names>H</given-names></name></person-group><article-title>Necrosis links neurodegeneration and neuroinflammation in neurodegenerative disease</article-title><source>Int J Mol Sci</source><year>2024</year><volume>25</volume><issue>7</issue><fpage>3636</fpage><pub-id pub-id-type="doi">10.3390/ijms25073636</pub-id><pub-id pub-id-type="pmid">38612448</pub-id><pub-id pub-id-type="pmcid">PMC11012149</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Homma H, Tanaka H, Fujita K, Okazawa H (2024) Necrosis links neurodegeneration and neuroinflammation in neurodegenerative disease. Int J Mol Sci 25(7):3636. 10.3390/ijms25073636<pub-id pub-id-type="pmid">38612448</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms25073636</pub-id><pub-id pub-id-type="pmcid">PMC11012149</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>K</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wan</surname><given-names>H</given-names></name><name name-style="western"><surname>Ban</surname><given-names>XX</given-names></name><name name-style="western"><surname>Chen</surname><given-names>XY</given-names></name><name name-style="western"><surname>Wan</surname><given-names>XX</given-names></name><name name-style="western"><surname>Lu</surname><given-names>R</given-names></name><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>K</given-names></name></person-group><article-title>TAK 1 at the crossroads of multiple regulated cell death pathways: from molecular mechanisms to human diseases</article-title><source>FEBS J</source><year>2025</year><pub-id pub-id-type="doi">10.1111/febs.70042</pub-id><pub-id pub-id-type="pmid">40047220</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Huang K, Zhang Q, Wan H, Ban XX, Chen XY, Wan XX, Lu R, He Y, Xiong K (2025) TAK 1 at the crossroads of multiple regulated cell death pathways: from molecular mechanisms to human diseases. FEBS J. 10.1111/febs.70042<pub-id pub-id-type="pmid">40047220</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/febs.70042</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jayaraman</surname><given-names>A</given-names></name><name name-style="western"><surname>Htike</surname><given-names>TT</given-names></name><name name-style="western"><surname>James</surname><given-names>R</given-names></name><name name-style="western"><surname>Picon</surname><given-names>C</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>R</given-names></name></person-group><article-title>TNF-mediated neuroinflammation is linked to neuronal necroptosis in Alzheimer's disease hippocampus</article-title><source>Acta Neuropathol Commun</source><year>2021</year><volume>9</volume><fpage>1</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1186/s40478-021-01264-w</pub-id><pub-id pub-id-type="pmid">34625123</pub-id><pub-id pub-id-type="pmcid">PMC8501605</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Jayaraman A, Htike TT, James R, Picon C, Reynolds R (2021) TNF-mediated neuroinflammation is linked to neuronal necroptosis in Alzheimer&#8217;s disease hippocampus. Acta Neuropathol Commun 9:1&#8211;21. 10.1186/s40478-021-01264-w<pub-id pub-id-type="pmid">34625123</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40478-021-01264-w</pub-id><pub-id pub-id-type="pmcid">PMC8501605</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>G</given-names></name><name name-style="western"><surname>Xie</surname><given-names>G</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>J</given-names></name></person-group><article-title>Cytoskeletal proteins and Alzheimer&#8217;s disease pathogenesis: focusing on the interplay with Tau pathology</article-title><source>Biomolecules</source><year>2025</year><volume>15</volume><issue>6</issue><fpage>831</fpage><pub-id pub-id-type="doi">10.3390/biom15060831</pub-id><pub-id pub-id-type="pmid">40563471</pub-id><pub-id pub-id-type="pmcid">PMC12190275</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Jiang G, Xie G, Li X, Xiong J (2025a) Cytoskeletal proteins and Alzheimer&#8217;s disease pathogenesis: focusing on the interplay with Tau pathology. Biomolecules 15(6):831. 10.3390/biom15060831<pub-id pub-id-type="pmid">40563471</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biom15060831</pub-id><pub-id pub-id-type="pmcid">PMC12190275</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X-Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G-H</given-names></name><name name-style="western"><surname>Ye</surname><given-names>K</given-names></name><name name-style="western"><surname>Song</surname><given-names>W</given-names></name><name name-style="western"><surname>Masters</surname><given-names>CL</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name></person-group><article-title>Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances</article-title><source>Signal Transduct Target Ther</source><year>2025</year><volume>10</volume><issue>1</issue><fpage>76</fpage><pub-id pub-id-type="doi">10.1038/s41392-025-02145-7</pub-id><pub-id pub-id-type="pmid">40059211</pub-id><pub-id pub-id-type="pmcid">PMC11891338</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Jiang Q, Liu J, Huang S, Wang X-Y, Chen X, Liu G-H, Ye K, Song W, Masters CL, Wang J (2025b) Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances. Signal Transduct Target Ther 10(1):76. 10.1038/s41392-025-02145-7<pub-id pub-id-type="pmid">40059211</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-025-02145-7</pub-id><pub-id pub-id-type="pmcid">PMC11891338</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>A</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Pan</surname><given-names>S</given-names></name><name name-style="western"><surname>Yan</surname><given-names>F</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name><name name-style="western"><surname>Bai</surname><given-names>Y</given-names></name></person-group><article-title>From RIPK1 to necroptosis: pathogenic mechanisms in neurodegenerative diseases</article-title><source>Neurochem Res</source><year>2025</year><volume>50</volume><issue>3</issue><fpage>194</fpage><pub-id pub-id-type="doi">10.1007/s11064-025-04448-1</pub-id><pub-id pub-id-type="pmid">40493155</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Kang A, Qiao Y, Pan S, Yan F, Chen H, Bai Y (2025) From RIPK1 to necroptosis: pathogenic mechanisms in neurodegenerative diseases. Neurochem Res 50(3):194. 10.1007/s11064-025-04448-1<pub-id pub-id-type="pmid">40493155</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11064-025-04448-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaur</surname><given-names>J</given-names></name><name name-style="western"><surname>Singh</surname><given-names>H</given-names></name><name name-style="western"><surname>Naqvi</surname><given-names>SJMN</given-names></name></person-group><article-title>Intracellular DAMPs in neurodegeneration and their role in clinical therapeutics</article-title><source>Mol Neurobiol</source><year>2023</year><volume>60</volume><issue>7</issue><fpage>3600</fpage><lpage>3616</lpage><pub-id pub-id-type="doi">10.1007/s12035-023-03289-9</pub-id><pub-id pub-id-type="pmid">36859688</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Kaur J, Singh H, Naqvi SJMN (2023) Intracellular DAMPs in neurodegeneration and their role in clinical therapeutics. Mol Neurobiol 60(7):3600&#8211;3616. 10.1007/s12035-023-03289-9<pub-id pub-id-type="pmid">36859688</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12035-023-03289-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ke</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>P</given-names></name><name name-style="western"><surname>Dai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X</given-names></name><name name-style="western"><surname>Chu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name></person-group><article-title>RIPK1 and RIPK3 inhibitors: potential weapons against inflammation to treat diabetic complications</article-title><source>Front Immunol</source><year>2023</year><volume>14</volume><fpage>1274654</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2023.1274654</pub-id><pub-id pub-id-type="pmid">37954576</pub-id><pub-id pub-id-type="pmcid">PMC10639174</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Ke D, Zhang Z, Liu J, Chen P, Dai Y, Sun X, Chu Y, Li L (2023) RIPK1 and RIPK3 inhibitors: potential weapons against inflammation to treat diabetic complications. Front Immunol 14:1274654. 10.3389/fimmu.2023.1274654<pub-id pub-id-type="pmid">37954576</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2023.1274654</pub-id><pub-id pub-id-type="pmcid">PMC10639174</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name><name name-style="western"><surname>Lu</surname><given-names>HC</given-names></name><name name-style="western"><surname>Steelman</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name></person-group><article-title>Myeloid caspase-8 restricts RIPK3-dependent proinflammatory IL-1&#946; production and CD4 T cell activation in autoimmune demyelination</article-title><source>Proc Natl Acad Sci USA</source><year>2022</year><volume>119</volume><issue>24</issue><fpage>e2117636119</fpage><pub-id pub-id-type="doi">10.1073/pnas.2117636119</pub-id><pub-id pub-id-type="pmid">35671429</pub-id><pub-id pub-id-type="pmcid">PMC9214530</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Kim S, Lu HC, Steelman AJ, Li J (2022) Myeloid caspase-8 restricts RIPK3-dependent proinflammatory IL-1&#946; production and CD4 T cell activation in autoimmune demyelination. Proc Natl Acad Sci USA 119(24):e2117636119. 10.1073/pnas.2117636119<pub-id pub-id-type="pmid">35671429</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2117636119</pub-id><pub-id pub-id-type="pmcid">PMC9214530</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klegeris</surname><given-names>A</given-names></name></person-group><article-title>Regulation of neuroimmune processes by damage-and resolution-associated molecular patterns</article-title><source>Neural Regen Res</source><year>2021</year><volume>16</volume><issue>3</issue><fpage>423</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.4103/1673-5374.293134</pub-id><pub-id pub-id-type="pmid">32985460</pub-id><pub-id pub-id-type="pmcid">PMC7996015</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Klegeris A (2021) Regulation of neuroimmune processes by damage-and resolution-associated molecular patterns. Neural Regen Res 16(3):423&#8211;429. 10.4103/1673-5374.293134<pub-id pub-id-type="pmid">32985460</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/1673-5374.293134</pub-id><pub-id pub-id-type="pmcid">PMC7996015</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koper</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Moonen</surname><given-names>S</given-names></name><name name-style="western"><surname>Ronisz</surname><given-names>A</given-names></name><name name-style="western"><surname>Ospitalieri</surname><given-names>S</given-names></name><name name-style="western"><surname>Callaerts-Vegh</surname><given-names>Z</given-names></name><name name-style="western"><surname>T&#8217;Syen</surname><given-names>D</given-names></name><name name-style="western"><surname>Rabe</surname><given-names>S</given-names></name><name name-style="western"><surname>Staufenbiel</surname><given-names>M</given-names></name><name name-style="western"><surname>De Strooper</surname><given-names>B</given-names></name><name name-style="western"><surname>Balusu</surname><given-names>S</given-names></name></person-group><article-title>Inhibition of an Alzheimer&#8217;s disease&#8211;associated form of necroptosis rescues neuronal death in mouse models</article-title><source>Sci Transl Med</source><year>2024</year><volume>16</volume><issue>771</issue><fpage>eadf5128</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.adf5128</pub-id><pub-id pub-id-type="pmid">39475569</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Koper MJ, Moonen S, Ronisz A, Ospitalieri S, Callaerts-Vegh Z, T&#8217;Syen D, Rabe S, Staufenbiel M, De Strooper B, Balusu S (2024) Inhibition of an Alzheimer&#8217;s disease&#8211;associated form of necroptosis rescues neuronal death in mouse models. Sci Transl Med 16(771):eadf5128. 10.1126/scitranslmed.adf5128<pub-id pub-id-type="pmid">39475569</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.adf5128</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koper</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Tom&#233;</surname><given-names>SO</given-names></name><name name-style="western"><surname>Gawor</surname><given-names>K</given-names></name><name name-style="western"><surname>Belet</surname><given-names>A</given-names></name><name name-style="western"><surname>Van Schoor</surname><given-names>E</given-names></name><name name-style="western"><surname>Schaeverbeke</surname><given-names>J</given-names></name><name name-style="western"><surname>Vandenberghe</surname><given-names>R</given-names></name><name name-style="western"><surname>Vandenbulcke</surname><given-names>M</given-names></name><name name-style="western"><surname>Ghebremedhin</surname><given-names>E</given-names></name><name name-style="western"><surname>Otto</surname><given-names>M</given-names></name></person-group><article-title>LATE-NC aggravates GVD-mediated necroptosis in Alzheimer&#8217;s disease</article-title><source>Acta Neuropathol Commun</source><year>2022</year><volume>10</volume><issue>1</issue><fpage>128</fpage><pub-id pub-id-type="doi">10.1186/s40478-022-01432-6</pub-id><pub-id pub-id-type="pmid">36057624</pub-id><pub-id pub-id-type="pmcid">PMC9441100</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Koper MJ, Tom&#233; SO, Gawor K, Belet A, Van Schoor E, Schaeverbeke J, Vandenberghe R, Vandenbulcke M, Ghebremedhin E, Otto M (2022) LATE-NC aggravates GVD-mediated necroptosis in Alzheimer&#8217;s disease. Acta Neuropathol Commun 10(1):128. 10.1186/s40478-022-01432-6<pub-id pub-id-type="pmid">36057624</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40478-022-01432-6</pub-id><pub-id pub-id-type="pmcid">PMC9441100</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>D</given-names></name><name name-style="western"><surname>Wu</surname><given-names>M</given-names></name></person-group><article-title>Pattern recognition receptors in health and diseases</article-title><source>Signal Transduct Target Ther</source><year>2021</year><volume>6</volume><issue>1</issue><fpage>291</fpage><pub-id pub-id-type="doi">10.1038/s41392-021-00687-0</pub-id><pub-id pub-id-type="pmid">34344870</pub-id><pub-id pub-id-type="pmcid">PMC8333067</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Li D, Wu M (2021) Pattern recognition receptors in health and diseases. Signal Transduct Target Ther 6(1):291. 10.1038/s41392-021-00687-0<pub-id pub-id-type="pmid">34344870</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-021-00687-0</pub-id><pub-id pub-id-type="pmcid">PMC8333067</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liccardi</surname><given-names>G</given-names></name><name name-style="western"><surname>Annibaldi</surname><given-names>A</given-names></name></person-group><article-title>MLKL post-translational modifications: road signs to infection, inflammation and unknown destinations</article-title><source>Cell Death Differ</source><year>2023</year><volume>30</volume><issue>2</issue><fpage>269</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1038/s41418-022-01061-5</pub-id><pub-id pub-id-type="pmid">36175538</pub-id><pub-id pub-id-type="pmcid">PMC9520111</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Liccardi G, Annibaldi A (2023) MLKL post-translational modifications: road signs to infection, inflammation and unknown destinations. Cell Death Differ 30(2):269&#8211;278. 10.1038/s41418-022-01061-5<pub-id pub-id-type="pmid">36175538</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41418-022-01061-5</pub-id><pub-id pub-id-type="pmcid">PMC9520111</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>Q</given-names></name><name name-style="western"><surname>Dan</surname><given-names>J</given-names></name><name name-style="western"><surname>Xie</surname><given-names>X</given-names></name></person-group><article-title>Crosstalk and Prospects of TBK1 in Inflammation</article-title><source>Immunol Invest</source><year>2024</year><volume>53</volume><issue>8</issue><fpage>1205</fpage><lpage>1233</lpage><pub-id pub-id-type="doi">10.1080/08820139.2024.2392587</pub-id><pub-id pub-id-type="pmid">39194013</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Liu H, Sheng Q, Dan J, Xie X (2024) Crosstalk and Prospects of TBK1 in Inflammation. Immunol Invest 53(8):1205&#8211;1233. 10.1080/08820139.2024.2392587<pub-id pub-id-type="pmid">39194013</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/08820139.2024.2392587</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Livingston</surname><given-names>G</given-names></name><name name-style="western"><surname>Huntley</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>KY</given-names></name><name name-style="western"><surname>Costafreda</surname><given-names>SG</given-names></name><name name-style="western"><surname>Selb&#230;k</surname><given-names>G</given-names></name><name name-style="western"><surname>Alladi</surname><given-names>S</given-names></name><name name-style="western"><surname>Ames</surname><given-names>D</given-names></name><name name-style="western"><surname>Banerjee</surname><given-names>S</given-names></name><name name-style="western"><surname>Burns</surname><given-names>A</given-names></name><name name-style="western"><surname>Brayne</surname><given-names>C</given-names></name></person-group><article-title>Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission</article-title><source>Lancet</source><year>2024</year><volume>404</volume><issue>10452</issue><fpage>572</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(24)01296-0</pub-id><pub-id pub-id-type="pmid">39096926</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Livingston G, Huntley J, Liu KY, Costafreda SG, Selb&#230;k G, Alladi S, Ames D, Banerjee S, Burns A, Brayne C (2024) Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet 404(10452):572&#8211;628. 10.1016/s0140-6736(24)01296-0<pub-id pub-id-type="pmid">39096926</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(24)01296-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>D</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wei</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name></person-group><article-title>Cornel iridoid glycoside ameliorated Alzheimer&#8217;s disease-like pathologies and necroptosis through RIPK1/MLKL pathway in young and aged SAMP8 mice</article-title><source>Evid-Based Complement Altern Med</source><year>2021</year><volume>2021</volume><issue>1</issue><fpage>9920962</fpage><pub-id pub-id-type="doi">10.1093/brain/awaa364</pub-id><pub-id pub-id-type="pmcid">PMC8407981</pub-id><pub-id pub-id-type="pmid">34475966</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Ma D, Li Y, Zhu Y, Wei W, Zhang L, Li Y, Li L, Zhang L (2021) Cornel iridoid glycoside ameliorated Alzheimer&#8217;s disease-like pathologies and necroptosis through RIPK1/MLKL pathway in young and aged SAMP8 mice. Evid-Based Complement Altern Med 2021(1):9920962. 10.1093/brain/awaa364<pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2021/9920962</pub-id><pub-id pub-id-type="pmcid">PMC8407981</pub-id><pub-id pub-id-type="pmid">34475966</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahboob</surname><given-names>A</given-names></name><name name-style="western"><surname>Ali</surname><given-names>H</given-names></name><name name-style="western"><surname>AlNaimi</surname><given-names>A</given-names></name><name name-style="western"><surname>Yousef</surname><given-names>M</given-names></name><name name-style="western"><surname>Rob</surname><given-names>M</given-names></name><name name-style="western"><surname>Al-Muhannadi</surname><given-names>NA</given-names></name><name name-style="western"><surname>Senevirathne</surname><given-names>DKL</given-names></name><name name-style="western"><surname>Chaari</surname><given-names>A</given-names></name></person-group><article-title>Immunotherapy for Parkinson&#8217;s disease and Alzheimer&#8217;s disease: a promising disease-modifying therapy</article-title><source>Cells</source><year>2024</year><volume>13</volume><issue>18</issue><fpage>1527</fpage><pub-id pub-id-type="doi">10.3390/cells13181527</pub-id><pub-id pub-id-type="pmid">39329711</pub-id><pub-id pub-id-type="pmcid">PMC11429902</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Mahboob A, Ali H, AlNaimi A, Yousef M, Rob M, Al-Muhannadi NA, Senevirathne DKL, Chaari A (2024) Immunotherapy for Parkinson&#8217;s disease and Alzheimer&#8217;s disease: a promising disease-modifying therapy. Cells 13(18):1527. 10.3390/cells13181527<pub-id pub-id-type="pmid">39329711</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells13181527</pub-id><pub-id pub-id-type="pmcid">PMC11429902</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manik</surname><given-names>MK</given-names></name><name name-style="western"><surname>Pan</surname><given-names>M</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>L</given-names></name><name name-style="western"><surname>Gu</surname><given-names>W</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H</given-names></name><name name-style="western"><surname>Pospich</surname><given-names>S</given-names></name><name name-style="western"><surname>Hedger</surname><given-names>A</given-names></name><name name-style="western"><surname>Vajjhala</surname><given-names>PR</given-names></name><name name-style="western"><surname>Lee</surname><given-names>MY</given-names></name><name name-style="western"><surname>Qian</surname><given-names>X</given-names></name></person-group><article-title>Structural basis for TIR domain&#8211;mediated innate immune signaling by Toll-like receptor adaptors TRIF and TRAM</article-title><source>Proc Natl Acad Sci USA</source><year>2025</year><volume>122</volume><issue>2</issue><fpage>e2418988122</fpage><pub-id pub-id-type="doi">10.1073/pnas.2418988122</pub-id><pub-id pub-id-type="pmid">39786929</pub-id><pub-id pub-id-type="pmcid">PMC11745336</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Manik MK, Pan M, Xiao L, Gu W, Kim H, Pospich S, Hedger A, Vajjhala PR, Lee MY, Qian X (2025) Structural basis for TIR domain&#8211;mediated innate immune signaling by Toll-like receptor adaptors TRIF and TRAM. Proc Natl Acad Sci USA 122(2):e2418988122. 10.1073/pnas.2418988122<pub-id pub-id-type="pmid">39786929</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2418988122</pub-id><pub-id pub-id-type="pmcid">PMC11745336</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manohar</surname><given-names>SM</given-names></name></person-group><article-title>At the crossroads of TNF &#945; signaling and cancer</article-title><source>Curr Mol Pharmacol</source><year>2024</year><volume>17</volume><issue>1</issue><fpage>E080923220828</fpage><pub-id pub-id-type="doi">10.2174/1874467217666230908111754</pub-id><pub-id pub-id-type="pmid">37691196</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Manohar SM (2024) At the crossroads of TNF &#945; signaling and cancer. Curr Mol Pharmacol 17(1):E080923220828. 10.2174/1874467217666230908111754<pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1874467217666230908111754</pub-id><pub-id pub-id-type="pmid">37691196</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#225;zl&#243;</surname><given-names>A</given-names></name><name name-style="western"><surname>Jenei</surname><given-names>V</given-names></name><name name-style="western"><surname>Burai</surname><given-names>S</given-names></name><name name-style="western"><surname>Moln&#225;r</surname><given-names>T</given-names></name><name name-style="western"><surname>B&#225;csi</surname><given-names>A</given-names></name><name name-style="western"><surname>Koncz</surname><given-names>G</given-names></name></person-group><article-title>Types of necroinflammation, the effect of cell death modalities on sterile inflammation</article-title><source>Cell Death Dis</source><year>2022</year><volume>13</volume><issue>5</issue><fpage>423</fpage><pub-id pub-id-type="doi">10.1038/s41419-022-04883-w</pub-id><pub-id pub-id-type="pmid">35501340</pub-id><pub-id pub-id-type="pmcid">PMC9061831</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">M&#225;zl&#243; A, Jenei V, Burai S, Moln&#225;r T, B&#225;csi A, Koncz G (2022) Types of necroinflammation, the effect of cell death modalities on sterile inflammation. Cell Death Dis 13(5):423. 10.1038/s41419-022-04883-w<pub-id pub-id-type="pmid">35501340</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-022-04883-w</pub-id><pub-id pub-id-type="pmcid">PMC9061831</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mishra</surname><given-names>S</given-names></name><name name-style="western"><surname>Dey</surname><given-names>AA</given-names></name><name name-style="western"><surname>Kesavardhana</surname><given-names>S</given-names></name></person-group><article-title>Z-nucleic acid sensing and activation of ZBP1 in cellular physiology and disease pathogenesis</article-title><source>Immunol Rev</source><year>2025</year><volume>329</volume><issue>1</issue><fpage>e13437</fpage><pub-id pub-id-type="doi">10.1111/imr.13437</pub-id><pub-id pub-id-type="pmid">39748135</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Mishra S, Dey AA, Kesavardhana S (2025) Z-nucleic acid sensing and activation of ZBP1 in cellular physiology and disease pathogenesis. Immunol Rev 329(1):e13437. 10.1111/imr.13437<pub-id pub-id-type="pmid">39748135</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/imr.13437</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mobaderi</surname><given-names>T</given-names></name><name name-style="western"><surname>Kazemnejad</surname><given-names>A</given-names></name><name name-style="western"><surname>Salehi</surname><given-names>M</given-names></name></person-group><article-title>Exploring the impacts of risk factors on mortality patterns of global Alzheimer&#8217;s disease and related dementias from 1990 to 2021</article-title><source>Sci Rep</source><year>2024</year><volume>14</volume><issue>1</issue><fpage>15583</fpage><pub-id pub-id-type="doi">10.1038/s41598-024-65887-4</pub-id><pub-id pub-id-type="pmid">38971870</pub-id><pub-id pub-id-type="pmcid">PMC11227499</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Mobaderi T, Kazemnejad A, Salehi M (2024) Exploring the impacts of risk factors on mortality patterns of global Alzheimer&#8217;s disease and related dementias from 1990 to 2021. Sci Rep 14(1):15583. 10.1038/s41598-024-65887-4<pub-id pub-id-type="pmid">38971870</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-024-65887-4</pub-id><pub-id pub-id-type="pmcid">PMC11227499</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><citation-alternatives><element-citation id="ec-CR60" publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Molyer Yildirir</surname><given-names>B</given-names></name></person-group><source>SMAC mimetics sensitize HIV-infected cells to MG1-mediated death</source><year>2024</year><publisher-loc>Ottawa</publisher-loc><publisher-name>University of Ottawa</publisher-name></element-citation><mixed-citation id="mc-CR60" publication-type="book">Molyer Yildirir B (2024) SMAC mimetics sensitize HIV-infected cells to MG1-mediated death. University of Ottawa, Ottawa</mixed-citation></citation-alternatives></ref><ref id="CR61"><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morgan</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y-S</given-names></name></person-group><article-title>Roles of RIPK3 in necroptosis, cell signaling, and disease</article-title><source>Exp Mol Med</source><year>2022</year><volume>54</volume><issue>10</issue><fpage>1695</fpage><lpage>1704</lpage><pub-id pub-id-type="doi">10.1038/s12276-022-00868-z</pub-id><pub-id pub-id-type="pmid">36224345</pub-id><pub-id pub-id-type="pmcid">PMC9636380</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Morgan MJ, Kim Y-S (2022) Roles of RIPK3 in necroptosis, cell signaling, and disease. Exp Mol Med 54(10):1695&#8211;1704. 10.1038/s12276-022-00868-z<pub-id pub-id-type="pmid">36224345</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s12276-022-00868-z</pub-id><pub-id pub-id-type="pmcid">PMC9636380</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moriwaki</surname><given-names>K</given-names></name><name name-style="western"><surname>Chan</surname><given-names>FK</given-names></name><name name-style="western"><surname>Miyoshi</surname><given-names>E</given-names></name></person-group><article-title>Sweet modification and regulation of death receptor signalling pathway</article-title><source>The Journal of Biochemistry</source><year>2021</year><volume>169</volume><issue>6</issue><fpage>643</fpage><lpage>652</lpage><pub-id pub-id-type="doi">10.1093/jb/mvab034</pub-id><pub-id pub-id-type="pmid">33752241</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Moriwaki K, Chan FK, Miyoshi E (2021) Sweet modification and regulation of death receptor signalling pathway. The Journal of Biochemistry 169(6):643&#8211;652. 10.1093/jb/mvab034<pub-id pub-id-type="pmid">33752241</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jb/mvab034</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naderi</surname><given-names>S</given-names></name><name name-style="western"><surname>Motamedi</surname><given-names>F</given-names></name><name name-style="western"><surname>Pourbadie</surname><given-names>HG</given-names></name><name name-style="western"><surname>Rafiei</surname><given-names>S</given-names></name><name name-style="western"><surname>Khodagholi</surname><given-names>F</given-names></name><name name-style="western"><surname>Naderi</surname><given-names>N</given-names></name><name name-style="western"><surname>Janahmadi</surname><given-names>M</given-names></name></person-group><article-title>Neuroprotective effects of ferrostatin and necrostatin against entorhinal amyloidopathy-induced electrophysiological alterations mediated by voltage-gated Ca2+ channels in the dentate gyrus granular cells</article-title><source>Neurochem Res</source><year>2024</year><volume>49</volume><issue>1</issue><fpage>99</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1007/s11064-023-04006-7</pub-id><pub-id pub-id-type="pmid">37615884</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Naderi S, Motamedi F, Pourbadie HG, Rafiei S, Khodagholi F, Naderi N, Janahmadi M (2024) Neuroprotective effects of ferrostatin and necrostatin against entorhinal amyloidopathy-induced electrophysiological alterations mediated by voltage-gated Ca2+ channels in the dentate gyrus granular cells. Neurochem Res 49(1):99&#8211;116. 10.1007/s11064-023-04006-7<pub-id pub-id-type="pmid">37615884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11064-023-04006-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakano</surname><given-names>H</given-names></name><name name-style="western"><surname>Murai</surname><given-names>S</given-names></name><name name-style="western"><surname>Moriwaki</surname><given-names>K</given-names></name></person-group><article-title>Regulation of the release of damage-associated molecular patterns from necroptotic cells</article-title><source>Biochem J</source><year>2022</year><volume>479</volume><issue>5</issue><fpage>677</fpage><lpage>685</lpage><pub-id pub-id-type="doi">10.1042/bcj20210604</pub-id><pub-id pub-id-type="pmid">35293986</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Nakano H, Murai S, Moriwaki K (2022) Regulation of the release of damage-associated molecular patterns from necroptotic cells. Biochem J 479(5):677&#8211;685. 10.1042/bcj20210604<pub-id pub-id-type="pmid">35293986</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/BCJ20210604</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nan</surname><given-names>H</given-names></name><name name-style="western"><surname>Chu</surname><given-names>M</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>D</given-names></name><name name-style="western"><surname>Liang</surname><given-names>W</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L</given-names></name></person-group><article-title>Identification and characterization of variants in PSEN1, PSEN2, and APP genes in Chinese patients with early-onset Alzheimer's disease</article-title><source>Alzheimer's Res Ther</source><year>2025</year><volume>17</volume><issue>1</issue><fpage>1</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1186/s13195-025-01702-0</pub-id><pub-id pub-id-type="pmid">40016812</pub-id><pub-id pub-id-type="pmcid">PMC11866898</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Nan H, Chu M, Jiang D, Liang W, Li Y, Wu Y, Wang Z, Wu L (2025) Identification and characterization of variants in PSEN1, PSEN2, and APP genes in Chinese patients with early-onset Alzheimer&#8217;s disease. Alzheimer&#8217;s Res Ther 17(1):1&#8211;18. 10.1186/s13195-025-01702-0<pub-id pub-id-type="pmid">40016812</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-025-01702-0</pub-id><pub-id pub-id-type="pmcid">PMC11866898</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naseri</surname><given-names>F</given-names></name><name name-style="western"><surname>Sirati-Sabet</surname><given-names>M</given-names></name><name name-style="western"><surname>Sarlaki</surname><given-names>F</given-names></name><name name-style="western"><surname>Keimasi</surname><given-names>M</given-names></name><name name-style="western"><surname>Mokarram</surname><given-names>P</given-names></name><name name-style="western"><surname>Siri</surname><given-names>M</given-names></name><name name-style="western"><surname>Ghasemi</surname><given-names>R</given-names></name><name name-style="western"><surname>Shahsavari</surname><given-names>Z</given-names></name><name name-style="western"><surname>Goshadrou</surname><given-names>F</given-names></name></person-group><article-title>The effect of ghrelin on apoptosis, necroptosis and autophagy programmed cell death pathways in the hippocampal neurons of amyloid-&#946; 1&#8211;42-induced rat model of alzheimer&#8217;s disease</article-title><source>Int J Pept Res Ther</source><year>2022</year><volume>28</volume><issue>5</issue><fpage>151</fpage><pub-id pub-id-type="doi">10.1007/s10989-022-10457-3</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Naseri F, Sirati-Sabet M, Sarlaki F, Keimasi M, Mokarram P, Siri M, Ghasemi R, Shahsavari Z, Goshadrou F (2022) The effect of ghrelin on apoptosis, necroptosis and autophagy programmed cell death pathways in the hippocampal neurons of amyloid-&#946; 1&#8211;42-induced rat model of alzheimer&#8217;s disease. Int J Pept Res Ther 28(5):151. 10.1007/s10989-022-10457-3</mixed-citation></citation-alternatives></ref><ref id="CR67"><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nasseri</surname><given-names>B</given-names></name><name name-style="western"><surname>Zareian</surname><given-names>P</given-names></name><name name-style="western"><surname>Alizade</surname><given-names>H</given-names></name></person-group><article-title>Apelin attenuates streptozotocin-induced learning and memory impairment by modulating necroptosis signaling pathway</article-title><source>Int Immunopharmacol</source><year>2020</year><volume>84</volume><fpage>106546</fpage><pub-id pub-id-type="doi">10.1016/j.intimp.2020.106546</pub-id><pub-id pub-id-type="pmid">32413735</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Nasseri B, Zareian P, Alizade H (2020) Apelin attenuates streptozotocin-induced learning and memory impairment by modulating necroptosis signaling pathway. Int Immunopharmacol 84:106546. 10.1016/j.intimp.2020.106546<pub-id pub-id-type="pmid">32413735</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.intimp.2020.106546</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Orning</surname><given-names>P</given-names></name><name name-style="western"><surname>Lien</surname><given-names>E</given-names></name></person-group><article-title>Multiple roles of caspase-8 in cell death, inflammation, and innate immunity</article-title><source>J Leucocyte Biol</source><year>2021</year><volume>109</volume><issue>1</issue><fpage>121</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1002/jlb.3mr0420-305r</pub-id><pub-id pub-id-type="pmcid">PMC8664275</pub-id><pub-id pub-id-type="pmid">32531842</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Orning P, Lien E (2021) Multiple roles of caspase-8 in cell death, inflammation, and innate immunity. J Leucocyte Biol 109(1):121&#8211;141. 10.1002/jlb.3mr0420-305r<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/JLB.3MR0420-305R</pub-id><pub-id pub-id-type="pmcid">PMC8664275</pub-id><pub-id pub-id-type="pmid">32531842</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><citation-alternatives><element-citation id="ec-CR69" publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Pandey</surname><given-names>P</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>C</given-names></name><name name-style="western"><surname>Khandia</surname><given-names>R</given-names></name></person-group><article-title>The insight into the role of protein misfolding and tau oligomers in Alzheimer&#8217;s disease</article-title><source>Proteostasis: investigating molecular dynamics in neurodegenerative disorders</source><year>2025</year><publisher-loc>New York</publisher-loc><publisher-name>Springer</publisher-name><fpage>253</fpage><lpage>275</lpage></element-citation><mixed-citation id="mc-CR69" publication-type="book">Pandey P, Kumar C, Khandia R (2025) The insight into the role of protein misfolding and tau oligomers in Alzheimer&#8217;s disease. Proteostasis: investigating molecular dynamics in neurodegenerative disorders. Springer, New York, pp 253&#8211;275</mixed-citation></citation-alternatives></ref><ref id="CR70"><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pang</surname><given-names>K</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>L-L</given-names></name><name name-style="western"><surname>Shimozawa</surname><given-names>M</given-names></name><name name-style="western"><surname>Tambaro</surname><given-names>S</given-names></name><name name-style="western"><surname>Mayer</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name></person-group><article-title>An App knock-in rat model for Alzheimer&#8217;s disease exhibiting A&#946; and tau pathologies, neuronal death and cognitive impairments</article-title><source>Cell Res</source><year>2022</year><volume>32</volume><issue>2</issue><fpage>157</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1038/s41422-021-00582-x</pub-id><pub-id pub-id-type="pmid">34789895</pub-id><pub-id pub-id-type="pmcid">PMC8807612</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Pang K, Jiang R, Zhang W, Yang Z, Li L-L, Shimozawa M, Tambaro S, Mayer J, Zhang B, Li M (2022) An App knock-in rat model for Alzheimer&#8217;s disease exhibiting A&#946; and tau pathologies, neuronal death and cognitive impairments. Cell Res 32(2):157&#8211;175. 10.1038/s41422-021-00582-x<pub-id pub-id-type="pmid">34789895</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41422-021-00582-x</pub-id><pub-id pub-id-type="pmcid">PMC8807612</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>J</given-names></name><name name-style="western"><surname>Ha</surname><given-names>H-J</given-names></name><name name-style="western"><surname>Chung</surname><given-names>ES</given-names></name><name name-style="western"><surname>Baek</surname><given-names>SH</given-names></name><name name-style="western"><surname>Cho</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HK</given-names></name><name name-style="western"><surname>Han</surname><given-names>J</given-names></name><name name-style="western"><surname>Sul</surname><given-names>JH</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J</given-names></name><name name-style="western"><surname>Kim</surname><given-names>E</given-names></name></person-group><article-title>O-GlcNAcylation ameliorates the pathological manifestations of Alzheimer&#8217;s disease by inhibiting necroptosis</article-title><source>Sci Adv</source><year>2021</year><volume>7</volume><issue>3</issue><fpage>eabd3207</fpage><pub-id pub-id-type="doi">10.1126/sciadv.abd3207</pub-id><pub-id pub-id-type="pmid">33523877</pub-id><pub-id pub-id-type="pmcid">PMC7806231</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Park J, Ha H-J, Chung ES, Baek SH, Cho Y, Kim HK, Han J, Sul JH, Lee J, Kim E (2021) O-GlcNAcylation ameliorates the pathological manifestations of Alzheimer&#8217;s disease by inhibiting necroptosis. Sci Adv 7(3):eabd3207. 10.1126/sciadv.abd3207<pub-id pub-id-type="pmid">33523877</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.abd3207</pub-id><pub-id pub-id-type="pmcid">PMC7806231</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR72"><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>L</given-names></name></person-group><article-title>Necroptosis and autoimmunity</article-title><source>Clin Immunol</source><year>2024</year><pub-id pub-id-type="doi">10.1016/j.clim.2024.110313</pub-id><pub-id pub-id-type="pmid">39002793</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Peng L (2024) Necroptosis and autoimmunity. Clin Immunol. 10.1016/j.clim.2024.110313<pub-id pub-id-type="pmid">39002793</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clim.2024.110313</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pimentel</surname><given-names>JM</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J-Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>GS</given-names></name></person-group><article-title>The role of TRAIL in apoptosis and immunosurveillance in cancer</article-title><source>Cancers</source><year>2023</year><volume>15</volume><issue>10</issue><fpage>2752</fpage><pub-id pub-id-type="doi">10.3390/cancers15102752</pub-id><pub-id pub-id-type="pmid">37345089</pub-id><pub-id pub-id-type="pmcid">PMC10216286</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">Pimentel JM, Zhou J-Y, Wu GS (2023) The role of TRAIL in apoptosis and immunosurveillance in cancer. Cancers 15(10):2752. 10.3390/cancers15102752<pub-id pub-id-type="pmid">37345089</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers15102752</pub-id><pub-id pub-id-type="pmcid">PMC10216286</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR74"><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richard</surname><given-names>R</given-names></name><name name-style="western"><surname>Mousa</surname><given-names>S</given-names></name></person-group><article-title>Necroptosis in Alzheimer&#8217;s disease: potential therapeutic target</article-title><source>Biomed Pharmacother</source><year>2022</year><volume>152</volume><fpage>113203</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2022.113203</pub-id><pub-id pub-id-type="pmid">35665670</pub-id></element-citation><mixed-citation id="mc-CR74" publication-type="journal">Richard R, Mousa S (2022) Necroptosis in Alzheimer&#8217;s disease: potential therapeutic target. Biomed Pharmacother 152:113203. 10.1016/j.biopha.2022.113203<pub-id pub-id-type="pmid">35665670</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2022.113203</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR75"><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riebeling</surname><given-names>T</given-names></name><name name-style="western"><surname>Kunzendorf</surname><given-names>U</given-names></name><name name-style="western"><surname>Krautwald</surname><given-names>S</given-names></name></person-group><article-title>The role of RHIM in necroptosis</article-title><source>Biochem Soc Trans</source><year>2022</year><volume>50</volume><issue>4</issue><fpage>1197</fpage><lpage>1205</lpage><pub-id pub-id-type="doi">10.1042/bst20220535</pub-id><pub-id pub-id-type="pmid">36040212</pub-id><pub-id pub-id-type="pmcid">PMC9444067</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Riebeling T, Kunzendorf U, Krautwald S (2022) The role of RHIM in necroptosis. Biochem Soc Trans 50(4):1197&#8211;1205. 10.1042/bst20220535<pub-id pub-id-type="pmid">36040212</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/BST20220535</pub-id><pub-id pub-id-type="pmcid">PMC9444067</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR76"><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salvadores</surname><given-names>N</given-names></name><name name-style="western"><surname>Moreno-Gonzalez</surname><given-names>I</given-names></name><name name-style="western"><surname>Gamez</surname><given-names>N</given-names></name><name name-style="western"><surname>Quiroz</surname><given-names>G</given-names></name><name name-style="western"><surname>Vegas-Gomez</surname><given-names>L</given-names></name><name name-style="western"><surname>Escand&#243;n</surname><given-names>M</given-names></name><name name-style="western"><surname>Jimenez</surname><given-names>S</given-names></name><name name-style="western"><surname>Vitorica</surname><given-names>J</given-names></name><name name-style="western"><surname>Gutierrez</surname><given-names>A</given-names></name><name name-style="western"><surname>Soto</surname><given-names>C</given-names></name></person-group><article-title>A&#946; oligomers trigger necroptosis-mediated neurodegeneration via microglia activation in Alzheimer&#8217;s disease</article-title><source>Acta Neuropathol Commun</source><year>2022</year><volume>10</volume><issue>1</issue><fpage>31</fpage><pub-id pub-id-type="doi">10.1186/s40478-022-01332-9</pub-id><pub-id pub-id-type="pmid">35264247</pub-id><pub-id pub-id-type="pmcid">PMC8908658</pub-id></element-citation><mixed-citation id="mc-CR76" publication-type="journal">Salvadores N, Moreno-Gonzalez I, Gamez N, Quiroz G, Vegas-Gomez L, Escand&#243;n M, Jimenez S, Vitorica J, Gutierrez A, Soto C (2022) A&#946; oligomers trigger necroptosis-mediated neurodegeneration via microglia activation in Alzheimer&#8217;s disease. Acta Neuropathol Commun 10(1):31. 10.1186/s40478-022-01332-9<pub-id pub-id-type="pmid">35264247</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40478-022-01332-9</pub-id><pub-id pub-id-type="pmcid">PMC8908658</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR77"><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sasaki</surname><given-names>K</given-names></name><name name-style="western"><surname>Iwai</surname><given-names>K</given-names></name></person-group><article-title>LUBAC-mediated linear ubiquitination in tissue homeostasis and disease</article-title><source>J Biochem</source><year>2023</year><volume>174</volume><issue>2</issue><fpage>99</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1093/jb/mvad045</pub-id><pub-id pub-id-type="pmid">37279649</pub-id></element-citation><mixed-citation id="mc-CR77" publication-type="journal">Sasaki K, Iwai K (2023) LUBAC-mediated linear ubiquitination in tissue homeostasis and disease. J Biochem 174(2):99&#8211;107. 10.1093/jb/mvad045<pub-id pub-id-type="pmid">37279649</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jb/mvad045</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR78"><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seo</surname><given-names>J</given-names></name><name name-style="western"><surname>Nam</surname><given-names>YW</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name><name name-style="western"><surname>Oh</surname><given-names>D-B</given-names></name><name name-style="western"><surname>Song</surname><given-names>J</given-names></name></person-group><article-title>Necroptosis molecular mechanisms: recent findings regarding novel necroptosis regulators</article-title><source>Exp Mol Med</source><year>2021</year><volume>53</volume><issue>6</issue><fpage>1007</fpage><lpage>1017</lpage><pub-id pub-id-type="doi">10.1038/s12276-021-00634-7</pub-id><pub-id pub-id-type="pmid">34075202</pub-id><pub-id pub-id-type="pmcid">PMC8166896</pub-id></element-citation><mixed-citation id="mc-CR78" publication-type="journal">Seo J, Nam YW, Kim S, Oh D-B, Song J (2021) Necroptosis molecular mechanisms: recent findings regarding novel necroptosis regulators. Exp Mol Med 53(6):1007&#8211;1017. 10.1038/s12276-021-00634-7<pub-id pub-id-type="pmid">34075202</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s12276-021-00634-7</pub-id><pub-id pub-id-type="pmcid">PMC8166896</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR79"><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>VK</given-names></name><name name-style="western"><surname>Singh</surname><given-names>TG</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S</given-names></name><name name-style="western"><surname>Garg</surname><given-names>N</given-names></name><name name-style="western"><surname>Dhiman</surname><given-names>S</given-names></name></person-group><article-title>Apoptotic pathways and Alzheimer&#8217;s disease: probing therapeutic potential</article-title><source>Neurochem Res</source><year>2021</year><volume>46</volume><issue>12</issue><fpage>3103</fpage><lpage>3122</lpage><pub-id pub-id-type="doi">10.1007/s11064-021-03418-7</pub-id><pub-id pub-id-type="pmid">34386919</pub-id></element-citation><mixed-citation id="mc-CR79" publication-type="journal">Sharma VK, Singh TG, Singh S, Garg N, Dhiman S (2021) Apoptotic pathways and Alzheimer&#8217;s disease: probing therapeutic potential. Neurochem Res 46(12):3103&#8211;3122. 10.1007/s11064-021-03418-7<pub-id pub-id-type="pmid">34386919</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11064-021-03418-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR80"><mixed-citation publication-type="other">Singh E, Dilawari R (2025) Recent advances in neurodegenerative disease research. In: The neurodegeneration revolution, pp&#160;527&#8211;548. 10.1016/B978-0-443-28822-7.00014-3.</mixed-citation></ref><ref id="CR81"><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>M</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>J</given-names></name><name name-style="western"><surname>Gan</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q</given-names></name></person-group><article-title>Second messenger 2&#8242; 3&#8242;-cyclic GMP&#8211;AMP (2&#8242; 3&#8242;-cGAMP): Synthesis, transmission, and degradation</article-title><source>Biochem Pharmacol</source><year>2022</year><volume>198</volume><fpage>114934</fpage><pub-id pub-id-type="doi">10.1016/j.bcp.2022.114934</pub-id><pub-id pub-id-type="pmid">35104477</pub-id></element-citation><mixed-citation id="mc-CR81" publication-type="journal">Su M, Zheng J, Gan L, Zhao Y, Fu Y, Chen Q (2022) Second messenger 2&#8242; 3&#8242;-cyclic GMP&#8211;AMP (2&#8242; 3&#8242;-cGAMP): Synthesis, transmission, and degradation. Biochem Pharmacol 198:114934. 10.1016/j.bcp.2022.114934<pub-id pub-id-type="pmid">35104477</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bcp.2022.114934</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR82"><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>C</given-names></name></person-group><article-title>Design, synthesis and anti-necroptosis activity of fused heterocyclic MLKL inhibitors</article-title><source>Bioorg Med Chem</source><year>2024</year><volume>102</volume><fpage>117659</fpage><pub-id pub-id-type="doi">10.1016/j.bmc.2024.117659</pub-id><pub-id pub-id-type="pmid">38442525</pub-id></element-citation><mixed-citation id="mc-CR82" publication-type="journal">Tang Y, Zhuang C (2024) Design, synthesis and anti-necroptosis activity of fused heterocyclic MLKL inhibitors. Bioorg Med Chem 102:117659. 10.1016/j.bmc.2024.117659<pub-id pub-id-type="pmid">38442525</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bmc.2024.117659</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR83"><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thadathil</surname><given-names>N</given-names></name><name name-style="western"><surname>Nicklas</surname><given-names>EH</given-names></name><name name-style="western"><surname>Mohammed</surname><given-names>S</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>TL</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>A</given-names></name><name name-style="western"><surname>Deepa</surname><given-names>SS</given-names></name></person-group><article-title>Necroptosis increases with age in the brain and contributes to age-related neuroinflammation</article-title><source>Geroscience</source><year>2021</year><volume>43</volume><fpage>2345</fpage><lpage>2361</lpage><pub-id pub-id-type="doi">10.1007/s11357-021-00448-5</pub-id><pub-id pub-id-type="pmid">34515928</pub-id><pub-id pub-id-type="pmcid">PMC8599532</pub-id></element-citation><mixed-citation id="mc-CR83" publication-type="journal">Thadathil N, Nicklas EH, Mohammed S, Lewis TL, Richardson A, Deepa SS (2021) Necroptosis increases with age in the brain and contributes to age-related neuroinflammation. Geroscience 43:2345&#8211;2361. 10.1007/s11357-021-00448-5<pub-id pub-id-type="pmid">34515928</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11357-021-00448-5</pub-id><pub-id pub-id-type="pmcid">PMC8599532</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR84"><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thapa</surname><given-names>P</given-names></name><name name-style="western"><surname>Marahatta</surname><given-names>K</given-names></name><name name-style="western"><surname>Upadhyay Raj</surname><given-names>S</given-names></name><name name-style="western"><surname>Sapkota</surname><given-names>N</given-names></name><name name-style="western"><surname>Baral</surname><given-names>P</given-names></name><name name-style="western"><surname>Lama</surname><given-names>S</given-names></name><name name-style="western"><surname>Kamholz</surname><given-names>B</given-names></name><name name-style="western"><surname>Paudel</surname><given-names>S</given-names></name><name name-style="western"><surname>Basnet</surname><given-names>M</given-names></name></person-group><article-title>Dementia care landscape in Nepal: Understanding the context, barriers, and opportunities for the development of a national dementia care plan</article-title><source>Int J Geriatr Psychiatry</source><year>2024</year><volume>39</volume><issue>6</issue><fpage>e6111</fpage><pub-id pub-id-type="doi">10.1002/gps.6111</pub-id><pub-id pub-id-type="pmid">38862409</pub-id></element-citation><mixed-citation id="mc-CR84" publication-type="journal">Thapa P, Marahatta K, Upadhyay Raj S, Sapkota N, Baral P, Lama S, Kamholz B, Paudel S, Basnet M (2024) Dementia care landscape in Nepal: Understanding the context, barriers, and opportunities for the development of a national dementia care plan. Int J Geriatr Psychiatry 39(6):e6111. 10.1002/gps.6111<pub-id pub-id-type="pmid">38862409</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/gps.6111</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR85"><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tondo</surname><given-names>G</given-names></name><name name-style="western"><surname>De Marchi</surname><given-names>F</given-names></name><name name-style="western"><surname>Bonardi</surname><given-names>F</given-names></name><name name-style="western"><surname>Menegon</surname><given-names>F</given-names></name><name name-style="western"><surname>Verrini</surname><given-names>G</given-names></name><name name-style="western"><surname>Aprile</surname><given-names>D</given-names></name><name name-style="western"><surname>Anselmi</surname><given-names>M</given-names></name><name name-style="western"><surname>Mazzini</surname><given-names>L</given-names></name><name name-style="western"><surname>Comi</surname><given-names>C</given-names></name></person-group><article-title>Novel therapeutic strategies in Alzheimer&#8217;s disease: pitfalls and challenges of anti-amyloid therapies and beyond</article-title><source>J Clin Med</source><year>2024</year><volume>13</volume><issue>11</issue><fpage>3098</fpage><pub-id pub-id-type="doi">10.3390/jcm13113098</pub-id><pub-id pub-id-type="pmid">38892809</pub-id><pub-id pub-id-type="pmcid">PMC11172489</pub-id></element-citation><mixed-citation id="mc-CR85" publication-type="journal">Tondo G, De Marchi F, Bonardi F, Menegon F, Verrini G, Aprile D, Anselmi M, Mazzini L, Comi C (2024) Novel therapeutic strategies in Alzheimer&#8217;s disease: pitfalls and challenges of anti-amyloid therapies and beyond. J Clin Med 13(11):3098. 10.3390/jcm13113098<pub-id pub-id-type="pmid">38892809</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm13113098</pub-id><pub-id pub-id-type="pmcid">PMC11172489</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR86"><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tu</surname><given-names>J-L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W-P</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Z-J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Q-H</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name></person-group><article-title>EGb761 ameliorates cell necroptosis by attenuating RIP1-mediated mitochondrial dysfunction and ROS production in both in vivo and in vitro models of Alzheimer&#8217;s disease</article-title><source>Brain Res</source><year>2020</year><volume>1736</volume><fpage>146730</fpage><pub-id pub-id-type="doi">10.1016/j.brainres.2020.146730</pub-id><pub-id pub-id-type="pmid">32081533</pub-id></element-citation><mixed-citation id="mc-CR86" publication-type="journal">Tu J-L, Chen W-P, Cheng Z-J, Zhang G, Luo Q-H, Li M, Liu X (2020) EGb761 ameliorates cell necroptosis by attenuating RIP1-mediated mitochondrial dysfunction and ROS production in both in vivo and in vitro models of Alzheimer&#8217;s disease. Brain Res 1736:146730. 10.1016/j.brainres.2020.146730<pub-id pub-id-type="pmid">32081533</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.brainres.2020.146730</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR87"><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Udawatte</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Rothman</surname><given-names>AL</given-names></name></person-group><article-title>Viral suppression of RIPK1-mediated signaling</article-title><source>MBio</source><year>2021</year><volume>12</volume><issue>4</issue><fpage>01723-01721</fpage><pub-id pub-id-type="doi">10.1128/mBio.01723-21</pub-id><pub-id pub-id-type="pmcid">PMC8406217</pub-id><pub-id pub-id-type="pmid">34372694</pub-id></element-citation><mixed-citation id="mc-CR87" publication-type="journal">Udawatte DJ, Rothman AL (2021) Viral suppression of RIPK1-mediated signaling. MBio 12(4):01723&#8211;01721<pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/mBio.01723-21</pub-id><pub-id pub-id-type="pmcid">PMC8406217</pub-id><pub-id pub-id-type="pmid">34372694</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR88"><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verheijen</surname><given-names>M</given-names></name><name name-style="western"><surname>Krauskopf</surname><given-names>J</given-names></name><name name-style="western"><surname>Caiment</surname><given-names>F</given-names></name><name name-style="western"><surname>Nazaruk</surname><given-names>M</given-names></name><name name-style="western"><surname>Wen</surname><given-names>Q</given-names></name><name name-style="western"><surname>Van Herwijnen</surname><given-names>M</given-names></name><name name-style="western"><surname>Hauser</surname><given-names>D</given-names></name><name name-style="western"><surname>Gajjar</surname><given-names>M</given-names></name><name name-style="western"><surname>Verfaillie</surname><given-names>C</given-names></name><name name-style="western"><surname>Vermeiren</surname><given-names>Y</given-names></name></person-group><article-title>iPSC-derived cortical neurons to study sporadic Alzheimer disease: a transcriptome comparison with post-mortem brain samples</article-title><source>Toxicol Lett</source><year>2022</year><volume>356</volume><fpage>89</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1016/j.toxlet.2021.12.009</pub-id><pub-id pub-id-type="pmid">34921933</pub-id></element-citation><mixed-citation id="mc-CR88" publication-type="journal">Verheijen M, Krauskopf J, Caiment F, Nazaruk M, Wen Q, Van Herwijnen M, Hauser D, Gajjar M, Verfaillie C, Vermeiren Y (2022) iPSC-derived cortical neurons to study sporadic Alzheimer disease: a transcriptome comparison with post-mortem brain samples. Toxicol Lett 356:89&#8211;99. 10.1016/j.toxlet.2021.12.009<pub-id pub-id-type="pmid">34921933</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.toxlet.2021.12.009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR89"><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vissers</surname><given-names>MF</given-names></name><name name-style="western"><surname>Heuberger</surname><given-names>JA</given-names></name><name name-style="western"><surname>Groeneveld</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Oude Nijhuis</surname><given-names>J</given-names></name><name name-style="western"><surname>De Deyn</surname><given-names>PP</given-names></name><name name-style="western"><surname>Hadi</surname><given-names>S</given-names></name><name name-style="western"><surname>Harris</surname><given-names>J</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>RM</given-names></name><name name-style="western"><surname>Cruz-Herranz</surname><given-names>A</given-names></name><name name-style="western"><surname>Huang</surname><given-names>F</given-names></name></person-group><article-title>Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: randomized, placebo-controlled, double-blind phase I/Ib studies in healthy subjects and patients</article-title><source>Clin Transl Sci</source><year>2022</year><volume>15</volume><issue>8</issue><fpage>2010</fpage><lpage>2023</lpage><pub-id pub-id-type="doi">10.1111/cts.13317</pub-id><pub-id pub-id-type="pmid">35649245</pub-id><pub-id pub-id-type="pmcid">PMC9372423</pub-id></element-citation><mixed-citation id="mc-CR89" publication-type="journal">Vissers MF, Heuberger JA, Groeneveld GJ, Oude Nijhuis J, De Deyn PP, Hadi S, Harris J, Tsai RM, Cruz-Herranz A, Huang F (2022) Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: randomized, placebo-controlled, double-blind phase I/Ib studies in healthy subjects and patients. Clin Transl Sci 15(8):2010&#8211;2023. 10.1111/cts.13317<pub-id pub-id-type="pmid">35649245</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cts.13317</pub-id><pub-id pub-id-type="pmcid">PMC9372423</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR90"><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wicherska-Paw&#322;owska</surname><given-names>K</given-names></name><name name-style="western"><surname>Wr&#243;bel</surname><given-names>T</given-names></name><name name-style="western"><surname>Rybka</surname><given-names>J</given-names></name></person-group><article-title>Toll-like receptors (TLRs), NOD-like receptors (NLRs), and RIG-I-like receptors (RLRs) in innate immunity. TLRs, NLRs, and RLRs ligands as immunotherapeutic agents for hematopoietic diseases</article-title><source>Int J Mol Sci</source><year>2021</year><volume>22</volume><issue>24</issue><fpage>13397</fpage><pub-id pub-id-type="doi">10.3390/ijms222413397</pub-id><pub-id pub-id-type="pmid">34948194</pub-id><pub-id pub-id-type="pmcid">PMC8704656</pub-id></element-citation><mixed-citation id="mc-CR90" publication-type="journal">Wicherska-Paw&#322;owska K, Wr&#243;bel T, Rybka J (2021) Toll-like receptors (TLRs), NOD-like receptors (NLRs), and RIG-I-like receptors (RLRs) in innate immunity. TLRs, NLRs, and RLRs ligands as immunotherapeutic agents for hematopoietic diseases. Int J Mol Sci 22(24):13397. 10.3390/ijms222413397<pub-id pub-id-type="pmid">34948194</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms222413397</pub-id><pub-id pub-id-type="pmcid">PMC8704656</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR91"><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wo&#378;niak</surname><given-names>K</given-names></name><name name-style="western"><surname>Gardian-Baj</surname><given-names>M</given-names></name><name name-style="western"><surname>Jung</surname><given-names>M</given-names></name><name name-style="western"><surname>Hedesz</surname><given-names>P</given-names></name><name name-style="western"><surname>Jung</surname><given-names>M</given-names></name><name name-style="western"><surname>&#379;uk-&#321;apan</surname><given-names>A</given-names></name><name name-style="western"><surname>Dory&#324;</surname><given-names>A</given-names></name><name name-style="western"><surname>J&#281;dral</surname><given-names>K</given-names></name><name name-style="western"><surname>W&#322;odarczyk</surname><given-names>A</given-names></name><name name-style="western"><surname>Szczerbiak</surname><given-names>A</given-names></name></person-group><article-title>Alzheimer's disease-a comprehensive review</article-title><source>J Educ Health Sport</source><year>2024</year><volume>56</volume><fpage>195</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.12775/JEHS.2024.56.013</pub-id></element-citation><mixed-citation id="mc-CR91" publication-type="journal">Wo&#378;niak K, Gardian-Baj M, Jung M, Hedesz P, Jung M, &#379;uk-&#321;apan A, Dory&#324; A, J&#281;dral K, W&#322;odarczyk A, Szczerbiak A (2024) Alzheimer&#8217;s disease-a comprehensive review. J Educ Health Sport 56:195&#8211;209. 10.12775/JEHS.2024.56.013</mixed-citation></citation-alternatives></ref><ref id="CR92"><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>C</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ren</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>G</given-names></name><name name-style="western"><surname>Fang</surname><given-names>EF</given-names></name><name name-style="western"><surname>Noh</surname><given-names>JH</given-names></name><name name-style="western"><surname>Liu</surname><given-names>YU</given-names></name><name name-style="western"><surname>Wei</surname><given-names>L</given-names></name></person-group><article-title>TNF-&#945;-dependent neuronal necroptosis regulated in Alzheimer's disease by coordination of RIPK1-p62 complex with autophagic UVRAG</article-title><source>Theranostics</source><year>2021</year><volume>11</volume><issue>19</issue><fpage>9452</fpage><pub-id pub-id-type="doi">10.7150/thno.62376</pub-id><pub-id pub-id-type="pmid">34646380</pub-id><pub-id pub-id-type="pmcid">PMC8490500</pub-id></element-citation><mixed-citation id="mc-CR92" publication-type="journal">Xu C, Wu J, Wu Y, Ren Z, Yao Y, Chen G, Fang EF, Noh JH, Liu YU, Wei L (2021) TNF-&#945;-dependent neuronal necroptosis regulated in Alzheimer&#8217;s disease by coordination of RIPK1-p62 complex with autophagic UVRAG. Theranostics 11(19):9452. 10.7150/thno.62376<pub-id pub-id-type="pmid">34646380</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.62376</pub-id><pub-id pub-id-type="pmcid">PMC8490500</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR93"><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>SH</given-names></name><name name-style="western"><surname>Lee</surname><given-names>DK</given-names></name><name name-style="western"><surname>Shin</surname><given-names>J</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S</given-names></name><name name-style="western"><surname>Baek</surname><given-names>S</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name><name name-style="western"><surname>Jung</surname><given-names>H</given-names></name><name name-style="western"><surname>Hah</surname><given-names>JM</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y</given-names></name></person-group><article-title>Nec-1 alleviates cognitive impairment with reduction of A&#946; and tau abnormalities in APP/PS 1 mice</article-title><source>EMBO Mol Med</source><year>2017</year><volume>9</volume><issue>1</issue><fpage>61</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.15252/emmm.201606566</pub-id><pub-id pub-id-type="pmid">27861127</pub-id><pub-id pub-id-type="pmcid">PMC5210088</pub-id></element-citation><mixed-citation id="mc-CR93" publication-type="journal">Yang SH, Lee DK, Shin J, Lee S, Baek S, Kim J, Jung H, Hah JM, Kim Y (2017) Nec-1 alleviates cognitive impairment with reduction of A&#946; and tau abnormalities in APP/PS 1 mice. EMBO Mol Med 9(1):61&#8211;77<pub-id pub-id-type="pmid">27861127</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/emmm.201606566</pub-id><pub-id pub-id-type="pmcid">PMC5210088</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR94"><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>J</given-names></name><name name-style="western"><surname>Amin</surname><given-names>P</given-names></name><name name-style="western"><surname>Ofengeim</surname><given-names>D</given-names></name></person-group><article-title>Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases</article-title><source>Nat Rev Neurosci</source><year>2019</year><volume>20</volume><issue>1</issue><fpage>19</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1038/s41583-018-0093-1</pub-id><pub-id pub-id-type="pmid">30467385</pub-id><pub-id pub-id-type="pmcid">PMC6342007</pub-id></element-citation><mixed-citation id="mc-CR94" publication-type="journal">Yuan J, Amin P, Ofengeim D (2019) Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases. Nat Rev Neurosci 20(1):19&#8211;33. 10.1038/s41583-018-0093-1<pub-id pub-id-type="pmid">30467385</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41583-018-0093-1</pub-id><pub-id pub-id-type="pmcid">PMC6342007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR95"><citation-alternatives><element-citation id="ec-CR95" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>J</given-names></name><name name-style="western"><surname>Ofengeim</surname><given-names>D</given-names></name></person-group><article-title>A guide to cell death pathways</article-title><source>Nat Rev Mol Cell Biol</source><year>2024</year><volume>25</volume><issue>5</issue><fpage>379</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1038/s41580-023-00689-6</pub-id><pub-id pub-id-type="pmid">38110635</pub-id></element-citation><mixed-citation id="mc-CR95" publication-type="journal">Yuan J, Ofengeim D (2024) A guide to cell death pathways. Nat Rev Mol Cell Biol 25(5):379&#8211;395. 10.1038/s41580-023-00689-6<pub-id pub-id-type="pmid">38110635</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41580-023-00689-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR96"><citation-alternatives><element-citation id="ec-CR96" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>S</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C</given-names></name><name name-style="western"><surname>Xie</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Mao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xie</surname><given-names>W</given-names></name><name name-style="western"><surname>L&#252;</surname><given-names>T</given-names></name></person-group><article-title>DHA attenuates A&#946;-induced necroptosis through the RIPK1/RIPK3 signaling pathway in THP-1 monocytes</article-title><source>Biomed Pharmacother</source><year>2020</year><volume>126</volume><fpage>110102</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2020.110102</pub-id><pub-id pub-id-type="pmid">32199223</pub-id></element-citation><mixed-citation id="mc-CR96" publication-type="journal">Yuan S, Li H, Yang C, Xie W, Wang Y, Zhang J, Mao Z, Xie W, L&#252; T (2020) DHA attenuates A&#946;-induced necroptosis through the RIPK1/RIPK3 signaling pathway in THP-1 monocytes. Biomed Pharmacother 126:110102. 10.1016/j.biopha.2020.110102<pub-id pub-id-type="pmid">32199223</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2020.110102</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR97"><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhan</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>X</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>E</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name></person-group><article-title>Apoptosis dysfunction: unravelling the interplay between ZBP1 activation and viral invasion in innate immune responses</article-title><source>Cell Commun Signal</source><year>2024</year><volume>22</volume><issue>1</issue><fpage>149</fpage><pub-id pub-id-type="doi">10.1186/s12964-024-01531-y</pub-id><pub-id pub-id-type="pmid">38402193</pub-id><pub-id pub-id-type="pmcid">PMC10893743</pub-id></element-citation><mixed-citation id="mc-CR97" publication-type="journal">Zhan J, Wang J, Liang Y, Wang L, Huang L, Liu S, Zeng X, Zeng E, Wang H (2024) Apoptosis dysfunction: unravelling the interplay between ZBP1 activation and viral invasion in innate immune responses. Cell Commun Signal 22(1):149. 10.1186/s12964-024-01531-y<pub-id pub-id-type="pmid">38402193</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12964-024-01531-y</pub-id><pub-id pub-id-type="pmcid">PMC10893743</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR98"><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>N</given-names></name><name name-style="western"><surname>Chai</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name></person-group><article-title>Assessing and projecting the global impacts of Alzheimer&#8217;s disease</article-title><source>Front Public Health</source><year>2025</year><volume>12</volume><fpage>1453489</fpage><pub-id pub-id-type="doi">10.3389/fpubh.2024.1453489</pub-id><pub-id pub-id-type="pmid">39882109</pub-id><pub-id pub-id-type="pmcid">PMC11775756</pub-id></element-citation><mixed-citation id="mc-CR98" publication-type="journal">Zhang N, Chai S, Wang J (2025) Assessing and projecting the global impacts of Alzheimer&#8217;s disease. Front Public Health 12:1453489. 10.3389/fpubh.2024.1453489<pub-id pub-id-type="pmid">39882109</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpubh.2024.1453489</pub-id><pub-id pub-id-type="pmcid">PMC11775756</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR99"><citation-alternatives><element-citation id="ec-CR99" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Niu</surname><given-names>Q</given-names></name></person-group><article-title>Necroptosis in aluminum-induced neural cells and animal models of Alzheimer's disease</article-title><source>J Trace Elem Miner</source><year>2024</year><pub-id pub-id-type="doi">10.1016/j.jtemin.2024.100125</pub-id></element-citation><mixed-citation id="mc-CR99" publication-type="journal">Zhang Q, Niu Q (2024) Necroptosis in aluminum-induced neural cells and animal models of Alzheimer&#8217;s disease. J Trace Elem Miner. 10.1016/j.jtemin.2024.100125</mixed-citation></citation-alternatives></ref><ref id="CR100"><citation-alternatives><element-citation id="ec-CR100" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>R</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y</given-names></name><name name-style="western"><surname>Su</surname><given-names>X</given-names></name></person-group><article-title>Necroptosis and Alzheimer&#8217;s disease: pathogenic mechanisms and therapeutic opportunities</article-title><source>J Alzheimer&#8217;s Dis</source><year>2023</year><volume>94</volume><issue>s1</issue><fpage>S367</fpage><lpage>S386</lpage><pub-id pub-id-type="doi">10.3233/jad-220809</pub-id><pub-id pub-id-type="pmid">36463451</pub-id><pub-id pub-id-type="pmcid">PMC10473100</pub-id></element-citation><mixed-citation id="mc-CR100" publication-type="journal">Zhang R, Song Y, Su X (2023) Necroptosis and Alzheimer&#8217;s disease: pathogenic mechanisms and therapeutic opportunities. J Alzheimer&#8217;s Dis 94(s1):S367&#8211;S386. 10.3233/jad-220809<pub-id pub-id-type="pmid">36463451</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-220809</pub-id><pub-id pub-id-type="pmcid">PMC10473100</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR101"><citation-alternatives><element-citation id="ec-CR101" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>W</given-names></name><name name-style="western"><surname>Liu</surname><given-names>A</given-names></name><name name-style="western"><surname>Xia</surname><given-names>N</given-names></name><name name-style="western"><surname>Chen</surname><given-names>N</given-names></name><name name-style="western"><surname>Meurens</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J</given-names></name></person-group><article-title>How the innate immune DNA sensing cGAS-STING pathway is involved in apoptosis</article-title><source>Int J Mol Sci</source><year>2023</year><volume>24</volume><issue>3</issue><fpage>3029</fpage><pub-id pub-id-type="doi">10.3390/ijms24033029</pub-id><pub-id pub-id-type="pmid">36769349</pub-id><pub-id pub-id-type="pmcid">PMC9917431</pub-id></element-citation><mixed-citation id="mc-CR101" publication-type="journal">Zheng W, Liu A, Xia N, Chen N, Meurens F, Zhu J (2023) How the innate immune DNA sensing cGAS-STING pathway is involved in apoptosis. Int J Mol Sci 24(3):3029. 10.3390/ijms24033029<pub-id pub-id-type="pmid">36769349</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms24033029</pub-id><pub-id pub-id-type="pmcid">PMC9917431</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR102"><citation-alternatives><element-citation id="ec-CR102" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>T</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Phan</surname><given-names>N</given-names></name><name name-style="western"><surname>Ren</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H</given-names></name><name name-style="western"><surname>Feldman</surname><given-names>CC</given-names></name><name name-style="western"><surname>Feltenberger</surname><given-names>JB</given-names></name><name name-style="western"><surname>Ye</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wildman</surname><given-names>SA</given-names></name><name name-style="western"><surname>Tang</surname><given-names>W</given-names></name></person-group><article-title>Identification of a novel class of RIP1/RIP3 dual inhibitors that impede cell death and inflammation in mouse abdominal aortic aneurysm models</article-title><source>Cell Death Dis</source><year>2019</year><volume>10</volume><issue>3</issue><fpage>226</fpage><pub-id pub-id-type="doi">10.1038/s41419-019-1468-6</pub-id><pub-id pub-id-type="pmid">30842407</pub-id><pub-id pub-id-type="pmcid">PMC6403222</pub-id></element-citation><mixed-citation id="mc-CR102" publication-type="journal">Zhou T, Wang Q, Phan N, Ren J, Yang H, Feldman CC, Feltenberger JB, Ye Z, Wildman SA, Tang W (2019) Identification of a novel class of RIP1/RIP3 dual inhibitors that impede cell death and inflammation in mouse abdominal aortic aneurysm models. Cell Death Dis 10(3):226. 10.1038/s41419-019-1468-6<pub-id pub-id-type="pmid">30842407</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-019-1468-6</pub-id><pub-id pub-id-type="pmcid">PMC6403222</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR103"><citation-alternatives><element-citation id="ec-CR103" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name><name name-style="western"><surname>He</surname><given-names>Q</given-names></name><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jitkaew</surname><given-names>S</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Z</given-names></name></person-group><article-title>Necroptosis inhibitors: mechanisms of action and therapeutic potential</article-title><source>Apoptosis</source><year>2024</year><volume>29</volume><issue>1</issue><fpage>22</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1007/s10495-023-01905-6</pub-id><pub-id pub-id-type="pmid">38001341</pub-id></element-citation><mixed-citation id="mc-CR103" publication-type="journal">Zhou Y, Cai Z, Zhai Y, Yu J, He Q, He Y, Jitkaew S, Cai Z (2024) Necroptosis inhibitors: mechanisms of action and therapeutic potential. Apoptosis 29(1):22&#8211;44. 10.1007/s10495-023-01905-6<pub-id pub-id-type="pmid">38001341</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10495-023-01905-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR104"><citation-alternatives><element-citation id="ec-CR104" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zou</surname><given-names>C</given-names></name><name name-style="western"><surname>Mifflin</surname><given-names>L</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T</given-names></name><name name-style="western"><surname>Shan</surname><given-names>B</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Xing</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H</given-names></name><name name-style="western"><surname>Adiconis</surname><given-names>X</given-names></name><name name-style="western"><surname>Levin</surname><given-names>JZ</given-names></name></person-group><article-title>Reduction of mNAT1/hNAT2 contributes to cerebral endothelial necroptosis and A&#946; accumulation in Alzheimer&#8217;s disease</article-title><source>Cell Rep</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.celrep.2020.108447</pub-id><pub-id pub-id-type="pmid">33296651</pub-id></element-citation><mixed-citation id="mc-CR104" publication-type="journal">Zou C, Mifflin L, Hu Z, Zhang T, Shan B, Wang H, Xing X, Zhu H, Adiconis X, Levin JZ (2020) Reduction of mNAT1/hNAT2 contributes to cerebral endothelial necroptosis and A&#946; accumulation in Alzheimer&#8217;s disease. Cell Rep. 10.1016/j.celrep.2020.108447<pub-id pub-id-type="pmid">33296651</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2020.108447</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="advs70718" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Adv Sci (Weinh)</journal-id><journal-id journal-id-type="iso-abbrev">Adv Sci (Weinh)</journal-id><journal-id journal-id-type="pmc-domain-id">2933</journal-id><journal-id journal-id-type="pmc-domain">advsci</journal-id><journal-id journal-id-type="publisher-id">ADVS</journal-id><journal-title-group><journal-title>Advanced Science</journal-title></journal-title-group><issn pub-type="epub">2198-3844</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12499389</article-id><article-id pub-id-type="pmcid-ver">PMC12499389.1</article-id><article-id pub-id-type="pmcaid">12499389</article-id><article-id pub-id-type="pmcaiid">12499389</article-id><article-id pub-id-type="pmid">40668682</article-id><article-id pub-id-type="doi">10.1002/advs.202417644</article-id><article-id pub-id-type="publisher-id">ADVS70718</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Aging and the Spectral Properties of Brain Hemodynamics</article-title></title-group><contrib-group><contrib id="advs70718-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>Park</surname><given-names initials="KY">Ki Yun</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2413-9421</contrib-id><xref rid="advs70718-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="advs70718-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="advs70718-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="advs70718-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><address><email>k.park@wustl.edu</email></address></contrib><contrib id="advs70718-cr-0002" contrib-type="author"><name name-style="western"><surname>Snyder</surname><given-names initials="AZ">Abraham Z.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3379-9627</contrib-id><xref rid="advs70718-aff-0005" ref-type="aff">
<sup>5</sup>
</xref><xref rid="advs70718-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="advs70718-cr-0003" contrib-type="author"><name name-style="western"><surname>Goyal</surname><given-names initials="MS">Manu S.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1970-4270</contrib-id><xref rid="advs70718-aff-0005" ref-type="aff">
<sup>5</sup>
</xref><xref rid="advs70718-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="advs70718-cr-0004" contrib-type="author"><name name-style="western"><surname>Laumann</surname><given-names initials="TO">Timothy O.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0428-427X</contrib-id><xref rid="advs70718-aff-0007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib id="advs70718-cr-0005" contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names initials="JJ">John J.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2269-6267</contrib-id><xref rid="advs70718-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="advs70718-cr-0006" contrib-type="author"><name name-style="western"><surname>Adeyemo</surname><given-names initials="B">Babatunde</given-names></name><xref rid="advs70718-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="advs70718-cr-0007" contrib-type="author"><name name-style="western"><surname>Metcalf</surname><given-names initials="N">Nicholas</given-names></name><xref rid="advs70718-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="advs70718-cr-0008" contrib-type="author"><name name-style="western"><surname>Vlassenko</surname><given-names initials="AG">Andrei G.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4776-4855</contrib-id><xref rid="advs70718-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="advs70718-cr-0009" contrib-type="author"><name name-style="western"><surname>Shimony</surname><given-names initials="JS">Joshua S.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6228-776X</contrib-id><xref rid="advs70718-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="advs70718-cr-0010" contrib-type="author" corresp="yes"><name name-style="western"><surname>Leuthardt</surname><given-names initials="EC">Eric C.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4154-3135</contrib-id><xref rid="advs70718-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="advs70718-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="advs70718-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><address><email>leuthardte@wustl.edu</email></address></contrib></contrib-group><aff id="advs70718-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Medical Scientist Training Program</named-content>
<institution>Washington University School of Medicine</institution>
<city>St. Louis</city>
<named-content content-type="country-part">MO</named-content>
<postal-code>63110</postal-code>
<country country="US">USA</country>
</aff><aff id="advs70718-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Neurological Surgery</named-content>
<institution>Washington University School of Medicine</institution>
<city>St. Louis</city>
<named-content content-type="country-part">MO</named-content>
<postal-code>63110</postal-code>
<country country="US">USA</country>
</aff><aff id="advs70718-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Center for Innovation in Neuroscience and Technology</named-content>
<institution>Washington University School of Medicine</institution>
<city>St. Louis</city>
<named-content content-type="country-part">MO</named-content>
<postal-code>63110</postal-code>
<country country="US">USA</country>
</aff><aff id="advs70718-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Division of Neurotechnology</named-content>
<institution>Washington University School of Medicine</institution>
<city>St. Louis</city>
<named-content content-type="country-part">MO</named-content>
<postal-code>63110</postal-code>
<country country="US">USA</country>
</aff><aff id="advs70718-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Mallinckrodt Institute of Radiology</named-content>
<institution>Washington University School of Medicine</institution>
<city>St. Louis</city>
<named-content content-type="country-part">MO</named-content>
<postal-code>63110</postal-code>
<country country="US">USA</country>
</aff><aff id="advs70718-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>Washington University School of Medicine</institution>
<city>St. Louis</city>
<named-content content-type="country-part">MO</named-content>
<postal-code>63110</postal-code>
<country country="US">USA</country>
</aff><aff id="advs70718-aff-0007">
<label>
<sup>7</sup>
</label>
<named-content content-type="organisation-division">Department of Psychiatry</named-content>
<institution>Washington University School of Medicine</institution>
<city>St. Louis</city>
<named-content content-type="country-part">MO</named-content>
<postal-code>63110</postal-code>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label>E&#8208;mail: <email>k.park@wustl.edu</email>; <email>leuthardte@wustl.edu</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>16</day><month>7</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><volume>12</volume><issue seq="230">37</issue><issue-id pub-id-type="pmc-issue-id">498395</issue-id><issue-id pub-id-type="doi">10.1002/advs.v12.37</issue-id><elocation-id>e17644</elocation-id><history><date date-type="rev-recd"><day>19</day><month>6</month><year>2025</year></date><date date-type="received"><day>27</day><month>12</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>16</day><month>07</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>07</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-07 10:25:20.703"><day>07</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). Advanced Science published by Wiley&#8208;VCH GmbH</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ADVS-12-e17644.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:ADVS-12-e17644.pdf"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="preprint" xml:lang="en" xlink:title="research-article" journal-id="bioRxiv" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC11661102"><article-title>
Aging and the Spectral Properties of Brain Hemodynamics
</article-title><date><day>10</day><month>12</month><year>2024</year></date><elocation-id>2024.12.05.626723</elocation-id><source>bioRxiv</source><pub-id pub-id-type="pmcid">PMC11661102</pub-id><pub-id pub-id-type="pmid">39713346</pub-id></related-article><abstract><title>Abstract</title><p>Cerebral glucose metabolism (CMRGlc) systematically decreases with advancing age. We sought to identify correlates of decreased CMRGlc in the spectral properties of fMRI signals imaged in the task&#8208;free state. Lifespan resting&#8208;state fMRI data acquired in 455 healthy adults (ages 18&#8211;87&#160;years) and cerebral metabolic data acquired in a separate cohort of 94 healthy adults (ages 25&#8211;45&#160;years, 65&#8211;85&#160;years) were analyzed. The spectral properties of the fMRI data were characterized in terms of the relative predominance of slow versus fast activity using the spectral slope (SS) measure. We found that the relative proportion of fast activity increases with advancing age (SS flattening) across most cortical regions. The regional distribution of spectral slope was topographically correlated with CMRGlc in young adults. Notably, whereas most older adults maintain a youthful pattern of SS topography, a distinct subset of older adults significantly diverged from the youthful pattern. This subset of older adults also diverged from the youthful pattern of CMRGlc metabolism. This divergent pattern was associated with T2&#8208;weighted signal changes in frontal lobe white matter, an independent marker of small vessel disease. These findings suggest that BOLD signal spectral slope flattening may represent a biomarker of age&#8208;associated neurometabolic pathology.</p></abstract><abstract id="advs70718-abs-0001" abstract-type="graphical"><p>As the brain ages, its metabolic demands decline&#8212;but not uniformly. Here, spectral slope flattening of resting&#8208;state fMRI signals is proposed as a potential biomarker of pathologic brain aging. A subset of older adults diverges from youthful spectral and metabolic patterns, with changes linked to frontal white matter pathology and regional loss of aerobic glycolysis.
<boxed-text position="anchor" content-type="graphic" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="ADVS-12-e17644-g003.jpg"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="advs70718-kwd-0001">aging</kwd><kwd id="advs70718-kwd-0002">cerebral glucose metabolism</kwd><kwd id="advs70718-kwd-0003">neuropathology</kwd><kwd id="advs70718-kwd-0004">resting&#8208;state fMRI</kwd><kwd id="advs70718-kwd-0005">spectral analysis</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>UK Biotechnology and Biological Sciences Research Council</institution></institution-wrap></funding-source><award-id>BB/H008217/1</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>Intellectual and Developmental Disabilities Research Center at Washington University</institution></institution-wrap></funding-source><award-id>P50 HD103525</award-id></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>National Institute on Aging</institution><institution-id institution-id-type="doi">10.13039/100000049</institution-id></institution-wrap></funding-source><award-id>R01 AG053503</award-id><award-id>R01 AG057536</award-id><award-id>RF1 AG073210</award-id></award-group></funding-group><counts><fig-count count="6"/><table-count count="0"/><page-count count="11"/><word-count count="9402"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 6, 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:06.10.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="advs70718-cit-0089"><string-name name-style="western"><given-names>K. Y.</given-names><surname>Park</surname></string-name>, <string-name name-style="western"><given-names>A. Z.</given-names><surname>Snyder</surname></string-name>, <string-name name-style="western"><given-names>M. S.</given-names><surname>Goyal</surname></string-name>, et al. &#8220;<article-title>Aging and the Spectral Properties of Brain Hemodynamics</article-title>.&#8221; <source>Adv. Sci.</source><volume>12</volume>, no. <issue>37</issue> (<year>2025</year>): <volume>12</volume>, <elocation-id>e17644</elocation-id>. <pub-id pub-id-type="doi">10.1002/advs.202417644</pub-id><pub-id pub-id-type="pmcid">PMC12499389</pub-id><pub-id pub-id-type="pmid">40668682</pub-id></mixed-citation>
</p></notes></front><body><sec id="advs70718-sec-0010"><label>1</label><title>Introduction</title><p>Brain metabolism and physiologic integrity decline with age in a manner parallel to numerous other measures.<sup>[</sup>
<xref rid="advs70718-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="advs70718-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>
<sup>]</sup> This principle has been demonstrated with positron emission tomography (PET)<sup>[</sup>
<xref rid="advs70718-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="advs70718-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="advs70718-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>
<sup>]</sup> as well as resting&#8208;state functional magnetic resonance imaging (rs&#8208;fMRI).<sup>[</sup>
<xref rid="advs70718-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>
<sup>]</sup> In particular, cerebral blood flow and oxidative metabolism of glucose globally decline with advancing age.<sup>[</sup>
<xref rid="advs70718-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>
<sup>]</sup> In contrast, glycolytic metabolism of glucose declines most in regions with high values in youth.<sup>[</sup>
<xref rid="advs70718-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="advs70718-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>
<sup>]</sup> Thus, the regional pattern of cerebral metabolism in older adults often diverges from the normative youthful pattern.<sup>[</sup>
<xref rid="advs70718-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>
<sup>]</sup> Intriguingly, some older adults retain youthful metabolic patterns while others do not.<sup>[</sup>
<xref rid="advs70718-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>
<sup>]</sup>
</p><p>Previous rs&#8208;fMRI studies of aging have largely focused on functional connectivity (FC).<sup>[</sup>
<xref rid="advs70718-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>
<sup>]</sup> FC refers to pairwise correlations of blood&#8208;oxygen&#8208;level&#8208;dependent (BOLD) signals in functionally related regions known as resting state networks (RSNs).<sup>[</sup>
<xref rid="advs70718-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="advs70718-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="advs70718-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="advs70718-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="advs70718-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="advs70718-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="advs70718-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="advs70718-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>
<sup>]</sup> Age&#8208;related FC changes&#8212;particularly within the default mode network&#8212;and reductions in network segregation have been widely reported.<sup>[</sup>
<xref rid="advs70718-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="advs70718-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="advs70718-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>
<sup>]</sup> However, studies that rigorously controlled for preclinical Alzheimer's disease using CSF and imaging biomarkers found that age&#8208;FC associations are modest.<sup>[</sup>
<xref rid="advs70718-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="advs70718-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>
<sup>]</sup> On the other hand, it has been shown that advanced age leads to reductions in the amplitude of spontaneous BOLD signal fluctuations.<sup>[</sup>
<xref rid="advs70718-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="advs70718-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>
<sup>]</sup>
</p><p>Comparatively fewer studies have evaluated age&#8208;related changes in the statistics of regional spontaneous BOLD signals. These studies have employed a variety of metrics including amplitude of low&#8208;frequency fluctuations (ALFF) and BOLD signal variability, both of which relate to the temporal variance of BOLD fMRI signals. The developmental trajectory of ALFF up to the age of 20&#160;years follows a topographic gradient along the sensorimotor&#8208;association cortex axis.<sup>[</sup>
<xref rid="advs70718-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>
<sup>]</sup> In aging, both signal amplitude and between&#8208;region variability are reduced in older compared to younger adults.<sup>[</sup>
<xref rid="advs70718-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="advs70718-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>
<sup>]</sup> However, whereas these measures quantify amplitude&#8208;based features of BOLD, they do not address changes in the spectral characteristics of BOLD fMRI signals.</p><p>BOLD fluctuations are 1/<italic toggle="yes">f</italic>&#8208;like, that is, characterized by an approximately linear decrease in log spectral power with increasing frequency.<sup>[</sup>
<xref rid="advs70718-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>, <xref rid="advs70718-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>, <xref rid="advs70718-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>
<sup>]</sup> Importantly, the spectral properties of resting&#8208;state BOLD signals vary across brain networks,<sup>[</sup>
<xref rid="advs70718-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>
<sup>]</sup> depend on the task state,<sup>[</sup>
<xref rid="advs70718-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>
<sup>]</sup> and change in patients with glioblastomas and clinical comorbidities.<sup>[</sup>
<xref rid="advs70718-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>
<sup>]</sup> These effects may be related to changes in brain glucose metabolism. It has been repeatedly shown that the spectral properties of BOLD signals vary regionally in relation to brain glucose metabolism.<sup>[</sup>
<xref rid="advs70718-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>, <xref rid="advs70718-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>, <xref rid="advs70718-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>
<sup>]</sup>
</p><p>The preceding considerations suggest that the spectral characteristics of resting&#8208;state BOLD signal fluctuations may correspond with changes in cerebral blood flow and metabolism across the lifespan. To address this question, we evaluated the spectral properties of BOLD signal fluctuations and their correlations with cerebral blood flow and metabolism using two independent datasets: the Cambridge Centre for Ageing and Neuroscience (Cam&#8208;CAN) rs&#8208;fMRI dataset of 455 subjects aged 20&#8211;87&#160;years<sup>[</sup>
<xref rid="advs70718-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref>, <xref rid="advs70718-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref>
<sup>]</sup> and the adult metabolism and brain resilience (AMBR) metabolic dataset including 94 subjects aged 25&#8211;85&#160;years.<sup>[</sup>
<xref rid="advs70718-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>
<sup>]</sup>
</p></sec><sec id="advs70718-sec-0020"><label>2</label><title>Results</title><p>We evaluated changes in the spectral slope (SS) of BOLD fluctuations across the cortex using a cross&#8208;sectional group of 455 individuals aged 20 to 87&#160;years. SS was computed using linear regression of log power against frequency within the 0.015&#8211;0.145&#160;Hz band. In general terms, this metric indexes the relative prevalence of slow versus fast BOLD activity. Prior works have demonstrated a correlation between steeper spectral slopes, that is, greater coherence at lower frequencies within the infraslow frequency range, and higher glucose metabolism.<sup>[</sup>
<xref rid="advs70718-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>, <xref rid="advs70718-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>
<sup>]</sup> To characterize age&#8208;related SS changes for each cortical parcel, we fit parcel&#8208;specific, generalized additive models (GAMs), parametric in age, with sex and head motion as linear covariates, as previously described in ref. [<xref rid="advs70718-bib-0024" ref-type="bibr">24</xref>] Each GAM estimates the parcel&#8208;wise trajectory of changes in SS with age.</p><sec id="advs70718-sec-0030"><label>2.1</label><title>Spectral Slope Flattens Across the Lifespan</title><p>SS flattens with increasing age. In <bold>Figure</bold>
<xref rid="advs70718-fig-0001" ref-type="fig">
<bold>1</bold>
</xref>, panel A shows BOLD fluctuations sampled from the same ROIs in two subjects in both time and frequency domains. Panel B illustrates the average power spectra, computed by averaging across all cortical voxels and participants within each age group. Panel C shows the topography of SS change from youth to old age. Warmer hues indicate a steeper SS, reflecting a greater prevalence of slow over fast activity within the infra&#8208;slow frequency range. The steepest spectral slopes were observed in medial and lateral parietal, prefrontal, and visual cortices. This topography remained consistent across all age groups, suggesting that, despite a general flattening observed in the brain, major features of SS topography are generally preserved in most older individuals.</p><fig position="float" fig-type="Figure" id="advs70718-fig-0001" orientation="portrait"><label>Figure 1</label><caption><p>Spectral slope (SS) flattens with advancing age. A) Two distinct BOLD fluctuations, sampled from the same ROIs, in two exemplar subjects, shown in both time and frequency domains. B) (left) Averaged power spectra across participants in three age groups. (right) Averaged power spectra plotted as log power versus frequency. SS is defined as the negative of the first derivative of the slope fitted to the log power. C) Parcellated surface SS maps (footnote: the volumetric data was projected onto the Conte&#8208;69 average inflated surface for surface&#8208;based visualization), averaged across participants within three age groups, illustrate the topography of age&#8208;related SS flattening across the lifespan. Cortical regions with steep spectral slopes include medial and lateral parietal, prefrontal, posterior cingulate, and visual cortices (warmer hues). The age cohorts are 20&#8211;40&#160;years (<italic toggle="yes">n</italic>&#160;=&#160;113), 41&#8211;65&#160;years (<italic toggle="yes">n</italic>&#160;=&#160;179), and 66&#8211;87&#160;years (<italic toggle="yes">n</italic>&#160;=&#160;163). Although age&#8208;related SS flattening differs across cortical regions, the characteristic features of SS topography persist across all age groups.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="ADVS-12-e17644-g004.jpg"/></fig></sec><sec id="advs70718-sec-0040"><label>2.2</label><title>Spectral Slope Flattening Exhibits Regional Specificity</title><p>Visualization of regional fits with significant age&#8208;related effects suggested that there were two distinct trajectories of spectral slope behavior across the lifespan: 1) consistent flattening of spectral slope throughout life, or 2) no decline until mid&#8208;adulthood, followed by marked and continuous flattening. Fuzzy c&#8208;means clustering confirmed the presence of these varying trajectories across cortical parcels. Silhouette score analysis<sup>[</sup>
<xref rid="advs70718-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref>
<sup>]</sup> indicated that two clusters were optimal (see Supporting Information). Whereas most cortical regions exhibited continuous SS flattening (<bold>Figure</bold>
<xref rid="advs70718-fig-0002" ref-type="fig">
<bold>2</bold>A</xref>), certain regions, particularly those coinciding with auditory (AUD), cingulo&#8208;opercular (CON), and salience networks (SAL), exhibited flattening starting in mid&#8208;adulthood (Figure&#160;<xref rid="advs70718-fig-0002" ref-type="fig">2B</xref>). Regions within Cluster 2 include dorsal anterior cingulate cortex (dACC), frontal operculum, supplementary motor area (SMA), supramarginal gyrus (SMG), inferior frontal gyrus (IFG), pars marginalis of the cingulate gyrus, and the mesial surface of the visual cortex.</p><fig position="float" fig-type="Figure" id="advs70718-fig-0002" orientation="portrait"><label>Figure 2</label><caption><p>Trajectories of age&#8208;related SS flattening across cortical parcels (Schaefer 300 parcellation scheme), identified by fuzzy c&#8208;means clustering. A) Cluster 1, comprising the majority of cortical parcels, exhibits a consistent flattening of the spectral slope with age. The right&#8208;most panel displays the &#8220;RSN&#8208;Cluster1 Correspondence Index,&#8221; computed as the normalized sum of dot products between RSN probability maps<sup>[</sup>
<xref rid="advs70718-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref>
<sup>]</sup> and membership values for Cluster 1. B) Cluster 2, comprising cortical parcels primarily within the auditory, cingulo&#8208;opercular, and salience networks, exhibits delayed flattening that begins in mid&#8208;adulthood (&#8776;50&#160;years). The &#8220;RSN&#8208;Cluster2 Correspondence Index&#8221; is shown on the rightmost panel. Clustering analysis was done using the Schaefer 300 parcellation scheme in a volumetric space; results are subsequently projected onto a surface for visualization. Parcels heavily affected by susceptibility&#8208;related signal loss<sup>[</sup>
<xref rid="advs70718-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref>
<sup>]</sup>) or insignificant age&#8208;related effects were excluded in this analysis.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="ADVS-12-e17644-g002.jpg"/></fig></sec><sec id="advs70718-sec-0050"><label>2.3</label><title>Spectral Flattening is Most Prominent in Cortical Regions with High Glycolytic Metabolism</title><p>Significant SS changes were observed in 82% of cortical parcels (<italic toggle="yes">p</italic>
<sub>FDR</sub>&#160;&lt;&#160;0.05). The regional magnitude of age effects was assessed using the age&#8208;specific <italic toggle="yes">R</italic>
<sup>2</sup> difference, which measures the differences in explained variance between the full model (with age) and the reduced model (without age) (<bold>Figure</bold>
<xref rid="advs70718-fig-0003" ref-type="fig">
<bold>3</bold>A</xref>). Age&#8208;specific <italic toggle="yes">R</italic>
<sup>2</sup> difference varied from 0 to 0.12, where 0 indicates that the SS change is attributable to covariates other than age. High age&#8208;specific <italic toggle="yes">R</italic>
<sup>2</sup> difference values denote regions where age heavily contributed to SS change. Significant age effects were found in lateral and medial prefrontal regions, superior parietal lobule, intraparietal sulcus, the posterior cingulate cortex, and the medial surface of the visual cortex. Interestingly, age&#8208;specific <italic toggle="yes">R</italic>
<sup>2</sup> difference topography markedly resembled the distribution of CMRGlc across the cortical regions (Figure&#160;<xref rid="advs70718-fig-0003" ref-type="fig">3B,C</xref>; Spearman correlation <italic toggle="yes">&#961;</italic>&#160;=&#160;0.66, spin test <italic toggle="yes">p</italic>&#8208;value (<italic toggle="yes">p</italic>
<sub>spin</sub>)&#160;=&#160;3e&#8208;04). Brain regions with higher levels of glucose metabolism in youth showed greater effects of age on SS (Figure&#160;<xref rid="advs70718-fig-0003" ref-type="fig">3C</xref>).</p><fig position="float" fig-type="Figure" id="advs70718-fig-0003" orientation="portrait"><label>Figure 3</label><caption><p>A) Effect of age on SS (age&#8208;specific <italic toggle="yes">R</italic>
<sup>2</sup> difference) across the cortical surface. B) Parcellated cerebral metabolic rate of glucose use (CMRGlc) map averaged across 30 healthy young adults aged 25&#8211;45&#160;years (AMBR dataset from ref. [<xref rid="advs70718-bib-0007" ref-type="bibr">7</xref>]). C) Spearman correlation between age&#8208;specific <italic toggle="yes">R</italic>
<sup>2</sup> difference and the average CMRGlc map (rho&#160;=&#160;0.66, <italic toggle="yes">p</italic>&#160;=&#160;3e&#8208;04). Each symbol represents one parcel. Both metrics were evaluated using the Schaefer 200 parcellation scheme in a volumetric space and subsequently projected onto the surface for visualization.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="ADVS-12-e17644-g001.jpg"/></fig></sec><sec id="advs70718-sec-0060"><label>2.4</label><title>Outliers from the Normative Aging Group Identified by the SS Youthful Index</title><p>With increasing age, cerebral glucose metabolism not only decreases quantitatively<sup>[</sup>
<xref rid="advs70718-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="advs70718-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="advs70718-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref>
<sup>]</sup> but also loses its youthful regional patterns in some &#8211; but not all &#8211; older adults.<sup>[</sup>
<xref rid="advs70718-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>
<sup>]</sup> Considering the established association between the spectral properties of BOLD signals and CMRGlc,<sup>[</sup>
<xref rid="advs70718-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>, <xref rid="advs70718-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>, <xref rid="advs70718-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>
<sup>]</sup> and based on our present finding that SS flattens with aging, we asked whether SS topography &#8211; its inherent youthful regional variations in spectral slope &#8211; also loses its youthful pattern with increasing age. We assessed this by evaluating the SS youthful index (SSYI), evaluated as the Spearman correlation between individual SS maps and the averaged SS<sub>young</sub> map (see Experimental Section; <bold>Figure</bold>
<xref rid="advs70718-fig-0004" ref-type="fig">
<bold>4</bold>A</xref>).</p><fig position="float" fig-type="Figure" id="advs70718-fig-0004" orientation="portrait"><label>Figure 4</label><caption><p>(Top) Topography of average spectral slope (SS) maps, CMRGlc, CMRO<sub>2</sub>, and CBF of the younger cohort (25&#8211;45&#160;years). The SS<sub>young</sub> map was computed by averaging SS maps of younger participants (&lt;45&#160;years) in the CamCAN dataset. CMRGlc, CBF, and CMRO<sub>2</sub> maps are from the AMBR dataset (see Experimental Section). (Bottom) Each symbol (grey or red) represents an individual's Spearman correlation between their SS map and CamCAN&#8208;average SS<sub>young</sub> map (panel A defined as SS Youthful Index). Spearman correlations between SS maps and AMBR&#8208;average CMRGlc<sub>young</sub>, CMRO2<sub>young</sub>, and CBF<sub>young</sub> maps are shown in panels (B&#8211;D). Red symbols identify outlier individuals whose correlation values are greater than 3 scaled median absolute deviations from the median. These individuals also show negative and weaker correlations with CMRGlc<sub>young</sub> and CMRO2<sub>young</sub> maps. Correlations between SS maps and CBF<sub>young</sub> and CMRO2<sub>young</sub> are weaker as compared to those with CMRGlc<sub>young</sub>. SS Youthful Indices (panel A) and correlations between CMRGlc<sub>young</sub> and SS maps (panel B) are generally positive in younger CamCAN participants. However, an increasing fraction of individuals diverge from the youthful pattern starting at age &#8776;45.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-9" orientation="portrait" xlink:href="ADVS-12-e17644-g006.jpg"/></fig><p>Notably, the youthful pattern of SS topography generally persisted across the lifespan. However, SSYI inter&#8208;subject variability increased cross&#8208;sectionally with advancing age. Importantly, a distinct subset of older individuals displayed significantly weaker or even negative values of SSYI (less than three scaled median absolute deviations from the median). We labeled these individuals as outliers (red symbols in Figure&#160;<xref rid="advs70718-fig-0004" ref-type="fig">4A</xref>) for further analysis. Interestingly, these outliers also exhibited weaker correlations with CMRGlc<sub>young</sub> and CMRO2<sub>young</sub> (Figure&#160;<xref rid="advs70718-fig-0004" ref-type="fig">4B,C</xref>). This trend appeared much less distinguishable when correlated with CBF (Figure&#160;<xref rid="advs70718-fig-0004" ref-type="fig">4D</xref>).</p></sec><sec id="advs70718-sec-0070"><label>2.5</label><title>SS Youthful Index Divergence is Associated with Frontal White Matter Changes</title><p>Considering that older subjects typically exhibit greater grey matter atrophy and increased head motion, we hypothesized that the identified outliers (red symbols in Figure&#160;<xref rid="advs70718-fig-0004" ref-type="fig">4A</xref>) would demonstrate smaller cortical volume and/or more head motion. Moreover, as previous findings demonstrated that the adult female brain is metabolically more &#8220;youthful&#8221;,<sup>[</sup>
<xref rid="advs70718-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref>
<sup>]</sup> we assessed the effect of sex on the SS Youthful index in outliers and non&#8208;outliers aged over 45&#160;years. No significant differences were observed in grey matter volume, head motion, or sex between these groups. In<bold>Figure</bold>&#160;<xref rid="advs70718-fig-0005" ref-type="fig">
<bold>5</bold>A,B</xref>, the overlays of black symbols on red symbols indicate comparable distributions of grey matter volume and head motion in both groups. The histogram in Figure&#160;<xref rid="advs70718-fig-0005" ref-type="fig">5C</xref> shows no clear dominance of either sex in either group.</p><fig position="float" fig-type="Figure" id="advs70718-fig-0005" orientation="portrait"><label>Figure 5</label><caption><p>SS Youthful Index is significantly negatively associated with frontal lobe white matter (FLWM) T2w image intensities. SS Youthful Index is not associated with grey matter volume, head motion, and sex. A group of older subjects (age&#160;&gt;&#160;45&#160;years) was selected to determine if the outliers identified in Figure&#160;<xref rid="advs70718-fig-0004" ref-type="fig">4</xref> exhibited significant differences in their grey matter volume, head motion, sex, or WM T2w image intensities (see Experimental Section). Outliers (red symbols in Figure&#160;<xref rid="advs70718-fig-0004" ref-type="fig">4</xref>) are shown as red symbols. Non&#8208;outliers (grey symbols in Figure&#160;<xref rid="advs70718-fig-0004" ref-type="fig">4</xref>) are shown in black. A) Grey matter volume versus SS Youthful Index. B) Head motion (mm) versus SS Youthful Index. C) Differences in sex distributions between the two groups: non&#8208;outliers (top, black symbols in Figure&#160;<xref rid="advs70718-fig-0005" ref-type="fig">5A,B</xref>) and outliers (bottom, red symbols in Figure&#160;<xref rid="advs70718-fig-0005" ref-type="fig">5A,B</xref>). D) Voxelwise correlations across participants between normalized T2w signal intensity and SSYI (as in voxel&#8208;based lesion&#8208;symptom mapping (VLSM)<sup>[</sup>
<xref rid="advs70718-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref>
<sup>]</sup>). Significant Pearson correlations (<italic toggle="yes">p</italic>&#160;&lt;&#160;0.05) are shown in blue. E) Averaged T2w signal intensity within the blue&#8208;shaded regions in panel D versus SSYI. Statistical significance was evaluated in terms of linear regression model fit of age, gray matter volume, head motion, sex, and frontal lobe WM T2w image intensity as predictors of SS Youthful Index outlier status. The <italic toggle="yes">p</italic>&#8208;values shown in panels A&#8211;C and E are from the fit linear regression model result (see Table <xref rid="advs70718-supinfo-0001" ref-type="">S1</xref>, Supporting Information).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-11" orientation="portrait" xlink:href="ADVS-12-e17644-g005.jpg"/></fig><p>Intriguingly, however, SS Youthful Index was associated with higher T2&#8208;weighted image intensities, predominantly in the frontal lobe white matter (FLWM; left panel in Figure&#160;<xref rid="advs70718-fig-0005" ref-type="fig">5D</xref>). This focal topography was identified by correlating participants normalized T2w image intensities with SS Youthful Indices in each voxel (see Experimental Section). The right panel of Figure&#160;<xref rid="advs70718-fig-0005" ref-type="fig">5D</xref> illustrates the relation between SSYI and FLWM T2w intensity values in the blue&#8208;shaded regions of FLWM.</p><p>To quantify these observations, we fit a linear regression model using age, grey matter volume, head motion, FLWM T2w image intensities, and sex as predictors, and the binarized SS Youthful Index as the response variable. The only statistically significant predictor was FLWM T2w image intensity (estimate&#160;=&#160;&#8722;7.40, <italic toggle="yes">p</italic>&#8208;value&#160;=&#160;1.99e&#8208;06). This result suggests that, among the middle&#8208;aged to elderly subjects, deviations in the SS Youthful Index are more associated with frontal lobe white matter abnormalities than grey matter atrophy, head motion, sex, or age (Table <xref rid="advs70718-supinfo-0001" ref-type="">S1</xref>, Supporting Information). FLWM T2w image intensities were also significantly positively correlated with body mass index (BMI) (Figure <xref rid="advs70718-supinfo-0001" ref-type="">S3</xref>, Supporting Information).</p></sec></sec><sec id="advs70718-sec-0080"><label>3</label><title>Discussion</title><p>As the global population ages, there is a pressing need for accessible whole&#8208;brain imaging biomarkers of functional integrity of the brain. Here, we propose that the spectral properties of rs&#8208;fMRI BOLD signals may provide a functional biomarker of pathologic brain aging. fMRI has historically been primarily used for mapping task&#8208;based regional changes or identifying functional topographies using resting&#8208;state functional connectivity.<sup>[</sup>
<xref rid="advs70718-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref>
<sup>]</sup> The current work focuses on a complementary approach that evaluates age&#8208;related changes in BOLD signal spectra, with a particular focus on their relations with cerebral metabolism.</p><p>Cerebral metabolism declines with age.<sup>[</sup>
<xref rid="advs70718-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>
<sup>]</sup> The author found that resting&#8208;state BOLD fMRI signal fluctuations typically exhibit progressive spectral slope (SS) flattening with age. Similar findings, obtained using a different computational strategy, have recently been reported by Wu and Gollo.<sup>[</sup>
<xref rid="advs70718-bib-0088" ref-type="bibr">
<sup>88</sup>
</xref>
<sup>]</sup> Spectral slope changes likely reflect multiple factors, including accumulated clinical comorbidities,<sup>[</sup>
<xref rid="advs70718-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>
<sup>]</sup> normal effects of aging (e.g., less sleep), and lifestyle changes (e.g., increased use of caffeine). In our data, spectral flattening was most prominent in cortical regions with high levels of glycolytic metabolism in younger individuals. These same regions also exhibit age&#8208;associated loss of aerobic glycolysis.<sup>[</sup>
<xref rid="advs70718-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>
<sup>]</sup> Thus, spectral flattening appears to be associated with loss of aerobic glycolysis. Consistent with prior work, we demonstrate a topographical correlation between the spectral characteristics of BOLD fluctuations and CMRGlc,<sup>[</sup>
<xref rid="advs70718-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>, <xref rid="advs70718-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>, <xref rid="advs70718-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>
<sup>]</sup> which is most apparent in younger adults. Additionally, the present results suggest that while most older individuals maintain a youthful SS topography (as evaluated using SSYI), a subset of older individuals deviates significantly from the youthful pattern. Notably, lower SSYI is associated with higher T2&#8208;weighted image intensities in frontal lobe white matter. Increased T2&#8208;weighted signal intensity is a marker of white matter disease,<sup>[</sup>
<xref rid="advs70718-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref>
<sup>]</sup> previously shown to be particularly prominent in older individuals in the same regions highlighted in Figure&#160;<xref rid="advs70718-fig-0005" ref-type="fig">5D</xref>.<sup>[</sup>
<xref rid="advs70718-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref>, <xref rid="advs70718-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref>
<sup>]</sup> These observations suggest that SSYI correlates with other biomarkers of pathological neurometabolic aging.</p><sec id="advs70718-sec-0090"><label>3.1</label><title>Analyzing BOLD Fluctuations in the Temporal Frequency Domain</title><p>The physiological significance of spectral slope flattening follows from the notion that infraslow frequencies (nominally, &lt;0.1&#160;Hz) primarily reflect signals of neural origin,<sup>[</sup>
<xref rid="advs70718-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref>, <xref rid="advs70718-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref>
<sup>]</sup> whereas faster frequencies represent artifact, primarily thermal noise, and head motion.<sup>[</sup>
<xref rid="advs70718-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref>
<sup>]</sup> As head motion manifests as intermittent burst noise, its spectrum is theoretically white, as is that of thermal noise. In contrast, direct measurements show that BOLD fMRI signals are very attenuated at frequencies greater than 0.2&#160;Hz.<sup>[</sup>
<xref rid="advs70718-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref>
<sup>]</sup> Thus, BOLD power spectra generally assume the characteristic of a 1/<italic toggle="yes">f</italic>&#8208;like spectrum superimposed on a flat noise floor. Hence, the spectral slope (SS) indexes the extent to which BOLD fMRI fluctuations are of neural&#8208; as opposed to non&#8208;neural origin. Empirically, in glioblastoma patients, an increased proportion of high versus low&#8208;frequency rs&#8208;fMRI BOLD activity is associated with compromised brain integrity.<sup>[</sup>
<xref rid="advs70718-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>
<sup>]</sup> Here, we extend this principle to aging.</p></sec><sec id="advs70718-sec-0100"><label>3.2</label><title>Spectral Slope Flattening in Aging</title><p>The underlying physiology defining the spectral slope of the BOLD signal, as well as its changes, is as yet uncertain. Despite this limited understanding, prior work has shown that the spectral properties of rs&#8208;fMRI signals depend on task state<sup>[</sup>
<xref rid="advs70718-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>
<sup>]</sup> correlate with cerebral glucose metabolism<sup>[</sup>
<xref rid="advs70718-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>, <xref rid="advs70718-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>, <xref rid="advs70718-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>
<sup>]</sup> and are functionally organized.<sup>[</sup>
<xref rid="advs70718-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>
<sup>]</sup> Critically, regions with steeper spectral slopes exhibit stronger functional connectivity across extensive regions<sup>[</sup>
<xref rid="advs70718-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>
<sup>]</sup> and spatially correspond with higher baseline CMRGlc (Figure&#160;<xref rid="advs70718-fig-0004" ref-type="fig">4B</xref>). This circumstantial evidence suggests a potential relation between the required metabolic supply and the maintenance of cellular or synaptic dynamics<sup>[</sup>
<xref rid="advs70718-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref>
<sup>]</sup> engaging in large&#8208;scale circuits over multiple timescales. Aging affects this process, perhaps owing to the simplification of neuronal architecture (e.g., reduced arborizations and dendritic length, decreased spine numbers,<sup>[</sup>
<xref rid="advs70718-bib-0051" ref-type="bibr">
<sup>51</sup>
</xref>
<sup>]</sup> accumulation of DNA damage and mutations,<sup>[</sup>
<xref rid="advs70718-bib-0052" ref-type="bibr">
<sup>52</sup>
</xref>
<sup>]</sup> or inefficiencies in DNA repair processes.<sup>[</sup>
<xref rid="advs70718-bib-0053" ref-type="bibr">
<sup>53</sup>
</xref>
<sup>]</sup> Accordingly, it is plausible that age&#8208;related neuropathology manifests as spectral slope flattening of BOLD signals.</p><p>Importantly, age&#8208;associated spectral slope flattening is more pronounced in regions with higher CMRGlc in young adults (Figure&#160;<xref rid="advs70718-fig-0003" ref-type="fig">3</xref>). The pathophysiological mechanisms underlying this relation are incompletely understood. It is known that A&#946; deposition is a correlate of neural activity in the APP mouse model of Alzheimer disease.<sup>[</sup>
<xref rid="advs70718-bib-0054" ref-type="bibr">
<sup>54</sup>
</xref>
<sup>]</sup> Moreover, A&#946; deposition is more prevalent in parts of the brain that are more strongly functionally connected with other parts of the brain (i.e., increased global FC magnitude), both in the APP mouse<sup>[</sup>
<xref rid="advs70718-bib-0055" ref-type="bibr">
<sup>55</sup>
</xref>
<sup>]</sup> and healthy humans.<sup>[</sup>
<xref rid="advs70718-bib-0056" ref-type="bibr">
<sup>56</sup>
</xref>
<sup>]</sup> These observations suggest a potential &#8220;burn&#8208;out&#8221; mechanism for neural integrity over the lifespan. The relevant stressor may not be a single unit discharge, as action potentials are energetically inexpensive.<sup>[</sup>
<xref rid="advs70718-bib-0057" ref-type="bibr">
<sup>57</sup>
</xref>
<sup>]</sup> Speculatively, the relevant stressor may be limits on the extent to which synaptic reweighting is able to preserve previously learned memories while simultaneously encoding new information.<sup>[</sup>
<xref rid="advs70718-bib-0058" ref-type="bibr">
<sup>58</sup>
</xref>, <xref rid="advs70718-bib-0059" ref-type="bibr">
<sup>59</sup>
</xref>
<sup>]</sup> This would be consistent with the observation that sustained neural plasticity over a lifetime is associated with loss of synaptic spines and dendritic simplification.<sup>[</sup>
<xref rid="advs70718-bib-0051" ref-type="bibr">
<sup>51</sup>
</xref>
<sup>]</sup> The preceding considerations suggest that these histological findings should be especially prevalent in individuals here identified as SS outliers. Testing this hypothesis would require a study combining ante&#8208;mortem rs&#8208;fMRI with post&#8208;mortem histology.</p></sec><sec id="advs70718-sec-0110"><label>3.3</label><title>Delayed Onset of SS Flattening Exhibits Regional Specificity</title><p>While the majority of cortical regions showed continuous flattening of SS with increasing age, a subset of regions exhibited a delayed onset of SS flattening starting in mid&#8208;adulthood (Figure&#160;<xref rid="advs70718-fig-0002" ref-type="fig">2</xref>). Despite their unique and varied functions, many of these regions share a common role in initiating and controlling goal&#8208;directed behaviors. Specifically, dACC, frontal operculum, and SMG are key components of the cingulo&#8208;opercular network, associated with initiating, maintaining, and controlling task sets.<sup>[</sup>
<xref rid="advs70718-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="advs70718-bib-0060" ref-type="bibr">
<sup>60</sup>
</xref>, <xref rid="advs70718-bib-0061" ref-type="bibr">
<sup>61</sup>
</xref>
<sup>]</sup> SMA and IFG (includes Broca's area) are involved in initiating and controlling movements and expressive language.<sup>[</sup>
<xref rid="advs70718-bib-0062" ref-type="bibr">
<sup>62</sup>
</xref>, <xref rid="advs70718-bib-0063" ref-type="bibr">
<sup>63</sup>
</xref>
<sup>]</sup> The dorsal PCC is functionally distinct from the DMN and has been proposed to be involved in both detecting and responding to changes in the environment.<sup>[</sup>
<xref rid="advs70718-bib-0064" ref-type="bibr">
<sup>64</sup>
</xref>
<sup>]</sup> The delayed onset of changes in these brain regions may indicate a decline in the control of complex motor behaviors in older age, as individuals become more sedentary.</p></sec><sec id="advs70718-sec-0120"><label>3.4</label><title>SS Youthful Index Progressively Separates Outliers from the &#8220;Normal&#8221; Aging Group with Increasing Age; This Separation Correlates with Frontal Lobe White Matter Changes</title><p>The youthful pattern of spectral slope topography is generally maintained across the lifespan in most individuals. However, a subset of older individuals showed weaker and even negative SS Youthful Index values (Figure&#160;<xref rid="advs70718-fig-0004" ref-type="fig">4A</xref>). Although all participants included in this study are cognitively unimpaired (as defined by MMSE score greater than 24),<sup>[</sup>
<xref rid="advs70718-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref>
<sup>]</sup> cognitive normality does not exclude the possibility of asymptomatic neuropathology. In fact, the appearance of abnormal biomarker values often precedes the onset of clinical symptoms by several years.<sup>[</sup>
<xref rid="advs70718-bib-0065" ref-type="bibr">
<sup>65</sup>
</xref>, <xref rid="advs70718-bib-0066" ref-type="bibr">
<sup>66</sup>
</xref>
<sup>]</sup> Furthermore, studies of normal aging have been shown to be confounded by failure to exclude participants positive for preclinical biomarkers (e.g., CSF biomarkers including A&#946;42 and tau).<sup>[</sup>
<xref rid="advs70718-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>
<sup>]</sup> Hence, it is plausible that the present outlier subset in our sample harbors covert neuropathology.</p><p>Notably, SS Youthful Index was independent from grey matter volume or head motion, and differences in sex (Figure&#160;<xref rid="advs70718-fig-0005" ref-type="fig">5A&#8211;C</xref>). However, we identified a significant negative correlation between SS Youthful Index and frontal lobe white matter (FLWM) T2w image intensities (Figure&#160;<xref rid="advs70718-fig-0005" ref-type="fig">5D</xref>). This finding echoes previous work that linked white matter hyperintensity burden to the loss of the youthful pattern of brain aerobic glycolysis.<sup>[</sup>
<xref rid="advs70718-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>
<sup>]</sup> Additionally, aged white matter is more vulnerable to neurological disorders,<sup>[</sup>
<xref rid="advs70718-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref>
<sup>]</sup> and significant changes in FLWM have been observed as correlates of aging and AD.<sup>[</sup>
<xref rid="advs70718-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref>, <xref rid="advs70718-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref>
<sup>]</sup> Hence, it is conceivable that macrostructural frontal lobe white matter damage could contribute to a greater decline in neural function related to both aging and metabolic health.</p><p>Moreover, we found a significant positive correlation between FLWM T2w image intensities and body mass index (BMI) (see Figure <xref rid="advs70718-supinfo-0001" ref-type="">S4</xref>, Supporting Information). Whole brain spectral slope (averaged over parcels) and SSYI also were also independently associated with BMI after accounting for age, sex, and head motion as covariates (Figure <xref rid="advs70718-supinfo-0001" ref-type="">S3</xref>, Tables <xref rid="advs70718-supinfo-0001" ref-type="">S2</xref>, and <xref rid="advs70718-supinfo-0001" ref-type="">S3</xref>, Supporting Information). White matter hyperintensities are known to be associated with hypertension<sup>[</sup>
<xref rid="advs70718-bib-0067" ref-type="bibr">
<sup>67</sup>
</xref>, <xref rid="advs70718-bib-0068" ref-type="bibr">
<sup>68</sup>
</xref>, <xref rid="advs70718-bib-0069" ref-type="bibr">
<sup>69</sup>
</xref>
<sup>]</sup> and BMI, a crude measure of body fat percentage, which is often regarded as a risk factor for cardiovascular disease.<sup>[</sup>
<xref rid="advs70718-bib-0070" ref-type="bibr">
<sup>70</sup>
</xref>
<sup>]</sup> Thus, multiple lines of evidence suggest that systemic metabolic health impacts brain structure and function. Future studies with more heterogeneous cohorts may disambiguate the extent to which these effects are related to age versus cardiovascular disease or other pathologies.</p></sec><sec id="advs70718-sec-0130"><label>3.5</label><title>rs&#8208;fMRI Spectral Slope: A Potential Biomarker of Neuropathology</title><p>We propose a conceptual framework wherein biomarkers of neuropathology are characterized by change points at which the range of observed values progressively increases with age. In some cases, pathology leads to decreased values (e.g., hippocampal volume<sup>[</sup>
<xref rid="advs70718-bib-0071" ref-type="bibr">
<sup>71</sup>
</xref>
<sup>]</sup> or cortical thickness.<sup>[</sup>
<xref rid="advs70718-bib-0072" ref-type="bibr">
<sup>72</sup>
</xref>, <xref rid="advs70718-bib-0073" ref-type="bibr">
<sup>73</sup>
</xref>
<sup>]</sup> In other cases, pathology leads to increased values (e.g., white matter hyperintensities,<sup>[</sup>
<xref rid="advs70718-bib-0074" ref-type="bibr">
<sup>74</sup>
</xref>
<sup>]</sup> A&#946; deposition,<sup>[</sup>
<xref rid="advs70718-bib-0071" ref-type="bibr">
<sup>71</sup>
</xref>
<sup>]</sup> and accumulation of p&#8208;tau.<sup>[</sup>
<xref rid="advs70718-bib-0071" ref-type="bibr">
<sup>71</sup>
</xref>
<sup>]</sup> In either case, the variance of biomarker values increases with age: some individuals maintain a normative or youthful state, whereas others deviate significantly from the youthful pattern. Within this framework, we hypothesize that the spectral slope of rs&#8208;fMRI BOLD signals is a potential accessible biomarker of pathological neurometabolic aging. The underlying mechanisms that lead to changes in the spectral characteristics of BOLD signal fluctuations remain to be determined.</p></sec></sec><sec id="advs70718-sec-0140"><label>4</label><title>Limitations</title><p>We discuss several limitations of this work. BOLD signals are inherently sensitive to vascular and respiratory factors, as well as head motion, which is more prevalent in aging populations. Despite stringent quality control measures and accounting for head motion as a covariate, these factors may still affect the current findings. Additionally, partial volume correction (PVC) was applied in the AMBR dataset but not in the CamCAN dataset. PVC is particularly important in PET studies owing to the poor spatial resolution of older PET images (5&#8211;6&#160;mm full&#8208;width half maximum) and is likely to have a lesser impact on fMRI images. However, it is still conceivable that the increased inter&#8208;subject variability observed in correlations between SS topographies and youthful metabolic maps may be attributed, at least in part, to a greater partial volume effect with aging. We also evaluated spatial correlations between rs&#8208;fMRI and PET&#8208;derived maps from two different cohorts. Despite efforts to account for methodological differences, for example, performing analyses at a coarse (200&#8208;parcel) resolution and applying validated partial volume correction procedures for the PET data, dataset&#8208;specific idiosyncrasies may still contribute to the current findings. Future studies incorporating both PET and rs&#8208;fMRI from the same individuals would eliminate potential cohort&#8208;dependent confounds. To evaluate white matter abnormalities, we used T2&#8208;weighted images, implementing a technique previously described by ref.,<sup>[</sup>
<xref rid="advs70718-bib-0075" ref-type="bibr">
<sup>75</sup>
</xref>
<sup>]</sup> which normalizes each participant's T2w image intensities to a reference intensity atlas. Future studies would benefit from using FLAIR to more accurately quantify abnormal white matter hyperintensities. Finally, the cross&#8208;sectional nature of our study limits our ability to track within&#8208;individual changes in BOLD fluctuations with aging. Longitudinal studies could provide more direct evidence of co&#8208;occurring age&#8208;related changes in metabolism and BOLD spectral slope.</p></sec><sec id="advs70718-sec-0150"><label>5</label><title>Experimental Section</title><sec id="advs70718-sec-0180"><title>Datasets&#8208;Cam&#8208;CAN Dataset</title><p>The study included 455 participants from the adult lifespan Cambridge Centre for Ageing and Neuroscience (CamCAN) dataset.<sup>[</sup>
<xref rid="advs70718-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref>, <xref rid="advs70718-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref>
<sup>]</sup> As specified by Shafto et&#160;al., participants of this study were given written informed consent for the study. Exclusion criteria included suboptimal registration due to compromised structural scans or significant head motion (averaged changes in head displacement and rotation in quadrature&#160;&gt;&#160;0.5&#160;mm). The demographics of this sample include an age range of 18 to 88&#160;years (54.7&#160;&#177;&#160;18.5&#160;years), comprising 276 males and 179 females. The recruitment and selection processes of the study participants are detailed in the ref. [<xref rid="advs70718-bib-0034" ref-type="bibr">34</xref>] Briefly, inclusion criteria included cognitively healthy subjects without communication or mobility issues, substance abuse problems, and those eligible for MRI scans. MRI datasets were collected at a single site using a 3T Siemens TIM Trio scanner with a 32&#8208;channel head coil. T1w and T2w structural images and resting state scans were used in this analysis. The resting&#8208;state fMRI data included an 8&#8208;minute 40&#8208;second run (261 frames) acquired while participants rested with their eyes closed. A T2*&#8208;weighted echoplanar imaging) sequence was used to collect 261 volumes, each containing 32 axial slices with slice thickness of 3.7&#160;mm, interslice gap of 0.74&#160;mm for whole brain coverage (TR&#160;=&#160;1970&#160;ms; TE&#160;=&#160;30&#160;ms; flip angle&#160;=&#160;78&#176;; field of view (FOV)&#160;=&#160;192&#160;&#215;&#160;192&#160;mm; voxel&#8208;size&#160;=&#160;3&#160;&#215;&#160;3&#160;&#215;&#160;4.44&#160;mm).<sup>[</sup>
<xref rid="advs70718-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref>
<sup>]</sup>
</p></sec><sec id="advs70718-sec-0190"><title>Aging Metabolism and Brain Resilience (AMBR) Dataset</title><p>Cognitively unimpaired adults without evidence of brain Alzheimer's Disease (AD) pathology were recruited from the Washington University in St. Louis community and the Knight Alzheimer's Disease Research Center. A detailed explanation of the full dataset is in the ref. [<xref rid="advs70718-bib-0007" ref-type="bibr">7</xref>] All research participants provided informed consent. All study procedures were approved by the Washington University School of Medicine Institutional Review Board. Data from a total of 94 participants from this dataset were selected and divided into two groups: 30 young adults (ages 25&#8211;45&#160;years; 16 males, 14 females); 64 older adults (ages 65&#8211;85&#160;years; 32 males, 32 females). All participants had undergone positron emission tomography (PET) imaging using a Siemens ECAT HR+ scanner. The protocol included a single 18F&#8208;FDG scan, following a slow intravenous injection of &#8776;5&#160;mCi FDG, and two sets of <sup>15</sup>O PET scans. The final 20&#160;min (40&#8211;60&#160;min post&#8208;injection) of dynamic acquisition of the FDG images were summed and converted to SUVR measurements relative to the whole brain to assess the cerebral metabolic rate of glucose (CMRGlc). Each <sup>15</sup>O PET session consisted of two sessions of three scans to measure cerebral blood volume, cerebral blood flow (CBF), and cerebral metabolic rate of O<sub>2</sub> (CMRO<sub>2</sub>). Participants were instructed to remain awake with their eyes closed throughout the scans. Please see ref. [<xref rid="advs70718-bib-0007" ref-type="bibr">7</xref>] for full details regarding data acquisition and preprocessing methods.</p></sec><sec id="advs70718-sec-0200"><title>Data Acquisition and Preprocessing&#8212;Cam&#8208;CAN Dataset</title><p>Initial fMRI preprocessing followed the conventional practice.<sup>[</sup>
<xref rid="advs70718-bib-0076" ref-type="bibr">
<sup>76</sup>
</xref>
<sup>]</sup> Briefly, this included compensation for slice&#8208;dependent time shifts and rigid body correction of head movement within and across runs.<sup>[</sup>
<xref rid="advs70718-bib-0077" ref-type="bibr">
<sup>77</sup>
</xref>
<sup>]</sup> The preprocessed data were then resampled to align the structural data in (3&#160;mm)<sup>3</sup> atlas space using a composition of an initial affine transform and a warping map (computed using the Advanced Normalization Tools (ANTs) registration) connecting the fMRI volumes with the T1w structural image. Details of the steps regarding ANTs registration are outlined in the ref. [<xref rid="advs70718-bib-0030" ref-type="bibr">30</xref>] Motion correction was included in the final resampling to generate volumetric timeseries in (3&#160;mm)<sup>3</sup> atlas space. Further preprocessing steps included the removal of voxel&#8208;wise linear trends from each fMRI run, temporal low&#8208;pass filtering to retain frequencies below 0.15&#160;Hz, and regression of nuisance waveforms. These regressors included six head motion timeseries, average signals from CSF regions, and the signal evaluated over the whole brain (global signal regression). Finally, spatial smoothing was applied (6&#160;mm full width at half maximum Gaussian blur in each direction).</p></sec><sec id="advs70718-sec-0210"><title>Adult Metabolism and Brain Resilience (AMBR) Dataset</title><p>To accurately estimate metabolic activity specific to a tissue type, partial volume correction (PVC) was essential owing to the limited spatial resolution of PET scans. The necessity arised from both &#8220;tissue fraction&#8221; and &#8220;point spread function&#8221; effects.<sup>[</sup>
<xref rid="advs70718-bib-0078" ref-type="bibr">
<sup>78</sup>
</xref>
<sup>]</sup> Here, a parcel&#8208;based approach was employed for PVC, using Schaefer's 200 parcellation scheme (detailed in the Experimental Section), presuming that each parcel exhibited a distinct and uniform activity level. A region&#8208;based, symmetric geometric transfer matrix (sGTM) framework for PVC was used, processing both PET images and parcel maps to compute a scalar activity estimate for each parcel. In brief, sGTM models signaled spill&#8208;over between regions using regional spread functions, derived by convolving each parcel mask with the PET scanner's point spread function. This generated a symmetric transfer matrix, which was solved using least&#8208;squares fitting to recover the true regional tracer uptake. Compared to conventional GTM, sGTM provided similar accuracy with improved noise robustness, computational efficiency, and better performance in the presence of misregistration or PSF estimation errors.<sup>[</sup>
<xref rid="advs70718-bib-0078" ref-type="bibr">
<sup>78</sup>
</xref>
<sup>]</sup> The current results were derived from sGTM&#8208;corrected PET measures of CMRglc, CBF, and CMRO<sub>2</sub>.</p></sec><sec id="advs70718-sec-0220"><title>Parcellations</title><p>Resting state networks (RSNs) were hierarchically organized at multiple levels of granularity.<sup>[</sup>
<xref rid="advs70718-bib-0079" ref-type="bibr">
<sup>79</sup>
</xref>, <xref rid="advs70718-bib-0080" ref-type="bibr">
<sup>80</sup>
</xref>
<sup>]</sup> In this study, cortical parcellations were obtained from ref. [<xref rid="advs70718-bib-0081" ref-type="bibr">81</xref>] and resampled to the (3&#160;mm)<sup>3</sup> atlas space. For analyses involving GAMs, the 300&#8208;parcellation scheme was used. From these 300 parcels, regions with a low signal&#8208;to&#8208;noise ratio, as defined previously on the basis of a mean BOLD signal map<sup>[</sup>
<xref rid="advs70718-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref>
<sup>]</sup> comprising the medial prefrontal cortex and anterior/ventral portions of the temporal lobe, were excluded. These regions were mainly associated with the limbic network as defined in Schaefer's 17 networks, reducing the number of parcels to 271 for analysis. For comparing spectral slope maps with metabolic measures from the AMBR dataset, which was processed for PVC using the 200&#8208;parcellation scheme, the 200&#8208;parcellation scheme was also used.</p></sec><sec id="advs70718-sec-0230"><title>Power Spectral Density (PSD) Calculation from Autocorrelation Function</title><p>The PSD was computed from the lagged autocovariance function by employing a cosine&#8208;based Fourier transform (&#8220;Wiener&#8208;Khinchin theorem&#8221;) to allow for the exclusion of high&#8208;motion frames. First, a scaled temporal lag <italic toggle="yes">q</italic> associated with each lag m (<italic toggle="yes">q</italic>&#160;=&#160;(<italic toggle="yes">m</italic>&#160;&#8722;&#160;1)*TR/30) was computed, where TR represents the sampling interval, and 30 serves as a normalization factor for this analysis. The autocovariance values were adjusted by an exponential decay factor (exp(&#8722;0.5<italic toggle="yes">q</italic>
<sup>2</sup>)/<italic toggle="yes">n</italic>) to account for the decrease in signal similarity with increasing time lags. This exponential decay factor was based on the temporal weighting factor q as well as the number of valid frame pairs n, thereby ensuring the analysis considers only those frames that were relatively motion&#8208;free (the term &#8220;motion&#8208;free&#8221; was used loosely, as these frames were still subject to head motion, albeit less so than the censored frames). Finally, a cosine transform was applied to the adjusted lagged autocovariance function for each voxel, yielding the PSD for each voxel.</p></sec><sec id="advs70718-sec-0240"><title>Spectral Slope Calculation</title><p>BOLD fluctuations exhibited a scale&#8208;free activity.<sup>[</sup>
<xref rid="advs70718-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>
<sup>]</sup> He and colleagues previously established that a power&#8211;law function, particularly within the &lt;0.1&#160;Hz frequency range, more accurately fits the fMRI power spectrum than exponential and log&#8208;normal functions.<sup>[</sup>
<xref rid="advs70718-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>
<sup>]</sup> Following this work, the prior work used the power&#8211;law exponent.<sup>[</sup>
<xref rid="advs70718-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>
<sup>]</sup> In the current study, the &#8220;fitness&#8221; of the spectral slope between fitting the slope in log&#8211;log versus log&#8208;normal function was compared by evaluating <italic toggle="yes">R</italic>
<sup>2</sup>&#8208;values. Log&#8208;normal functions consistently yield higher <italic toggle="yes">R</italic>
<sup>2</sup>&#8208;values compared to those derived from the log&#8211;log functions (see Supporting Information). Accordingly, in the present study, spectral slope was defined as the negative of the first derivative of the slope fitted to the logged power versus raw frequency values.</p></sec><sec id="advs70718-sec-0250"><title>Characterizing Age Effects&#8212;Generalized Additive Models (GAMs)</title><p>Statistics for GAMs were performed using RStudio 2023.12.1&#160;+&#160;402 &#8220;Ocean Storm&#8221; and R 4.3.3. Drawing from prior work that utilized GAMs to analyze developmental effects,<sup>[</sup>
<xref rid="advs70718-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="advs70718-bib-0082" ref-type="bibr">
<sup>82</sup>
</xref>
<sup>]</sup> the current study expanded on GAMs to characterize the impacts of aging, seen as part of continuing development/lifespan changes. GAMs were advantageous for the flexibility in modeling both linear and non&#8208;linear relations between independent and dependent variables. The methodology for GAMs used in this work followed the framework detailed in ref. [<xref rid="advs70718-bib-0024" ref-type="bibr">24</xref>] Briefly, GAMs were fit with parcel&#8208;specific spectral slope as the dependent variable, including age as a smooth term and sex and in&#8208;scanner head motion as linear covariates. Models for each parcel were evaluated using thin plate regression splines as the smooth term basis set, applying the restricted maximal likelihood approach for smoothing parameters and limiting the maximum basis complexity (<italic toggle="yes">k</italic>) to 4. The significance of the association between spectral slope and age for each parcel was assessed using an analysis of variance (ANOVA), contrasting the full model (including both age and covariates) with a reduced model (only including covariates). The difference in the explained variance between the full model and the reduced model was denoted as the age&#8208;specific <italic toggle="yes">R</italic>
<sup>2</sup> difference. A significant result indicated a substantial reduction in residual deviation when age was included, as determined using the <italic toggle="yes">&#967;</italic>
<sup>2</sup>&#8208;test statistic. The <italic toggle="yes">p</italic>&#8208;values from the ANOVA across all parcel&#8208;specific GAMs were adjusted using the FDR correction. The threshold for statistical significance was set at <italic toggle="yes">P</italic>
<sub>FDR</sub>&#160;&lt;&#160;0.05.</p></sec><sec id="advs70718-sec-0260"><title>Associations with Cerebral Metabolic Rate of Glucose (CMRGlc)</title><p>The authors evaluated whether the extent to which spectral slope changed with age correlated spatially with &#8220;normative&#8221; CMRGlc topography. The &#8220;normative&#8221; CMRGlc topography was defined by the average baseline CMRGlc of young adults, corrected for PVC across Schaefer's 200 parcels in the AMBR dataset. The correlation coefficient was computed between the age&#8208;specific <italic toggle="yes">R</italic>
<sup>2</sup> values (comparing the full GAM model against the reduced GAM model) and the &#8220;normative&#8221; CMRglc map. The association between these two spatial maps was quantified with Spearman correlation, a non&#8208;parametric, rank&#8208;based method that did not depend on the assumption of normality.</p><p>To test the significance of Spearman correlation, spin permutation tests similar to those described by<sup>[</sup>
<xref rid="advs70718-bib-0083" ref-type="bibr">
<sup>83</sup>
</xref>, <xref rid="advs70718-bib-0084" ref-type="bibr">
<sup>84</sup>
</xref>
<sup>]</sup> were adapted. Since age&#8208;specific <italic toggle="yes">R</italic>
<sup>2</sup> difference and CMRGlc values were both computed in volumetric space using the Schaefer 200 parcellation scheme, the centroid coordinates of these parcellations were first resampled in surface space for random rotations. Each random rotation, repeated 10&#160;000 times using the quaternion approach<sup>[</sup>
<xref rid="advs70718-bib-0085" ref-type="bibr">
<sup>85</sup>
</xref>
<sup>]</sup> generated distributions of randomly rotated age&#8208;specific <italic toggle="yes">R</italic>
<sup>2</sup> difference values. The detailed approach is included in the Supporting Information. In each rotation, parcels rotated into the medial wall were excluded when computing Spearman correlation between the rotated values and parcel&#8208;specific CMRGlc values. The <italic toggle="yes">p</italic>&#8208;value from the spin permutation tests, <italic toggle="yes">p</italic>
<sub>spin</sub>, was defined as the number of permuted correlations that were greater than the original Spearman correlations.</p></sec><sec id="advs70718-sec-0270"><title>Fuzzy c&#8208;Means Clustering</title><p>The fuzzy&#8208;c&#8208;means clustering analysis was conducted in MATLAB 2023b. The <italic toggle="yes">predict fu</italic>nction in R used for the full GAM model outputs the smooth function for age, which function represented the lifespan trajectory of each parcel's spectral slope. Observing distinct patterns in each parcel's lifespan trajectory showing varying levels of linearity, fuzzy c&#8208;means clustering was applied to assign a weighted membership between zero and one to each parcel's trajectory. First, to determine the optimal cluster number, <italic toggle="yes">fcm</italic> was evaluated by incrementally increasing the cluster count (<italic toggle="yes">N</italic>&#160;=&#160;2&#8211;15). Options used for <italic toggle="yes">fcm</italic> were as follows: the exponent of the fuzzy partition matrix was set to 5 to allow a greater degree of overlap; the maximum iteration count was set to 10&#160;000; the default value for the minimum objective function improvement between two consecutive iterations was used (1e&#8208;5); Euclidean distance was used as a distance metric. Subsequently, for each cluster number, a silhouette score was computed by first converting the weighted membership into a binary format using a winner&#8208;take&#8208;all analysis. Two clusters resulted in the highest silhouette score (see Supporting Information). Thus, <italic toggle="yes">N</italic>&#160;=&#160;2 was used to cluster the trajectories and their corresponding cortical regions. Subsequently, the authors evaluated whether clustering based on aging trajectories aligned with well&#8208;known resting state networks (RSNs).<sup>[</sup>
<xref rid="advs70718-bib-0086" ref-type="bibr">
<sup>86</sup>
</xref>, <xref rid="advs70718-bib-0087" ref-type="bibr">
<sup>87</sup>
</xref>
<sup>]</sup> Specifically, voxelwise RSN membership probability maps<sup>[</sup>
<xref rid="advs70718-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref>
<sup>]</sup> were leveraged and computed the normalized sum of dot products between RSN probability maps and clustering membership values assigned for all parcels in each cluster.</p></sec><sec id="advs70718-sec-0280"><title>Spectral Slope Youthful Index Analysis&#8212;Spectral Slope Youthful Index</title><p>Goyal et&#160;al. introduced the &#8220;youthful pattern&#8221; analysis, where individual brain metabolism (fludeoxyglucose and oxygen metabolism) and cerebral blood flow (CBF) maps were compared to the corresponding group maps from a young adult cohort using Spearman rank correlation.<sup>[</sup>
<xref rid="advs70718-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>
<sup>]</sup> Extending this approach, the spectral slope (SS) Youthful Index was defined by evaluating the Spearman correlation between individual SS maps and the averaged SS maps from younger individuals (&lt;45&#160;years) in the CamCAN dataset (dataset described in Experimental Section). For outlier analysis, subjects whose SS youthful indices were greater than 3 scaled median absolute deviations from the median across all individuals in the CamCAN dataset were identified. These outliers, represented as red symbols and outlined with a red dashed box in Figure&#160;<xref rid="advs70718-fig-0004" ref-type="fig">4A</xref>, are also highlighted in Figure&#160;<xref rid="advs70718-fig-0004" ref-type="fig">4B&#8211;D</xref>.</p></sec><sec id="advs70718-sec-0290"><title>Spectral Slope Topography versus Metabolic and Hemodynamic Maps</title><p>SS maps were additionally compared with averaged metabolic (CMRGlc/CMRO<sub>2</sub>) and hemodynamic (CBF) maps from individuals under 45&#160;years in the AMBR dataset (dataset described in Experimental Section). The objective of this analysis was twofold: 1) to evaluate changes in SS topography with aging and 2) to assess its similarity and changes in its similarity to &#8220;youthful&#8221; CMRGlc/CMRO<sub>2</sub>/CBF maps with aging.</p></sec><sec id="advs70718-sec-0300"><title>Evaluation of Potential Confounders in Outliers Identified by the Spectral Slope Youthful Index</title><p>The authors tested whether outliers identified by the SS Youthful Index were driven by potential confounding factors including grey matter volume, head motion, sex differences, or white matter abnormalities. Considering the greater variability observed among older subjects, individuals aged over 45&#160;years were specifically included. Grey matter volume for each individual was quantified using FSL FAST segmentation, which segmented the atlas&#8208;registered individual's T1w image into three tissue types: grey matter, white matter, and CSF. Total individual&#8208;specific grey matter volume was defined by summing the number of segmented grey matter voxels in (3&#160;mm)<sup>3</sup> atlas space. Head motion was assessed using the previously described realignment procedure.<sup>[</sup>
<xref rid="advs70718-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>
<sup>]</sup> Briefly, this measure averaged the changes in head displacement and rotation in quadrature.</p><p>White matter abnormalities were assessed using normalized T2&#8208;weighted (T2w) image intensities based on an intensity atlas, adopting a technique described in ref. [<xref rid="advs70718-bib-0075" ref-type="bibr">75</xref>] Brier and colleagues used T1&#8208;weighted and FLAIR images. However, as the authors did not have an FLAIR image available, T1w and T2w images were used for image intensity normalization. The reference intensity atlas was computed based on CamCAN participants under 40 years. Each participant's T2w image was normalized to the reference intensity atlas. To analyze the association between white matter and SSYI on a voxel&#8208;by&#8208;voxel basis, an approach similar to voxel&#8208;based lesion&#8208;symptom mapping (VLSM) was implemented.<sup>[</sup>
<xref rid="advs70718-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref>
<sup>]</sup> For each voxel, instead of employing conventional group comparisons, SSYI and T2w image intensities were treated as continuous variables for computing Pearson correlations. Considering the exploratory nature of this analysis, the significance threshold was set at <italic toggle="yes">&#945;</italic>&#160;=&#160;0.05. Voxels showing significant correlations with SSYI were subsequently used as an ROI. The averaged T2w image intensity value within this ROI was used as a representative measure of white matter abnormalities.</p><p>To quantitatively determine if any of these variables explain the difference between individuals in the outlier versus non&#8208;outlier groups, a linear regression model was fitted with the binarized SS Youthful Index as the response variable. Age, grey matter volume (GMV), head motion (HM), and frontal lobe white matter T2w image intensities (FLWM T2w) were used as continuous predictor variables, and sex as a categorical predictor variable:
<disp-formula id="advs70718-disp-0001"><label>(1)</label><mml:math id="jats-math-1" display="block"><mml:mrow><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi><mml:mspace width="0.28em"/><mml:mi>Y</mml:mi><mml:mi>o</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi><mml:mi>h</mml:mi><mml:mi>f</mml:mi><mml:mi>u</mml:mi><mml:mi>l</mml:mi><mml:mspace width="0.28em"/><mml:mi>I</mml:mi><mml:mi>n</mml:mi><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>x</mml:mi><mml:mo linebreak="badbreak">&#8776;</mml:mo><mml:msub><mml:mi>&#946;</mml:mi><mml:mi>o</mml:mi></mml:msub></mml:mrow></mml:mtd><mml:mtd><mml:mo>+</mml:mo></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:msub><mml:mi>&#946;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi><mml:mo linebreak="badbreak">+</mml:mo><mml:msub><mml:mi>&#946;</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mi>G</mml:mi><mml:mi>M</mml:mi><mml:mi>V</mml:mi><mml:mo linebreak="goodbreak">+</mml:mo><mml:msub><mml:mi>&#946;</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mi>H</mml:mi><mml:mi>M</mml:mi><mml:mo linebreak="goodbreak">+</mml:mo><mml:msub><mml:mi>&#946;</mml:mi><mml:mn>4</mml:mn></mml:msub><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>x</mml:mi><mml:mo linebreak="goodbreak">+</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd/><mml:mtd columnalign="left"><mml:mrow><mml:msub><mml:mi>&#946;</mml:mi><mml:mn>5</mml:mn></mml:msub><mml:mi>F</mml:mi><mml:mi>L</mml:mi><mml:mi>W</mml:mi><mml:mi>M</mml:mi><mml:mspace width="0.28em"/><mml:mi>T</mml:mi><mml:mn>2</mml:mn><mml:mi>w</mml:mi></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula>
</p></sec><sec id="advs70718-sec-0310"><title>Statistical Analysis</title><p>Preprocessing steps for fMRI data&#8212;including PSD computation, spectral slope estimation, and fuzzy&#8208;c&#8208;means clustering&#8212;were performed in MATLAB 2023b and are described in detail in the Experimental Section. The fMRI preprocessing pipeline, including dataset&#8208;specific details, is outlined in the Experimental Section, and the primary atlas registration tool used is publicly available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/robbisg/4dfp_tools" ext-link-type="uri">https://github.com/robbisg/4dfp_tools</ext-link>. Statistical analyses involving GAMs were conducted using RStudio 2023.12.1 with R version 4.3.3, as detailed in Section&#160;6.1.</p></sec></sec><sec sec-type="COI-statement" id="advs70718-sec-0330"><title>Conflict of Interest</title><p>K.Y.P., T.O.L., J.J.L., J.S.S., A.Z.S., and E.C.L.: Licensing of Intellectual Property: Sora Neuroscience E.C.L.: Stock ownership: Sora Neuroscience</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="advs70718-supinfo-0001" position="float" content-type="local-data" orientation="portrait"/><supplementary-material id="advs70718-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ADVS-12-e17644-s001.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="advs70718-sec-0320"><title>Acknowledgements</title><p>Data collection and sharing for this work were provided by the NIH/NIA grants R01 AG053503 (PI: AGV), R01 AG057536 (PIs: M.S.G. and A.G.V.), and RF1 AG073210 (PIs: M.S.G. and A.G.V.), and the Cambridge Centre for Ageing and Neuroscience (CamCAN). Funding for CamCAN was provided by the UK Biotechnology and Biological Sciences Research Council under grant number BB/H008217/1 and was additionally supported by the UK Medical Research Council and the University of Cambridge, UK. Parts of this work were funded by the Intellectual and Developmental Disabilities Research Center at Washington University award Number P50 HD103525.</p></ack><sec sec-type="data-availability" id="advs70718-sec-0350"><title>Data Availability Statement</title><p>The Cam&#8208;CAN dataset is publicly available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cam-can.mrc-cbu.cam.ac.uk/dataset/" ext-link-type="uri" specific-use="software is-supplemented-by">https://cam&#8208;can.mrc&#8208;cbu.cam.ac.uk/dataset/</ext-link>. AMBR dataset: Data availability is based on prior subject consents and the 2018 Common Rule. Coded and processed regional data, suitable for additional data and statistical analyses, can be obtained from the study authors upon reasonable request by a qualified researcher under a data use agreement. For access to raw imaging data, requests should be directed to the VG Lab (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mir.wustl.edu/research/research-centers/neuroimaging-labs-research-center-nil-rc/labs/vlassenko-goyal-lab/" ext-link-type="uri" specific-use="software is-supplemented-by">https://www.mir.wustl.edu/research/research&#8208;centers/neuroimaging&#8208;labs&#8208;research&#8208;center&#8208;nil&#8208;rc/labs/vlassenko&#8208;goyal&#8208;lab/</ext-link>), where these data were originally collected. The primary atlas registration pipeline used in this work is available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/robbisg/4dfp_tools" ext-link-type="uri" specific-use="software is-supplemented-by">https://github.com/robbisg/4dfp_tools</ext-link>. ANTs registration can be found at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://stnava.github.io/ANTs/" ext-link-type="uri" specific-use="software is-supplemented-by">http://stnava.github.io/ANTs/</ext-link>. Any other codes used in this study will be available upon request to KYP.</p></sec><ref-list id="advs70718-bibl-0001"><ref id="advs70718-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="advs70718-cit-0001"><string-name name-style="western"><given-names>T. B.</given-names><surname>Kirkwood</surname></string-name>, <source>Cell</source><year>2005</year>, <volume>120</volume>, <fpage>437</fpage>.<pub-id pub-id-type="pmid">15734677</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2005.01.027</pub-id></mixed-citation></ref><ref id="advs70718-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="advs70718-cit-0002"><string-name name-style="western"><given-names>C.</given-names><surname>Lopez&#8208;Otin</surname></string-name>, <string-name name-style="western"><given-names>M. A.</given-names><surname>Blasco</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Partridge</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Serrano</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Kroemer</surname></string-name>, <source>Cell</source><year>2013</year>, <volume>153</volume>, <fpage>1194</fpage>.<pub-id pub-id-type="pmid">23746838</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2013.05.039</pub-id><pub-id pub-id-type="pmcid">PMC3836174</pub-id></mixed-citation></ref><ref id="advs70718-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="advs70718-cit-0003"><string-name name-style="western"><given-names>M. S.</given-names><surname>Goyal</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Hawrylycz</surname></string-name>, <string-name name-style="western"><given-names>J. A.</given-names><surname>Miller</surname></string-name>, <string-name name-style="western"><given-names>A. Z.</given-names><surname>Snyder</surname></string-name>, <string-name name-style="western"><given-names>M. E.</given-names><surname>Raichle</surname></string-name>, <source>Cell Metab.</source><year>2014</year>, <volume>19</volume>, <fpage>49</fpage>.<pub-id pub-id-type="pmid">24411938</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2013.11.020</pub-id><pub-id pub-id-type="pmcid">PMC4389678</pub-id></mixed-citation></ref><ref id="advs70718-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="advs70718-cit-0004"><string-name name-style="western"><given-names>S. S.</given-names><surname>Kety</surname></string-name>, <source>J. Chronic Dis.</source><year>1956</year>, <volume>3</volume>, <fpage>478</fpage>.<pub-id pub-id-type="pmid">13306754</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0021-9681(56)90146-1</pub-id></mixed-citation></ref><ref id="advs70718-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="advs70718-cit-0005"><string-name name-style="western"><given-names>D. E.</given-names><surname>Kuhl</surname></string-name>, <string-name name-style="western"><given-names>E. J.</given-names><surname>Metter</surname></string-name>, <string-name name-style="western"><given-names>W. H.</given-names><surname>Riege</surname></string-name>, <string-name name-style="western"><given-names>M. E.</given-names><surname>Phelps</surname></string-name>, <source>J. Cereb. Blood Flow Metab.</source><year>1982</year>, <volume>2</volume>, <fpage>163</fpage>.<pub-id pub-id-type="pmid">6978885</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/jcbfm.1982.15</pub-id></mixed-citation></ref><ref id="advs70718-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="advs70718-cit-0006"><string-name name-style="western"><given-names>R.</given-names><surname>Sala&#8208;Llonch</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Bartres&#8208;Faz</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Junque</surname></string-name>, <source>Front. Psychol.</source><year>2015</year>, <volume>6</volume>, <fpage>663</fpage>.<pub-id pub-id-type="pmid">26052298</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpsyg.2015.00663</pub-id><pub-id pub-id-type="pmcid">PMC4439539</pub-id></mixed-citation></ref><ref id="advs70718-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="advs70718-cit-0007"><string-name name-style="western"><given-names>M. S.</given-names><surname>Goyal</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Blazey</surname></string-name>, <string-name name-style="western"><given-names>N. V.</given-names><surname>Metcalf</surname></string-name>, <string-name name-style="western"><given-names>M. P.</given-names><surname>McAvoy</surname></string-name>, <string-name name-style="western"><given-names>J. F.</given-names><surname>Strain</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Rahmani</surname></string-name>, <string-name name-style="western"><given-names>T. J.</given-names><surname>Durbin</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Xiong</surname></string-name>, <string-name name-style="western"><given-names>T. L.</given-names><surname>Benzinger</surname></string-name>, <string-name name-style="western"><given-names>J. C.</given-names><surname>Morris</surname></string-name>, <string-name name-style="western"><given-names>M. E.</given-names><surname>Raichle</surname></string-name>, <string-name name-style="western"><given-names>A. G.</given-names><surname>Vlassenko</surname></string-name>, <source>Proc. Natl. Acad. Sci. U. S. A.</source><year>2023</year>, <volume>120</volume>, <elocation-id>2212256120</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2212256120</pub-id><pub-id pub-id-type="pmcid">PMC9963219</pub-id><pub-id pub-id-type="pmid">36745794</pub-id></mixed-citation></ref><ref id="advs70718-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="advs70718-cit-0008"><string-name name-style="western"><given-names>M. S.</given-names><surname>Goyal</surname></string-name>, <string-name name-style="western"><given-names>A. G.</given-names><surname>Vlassenko</surname></string-name>, <string-name name-style="western"><given-names>T. M.</given-names><surname>Blazey</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Su</surname></string-name>, <string-name name-style="western"><given-names>L. E.</given-names><surname>Couture</surname></string-name>, <string-name name-style="western"><given-names>T. J.</given-names><surname>Durbin</surname></string-name>, <string-name name-style="western"><given-names>R. J.</given-names><surname>Bateman</surname></string-name>, <string-name name-style="western"><given-names>T. L.</given-names><surname>Benzinger</surname></string-name>, <string-name name-style="western"><given-names>J. C.</given-names><surname>Morris</surname></string-name>, <string-name name-style="western"><given-names>M. E.</given-names><surname>Raichle</surname></string-name>, <source>Cell Metab.</source><year>2017</year>, <volume>26</volume>, <fpage>353</fpage>.<pub-id pub-id-type="pmid">28768174</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2017.07.010</pub-id><pub-id pub-id-type="pmcid">PMC5573225</pub-id></mixed-citation></ref><ref id="advs70718-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="advs70718-cit-0009"><string-name name-style="western"><given-names>C. F.</given-names><surname>Beckmann</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>DeLuca</surname></string-name>, <string-name name-style="western"><given-names>J. T.</given-names><surname>Devlin</surname></string-name>, <string-name name-style="western"><given-names>S. M.</given-names><surname>Smith</surname></string-name>, <source>Biol. Sci.</source><year>2005</year>, <volume>360</volume>, <fpage>1001</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1098/rstb.2005.1634</pub-id><pub-id pub-id-type="pmcid">PMC1854918</pub-id><pub-id pub-id-type="pmid">16087444</pub-id></mixed-citation></ref><ref id="advs70718-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="advs70718-cit-0010"><string-name name-style="western"><given-names>B.</given-names><surname>Biswal</surname></string-name>, <string-name name-style="western"><given-names>F. Z.</given-names><surname>Yetkin</surname></string-name>, <string-name name-style="western"><given-names>V. M.</given-names><surname>Haughton</surname></string-name>, <string-name name-style="western"><given-names>J. S.</given-names><surname>Hyde</surname></string-name>, <source>Magn. Reson. Med.</source><year>1995</year>, <volume>34</volume>, <fpage>537</fpage>.<pub-id pub-id-type="pmid">8524021</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mrm.1910340409</pub-id></mixed-citation></ref><ref id="advs70718-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="advs70718-cit-0011"><string-name name-style="western"><given-names>D.</given-names><surname>Cordes</surname></string-name>, <string-name name-style="western"><given-names>V. M.</given-names><surname>Haughton</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Arfanakis</surname></string-name>, <string-name name-style="western"><given-names>G. J.</given-names><surname>Wendt</surname></string-name>, <string-name name-style="western"><given-names>P. A.</given-names><surname>Turski</surname></string-name>, <string-name name-style="western"><given-names>C. H.</given-names><surname>Moritz</surname></string-name>, <string-name name-style="western"><given-names>M. A.</given-names><surname>Quigley</surname></string-name>, <string-name name-style="western"><given-names>M. E.</given-names><surname>Meyerand</surname></string-name>, <source>Am. J. Neuroradiol.</source><year>2000</year>, <volume>21</volume>, <fpage>1636</fpage>.<pub-id pub-id-type="pmid">11039342</pub-id><pub-id pub-id-type="pmcid">PMC8174861</pub-id></mixed-citation></ref><ref id="advs70718-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="advs70718-cit-0012"><string-name name-style="western"><given-names>M. D.</given-names><surname>Fox</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Corbetta</surname></string-name>, <string-name name-style="western"><given-names>A. Z.</given-names><surname>Snyder</surname></string-name>, <string-name name-style="western"><given-names>J. L.</given-names><surname>Vincent</surname></string-name>, <string-name name-style="western"><given-names>M. E.</given-names><surname>Raichle</surname></string-name>, <source>Proc. Natl. Acad. Sci. U. S. A.</source><year>2006</year>, <volume>103</volume>, <elocation-id>10046</elocation-id>.<pub-id pub-id-type="pmid">16788060</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0604187103</pub-id><pub-id pub-id-type="pmcid">PMC1480402</pub-id></mixed-citation></ref><ref id="advs70718-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="advs70718-cit-0013"><string-name name-style="western"><given-names>M. D.</given-names><surname>Greicius</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Krasnow</surname></string-name>, <string-name name-style="western"><given-names>A. L.</given-names><surname>Reiss</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Menon</surname></string-name>, <source>Proc. Natl. Acad. Sci. U. S. A.</source><year>2003</year>, <volume>100</volume>, <fpage>253</fpage>.<pub-id pub-id-type="pmid">12506194</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0135058100</pub-id><pub-id pub-id-type="pmcid">PMC140943</pub-id></mixed-citation></ref><ref id="advs70718-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="advs70718-cit-0014"><string-name name-style="western"><given-names>M.</given-names><surname>Hampson</surname></string-name>, <string-name name-style="western"><given-names>B. S.</given-names><surname>Peterson</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Skudlarski</surname></string-name>, <string-name name-style="western"><given-names>J. C.</given-names><surname>Gatenby</surname></string-name>, <string-name name-style="western"><given-names>J. C.</given-names><surname>Gore</surname></string-name>, <source>Hum. Brain Mapp.</source><year>2002</year>, <volume>15</volume>, <fpage>247</fpage>.<pub-id pub-id-type="pmid">11835612</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hbm.10022</pub-id><pub-id pub-id-type="pmcid">PMC6872035</pub-id></mixed-citation></ref><ref id="advs70718-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="advs70718-cit-0015"><string-name name-style="western"><given-names>M. J.</given-names><surname>Lowe</surname></string-name>, <string-name name-style="western"><given-names>B. J.</given-names><surname>Mock</surname></string-name>, <string-name name-style="western"><given-names>J. A.</given-names><surname>Sorenson</surname></string-name>, <source>NeuroImage</source><year>1998</year>, <volume>7</volume>, <fpage>119</fpage>.<pub-id pub-id-type="pmid">9558644</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/nimg.1997.0315</pub-id></mixed-citation></ref><ref id="advs70718-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="advs70718-cit-0016"><string-name name-style="western"><given-names>W. W.</given-names><surname>Seeley</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Menon</surname></string-name>, <string-name name-style="western"><given-names>A. F.</given-names><surname>Schatzberg</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Keller</surname></string-name>, <string-name name-style="western"><given-names>G. H.</given-names><surname>Glover</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Kenna</surname></string-name>, <string-name name-style="western"><given-names>A. L.</given-names><surname>Reiss</surname></string-name>, <string-name name-style="western"><given-names>M. D.</given-names><surname>Greicius</surname></string-name>, <source>J. Neurosci.</source><year>2007</year>, <volume>27</volume>, <fpage>2349</fpage>.<pub-id pub-id-type="pmid">17329432</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.5587-06.2007</pub-id><pub-id pub-id-type="pmcid">PMC2680293</pub-id></mixed-citation></ref><ref id="advs70718-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="advs70718-cit-0017"><string-name name-style="western"><given-names>N. U.</given-names><surname>Dosenbach</surname></string-name>, <string-name name-style="western"><given-names>D. A.</given-names><surname>Fair</surname></string-name>, <string-name name-style="western"><given-names>F. M.</given-names><surname>Miezin</surname></string-name>, <string-name name-style="western"><given-names>A. L.</given-names><surname>Cohen</surname></string-name>, <string-name name-style="western"><given-names>K. K.</given-names><surname>Wenger</surname></string-name>, <string-name name-style="western"><given-names>R. A.</given-names><surname>Dosenbach</surname></string-name>, <string-name name-style="western"><given-names>M. D.</given-names><surname>Fox</surname></string-name>, <string-name name-style="western"><given-names>A. Z.</given-names><surname>Snyder</surname></string-name>, <string-name name-style="western"><given-names>J. L.</given-names><surname>Vincent</surname></string-name>, <string-name name-style="western"><given-names>M. E.</given-names><surname>Raichle</surname></string-name>, <string-name name-style="western"><given-names>B. L.</given-names><surname>Schlaggar</surname></string-name>, <string-name name-style="western"><given-names>S. E.</given-names><surname>Petersen</surname></string-name>, <source>Proc. Natl. Acad. Sci. U. S. A.</source><year>2007</year>, <volume>104</volume>, <elocation-id>11073</elocation-id>.<pub-id pub-id-type="pmid">17576922</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0704320104</pub-id><pub-id pub-id-type="pmcid">PMC1904171</pub-id></mixed-citation></ref><ref id="advs70718-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="advs70718-cit-0018"><string-name name-style="western"><given-names>L.</given-names><surname>Geerligs</surname></string-name>, <string-name name-style="western"><given-names>R. J.</given-names><surname>Renken</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Saliasi</surname></string-name>, <string-name name-style="western"><given-names>N. M.</given-names><surname>Maurits</surname></string-name>, <string-name name-style="western"><given-names>M. M.</given-names><surname>Lorist</surname></string-name>, <source>Cereb Cortex</source><year>2015</year>, <volume>25</volume>, <fpage>1987</fpage>.<pub-id pub-id-type="pmid">24532319</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cercor/bhu012</pub-id></mixed-citation></ref><ref id="advs70718-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="advs70718-cit-0019"><string-name name-style="western"><given-names>D.</given-names><surname>Tomasi</surname></string-name>, <string-name name-style="western"><given-names>N. D.</given-names><surname>Volkow</surname></string-name>, <source>Mol Psychiatry</source><year>2012</year>, <volume>17</volume>, <fpage>549</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/mp.2011.81</pub-id><pub-id pub-id-type="pmcid">PMC3193908</pub-id><pub-id pub-id-type="pmid">21727896</pub-id></mixed-citation></ref><ref id="advs70718-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="advs70718-cit-0020"><string-name name-style="western"><given-names>M. R.</given-names><surname>Brier</surname></string-name>, <string-name name-style="western"><given-names>J. B.</given-names><surname>Thomas</surname></string-name>, <string-name name-style="western"><given-names>A. Z.</given-names><surname>Snyder</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>A. M.</given-names><surname>Fagan</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Benzinger</surname></string-name>, <string-name name-style="western"><given-names>J. C.</given-names><surname>Morris</surname></string-name>, <string-name name-style="western"><given-names>B. M.</given-names><surname>Ances</surname></string-name>, <source>Neurology</source><year>2014</year>, <volume>83</volume>, <fpage>1613</fpage>.<pub-id pub-id-type="pmid">25261500</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000000939</pub-id><pub-id pub-id-type="pmcid">PMC4223085</pub-id></mixed-citation></ref><ref id="advs70718-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="advs70718-cit-0021"><string-name name-style="western"><given-names>J. F.</given-names><surname>Strain</surname></string-name>, <string-name name-style="western"><given-names>M. R.</given-names><surname>Brier</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Tanenbaum</surname></string-name>, <string-name name-style="western"><given-names>B. A.</given-names><surname>Gordon</surname></string-name>, <string-name name-style="western"><given-names>J. E.</given-names><surname>McCarthy</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Dincer</surname></string-name>, <string-name name-style="western"><given-names>D. S.</given-names><surname>Marcus</surname></string-name>, <string-name name-style="western"><given-names>J. P.</given-names><surname>Chhatwal</surname></string-name>, <string-name name-style="western"><given-names>N. R.</given-names><surname>Graff&#8208;Radford</surname></string-name>, <string-name name-style="western"><given-names>G. S.</given-names><surname>Day</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>la Fougere</surname></string-name>, <string-name name-style="western"><given-names>R. J.</given-names><surname>Perrin</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Salloway</surname></string-name>, <string-name name-style="western"><given-names>P. R.</given-names><surname>Schofield</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Yakushev</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Ikeuchi</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Voglein</surname></string-name>, <string-name name-style="western"><given-names>J. C.</given-names><surname>Morris</surname></string-name>, <string-name name-style="western"><given-names>T. L.</given-names></string-name><string-name name-style="western"><given-names>S.</given-names><surname>Benzinger</surname></string-name>, <string-name name-style="western"><given-names>R. J.</given-names><surname>Bateman</surname></string-name>, <string-name name-style="western"><given-names>B. M.</given-names><surname>Ances</surname></string-name>, <string-name name-style="western"><given-names>A. Z.</given-names><surname>Snyder</surname></string-name>, <source>Neuroimage</source><year>2022</year>, <volume>261</volume>, <elocation-id>119511</elocation-id>.<pub-id pub-id-type="pmid">35914670</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2022.119511</pub-id><pub-id pub-id-type="pmcid">PMC9750733</pub-id></mixed-citation></ref><ref id="advs70718-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="advs70718-cit-0022"><string-name name-style="western"><given-names>C. L.</given-names><surname>Grady</surname></string-name>, <string-name name-style="western"><given-names>D. D.</given-names><surname>Garrett</surname></string-name>, <source>Brain Imaging Behav.</source><year>2014</year>, <volume>8</volume>, <fpage>274</fpage>.<pub-id pub-id-type="pmid">24008589</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11682-013-9253-0</pub-id><pub-id pub-id-type="pmcid">PMC3922711</pub-id></mixed-citation></ref><ref id="advs70718-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="advs70718-cit-0023"><string-name name-style="western"><given-names>D. D.</given-names><surname>Garrett</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Kovacevic</surname></string-name>, <string-name name-style="western"><given-names>A. R.</given-names><surname>McIntosh</surname></string-name>, <string-name name-style="western"><given-names>C. L.</given-names><surname>Grady</surname></string-name>, <source>Cereb Cortex</source><year>2013</year>, <volume>23</volume>, <fpage>684</fpage><pub-id pub-id-type="pmid">22419679</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cercor/bhs055</pub-id><pub-id pub-id-type="pmcid">PMC3823571</pub-id></mixed-citation></ref><ref id="advs70718-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="advs70718-cit-0024"><string-name name-style="western"><given-names>V. J.</given-names><surname>Sydnor</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Larsen</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Seidlitz</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Adebimpe</surname></string-name>, <string-name name-style="western"><given-names>A. F.</given-names><surname>Alexander&#8208;Bloch</surname></string-name>, <string-name name-style="western"><given-names>D. S.</given-names><surname>Bassett</surname></string-name>, <string-name name-style="western"><given-names>M. A.</given-names><surname>Bertolero</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Cieslak</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Covitz</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Fan</surname></string-name>, <string-name name-style="western"><given-names>R. E.</given-names><surname>Gur</surname></string-name>, <string-name name-style="western"><given-names>R. C.</given-names><surname>Gur</surname></string-name>, <string-name name-style="western"><given-names>A. P.</given-names><surname>Mackey</surname></string-name>, <string-name name-style="western"><given-names>T. M.</given-names><surname>Moore</surname></string-name>, <string-name name-style="western"><given-names>D. R.</given-names><surname>Roalf</surname></string-name>, <string-name name-style="western"><given-names>R. T.</given-names><surname>Shinohara</surname></string-name>, <string-name name-style="western"><given-names>T. D.</given-names><surname>Satterthwaite</surname></string-name>, <source>Nat. Neurosci.</source><year>2023</year>, <volume>26</volume>, <fpage>638</fpage>.<pub-id pub-id-type="pmid">36973514</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41593-023-01282-y</pub-id><pub-id pub-id-type="pmcid">PMC10406167</pub-id></mixed-citation></ref><ref id="advs70718-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="advs70718-cit-0025"><string-name name-style="western"><given-names>D. D.</given-names><surname>Garrett</surname></string-name>, <string-name name-style="western"><given-names>A. R.</given-names><surname>McIntosh</surname></string-name>, <string-name name-style="western"><given-names>C. L.</given-names><surname>Grady</surname></string-name>, <source>Nat. Rev. Neurosci.</source><year>2011</year>, <volume>12</volume>, <fpage>612</fpage>.<pub-id pub-id-type="pmid">21897432</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrn3061-c1</pub-id></mixed-citation></ref><ref id="advs70718-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="advs70718-cit-0026"><string-name name-style="western"><given-names>E.</given-names><surname>Bullmore</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Long</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Suckling</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Fadili</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Calvert</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Zelaya</surname></string-name>, <string-name name-style="western"><given-names>T. A.</given-names><surname>Carpenter</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Brammer</surname></string-name>, <source>Hum. Brain Mapp.</source><year>2001</year>, <volume>12</volume>, <fpage>61</fpage>.<pub-id pub-id-type="pmid">11169871</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1097-0193(200102)12:2&amp;#x0003c;61::AID-HBM1004&amp;#x0003e;3.0.CO;2-W</pub-id><pub-id pub-id-type="pmcid">PMC6871881</pub-id></mixed-citation></ref><ref id="advs70718-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="advs70718-cit-0027"><string-name name-style="western"><given-names>B. J.</given-names><surname>He</surname></string-name>, <source>J. Neurosci.</source><year>2011</year>, <volume>31</volume>, <elocation-id>13786</elocation-id>.21957241
</mixed-citation></ref><ref id="advs70718-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="advs70718-cit-0028"><string-name name-style="western"><given-names>E.</given-names><surname>Tagliazucchi</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>von Wegner</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Morzelewski</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Brodbeck</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Jahnke</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Laufs</surname></string-name>, <source>Proc. Natl. Acad. Sci. U. S. A.</source><year>2013</year>, <volume>110</volume>, <elocation-id>15419</elocation-id>.<pub-id pub-id-type="pmid">24003146</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1312848110</pub-id><pub-id pub-id-type="pmcid">PMC3780893</pub-id></mixed-citation></ref><ref id="advs70718-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="advs70718-cit-0029"><string-name name-style="western"><given-names>R. V.</given-names><surname>Raut</surname></string-name>, <string-name name-style="western"><given-names>A. Z.</given-names><surname>Snyder</surname></string-name>, <string-name name-style="western"><given-names>M. E.</given-names><surname>Raichle</surname></string-name>, <source>Proc. Natl. Acad. Sci. U. S. A.</source><year>2020</year>, <volume>117</volume>, <elocation-id>20890</elocation-id>.<pub-id pub-id-type="pmid">32817467</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2003383117</pub-id><pub-id pub-id-type="pmcid">PMC7456098</pub-id></mixed-citation></ref><ref id="advs70718-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="advs70718-cit-0030"><string-name name-style="western"><given-names>K. Y.</given-names><surname>Park</surname></string-name>, <string-name name-style="western"><given-names>A. Z.</given-names><surname>Snyder</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Olufawo</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Trevino</surname></string-name>, <string-name name-style="western"><given-names>P. H.</given-names><surname>Luckett</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Lamichhane</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Xie</surname></string-name>, <string-name name-style="western"><given-names>J. J.</given-names><surname>Lee</surname></string-name>, <string-name name-style="western"><given-names>J. S.</given-names><surname>Shimony</surname></string-name>, <string-name name-style="western"><given-names>E. C.</given-names><surname>Leuthardt</surname></string-name>, <source>NeuroImage: Clin.</source><year>2023</year>, <volume>39</volume>, <elocation-id>103476</elocation-id>.<pub-id pub-id-type="pmid">37453204</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nicl.2023.103476</pub-id><pub-id pub-id-type="pmcid">PMC10371854</pub-id></mixed-citation></ref><ref id="advs70718-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="advs70718-cit-0031"><string-name name-style="western"><given-names>M.</given-names><surname>Aiello</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Salvatore</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Cachia</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Pappat&#224;</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Cavaliere</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Prinster</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Nicolai</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Salvatore</surname></string-name>, <string-name name-style="western"><given-names>J.&#8208;C.</given-names><surname>Baron</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Quarantelli</surname></string-name>, <source>NeuroImage</source><year>2015</year>, <volume>113</volume>, <fpage>111</fpage>.<pub-id pub-id-type="pmid">25791784</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2015.03.017</pub-id></mixed-citation></ref><ref id="advs70718-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="advs70718-cit-0032"><string-name name-style="western"><given-names>S.</given-names><surname>Deng</surname></string-name>, <string-name name-style="western"><given-names>C. G.</given-names><surname>Franklin</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>O'Boyle</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>B. L.</given-names><surname>Heyl</surname></string-name>, <string-name name-style="western"><given-names>P. A.</given-names><surname>Jerabek</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Lu</surname></string-name>, <string-name name-style="western"><given-names>P. T.</given-names><surname>Fox</surname></string-name>, <source>NeuroImage</source><year>2022</year>, <volume>250</volume>, <elocation-id>118923</elocation-id>.<pub-id pub-id-type="pmid">35066157</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2022.118923</pub-id><pub-id pub-id-type="pmcid">PMC9201851</pub-id></mixed-citation></ref><ref id="advs70718-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="advs70718-cit-0033"><string-name name-style="western"><given-names>A. C.</given-names><surname>Nugent</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Martinez</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>D'Alfonso</surname></string-name>, <string-name name-style="western"><given-names>C. A.</given-names><surname>Zarate</surname></string-name>, <string-name name-style="western"><given-names>W. H.</given-names><surname>Theodore</surname></string-name>, <source>J. Cereb. Blood Flow Metab.</source><year>2015</year>, <volume>35</volume>, <fpage>583</fpage>.<pub-id pub-id-type="pmid">25564232</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/jcbfm.2014.228</pub-id><pub-id pub-id-type="pmcid">PMC4420874</pub-id></mixed-citation></ref><ref id="advs70718-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="advs70718-cit-0034"><string-name name-style="western"><given-names>M. A.</given-names><surname>Shafto</surname></string-name>, <string-name name-style="western"><given-names>L. K.</given-names><surname>Tyler</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Dixon</surname></string-name>, <string-name name-style="western"><given-names>J. R.</given-names><surname>Taylor</surname></string-name>, <string-name name-style="western"><given-names>J. B.</given-names><surname>Rowe</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Cusack</surname></string-name>, <string-name name-style="western"><given-names>A. J.</given-names><surname>Calder</surname></string-name>, <string-name name-style="western"><given-names>W. D.</given-names><surname>Marslen&#8208;Wilson</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Duncan</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Dalgleish</surname></string-name>, <string-name name-style="western"><given-names>R. N.</given-names><surname>Henson</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Brayne</surname></string-name>, <string-name name-style="western"><given-names>F. E.</given-names><surname>Matthews</surname></string-name>, <source>BMC Neurol.</source><year>2014</year>, <volume>14</volume>, <fpage>204</fpage>.<pub-id pub-id-type="pmid">25412575</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12883-014-0204-1</pub-id><pub-id pub-id-type="pmcid">PMC4219118</pub-id></mixed-citation></ref><ref id="advs70718-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="advs70718-cit-0035"><string-name name-style="western"><given-names>J. R.</given-names><surname>Taylor</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Williams</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Cusack</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Auer</surname></string-name>, <string-name name-style="western"><given-names>M. A.</given-names><surname>Shafto</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Dixon</surname></string-name>, <string-name name-style="western"><given-names>L. K.</given-names><surname>Tyler</surname></string-name>, <string-name name-style="western"><given-names>R. N.</given-names><surname>Henson</surname></string-name>, <source>NeuroImage</source><year>2017</year>, <volume>144</volume>, <fpage>262</fpage>.<pub-id pub-id-type="pmid">26375206</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2015.09.018</pub-id><pub-id pub-id-type="pmcid">PMC5182075</pub-id></mixed-citation></ref><ref id="advs70718-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="advs70718-cit-0036"><string-name name-style="western"><given-names>P. H.</given-names><surname>Luckett</surname></string-name>, <string-name name-style="western"><given-names>J. J.</given-names><surname>Lee</surname></string-name>, <string-name name-style="western"><given-names>K. Y.</given-names><surname>Park</surname></string-name>, <string-name name-style="western"><given-names>R. V.</given-names><surname>Raut</surname></string-name>, <string-name name-style="western"><given-names>K. L.</given-names><surname>Meeker</surname></string-name>, <string-name name-style="western"><given-names>E. M.</given-names><surname>Gordon</surname></string-name>, <string-name name-style="western"><given-names>A. Z.</given-names><surname>Snyder</surname></string-name>, <string-name name-style="western"><given-names>B. M.</given-names><surname>Ances</surname></string-name>, <string-name name-style="western"><given-names>E. C.</given-names><surname>Leuthardt</surname></string-name>, <string-name name-style="western"><given-names>J. S.</given-names><surname>Shimony</surname></string-name>, <source>Front. Neurol.</source><year>2022</year>, <volume>13</volume>, <elocation-id>1055437</elocation-id>.<pub-id pub-id-type="pmid">36712434</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2022.1055437</pub-id><pub-id pub-id-type="pmcid">PMC9878609</pub-id></mixed-citation></ref><ref id="advs70718-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="advs70718-cit-0037"><string-name name-style="western"><given-names>J. G.</given-names><surname>Ojemann</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Akbudak</surname></string-name>, <string-name name-style="western"><given-names>A. Z.</given-names><surname>Snyder</surname></string-name>, <string-name name-style="western"><given-names>R. C.</given-names><surname>McKinstry</surname></string-name>, <string-name name-style="western"><given-names>M. E.</given-names><surname>Raichle</surname></string-name>, <string-name name-style="western"><given-names>T. E.</given-names><surname>Conturo</surname></string-name>, <source>Neuroimage</source><year>1997</year>, <volume>6</volume>, <fpage>156</fpage>.<pub-id pub-id-type="pmid">9344820</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/nimg.1997.0289</pub-id></mixed-citation></ref><ref id="advs70718-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="advs70718-cit-0038"><string-name name-style="western"><given-names>P. J.</given-names><surname>Rousseeuw</surname></string-name>, <source>J. Comput. Appl. Mathematics</source><year>1987</year>, <volume>20</volume>, <fpage>53</fpage>.</mixed-citation></ref><ref id="advs70718-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="advs70718-cit-0039"><string-name name-style="western"><given-names>D. K.</given-names><surname>Dastur</surname></string-name>, <source>J. Cereb. Blood Flow Metab.</source><year>1985</year>, <volume>5</volume>, <fpage>1</fpage>.<pub-id pub-id-type="pmid">3972914</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/jcbfm.1985.1</pub-id></mixed-citation></ref><ref id="advs70718-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="advs70718-cit-0040"><string-name name-style="western"><given-names>E.</given-names><surname>Bates</surname></string-name>, <string-name name-style="western"><given-names>S. M.</given-names><surname>Wilson</surname></string-name>, <string-name name-style="western"><given-names>A. P.</given-names><surname>Saygin</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Dick</surname></string-name>, <string-name name-style="western"><given-names>M. I.</given-names><surname>Sereno</surname></string-name>, <string-name name-style="western"><given-names>R. T.</given-names><surname>Knight</surname></string-name>, <string-name name-style="western"><given-names>N. F.</given-names><surname>Dronkers</surname></string-name>, <source>Nat. Neurosci.</source><year>2003</year>, <volume>6</volume>, <fpage>448</fpage>.<pub-id pub-id-type="pmid">12704393</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nn1050</pub-id></mixed-citation></ref><ref id="advs70718-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="advs70718-cit-0041"><string-name name-style="western"><given-names>M. S.</given-names><surname>Goyal</surname></string-name>, <string-name name-style="western"><given-names>T. M.</given-names><surname>Blazey</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Su</surname></string-name>, <string-name name-style="western"><given-names>L. E.</given-names><surname>Couture</surname></string-name>, <string-name name-style="western"><given-names>T. J.</given-names><surname>Durbin</surname></string-name>, <string-name name-style="western"><given-names>R. J.</given-names><surname>Bateman</surname></string-name>, <string-name name-style="western"><given-names>T. L.</given-names><surname>Benzinger</surname></string-name>, <string-name name-style="western"><given-names>J. C.</given-names><surname>Morris</surname></string-name>, <string-name name-style="western"><given-names>M. E.</given-names><surname>Raichle</surname></string-name>, <string-name name-style="western"><given-names>A. G.</given-names><surname>Vlassenko</surname></string-name>, <source>Proc. Natl. Acad. Sci. U. S. A.</source><year>2019</year>, <volume>116</volume>, <fpage>3251</fpage>.<pub-id pub-id-type="pmid">30718410</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1815917116</pub-id><pub-id pub-id-type="pmcid">PMC6386682</pub-id></mixed-citation></ref><ref id="advs70718-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="advs70718-cit-0042"><string-name name-style="western"><given-names>D. C.</given-names><surname>Van Essen</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Ugurbil</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Auerbach</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Barch</surname></string-name>, <string-name name-style="western"><given-names>T. E.</given-names><surname>Behrens</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Bucholz</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Chang</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Corbetta</surname></string-name>, <string-name name-style="western"><given-names>S. W.</given-names><surname>Curtiss</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Della Penna</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Feinberg</surname></string-name>, <string-name name-style="western"><given-names>M. F.</given-names><surname>Glasser</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Harel</surname></string-name>, <string-name name-style="western"><given-names>A. C.</given-names><surname>Heath</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Larson&#8208;Prior</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Marcus</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Michalareas</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Moeller</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Oostenveld</surname></string-name>, <string-name name-style="western"><given-names>S. E.</given-names><surname>Petersen</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Prior</surname></string-name>, <string-name name-style="western"><given-names>B. L.</given-names><surname>Schlaggar</surname></string-name>, <string-name name-style="western"><given-names>S. M.</given-names><surname>Smith</surname></string-name>, <string-name name-style="western"><given-names>A. Z.</given-names><surname>Snyder</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Xu</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Yacoub</surname></string-name>, <string-name name-style="western"><given-names>W. U. M. H.</given-names><surname>Consortium</surname></string-name>, <source>Neuroimage</source><year>2012</year>, <volume>62</volume>, <fpage>2222</fpage>.<pub-id pub-id-type="pmid">22366334</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2012.02.018</pub-id><pub-id pub-id-type="pmcid">PMC3606888</pub-id></mixed-citation></ref><ref id="advs70718-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="advs70718-cit-0043"><string-name name-style="western"><given-names>H.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Yang</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Xia</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Zhu</surname></string-name>, <string-name name-style="western"><given-names>R. K.</given-names><surname>Leak</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Wei</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Hu</surname></string-name>, <source>Ageing Res. Rev.</source><year>2017</year>, <volume>34</volume>, <fpage>64</fpage>.<pub-id pub-id-type="pmid">27865980</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2016.11.006</pub-id><pub-id pub-id-type="pmcid">PMC5250573</pub-id></mixed-citation></ref><ref id="advs70718-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="advs70718-cit-0044"><string-name name-style="western"><given-names>G.</given-names><surname>Bartzokis</surname></string-name>, <string-name name-style="western"><given-names>J. L.</given-names><surname>Cummings</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Sultzer</surname></string-name>, <string-name name-style="western"><given-names>V. W.</given-names><surname>Henderson</surname></string-name>, <string-name name-style="western"><given-names>K. H.</given-names><surname>Nuechterlein</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Mintz</surname></string-name>, <source>Arch. Neurol.</source><year>2003</year>, <volume>60</volume>, <fpage>393</fpage>.<pub-id pub-id-type="pmid">12633151</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archneur.60.3.393</pub-id></mixed-citation></ref><ref id="advs70718-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="advs70718-cit-0045"><string-name name-style="western"><given-names>D. H.</given-names><surname>Salat</surname></string-name>, <string-name name-style="western"><given-names>J. A.</given-names><surname>Kaye</surname></string-name>, <string-name name-style="western"><given-names>J. S.</given-names><surname>Janowsky</surname></string-name>, <source>Arch. Neurol.</source><year>1999</year>, <volume>56</volume>, <fpage>338</fpage>.<pub-id pub-id-type="pmid">10190825</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archneur.56.3.338</pub-id></mixed-citation></ref><ref id="advs70718-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="advs70718-cit-0046"><string-name name-style="western"><given-names>A.</given-names><surname>Mitra</surname></string-name>, <string-name name-style="western"><given-names>M. E.</given-names><surname>Raichle</surname></string-name>, <source>Philos. Trans. R. Soc., B</source><year>2016</year>, <volume>371</volume>, <fpage>1705</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1098/rstb.2015.0546</pub-id><pub-id pub-id-type="pmcid">PMC5003863</pub-id><pub-id pub-id-type="pmid">27574315</pub-id></mixed-citation></ref><ref id="advs70718-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="advs70718-cit-0047"><string-name name-style="western"><given-names>J. M.</given-names><surname>Palva</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Palva</surname></string-name>, <source>Neuroimage</source><year>2012</year>, <volume>62</volume>, <fpage>2201</fpage>.<pub-id pub-id-type="pmid">22401756</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2012.02.060</pub-id></mixed-citation></ref><ref id="advs70718-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="advs70718-cit-0048"><string-name name-style="western"><given-names>T. T.</given-names><surname>Liu</surname></string-name>, <source>Neuroimage</source><year>2016</year>, <volume>143</volume>, <fpage>141</fpage>.<pub-id pub-id-type="pmid">27612646</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2016.09.008</pub-id></mixed-citation></ref><ref id="advs70718-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="advs70718-cit-0049"><string-name name-style="western"><given-names>G. M.</given-names><surname>Boynton</surname></string-name>, <string-name name-style="western"><given-names>S. A.</given-names><surname>Engel</surname></string-name>, <string-name name-style="western"><given-names>G. H.</given-names><surname>Glover</surname></string-name>, <string-name name-style="western"><given-names>D. J.</given-names><surname>Heeger</surname></string-name>, <source>J. Neurosci.</source><year>1996</year>, <volume>16</volume>, <fpage>4207</fpage>.<pub-id pub-id-type="pmid">8753882</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.16-13-04207.1996</pub-id><pub-id pub-id-type="pmcid">PMC6579007</pub-id></mixed-citation></ref><ref id="advs70718-bib-0050"><label>50</label><mixed-citation publication-type="book" id="advs70718-cit-0050"><string-name name-style="western"><given-names>M. S.</given-names><surname>Goldman</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Compte</surname></string-name>, <string-name name-style="western"><given-names>X. J.</given-names><surname>Wang</surname></string-name>, <source>Neural Integrator Models. Encyclopedia of Neuroscience</source>, <publisher-name>Academic Press</publisher-name>, <publisher-loc>Oxford, MS, USA</publisher-loc>, <year>2009</year>, pp. <fpage>165</fpage>&#8211;<lpage>178</lpage>.</mixed-citation></ref><ref id="advs70718-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="advs70718-cit-0051"><string-name name-style="western"><given-names>D. L.</given-names><surname>Dickstein</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Kabaso</surname></string-name>, <string-name name-style="western"><given-names>A. B.</given-names><surname>Rocher</surname></string-name>, <string-name name-style="western"><given-names>J. I.</given-names><surname>Luebke</surname></string-name>, <string-name name-style="western"><given-names>S. L.</given-names><surname>Wearne</surname></string-name>, <string-name name-style="western"><given-names>P. R.</given-names><surname>Hof</surname></string-name>, <source>Aging Cell</source><year>2007</year>, <volume>6</volume>, <fpage>275</fpage>.<pub-id pub-id-type="pmid">17465981</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1474-9726.2007.00289.x</pub-id><pub-id pub-id-type="pmcid">PMC2441530</pub-id></mixed-citation></ref><ref id="advs70718-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="advs70718-cit-0052"><string-name name-style="western"><given-names>D. B.</given-names><surname>Lombard</surname></string-name>, <string-name name-style="western"><given-names>K. F.</given-names><surname>Chua</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Mostoslavsky</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Franco</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Gostissa</surname></string-name>, <string-name name-style="western"><given-names>F. W.</given-names><surname>Alt</surname></string-name>, <source>Cell</source><year>2005</year>, <volume>120</volume>, <fpage>497</fpage>.<pub-id pub-id-type="pmid">15734682</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2005.01.028</pub-id></mixed-citation></ref><ref id="advs70718-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="advs70718-cit-0053"><string-name name-style="western"><given-names>V.</given-names><surname>Gorbunova</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Seluanov</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Mao</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Hine</surname></string-name>, <source>Nucleic Acids Res.</source><year>2007</year>, <volume>35</volume>, <fpage>7466</fpage>.<pub-id pub-id-type="pmid">17913742</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkm756</pub-id><pub-id pub-id-type="pmcid">PMC2190694</pub-id></mixed-citation></ref><ref id="advs70718-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="advs70718-cit-0054"><string-name name-style="western"><given-names>A. W.</given-names><surname>Bero</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Yan</surname></string-name>, <string-name name-style="western"><given-names>J. H.</given-names><surname>Roh</surname></string-name>, <string-name name-style="western"><given-names>J. R.</given-names><surname>Cirrito</surname></string-name>, <string-name name-style="western"><given-names>F. R.</given-names><surname>Stewart</surname></string-name>, <string-name name-style="western"><given-names>M. E.</given-names><surname>Raichle</surname></string-name>, <string-name name-style="western"><given-names>J. M.</given-names><surname>Lee</surname></string-name>, <string-name name-style="western"><given-names>D. M.</given-names><surname>Holtzman</surname></string-name>, <source>Nat. Neurosci.</source><year>2011</year>, <volume>14</volume>, <fpage>750</fpage>.<pub-id pub-id-type="pmid">21532579</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nn.2801</pub-id><pub-id pub-id-type="pmcid">PMC3102784</pub-id></mixed-citation></ref><ref id="advs70718-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="advs70718-cit-0055"><string-name name-style="western"><given-names>A. W.</given-names><surname>Bero</surname></string-name>, <string-name name-style="western"><given-names>A. Q.</given-names><surname>Bauer</surname></string-name>, <string-name name-style="western"><given-names>F. R.</given-names><surname>Stewart</surname></string-name>, <string-name name-style="western"><given-names>B. R.</given-names><surname>White</surname></string-name>, <string-name name-style="western"><given-names>J. R.</given-names><surname>Cirrito</surname></string-name>, <string-name name-style="western"><given-names>M. E.</given-names><surname>Raichle</surname></string-name>, <string-name name-style="western"><given-names>J. P.</given-names><surname>Culver</surname></string-name>, <string-name name-style="western"><given-names>D. M.</given-names><surname>Holtzman</surname></string-name>, <source>J. Neurosci.</source><year>2012</year>, <volume>32</volume>, <fpage>4334</fpage>.<pub-id pub-id-type="pmid">22457485</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.5845-11.2012</pub-id><pub-id pub-id-type="pmcid">PMC3326343</pub-id></mixed-citation></ref><ref id="advs70718-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="advs70718-cit-0056"><string-name name-style="western"><given-names>R. L.</given-names><surname>Buckner</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Sepulcre</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Talukdar</surname></string-name>, <string-name name-style="western"><given-names>F. M.</given-names><surname>Krienen</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Hedden</surname></string-name>, <string-name name-style="western"><given-names>J. R.</given-names><surname>Andrews&#8208;Hanna</surname></string-name>, <string-name name-style="western"><given-names>R. A.</given-names><surname>Sperling</surname></string-name>, <string-name name-style="western"><given-names>K. A.</given-names><surname>Johnson</surname></string-name>, <source>J. Neurosci.</source><year>2009</year>, <volume>29</volume>, <fpage>1860</fpage>.<pub-id pub-id-type="pmid">19211893</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.5062-08.2009</pub-id><pub-id pub-id-type="pmcid">PMC2750039</pub-id></mixed-citation></ref><ref id="advs70718-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="advs70718-cit-0057"><string-name name-style="western"><given-names>M. E.</given-names><surname>Raichle</surname></string-name>, <string-name name-style="western"><given-names>M. A.</given-names><surname>Mintun</surname></string-name>, <source>Annu. Rev. Neurosci.</source><year>2006</year>, <volume>29</volume>, <fpage>449</fpage>.<pub-id pub-id-type="pmid">16776593</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev.neuro.29.051605.112819</pub-id></mixed-citation></ref><ref id="advs70718-bib-0058"><label>58</label><mixed-citation publication-type="journal" id="advs70718-cit-0058"><string-name name-style="western"><given-names>T. O.</given-names><surname>Laumann</surname></string-name>, <string-name name-style="western"><given-names>A. Z.</given-names><surname>Snyder</surname></string-name>, <source>Curr. Opin. Behav. Sci.</source><year>2021</year>, <volume>40</volume>, <fpage>130</fpage>.</mixed-citation></ref><ref id="advs70718-bib-0059"><label>59</label><mixed-citation publication-type="journal" id="advs70718-cit-0059"><string-name name-style="western"><given-names>G.</given-names><surname>Tononi</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Cirelli</surname></string-name>, <source>Neuron</source><year>2014</year>, <volume>81</volume>, <fpage>12</fpage>.<pub-id pub-id-type="pmid">24411729</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2013.12.025</pub-id><pub-id pub-id-type="pmcid">PMC3921176</pub-id></mixed-citation></ref><ref id="advs70718-bib-0060"><label>60</label><mixed-citation publication-type="journal" id="advs70718-cit-0060"><string-name name-style="western"><given-names>N. U.</given-names><surname>Dosenbach</surname></string-name>, <string-name name-style="western"><given-names>D. A.</given-names><surname>Fair</surname></string-name>, <string-name name-style="western"><given-names>A. L.</given-names><surname>Cohen</surname></string-name>, <string-name name-style="western"><given-names>B. L.</given-names><surname>Schlaggar</surname></string-name>, <string-name name-style="western"><given-names>S. E.</given-names><surname>Petersen</surname></string-name>, <source>Trends Cogn. Sci.</source><year>2008</year>, <volume>12</volume>, <fpage>99</fpage>.<pub-id pub-id-type="pmid">18262825</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tics.2008.01.001</pub-id><pub-id pub-id-type="pmcid">PMC3632449</pub-id></mixed-citation></ref><ref id="advs70718-bib-0061"><label>61</label><mixed-citation publication-type="journal" id="advs70718-cit-0061"><string-name name-style="western"><given-names>N. U.</given-names><surname>Dosenbach</surname></string-name>, <string-name name-style="western"><given-names>D. A.</given-names><surname>Fair</surname></string-name>, <string-name name-style="western"><given-names>F. M.</given-names><surname>Miezin</surname></string-name>, <string-name name-style="western"><given-names>A. L.</given-names><surname>Cohen</surname></string-name>, <string-name name-style="western"><given-names>K. K.</given-names><surname>Wenger</surname></string-name>, <string-name name-style="western"><given-names>R. A.</given-names><surname>Dosenbach</surname></string-name>, <string-name name-style="western"><given-names>M. D.</given-names><surname>Fox</surname></string-name>, <string-name name-style="western"><given-names>A. Z.</given-names><surname>Snyder</surname></string-name>, <string-name name-style="western"><given-names>J. L.</given-names><surname>Vincent</surname></string-name>, <string-name name-style="western"><given-names>M. E.</given-names><surname>Raichle</surname></string-name>, <string-name name-style="western"><given-names>B. L.</given-names><surname>Schlaggar</surname></string-name>, <string-name name-style="western"><given-names>S. E.</given-names><surname>Petersen</surname></string-name>, <source>Proc Natl Acad Sci</source><year>2007</year>, <volume>104</volume>, <elocation-id>11073</elocation-id>.<pub-id pub-id-type="pmid">17576922</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0704320104</pub-id><pub-id pub-id-type="pmcid">PMC1904171</pub-id></mixed-citation></ref><ref id="advs70718-bib-0062"><label>62</label><mixed-citation publication-type="journal" id="advs70718-cit-0062"><string-name name-style="western"><given-names>G.</given-names><surname>Liakakis</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Nickel</surname></string-name>, <string-name name-style="western"><given-names>R. J.</given-names><surname>Seitz</surname></string-name>, <source>Behav. Brain Res.</source><year>2011</year>, <volume>225</volume>, <fpage>341</fpage>.<pub-id pub-id-type="pmid">21729721</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbr.2011.06.022</pub-id></mixed-citation></ref><ref id="advs70718-bib-0063"><label>63</label><mixed-citation publication-type="journal" id="advs70718-cit-0063"><string-name name-style="western"><given-names>P.</given-names><surname>Nachev</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Kennard</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Husain</surname></string-name>, <source>Nat. Rev. Neurosci.</source><year>2008</year>, <volume>9</volume>, <fpage>856</fpage>.<pub-id pub-id-type="pmid">18843271</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrn2478</pub-id></mixed-citation></ref><ref id="advs70718-bib-0064"><label>64</label><mixed-citation publication-type="journal" id="advs70718-cit-0064"><string-name name-style="western"><given-names>R.</given-names><surname>Leech</surname></string-name>, <string-name name-style="western"><given-names>D. J.</given-names><surname>Sharp</surname></string-name>, <source>Brain</source><year>2014</year>, <volume>137</volume>, <fpage>12</fpage>.<pub-id pub-id-type="pmid">23869106</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awt162</pub-id><pub-id pub-id-type="pmcid">PMC3891440</pub-id></mixed-citation></ref><ref id="advs70718-bib-0065"><label>65</label><mixed-citation publication-type="journal" id="advs70718-cit-0065"><string-name name-style="western"><given-names>M. K.</given-names><surname>Chan</surname></string-name>, <string-name name-style="western"><given-names>M. O.</given-names><surname>Krebs</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Cox</surname></string-name>, <string-name name-style="western"><given-names>P. C.</given-names><surname>Guest</surname></string-name>, <string-name name-style="western"><given-names>R. H.</given-names><surname>Yolken</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Rahmoune</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Rothermundt</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Steiner</surname></string-name>, <string-name name-style="western"><given-names>F. M.</given-names><surname>Leweke</surname></string-name>, <string-name name-style="western"><given-names>N. J.</given-names><surname>van Beveren</surname></string-name>, <string-name name-style="western"><given-names>D. W.</given-names><surname>Niebuhr</surname></string-name>, <string-name name-style="western"><given-names>N. S.</given-names><surname>Weber</surname></string-name>, <string-name name-style="western"><given-names>D. N.</given-names><surname>Cowan</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Suarez&#8208;Pinilla</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Crespo&#8208;Facorro</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Mam&#8208;Lam&#8208;Fook</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Bourgin</surname></string-name>, <string-name name-style="western"><given-names>R. J.</given-names><surname>Wenstrup</surname></string-name>, <string-name name-style="western"><given-names>R. R.</given-names><surname>Kaldate</surname></string-name>, <string-name name-style="western"><given-names>J. D.</given-names><surname>Cooper</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Bahn</surname></string-name>, <source>Transl. Psychiatry</source><year>2015</year>, <volume>5</volume>, <elocation-id>601</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/tp.2015.91</pub-id><pub-id pub-id-type="pmcid">PMC5068725</pub-id><pub-id pub-id-type="pmid">26171982</pub-id></mixed-citation></ref><ref id="advs70718-bib-0066"><label>66</label><mixed-citation publication-type="journal" id="advs70718-cit-0066"><string-name name-style="western"><given-names>A. M.</given-names><surname>Fagan</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Xiong</surname></string-name>, <string-name name-style="western"><given-names>M. S.</given-names><surname>Jasielec</surname></string-name>, <string-name name-style="western"><given-names>R. J.</given-names><surname>Bateman</surname></string-name>, <string-name name-style="western"><given-names>A. M.</given-names><surname>Goate</surname></string-name>, <string-name name-style="western"><given-names>T. L.</given-names><surname>Benzinger</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Ghetti</surname></string-name>, <string-name name-style="western"><given-names>R. N.</given-names><surname>Martins</surname></string-name>, <string-name name-style="western"><given-names>C. L.</given-names><surname>Masters</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Mayeux</surname></string-name>, <string-name name-style="western"><given-names>J. M.</given-names><surname>Ringman</surname></string-name>, <string-name name-style="western"><given-names>M. N.</given-names><surname>Rossor</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Salloway</surname></string-name>, <string-name name-style="western"><given-names>P. R.</given-names><surname>Schofield</surname></string-name>, <string-name name-style="western"><given-names>R. A.</given-names><surname>Sperling</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Marcus</surname></string-name>, <string-name name-style="western"><given-names>N. J.</given-names><surname>Cairns</surname></string-name>, <string-name name-style="western"><given-names>V. D.</given-names><surname>Buckles</surname></string-name>, <string-name name-style="western"><given-names>J. H.</given-names><surname>Ladenson</surname></string-name>, <string-name name-style="western"><given-names>J. C.</given-names><surname>Morris</surname></string-name>, <string-name name-style="western"><given-names>D. M.</given-names><surname>Holtzman</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Dominantly Inherited Alzheimer</surname></string-name>, <source>Sci. Transl. Med.</source><year>2014</year>, <volume>6</volume>, <elocation-id>226ra230</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.3007901</pub-id><pub-id pub-id-type="pmcid">PMC4038930</pub-id><pub-id pub-id-type="pmid">24598588</pub-id></mixed-citation></ref><ref id="advs70718-bib-0067"><label>67</label><mixed-citation publication-type="journal" id="advs70718-cit-0067"><string-name name-style="western"><given-names>C.</given-names><surname>Dufouil</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>de Kersaint&#8208;Gilly</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Besancon</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Levy</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Auffray</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Brunnereau</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Alperovitch</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Tzourio</surname></string-name>, <source>Neurology</source><year>2001</year>, <volume>56</volume>, <fpage>921</fpage>.<pub-id pub-id-type="pmid">11294930</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.56.7.921</pub-id></mixed-citation></ref><ref id="advs70718-bib-0068"><label>68</label><mixed-citation publication-type="journal" id="advs70718-cit-0068"><string-name name-style="western"><given-names>T.</given-names><surname>Rashid</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>J. B.</given-names><surname>Toledo</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Nasrallah</surname></string-name>, <string-name name-style="western"><given-names>N. M.</given-names><surname>Pajewski</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Dolui</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Detre</surname></string-name>, <string-name name-style="western"><given-names>D. A.</given-names><surname>Wolk</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>S. R.</given-names><surname>Heckbert</surname></string-name>, <string-name name-style="western"><given-names>R. N.</given-names><surname>Bryan</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Williamson</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Davatzikos</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Seshadri</surname></string-name>, <string-name name-style="western"><given-names>L. J.</given-names><surname>Launer</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Habes</surname></string-name>, <source>JAMA Netw. Open</source><year>2023</year>, <volume>6</volume>, <elocation-id>231055</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2023.1055</pub-id><pub-id pub-id-type="pmcid">PMC9978954</pub-id><pub-id pub-id-type="pmid">36857053</pub-id></mixed-citation></ref><ref id="advs70718-bib-0069"><label>69</label><mixed-citation publication-type="journal" id="advs70718-cit-0069"><string-name name-style="western"><given-names>J. M.</given-names><surname>Wardlaw</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Smith</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Dichgans</surname></string-name>, <source>Lancet Neurol.</source><year>2013</year>, <volume>12</volume>, <fpage>483</fpage>.<pub-id pub-id-type="pmid">23602162</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(13)70060-7</pub-id><pub-id pub-id-type="pmcid">PMC3836247</pub-id></mixed-citation></ref><ref id="advs70718-bib-0070"><label>70</label><mixed-citation publication-type="journal" id="advs70718-cit-0070"><string-name name-style="western"><given-names>C. D.</given-names><surname>Brown</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Higgins</surname></string-name>, <string-name name-style="western"><given-names>K. A.</given-names><surname>Donato</surname></string-name>, <string-name name-style="western"><given-names>F. C.</given-names><surname>Rohde</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Garrison</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Obarzanek</surname></string-name>, <string-name name-style="western"><given-names>N. D.</given-names><surname>Ernst</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Horan</surname></string-name>, <source>Obes. Res.</source><year>2000</year>, <volume>8</volume>, <fpage>605</fpage>.<pub-id pub-id-type="pmid">11225709</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/oby.2000.79</pub-id></mixed-citation></ref><ref id="advs70718-bib-0071"><label>71</label><mixed-citation publication-type="journal" id="advs70718-cit-0071"><string-name name-style="western"><given-names>J.</given-names><surname>Luo</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Agboola</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Grant</surname></string-name>, <string-name name-style="western"><given-names>C. L.</given-names><surname>Masters</surname></string-name>, <string-name name-style="western"><given-names>M. S.</given-names><surname>Albert</surname></string-name>, <string-name name-style="western"><given-names>S. C.</given-names><surname>Johnson</surname></string-name>, <string-name name-style="western"><given-names>E. M.</given-names><surname>McDade</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Voglein</surname></string-name>, <string-name name-style="western"><given-names>A. M.</given-names><surname>Fagan</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Benzinger</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Massoumzadeh</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Hassenstab</surname></string-name>, <string-name name-style="western"><given-names>R. J.</given-names><surname>Bateman</surname></string-name>, <string-name name-style="western"><given-names>J. C.</given-names><surname>Morris</surname></string-name>, <string-name name-style="western"><given-names>R. J.</given-names><surname>Perrin</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Chhatwal</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Jucker</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Ghetti</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Cruchaga</surname></string-name>, <string-name name-style="western"><given-names>N. R.</given-names><surname>Graff&#8208;Radford</surname></string-name>, <string-name name-style="western"><given-names>P. R.</given-names><surname>Schofield</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Mori</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Xiong</surname></string-name>, <source>Neurology</source><year>2020</year>, <volume>95</volume>, <elocation-id>3104</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000010747</pub-id><pub-id pub-id-type="pmcid">PMC7734923</pub-id><pub-id pub-id-type="pmid">32873693</pub-id></mixed-citation></ref><ref id="advs70718-bib-0072"><label>72</label><mixed-citation publication-type="journal" id="advs70718-cit-0072"><string-name name-style="western"><given-names>J. B.</given-names><surname>Pereira</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Svenningsson</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Weintraub</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Bronnick</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Lebedev</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Westman</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Aarsland</surname></string-name>, <source>Neurology</source><year>2014</year>, <volume>82</volume>, <fpage>2017</fpage>.<pub-id pub-id-type="pmid">24808018</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000000483</pub-id><pub-id pub-id-type="pmcid">PMC4105257</pub-id></mixed-citation></ref><ref id="advs70718-bib-0073"><label>73</label><mixed-citation publication-type="journal" id="advs70718-cit-0073"><string-name name-style="western"><given-names>K. B.</given-names><surname>Walhovd</surname></string-name>, <string-name name-style="western"><given-names>A. B.</given-names><surname>Storsve</surname></string-name>, <string-name name-style="western"><given-names>L. T.</given-names><surname>Westlye</surname></string-name>, <string-name name-style="western"><given-names>C. A.</given-names><surname>Drevon</surname></string-name>, <string-name name-style="western"><given-names>A. M.</given-names><surname>Fjell</surname></string-name>, <source>Neurobiol. Aging</source><year>2014</year>, <volume>35</volume>, <fpage>1055</fpage>.<pub-id pub-id-type="pmid">24332985</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2013.11.011</pub-id></mixed-citation></ref><ref id="advs70718-bib-0074"><label>74</label><mixed-citation publication-type="journal" id="advs70718-cit-0074"><string-name name-style="western"><given-names>J.</given-names><surname>Luo</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Ma</surname></string-name>, <string-name name-style="western"><given-names>F. J.</given-names><surname>Agboola</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Grant</surname></string-name>, <string-name name-style="western"><given-names>J. C.</given-names><surname>Morris</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>McDade</surname></string-name>, <string-name name-style="western"><given-names>A. M.</given-names><surname>Fagan</surname></string-name>, <string-name name-style="western"><given-names>T. L. S.</given-names><surname>Benzinger</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Hassenstab</surname></string-name>, <string-name name-style="western"><given-names>R. J.</given-names><surname>Bateman</surname></string-name>, <string-name name-style="western"><given-names>R. J.</given-names><surname>Perrin</surname></string-name>, <string-name name-style="western"><given-names>B. A.</given-names><surname>Gordon</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Goyal</surname></string-name>, <string-name name-style="western"><given-names>J. F.</given-names><surname>Strain</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Yakushev</surname></string-name>, <string-name name-style="western"><given-names>G. S.</given-names><surname>Day</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Xiong</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>for</surname></string-name>, <source>Neurology</source><year>2023</year>, <volume>101</volume>, <elocation-id>164</elocation-id>.</mixed-citation></ref><ref id="advs70718-bib-0075"><label>75</label><mixed-citation publication-type="journal" id="advs70718-cit-0075"><string-name name-style="western"><given-names>M. R.</given-names><surname>Brier</surname></string-name>, <string-name name-style="western"><given-names>A. Z.</given-names><surname>Snyder</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Tanenbaum</surname></string-name>, <string-name name-style="western"><given-names>R. A.</given-names><surname>Rudick</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Fisher</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Jones</surname></string-name>, <string-name name-style="western"><given-names>J. S.</given-names><surname>Shimony</surname></string-name>, <string-name name-style="western"><given-names>A. H.</given-names><surname>Cross</surname></string-name>, <string-name name-style="western"><given-names>T. L. S.</given-names><surname>Benzinger</surname></string-name>, <string-name name-style="western"><given-names>R. T.</given-names><surname>Naismith</surname></string-name>, <source>Ann. Clin. Transl. Neurol.</source><year>2021</year>, <volume>8</volume>, <fpage>1096</fpage>.<pub-id pub-id-type="pmid">33943045</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/acn3.51354</pub-id><pub-id pub-id-type="pmcid">PMC8108425</pub-id></mixed-citation></ref><ref id="advs70718-bib-0076"><label>76</label><mixed-citation publication-type="journal" id="advs70718-cit-0076"><string-name name-style="western"><given-names>G. L.</given-names><surname>Shulman</surname></string-name>, <string-name name-style="western"><given-names>D. L.</given-names><surname>Pope</surname></string-name>, <string-name name-style="western"><given-names>S. V.</given-names><surname>Astafiev</surname></string-name>, <string-name name-style="western"><given-names>M. P.</given-names><surname>McAvoy</surname></string-name>, <string-name name-style="western"><given-names>A. Z.</given-names><surname>Snyder</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Corbetta</surname></string-name>, <source>J. Neurosci.</source><year>2010</year>, <volume>30</volume>, <fpage>3640</fpage>.<pub-id pub-id-type="pmid">20219998</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.4085-09.2010</pub-id><pub-id pub-id-type="pmcid">PMC2872555</pub-id></mixed-citation></ref><ref id="advs70718-bib-0077"><label>77</label><mixed-citation publication-type="journal" id="advs70718-cit-0077"><string-name name-style="western"><given-names>J. D.</given-names><surname>Power</surname></string-name>, <string-name name-style="western"><given-names>K. A.</given-names><surname>Barnes</surname></string-name>, <string-name name-style="western"><given-names>A. Z.</given-names><surname>Snyder</surname></string-name>, <string-name name-style="western"><given-names>B. L.</given-names><surname>Schlaggar</surname></string-name>, <string-name name-style="western"><given-names>S. E.</given-names><surname>Petersen</surname></string-name>, <source>Neuroimage</source><year>2012</year>, <volume>59</volume>, <fpage>2142</fpage>.<pub-id pub-id-type="pmid">22019881</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2011.10.018</pub-id><pub-id pub-id-type="pmcid">PMC3254728</pub-id></mixed-citation></ref><ref id="advs70718-bib-0078"><label>78</label><mixed-citation publication-type="journal" id="advs70718-cit-0078"><string-name name-style="western"><given-names>M.</given-names><surname>Sattarivand</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Kusano</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Poon</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Caldwell</surname></string-name>, <source>Phys. Med. Biol.</source><year>2012</year>, <volume>57</volume>, <fpage>7101</fpage>.<pub-id pub-id-type="pmid">23051703</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1088/0031-9155/57/21/7101</pub-id></mixed-citation></ref><ref id="advs70718-bib-0079"><label>79</label><mixed-citation publication-type="journal" id="advs70718-cit-0079"><string-name name-style="western"><given-names>G.</given-names><surname>Doucet</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Naveau</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Petit</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Delcroix</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Zago</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Crivello</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Jobard</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Tzourio&#8208;Mazoyer</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Mazoyer</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Mellet</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Joliot</surname></string-name>, <source>J. Neurophysiol.</source><year>2011</year>, <volume>105</volume>, <fpage>2753</fpage>.<pub-id pub-id-type="pmid">21430278</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/jn.00895.2010</pub-id></mixed-citation></ref><ref id="advs70718-bib-0080"><label>80</label><mixed-citation publication-type="journal" id="advs70718-cit-0080"><string-name name-style="western"><given-names>S. J.</given-names><surname>Gotts</surname></string-name>, <string-name name-style="western"><given-names>A. W.</given-names><surname>Gilmore</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Martin</surname></string-name>, <source>Neuroimage</source><year>2020</year>, <volume>205</volume>, <elocation-id>116289</elocation-id>.<pub-id pub-id-type="pmid">31629827</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2019.116289</pub-id><pub-id pub-id-type="pmcid">PMC6919311</pub-id></mixed-citation></ref><ref id="advs70718-bib-0081"><label>81</label><mixed-citation publication-type="journal" id="advs70718-cit-0081"><string-name name-style="western"><given-names>A.</given-names><surname>Schaefer</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Kong</surname></string-name>, <string-name name-style="western"><given-names>E. M.</given-names><surname>Gordon</surname></string-name>, <string-name name-style="western"><given-names>T. O.</given-names><surname>Laumann</surname></string-name>, <string-name name-style="western"><given-names>X. N.</given-names><surname>Zuo</surname></string-name>, <string-name name-style="western"><given-names>A. J.</given-names><surname>Holmes</surname></string-name>, <string-name name-style="western"><given-names>S. B.</given-names><surname>Eickhoff</surname></string-name>, <string-name name-style="western"><given-names>B. T. T.</given-names><surname>Yeo</surname></string-name>, <source>Cereb. Cortex</source><year>2018</year>, <volume>28</volume>, <fpage>3095</fpage>.<pub-id pub-id-type="pmid">28981612</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cercor/bhx179</pub-id><pub-id pub-id-type="pmcid">PMC6095216</pub-id></mixed-citation></ref><ref id="advs70718-bib-0082"><label>82</label><mixed-citation publication-type="journal" id="advs70718-cit-0082"><string-name name-style="western"><given-names>G. L.</given-names><surname>Baum</surname></string-name>, <string-name name-style="western"><given-names>J. C.</given-names><surname>Flournoy</surname></string-name>, <string-name name-style="western"><given-names>M. F.</given-names><surname>Glasser</surname></string-name>, <string-name name-style="western"><given-names>M. P.</given-names><surname>Harms</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Mair</surname></string-name>, <string-name name-style="western"><given-names>A. F. P.</given-names><surname>Sanders</surname></string-name>, <string-name name-style="western"><given-names>D. M.</given-names><surname>Barch</surname></string-name>, <string-name name-style="western"><given-names>R. L.</given-names><surname>Buckner</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Bookheimer</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Dapretto</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Smith</surname></string-name>, <string-name name-style="western"><given-names>K. M.</given-names><surname>Thomas</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Yacoub</surname></string-name>, <string-name name-style="western"><given-names>D. C.</given-names><surname>Van Essen</surname></string-name>, <string-name name-style="western"><given-names>L. H.</given-names><surname>Somerville</surname></string-name>, <source>J. Neurosci.</source><year>2022</year>, <volume>42</volume>, <fpage>5681</fpage>.<pub-id pub-id-type="pmid">35705486</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.2380-21.2022</pub-id><pub-id pub-id-type="pmcid">PMC9302463</pub-id></mixed-citation></ref><ref id="advs70718-bib-0083"><label>83</label><mixed-citation publication-type="journal" id="advs70718-cit-0083"><string-name name-style="western"><given-names>A. F.</given-names><surname>Alexander&#8208;Bloch</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Shou</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>T. D.</given-names><surname>Satterthwaite</surname></string-name>, <string-name name-style="western"><given-names>D. C.</given-names><surname>Glahn</surname></string-name>, <string-name name-style="western"><given-names>R. T.</given-names><surname>Shinohara</surname></string-name>, <string-name name-style="western"><given-names>S. N.</given-names><surname>Vandekar</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Raznahan</surname></string-name>, <source>Neuroimage</source><year>2018</year>, <volume>178</volume>, <fpage>540</fpage>.<pub-id pub-id-type="pmid">29860082</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2018.05.070</pub-id><pub-id pub-id-type="pmcid">PMC6095687</pub-id></mixed-citation></ref><ref id="advs70718-bib-0084"><label>84</label><mixed-citation publication-type="journal" id="advs70718-cit-0084"><string-name name-style="western"><given-names>E. M.</given-names><surname>Gordon</surname></string-name>, <string-name name-style="western"><given-names>T. O.</given-names><surname>Laumann</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Adeyemo</surname></string-name>, <string-name name-style="western"><given-names>J. F.</given-names><surname>Huckins</surname></string-name>, <string-name name-style="western"><given-names>W. M.</given-names><surname>Kelley</surname></string-name>, <string-name name-style="western"><given-names>S. E.</given-names><surname>Petersen</surname></string-name>, <source>Cereb. Cortex</source><year>2016</year>, <volume>26</volume>, <fpage>288</fpage>.<pub-id pub-id-type="pmid">25316338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cercor/bhu239</pub-id><pub-id pub-id-type="pmcid">PMC4677978</pub-id></mixed-citation></ref><ref id="advs70718-bib-0085"><label>85</label><mixed-citation publication-type="book" id="advs70718-cit-0085"><string-name name-style="western"><given-names>J. B.</given-names><surname>Kuipers</surname></string-name>, <source>Quaternions and Rotation Sequences</source>, <publisher-name>Princeton University Press</publisher-name>, <publisher-loc>Princeton, NJ, USA</publisher-loc>, <year>1999</year>.</mixed-citation></ref><ref id="advs70718-bib-0086"><label>86</label><mixed-citation publication-type="journal" id="advs70718-cit-0086"><string-name name-style="western"><given-names>A.</given-names><surname>Dworetsky</surname></string-name>, <string-name name-style="western"><given-names>B. A.</given-names><surname>Seitzman</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Adeyemo</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Neta</surname></string-name>, <string-name name-style="western"><given-names>R. S.</given-names><surname>Coalson</surname></string-name>, <string-name name-style="western"><given-names>S. E.</given-names><surname>Petersen</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Gratton</surname></string-name>, <source>Neuroimage</source><year>2021</year>, <volume>237</volume>, <elocation-id>118164</elocation-id>.<pub-id pub-id-type="pmid">34000397</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2021.118164</pub-id><pub-id pub-id-type="pmcid">PMC8296467</pub-id></mixed-citation></ref><ref id="advs70718-bib-0087"><label>87</label><mixed-citation publication-type="journal" id="advs70718-cit-0087"><string-name name-style="western"><given-names>B. A.</given-names><surname>Seitzman</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Gratton</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Marek</surname></string-name>, <string-name name-style="western"><given-names>R. V.</given-names><surname>Raut</surname></string-name>, <string-name name-style="western"><given-names>N. U. F.</given-names><surname>Dosenbach</surname></string-name>, <string-name name-style="western"><given-names>B. L.</given-names><surname>Schlaggar</surname></string-name>, <string-name name-style="western"><given-names>S. E.</given-names><surname>Petersen</surname></string-name>, <string-name name-style="western"><given-names>D. J.</given-names><surname>Greene</surname></string-name>, <source>Neuroimage</source><year>2020</year>, <volume>206</volume>, <elocation-id>116290</elocation-id>.<pub-id pub-id-type="pmid">31634545</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2019.116290</pub-id><pub-id pub-id-type="pmcid">PMC6981071</pub-id></mixed-citation></ref><ref id="advs70718-bib-0088"><label>88</label><mixed-citation publication-type="journal" id="advs70718-cit-0088"><string-name name-style="western"><given-names>K.</given-names><surname>Wu</surname></string-name>, <string-name name-style="western"><given-names>L. L.</given-names><surname>Gollo</surname></string-name>, <source>Commun Biol</source><year>2025</year>, <volume>8</volume>, <fpage>167</fpage>.<pub-id pub-id-type="pmid">39901043</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s42003-025-07517-x</pub-id><pub-id pub-id-type="pmcid">PMC11791184</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Comput Struct Biotechnol J</journal-id><journal-id journal-id-type="iso-abbrev">Comput Struct Biotechnol J</journal-id><journal-id journal-id-type="pmc-domain-id">2373</journal-id><journal-id journal-id-type="pmc-domain">csbj</journal-id><journal-title-group><journal-title>Computational and Structural Biotechnology Journal</journal-title></journal-title-group><issn pub-type="epub">2001-0370</issn><publisher><publisher-name>Research Network of Computational and Structural Biotechnology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12495422</article-id><article-id pub-id-type="pmcid-ver">PMC12495422.1</article-id><article-id pub-id-type="pmcaid">12495422</article-id><article-id pub-id-type="pmcaiid">12495422</article-id><article-id pub-id-type="pmid">41050469</article-id><article-id pub-id-type="doi">10.1016/j.csbj.2025.09.013</article-id><article-id pub-id-type="pii">S2001-0370(25)00373-3</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Identifying Alzheimer&#8217;s disease-related pathways based on whole-genome sequencing data</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0005"><name name-style="western"><surname>Wang</surname><given-names initials="Y">Yongheng</given-names></name><email>yhwang@stu.cqmu.edu.cn</email><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0010" ref-type="aff">b</xref><xref rid="aff0015" ref-type="aff">c</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au0010"><name name-style="western"><surname>Liu</surname><given-names initials="T">Taihang</given-names></name><email>liuth@cqmu.edu.cn</email><xref rid="aff0005" ref-type="aff">a</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au0015"><name name-style="western"><surname>He</surname><given-names initials="Y">Yijie</given-names></name><email>heyijie456@163.com</email><xref rid="aff0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0020"><name name-style="western"><surname>Tang</surname><given-names initials="Y">Yaqin</given-names></name><email>yqtang@cqmu.edu.cn</email><xref rid="aff0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0025"><name name-style="western"><surname>Tan</surname><given-names initials="P">Pengcheng</given-names></name><email>tanpengcheng@cqmu.edu.cn</email><xref rid="aff0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0030"><name name-style="western"><surname>Huang</surname><given-names initials="L">Lin</given-names></name><email>huanglin.bio@outlook.com</email><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0020" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au0035"><name name-style="western"><surname>Huang</surname><given-names initials="D">Dongyu</given-names></name><email>huangdongyu@stu.cqmu.edu.cn</email><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0020" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au0040"><name name-style="western"><surname>Wen</surname><given-names initials="T">Tong</given-names></name><email>wentong@stu.cqmu.edu.cn</email><xref rid="aff0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0045"><name name-style="western"><surname>Shao</surname><given-names initials="L">Lizhen</given-names></name><email>shaolizhen@stu.cqmu.edu.cn</email><xref rid="aff0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0050"><name name-style="western"><surname>Wang</surname><given-names initials="J">Jia</given-names></name><email>17382892177@163.com</email><xref rid="aff0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0055"><name name-style="western"><surname>Wang</surname><given-names initials="Y">Yingxiong</given-names></name><email>yxwang@cqmu.edu.cn</email><xref rid="aff0005" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">&#8270;</xref></contrib><contrib contrib-type="author" id="au0060"><name name-style="western"><surname>Han</surname><given-names initials="Z">Zhijie</given-names></name><email>zhijiehan@cqmu.edu.cn</email><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0015" ref-type="aff">c</xref><xref rid="aff0020" ref-type="aff">d</xref><xref rid="cor2" ref-type="corresp">&#8270;&#8270;</xref></contrib><aff id="aff0005"><label>a</label>Department of Bioinformatics, School of Basic Medicine, Chongqing Medical University, Chongqing, China</aff><aff id="aff0010"><label>b</label>Department of Laboratory Medicine, Chongqing Jiulongpo People's Hospital, Chongqing, China</aff><aff id="aff0015"><label>c</label>Key Laboratory of Major Brain Disease and Aging Research (Ministry of Education), Chongqing Medical University, Chongqing, China</aff><aff id="aff0020"><label>d</label>Institute for Brain Science and Disease, Chongqing Medical University, Chongqing, China</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8270;</label>Corresponding author. <email>yxwang@cqmu.edu.cn</email></corresp><corresp id="cor2"><label>&#8270;&#8270;</label>Corresponding author at: Department of Bioinformatics, School of Basic Medicine, Chongqing Medical University, Chongqing, China. <email>zhijiehan@cqmu.edu.cn</email></corresp><fn id="fn1"><label>1</label><p id="ntp0005">These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>12</day><month>9</month><year>2025</year></pub-date><volume>27</volume><issue-id pub-id-type="pmc-issue-id">478314</issue-id><fpage>4132</fpage><lpage>4144</lpage><history><date date-type="received"><day>1</day><month>4</month><year>2025</year></date><date date-type="rev-recd"><day>8</day><month>9</month><year>2025</year></date><date date-type="accepted"><day>9</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>12</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>05</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-06 15:25:14.893"><day>06</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="ab0010"><p>Alzheimer&#8217;s disease (AD) is a highly inheritable neurodegenerative disorder for which pathway-specific genetic profiling provides insights into its key biological mechanisms and potential treatment targets. Traditional disease-pathway analyses for AD have certain limitations, such as environmental interference and arbitrary sample division. We present a comprehensive framework that starts with genome data, avoiding these drawbacks and offering intrinsic pathway-specific genetic profiling for AD. Whole genome sequencing data from 173 individuals were used to quantify transcriptomes in 14 brain regions, estimate individual-level pathway variant scores, and analyze AD risk for each patient. These results were combined to identify AD-related pathways and quantify their interactions. The predicted expression levels were consistent with previous findings, and the estimated AD risk showed a significant correlation with Braak/Thal scores. A total of 3798 pathways were identified as potentially associated with AD, with about 19.7&#8239;% previously reported. The pathways identified as AD risk related primarily address six core biological themes, including: Immunity and inflammation, Metabolism, Protein homeostasis, DNA/RNA and Epigenetics, Synapse and structure, Cell cycle. Specifically, key pathways, such as NF-&#954;B signaling and GSK3&#946; activation, were linked to AD pathogenesis. The interactions among pathways highlighted shared gene functions in AD. In summary, we provided an effective framework for disease-pathway analysis, revealing the interdependence or compensatory effects of pathways in AD.</p></abstract><abstract abstract-type="graphical" id="ab0015"><title>Graphical Abstract</title><fig id="fig0030" position="anchor" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="lk0030" position="float" orientation="portrait" xlink:href="ga1.jpg"/></fig></abstract><abstract abstract-type="author-highlights" id="ab0020"><title>Highlights</title><p><list list-type="simple" id="li0005"><list-item id="u0005"><label>&#8226;</label><p id="p0005">This study presented a novel comprehensive framework starting from genome data to identify the Alzheimer&#8217;s disease (AD)-related pathways.</p></list-item><list-item id="u0010"><label>&#8226;</label><p id="p0010">The framework can overcome the limitations of traditional disease-pathway analyses for AD, such as environmental interference and arbitrary sample division.</p></list-item><list-item id="u0015"><label>&#8226;</label><p id="p0015">The largest number of novel pathways related to AD was identified, and numerous previously reported findings were confirmed.</p></list-item><list-item id="u0020"><label>&#8226;</label><p id="p0020">The interactions among pathways emphasized shared gene functions in AD.</p></list-item></list></p></abstract><kwd-group id="keys0005"><title>Keywords</title><kwd>Alzheimer&#8217;s disease</kwd><kwd>Pathway</kwd><kwd>Polygenic risk score</kwd><kwd>Single sample gene set variation analysis</kwd><kwd>Structural equation modeling</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec0005"><label>1</label><title>Introduction</title><p id="p0040">Alzheimer&#8217;s disease (AD) is a progressive neurodegenerative disorder with a high heritability estimated between 60&#8239;% and 80&#8239;% <xref rid="bib1" ref-type="bibr">[1]</xref>. Despite the identification of numerous genetic variants associated with AD risk and pathology <xref rid="bib2" ref-type="bibr">[2]</xref>, <xref rid="bib3" ref-type="bibr">[3]</xref>, <xref rid="bib4" ref-type="bibr">[4]</xref>, <xref rid="bib5" ref-type="bibr">[5]</xref>, its precise pathogenesis is not fully understood, and effective clinical treatments are still lacking. Pathway-specific genetic analysis offers a powerful approach to understand the key biological mechanisms involved in diseases and enables the identification of causal genes and potential therapeutic targets <xref rid="bib6" ref-type="bibr">[6]</xref>. Therefore, studying the genetic characteristics of AD-related pathways is essential. Typically, the protocol for inferring disease-related pathways relies on detecting differential characteristics between disease and control groups. For example, a case-control-based genotype-phenotype association analysis highlighted the involvement of amyloid/tau pathways in AD <xref rid="bib7" ref-type="bibr">[7]</xref>. Furthermore, analyses of transcriptomic <xref rid="bib8" ref-type="bibr">[8]</xref>, <xref rid="bib9" ref-type="bibr">[9]</xref> and proteomic <xref rid="bib10" ref-type="bibr">[10]</xref>, <xref rid="bib11" ref-type="bibr">[11]</xref> differences between AD patients and controls have uncovered several new AD-related pathways.</p><p id="p0045">However, the case-control design has several key limitations: (1) These analyses require artificially dividing samples into disease and control groups. For a progressive disease like AD, establishing a progressive state of risk and severity, it is challenging to establish a clear standard for distinguishing whether a person is diseased or not. For example, early AD diagnosis relies on assessing AD neuropathological changes, including neurofibrillary tangle distribution (Braak NFT stage), amyloid-beta plaques (Thal stage), and the neuronal plaques density in the neocortex (CERAD score). In the preclinical (asymptomatic) phase of the AD continuum, misdiagnosis and missed diagnosis may occur <xref rid="bib12" ref-type="bibr">[12]</xref>. Additionally, the observed phenotype of AD patients (e.g., behavioral rating scale) and their pathological diagnosis (e.g., senile plaque and neurofibrillary tangle pathology) can sometimes be contradictory <xref rid="bib13" ref-type="bibr">[13]</xref>. (2) Analysis based on quantifying expression levels, which can be influenced by several factors such as cell type heterogeneity effects and environmental factors, leading to potentially false associations with disease pathogenesis. This includes incorrect findings of blood and cerebrospinal fluid-based biomarkers used for early AD diagnosis <xref rid="bib14" ref-type="bibr">[14]</xref>. (3) Even considering influence factors, determining disease-related genes and pathways is often based on a one-size-fits-all threshold, which may result in losing a significant amount of potentially relevant gene information.</p><p id="p0050">Genomic information provides valuable insights into the original genetic characteristics and the molecular basis of pathogenesis. Disease-related single nucleotide polymorphisms (SNPs), genes, and individual disease risks can be identified from genomic data using methods like genome-wide association studies (GWAS), fine-mapping, linkage disequilibrium score regression (LDSC), and polygenic risk score (PRS) <xref rid="bib15" ref-type="bibr">[15]</xref>, <xref rid="bib16" ref-type="bibr">[16]</xref>. Compared to single SNP analyses, gene and gene set analyses are considered more powerful <xref rid="bib17" ref-type="bibr">[17]</xref>. Gene set analysis, in particular, offers valuable insights into the role of specific biological pathways or cellular functions in the genetic basis of phenotypes <xref rid="bib18" ref-type="bibr">[18]</xref>. While pathway-based PRS tools like PRSet <xref rid="bib19" ref-type="bibr">[19]</xref>, MAGMA <xref rid="bib18" ref-type="bibr">[18]</xref>, and stratified LDSC <xref rid="bib17" ref-type="bibr">[17]</xref> exist, they typically only assign SNPs to genes, then genes to gene sets, and construct test statistics. These tools link variants to pathways based on their location, without considering the correlation between SNPs and gene expression levels, which are captured by expression quantitative trait loci (eQTL).</p><p id="p0055">To address these limitations, this study developed a novel framework that investigate the genetic characteristics of AD pathways directly from the genome. Our approach successfully identified pathways related to AD across different brain regions based on their genetic characteristics. The advantages of our analysis are noteworthy: it requires only genotyping data (obtaining brain tissue is challenging, but blood samples are easily accessible), does not require discrete case-control labels and can analyze continuous phenotypes. By starting our analysis directly from the genome, our framework provides results that reflect primary genetic characteristics, minimizing potential confounding from downstream biological or environmental factors. We believe this framework holds promise for providing quantitative insights into the combined effects between pathways in complex diseases.</p></sec><sec id="sec0010"><label>2</label><title>Results</title><sec id="sec0015"><label>2.1</label><title>Pipeline overview</title><p id="p0060">To investigate the genetic characteristics of AD, we used whole genome sequencing (WGS) data from 173 individuals (including 92 AD cases and 81 controls according to the original annotations) obtained from the MayoRNAseq (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.7303/syn10901601" id="ir0050">https://doi.org/10.7303/syn10901601</ext-link>). Since most associations between genes/pathways and diseases are tissue-specific <xref rid="bib20" ref-type="bibr">[20]</xref>, we first used a method called genetically regulated component of expression (GReX) to produce genome-wide expression data from 14 brain regions of GTEx (v8) <xref rid="bib21" ref-type="bibr">[21]</xref>. This genotype data-based approach eliminates potential confounding factors that affect gene expression levels, such as environmental influences, allowing us to focus on the genetic regulation <xref rid="bib22" ref-type="bibr">[22]</xref>. We then used the quality-controlled genotype data to estimate individual AD risk scores by PRS, instead of categorizing individuals based on original annotations. Subsequently, we performed a single sample gene set variation analysis (ssGSVA) to analyze individual-level pathway variant scores based on quantified gene expression <xref rid="bib23" ref-type="bibr">[23]</xref>. We combined these scores with PRS to identify AD-related pathways through a distance rank correlation analysis <xref rid="bib24" ref-type="bibr">[24]</xref>. Finally, we conducted a structural equation modeling (SEM) analysis to quantify interactions among the AD-related pathways, identifying possible genetic etiology and pathway mechanisms of AD (<xref rid="fig0005" ref-type="fig">Fig. 1</xref>).<fig id="fig0005" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Pipeline schematic of investigating the original genetic characteristics of AD pathways. In this pipeline, only genotype data is required, which can be obtained through various methods such as WGS, whole exome sequencing (WES), or SNP array analysis. Pathway scores and disease risk scores for each individual were calculated based on their genotype data. Subsequently, analyses were conducted to explore AD-related pathways and the interaction models between these pathways. This genotype data-driven approach eliminates potential confounding factors that influence gene expression levels, allowing for a focused investigation into genetic regulation. Furthermore, this approach can also be adapted for analyzing genetic regulatory pathways in other diseases.</p></caption><alt-text id="at0005">Fig. 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="lk0005" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p></sec><sec id="sec0020"><label>2.2</label><title>Transcriptome prediction and gene sets variation analysis based on genotype data</title><p id="p0065">The total measured expression level of a gene (e.g. obtained through RNA-seq) can be conceptually divided into the following parts:</p><p id="p0070">Total Measured Expression =&#8201;Genetically Regulated Expression +&#8201;Non-heritable Genetic Effects +&#8201;Environmental Effects +&#8201;Cell type Heterogeneity Effects +&#8201;Stochastic Noise +&#8201;Technical Artifacts</p><p id="p0075">This research focus on the original genetic characteristics of AD, the Genetically Regulated Expression part. To measure this part, we predicted the gene expression from the genomic data by GReX method <xref rid="bib22" ref-type="bibr">[22]</xref>. From the 349 samples in the MayoRNAseq WGS study, we selected 92 AD samples and 81 control samples, all of White individuals. The results of principal component analysis (PCA) and Tracy-Widom statistical test (<italic toggle="yes">P</italic>&#8201;&gt;&#8201;0.05) showed that there was no significant population structure in the WGS data. Based on the genomic features, we predicted transcriptome expression in 14 brain regions from GTEx (v8), including: amygdala, anterior cingulate cortex BA24, caudate basal ganglia, cerebellar hemisphere, cerebellum, cortex, frontal cortex BA9, hippocampus, hypothalamus, nucleus accumbens basal ganglia, putamen basal ganglia, spinal cord cervical c-1, substantia nigra, and pituitary. As shown in <xref rid="fig0010" ref-type="fig">Fig. 2</xref><bold>A</bold>, the number of predicted genes varied, ranging from 5013 in substantia nigra to 9186 in cerebellum. The predicted gene expression levels ranged from &#8722;3&#8211;3. Furthermore, pairwise correlation analysis of brain regions revealed that gene expression correlations between the cerebellum, cerebellar hemisphere, and pituitary, and other brain regions were all below 0.85 (<xref rid="fig0010" ref-type="fig">Fig. 2</xref><bold>B</bold>). In contrast, correlations between other brain regions were relatively high. The correlation between similar brain regions exceeded 0.93, including the caudate basal ganglia, nucleus accumbens basal ganglia, and putamen basal ganglia; the cortex and frontal cortex BA9; and the cerebellar hemisphere and cerebellum. These results align with previous findings that gene expression regulation shows specificity in the cerebellum and similarity across various regions of the cerebral cortex <xref rid="bib25" ref-type="bibr">[25]</xref>.<fig id="fig0010" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Performance of GReX and ssGSVA. (<bold>A</bold>) The number of genes predicted by GReX method for the 14 brain regions. (<bold>B</bold>) The pairwise correlations computed using the Pearson method among 14 brain regions based on the predicted expression levels. (<bold>C</bold>) The spearman correlation between predicted expression profile and RNA-seq gene expression data of cerebellum region. (<bold>D</bold>) The number of pathways with ssGSVA score enriched by ssGSVA method using the 31,824 pathways with number of genes limitation in 10&#8211;300 for the 14 brain regions. (<bold>E</bold>) The number of pathways with ssGSVA score enriched by ssGSVA method using all pathways for the 14 brain regions. (<bold>F</bold>) The distribution of ssGSVA scores in AD and control samples.</p></caption><alt-text id="at0010">Fig. 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="lk0010" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p><p id="p0080">In addition, we evaluated the correlation between predicted expression profile and RNA-seq gene expression data of cerebellum region, revealing a weak but expected association (range: &#8722;0.012&#8211;0.031; <xref rid="fig0010" ref-type="fig">Fig. 2</xref>C). The correlations are associated with the expected performance of the model. Then we summarized the prediction performance using GTEx v8. As shown in <xref rid="sec0100" ref-type="fn">Supplementary Table S1</xref>, for &#8764;50&#8201;% of the genes, either in the cerebellum or across all 14 brain regions, the model explained less than 10&#8201;% of the expression variance (R2). For &#8764;75&#8201;% of the genes, the variance explained was less than 20&#8201;%. The median R2 was 0.095 for cerebellum and 0.083 for all regions, while mean values were 0.148 and 0.132, respectively. The mean values were higher than the medians, indicating a right-skewed distribution with most genes showing low explanatory power.</p><p id="p0085">Further, to identify AD-related pathways, we performed non-parametric, unsupervised ssGSVA <xref rid="bib23" ref-type="bibr">[23]</xref> analysis using gene sets from multiple resources, including GSEA <xref rid="bib26" ref-type="bibr">[26]</xref>, DAVID <xref rid="bib27" ref-type="bibr">[27]</xref>, Reactome <xref rid="bib28" ref-type="bibr">[28]</xref>, NetPath <xref rid="bib29" ref-type="bibr">[29]</xref>, PANTHER <xref rid="bib30" ref-type="bibr">[30]</xref>, WikiPathways <xref rid="bib31" ref-type="bibr">[31]</xref>, and PathBank database <xref rid="bib32" ref-type="bibr">[32]</xref>, totaling 1649,335 pathways. The type, number, version and detail description information of the pathways is shown in <xref rid="sec0100" ref-type="fn">Supplementary Table S2</xref>. We firstly focused on 31,824 commonly used or well-annotated pathways, including type: GOBP, GOCC, COMF, KEGG, Reactome, WikiPathways, and four types from MSigDB (CP, CP:BIOCARTA, CP:PID, IMMUNESIGDB) that are worth paying attention to in AD research. The ssGSVA scores were calculated for each individual across 14 brain regions, and the parameter for the number of genes (n_genes) in the pathway was set to 10&#8211;300 to make the enrichment results more reliable. As shown in <xref rid="fig0010" ref-type="fig">Fig. 2</xref><bold>D</bold>, the number of detectable pathways ranged from 9269 (substantia nigra) to 11,585 (cerebellum). For comprehensive screening, we enriched using all 1649,335 pathways with a loose parameter n_genes &gt;&#8201;1. As shown in <xref rid="fig0010" ref-type="fig">Fig. 2</xref><bold>E</bold>, the number of pathways range expanded to 128,873 (substantia nigra) and 254,105 (cerebellum). These trends are consistent with the trend observed in the number of predicted genes. Additionally, we calculated the average ssGSVA score when using all pathways among the originally annotated AD cases and controls, respectively, and compared their distribution in the 14 brain regions using a two-tailed Wilcoxon test (the threshold of <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05). We observed significant differences in most brain regions, except the spinal cord cervical c-1 (<italic toggle="yes">P</italic>&#8201;=&#8201;0.39) (<xref rid="fig0010" ref-type="fig">Fig. 2</xref><bold>F</bold>).</p></sec><sec id="sec0025"><label>2.3</label><title>Identification of AD risk associated pathways</title><p id="p0090">To estimate the genetic liability to AD risk in individuals, we performed PRS analysis. Following PRS guidelines, we retained 173 samples (92 AD cases and 81 controls according to the original annotations) and 10,070,779 SNPs after applying filters and quality control (QC). By combining with the QCed AD GWAS summary data based on Jansen et al. <xref rid="bib33" ref-type="bibr">[33]</xref>, we calculated an AD risk score for these 173 individuals, known as the PRS. We assessed the similarity between the AD risk scores and the original annotations by performing linear Pearson's analysis. Despite some differences, the AD risk score showed a significant correlation with individual group (<italic toggle="yes">R</italic> = 0.48, <italic toggle="yes">P</italic>&#8201;=&#8201;3.54&#8201;&#215;10<sup>&#8722;11</sup>), Thal stage (<italic toggle="yes">R</italic> = 0.54, <italic toggle="yes">P</italic>&#8201;=&#8201;3.39&#8201;&#215;10<sup>&#8722;14</sup>), and Braak NFT stage (<italic toggle="yes">R</italic> = 0.56, <italic toggle="yes">P</italic>&#8201;=&#8201;5.25&#8201;&#215;10<sup>&#8722;12</sup>) (<xref rid="fig0015" ref-type="fig">Fig. 3</xref><bold>A</bold>). We also compared the distribution of the average ssGSVA scores between individuals with high (more than zero) and low (less than zero) AD risk scores in the 14 brain regions using the two-tailed Wilcoxon test. Significant differences were found in all 14 brain regions (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05), and these differences were more pronounced overall compared to those observed in the previous step (grouping by original annotations) (<xref rid="fig0015" ref-type="fig">Fig. 3</xref><bold>B</bold>).<fig id="fig0015" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Performance of PRS and identification of AD-related pathways. (<bold>A</bold>) Spearman correlation analysis depicting the association between AD risk score (measured by PRS analysis) and AD/control group, Braak stage, and Thal stage. (<bold>B</bold>) The distribution of ssGSVA scores in high (more than zero) and low (less than zero) AD risk samples. (<bold>C</bold>) Visualization of intersecting sets of AD-related pathways identified by HHG analysis and permutation procedure. (<bold>D</bold>) The relationship between the proportion of pathways with high-ratio quantified genes and the efficiency of AD-related pathway identification. (<bold>E</bold>) The proportion of direct (green), indirect (burlywood) and unrelated (grey) pathways within each brain region among all AD risk-related pathways and (<bold>F</bold>) among all pathways in SEM results.</p></caption><alt-text id="at0015">Fig. 3</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="lk0015" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p><p id="p0095">Further, we identified the AD risk associated pathways. Since most ssGSVA scores do not follow a normal distribution (Shapiro-Wilk test, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05), and the correlation pattern between ssGSVA scores and AD risk scores was unknown, we employed the Heller-Heller-Gorfine (HHG) method to assess the correlation <xref rid="bib34" ref-type="bibr">[34]</xref>, <xref rid="bib35" ref-type="bibr">[35]</xref>. Before conducting the correlation analysis, we removed outliers from the scores. Finally, the AD-related pathways were identified through a permutation procedure. It is worth noting that the significant correlation pathways identified by HHG (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001) matched those identified by the permutation procedure. As results, 252 pathways were identified as significantly associated with the AD risk score when using 31,824 pathways with n_genes limitation. Pathways identified in each brain region are listed in <xref rid="sec0100" ref-type="fn">Supplementary Table S3</xref>. As summarized in <xref rid="tbl0005" ref-type="table">Table 1</xref>, the pathways primarily involve six core pathological characteristics, including Immunity and inflammation, Metabolism, Protein homeostasis, DNA/RNA and Epigenetics, Synapse and structure, and Cell cycle, among which immunity and inflammation represent the foremost pathological feature. Moreover, 3798 pathways were significantly associated with the AD risk using all pathways, and the 252 pathways are fully included in the expanded 3798 pathways. The pathways also include these 6 core pathological features (<xref rid="tbl0010" ref-type="table">Table 2</xref>). The expanding data demonstrate that AD is a complex network disease affecting multiple systems throughout the brain. Since we focus on the all AD-related pathways, the expanded 3798 pathways were used for subsequent analysis. <xref rid="tbl0015" ref-type="table">Table 3</xref> demonstrates that the number of pathways significantly related to AD risk in each brain region, ranged from 48 (anterior cingulate cortex BA24) to 843 (cortex). Moreover, pathways were identified in at least two brain regions accounting for about 16&#8201;% of the total (<xref rid="fig0015" ref-type="fig">Fig. 3</xref><bold>C</bold>). In addition, we define a pathway in which more than 50&#8201;% of genes are quantified by GReX and used for ssGSVA scoring as a pathway with high-ratio quantified genes. We observed that the more pathway-related genes quantified in a tissue, the more AD-related pathways were identified within it. <xref rid="fig0015" ref-type="fig">Fig. 3</xref><bold>D</bold> shows a significant positive correlation between the proportion of pathways with high-ratio quantified genes and the percentage of identified AD-related pathways (<italic toggle="yes">R</italic> = 0.79, <italic toggle="yes">P</italic>&#8201;=&#8201;8.12&#8201;&#215;10<sup>&#8722;4</sup>). This suggests that more comprehensive eQTL data can enhance the efficiency of our framework.<table-wrap position="float" id="tbl0005" orientation="portrait"><label>Table 1</label><caption><p>Overview of the pathways predicted in 14 brain regions when using 31,824 pathways with the number of genes limitation in: 10&#8211;300.</p></caption><alt-text id="at0030">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Brain region</th><th colspan="1" rowspan="1">Immunity and inflammation</th><th colspan="1" rowspan="1">Metabolism</th><th colspan="1" rowspan="1">Protein homeostasis</th><th colspan="1" rowspan="1">DNA/RNA and Epigenetics</th><th colspan="1" rowspan="1">Synapse and structure</th><th colspan="1" rowspan="1">Cell cycle</th><th colspan="1" rowspan="1">Other</th><th colspan="1" rowspan="1">Total</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Amygdala</td><td align="char" colspan="1" rowspan="1">15</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">1</td><td align="char" colspan="1" rowspan="1">3</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">1</td><td align="char" colspan="1" rowspan="1">20</td></tr><tr><td colspan="1" rowspan="1">Anterior cingulate cortex BA24</td><td align="char" colspan="1" rowspan="1">1</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">Caudate basal ganglia</td><td align="char" colspan="1" rowspan="1">12</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">1</td><td align="char" colspan="1" rowspan="1">1</td><td align="char" colspan="1" rowspan="1">2</td><td align="char" colspan="1" rowspan="1">8</td><td align="char" colspan="1" rowspan="1">24</td></tr><tr><td colspan="1" rowspan="1">Cerebellar hemisphere</td><td align="char" colspan="1" rowspan="1">7</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">1</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">3</td><td align="char" colspan="1" rowspan="1">11</td></tr><tr><td colspan="1" rowspan="1">Cerebellum</td><td align="char" colspan="1" rowspan="1">13</td><td align="char" colspan="1" rowspan="1">1</td><td align="char" colspan="1" rowspan="1">2</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">1</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">5</td><td align="char" colspan="1" rowspan="1">22</td></tr><tr><td colspan="1" rowspan="1">Cortex</td><td align="char" colspan="1" rowspan="1">15</td><td align="char" colspan="1" rowspan="1">2</td><td align="char" colspan="1" rowspan="1">1</td><td align="char" colspan="1" rowspan="1">1</td><td align="char" colspan="1" rowspan="1">1</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">8</td><td align="char" colspan="1" rowspan="1">28</td></tr><tr><td colspan="1" rowspan="1">Frontal cortex BA9</td><td align="char" colspan="1" rowspan="1">15</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">3</td><td align="char" colspan="1" rowspan="1">6</td><td align="char" colspan="1" rowspan="1">4</td><td align="char" colspan="1" rowspan="1">1</td><td align="char" colspan="1" rowspan="1">6</td><td align="char" colspan="1" rowspan="1">35</td></tr><tr><td colspan="1" rowspan="1">Hippocampus</td><td align="char" colspan="1" rowspan="1">4</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">1</td><td align="char" colspan="1" rowspan="1">3</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">8</td></tr><tr><td colspan="1" rowspan="1">Hypothalamus</td><td align="char" colspan="1" rowspan="1">17</td><td align="char" colspan="1" rowspan="1">2</td><td align="char" colspan="1" rowspan="1">3</td><td align="char" colspan="1" rowspan="1">1</td><td align="char" colspan="1" rowspan="1">1</td><td align="char" colspan="1" rowspan="1">1</td><td align="char" colspan="1" rowspan="1">7</td><td align="char" colspan="1" rowspan="1">32</td></tr><tr><td colspan="1" rowspan="1">Nucleus accumbens basal ganglia</td><td align="char" colspan="1" rowspan="1">19</td><td align="char" colspan="1" rowspan="1">4</td><td align="char" colspan="1" rowspan="1">1</td><td align="char" colspan="1" rowspan="1">1</td><td align="char" colspan="1" rowspan="1">4</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">8</td><td align="char" colspan="1" rowspan="1">37</td></tr><tr><td colspan="1" rowspan="1">Putamen basal ganglia</td><td align="char" colspan="1" rowspan="1">7</td><td align="char" colspan="1" rowspan="1">3</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">10</td></tr><tr><td colspan="1" rowspan="1">Spinal cord cervical c&#8722;1</td><td align="char" colspan="1" rowspan="1">8</td><td align="char" colspan="1" rowspan="1">2</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">1</td><td align="char" colspan="1" rowspan="1">1</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">2</td><td align="char" colspan="1" rowspan="1">14</td></tr><tr><td colspan="1" rowspan="1">Substantia nigra</td><td align="char" colspan="1" rowspan="1">8</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">1</td><td align="char" colspan="1" rowspan="1">1</td><td align="char" colspan="1" rowspan="1">1</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">1</td><td align="char" colspan="1" rowspan="1">12</td></tr><tr><td colspan="1" rowspan="1">Pituitary</td><td align="char" colspan="1" rowspan="1">2</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">1</td><td align="char" colspan="1" rowspan="1">0</td><td align="char" colspan="1" rowspan="1">1</td><td align="char" colspan="1" rowspan="1">4</td></tr></tbody></table></table-wrap><table-wrap position="float" id="tbl0010" orientation="portrait"><label>Table 2</label><caption><p>Overview of the pathways predicted in 14 brain regions when using all pathways.</p></caption><alt-text id="at0035">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Brain region</th><th colspan="1" rowspan="1">Immunity and inflammation</th><th colspan="1" rowspan="1">Metabolism</th><th colspan="1" rowspan="1">Protein homeostasis</th><th colspan="1" rowspan="1">DNA/RNA and Epigenetics</th><th colspan="1" rowspan="1">Synapse and structure</th><th colspan="1" rowspan="1">Cell cycle</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Amygdala</td><td align="char" colspan="1" rowspan="1">25</td><td align="char" colspan="1" rowspan="1">14</td><td align="char" colspan="1" rowspan="1">9</td><td align="char" colspan="1" rowspan="1">39</td><td align="char" colspan="1" rowspan="1">10</td><td align="char" colspan="1" rowspan="1">29</td></tr><tr><td colspan="1" rowspan="1">Anterior cingulate cortex BA24</td><td align="char" colspan="1" rowspan="1">2</td><td align="char" colspan="1" rowspan="1">4</td><td align="char" colspan="1" rowspan="1">1</td><td align="char" colspan="1" rowspan="1">7</td><td align="char" colspan="1" rowspan="1">2</td><td align="char" colspan="1" rowspan="1">16</td></tr><tr><td colspan="1" rowspan="1">Caudate basal ganglia</td><td align="char" colspan="1" rowspan="1">23</td><td align="char" colspan="1" rowspan="1">19</td><td align="char" colspan="1" rowspan="1">12</td><td align="char" colspan="1" rowspan="1">28</td><td align="char" colspan="1" rowspan="1">5</td><td align="char" colspan="1" rowspan="1">28</td></tr><tr><td colspan="1" rowspan="1">Cerebellar hemisphere</td><td align="char" colspan="1" rowspan="1">14</td><td align="char" colspan="1" rowspan="1">10</td><td align="char" colspan="1" rowspan="1">6</td><td align="char" colspan="1" rowspan="1">18</td><td align="char" colspan="1" rowspan="1">8</td><td align="char" colspan="1" rowspan="1">21</td></tr><tr><td colspan="1" rowspan="1">Cerebellum</td><td align="char" colspan="1" rowspan="1">18</td><td align="char" colspan="1" rowspan="1">22</td><td align="char" colspan="1" rowspan="1">15</td><td align="char" colspan="1" rowspan="1">31</td><td align="char" colspan="1" rowspan="1">11</td><td align="char" colspan="1" rowspan="1">45</td></tr><tr><td colspan="1" rowspan="1">Cortex</td><td align="char" colspan="1" rowspan="1">24</td><td align="char" colspan="1" rowspan="1">18</td><td align="char" colspan="1" rowspan="1">14</td><td align="char" colspan="1" rowspan="1">35</td><td align="char" colspan="1" rowspan="1">20</td><td align="char" colspan="1" rowspan="1">52</td></tr><tr><td colspan="1" rowspan="1">Frontal cortex BA9</td><td align="char" colspan="1" rowspan="1">22</td><td align="char" colspan="1" rowspan="1">12</td><td align="char" colspan="1" rowspan="1">10</td><td align="char" colspan="1" rowspan="1">33</td><td align="char" colspan="1" rowspan="1">15</td><td align="char" colspan="1" rowspan="1">38</td></tr><tr><td colspan="1" rowspan="1">Hippocampus</td><td align="char" colspan="1" rowspan="1">11</td><td align="char" colspan="1" rowspan="1">8</td><td align="char" colspan="1" rowspan="1">7</td><td align="char" colspan="1" rowspan="1">15</td><td align="char" colspan="1" rowspan="1">6</td><td align="char" colspan="1" rowspan="1">12</td></tr><tr><td colspan="1" rowspan="1">Hypothalamus</td><td align="char" colspan="1" rowspan="1">23</td><td align="char" colspan="1" rowspan="1">16</td><td align="char" colspan="1" rowspan="1">18</td><td align="char" colspan="1" rowspan="1">30</td><td align="char" colspan="1" rowspan="1">9</td><td align="char" colspan="1" rowspan="1">35</td></tr><tr><td colspan="1" rowspan="1">Nucleus accumbens basal ganglia</td><td align="char" colspan="1" rowspan="1">19</td><td align="char" colspan="1" rowspan="1">15</td><td align="char" colspan="1" rowspan="1">11</td><td align="char" colspan="1" rowspan="1">29</td><td align="char" colspan="1" rowspan="1">10</td><td align="char" colspan="1" rowspan="1">31</td></tr><tr><td colspan="1" rowspan="1">Putamen basal ganglia</td><td align="char" colspan="1" rowspan="1">15</td><td align="char" colspan="1" rowspan="1">11</td><td align="char" colspan="1" rowspan="1">8</td><td align="char" colspan="1" rowspan="1">21</td><td align="char" colspan="1" rowspan="1">7</td><td align="char" colspan="1" rowspan="1">25</td></tr><tr><td colspan="1" rowspan="1">Spinal cord cervical c&#8722;1</td><td align="char" colspan="1" rowspan="1">5</td><td align="char" colspan="1" rowspan="1">3</td><td align="char" colspan="1" rowspan="1">2</td><td align="char" colspan="1" rowspan="1">6</td><td align="char" colspan="1" rowspan="1">4</td><td align="char" colspan="1" rowspan="1">8</td></tr><tr><td colspan="1" rowspan="1">Substantia nigra</td><td align="char" colspan="1" rowspan="1">20</td><td align="char" colspan="1" rowspan="1">14</td><td align="char" colspan="1" rowspan="1">10</td><td align="char" colspan="1" rowspan="1">26</td><td align="char" colspan="1" rowspan="1">9</td><td align="char" colspan="1" rowspan="1">29</td></tr><tr><td colspan="1" rowspan="1">Pituitary</td><td align="char" colspan="1" rowspan="1">10</td><td align="char" colspan="1" rowspan="1">7</td><td align="char" colspan="1" rowspan="1">9</td><td align="char" colspan="1" rowspan="1">14</td><td align="char" colspan="1" rowspan="1">5</td><td align="char" colspan="1" rowspan="1">13</td></tr></tbody></table></table-wrap><table-wrap position="float" id="tbl0015" orientation="portrait"><label>Table 3</label><caption><p>Overview of the genes and pathways predicted in 14 brain regions when using all pathways with the number of genes &gt;&#8201;1.</p></caption><alt-text id="at0040">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">Brain region</th><th colspan="4" rowspan="1">Pathway<hr/></th><th colspan="3" rowspan="1">Gene<hr/></th></tr><tr><th colspan="1" rowspan="1"><bold>ssGSVA</bold></th><th colspan="1" rowspan="1"><bold>AD risk- related</bold></th><th colspan="1" rowspan="1"><bold>Literature-reported AD-related</bold></th><th colspan="1" rowspan="1"><bold>Percentage</bold><sup><bold>a</bold></sup></th><th colspan="1" rowspan="1"><bold>predicted</bold></th><th colspan="1" rowspan="1"><bold>In literature-reported AD pathways</bold></th><th colspan="1" rowspan="1"><bold>Percentage</bold><sup><bold>b</bold></sup></th></tr></thead><tbody><tr><td colspan="1" rowspan="1"><bold>Amygdala</bold></td><td align="char" colspan="1" rowspan="1">140665</td><td align="char" colspan="1" rowspan="1">224</td><td align="char" colspan="1" rowspan="1">50</td><td align="char" colspan="1" rowspan="1">22.32&#8201;%</td><td align="char" colspan="1" rowspan="1">5230</td><td align="char" colspan="1" rowspan="1">1038</td><td align="char" colspan="1" rowspan="1">19.85&#8201;%</td></tr><tr><td colspan="1" rowspan="1"><bold>Anterior cingulate cortex BA24</bold></td><td align="char" colspan="1" rowspan="1">151201</td><td align="char" colspan="1" rowspan="1">48</td><td align="char" colspan="1" rowspan="1">10</td><td align="char" colspan="1" rowspan="1">20.83&#8201;%</td><td align="char" colspan="1" rowspan="1">6313</td><td align="char" colspan="1" rowspan="1">160</td><td align="char" colspan="1" rowspan="1">2.53&#8201;%</td></tr><tr><td colspan="1" rowspan="1"><bold>Caudate basal ganglia</bold></td><td align="char" colspan="1" rowspan="1">211425</td><td align="char" colspan="1" rowspan="1">253</td><td align="char" colspan="1" rowspan="1">59</td><td align="char" colspan="1" rowspan="1">23.32&#8201;%</td><td align="char" colspan="1" rowspan="1">7998</td><td align="char" colspan="1" rowspan="1">1015</td><td align="char" colspan="1" rowspan="1">12.69&#8201;%</td></tr><tr><td colspan="1" rowspan="1"><bold>Cerebellar hemisphere</bold></td><td align="char" colspan="1" rowspan="1">239101</td><td align="char" colspan="1" rowspan="1">152</td><td align="char" colspan="1" rowspan="1">44</td><td align="char" colspan="1" rowspan="1">28.95&#8201;%</td><td align="char" colspan="1" rowspan="1">8250</td><td align="char" colspan="1" rowspan="1">1007</td><td align="char" colspan="1" rowspan="1">12.21&#8201;%</td></tr><tr><td colspan="1" rowspan="1"><bold>Cerebellum</bold></td><td align="char" colspan="1" rowspan="1">254105</td><td align="char" colspan="1" rowspan="1">797</td><td align="char" colspan="1" rowspan="1">76</td><td align="char" colspan="1" rowspan="1">9.54&#8201;%</td><td align="char" colspan="1" rowspan="1">9186</td><td align="char" colspan="1" rowspan="1">906</td><td align="char" colspan="1" rowspan="1">9.86&#8201;%</td></tr><tr><td colspan="1" rowspan="1"><bold>Cortex</bold></td><td align="char" colspan="1" rowspan="1">237011</td><td align="char" colspan="1" rowspan="1">843</td><td align="char" colspan="1" rowspan="1">72</td><td align="char" colspan="1" rowspan="1">8.54&#8201;%</td><td align="char" colspan="1" rowspan="1">8436</td><td align="char" colspan="1" rowspan="1">4078</td><td align="char" colspan="1" rowspan="1">48.34&#8201;%</td></tr><tr><td colspan="1" rowspan="1"><bold>Frontal cortex BA9</bold></td><td align="char" colspan="1" rowspan="1">198891</td><td align="char" colspan="1" rowspan="1">452</td><td align="char" colspan="1" rowspan="1">64</td><td align="char" colspan="1" rowspan="1">14.16&#8201;%</td><td align="char" colspan="1" rowspan="1">7363</td><td align="char" colspan="1" rowspan="1">786</td><td align="char" colspan="1" rowspan="1">10.67&#8201;%</td></tr><tr><td colspan="1" rowspan="1"><bold>Hippocampus</bold></td><td align="char" colspan="1" rowspan="1">155530</td><td align="char" colspan="1" rowspan="1">111</td><td align="char" colspan="1" rowspan="1">27</td><td align="char" colspan="1" rowspan="1">24.32&#8201;%</td><td align="char" colspan="1" rowspan="1">6450</td><td align="char" colspan="1" rowspan="1">431</td><td align="char" colspan="1" rowspan="1">6.68&#8201;%</td></tr><tr><td colspan="1" rowspan="1"><bold>Hypothalamus</bold></td><td align="char" colspan="1" rowspan="1">177654</td><td align="char" colspan="1" rowspan="1">355</td><td align="char" colspan="1" rowspan="1">83</td><td align="char" colspan="1" rowspan="1">23.38&#8201;%</td><td align="char" colspan="1" rowspan="1">6488</td><td align="char" colspan="1" rowspan="1">2494</td><td align="char" colspan="1" rowspan="1">38.44&#8201;%</td></tr><tr><td colspan="1" rowspan="1"><bold>Nucleus accumbens basal ganglia</bold></td><td align="char" colspan="1" rowspan="1">200953</td><td align="char" colspan="1" rowspan="1">741</td><td align="char" colspan="1" rowspan="1">187</td><td align="char" colspan="1" rowspan="1">25.24&#8201;%</td><td align="char" colspan="1" rowspan="1">7822</td><td align="char" colspan="1" rowspan="1">1567</td><td align="char" colspan="1" rowspan="1">20.03&#8201;%</td></tr><tr><td colspan="1" rowspan="1"><bold>Putamen basal ganglia</bold></td><td align="char" colspan="1" rowspan="1">203271</td><td align="char" colspan="1" rowspan="1">152</td><td align="char" colspan="1" rowspan="1">34</td><td align="char" colspan="1" rowspan="1">22.37&#8201;%</td><td align="char" colspan="1" rowspan="1">7341</td><td align="char" colspan="1" rowspan="1">651</td><td align="char" colspan="1" rowspan="1">8.87&#8201;%</td></tr><tr><td colspan="1" rowspan="1"><bold>Spinal cord cervical c&#8722;1</bold></td><td align="char" colspan="1" rowspan="1">171460</td><td align="char" colspan="1" rowspan="1">201</td><td align="char" colspan="1" rowspan="1">43</td><td align="char" colspan="1" rowspan="1">21.39&#8201;%</td><td align="char" colspan="1" rowspan="1">5634</td><td align="char" colspan="1" rowspan="1">398</td><td align="char" colspan="1" rowspan="1">7.06&#8201;%</td></tr><tr><td colspan="1" rowspan="1"><bold>Substantia nigra</bold></td><td align="char" colspan="1" rowspan="1">128873</td><td align="char" colspan="1" rowspan="1">128</td><td align="char" colspan="1" rowspan="1">29</td><td align="char" colspan="1" rowspan="1">22.66&#8201;%</td><td align="char" colspan="1" rowspan="1">5013</td><td align="char" colspan="1" rowspan="1">254</td><td align="char" colspan="1" rowspan="1">5.07&#8201;%</td></tr><tr><td colspan="1" rowspan="1"><bold>Pituitary</bold></td><td align="char" colspan="1" rowspan="1">230222</td><td align="char" colspan="1" rowspan="1">58</td><td align="char" colspan="1" rowspan="1">12</td><td align="char" colspan="1" rowspan="1">20.69&#8201;%</td><td align="char" colspan="1" rowspan="1">8582</td><td align="char" colspan="1" rowspan="1">109</td><td align="char" colspan="1" rowspan="1">1.27&#8201;%</td></tr></tbody></table><table-wrap-foot><fn><p>Percentage<sup>a</sup>: number of literature-reported AD-related pathways/number of AD risk-related pathways. Percentage<sup>b</sup>: number of genes in literature-reported AD-related pathways/number of predicted genes.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec0030"><label>2.4</label><title>Literature reported relation between AD risk-related pathways and AD</title><p id="p0100">To verify the relevance of the identified pathways to AD, we investigated the literature-reported correlation between the 3798 AD risk-related pathways identified across 14 brain regions and AD. These correlations were classified as direct, indirect (associated with features linked to AD), or unrelated (Detailed definition scheme is in Methods). <xref rid="tbl0015" ref-type="table">Table 3</xref> provides the number of identified AD risk-related pathways, literature-reported directly AD-related pathways, and the percentage of direct correlations within each brain region. Detailed descriptions of the reported relevance between the enriched pathways and AD are listed in <xref rid="sec0100" ref-type="fn">Supplementary Table S4</xref>, along with corresponding references. Additionally, <xref rid="fig0015" ref-type="fig">Fig. 3</xref><bold>E</bold> illustrates the proportion of direct, indirect, and unrelated pathways within each brain region among all AD risk-related pathways. The pathways directly correlated with AD widely distributed in important brain regions related to cognition, memory, and motor function, such as the cortex, hippocampus, basal ganglia, and cerebellum. The NF-&#954;B signaling pathway, a core neuroinflammatory pathway, and its related molecules has been found to be associated with AD in multiple brain regions, including the frontal cortex BA9, putamen basal ganglia, nucleus accumbens basal ganglia, substantia nigra, and cervical spinal cord c-1. TLR4 and TRAF6, as upstream molecules of NF-&#954;B, are both significantly enriched in the cortex. GSK3&#946; (glycogen synthase kinase 3&#946;), a key kinase regulating tau phosphorylation, is involved in the cortex, cerebellum, and basal ganglia. Tau protein: As one of the core pathological proteins in AD, its abnormal phosphorylation and aggregation have been studied in multiple brain regions, including the cortex, cerebellum, amygdala, and nucleus accumbens basal ganglia. &#946;-catenin and Wnt signaling pathways: This pathway is closely related to neuronal function and is enriched in the cortex, cerebellar hemisphere, hypothalamus, and amygdala. The PI3K/AKT signaling pathway: This is a key cell survival and metabolic pathway, expressed in hypothalamus, substantia nigra, and caudate basal ganglia. MACF1 (microtubule-actin cross-linking factor 1), as a molecule that directly affects microtubule stability, its expression in the spinal cord cervical c-1 has been reported to be associated with AD pathology. Other major AD-related pathways include immune, mitochondrial dysfunction, apoptosis, autophagy, and cholesterol metabolism. Specifically, they are related to the immune system, regulation of A&#946;, APP, tau, and other key genes/proteins, autophagy, mitochondrial/endoplasmic reticulum (ER)-mitochondria interactions, mTOR, NFkappaB, estrogens/androgens, helicase/DNA repair, HLA, metal ion metabolism, miRNAs, ROS, p38 MAPK, and VEGF.</p><p id="p0105">We also evaluated the impact of pathway size on our findings, with detailed results listed in <xref rid="tbl0015" ref-type="table">Table 3</xref>. We observed that two brain regions accounted for a disproportionately large number of the genes analyzed: the cortex (48.34&#8201;%) and the hypothalamus (38.44&#8201;%). This imbalance was driven by four exceptionally large pathways, two within each of these regions. Specifically, the total number of genes included in the pathways used for ssGSVA is 44,659, with each of these four pathways containing more than 4000 genes. In the cortex, two pathways (GOBP &#8764; GO:0008152 &#8764; metabolic process and GOBP &#8764; GO:0071704 &#8764; organic substance metabolic process) originally contain a high number of genes (12,193 and 11,793, respectively), and 3820 and 3664 of them were used in ssGSVA, respectively. Similarly, in the hypothalamus, two pathways (UCSC_TFBS &#8764; TBP and UCSC_TFBS &#8764; CEBPA) also originally contain a high number of genes (5762 and 4661, respectively), and 1235 and 977 of them were used in ssGSVA, respectively. The rest of the pathways in these two brain regions contain several to several tens of genes (totaling 1058 in the cortex and 1220 in the hypothalamus), which is similar to other brain regions. Additionally, the nucleus accumbens basal ganglia has the highest proportion of AD-related genes (20.03&#8201;%).</p></sec><sec id="sec0035"><label>2.5</label><title>Quantitatively investigate the interaction relationships among pathways</title><p id="p0110">Given that pathways do not work independently <xref rid="bib36" ref-type="bibr">[36]</xref>, <xref rid="bib37" ref-type="bibr">[37]</xref>, we utilized SEM analysis to quantitatively assess their interactions and contributions to the phenotype. This process involved factor analysis, model building, and optimization using AD risk-related pathways with unreplicated ssGSVA scores. As shown in <xref rid="tbl0020" ref-type="table">Table 4</xref>, the Bartlett test for all 14 brain regions was significant after removing variables with inadequate loadings and those with only one variable in a factor. Additionally, the Kaiser-Meyer-Olkin (KMO) values exceeded 0.5 for most brain regions (except for the anterior cingulate cortex BA24, frontal cortex BA9, and pituitary), indicating the appropriateness of factor analysis. After model optimization, the standard error of pathway loading in all brain regions within their respective factors was significant (generally t value &gt; 2), except for the anterior cingulate cortex BA24. The modification indices for pathways in other factors remained relatively low, indicating a generally well-fitting model. Except for the anterior cingulate cortex BA24, the key results of the SEM models for the other 13 brain regions (including pathway attribution factors, loadings, and inter-factor correlations, as well as the corresponding pathways and their associations with AD) can be found in <xref rid="sec0100" ref-type="fn">Supplementary Table S5 to S17</xref>. <xref rid="tbl0020" ref-type="table">Table 4</xref> lists the number and proportion of literature-reported AD-related pathways in each brain region model. Consistent with the proportion of gene counts (<xref rid="tbl0015" ref-type="table">Table 3</xref>), the model for the nucleus accumbens basal ganglia also contains the largest number of AD-related pathways. Additionally, <xref rid="fig0015" ref-type="fig">Fig. 3</xref><bold>F</bold> shows the proportion of direct, indirect, and unrelated pathways within each brain region among all pathways in the SEM results. <xref rid="fig0020" ref-type="fig">Fig. 4</xref> provides a detailed overview of the SEM results for the nucleus accumbens basal ganglia, grouping pathways with similar functions into the same factor, regardless of their originating databases. For instance, four pathways, including &#8220;anti-inflammatory actions mediated by gliotoxin include HO-1 induction and the subsequent blockade of NF-kappaB-dependent signaling pathways in vitro and in vivo (GENERIF_SUMMARY&#8764;16804400)&#8221;, &#8220;GA could inhibit NF-kappaB and MAPK/HO-1 signalling pathways (GENERIF_SUMMARY&#8764;24300974)&#8221;, &#8220;induction of HO-1 by CO-RM2 exerted anti-inflammatory and antioxidant effects which are required in concert to prevent the activation of NF-kappaB leading to induction of various inflammatory genes implicated in the pathogenesis of RA (GENERIF_SUMMARY&#8764;24616552)&#8221;, and &#8220;Induction of Prx1 by hypoxia regulates heme oxygenase-1 via NF-kappaB in oral cancer (GENERIF_SUMMARY&#8764;25162226)&#8221; belong to factor KSI8 within the NFkappaB category. These pathways share the genes HMOX1 (ENSG00000100292) and NFKB1 (ENSG00000109320), which interact and affect AD risk <xref rid="bib38" ref-type="bibr">[38]</xref>. The inter-factor correlations in this brain region can be found in <xref rid="sec0100" ref-type="fn">Supplementary Table S13</xref>.<table-wrap position="float" id="tbl0020" orientation="portrait"><label>Table 4</label><caption><p>SEM analysis results of 14 brain regions when using all pathways with the number of genes &gt;&#8201;1.</p></caption><alt-text id="at0045">Table 4</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Brain region</th><th colspan="1" rowspan="1">KMO</th><th colspan="1" rowspan="1">Bartlett</th><th colspan="1" rowspan="1">Number of pathways in module</th><th colspan="1" rowspan="1">Number of factors</th><th colspan="1" rowspan="1">Number of literature-reported AD-related pathways</th><th colspan="1" rowspan="1">Percentage</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Brain amygdala</td><td align="char" colspan="1" rowspan="1">0.516</td><td align="char" colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">16</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">6.25&#8201;%</td></tr><tr><td colspan="1" rowspan="1">Brain anterior cingulate cortex BA24</td><td align="char" colspan="1" rowspan="1">0.483</td><td align="char" colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">NA</td></tr><tr><td colspan="1" rowspan="1">Brain caudate basal ganglia</td><td align="char" colspan="1" rowspan="1">0.588</td><td align="char" colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">11.36&#8201;%</td></tr><tr><td colspan="1" rowspan="1">Brain cerebellar hemisphere</td><td align="char" colspan="1" rowspan="1">0.615</td><td align="char" colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">23.08&#8201;%</td></tr><tr><td colspan="1" rowspan="1">Brain cerebellum</td><td align="char" colspan="1" rowspan="1">0.617</td><td align="char" colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">541</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">1.66&#8201;%</td></tr><tr><td colspan="1" rowspan="1">Brain cortex</td><td align="char" colspan="1" rowspan="1">0.632</td><td align="char" colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">551</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">2.36&#8201;%</td></tr><tr><td colspan="1" rowspan="1">Brain frontal cortex BA9</td><td align="char" colspan="1" rowspan="1">0.493</td><td align="char" colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">25.00&#8201;%</td></tr><tr><td colspan="1" rowspan="1">Brain hippocampus</td><td align="char" colspan="1" rowspan="1">0.539</td><td align="char" colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">35.71&#8201;%</td></tr><tr><td colspan="1" rowspan="1">Brain hypothalamus</td><td align="char" colspan="1" rowspan="1">0.607</td><td align="char" colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">18.18&#8201;%</td></tr><tr><td colspan="1" rowspan="1">Brain nucleus accumbens basal ganglia</td><td align="char" colspan="1" rowspan="1">0.649</td><td align="char" colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">275</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">78</td><td colspan="1" rowspan="1">28.36&#8201;%</td></tr><tr><td colspan="1" rowspan="1">Brain putamen basal ganglia</td><td align="char" colspan="1" rowspan="1">0.506</td><td align="char" colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">30.00&#8201;%</td></tr><tr><td colspan="1" rowspan="1">Brain spinal cord cervical c&#8722;1</td><td align="char" colspan="1" rowspan="1">0.516</td><td align="char" colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">46.15&#8201;%</td></tr><tr><td colspan="1" rowspan="1">Brain substantia nigra</td><td align="char" colspan="1" rowspan="1">0.506</td><td align="char" colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">18.18&#8201;%</td></tr><tr><td colspan="1" rowspan="1">Pituitary</td><td align="char" colspan="1" rowspan="1">0.499</td><td align="char" colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">37.50&#8201;%</td></tr></tbody></table><table-wrap-foot><fn><p>Number of pathways in module: pathways in module including those with replicated ssGSVA score. Percentage: Number of literature-reported AD-related pathways/Number of pathways in module. More detailed results of each brain region can be found in <xref rid="sec0100" ref-type="fn">Supplementary Table S5-S17</xref><bold>.</bold></p></fn></table-wrap-foot></table-wrap><fig id="fig0020" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>The SEM result of nucleus accumbens basal ganglia. The red numbers in parentheses represent number of pathways with the same ssGSVA score as this pathway in this model. The inter-factor correlations in this brain region can be found in <xref rid="sec0100" ref-type="fn">Supplementary Table S13</xref>.</p></caption><alt-text id="at0020">Fig. 4</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="lk0020" position="float" orientation="portrait" xlink:href="gr4.jpg"/></fig></p></sec></sec><sec id="sec0040"><label>3</label><title>Discussion</title><p id="p0115">In this study, we predicted transcriptomes of 14 brain regions based on genotype data. We then combined these transcriptomes with GWAS summary data to estimate the PRS for AD risk. Subsequently, we characterized the primary inheritance pathways associated with AD. This framework for identifying disease-related pathways offers three main advantages: (1) By starting from genome data, we avoided environmental factors' interference, yielding results that more accurately reflect the disease's intrinsic genetic mechanisms. (2) Our approach relied solely on genotype data, eliminating the need to divide samples into disease or control groups. This enabled us to analyze continuous variables, which provide a more nuanced representation of the real-world disease landscape. (3) Our research covered the entire genome without imposing an arbitrary threshold, preventing the loss of important genomic information.</p><p id="p0120">By translating genetic evidence into gene expression, our approach can circumvent non-genetic confounding factors, a strategy similarly applied by Chen et al. (2021) <xref rid="bib39" ref-type="bibr">[39]</xref> in their recent study on late-onset AD. The number of genes predicted by GReX is relatively high in the cerebellum/cerebellar hemisphere and pituitary, but their correlation with other brain regions is low. This is consistent with the eQTL results, indicating a higher prevalence of genes exhibiting allele-specific expression in these tissues <xref rid="bib21" ref-type="bibr">[21]</xref>, <xref rid="bib40" ref-type="bibr">[40]</xref>. The correlation between predicted and measured gene expression levels by RNA-seq was low in the cerebellum region. This is most likely due to the inherent performance limitation of the model. The cross-validated prediction R2 (pred_perf_r2) showed that the prediction model performance of many genes is inherently very limited for all brain tissue in GTEx v8. A study using GTEx v8 data found that for some tissues, the median 5-fold cross-validation R2 for all genes was as low as about 0.04 <xref rid="bib41" ref-type="bibr">[41]</xref>. The significant positive correlation between the proportion of pathways with high-ratio quantified genes and the percentage of identified AD-related pathways also suggests that more comprehensive eQTL data can enhance the efficiency of our framework.</p><p id="p0125">The trend of pathway numbers enriched by ssGSVA aligned with the predicted gene numbers. The PRS reflected the genetic risk for AD and showed a significant correlation with AD/control grouping, as well as the Braak and Thal stages of the samples. Overall, the higher the Braak and Thal stages, the greater the AD risk. There is a significant difference in pathway GSVA score between the AD/high AD risk group and the contra/low AD risk group. Therefore, we further screened pathways significantly associated with AD risk score. Through correlation analysis, we identified pathways associated with AD risk in each brain region. Of these pathways, 19.7&#8201;% have been previously reported to be related to AD, while 39.7&#8201;% may potentially be associated with AD. Both PRS and ssGSVA scores are derived from genomic data, allowing us to elucidate AD-related pathways purely from a genetic perspective. Further, the SEM analysis enabled us to assess the interaction and coefficient among pathways. Pathways assigned to one factor tended to share more genes and exhibit similar functions.</p><p id="p0130">Research on AD encompasses various aspects such as immune regulation <xref rid="bib42" ref-type="bibr">[42]</xref>, autophagy <xref rid="bib43" ref-type="bibr">[43]</xref>, <xref rid="bib44" ref-type="bibr">[44]</xref>, mitochondrial function <xref rid="bib45" ref-type="bibr">[45]</xref>, and more. The AD-related pathways identified across 14 brain regions span multiple domains, highlighting their significance. Use commonly used or well-annotated pathways or use all genes, the pathways identified as AD risk related primarily address six core biological themes: (1) neuroinflammation and glial dysfunction, as ubiquitous and key drivers; (2) synaptic failure and neurotransmitter system dysregulation, as direct molecular correlates of cognitive impairment; (3) breakdown of cellular proteostasis, involving protein misfolding, ubiquitin-proteasome system (UPS) dysfunction, and impaired autophagy-lysosome pathways; (4) metabolic disturbances and bioenergetics, centered on mitochondrial dysfunction and oxidative stress; (5) genomic instability, manifested by DNA damage accumulation and abnormalities in repair pathways; and (6) dysregulation of key signaling cascades, such as the RAS/MAPK and PI3K/Akt pathways, which integrate and amplify the aforementioned pathological processes. As illustrated in <xref rid="fig0025" ref-type="fig">Fig. 5</xref>, reviewing these pathways and the literature reports related to AD, we noticed complex crosstalk and regulation between brain regions. Specifically, the accumulation of A&#946;, the well-known foundation of AD pathogenesis, serves as a core trigger, activating multiple signaling pathways, ultimately leading to neuroinflammation, neuronal dysfunction, and microtubule structural abnormalities, all contributing to the pathological progression of AD. The transcription factor NF-&#954;B signaling can be activated through the TLR4/TRAF6/IKK or PI3K/AKT signaling pathways, promoting the transcription of cytokines such as IL-1, TNF-&#945;, and chemokines like MCP-1 <xref rid="bib46" ref-type="bibr">[46]</xref>, <xref rid="bib47" ref-type="bibr">[47]</xref>. This activation stimulates neuroinflammation in cells such as microglia, contributing to the pathogenesis of AD. Amyloid &#946; can transmit signals by binding to its membrane receptor PirB, which then activates GSK3&#946; via PP2A <xref rid="bib48" ref-type="bibr">[48]</xref>. GSK3&#946;, acting as a multifunctional factor, promotes the phosphorylation of tau and MACF1, leading to their detachment from microtubules, resulting in abnormal microtubule structures and neuronal damage <xref rid="bib48" ref-type="bibr">[48]</xref>, <xref rid="bib49" ref-type="bibr">[49]</xref>. Additionally, it promotes the degradation of &#946;-catenin by phosphorylation, inactivating the Wnt signaling pathway and impairing neuronal development and function <xref rid="bib50" ref-type="bibr">[50]</xref>, <xref rid="bib51" ref-type="bibr">[51]</xref>. HSP90 binds to phosphorylated tau and restores its normal structure by dephosphorylation. Abnormal ubiquitination of the protein c-Cbl is closely associated with AD, as it can ubiquitinate and degrade proteins such as AKT, NF-&#954;B, &#946;-catenin, and HSP90 <xref rid="bib52" ref-type="bibr">[52]</xref>, all of which are involved in the occurrence of AD.<fig id="fig0025" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>A pathway network summarized by consolidating several AD-related pathways that we have identified.</p></caption><alt-text id="at0025">Fig. 5</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="lk0025" position="float" orientation="portrait" xlink:href="gr5.jpg"/></fig></p><p id="p0135">Based on our previous research on AD and genomic data <xref rid="bib53" ref-type="bibr">[53]</xref>, <xref rid="bib54" ref-type="bibr">[54]</xref>, we constructed this analysis pipeline and hope that our results can provide some theoretical basis for the study of AD or other complex diseases. However, some inevitable limitations still exist. The number of genes included in a pathway is worthy of consideration when performing enrichment analysis. Given that the predicted number of genes ranges from about 5000 to 10,000, we suggest that the upper limit of the number of genes in a pathway can be set at 300 (&#8764;5&#8201;%). Further research is needed to confirm this parameter. Furthermore, ssGSVA only considers genes present in the expression matrix, which can result in pathways containing different genes having identical scores. While randomly selecting a representative for pathways with identical scores during SEM model construction is unlikely to bias the main findings, we cannot completely rule out subtle influences on SEM factor loadings. This handling of identical scores is a limitation of our current method, and future improvements in gene expression prediction may address this issue, further improving SEM accuracy. In addition, manually searching and reading literature takes a lot of time, and artificial intelligence (AI) tools should be used to improve retrieval efficiency and accuracy. On the other hand, we try to avoid using data affected by confounding factors at every step, but we cannot avoid using existing GWAS summary data when making disease risk predictions. Although this data obtained from disease phenotypes may be affected by confounding factors, to our knowledge, this is the least affected option.</p><p id="p0140">In conclusion, given the numerous alterations observed in various pathways in AD, targeting a single process will likely prove insufficient to halt disease progression. More importantly, our findings have pinpointed specific categories that could serve as a reference for investigating pathway-dependent AD risk, offering valuable quantitative insights into the interdependence or compensatory effects among pathways. Further research is warranted to explore the precise roles of pathways and their interrelationships with AD.</p></sec><sec id="sec0045"><label>4</label><title>Methods</title><sec id="sec0050"><label>4.1</label><title>Whole genomic data</title><p id="p0145">The WGS data from the MayoRNAseq study were utilized in this study. All samples passed data QC as described. Based on the phenotypic information provided, the samples were diagnosed according to the NINCDS-ADRDA criteria and the neuropathologic evaluation <xref rid="bib55" ref-type="bibr">[55]</xref>. All individuals diagnosed with AD had an empirical diagnosis and were in Braak NFT stage IV or greater. For the control subjects, their Braak NFT stage was III or less, and they exhibited CERAD neuritic and cortical plaque densities of 0 (none) or 1 (sparse). Additionally, the control group did not have any other pathological diagnosis that could potentially confound the AD-related results. We selected samples with a description of white and a diagnosis of AD or control for the following analysis. The genotype profile data of the selected samples were then processed into the format required for gene expression prediction and PRS analysis using plink 1.9 <xref rid="bib56" ref-type="bibr">[56]</xref>. Referring to Below et al. <xref rid="bib39" ref-type="bibr">[39]</xref>, we performed PCA using plink software and examined the underlying population structure using the Tracy&#8211;Widom statistic of the EIGENSOFT software package.</p></sec><sec id="sec0055"><label>4.2</label><title>Genome-wide gene expression prediction</title><p id="p0150">The gene expression patterns in different brain regions of individuals were assessed based on GReX approach from the MetaXcan project (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://github.com/hakyimlab/MetaXcan" id="ir0055">https://github.com/hakyimlab/MetaXcan</ext-link>) <xref rid="bib22" ref-type="bibr">[22]</xref>. To achieve this, we combined the genotype data of MayoRNAseq and eQTL data of GTEx (v8) to establish associations between gene expression and genetic variation in 14 brain regions through linear regression modeling. Subsequently, we used the GReX model with its default parameters to calculate the gene expression in these brain regions. Pairwise correlations between brain regions were calculated using the average gene expression for each region. In addition, the correlation between predicted expression and RNA-seq expression was calculated by the Spearman method using RNA-seq data of the cerebellum region from MayoRNA cohort.</p></sec><sec id="sec0060"><label>4.3</label><title>Gene-pathway association collection and ssGSVA</title><p id="p0155">We build a comprehensive, yet non-redundant, knowledge base that integrates established, manually curated biological pathways with broader, interaction-based networks to maximize our discovery potential for complex diseases like AD. We integrated the mapping relationships between pathways and genes from several authoritative databases. Since the pathway data were collected in various formats, we converted them into the list format necessary for conducting ssGSVA. First, we filtered out pathways from various databases that encompassed multiple species, including PathBank (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pathbank.org/" id="ir0060">https://pathbank.org/</ext-link>) <xref rid="bib32" ref-type="bibr">[32]</xref>, DAVID (v.2022q2) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://david.ncifcrf.gov/" id="ir0065">https://david.ncifcrf.gov/</ext-link>) <xref rid="bib27" ref-type="bibr">[27]</xref>, NetPath (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://netpath.org/" id="ir0070">http://netpath.org/</ext-link>) <xref rid="bib29" ref-type="bibr">[29]</xref>, Reactome (v81) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://reactome.org/" id="ir0075">https://reactome.org/</ext-link>) <xref rid="bib28" ref-type="bibr">[28]</xref>, WikiPathways (v.20220710) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://classic.wikipathways.org/index.php/" id="ir0080">https://classic.wikipathways.org/index.php/</ext-link>) <xref rid="bib31" ref-type="bibr">[31]</xref>, GSEA (MSigDB v7.5.1) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.gsea-msigdb.org/gsea/index.jsp" id="ir0085">https://www.gsea-msigdb.org/gsea/index.jsp</ext-link>) <xref rid="bib26" ref-type="bibr">[26]</xref>, and PANTHER (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.pantherdb.org/" id="ir0090">http://www.pantherdb.org/</ext-link>) <xref rid="bib30" ref-type="bibr">[30]</xref>. Only the human pathways were exclusively selected for further analysis. Second, all gene names or IDs were converted to Ensembl gene IDs. Pathway names were organized in the format of type &#8764; ID &#8764; term (e.g., GOBP &#8764; GO:0000002 &#8764; mitochondrial genome maintenance). Some pathways were in type &#8764; term format if they did not have IDs. Additionally, same pathway in different databases was updated to the latest version. Finally, the curated data were organized into lists of gene sets for ssGSVA. We integrated the pathway information into the Rdata format and stored them at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://github.com/BFGBgroup/Pathway/blob/main/geneSets.Rdata" id="ir0095">https://github.com/BFGBgroup/Pathway/blob/main/geneSets.Rdata</ext-link>. The R package &#8216;GSVA&#8217; was used to calculate the score of each pathway in different brain regions for individuals. The number of expressed genes in the pathways was first determined, and pathways containing more than 1 gene or more than 1 and less than 301 genes were further screened.</p></sec><sec id="sec0065"><label>4.4</label><title>PRS analysis</title><p id="p0160">The GWAS summary statistics data used in this study were obtained from the research of Jansen <italic toggle="yes">et al.</italic>, including 71,880 AD cases and 383,378 controls <xref rid="bib33" ref-type="bibr">[33]</xref>. The data were downloaded from a public database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://ctg.cncr.nl/software/summary_statistics/" id="ir0100">https://ctg.cncr.nl/software/summary_statistics/</ext-link>). For PRS analysis, standard quality control of GWAS summary data and genotype profile data was performed according to the guidelines for PRS analysis <xref rid="bib57" ref-type="bibr">[57]</xref>. PRScs was then used to calculate the posterior SNP effect size for each chromosome, and the output files from all chromosomes were concatenated <xref rid="bib58" ref-type="bibr">[58]</xref>. The 1000 Genomes Project phase 3 European subset was employed as the LD reference panel <xref rid="bib59" ref-type="bibr">[59]</xref>. Finally, the individual-level polygenic score was generated using plink 1.9 <xref rid="bib56" ref-type="bibr">[56]</xref>. Correlations between PRS and phenotypes (AD/control, Braak NFT stage, Thal) were calculated using the Spearman method.</p></sec><sec id="sec0070"><label>4.5</label><title>Correlation analysis between PRS and ssGSVA score</title><p id="p0165">The Shapiro-Wilk test was used to assess the normality of pathway ssGSVA scores. Prior to analysis, outliers were adjusted using the winsor function from the R package psych. The R package &#8216;HHG&#8217; was employed to calculate the correlation between ssGSVA scores and PRS <xref rid="bib34" ref-type="bibr">[34]</xref>, <xref rid="bib35" ref-type="bibr">[35]</xref>. To identify pathways significantly associated with the PRS and to correct for multiple comparisons, an adaptive permutation procedure was employed. Specifically, for each pathway, 1000 to 10,000 permutations were performed by randomizing the PRS and ssGSVA scores. The procedure for a given pathway was stopped once the observed <italic toggle="yes">P</italic> value was exceeded by at least 15 permuted <italic toggle="yes">P</italic> values. The threshold for each pathway was determined as follows: First, the empirical <italic toggle="yes">P</italic> value of each pathway was defined as the ratio of occurrences of extreme events (permuted <italic toggle="yes">P</italic> values smaller than the nominal <italic toggle="yes">P</italic> value) to the total number of permutations. Then, for each brain region, the empirical <italic toggle="yes">P</italic> values were corrected to empirical q-values using Storey's approach. The empirical <italic toggle="yes">P</italic> value that corresponded to the empirical q-value closest to 0.05 was selected. Finally, the threshold for each pathway was set as the nth permuted <italic toggle="yes">P</italic> value in ascending order, where n represents the ceiling integer of multiplying the selected empirical <italic toggle="yes">P</italic> value for the brain region by the number of permutations for each pathway.</p></sec><sec id="sec0075"><label>4.6</label><title>SEM analysis</title><p id="p0170">To quantitatively investigate the interactions among multiple pathways, we conducted a SEM analysis. Because factor analysis in SEM does not allow for identical variables, we temporarily randomly excluded pathways with identical ssGSVA scores from the analysis. It's important to note that the pathways temporarily excluded from the model input were not discarded from our overall interpretation. First, we used SPSS software (V26.0) to determine the relationship between pathways and factors. Specifically, we obtained the factor loading matrix using principal component analysis (PCA). The number of factors extracted was based on those with eigenvalues greater than 1. We examined the factor loading coefficients in the rotated factor matrix, and variables with inadequate loadings were removed. Specifically, variables were deleted if their loadings on different factors were all below 0.6. This deletion process was repeated until all variables had meaningful associations with the factors. Additionally, factors with only one variable were removed.</p><p id="p0175">Subsequently, the model was constructed and evaluated using LISREL software (V8.7). The model was built based on the Spearman correlation coefficient matrix between pathways and the correspondence between pathways and factors. Modification indices were used to guide the model development. Model improvements were made by considering these indices and the significance of loadings. Specifically, the standard error of the loading of the pathway within their respective factors was considered significant (generally t value &gt;2), and the modification indices for the pathways in other factors remained relatively low. Once the model was finalized, we added the pathways that were temporarily excluded from the model input back to the model results.</p></sec><sec id="sec0080"><label>4.7</label><title>Validation with literature evidence</title><p id="p0180">We manually retrieved and summarized AD-related pathways from the literature that were validated by high-throughput data analysis or experiments. To determine the association between identified pathways and AD, we performed an extensive manual literature review. This process involved systematic searches in databases including PubMed and Google Scholar, using keywords such as the pathway name, its critical genes, and Alzheimer's Disease. We defined an association based on published evidence directly linking a pathway to AD or strong evidence linking its key genes to other established AD-related genes or pathways. To ensure the reliability of our findings, all curated associations were independently reviewed and confirmed by multiple team members. These correlations were classified as direct, indirect, or unrelated. "Direct" refers to a direct association of the pathway or factors within the pathway with AD. "Indirect" means the pathway or its factors are correlated with a specific feature that is linked to AD. Other pathways were deemed unrelated to AD.</p></sec></sec><sec id="sec0085"><title>CRediT authorship contribution statement</title><p id="p0185"><bold>Jia Wang:</bold> Validation. <bold>Yijie He:</bold> Visualization, Resources, Data curation. <bold>Yaqin Tang:</bold> Visualization, Software, Resources. <bold>Yongheng Wang:</bold> Writing &#8211; original draft, Resources, Investigation, Formal analysis, Data curation. <bold>Yingxiong Wang:</bold> Supervision, Conceptualization. <bold>Taihang Liu:</bold> Visualization, Methodology, Investigation, Formal analysis, Data curation. <bold>Zhijie Han:</bold> Writing &#8211; review &amp; editing, Validation, Supervision, Methodology, Investigation, Formal analysis, Conceptualization. <bold>Lin Huang:</bold> Visualization, Validation, Conceptualization. <bold>Dongyu Huang:</bold> Visualization. <bold>Pengcheng Tan:</bold> Visualization, Validation, Software. <bold>Zeng Jie:</bold> Visualization, Resources. <bold>Tong Wen:</bold> Visualization. <bold>Lizhen Shao:</bold> Validation.</p></sec><sec id="sec0090"><title>Consent statement</title><p id="p0190">The study procedures received approval from the Chongqing Medical University Institutional Review Board.</p></sec><sec id="sec0095"><title>Funding</title><p id="p0195">This research is financially supported by the <funding-source id="spnsr1">Science and Technology Research Program of National Natural Science Foundation of China</funding-source> (Grant No. <award-id award-type="grant" rid="spnsr1">32200446</award-id>), <funding-source id="spnsr2">CQMU Program for Youth Innovation in Future Medicine</funding-source> (Grant No. <award-id award-type="grant" rid="spnsr2">W0147</award-id>), and <funding-source id="spnsr3"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100007957</institution-id><institution>Chongqing Municipal Education Commission</institution></institution-wrap></funding-source> (Grant No. <award-id award-type="grant" rid="spnsr3">KJQN202100402</award-id>).</p></sec><sec sec-type="COI-statement" id="coi0005"><title>Declaration of Competing Interest</title><p id="p0200">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="bibliog0005"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sbref1"><person-group person-group-type="author"><name name-style="western"><surname>Gatz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Fratiglioni</surname><given-names>L.</given-names></name><name name-style="western"><surname>Johansson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mortimer</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Berg</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Role of genes and environments for explaining Alzheimer disease</article-title><source>Arch Gen Psychiatry</source><volume>63</volume><issue>2</issue><year>2006</year><fpage>168</fpage><lpage>174</lpage><pub-id pub-id-type="pmid">16461860</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archpsyc.63.2.168</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sbref2"><person-group person-group-type="author"><name name-style="western"><surname>Sherrington</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rogaev</surname><given-names>E.I.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Rogaeva</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Levesque</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Cloning of a gene bearing missense mutations in early-onset familial Alzheimer&#8217;s disease</article-title><source>Nature</source><volume>375</volume><issue>6534</issue><year>1995</year><fpage>754</fpage><lpage>760</lpage><pub-id pub-id-type="pmid">7596406</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/375754a0</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sbref3"><person-group person-group-type="author"><name name-style="western"><surname>Rovelet-Lecrux</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hannequin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Raux</surname><given-names>G.</given-names></name><name name-style="western"><surname>Le Meur</surname><given-names>N.</given-names></name><name name-style="western"><surname>Laquerriere</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vital</surname><given-names>A.</given-names></name><etal/></person-group><article-title>APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy</article-title><source>Nat Genet</source><volume>38</volume><issue>1</issue><year>2006</year><fpage>24</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">16369530</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng1718</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sbref4"><person-group person-group-type="author"><name name-style="western"><surname>Levy-Lahad</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wasco</surname><given-names>W.</given-names></name><name name-style="western"><surname>Poorkaj</surname><given-names>P.</given-names></name><name name-style="western"><surname>Romano</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Oshima</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pettingell</surname><given-names>W.H.</given-names></name><etal/></person-group><article-title>Candidate gene for the chromosome 1 familial Alzheimer&#8217;s disease locus</article-title><source>Science</source><volume>269</volume><issue>5226</issue><year>1995</year><fpage>973</fpage><lpage>977</lpage><pub-id pub-id-type="pmid">7638622</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.7638622</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sbref5"><person-group person-group-type="author"><name name-style="western"><surname>Corder</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Saunders</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Risch</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Strittmatter</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Schmechel</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Gaskell</surname><given-names>P.C.</given-names><suffix>Jr.</suffix></name><etal/></person-group><article-title>Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease</article-title><source>Nat Genet</source><volume>7</volume><issue>2</issue><year>1994</year><fpage>180</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">7920638</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng0694-180</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sbref6"><person-group person-group-type="author"><name name-style="western"><surname>Hall</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bandres-Ciga</surname><given-names>S.</given-names></name><name name-style="western"><surname>Diez-Fairen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Quinn</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Billingsley</surname><given-names>K.J.</given-names></name></person-group><article-title>Genetic risk profiling in parkinson's disease and utilizing genetics to gain insight into disease-related biological pathways</article-title><source>Int J Mol Sci</source><volume>21</volume><issue>19</issue><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms21197332</pub-id><pub-id pub-id-type="pmcid">PMC7584037</pub-id><pub-id pub-id-type="pmid">33020390</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sbref7"><person-group person-group-type="author"><name name-style="western"><surname>Bellenguez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kucukali</surname><given-names>F.</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>I.E.</given-names></name><name name-style="western"><surname>Kleineidam</surname><given-names>L.</given-names></name><name name-style="western"><surname>Moreno-Grau</surname><given-names>S.</given-names></name><name name-style="western"><surname>Amin</surname><given-names>N.</given-names></name><etal/></person-group><article-title>New insights into the genetic etiology of Alzheimer&#8217;s disease and related dementias</article-title><source>Nat Genet</source><volume>54</volume><issue>4</issue><year>2022</year><fpage>412</fpage><lpage>436</lpage><pub-id pub-id-type="pmid">35379992</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-022-01024-z</pub-id><pub-id pub-id-type="pmcid">PMC9005347</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sbref8"><person-group person-group-type="author"><name name-style="western"><surname>Ray</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ruan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name></person-group><article-title>Variations in the transcriptome of alzheimer's disease reveal molecular networks involved in cardiovascular diseases</article-title><source>Genome Biol</source><volume>9</volume><issue>10</issue><year>2008</year><object-id pub-id-type="publisher-id">R148</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/gb-2008-9-10-r148</pub-id><pub-id pub-id-type="pmcid">PMC2760875</pub-id><pub-id pub-id-type="pmid">18842138</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sbref9"><person-group person-group-type="author"><name name-style="western"><surname>Raj</surname><given-names>T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.I.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>G.</given-names></name><name name-style="western"><surname>Humphrey</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ramdhani</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Integrative transcriptome analyses of the aging brain implicate altered splicing in Alzheimer&#8217;s disease susceptibility</article-title><source>Nat Genet</source><volume>50</volume><issue>11</issue><year>2018</year><fpage>1584</fpage><lpage>1592</lpage><pub-id pub-id-type="pmid">30297968</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-018-0238-1</pub-id><pub-id pub-id-type="pmcid">PMC6354244</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sbref10"><person-group person-group-type="author"><name name-style="western"><surname>Walker</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fornage</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Proteomics analysis of plasma from middle-aged adults identifies protein markers of dementia risk in later life</article-title><source>Sci Transl Med</source><volume>15</volume><issue>705</issue><year>2023</year><fpage>eadf5681</fpage><pub-id pub-id-type="pmid">37467317</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.adf5681</pub-id><pub-id pub-id-type="pmcid">PMC10665113</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sbref11"><person-group person-group-type="author"><name name-style="western"><surname>Modeste</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Ping</surname><given-names>L.</given-names></name><name name-style="western"><surname>Watson</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Duong</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Dammer</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>E.C.B.</given-names></name><etal/></person-group><article-title>Quantitative proteomics of cerebrospinal fluid from African Americans and Caucasians reveals shared and divergent changes in Alzheimer&#8217;s disease</article-title><source>Mol Neurodegener</source><volume>18</volume><issue>1</issue><year>2023</year><fpage>48</fpage><pub-id pub-id-type="pmid">37468915</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-023-00638-z</pub-id><pub-id pub-id-type="pmcid">PMC10355042</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sbref12"><article-title>2023 alzheimer's disease facts and figures</article-title><source>Alzheimers Dement</source><volume>19</volume><issue>4</issue><year>2023</year><fpage>1598</fpage><lpage>1695</lpage><pub-id pub-id-type="pmid">36918389</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13016</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sbref13"><person-group person-group-type="author"><name name-style="western"><surname>Head</surname><given-names>E.</given-names></name><name name-style="western"><surname>Corrada</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Kahle-Wrobleski</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Sarsoza</surname><given-names>F.</given-names></name><name name-style="western"><surname>Goodus</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Synaptic proteins, neuropathology and cognitive status in the oldest-old</article-title><source>Neurobiol Aging</source><volume>30</volume><issue>7</issue><year>2009</year><fpage>1125</fpage><lpage>1134</lpage><pub-id pub-id-type="pmid">18006193</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2007.10.001</pub-id><pub-id pub-id-type="pmcid">PMC7295175</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sbref14"><person-group person-group-type="author"><name name-style="western"><surname>Kraemer</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Schultz</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Arndt</surname><given-names>S.</given-names></name></person-group><article-title>Biomarkers in psychiatry: methodological issues</article-title><source>Am J Geriatr Psychiatry</source><volume>10</volume><issue>6</issue><year>2002</year><fpage>653</fpage><lpage>659</lpage><pub-id pub-id-type="pmid">12427574</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sbref15"><person-group person-group-type="author"><name name-style="western"><surname>Farh</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Marson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kleinewietfeld</surname><given-names>M.</given-names></name><name name-style="western"><surname>Housley</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Beik</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Genetic and epigenetic fine mapping of causal autoimmune disease variants</article-title><source>Nature</source><volume>518</volume><issue>7539</issue><year>2015</year><fpage>337</fpage><lpage>343</lpage><pub-id pub-id-type="pmid">25363779</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature13835</pub-id><pub-id pub-id-type="pmcid">PMC4336207</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sbref16"><person-group person-group-type="author"><name name-style="western"><surname>Bulik-Sullivan</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Loh</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Finucane</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Ripke</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><etal/><collab>Schizophrenia Working Group of the Psychiatric Genomics C</collab></person-group><article-title>LD Score regression distinguishes confounding from polygenicity in genome-wide association studies</article-title><source>Nat Genet</source><volume>47</volume><issue>3</issue><year>2015</year><fpage>291</fpage><lpage>295</lpage><pub-id pub-id-type="pmid">25642630</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.3211</pub-id><pub-id pub-id-type="pmcid">PMC4495769</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sbref17"><person-group person-group-type="author"><name name-style="western"><surname>Finucane</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Bulik-Sullivan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gusev</surname><given-names>A.</given-names></name><name name-style="western"><surname>Trynka</surname><given-names>G.</given-names></name><name name-style="western"><surname>Reshef</surname><given-names>Y</given-names></name><name name-style="western"><surname>Loh</surname><given-names>PR</given-names></name><etal/></person-group><article-title>Partitioning heritability by functional annotation using genome-wide association summary statistics</article-title><source>Nat Genet</source><volume>47</volume><issue>11</issue><year>2015</year><fpage>1228</fpage><lpage>1235</lpage><pub-id pub-id-type="pmid">26414678</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.3404</pub-id><pub-id pub-id-type="pmcid">PMC4626285</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sbref18"><person-group person-group-type="author"><name name-style="western"><surname>de Leeuw</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Mooij</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Heskes</surname><given-names>T.</given-names></name><name name-style="western"><surname>Posthuma</surname><given-names>D.</given-names></name></person-group><article-title>Magma: generalized gene-set analysis of gwas data</article-title><source>PLoS Comput Biol</source><volume>11</volume><issue>4</issue><year>2015</year><object-id pub-id-type="publisher-id">e1004219</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pcbi.1004219</pub-id><pub-id pub-id-type="pmcid">PMC4401657</pub-id><pub-id pub-id-type="pmid">25885710</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sbref19"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Garcia-Gonzalez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ruan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Porras</surname><given-names>C.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>J.</given-names></name><etal/></person-group><article-title>PRSet: Pathway-based polygenic risk score analyses and software</article-title><source>PLoS Genet</source><volume>19</volume><issue>2</issue><year>2023</year><object-id pub-id-type="publisher-id">e1010624</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pgen.1010624</pub-id><pub-id pub-id-type="pmcid">PMC9937466</pub-id><pub-id pub-id-type="pmid">36749789</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sbref20"><person-group person-group-type="author"><name name-style="western"><surname>Barbeira</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Dickinson</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Bonazzola</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wheeler</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Torres</surname><given-names>J.M.</given-names></name><etal/></person-group><article-title>Exploring the phenotypic consequences of tissue specific gene expression variation inferred from GWAS summary statistics</article-title><source>Nat Commun</source><volume>9</volume><issue>1</issue><year>2018</year><fpage>1825</fpage><pub-id pub-id-type="pmid">29739930</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-018-03621-1</pub-id><pub-id pub-id-type="pmcid">PMC5940825</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sbref21"><article-title>Consortium GT. The gtex consortium Atlas of genetic regulatory effects across human tissues</article-title><source>Science</source><volume>369</volume><issue>6509</issue><year>2020</year><fpage>1318</fpage><lpage>1330</lpage><pub-id pub-id-type="pmid">32913098</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aaz1776</pub-id><pub-id pub-id-type="pmcid">PMC7737656</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sbref22"><person-group person-group-type="author"><name name-style="western"><surname>Gamazon</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Wheeler</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Mozaffari</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>Aquino-Michaels</surname><given-names>K.</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>R.J.</given-names></name><etal/></person-group><article-title>A gene-based association method for mapping traits using reference transcriptome data</article-title><source>Nat Genet</source><volume>47</volume><issue>9</issue><year>2015</year><fpage>1091</fpage><lpage>1098</lpage><pub-id pub-id-type="pmid">26258848</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.3367</pub-id><pub-id pub-id-type="pmcid">PMC4552594</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sbref23"><person-group person-group-type="author"><name name-style="western"><surname>Hanzelmann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Castelo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Guinney</surname><given-names>J.</given-names></name></person-group><article-title>Gsva: gene set variation analysis for microarray and rna-seq data</article-title><source>BMC Bioinforma</source><volume>14</volume><year>2013</year><fpage>7</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-2105-14-7</pub-id><pub-id pub-id-type="pmcid">PMC3618321</pub-id><pub-id pub-id-type="pmid">23323831</pub-id></element-citation></ref><ref id="bib24"><label>24</label><mixed-citation publication-type="other" id="othref0005">Heller R., Heller Y., Gorfine M.J.B. A consistent multivariate test of association based on ranks of distances. 2013;100(2):503-510.</mixed-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sbref24"><person-group person-group-type="author"><name name-style="western"><surname>Qi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Identifying gene targets for brain-related traits using transcriptomic and methylomic data from blood</article-title><source>Nat Commun</source><volume>9</volume><issue>1</issue><year>2018</year><fpage>2282</fpage><pub-id pub-id-type="pmid">29891976</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-018-04558-1</pub-id><pub-id pub-id-type="pmcid">PMC5995828</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sbref25"><person-group person-group-type="author"><name name-style="western"><surname>Subramanian</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tamayo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mootha</surname><given-names>V.K.</given-names></name><name name-style="western"><surname>Mukherjee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ebert</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Gillette</surname><given-names>M.A.</given-names></name><etal/></person-group><article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>Proc Natl Acad Sci U S A</source><volume>102</volume><issue>43</issue><year>2005</year><fpage>15545</fpage><lpage>15550</lpage><pub-id pub-id-type="pmid">16199517</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0506580102</pub-id><pub-id pub-id-type="pmcid">PMC1239896</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sbref26"><person-group person-group-type="author"><name name-style="western"><surname>Sherman</surname><given-names>B.T.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Baseler</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Lane</surname><given-names>H.C.</given-names></name><etal/></person-group><article-title>a web server for functional enrichment analysis and functional annotation of gene lists (2021 update)</article-title><source>Nucleic Acids Res</source><volume>50</volume><issue>W1</issue><year>2022</year><fpage>W216</fpage><lpage>W221</lpage><pub-id pub-id-type="pmid">35325185</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkac194</pub-id><pub-id pub-id-type="pmcid">PMC9252805</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sbref27"><person-group person-group-type="author"><name name-style="western"><surname>Gillespie</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jassal</surname><given-names>B.</given-names></name><name name-style="western"><surname>Stephan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Milacic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rothfels</surname><given-names>K.</given-names></name><name name-style="western"><surname>Senff-Ribeiro</surname><given-names>A.</given-names></name><etal/></person-group><article-title>The reactome pathway knowledgebase 2022</article-title><source>Nucleic Acids Res</source><volume>50</volume><issue>D1</issue><year>2022</year><fpage>D687</fpage><lpage>D692</lpage><pub-id pub-id-type="pmid">34788843</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkab1028</pub-id><pub-id pub-id-type="pmcid">PMC8689983</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sbref28"><person-group person-group-type="author"><name name-style="western"><surname>Kandasamy</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mohan</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Raju</surname><given-names>R.</given-names></name><name name-style="western"><surname>Keerthikumar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Venugopal</surname><given-names>A.K.</given-names></name><etal/></person-group><article-title>NetPath: a public resource of curated signal transduction pathways</article-title><source>Genome Biol</source><volume>11</volume><issue>1</issue><year>2010</year><fpage>R3</fpage><pub-id pub-id-type="pmid">20067622</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/gb-2010-11-1-r3</pub-id><pub-id pub-id-type="pmcid">PMC2847715</pub-id></element-citation></ref><ref id="bib30"><label>30</label><mixed-citation publication-type="other" id="othref0010">Thomas PD, Ebert D, Muruganujan A, Mushayahama T, Albou LP, Mi H. PANTHER: Making genome-scale phylogenetics accessible to all. Protein Sci 2022;31(1):8-22.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/pro.4218</pub-id><pub-id pub-id-type="pmcid">PMC8740835</pub-id><pub-id pub-id-type="pmid">34717010</pub-id></mixed-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sbref29"><person-group person-group-type="author"><name name-style="western"><surname>Slenter</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Kutmon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hanspers</surname><given-names>K.</given-names></name><name name-style="western"><surname>Riutta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Windsor</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nunes</surname><given-names>N.</given-names></name><etal/></person-group><article-title>WikiPathways: a multifaceted pathway database bridging metabolomics to other omics research</article-title><source>Nucleic Acids Res</source><volume>46</volume><issue>D1</issue><year>2018</year><fpage>D661</fpage><lpage>D667</lpage><pub-id pub-id-type="pmid">29136241</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkx1064</pub-id><pub-id pub-id-type="pmcid">PMC5753270</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sbref30"><person-group person-group-type="author"><name name-style="western"><surname>Wishart</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Marcu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Badran</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pon</surname><given-names>A</given-names></name><name name-style="western"><surname>Budinski</surname><given-names>Z</given-names></name><etal/></person-group><article-title>PathBank: a comprehensive pathway database for model organisms</article-title><source>Nucleic Acids Res</source><volume>48</volume><issue>D1</issue><year>2020</year><fpage>D470</fpage><lpage>D478</lpage><pub-id pub-id-type="pmid">31602464</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkz861</pub-id><pub-id pub-id-type="pmcid">PMC6943071</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sbref31"><person-group person-group-type="author"><name name-style="western"><surname>Jansen</surname><given-names>I.E.</given-names></name><name name-style="western"><surname>Savage</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bryois</surname><given-names>J.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Steinberg</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer&#8217;s disease risk</article-title><source>Nat Genet</source><volume>51</volume><issue>3</issue><year>2019</year><fpage>404</fpage><lpage>413</lpage><pub-id pub-id-type="pmid">30617256</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-018-0311-9</pub-id><pub-id pub-id-type="pmcid">PMC6836675</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sbref32"><person-group person-group-type="author"><name name-style="western"><surname>Heller</surname><given-names>R.</given-names></name><name name-style="western"><surname>Heller</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gorfine</surname><given-names>M.J.B.</given-names></name></person-group><article-title>A consistent multivariate test of association based on ranks of distances</article-title><source>Biometrika</source><volume>100</volume><issue>2</issue><year>2013</year><fpage>503</fpage><lpage>510</lpage></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sbref33"><person-group person-group-type="author"><name name-style="western"><surname>de Siqueira Santos</surname><given-names>S.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>D.Y.</given-names></name><name name-style="western"><surname>Nakata</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fujita</surname><given-names>A.</given-names></name></person-group><article-title>A comparative study of statistical methods used to identify dependencies between gene expression signals</article-title><source>Brief Bioinform</source><volume>15</volume><issue>6</issue><year>2014</year><fpage>906</fpage><lpage>918</lpage><pub-id pub-id-type="pmid">23962479</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bib/bbt051</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sbref34"><person-group person-group-type="author"><name name-style="western"><surname>Schaefer</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Anthony</surname><given-names>K.</given-names></name><name name-style="western"><surname>Krupa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Buchoff</surname><given-names>J.</given-names></name><name name-style="western"><surname>Day</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hannay</surname><given-names>T.</given-names></name><etal/></person-group><article-title>PID: the Pathway Interaction Database</article-title><source>Nucleic Acids Res</source><year>2009</year><comment>37 (Database issue) D674-9.</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkn653</pub-id><pub-id pub-id-type="pmcid">PMC2686461</pub-id><pub-id pub-id-type="pmid">18832364</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sbref35"><person-group person-group-type="author"><name name-style="western"><surname>Aguirre</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rubio</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Gallo</surname><given-names>V.</given-names></name></person-group><article-title>Notch and egfr pathway interaction regulates neural stem cell number and self-renewal</article-title><source>Nature</source><volume>467</volume><issue>7313</issue><year>2010</year><fpage>323</fpage><lpage>327</lpage><pub-id pub-id-type="pmid">20844536</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature09347</pub-id><pub-id pub-id-type="pmcid">PMC2941915</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sbref36"><person-group person-group-type="author"><name name-style="western"><surname>Collister</surname><given-names>K.A.</given-names></name></person-group><article-title>Albensi BC. Potential therapeutic targets in the nf-kappab pathway for alzheimer's disease</article-title><source>Drug N Perspect</source><volume>18</volume><issue>10</issue><year>2005</year><fpage>623</fpage><lpage>629</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1358/dnp.2005.18.10.959576</pub-id><pub-id pub-id-type="pmid">16491164</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sbref37"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Petty</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Sha</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kuzma</surname><given-names>A.</given-names></name><name name-style="western"><surname>Valladares</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Genetically regulated expression in late-onset Alzheimer&#8217;s disease implicates risk genes within known and novel loci</article-title><source>Transl Psychiatry</source><volume>11</volume><issue>1</issue><year>2021</year><fpage>618</fpage><pub-id pub-id-type="pmid">34873149</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41398-021-01677-0</pub-id><pub-id pub-id-type="pmcid">PMC8648734</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sbref38"><article-title>Consortium GT. Human genomics. The genotype-tissue expression (gtex) pilot analysis: multitissue gene regulation in humans</article-title><source>Science</source><volume>348</volume><issue>6235</issue><year>2015</year><fpage>648</fpage><lpage>660</lpage><pub-id pub-id-type="pmid">25954001</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1262110</pub-id><pub-id pub-id-type="pmcid">PMC4547484</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sbref39"><person-group person-group-type="author"><name name-style="western"><surname>Parrish</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Epstein</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name></person-group><article-title>Tigar-v2: efficient twas tool with nonparametric Bayesian eqtl weights of 49 tissue types from gtex v8</article-title><source>HGG Adv</source><volume>3</volume><issue>1</issue><year>2022</year><object-id pub-id-type="publisher-id">100068</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xhgg.2021.100068</pub-id><pub-id pub-id-type="pmcid">PMC8756507</pub-id><pub-id pub-id-type="pmid">35047855</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sbref40"><person-group person-group-type="author"><name name-style="western"><surname>Heppner</surname><given-names>F.L.</given-names></name><name name-style="western"><surname>Ransohoff</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Becher</surname><given-names>B.</given-names></name></person-group><article-title>Immune attack: the role of inflammation in alzheimer disease</article-title><source>Nat Rev Neurosci</source><volume>16</volume><issue>6</issue><year>2015</year><fpage>358</fpage><lpage>372</lpage><pub-id pub-id-type="pmid">25991443</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrn3880</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sbref41"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y.Q.</given-names></name><name name-style="western"><surname>Tu</surname><given-names>J.</given-names></name></person-group><article-title>Autophagy in alzheimer's disease pathogenesis: therapeutic potential and future perspectives</article-title><source>Ageing Res Rev</source><volume>72</volume><year>2021</year><object-id pub-id-type="publisher-id">101464</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2021.101464</pub-id><pub-id pub-id-type="pmid">34551326</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sbref42"><person-group person-group-type="author"><name name-style="western"><surname>Hung</surname><given-names>C.</given-names></name><name name-style="western"><surname>Livesey</surname><given-names>F.J.</given-names></name></person-group><article-title>Endolysosome and autophagy dysfunction in alzheimer disease</article-title><source>Autophagy</source><volume>17</volume><issue>11</issue><year>2021</year><fpage>3882</fpage><lpage>3883</lpage><pub-id pub-id-type="pmid">34429033</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15548627.2021.1963630</pub-id><pub-id pub-id-type="pmcid">PMC8632268</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sbref43"><person-group person-group-type="author"><name name-style="western"><surname>Kerr</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Adriaanse</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Greig</surname><given-names>N.H.</given-names></name><name name-style="western"><surname>Mattson</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Cader</surname><given-names>M.Z.</given-names></name><name name-style="western"><surname>Bohr</surname><given-names>V.A.</given-names></name><etal/></person-group><article-title>Mitophagy and Alzheimer&#8217;s Disease: Cellular and Molecular Mechanisms</article-title><source>Trends Neurosci</source><volume>40</volume><issue>3</issue><year>2017</year><fpage>151</fpage><lpage>166</lpage><pub-id pub-id-type="pmid">28190529</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tins.2017.01.002</pub-id><pub-id pub-id-type="pmcid">PMC5341618</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sbref44"><person-group person-group-type="author"><name name-style="western"><surname>Sanford</surname><given-names>S.A.I.</given-names></name><name name-style="western"><surname>McEwan</surname><given-names>W.A.</given-names></name></person-group><article-title>Type-I interferons in alzheimer's disease and other tauopathies</article-title><source>Front Cell Neurosci</source><volume>16</volume><year>2022</year><object-id pub-id-type="publisher-id">949340</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fncel.2022.949340</pub-id><pub-id pub-id-type="pmcid">PMC9334774</pub-id><pub-id pub-id-type="pmid">35910253</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sbref45"><person-group person-group-type="author"><name name-style="western"><surname>Dou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>G.</given-names></name></person-group><article-title>Roles of traf6 in central nervous system</article-title><source>Curr Neuropharmacol</source><volume>16</volume><issue>9</issue><year>2018</year><fpage>1306</fpage><lpage>1313</lpage><pub-id pub-id-type="pmid">29651950</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1570159X16666180412094655</pub-id><pub-id pub-id-type="pmcid">PMC6251041</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sbref46"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>C.</given-names></name></person-group><article-title>Alteration of scaffold: possible role of macf1 in alzheimer's disease pathogenesis</article-title><source>Med Hypotheses</source><volume>130</volume><year>2019</year><object-id pub-id-type="publisher-id">109259</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mehy.2019.109259</pub-id><pub-id pub-id-type="pmid">31383338</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sbref47"><person-group person-group-type="author"><name name-style="western"><surname>Cavallini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brewerton</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bell</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sargent</surname><given-names>S.</given-names></name><name name-style="western"><surname>Glover</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hardy</surname><given-names>C.</given-names></name><etal/></person-group><article-title>An unbiased approach to identifying tau kinases that phosphorylate tau at sites associated with Alzheimer disease</article-title><source>J Biol Chem</source><volume>288</volume><issue>32</issue><year>2013</year><fpage>23331</fpage><lpage>23347</lpage><pub-id pub-id-type="pmid">23798682</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M113.463984</pub-id><pub-id pub-id-type="pmcid">PMC3743503</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sbref48"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>V.S.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Boersema</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Low</surname><given-names>T.Y.</given-names></name><name name-style="western"><surname>Karthaus</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>Gerlach</surname><given-names>J.P.</given-names></name><etal/></person-group><article-title>Wnt signaling through inhibition of beta-catenin degradation in an intact Axin1 complex</article-title><source>Cell</source><volume>149</volume><issue>6</issue><year>2012</year><fpage>1245</fpage><lpage>1256</lpage><pub-id pub-id-type="pmid">22682247</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2012.05.002</pub-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sbref49"><person-group person-group-type="author"><name name-style="western"><surname>Tapia-Rojas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Inestrosa</surname><given-names>N.C.</given-names></name></person-group><article-title>Loss of canonical wnt signaling is involved in the pathogenesis of alzheimer's disease</article-title><source>Neural Regen Res</source><volume>13</volume><issue>10</issue><year>2018</year><fpage>1705</fpage><lpage>1710</lpage><pub-id pub-id-type="pmid">30136680</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/1673-5374.238606</pub-id><pub-id pub-id-type="pmcid">PMC6128062</pub-id></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sbref50"><person-group person-group-type="author"><name name-style="western"><surname>Salminen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ojala</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kaarniranta</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hiltunen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Soininen</surname><given-names>H.</given-names></name></person-group><article-title>Hsp90 regulates tau pathology through co-chaperone complexes in alzheimer's disease</article-title><source>Prog Neurobiol</source><volume>93</volume><issue>1</issue><year>2011</year><fpage>99</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">21056617</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pneurobio.2010.10.006</pub-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sbref51"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Genetic regulation of lncRNA expression in whole human brain and their contribution to CNS disorders</article-title><source>Brief Bioinform</source><volume>26</volume><issue>3</issue><year>2025</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bib/bbaf291</pub-id><pub-id pub-id-type="pmcid">PMC12205935</pub-id><pub-id pub-id-type="pmid">40542816</pub-id></element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sbref52"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>W.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>F.</given-names></name></person-group><article-title>Identification of key long non-coding rnas in the pathology of alzheimer's disease and their functions based on genome-wide associations study, microarray, and rna-seq data</article-title><source>J Alzheimers Dis</source><volume>68</volume><issue>1</issue><year>2019</year><fpage>339</fpage><lpage>355</lpage><pub-id pub-id-type="pmid">30776002</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-181051</pub-id></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sbref53"><person-group person-group-type="author"><name name-style="western"><surname>McKhann</surname><given-names>G.</given-names></name><name name-style="western"><surname>Drachman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Folstein</surname><given-names>M.</given-names></name><name name-style="western"><surname>Katzman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Price</surname><given-names>D.</given-names></name><name name-style="western"><surname>Stadlan</surname><given-names>E.M.</given-names></name></person-group><article-title>Clinical diagnosis of Alzheimer&#8217;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#8217;s Disease</article-title><source>Neurology</source><volume>34</volume><issue>7</issue><year>1984</year><fpage>939</fpage><lpage>944</lpage><pub-id pub-id-type="pmid">6610841</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.34.7.939</pub-id></element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="sbref54"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Chow</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Tellier</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Vattikuti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Purcell</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.J.</given-names></name></person-group><article-title>Second-generation PLINK: rising to the challenge of larger and richer datasets</article-title><source>Gigascience</source><volume>4</volume><issue>7</issue><year>2015</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13742-015-0047-8</pub-id><pub-id pub-id-type="pmcid">PMC4342193</pub-id><pub-id pub-id-type="pmid">25722852</pub-id></element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sbref55"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Mak</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>O'Reilly</surname><given-names>P.F.</given-names></name></person-group><article-title>Tutorial: a guide to performing polygenic risk score analyses</article-title><source>Nat Protoc</source><volume>15</volume><issue>9</issue><year>2020</year><fpage>2759</fpage><lpage>2772</lpage><pub-id pub-id-type="pmid">32709988</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41596-020-0353-1</pub-id><pub-id pub-id-type="pmcid">PMC7612115</pub-id></element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="sbref56"><person-group person-group-type="author"><name name-style="western"><surname>Ge</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Ni</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Y.A.</given-names></name><name name-style="western"><surname>Smoller</surname><given-names>J.W.</given-names></name></person-group><article-title>Polygenic prediction via Bayesian regression and continuous shrinkage priors</article-title><source>Nat Commun</source><volume>10</volume><issue>1</issue><year>2019</year><fpage>1776</fpage><pub-id pub-id-type="pmid">30992449</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-019-09718-5</pub-id><pub-id pub-id-type="pmcid">PMC6467998</pub-id></element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="sbref57"><person-group person-group-type="author"><name name-style="western"><surname>Genomes Project</surname><given-names>C.</given-names></name><name name-style="western"><surname>Auton</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>Durbin</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Garrison</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>H.M.</given-names></name><etal/></person-group><article-title>A global reference for human genetic variation</article-title><source>Nature</source><volume>526</volume><issue>7571</issue><year>2015</year><fpage>68</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">26432245</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature15393</pub-id><pub-id pub-id-type="pmcid">PMC4750478</pub-id></element-citation></ref></ref-list><bio><p><bold>Yongheng Wang, Dr.</bold> Title: Postdoctoral Researcher Research Interests: Utilizing bioinformatics approaches to investigate the molecular mechanisms of complex human diseases, primarily through integrating and analyzing large-scale multi-omics data to uncover the pathogenesis of neurological and reproductive system disorders.</p></bio><bio><p><bold>Taihang Liu, Dr.</bold> Title: Associate Researcher Research Interests: Primarily engaged in research on the etiology and mechanisms of placental-derived disorders within reproductive biology.</p></bio><bio><p><bold>Yijie He, M.S.</bold> Title: Doctoral Candidate Research Interests: Applying bioinformatic approaches to study multi-omics regulation (eQTL, lncRNA, SNP) in the nervous system.</p></bio><bio><p><bold>Yaqin Tang, M.S.</bold> Title: Lecturer Research Interests: Utilizing bioinformatics to investigate multi-omics regulatory mechanisms in the nervous system.</p></bio><bio><p><bold>Pengcheng Tan, M.S.</bold> Title: Lecturer Research Interests: Research and development of bioinformatics tools and databases.</p></bio><bio><p><bold>Lin Huang, M.S.</bold> Title: Doctoral Candidate Research Interests: Applying bioinformatic approaches to study multi-omics regulation (GWAS, pQTL, scRNA) in the nervous system.</p></bio><bio><p><bold>Dongyu Huang, M.S.</bold> Research Interests: Applying bioinformatic approaches to study multi-omics regulation (GWAS, eQTL, scRNA) in the nervous system.</p></bio><bio><p><bold>Tong Wen, M.S.</bold> Research Interests: Investigating the disease regulatory mechanisms of Alzheimer's Disease through large-scale single-cell omics sequencing.</p></bio><bio><p><bold>Lizhen Shao, M.S.</bold> Title: Doctoral Candidate Research Interests: Integrating large-scale single-cell sequencing to study disease regulatory mechanisms.</p></bio><bio><p><bold>Jia Wang, M.S.</bold> Research Interests: Applying bioinformatic approaches to study multi-omics regulation in the nervous system.</p></bio><bio><p><bold>Yingxiong Wang, Dr.</bold> Title: Professor Research Interests: Primarily engaged in investigating the molecular mechanisms of embryo implantation and development, as well as the pathogenesis of birth defects.</p></bio><bio><p><bold>Zhijie Han, Dr.</bold> Title: Associate Professor Research Interests: Employing bioinformatics approaches to investigate the pathogenesis of central nervous system (CNS) disorders at genomic and transcriptomic levels, with parallel development of novel algorithms, tools, and databases to address related biological questions. Google Scholar&#65306;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://scholar.google.com/citations?hl=zhCN&amp;user=rnIERmUAAAAJ" id="ir0110">https://scholar.google.com/citations?hl=zhCN&amp;user=rnIERmUAAAAJ</ext-link></p></bio><sec id="sec0105" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary material</title><p id="p0215">
<supplementary-material content-type="local-data" id="ec0005" position="float" orientation="portrait"><caption><p>Supplementary material</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.xlsx" position="float" orientation="portrait"/></supplementary-material>
</p></sec><sec sec-type="data-availability" id="da0005"><title>Data Availability</title><p id="p0025">The data used in this study include MayoRNAseq whole-genome sequencing variant call formats (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.synapse.org/#!Synapse:syn11724002" id="ir0005">https://www.synapse.org/#!Synapse:syn11724002</ext-link>), models of gene expression for use in GReX (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://zenodo.org/records/3842289#.YrvrM7FBVYA" id="ir0010">https://zenodo.org/records/3842289#.YrvrM7FBVYA</ext-link>), and genome-wide summary statistics: (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://ctg.cncr.nl/software/summary_statistics/" id="ir0015">https://ctg.cncr.nl/software/summary_statistics/</ext-link>).</p><p id="p0030">We used publicly available software for all analyses, including Plink 1.9 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cog-genomics.org/plink2/" id="ir0020">https://www.cog-genomics.org/plink2/</ext-link>), PRScs (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://github.com/getian107/PRScs" id="ir0025">https://github.com/getian107/PRScs</ext-link>), PRS tutorial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://choishingwan.github.io/PRS-Tutorial" id="ir0030">https://choishingwan.github.io/PRS-Tutorial</ext-link>), and MetaXcan (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://github.com" id="ir0035">https://github.com</ext-link> /hakyimlab/PrediXcan and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://github.com/hakyimlab/MetaXcan/wiki/Individual-level-PrediXcan:-introduction,-tutorials-and-manual" id="ir0040">https://github.com/hakyimlab/MetaXcan/wiki/Individual-level-PrediXcan:-introduction,-tutorials-and-manual</ext-link>).</p><p id="p0035">Our framework is stored in Github: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://github.com/BFGBgroup/Pathway/tree/main" id="ir0045">https://github.com/BFGBgroup/Pathway/tree/main</ext-link>.</p></sec><ack id="ack0005"><title>Acknowledgements</title><p id="p0205">Authors would like to thank the Dr. Nil&#252;fer Ertekin-Taner who leads MayoRNAseq study. The results published here are in whole or in part based on MayoRNAseq data obtained from the AD Knowledge Portal. We also thank the Supercomputer Center of Chongqing Medical University for their computing power and technical support.</p></ack><fn-group><fn id="sec0100" fn-type="supplementary-material"><label>Appendix A</label><p id="p0210">Supplementary data associated with this article can be found in the online version at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.csbj.2025.09.013" id="ir0105">doi:10.1016/j.csbj.2025.09.013</ext-link>.</p></fn></fn-group></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Radiol Adv</journal-id><journal-id journal-id-type="iso-abbrev">Radiol Adv</journal-id><journal-id journal-id-type="pmc-domain-id">4788</journal-id><journal-id journal-id-type="pmc-domain">radadv</journal-id><journal-id journal-id-type="publisher-id">radadv</journal-id><journal-title-group><journal-title>Radiology Advances</journal-title></journal-title-group><issn pub-type="epub">2976-9337</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12429267</article-id><article-id pub-id-type="pmcid-ver">PMC12429267.1</article-id><article-id pub-id-type="pmcaid">12429267</article-id><article-id pub-id-type="pmcaiid">12429267</article-id><article-id pub-id-type="pmid">41059393</article-id><article-id pub-id-type="doi">10.1093/radadv/umae019</article-id><article-id pub-id-type="publisher-id">umae019</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject><subj-group subj-group-type="category-toc-heading"><subject>Neuroradiology</subject></subj-group></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00870</subject></subj-group></article-categories><title-group><article-title>Deep learning-based amyloid PET harmonization to predict cognitive decline in non-demented elderly</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6034-9912</contrib-id><name name-style="western"><surname>Choi</surname><given-names initials="YS">Yoon Seong</given-names></name><degrees>MD, PhD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft">Writing - original draft</role><aff><institution>Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore</institution>, Singapore 119074, <country country="SG">Singapore</country></aff><aff><institution>Clinical Imaging Research Centre, Yong Loo Lin School of Medicine, National University of Singapore</institution>, Singapore 117599, <country country="SG">Singapore</country></aff><xref rid="umae019-cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ngam</surname><given-names initials="PI">Pei Ing</given-names></name><degrees>MBBS</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing">Writing - review &amp; editing</role><aff><institution>Department of Diagnostic Imaging, National University Health System</institution>, Singapore 119074, <country country="SG">Singapore</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names initials="JR">Jeong Ryong</given-names></name><degrees>BS</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology">Methodology</role><aff><institution>Medical Artificial Intelligence Lab, School of Electrical and Electronic Engineering, Yonsei University</institution>, Seoul 03722, <country country="KR">Korea</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hwang</surname><given-names initials="D">Dosik</given-names></name><degrees>PhD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization">Visualization</role><aff><institution>Medical Artificial Intelligence Lab, School of Electrical and Electronic Engineering, Yonsei University</institution>, Seoul 03722, <country country="KR">Korea</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2977-9743</contrib-id><name name-style="western"><surname>Tan</surname><given-names initials="EK">Eng-King</given-names></name><degrees>MD, PhD</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing">Writing - review &amp; editing</role><aff><institution>National Neuroscience Institute, Duke NUS Medical School</institution>, Singapore 169857, <country country="SG">Singapore</country></aff></contrib><contrib contrib-type="author"><collab>for the Harvard Aging Brain Study</collab></contrib><contrib contrib-type="author"><collab>for the Australian Imaging Biomarkers and Lifestyle Study of Aging</collab></contrib><contrib contrib-type="author"><collab>for the Japanese Alzheimer&#8217;s Disease Neuroimaging Initiative</collab></contrib><contrib contrib-type="author"><collab>for the Alzheimer&#8217;s Disease Neuroimaging Initiative</collab></contrib></contrib-group><author-notes><corresp id="umae019-cor1">Corresponding author: Yoon Seong Choi, MD, PhD, Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, MD 6 Basement, National University of Singapore, 14 Medical Dr, Singapore 117599, Singapore (<email>yoonseong.choi07@gmail.com</email>)</corresp></author-notes><pub-date pub-type="collection"><month>7</month><year>2024</year></pub-date><pub-date pub-type="epub" iso-8601-date="2024-08-06"><day>06</day><month>8</month><year>2024</year></pub-date><volume>1</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">496793</issue-id><elocation-id>umae019</elocation-id><history><date date-type="received"><day>05</day><month>2</month><year>2024</year></date><date date-type="rev-recd"><day>02</day><month>6</month><year>2024</year></date><date date-type="accepted"><day>08</day><month>7</month><year>2024</year></date><date date-type="corrected-typeset"><day>29</day><month>8</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>06</day><month>08</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>07</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 16:25:24.343"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2024. Published by Oxford University Press on behalf of the Radiological Society of North America.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="umae019.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="umae019.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>The robustness of conventional amyloid PET harmonization across tracers has been questioned.</p></sec><sec id="s2"><title>Purpose</title><p>To evaluate deep learning-based harmonization of amyloid PET in predicting conversion from cognitively unimpaired (CU) to mild cognitive impairment (MCI) and MCI to Alzheimer&#8217;s disease (AD).</p></sec><sec id="s3"><title>Materials and Methods</title><p>We developed an amyloid PET-based deep-learning model to classify participants with a clinical diagnosis of AD-dementia vs CU across different tracers from the Alzheimer&#8217;s Disease Neuroimaging Initiative (ADNI), Japanese ADNI, and Australian Imaging, Biomarker, and Lifestyle cohorts (<italic toggle="yes">n</italic>&#8201;=&#8201;1050). The model output [deep learning-based probability of Alzheimer&#8217;s disease-dementia (DL-ADprob)], with other prognostic factors, was evaluated for predicting cognitive decline in ADNI-MCI (<italic toggle="yes">n</italic>&#8201;=&#8201;451) and Harvard Aging Brain Study (HABS)-CU (<italic toggle="yes">n</italic>&#8201;=&#8201;271) participants using Cox regression and area under time-dependent receiver operating characteristics curve (tdAUC) at 4-year follow-up. Subgroup analyses were performed in the ADNI-MCI group for conversion from amyloid-positive to AD and from amyloid negative to positive. Intraclass correlation coefficient (ICC) of DL-ADprob between tracers was calculated in the Global Alzheimer&#8217;s Association Interactive Network dataset (<italic toggle="yes">n</italic>&#8201;=&#8201;155).</p></sec><sec id="s4"><title>Results</title><p>DL-ADprob was independently prognostic in both ADNI-MCI (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;.001) and HABS-CU (<italic toggle="yes">P</italic>&#8201;=&#8201;.048) sets. Adding DL-ADprob to other factors increased prognostic performances in both ADNI-MCI (tdAUC 0.758 [0.721-0.792] vs 0.782 [0.742-0.818], tdAUC difference 0.023 [0.007-0.038]) and HABS-CU (tdAUC 0.846 [0.755-0.925] vs 0.870 [0.773-0.943], tdAUC difference 0.022 [&#8722;0.004 to 0.053]). DL-ADprob was independently prognostic in amyloid-positive (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;.001) and amyloid-negative subgroups (<italic toggle="yes">P</italic>&#8201;=&#8201;.007). DL-ADprob showed incremental prognostic value in amyloid-positive (tdAUC 0.666 [0.623-0.713] vs 0.706 [0.657-0.755], tdAUC difference 0.039 [0.016-0.064]), but not in amyloid-negative (tdAUC 0.818 [0.757-0.882] vs 0.816 [0.751-0.880], tdAUC difference &#8722;0.002 [&#8722;0.031 to 0.029]) subgroup. The pairwise ICCs of DL-ADprob between Pittsburgh compound B and florbetapir, florbetaben, and flutemetamol, respectively, ranged from 0.913 to 0.935.</p></sec><sec id="s5"><title>Conclusion</title><p>Deep learning-based harmonization of amyloid PET improves cognitive decline prediction in non-demented elderly, suggesting it could complement conventional amyloid PET measures.</p></sec></abstract><kwd-group><kwd>Alzheimer&#8217;s disease</kwd><kwd>amyloid PET</kwd><kwd>deep learning</kwd><kwd>prognosis</kwd><kwd>cognitive decline</kwd><kwd>cognitive impairment</kwd><kwd>dementia</kwd></kwd-group><funding-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Samsung Research Funding Center of Samsung Electronics</institution></institution-wrap></funding-source><award-id>SRFC-TF2103-01</award-id></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>National Research Foundation of Korea</institution><institution-id institution-id-type="DOI">10.13039/501100003725</institution-id></institution-wrap></funding-source></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Korea government</institution></institution-wrap></funding-source><award-id>2022-31-0220</award-id></award-group></funding-group><counts><page-count count="8"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text id="umae019-BOX1" position="float" orientation="portrait"><label>Abbreviations</label><p>AD = Alzheimer&#8217;s disease; ADNI = Alzheimer&#8217;s disease neuroimaging initiative; AIBL = Australian Imaging Biomarkers and Lifestyle; CU = cognitively unimpaired elderly; DL-ADprob = the probability of AD from the amyloid PET-based deep learning model; HABS = Harvard Aging Brain Study; J-ADNI = Japanese Alzheimer&#8217;s Disease Neuroimaging Initiative; MCI = mild cognitive impairment; SUVR = standardized uptake value ratio; tdAUC = area under the time-dependent receiver operating characteristics curve</p><p>
<bold>Summary</bold>
</p><p>Deep learning-based amyloid PET harmonization across various tracers improves the prediction of cognitive decline in non-demented elderly individuals beyond conventional amyloid PET and MRI measures and clinical characteristics.</p><p>
<bold>Key Results</bold>
</p><list list-type="bullet"><list-item><p>A deep learning (DL) model for amyloid PET harmonization identified Alzheimer&#8217;s disease (AD) disease-related patterns across tracers, providing the probability of AD-dementia.</p></list-item><list-item><p>The DL output showed independent and incremental prognostic value for predicting cognitive decline in non-demented elderly beyond conventional amyloid PET and MRI measures and clinical information, showing reliability across tracers.</p></list-item><list-item><p>The DL also showed independent and incremental prognostic value for predicting cognitive decline in the amyloid-positive subgroup.</p></list-item></list></boxed-text><sec sec-type="intro"><title>Introduction</title><p>Alzheimer&#8217;s disease (AD) is characterized by the accumulation of amyloid plaques and neurofibrillary tangles in the brain, which appear decades before symptoms appear.<xref rid="umae019-B1" ref-type="bibr"><sup>1&#8211;3</sup></xref> Amyloid PET imaging is a valuable method for visualizing and quantifying amyloid plaque accumulation in the brain as it offers spatial information about the distribution changes of amyloid plaques,<xref rid="umae019-B3" ref-type="bibr"><sup>3</sup></xref><sup>,</sup><xref rid="umae019-B4" ref-type="bibr"><sup>4</sup></xref> unlike cerebrospinal fluid and plasma assays that only provide overall estimates of amyloid level. Although dichotomous visual PET image reading is effective for advanced clinical subjects, quantification of amyloid plaque burden provides enhanced sensitivity and more detailed information across the AD continuum, particularly in the early stages of accumulation that may be visually occult.<xref rid="umae019-B5" ref-type="bibr"><sup>5</sup></xref><sup>,</sup><xref rid="umae019-B6" ref-type="bibr"><sup>6</sup></xref></p><p>Previous studies used quantitative amyloid PET measures to identify elderly individuals who are cognitively unimpaired (CU) or have mild cognitive impairment (MCI) but show positive AD biomarkers indicative of early AD.<xref rid="umae019-B7" ref-type="bibr"><sup>7&#8211;10</sup></xref> However, variations in processing and acquisition parameters introduce uncertainties, affecting measurement accuracy.<xref rid="umae019-B11" ref-type="bibr"><sup>11</sup></xref><sup>,</sup><xref rid="umae019-B12" ref-type="bibr"><sup>12</sup></xref> The widely used standardized uptake value ratio (SUVR) is affected by various factors such as choice of reference region and cortical region, imaging parameters, stability over time, and variations in hemodynamic biodistribution and non-specific bindings among different amyloid PET tracers.<xref rid="umae019-B11" ref-type="bibr"><sup>11</sup></xref><sup>,</sup><xref rid="umae019-B13" ref-type="bibr"><sup>13</sup></xref><sup>,</sup><xref rid="umae019-B14" ref-type="bibr"><sup>14</sup></xref> Additionally, SUVR values are not directly comparable across different amyloid tracers, limiting their utility for multicenter or longitudinal analysis.<xref rid="umae019-B15" ref-type="bibr"><sup>15</sup></xref> To address these limitations, the centiloid scale was proposed to provide a standardized measurement of amyloid burden. It harmonizes SUVR values by using linear transformations calibrated to a reference Pittsburgh Compound B (PiB)-based SUVR dataset.<xref rid="umae019-B15" ref-type="bibr"><sup>15</sup></xref> However, it has limitations, such as the need for scans of multiple tracers to establish the calibration equation for a new tracer and susceptibility to variability associated with SUVR, leading to the exploration of alternative methods to quantify and standardize amyloid plaque burden.<xref rid="umae019-B16" ref-type="bibr"><sup>16&#8211;18</sup></xref></p><p>We hypothesize that deep learning could provide an imaging biomarker that harmonizes different amyloid tracers to provide prognostic information beyond conventional amyloid PET measures. The goal was to improve the prediction of conversion from MCI to AD-dementia and from CU to MCI using a deep learning-based imaging biomarker. We leveraged multiple independent cohorts to develop an amyloid PET-based deep learning model that is applicable across different tracers and evaluate its prognostic value in non-demented elderly individuals. Our aim was to evaluate whether deep learning improves the prediction of cognitive decline beyond the conventional amyloid PET measures from different amyloid tracers in CU and MCI individuals across the clinical AD spectrum.</p></sec><sec><title>Materials and methods</title><sec><title>Study population</title><p>The enrollment process of the study populations is shown in <xref rid="umae019-F1" ref-type="fig">Figure&#160;1</xref>. Data used in this retrospective, Health Insurance Portability and Accountability Act-compliant study were obtained from the Alzheimer&#8217;s Disease Neuroimaging Initiative (ADNI, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://adni.loni.usc.edu" ext-link-type="uri">https://adni.loni.usc.edu</ext-link>), Australian Imaging Biomarkers and Lifestyle (AIBL, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://aibl.csiro.au" ext-link-type="uri">https://aibl.csiro.au</ext-link>),<xref rid="umae019-B19" ref-type="bibr"><sup>19</sup></xref> Japanese ADNI (J-ADNI, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.j-adni.org" ext-link-type="uri">https://www.j-adni.org</ext-link>),<xref rid="umae019-B20" ref-type="bibr"><sup>20</sup></xref> Harvard Aging Brain Study (HABS, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://habs.mgh.harvard.edu/" ext-link-type="uri">https://habs.mgh.harvard.edu/</ext-link>),<xref rid="umae019-B21" ref-type="bibr"><sup>21</sup></xref> and Global Alzheimer Association Interactive Network (GAAIN, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.gaain.org" ext-link-type="uri">http://www.gaain.org</ext-link>).<xref rid="umae019-B15" ref-type="bibr"><sup>15</sup></xref><sup>,</sup><xref rid="umae019-B22" ref-type="bibr"><sup>22</sup></xref><sup>,</sup><xref rid="umae019-B23" ref-type="bibr"><sup>23</sup></xref> Details of the datasets are provided in the <xref rid="sup1" ref-type="supplementary-material">Supplementary material</xref>. Approval was obtained by the institutional review boards of all participating sites. All participants provided written informed consent at the participating institutions.</p><fig position="float" id="umae019-F1" orientation="portrait"><label>Figure 1.</label><caption><p>Study population and design.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="umae019f1.jpg"/></fig><p>From the ADNI dataset, out of 2282 participants with baseline T1WI, those with a baseline diagnosis of subjective memory concern (<italic toggle="yes">n</italic>&#8201;=&#8201;320) or no amyloid PET scans (<italic toggle="yes">n</italic>&#8201;=&#8201;964) were excluded. Of 998 participants who had a baseline diagnosis of either CU, MCI, or AD-dementia and with baseline T1WIs and amyloid PET, 2 groups were enrolled: (1) ADNI AD-dementia/CU group (<italic toggle="yes">n</italic>&#8201;=&#8201;445) from individuals with AD-dementia and CU and (2) ADNI-MCI group (<italic toggle="yes">n</italic>&#8201;=&#8201;451) from individuals with MCI who had follow-up &#8805; 6&#8201;months, and complete baseline clinical profiles of age, sex, years of education, number of apolipoprotein E4 alleles, and Mini-Mental State Examination score. Participants with MCI who had incomplete baseline information (<italic toggle="yes">n</italic>&#8201;=&#8201;16) or follow-up &lt;6&#8201;months (<italic toggle="yes">n</italic>&#8201;=&#8201;86) were excluded.</p><p>In the AIBL dataset, 607 out of 847 individuals with baseline T1WI had baseline amyloid PET scans. After excluding individuals with missing amyloid PET tracer information (<italic toggle="yes">n</italic>&#8201;=&#8201;8), baseline diagnosis (<italic toggle="yes">n</italic>&#8201;=&#8201;3), or baseline diagnosis of MCI (<italic toggle="yes">n</italic>&#8201;=&#8201;95), individuals with AD-dementia and CU were enrolled as the AIBL AD-dementia/CU group (<italic toggle="yes">n</italic>&#8201;=&#8201;501).</p><p>In the J-ADNI dataset, 199 out of 536 individuals with baseline T1WI had baseline amyloid PET scans. After excluding individuals without a baseline diagnosis (<italic toggle="yes">n</italic>&#8201;=&#8201;1), those imaged with the non-FDA-approved amyloid PET tracer ([<sup>11</sup>C]BF-227, <italic toggle="yes">n</italic>&#8201;=&#8201;33), or baseline diagnosis of MCI (<italic toggle="yes">n</italic>&#8201;=&#8201;61), individuals with AD-dementia and CU were enrolled as the J-ADNI AD-dementia/CU group (<italic toggle="yes">n</italic>&#8201;=&#8201;104).</p><p>From the HABS dataset, 278 out of 291 individuals with baseline MRI had baseline amyloid PET scans. After excluding individuals initially diagnosed with MCI (<italic toggle="yes">n</italic>&#8201;=&#8201;3) and those with follow-up &lt;6&#8201;months (<italic toggle="yes">n</italic>&#8201;=&#8201;4), a total of 271 CU individuals were enrolled as the HABS-CU group. All the HABS-CU set participants had the same complete baseline clinical information as in the ADNI-MCI set.</p><p>Additionally, we enrolled individuals from the GAAIN dataset who underwent amyloid PET scans using multiple tracers (<italic toggle="yes">n</italic>&#8201;=&#8201;155) to test the reliability of the deep learning-based imaging marker across different tracers as described later.</p></sec><sec><title>Study design and deep learning model development</title><p>This study consisted of two main components (<xref rid="umae019-F1" ref-type="fig">Figure&#160;1</xref>). First, an amyloid-PET-based deep learning model of revised residual network for binary classification (<xref rid="sup1" ref-type="supplementary-material">Figure S1</xref>)<xref rid="umae019-B24" ref-type="bibr"><sup>24</sup></xref> was developed using the clinical diagnosis of AD-dementia vs CU as ground truth, and amyloid PET images resampled to a size of 72 &#215; 72 &#215; 72 matrix as input. The model output was a continuous scale from 0 to 1 of the sigmoid function after the last fully connected layer, with higher values indicating a greater probability of clinical AD-dementia, as previously used<xref rid="umae019-B25" ref-type="bibr"><sup>25</sup></xref> (hereafter, referred to as probability of AD-dementia [DL-ADprob]). For the applicability of the DL model across different tracers, the ADNI and AIBL AD-dementia/CU groups with different amyloid PET tracers were merged and semirandomly divided into ADNI/AIBL diagnostic development set (<italic toggle="yes">n</italic>&#8201;=&#8201;823) and diagnostic test set (<italic toggle="yes">n</italic>&#8201;=&#8201;123), while maintaining the same ratios of AD-dementia/CU, and amyloid PET tracers. The J-ADNI AD-dementia/CU set was used as the external diagnostic test set to test the model performance in classifying CU vs AD-dementia in different ethnicities and tracers. Saliency maps were generated using layer-wise relevance propagation.<xref rid="umae019-B26" ref-type="bibr"><sup>26</sup></xref> Second, the developed model was applied to amyloid PET images of ADNI-MCI and HABS-CU sets to obtain DL-ADprob. The prognostic value of DL-ADprob was assessed in the ADNI-MCI and HABS-CU sets to predict cognitive decline in a time-to-event manner, together with clinical information (age, gender, education, apolipoprotein E4, and Mini-Mental State Examination score), hippocampal volume from MRI, and centiloids or SUVR from amyloid PET. Cognitive decline was defined as MCI-to-AD-dementia conversion for ADNI-MCI set and CU-to-MCI conversion for HABS-CU set. Details of image processing, deep learning model development, and saliency map are provided in <xref rid="sup1" ref-type="supplementary-material">Supplementary Material</xref>.</p></sec><sec><title>Statistical analysis</title><p>Statistical tests were performed in R, version 4.1.0 (R Foundation for Statistical Computing). <italic toggle="yes">P</italic>&#8201;&lt;&#8201;.05 was considered statistically significant. Continuous variables are expressed as the mean &#177; standard deviation or the median (interquartile range), while categorial variables are presented as number (percentage).</p><p>Performances of DL-ADprob vs centiloid or SUVR in distinguishing AD-dementia from CU were assessed using area under receiver operating characteristics curve using the method by DeLong et al.<xref rid="umae019-B27" ref-type="bibr"><sup>27</sup></xref> DL-ADprob predictions of &#8805; 0.5 were classified as AD-dementia, otherwise considered CU for calculating accuracy.</p><p>The prognostic value of DL-ADprob for cognitive decline was analyzed along with other prognostic factors in 2 steps as follows: First, Cox regression analysis was performed to evaluate the independent prognostic value of DL-ADprob among other prognostic factors. Second, area under time-dependent receiver operating characteristics curves (tdAUC) was calculated for predicting cognitive decline at 4-year follow-up, to assess the incremental prognostic value of DL-ADprob beyond other prognostic factors. The tdAUCs were compared before and after adding DL-ADprob to other prognostic factors through 1000 iterations of resampling. The tdAUC difference was considered statistically different if its 95% confidence interval (95% CI) from resampling did not include zero. Additionally, subgroup analyses were performed in ADNI-MCI set for predicting MCI-to-AD-dementia conversion in amyloid-positive participants and amyloid-positive conversion in amyloid-negative participants.</p><p>The intraclass correlation coefficient (ICC) was calculated for DL-ADprob between PiB and other tracers (ie, florbetapir, florbetaben, and flutemetamol) in the GAAIN dataset, based on a single-rating, consistency, 2-way random-effects model.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Population characteristics</title><p>The number of CU and AD-dementia individuals from the ADNI, AIBL, and J-ADNI datasets were as follows: 254/191, 432/69, and 58/46, respectively (<xref rid="umae019-F1" ref-type="fig">Figure&#160;1</xref> and <xref rid="sup1" ref-type="supplementary-material">Table S1</xref>). The use of amyloid tracers varied across the datasets. The majority of ADNI participants used florbetapir (76.8% for CU, 83.8% for AD-dementia), while the rest used florbetaben. In AIBL, PiB was the primary tracer (41.2% for CU, 66.7% for AD-dementia), followed by flutemetamol (33.3% for CU, 23.2% for AD-dementia), and florbetapir (25.5% for CU, 10.1% for AD-dementia). In J-ADNI, PiB was the only tracer used (100% for both CU and AD-dementia).</p><p>Population characteristics for the ADNI-MCI (<italic toggle="yes">n</italic>&#8201;=&#8201;451), and HABS-CU (<italic toggle="yes">n</italic>&#8201;=&#8201;271) sets are summarized in <xref rid="umae019-T1" ref-type="table">Table&#160;1</xref>. The mean ages were 71.8&#8201;&#177;&#8201;7.4, and 73.6&#8201;&#177;&#8201;6.1&#8201;years, the male-to-female ratio was 255/196, and 109/162, and the median follow-up duration in years were 4.0 (2.0-6.6), and 5.0 (4.4-5.2) for the ADNI-MCI, and HABS-CU sets, respectively. In terms of progression of cognitive decline, 120 out of 451 (26.6%) in the ADNI-MCI set progressed, while 22 out of 271 (8.1%) in the HABS-CU set progressed. The median time to progression in years were 3.1 (1.5-5.0), and 5.0 (4.3-5.2) for the ADNI-MCI and HABS-CU sets, respectively. The ADNI-MCI set predominantly used florbetapir scans (91.6%), with a smaller percentage using florbetaben (8.4%), while the HABS-CU sets used only PiB.</p><table-wrap position="float" id="umae019-T1" orientation="portrait"><label>Table 1.</label><caption><p>Study population characteristics of the ADNI-MCI and HABS-CU sets used to assess the prognostic value of DL-ADprob.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">ADNI-MCI</th><th rowspan="1" colspan="1">HABS-CU</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<bold>Diagnosis at baseline</bold>
</td><td rowspan="1" colspan="1">MCI</td><td rowspan="1" colspan="1">CU</td></tr><tr><td rowspan="1" colspan="1">
<bold>Number of subjects</bold>
</td><td rowspan="1" colspan="1">451</td><td rowspan="1" colspan="1">271</td></tr><tr><td rowspan="1" colspan="1">
<bold>Age (mean &#177; SD)</bold>
</td><td rowspan="1" colspan="1">71.8&#8201;&#177;&#8201;7.4</td><td rowspan="1" colspan="1">73.6&#8201;&#177;&#8201;6.1</td></tr><tr><td rowspan="1" colspan="1">
<bold>Gender</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;<bold>Male</bold></td><td rowspan="1" colspan="1">255 (56.5%)</td><td rowspan="1" colspan="1">109 (40.2%)</td></tr><tr><td rowspan="1" colspan="1">&#8195;<bold>Female</bold></td><td rowspan="1" colspan="1">196 (43.5.%)</td><td rowspan="1" colspan="1">162 (59.8%)</td></tr><tr><td rowspan="1" colspan="1">
<bold>Education (in years, mean &#177; SD)</bold>
</td><td rowspan="1" colspan="1">16.2&#8201;&#177;&#8201;2.6</td><td rowspan="1" colspan="1">15.9&#8201;&#177;&#8201;3.0</td></tr><tr><td rowspan="1" colspan="1">
<bold>Number of apolipoprotein E4 alleles</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;<bold>0</bold></td><td rowspan="1" colspan="1">235 (52.1%)</td><td rowspan="1" colspan="1">194 (71.6%)</td></tr><tr><td rowspan="1" colspan="1">&#8195;<bold>1</bold></td><td rowspan="1" colspan="1">166 (36.8%)</td><td rowspan="1" colspan="1">73 (26.9%)</td></tr><tr><td rowspan="1" colspan="1">&#8195;<bold>2</bold></td><td rowspan="1" colspan="1">50 (11.1%)</td><td rowspan="1" colspan="1">4 (1.5%)</td></tr><tr><td rowspan="1" colspan="1">
<bold>Mini-mental state examination (mean &#177; SD)</bold>
</td><td rowspan="1" colspan="1">28.0&#8201;&#177;&#8201;1.8</td><td rowspan="1" colspan="1">29.0&#8201;&#177;&#8201;1.1</td></tr><tr><td rowspan="1" colspan="1">
<bold>Follow-up time (median and interquartile range in years)</bold>
</td><td rowspan="1" colspan="1">4.0 (2.0-6.6)</td><td rowspan="1" colspan="1">5.0 (4.4-5.2)</td></tr><tr><td rowspan="1" colspan="1">
<bold>Progressors</bold>
</td><td rowspan="1" colspan="1">120 (26.6%)</td><td rowspan="1" colspan="1">22 (8.1%)</td></tr><tr><td rowspan="1" colspan="1">
<bold>Time to progression (median and interquartile range in years)</bold>
</td><td rowspan="1" colspan="1">3.1 (1.5-5.8)</td><td rowspan="1" colspan="1">5.0 (4.3-5.2)</td></tr><tr><td rowspan="1" colspan="1">
<bold>Amyloid tracers</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;<bold>Florbetapir</bold></td><td rowspan="1" colspan="1">415 (91.6%)</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">&#8195;<bold>Florbetaben</bold></td><td rowspan="1" colspan="1">38 (8.4%)</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">&#8195;<bold>PiB</bold></td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">271 (100.0%)</td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><p>Abbreviations: ADNI = Alzheimer&#8217;s Disease Neuroimaging Initiative; APOE4 = apolipoprotein E4; CU = cognitively unimpaired; HABS = Harvard Aging Brain Study; MCI = mild cognitive impairment; MMSE = Mini-Mental State Examination; PiB = Pittsburgh compound B.</p></fn><fn id="tblfn2"><p>Continuous variables are expressed as the mean &#177; standard deviation or the median (interquartile range), while categorial variables are presented as number (percentage).</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Model performance in classifying AD-dementia vs CU individuals</title><p>Our amyloid PET-based deep learning model showed excellent performance in distinguishing between AD-dementia and CU individuals (<xref rid="sup1" ref-type="supplementary-material">Table S2</xref>), which outperformed centiloids in the ADNI/AIBL diagnostic test set (area under the receiver operating characteristic curve 0.996 [0.990-1.000] vs 0.881 [0.797-0.965], <italic toggle="yes">P</italic>&#8201;=&#8201;.006, accuracy 95.9% vs 87.0%, sensitivity 96.7% vs 89.3%, and specificity 93.9% vs 80.0% for DL-ADprob and centiloids, respectively), while showing a compatible diagnostic performance with SUVR in the J-ADNI diagnostic test set (area under the receiver operating characteristic curve 0.942 [0.891-0.992] vs 0.904 [0.844-0.964], <italic toggle="yes">P</italic>&#8201;=&#8201;.220, accuracy 88.5% vs 83.5%, sensitivity 94.2% vs 83.3%, and specificity 82.7% vs 83.7% for DL-ADprob and SUVR, respectively). In the tracer-specific subgroups of the ADNI/AIBL diagnostic test set, DL-ADprob was superior to or compatible with the diagnostic performance of centiloids (<xref rid="sup1" ref-type="supplementary-material">Table S2</xref>). On the saliency map, the top 10 cortical areas of the highest relevance consisted of inferior and middle temporal and inferior and middle frontal gyri, with the inferior frontal gyrus having the highest relevance, followed by the middle temporal gyrus (<xref rid="sup1" ref-type="supplementary-material">Figure S2</xref>).</p></sec><sec><title>Model performance in prognosis prediction</title><p>The Cox regression analysis results are summarized in <xref rid="umae019-T2" ref-type="table">Table&#160;2</xref>. DL-ADprob retained independent prognostic significance after adjusting for clinical information, hippocampal volume and conventional amyloid PET measures in both the ADNI-MCI (HR 3.40 [1.87-6.18], <italic toggle="yes">P</italic>&#8201;&lt;&#8201;.001) and HABS-CU sets (HR 3.55 [1.01-12.46], <italic toggle="yes">P</italic>&#8201;=&#8201;.048). The time-dependent receiver operating characteristics analysis results are summarized in <xref rid="umae019-T3" ref-type="table">Table&#160;3</xref> and <xref rid="umae019-F2" ref-type="fig">Figure&#160;2</xref>. 92 and 8 participants from the ADNI-MCI and HABS-CU, respectively, progressed at the 4-year follow-up. The addition of DL-ADprob to the other prognostic factors significantly improved prognostic performance in the ADNI-MCI set (tdAUC 0.758 [0.721-0.792] vs 0.782 [0.742-0.818], tdAUC difference 0.023 [0.007-0.038]). Similarly, adding DL-ADprob to other prognostic factors increased the tdAUC for predicting cognitive decline in the HABS-CU set (tdAUC 0.846 [0.755-0.925] vs 0.870 [0.773-0.943]), albeit not statistically significant (tdAUC difference 0.022 [&#8722;0.004 to 0.053]).</p><fig position="float" id="umae019-F2" orientation="portrait"><label>Figure 2.</label><caption><p>Prediction of cognitive decline with the DL-ADprob. Time-dependent receiver operating characteristics curves before and after adding DL-ADprob to the other prognostic factors in the ADNI-MCI for conversion from MCI to Alzheimer&#8217;s disease-dementia (A), and in the HABS-CU set for conversion from CU to MCI (B) at 4&#8201;years of follow-up.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="umae019f2.jpg"/></fig><table-wrap position="float" id="umae019-T2" orientation="portrait"><label>Table 2.</label><caption><p>Cox regression analyses with DL-ADprob and other prognostic factors for predicting cognitive decline and amyloid-positive conversion in the ADNI-MCI and HABS-CU sets.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="char" char="." span="1"/><col valign="top" align="char" char="." span="1"/><col valign="top" align="char" char="." span="1"/><col valign="top" align="char" char="." span="1"/><col valign="top" align="char" char="." span="1"/><col valign="top" align="char" char="." span="1"/><col valign="top" align="char" char="." span="1"/><col valign="top" align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th colspan="2" rowspan="1">ADNI-MCI<hr/></th><th colspan="2" rowspan="1">HABS-CU<hr/></th><th colspan="2" rowspan="1">ADNI-MCI-amyloid (+) subgroup<hr/></th><th colspan="2" rowspan="1">ADNI-MCI-amyloid (-) subgroup<hr/></th></tr><tr><th rowspan="1" colspan="1">Outcome</th><th colspan="2" rowspan="1">Cognitive decline<hr/></th><th colspan="2" rowspan="1">Cognitive decline<hr/></th><th colspan="2" rowspan="1">Cognitive decline<hr/></th><th colspan="2" rowspan="1">Amyloid-positive conversion<hr/></th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Hazard ratio (95% CI)</th><th rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th><th rowspan="1" colspan="1">Hazard ratio (95% CI)</th><th rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th><th rowspan="1" colspan="1">Hazard ratio (95% CI)</th><th rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th><th rowspan="1" colspan="1">Hazard ratio (95% CI)</th><th rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<bold>Age (years)</bold>
</td><td rowspan="1" colspan="1">1.00 (0.97-1.03)</td><td rowspan="1" colspan="1">.931</td><td rowspan="1" colspan="1">1.02 (0.93-1.11)</td><td rowspan="1" colspan="1">.702</td><td rowspan="1" colspan="1">0.99 (0.96-1.03)</td><td rowspan="1" colspan="1">.704</td><td rowspan="1" colspan="1">1.03 (0.97-1.09)</td><td rowspan="1" colspan="1">.288</td></tr><tr><td rowspan="1" colspan="1">
<bold>Gender</bold>
</td><td rowspan="1" colspan="1">0.84 (0.57-1.24)</td><td rowspan="1" colspan="1">.379</td><td rowspan="1" colspan="1">0.17 (0.05-0.61)</td><td rowspan="1" colspan="1">.007</td><td rowspan="1" colspan="1">0.77 (0.51-1.18)</td><td rowspan="1" colspan="1">.230</td><td rowspan="1" colspan="1">0.97 (0.43-2.19)</td><td rowspan="1" colspan="1">.949</td></tr><tr><td rowspan="1" colspan="1">
<bold>Education (years)</bold>
</td><td rowspan="1" colspan="1">1.02 (0.94-1.09)</td><td rowspan="1" colspan="1">.682</td><td rowspan="1" colspan="1">0.95 (0.81-1.11)</td><td rowspan="1" colspan="1">.523</td><td rowspan="1" colspan="1">1.05 (0.97-1.14)</td><td rowspan="1" colspan="1">.186</td><td rowspan="1" colspan="1">0.89 (0.75-1.05)</td><td rowspan="1" colspan="1">.173</td></tr><tr><td rowspan="1" colspan="1">
<bold>Apolipoprotein E4 status</bold>
</td><td rowspan="1" colspan="1">1.37 (1.05-1.79)</td><td rowspan="1" colspan="1">.021</td><td rowspan="1" colspan="1">0.77 (0.35-1.67)</td><td rowspan="1" colspan="1">.510</td><td rowspan="1" colspan="1">1.29 (0.96-1.72)</td><td rowspan="1" colspan="1">.088</td><td rowspan="1" colspan="1">3.52 (1.85-6.68)</td><td rowspan="1" colspan="1">&lt;.001</td></tr><tr><td rowspan="1" colspan="1">
<bold>Mini-mental state examination</bold>
</td><td rowspan="1" colspan="1">0.89 (0.80-0.98)</td><td rowspan="1" colspan="1">.019</td><td rowspan="1" colspan="1">0.70 (0.49-1.00)</td><td rowspan="1" colspan="1">.050</td><td rowspan="1" colspan="1">0.89 (0.80-0.99)</td><td rowspan="1" colspan="1">.032</td><td rowspan="1" colspan="1">1.09 (0.80-1.47)</td><td rowspan="1" colspan="1">.583</td></tr><tr><td rowspan="1" colspan="1">
<bold>Hippocampal volume</bold>
</td><td rowspan="1" colspan="1">0.48 (0.29-0.79)</td><td rowspan="1" colspan="1">.004</td><td rowspan="1" colspan="1">0.07 (0.01-0.48)</td><td rowspan="1" colspan="1">.006</td><td rowspan="1" colspan="1">0.52 (0.31-0.90)</td><td rowspan="1" colspan="1">.019</td><td rowspan="1" colspan="1">0.77 (0.34-1.73)</td><td rowspan="1" colspan="1">.525</td></tr><tr><td rowspan="1" colspan="1">
<bold>Centiloid or SUVR</bold>
</td><td rowspan="1" colspan="1">1.01 (1.01-1.02)</td><td rowspan="1" colspan="1">&lt;.001</td><td rowspan="1" colspan="1">18.23 (4.28-77.7)</td><td rowspan="1" colspan="1">&lt;.001</td><td rowspan="1" colspan="1">1.01 (1.00-1.01)</td><td rowspan="1" colspan="1">.034</td><td rowspan="1" colspan="1">1.13 (1.08-1.19)</td><td rowspan="1" colspan="1">&lt;.001</td></tr><tr><td rowspan="1" colspan="1">
<bold>DL-ADprob</bold>
</td><td rowspan="1" colspan="1">3.40 (1.87-6.18)</td><td rowspan="1" colspan="1">&lt;.001</td><td rowspan="1" colspan="1">3.55 (1.01-12.46)</td><td rowspan="1" colspan="1">.048</td><td rowspan="1" colspan="1">3.21 (1.68-6.13)</td><td rowspan="1" colspan="1">&lt;.001</td><td rowspan="1" colspan="1">6.64 (1.68-26.17)</td><td rowspan="1" colspan="1">.007</td></tr></tbody></table><table-wrap-foot><fn id="tblfn3"><p>Abbreviations: ADNI = Alzheimer&#8217;s Disease Neuroimaging Initiative; CU = cognitively unimpaired; DL-ADprob = deep learning-based probability of Alzheimer&#8217;s disease-dementia; HABS = Harvard Aging Brain Study; MCI = mild cognitive impairment; SUVR = standardized uptake value ratio.</p></fn><fn id="tblfn4"><p>The other prognostic factors included age, gender, years of education, number of apolipoprotein E4 alleles, mini-mental state examination score, hippocampal volume from MRI, and centiloid or SUVR from amyloid PET.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="umae019-T3" orientation="portrait"><label>Table 3.</label><caption><p>Time-dependent receiver operating characteristics analysis before and after adding DL-ADprob to other prognostic factors for predicting cognitive decline and amyloid-positive conversion at 4&#8201;years of follow-up in the ADNI-MCI and HABS-CU sets.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Dataset</th><th rowspan="1" colspan="1">Outcome</th><th rowspan="1" colspan="1">Predictors</th><th align="left" rowspan="1" colspan="1">tdAUC (95% CI)</th><th rowspan="1" colspan="1">tdAUC difference (95% CI)</th></tr></thead><tbody><tr><td rowspan="2" colspan="1">
<bold>ADNI-MCI</bold>
</td><td rowspan="2" colspan="1">Cognitive decline</td><td rowspan="1" colspan="1">Reference</td><td rowspan="1" colspan="1">0.758 (0.721-0.792)</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Reference + DL-ADprob</td><td rowspan="1" colspan="1">0.782 (0.742-0.818)</td><td rowspan="1" colspan="1">0.023 (0.007-0.038)</td></tr><tr><td rowspan="2" colspan="1">
<bold>HABS-CU</bold>
</td><td rowspan="2" colspan="1">Cognitive decline</td><td rowspan="1" colspan="1">Reference</td><td rowspan="1" colspan="1">0.846 (0.755-0.925)</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Reference + DL-ADprob</td><td rowspan="1" colspan="1">0.870 (0.773-0.943)</td><td rowspan="1" colspan="1">0.022 (&#8722;0.004 to 0.053)</td></tr><tr><td rowspan="2" colspan="1">
<bold>ADNI-MCI-amyloid(+) subgroup</bold>
</td><td rowspan="2" colspan="1">Cognitive decline</td><td rowspan="1" colspan="1">Reference</td><td rowspan="1" colspan="1">0.666 (0.623-0.713)</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Reference + DL-ADprob</td><td rowspan="1" colspan="1">0.706 (0.657-0.755)</td><td rowspan="1" colspan="1">0.039 (0.016-0.064)</td></tr><tr><td rowspan="2" colspan="1">
<bold>ADNI-MCI-amyloid(-) subgroup</bold>
</td><td rowspan="2" colspan="1">Amyloid-positive conversion</td><td rowspan="1" colspan="1">Reference</td><td rowspan="1" colspan="1">0.818 (0.757-0.882)</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Reference + DL-ADprob</td><td rowspan="1" colspan="1">0.816 (0.751-0.880)</td><td rowspan="1" colspan="1">&#8722;0.002 (&#8722;0.031 to 0.029)</td></tr></tbody></table><table-wrap-foot><fn id="tblfn5"><p>Abbreviations: ADNI = Alzheimer&#8217;s Disease Neuroimaging Initiative; CU = cognitively unimpaired; DL-ADprob = deep learning-based probability of Alzheimer&#8217;s disease-dementia; HABS = Harvard Aging Brain Study; MCI = mild cognitive impairment; tdAUC = time-dependent area under the receiver operating characteristics curve.</p></fn><fn id="tblfn6"><p>The other prognostic factors included age, gender, years of education, number of apolipoprotein E4 alleles, mini-mental state examination score, hippocampal volume from MRI, and centiloid or SUVR from amyloid PET.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Subgroup analysis according to amyloid positivity in the ADNI-MCI group</title><p>240 of 451 participants in the ADNI-MCI set were amyloid-positive, of whom 103 and 83 participants progressed to AD-dementia during the entire follow-up period and at 4&#8201;years, respectively. The remaining 211 participants in the ADNI-MCI set were amyloid-negative, of whom 28 and 21 converted to amyloid-positive during the entire follow-up period and at 4&#8201;years, respectively. In the amyloid positive group, the DL-ADprob remained independently prognostic in the Cox regression analysis (HR 3.21 [1.68-6.13], <italic toggle="yes">P</italic>&#8201;&lt;&#8201;.001, <xref rid="umae019-T2" ref-type="table">Table&#160;2</xref>), and showed significant incremental prognostic value in the time-dependent receiver operating characteristics analysis when added to other prognostic factors for predicting MCI-to-AD-dementia conversion (tdAUC 0.666 [0.623-0.713] vs 0.706 [0.657-0.755], tdAUC difference 0.039 [0.016-0.064], <xref rid="umae019-T3" ref-type="table">Table&#160;3</xref> and <xref rid="umae019-F3" ref-type="fig">Figure&#160;3</xref>). In the amyloid-negative group, DL-ADprob was independently prognostic in the Cox regression analysis (HR 6.64 [1.68-26.17], <italic toggle="yes">P</italic>&#8201;=&#8201;.007, <xref rid="umae019-T2" ref-type="table">Table&#160;2</xref>) but did not show incremental prognostic value for predicting future amyloid-positive conversion in the time-dependent receiver operating characteristics analysis when added to other prognostic factors (tdAUC 0.818 [0.757-0.882] vs 0.816 [0.751-0.880], tdAUC difference &#8722;0.002 [&#8722;0.031 to 0.029], <xref rid="umae019-T3" ref-type="table">Table&#160;3</xref> and <xref rid="umae019-F3" ref-type="fig">Figure&#160;3</xref>). Representative cases are shown in <xref rid="umae019-F4" ref-type="fig">Figure&#160;4</xref>.</p><fig position="float" id="umae019-F3" orientation="portrait"><label>Figure 3.</label><caption><p>Prediction of cognitive decline and amyloid-positive conversion with the DL-ADprob. Time-dependent receiver operating characteristics curves before and after adding DL-ADprob to the other prognostic factors for predicting conversion from mild cognitive impairment to Alzheimer&#8217;s disease-dementia in amyloid-positive participants (A), and for predicting amyloid-positive conversion in amyloid-negative participants (B) from the ADNI-MCI set at 4&#8201;years of follow-up.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="umae019f3.jpg"/></fig><fig position="float" id="umae019-F4" orientation="portrait"><label>Figure 4.</label><caption><p>Representative cases from the Alzheimer&#8217;s Disease (AD) Neuroimaging Initiative cohort. (A) Amyloid-positive participant with MCI [centiloid: 43, deep learning-based probability of AD-dementia (DL-ADprob): 0.960] who converted to AD-dementia after 1.0&#8201;years of follow-up. (B) Amyloid-positive participant with MCI (centiloid: 105, DL-ADprob: 0.788) who had stable MCI without conversion to AD-dementia during 5.1&#8201;years of the entire follow-up. (C) Amyloid-negative participant with MCI (centiloid: 12, DL-ADprob: 0.531) who converted to amyloid-positive after 2.0&#8201;years of follow-up. (D) Amyloid-negative participant with MCI (centiloid: 19, DL-ADprob: 0.009) who remained amyloid-negative during the entire 8.4&#8201;years of follow-up. (E) CU participant (centiloid: 2, DL-ADprob: 0.001). (F) Participant with AD-dementia (centiloid: 127, DL-ADprob: 0.981).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="umae019f4.jpg"/></fig></sec><sec><title>Reliability of DL-ADprob across different amyloid tracers</title><p>DL-ADprob showed excellent agreement among different amyloid tracers, with ICC of 0.913 (0.849-0.951) for PiB-florbetapir, 0.935 (0.876-0.967) for PiB-florbetaben, and 0.925 (0.884-0.952) for PiB-flutemetamol paired scans from the GAAIN dataset.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>We developed a deep learning-based imaging biomarker that harmonizes amyloid PET images from different tracers and found a distinct AD-dementia-related pattern. The deep learning-based imaging biomarker showed independent and incremental prognostic value over conventional amyloid PET measures, clinical information and hippocampal volume for predicting cognitive decline in MCI and CU individuals across different amyloid PET tracers. This biomarker also demonstrated independent prognostic value for predicting future amyloid-positive conversion in amyloid-negative participants.</p><p>The shift from diagnosing AD based on clinical symptoms to using amyloid, tau, and neurodegeneration (ATN) biomarkers underscores the importance of CU and MCI individuals as potential early stages of AD.<xref rid="umae019-B2" ref-type="bibr"><sup>2</sup></xref> Furthermore, recent FDA-approved disease-modifying treatments highlighted a potential for early intervention.<xref rid="umae019-B28" ref-type="bibr"><sup>28</sup></xref><sup>,</sup><xref rid="umae019-B29" ref-type="bibr"><sup>29</sup></xref> However, identifying candidates for early intervention remains challenging, due to the uncertain prognosis of future cognitive decline among CU and MCI individuals with positive amyloid burden.<xref rid="umae019-B30" ref-type="bibr"><sup>30</sup></xref> Additionally, there is debate regarding whether the ATN-dichotomous criterion, which uses single SUVR cut-offs to determine biomarker positivity, provides adequate prognostic data for CU and MCI individuals.<xref rid="umae019-B31" ref-type="bibr"><sup>31</sup></xref> This led to studies exploring continuous values of SUVR and centiloids from amyloid PET, rather than categorizing them as positive or negative, to identify high-risk individuals for future conversion to AD-dementia.<xref rid="umae019-B31" ref-type="bibr"><sup>31</sup></xref> However, we hypothesized that a deep learning model could extract even more prognostic information from amyloid PET beyond SUVR and centiloid values. While previous studies have employed deep learning to amyloid PET, their usage has primarily focused on enhancing the reliability of SUVR and centiloid measurements, such as automating image processing or synthesizing amyloid PET images from different tracers.<xref rid="umae019-B32" ref-type="bibr"><sup>32&#8211;34</sup></xref> These studies typically trained deep learning models using SUVR or centiloid scales as ground truths without directly considering clinical status on the AD spectrum.<xref rid="umae019-B32" ref-type="bibr"><sup>32&#8211;34</sup></xref> Instead, we trained the model using the two ends of the AD clinical spectrum, CU and AD-dementia as ground truths.</p><p>The excellent performance of the DL-ADprob in AD-dementia vs CU classification suggests its ability to detect a distinct pattern of amyloid plaque accumulation in AD that is consistent across different PET tracers and ethnicities. The independent and incremental prognostic value of DL-ADprob provides support for using this marker to complement conventional amyloid PET measures, MRI, and clinical information to predict cognitive decline in both MCI and CU individuals in a clinical setting. Notably, DL-ADprob showed both independent and incremental prognostic value for AD-dementia conversion in the amyloid-positive subgroup, and independent prognostic value for amyloid-positive conversion in the amyloid-negative subgroup. This illustrates that DL-ADprob has applicability for improving prognostic prediction in a multilayered follow-up strategy within the ATN framework. However, it only showed independent prognostic value, with no incremental value in predicting future amyloid-positive conversion when added to other prognostic factors. Future investigations are needed to tailor the prognostic capabilities of the deep learning-based imaging marker for the amyloid-negative elderly population.</p><p>Several limitations of this study warrant discussion. First, although the process of obtaining the DL-ADprob is fully automated, it still requires image processing and the availability of T1WI. By incorporating PET-only processing approaches proposed by previous studies,<xref rid="umae019-B35" ref-type="bibr"><sup>35</sup></xref> our method may become more feasible without the need for T1WIs. Second, in the ATN framework of AD, our study did not consider tau PET to represent the &#8220;T.&#8221; Third, the diagnostic value of DL-ADprob was assessed primarily in Caucasian and Japanese ethnicities; future research is needed to determine the prognostic value of DL-ADprob across more diverse ethnicities.</p><p>In conclusion, our amyloid PET-based deep learning model showed independent and incremental prognostic value over conventional amyloid PET measures and other prognostic factors for predicting cognitive decline in non-demented elderly individuals, with applicability across different amyloid tracers. The marker has the potential to complement conventional amyloid PET measures to improve and individualize prognostic predictions.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sup1" position="float" content-type="local-data" orientation="portrait"><label>umae019_Supplementary_Data</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="umae019_Supplementary_Data.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><sec><title>Author contributions</title><p>Yoon Seong Choi (Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing&#8212;original draft), Pei Ing Ngam (Conceptualization, Writing&#8212;review &amp; editing), Jeong Ryong Lee (Formal analysis, Methodology), Dosik Hwang (Conceptualization, Formal analysis, Methodology, Visualization), and Eng-King Tan (Conceptualization, Supervision, Writing&#8212;review &amp; editing)</p></sec><sec><title>Supplementary material</title><p><xref rid="sup1" ref-type="supplementary-material">Supplementary material</xref> is available at <italic toggle="yes">Radiology Advances</italic> online.</p></sec><sec><title>Funding</title><p>This study was supported by Samsung Research Funding Center of Samsung Electronics (SRFC-TF2103-01), the National Research Foundation of Korea grant funded by the Korea government (MSIT, 2022-31-0220), and Start-up Grant funded by National University of Singapore, Yong Loo Lin School of Medicine (A-0009827-01-00 and A-0009827-00-00).</p></sec><sec sec-type="COI-statement"><title>Conflicts of interest</title><p>Please see ICMJE form(s) for author conflicts of interest. These have been provided as <xref rid="sup1" ref-type="supplementary-material">supplementary materials</xref>. Nothing to disclose.</p></sec><sec sec-type="data-availability"><title>Data availability</title><p>Data used in preparation of this study were obtained from the Alzheimer&#8217;s Disease Neuroimaging Initiative (ADNI), Japanese Alzheimer&#8217;s Disease Neuroimaging Initiative (J-ADNI), Australian Imaging, Biomarker and Lifestyle Flagship Study of Ageing (AIBL) and the Harvard Aging Brain Study (HABS) databases, where the data can be obtained upon request.</p><p> The investigators of the ADNI, AIBL, J-ADNI and HABS contributed to the design and implementation of datasets and/or provided data but did not participate in analysis or writing of this article. A complete listing of investigators are listed at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf" ext-link-type="uri">http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf</ext-link> (ADNI), <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.aibl.csiro.au" ext-link-type="uri">https://www.aibl.csiro.au</ext-link> (AIBL study), <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://humandbs.biosciencedbc.jp/en/hum0043-j-adni-authors" ext-link-type="uri">https://humandbs.biosciencedbc.jp/en/hum0043-j-adni-authors</ext-link> (J-ADNI), and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://habs.mgh.harvard.edu/" ext-link-type="uri">https://habs.mgh.harvard.edu/</ext-link> (HABS).</p><p><bold>Data and code sharing:</bold> The data of this study are available with/without application through the portals of the databases. The deep learning model and code for DL-ADprob are available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/yoonchoi-neuro/amylPET_DL-ADprob" ext-link-type="uri">https://github.com/yoonchoi-neuro/amylPET_DL-ADprob</ext-link></p></sec><ref-list id="ref1"><title>References</title><ref id="umae019-B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gordon</surname><given-names>BA</given-names></string-name>, <string-name name-style="western"><surname>Blazey</surname><given-names>TM</given-names></string-name>, <string-name name-style="western"><surname>Su</surname><given-names>Y</given-names></string-name></person-group>, <etal>et al</etal><article-title>Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer&#8217;s disease: a longitudinal study</article-title>. <source>Lancet Neurol</source>. <year>2018</year>;<volume>17</volume>(<issue>3</issue>):<fpage>241</fpage>-<lpage>250</lpage>.<pub-id pub-id-type="pmid">29397305</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(18)30028-0</pub-id><pub-id pub-id-type="pmcid">PMC5816717</pub-id></mixed-citation></ref><ref id="umae019-B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jack</surname><given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Blennow</surname><given-names>K</given-names></string-name></person-group>, <etal>et al</etal><article-title>NIA-AA research framework: toward a biological definition of Alzheimer&#8217;s disease</article-title>. <source>Alzheimers Dement</source>. <year>2018</year>;<volume>14</volume>(<issue>4</issue>):<fpage>535</fpage>-<lpage>562</lpage>.<pub-id pub-id-type="pmid">29653606</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2018.02.018</pub-id><pub-id pub-id-type="pmcid">PMC5958625</pub-id></mixed-citation></ref><ref id="umae019-B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Villemagne</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Burnham</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bourgeat</surname><given-names>P</given-names></string-name></person-group>, <etal>et al</etal><article-title>Amyloid &#946; deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer&#8217;s disease: a prospective cohort study</article-title>. <source>Lancet Neurol</source>. <year>2013</year>;<volume>12</volume>(<issue>4</issue>):<fpage>357</fpage>-<lpage>367</lpage>.<pub-id pub-id-type="pmid">23477989</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(13)70044-9</pub-id></mixed-citation></ref><ref id="umae019-B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ozlen</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Binette</surname><given-names>AP</given-names></string-name>, <string-name name-style="western"><surname>K&#246;be</surname><given-names>T</given-names></string-name></person-group>, <etal>et al</etal><article-title>Spatial extent of amyloid-&#946; levels and associations with tau-PET and cognition</article-title>. <source>JAMA Neurol</source>. <year>2022</year>;<volume>79</volume>(<issue>10</issue>):<fpage>1025</fpage>-<lpage>1035</lpage>.<pub-id pub-id-type="pmid">35994280</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2022.2442</pub-id><pub-id pub-id-type="pmcid">PMC9396472</pub-id></mixed-citation></ref><ref id="umae019-B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Harn</surname><given-names>NR</given-names></string-name>, <string-name name-style="western"><surname>Hunt</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Hill</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Vidoni</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Perry</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Burns</surname><given-names>JM.</given-names></string-name></person-group><article-title>Augmenting amyloid PET interpretations with quantitative information improves consistency of early amyloid detection</article-title>. <source>Clin Nucl Med</source>. <year>2017</year>;<volume>42</volume>(<issue>8</issue>):<fpage>577</fpage>-<lpage>581</lpage>.<pub-id pub-id-type="pmid">28574875</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/RLU.0000000000001693</pub-id><pub-id pub-id-type="pmcid">PMC5491352</pub-id></mixed-citation></ref><ref id="umae019-B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pemberton</surname><given-names>HG</given-names></string-name>, <string-name name-style="western"><surname>Collij</surname><given-names>LE</given-names></string-name>, <string-name name-style="western"><surname>Heeman</surname><given-names>F</given-names></string-name></person-group>, <etal>et al</etal><article-title>Quantification of amyloid PET for future clinical use: a state-of-the-art review</article-title>. <source>Eur J Nucl Med Mol Imaging</source>. <year>2022</year>;<volume>49</volume>(<issue>10</issue>):<fpage>3508</fpage>-<lpage>3528</lpage>.<pub-id pub-id-type="pmid">35389071</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-022-05784-y</pub-id><pub-id pub-id-type="pmcid">PMC9308604</pub-id></mixed-citation></ref><ref id="umae019-B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ben Bouall&#232;gue</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Mariano-Goulart</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Payoux</surname><given-names>P</given-names></string-name></person-group>; <collab>the Alzheimer&#8217;s Disease Neuroimaging Initiative (ADNI)</collab>. <article-title>Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer&#8217;s disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database</article-title>. <source>Alzheimers Res Ther</source>. <year>2017</year>;<volume>9</volume>(<issue>1</issue>):<fpage>32</fpage>-<lpage>13</lpage>.<pub-id pub-id-type="pmid">28441967</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-017-0260-z</pub-id><pub-id pub-id-type="pmcid">PMC5405503</pub-id></mixed-citation></ref><ref id="umae019-B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lopes Alves</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Collij</surname><given-names>LE</given-names></string-name>, <string-name name-style="western"><surname>Altomare</surname><given-names>D</given-names></string-name></person-group>, <etal>et al</etal><article-title>Quantitative amyloid PET in Alzheimer&#8217;s disease: the AMYPAD prognostic and natural history study</article-title>. <source>Alzheimers Dement</source>. <year>2020</year>;<volume>16</volume>(<issue>5</issue>):<fpage>750</fpage>-<lpage>758</lpage>.<pub-id pub-id-type="pmid">32281303</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12069</pub-id><pub-id pub-id-type="pmcid">PMC7984341</pub-id></mixed-citation></ref><ref id="umae019-B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sevigny</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Suhy</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Chiao</surname><given-names>P</given-names></string-name></person-group>, <etal>et al</etal><article-title>Amyloid PET screening for enrichment of early-stage Alzheimer disease clinical trials</article-title>. <source>Alzheimer Dis Assoc Disord</source>. <year>2016</year>;<volume>30</volume>(<issue>1</issue>):<fpage>1</fpage>-<lpage>7</lpage>.<pub-id pub-id-type="pmid">26885819</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/WAD.0000000000000144</pub-id></mixed-citation></ref><ref id="umae019-B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Palmqvist</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zetterberg</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Mattsson</surname><given-names>N</given-names></string-name></person-group>, <etal>et al</etal><article-title>Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease</article-title>. <source>Neurology</source>. <year>2015</year>;<volume>85</volume>(<issue>14</issue>):<fpage>1240</fpage>-<lpage>1249</lpage>.<pub-id pub-id-type="pmid">26354982</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000001991</pub-id><pub-id pub-id-type="pmcid">PMC4607601</pub-id></mixed-citation></ref><ref id="umae019-B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bollack</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Pemberton</surname><given-names>HG</given-names></string-name>, <string-name name-style="western"><surname>Collij</surname><given-names>LE</given-names></string-name></person-group>, <etal>et al</etal><article-title>Longitudinal amyloid and tau PET imaging in Alzheimer&#8217;s disease: a systematic review of methodologies and factors affecting quantification</article-title>. <source>Alzheimers Dement</source>. <year>2023</year>;<volume>19</volume>(<issue>11</issue>):<fpage>5232</fpage>-<lpage>5252</lpage>. <pub-id pub-id-type="doi">10.1002/alz.13158</pub-id><pub-id pub-id-type="pmid">37303269</pub-id></mixed-citation></ref><ref id="umae019-B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schmidt</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Chiao</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Klein</surname><given-names>G</given-names></string-name></person-group>, <etal>et al</etal><article-title>The influence of biological and technical factors on quantitative analysis of amyloid PET: points to consider and recommendations for controlling variability in longitudinal data</article-title>. <source>Alzheimers Dement</source>. <year>2015</year>;<volume>11</volume>(<issue>9</issue>):<fpage>1050</fpage>-<lpage>1068</lpage>.<pub-id pub-id-type="pmid">25457431</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2014.09.004</pub-id></mixed-citation></ref><ref id="umae019-B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Heeman</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Yaqub</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hendriks</surname><given-names>J</given-names></string-name></person-group>, <etal>et al</etal><article-title>Impact of cerebral blood flow and amyloid load on SUVR bias</article-title>. <source>EJNMMI Res</source>. <year>2022</year>;<volume>12</volume>(<issue>1</issue>):<fpage>29</fpage>.<pub-id pub-id-type="pmid">35553267</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13550-022-00898-8</pub-id><pub-id pub-id-type="pmcid">PMC9098761</pub-id></mixed-citation></ref><ref id="umae019-B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schwarz</surname><given-names>CG</given-names></string-name>, <string-name name-style="western"><surname>Gunter</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Lowe</surname><given-names>VJ</given-names></string-name></person-group>, <etal>et al</etal><article-title>A comparison of partial volume correction techniques for measuring change in serial amyloid PET SUVR</article-title>. <source>J Alzheimers Dis</source>. <year>2019</year>;<volume>67</volume>(<issue>1</issue>):<fpage>181</fpage>-<lpage>195</lpage>.<pub-id pub-id-type="pmid">30475770</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-180749</pub-id><pub-id pub-id-type="pmcid">PMC6398556</pub-id></mixed-citation></ref><ref id="umae019-B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Klunk</surname><given-names>WE</given-names></string-name>, <string-name name-style="western"><surname>Koeppe</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Price</surname><given-names>JC</given-names></string-name></person-group>, <etal>et al</etal><article-title>The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET</article-title>. <source>Alzheimers Dement</source>. <year>2015</year>;<volume>11</volume>(<issue>1</issue>):<fpage>1</fpage>-<lpage>15.e14</lpage>.<pub-id pub-id-type="pmid">25443857</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2014.07.003</pub-id><pub-id pub-id-type="pmcid">PMC4300247</pub-id></mixed-citation></ref><ref id="umae019-B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bourgeat</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Dor&#233;</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Fripp</surname><given-names>J</given-names></string-name></person-group>, <etal>et al</etal><article-title>Implementing the centiloid transformation for 11C-PiB and &#946;-amyloid 18F-PET tracers using CapAIBL</article-title>. <source>Neuroimage</source>. <year>2018</year>;<volume>183</volume>:<fpage>387</fpage>-<lpage>393</lpage>.<pub-id pub-id-type="pmid">30130643</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2018.08.044</pub-id></mixed-citation></ref><ref id="umae019-B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bourgeat</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Dor&#233;</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Doecke</surname><given-names>J</given-names></string-name></person-group>, <etal>et al</etal><article-title>Non-negative matrix factorisation improves Centiloid robustness in longitudinal studies</article-title>. <source>Neuroimage</source>. <year>2021</year>;<volume>226</volume>:<fpage>117593</fpage>.<pub-id pub-id-type="pmid">33248259</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2020.117593</pub-id><pub-id pub-id-type="pmcid">PMC8049633</pub-id></mixed-citation></ref><ref id="umae019-B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cho</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Choe</surname><given-names>YS</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>HJ</given-names></string-name></person-group>, <etal>et al</etal><article-title>A new Centiloid method for 18 F-florbetaben and 18 F-flutemetamol PET without conversion to PiB</article-title>. <source>Eur J Nucl Med Mol Imaging</source>. <year>2020</year>;<volume>47</volume>(<issue>8</issue>):<fpage>1938</fpage>-<lpage>1948</lpage>.<pub-id pub-id-type="pmid">31834446</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-019-04596-x</pub-id></mixed-citation></ref><ref id="umae019-B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ellis</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Bush</surname><given-names>AI</given-names></string-name>, <string-name name-style="western"><surname>Darby</surname><given-names>D</given-names></string-name></person-group>, <etal>et al</etal><article-title>The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer&#8217;s disease</article-title>. <source>Int Psychogeriatr</source>. <year>2009</year>;<volume>21</volume>(<issue>4</issue>):<fpage>672</fpage>-<lpage>687</lpage>.<pub-id pub-id-type="pmid">19470201</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S1041610209009405</pub-id></mixed-citation></ref><ref id="umae019-B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Iwatsubo</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Iwata</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Suzuki</surname><given-names>K</given-names></string-name></person-group>, <etal>et al</etal><article-title>Japanese and North American Alzheimer&#8217;s Disease Neuroimaging Initiative studies: harmonization for international trials. Alzheimer&#8217;s</article-title>. <source>Alzheimers Dement</source>. <year>2018</year>;<volume>14</volume>(<issue>8</issue>):<fpage>1077</fpage>-<lpage>1087</lpage>.<pub-id pub-id-type="pmid">29753531</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2018.03.009</pub-id></mixed-citation></ref><ref id="umae019-B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dagley</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>LaPoint</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Huijbers</surname><given-names>W</given-names></string-name></person-group>, <etal>et al</etal><article-title>Harvard aging brain study: dataset and accessibility</article-title>. <source>Neuroimage</source>. <year>2017</year>;<volume>144</volume>(<issue>Pt B</issue>):<fpage>255</fpage>-<lpage>258</lpage>.<pub-id pub-id-type="pmid">25843019</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2015.03.069</pub-id><pub-id pub-id-type="pmcid">PMC4592689</pub-id></mixed-citation></ref><ref id="umae019-B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Battle</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Pillay</surname><given-names>LC</given-names></string-name>, <string-name name-style="western"><surname>Lowe</surname><given-names>VJ</given-names></string-name></person-group>, <etal>et al</etal><article-title>Centiloid scaling for quantification of brain amyloid with [18 F] flutemetamol using multiple processing methods</article-title>. <source>EJNMMI Res</source>. <year>2018</year>;<volume>8</volume>(<issue>1</issue>):<fpage>107</fpage>-<lpage>111</lpage>.<pub-id pub-id-type="pmid">30519791</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13550-018-0456-7</pub-id><pub-id pub-id-type="pmcid">PMC6281542</pub-id></mixed-citation></ref><ref id="umae019-B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rowe</surname><given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Dor&#233;</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>G</given-names></string-name></person-group>, <etal>et al</etal><article-title>18 F-Florbetaben PET beta-amyloid binding expressed in Centiloids</article-title>. <source>Eur J Nucl Med Mol Imaging</source>. <year>2017</year>;<volume>44</volume>(<issue>12</issue>):<fpage>2053</fpage>-<lpage>2059</lpage>.<pub-id pub-id-type="pmid">28643043</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-017-3749-6</pub-id><pub-id pub-id-type="pmcid">PMC5656696</pub-id></mixed-citation></ref><ref id="umae019-B24"><label>24</label><mixed-citation publication-type="other"><person-group person-group-type="author"><string-name name-style="western"><surname>He</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Ren</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>J.</given-names></string-name></person-group> Deep residual learning for image recognition. In: <italic toggle="yes">Proceedings of the IEEE Conference on Computer Vision and Pattern Recognition</italic>. <year>2016</year>;<fpage>770</fpage>-<lpage>778</lpage>.</mixed-citation></ref><ref id="umae019-B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Habes</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wolk</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Fan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>AsDN</surname><given-names>I</given-names></string-name></person-group>, <collab>Alzheimer&#8217;s Disease Neuroimaging Initiative and the Australian Imaging Biomarkers and Lifestyle Study of Aging</collab>. <article-title>A deep learning model for early prediction of Alzheimer&#8217;s disease dementia based on hippocampal magnetic resonance imaging data</article-title>. <source>Alzheimers Dement</source>. <year>2019</year>;<volume>15</volume>(<issue>8</issue>):<fpage>1059</fpage>-<lpage>1070</lpage>.<pub-id pub-id-type="pmid">31201098</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2019.02.007</pub-id><pub-id pub-id-type="pmcid">PMC6719787</pub-id></mixed-citation></ref><ref id="umae019-B26"><label>26</label><mixed-citation publication-type="other"><person-group person-group-type="author"><string-name name-style="western"><surname>Lee</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Eo</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Hwang</surname><given-names>D.</given-names></string-name></person-group> Relevance-cam: your model already knows where to look. In: <italic toggle="yes">Proceedings of the IEEE/CVF Conference on Computer Vision and Pattern Recognition</italic>. <year>2021</year>;<fpage>14944</fpage>-<lpage>14953</lpage>.</mixed-citation></ref><ref id="umae019-B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>DeLong</surname><given-names>ER</given-names></string-name>, <string-name name-style="western"><surname>DeLong</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Clarke-Pearson</surname><given-names>DL.</given-names></string-name></person-group><article-title>Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach</article-title>. <source>Biometrics</source>. <year>1988</year>;<volume>44</volume>(<issue>3</issue>):<fpage>837</fpage>-<lpage>845</lpage>.<pub-id pub-id-type="pmid">3203132</pub-id></mixed-citation></ref><ref id="umae019-B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>van Dyck</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Swanson</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Aisen</surname><given-names>P</given-names></string-name></person-group>, <etal>et al</etal><article-title>Lecanemab in early Alzheimer&#8217;s disease</article-title>. <source>N Engl J Med</source>. <year>2023</year>;<volume>388</volume>(<issue>1</issue>):<fpage>9</fpage>-<lpage>21</lpage>.<pub-id pub-id-type="pmid">36449413</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2212948</pub-id></mixed-citation></ref><ref id="umae019-B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Alexander</surname><given-names>GC</given-names></string-name>, <string-name name-style="western"><surname>Knopman</surname><given-names>DS</given-names></string-name>, <string-name name-style="western"><surname>Emerson</surname><given-names>SS</given-names></string-name></person-group>, <etal>et al</etal><article-title>Revisiting FDA approval of aducanumab</article-title>. <source>N Engl J Med</source>. <year>2021</year>;<volume>385</volume>(<issue>9</issue>):<fpage>769</fpage>-<lpage>771</lpage>.<pub-id pub-id-type="pmid">34320282</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMp2110468</pub-id><pub-id pub-id-type="pmcid">PMC11694499</pub-id></mixed-citation></ref><ref id="umae019-B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sperling</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Aisen</surname><given-names>PS</given-names></string-name>, <string-name name-style="western"><surname>Beckett</surname><given-names>LA</given-names></string-name></person-group>, <etal>et al</etal><article-title>Toward defining the preclinical stages of Alzheimer&#8217;s disease: recommendations from the National Institute on Aging-Alzheimer&#8217;s Association workgroups on diagnostic guidelines for Alzheimer&#8217;s disease. Alzheimer&#8217;s</article-title>. <source>Alzheimers Dement</source>. <year>2011</year>;<volume>7</volume>(<issue>3</issue>):<fpage>280</fpage>-<lpage>292</lpage>.<pub-id pub-id-type="pmid">21514248</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2011.03.003</pub-id><pub-id pub-id-type="pmcid">PMC3220946</pub-id></mixed-citation></ref><ref id="umae019-B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ezzati</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Abdulkadir</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Jack</surname><given-names>CR</given-names><suffix>Jr,</suffix></string-name></person-group><etal>et al</etal><article-title>Predictive value of ATN biomarker profiles in estimating disease progression in Alzheimer&#8217;s disease dementia</article-title>. <source>Alzheimers Dementia</source>. <year>2021</year>;<volume>17</volume>(<issue>11</issue>):<fpage>1855</fpage>-<lpage>1867</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12491</pub-id><pub-id pub-id-type="pmcid">PMC8842842</pub-id><pub-id pub-id-type="pmid">34870371</pub-id></mixed-citation></ref><ref id="umae019-B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Nai</surname><given-names>Y-H</given-names></string-name>, <string-name name-style="western"><surname>Saridin</surname><given-names>F</given-names></string-name></person-group>, <etal>et al</etal><article-title>Improved amyloid burden quantification with nonspecific estimates using deep learning</article-title>. <source>Eur J Nucl Med Mol Imaging</source>. <year>2021</year>;<volume>48</volume>(<issue>6</issue>):<fpage>1842</fpage>-<lpage>1853</lpage>.<pub-id pub-id-type="pmid">33415430</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-020-05131-z</pub-id><pub-id pub-id-type="pmcid">PMC8113180</pub-id></mixed-citation></ref><ref id="umae019-B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kim</surname><given-names>J-Y</given-names></string-name>, <string-name name-style="western"><surname>Suh</surname><given-names>HY</given-names></string-name>, <string-name name-style="western"><surname>Ryoo</surname><given-names>HG</given-names></string-name></person-group>, <etal>et al</etal><article-title>Amyloid PET quantification via end-to-end training of a deep learning</article-title>. <source>Nucl Med Mol Imaging</source>. <year>2019</year>;<volume>53</volume>(<issue>5</issue>):<fpage>340</fpage>-<lpage>348</lpage>.<pub-id pub-id-type="pmid">31723364</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13139-019-00610-0</pub-id><pub-id pub-id-type="pmcid">PMC6821901</pub-id></mixed-citation></ref><ref id="umae019-B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shah</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>B</given-names></string-name></person-group>, <etal>et al</etal><article-title>Deep residual inception encoder-decoder network for amyloid PET harmonization</article-title>. <source>Alzheimers Dement</source>. <year>2022</year>;<volume>18</volume>(<issue>12</issue>):<fpage>2448</fpage>-<lpage>2457</lpage>.<pub-id pub-id-type="pmid">35142053</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12564</pub-id><pub-id pub-id-type="pmcid">PMC9360199</pub-id></mixed-citation></ref><ref id="umae019-B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Iaccarino</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>La Joie</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Koeppe</surname><given-names>R</given-names></string-name></person-group>, <etal>et al</etal><article-title>rPOP: robust PET-only processing of community acquired heterogeneous amyloid-PET data</article-title>. <source>Neuroimage</source>. <year>2022</year>;<volume>246</volume>:<fpage>118775</fpage>.<pub-id pub-id-type="pmid">34890793</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2021.118775</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Alzheimers Dis</journal-id><journal-id journal-id-type="iso-abbrev">J Alzheimers Dis</journal-id><journal-id journal-id-type="pmc-domain-id">464</journal-id><journal-id journal-id-type="pmc-domain">sageopen</journal-id><journal-id journal-id-type="publisher-id">ALZ</journal-id><journal-title-group><journal-title>Journal of Alzheimer's Disease</journal-title></journal-title-group><issn pub-type="ppub">1387-2877</issn><issn pub-type="epub">1875-8908</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Sage Choice</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12495114</article-id><article-id pub-id-type="pmcid-ver">PMC12495114.1</article-id><article-id pub-id-type="pmcaid">12495114</article-id><article-id pub-id-type="pmcaiid">12495114</article-id><article-id pub-id-type="pmid">40888514</article-id><article-id pub-id-type="doi">10.1177/13872877251372603</article-id><article-id pub-id-type="publisher-id">10.1177_13872877251372603</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Articles</subject></subj-group></article-categories><title-group><article-title>Phosphorylation at serine 214 correlates with tau seeding activity in an age-dependent manner in two mouse models for tauopathies and is required for tau transsynaptic propagation</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Martinez</surname><given-names initials="P">Pablo</given-names></name><xref rid="aff1-13872877251372603" ref-type="aff">1</xref><xref rid="aff2-13872877251372603" ref-type="aff">2</xref><xref rid="corresp2-13872877251372603" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jury-Garfe</surname><given-names initials="N">Nur</given-names></name><xref rid="aff1-13872877251372603" ref-type="aff">1</xref><xref rid="aff2-13872877251372603" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Patel</surname><given-names initials="H">Henika</given-names></name><xref rid="aff1-13872877251372603" ref-type="aff">1</xref><xref rid="aff2-13872877251372603" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>You</surname><given-names initials="Y">Yanwen</given-names></name><xref rid="aff2-13872877251372603" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Perkins</surname><given-names initials="A">Abigail</given-names></name><xref rid="aff2-13872877251372603" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>You</surname><given-names initials="Y">Yingjian</given-names></name><xref rid="aff2-13872877251372603" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lee-Gosselin</surname><given-names initials="A">Audrey</given-names></name><xref rid="aff2-13872877251372603" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Vidal</surname><given-names initials="R">Ruben</given-names></name><xref rid="aff2-13872877251372603" ref-type="aff">2</xref><xref rid="aff3-13872877251372603" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5499-3082</contrib-id><name name-style="western"><surname>Lasagna-Reeves</surname><given-names initials="CA">Cristian A</given-names></name><xref rid="aff1-13872877251372603" ref-type="aff">1</xref><xref rid="aff2-13872877251372603" ref-type="aff">2</xref><xref rid="corresp1-13872877251372603" ref-type="corresp"/></contrib></contrib-group><aff id="aff1-13872877251372603">
<label>1</label>Department of Neurology, Baylor College of Medicine, Houston, TX, USA</aff><aff id="aff2-13872877251372603">
<label>2</label>Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA</aff><aff id="aff3-13872877251372603">
<label>3</label>Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA</aff><author-notes><corresp id="corresp1-13872877251372603">Cristian Lasagna-Reeves, PhD, Associate Professor, Department of Neurology, Baylor College of Medicine, 1 Baylor Plaza, Houston TX 77030, USA. 
Email: <email>cristian.lasagna@bcm.edu</email></corresp><corresp id="corresp2-13872877251372603">Pablo Martinez, PhD, Instructor, Department of Neurology, Baylor College of Medicine, 1 Baylor Plaza, Houston TX 77030, USA. 
Email: <email>pablo.martinez@bcm.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>1</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><volume>107</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">498304</issue-id><fpage>1706</fpage><lpage>1720</lpage><history><date date-type="received"><day>9</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>16</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>04</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>05</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-05 00:26:29.067"><day>05</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder content-type="sage">SAGE Publications</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="10.1177_13872877251372603.pdf"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="preprint" xml:lang="en" xlink:title="research-article" journal-id="bioRxiv" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC11361173"><article-title>
Phosphorylation at serine 214 correlates with tau seeding activity in an age-dependent manner in two mouse models for tauopathies and is required for tau transsynaptic propagation
</article-title><date><day>23</day><month>7</month><year>2024</year></date><elocation-id>2024.07.22.604618</elocation-id><source>bioRxiv</source><pub-id pub-id-type="pmcid">PMC11361173</pub-id><pub-id pub-id-type="pmid">39211286</pub-id></related-article><abstract><sec><title>Background</title><p>Tau aggregation and propagation are hallmark features of Alzheimer's disease and related tauopathies. The molecular identity and post-translational modifications that contribute to tau seeding activity remain incompletely understood.</p></sec><sec><title>Objective</title><p>To characterize the temporal dynamics of tau seeding activity and identify specific phosphorylated tau species associated with tau propagation in vivo.</p></sec><sec><title>Methods</title><p>We profiled tau seeding activity using a FRET-based biosensor cell line and correlated it with the abundance of phospho- and conformational tau species in two transgenic mouse models of tauopathy (P301S-1N4R and P301S-0N4R). Immunohistochemistry and subcellular fractionation were used to examine the spatial distribution of tau species. Functional relevance of serine 214 phosphorylation was assessed via phospho-dead mutants in <italic toggle="yes">Drosophila</italic> and primary neuronal cultures using a microfluidic platform.</p></sec><sec><title>Results</title><p>Tau seeding activity was detected as early as 2 months and increased with age in both mouse models, preceding AT8-positive neurofibrillary tangles. Phosphorylation at serine 214 (pTau-Ser214) positively correlated with tau seeding in both models and was observed earlier and in distinct histological compartments compared to AT8. pTau-Ser214, but not AT8, localized to the synaptic compartment. Mutation of serine 214 to alanine reduced tau propagation in primary neurons and seeding activity in <italic toggle="yes">Drosophila</italic>, without affecting total tau levels.</p></sec><sec><title>Conclusions</title><p>pTau-Ser214 marks an early, synaptically enriched tau species that correlates with seeding activity and promotes transsynaptic propagation. These findings highlight the functional diversity of tau species and support pTau-Ser214 as a potential biomarker and therapeutic target for early-stage tauopathy.</p></sec></abstract><kwd-group><kwd>Alzheimer's disease</kwd><kwd>propagation</kwd><kwd>tau</kwd><kwd>tau phosphorylation</kwd></kwd-group><funding-group specific-use="FundRef"><award-group id="award1-13872877251372603"><funding-source id="funding1-13872877251372603"><institution-wrap><institution>Alzheimer&#8216;s Association</institution></institution-wrap></funding-source><award-id rid="funding1-13872877251372603">ALZDISCOVERY-1049108 </award-id></award-group><award-group id="award2-13872877251372603"><funding-source id="funding2-13872877251372603"><institution-wrap><institution>National Institute on Aging</institution><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000049</institution-id></institution-wrap></funding-source><award-id rid="funding2-13872877251372603">1RF1AG059639</award-id></award-group><award-group id="award3-13872877251372603"><funding-source id="funding3-13872877251372603"><institution-wrap><institution>Cure Alzheimer's Fund</institution><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100007625</institution-id></institution-wrap></funding-source></award-group><award-group id="award4-13872877251372603"><funding-source id="funding4-13872877251372603"><institution-wrap><institution>Alzheimer's Association</institution><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000957</institution-id></institution-wrap></funding-source><award-id rid="funding4-13872877251372603">AARFD-21-847663 </award-id></award-group><award-group id="award5-13872877251372603"><funding-source id="funding5-13872877251372603"><institution-wrap><institution>National Center for Advancing Translational Sciences</institution><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100006108</institution-id></institution-wrap></funding-source><award-id rid="funding5-13872877251372603">UL1TR002529</award-id></award-group><award-group id="award6-13872877251372603"><funding-source id="funding6-13872877251372603"><institution-wrap><institution>National Institute of Neurological Disorders and Stroke</institution><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000065</institution-id></institution-wrap></funding-source><award-id rid="funding6-13872877251372603">1R01NS119280</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>typesetter</meta-name><meta-value>ts19</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="section1-13872877251372603"><title>Introduction</title><p>The microtubule-associated protein tau is required for microtubule assembly, axonal transport, and neurite outgrowth. Tau is encoded by a single gene, with 6 splice isoforms, ranging in size from 352 to 441 amino acids, which are expressed in the human central nervous system.<sup><xref rid="bibr1-13872877251372603" ref-type="bibr">1</xref>,<xref rid="bibr2-13872877251372603" ref-type="bibr">2</xref></sup> These isoforms differ from each other by the presence of 0, 1, or 2 N-terminal inserts and 3 or 4 tandemly arranged microtubule-binding repeats. Tau undergoes many post-translational modifications including phosphorylation, glycosylation, ubiquitination, glycation, polyamination, nitrosylation, and truncation. Most of the biological functions of tau are modulated by site-specific phosphorylations.<sup>
<xref rid="bibr3-13872877251372603" ref-type="bibr">3</xref>
</sup> Under pathological conditions, the most important and disease-relevant tau post-translational modification are hyperphosphorylations,<sup>
<xref rid="bibr4-13872877251372603" ref-type="bibr">4</xref>
</sup> which alters tau's biological functions and causes tau self-assembly and accumulation as neurofibrillary tangles (NFT), a hallmark of Alzheimer's disease (AD) and other neurodegenerative diseases.<sup><xref rid="bibr5-13872877251372603" ref-type="bibr">5</xref>,<xref rid="bibr6-13872877251372603" ref-type="bibr">6</xref></sup> All tau isoforms contain at least 30 phosphorylation sites,<sup>
<xref rid="bibr4-13872877251372603" ref-type="bibr">4</xref>
</sup> most of which are believed to be unphosphorylated under physiological conditions. However, under pathological conditions, hyperphosphorylation of various sites occurs resulting in tau accumulation.<sup><xref rid="bibr7-13872877251372603" ref-type="bibr">7</xref>,<xref rid="bibr8-13872877251372603" ref-type="bibr">8</xref></sup> Tau phosphorylation, especially at specific sites, reduces its affinity for microtubules.<sup><xref rid="bibr9-13872877251372603" ref-type="bibr">9</xref>,<xref rid="bibr10-13872877251372603" ref-type="bibr">10</xref></sup> Therefore, it is not surprising that considerable attention has been paid to determining which protein kinases and phosphatases control tau phosphorylation.<sup>
<xref rid="bibr11-13872877251372603" ref-type="bibr">11</xref>
</sup></p><p>In AD, several studies have described a spatial and temporal pattern in the appearance of tau tangles in patient brains that follow neuronal networks and correlate with cognitive decline.<sup>
<xref rid="bibr12-13872877251372603" ref-type="bibr">12</xref>
</sup> In the case of AD, tau tangles first appear in the transentorhinal region and progress along anatomical pathways to the hippocampus and eventually the neocortex.<sup>
<xref rid="bibr12-13872877251372603" ref-type="bibr">12</xref>
</sup> Similar temporal progression of tau pathology is observed in argyrophilic grain disease, though the brain regions involved differ.<sup><xref rid="bibr13-13872877251372603" ref-type="bibr">13</xref>,<xref rid="bibr14-13872877251372603" ref-type="bibr">14</xref></sup> Likewise, the spatial distribution of tangles is distinct in other tauopathies.<sup>
<xref rid="bibr15-13872877251372603" ref-type="bibr">15</xref>
</sup> While still a contentious topic, strong evidence supports the idea that propagation of pathological tau species occurs between cells,<sup><xref rid="bibr16-13872877251372603" ref-type="bibr">16</xref><xref rid="bibr17-13872877251372603" ref-type="bibr"/>&#8211;<xref rid="bibr18-13872877251372603" ref-type="bibr">18</xref></sup> which suggests that this could contribute to the spatial and temporal pattern of the tangles observed in different tauopathies. Cell culture studies have demonstrated that misfolded tau aggregates can mediate a template misfolding or &#8220;seeding&#8221; of normal, monomeric tau to induce intracellular tau aggregation.<sup><xref rid="bibr19-13872877251372603" ref-type="bibr">19</xref><xref rid="bibr20-13872877251372603" ref-type="bibr"/>&#8211;<xref rid="bibr21-13872877251372603" ref-type="bibr">21</xref></sup> Furthermore, in vivo tau spreading models support the mechanism of tau propagation. Injection of recombinant tau aggregates or brain lysate containing tau aggregates into the brains of wild-type (WT) or young transgenic mice can induce robust pathology at the site of injection and in anatomically connected regions.<sup><xref rid="bibr20-13872877251372603" ref-type="bibr">20</xref>,<xref rid="bibr22-13872877251372603" ref-type="bibr">22</xref>,<xref rid="bibr23-13872877251372603" ref-type="bibr">23</xref></sup> The induction of tau pathology in mice that do not otherwise develop tau inclusions supports the concept of seeding and the propagation of tau aggregates to anatomically connected neurons.</p><p>Blocking the spread of the tau seed with antibodies has been proposed as a viable therapeutic approach. However, the facts that the tau seed structure remains unknown, and recent studies indicating a distinct molecular diversity of the seeding-competent tau in in vitro and in vivo models,<sup><xref rid="bibr23-13872877251372603" ref-type="bibr">23</xref><xref rid="bibr24-13872877251372603" ref-type="bibr"/><xref rid="bibr25-13872877251372603" ref-type="bibr"/><xref rid="bibr26-13872877251372603" ref-type="bibr"/>&#8211;<xref rid="bibr27-13872877251372603" ref-type="bibr">27</xref></sup> make it extremely challenging to determine the exact epitope or post-translational modification to target. Recently, studies suggested that tau antibodies directed to the middle region neutralized tau propagation more efficiently than antibodies targeting the N-terminal region.<sup>
<xref rid="bibr28-13872877251372603" ref-type="bibr">28</xref>
</sup> The ability of many of these antibodies to block tau seeding has been tested in vitro using brain tissue extract from a low number of donors at a single point of the pathology.<sup><xref rid="bibr29-13872877251372603" ref-type="bibr">29</xref>,<xref rid="bibr30-13872877251372603" ref-type="bibr">30</xref></sup> Considering the heterogeneity of the tau seed among individuals with tauopathies and even in disease progression,<sup>
<xref rid="bibr31-13872877251372603" ref-type="bibr">31</xref>
</sup> the efficiency of each of these antibodies to inhibit tau seeding could be diminished if tested in a different experimental model or even at a different time point in humans. Therefore, it is necessary to understand the nature of the tau species involved in spreading and the precise seeding/template.</p><p>In the present study, we utilized a well-characterized FRET-based biosensor cell line<sup>
<xref rid="bibr32-13872877251372603" ref-type="bibr">32</xref>
</sup> to profile the temporal progression of tau seeding activity in the brains of two mouse models of human tauopathies.<sup><xref rid="bibr33-13872877251372603" ref-type="bibr">33</xref>,<xref rid="bibr34-13872877251372603" ref-type="bibr">34</xref></sup> First, we show that tau seeding activity is a pathological event that happens several weeks earlier than the appearance of the first symptoms in these mouse models. We then profiled the seeding activity at different ages from these mouse models to the levels of a diverse set of phospho- and conformational tau species analyzed from the same brain samples. We found that the level of phosphorylated tau at serine 214 (pTau-Ser214) correlated with tau seeding activity within the individual disease progression in both mouse models for tauopathies. We also observed that tau seeding occurred before the appearance of conventional AT8-positive NFTs and that pTau-Ser214 histopathology manifested earlier and displayed a distinct pattern and compartmentalization compared to AT8 pathology, demonstrating the diversity of tau species within the same brain region. Furthermore, preventing the phosphorylation of tau at Ser214 by introducing the amino acid change from serine to alanine significantly reduced tau propagation in mouse primary neurons, and interestingly reduced seeding activity in a <italic toggle="yes">Drosophila</italic> model of tauopathy, suggesting a role for this tau phosphorylation in the spreading and formation of toxic aberrant forms of tau. Our study highlights the importance of dissecting the nature of the tau seed both in the context of individual disease progression and in different tau models that will allow us to better dissect the mechanism behind the formation of distinct tau species at different stages of disease progression.</p></sec><sec id="section2-13872877251372603"><title>Methods</title><sec id="section2A-13872877251372603"><title>Transgenic mouse model</title><p>Mice were housed at the Indiana University School of Medicine (IUSM) animal care facility and were maintained according to USDA standards (12-h light/dark cycle, food, and water <italic toggle="yes">ad libitum</italic>), following the Guide for the Care and Use of Laboratory Animals (National Institutes of Health, Bethesda, MD). The PS19 mouse model,<sup>
<xref rid="bibr33-13872877251372603" ref-type="bibr">33</xref>
</sup> which overexpresses human 1N4R tau with the P301S mutation, was directly purchased from Jackson Laboratories (stock number 008169). A second mouse model that overexpresses human 0N4R tau with the P301S mutation was developed and provided by Dr Ruben Vidal.<sup>
<xref rid="bibr34-13872877251372603" ref-type="bibr">34</xref>
</sup> Animals were anesthetized and euthanized according to IUSM Institutional Animal Care and Use Committee-approved procedures. We used 2, 3, 4, 5, 6, and 9-month-old animals. Mice were perfused transcardially with PBS before decapitation. Brains were extracted, the right hemisphere was stored at &#8722;80 &#176;C for biochemical analysis, and the left hemisphere was formalin-fixed to prepare paraffin blocks as previously described.<sup>
<xref rid="bibr35-13872877251372603" ref-type="bibr">35</xref>
</sup> We did not detect sex differences based on our results.</p></sec><sec id="section2B-13872877251372603"><title>Mouse brain samples preparation and immunoblot analysis</title><p>Both P301S (0N4R) and P301S (1N4R) mouse brains were homogenized at a 1:10 (w/vol) ratio of the brain in 1&#215; TBS supplemented with protease inhibitor cocktail (Roche), using a Bead Beater (1&#8197;min) and then sonicated for 1&#8197;min (50% amplitude, pulse on 12&#8197;s, pulse off 3&#8197;s). Samples were then centrifuged at 15,000&#8197;rpm for 10&#8197;min at 4 &#176;C. TBS soluble supernatant was aliquoted into fresh tubes. For immunoblot analysis, TBS soluble fractions (20&#8197;&#181;g) were run on NuPAGE 4&#8211;12% Bis-Tris protein gel (Invitrogen) and transferred to a nitrocellulose membrane. The primary antibodies used against tau species were PHF1 (1:1000, from Peter Davies), MC1 (1:1000, from Peter Davies), anti-pS214 tau (1:1000; Abcam ab170892), anti-pT217 tau (1:1000; ThermoFisher, 44&#8211;744), total human tau HT7 (1:1000; ThermoFisher, MN1000), anti-tau pS202/T205 (AT8; 1:1000; Invitrogen, MN 1020), anti-tau pT212 (1:1000; Invitrogen, 44-740G), anti-tau pT212/S214 (AT100; 1:1000; Invitrogen, MN1060), anti-tau pT231 (PHF6; 1:1000; EMD Millipore, MAB5450), anti-tau pS262 (1:1000; Abcam, ab131354) and anti-Vinculin (1:1000; Sigma, V9131). The secondary antibodies used were goat anti-mouse HRP IgG (1:5000; Invitrogen, A16066) and goat anti-rabbit HRP IgG (1:5000; Invitrogen A16066). For each analysis, the relative level of each tau antibody and Vinculin was quantified from western blot images using ImageJ software (NIH, v.1.53t). The level of each tau species was normalized to HT7 to determine the relative abundance of each tau species with respect to total tau levels.</p></sec><sec id="section2C-13872877251372603"><title>Flow cytometry and analysis of seeding activity</title><p>The seeding assay was performed as previously described.<sup><xref rid="bibr35-13872877251372603" ref-type="bibr">35</xref><xref rid="bibr36-13872877251372603" ref-type="bibr"/>&#8211;<xref rid="bibr37-13872877251372603" ref-type="bibr">37</xref></sup> Tau RD P301S FRET Biosensor cells (ATCC, CRL-3275) were plated at 35,000 cells in 130&#8197;&#181;l media per well in a 96-well plate, then incubated at 37 &#176;C overnight. The next day, cells were transfected with brain lysate at a concentration of 20&#8197;&#181;g total protein per well using Lipofectamine 2000 and incubated at 37 &#176;C for 2 days.<sup>
<xref rid="bibr37-13872877251372603" ref-type="bibr">37</xref>
</sup> Cells were harvested by trypsinization and fixed with 2% PFA for flow cytometry.</p><p>Flow Cytometry was conducted on a BD LSRFortessa&#8482; X-20 with a High Throughput Sampler. BV421 channel was used to detect CFP (405&#8197;nm Ex, 450/50 Em filter), and BV510 channel to detect FRET signal (405&#8197;nm Ex, 525/50&#8201;+&#8201;505LP Em filter), with compensation used to remove the CFP emission from the FRET signal. Gating cells with a positive FRET signal, seeding was quantified by measuring % positive cells and median fluorescent intensity (MFI) of the compensated BV510 channel. Integrated FRET density was calculated by multiplying % positive cells and MFI.</p></sec><sec id="section2D-13872877251372603"><title>Correlation analysis</title><p>For each case, the relative level of each tau antibody and Vinculin was quantified from western blot images as described.<sup>
<xref rid="bibr35-13872877251372603" ref-type="bibr">35</xref>
</sup> The level of each tau species was normalized by Vinculin, then normalized again to total human tau (HT7 normalized by Vinculin) to give a relative abundance for each tau species. Spearman's rank correlation between % positive FRET signal and tau species abundance was used to identify tau species that correlate with seeding. For graphing of the results, each species&#8217; abundance was normalized to the average abundance over all cases. This ensures that the average of normalized abundance is equal to 1 for each tau species, to enable comparison of each species on the same axis range. Since all abundances are relative, this final normalization step does not affect the correlation analysis.</p></sec><sec id="section2E-13872877251372603"><title>Brain section immunofluorescence</title><p>Paraffin sections from 9-month-old mice were deparaffinized, rehydrated, and washed in 0.01&#8197;M PBS 1&#215; plus Triton X-100 0.01% three times for 5&#8197;min each. After blocking in normal goat serum for 1&#8197;h, sections were incubated overnight with AT8 antibody (1:200) and anti-pTau-Ser214 antibody (1:200). The next day, the sections were washed in PBS 1&#215; 3 times for 10&#8197;min each and then incubated with goat anti-mouse Alexa Fluor 488 (1:700, Invitrogen,) and goat anti-rabbit Alexa Fluor 568 (1:700, Invitrogen,) for 1&#8197;h. Sections were washed and mounted in Fluoromount (Sigma, F4680) mounting medium with DAPI (Vector Laboratories). The sections were examined using a Nikon A1-R laser scanning confocal microscope coupled with Nikon AR software (v.5.21.03).</p></sec><sec id="section2F-13872877251372603"><title>Brain sections: immunohistochemistry</title><p>Immunohistochemistry was performed on paraffin-embedded sections. In brief, sections (5 &#956;m) were deparaffinized and rehydrated. After blocking in normal goat serum for 1&#8197;h, sections were incubated overnight with AT8 antibody (1:100) or anti-pTau-Ser214 antibody (1:100). The next day, the sections were washed in PBS 1&#215; three times for 10&#8197;min each and then incubated with biotinylated goat anti-mouse IgG or goat anti-rabbit IgG and visualized using an ABC reagent kit (Vector Laboratories) according to the manufacturer's recommendations. Bright-field images were acquired using a Leica Application Suite X 3.6.0.20104 on a Leica DMi8 microscope. Sections were counterstained with hematoxylin (Vector Laboratories) for nuclear staining.</p></sec><sec id="section2G-13872877251372603"><title>Synaptosomes isolation</title><p>Synaptic and cytosolic fractions were isolated using the Syn-PERTM synaptic protein extraction reagent (Thermo Scientific, 87793) using the manufacturer's instructions. Briefly, hippocampal tissue was homogenized with Syn-PER reagent and the PierceTM protease/phosphatase inhibitor cocktail (Thermo Scientific, A32959,). Then, samples were centrifugated at 1200&#8201;&#215;&#8201;g for 15&#8197;min, and the remaining supernatant was centrifuged at 15 000&#8201;&#215;&#8201;g for 20&#8197;min to obtain synaptosome pellet and cytosolic supernatant. Ten micrograms of each sample were heated at 95 &#176;C for10&#8197;min in Laemmli sample buffer and subjected to SDS-PAGE for 1&#8197;h at 100&#8197;V. Proteins were wet-transferred to a nitrocellulose membrane for 2&#8197;h at 400&#8197;mA. Membranes were blocked with EveryBlot blocking buffer (Bio-Rad, 12010020), followed by blotting protocol, as previously mentioned.<sup>
<xref rid="bibr38-13872877251372603" ref-type="bibr">38</xref>
</sup></p></sec><sec id="section2H-13872877251372603"><title>Mouse primary cortical neurons</title><p>Primary cortical neurons were obtained from mouse postnatal animals&#8217; day 0 (P0). Briefly, P0 mouse pups were obtained following ethical approval procedures. Pups were rapidly decapitated, and the brains were carefully removed and placed in cold PBS 1&#215;. Under a dissecting microscope, the cerebral cortices were isolated from the meninges and hippocampi. Isolated cortices were mechanically dissociated into small pieces using sterile scalpels. The tissue fragments were then incubated for 15&#8197;min at 37 &#176;C in an enzyme solution containing trypsin (Thermo Fisher, 15090046) 2.5% (wt/vol) in PBS 1&#215; supplemented with 20&#8197;U/ml DNAse I (Sigma-Aldrich, 11284932001). Following incubation, the tissue was gently triturated using fire-polished Pasteur pipettes of varying diameters to achieve a homogenous cell suspension. The cell suspension was centrifuged at 200&#8201;&#215;&#8201;g for 5&#8197;min at room temperature. The supernatant was discarded, and the cell pellet was resuspended in a complete neuronal culture medium containing Neurobasal medium (Invitrogen, 21103049) supplemented with 2% B27 supplement (Invitrogen, 17504044), 1% Penicillin/Streptomycin (Invitrogen, 15140148), and 200&#8197;mM of Glutamax 1&#215; (Invitrogen, 35050061). Cell viability was assessed using trypan blue, and the cells were plated at a density of 50,000 on poly-D-lysine-coated (Invitrogen, A3890401) microfluidic chambers (Xona Microfluidics, SND450). Cultures were maintained in a humidified incubator at 37 &#176;C with 5% CO<sub>2</sub>. After 2&#8197;h, half of the medium was replaced with fresh neuronal culture medium. Thereafter, half of the medium was exchanged with fresh neuronal media every other day.</p></sec><sec id="section2I-13872877251372603"><title>Microfluidic system</title><p>Microfluidic chambers were used from Xona, No. SND450. The sterile chambers were mounted on glass coverslips previously treated with poly-L-lysine for 30&#8197;min at 37 &#176;C. Once adhered, chambers were incubated at 80 &#176;C for 1&#8197;h to allow the adhesion between the chamber and the glass. Chambers were exposed to UV light for 5&#8197;min for sterilization followed by the application of 100&#8197;&#956;l of neuronal culture medium to each chamber, and then 50,000 primary WT mouse neurons were plated (Adapted from previous work<sup>
<xref rid="bibr39-13872877251372603" ref-type="bibr">39</xref>
</sup>).</p></sec><sec id="section2J-13872877251372603"><title>Adeno associated virus (AAV) production and transduction</title><p>P301S (0N4R) was cloned and packaged in an AAV9 vector as described before,<sup>
<xref rid="bibr40-13872877251372603" ref-type="bibr">40</xref>
</sup> with modifications. Briefly, V5-tagged Tau (1N4R<sup>P301L</sup>) and Tau (1N4R<sup>P301L/S214A</sup>), and GFP expression plasmids were cloned into an AAV vector and then the different AAV were packaged by VectorBuilder.</p><p>For transduction in microfluidics, 1&#8197;&#181;L with 10<sup>
<xref rid="bibr10-13872877251372603" ref-type="bibr">10</xref>
</sup> viral particles was applied directly to the upper-left compartment and allowed to diffuse through the left chamber by volume difference. Neuronal culture medium was changed every 48&#8197;h.</p></sec><sec id="section2K-13872877251372603"><title>Drosophila stocks and genetics</title><p><italic toggle="yes">Drosophila melanogaster</italic> stocks and crosses were maintained on Nutri-fly Bloomington formulation (Genesee Scientific) at 25 &#176;C in a 12-h light/dark cycle. All the fly experiments were performed on day 10 post-eclosion. Transgene overexpression was achieved with the Gal4/UAS system, using the GMR-Gal4 line (BDSC, #9146). For human tau overexpression, tau 2N4R harboring the P301L and S214A mutation sequences was cloned downstream of the Gal4-responsive upstream activating sequences into the pUAST plasmid (Vectorbuilder) and then microinjected in fly embryos (Bestgene). pUAST plasmid allows the integration of the plasmid containing the gene of interest in the <italic toggle="yes">Drosophila</italic> genome. Selection of transformants is possible due to the white gene, conferring eye color to transgenic flies. Soluble fly head homogenates were obtained by manual homogenization of at least 10 fly heads in TBS 1&#215; and proteinase/phosphatase cocktail inhibitors (Thermo) followed by centrifugation at 15,000&#8197;rpm for 10&#8197;min. Supernatants were stored at &#8722;80 &#176;C.</p></sec><sec id="section2L-13872877251372603"><title>Statistical analyses</title><p>All experimental analyses and data collection was performed in a blinded fashion. All p-values were determined using the appropriate statistical method using GraphPad Prism, as described throughout the manuscript. For simple comparisons, a Student's t-test was used. For multiple comparisons, ANOVA followed by the appropriate post hoc analysis was utilized. Data are presented as the mean&#8201;&#177;&#8201;SEM (*p&#8201;&lt;&#8201;0.05, **p&#8201;&lt;&#8201;0.01, and ***p&#8201;&lt;&#8201;0.001). To identify correlations between phospho-tau epitopes and seeding activity, Spearman's correlation was used.</p></sec></sec><sec id="section3-13872877251372603"><title>Results</title><sec id="section3A-13872877251372603"><title>Tau seeding activity is an early pathological manifestation and increases with age in two mouse models of tauopathy</title><p>Considering the significant heterogeneity of the tau seed observed among individuals with tauopathies<sup>
<xref rid="bibr31-13872877251372603" ref-type="bibr">31</xref>
</sup> as well as in disease progression, we aimed to investigate and characterize the tau seeding activity in relation to disease progression. To gain a deeper understanding of the underlying mechanism of tau pathology, we used two different mouse models of human tauopathies. We chose these models due to their relevance and proven efficacy in studying the pathological changes in tau protein.<sup><xref rid="bibr33-13872877251372603" ref-type="bibr">33</xref>,<xref rid="bibr34-13872877251372603" ref-type="bibr">34</xref></sup> One of the models expresses the human tau isoform 1N4R with the P301S mutation (P301S (1N4R), also known as the PS19 mouse model).<sup>
<xref rid="bibr33-13872877251372603" ref-type="bibr">33</xref>
</sup> This model has been extensively characterized and is known to develop NFTs-like pathology at 6 months of age and behavioral impairment at 9 months of age. The second model expresses the smallest 4-repeat human isoform of tau (0N4R) with the P301S mutation (P301S (0N4R)).<sup>
<xref rid="bibr34-13872877251372603" ref-type="bibr">34</xref>
</sup> In this model, it is possible to observe AT8-positive tau deposits as early as 5 to 6 months of age, and, starting at 8 months of age, these mice show motor and behavioral deficits such as the inability to spread hind limbs upon tail elevation, lack of grooming, inability to grip a wire cage, and hind limb dystonia.<sup>
<xref rid="bibr34-13872877251372603" ref-type="bibr">34</xref>
</sup> To measure tau seeding bioactivity in these models, we utilized a widely used HEK cell-based assay that relies on flow cytometry detection of FRET.<sup>
<xref rid="bibr32-13872877251372603" ref-type="bibr">32</xref>
</sup> FRET can be created by the intracellular aggregation of the endogenously expressed repeat domain of tau (TauRD) fused with the cyan fluorescent protein (TauRD-CFP) and the yellow fluorescent protein (TauRD-YFP) in stably expressing HEK-293 cells.<sup>
<xref rid="bibr32-13872877251372603" ref-type="bibr">32</xref>
</sup></p><p>We collected mouse brains aged 2&#8211;9 months from both tauopathy models. Each brain was fully homogenized in TBS buffer with no detergent, and lysates were transfected into the tau-biosensor cell line. After forty-eight hours, we detected strong seeding activity from both tauopathy model brain homogenates, whereas WT and tau knock-out mice did not display any seeding activity (<xref rid="fig1-13872877251372603" ref-type="fig">Figure 1</xref>). The seeding activity was observed as early as in 2-month-old brain samples and seems to be increased over time in both tau models. This data supports the notion that tau seeding is an early and robust marker of pathology progression and occurs much earlier than the appearance of standard NFT histopathology in two different mouse models of human tauopathies.</p><fig position="float" id="fig1-13872877251372603" orientation="portrait"><label>Figure 1.</label><caption><p>Tau seeding activity is an early pathological manifestation and increases with age in two models of tauopathy. (A, B) Integrated FRET quantification from cells transfected with TBS-based brain lysates from 2&#8211;9 months old P301S (0N4R) (A) and P301S (1N4R) (B) mouse models. Each dot represents the average of three technical replicates per lysate. (C, D) representative integrated FRET signals (C) and fluorescent images (D) from HEK tau-biosensor cell lines used from tau seeding activity qualifications. Each dot represents the average of 3 technical replicates for one individual, and the experiment was performed using 3 different animals (n&#8201;=&#8201;3). Values are represented as the mean&#8201;&#177;&#8201;s.e.m.; n&#8201;=&#8201;3. Scale bar: 100&#8197;&#181;m.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_13872877251372603-fig1.jpg"/></fig></sec><sec id="section3B-13872877251372603"><title>Tau phosphorylation at serine 214 correlates with seeding activity in disease progression in two mouse models of tauopathy</title><p>After characterizing the temporal profile of tau seeding activity in the brains of both tauopathy mouse models, we aimed to correlate these profiles with a diverse set of phospho-tau and conformational tau species. To do so, we utilized the same mouse brain TBS-lysates used for seeding activity analysis and performed western blot analysis using the following antibodies: HT7 for total human tau, AT8 for pTau-S202/T205, AT100 for pTau-T212/S214, PHF6 for pTau-T231, anti pTau-T212, anti pTau-S214, anti pTau-T217, anti pTau-S262, PHF1 for pTau-S396/S404 and MC1 that recognizes amino acids on both the N-terminal (amino acids 7&#8211;9) and within the repeat domain (amino acids 313&#8211;322) of tau (<xref rid="fig2-13872877251372603" ref-type="fig">Figure 2A</xref>, B). Spearman's rank correlation between the percentage of positive FRET signal and tau species abundance quantified from the blots was used to identify tau species that correlate with the temporal evolution of tau seeding. To enable a comparison of each tau species on the same axis (<xref rid="fig2-13872877251372603" ref-type="fig">Figure 2C</xref>, D), each species&#8217; abundance was normalized to the average abundance over all the cases. This ensures that the average in normalized abundance is equal to 1 for each tau species. In this study, we focused on tau species with a positive correlation with seeding activity, which allowed us to determine the species that followed the disease progression in the context of the amount of seeding activity. In the case of the P301S (0N4R) mouse model, pTau-Ser214 species displayed a significant positive correlation (p&#8201;=&#8201;0.007) with tau seeding activity in overall disease progression (<xref rid="fig2-13872877251372603" ref-type="fig">Figure 2C</xref>). Furthermore, the tau species with a significant positive correlation with the tau seeding activity in the P301S (1N4R) model were pTau-Thr217 (p&#8201;=&#8201;0.0226) and pTau-Ser214 (p&#8201;=&#8201;0.0142) (<xref rid="fig2-13872877251372603" ref-type="fig">Figure 2D</xref>).</p><fig position="float" id="fig2-13872877251372603" orientation="portrait"><label>Figure 2.</label><caption><p>Tau phosphorylation at serine 214 correlates with seeding activity in disease progression in two mouse models of tauopathy. (A, B) Characterization of different tau species (HT7 for total human tau, AT8 for pTau-Ser202/Thr205, AT100 for pTau-Thr212/Ser214, PHF6 for pTau-Thr231, anti-pTau-Thr212, anti-pTau-Ser214, anti-pTau-Thr217, anti-pTau-Ser262, PHF1 for pTau-Ser396/S404, and MC1 that recognizes misfolded tau) in full brain TBS-lysates from 2&#8211;9 months P301S (0N4R) (A) and P301S (1N4R) (B) mouse models. (C, D) Correlation between percentage of FRET signal in the P301S (0N4R) (C) and P301S (1N4R) (D) mouse models with phosphorylated tau species. Dots indicate the average of three animals, each one quantified in technical triplicates. Red values indicate significance for positive correlations. Values are represented as the mean&#8201;&#177;&#8201;s.e.m.; n&#8201;=&#8201;3.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_13872877251372603-fig2.jpg"/></fig><p>Considering that pTau-Ser214 was the only tau species with a significant positive correlation with tau seeding activity during disease progression in both mouse models of tauopathy, these results suggested that tau phosphorylation at serine 214 could be a reliable marker to correlate and/or follow the pathogenic evolution of tau species with seeding activity despite the heterogeneity of the tau seed among individuals and animal models of tauopathy.<sup>
<xref rid="bibr31-13872877251372603" ref-type="bibr">31</xref>
</sup></p></sec><sec id="section3C-13872877251372603"><title>Tau phosphorylated at serine 214 is observed at an early-stage disease with distinct histopathological features from AT8-positive tau species</title><p>To characterize the histopathological features of pTau-Ser214 during disease progression, hippocampal sections from both tauopathy models were stained with anti pTau-Ser214 antibodies at three different ages (3, 6, and 9 months). Interestingly, pTau-Ser214 pathology was observed in the hippocampus of 3-month-old P301S (0N4R) and P301S (1N4R) mice (<xref rid="fig3-13872877251372603" ref-type="fig">Figure 3A</xref>, B), much earlier than the appearance of NFT-like pathology.<sup><xref rid="bibr33-13872877251372603" ref-type="bibr">33</xref>,<xref rid="bibr34-13872877251372603" ref-type="bibr">34</xref></sup> In both models, pTau-Ser214 pathology was initially observed in the CA3 region of the hippocampus and mossy fiber projecting from the dentate gyrus. An increase of pTau-Ser214 staining was observed in both models at 6 months of age in the dentate gyrus, CA3, and other areas of the hippocampus such as CA2 and even CA1 in the case of the P301S (0N4R) model (<xref rid="fig3-13872877251372603" ref-type="fig">Figure 3A</xref>, B, top panels). At 9 months of age, which represents a late stage of the pathology for both models,<sup><xref rid="bibr33-13872877251372603" ref-type="bibr">33</xref>,<xref rid="bibr34-13872877251372603" ref-type="bibr">34</xref></sup> pTau-Ser214 staining was significantly increased in the hippocampus, mossy fibers, and dentate gyrus (<xref rid="fig3-13872877251372603" ref-type="fig">Figure 3A</xref>, B, top panels). The monoclonal antibody AT8, which recognizes the double phosphorylation at serine 202 and Threonine 205 on aggregated tau protein, has been widely recognized as a gold standard for the detection of tau pathology, particularly in the form of NFTs by IHC.<sup><xref rid="bibr12-13872877251372603" ref-type="bibr">12</xref>,<xref rid="bibr41-13872877251372603" ref-type="bibr">41</xref></sup> Therefore, we stained adjacent sections from both models with the AT8 antibody. As previously reported for both mouse models used in this study, AT8-positive tau was observed at later stages of pathology (<xref rid="fig3-13872877251372603" ref-type="fig">Figure 3A</xref>, B, bottom panels). In the P301S (0N4R) model, AT8 staining was barely observed at 6 months with a substantial increase in signal at 9 months (<xref rid="fig3-13872877251372603" ref-type="fig">Figure 3A</xref>, bottom panel). Similarly, in the P301S (1N4R) model, AT8-positive tau pathology was observed at 9 months (<xref rid="fig3-13872877251372603" ref-type="fig">Figure 3B</xref>, bottom panel).</p><fig position="float" id="fig3-13872877251372603" orientation="portrait"><label>Figure 3.</label><caption><p>Tau phosphorylated at serine 214 is observed at an early stage of the disease and develops before the formation of AT8-positive tau inclusions. Sagittal hippocampal brain sections from both (A) Tau P301S (0N4R) and (B) Tau P301S (1N4R) tauopathy models were stained using specific antibodies against pTau-Ser214 and AT8 at 3, 6, and 9-month-old to characterize the histopathological deposition of these phospho-tau species. No positive immunostaining was observed in wild-type mice (right panel). Staining was performed with an n&#8201;=&#8201;3.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_13872877251372603-fig3.jpg"/></fig><p>To better characterize the differences observed at a late stage of pathology between AT8 and pTau-Ser124 pathology, we performed IHC of both markers in 9-month-old mice from both tauopathy models. Upon closer examination of the hippocampus of brain sections using higher magnification, pTau-Ser214 pathology was widely distributed in both tau models. The staining was not limited to the cytoplasm but was predominantly distributed to the axons in the CA3 and DG regions (<xref rid="fig4-13872877251372603" ref-type="fig">Figure 4</xref>, top panel). Whereas in adjacent sections AT8 staining revealed the presence of NFTs-like pathology, which is not detected by the pTau-Ser214 antibody, in the hippocampus and DG from both mouse models (<xref rid="fig4-13872877251372603" ref-type="fig">Figure 4</xref>, bottom panel). It is worth noticing that the AT8 antibody did not stain for tau in axons in CA3 and DG.</p><fig position="float" id="fig4-13872877251372603" orientation="portrait"><label>Figure 4.</label><caption><p>The staining pattern of tau phosphorylated at serine 214 differs from AT8-positive tau species in two different tauopathies mouse models. (A) Immunohistochemical staining using antibodies against pTau-Ser214 and AT8 at 9 months old in both the P301S (0N4R, upper panel) and P301S (1N4R, lower panel) mouse models. Scale bar: 250&#8197;&#181;m (low magnification hippocampus), and 100&#8197;&#181;m (region-specific hippocampal insets); n&#8201;=&#8201;3.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_13872877251372603-fig4.jpg"/></fig><p>To confirm this observation, we perform double immunofluorescences of pTau-Ser214 and AT8 in the hippocampal brain section of 9-month-old of both mouse models. Double immunostaining confirmed that the AT8 staining pattern differs from pTau-Ser214 in both models, where AT8 detected NFTs-like pathology and pTau-Ser214 resembled pre-tangles and tau in axons (<xref rid="fig5-13872877251372603" ref-type="fig">Figure 5A</xref>, B), suggesting the diversity of tau species within the brain.</p><fig position="float" id="fig5-13872877251372603" orientation="portrait"><label>Figure 5.</label><caption><p>Tau phosphorylated at serine 214 is differentially distributed compared to AT8-positive staining. (A, B) Double immunofluorescence using specific antibodies against pTau-Ser214 (red) and AT8 (green) was performed in brain sections of 9-month-old brains in the (A) Tau P301S (0N4R) and (B) Tau P301S (1N4R) tauopathy models to analyze their spatial distribution in the hippocampus; n&#8201;=&#8201;3.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_13872877251372603-fig5.jpg"/></fig></sec><sec id="section3D-13872877251372603"><title>Tau species phosphorylated at serine 214 but not at serine 202/ Threonine 205 (AT8) are deposited in the synaptic compartment</title><p>A recent study has demonstrated the presence of tau species with seeding activity in cytosolic and synaptic fractions from AD patients&#8217; brain samples.<sup>
<xref rid="bibr17-13872877251372603" ref-type="bibr">17</xref>
</sup> Based on this observation, we aimed to determine if there is a compartmentalized accumulation of pTau-Ser214 species with seeding activity present in the cytosol and/or synapses as observed in AD patients.<sup>
<xref rid="bibr17-13872877251372603" ref-type="bibr">17</xref>
</sup> To do this, we isolated TBS-soluble synaptosomes and cytosolic fractions from the hippocampus of 9-month-old P301S (1N4R) animals (<xref rid="fig6-13872877251372603" ref-type="fig">Figure 6</xref>). Tau seeding activity in P301S (1N4R) mice was detected in both cytosolic and synaptic fractions (<xref rid="fig6-13872877251372603" ref-type="fig">Figure 6A</xref>). We then performed western blot analysis using anti pTau-Ser214, AT8, and HT7 tau antibodies; PSD95 was used to confirm synaptic compartment enrichment. The analysis revealed that pTau-Ser214 is accumulated in the cytosolic fraction and the synaptic compartment (<xref rid="fig6-13872877251372603" ref-type="fig">Figure 6B</xref>, E). Interestingly, AT8 is highly accumulated in the cytosolic fraction and was not detected in the synaptic fraction (<xref rid="fig6-13872877251372603" ref-type="fig">Figure 6C</xref>, E), with no changes in the distribution of total human tau quantified with HT7 antibody (<xref rid="fig6-13872877251372603" ref-type="fig">Figure 6D</xref>). Altogether, these results suggest differences in the accumulation of tau species between synaptic and cytosolic compartments, supporting the idea of the heterogeneity of pathological tau species with seeding activity that are not only within the same brain tissue but also within the same individual cell.</p><fig position="float" id="fig6-13872877251372603" orientation="portrait"><label>Figure 6.</label><caption><p>Tau phosphorylation at serine 214 is deposited in the synaptic compartment. (A) Tau seeding activity in cytosolic and synaptic TBS-soluble hippocampal fractions from 6 months old Tau P301S (1N4R) mouse model. Significance was determined by ordinary one-way ANOVA; n&#8201;=&#8201;6. (B-E) Quantifications of pTau-Ser214 (B), AT8 (C), and HT7 (D) levels of a western blot (E) using cytosolic (C) and synaptic (S) fractions. PSD95 antibody was used to confirm synaptic compartment enrichment. Values are represented as the mean&#8201;&#177;&#8201;s.e.m, and significance was determined by two-way ANOVA; n&#8201;=&#8201;3.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_13872877251372603-fig6.jpg"/></fig></sec><sec id="section3E-13872877251372603"><title>Phosphorylation of tau<sup>P301L</sup> at serine 214 is involved in the transsynaptic propagation of pathological tau species</title><p>Considering previous studies suggesting that tau aggregates propagate transynaptically and our results showing that the levels of pTau-Ser214 correlate with tau seeding activity during disease progression and how this phospho-tau species accumulates at the synapse, we addressed the question of whether phosphorylation of tau at serine 214 has a pathological role in tau seeding activity as well as the transsynaptic propagation of tau. First, to evaluate the effect of pTau-Ser214 in seeding activity, we utilized a transgenic <italic toggle="yes">Drosophila melanogaster</italic> model developed in our laboratory, which consists of a fly overexpressing the human tau 2N4R carrying the P301L (tau<sup>P301L</sup>), or both P301L and S214A mutations (tau<sup>P301L/S214A</sup>) under the GMR-Gal4 driver (<xref rid="fig7-13872877251372603" ref-type="fig">Figure 7A</xref>). This in vivo model allows us to study the effect of introducing specific mutation to tau models in the context of the seeding activity and other pathological events as tau accumulation. We used head TBS-soluble lysate from 10-day-old flies to further quantify seeding activity in the HEK biosensor cell line. The overexpression of the tau<sup>P301L</sup> mutant showed a robust seeding activity (<xref rid="fig7-13872877251372603" ref-type="fig">Figure 7B</xref>). Interestingly, when introducing the phospho-dead mutation S214A in tau<sup>P301L</sup> flies, fly head lysates showed a slight but significant decrease in seeding activity (p&#8201;=&#8201;0.006), suggesting that S214A may influence seeding activity but is not critical for tau-seed formation itself (<xref rid="fig7-13872877251372603" ref-type="fig">Figure 7B</xref>). Quantification of tau levels by western blot revealed that tau<sup>P301L</sup>, and tau<sup>P301L/S214A</sup> flies had no significant differences on the accumulation of human tau (<xref rid="fig7-13872877251372603" ref-type="fig">Figure 7C</xref>).</p><fig position="float" id="fig7-13872877251372603" orientation="portrait"><label>Figure 7.</label><caption><p>Phosphorylation of tau<sup>P301L</sup> at serine 214 is involved in spreading pathological tau. (A) Schematic of the Gal4-UAS crosses utilized to overexpress human tau<sup>P301L</sup> or tau<sup>P301L/S214</sup> under the GMR driver (eye promoter). (B) Integrated FRET density (seeding activity) in fly head lysates from WT controls, and flies overexpressing human tau<sup>P301L</sup> or tau<sup>P301L/S214A</sup> mutations. Significance was determined by one-way ANOVA. Each dot represents a pool of 20 heads (each pool of 20 heads is represented as a single dot in the quantification; equal number of males and females). (C) Total tau levels were quantified by western blot using the HT7 antibody to specifically detect human tau. Significance was determined by one-way ANOVA. Each dot represents a pool of 20 heads. (D) Immunofluorescence against hTau (HT7, Red) in primary mouse neonatal cortical neurons plated in both microfluidic chambers. Neurons were transduced in the first chamber at 1 DIV with an AAV9 harboring plasmids coding for either tau<sup>P301L</sup> or tau<sup>P301L/S214A</sup> and tagged with V5. The second chamber shows the spreading of tau from the first chamber. Scale bar: 100&#8197;&#181;m. (E) Quantification of Tau spreading in Chamber 2 and normalized by the number of nuclei in (F); Triangle for N1, Square for N2, and Circle for N3. Values are represented as the mean&#8201;&#177;&#8201;s.e.m from 3 independent experiments (n&#8201;=&#8201;3, each n represent a different mouse brain for neuronal culture), and significance was determined by t-test.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_13872877251372603-fig7.jpg"/></fig><p>In another set of experiments, to evaluate if phosphorylation of tau at serine 214 is relevant for transsynaptic propagation, we cultured mouse wild-type neonatal cortical neurons in microfluidic chambers and transduced them with two different AAV9, one coding for the human tau harboring the pathological mutation tau<sup>P301L</sup>, and another one harboring the tau<sup>P301L/S214A</sup> double mutant. The microfluidic chamber facilitates the culture of neurons in two distinct chambers, which are separated by microchannels, allowing the visualization and quantification of the propagation of pathological tau from one chamber to the next one, as previously reported.<sup>
<xref rid="bibr42-13872877251372603" ref-type="bibr">42</xref>
</sup> This design enables the extension of neuron axons through the microchannels, allowing them to establish synaptic connections with neurons located in the second chamber.<sup><xref rid="bibr43-13872877251372603" ref-type="bibr">43</xref>,<xref rid="bibr44-13872877251372603" ref-type="bibr">44</xref></sup> While one chamber was transduced with the tau encoding AAV9, the second chamber was not transduced, to allow tau to spread from the first chamber to the second one. Immunostainings against HT7 revealed that tau<sup>P301L</sup> propagation was increased in the neurons in the second chamber (<xref rid="fig7-13872877251372603" ref-type="fig">Figure 7D</xref>-F), consistent with previous literature.<sup><xref rid="bibr42-13872877251372603" ref-type="bibr">42</xref>,<xref rid="bibr45-13872877251372603" ref-type="bibr">45</xref></sup> Interestingly, the replacement of the serine 214 by alanine prevented phosphorylation at this site and more importantly, significantly decreased the spreading of the pathological tau into the second chamber (p&#8201;=&#8201;0.01), supporting the notion of the role of pTau-Ser214 in tau transsynaptic spreading (<xref rid="fig7-13872877251372603" ref-type="fig">Figure 7D</xref>-F). Overall, these results suggest that the phosphorylation of tau at serine 214 is not an essential phosphorylation to promote the formation of the tau-seed but rather is important for tau to reach the synaptic terminal, facilitating the synaptic accumulation of tau which could be a key event for the transsynaptic propagation of the tau-seed.</p></sec></sec><sec id="section4-13872877251372603"><title>Discussion</title><p>The accumulation and deposition of abnormal tau protein in the brain is a hallmark feature of tauopathies, a group of neurodegenerative disorders that includes Alzheimer's disease. One important aspect of tau pathology is the spreading and seeding activity of these aberrant and toxic forms of tau, which refers to its ability to induce the aggregation of other tau molecules and promote the spread of tau pathology throughout the brain. Despite the significant progress in understanding tau pathology,<sup>
<xref rid="bibr17-13872877251372603" ref-type="bibr">17</xref>
</sup> the precise cellular mechanism underlying tau propagation and the identity of the specific tau species involved in the seeding process remain unanswered. Our results support previous findings demonstrating tau seeding activity as early as 2 months in two mouse models of tauopathy, a significant period before the onset of synaptic impairments, glial activation, NFT pathology, and behavioral deficits.<sup><xref rid="bibr33-13872877251372603" ref-type="bibr">33</xref>,<xref rid="bibr34-13872877251372603" ref-type="bibr">34</xref></sup> Additionally, we found that the early seeding activity increases with age in these tau models. These observations suggest that tau seeding activity may represent an early and important step in the pathogenesis and temporal progression of tauopathy and that targeting this process may represent a promising therapeutic strategy.</p><p>Toxic aberrant tau species can be found in a hyperphosphorylated and aggregated state leading to the formation of NFTs, that accumulate within the neurons, leading to dysfunction and eventual death.<sup><xref rid="bibr46-13872877251372603" ref-type="bibr">46</xref>,<xref rid="bibr47-13872877251372603" ref-type="bibr">47</xref></sup> Nevertheless, a growing literature on tauopathies suggests that NFTs are not the primary toxic entities in these disorders.<sup><xref rid="bibr33-13872877251372603" ref-type="bibr">33</xref>,<xref rid="bibr48-13872877251372603" ref-type="bibr">48</xref><xref rid="bibr49-13872877251372603" ref-type="bibr"/>&#8211;<xref rid="bibr50-13872877251372603" ref-type="bibr">50</xref></sup> Instead, accumulating evidence suggests that soluble hyperphosphorylated tau species are the primary mediators of seeding activity and neurotoxicity.<sup><xref rid="bibr33-13872877251372603" ref-type="bibr">33</xref>,<xref rid="bibr51-13872877251372603" ref-type="bibr">51</xref><xref rid="bibr52-13872877251372603" ref-type="bibr"/><xref rid="bibr53-13872877251372603" ref-type="bibr"/><xref rid="bibr54-13872877251372603" ref-type="bibr"/>&#8211;<xref rid="bibr55-13872877251372603" ref-type="bibr">55</xref></sup> In addition, it has been observed that different tauopathies exhibit a great diversity of hyperphosphorylated tau aggregates, which correspond to distinct pathological tau &#8220;strains&#8221; that are associated with different clinical manifestations.<sup><xref rid="bibr24-13872877251372603" ref-type="bibr">24</xref>,<xref rid="bibr27-13872877251372603" ref-type="bibr">27</xref></sup> The identification of these pathological tau strains adds a layer of complexity when attempting to block the spread of tau seed, which has proven difficult due to the unknown structure of the tau seed and the recent studies confirming the molecular diversity of seeding-competent tau in both in vitro and in vivo models.<sup><xref rid="bibr23-13872877251372603" ref-type="bibr">23</xref><xref rid="bibr24-13872877251372603" ref-type="bibr"/><xref rid="bibr25-13872877251372603" ref-type="bibr"/><xref rid="bibr26-13872877251372603" ref-type="bibr"/>&#8211;<xref rid="bibr27-13872877251372603" ref-type="bibr">27</xref></sup> This complexity makes it exceedingly challenging to determine the exact epitope or post-translational modification to target tau. Here, we performed a detailed correlation analysis between a diverse set of phospho-tau and conformational tau species with seeding activity and demonstrated that the tau phosphorylation at serine 214 (pTau-Ser214) is the only one that positively correlated with seeding activity in two different mouse models of tauopathy during disease progression. This suggests that the pTau-Ser214 site represents a possible candidate as a reliable biomarker to track and correlate the evolution and progression of tau species with seeding capability, within individuals and animal models of tauopathy. pTau-Ser214 phosphorylation is a post-translational modification of tau that has been implicated in various aspects of neuronal function, including microtubule binding and stability. While the exact physiological role of 214 phosphorylation is still under investigation, it is known to be involved in early-stage tau pathology.<sup>
<xref rid="bibr56-13872877251372603" ref-type="bibr">56</xref>
</sup></p><p>Interestingly, at an early stage of the disease, we observed that pTau-Ser214 has a distinct histopathological distribution from other tau species that are positive for the AT8 antibody, a marker for late-stage tau pathology. AT8 has been widely utilized for tau pathology detection, particularly in the form of NFTs by IHC in AD patients.<sup><xref rid="bibr12-13872877251372603" ref-type="bibr">12</xref>,<xref rid="bibr44-13872877251372603" ref-type="bibr">44</xref></sup> Its relevance lies in its ability to identify and quantify the accumulation of NFT in brain tissue samples, providing a tool to determine the AD stage. Although both pTau-Ser214 and AT8-positive tau species increase with disease progression, we observed a lack of spatial and temporal overlap between these two markers in the hippocampus, particularly at late stages. This apparent discrepancy may reflect the existence of distinct tau species with unique post-translational modification profiles and aggregation behaviors. Recent evidence supports the notion that tau can misfold into conformationally distinct assemblies (referred to as &#8220;strains&#8221;) that exhibit different seeding potencies and pathological outcomes.<sup>
<xref rid="bibr57-13872877251372603" ref-type="bibr">57</xref>
</sup> These tau strains may preferentially adopt phosphorylation signatures that are not uniformly detectable by canonical antibodies such as AT8.</p><p>Our results demonstrate that AT8-positive tau species are absent in synaptic compartments. On the other hand, we found that pTau-Ser214 is deposited in the synaptic compartment. This is an important observation, not only because the synaptic compartment is a critical site for neuronal communication and function, but also because the deposition of hyperphosphorylated tau species at this site may contribute to the cognitive and behavioral deficits observed in tauopathies and could promote the transsynaptic propagation of tau.<sup>
<xref rid="bibr17-13872877251372603" ref-type="bibr">17</xref>
</sup> Synaptic accumulation of pTau-Ser214 with seeding activity and the distinct pattern to AT8 species not only reveals the diversity in aberrant tau conformations and phosphorylation states within the brain during disease progression but also supports the idea that phosphorylation at serine 214 could be key for toxic tau species to reach and accumulate at the synapse and subsequently trigger the transsynaptic propagation. Recent work from our laboratory established a correlation between behavioral deficits and different pathological tau species in a mouse model for tauopathy, suggesting that each tau species analyzed (including soluble pTau-Ser214) could be responsible for a variety of behavioral deficits in PS19 (1N4R tau isoform) mouse model.<sup>
<xref rid="bibr35-13872877251372603" ref-type="bibr">35</xref>
</sup> Other studies suggest that the structural diversity of tau aggregates may contribute to the differences in symptoms and pathologies observed in neurodegenerative tauopathies.<sup>
<xref rid="bibr58-13872877251372603" ref-type="bibr">58</xref>
</sup> However, conclusive mechanistic investigations of tau proteins face significant barriers due to the inconsistent tau species being studied, which is crucial since the aggregated state of tau plays a critical role in its pathological evolution.<sup>
<xref rid="bibr59-13872877251372603" ref-type="bibr">59</xref>
</sup> Moreover, tau can exhibit conformational differences, leading to various downstream effects,<sup><xref rid="bibr27-13872877251372603" ref-type="bibr">27</xref>,<xref rid="bibr60-13872877251372603" ref-type="bibr">60</xref></sup> based on a novel study showing that different tau conformations resulting from the Tau<sup>P301L</sup> mutation can drive distinct phenotypes in FTLD patients.<sup>
<xref rid="bibr61-13872877251372603" ref-type="bibr">61</xref>
</sup></p><p>The phosphorylation of tau at specific sites can influence other toxic characteristics. For instance, phosphorylation of tau at specific sites has been shown to influence tau aggregation and tau seeding activity.<sup>
<xref rid="bibr8-13872877251372603" ref-type="bibr">8</xref>
</sup> Similarly, phosphorylation at specific sites may contribute to a greater propensity of tau to spread/propagate and the pattern in which it propagates.<sup><xref rid="bibr62-13872877251372603" ref-type="bibr">62</xref>,<xref rid="bibr63-13872877251372603" ref-type="bibr">63</xref></sup> Our results suggested that pTau-Ser214 is involved in the transsynaptic propagation of pathological tau in neuronal culture with a minor effect to in vivo seed formation. Taking into consideration that pTau-Ser214 is also enriched in the synaptic terminal, altogether these results suggest that tau phosphorylation at serine 214 is not required for the formation of the tau-seed but rather is essential to reach the synaptic terminal, therefore facilitating tau transsynaptic transmission.</p><p>In conclusion, our study establishes the heterogeneity of tau species with seeding activity not only in the same brain region but at the cellular level as well. Additionally, our findings reveal that tau phosphorylation at serine 214 is an early event in tau pathology, and its levels strongly correlate with seeding activity in an age-dependent manner in two mouse models for tauopathies. Even more, our results suggest that phosphorylation of tau at serine 214 does not significantly affect the formation of the tau-seed but is essential for the accumulation of tau at the synapses which is a key event for the transsynaptic propagation of tau aggregates. Altogether, this study supports the importance of precision strategies to develop tau biomarkers to measure disease progression during aging tailored to the individual patient.</p></sec></body><back><ack><title>Acknowledgements</title><p>We thank all co-authors for their essential contributions to the design and execution of experiments, data analysis, and critical review and editing of the manuscript. Their collaborative efforts were fundamental to the completion of this study.</p></ack><fn-group><fn fn-type="other"><p><bold>ORCID iD:</bold> Cristian A Lasagna-Reeves <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0002-5499-3082" ext-link-type="uri">https://orcid.org/0000-0002-5499-3082</ext-link></p></fn><fn fn-type="other"><p><bold>Ethical considerations:</bold> All animal procedures were conducted in accordance with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health, Bethesda, MD) and approved by the Institutional Animal Care and Use Committee (IACUC) of Indiana University School of Medicine under protocol number 22120. All efforts were made to minimize animal suffering and reduce the number of animals used.</p></fn><fn fn-type="con"><p><bold>Author contributions:</bold>
<bold>Pablo Martinez:</bold> Conceptualization; Funding acquisition; 
Writing &#8211; original draft, Writing &#8211; review &amp; editing.</p><p><bold>Nur Jury-Garfe:</bold> Formal analysis; Investigation. 
<bold>Henika Patel:</bold> Formal analysis; Investigation.</p><p><bold>Yanwen You:</bold> Formal analysis; Investigation.</p><p><bold>Abigail Perkins:</bold> Investigation.</p><p><bold>Yingjian You:</bold> Investigation. 
<bold>Audrey Lee-Gosselin:</bold> Investigation.</p><p><bold>Ruben Vidal:</bold> Formal analysis; Investigation.</p><p><bold>Cristian Lasagna-Reeves:</bold> Conceptualization; Funding acquisition; Resources; Supervision.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by NINDS 1R01NS119280, NIA 1RF1AG059639 grants, and ALZDISCOVERY-1049108 from the Alzheimer's Association grant; the Cure Alzheimer's Foundation and the Rainwater Charitable Foundation to C.A.L.-R., AARFD-21-847663 to P.M. This publication was also supported by the Sara Roush Memorial Fellowship in Alzheimer's Disease, the Indiana Alzheimer's Disease Research Center, and the Stark Neurosciences Research Institute, and made possible by the Indiana Clinical and Translational Sciences Institute, funded in part by grant # UL1TR002529 from the National Institutes of Health, National Center for Advancing Translational Sciences. The funders had no role in the study design, data collection and analysis, decision to publish, or manuscript preparation.</p></fn><fn fn-type="COI-statement"><p>The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: C.A.L.-R. declares a financial interest in Monument Biosciences through stock ownership.</p><p>The remaining authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p></fn><fn fn-type="other"><p><bold>Data availability statement:</bold> Source data are provided in this paper. All other numerical data are available from the corresponding author upon request.</p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-13872877251372603"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>F</given-names></name><name name-style="western"><surname>Gong</surname><given-names>C-X</given-names></name></person-group>. <article-title>Tau exon 10 alternative splicing and tauopathies</article-title>. <source>Mol Neurodegener</source><year>2008</year>; <volume>3</volume>: <fpage>8</fpage>.<pub-id pub-id-type="pmid">18616804</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1750-1326-3-8</pub-id><pub-id pub-id-type="pmcid">PMC2483273</pub-id></mixed-citation></ref><ref id="bibr2-13872877251372603"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goedert</surname><given-names>M</given-names></name><name name-style="western"><surname>Spillantini</surname><given-names>MG</given-names></name><name name-style="western"><surname>Jakes</surname><given-names>R</given-names></name></person-group>, <etal>et al.</etal><article-title>Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer&#8217;s disease</article-title>. <source>Neuron</source><year>1989</year>; <volume>3</volume>: <fpage>519</fpage>&#8211;<lpage>526</lpage>.<pub-id pub-id-type="pmid">2484340</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0896-6273(89)90210-9</pub-id></mixed-citation></ref><ref id="bibr3-13872877251372603"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>GVW</given-names></name><name name-style="western"><surname>Stoothoff</surname><given-names>WH</given-names></name></person-group>. <article-title>Tau phosphorylation in neuronal cell function and dysfunction</article-title>. <source>J Cell Sci</source><year>2004</year>; <volume>117</volume>: <fpage>5721</fpage>&#8211;<lpage>5729</lpage>.<pub-id pub-id-type="pmid">15537830</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1242/jcs.01558</pub-id></mixed-citation></ref><ref id="bibr4-13872877251372603"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gendron</surname><given-names>TF</given-names></name><name name-style="western"><surname>Petrucelli</surname><given-names>L</given-names></name></person-group>. <article-title>The role of tau in neurodegeneration</article-title>. <source>Mol Neurodegener</source><year>2009</year>; <volume>4</volume>: <fpage>13</fpage>.<pub-id pub-id-type="pmid">19284597</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1750-1326-4-13</pub-id><pub-id pub-id-type="pmcid">PMC2663562</pub-id></mixed-citation></ref><ref id="bibr5-13872877251372603"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arriagada</surname><given-names>PV</given-names></name><name name-style="western"><surname>Growdon</surname><given-names>JH</given-names></name><name name-style="western"><surname>Hedley-Whyte</surname><given-names>ET</given-names></name></person-group>, <etal>et al.</etal><article-title>Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer&#8217;s disease</article-title>. <source>Neurology</source><year>1992</year>; <volume>42</volume>: <fpage>631</fpage>&#8211;<lpage>639</lpage>.<pub-id pub-id-type="pmid">1549228</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.42.3.631</pub-id></mixed-citation></ref><ref id="bibr6-13872877251372603"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>G&#243;mez-Isla</surname><given-names>T</given-names></name><name name-style="western"><surname>Hollister</surname><given-names>R</given-names></name><name name-style="western"><surname>West</surname><given-names>H</given-names></name></person-group>, <etal>et al.</etal><article-title>Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer&#8217;s disease</article-title>. <source>Ann Neurol</source><year>1997</year>; <volume>41</volume>: <fpage>17</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="pmid">9005861</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.410410106</pub-id></mixed-citation></ref><ref id="bibr7-13872877251372603"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Augustinack</surname><given-names>JC</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>A</given-names></name><name name-style="western"><surname>Mandelkow</surname><given-names>E-M</given-names></name></person-group>, <etal>et al.</etal><article-title>Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer&#8217;s disease</article-title>. <source>Acta Neuropathol</source><year>2002</year>; <volume>103</volume>: <fpage>26</fpage>&#8211;<lpage>35</lpage>.<pub-id pub-id-type="pmid">11837744</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s004010100423</pub-id></mixed-citation></ref><ref id="bibr8-13872877251372603"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steinhilb</surname><given-names>ML</given-names></name><name name-style="western"><surname>Dias-Santagata</surname><given-names>D</given-names></name><name name-style="western"><surname>Fulga</surname><given-names>TA</given-names></name></person-group>, <etal>et al.</etal><article-title>Tau phosphorylation sites work in concert to promote neurotoxicity in vivo</article-title>. <source>Mol Biol Cell</source><year>2007</year>; <volume>18</volume>: <fpage>5060</fpage>&#8211;<lpage>5068</lpage>.<pub-id pub-id-type="pmid">17928404</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1091/mbc.E07-04-0327</pub-id><pub-id pub-id-type="pmcid">PMC2096612</pub-id></mixed-citation></ref><ref id="bibr9-13872877251372603"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>M</given-names></name><name name-style="western"><surname>Lee</surname><given-names>VM-Y</given-names></name></person-group>. <article-title>Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons</article-title>. <source>J Biol Chem</source><year>1997</year>; <volume>272</volume>: <fpage>19547</fpage>&#8211;<lpage>19553</lpage>.<pub-id pub-id-type="pmid">9235959</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.272.31.19547</pub-id></mixed-citation></ref><ref id="bibr10-13872877251372603"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Drechsel</surname><given-names>DN</given-names></name><name name-style="western"><surname>Hyman</surname><given-names>AA</given-names></name><name name-style="western"><surname>Cobb</surname><given-names>MH</given-names></name></person-group>, <etal>et al.</etal><article-title>Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau</article-title>. <source>Mol Biol Cell</source><year>1992</year>; <volume>3</volume>: <fpage>1141</fpage>&#8211;<lpage>1154</lpage>.<pub-id pub-id-type="pmid">1421571</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1091/mbc.3.10.1141</pub-id><pub-id pub-id-type="pmcid">PMC275678</pub-id></mixed-citation></ref><ref id="bibr11-13872877251372603"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>Y</given-names></name><name name-style="western"><surname>Prokop</surname><given-names>S</given-names></name><name name-style="western"><surname>Giasson</surname><given-names>BI</given-names></name></person-group>. <article-title>&#8220;Don&#8217;t phos over tau&#8221;: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer&#8217;s disease and other tauopathies</article-title>. <source>Mol Neurodegener</source><year>2021</year>; <volume>16</volume>: <fpage>37</fpage>.<pub-id pub-id-type="pmid">34090488</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-021-00460-5</pub-id><pub-id pub-id-type="pmcid">PMC8180161</pub-id></mixed-citation></ref><ref id="bibr12-13872877251372603"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Braak</surname><given-names>H</given-names></name><name name-style="western"><surname>Braak</surname><given-names>E</given-names></name></person-group>. <article-title>Frequency of stages of Alzheimer-related lesions in different age categories</article-title>. <source>Neurobiol Aging</source><year>1997</year>; <volume>18</volume>: <fpage>351</fpage>&#8211;<lpage>357</lpage>.<pub-id pub-id-type="pmid">9330961</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0197-4580(97)00056-0</pub-id></mixed-citation></ref><ref id="bibr13-13872877251372603"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodriguez</surname><given-names>RD</given-names></name><name name-style="western"><surname>Grinberg</surname><given-names>LT</given-names></name></person-group>. <article-title>Argyrophilic grain disease: an underestimated tauopathy</article-title>. <source>Dement Neuropsychol</source><year>2014</year>; <volume>9</volume>: <fpage>2</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1590/S1980-57642015DN91000002</pub-id><pub-id pub-id-type="pmcid">PMC5618985</pub-id><pub-id pub-id-type="pmid">29213935</pub-id></mixed-citation></ref><ref id="bibr14-13872877251372603"><label>14</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Murray</surname><given-names>ME</given-names></name><name name-style="western"><surname>DeTure</surname><given-names>M</given-names></name></person-group>. <part-title>The neuropathology of dementia</part-title>. In: <person-group person-group-type="editor"><name name-style="western"><surname>Smith</surname><given-names>GE</given-names></name><name name-style="western"><surname>Farias</surname><given-names>ST</given-names></name></person-group> (eds) <source>APA Handbook of dementia</source>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>American Psychological Association</publisher-name>, <year>2018</year>, pp.<fpage>41</fpage>&#8211;<lpage>66</lpage>.</mixed-citation></ref><ref id="bibr15-13872877251372603"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>DC</given-names></name><name name-style="western"><surname>Roemer</surname><given-names>S</given-names></name><name name-style="western"><surname>Petrucelli</surname><given-names>L</given-names></name></person-group>, <etal>et al.</etal><article-title>Cellular and pathological heterogeneity of primary tauopathies</article-title>. <source>Mol Neurodegener</source><year>2021</year>; <volume>16</volume>: <fpage>57</fpage>.<pub-id pub-id-type="pmid">34425874</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-021-00476-x</pub-id><pub-id pub-id-type="pmcid">PMC8381569</pub-id></mixed-citation></ref><ref id="bibr16-13872877251372603"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fuster-Matanzo</surname><given-names>A</given-names></name><name name-style="western"><surname>Hern&#225;ndez</surname><given-names>F</given-names></name><name name-style="western"><surname>&#193;vila</surname><given-names>J</given-names></name></person-group>. <article-title>Tau spreading mechanisms; implications for dysfunctional tauopathies</article-title>. <source>Int J Mol Sci</source><year>2018</year>; <volume>19</volume>: <fpage>645</fpage>.<pub-id pub-id-type="pmid">29495325</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms19030645</pub-id><pub-id pub-id-type="pmcid">PMC5877506</pub-id></mixed-citation></ref><ref id="bibr17-13872877251372603"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeVos</surname><given-names>SL</given-names></name><name name-style="western"><surname>Corjuc</surname><given-names>BT</given-names></name><name name-style="western"><surname>Oakley</surname><given-names>DH</given-names></name></person-group>, <etal>et al.</etal><article-title>Synaptic tau seeding precedes tau pathology in human Alzheimer&#8217;s disease brain</article-title>. <source>Front Neurosci</source><year>2018</year>; <volume>12</volume>: <fpage>267</fpage>.<pub-id pub-id-type="pmid">29740275</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2018.00267</pub-id><pub-id pub-id-type="pmcid">PMC5928393</pub-id></mixed-citation></ref><ref id="bibr18-13872877251372603"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>JW</given-names></name><name name-style="western"><surname>Hussaini</surname><given-names>SA</given-names></name><name name-style="western"><surname>Bastille</surname><given-names>IM</given-names></name></person-group>, <etal>et al.</etal><article-title>Neuronal activity enhances tau propagation and tau pathology in vivo</article-title>. <source>Nat Neurosci</source><year>2016</year>; <volume>19</volume>: <fpage>1085</fpage>&#8211;<lpage>1092</lpage>.<pub-id pub-id-type="pmid">27322420</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nn.4328</pub-id><pub-id pub-id-type="pmcid">PMC4961585</pub-id></mixed-citation></ref><ref id="bibr19-13872877251372603"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Calignon</surname><given-names>A</given-names></name><name name-style="western"><surname>Polydoro</surname><given-names>M</given-names></name><name name-style="western"><surname>Su&#225;rez-Calvet</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Propagation of tau pathology in a model of early Alzheimer&#8217;s disease</article-title>. <source>Neuron</source><year>2012</year>; <volume>73</volume>: <fpage>685</fpage>&#8211;<lpage>697</lpage>.<pub-id pub-id-type="pmid">22365544</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2011.11.033</pub-id><pub-id pub-id-type="pmcid">PMC3292759</pub-id></mixed-citation></ref><ref id="bibr20-13872877251372603"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lasagna-Reeves</surname><given-names>CA</given-names></name><name name-style="western"><surname>Castillo-Carranza</surname><given-names>DL</given-names></name><name name-style="western"><surname>Sengupta</surname><given-names>U</given-names></name></person-group>, <etal>et al.</etal><article-title>Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau</article-title>. <source>Sci Rep</source><year>2012</year>; <volume>2</volume>: <fpage>700</fpage>.<pub-id pub-id-type="pmid">23050084</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep00700</pub-id><pub-id pub-id-type="pmcid">PMC3463004</pub-id></mixed-citation></ref><ref id="bibr21-13872877251372603"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanaka</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>K</given-names></name><name name-style="western"><surname>Satake</surname><given-names>K</given-names></name></person-group>, <etal>et al.</etal><article-title>Seeding activity-based detection uncovers the different release mechanisms of seed-competent tau versus inert tau via lysosomal exocytosis</article-title>. <source>Front Neurosci</source><year>2019</year>; <volume>13</volume>: <fpage>1258</fpage>.<pub-id pub-id-type="pmid">31824253</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2019.01258</pub-id><pub-id pub-id-type="pmcid">PMC6881304</pub-id></mixed-citation></ref><ref id="bibr22-13872877251372603"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>JL</given-names></name><name name-style="western"><surname>Narasimhan</surname><given-names>S</given-names></name><name name-style="western"><surname>Changolkar</surname><given-names>L</given-names></name></person-group>, <etal>et al.</etal><article-title>Unique pathological tau conformers from Alzheimer&#8217;s brains transmit tau pathology in nontransgenic mice</article-title>. <source>J Exp Medicine</source><year>2016</year>; <volume>213</volume>: <fpage>2635</fpage>&#8211;<lpage>2654</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20160833</pub-id><pub-id pub-id-type="pmcid">PMC5110027</pub-id><pub-id pub-id-type="pmid">27810929</pub-id></mixed-citation></ref><ref id="bibr23-13872877251372603"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Narasimhan</surname><given-names>S</given-names></name><name name-style="western"><surname>Guo</surname><given-names>JL</given-names></name><name name-style="western"><surname>Changolkar</surname><given-names>L</given-names></name></person-group>, <etal>et al.</etal><article-title>Pathological tau strains from human brains recapitulate the diversity of tauopathies in nontransgenic mouse brain</article-title>. <source>J Neurosci</source><year>2017</year>; <volume>37</volume>: <fpage>11406</fpage>&#8211;<lpage>11423</lpage>.<pub-id pub-id-type="pmid">29054878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.1230-17.2017</pub-id><pub-id pub-id-type="pmcid">PMC5700423</pub-id></mixed-citation></ref><ref id="bibr24-13872877251372603"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clavaguera</surname><given-names>F</given-names></name><name name-style="western"><surname>Akatsu</surname><given-names>H</given-names></name><name name-style="western"><surname>Fraser</surname><given-names>G</given-names></name></person-group>, <etal>et al.</etal><article-title>Brain homogenates from human tauopathies induce tau inclusions in mouse brain</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2013</year>; <volume>110</volume>: <fpage>9535</fpage>&#8211;<lpage>9540</lpage>.<pub-id pub-id-type="pmid">23690619</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1301175110</pub-id><pub-id pub-id-type="pmcid">PMC3677441</pub-id></mixed-citation></ref><ref id="bibr25-13872877251372603"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaufman</surname><given-names>SK</given-names></name><name name-style="western"><surname>Diamond</surname><given-names>MI</given-names></name></person-group>. <article-title>Prion-like propagation of protein aggregation and related therapeutic strategies</article-title>. <source>Neurotherapeutics</source><year>2013</year>; <volume>10</volume>: <fpage>371</fpage>&#8211;<lpage>382</lpage>.<pub-id pub-id-type="pmid">23801258</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13311-013-0196-3</pub-id><pub-id pub-id-type="pmcid">PMC3701767</pub-id></mixed-citation></ref><ref id="bibr26-13872877251372603"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaufman</surname><given-names>SK</given-names></name><name name-style="western"><surname>Sanders</surname><given-names>DW</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>TL</given-names></name></person-group>, <etal>et al.</etal><article-title>Tau prion strains dictate patterns of cell pathology, progression rate, and regional vulnerability in vivo</article-title>. <source>Neuron</source><year>2016</year>; <volume>92</volume>: <fpage>796</fpage>&#8211;<lpage>812</lpage>.<pub-id pub-id-type="pmid">27974162</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2016.09.055</pub-id><pub-id pub-id-type="pmcid">PMC5392364</pub-id></mixed-citation></ref><ref id="bibr27-13872877251372603"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanders</surname><given-names>DW</given-names></name><name name-style="western"><surname>Kaufman</surname><given-names>SK</given-names></name><name name-style="western"><surname>DeVos</surname><given-names>SL</given-names></name></person-group>, <etal>et al.</etal><article-title>Distinct tau prion strains propagate in cells and mice and define different tauopathies</article-title>. <source>Neuron</source><year>2014</year>; <volume>82</volume>: <fpage>1271</fpage>&#8211;<lpage>1288</lpage>.<pub-id pub-id-type="pmid">24857020</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2014.04.047</pub-id><pub-id pub-id-type="pmcid">PMC4171396</pub-id></mixed-citation></ref><ref id="bibr28-13872877251372603"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Albert</surname><given-names>M</given-names></name><name name-style="western"><surname>Mairet-Coello</surname><given-names>G</given-names></name><name name-style="western"><surname>Danis</surname><given-names>C</given-names></name></person-group>, <etal>et al.</etal><article-title>Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody</article-title>. <source>Brain</source><year>2019</year>; <volume>142</volume>: <fpage>1736</fpage>&#8211;<lpage>1750</lpage>.<pub-id pub-id-type="pmid">31038156</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awz100</pub-id><pub-id pub-id-type="pmcid">PMC6536853</pub-id></mixed-citation></ref><ref id="bibr29-13872877251372603"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yanamandra</surname><given-names>K</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H</given-names></name><name name-style="western"><surname>Mahan</surname><given-names>TE</given-names></name></person-group>, <etal>et al.</etal><article-title>Anti-tau antibody reduces insoluble tau and decreases brain atrophy</article-title>. <source>Ann Clin Transl Neur</source><year>2015</year>; <volume>2</volume>: <fpage>278</fpage>&#8211;<lpage>288</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/acn3.176</pub-id><pub-id pub-id-type="pmcid">PMC4369277</pub-id><pub-id pub-id-type="pmid">25815354</pub-id></mixed-citation></ref><ref id="bibr30-13872877251372603"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Courade</surname><given-names>J-P</given-names></name><name name-style="western"><surname>Angers</surname><given-names>R</given-names></name><name name-style="western"><surname>Mairet-Coello</surname><given-names>G</given-names></name></person-group>, <etal>et al.</etal><article-title>Epitope determines efficacy of therapeutic anti-tau antibodies in a functional assay with human Alzheimer tau</article-title>. <source>Acta Neuropathol</source><year>2018</year>; <volume>136</volume>: <fpage>729</fpage>&#8211;<lpage>745</lpage>.<pub-id pub-id-type="pmid">30238240</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-018-1911-2</pub-id><pub-id pub-id-type="pmcid">PMC6208734</pub-id></mixed-citation></ref><ref id="bibr31-13872877251372603"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dujardin</surname><given-names>S</given-names></name><name name-style="western"><surname>Commins</surname><given-names>C</given-names></name><name name-style="western"><surname>Lathuiliere</surname><given-names>A</given-names></name></person-group>, <etal>et al.</etal><article-title>Tau molecular diversity contributes to clinical heterogeneity in Alzheimer&#8217;s disease</article-title>. <source>Nat Med</source><year>2020</year>; <volume>26</volume>: <fpage>1256</fpage>&#8211;<lpage>1263</lpage>.<pub-id pub-id-type="pmid">32572268</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-020-0938-9</pub-id><pub-id pub-id-type="pmcid">PMC7603860</pub-id></mixed-citation></ref><ref id="bibr32-13872877251372603"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holmes</surname><given-names>BB</given-names></name><name name-style="western"><surname>Furman</surname><given-names>JL</given-names></name><name name-style="western"><surname>Mahan</surname><given-names>TE</given-names></name></person-group>, <etal>et al.</etal><article-title>Proteopathic tau seeding predicts tauopathy in vivo</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2014</year>; <volume>111</volume>: <comment>E4376</comment>&#8211;<lpage>E4385</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1411649111</pub-id><pub-id pub-id-type="pmcid">PMC4205609</pub-id><pub-id pub-id-type="pmid">25261551</pub-id></mixed-citation></ref><ref id="bibr33-13872877251372603"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoshiyama</surname><given-names>Y</given-names></name><name name-style="western"><surname>Higuchi</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name></person-group>, <etal>et al.</etal><article-title>Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model</article-title>. <source>Neuron</source><year>2007</year>; <volume>53</volume>: <fpage>337</fpage>&#8211;<lpage>351</lpage>.<pub-id pub-id-type="pmid">17270732</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2007.01.010</pub-id></mixed-citation></ref><ref id="bibr34-13872877251372603"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garringer</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Murrell</surname><given-names>J</given-names></name><name name-style="western"><surname>Sammeta</surname><given-names>N</given-names></name></person-group>, <etal>et al.</etal><article-title>Increased tau phosphorylation and tau truncation, and decreased synaptophysin levels in mutant BRI2/tau transgenic mice</article-title>. <source>Plos One</source><year>2013</year>; <volume>8</volume>: <comment>e56426</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0056426</pub-id><pub-id pub-id-type="pmcid">PMC3572042</pub-id><pub-id pub-id-type="pmid">23418567</pub-id></mixed-citation></ref><ref id="bibr35-13872877251372603"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>H</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>P</given-names></name><name name-style="western"><surname>Perkins</surname><given-names>A</given-names></name></person-group>, <etal>et al.</etal><article-title>Pathological tau and reactive astrogliosis are associated with distinct functional deficits in a mouse model of tauopathy</article-title>. <source>Neurobiol Aging</source><year>2022</year>; <volume>109</volume>: <fpage>52</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="pmid">34655981</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2021.09.006</pub-id><pub-id pub-id-type="pmcid">PMC8671336</pub-id></mixed-citation></ref><ref id="bibr36-13872877251372603"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martinez</surname><given-names>P</given-names></name><name name-style="western"><surname>Patel</surname><given-names>H</given-names></name><name name-style="western"><surname>You</surname><given-names>Y</given-names></name></person-group>, <etal>et al.</etal><article-title>Bassoon contributes to tau-seed propagation and neurotoxicity</article-title>. <source>Nat Neurosci</source><year>2022</year>; <volume>25</volume>: <fpage>1597</fpage>&#8211;<lpage>1607</lpage>.<pub-id pub-id-type="pmid">36344699</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41593-022-01191-6</pub-id><pub-id pub-id-type="pmcid">PMC9708566</pub-id></mixed-citation></ref><ref id="bibr37-13872877251372603"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martinez</surname><given-names>P</given-names></name><name name-style="western"><surname>Patel</surname><given-names>H</given-names></name><name name-style="western"><surname>You</surname><given-names>Y</given-names></name></person-group>, <etal>et al.</etal><article-title>Protocol for the isolation and proteomic analysis of pathological tau-seeds</article-title>. <source>STAR Protoc</source><year>2024</year>; <volume>5</volume>: <fpage>103185</fpage>.<pub-id pub-id-type="pmid">39078738</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xpro.2024.103185</pub-id><pub-id pub-id-type="pmcid">PMC11333924</pub-id></mixed-citation></ref><ref id="bibr38-13872877251372603"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jury-Garfe</surname><given-names>N</given-names></name><name name-style="western"><surname>Redding-Ochoa</surname><given-names>J</given-names></name><name name-style="western"><surname>You</surname><given-names>Y</given-names></name></person-group>, <etal>et al.</etal><article-title>Enhanced microglial dynamics and a paucity of tau seeding in the amyloid plaque microenvironment contribute to cognitive resilience in Alzheimer&#8217;s disease</article-title>. <source>Acta Neuropathol</source><year>2024</year>; <volume>148</volume>: <fpage>15</fpage>.<pub-id pub-id-type="pmid">39102080</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-024-02775-1</pub-id><pub-id pub-id-type="pmcid">PMC11300572</pub-id></mixed-citation></ref><ref id="bibr39-13872877251372603"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Southam</surname><given-names>KA</given-names></name><name name-style="western"><surname>King</surname><given-names>AE</given-names></name><name name-style="western"><surname>Blizzard</surname><given-names>CA</given-names></name></person-group>, <etal>et al.</etal><article-title>Microfluidic primary culture model of the lower motor neuron&#8211;neuromuscular junction circuit</article-title>. <source>J Neurosci Meth</source><year>2013</year>; <volume>218</volume>: <fpage>164</fpage>&#8211;<lpage>169</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jneumeth.2013.06.002</pub-id><pub-id pub-id-type="pmid">23774648</pub-id></mixed-citation></ref><ref id="bibr40-13872877251372603"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cook</surname><given-names>C</given-names></name><name name-style="western"><surname>Kang</surname><given-names>SS</given-names></name><name name-style="western"><surname>Carlomagno</surname><given-names>Y</given-names></name></person-group>, <etal>et al.</etal><article-title>Tau deposition drives neuropathological, inflammatory and behavioral abnormalities independently of neuronal loss in a novel mouse model</article-title>. <source>Hum Mol Genet</source><year>2015</year>; <volume>24</volume>: <fpage>6198</fpage>&#8211;<lpage>6212</lpage>.<pub-id pub-id-type="pmid">26276810</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/hmg/ddv336</pub-id><pub-id pub-id-type="pmcid">PMC4599677</pub-id></mixed-citation></ref><ref id="bibr41-13872877251372603"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mercken</surname><given-names>M</given-names></name><name name-style="western"><surname>Vandermeeren</surname><given-names>M</given-names></name><name name-style="western"><surname>L&#252;bke</surname><given-names>U</given-names></name></person-group>, <etal>et al.</etal><article-title>Monoclonal antibodies with selective specificity for Alzheimer tau are directed against phosphatase-sensitive epitopes</article-title>. <source>Acta Neuropathol</source><year>1992</year>; <volume>84</volume>: <fpage>265</fpage>&#8211;<lpage>272</lpage>.<pub-id pub-id-type="pmid">1384266</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00227819</pub-id></mixed-citation></ref><ref id="bibr42-13872877251372603"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katsikoudi</surname><given-names>A</given-names></name><name name-style="western"><surname>Ficulle</surname><given-names>E</given-names></name><name name-style="western"><surname>Cavallini</surname><given-names>A</given-names></name></person-group>, <etal>et al.</etal><article-title>Quantitative propagation of assembled human Tau from Alzheimer&#8217;s disease brain in microfluidic neuronal cultures</article-title>. <source>J Biol Chem</source><year>2020</year>; <volume>295</volume>: <fpage>13079</fpage>&#8211;<lpage>13093</lpage>.<pub-id pub-id-type="pmid">32699110</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.RA120.013325</pub-id><pub-id pub-id-type="pmcid">PMC7489902</pub-id></mixed-citation></ref><ref id="bibr43-13872877251372603"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bomba-Warczak</surname><given-names>E</given-names></name><name name-style="western"><surname>Vevea</surname><given-names>JD</given-names></name><name name-style="western"><surname>Brittain</surname><given-names>JM</given-names></name></person-group>, <etal>et al.</etal><article-title>Interneuronal transfer and distal action of tetanus toxin and botulinum neurotoxins A and D in central neurons</article-title>. <source>Cell Rep</source><year>2016</year>; <volume>16</volume>: <fpage>1974</fpage>&#8211;<lpage>1987</lpage>.<pub-id pub-id-type="pmid">27498860</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2016.06.104</pub-id><pub-id pub-id-type="pmcid">PMC4988880</pub-id></mixed-citation></ref><ref id="bibr44-13872877251372603"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>AM</given-names></name><name name-style="western"><surname>Blurton-Jones</surname><given-names>M</given-names></name><name name-style="western"><surname>Rhee</surname><given-names>SW</given-names></name></person-group>, <etal>et al.</etal><article-title>A microfluidic culture platform for CNS axonal injury, regeneration and transport</article-title>. <source>Nat Methods</source><year>2005</year>; <volume>2</volume>: <fpage>599</fpage>&#8211;<lpage>605</lpage>.<pub-id pub-id-type="pmid">16094385</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nmeth777</pub-id><pub-id pub-id-type="pmcid">PMC1558906</pub-id></mixed-citation></ref><ref id="bibr45-13872877251372603"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dujardin</surname><given-names>S</given-names></name><name name-style="western"><surname>L&#233;colle</surname><given-names>K</given-names></name><name name-style="western"><surname>Caillierez</surname><given-names>R</given-names></name></person-group>, <etal>et al.</etal><article-title>Neuron-to-neuron wild-type Tau protein transfer through a trans-synaptic mechanism: relevance to sporadic tauopathies</article-title>. <source>Acta Neuropathol Commun</source><year>2014</year>; <volume>2</volume>: <fpage>14</fpage>.<pub-id pub-id-type="pmid">24479894</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/2051-5960-2-14</pub-id><pub-id pub-id-type="pmcid">PMC3922636</pub-id></mixed-citation></ref><ref id="bibr46-13872877251372603"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bu&#233;e</surname><given-names>L</given-names></name><name name-style="western"><surname>Troquier</surname><given-names>L</given-names></name><name name-style="western"><surname>Burnouf</surname><given-names>S</given-names></name></person-group>, <etal>et al.</etal><article-title>From tau phosphorylation to tau aggregation: what about neuronal death?</article-title><source>Biochem Soc Trans</source><year>2010</year>; <volume>38</volume>: <fpage>967</fpage>&#8211;<lpage>972</lpage>.<pub-id pub-id-type="pmid">20658986</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/BST0380967</pub-id></mixed-citation></ref><ref id="bibr47-13872877251372603"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chun</surname><given-names>W</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>GVW</given-names></name></person-group>. <article-title>The role of tau phosphorylation and cleavage in neuronal cell death</article-title>. <source>Frontiers Biosci</source><year>2006</year>; <volume>12</volume>: <fpage>733</fpage>&#8211;<lpage>756</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2741/2097</pub-id><pub-id pub-id-type="pmid">17127334</pub-id></mixed-citation></ref><ref id="bibr48-13872877251372603"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berger</surname><given-names>Z</given-names></name><name name-style="western"><surname>Roder</surname><given-names>H</given-names></name><name name-style="western"><surname>Hanna</surname><given-names>A</given-names></name></person-group>, <etal>et al.</etal><article-title>Accumulation of pathological tau species and memory loss in a conditional model of tauopathy</article-title>. <source>J Neurosci</source><year>2007</year>; <volume>27</volume>: <fpage>3650</fpage>&#8211;<lpage>3662</lpage>.<pub-id pub-id-type="pmid">17409229</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.0587-07.2007</pub-id><pub-id pub-id-type="pmcid">PMC6672413</pub-id></mixed-citation></ref><ref id="bibr49-13872877251372603"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castillo-Carranza</surname><given-names>DL</given-names></name><name name-style="western"><surname>Sengupta</surname><given-names>U</given-names></name><name name-style="western"><surname>Guerrero-Mu&#241;oz</surname><given-names>MJ</given-names></name></person-group>, <etal>et al.</etal><article-title>Passive immunization with tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles</article-title>. <source>J Neurosci</source><year>2014</year>; <volume>34</volume>: <fpage>4260</fpage>&#8211;<lpage>4272</lpage>.<pub-id pub-id-type="pmid">24647946</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.3192-13.2014</pub-id><pub-id pub-id-type="pmcid">PMC6608097</pub-id></mixed-citation></ref><ref id="bibr50-13872877251372603"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>SantaCruz</surname><given-names>K</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>J</given-names></name><name name-style="western"><surname>Spires</surname><given-names>T</given-names></name></person-group>, <etal>et al.</etal><article-title>Tau suppression in a neurodegenerative mouse model improves memory function</article-title>. <source>Science</source><year>2005</year>; <volume>309</volume>: <fpage>476</fpage>&#8211;<lpage>481</lpage>.<pub-id pub-id-type="pmid">16020737</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1113694</pub-id><pub-id pub-id-type="pmcid">PMC1574647</pub-id></mixed-citation></ref><ref id="bibr51-13872877251372603"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haroutunian</surname><given-names>V</given-names></name><name name-style="western"><surname>Davies</surname><given-names>P</given-names></name><name name-style="western"><surname>Vianna</surname><given-names>C</given-names></name></person-group>, <etal>et al.</etal><article-title>Tau protein abnormalities associated with the progression of Alzheimer disease type dementia</article-title>. <source>Neurobiol Aging</source><year>2007</year>; <volume>28</volume>: <fpage>1</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">16343696</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2005.11.001</pub-id></mixed-citation></ref><ref id="bibr52-13872877251372603"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lasagna-Reeves</surname><given-names>CA</given-names></name><name name-style="western"><surname>Castillo-Carranza</surname><given-names>DL</given-names></name><name name-style="western"><surname>Sengupta</surname><given-names>U</given-names></name></person-group>, <etal>et al.</etal><article-title>Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice</article-title>. <source>Mol Neurodegener</source><year>2011</year>; <volume>6</volume>: <fpage>39</fpage>.<pub-id pub-id-type="pmid">21645391</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1750-1326-6-39</pub-id><pub-id pub-id-type="pmcid">PMC3224595</pub-id></mixed-citation></ref><ref id="bibr53-13872877251372603"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lasagna-Reeves</surname><given-names>CA</given-names></name><name name-style="western"><surname>Castillo-Carranza</surname><given-names>DL</given-names></name><name name-style="western"><surname>Sengupta</surname><given-names>U</given-names></name></person-group>, <etal>et al.</etal><article-title>Identification of oligomers at early stages of tau aggregation in Alzheimer&#8217;s disease</article-title>. <source>FASEB J</source><year>2012</year>; <volume>26</volume>: <fpage>1946</fpage>&#8211;<lpage>1959</lpage>.<pub-id pub-id-type="pmid">22253473</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fj.11-199851</pub-id><pub-id pub-id-type="pmcid">PMC4046102</pub-id></mixed-citation></ref><ref id="bibr54-13872877251372603"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maeda</surname><given-names>S</given-names></name><name name-style="western"><surname>Takashima</surname><given-names>A</given-names></name></person-group>. <article-title>Tau biology</article-title>. <source>Adv Exp Med Biol</source><year>2020</year>; <volume>1184</volume>: <fpage>373</fpage>&#8211;<lpage>380</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-981-32-9358-8_27</pub-id><pub-id pub-id-type="pmid">32096050</pub-id></mixed-citation></ref><ref id="bibr55-13872877251372603"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takashima</surname><given-names>A</given-names></name></person-group>. <article-title>Hyperphosphorylated tau is a cause of neuronal dysfunction in tauopathy</article-title>. <source>J Alzheimers Dis</source><year>2008</year>; <volume>14</volume>: <fpage>371</fpage>&#8211;<lpage>375</lpage>.<pub-id pub-id-type="pmid">18688086</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/jad-2008-14403</pub-id></mixed-citation></ref><ref id="bibr56-13872877251372603"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sadik</surname><given-names>G</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>T</given-names></name><name name-style="western"><surname>Kato</surname><given-names>K</given-names></name></person-group>, <etal>et al.</etal><article-title>Phosphorylation of tau at Ser214 mediates its interaction with 14-3-3 protein: implications for the mechanism of tau aggregation</article-title>. <source>J Neurochem</source><year>2009</year>; <volume>108</volume>: <fpage>33</fpage>&#8211;<lpage>43</lpage>.<pub-id pub-id-type="pmid">19014373</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1471-4159.2008.05716.x</pub-id></mixed-citation></ref><ref id="bibr57-13872877251372603"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vaquer-Alicea</surname><given-names>J</given-names></name><name name-style="western"><surname>Diamond</surname><given-names>MI</given-names></name><name name-style="western"><surname>Joachimiak</surname><given-names>LA</given-names></name></person-group>. <article-title>Tau strains shape disease</article-title>. <source>Acta Neuropathol</source><year>2021</year>; <volume>142</volume>: <fpage>57</fpage>&#8211;<lpage>71</lpage>.<pub-id pub-id-type="pmid">33830330</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-021-02301-7</pub-id><pub-id pub-id-type="pmcid">PMC8217038</pub-id></mixed-citation></ref><ref id="bibr58-13872877251372603"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gerson</surname><given-names>JE</given-names></name><name name-style="western"><surname>Mudher</surname><given-names>A</given-names></name><name name-style="western"><surname>Kayed</surname><given-names>R</given-names></name></person-group>. <article-title>Potential mechanisms and implications for the formation of tau oligomeric strains</article-title>. <source>Crit Rev Biochem Mol</source><year>2016</year>; <volume>51</volume>: <fpage>482</fpage>&#8211;<lpage>496</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/10409238.2016.1226251</pub-id><pub-id pub-id-type="pmcid">PMC5285467</pub-id><pub-id pub-id-type="pmid">27650389</pub-id></mixed-citation></ref><ref id="bibr59-13872877251372603"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cowan</surname><given-names>CM</given-names></name><name name-style="western"><surname>Mudher</surname><given-names>A</given-names></name></person-group>. <article-title>Are tau aggregates toxic or protective in tauopathies?</article-title><source>Front Neurol</source><year>2013</year>; <volume>4</volume>: <fpage>114</fpage>.<pub-id pub-id-type="pmid">23964266</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2013.00114</pub-id><pub-id pub-id-type="pmcid">PMC3741634</pub-id></mixed-citation></ref><ref id="bibr60-13872877251372603"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hyman</surname><given-names>BT</given-names></name></person-group>. <article-title>Tau propagation, different tau phenotypes, and prion-like properties of tau</article-title>. <source>Neuron</source><year>2014</year>; <volume>82</volume>: <fpage>1189</fpage>&#8211;<lpage>1190</lpage>.<pub-id pub-id-type="pmid">24945760</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2014.06.004</pub-id></mixed-citation></ref><ref id="bibr61-13872877251372603"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daude</surname><given-names>N</given-names></name><name name-style="western"><surname>Kim</surname><given-names>C</given-names></name><name name-style="western"><surname>Kang</surname><given-names>S-G</given-names></name></person-group>, <etal>et al.</etal><article-title>Diverse, evolving conformer populations drive distinct phenotypes in frontotemporal lobar degeneration caused by the same MAPT-P301L mutation</article-title>. <source>Acta Neuropathol</source><year>2020</year>; <volume>139</volume>: <fpage>1045</fpage>&#8211;<lpage>1070</lpage>.<pub-id pub-id-type="pmid">32219515</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-020-02148-4</pub-id><pub-id pub-id-type="pmcid">PMC7244472</pub-id></mixed-citation></ref><ref id="bibr62-13872877251372603"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brunello</surname><given-names>CA</given-names></name><name name-style="western"><surname>Merezhko</surname><given-names>M</given-names></name><name name-style="western"><surname>Uronen</surname><given-names>R-L</given-names></name></person-group>, <etal>et al.</etal><article-title>Mechanisms of secretion and spreading of pathological tau protein</article-title>. <source>Cell Mol Life Sci</source><year>2020</year>; <volume>77</volume>: <fpage>1721</fpage>&#8211;<lpage>1744</lpage>.<pub-id pub-id-type="pmid">31667556</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00018-019-03349-1</pub-id><pub-id pub-id-type="pmcid">PMC7190606</pub-id></mixed-citation></ref><ref id="bibr63-13872877251372603"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dujardin</surname><given-names>S</given-names></name><name name-style="western"><surname>B&#233;gard</surname><given-names>S</given-names></name><name name-style="western"><surname>Caillierez</surname><given-names>R</given-names></name></person-group>, <etal>et al.</etal><article-title>Different tau species lead to heterogeneous tau pathology propagation and misfolding</article-title>. <source>Acta Neuropathol Commun</source><year>2018</year>; <volume>6</volume>: <fpage>132</fpage>.<pub-id pub-id-type="pmid">30497516</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40478-018-0637-7</pub-id><pub-id pub-id-type="pmcid">PMC6263555</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Am J Epidemiol</journal-id><journal-id journal-id-type="iso-abbrev">Am J Epidemiol</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>American journal of epidemiology</journal-title></journal-title-group><issn pub-type="ppub">0002-9262</issn><issn pub-type="epub">1476-6256</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12497661</article-id><article-id pub-id-type="pmcid-ver">PMC12497661.1</article-id><article-id pub-id-type="pmcaid">12497661</article-id><article-id pub-id-type="pmcaiid">12497661</article-id><article-id pub-id-type="manuscript-id">NIHMS2114315</article-id><article-id pub-id-type="pmid">40838581</article-id><article-id pub-id-type="doi">10.1093/aje/kwaf179</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS2114315</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA2114315</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Association of blood-based neurodegenerative biomarkers with cognitive functioning and dementia in India (LASI-DAD) and the United States (HRS)</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-4842-0579</contrib-id><name name-style="western"><surname>Kim</surname><given-names initials="JK">Jung Ki</given-names></name><xref rid="CR1" ref-type="corresp">*</xref><xref rid="FN1" ref-type="author-notes">&#8224;</xref><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Anwar</surname><given-names initials="M">Masroor</given-names></name><xref rid="FN1" ref-type="author-notes">&#8224;</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gupta</surname><given-names initials="A">Abhishek</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-6968-6985</contrib-id><name name-style="western"><surname>Thyagarajan</surname><given-names initials="B">Bharat</given-names></name><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hu</surname><given-names initials="P">Peifeng</given-names></name><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-6969-6478</contrib-id><name name-style="western"><surname>Faul</surname><given-names initials="JD">Jessica D.</given-names></name><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Weir</surname><given-names initials="DR">David R.</given-names></name><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Langa</surname><given-names initials="KM">Kenneth M.</given-names></name><xref rid="A6" ref-type="aff">6</xref><xref rid="A7" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names initials="J">Jinkook</given-names></name><xref rid="A8" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-4122-7415</contrib-id><name name-style="western"><surname>Dey</surname><given-names initials="S">Sharmistha</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-5459-5239</contrib-id><name name-style="western"><surname>Crimmins</surname><given-names initials="EM">Eileen M.</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib></contrib-group><aff id="A1"><label>1</label>Davis School of Gerontology, University of Southern California, Los Angeles, CA, United States</aff><aff id="A2"><label>2</label>Department of Biophysics, All India Institute of Medical Sciences, New Delhi, India</aff><aff id="A3"><label>3</label>Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, United States</aff><aff id="A4"><label>4</label>Division of Geriatric Medicine, University of California, Los Angeles, Los Angeles, CA, United States</aff><aff id="A5"><label>5</label>Institute for Social Research, Survey Research Center, University of Michigan, Ann Arbor, MI, United States</aff><aff id="A6"><label>6</label>Division of General Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States</aff><aff id="A7"><label>7</label>Institute of Gerontology, University of Michigan, Ann Arbor, MI, United States</aff><aff id="A8"><label>8</label>Department of Economics and Center for Economic and Social Research, University of Southern California, Los Angeles, CA, United States</aff><author-notes><fn fn-type="con" id="FN1"><label>&#8224;</label><p id="P1">Author Contributions: J.K.K. and M.A. are designated as joint first authors. E.M.C. and S.D. are designated as joint senior authors.</p></fn><corresp id="CR1"><label>*</label>Corresponding author: Jung Ki Kim, Davis School of Gerontology, University of Southern California, 3715 McClintock Ave, Los Angeles, CA 90089-0191, United States (<email>jungk@usc.edu</email>)</corresp></author-notes><pub-date pub-type="epub"><day>21</day><month>8</month><year>2025</year></pub-date><issue-id pub-id-type="pmc-issue-id">498359</issue-id><elocation-id>kwaf179</elocation-id><pub-history><event event-type="nihms-submitted"><date><day>30</day><month>09</month><year>2025</year></date></event><event event-type="pmc-release"><date><day>06</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>07</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-07 00:25:38.680"><day>07</day><month>10</month><year>2025</year></date></event></pub-history><permissions><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-2114315.pdf"/><abstract id="ABS1"><p id="P2">This study examines associations between blood-based neurodegenerative biomarkers and cognitive functioning in nationally representative samples of older adults in India and the United States. Using data from the Longitudinal Aging Study in India-Diagnostic Assessment of Dementia (LASI-DAD) and the Health and Retirement Study (HRS), we analyzed 4 biomarkers&#8212;the ratio of Amyloid beta 42-40 (A&#946;42/A&#946;40), Glial Fibrillary Acidic Protein (GFAP), Neurofilament Light Chain (NfL), and Phosphorylated Tau at Threonine 181 (pTau181)&#8212;in relation to cognitive outcomes. Higher levels of GFAP and NfL were associated with worse cognitive function and a greater likelihood of dementia in both populations. GFAP and NfL were also associated with cognitive decline in the HRS, but not in LASI-DAD. Higher A&#946;42/A&#946;40 ratio was associated with worse cognitive functioning and more dementia in HRS; on the other hand, higher levels of the A&#946;42/A&#946;40 ratio were significantly linked with better cognitive functioning in LASI-DAD. pTau181 was generally not associated with cognitive functioning in either country. Our findings suggest few potential biomarker especially GFAP and NfL, for early manifestation of cognitive decline and dementia. The associations of the whole set of markers with subsequent mortality suggest they may serve as markers for general aging.</p></abstract><kwd-group><kwd>HRS</kwd><kwd>LASI-DAD</kwd><kwd>cognitive function</kwd><kwd>dementia</kwd><kwd>neurodegenerative biomarkers</kwd><kwd>cross-country comparison</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="S1"><title>Introduction</title><p id="P3">Cognitive decline and dementia are among the most pressing challenges facing aging societies worldwide. As global life expectancy continues to rise, the number of individuals with cognitive impairment and dementia will increase significantly, imposing substantial burdens not only on older people, but also on affected families, healthcare systems, and economies,<sup><xref rid="R1" ref-type="bibr">1</xref></sup> thus making it a crucial area for public health intervention. Developing effective tools for the early detection of dementia is, therefore, critical.</p><p id="P4">Recent advances in biomarker research have identified blood-based neurodegenerative markers as efficient and practical tools for predicting cognitive impairment, cognitive decline, and the onset of dementia.<sup><xref rid="R2" ref-type="bibr">2</xref></sup> These markers are particularly promising because of their potential for widespread use in clinical practice, overcoming the current limitations associated with costly amyloid positron emission tomography (PET) scans and cerebrospinal fluid (CSF) biomarkers. Blood-based tests are less invasive, more cost-effective, and easier to implement for large-scale screening and monitoring of neurodegenerative processes in diverse populations.<sup><xref rid="R3" ref-type="bibr">3</xref>&#8211;<xref rid="R5" ref-type="bibr">5</xref></sup> They could change how we monitor progression of Alzheimer&#8217;s disease (AD) and treatment effects.<sup><xref rid="R5" ref-type="bibr">5</xref></sup> Recent technological advancements have enhanced the sensitivity and specificity of blood-based biomarker assays, allowing for the detection of very low levels of neurodegenerative markers that were previously undetectable in plasma or serum.<sup><xref rid="R6" ref-type="bibr">6</xref></sup> This has paved the way for the broader use of blood-based biomarkers in both clinical practice and epidemiological research across different countries.<sup><xref rid="R7" ref-type="bibr">7</xref></sup></p><p id="P5">Amyloid beta 42 (A&#946;42) and Amyloid beta 40 (A&#946;40), often used as a ratio (A&#946;42/A&#946;40), Glial Fibrillary Acidic Protein (GFAP), Neurofilament Light Chain (NfL), and Phosphorylated Tau at Threonine 181 (pTau181) are among the blood-based neurodegenerative biomarkers now assayed in population studies where collection is done in the field rather than a clinic or laboratory. pTau181 is a biomarker of tau pathology, correlating with neurofibrillary tangles, a hallmark of AD.<sup><xref rid="R8" ref-type="bibr">8</xref></sup> Elevated plasma pTau181 levels have been shown to predict future cognitive decline and proposed as a tool for diagnosis and prognosis of cognitive impairments and dementia, tracking progression and assessing treatment response.<sup><xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R9" ref-type="bibr">9</xref></sup> The A&#946;42/A&#946;40 ratio is indicative of amyloid plaque accumulation in the brain, also a hallmark of AD pathology. It is thought to serve as an early marker of amyloid pathology and is a reliable predictor of amyloid positivity as determined by PET scans.<sup><xref rid="R10" ref-type="bibr">10</xref>&#8211;<xref rid="R14" ref-type="bibr">14</xref></sup> While a number of studies have reported that CSF A&#946;42 concentrations are decreased with AD, studies generally report no change or higher plasma A&#946;42 levels with AD.<sup><xref rid="R15" ref-type="bibr">15</xref></sup> Recent studies provided additional clarity by demonstrating that decline in plasma A&#946;42/A&#946;40 ratio may occur prior to amyloid positivity on PET imaging (eg, PiB), potentially making this marker a useful tool for early diagnosis that could reduce the need for expensive PET scans in some cases.<sup><xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R17" ref-type="bibr">17</xref></sup> NfL, a marker of axonal damage and neurodegeneration, is elevated in several neurodegenerative diseases including AD. Higher plasma NfL levels are associated with greater disease severity, faster cognitive decline, and more pronounced brain atrophy.<sup><xref rid="R11" ref-type="bibr">11</xref>,<xref rid="R18" ref-type="bibr">18</xref></sup> GFAP is recognized for its role in reflecting astrocytic activation and neuroinflammation.<sup><xref rid="R17" ref-type="bibr">17</xref></sup> Elevated plasma GFAP levels have been linked to AD, particularly in individuals with early amyloid pathology but without significant tau deposition, suggesting that GFAP may serve as an early marker of amyloid-related neuroinflammation that could help identify individuals at risk of progressing to clinical stages of dementia.<sup><xref rid="R19" ref-type="bibr">19</xref>,<xref rid="R20" ref-type="bibr">20</xref></sup></p><p id="P6">Given their broad applicability, these biomarkers are particularly valuable for cross-national research in populations with varying genetic, demographic, social, and environmental risk factors. India and the United States differ markedly in environmental, social, and economic factors that may contribute to effect modification on the associations between biomarkers and cognitive outcomes. For example, environmental exposures such as air pollution and poor water quality may disproportionately affect populations in India. Social and cultural differences, including education systems, societal roles of older adults, and levels of social engagement, may also shape cognitive aging differently. It is also true that lifestyle factors such as diet, physical activity, and access to healthcare differ significantly between the 2 countries. Economically, lifetime disparities in income, wealth distribution, and healthcare infrastructure are likely to influence both the levels of neurodegenerative biomarkers and their relationships to cognitive outcomes. The incorporation of neurodegenerative biomarkers into large-scale, population-based cohort studies is expected to significantly advance research on cognitive decline and dementia by indicating whether these biomarkers have similar utility in predicting cognitive outcomes in non-Western and Western contexts.<sup><xref rid="R21" ref-type="bibr">21</xref>,<xref rid="R22" ref-type="bibr">22</xref></sup> Rigorous cross-laboratory validation procedures were done to ensure the reliability and comparability of the biomarker measurements across these 2 countries in order to minimize measurement artifacts and biases when making cross-country comparisons.<sup><xref rid="R21" ref-type="bibr">21</xref>&#8211;<xref rid="R24" ref-type="bibr">24</xref></sup> Measurement of cognition using the Harmonized Cognitive Assessment Protocol (HCAP), which is implemented in both the Longitudinal Aging Study in India-Diagnostic Assessment of Dementia (LASI-DAD) and the Health and Retirement Study (HRS), further enhances the comparability of cognitive assessments across these contexts. Our expectation is that major differences in the exposures of the populations in the 2 countries to environmental, social, and economic risks may not only influence the levels of neurodegenerative biomarkers but also how these biomarkers relate to cognitive outcomes.</p></sec><sec id="S2"><title>Methods</title><sec id="S3"><title>Study populations</title><p id="P7">This study uses data from 2 large nationally representative studies: the LASI-DAD and HRS. LASI is a survey of health, economic and social well-being of the population aged 45 and over in India; LASI-DAD is a representative subsample of LASI that has a focus on cognitive aging and dementia among persons aged 60 and over in India, with an oversampling of those at a higher risk of cognitive impairment.<sup><xref rid="R22" ref-type="bibr">22</xref></sup> To measure cognition and dementia, LASI-DAD adopted an assessment protocol of the Harmonized Cognitive Assessment Protocol Project of the HRS (HRS HCAP) while considering India&#8217;s specific social and cultural context. A comprehensive overview of the study design and methods is available in Lee et al.<sup><xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R25" ref-type="bibr">25</xref></sup> We use data from LASI-DAD wave 1 collected between 2017 and 2019, and wave 2 collected in 2022-2024 with an average time of 4.5 years between the 2 waves.</p><p id="P8">The HRS is a longitudinal study of Americans over the age of 50 conducted biannually. The survey covers social, behavioral, and economic characteristics as well as physical and mental health. The HRS HCAP is a representative subset of the parent study, with extensive information on cognitive functioning and dementia that was initiated in 2016 with an extended cognitive protocol for HRS respondents aged 65 or older.<sup><xref rid="R23" ref-type="bibr">23</xref></sup> The sample with neurodegenerative markers in HRS is a probability sample drawn from the 2016 venous blood study (VBS) sample who were eligible for the 2016 HCAP (aged 65 and over) or those younger than 65 who will be eligible for a future HCAP (a random half of HRS sample younger than age 65) (<italic toggle="yes">n</italic> = 4214).</p><p id="P9">Blood-based neurodegenerative biomarkers assayed from the HRS 2016 and LASI-DAD wave 1 data (2017-2019) are the focus of this paper. Those with information on blood-based neurodegenerative markers, cognitive functioning, and dementia were included in the analytic sample (see <xref rid="SD1" ref-type="supplementary-material">Figure S1</xref>). The sample with neurodegenerative biomarkers was 2669 in LASI-DAD and the final analytical sample consisted of 2151 participants with all 4 biomarkers available for analysis as well as the cognitive factor score, 1405 for dementia analysis, and 1128 for cognitive change analysis. Among those included at the first cognitive assessment, 496 participants died between waves (22.9%, weighted). The HRS sample was limited to those aged 60 and over (<italic toggle="yes">N</italic> = 3493) to match the age of the LASI-DAD sample. The final HRS sample included 3466 participants with all four neurodegenerative biomarkers, of whom 2333 were part of the HCAP sample and had a cognitive factor score, 2323 had HCAP data indicating whether they had dementia, and 2989 were included in the cognitive status change analysis. A total of 432 participants died in 4 years (11.2%, weighted).</p></sec><sec id="S4"><title>Measures</title><sec id="S5"><title>Neurodegenerative markers</title><p id="P10">Four biomarkers related to brain health and AD were examined: A&#946;42/A&#946;40 ratio, GFAP, NfL, and pTau181. These markers are plasma-based with the exception of HRS pTau181, which is serum-based. In addition, a summary biomarker factor score was developed using confirmatory factor analysis (CFA). Initially, all 4 neurodegenerative markers were included in the factor score model; but when A&#946;42/A&#946;40 was included, the measure did not converge and this measure was therefore omitted from the summary score. The final factor score was based on non-log-transformed GFAP, NfL, and pTAU181 for both LASI-DAD and HRS. The CFA factor loadings and fit statistics for neurodegenerative biomarker factors in LASI-DAD and HRS are provided in <xref rid="SD1" ref-type="supplementary-material">Table S1</xref>. There is no evidence that factor loadings differ significantly between HRS and LASI-DAD.</p><p id="P11">In India, trained phlebotomists collected blood samples from participants between 2017 and 2019. A total of 17 mL of blood was drawn, which was transported to local labs within 2 hours and processed to obtain serum and plasma and then shipped at 4 &#176;C to the central laboratory in Delhi<sup><xref rid="R26" ref-type="bibr">26</xref></sup>; subsequently it was shipped to the AIIMS laboratory in Delhi and stored at &#8722;80 &#176;C until the samples were assayed for the neurodegenerative markers in 2023 and 2024.</p><p id="P12">Assays for neurodegenerative markers were done in HRS after a pilot test to determine their validity and reliability using the HRS protocol for collection and overnight shipping to the laboratory.<sup><xref rid="R27" ref-type="bibr">27</xref></sup> In 2016, phlebotomists collected blood samples for HRS at home visits and all tubes were shipped cold overnight to the University of Minnesota&#8217;s (UMN) Advanced Research and Diagnostic Laboratory arriving mostly within 24 hours (92% of the sample). The aliquoted samples were frozen on arrival and stored under &#8722;80 &#176;C until assay was performed. Detailed description of the venous blood collection, laboratory equipment, and assay protocol has been reported previously by Crimmins et al.<sup><xref rid="R28" ref-type="bibr">28</xref></sup></p><p id="P13">For the purpose of comparing cross-country associations between the neurodegenerative biomarkers and cognitive outcomes, lab approaches were harmonized across the studies. Results of the harmonization work indicated high correlation between the values obtained in the 2 labs; details are provided in the <xref rid="SD1" ref-type="supplementary-material">supplemental material</xref> (<xref rid="SD1" ref-type="supplementary-material">Appendix S1</xref>, <xref rid="SD1" ref-type="supplementary-material">Table S2</xref>, <xref rid="SD1" ref-type="supplementary-material">Figure S2a</xref> and <xref rid="SD1" ref-type="supplementary-material">b</xref>). In order to compare the relationships among biomarkers, compare across studies, and account for lab variability, biomarker values were standardized within each sample to transform the biomarkers to have a mean of 0 and an SD of 1 in our analyses.</p></sec><sec id="S6"><title>Cognitive functioning and dementia</title><p id="P14">Cognitive functioning was assessed using a harmonized factor score developed for both LASI-DAD and HRS HCAP. This general cognitive factor score reflects the broadest cognitive summary variable including memory, executive functioning, visuospatial, and language domains.<sup><xref rid="R29" ref-type="bibr">29</xref></sup></p><p id="P15">Dementia was defined in LASI-DAD using the consensus clinical dementia rating (CDR) which clinicians determined based on cognitive test results and informant reports using an online platform. Six cognitive and functional domains (memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care) are the basis for the CDR. No impairment and questionable impairment in the CDR were coded as not demented while mild, moderate, and severe impairment as demented.<sup><xref rid="R30" ref-type="bibr">30</xref></sup></p><p id="P16">In the HRS HCAP, dementia was defined through a 3-phase process involving the selection of a normative sample, standardization of cognitive test performance, and an algorithm-based classification.<sup><xref rid="R31" ref-type="bibr">31</xref></sup> Dementia is defined by impairment in at least 2 cognitive domains along with informant-reported functional decline.<sup><xref rid="R31" ref-type="bibr">31</xref></sup></p></sec><sec id="S7"><title>Cognitive decline</title><p id="P17">For analysis of cognitive decline between the two waves, decline in the factor score between wave 1 and wave 2 was used for LASI-DAD. Because the factor score is not available for HRS at time 2 (2020), cognitive change is based on comparing the 2016 and 2020 Langa-Weir (LW) score of cognitive functioning.<sup><xref rid="R32" ref-type="bibr">32</xref></sup> The change analysis was limited to those without dementia in the first wave (CDR-based dementia in LASI-DAD and LW classification-based dementia in HRS). Cognitive decline was defined as negative change from time 1 to time 2 in the factor score for LASI-DAD or LW cognitive score for HRS. Since people could die during the follow-up period, we included death as a separate outcome with cognitive decline.</p></sec><sec id="S8"><title>Sociodemographic background</title><p id="P18">Sociodemographic factors such as age and sex, race/ethnicity, education, and rural residency may influence how these biomarkers are associated with cognitive outcomes.<sup><xref rid="R33" ref-type="bibr">33</xref></sup> We divided the samples into 3 education categories that differed across both the countries. In LASI-DAD, low education was defined as never having attended school, midlevel education as having some primary or middle school, and high education as having completed middle school or higher. In HRS, low education was defined as having a high school education or less, midlevel education as having some college education but not graduating, and high education as having completed a college degree or higher.</p></sec></sec><sec id="S9"><title>Statistical analysis</title><p id="P19">We show descriptive statistics at baseline in each sample; as well as the distribution of each marker in the 2 countries. Pearson&#8217;s correlations among the AD biomarkers in each country are also shown. We compared mean levels of each standardized biomarker by age to see if the biomarkers show expected differences. We examined the relationship of the neurodegenerative markers to cognitive functioning using ordinary least squares (OLS) regressions and logit regressions for dementia. In order to examine how neurodegenerative biomarkers are related to cognitive decline among those who did not have dementia in the first wave, we ran multinomial logistic regressions where the outcomes of cognitive decline and death were compared to no decline in cognitive function. We ran the models with each biomarker separately, and then with all biomarkers together since some studies in the literature show the predicted effect of combined biomarkers.<sup><xref rid="R11" ref-type="bibr">11</xref></sup> For the cognitive change analysis, we present only the individual models since the results from the combined model were not different. We initially ran all models with controls for age, sex, and race/ethnicity in HRS, and age and sex in LASI-DAD. We also examined the associations with additional controls for education, caste, and living in a rural area for LASI-DAD and education for HRS. Since the inclusion of these factors did not change results in a meaningful way, we present the results from the more parsimonious model. In the supplementary analyses, we present the same multivariate results while controlling for assay plate. All statistical analyses were conducted using SAS and R, and statistical significance was defined as <italic toggle="yes">P</italic> &lt; 0.05 in plots but the exact <italic toggle="yes">P</italic>-values are provided in the <xref rid="SD1" ref-type="supplementary-material">supplemental tables</xref>. Alzheimer&#8217;s disease biomarker weight for LASI-DAD and the VBS subsample weight for HRS were applied to all analyses.</p></sec></sec><sec id="S10"><title>Results</title><p id="P20">Baseline characteristics of the LASI-DAD and HRS samples are presented in <xref rid="T1" ref-type="table">Table 1</xref>. The mean age of the participants from both the countries were similar, with LASI-DAD having a mean age of 69.6 years and HRS 70.5 years. A slightly higher percent of the HRS sample was female compared to the LASI-DAD sample (54.6% vs 50.2%). There were substantial differences in education levels between the two populations.</p><p id="P21">The LASI-DAD sample had higher median levels of GFAP (129.27 vs 90.30 pg/mL in HRS) and NfL (31.02 vs 18.60 pg/mL in HRS in <xref rid="T1" ref-type="table">Table 1</xref>). Higher levels of biomarkers among LASI-DAD were also evident in the distributions (<xref rid="F1" ref-type="fig">Figure 1</xref>) where HRS tended to show a sharp peak at lower levels of GFAP, NfL, and pTau181 compared to LASI-DAD. The difference in the means of pTau181 is primarily due to the difference between plasma and serum values (<xref rid="T1" ref-type="table">Table 1</xref>).</p><p id="P22">Correlations among GFAP, NfL, and pTau181 in the 2 countries were generally similar although somewhat stronger in HRS (<xref rid="F2" ref-type="fig">Figure 2</xref>). Significant positive correlations were observed between GFAP and NfL (<italic toggle="yes">r</italic> = 0.40 for LASI-DAD; <italic toggle="yes">r</italic> = 0.47 for HRS), and the correlation between GFAP and pTau181 was 0.14 in LASI-DAD and 0.28 in HRS and that of NfL with pTau181 was 0.16 for LASI-DAD and 0.28 for HRS. On the other hand, a negative correlation of GFAP and NfL with A&#946;42/A&#946;40 was observed in LASI-DAD but not in HRS.</p><p id="P23">Given that age can influence biomarker levels and their impact could differ in two populations, we examined the variation in these biomarkers by age in LASI-DAD and HRS (<xref rid="F3" ref-type="fig">Figure 3</xref>). The levels of GFAP and NfL were significantly higher at older ages in both the countries, while there was no difference in the level of A&#946;42/A&#946;40 among different age groups in either LASI-DAD or HRS. The level of standardized pTau181 was significantly higher at older ages in HRS, but not in LASI-DAD.</p><p id="P24">The associations between neurodegenerative biomarkers and cognitive functioning are shown in <xref rid="F4" ref-type="fig">Figure 4</xref> (all numeric details are provided in <xref rid="SD1" ref-type="supplementary-material">Table S3</xref>). Two indicators of the association are shown for each marker: blue indicates the effect with 1 neurodegenerative marker in the equation and red indicates the association with all neurodegenerative markers in the equation. Associations are from regression equations, with age, sex, and race/ethnicity (HRS only) included as controls. For both GFAP and NfL, the direction of association was the same in LASI-DAD and HRS: higher levels of GFAP and NfL were associated with poorer cognitive functioning in both studies (for individual models, <italic toggle="yes">b</italic> = &#8722;0.10, in LASI-DAD; <italic toggle="yes">b</italic> = &#8722;0.20, in HRS for GFAP; <italic toggle="yes">b</italic> = &#8722;0.09, in LASI-DAD; <italic toggle="yes">b</italic> = &#8722;0.15, in HRS for NfL, with similar, but lower, coefficients for combined models). Lower A&#946;42/A&#946;40 was related to better cognitive functioning in HRS; in the LASI-DAD individual marker model, but not combined model, higher A&#946;42/A&#946;40 was associated with a better cognitive score. A higher pTau181 was related to worse cognitive functioning in HRS, but not in LASI-DAD. A higher summary biomarker factor score was related to a lower cognitive score for both LASI-DAD and HRS.</p><p id="P25">We found fairly similar results for GFAP and NfL in the association of the neurodegenerative biomarkers with dementia in both the countries; those with higher levels of GFAP and NfL were more likely to have dementia both in the individual models and the combined models in both countries (<xref rid="F5" ref-type="fig">Figure 5</xref>, <xref rid="SD1" ref-type="supplementary-material">Table S4</xref>). A higher standardized GFAP increased the relative likelihood of having dementia by 45% for the individual model in LASI-DAD and 67% for the individual model in HRS. The A&#946;42/A&#946;40 ratio was not significantly related to having dementia in LASI-DAD, but a higher A&#946;42/A&#946;40 was associated with an increased likelihood of having dementia (14%-15%) in HRS. pTau181 was not related to dementia in either country. A higher combined biomarker factor score was associated with an increased likelihood of having dementia in both LASI-DAD and HRS.</p><p id="P26">While some neurodegenerative markers were shown to be cross-sectionally related to cognitive function and dementia in the two countries, how those markers relate to cognitive change may not show the same pattern. Multinomial logistic regression results for cognitive decline with a competing risk of death, are presented in <xref rid="F6" ref-type="fig">Figure 6</xref> and also in <xref rid="SD1" ref-type="supplementary-material">Table S5</xref>. There are different associations of neurodegenerative biomarkers with cognitive decline in LASI-DAD and HRS. In LASI-DAD, none of the markers including the biomarker factor score was associated with cognitive decline. In HRS, higher GFAP levels (OR = 1.19) and a higher factor score (OR = 1.19) were related to an increased likelihood of cognitive decline compared to no cognitive change in HRS. We should note that all markers (higher GFAP, higher NfL, lower A&#946;42/A&#946;40, and higher pTau181) were associated with a greater likelihood of death in HRS; and all except pTau181 were associated with higher likelihood of death in LASI-DAD.</p></sec><sec id="S11"><title>Discussion</title><p id="P27">In this study, we examined the associations between blood-based neurodegenerative biomarkers and cognitive outcomes in two nationally representative samples of populations living under quite different circumstances&#8212;India and the United States. Overall, the results indicated that the associations between some neurodegenerative biomarkers&#8212;GFAP and NfL&#8212;and cognitive outcomes were in the expected direction and fairly consistent across the LASI-DAD and HRS samples when analyzed cross-sectionally. The findings that higher levels of GFAP and NfL were strongly associated with poorer cognitive functioning and an increased likelihood of dementia in both populations suggest that despite the differences in genetic background, environmental exposures, economic development, lifestyle factors, and healthcare systems between the two countries, these biomarkers are robust indicators of cognitive function and dementia.</p><p id="P28">While our regression models controlled for age and sex, and additionally for race/ethnicity for HRS, the results were consistent even after controlling for education, caste, and rural residency in India and for education in the United States (<xref rid="SD1" ref-type="supplementary-material">Tables S6</xref>&#8211;<xref rid="SD1" ref-type="supplementary-material">S8</xref>). This suggests that these biomarkers&#8217; associations with cognitive outcomes may not be confounded by socioeconomic status and reinforces the potential utility of these neurodegenerative markers, particularly GFAP and NfL, as key biomarkers in predicting cognitive decline and dementia across diverse populations.</p><p id="P29">However, the similarities of the associations of biomarkers with cognitive outcomes in cross-sectional relationships did not extend to the ability of these biomarkers to predict cognitive change over the time observed here. While higher levels of GFAP and a summary biomarker factor score based on three of the neurodegenerative biomarkers were related to cognitive decline in the HRS, these associations were not observed in LASI-DAD. This inconsistency may be due to the difference in sample size between the countries, or the demographic and environmental variation between the populations, which could influence the progression of neurodegeneration and its impact on cognitive outcomes over the time. The differential impact observed in two countries could result from varying capacities to cope with neurodegenerative changes as people age, potentially due to differences in cognitive reserve developed over time.<sup><xref rid="R34" ref-type="bibr">34</xref>,<xref rid="R35" ref-type="bibr">35</xref></sup> Additionally, cognitive decline in our analysis was based on different measures in LASI-DAD and HRS. To check whether the results were affected by having measures that are on different scales, we conducted a sensitivity analysis by transforming the LW scores into the same scale as LASI-DAD&#8217;s factor score, and found that most findings (except NfL) remained the same as the original results (<xref rid="SD1" ref-type="supplementary-material">Table S9</xref>). The absolute magnitude of cognitive change is similar in LASI-DAD (mean = &#8722;0.1, SD = 0.5, range: &#8722;2.5 to 2.0) and the HRS when transformed to LASI-DAD scale (mean = &#8722;0.1, SD = 0.9, range: &#8722;3.5 to 5.0) although the range is much wider in HRS. Along with that, these biomarkers may be more strongly associated with cognitive decline when baseline cognitive function is relatively high, but they may not be as predictive when baseline cognitive function is low.</p><p id="P30">Interestingly, while GFAP and NfL emerged as strong predictors of cognitive outcomes, the A&#946;42/A&#946;40 ratio and pTau181 was not found to be significant as was hypothesized. The neurodegenerative markers such as GFAP and NfL appear to be quitepromising. The A&#946;42/A&#946;40 showed only modest associations with cognitive outcomes, particularly in LASI-DAD, where the associations were relatively small and, in HRS, the associations were less consistent. Recent studies have suggested the plasma pTau181/A&#946;42 ratio is a potentially sensitive marker of brain pathology.<sup><xref rid="R36" ref-type="bibr">36</xref>&#8211;<xref rid="R41" ref-type="bibr">41</xref></sup> We tested whether this measure combining amyloid and tau levels could provide insights into the relationship between neurodegenerative markers, particularly A&#946;42/A&#946;40, and cognitive score. Interestingly, the unexpected direction of the relationship was observed between pTau181/A&#946;42 and the cognitive score (ie, lower pTau181/A&#946;42 ratio is related to a higher cognitive score) mirrored the pattern previously observed between A&#946;42/A&#946;40 and cognitive score. Further studies would be necessary to better understand the underlying mechanisms driving this unexpected association.</p><p id="P31">Furthermore, It is interesting to note that when we controlled for plate, there were very few changes from the analysis presented above, but the most frequent were the changes in the significance of A&#946;42/A&#946;40 (see <xref rid="SD1" ref-type="supplementary-material">Tables S10</xref>&#8211;<xref rid="SD1" ref-type="supplementary-material">S12</xref>). pTau181, on the other hand, did not show the expected associations in either sample, suggesting potential variation in the quantitative i measurement. Several potential measurement issues can be noted. First, in HRS, serum rather than plasma was used as the source for pTau181. Serum and plasma are not always comparable across different biomarkers, which could lead to variability in results for pTau181. Since the field conditions for LASI-DAD and HRS are very different, preanalytic factors such as sample handling, processing times, and storage conditions can introduce variability inspite of following all the preanalytical guidelines.</p><p id="P32">The fact that these biomarkers relate to mortality in both samples may indicate that they really are markers of general &#8220;aging&#8221; and not just indicators of neurodegeneration. Further work should follow up on how these neurodegenerative makers are associated with other markers of general aging such as epigenetic age and biological age. This highlights the complexity of cognitive aging and suggests that while neurodegenerative biomarkers are important, other factors, such as genetic predisposition and cognitive reserve developed by stimulating lifestyle and environmental factor, better education and occupation, that play significant roles in cognitive decline and dementia, should be explored together in future research.</p><p id="P33">This study has some limitations that should be noted. First, as mentioned, while we attempted to standardize biomarker measurements in the samples across the two countries, differences in laboratory procedures, sample handling, and assay sensitivity may have introduced variability that could affect the comparability of the results. However, when applying the harmonization equations among the two laboratories (<xref rid="SD1" ref-type="supplementary-material">Table S2</xref>), similar mean values were observed for original and harmonized levels of the biomarkers. The relatively short follow-up period (4.5 years, on average, in LASI-DAD and 4 years in HRS) might have constrained our ability to detect longer term cognitive changes associated with neurodegenerative biomarkers.</p><p id="P34">The findings from this study point to several important directions for future research on neurodegenerative markers and cognition in an international context. First, there may be a need to improve the measurement and standardization of biomarkers like A&#946;42/A&#946;40 and pTau181 to ensure their reliability and validity across different populations. This could involve developing more sensitive assays and conducting further cross-laboratory validations to address potential measurement issues. Second, future studies should focus on longitudinal analyses that track the progression of neurodegeneration over time in diverse populations. Both HRS and LASI-DAD will soon release the second wave of neurodegenerative marker data, which will help clarify the predictive value of these biomarkers for cognitive decline and incidence of dementia, and determine how factors like genetics, environment, and healthcare access interact with these biomarkers to influence cognitive change over time. Finally, expanding data collection to include other promising neurodegenerative biomarkers (eg, pTau 217)<sup><xref rid="R42" ref-type="bibr">42</xref></sup> may improve our understanding of the pathways linking neurodegenerative markers to future cognitive outcomes and dementia.</p></sec><sec sec-type="supplementary-material" id="SM1"><title>Supplementary Material</title><supplementary-material id="SD1" position="float" content-type="local-data" orientation="portrait"><label>supplementary material</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="NIHMS2114315-supplement-supplementary_material.docx" id="d67e556" position="anchor" orientation="portrait"/></supplementary-material><p id="P35"><xref rid="SD1" ref-type="supplementary-material">Supplementary material</xref> is available at the <italic toggle="yes">American Journal of Epidemiology</italic> online.</p></sec></body><back><ack id="S12"><title>Funding</title><p id="P36">This work was supported by the National Institute on Aging (R01AG051125, U01AG064948, RF1AG088003, R01AG030153, R01AG042778, P30 AG017265), Bright Focus Foundation (CA2023001). The Health and Retirement Study Biomarker data have been funded by the National Institute on Aging (NIA U01AG009740).</p><sec id="S13"><title>Disclaimer</title><p id="P37">The findings and conclusions in this manuscript are those of the authors and the authors are solely responsible for the content.</p></sec></ack><fn-group><fn fn-type="COI-statement" id="FN2"><p id="P39">Conflict of interest</p><p id="P40">The authors have no conflicts of interest to report.</p></fn></fn-group><sec sec-type="data-availability" id="S14"><title>Data availability</title><p id="P38">All data relevant to the study are included in the article or uploaded as <xref rid="SD1" ref-type="supplementary-material">supplementary information</xref>.</p></sec><ref-list><title>References</title><ref id="R1"><label>1.</label><mixed-citation publication-type="book"><name name-style="western"><surname>Prince</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Wimo</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Guerchet</surname><given-names>M</given-names></name>. <source>World Alzheimer Report 2015: The Global Impact of Dementia</source>. <publisher-name>Alzheimer&#8217;s Disease International</publisher-name>; <year>2015</year>.</mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name>, <name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Blennow</surname><given-names>K</given-names></name>, <etal/><article-title>NIA-AA research framework: toward a biological definition of Alzheimer&#8217;s disease</article-title>. <source>Alzheimers Dement</source>. <year>2018</year>;<volume>14</volume>(<issue>4</issue>):<fpage>535</fpage>&#8211;<lpage>562</lpage>. <pub-id pub-id-type="doi">10.1016/j.jalz.2018.02.018</pub-id><pub-id pub-id-type="pmid">29653606</pub-id><pub-id pub-id-type="pmcid">PMC5958625</pub-id></mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Janelidze</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Stomrud</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Palmqvist</surname><given-names>S</given-names></name>, <etal/><article-title>Plasma p-tau181 in Alzheimer&#8217;s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer&#8217;s dementia</article-title>. <source>Nat Med</source>. <year>2020</year>;<volume>26</volume>(<issue>3</issue>):<fpage>379</fpage>&#8211;<lpage>386</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-020-0755-1</pub-id><pub-id pub-id-type="pmid">32123385</pub-id></mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hampel</surname><given-names>H</given-names></name>, <name name-style="western"><surname>O&#8217;Bryant</surname><given-names>SE</given-names></name>, <name name-style="western"><surname>Molinuevo</surname><given-names>JL</given-names></name>, <etal/><article-title>Blood-based biomarkers for Alzheimer&#8217;s disease: mapping the road to the clinic</article-title>. <source>Nat Rev Neurol</source>. <year>2018</year>;<volume>14</volume>(<issue>11</issue>):<fpage>639</fpage>&#8211;<lpage>652</lpage>. <pub-id pub-id-type="doi">10.1038/s41582-018-0079-7</pub-id><pub-id pub-id-type="pmid">30297701</pub-id><pub-id pub-id-type="pmcid">PMC6211654</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Teunissen</surname><given-names>CE</given-names></name>, <name name-style="western"><surname>Verberk</surname><given-names>IMW</given-names></name>, <name name-style="western"><surname>Thijssen</surname><given-names>EH</given-names></name>, <etal/><article-title>Blood-based biomarkers for Alzheimer&#8217;s disease: towards clinical implementation</article-title>. <source>Lancet Neurol</source>. <year>2022</year>;<volume>21</volume>(<issue>1</issue>):<fpage>66</fpage>&#8211;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1016/S1474-4422(21)00361-6</pub-id><pub-id pub-id-type="pmid">34838239</pub-id></mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ehtewish</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Mesleh</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ponirakis</surname><given-names>G</given-names></name>, <etal/><article-title>Blood-based proteomic profiling identifies potential biomarker candidates and pathogenic pathways in dementia</article-title>. <source>Int J Mol Sci</source>. <year>2023</year>;<volume>24</volume>(<issue>9</issue>):<fpage>8117</fpage>. <pub-id pub-id-type="doi">10.3390/ijms24098117</pub-id><pub-id pub-id-type="pmid">37175824</pub-id><pub-id pub-id-type="pmcid">PMC10179172</pub-id></mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hansson</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Zetterberg</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Buchhave</surname><given-names>P</given-names></name>, <etal/><article-title>Association between CSF biomarkers and incipient Alzheimer&#8217;s disease in patients with mild cognitive impairment: a follow-up study</article-title>. <source>Lancet Neurol</source>. <year>2006</year>;<volume>5</volume>(<issue>3</issue>):<fpage>228</fpage>&#8211;<lpage>234</lpage>. Erratum in: <italic toggle="yes">Lancet Neurol.</italic> 2006;5(4):293. <pub-id pub-id-type="doi">10.1016/S1474-4422(06)70355-6</pub-id><pub-id pub-id-type="pmid">16488378</pub-id></mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Karikari</surname><given-names>TK</given-names></name>, <name name-style="western"><surname>Pascoal</surname><given-names>TA</given-names></name>, <name name-style="western"><surname>Ashton</surname><given-names>NJ</given-names></name>, <etal/><article-title>Blood phosphorylated tau 181 as a biomarker for Alzheimer&#8217;s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts</article-title>. <source>Lancet Neurol</source>. <year>2020</year>;<volume>19</volume>(<issue>5</issue>):<fpage>422</fpage>&#8211;<lpage>433</lpage>. <pub-id pub-id-type="doi">10.1016/S1474-4422(20)30071-5</pub-id><pub-id pub-id-type="pmid">32333900</pub-id></mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Thijssen</surname><given-names>EH</given-names></name>, <name name-style="western"><surname>La Joie</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Wolf</surname><given-names>A</given-names></name>, <etal/><article-title>Diagnostic value of plasma phosphorylated tau181 in Alzheimer&#8217;s disease</article-title>. <source>Nat Med</source>. <year>2020</year>;<volume>26</volume>(<issue>3</issue>):<fpage>387</fpage>&#8211;<lpage>397</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-020-0762-2</pub-id><pub-id pub-id-type="pmid">32123386</pub-id><pub-id pub-id-type="pmcid">PMC7101073</pub-id></mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ashton</surname><given-names>NJ</given-names></name>, <name name-style="western"><surname>Janelidze</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Mattsson-Carlgren</surname><given-names>N</given-names></name>, <etal/><article-title>Differential roles of A&#946;42/40, p-tau231 and p-tau217 for Alzheimer&#8217;s trial selection and disease monitoring</article-title>. <source>Nat Med</source>. <year>2022</year>;<volume>28</volume>(<issue>12</issue>):<fpage>2555</fpage>&#8211;<lpage>2562</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-022-02074-w</pub-id><pub-id pub-id-type="pmid">36456833</pub-id><pub-id pub-id-type="pmcid">PMC9800279</pub-id></mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Cullen</surname><given-names>NC</given-names></name>, <name name-style="western"><surname>Leuzy</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Janelidze</surname><given-names>S</given-names></name>, <etal/><article-title>Plasma biomarkers of Alzheimer&#8217;s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations</article-title>. <source>Nat Commun</source>. <year>2021</year>;<volume>12</volume>(<issue>1</issue>):<fpage>3555</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-021-23746-0</pub-id><pub-id pub-id-type="pmid">34117234</pub-id><pub-id pub-id-type="pmcid">PMC8196018</pub-id></mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hampel</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Hardy</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Blennow</surname><given-names>K</given-names></name>, <etal/><article-title>The amyloid-&#946; pathway in Alzheimer&#8217;s disease</article-title>. <source>Mol Psychiatry</source>. <year>2021</year>;<volume>26</volume>(<issue>10</issue>):<fpage>5481</fpage>&#8211;<lpage>5503</lpage>. <pub-id pub-id-type="doi">10.1038/s41380-021-01249-0</pub-id><pub-id pub-id-type="pmid">34456336</pub-id><pub-id pub-id-type="pmcid">PMC8758495</pub-id></mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Schindler</surname><given-names>SE</given-names></name>, <name name-style="western"><surname>Bollinger</surname><given-names>JG</given-names></name>, <name name-style="western"><surname>Ovod</surname><given-names>V</given-names></name>, <etal/><article-title>High-precision plasma &#946;-amyloid 42/40 predicts current and future brain amyloidosis</article-title>. <source>Neurology</source>. <year>2019</year>;<volume>93</volume>(<issue>17</issue>):<fpage>e1647</fpage>&#8211;<lpage>e1659</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0000000000008081</pub-id><pub-id pub-id-type="pmid">31371569</pub-id><pub-id pub-id-type="pmcid">PMC6946467</pub-id></mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Zaretsky</surname><given-names>DV</given-names></name>, <name name-style="western"><surname>Zaretskaia</surname><given-names>MV</given-names></name>, <name name-style="western"><surname>Molkov</surname><given-names>YI</given-names></name>, <etal/><article-title>Alzheimer&#8217;s disease neuroimaging initiative. Patients with Alzheimer&#8217;s disease have an increased removal rate of soluble beta-amyloid-42</article-title>. <source>PloS One</source>. <year>2022</year>;<volume>17</volume>(<issue>10</issue>):<fpage>e0276933</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0276933</pub-id><pub-id pub-id-type="pmid">36315527</pub-id><pub-id pub-id-type="pmcid">PMC9621436</pub-id></mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Teunissen</surname><given-names>CE</given-names></name>, <name name-style="western"><surname>Chiu</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>CC</given-names></name>, <etal/><article-title>Plasma amyloid-&#946; (A&#946;42) correlates with cerebrospinal fluid A&#946;42 in Alzheimer&#8217;s disease</article-title>. <source>J Alzheimer&#8217;s Dis</source>. <year>2018</year>;<volume>62</volume>(<issue>4</issue>):<fpage>1857</fpage>&#8211;<lpage>1863</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-170784</pub-id><pub-id pub-id-type="pmid">29614646</pub-id></mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Luo</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Agboola</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Grant</surname><given-names>E</given-names></name>, <etal/><article-title>Accelerated longitudinal changes and ordering of Alzheimer disease biomarkers across the adult lifespan</article-title>. <source>Brain</source>. <year>2022</year>;<volume>145</volume>(<issue>12</issue>):<fpage>4459</fpage>&#8211;<lpage>4473</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awac238</pub-id><pub-id pub-id-type="pmid">35925685</pub-id><pub-id pub-id-type="pmcid">PMC10200301</pub-id></mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Weber</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Taylor</surname><given-names>SW</given-names></name>, <name name-style="western"><surname>Lagier</surname><given-names>RJ</given-names></name>, <etal/><article-title>Clinical utility of plasma A&#946;42/40 ratio by LC-MS/MS in Alzheimer&#8217;s disease assessment</article-title>. <source>Front Neurol</source>. <year>2024</year>;<volume>15</volume>:<fpage>1364658</fpage>. <pub-id pub-id-type="doi">10.3389/fneur.2024.1364658</pub-id><pub-id pub-id-type="pmid">38595851</pub-id><pub-id pub-id-type="pmcid">PMC11003272</pub-id></mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Preische</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Schultz</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Apel</surname><given-names>A</given-names></name>, <etal/><article-title>Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer&#8217;s disease</article-title>. <source>Nat Med</source>. <year>2019</year>;<volume>25</volume>(<issue>2</issue>):<fpage>277</fpage>&#8211;<lpage>283</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-018-0304-3</pub-id><pub-id pub-id-type="pmid">30664784</pub-id><pub-id pub-id-type="pmcid">PMC6367005</pub-id></mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Varma</surname><given-names>VR</given-names></name>, <name name-style="western"><surname>An</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Kac</surname><given-names>PR</given-names></name>, <etal/><article-title>Longitudinal progression of blood biomarkers reveals a key role of astrocyte reactivity in preclinical Alzheimer&#8217;s disease</article-title>. <source>medRxiv</source>. <year>2024</year>. <pub-id pub-id-type="doi">10.1101/2024.01.25.24301779</pub-id><pub-id pub-id-type="pmid">40494355</pub-id></mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Pereira</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Janelidze</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>R</given-names></name>, <etal/><article-title>Plasma GFAP is an early marker of amyloid-&#946; but not tau pathology in Alzheimer&#8217;s disease</article-title>. <source>Brain</source>. <year>2021</year>;<volume>144</volume>(<issue>11</issue>):<fpage>3505</fpage>&#8211;<lpage>3516</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awab223</pub-id><pub-id pub-id-type="pmid">34259835</pub-id><pub-id pub-id-type="pmcid">PMC8677538</pub-id></mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Khobragade</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Petrosyan</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Dey</surname><given-names>S</given-names></name>, <etal/><article-title>Design and methodology of the harmonized diagnostic assessment of dementia for the longitudinal aging study in India: wave 2</article-title>. <source>J Am Geriatr Soc</source>. <year>2024</year>;<volume>73</volume>(<issue>3</issue>):<fpage>685</fpage>&#8211;<lpage>696</lpage>. <pub-id pub-id-type="doi">10.1111/jgs.19252</pub-id><pub-id pub-id-type="pmid">39482079</pub-id><pub-id pub-id-type="pmcid">PMC11907746</pub-id></mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lee</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Petrosyan</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Khobragade</surname><given-names>P</given-names></name>, <etal/><article-title>The LASI-DAD deep phenotyping and genomic data for the study of cognition and dementia in India</article-title>. <source>Sci Data</source>. <year>2023</year>;<volume>10</volume>(<issue>1</issue>):<fpage>45</fpage>. <pub-id pub-id-type="doi">10.1038/s41597-023-01941-6</pub-id><pub-id pub-id-type="pmid">36670106</pub-id><pub-id pub-id-type="pmcid">PMC9852797</pub-id></mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Langa</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Larson</surname><given-names>EB</given-names></name>, <name name-style="western"><surname>Crimmins</surname><given-names>EM</given-names></name>, <etal/><article-title>A comparison of the HRS and ADAMS: data sources, sampling, and methods</article-title>. <source>Alzheimers Dement</source>. <year>2020</year>;<volume>16</volume>(<issue>8</issue>):<fpage>1372</fpage>&#8211;<lpage>1383</lpage>. <pub-id pub-id-type="doi">10.1002/alz.12104</pub-id><pub-id pub-id-type="pmid">32827351</pub-id><pub-id pub-id-type="pmcid">PMC8103951</pub-id></mixed-citation></ref><ref id="R24"><label>24.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Weir</surname><given-names>DR</given-names></name>, <name name-style="western"><surname>Wallace</surname><given-names>RB</given-names></name>, <name name-style="western"><surname>Langa</surname><given-names>KM</given-names></name>. <article-title>HRS HCAP: cognitive aging research harmonization across international studies</article-title>. <source>J Gerontol B Psychol Sci Soc Sci</source>. <year>2022</year>;<volume>77</volume>(<issue>Suppl 2</issue>):<fpage>S11</fpage>&#8211;<lpage>S20</lpage>. <pub-id pub-id-type="doi">10.1093/geronb/gbac006</pub-id><pub-id pub-id-type="pmid">35034123</pub-id><pub-id pub-id-type="pmcid">PMC9122661</pub-id></mixed-citation></ref><ref id="R25"><label>25.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lee</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Khobragade</surname><given-names>PY</given-names></name>, <name name-style="western"><surname>Banerjee</surname><given-names>J</given-names></name>, <etal/><article-title>Design and methodology of the longitudinal aging study in India-diagnostic assessment of dementia (LASI-DAD)</article-title>. <source>J Am Geriatr Soc</source>. <year>2020</year>;<volume>68</volume>(<issue>Suppl 3</issue>):<fpage>S5</fpage>&#8211;<lpage>S10</lpage>. <pub-id pub-id-type="doi">10.1111/jgs.16737</pub-id><pub-id pub-id-type="pmid">32815602</pub-id><pub-id pub-id-type="pmcid">PMC7503220</pub-id></mixed-citation></ref><ref id="R26"><label>26.</label><mixed-citation publication-type="book"><name name-style="western"><surname>Dey</surname><given-names>AB</given-names></name>, <name name-style="western"><surname>Banerjee</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Khobragade</surname><given-names>P</given-names></name>, <etal/><source>Diagnostic Assessment of Dementia for LASI Documentation&#8212;2019 Wave 1, Early Release Version A, Venous Blood Collection and Assay Protocol</source>, <publisher-name>All India Institute of Medical Sciences and University of Southern California</publisher-name>; <year>2019</year>. Accessed <date-in-citation>September 11, 2024</date-in-citation>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://lasi-dad.org/public/documentation/codebooks/VBS_Document.pdf" ext-link-type="uri">https://lasi-dad.org/public/documentation/codebooks/VBS_Document.pdf</ext-link></mixed-citation></ref><ref id="R27"><label>27.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Panikkar</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Vivek</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Crimmins</surname><given-names>E</given-names></name>, <etal/><article-title>Pre-analytical variables influencing stability of blood-based biomarkers of neuropathology</article-title>. <source>J Alzheimer&#8217;s Dis</source>. <year>2023</year>;<volume>95</volume>(<issue>2</issue>):<fpage>735</fpage>&#8211;<lpage>748</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-230384</pub-id><pub-id pub-id-type="pmid">37574735</pub-id><pub-id pub-id-type="pmcid">PMC11520930</pub-id></mixed-citation></ref><ref id="R28"><label>28.</label><mixed-citation publication-type="book"><name name-style="western"><surname>Crimmins</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Faul</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Thyagarajan</surname><given-names>B</given-names></name>, <etal/><source>Venous Blood Collection and Assay Protocol in the 2016 Health and Retirement Study</source>. <publisher-name>Survey Research Center, Institute for Social Research, University of Michigan</publisher-name>; <year>2017</year>. Accessed <date-in-citation>September 11, 2024</date-in-citation>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://hrsonline.isr.umich.edu/modules/meta/vbs/2016/desc/HRS2016VBSDD.pdf" ext-link-type="uri">http://hrsonline.isr.umich.edu/modules/meta/vbs/2016/desc/HRS2016VBSDD.pdf</ext-link></mixed-citation></ref><ref id="R29"><label>29.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Gross</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Brice&#241;o</surname><given-names>EM</given-names></name>, <etal/><article-title>Harmonisation of later-life cognitive function across national contexts: results from the harmonized cognitive assessment protocols</article-title>. <source>Lancet Healthy Longev</source>. <year>2023</year>;<volume>4</volume>(<issue>10</issue>):<fpage>e573</fpage>&#8211;<lpage>e583</lpage>. <pub-id pub-id-type="doi">10.1016/S2666-7568(23)00170-8</pub-id><pub-id pub-id-type="pmid">37804847</pub-id><pub-id pub-id-type="pmcid">PMC10637129</pub-id></mixed-citation></ref><ref id="R30"><label>30.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lee</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ganguli</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Weerman</surname><given-names>A</given-names></name>, <etal/><article-title>Online clinical consensus diagnosis of dementia: development and validation</article-title>. <source>J Am Geriatr Soc</source>. <year>2020</year>;<volume>68</volume>(<issue>Suppl 3</issue>):<fpage>S54</fpage>&#8211;<lpage>S59</lpage>. <pub-id pub-id-type="doi">10.1111/jgs.16736</pub-id><pub-id pub-id-type="pmid">32815604</pub-id><pub-id pub-id-type="pmcid">PMC7513553</pub-id></mixed-citation></ref><ref id="R31"><label>31.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Manly</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Jones</surname><given-names>RN</given-names></name>, <name name-style="western"><surname>Langa</surname><given-names>KM</given-names></name>, <etal/><article-title>Estimating the prevalence of dementia and mild cognitive impairment in the US: the 2016 health and retirement study harmonized cognitive assessment protocol project</article-title>. <source>JAMA Neurol</source>. <year>2022</year>;<volume>79</volume>(<issue>12</issue>):<fpage>1242</fpage>&#8211;<lpage>1249</lpage>. <pub-id pub-id-type="doi">10.1001/jamaneurol.2022.3543</pub-id><pub-id pub-id-type="pmid">36279130</pub-id><pub-id pub-id-type="pmcid">PMC9593315</pub-id></mixed-citation></ref><ref id="R32"><label>32.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Crimmins</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>JK</given-names></name>, <name name-style="western"><surname>Langa</surname><given-names>KM</given-names></name>, <etal/><article-title>Assessment of cognition using surveys and neuropsychological assessment: the health and retirement study and the aging, demographics, and memory study</article-title>. <source>J Gerontol B Psychol Sci Soc Sci</source>. <year>2011</year>;<volume>66</volume>(<issue>Suppl 1</issue>):<fpage>i162</fpage>&#8211;<lpage>i171</lpage>. <pub-id pub-id-type="doi">10.1093/geronb/gbr048</pub-id><pub-id pub-id-type="pmid">21743047</pub-id><pub-id pub-id-type="pmcid">PMC3165454</pub-id></mixed-citation></ref><ref id="R33"><label>33.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Mattsson</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Andreasson</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Persson</surname><given-names>S</given-names></name>, <etal/><article-title>CSF biomarker variability in the Alzheimer&#8217;s association quality control program</article-title>. <source>Alzheimers Dement</source>. <year>2019</year>;<volume>15</volume>(<issue>10</issue>):<fpage>1468</fpage>&#8211;<lpage>1477</lpage>. <pub-id pub-id-type="doi">10.1016/j.jalz.2019.06.4952</pub-id><pub-id pub-id-type="pmid">23622690</pub-id><pub-id pub-id-type="pmcid">PMC3707386</pub-id></mixed-citation></ref><ref id="R34"><label>34.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Stern</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Alexander</surname><given-names>GE</given-names></name>, <name name-style="western"><surname>Prohovnik</surname><given-names>I</given-names></name>, <etal/><article-title>Inverse relationship between education and parietotemporal perfusion deficit in Alzheimer&#8217;s disease</article-title>. <source>Ann Neurol</source>. <year>1992</year>;<volume>32</volume>(<issue>3</issue>):<fpage>371</fpage>&#8211;<lpage>375</lpage>. <pub-id pub-id-type="doi">10.1002/ana.410320311</pub-id><pub-id pub-id-type="pmid">1416806</pub-id></mixed-citation></ref><ref id="R35"><label>35.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Stern</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Alexander</surname><given-names>GE</given-names></name>, <name name-style="western"><surname>Prohovnik</surname><given-names>I</given-names></name>, <etal/><article-title>Relationship between lifetime occupation and parietal flow: implications for a reserve against Alzheimer&#8217;s disease pathology</article-title>. <source>Neurology</source>. <year>1995</year>;<volume>45</volume>(<issue>1</issue>):<fpage>55</fpage>&#8211;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1212/wnl.45.1.55</pub-id><pub-id pub-id-type="pmid">7824135</pub-id></mixed-citation></ref><ref id="R36"><label>36.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Campbell</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Ashrafzadeh-Kian</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Petersen</surname><given-names>RC</given-names></name>, <etal/><article-title>P-tau/Abeta42 and Abeta42/40 ratios in CSF are equally predictive of amyloid PET status</article-title>. <source>Alzheimers Dement (Amst)</source>. <year>2021</year>;<volume>13</volume>(<issue>1</issue>):<fpage>e12190</fpage>. <pub-id pub-id-type="doi">10.1002/dad2.12190</pub-id><pub-id pub-id-type="pmid">34027020</pub-id><pub-id pub-id-type="pmcid">PMC8129859</pub-id></mixed-citation></ref><ref id="R37"><label>37.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Chong</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Ashton</surname><given-names>NJ</given-names></name>, <name name-style="western"><surname>Karikari</surname><given-names>TK</given-names></name>, <etal/><article-title>Plasma P-tau181 to Abeta42 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer&#8217;s disease patients with concomitant cerebrovascular disease</article-title>. <source>Alzheimers Dement</source>. <year>2021</year>;<volume>17</volume>(<issue>10</issue>):<fpage>1649</fpage>&#8211;<lpage>1662</lpage>. <pub-id pub-id-type="doi">10.1002/alz.12332</pub-id><pub-id pub-id-type="pmid">33792168</pub-id></mixed-citation></ref><ref id="R38"><label>38.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Doecke</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Ward</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Burnham</surname><given-names>SC</given-names></name>, <etal/><article-title>Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging</article-title>. <source>Alzheimer&#8217;s Res Ther</source>. <year>2020</year>;<volume>12</volume>(<issue>1</issue>):<fpage>36</fpage>. <pub-id pub-id-type="doi">10.1186/s13195-020-00595-5</pub-id><pub-id pub-id-type="pmid">32234072</pub-id><pub-id pub-id-type="pmcid">PMC7110644</pub-id></mixed-citation></ref><ref id="R39"><label>39.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Fowler</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Stoops</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Rainey-Smith</surname><given-names>SR</given-names></name>, <etal/><article-title>Plasma p-tau181/A&#946;<sub>1-42</sub> ratio predicts a&#946;-PET status and correlates with CSF-p-tau181/A&#946;<sub>1-42</sub> and future cognitive decline</article-title>. <source>Alzheimers Dement (Amst)</source>. <year>2022</year>;<volume>14</volume>(<issue>1</issue>):<fpage>e12375</fpage>. <pub-id pub-id-type="doi">10.1002/dad2.12375</pub-id><pub-id pub-id-type="pmid">36447478</pub-id><pub-id pub-id-type="pmcid">PMC9695763</pub-id></mixed-citation></ref><ref id="R40"><label>40.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>van Harten</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Wiste</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>Weigand</surname><given-names>SD</given-names></name>, <etal/><article-title>Detection of Alzheimer&#8217;s disease amyloid beta 1-42, p-tau, and t-tau assays</article-title>. <source>Alzheimers Dement</source>. <year>2022</year>;<volume>18</volume>(<issue>4</issue>):<fpage>635</fpage>&#8211;<lpage>644</lpage>. <pub-id pub-id-type="doi">10.1002/alz.12406</pub-id><pub-id pub-id-type="pmid">34310035</pub-id><pub-id pub-id-type="pmcid">PMC9249966</pub-id></mixed-citation></ref><ref id="R41"><label>41.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Willemse</surname><given-names>EAJ</given-names></name>, <name name-style="western"><surname>Tijms</surname><given-names>BM</given-names></name>, <name name-style="western"><surname>van Berckel</surname><given-names>BNM</given-names></name>, <etal/><article-title>Comparing CSF amyloid-beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status</article-title>. <source>Alzheimers Dement (Amst)</source>. <year>2021</year>;<volume>13</volume>(<issue>1</issue>):<fpage>e12182</fpage>. <pub-id pub-id-type="doi">10.1002/dad2.12182</pub-id><pub-id pub-id-type="pmid">33969174</pub-id><pub-id pub-id-type="pmcid">PMC8088096</pub-id></mixed-citation></ref><ref id="R42"><label>42.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Palmqvist</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Janelidze</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Quiroz</surname><given-names>YT</given-names></name>, <etal/><article-title>Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders</article-title>. <source>JAMA</source>. <year>2020</year>;<volume>324</volume>(<issue>8</issue>):<fpage>772</fpage>&#8211;<lpage>781</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2020.12134</pub-id><pub-id pub-id-type="pmid">32722745</pub-id><pub-id pub-id-type="pmcid">PMC7388060</pub-id></mixed-citation></ref></ref-list></back><floats-group><fig position="float" id="F1" orientation="portrait"><label>Figure 1.</label><caption><p id="P41">Distributions of neurodegenerative biomarkers in India (<italic toggle="yes">N</italic> = 2151) and the Unites States (<italic toggle="yes">N</italic> = 3466).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-2114315-f0001.jpg"/></fig><fig position="float" id="F2" orientation="portrait"><label>Figure 2.</label><caption><p id="P42">Correlations among neurodegenerative biomarkers in India (<italic toggle="yes">N</italic> = 2151) and the United States (<italic toggle="yes">N</italic> = 3466).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-2114315-f0002.jpg"/></fig><fig position="float" id="F3" orientation="portrait"><label>Figure 3.</label><caption><p id="P43">Standardized neurodegenerative biomarker levels by age in LASI-DAD (<italic toggle="yes">N</italic> = 2151) and HRS (<italic toggle="yes">N</italic> = 3466).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-2114315-f0003.jpg"/></fig><fig position="float" id="F4" orientation="portrait"><label>Figure 4.</label><caption><p id="P44">Association of standardized factor cognitive score on neurodegenerative biomarkers in India (<italic toggle="yes">N</italic> = 2151) and the United States (<italic toggle="yes">N</italic> = 2323). Note: Regression coefficients from OLS regression of standardized cognitive score on standardized GFAP, NfL, A&#946;42/A&#946;40, and pTau181 or neurodegenerative biomarker factor score (based on GFAP, NfL, pTau181); HRS: Age-, gender-, race/ethnicity-controlled; LASI-DAD: Age-, gender-controlled. Note: Individual models show when each biomarker was included in the model separately; combined model shows when all biomarkers were entered at the same time; biomarker factor score shows when biomarker factor score was included in the model. Note: Coefficients, 95% CI, and <italic toggle="yes">P</italic>-values are included in <xref rid="SD1" ref-type="supplementary-material">Table S3</xref>. <italic toggle="yes">P</italic> &lt; 0.05.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-2114315-f0004.jpg"/></fig><fig position="float" id="F5" orientation="portrait"><label>Figure 5.</label><caption><p id="P45">Association of dementia with neurodegenerative biomarkers in India (<italic toggle="yes">N</italic> = 1405) and the United States (<italic toggle="yes">N</italic> = 2333). Note: Odds ratios from logistic regression of having &#8220;dementia&#8221; on standardized GFAP, NfL, A&#946;42/A&#946;40, and pTau181 or neurodegenerative biomarker factor score; HRS: Age-, gender-, race/ethnicity-controlled; LASI-DAD: Age-, gender-controlled. Note: Individual models show when each biomarker was included in the model separately; combined model shows when all biomarkers were entered at the same time; biomarker factor score shows when biomarker factor score was included in the model. Note: Odds ratios, 95% CI, and <italic toggle="yes">P</italic>-values are included in <xref rid="SD1" ref-type="supplementary-material">Table S4</xref>. <italic toggle="yes">P</italic> &lt; 0.05.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-2114315-f0005.jpg"/></fig><fig position="float" id="F6" orientation="portrait"><label>Figure 6.</label><caption><p id="P46">Association of cognitive decline and death with neurodegenerative biomarkers in India (<italic toggle="yes">N</italic> = 1128) and the United States (<italic toggle="yes">N</italic> = 2989). Note: Cognitive decline is defined as having a negative change between time 1 and time 2 cognitive score among those without dementia at time 1. Note: Each biomarker was included in the model separately. Note: Odds ratios, 95% CI, and <italic toggle="yes">P</italic>-values are included in <xref rid="SD1" ref-type="supplementary-material">Table S5</xref>. <italic toggle="yes">P</italic> &lt; 0.05.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-2114315-f0006.jpg"/></fig><table-wrap position="float" id="T1" orientation="landscape"><label>Table 1.</label><caption><p id="P47">Description of the samples.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1"/><th align="left" valign="middle" rowspan="1" colspan="1">LASI-DAD <italic toggle="yes">N</italic> = 2151</th><th align="left" valign="middle" rowspan="1" colspan="1">HRS <italic toggle="yes">N</italic> = 3466</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Mean (SD) age (years)</td><td align="left" valign="middle" rowspan="1" colspan="1">69.6 (7.4)</td><td align="left" valign="middle" rowspan="1" colspan="1">70.5 (8.6)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Female (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">50.2</td><td align="left" valign="middle" rowspan="1" colspan="1">54.6</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Race/ethnicity (%)</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;Non-Hispanic White/other</td><td align="left" valign="middle" rowspan="1" colspan="1">NA</td><td align="left" valign="middle" rowspan="1" colspan="1">81.4</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;Non-Hispanic Black</td><td align="left" valign="middle" rowspan="1" colspan="1">NA</td><td align="left" valign="middle" rowspan="1" colspan="1">9.6</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;Hispanic</td><td align="left" valign="middle" rowspan="1" colspan="1">NA</td><td align="left" valign="middle" rowspan="1" colspan="1">9.0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Education (%)</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;Low education</td><td align="left" valign="middle" rowspan="1" colspan="1">52.0</td><td align="left" valign="middle" rowspan="1" colspan="1">14.7</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;Mid education</td><td align="left" valign="middle" rowspan="1" colspan="1">25.7</td><td align="left" valign="middle" rowspan="1" colspan="1">30.3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;High education</td><td align="left" valign="middle" rowspan="1" colspan="1">22.3</td><td align="left" valign="middle" rowspan="1" colspan="1">55.0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Rural residency (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">69.9</td><td align="left" valign="middle" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Mean (SD)/Median neurodegenerative marker</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;GFAP<sup><xref rid="TFN1" ref-type="table-fn">a</xref></sup></td><td align="left" valign="middle" rowspan="1" colspan="1">153.92 (107.40)/129.27</td><td align="left" valign="middle" rowspan="1" colspan="1">109.37 (77.38)/90.30</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;NfL<sup><xref rid="TFN1" ref-type="table-fn">a</xref></sup></td><td align="left" valign="middle" rowspan="1" colspan="1">44.38 (55.76)/31.02</td><td align="left" valign="middle" rowspan="1" colspan="1">25.48 (26.27)/18.60</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;A&#946;42/A&#946;40</td><td align="left" valign="middle" rowspan="1" colspan="1">0.06 (0.04)/0.06</td><td align="left" valign="middle" rowspan="1" colspan="1">0.07 (0.02)/0.06</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;pTau181</td><td align="left" valign="middle" rowspan="1" colspan="1">41.21 (29.46)/35.20</td><td align="left" valign="middle" rowspan="1" colspan="1">2.18 (2.27)/1.64</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;zpTau181</td><td align="left" valign="middle" rowspan="1" colspan="1">&#8722;0.00 (0.96)/&#8722;0.20</td><td align="left" valign="middle" rowspan="1" colspan="1">&#8722;0.05 (0.90)/&#8722;0.26</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Mean (SD)/Median biomarker factor score (from GFAP, NfL, pTau181)<sup><xref rid="TFN1" ref-type="table-fn">a</xref></sup></td><td align="left" valign="middle" rowspan="1" colspan="1">1.33 (25.49)/&#8722;4.80</td><td align="left" valign="middle" rowspan="1" colspan="1">&#8722;0.02 (14.65)/&#8722;4.16</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Cognitive measures</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Mean (SD) cognitive score</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;Cognitive factor score</td><td align="left" valign="middle" rowspan="1" colspan="1">&#8722;0.07 (0.91)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.23 (0.92) <italic toggle="yes">N</italic> = 2323</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Dementia</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;Demented (CDR) (<italic toggle="yes">N</italic> = 1405) (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">6.7</td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;Demented (HCAP) (<italic toggle="yes">N</italic> = 2333) (%)</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">6.8</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Cognitive change</td><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">N</italic> = 1128</td><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">N</italic> = 2989</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;No cognitive decline (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">29.7</td><td align="left" valign="middle" rowspan="1" colspan="1">43.4</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;Cognitive decline (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">48.4</td><td align="left" valign="middle" rowspan="1" colspan="1">45.3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;Death (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">21.9</td><td align="left" valign="middle" rowspan="1" colspan="1">11.3</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><label>a</label><p id="P48">Mean country difference at <italic toggle="yes">P</italic> &lt; .05;</p></fn><fn id="TFN2"><p id="P49">Note: NA - Not applicable.</p></fn></table-wrap-foot></table-wrap></floats-group></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="mco270401" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">MedComm (2020)</journal-id><journal-id journal-id-type="iso-abbrev">MedComm (2020)</journal-id><journal-id journal-id-type="pmc-domain-id">4101</journal-id><journal-id journal-id-type="pmc-domain">mcomm</journal-id><journal-id journal-id-type="publisher-id">MCO2</journal-id><journal-title-group><journal-title>MedComm</journal-title></journal-title-group><issn pub-type="epub">2688-2663</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12495453</article-id><article-id pub-id-type="pmcid-ver">PMC12495453.1</article-id><article-id pub-id-type="pmcaid">12495453</article-id><article-id pub-id-type="pmcaiid">12495453</article-id><article-id pub-id-type="pmid">41049269</article-id><article-id pub-id-type="doi">10.1002/mco2.70401</article-id><article-id pub-id-type="publisher-id">MCO270401</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Review</subject></subj-group><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Proteolysis&#8208;Targeting Chimera (PROTAC): Current Applications and Future Directions</article-title></title-group><contrib-group><contrib id="mco270401-cr-0001" contrib-type="author"><name name-style="western"><surname>Fan</surname><given-names initials="G">Gang</given-names></name><xref rid="mco270401-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="mco270401-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="mco270401-cr-0002" contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="S">Shilin</given-names></name><xref rid="mco270401-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="mco270401-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="mco270401-cr-0003" contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="Q">Qingping</given-names></name><xref rid="mco270401-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="mco270401-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="mco270401-cr-0004" contrib-type="author"><name name-style="western"><surname>Yu</surname><given-names initials="N">Na</given-names></name><xref rid="mco270401-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="mco270401-cr-0005" contrib-type="author"><name name-style="western"><surname>Shen</surname><given-names initials="Z">Ziyang</given-names></name><xref rid="mco270401-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="mco270401-cr-0006" contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="Z">Zhaoji</given-names></name><xref rid="mco270401-aff-0007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib id="mco270401-cr-0007" contrib-type="author"><name name-style="western"><surname>Guo</surname><given-names initials="W">Weiming</given-names></name><xref rid="mco270401-aff-0008" ref-type="aff">
<sup>8</sup>
</xref><xref rid="mco270401-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="mco270401-cr-0008" contrib-type="author" corresp="yes"><name name-style="western"><surname>Tang</surname><given-names initials="Z">Zhihan</given-names></name><xref rid="mco270401-aff-0009" ref-type="aff">
<sup>9</sup>
</xref><xref rid="mco270401-aff-0010" ref-type="aff">
<sup>10</sup>
</xref><address><email>tangzhihan@usc.edu.cn</email></address></contrib><contrib id="mco270401-cr-0009" contrib-type="author" corresp="yes"><name name-style="western"><surname>Yang</surname><given-names initials="J">Jing</given-names></name><xref rid="mco270401-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="mco270401-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>yangjing.med@email.szu.edu.cn</email></address></contrib><contrib id="mco270401-cr-0010" contrib-type="author" corresp="yes"><name name-style="western"><surname>Liu</surname><given-names initials="M">Miao</given-names></name><xref rid="mco270401-aff-0006" ref-type="aff">
<sup>6</sup>
</xref><address><email>mliu0@bwh.harvard.edu</email></address></contrib></contrib-group><aff id="mco270401-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Medical Research Center</named-content>
<institution>Affiliated Nanshan Hospital of Shenzhen University</institution>
<city>Shenzhen</city>
<country country="CN">China</country>
</aff><aff id="mco270401-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Pan&#8208;Vascular Research Group</named-content>
<institution>Affiliated Nanshan Hospital of Shenzhen University</institution>
<city>Shenzhen</city>
<country country="CN">China</country>
</aff><aff id="mco270401-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Endocrinology</named-content>
<institution>Affiliated Nanshan Hospital of Shenzhen University</institution>
<city>Shenzhen</city>
<country country="CN">China</country>
</aff><aff id="mco270401-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Neurosurgery</named-content>
<institution>Affiliated Nanshan Hospital of Shenzhen University</institution>
<city>Shenzhen</city>
<country country="CN">China</country>
</aff><aff id="mco270401-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Department of Biology</named-content>
<institution>Boston University</institution>
<city>Boston</city>
<named-content content-type="country-part">Massachusetts</named-content>
<country country="US">USA</country>
</aff><aff id="mco270401-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology</named-content>
<institution>Brigham and Women's Hospital</institution>
<institution>Harvard Medical School</institution>
<city>Boston</city>
<named-content content-type="country-part">Massachusetts</named-content>
<country country="US">USA</country>
</aff><aff id="mco270401-aff-0007">
<label>
<sup>7</sup>
</label>
<named-content content-type="organisation-division">Department of Medicine</named-content>
<institution>Beth Israel Deaconess Medical Center</institution>
<city>Boston</city>
<named-content content-type="country-part">Massachusetts</named-content>
<country country="US">USA</country>
</aff><aff id="mco270401-aff-0008">
<label>
<sup>8</sup>
</label>
<named-content content-type="organisation-division">Department of Orthopaedics</named-content>
<institution>The First Affiliated Hospital of Guilin Medical University</institution>
<city>Guilin</city>
<country country="CN">China</country>
</aff><aff id="mco270401-aff-0009">
<label>
<sup>9</sup>
</label>
<named-content content-type="organisation-division">Institute of Cardiovascular Disease</named-content>
<named-content content-type="organisation-division">Key Laboratory for Arteriosclerology of Hunan Province</named-content>
<named-content content-type="organisation-division">Hunan International Scientific and Technological Cooperation Base of Arteriosclerotic Disease</named-content>
<named-content content-type="organisation-division">School of Basic Medical Sciences</named-content>
<named-content content-type="organisation-division">Hengyang Medical School</named-content>
<institution>University of South China</institution>
<city>Hengyang</city>
<named-content content-type="country-part">Hunan</named-content>
<country country="CN">China</country>
</aff><aff id="mco270401-aff-0010">
<label>
<sup>10</sup>
</label>
<named-content content-type="organisation-division">School of Basic Medical Sciences</named-content>
<institution>Hunan University of Medicine</institution>
<city>Huaihua</city>
<country country="CN">China</country>
</aff><pub-date pub-type="epub"><day>04</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><volume>6</volume><issue seq="410">10</issue><issue-id pub-id-type="pmc-issue-id">496875</issue-id><issue-id pub-id-type="doi">10.1002/mco2.v6.10</issue-id><elocation-id>e70401</elocation-id><history><date date-type="rev-recd"><day>27</day><month>8</month><year>2025</year></date><date date-type="received"><day>26</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>28</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>04</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>05</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-06 17:25:22.027"><day>06</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">MedComm</italic> published by Sichuan International Medical Exchange &amp; Promotion Association (SCIMEA) and John Wiley &amp; Sons Australia, Ltd.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="MCO2-6-e70401.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:MCO2-6-e70401.pdf"/><abstract><title>ABSTRACT</title><p>Targeted protein degradation (TPD) represents a paradigm shift in drug discovery, moving beyond traditional binding&#8208;based inhibition toward active removal of disease&#8208;driving proteins. This approach has unlocked therapeutic possibilities for previously &#8220;undruggable&#8221; targets, including transcription factors like MYC and STAT3, mutant oncoproteins such as KRAS G12C, and scaffolding molecules lacking conventional binding pockets. Among TPD strategies, proteolysis&#8208;targeting chimeras (PROTACs) have emerged as the leading clinical platform, with the first molecule entering trials in 2019 and progression to Phase III completion by 2024. This comprehensive review examines PROTAC development across diverse therapeutic areas, analyzing key targets including kinases, hormone receptors, antiapoptotic proteins, and epigenetic modulators. We evaluate clinical progression of breakthrough candidates such as ARV&#8208;110 for prostate cancer, ARV&#8208;471 for breast cancer, and BTK degraders, while discussing critical challenges including the &#8220;hook effect&#8221; and oral bioavailability limitations. The review explores future directions encompassing innovative delivery strategies, tissue&#8208;specific degrader design, and approaches for expanding E3 ligase repertoires and overcoming resistance. This review provides essential foundations for rational target selection, molecular optimization, and clinical translation strategies. By integrating mechanistic insights with clinical realities, this analysis offers perspectives on PROTAC technology advancement and identifies opportunities for transforming treatment of complex diseases resistant to conventional therapies.</p></abstract><abstract id="mco270401-abs-0001" abstract-type="graphical"><p>PROTACs are reshaping drug discovery through targeted protein degradation. Clinical programs now extend to prostate, breast, lung, hematologic, and solid tumors, with key targets including AR, ER, BTK, STAT3, Bcl&#8208;xL, BRD9, Kras, and so on. These degraders overcome resistance, broaden therapeutic scope, and provide solutions for &#8220;undruggable&#8221; proteins, advancing from molecular design to Phase III trials and opening opportunities across oncology, immunology, neurology, and metabolic disease.
<boxed-text position="anchor" content-type="graphic" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="MCO2-6-e70401-g003.jpg"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="mco270401-kwd-0001">clinical translation</kwd><kwd id="mco270401-kwd-0002">drug discovery</kwd><kwd id="mco270401-kwd-0003">PROTAC</kwd><kwd id="mco270401-kwd-0004">target protein degradation</kwd><kwd id="mco270401-kwd-0005">ubiquitin&#8211;proteasome system</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>National Natural Science Foundation of China</institution><institution-id institution-id-type="doi">10.13039/501100001809</institution-id></institution-wrap></funding-source><award-id>82471623</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>Guangdong Natural Science Foundation</institution><institution-id institution-id-type="doi">10.13039/501100003453</institution-id></institution-wrap></funding-source><award-id>2025A1515010482</award-id></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>Shenzhen Medical Research Fund</institution></institution-wrap></funding-source><award-id>A2403066</award-id></award-group><award-group id="funding-0004"><funding-source><institution-wrap><institution>Shenzhen Natural Science Foundation</institution></institution-wrap></funding-source><award-id>JCYJ20240813114423031</award-id></award-group><award-group id="funding-0005"><funding-source><institution-wrap><institution>Shenzhen Nanshan District Science and Technology Plan</institution></institution-wrap></funding-source><award-id>NSZD2023041</award-id></award-group><award-group id="funding-0006"><funding-source><institution-wrap><institution>Key Project of the Hunan Provincial Natural Science Foundation University Joint Fund</institution></institution-wrap></funding-source><award-id>2025JJ90128</award-id></award-group></funding-group><counts><fig-count count="5"/><table-count count="2"/><page-count count="45"/><word-count count="33570"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:04.10.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="mco270401-cit-0454"><string-name name-style="western"><given-names>G.</given-names><surname>Fan</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>Q.</given-names><surname>Zhang</surname></string-name>, et al. &#8220;<article-title>Proteolysis&#8208;Targeting Chimera (PROTAC): Current Applications and Future Directions</article-title>.&#8221; <source>MedComm</source><volume>6</volume>, no. <issue>10</issue> (<year>2025</year>): <elocation-id>e70401</elocation-id>. <pub-id pub-id-type="doi">10.1002/mco2.70401</pub-id></mixed-citation>
</p><fn-group><fn id="mco270401-note-0002"><p>
<bold>Funding</bold>: This work was supported by funding from National Natural Science Foundation of China (82471623), Guangdong Natural Science Foundation (2025A1515010482), Shenzhen Medical Research Fund (A2403066), Shenzhen Natural Science Foundation (JCYJ20240813114423031), Shenzhen Nanshan District Science and Technology Plan Project (NSZD2023041), and the Key Project of the Hunan Provincial Natural Science Foundation University Joint Fund (2025JJ90128).</p></fn><fn id="mco270401-note-0001" fn-type="equal"><p>Gang Fan, Shilin Chen, and Qingping Zhang have contributed equally to this work.</p></fn></fn-group></notes></front><body><sec id="mco270401-sec-0010"><label>1</label><title>Introduction</title><p>Recent years have witnessed remarkable advances in proteomics and structural biology that have significantly deepened our understanding of disease&#8208;associated molecular mechanisms, yet these developments have simultaneously exposed critical limitations inherent in conventional drug discovery approaches. While small&#8208;molecule inhibitors [<xref rid="mco270401-bib-0001" ref-type="bibr">1</xref>], agonists [<xref rid="mco270401-bib-0002" ref-type="bibr">2</xref>], and monoclonal antibodies (mAbs) [<xref rid="mco270401-bib-0003" ref-type="bibr">3</xref>] have found widespread application in clinical therapeutics, these modalities typically operate through occupancy&#8208;based binding to active sites or allosteric pockets to block protein function or downstream signaling pathways. However, many pathogenic proteins, including transcription factors, structural scaffolding proteins, and intracellular aggregates, lack well&#8208;defined binding pockets, exhibit high conformational plasticity, or display functional redundancy, characteristics that have long rendered them &#8220;undruggable&#8221;[<xref rid="mco270401-bib-0004" ref-type="bibr">4</xref>, <xref rid="mco270401-bib-0005" ref-type="bibr">5</xref>, <xref rid="mco270401-bib-0006" ref-type="bibr">6</xref>, <xref rid="mco270401-bib-0007" ref-type="bibr">7</xref>]. Current estimates suggest that only 10&#8211;15% of the human proteome remains accessible to conventional small&#8208;molecule approaches [<xref rid="mco270401-bib-0008" ref-type="bibr">8</xref>], leaving vast territories of disease&#8208;relevant biology beyond the reach of therapeutic intervention. Against this backdrop, the emergence of targeted protein degradation (TPD) strategies represents a fundamental paradigm shift in drug discovery. Rather than attempting to inhibit protein activity, TPD technologies harness the cell's intrinsic protein quality control machinery to induce proteolytic elimination of the target protein [<xref rid="mco270401-bib-0009" ref-type="bibr">9</xref>, <xref rid="mco270401-bib-0010" ref-type="bibr">10</xref>, <xref rid="mco270401-bib-0011" ref-type="bibr">11</xref>, <xref rid="mco270401-bib-0012" ref-type="bibr">12</xref>]. Among TPD strategies, proteolysis&#8208;targeting chimeras (PROTACs) have emerged as a particularly mature platform. Originally conceived in 2001 as experimental tools for studying protein function [<xref rid="mco270401-bib-0013" ref-type="bibr">13</xref>], PROTACs have undergone rapid evolution into promising clinical candidates. The extraordinary promise of these novel therapeutic approaches has been dramatically demonstrated through recent clinical milestones: the first PROTAC molecule entered clinical trials in 2019 [<xref rid="mco270401-bib-0014" ref-type="bibr">14</xref>], and remarkably, just 5 years later, the field has achieved an even more significant milestone with a PROTAC molecule successfully completing Phase III clinical trials and formally submitting a New Drug Application to the United States Food and Drug Administration (US FDA) for market approval [<xref rid="mco270401-bib-0015" ref-type="bibr">15</xref>].</p><p>Clinical validation of PROTAC technology has been most compelling in oncology, where conventional approaches have repeatedly failed. For example, androgen receptor (AR) variants that drive resistance to standard antagonists remain susceptible to degradation&#8208;based strategies [<xref rid="mco270401-bib-0016" ref-type="bibr">16</xref>, <xref rid="mco270401-bib-0017" ref-type="bibr">17</xref>], and transcription factors such as STAT3&#8212;long considered among the most challenging cancer targets&#8212;are now tractable through systematic degradation [<xref rid="mco270401-bib-0018" ref-type="bibr">18</xref>]. These successes in cancer have established PROTACs as a leading therapeutic modality. Building on this foundation, research has begun to explore applications beyond oncology, including neurodegenerative diseases [<xref rid="mco270401-bib-0019" ref-type="bibr">19</xref>, <xref rid="mco270401-bib-0020" ref-type="bibr">20</xref>], metabolic disorders [<xref rid="mco270401-bib-0021" ref-type="bibr">21</xref>], inflammatory conditions [<xref rid="mco270401-bib-0022" ref-type="bibr">22</xref>], and, more recently, cellular senescence [<xref rid="mco270401-bib-0023" ref-type="bibr">23</xref>]. Although senescence&#8208;related targets are still at an early stage of investigation, innovative PROTAC designs have demonstrated that proteins central to senescence, a process increasingly recognized as critical in aging and age&#8208;related diseases, can be effectively degraded [<xref rid="mco270401-bib-0023" ref-type="bibr">23</xref>, <xref rid="mco270401-bib-0024" ref-type="bibr">24</xref>, <xref rid="mco270401-bib-0025" ref-type="bibr">25</xref>, <xref rid="mco270401-bib-0026" ref-type="bibr">26</xref>]. Each therapeutic area presents unique challenges in target selection, molecular design, and delivery, yet most current literature remains fragmented, with cancer&#8208;focused reports dominating and limited synthesis across disease contexts. This review aims to bridge that gap by providing an integrated analytical framework that captures both the well&#8208;established oncology applications and the emerging potential of PROTACs in noncancer indications.</p><p>The challenges confronting PROTAC technology are as substantial as its promise. Molecular weight and polarity constraints continue to limit oral bioavailability and tissue distribution profiles. The &#8220;hook effect,&#8221; whereby higher concentrations paradoxically reduce activity, complicates dose optimization strategies [<xref rid="mco270401-bib-0027" ref-type="bibr">27</xref>, <xref rid="mco270401-bib-0028" ref-type="bibr">28</xref>]. Resistance mechanisms, while less prevalent than with traditional inhibitors, are beginning to emerge as clinical experience accumulates. Perhaps most critically, the field currently lacks robust predictive frameworks for identifying which proteins will prove amenable to degradation and which patients will respond favorably to specific PROTAC therapies. To address these gaps, we provide a comprehensive analysis that contextualizes PROTAC development across disease systems, examines both successful applications and persistent challenges, and identifies emerging opportunities for therapeutic innovation. Our review encompasses several key dimensions: the mechanistic foundations and pharmacological advantages that distinguish PROTACs from conventional therapies; representative targets and molecules across major therapeutic areas, highlighting both breakthrough successes and instructive failures; current clinical landscape analysis that draws lessons from early trials; innovative delivery approaches that expand PROTAC accessibility to previously challenging targets and tissues; and forward&#8208;looking directions for technology advancement, including strategies for overcoming current limitations and expanding therapeutic applications.</p><p>This comprehensive review seeks to provide a systematic analytical framework for understanding PROTAC technology development. We begin by examining the design principles and degradation mechanisms that underpin PROTAC function, followed by a systematic comparison with traditional therapeutic modalities to establish their unique pharmacological advantages. Subsequently, we provide comprehensive coverage of representative targets and molecules across diverse therapeutic areas, ranging from well&#8208;established kinase and hormone receptor degraders to emerging applications targeting transcription factors and immune regulatory proteins. The clinical landscape section evaluates current programs across different developmental phases, analyzing both successes and setbacks to identify key lessons for future development strategies. Our discussion of delivery systems addresses one of the field's most pressing challenges, exploring both molecular optimization strategies and advanced carrier technologies. Finally, we outline future directions encompassing molecular design optimization, E3 ligase toolbox expansion, organ&#8208;specific targeting strategies, and approaches for overcoming clinical translation barriers. Through integration of mechanistic insights with clinical realities, this analysis provides both a current state assessment and a roadmap for future innovation as PROTAC technology transitions from a promising concept to transformative clinical reality across multiple therapeutic domains.</p></sec><sec id="mco270401-sec-0020"><label>2</label><title>Design Principles and Degradation Mechanism of PROTACs</title><p>PROTAC technology leverages the endogenous ubiquitin&#8211;proteasome system (UPS) to achieve selective elimination of target proteins and represents a hallmark of event&#8208;driven pharmacology [<xref rid="mco270401-bib-0029" ref-type="bibr">29</xref>]. Unlike traditional occupancy&#8208;based inhibition, PROTACs function by inducing spatial proximity between the POI and an E3 ligase, resulting in ubiquitination and subsequent degradation via the 26S proteasome [<xref rid="mco270401-bib-0030" ref-type="bibr">30</xref>, <xref rid="mco270401-bib-0031" ref-type="bibr">31</xref>, <xref rid="mco270401-bib-0032" ref-type="bibr">32</xref>]. Rather than functionally blocking the protein, this approach catalytically erases it from the system. A canonical PROTAC comprises three covalently linked components: a ligand that binds the POI, a ligand that recruits the E3 ligase, and a linker that bridges the two (Figure&#160;<xref rid="mco270401-fig-0001" ref-type="fig">1</xref>) [<xref rid="mco270401-bib-0033" ref-type="bibr">33</xref>]. The resulting chimeric molecule facilitates the formation of a POI&#8211;PROTAC&#8211;E3 ternary complex [<xref rid="mco270401-bib-0034" ref-type="bibr">34</xref>]. Upon productive ternary complex formation, the E3 ligase transfers ubiquitin moieties to lysine residues on the target protein, marking it for proteasomal degradation. The degradation efficiency, selectivity, and target scope of a PROTAC are influenced by several interdependent factors. While high&#8208;affinity binding of both the POI ligand and the E3 ligand is important, the stability and cooperativity of the ternary complex are often more critical [<xref rid="mco270401-bib-0035" ref-type="bibr">35</xref>, <xref rid="mco270401-bib-0036" ref-type="bibr">36</xref>, <xref rid="mco270401-bib-0037" ref-type="bibr">37</xref>, <xref rid="mco270401-bib-0038" ref-type="bibr">38</xref>, <xref rid="mco270401-bib-0039" ref-type="bibr">39</xref>]. Studies have shown that even weak&#8208;affinity ligands can drive potent degradation if the linker supports favorable ternary complex geometry [<xref rid="mco270401-bib-0040" ref-type="bibr">40</xref>, <xref rid="mco270401-bib-0041" ref-type="bibr">41</xref>, <xref rid="mco270401-bib-0042" ref-type="bibr">42</xref>]. Linker properties&#8212;such as length, flexibility, polarity, and spatial orientation&#8212;directly affect the protein&#8211;protein interface and determine whether the ternary complex adopts a ubiquitination&#8208;competent conformation [<xref rid="mco270401-bib-0043" ref-type="bibr">43</xref>, <xref rid="mco270401-bib-0044" ref-type="bibr">44</xref>, <xref rid="mco270401-bib-0045" ref-type="bibr">45</xref>, <xref rid="mco270401-bib-0046" ref-type="bibr">46</xref>]. Notably, the linker serves as a tunable element in PROTAC design, and its structural optimization has been shown to significantly impact both pharmacokinetics and target selectivity [<xref rid="mco270401-bib-0047" ref-type="bibr">47</xref>, <xref rid="mco270401-bib-0048" ref-type="bibr">48</xref>]. Among E3 ligase ligands, CRBN&#8208; and VHL&#8208;based molecules are the most widely used due to their defined structure&#8211;activity relationships, favorable stability, and synthetic accessibility. These ligands underpin the design of numerous PROTACs that have progressed to clinical evaluation. More recently, alternative E3 recruiters such as IAPs, MDM2, and DCAF family members have been explored to enhance tissue selectivity, reduce off&#8208;target toxicity, and broaden therapeutic scope [<xref rid="mco270401-bib-0049" ref-type="bibr">49</xref>, <xref rid="mco270401-bib-0050" ref-type="bibr">50</xref>, <xref rid="mco270401-bib-0051" ref-type="bibr">51</xref>]. A unique advantage of PROTACs is their sub&#8208;stoichiometric mode of action [<xref rid="mco270401-bib-0052" ref-type="bibr">52</xref>]. Once a target protein is degraded, the PROTAC molecule can be recycled, eliminating the need for continuous occupancy [<xref rid="mco270401-bib-0053" ref-type="bibr">53</xref>, <xref rid="mco270401-bib-0054" ref-type="bibr">54</xref>]. This feature not only reduces systemic exposure requirements but also enables more robust activity against proteins harboring resistance mutations. Compared with classical inhibitors, PROTACs show clear superiority when targeting multidomain scaffolds, dynamic complexes, or proteins lacking conventional ligandable pockets [<xref rid="mco270401-bib-0055" ref-type="bibr">55</xref>]. PROTAC design is not merely a matter of chemical assembly&#8212;it is a systems&#8208;level integration of conformational biology, complex thermodynamics, and pharmacological engineering. The linker, ternary complex dynamics, and degradation machinery must be harmonized to deliver efficient, selective, and therapeutically viable protein elimination.</p><fig position="float" fig-type="FIGURE" id="mco270401-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Mechanism and molecular architecture of PROTACs. Schematic illustration of a canonical PROTAC molecule comprising three components: a target protein (POI)&#8208;binding ligand, an E3 ubiquitin ligase&#8208;recruiting ligand, and a linker connecting the two functional domains. Degradation mechanism: The PROTAC facilitates ternary complex formation (POI&#8211;PROTAC&#8211;E3), enabling ubiquitin (Ub) transfer to lysine residues on the POI. The polyubiquitinated POI is subsequently recognized and degraded by the 26S proteasome. Following target degradation, the PROTAC molecule is recycled to engage additional target proteins, demonstrating the catalytic nature that enables sub&#8208;stoichiometric target elimination.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="MCO2-6-e70401-g004.jpg"/></fig></sec><sec id="mco270401-sec-0030"><label>3</label><title>Pharmacological Advantages of PROTACs Compared with Traditional Therapies</title><p>The emergence of PROTAC technology marks a paradigm shift in pharmacological strategy&#8212;from traditional inhibition to targeted degradation&#8212;opening new avenues in precision medicine. Table&#160;<xref rid="mco270401-tbl-0001" ref-type="table">1</xref> systematically compares PROTACs with conventional therapeutic modalities across key dimensions, highlighting their unique advantages and clinical potential.</p><table-wrap position="float" id="mco270401-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Systematic comparison of PROTACs with conventional therapeutic modalities.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Feature/capability</th><th align="center" rowspan="1" colspan="1">Small molecule inhibitors</th><th align="center" rowspan="1" colspan="1">Monoclonal antibodies (mAbs)</th><th align="center" rowspan="1" colspan="1">Gene&#8208;based medicines</th><th align="center" rowspan="1" colspan="1">PROTAC protein degraders</th></tr></thead><tbody><tr><td colspan="5" align="left" rowspan="1">
<bold>Mechanism of action</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Occupancy&#8208;driven (binds &amp; inhibits)</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">Event&#8208;driven (catalytic degradation)</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Possible</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Sub&#8208;stoichiometric activity (catalytic)</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Possible</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td colspan="5" align="left" rowspan="1">
<bold>Target engagement</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Eliminates disease&#8208;causing proteins</td><td align="center" rowspan="1" colspan="1">Indirectly</td><td align="center" rowspan="1" colspan="1">Indirectly</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Disrupts Scaffolding/nonenzymatic function</td><td align="center" rowspan="1" colspan="1">Weak/no</td><td align="center" rowspan="1" colspan="1">Possible</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Targets &#8220;undruggable&#8221; proteins</td><td align="center" rowspan="1" colspan="1">Rarely</td><td align="center" rowspan="1" colspan="1">Rarely</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Targets intracellular proteins</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Targets cell surface proteins</td><td align="center" rowspan="1" colspan="1">Possible</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Limited</td><td align="center" rowspan="1" colspan="1">Possible</td></tr><tr><td colspan="5" align="left" rowspan="1">
<bold>Pharmacokinetics/administration</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Broad tissue penetration</td><td align="center" rowspan="1" colspan="1">High</td><td align="center" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">Low/variable</td><td align="center" rowspan="1" colspan="1">Moderate</td></tr><tr><td align="left" rowspan="1" colspan="1">Systemic delivery</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Limited/challenging</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Oral bioavailability</td><td align="center" rowspan="1" colspan="1">High (many)</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Possible/developing</td></tr><tr><td align="left" rowspan="1" colspan="1">Route of administration</td><td align="center" rowspan="1" colspan="1">Oral/Injection</td><td align="center" rowspan="1" colspan="1">Injection</td><td align="center" rowspan="1" colspan="1">Injection/complex</td><td align="center" rowspan="1" colspan="1">Oral/injection</td></tr><tr><td colspan="5" align="left" rowspan="1">
<bold>Development &amp; practicality</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Ease of manufacturing</td><td align="center" rowspan="1" colspan="1">Relatively easy</td><td align="center" rowspan="1" colspan="1">Complex</td><td align="center" rowspan="1" colspan="1">Very complex</td><td align="center" rowspan="1" colspan="1">Moderate/developing</td></tr><tr><td align="left" rowspan="1" colspan="1">Ease of development (drug discovery)</td><td align="center" rowspan="1" colspan="1">Challenging</td><td align="center" rowspan="1" colspan="1">Established</td><td align="center" rowspan="1" colspan="1">Complex</td><td align="center" rowspan="1" colspan="1">Emerging/potential</td></tr><tr><td align="left" rowspan="1" colspan="1">Potential for high dose dependence</td><td align="center" rowspan="1" colspan="1">Yes (often)</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Variable</td><td align="center" rowspan="1" colspan="1">Low (catalytic)</td></tr></tbody></table><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><sec id="mco270401-sec-0040"><label>3.1</label><title>Fundamental Differences in Mechanism of Action</title><sec id="mco270401-sec-0050"><label>3.1.1</label><title>A Pharmacological Revolution: Occupancy&#8208;Driven versus Event&#8208;Driven</title><p>Traditional small&#8208;molecule inhibitors and mAbs rely on an occupancy&#8208;driven mechanism, requiring sustained binding to the target protein's active site to maintain inhibitory effects [<xref rid="mco270401-bib-0040" ref-type="bibr">40</xref>, <xref rid="mco270401-bib-0056" ref-type="bibr">56</xref>, <xref rid="mco270401-bib-0057" ref-type="bibr">57</xref>]. This necessitates high systemic drug concentrations, with effects diminishing as concentrations fall. In contrast, PROTACs utilize an event&#8208;driven mechanism, inducing catalytic degradation of target proteins rather than merely inhibiting them, thereby achieving an irreversible elimination rather than reversible inhibition [<xref rid="mco270401-bib-0058" ref-type="bibr">58</xref>, <xref rid="mco270401-bib-0059" ref-type="bibr">59</xref>, <xref rid="mco270401-bib-0060" ref-type="bibr">60</xref>]. While genetic drugs may also offer event&#8208;driven effects, their primary action is at the transcriptional level, limiting their ability to clear pre&#8208;existing pathogenic protein aggregates.</p></sec><sec id="mco270401-sec-0060"><label>3.1.2</label><title>Sub&#8208;Stoichiometric Activity: A Distinct Advantage</title><p>One of PROTACs&#8217; most compelling features is their sub&#8208;stoichiometric activity [<xref rid="mco270401-bib-0061" ref-type="bibr">61</xref>], where a small amount of PROTAC molecules can degrade large amounts of the target protein. This catalytic property allows a single PROTAC molecule to initiate multiple degradation cycles, in stark contrast to the 1:1 binding stoichiometry of conventional inhibitors and mAbs [<xref rid="mco270401-bib-0003" ref-type="bibr">3</xref>, <xref rid="mco270401-bib-0062" ref-type="bibr">62</xref>]. While genetic therapies may demonstrate similar effects in regulating gene expression, they lack the proteome&#8208;level catalytic degradation capability and often require complex delivery systems and delayed onset.</p></sec></sec><sec id="mco270401-sec-0070"><label>3.2</label><title>Target Engagement and Functional Disruption</title><sec id="mco270401-sec-0080"><label>3.2.1</label><title>Direct Elimination versus Indirect Suppression of Pathogenic Proteins</title><p>Traditional small molecules and mAbs indirectly suppress pathogenic proteins by inhibiting their function, leaving the proteins intact and potentially active through alternative pathways [<xref rid="mco270401-bib-0063" ref-type="bibr">63</xref>, <xref rid="mco270401-bib-0064" ref-type="bibr">64</xref>, <xref rid="mco270401-bib-0065" ref-type="bibr">65</xref>]. In contrast, PROTACs and gene therapies eliminate pathogenic proteins&#8212;PROTACs through proteasomal degradation, and gene therapies by downregulating transcription&#8212;offering a more complete therapeutic strategy [<xref rid="mco270401-bib-0066" ref-type="bibr">66</xref>].</p></sec><sec id="mco270401-sec-0090"><label>3.2.2</label><title>Disruption of Scaffold and Nonenzymatic Functions</title><p>Many disease&#8208;related proteins exert pathogenicity via scaffold functions or protein&#8211;protein interactions rather than enzymatic activity [<xref rid="mco270401-bib-0067" ref-type="bibr">67</xref>, <xref rid="mco270401-bib-0068" ref-type="bibr">68</xref>, <xref rid="mco270401-bib-0069" ref-type="bibr">69</xref>]. Traditional small molecules, designed to block catalytic sites, struggle in this context. mAbs are limited to extracellular targets. In contrast, PROTACs and genetic therapies can abrogate both enzymatic and nonenzymatic functions by eliminating the entire protein, making them particularly effective against structurally or functionally complex targets [<xref rid="mco270401-bib-0070" ref-type="bibr">70</xref>, <xref rid="mco270401-bib-0071" ref-type="bibr">71</xref>, <xref rid="mco270401-bib-0072" ref-type="bibr">72</xref>, <xref rid="mco270401-bib-0073" ref-type="bibr">73</xref>].</p></sec><sec id="mco270401-sec-0100"><label>3.2.3</label><title>Unlocking the &#8220;Undruggable&#8221;</title><p>A major challenge in drug development is the vast array of so&#8208;called &#8220;undruggable&#8221; targets&#8212;proteins lacking well&#8208;defined binding pockets or catalytic sites [<xref rid="mco270401-bib-0074" ref-type="bibr">74</xref>, <xref rid="mco270401-bib-0075" ref-type="bibr">75</xref>, <xref rid="mco270401-bib-0076" ref-type="bibr">76</xref>]. PROTACs address this by requiring only a binding ligand to the target protein, without needing to inhibit a functional domain [<xref rid="mco270401-bib-0077" ref-type="bibr">77</xref>, <xref rid="mco270401-bib-0078" ref-type="bibr">78</xref>]. Gene therapies indirectly regulate these proteins by modulating gene expression. Both approaches significantly expand the druggable proteome beyond traditional boundaries.</p></sec><sec id="mco270401-sec-0110"><label>3.2.4</label><title>Intracellular and Extracellular Target Coverage</title><p>Small molecules and PROTACs exhibit excellent cell permeability, enabling efficient targeting of intracellular proteins [<xref rid="mco270401-bib-0079" ref-type="bibr">79</xref>]. Gene therapies, though capable, often require elaborate delivery systems. mAbs are largely restricted to extracellular proteins due to their size [<xref rid="mco270401-bib-0080" ref-type="bibr">80</xref>, <xref rid="mco270401-bib-0081" ref-type="bibr">81</xref>]. For membrane&#8208;bound proteins, mAbs have inherent advantages; however, PROTACs&#8212;especially through innovative modalities such as antibody&#8211;drug conjugates (ADCs) or antibody&#8211;PROTAC conjugates (AOCs)&#8212;are increasingly bridging this gap [<xref rid="mco270401-bib-0082" ref-type="bibr">82</xref>, <xref rid="mco270401-bib-0083" ref-type="bibr">83</xref>, <xref rid="mco270401-bib-0084" ref-type="bibr">84</xref>, <xref rid="mco270401-bib-0085" ref-type="bibr">85</xref>].</p></sec></sec><sec id="mco270401-sec-0120"><label>3.3</label><title>Pharmacokinetics and Administration</title><sec id="mco270401-sec-0130"><label>3.3.1</label><title>Tissue Distribution</title><p>Small molecules offer superior tissue permeability, enabling broad distribution. PROTACs, with molecular weights between small molecules and biologics, offer moderate tissue penetration [<xref rid="mco270401-bib-0086" ref-type="bibr">86</xref>, <xref rid="mco270401-bib-0087" ref-type="bibr">87</xref>, <xref rid="mco270401-bib-0088" ref-type="bibr">88</xref>]. mAbs have limited distribution due to their size, while gene therapies vary widely depending on delivery systems and targeting strategies [<xref rid="mco270401-bib-0089" ref-type="bibr">89</xref>, <xref rid="mco270401-bib-0090" ref-type="bibr">90</xref>].</p></sec><sec id="mco270401-sec-0140"><label>3.3.2</label><title>Delivery Platforms and Routes of Administration</title><p>Systemic delivery is feasible for all modalities but varies in complexity. Small molecules, mAbs, and PROTACs are generally straightforward to administer. Gene therapies face greater challenges due to their reliance on complex vectors [<xref rid="mco270401-bib-0091" ref-type="bibr">91</xref>]. Oral bioavailability is a critical consideration&#8212;small molecules lead in this area, while mAbs and gene therapies typically require parenteral routes. Although PROTACs face formulation challenges, advances in medicinal chemistry are improving their oral availability and diversifying their delivery options.</p></sec></sec><sec id="mco270401-sec-0150"><label>3.4</label><title>Development and Practical Considerations</title><sec id="mco270401-sec-0160"><label>3.4.1</label><title>Manufacturing Complexity</title><p>Small molecules are synthetically straightforward. mAbs require biotechnological production [<xref rid="mco270401-bib-0092" ref-type="bibr">92</xref>], while gene therapies involve vector construction and packaging, making them the most complex [<xref rid="mco270401-bib-0093" ref-type="bibr">93</xref>, <xref rid="mco270401-bib-0094" ref-type="bibr">94</xref>]. PROTACs occupy an intermediate position&#8212;more complex than small molecules, but simpler than biologics or gene therapies.</p></sec><sec id="mco270401-sec-0170"><label>3.4.2</label><title>Drug Discovery Efficiency</title><p>Small molecule development is hindered by the limitations of target druggability [<xref rid="mco270401-bib-0095" ref-type="bibr">95</xref>]. mAbs benefit from mature development pipelines. Gene therapies are technically challenging due to multidisciplinary requirements [<xref rid="mco270401-bib-0096" ref-type="bibr">96</xref>]. PROTACs, as an emerging modality, show rapid development potential and are increasingly supported by structure&#8208;based drug design and high&#8208;throughput screening.</p></sec><sec id="mco270401-sec-0180"><label>3.4.3</label><title>Dose Dependency and Therapeutic Window</title><p>Traditional therapies often show strong dose dependence, requiring high systemic exposure for efficacy. Gene therapies vary in dose response [<xref rid="mco270401-bib-0097" ref-type="bibr">97</xref>]. PROTACs, due to their catalytic nature, display lower dose dependency and wider therapeutic windows, potentially reducing toxicity and side effects. A systematic comparison of PROTACs with traditional modalities clearly underscores the transformative value of TPD in modern therapeutics. PROTACs provide mechanistic innovations, such as event&#8208;driven action and sub&#8208;stoichiometric efficiency, pharmacological breadth, including engagement with undruggable targets and disruption of nonenzymatic functions, and practical advantages like lower dose dependency and potential for oral delivery. Nevertheless, challenges remain, including optimizing tissue permeability, improving oral bioavailability, and reducing manufacturing costs. With ongoing technological advancements and accumulating clinical experience, PROTACs are poised to play a central role in future therapeutic paradigms, offering safer, more effective, and convenient treatment options for a wide range of diseases.</p></sec></sec></sec><sec id="mco270401-sec-0190"><label>4</label><title>Representative Targets and PROTAC Molecules</title><p>PROTAC technology has exploded onto the drug discovery scene in recent years, capturing attention primarily because it works so differently from traditional inhibitors. While conventional drugs need to continuously occupy their targets to maintain effect, PROTACs can essentially &#8220;tag&#8221; proteins for destruction and walk away [<xref rid="mco270401-bib-0098" ref-type="bibr">98</xref>]. This makes them particularly attractive for going after those notorious &#8220;undruggable&#8221; proteins that have frustrated medicinal chemists for decades. Recent breakthroughs in molecular engineering, E3 ligase recruitment strategies, structural optimization, and getting these molecules into cells have pushed multiple PROTAC candidates into clinical trials, opening up therapeutic possibilities that seemed impossible just a few years ago (Figure&#160;<xref rid="mco270401-fig-0002" ref-type="fig">2</xref>).</p><fig position="float" fig-type="FIGURE" id="mco270401-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Therapeutic targets and representative PROTAC degraders. The major target classes addressed by PROTAC technology include kinases, transcription factors, hormone receptors, epigenetic regulators, immune targets, metabolic enzymes, and components of the ubiquitin&#8211;proteasome system. Key representative degraders are illustrated for each target category.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="MCO2-6-e70401-g001.jpg"/></fig><sec id="mco270401-sec-0200"><label>4.1</label><title>Kinase Targets</title><p>Kinases have emerged as the poster children of PROTAC development, and for good reason. These proteins occupy central roles in numerous disease pathways, and an extensive library of kinase inhibitors is already available to serve as starting points for PROTAC design&#8212;providing a significant advantage. Kinases span several major families, including receptor tyrosine kinases (EGFR, FGFR, VEGFR, IGF&#8208;1R, FLT3) [<xref rid="mco270401-bib-0099" ref-type="bibr">99</xref>], nonreceptor tyrosine kinases (Bruton's tyrosine kinase [BTK], BCR&#8211;ABL, SRC, FAK, JAK) [<xref rid="mco270401-bib-0100" ref-type="bibr">100</xref>], serine/threonine kinases (CDK, MEK, BRAF, AKT, PLK1, Wee1, p38, Aurora A/B) [<xref rid="mco270401-bib-0101" ref-type="bibr">101</xref>], and immune&#8208;related kinases (interleukin&#8208;1 receptor&#8208;associated kinase [IRAK]1/4) (Figure&#160;<xref rid="mco270401-fig-0002" ref-type="fig">2</xref>) [<xref rid="mco270401-bib-0072" ref-type="bibr">72</xref>, <xref rid="mco270401-bib-0102" ref-type="bibr">102</xref>]. Take EGFR&#8212;it has become something of a showcase for what PROTACs can accomplish. Molecules such as MS154, MS39, SIAIS125, and SIAIS126 have demonstrated the ability to selectively degrade mutant EGFR variants (L858R, T790M) [<xref rid="mco270401-bib-0103" ref-type="bibr">103</xref>, <xref rid="mco270401-bib-0104" ref-type="bibr">104</xref>, <xref rid="mco270401-bib-0105" ref-type="bibr">105</xref>], while leaving the normal protein alone, something that has been a holy grail in lung cancer research. But the EGFR story does not stop there. Researchers have gotten creative with delivery approaches, like Cer&#8211;Pom&#8211;PEG@GNP&#8208;S [<xref rid="mco270401-bib-0106" ref-type="bibr">106</xref>], which packages the degrader in nanoparticles for better cellular uptake. The SIAIS team has been particularly productive, churning out SIAIS091 [<xref rid="mco270401-bib-0107" ref-type="bibr">107</xref>], SIAIS117 [<xref rid="mco270401-bib-0108" ref-type="bibr">108</xref>], and SIAIS164018 [<xref rid="mco270401-bib-0109" ref-type="bibr">109</xref>], each iteration getting better at hitting the target. PROTAC&#8211;CPF brings fresh chemistry to the table with novel E3 ligase recruitment strategies. FGFR has not been left behind either&#8212;DGY&#8208;09&#8208;192 [<xref rid="mco270401-bib-0110" ref-type="bibr">110</xref>, <xref rid="mco270401-bib-0111" ref-type="bibr">111</xref>], built around the BGJ398 [<xref rid="mco270401-bib-0112" ref-type="bibr">112</xref>, <xref rid="mco270401-bib-0113" ref-type="bibr">113</xref>, <xref rid="mco270401-bib-0114" ref-type="bibr">114</xref>] inhibitor backbone, can efficiently degrade FGFR1/2 and shut down their downstream signaling. For VEGFR2, successful inhibition of angiogenesis has been achieved with molecules such as P22A, PROTAC&#8208;2, and PROTAC&#8208;5, with PROTAC&#8208;5 demonstrating particularly impressive efficacy in disrupting blood vessel formation [<xref rid="mco270401-bib-0115" ref-type="bibr">115</xref>, <xref rid="mco270401-bib-0116" ref-type="bibr">116</xref>, <xref rid="mco270401-bib-0117" ref-type="bibr">117</xref>]. Similar progress has also been made in targeting IGF&#8208;1R [<xref rid="mco270401-bib-0118" ref-type="bibr">118</xref>] and FLT3 [<xref rid="mco270401-bib-0119" ref-type="bibr">119</xref>] have their champions too&#8212;CPR3/CPR4 for breast cancer applications and PF15 for leukemia, respectively. The FLT3 field has really taken off recently with SPBS208, SJF020, GBD&#8208;9, and BCPyr all bringing different structural approaches to tackling acute myeloid leukemia. Moving to the nonreceptor kinases, BTK was actually one of the early PROTAC success stories. GMB&#8208;475 [<xref rid="mco270401-bib-0120" ref-type="bibr">120</xref>], RC&#8208;1 [<xref rid="mco270401-bib-0121" ref-type="bibr">121</xref>], and RC&#8208;3 [<xref rid="mco270401-bib-0122" ref-type="bibr">122</xref>] paved the way, but the field has matured considerably. GMB&#8208;805 improved on GMB&#8208;475's pharmacokinetics, while P22D explored completely different chemical scaffolds [<xref rid="mco270401-bib-0123" ref-type="bibr">123</xref>]. P19As and P19P [<xref rid="mco270401-bib-0124" ref-type="bibr">124</xref>] represent newer thinking about how to achieve selectivity. All of these work by hijacking either CRBN or VHL E3 ligases to tag BTK for destruction, which has been particularly exciting for B&#8208;cell malignancies [<xref rid="mco270401-bib-0125" ref-type="bibr">125</xref>, <xref rid="mco270401-bib-0126" ref-type="bibr">126</xref>]. BCR&#8211;ABL [<xref rid="mco270401-bib-0124" ref-type="bibr">124</xref>, <xref rid="mco270401-bib-0127" ref-type="bibr">127</xref>] is where PROTACs have really shown their muscle against drug resistance. This fusion protein is notorious for developing resistance mutations to kinase inhibitors, but degraders like SIAIS178 [<xref rid="mco270401-bib-0128" ref-type="bibr">128</xref>], BT1 [<xref rid="mco270401-bib-0129" ref-type="bibr">129</xref>], and AZO&#8211;PROTAC&#8208;4C [<xref rid="mco270401-bib-0130" ref-type="bibr">130</xref>] can still take it out even when it is mutated. The SIAIS team has been busy here too&#8212;SIAIS056 [<xref rid="mco270401-bib-0131" ref-type="bibr">131</xref>] was an early proof&#8208;of&#8208;concept, while SIAIS629050 and SIAIS629051 [<xref rid="mco270401-bib-0132" ref-type="bibr">132</xref>, <xref rid="mco270401-bib-0133" ref-type="bibr">133</xref>] represent the next generation with improved selectivity profiles. It is encouraging to see chemistry solving problems that seemed intractable. SRC and FAK have had their moments too, with CL1&#8208;YL2 making headway against SRC signaling and FAK degraders showing promise for blocking cancer cell migration [<xref rid="mco270401-bib-0134" ref-type="bibr">134</xref>, <xref rid="mco270401-bib-0135" ref-type="bibr">135</xref>]. But JAK is where things get interesting from a scope perspective. What started with just GSK215 [<xref rid="mco270401-bib-0136" ref-type="bibr">136</xref>] has exploded into the JP series&#8212;JP&#8208;1 through JP&#8208;6&#8212;representing a systematic effort to optimize JAK degradation. JP&#8208;1 got the ball rolling with JAK1/2 targeting, JP&#8208;2 sharpened the selectivity, JP&#8208;3 tackled cell penetration issues, JP&#8208;4 focused on JAK2 specificity, JP&#8208;5 proved the concept in inflammatory disease models, and JP&#8208;6 finally achieved the pharmacokinetic properties needed for clinical development. The serine/threonine kinases tell a similar story of rapid expansion. CDKs control cell division, so naturally they have attracted intense interest. Early molecules like YKL&#8208;06&#8208;101 [<xref rid="mco270401-bib-0137" ref-type="bibr">137</xref>], BSJ&#8208;4&#8208;116 [<xref rid="mco270401-bib-0138" ref-type="bibr">138</xref>], and L055 [<xref rid="mco270401-bib-0139" ref-type="bibr">139</xref>] proved the concept in leukemia and breast cancer models, but the field has exploded from there. A9 emerged as a particularly potent CDK4/6 degrader [<xref rid="mco270401-bib-0140" ref-type="bibr">140</xref>], CPS2 brought cell cycle specificity, PROTAC&#8208;8 went for a multitarget approach hitting CDK2/4/6 simultaneously [<xref rid="mco270401-bib-0141" ref-type="bibr">141</xref>], and TMX&#8208;2172 [<xref rid="mco270401-bib-0142" ref-type="bibr">142</xref>] explored new linker chemistry. Then you have CDK2/5 for dual targeting, CDK9 specifically for transcriptional control, PRN showing impressive cancer cell activity, and PROTAC 45 with enhanced stability. It has been a rapid evolution. MEK sits at a critical node in cancer signaling, so the MS series (MS432, MS928, MS910, MS934) along with YX&#8208;2&#8208;107 [<xref rid="mco270401-bib-0143" ref-type="bibr">143</xref>] have been attacking it from multiple angles. MS934 represents the latest thinking in the MS series [<xref rid="mco270401-bib-0144" ref-type="bibr">144</xref>], while YX&#8208;2&#8208;107 brings an alternative chemical approach. BRAF [<xref rid="mco270401-bib-0145" ref-type="bibr">145</xref>], particularly the V600E mutant that drives many melanomas, has been targeted by P4B, SJF&#8208;0628, and the newer SJF&#8208;0651, which shows improved selectivity for the mutant form. AKT pathway degradation has been another success story. INY&#8208;03&#8208;041 [<xref rid="mco270401-bib-0146" ref-type="bibr">146</xref>, <xref rid="mco270401-bib-0147" ref-type="bibr">147</xref>] can take out all three AKT isoforms, which is impressive given how central this pathway is to cancer cell survival. MS98 offers AKT1 selectivity when you need it, while MS170 provides pan&#8208;AKT coverage [<xref rid="mco270401-bib-0148" ref-type="bibr">148</xref>]. The fact that these molecules can improve both signal persistence and antiproliferative effects suggests they're doing something fundamentally different from inhibitors. Cell cycle control is another arena where PROTACs are making their mark. PLK1, Wee1, and Aurora kinases all play critical roles in mitosis, making them attractive cancer targets. HBL&#8208;4 (PLK1) [<xref rid="mco270401-bib-0149" ref-type="bibr">149</xref>], PP&#8208;C8 [<xref rid="mco270401-bib-0150" ref-type="bibr">150</xref>] and ZNL&#8208;02&#8208;096 (Wee1) [<xref rid="mco270401-bib-0151" ref-type="bibr">151</xref>], and JB170 [<xref rid="mco270401-bib-0152" ref-type="bibr">152</xref>], PROTAC&#8208;D, and dAURK&#8208;1 (Aurora) [<xref rid="mco270401-bib-0153" ref-type="bibr">153</xref>, <xref rid="mco270401-bib-0154" ref-type="bibr">154</xref>] have all shown they can trigger G2/M arrest and tumor suppression. ZNL&#8208;02&#8208;096 has been particularly interesting for DNA damage response studies, while dAURK&#8208;1's Aurora A specificity makes it useful for dissecting mitotic mechanisms. Even p38, with its role in inflammation and immune regulation, has its degraders&#8212;NR&#8208;6a and NR&#8208;7&#160;h can knock down p38&#945;/&#946; at nanomolar concentrations [<xref rid="mco270401-bib-0133" ref-type="bibr">133</xref>, <xref rid="mco270401-bib-0155" ref-type="bibr">155</xref>]. And the immune kinases IRAK1/4 have not been forgotten, with Degrader&#8208;3 and INJ&#8208;1013 offering new ways to modulate Toll&#8208;like receptor and NF&#8208;&#954;B signaling. INJ&#8208;1013's IRAK1 selectivity is particularly valuable for inflammatory disease research [<xref rid="mco270401-bib-0156" ref-type="bibr">156</xref>, <xref rid="mco270401-bib-0157" ref-type="bibr">157</xref>].</p><p>What is remarkable about this kinase PROTAC explosion is how it reflects the underlying biology. These are not just random targets&#8212;they represent the key nodes in disease&#8208;relevant signaling networks. The rapid expansion from initial proof&#8208;of&#8208;concept molecules to numerous validated degraders across nearly every major kinase family underscores the broad applicability of this technology. More importantly, it is giving us shots at targets that traditional drug discovery could not touch, which could translate into new therapeutic options for patients who have run out of alternatives.</p></sec><sec id="mco270401-sec-0210"><label>4.2</label><title>Transcription Factors</title><p>Transcription factors, functioning within the cell nucleus and predominantly featuring flat surface structures lacking druggable pockets, have long been considered &#8220;undruggable&#8221; targets for traditional small molecules and mAbs [<xref rid="mco270401-bib-0158" ref-type="bibr">158</xref>, <xref rid="mco270401-bib-0159" ref-type="bibr">159</xref>]. PROTAC technology provides a novel intervention modality for such targets (Figure&#160;<xref rid="mco270401-fig-0002" ref-type="fig">2</xref>). Myc, a representative oncogenic transcription factor, serves as a core driver for maintaining tumor cell metabolism and cell cycle progression [<xref rid="mco270401-bib-0160" ref-type="bibr">160</xref>]. Its basic helix&#8211;loop&#8211;helix&#8211;zipper structure exists in a disordered state when not bound to its partner protein MAX. MDEG&#8208;541 [<xref rid="mco270401-bib-0161" ref-type="bibr">161</xref>] represents a Myc&#8208;targeting PROTAC molecule that, through linking Myc ligands with VHL ligands and optimizing linker configuration, can induce formation of tight Myc&#8211;POI and E3 complexes, ultimately achieving targeted intracellular degradation and effectively inhibiting Myc target gene transcription.</p><p>&#946;&#8208;Catenin, as the core transcriptional regulatory factor of the Wnt/&#946;&#8208;catenin signaling pathway, is abnormally activated in various malignancies including colorectal cancer [<xref rid="mco270401-bib-0162" ref-type="bibr">162</xref>] and hepatocellular carcinoma [<xref rid="mco270401-bib-0163" ref-type="bibr">163</xref>]. xStAx&#8211;VHLL [<xref rid="mco270401-bib-0164" ref-type="bibr">164</xref>] represents a PROTAC molecule designed for &#946;&#8208;catenin degradation, with its design strategy stemming from identification of small molecule&#8208;bindable &#8220;receptor arms&#8221; within the &#946;&#8208;catenin structure, while utilizing VHL ligands to guide E3 binding through regulation of linker flexibility and spatial conformation to enhance complex formation probability. In functional validation, xStAx&#8211;VHLL effectively reduces intracellular &#946;&#8208;catenin protein levels, thereby disrupting its transcriptional complex formation with TCF/LEF.</p><p>RNA/DNA&#8208;binding proteins also represent important transcriptional regulatory nodes, with multiple related targets currently incorporated into PROTAC development pipelines. RHAU (DHX36)[<xref rid="mco270401-bib-0165" ref-type="bibr">165</xref>], a G&#8208;quadruplex structure&#8208;recognizing RNA helicase, plays important roles in regulating oncogene mRNA stability. G4&#8211;PROTAC represents the first degrader targeting G&#8208;quadruplex structures, successfully inducing G&#8208;quadruplex degradation through recognition of G4 binding sites for ligand construction and coupling with CRBN ligands, thereby reducing related mRNA stability and translation efficiency. SF3B1, as a core component of the spliceosome U2 complex, plays crucial roles in pre&#8208;mRNA splicing [<xref rid="mco270401-bib-0166" ref-type="bibr">166</xref>]. PROTAC&#8211;O4I2, constructed based on coupling of 2&#8208;aminothiazole derivative O4I2 with thalidomide, can specifically degrade SF3B1 with an IC<sub>50</sub> of 0.244&#160;&#181;M. This molecule induces SF3B1 degradation through CRBN&#8208;dependent mechanisms, leading to splicing errors and transcriptional program disorders, subsequently inducing cell apoptosis. In Drosophila intestinal tumor models, PROTAC&#8211;O4I2 significantly improves survival rates and interferes with tumor stem cell maintenance and proliferation [<xref rid="mco270401-bib-0167" ref-type="bibr">167</xref>].</p><p>The antagonistic roles of transcription factors STAT3 and STAT5 signaling pathways in dendritic cells represent important factors determining immunotherapy responsiveness. Research by Zhou et&#160;al. [<xref rid="mco270401-bib-0168" ref-type="bibr">168</xref>] not only revealed the critical role of STAT3 in suppressing DC function and limiting T&#8208;cell activation within the tumor microenvironment but also developed highly efficient STAT3&#8208;targeting PROTAC molecules&#8212;SD&#8208;36 and SD&#8208;2301. These molecules achieve selective STAT3 degradation through &#8220;event&#8208;driven&#8221; mechanisms, thereby relieving its suppression of DCs, enhancing antigen presentation capabilities and T&#8208;cell immune activity. In various tumor models, these STAT3 degraders significantly inhibited tumor progression, particularly demonstrating significant synergistic effects in immune checkpoint therapy&#8208;resistant models, showing promising safety profiles and clinical translation potential.</p><p>PROTAC research targeting transcription factors and their related regulatory factors has gradually overcome &#8220;undruggable&#8221; limitations, with current strategies primarily focusing on indirect interference (such as the BRD4&#8211;cMyc axis), structure&#8208;induced binding (such as &#946;&#8208;catenin), and precise degradation of posttranscriptional regulatory targets (such as RHAU and SF3B1) [<xref rid="mco270401-bib-0169" ref-type="bibr">169</xref>]. With advances in protein&#8211;ligand structural analysis and linker conformational engineering, more traditionally undruggable transcriptional regulatory factors will be incorporated into targeted degradation paradigms, expanding the target boundaries for precision anticancer therapy.</p></sec><sec id="mco270401-sec-0220"><label>4.3</label><title>Hormone Receptors</title><p>Among hormone receptor&#8208;related targets, AR and estrogen receptor (ER) represent among the most mature targets for PROTAC technology, with multiple representative degraders emerging (Figure&#160;<xref rid="mco270401-fig-0002" ref-type="fig">2</xref>). The first PROTAC drug to enter clinical trials, ARV&#8208;110 [<xref rid="mco270401-bib-0170" ref-type="bibr">170</xref>], targets prostate cancer treatment. AR, a nuclear receptor family member, is persistently activated in malignancies such as prostate cancer. Multiple PROTACs have been developed, including ARD&#8208;69 [<xref rid="mco270401-bib-0047" ref-type="bibr">47</xref>], ARD&#8208;61 [<xref rid="mco270401-bib-0171" ref-type="bibr">171</xref>], ARD&#8208;266 [<xref rid="mco270401-bib-0172" ref-type="bibr">172</xref>], ARD&#8208;2128 [<xref rid="mco270401-bib-0173" ref-type="bibr">173</xref>], ARD&#8208;2585 [<xref rid="mco270401-bib-0174" ref-type="bibr">174</xref>], 21&#8208;ARL, TD&#8208;802 [<xref rid="mco270401-bib-0175" ref-type="bibr">175</xref>], A031, PAP508, MTX&#8208;23, A16, and VPC&#8208;14228 derivatives (Figure&#160;<xref rid="mco270401-fig-0002" ref-type="fig">2</xref>) [<xref rid="mco270401-bib-0176" ref-type="bibr">176</xref>]. The ARD series (such as ARD&#8208;69, ARD&#8208;2128) are predominantly derived from Pfizer AR antagonists, forming highly efficient ternary complexes through linkage with VHL or CRBN ligands, capable of inducing sub&#8208;nanomolar AR degradation in AR&#8208;positive cells such as LNCaP and VCaP [<xref rid="mco270401-bib-0047" ref-type="bibr">47</xref>, <xref rid="mco270401-bib-0177" ref-type="bibr">177</xref>]. MTX&#8208;23 [<xref rid="mco270401-bib-0178" ref-type="bibr">178</xref>] further addresses both full&#8208;length AR and splice variant AR&#8208;V7, which is particularly significant for patients with hormone blockade therapy resistance [<xref rid="mco270401-bib-0179" ref-type="bibr">179</xref>]. PAP508 and VPC&#8208;14228 expand the targeting spectrum through different binding sites, demonstrating excellent cellular inhibition and tumorigenesis suppression capabilities.</p><p>ER&#945; is abnormally activated in over 70% of breast cancers [<xref rid="mco270401-bib-0180" ref-type="bibr">180</xref>]. Representative molecule ARV&#8208;471 has entered Phase III clinical trials [<xref rid="mco270401-bib-0181" ref-type="bibr">181</xref>], demonstrating promising oral pharmacokinetics and degradation activity. Its degradation mechanism depends on highly efficient conjugation of ER&#945; ligands with CRBN. Beyond ARV&#8208;471, molecules such as I&#8208;6, ERD&#8208;148, AM&#8208;A3, and UI&#8208;EP002 have been developed [<xref rid="mco270401-bib-0182" ref-type="bibr">182</xref>, <xref rid="mco270401-bib-0183" ref-type="bibr">183</xref>, <xref rid="mco270401-bib-0184" ref-type="bibr">184</xref>, <xref rid="mco270401-bib-0185" ref-type="bibr">185</xref>]. For instance, ERD&#8208;148 demonstrates low nanomolar DC<sub>50</sub> values against both MCF&#8208;7 and ER&#945; mutants (Y537S/D538G), while AM&#8208;A3 and its improved versions exhibit maximum degradation rates exceeding 90% [<xref rid="mco270401-bib-0186" ref-type="bibr">186</xref>]. UI&#8208;EP002 represents a unique pan&#8208;ER degrader capable of targeting not only ER&#945; but also ER&#946; and GPER, showing dual regulatory potential for membrane and nuclear receptors.</p><p>PROTAC design strategies for AR/ER targets primarily focus on two aspects: first, selecting existing antagonists (such as enzalutamide, tamoxifen) [<xref rid="mco270401-bib-0187" ref-type="bibr">187</xref>] as recognition arms; second, pairing with optimized E3 linkers (VHL, CRBN, or DCAF11) [<xref rid="mco270401-bib-0188" ref-type="bibr">188</xref>], regulating stereochemical conformation and proximity through linker optimization. These molecules generally demonstrate sustained degradation effects far superior to traditional inhibitors and are most advanced in clinical translation, representing important new directions for hormone&#8208;driven tumor therapy.</p></sec><sec id="mco270401-sec-0230"><label>4.4</label><title>Antiapoptotic and Oncogenic Proteins</title><p>Among &#8220;undruggable&#8221; targets, antiapoptotic proteins and oncogenic mutant proteins have long been considered difficult to effectively inhibit. However, with PROTAC technology development, this situation is rapidly changing. Degraders targeting key proteins such as Bcl&#8208;2 family members, MDM2, KRAS, and SHP2 have successively emerged, demonstrating considerable selectivity and biological activity (Figure&#160;<xref rid="mco270401-fig-0002" ref-type="fig">2</xref>).</p><p>Bcl&#8208;xL, a key regulatory factor inhibiting cell apoptosis within the Bcl&#8208;2 family, is widely involved in cell survival and chemotherapy resistance processes in various malignancies [<xref rid="mco270401-bib-0189" ref-type="bibr">189</xref>]. Traditional inhibitors such as navitoclax, while showing some efficacy, are limited in clinical application due to platelet toxicity [<xref rid="mco270401-bib-0190" ref-type="bibr">190</xref>]. To address this challenge, multiple Bcl&#8208;xL inhibitor&#8208;based PROTACs have emerged, including DT2216, X2739, P215527, PZ703b, XZ424, and 753b [<xref rid="mco270401-bib-0191" ref-type="bibr">191</xref>, <xref rid="mco270401-bib-0192" ref-type="bibr">192</xref>, <xref rid="mco270401-bib-0193" ref-type="bibr">193</xref>, <xref rid="mco270401-bib-0194" ref-type="bibr">194</xref>, <xref rid="mco270401-bib-0195" ref-type="bibr">195</xref>]. These molecules predominantly use ABT&#8208;263 or its derivatives as POI ligands, combined with CRBN or VHL recruitment elements, significantly reducing platelet toxicity burden by degrading Bcl&#8208;xL protein rather than merely inhibiting its function. DT2216 [<xref rid="mco270401-bib-0196" ref-type="bibr">196</xref>, <xref rid="mco270401-bib-0197" ref-type="bibr">197</xref>], in particular, has entered preclinical research stages, demonstrating promising safety and selectivity in various Bcl&#8208;xL&#8208;dependent tumor models, providing new approaches for addressing Bcl&#8208;xL &#8220;druggability challenges.&#8221;</p><p>Similar to Bcl&#8208;xL, MDM2, as an E3 ligase for p53 protein, represents a core node for negative p53 regulation. In TP53 wild&#8208;type tumors, MDM2 overexpression can mediate p53 degradation through ubiquitination, suppressing its tumor suppressor function [<xref rid="mco270401-bib-0198" ref-type="bibr">198</xref>]. Multiple MDM2&#8208;targeting PROTAC molecules have been reported, such as MG&#8208;277, WB214, 1B, 11a, and 11a&#8208;1, all designed using Nutlin&#8208;class structures as templates [<xref rid="mco270401-bib-0199" ref-type="bibr">199</xref>, <xref rid="mco270401-bib-0200" ref-type="bibr">200</xref>, <xref rid="mco270401-bib-0201" ref-type="bibr">201</xref>]. These molecules demonstrate stronger antiproliferative capabilities and broader applicability compared with traditional MDM2 inhibitors by restoring p53 stability and activating its downstream apoptotic pathways, particularly showing potential in p53&#8208;dependent tumors such as malignant melanoma and soft tissue sarcomas.</p><p>For mutant protein targets, BRAFV600E and KRASG12C represent typical driver mutations long considered &#8220;undruggable&#8221; [<xref rid="mco270401-bib-0202" ref-type="bibr">202</xref>]. BRAFV600E&#8208;related degraders such as SJF&#8208;0628 [<xref rid="mco270401-bib-0203" ref-type="bibr">203</xref>] and P4B [<xref rid="mco270401-bib-0204" ref-type="bibr">204</xref>], designed based on vemurafenib [<xref rid="mco270401-bib-0205" ref-type="bibr">205</xref>] and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="BI882370">BI882370</ext-link>, respectively, retain selectivity in wild&#8208;type BRAF backgrounds while significantly inhibiting MEK/ERK pathway activity. SJF&#8208;0628 achieves &gt;95% <italic toggle="yes">D</italic>
<sub>max</sub> degradation efficiency, while P4B effectively inhibits tumor cell proliferation, demonstrating mutation&#8208;specific effects. KRASG12C, due to its smooth surface structure and lack of binding cavities, has been considered a representative &#8220;undruggable&#8221; target [<xref rid="mco270401-bib-0206" ref-type="bibr">206</xref>]. With the emergence of covalent inhibitor MRTX849 [<xref rid="mco270401-bib-0207" ref-type="bibr">207</xref>], PROTAC LC&#8208;2 [<xref rid="mco270401-bib-0208" ref-type="bibr">208</xref>] achieves highly efficient KRASG12C degradation through coupling with VHL ligands. Subsequently developed molecules KP&#8208;14, YF135, and XY&#8208;4&#8208;88 demonstrate anticlonogenic formation and signal blocking effects in various KRAS mutation models [<xref rid="mco270401-bib-0209" ref-type="bibr">209</xref>, <xref rid="mco270401-bib-0210" ref-type="bibr">210</xref>]. YF135 represents the first reversible covalent PROTAC, providing new molecular tools for overcoming drug resistance risks caused by covalent binding limitations.</p><p>SHP2, a protein tyrosine phosphatase, plays critical signal bridging and amplification roles across multiple receptor tyrosine kinase pathways, representing a key synergistic factor for EGFR, ALK, and other driver mutation tumors [<xref rid="mco270401-bib-0198" ref-type="bibr">198</xref>]. Conventional SHP2 inhibitors exhibit limited efficacy due to binding site constraints, whereas next&#8208;generation SHP2 PROTACs have reshaped the pharmacological landscape through whole&#8208;protein degradation strategies. To achieve selective SHP2 degradation, several PROTAC molecules targeting SHP2 have been developed: SHP2&#8208;D26, constructed from SHP099 and VHL ligands, induces rapid and sustained SHP2 degradation at nanomolar concentrations while significantly inhibiting downstream ERK activation [<xref rid="mco270401-bib-0199" ref-type="bibr">199</xref>]; SP4 employs CRBN ligands conjugated to SHP099 [<xref rid="mco270401-bib-0200" ref-type="bibr">200</xref>], optimizing conformational pairing through PEG linkers to achieve approximately 40% SHP2 degradation in HeLa cells with modest antiproliferative effects; ZB&#8208;S&#8208;29 utilizes TNO155 as the binding moiety, also based on the CRBN system [<xref rid="mco270401-bib-0201" ref-type="bibr">201</xref>], achieving &gt;90% SHP2 protein degradation in MV&#8208;4&#8208;11 cells. These molecules comprehensively block SHP2&#8208;dependent signal transduction, thereby enhancing synergistic efficacy with RTK inhibitors, particularly demonstrating promising applications in lung cancer, breast cancer, and other malignancies [<xref rid="mco270401-bib-0202" ref-type="bibr">202</xref>]. Of particular importance, SHP2 function within the RAS&#8211;ERK pathway is essential for maintaining sustained tumor cell proliferation and immunosuppressive states [<xref rid="mco270401-bib-0203" ref-type="bibr">203</xref>]. Further investigations reveal that ZB&#8208;S&#8208;29 treatment results in cell cycle arrest and apoptosis induction [<xref rid="mco270401-bib-0204" ref-type="bibr">204</xref>]. Additionally, the R1&#8208;5C molecule combines RMC&#8208;4550 [<xref rid="mco270401-bib-0205" ref-type="bibr">205</xref>] with pomalidomide, demonstrating superior selective degradation capabilities and effectively attenuating MAPK pathway signal transduction while inhibiting tumor cell growth.</p><p>Overall, targeted degradation strategies for antiapoptotic and tumor suppressor pathway&#8208;related proteins are breaking through inherent &#8220;undruggable&#8221; barriers. The common characteristics of this target class include structural complexity, functional diversity, and high involvement in tumor cell survival regulation. PROTACs achieve novel dimensional intervention modalities by reconstructing protein fate, not only providing breakthroughs for treating highly drug&#8208;resistant malignancies with cryptic targets but also continuously expanding the theoretical and practical boundaries of protein degradation technology.</p></sec><sec id="mco270401-sec-0240"><label>4.5</label><title>Epigenetic Regulatory Targets</title><p>Among epigenetic regulatory targets, BRD4 undoubtedly remains one of the most intensively studied subjects [<xref rid="mco270401-bib-0211" ref-type="bibr">211</xref>]. As a core member of the BET family, BRD4 can directly recruit transcriptional initiation complexes, activating expression of multiple oncogenes including Myc. The field has seen an explosion of creativity in BRD4 degrader design, moving well beyond the early proof&#8208;of&#8208;concept molecules. Early developed PROTAC molecules such as dBET1 [<xref rid="mco270401-bib-0212" ref-type="bibr">212</xref>], MZ1 [<xref rid="mco270401-bib-0213" ref-type="bibr">213</xref>], and ARV&#8208;825 [<xref rid="mco270401-bib-0214" ref-type="bibr">214</xref>] have been widely used to validate their degradability and antitumor potential. dBET1 uses pomalidomide as a CRBN ligand and represents among the first molecules to achieve highly efficient BRD4 degradation, effectively downregulating Myc expression and inducing acute myeloid leukemia cell apoptosis. MZ1 employs the VHL system, enhancing ternary complex stability through optimized linker conformation, demonstrating excellent degradation efficiency in various solid tumor models. ARV&#8208;825 integrates BRD4 ligand OTX015 with pomalidomide, combining broad&#8208;spectrum activity with favorable pharmacokinetic properties [<xref rid="mco270401-bib-0215" ref-type="bibr">215</xref>]. However, it should be noted that ARV&#8208;825 is actually a pan&#8208;BET protein degrader that can simultaneously degrade multiple members of the entire BET protein family. In addition to BRD4, BRD2, BRD3, and others can also be degraded, although the degradation effect on BRD4 is the most pronounced. This multitarget characteristic is determined by the molecular design of ARV&#8208;825, as its BRD4&#8208;binding domain inherently has affinity for multiple BET proteins, thus the final PROTAC molecule also retains this multitarget feature.</p><p>Researchers have continued to push the boundaries with increasingly sophisticated designs. QCA represents a newer generation of BRD4 degraders that builds on lessons learned from earlier molecules, offering improved potency profiles [<xref rid="mco270401-bib-0216" ref-type="bibr">216</xref>]. The field took another leap forward with SJ995973 [<xref rid="mco270401-bib-0217" ref-type="bibr">217</xref>], which utilizes phenyl&#8208;glutarimide analogs to achieve remarkable stability while maintaining potent BRD4 degradation at picomolar concentrations&#8212;a real game&#8208;changer for in vivo applications. Meanwhile, molecules like DB1, VS3, and XY&#8208;06&#8208;007 [<xref rid="mco270401-bib-0218" ref-type="bibr">218</xref>] have explored different chemical scaffolds and linker strategies, each bringing something unique to the table in terms of selectivity profiles or pharmacokinetic properties. What is particularly exciting is how these diverse approaches have collectively expanded our understanding of what makes an effective BRD4 degrader. Beyond BRD4, multiple chromatin regulatory proteins outside the BET family have gradually entered PROTAC development perspectives. Taking PRC2 as an example, its core members EZH2 and EED synergistically regulate H3K27me3 silencing marks, serving as oncogenic drivers in various lymphomas and solid tumors [<xref rid="mco270401-bib-0219" ref-type="bibr">219</xref>, <xref rid="mco270401-bib-0220" ref-type="bibr">220</xref>]. Degrader series such as HBL&#8208;4, MaCrOPROTAC.1 [<xref rid="mco270401-bib-0221" ref-type="bibr">221</xref>], SM1, pc&#8208;PROTAC1 [<xref rid="mco270401-bib-0222" ref-type="bibr">222</xref>], and N2 have achieved effective targeting of PRC2 complexes, with some molecules retaining degradation capabilities even in EZH2 inhibitor&#8208;resistant backgrounds, expanding their clinical applicability. HDAC3, PRMT5, and SIRT2 have also been gradually incorporated into targeting spectra, mediated by molecules such as UNC6852 [<xref rid="mco270401-bib-0223" ref-type="bibr">223</xref>], MS1943 [<xref rid="mco270401-bib-0224" ref-type="bibr">224</xref>], E7 [<xref rid="mco270401-bib-0225" ref-type="bibr">225</xref>], and YM181 [<xref rid="mco270401-bib-0226" ref-type="bibr">226</xref>], respectively, demonstrating multidimensional intervention potential for histone acetylation, arginine methylation, and deacetylation balance. Another key target class is CBP/p300, histone acetyltransferases that regulate transcriptional initiation, which can be selectively degraded through molecules such as dCBP&#8208;1 [<xref rid="mco270401-bib-0227" ref-type="bibr">227</xref>, <xref rid="mco270401-bib-0228" ref-type="bibr">228</xref>]. The CBP/p300 degrader landscape has really matured over the past few years, with researchers developing increasingly sophisticated molecules. Beyond dCBP&#8208;1, AGB1 provides an alternative chemical approach to CBP targeting [<xref rid="mco270401-bib-0229" ref-type="bibr">229</xref>]. The SIAIS team has been particularly productive here, developing SIAIS629048 and SIAIS629049 as part of their systematic exploration of CBP/p300 degradation&#8212;these molecules showcase how iterative medicinal chemistry can fine&#8208;tune both potency and selectivity. The compound WWLJ245 rounds out this collection with yet another structural approach, demonstrating that there are multiple viable paths to effective CBP/p300 degradation. Compared with traditional inhibitors, these degraders potentially circumvent toxicity accumulation issues while maintaining dynamic regulation of epigenetic states and improving therapeutic windows.</p><p>Additionally, the compounds, ENL [<xref rid="mco270401-bib-0230" ref-type="bibr">230</xref>], WDR5 [<xref rid="mco270401-bib-0231" ref-type="bibr">231</xref>], and SMARCA2/4 [<xref rid="mco270401-bib-0232" ref-type="bibr">232</xref>, <xref rid="mco270401-bib-0233" ref-type="bibr">233</xref>] structural proteins have also become recent focal points. ENL promotes abnormal activation of leukemic transcriptional programs through binding to transcriptional elongation complexes, with selective degrader SR&#8208;1114 effectively interrupting this process [<xref rid="mco270401-bib-0234" ref-type="bibr">234</xref>]. WDR5 degraders MS33 and MS67 show promise for MYC&#8208;driven tumor models [<xref rid="mco270401-bib-0235" ref-type="bibr">235</xref>, <xref rid="mco270401-bib-0236" ref-type="bibr">236</xref>]. SMARCA2/4 belong to the SWI/SNF complex, and in SMARCA4&#8208;deficient backgrounds, SMARCA2 becomes a critical &#8220;synthetic lethal&#8221; dependency target, with related degraders such as ACBI1 and AU&#8208;15330 demonstrating promising targeting and therapeutic potential in SMARCA4&#8208;deficient and NSCLC models [<xref rid="mco270401-bib-0237" ref-type="bibr">237</xref>]. At the transcriptional regulation level, NSD3 and eIF4E as emerging epigenetic targets have also received attention. NSD3 degrader MS9715 can effectively disrupt chromatin open state maintenance, while eIF4E&#8208;targeting degraders d4E&#8208;4 and d4E&#8208;6 attempt to sever cancer cell mRNA translation activity through protein degradation strategies, thereby suppressing oncogenic protein expression from the source [<xref rid="mco270401-bib-0238" ref-type="bibr">238</xref>, <xref rid="mco270401-bib-0239" ref-type="bibr">239</xref>]. Although these targets remain in validation or optimization stages, they possess breakthrough value in target structure, regulatory levels, and therapeutic indication selection.</p></sec><sec id="mco270401-sec-0250"><label>4.6</label><title>Immune and Inflammatory Targets</title><p>Among immune and inflammatory targets, the PD&#8208;1/PD&#8208;L1 pathway and STAT3 represent extremely promising key nodes in current PROTAC research (Figure&#160;<xref rid="mco270401-fig-0002" ref-type="fig">2</xref>). PD&#8208;L1, through binding with PD&#8208;1 on T&#8208;cell surfaces, inhibits their activation, maintaining immunosuppressive states within tumor microenvironments [<xref rid="mco270401-bib-0240" ref-type="bibr">240</xref>]. While traditional antibody drugs have achieved clinical progress, their therapeutic effects remain limited due to individual efficacy variations, toxicity accumulation, and secondary resistance issues. PROTAC technology provides novel strategies for overcoming these challenges. Several molecules capable of inducing PD&#8208;L1 degradation have been developed. Small molecule degrader P22 can mediate CRBN&#8208;dependent degradation of PD&#8208;L1 protein, demonstrating strong immune activation capabilities [<xref rid="mco270401-bib-0241" ref-type="bibr">241</xref>]. Additionally, strategies for indirectly inducing PD&#8208;L1 cleavage and inactivation through interference with its palmitoylation modifications have also progressed. Cyclic peptide PROTACs can target transferase DHHC3 [<xref rid="mco270401-bib-0242" ref-type="bibr">242</xref>, <xref rid="mco270401-bib-0243" ref-type="bibr">243</xref>], reducing PD&#8208;L1 stability in tumor cells and promoting IFN&#8208;&#947; and TNF&#8208;&#945; secretion, reshaping immune environments from the modification level. In contrast, PD&#8208;1, due to its transmembrane structure lacking designable binding sites, has not been effectively degraded through traditional small molecule PROTACs. Recently, a study employing peptide&#8208;structured peptide&#8211;PROTACs achieved the first successful intracellular PD&#8208;1 protein degradation [<xref rid="mco270401-bib-0244" ref-type="bibr">244</xref>], resolving the technical bottleneck of this target being &#8220;undegradable.&#8221; This strategy integrates cell&#8208;penetrating peptides, target protein recognition peptides, linkers, and VHL recruitment peptides into a unified system. The designed peptide PROTAC can significantly reduce PD&#8208;1 protein expression at concentrations below 5&#160;&#181;M in cervical cancer cells C33A and HeLa, functioning through proteasome&#8208;dependent pathways. Functional experiments confirm its ability to significantly weaken tumor cell suppression of T&#8208;cells, enhance immune responses, and demonstrate synergistic tumor proliferation inhibition effects when combined with cisplatin. This research not only validates that PD&#8208;1 protein can be targeted for degradation through PROTAC pathways but also demonstrates the unique advantages of peptide molecules in handling transmembrane proteins. In upstream regulation of the PD&#8208;1/PD&#8208;L1 pathway, STAT3, as a key transcription factor, regulates expression of immunosuppressive factors such as PD&#8208;L1 and IL&#8208;10, playing important roles in immune escape and tumor progression. Multiple STAT3 PROTACs have achieved effective degradation, such as SD&#8208;91 [<xref rid="mco270401-bib-0245" ref-type="bibr">245</xref>] and KP&#8208;18, both utilizing STAT3 inhibitors as ligand constructs. Postdegradation, they can significantly inhibit STAT3 target gene expression and tumor cell proliferation, possessing broad&#8208;spectrum immunoregulatory capabilities.</p><p>Additionally, some immune&#8208;related factors have also developed effective degradation tools. Macrophage migration inhibitory factor participates in inflammatory factor secretion and tumor immunosuppression formation, with its degradation capable of blocking proinflammatory signaling axes [<xref rid="mco270401-bib-0246" ref-type="bibr">246</xref>]. CCR9, a chemokine receptor involved in lymphocyte recruitment, has been targeted by molecules such as CCRB&#8211;PROTAC, which demonstrate regulatory potential in mucosa&#8208;associated tumors and autoimmune disease models. CRABP (cellular retinoic acid&#8208;binding protein) plays important roles in regulating retinoic acid metabolism and nuclear receptor activity, with related degrader &#946;&#8208;NF&#8211;ATRA validated in retinoic acid pathway&#8208;dependent disease models [<xref rid="mco270401-bib-0247" ref-type="bibr">247</xref>, <xref rid="mco270401-bib-0248" ref-type="bibr">248</xref>].</p><p>PROTAC designs targeting immune and inflammatory regulatory proteins continuously advance the possibilities for targeted degradation of transmembrane proteins, transcription factors, and immune auxiliary molecules. Particularly, PD&#8208;1 peptide PROTAC strategies demonstrate clear advantages, providing new intervention pathways for overcoming immune checkpoint blockade therapy resistance and enhancing T&#8208;cell activation levels, while establishing molecular foundations for future combination therapeutic strategies.</p></sec><sec id="mco270401-sec-0260"><label>4.7</label><title>Metabolic and Enzymatic Targets</title><p>Among metabolic and enzymatic targets, NAMPT, the rate&#8208;limiting enzyme in NAD&#8314; biosynthetic pathways, frequently participates in dynamic physiological regulation and stress responses (Figure&#160;<xref rid="mco270401-fig-0002" ref-type="fig">2</xref>). Inhibiting MDSC growth and boosting antitumor immunological responses, PROTAC A7, created by linking VHL ligands to NAMPT inhibitors, destroys cellular NAMPT at small nanomolar concentrations while lowering external NAMPT levels [<xref rid="mco270401-bib-0249" ref-type="bibr">249</xref>, <xref rid="mco270401-bib-0250" ref-type="bibr">250</xref>]. Its structurally optimized version B3 demonstrates stronger activity in A2780 cells (DC50&#160;&lt;&#160;0.17&#160;nM, <italic toggle="yes">D</italic>
<sub>max</sub>&#160;&gt;&#160;90%) [<xref rid="mco270401-bib-0251" ref-type="bibr">251</xref>].</p><p>H&#8208;PGDS plays a critical role in prostaglandin D<sub>2</sub> (PGD<sub>2</sub>) synthesis and represents an important therapeutic target in inflammatory and allergic conditions. Significant progress has been made in this field with the development of molecules targeting this enzyme through various mechanisms. Among these molecules, PROTAC(HPGDS)&#8208;7 has demonstrated notable efficacy in reducing H&#8208;PGDS protein levels and suppressing PGD<sub>2</sub> production [<xref rid="mco270401-bib-0252" ref-type="bibr">252</xref>, <xref rid="mco270401-bib-0253" ref-type="bibr">253</xref>]. This molecule, along with related degraders in this space, provides new molecular tools for regulating inflammatory mediator synthesis. Mitochondrial carbonic anhydrase Ca5 participates in cellular pH balance and metabolic regulation, with preliminary studies constructing PROTAC molecules targeting it, indicating that its protein stability can be modulated through degradation mechanisms.</p><p>Among other enzyme classes, PARP1/14 degradation mechanisms can achieve complete clearance of DNA repair enzymes, helping resolve residual activity and drug resistance issues faced by traditional PARP inhibitors in tumor therapy [<xref rid="mco270401-bib-0254" ref-type="bibr">254</xref>]. An interesting aspect of the PARP1/14 degradation approach is its potential to overcome the limitations associated with conventional PARP inhibitors, particularly in addressing resistance mechanisms. Tyrosinase plays roles in melanin synthesis and related skin lesions, with TD&#8208;9 representing one of its early PROTAC degraders, providing structural foundations for melanin metabolism regulation [<xref rid="mco270401-bib-0255" ref-type="bibr">255</xref>]. SLC (solute carrier) family members, as transmembrane transport proteins, are difficult to effectively modulate with traditional drugs due to their strong hydrophobicity and complex transmembrane structures [<xref rid="mco270401-bib-0256" ref-type="bibr">256</xref>]. d9A&#8208;2 [<xref rid="mco270401-bib-0257" ref-type="bibr">257</xref>], developed using AP1867 ligands, achieves targeted degradation of SLC proteins, providing feasible solutions for modulating membrane transport functions through protein degradation methods. Additionally, molecules such as P22A, PROTAC&#8208;2, and PROTAC&#8208;5 can simultaneously degrade multiple proteins related to cellular signaling and metabolism, including Cas proteins, HMGCR, and VEGFR2. PROTAC&#8211;FCPF also possesses multitarget binding capabilities, with configurations supporting synchronized intervention of key enzymes during cellular proliferation and metabolic regulation processes.</p></sec><sec id="mco270401-sec-0270"><label>4.8</label><title>UPS&#8208;Related Targets</title><p>In UPS&#8208;related targets, researchers focus not only on substrate protein degradation but also begin exploring targeted modulation of key regulatory factors within the system. For instance, E3 ligases themselves can become targets for PROTAC molecules. CRBN and VHL represent the most commonly used E3 ligands, while degradation attempts of these components themselves expand PROTAC application boundaries in &#8220;self&#8208;regulation&#8221; and systemic intervention aspects (Figure&#160;<xref rid="mco270401-fig-0002" ref-type="fig">2</xref>). Representative molecules such as CRBN&#8208;6&#8208;5&#8208;5&#8211;VHL, TD&#8208;165, ZXH&#8208;4&#8208;130, and ZXH&#8208;4&#8208;137 can regulate substrate recognition characteristics by inducing CRBN self&#8208;degradation, while CM11 targets VHL for feedback regulation [<xref rid="mco270401-bib-0258" ref-type="bibr">258</xref>, <xref rid="mco270401-bib-0259" ref-type="bibr">259</xref>, <xref rid="mco270401-bib-0260" ref-type="bibr">260</xref>]. XD2&#8208;149 can effectively downregulate ZFP91 expression. ZFP91, as an E3 ubiquitin ligase, has been implicated in the regulation of inflammatory and stress response pathways, including potential connections to NF&#8208;&#954;B signaling, showing prospects for inflammation and cancer intervention [<xref rid="mco270401-bib-0261" ref-type="bibr">261</xref>].</p><p>Additionally, PSMD13 (also known as hRpn13), as a 26S proteasome regulatory subunit, has degrader XL5&#8211;VHL&#8208;2 proven to block I&#954;B&#945; degradation and inhibit NF&#8208;&#954;B activation [<xref rid="mco270401-bib-0262" ref-type="bibr">262</xref>], bringing new strategies for inflammatory disease treatment. Regarding cell cycle regulation&#8208;related targets, Cdc20 serves as a core regulatory factor driving mitotic progression, with degrader CP5V specifically inducing its rapid ubiquitination and interfering with cell cycle progression [<xref rid="mco270401-bib-0263" ref-type="bibr">263</xref>]. WDR5, as a core subunit of the MLL/SET1 methyltransferase complexes, regulates histone H3K4 methylation and gene expression [<xref rid="mco270401-bib-0264" ref-type="bibr">264</xref>]. PROTAC&#8208;mediated WDR5 degradation has shown therapeutic potential in various cancer models by disrupting oncogenic transcriptional programs.</p><p>Simultaneously, some uncategorized targets have also been validated for degradability in recent years. LXR&#8208;&#946;, a nuclear receptor participating in cholesterol homeostasis and immune regulation [<xref rid="mco270401-bib-0265" ref-type="bibr">265</xref>], has degrader GW3965&#8211;PEG5&#8211;VH032 effectively interfering with its transcriptional functions and demonstrating effects in atherosclerosis models [<xref rid="mco270401-bib-0266" ref-type="bibr">266</xref>]. Research on these &#8220;nontraditional&#8221; targets continuously pushes the boundaries of PROTAC target space expansion, suggesting the technology's potential for modulating complex signaling axes and metabolic networks.</p><p>These targets, located at ubiquitin system hub nodes or cell cycle core regulatory positions, provide important breakthroughs for precisely regulating intracellular homeostasis and developing novel anticancer or anti&#8208;inflammatory therapeutic methods. Unlike traditional POI targeting strategies, PROTACs can achieve multipathway synergistic regulation through &#8220;degrading core regulatory factors.&#8221;</p></sec><sec id="mco270401-sec-0280"><label>4.9</label><title>Novel PROTAC Formats and Conjugation Technologies</title><p>Several new PROTAC formats have been developed due to the development of PROTAC technology (Figure&#160;<xref rid="mco270401-fig-0002" ref-type="fig">2</xref>), including dual&#8208;target degradation and conjugation technologies, which represent novel PROTAC design methodologies with several innovations. DP&#8208;V&#8208;4 [<xref rid="mco270401-bib-0267" ref-type="bibr">267</xref>] represents dual&#8208;target&#8208;specific degradation technologies capable of simultaneously degrading two protein targets, EGFR and PARP. Through antibody targeting, Ab&#8211;PROTAC3 uses antibody&#8211;PROTAC conjugation techniques to enhance PROTAC&#8208;specific delivery. For specific targeting, aptamer&#8211;PROTAC conjugates (APCs) use the high&#8208;specificity binding abilities of aptamers. These fascinating PROTACs expand the range of targets that degrader systems can handle.</p><p>Specific types are still growing in the PROTAC research. Progressive additions to degradation approaches include traditional driver proteins, E3 ligases, proteasome proteins, and governmental cells [<xref rid="mco270401-bib-0268" ref-type="bibr">268</xref>]. Such targets are typically found at upstream or main nodes of protein homeostasis regulation, where degradation frequently instantly affects many signaling axes, leading to enhanced intervention effects. Most modern PROTACs still primarily rely on VHL and CRBN E3 ligases to obtain substrate ubiquitination, with their reasonably sophisticated and stable derived receptor designs making them chosen choices for degradation system construction despite the increase in target diversity. Newly developed E3 enzyme targets, like ZFP91 [<xref rid="mco270401-bib-0261" ref-type="bibr">261</xref>], provide stronger organized regulatory possibilities, demonstrating large therapeutic prospects in neurotic states, including tumors, disease, and cell cycle abnormalities.</p></sec><sec id="mco270401-sec-0290"><label>4.10</label><title>Summary and Comparative Analysis of Representative PROTAC Targets</title><p>PROTAC has advanced rapidly across multiple classes of targets, including kinases, transcription factors, hormone receptors, and others [<xref rid="mco270401-bib-0269" ref-type="bibr">269</xref>]. In selecting a suitable target, several principles must be considered: disease context, with oncology remaining the dominant area but opportunities expanding in immunology, neurology, and metabolic disease; structural accessibility and the availability of high&#8208;affinity ligands for at least one binding site; degradation advantage, especially for multifunctional proteins with catalytic and scaffolding roles (e.g., IRAK4 [<xref rid="mco270401-bib-0270" ref-type="bibr">270</xref>], SHP2 [<xref rid="mco270401-bib-0271" ref-type="bibr">271</xref>]); and established therapeutic precedent, including targets such as AR [<xref rid="mco270401-bib-0272" ref-type="bibr">272</xref>], ER [<xref rid="mco270401-bib-0273" ref-type="bibr">273</xref>], and BTK [<xref rid="mco270401-bib-0274" ref-type="bibr">274</xref>]. These criteria may determine whether a target can successfully move from bench to clinic.</p><p>Among these targets, kinases remain one of the most intensively studied classes, supported by rich inhibitor libraries and well&#8208;characterized disease associations. For example, BTK reached Phase III trials (e.g., BGB&#8208;16673) [<xref rid="mco270401-bib-0275" ref-type="bibr">275</xref>], demonstrating high efficacy in B&#8208;cell malignancies. EGFR and FGFR degraders further show how mutation selectivity can be incorporated into degrader design, thereby overcoming on&#8208;target resistance while limiting toxicity [<xref rid="mco270401-bib-0276" ref-type="bibr">276</xref>, <xref rid="mco270401-bib-0277" ref-type="bibr">277</xref>]. The challenge, however, is less about generating new degraders than about establishing a clear clinical rationale and differentiation from the extensive repertoire of existing kinase inhibitors. Hormone receptors, by contrast, represent the most clinically advanced area. AR and ER&#945; degraders such as ARV&#8208;110, CC&#8208;94676, and ARV&#8208;471 have already progressed to pivotal trials [<xref rid="mco270401-bib-0272" ref-type="bibr">272</xref>, <xref rid="mco270401-bib-0278" ref-type="bibr">278</xref>, <xref rid="mco270401-bib-0279" ref-type="bibr">279</xref>], offering advantages over traditional antagonists by eliminating variants such as AR&#8208;V7 [<xref rid="mco270401-bib-0280" ref-type="bibr">280</xref>] and ligand&#8208;binding domain mutants that underlie resistance. Linker design and E3 ligase selection remain central for optimizing breadth and potency. Equally critical will be improvements in oral bioavailability and tissue distribution, which determine whether applications can expand beyond oncology, as illustrated by dermatology programs like GT20029 [<xref rid="mco270401-bib-0281" ref-type="bibr">281</xref>]. These developments highlight how receptor&#8208;targeting strategies can serve as a model for more rapid clinical translation when therapeutic precedent is well established.</p><p>Beyond these relatively mature categories, PROTACs are beginning to tackle nuclear proteins long regarded as &#8220;undruggable,&#8221; including Myc, &#946;&#8208;catenin, and STAT3 [<xref rid="mco270401-bib-0282" ref-type="bibr">282</xref>, <xref rid="mco270401-bib-0283" ref-type="bibr">283</xref>, <xref rid="mco270401-bib-0284" ref-type="bibr">284</xref>]. By removing such drivers directly, degraders can disrupt transcriptional programs in ways that inhibitors cannot achieve. Yet the hurdles are substantial: nuclear delivery remains difficult, and ligands must be highly selective to avoid widespread perturbation of gene expression. Advances in structural biology and computational discovery have improved prospects, though progress here continues to lag behind kinases and receptors. Antiapoptotic and mutant oncoproteins represent another promising area, with Bcl&#8208;xL degraders limiting platelet toxicity by selectively targeting tumor cells [<xref rid="mco270401-bib-0285" ref-type="bibr">285</xref>], and KRAS^G12C and G12D degraders addressing both catalytic and scaffolding functions [<xref rid="mco270401-bib-0286" ref-type="bibr">286</xref>, <xref rid="mco270401-bib-0287" ref-type="bibr">287</xref>, <xref rid="mco270401-bib-0288" ref-type="bibr">288</xref>]. These cases illustrate the potential of targeted degradation to circumvent long&#8208;standing liabilities of inhibitors, including toxicity and acquired resistance. At the same time, the difficulty of identifying ligands for smooth or dynamic protein surfaces remains one of the most persistent obstacles.</p><p>Epigenetic regulators such as BRD4, EZH2, and CBP/p300 are also compelling targets, given their central role in transcriptional reprogramming [<xref rid="mco270401-bib-0289" ref-type="bibr">289</xref>, <xref rid="mco270401-bib-0290" ref-type="bibr">290</xref>, <xref rid="mco270401-bib-0291" ref-type="bibr">291</xref>]. Degraders in this space offer opportunities to bypass compensatory pathways that limit inhibitors, although their broad activity increases the risk of off&#8208;target epigenomic effects. Expanding beyond epigenetic proteins, immune&#8208;related proteins are also under exploration. In immuno&#8208;oncology, PD&#8208;L1, PD&#8208;1 (via peptide&#8208;based PROTACs), and STAT3 degraders may help overcome checkpoint resistance [<xref rid="mco270401-bib-0292" ref-type="bibr">292</xref>], though systemic delivery of peptide agents remains particularly challenging. This domain arguably represents one of the most dynamic but also uncertain frontiers of PROTAC research&#8212;scientifically exciting, yet clinically demanding. Moving forward, progress will depend heavily on advances in computational triaging, the diversification of available E3 ligases, and the development of innovative delivery systems such as nanoparticle&#8208; or antibody&#8208;conjugated PROTACs. These factors will be decisive in broadening the accessible target space and ensuring that preclinical discoveries are converted into durable therapeutic benefit.</p></sec></sec><sec id="mco270401-sec-0300"><label>5</label><title>PROTACs in the Clinic: Current Landscape and Leading Programs</title><p>An increasing number of PROTAC programs are entering clinical trials, demonstrating strong momentum in the field. According to US FDA clinical trial registry data, over 50 PROTAC candidates are currently under evaluation across various clinical phases (Table&#160;<xref rid="mco270401-tbl-0002" ref-type="table">2</xref>). These investigational programs span multiple important therapeutic targets, including AR, ER, BTK, and IRAK4 [<xref rid="mco270401-bib-0293" ref-type="bibr">293</xref>]. The clinical stage distribution follows a typical drug development pattern: most programs remain in early&#8208;phase trials (Phase I and Phase I/II), reflecting the relatively novel nature of this technology. Simultaneously, several leading programs have successfully advanced to mid&#8208; and late&#8208;stage clinical trials (Phase II and III), marking PROTAC technology's steady progress toward clinical applications [<xref rid="mco270401-bib-0181" ref-type="bibr">181</xref>].</p><table-wrap position="float" id="mco270401-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Clinical landscape of PROTAC therapeutics.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">PROTAC</th><th align="center" rowspan="1" colspan="1">NCT number</th><th align="center" rowspan="1" colspan="1">Phase</th><th align="center" rowspan="1" colspan="1">Status</th><th align="center" rowspan="1" colspan="1">Target</th><th align="center" rowspan="1" colspan="1">Objectives</th><th align="center" rowspan="1" colspan="1">Preliminary findings</th><th align="center" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td rowspan="21" align="left" colspan="1">ARV&#8208;471</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05930925">NCT05930925</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">ER&#945;</td><td align="center" rowspan="1" colspan="1">Healthy volunteers</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05538312">NCT05538312</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">ER&#945;</td><td align="center" rowspan="1" colspan="1">Healthy volunteers</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0294" ref-type="bibr">294</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04072952">NCT04072952</ext-link></td><td align="center" rowspan="1" colspan="1">I/II</td><td align="center" rowspan="1" colspan="1">Active, not recruiting</td><td align="center" rowspan="1" colspan="1">ER&#945;</td><td align="center" rowspan="1" colspan="1">Breast cancer</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0295" ref-type="bibr">295</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06125522">NCT06125522</ext-link></td><td align="center" rowspan="1" colspan="1">I/II</td><td align="center" rowspan="1" colspan="1">Active, not recruiting</td><td align="center" rowspan="1" colspan="1">ER&#945;</td><td align="center" rowspan="1" colspan="1">Breast cancer</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05501769">NCT05501769</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Active, not recruiting</td><td align="center" rowspan="1" colspan="1">ER&#945;</td><td align="center" rowspan="1" colspan="1">Breast cancer</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0296" ref-type="bibr">296</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05573555">NCT05573555</ext-link></td><td align="center" rowspan="1" colspan="1">I/II</td><td align="center" rowspan="1" colspan="1">Active, not recruiting</td><td align="center" rowspan="1" colspan="1">ER&#945;</td><td align="center" rowspan="1" colspan="1">Breast cancer</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05732428">NCT05732428</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">ER&#945;</td><td align="center" rowspan="1" colspan="1">Breast cancer</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0297" ref-type="bibr">297</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05549505">NCT05549505</ext-link></td><td align="center" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">ER&#945;</td><td align="center" rowspan="1" colspan="1">Breast cancer</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0298" ref-type="bibr">298</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05548127">NCT05548127</ext-link></td><td align="center" rowspan="1" colspan="1">I/II</td><td align="center" rowspan="1" colspan="1">Active, not recruiting</td><td align="center" rowspan="1" colspan="1">ER&#945;</td><td align="center" rowspan="1" colspan="1">Breast cancer</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0299" ref-type="bibr">299</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05673889">NCT05673889</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">ER&#945;</td><td align="center" rowspan="1" colspan="1">Healthy volunteers</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0300" ref-type="bibr">300</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05652660">NCT05652660</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">ER&#945;</td><td align="center" rowspan="1" colspan="1">Healthy volunteers</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0300" ref-type="bibr">300</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05909397">NCT05909397</ext-link></td><td align="center" rowspan="1" colspan="1">III</td><td align="center" rowspan="1" colspan="1">Active, not recruiting</td><td align="center" rowspan="1" colspan="1">ER&#945;</td><td align="center" rowspan="1" colspan="1">Breast cancer</td><td align="center" rowspan="1" colspan="1">Significant PFS benefit in ESR1&#8208;mutated patients; well&#8208;tolerated</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0301" ref-type="bibr">301</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05463952">NCT05463952</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Active, not recruiting</td><td align="center" rowspan="1" colspan="1">ER&#945;</td><td align="center" rowspan="1" colspan="1">Breast cancer</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0301" ref-type="bibr">301</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05654623">NCT05654623</ext-link></td><td align="center" rowspan="1" colspan="1">III</td><td align="center" rowspan="1" colspan="1">Active, not recruiting</td><td align="center" rowspan="1" colspan="1">ER&#945;</td><td align="center" rowspan="1" colspan="1">Breast cancer</td><td align="center" rowspan="1" colspan="1">Enhanced PFS in the ESR1&#8208;mutated subgroup</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0302" ref-type="bibr">302</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06347861">NCT06347861</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">ER&#945;</td><td align="center" rowspan="1" colspan="1">Healthy volunteers</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06911788">NCT06911788</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">ER&#945;</td><td align="center" rowspan="1" colspan="1">Healthy volunteers</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06645938">NCT06645938</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">ER&#945;</td><td align="center" rowspan="1" colspan="1">Healthy volunteers</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06005688">NCT06005688</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">ER&#945;</td><td align="center" rowspan="1" colspan="1">Healthy volunteers</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06256510">NCT06256510</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">ER&#945;</td><td align="center" rowspan="1" colspan="1">Healthy volunteers</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0303" ref-type="bibr">303</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06206837">NCT06206837</ext-link></td><td align="center" rowspan="1" colspan="1">I/II</td><td align="center" rowspan="1" colspan="1">Active, not recruiting</td><td align="center" rowspan="1" colspan="1">ER&#945;</td><td align="center" rowspan="1" colspan="1">Breast cancer</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0304" ref-type="bibr">304</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06275841">NCT06275841</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">ER&#945;</td><td align="center" rowspan="1" colspan="1">Healthy volunteers</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td rowspan="2" align="left" colspan="1">ARV&#8208;110</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03888612">NCT03888612</ext-link></td><td align="center" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">AR</td><td align="center" rowspan="1" colspan="1">Prostate cancer</td><td align="center" rowspan="1" colspan="1">PSA50 response 16% overall, 46% in AR T878A/H875Y mutants</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0305" ref-type="bibr">305</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05177042">NCT05177042</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">AR</td><td align="center" rowspan="1" colspan="1">Prostate cancer</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0306" ref-type="bibr">306</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">ARV&#8208;766</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05067140">NCT05067140</ext-link></td><td align="center" rowspan="1" colspan="1">I/II</td><td align="center" rowspan="1" colspan="1">Active, not recruiting</td><td align="center" rowspan="1" colspan="1">AR</td><td align="center" rowspan="1" colspan="1">Prostate cancer</td><td align="center" rowspan="1" colspan="1">Pan&#8208;AR degradation; 51% PSA50 in AR LBD mutants</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0307" ref-type="bibr">307</xref>]</td></tr><tr><td rowspan="4" align="left" colspan="1">CC&#8208;94676</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06764485">NCT06764485</ext-link></td><td align="center" rowspan="1" colspan="1">III</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">AR</td><td align="center" rowspan="1" colspan="1">Prostate cancer</td><td align="center" rowspan="1" colspan="1">Ongoing rechARge study; rPFS primary endpoint</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0308" ref-type="bibr">308</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04428788">NCT04428788</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Active, not recruiting</td><td align="center" rowspan="1" colspan="1">AR</td><td align="center" rowspan="1" colspan="1">Prostate cancer</td><td align="center" rowspan="1" colspan="1">Preliminary efficacy and manageable safety in heavily</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0309" ref-type="bibr">309</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06417229">NCT06417229</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">AR</td><td align="center" rowspan="1" colspan="1">Healthy volunteers</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06433505">NCT06433505</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">AR</td><td align="center" rowspan="1" colspan="1">Healthy volunteers</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td rowspan="2" align="left" colspan="1">AC176</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05241613">NCT05241613</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Terminated</td><td align="center" rowspan="1" colspan="1">AR</td><td align="center" rowspan="1" colspan="1">mCRPC</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05673109">NCT05673109</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Terminated</td><td align="center" rowspan="1" colspan="1">AR</td><td align="center" rowspan="1" colspan="1">mCRPC</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td rowspan="2" align="left" colspan="1">HP518</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06155084">NCT06155084</ext-link></td><td align="center" rowspan="1" colspan="1">I/II</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">AR</td><td align="center" rowspan="1" colspan="1">mCRPC</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05252364">NCT05252364</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">AR</td><td align="center" rowspan="1" colspan="1">mCRPC</td><td align="center" rowspan="1" colspan="1">most AEs Grade 1&#8211;2</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0002" ref-type="bibr">2</xref>]</td></tr><tr><td rowspan="7" align="left" colspan="1">HRS&#8208;5041</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05942001">NCT05942001</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">AR</td><td align="center" rowspan="1" colspan="1">Prostate cancer</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06559007">NCT06559007</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">AR</td><td align="center" rowspan="1" colspan="1">Prostate cancer</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT07014488">NCT07014488</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Not yet recruiting</td><td align="center" rowspan="1" colspan="1">AR</td><td align="center" rowspan="1" colspan="1">Prostate cancer</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06568094">NCT06568094</ext-link></td><td align="center" rowspan="1" colspan="1">I/II</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">AR</td><td align="center" rowspan="1" colspan="1">Prostate cancer</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06738745">NCT06738745</ext-link></td><td align="center" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">Not yet recruiting</td><td align="center" rowspan="1" colspan="1">AR</td><td align="center" rowspan="1" colspan="1">Prostate cancer</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT07115446">NCT07115446</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Not yet recruiting</td><td align="center" rowspan="1" colspan="1">AR</td><td align="center" rowspan="1" colspan="1">Prostate cancer</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06830850">NCT06830850</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">AR</td><td align="center" rowspan="1" colspan="1">mCRPC</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td rowspan="3" align="left" colspan="1">GT20029</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06692465">NCT06692465</ext-link></td><td align="center" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">AR</td><td align="center" rowspan="1" colspan="1">Androgenetic alopecia and acne vulgaris</td><td align="center" rowspan="1" colspan="1">Met primary endpoint; good safety and efficacy</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0310" ref-type="bibr">310</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06468579">NCT06468579</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">AR</td><td align="center" rowspan="1" colspan="1">Acne, alopecia</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05428449">NCT05428449</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">AR</td><td align="center" rowspan="1" colspan="1">Androgenetic alopecia, acne vulgaris</td><td align="center" rowspan="1" colspan="1">Good safety/tolerability</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0311" ref-type="bibr">311</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">AH&#8208;001</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06927960">NCT06927960</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">AR</td><td align="center" rowspan="1" colspan="1">Androgenetic alopecia</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td rowspan="3" align="left" colspan="1">KT&#8208;474</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06058156">NCT06058156</ext-link></td><td align="center" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">Active, not recruiting</td><td align="center" rowspan="1" colspan="1">IRAK4</td><td align="center" rowspan="1" colspan="1">Atopic dermatitis</td><td align="center" rowspan="1" colspan="1">&#8805;95% IRAK4 degradation in blood and skin</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0312" ref-type="bibr">312</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04772885">NCT04772885</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">IRAK4</td><td align="center" rowspan="1" colspan="1">Healthy volunteer, atopic dermatitis, hidradenitis suppurativa</td><td align="center" rowspan="1" colspan="1">Good safety/tolerability</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0313" ref-type="bibr">313</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06028230">NCT06028230</ext-link></td><td align="center" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">Active, not recruiting</td><td align="center" rowspan="1" colspan="1">IRAK4</td><td align="center" rowspan="1" colspan="1">Hidradenitis suppurativa</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0314" ref-type="bibr">314</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">KT&#8208;413</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05233033">NCT05233033</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">IRAK4, IKZF1/3</td><td align="center" rowspan="1" colspan="1">Non&#8208;Hodgkin lymphoma, DLBCL</td><td align="center" rowspan="1" colspan="1">Good safety/tolerability</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0315" ref-type="bibr">315</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">KT&#8208;333</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05225584">NCT05225584</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">STAT3</td><td align="center" rowspan="1" colspan="1">Liquid and solid tumors, T cell lymphomas</td><td align="center" rowspan="1" colspan="1">31.4% ORR in 51 patients</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0316" ref-type="bibr">316</xref>]</td></tr><tr><td rowspan="2" align="left" colspan="1">KT&#8208;621</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06945458">NCT06945458</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">STAT6</td><td align="center" rowspan="1" colspan="1">Atopic dermatitis</td><td align="center" rowspan="1" colspan="1">Rapid STAT6 degradation in blood cells</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0317" ref-type="bibr">317</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06673667">NCT06673667</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">STAT6</td><td align="center" rowspan="1" colspan="1">Healthy volunteers</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">KT&#8208;253</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05775406">NCT05775406</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">MDM2</td><td align="center" rowspan="1" colspan="1">High grade myeloid malignancies, acute lymphocytic, leukemia, lymphoma, solid tumors</td><td align="center" rowspan="1" colspan="1">Tolerability</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0318" ref-type="bibr">318</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">NX&#8208;2127</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04830137">NCT04830137</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">BTK, IKZF1/3</td><td align="center" rowspan="1" colspan="1">Relapsed/Refractory B&#8208;cell malignancies</td><td align="center" rowspan="1" colspan="1">80% BTK degradation at 100&#160;mg dose; preliminary antitumor activity</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0319" ref-type="bibr">319</xref>]</td></tr><tr><td rowspan="4" align="left" colspan="1">NX&#8208;5948</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06717269">NCT06717269</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">BTK</td><td align="center" rowspan="1" colspan="1">Healthy volunteers</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06691828">NCT06691828</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">BTK</td><td align="center" rowspan="1" colspan="1">Healthy volunteers</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06593457">NCT06593457</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">BTK</td><td align="center" rowspan="1" colspan="1">Healthy volunteers</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05131022">NCT05131022</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">BTK</td><td align="center" rowspan="1" colspan="1">Relapsed/refractory B&#8208;cell malignancies</td><td align="center" rowspan="1" colspan="1">84.2% ORR in 49 patients</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0320" ref-type="bibr">320</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">HSK29116</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04861779">NCT04861779</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Unknown status</td><td align="center" rowspan="1" colspan="1">BTK</td><td align="center" rowspan="1" colspan="1">Relapsed/refractory B&#8208;cell malignancies</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0321" ref-type="bibr">321</xref>]</td></tr><tr><td rowspan="7" align="left" colspan="1">BGB&#8208;16673</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05294731">NCT05294731</ext-link></td><td align="center" rowspan="1" colspan="1">I/II</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">BTK</td><td align="center" rowspan="1" colspan="1">B&#8208;cell malignancy, non&#8208;Hodgkin lymphoma, mantle cell lymphoma</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT07005713">NCT07005713</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">BTK</td><td align="center" rowspan="1" colspan="1">Chronic spontaneous urticaria</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06634589">NCT06634589</ext-link></td><td align="center" rowspan="1" colspan="1">I/II</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">BTK</td><td align="center" rowspan="1" colspan="1">B&#8208;cell malignancy, relapsed cancer, refractory cancer</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0322" ref-type="bibr">322</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06973187">NCT06973187</ext-link></td><td align="center" rowspan="1" colspan="1">III</td><td align="center" rowspan="1" colspan="1">Active, not recruiting</td><td align="center" rowspan="1" colspan="1">BTK</td><td align="center" rowspan="1" colspan="1">CLL, SLL</td><td align="center" rowspan="1" colspan="1">78% ORR in CLL, 94% at 200&#160;mg dose</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0323" ref-type="bibr">323</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05006716">NCT05006716</ext-link></td><td align="center" rowspan="1" colspan="1">I/II</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">BTK</td><td align="center" rowspan="1" colspan="1">B&#8208;cell malignancy, marginal zone lymphoma, follicular lymphoma</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0324" ref-type="bibr">324</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06970743">NCT06970743</ext-link></td><td align="center" rowspan="1" colspan="1">III</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">BTK</td><td align="center" rowspan="1" colspan="1">CLL, SLL</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06846671">NCT06846671</ext-link></td><td align="center" rowspan="1" colspan="1">III</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">BTK</td><td align="center" rowspan="1" colspan="1">CLL</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td rowspan="3" align="left" colspan="1">DT&#8208;2216</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04886622">NCT04886622</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">BCL&#8208;X</td><td align="center" rowspan="1" colspan="1">T cell lymphomas</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0325" ref-type="bibr">325</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06620302">NCT06620302</ext-link></td><td align="center" rowspan="1" colspan="1">I/II</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="center" rowspan="1" colspan="1">BCL&#8208;X</td><td align="center" rowspan="1" colspan="1">Childhood fibrolamellar carcinoma, recurrent childhood fibrolamellar carcinoma, recurrent childhood malignant solid neoplasm</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0326" ref-type="bibr">326</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06964009">NCT06964009</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">BCL&#8208;X</td><td align="center" rowspan="1" colspan="1">Ovarian cancer</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CFT&#8208;8634</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05355753">NCT05355753</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Terminated</td><td align="center" rowspan="1" colspan="1">BRD9</td><td align="center" rowspan="1" colspan="1">Synovial sarcoma, soft tissue sarcoma</td><td align="center" rowspan="1" colspan="1">Failed to show efficacy in heavily pretreated patients</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0327" ref-type="bibr">327</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">FHD&#8208;609</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04965753">NCT04965753</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Terminated</td><td align="center" rowspan="1" colspan="1">BRD9</td><td align="center" rowspan="1" colspan="1">Synovial sarcoma</td><td align="center" rowspan="1" colspan="1">Grade 4 QTc prolongation led to clinical hold</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0328" ref-type="bibr">328</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">CFT&#8208;1946</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05668585">NCT05668585</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Active, not recruiting</td><td align="center" rowspan="1" colspan="1">BRAF V600</td><td align="center" rowspan="1" colspan="1">Solid tumors, melanoma, NSCLC</td><td align="center" rowspan="1" colspan="1">Avoids paradoxical RAF activation</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0329" ref-type="bibr">329</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="CG001419">CG001419</ext-link></td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06636500">NCT06636500</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">NTRK</td><td align="center" rowspan="1" colspan="1">Healthy volunteer, pain management</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td rowspan="2" align="left" colspan="1">PRT3789</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06682806">NCT06682806</ext-link></td><td align="center" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">SMARCA2</td><td align="center" rowspan="1" colspan="1">Advanced solid tumor, esophageal cancer, metastatic solid tumor</td><td align="center" rowspan="1" colspan="1">Tumor shrinkage in NSCLC and esophageal cancer</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0330" ref-type="bibr">330</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05639751">NCT05639751</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">On hold</td><td align="center" rowspan="1" colspan="1">SMARCA2</td><td align="center" rowspan="1" colspan="1">Advanced solid tumor, NSCLC</td><td align="center" rowspan="1" colspan="1">Tumor shrinkage in NSCLC and esophageal cancer</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0331" ref-type="bibr">331</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">PRT7732</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06560645">NCT06560645</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">SMARCA2</td><td align="center" rowspan="1" colspan="1">Advanced solid tumor, NSCLC</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0332" ref-type="bibr">332</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">MT&#8208;4561</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06943521">NCT06943521</ext-link></td><td align="center" rowspan="1" colspan="1">I/II</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">BRD4</td><td align="center" rowspan="1" colspan="1">Advanced solid tumors</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td rowspan="3" align="left" colspan="1">LT&#8208;002&#8208;158</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06932003">NCT06932003</ext-link></td><td align="center" rowspan="1" colspan="1">I/II</td><td align="center" rowspan="1" colspan="1">Not yet recruiting</td><td align="center" rowspan="1" colspan="1">IRAK4</td><td align="center" rowspan="1" colspan="1">Hidradenitis suppurativa</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06082323">NCT06082323</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">IRAK4</td><td align="center" rowspan="1" colspan="1">Healthy volunteer, hidradenitis suppurativa, atopic dermatitis</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06931990">NCT06931990</ext-link></td><td align="center" rowspan="1" colspan="1">I/II</td><td align="center" rowspan="1" colspan="1">Not yet recruiting</td><td align="center" rowspan="1" colspan="1">IRAK4</td><td align="center" rowspan="1" colspan="1">Atopic dermatitis</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">TQB3019</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06943677">NCT06943677</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">BTK</td><td align="center" rowspan="1" colspan="1">Advanced malignant cancer</td><td align="center" rowspan="1" colspan="1">Active against both BTK WT and C481S; exhibits excellent metabolic stability and favorable oral bioavailability</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0333" ref-type="bibr">333</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">AUTX&#8208;703</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06846606">NCT06846606</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">KAT2A/KAT2B</td><td align="center" rowspan="1" colspan="1">Myelodysplastic syndromes, acute myeloid leukemia</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">PT0253</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06797336">NCT06797336</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">Kras G12D</td><td align="center" rowspan="1" colspan="1">Solid tumor</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">BG&#8208;60366</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06685718">NCT06685718</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">EGFR</td><td align="center" rowspan="1" colspan="1">NSCLC</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CFT8919</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06641609">NCT06641609</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Not Yet Recruiting</td><td align="center" rowspan="1" colspan="1">EGFR</td><td align="center" rowspan="1" colspan="1">NSCLC</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0334" ref-type="bibr">334</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">BTX&#8208;9341</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06515470">NCT06515470</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">CDK4/6</td><td align="center" rowspan="1" colspan="1">Breast cancer</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">ARV&#8208;393</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06393738">NCT06393738</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">BCL6</td><td align="center" rowspan="1" colspan="1">Non&#8208;Hodgkin lymphoma, angioimmunoblastic T&#8208;cell lymphoma</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0335" ref-type="bibr">335</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">ASP4396</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06364696">NCT06364696</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">Kras G12D</td><td align="center" rowspan="1" colspan="1">Solid tumor</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0336" ref-type="bibr">336</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">ASP3082</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05382559">NCT05382559</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">Kras G12D</td><td align="center" rowspan="1" colspan="1">Solid tumor</td><td align="center" rowspan="1" colspan="1">Selective degradation of KRAS G12D in preclinical models</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0337" ref-type="bibr">337</xref>]</td></tr><tr><td rowspan="2" align="left" colspan="1">BGB&#8208;45035</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06342713">NCT06342713</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">IRAK4</td><td align="center" rowspan="1" colspan="1">Healthy volunteers</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT07100938">NCT07100938</ext-link></td><td align="center" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">IRAK4</td><td align="center" rowspan="1" colspan="1">Rheumatoid arthritis</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">BMS&#8208;986458</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06090539">NCT06090539</ext-link></td><td align="center" rowspan="1" colspan="1">I/II</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">BCL6</td><td align="center" rowspan="1" colspan="1">Relapsed/refractory non&#8208;Hodgkin lymphoma</td><td align="center" rowspan="1" colspan="1">Increased CD20 expression; tumor regression in preclinical models</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0338" ref-type="bibr">338</xref>]</td></tr><tr><td rowspan="2" align="left" colspan="1">AXT&#8208;1003</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05965505">NCT05965505</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Terminated</td><td align="center" rowspan="1" colspan="1">EZH2</td><td align="center" rowspan="1" colspan="1">Relapsed/refractory non&#8208;Hodgkin lymphoma</td><td align="center" rowspan="1" colspan="1">Early termination; reasons undisclosed</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0339" ref-type="bibr">339</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06484985">NCT06484985</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">EZH2</td><td align="center" rowspan="1" colspan="1">Non&#8208;Hodgkin lymphoma, advanced solid tumor</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">HSK40118</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06050980">NCT06050980</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">EGFR</td><td align="center" rowspan="1" colspan="1">NSCLC</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0340" ref-type="bibr">340</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">AC676</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05780034">NCT05780034</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">BTK</td><td align="center" rowspan="1" colspan="1">Relapsed/refractory B&#8208;cell malignancies</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0341" ref-type="bibr">341</xref>]</td></tr><tr><td rowspan="2" align="left" colspan="1">AC682</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05489679">NCT05489679</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Terminated</td><td align="center" rowspan="1" colspan="1">ER&#945;</td><td align="center" rowspan="1" colspan="1">Breast cancer</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0342" ref-type="bibr">342</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05080842">NCT05080842</ext-link></td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Terminated</td><td align="center" rowspan="1" colspan="1">ER&#945;</td><td align="center" rowspan="1" colspan="1">Breast cancer</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1">[<xref rid="mco270401-bib-0342" ref-type="bibr">342</xref>]</td></tr></tbody></table><table-wrap-foot><fn id="mco270401-tbl2-note-0001"><p>
<italic toggle="yes">Abbreviations</italic>: PFS, progression&#8208;free survival; ESR1, estrogen receptor 1; PSA50, prostate&#8208;specific antigen 50% decline; AR, androgen receptor; LBD, ligand&#8208;binding domain; rPFS, radiographic progression&#8208;free survival; mCRPC, metastatic castration&#8208;resistant prostate cancer; AEs, adverse events; IRAK4, interleukin&#8208;1 receptor&#8208;associated kinase 4; STAT6, signal transducer and activator of transcription 6; ORR, overall response rate; BTK, Bruton's tyrosine kinase; CLL, chronic lymphocytic leukemia; SLL, small lymphocytic lymphoma; NSCLC, non&#8208;small cell lung cancer; KRAS, Kirsten rat sarcoma viral oncogene homolog; DLBCL, diffuse large B cell lymphoma; ER&#945;, estrogen receptor &#945;.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>The first PROTAC molecule, ARV&#8208;110, entered clinical trials in 2019&#8212;a watershed moment that marked PROTAC technology's transition from the laboratory bench to actual clinical practice [<xref rid="mco270401-bib-0343" ref-type="bibr">343</xref>]. The success of ARV&#8208;110 set off a wave of activity between 2020 and 2022, with numerous pharmaceutical companies jumping into the field and launching their own PROTAC programs [<xref rid="mco270401-bib-0344" ref-type="bibr">344</xref>]. This created a period of rapid pipeline growth. Then, in 2023 and 2024, we started seeing the leading programs move into pivotal trials, really setting the stage for commercial viability.</p><p>By mid&#8208;2025, three PROTAC drugs have made it to Phase III trials with US FDA: vepdegestrant (ARV&#8208;471), catadegbrutinib (BGB&#8208;16673, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06973187">NCT06973187</ext-link>), and gridegalutamide (BMS&#8208;986365, CC&#8208;94676&#8212;going after ER, BTK, and AR, respectively [<xref rid="mco270401-bib-0345" ref-type="bibr">345</xref>]. What is really exciting is that vepdegestrant has already submitted its marketing application to US FDA based on Phase III data in patients with previously treated ER+/HER2&#8722; <xref rid="mco270401-bib-0346" ref-type="bibr">346</xref>], ESR1&#8208;mutated advanced or metastatic breast cancer, potentially becoming the world's first approved PROTAC drug. This development timeline is remarkable: from the first PROTAC entering clinical trials in 2019 to the first drug submission in 2025 represents just 6 years, fully demonstrating PROTAC technology's tremendous potential and the pharmaceutical industry's strong endorsement of this revolutionary approach.</p><p>Overall, PROTAC technology has evolved from early proof&#8208;of&#8208;concept stages to a mature technology platform with clear commercialization prospects. The breakthrough of three drugs entering Phase III trials and the first NDA submission marks PROTAC technology's imminent entry into the industrialization era.</p><sec id="mco270401-sec-0310"><label>5.1</label><title>Hormone Receptor Degraders&#8212;The Most Mature Clinical Domain: AR Degraders</title><p>AR degraders represent a significant breakthrough in PROTAC technology for treating genitourinary malignancies. Prostate cancer, one of the most common male malignancies [<xref rid="mco270401-bib-0347" ref-type="bibr">347</xref>], is closely associated with abnormal AR signaling pathway activation. While existing AR antagonists like enzalutamide and abiraterone demonstrate excellent clinical performance, most patients receiving androgen deprivation therapy ultimately develop castration&#8208;resistant prostate cancer (CRPC) [<xref rid="mco270401-bib-0348" ref-type="bibr">348</xref>]. This resistance often relates to AR overexpression, mutations, or splice variant generation. PROTAC degraders offer a new strategy by directly eliminating AR protein (Table&#160;<xref rid="mco270401-tbl-0002" ref-type="table">2</xref>).</p><sec id="mco270401-sec-0320"><label>5.1.1</label><title>ARV&#8208;110</title><p>As the world's first AR&#8211;PROTAC entering clinical trials, ARV&#8208;110 employs classic bifunctional molecular design, with one end binding AR and the other recruiting E3 ubiquitin ligase CRBN to achieve AR&#8208;specific degradation through ternary complex formation. In Phase I/II clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03888612">NCT03888612</ext-link>), ARV&#8208;110 demonstrated favorable safety characteristics. At the recommended Phase II dose (420&#160;mg once daily), major adverse reactions included nausea (42%), fatigue (27%), and vomiting (23%), with no Grade 4 or higher treatment&#8208;related adverse events observed [<xref rid="mco270401-bib-0349" ref-type="bibr">349</xref>, <xref rid="mco270401-bib-0350" ref-type="bibr">350</xref>]. Regarding efficacy, data through August 2021 [<xref rid="mco270401-bib-0272" ref-type="bibr">272</xref>] showed an overall PSA50 response rate of 16% and PSA30 response rate of 29% among 140 evaluable patients. Notably, 26 patients carrying AR T878A/S and/or H875Y mutations showed significantly higher response rates: PSA50 response rate reached 46% and PSA30 response rate reached 58%, while 114 patients without these mutations had corresponding response rates of only 10 and 23%. This finding provides important evidence for biomarker&#8208;based precision therapy strategies.</p></sec><sec id="mco270401-sec-0330"><label>5.1.2</label><title>CC&#8208;94676 (BMS&#8208;986365)</title><p>CC&#8208;94676 (also known as BMS&#8208;986365) is the second PROTAC molecule globally to enter Phase III. In Phase I first&#8208;in&#8208;human clinical trials (CC&#8208;94676&#8208;PCA&#8208;001, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04428788">NCT04428788</ext-link>), BMS&#8208;986365 demonstrated preliminary efficacy and manageable safety in heavily pretreated metastatic CRPC (mCRPC) patients [<xref rid="mco270401-bib-0351" ref-type="bibr">351</xref>]. The trial did not reach maximum tolerated dose, with the most common treatment&#8208;related adverse reactions being asymptomatic QTc prolongation and bradycardia, primarily occurring in the first two cycles. Clinical and biochemical responses were observed in patients with or without AR gene LBD mutations, supporting evaluation in all patients regardless of AR receptor mutation status. Posthoc analysis showed patients unexposed to prior chemotherapy and not using opioid treatment had longer radiographic progression&#8208;free survival (rPFS), supporting further development in mCRPC patients unexposed to chemotherapy with asymptomatic or mildly symptomatic disease. The ongoing rechARge study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06764485">NCT06764485</ext-link>) is a global Phase III, prospective, multicenter, randomized, adaptive, two&#8208;part, open&#8208;label trial planning to enroll approximately 960 mCRPC patients, evaluating BMS&#8208;986365 versus investigator's choice of treatment (docetaxel or alternative ARPI like abiraterone or enzalutamide) [<xref rid="mco270401-bib-0351" ref-type="bibr">351</xref>]. The primary endpoint is rPFS, with trial initiation in March 2025.</p></sec><sec id="mco270401-sec-0340"><label>5.1.3</label><title>ARV&#8208;766</title><p>ARV&#8208;766 is Arvinas&#8217; second&#8208;generation AR degrader, a novel, potent oral PROTAC AR degrader. Compared with first&#8208;generation ARV&#8208;110, ARV&#8208;766 incorporates three key structural optimizations: replacing the middle six&#8208;membered ring with a substituted four&#8208;membered ring, substituting the chlorine atom on the left aromatic ring with methoxy, and replacing fluorinated thalidomide with fluorinated benzamide, which serves as a CRBN ligand with high selectivity and plasma stability. ARV&#8208;766's important breakthrough lies in its pan&#8208;AR degradation capability, degrading AR LBD mutations including AR L702H, H875Y, and T878A, while ARV&#8208;110 cannot degrade AR L702H mutations, which account for approximately 11% of metastatic CRPC patients [<xref rid="mco270401-bib-0352" ref-type="bibr">352</xref>] and represent a major resistance mechanism. In the ongoing Phase I/II clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05067140">NCT05067140</ext-link>), as of April 15, 2024, 123 patients received ARV&#8208;766 treatment, with 53 carrying AR LBD mutations. In Phase I dose escalation studies, ARV&#8208;766 showed no dose&#8208;limiting toxicity at 20&#8211;500&#160;mg once daily, with no maximum tolerated dose reached; 100 and 300&#160;mg were selected as Phase II recommended doses. Among 47 evaluable PSA AR LBD mutation patients, 51% achieved PSA decline &#8805;30% and 43% achieved PSA decline &#8805;50%. Among 20 evaluable soft tissue lesion AR LBD mutation patients, objective response rate was 30%. Major treatment&#8208;related adverse reactions included fatigue (33%), nausea (20%), and diarrhea (15%), mostly mild to moderate, with only nine patients (7%) requiring dose reduction and 10 patients (8%) discontinuing due to adverse reactions [<xref rid="mco270401-bib-0353" ref-type="bibr">353</xref>]. Based on these excellent clinical data, particularly significant efficacy in patients carrying AR LBD mutations, ARV&#8208;766 is considered likely to enter Phase III clinical trials ahead of ARV&#8208;110.</p></sec><sec id="mco270401-sec-0350"><label>5.1.4</label><title>Other AR&#8211;PROTAC Programs in Development</title><p>Beyond the major programs above, multiple AR&#8211;PROTAC candidates are currently in development, including Accutar Biotech's AC&#8208;0176 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05241613">NCT05241613</ext-link>) [<xref rid="mco270401-bib-0354" ref-type="bibr">354</xref>], Hinova Pharmaceuticals&#8217; HP518 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05252364">NCT05252364</ext-link>) [<xref rid="mco270401-bib-0002" ref-type="bibr">2</xref>], and HRS&#8208;5041 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06559007">NCT06559007</ext-link>) entering Phase I, which, while still in early development stages, collectively constitute diversified technological positioning in the AR&#8211;PROTAC field.</p></sec><sec id="mco270401-sec-0360"><label>5.1.5</label><title>Dermatology Indications&#8212;Innovative Exploration of Expanded Applications</title><p>AR&#8211;PROTAC applications in dermatology represent an important expansion of TPD technology into nononcology indications. Kintor Pharmaceutical's GT20029, as the world's first topical PROTAC compound entering clinical trials [<xref rid="mco270401-bib-0355" ref-type="bibr">355</xref>], innovatively targets both androgenetic alopecia and acne simultaneously, based on the common pathophysiological mechanism of excessive AR activation in hair follicles and sebaceous glands. GT20029 employs topical administration to maximize drug concentration at lesion sites while significantly reducing systemic exposure, thereby minimizing potential systemic adverse reactions. In completed Phase I clinical trials, GT20029 demonstrated good safety and tolerability in both China and the United States, with major adverse reactions limited to mild local irritation. In 2024, GT20029's multicenter, randomized, double&#8208;blind, placebo&#8208;controlled Phase II clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06692465">NCT06692465</ext-link>) successfully met its primary endpoint [<xref rid="mco270401-bib-0310" ref-type="bibr">310</xref>]. This trial randomized 180 male androgenetic alopecia patients for 12&#8208;week treatment, showing GT20029 achieved statistically significant and clinically meaningful efficacy, marking an important breakthrough for PROTAC technology in dermatological applications. Besides GT20029, other AR&#8211;PROTAC projects based on similar principles are in development, such as AH&#8208;001 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06927960">NCT06927960</ext-link>) [<xref rid="mco270401-bib-0356" ref-type="bibr">356</xref>], collectively constituting diversified positioning for PROTAC technology applications in dermatology and providing strong evidence for this innovative technology platform's clinical translation into broader therapeutic areas.</p></sec></sec><sec id="mco270401-sec-0370"><label>5.2</label><title>ER&#945; Degraders&#8212;Breast Cancer Breakthrough ARV&#8208;471 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05654623">NCT05654623</ext-link>, Phase III)&#8212;The PROTAC Drug Closest to Market</title><p>ER&#945; degraders represent the most promising breakthrough in PROTAC technology for solid tumor treatment, with this field forming a complete pipeline from proof&#8208;of&#8208;concept to late&#8208;stage clinical development (Table&#160;<xref rid="mco270401-tbl-0002" ref-type="table">2</xref>). According to latest clinical trial registry analysis, currently two PROTAC drugs specifically targeting ER&#945; have entered clinical development, with ARV&#8208;471 (vepdegestrant) having entered pivotal Phase III clinical trials, becoming the PROTAC drug closest to market [<xref rid="mco270401-bib-0181" ref-type="bibr">181</xref>], while AC682 as an emerging candidate is showing potential in Phase I clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05489679">NCT05489679</ext-link>) [<xref rid="mco270401-bib-0357" ref-type="bibr">357</xref>]. ARV&#8208;471, as the world's first PROTAC molecule entering Phase III clinical trials, holds milestone significance in breast cancer treatment. This drug achieves selective ER&#945; degradation through CRBN E3 ligase, with its unique mechanism potentially overcoming traditional endocrine therapy resistance. In the VERITAC&#8208;2 pivotal Phase III clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05654623">NCT05654623</ext-link>), the study enrolled 624 patients with ER+/HER2&#8722; advanced breast cancer previously treated with CDK4/6 inhibitors and endocrine therapy, with primary endpoint of PFS [<xref rid="mco270401-bib-0358" ref-type="bibr">358</xref>]. Trial results showed that in the ESR1&#8208;mutated patient subgroup, vepdegestrant significantly prolonged PFS compared with fulvestrant, with median PFS of 5.0 months (95% CI: 3.7&#8211;7.4) versus 2.1 months (95% CI: 1.9&#8211;3.5), hazard ratio 0.58 (95% CI: 0.43&#8211;0.78, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001), meeting the prespecified primary endpoint. However, in the overall intent&#8208;to&#8208;treat population, median PFS was 3.8 versus 3.6 months, respectively, hazard ratio 0.83 (95% CI: 0.69&#8211;1.01, <italic toggle="yes">p</italic>&#160;=&#160;0.07), not reaching statistical significance. These results indicate vepdegestrant provides clear clinical benefit in ESR1&#8208;mutated patients, providing important evidence for precision medicine. From a safety perspective, vepdegestrant demonstrated relatively favorable tolerability. In the safety analysis population, 86.9% of patients experienced adverse events of any grade, 23.4% experienced Grade 3 or higher adverse events, with only 2.9% discontinuing treatment due to adverse events. Most common adverse events included fatigue (26.6%), AST elevation (14.4%), ALT elevation (14.4%), and nausea (13.5%), mostly Grade 1&#8211;2 mild to moderate events [<xref rid="mco270401-bib-0359" ref-type="bibr">359</xref>]. Notably, QT prolongation occurred in 9.9% of patients, but no serious arrhythmia complications were observed, providing important safety data for clinical application.</p></sec><sec id="mco270401-sec-0380"><label>5.3</label><title>BTK Degraders</title><sec id="mco270401-sec-0390"><label>5.3.1</label><title>BGB&#8208;16673 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06973187">NCT06973187</ext-link>, Phase III)</title><p>BGB&#8208;16673, as the most promising BTK&#8211;PROTAC, is the first such drug entering Phase III clinical trials, marking an important milestone for BTK degrader technology [<xref rid="mco270401-bib-0360" ref-type="bibr">360</xref>]. In early clinical trials, BGB&#8208;16673 demonstrated encouraging efficacy data. Among 49 treated relapsed/refractory CLL patients, overall response rate (ORR) reached 78%, with the 200&#160;mg dose group achieving 94% ORR. More importantly, BGB&#8208;16673 showed broad antitumor activity in other hematologic malignancies: 90% ORR in Waldenstr&#246;m's macroglobulinemia patients (21 patients), 50% ORR in follicular lymphoma (eight patients), and 67% ORR in marginal zone lymphoma (eight patients) [<xref rid="mco270401-bib-0323" ref-type="bibr">323</xref>]. These results highlight BGB&#8208;16673's broad activity potential as a first&#8208;in&#8208;class BTK degrader in B&#8208;cell malignancies.</p></sec><sec id="mco270401-sec-0400"><label>5.3.2</label><title>NX&#8208;2127 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04830137">NCT04830137</ext-link>, Phase I)</title><p>NX&#8208;2127 [<xref rid="mco270401-bib-0361" ref-type="bibr">361</xref>] is a multitarget PROTAC simultaneously targeting BTK and IKZF1/3 proteins, embodying PROTAC technology's unique advantage of simultaneously degrading multiple pathogenic proteins. This drug is currently in Phase I clinical trials evaluating safety and efficacy in B&#8208;cell malignancies.</p></sec><sec id="mco270401-sec-0410"><label>5.3.3</label><title>NX&#8208;5948 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06717269">NCT06717269</ext-link>, Phase I)</title><p>NX&#8208;5948 [<xref rid="mco270401-bib-0362" ref-type="bibr">362</xref>] specifically targets BTK protein degradation, with indications expanded to B&#8208;cell malignancies and autoimmune diseases, reflecting BTK PROTAC application potential across different disease areas.</p></sec><sec id="mco270401-sec-0420"><label>5.3.4</label><title>Other Candidates</title><p>HSK29116 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04861779">NCT04861779</ext-link>), TQB3019 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06943677">NCT06943677</ext-link>), and AC676 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05780034">NCT05780034</ext-link>) are all in Phase I clinical trials targeting different types of B&#8208;cell malignancies, forming a complete BTK PROTAC drug clinical development pipeline [<xref rid="mco270401-bib-0321" ref-type="bibr">321</xref>, <xref rid="mco270401-bib-0363" ref-type="bibr">363</xref>, <xref rid="mco270401-bib-0364" ref-type="bibr">364</xref>].</p></sec></sec><sec id="mco270401-sec-0430"><label>5.4</label><title>IRAK4 Degraders</title><p>IRAK4 degraders represent an important breakthrough in immune inflammatory disease treatment, with significant mechanistic advantages over traditional small molecule inhibitors. IRAK4, as a key component of the MyD88 complex, not only possesses kinase activity but also serves important scaffolding functions, while traditional IRAK4 kinase inhibitors only block kinase activity without completely inhibiting scaffolding function. Protein degraders achieve more complete target inhibition by utilizing cellular UPSs to completely eliminate IRAK4 protein, simultaneously eliminating both kinase and scaffolding functions. KT&#8208;413 is a bifunctional molecule that not only degrades IRAK4 but also simultaneously degrades IMiD substrates Ikaros and Aiolos, currently in Phase I clinical trials for MYD88&#8208;mutated tumors (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05233033">NCT05233033</ext-link>) [<xref rid="mco270401-bib-0365" ref-type="bibr">365</xref>, <xref rid="mco270401-bib-0366" ref-type="bibr">366</xref>]. KT&#8208;474 (SAR444656) is the first selective IRAK4 degrader entering autoimmune indication clinical trials, focusing on immune inflammatory skin diseases, currently in Phase II clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06058156">NCT06058156</ext-link>) [<xref rid="mco270401-bib-0367" ref-type="bibr">367</xref>]. In Phase I clinical trials, KT&#8208;474 achieved &#8805;93% blood IRAK4 degradation with single doses of 600&#8212;1600&#160;mg in healthy volunteers, and &#8805;95% IRAK4 degradation with continuous 14&#8208;day daily dosing of 50&#8212;200&#160;mg. In HS and AD patients, KT&#8208;474 not only achieved similar blood IRAK4 degradation effects but also normalized overexpressed IRAK4 levels in skin lesions and significantly improved disease&#8208;related inflammatory biomarkers [<xref rid="mco270401-bib-0313" ref-type="bibr">313</xref>]. Other drugs are also in development, with LT&#8208;002&#8208;158 in Phase I/II clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06932003">NCT06932003</ext-link>) for indications including acne, autoimmune diseases, hidradenitis suppurativa, and atopic dermatitis. BGB&#8208;45035 is in Phase I clinical trials for atopic dermatitis and prurigo nodularis (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06342713">NCT06342713</ext-link>). These programs&#8217; successful advancement validates IRAK4 degradation therapeutic potential in hematologic malignancies and autoimmune diseases, providing important proof&#8208;of&#8208;concept for TPD technology applications across different disease areas.</p></sec><sec id="mco270401-sec-0440"><label>5.5</label><title>KRAS G12D Degraders</title><p>KRAS occupies a special position in cancer research history. For over 40 years since its discovery by Harvey and Kirsten in the 1960s [<xref rid="mco270401-bib-0368" ref-type="bibr">368</xref>, <xref rid="mco270401-bib-0369" ref-type="bibr">369</xref>], KRAS has been considered an &#8220;undruggable&#8221; target. This is primarily because KRAS protein has a relatively smooth spherical structure, lacking deep hydrophobic pockets and obvious binding sites, with GTP binding affinity reaching picomolar levels while intracellular GTP concentrations are as high as 0.5&#160;&#181;M, making competitive inhibitor development nearly impossible [<xref rid="mco270401-bib-0370" ref-type="bibr">370</xref>]. A major breakthrough occurred in 2013 when researchers discovered a compound capable of binding a small pocket in KRAS G12C mutant protein, reigniting efforts to develop active inhibitors [<xref rid="mco270401-bib-0371" ref-type="bibr">371</xref>]. In May 2021, US FDA approved the first KRAS G12C inhibitor sotorasib (Lumakras), marking the historic transition of KRAS from &#8220;undruggable&#8221; to &#8220;druggable&#8221; [<xref rid="mco270401-bib-0372" ref-type="bibr">372</xref>, <xref rid="mco270401-bib-0373" ref-type="bibr">373</xref>]. However, KRAS G12D, as one of the most common KRAS mutation subtypes (accounting for approximately 34% of pancreatic ductal adenocarcinoma patients, 12% of colorectal cancer patients, and 4% of lung adenocarcinoma patients), still faces enormous challenges in targeted therapy due to lacking cysteine residues similar to G12C for covalent binding [<xref rid="mco270401-bib-0374" ref-type="bibr">374</xref>]. Protein degradation technology provides new possibilities for overcoming this bottleneck, with three major KRAS G12D degrader programs currently advancing clinical development:</p><p>ASP3082 is the first KRAS G12D proteasome&#8208;targeting chimeric degrader entering clinical trials [<xref rid="mco270401-bib-0375" ref-type="bibr">375</xref>], selectively targeting KRAS G12D mutant protein for degradation by recruiting E3 ubiquitin ligase proteins. In preclinical studies, ASP3082 selectively degraded KRAS G12D mutant protein and showed growth inhibitory activity in KRAS G12D mutant cancer cells while having no effect on KRAS wild&#8208;type cancer cells. When administered weekly intravenously to mice transplanted with KRAS G12D mutant cancer cells, it demonstrated significant antitumor effects. Currently in Phase I clinical trials for solid tumors including pancreatic, colorectal, and non&#8208;small cell lung cancers (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05382559">NCT05382559</ext-link>), using 3&#8211;12 patient dose escalation cohorts with 21&#8208;day cycle intravenous administration and tumor&#8208;specific expansion cohorts enrolling &#8804;20 participants per tumor type [<xref rid="mco270401-bib-0376" ref-type="bibr">376</xref>].</p><p>ASP4396 from the same company is another KRAS G12D degrader designed to target KRAS G12D mutant protein degradation through the UPS, potentially providing higher efficacy and safety than inhibitors by blocking both enzymatic activity and scaffolding functions with higher target selectivity [<xref rid="mco270401-bib-0336" ref-type="bibr">336</xref>]. Currently in Phase I clinical trials for locally advanced or metastatic solid tumors (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06364696">NCT06364696</ext-link>), using open&#8208;label, multicenter, dose escalation and dose expansion design, enrolling adult patients with &#8805;1 measurable lesion and ECOG performance status 0 or 1.</p><p>PT0253 is an emerging program that, according to preclinical comparative data, shows best&#8208;in&#8208;class potential and may overcome limitations of current clinical&#8208;stage KRAS inhibitors, currently in Phase I clinical trials for KRAS G12D mutant advanced solid tumors (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06797336">NCT06797336</ext-link>) [<xref rid="mco270401-bib-0377" ref-type="bibr">377</xref>]. These KRAS G12D degrader programs represent important attempts to conquer &#8220;undruggable&#8221; targets, potentially providing more effective and durable treatment options for KRAS&#8208;driven tumors with extremely poor prognosis like pancreatic cancer through complete elimination of mutant proteins rather than simple functional inhibition.</p></sec><sec id="mco270401-sec-0450"><label>5.6</label><title>EGFR Degraders</title><p>EGFR degraders represent an innovative therapeutic strategy for overcoming traditional EGFR inhibitor resistance, showing tremendous clinical value in NSCLC treatment. Traditional EGFR inhibitors like gefitinib, erlotinib, and osimertinib have achieved significant efficacy in EGFR&#8208;mutated NSCLC patients but inevitably develop acquired resistance, mainly caused by secondary mutations like T790M and C797S [<xref rid="mco270401-bib-0378" ref-type="bibr">378</xref>]. EGFR degraders potentially overcome this therapeutic bottleneck by completely eliminating mutant EGFR proteins through TPD rather than simply blocking kinase activity.</p><p>CFT8919 is a representative program in this field&#8212;a potent and selective EGFR L858R degrader based on allosteric EGFR binding motifs, developed using the company's proprietary BiDAC degradation platform technology [<xref rid="mco270401-bib-0379" ref-type="bibr">379</xref>]. In preclinical studies, CFT8919 as monotherapy showed activity in EGFR L858R&#8208;driven NSCLC models both in vitro and in vivo, and importantly remained effective in models carrying secondary resistance mutations (like EGFR T790M and C797S) [<xref rid="mco270401-bib-0380" ref-type="bibr">380</xref>], suggesting CFT8919 may be effective in patients with resistance due to EGFR secondary mutations. Additionally, CFT8919 demonstrated intracranial activity, suggesting potential for treating brain metastases, which is particularly important for NSCLC patients since brain metastases are common and poor&#8208;prognosis complications. This drug is currently in Phase I clinical trials for NSCLC (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06641609">NCT06641609</ext-link>) [<xref rid="mco270401-bib-0381" ref-type="bibr">381</xref>]. Beyond CFT8919, other drugs like BG&#8208;60366 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06685718">NCT06685718</ext-link>) and HSK40118 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06050980">NCT06050980</ext-link>) are also in Phase I clinical trials evaluating safety and efficacy in NSCLC. The emergence of EGFR degraders not only provides new therapeutic approaches for solving EGFR inhibitor resistance but, more importantly, their potential as monotherapy in first&#8208;line settings may avoid secondary EGFR mutations commonly seen with currently approved EGFR inhibitors, potentially providing more durable treatment benefits for EGFR&#8208;mutated NSCLC patients.</p></sec><sec id="mco270401-sec-0460"><label>5.7</label><title>BCL6 Degraders</title><p>BMS&#8208;986458 is a first&#8208;in&#8208;class highly selective BCL6 ligand&#8208;directed degrader currently in Phase I/II clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06090539">NCT06090539</ext-link>) treating follicular lymphoma and diffuse large B&#8208;cell lymphoma. Preclinical data show this drug demonstrates antitumor effects in 80% of BCL6&#8208;expressing NHL cell lines in vitro, increasing CD20 expression up to 20&#8208;fold within 72 h, which is significant for relapsed/refractory disease [<xref rid="mco270401-bib-0382" ref-type="bibr">382</xref>]. In vivo studies showed daily oral administration achieved tumor regression, and when combined with anti&#8208;CD20 drugs, achieved tumor&#8208;free status in 70% of animal models. The 28&#8208;day canine toxicity study showed good tolerability. Its multimodal mechanism not only directly acts on tumor cells but also modulates follicular helper T cells in the immune microenvironment, potentially becoming a first&#8208;in&#8208;class chemotherapy&#8208;free treatment option for B&#8208;cell NHL patients. ARV&#8208;393 is in earlier Phase I clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06393738">NCT06393738</ext-link>) for treating B&#8208;cell non&#8208;Hodgkin lymphoma and angioimmunoblastic T&#8208;cell lymphoma, currently still evaluating safety and preliminary efficacy [<xref rid="mco270401-bib-0383" ref-type="bibr">383</xref>].</p></sec><sec id="mco270401-sec-0470"><label>5.8</label><title>BRD4 and BRD9 Targeting: Innovative Strategies and Clinical Challenges</title><p>MT&#8208;4561 is a novel BRD4 degrader currently undergoing Phase II clinical evaluation. (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06943521">NCT06943521</ext-link>) for BRD4&#8208;dependent solid tumors, covering broad tumor types including NSCLC, breast cancer, and prostate cancer.</p><p>BRD9 is a key protein in chromatin regulatory systems, participating in BAF complex functional regulation, playing crucial roles in cancers like synovial sarcoma and SMARCB1&#8208;deficient tumors [<xref rid="mco270401-bib-0384" ref-type="bibr">384</xref>]. However, since traditional bromodomain inhibitors cannot effectively treat BRD9&#8208;dependent cancers, this target has long been considered an &#8220;undruggable&#8221; difficult target. CFT&#8208;8634 and FHD&#8208;609 are both innovative PROTAC/BiDAC protein degraders that exert antitumor effects by degrading rather than inhibiting BRD9 [<xref rid="mco270401-bib-0327" ref-type="bibr">327</xref>, <xref rid="mco270401-bib-0328" ref-type="bibr">328</xref>]. CFT&#8208;8634 received US FDA orphan drug designation, while FHD&#8208;609 is an intravenous BRD9 degrader, both showing good activity against BRD9&#8208;dependent tumors in preclinical studies.</p><p>However, while CFT&#8208;8634 was well&#8208;tolerated in clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05355753">NCT05355753</ext-link>) and achieved high&#8208;level BRD9 degradation, it failed to produce sufficient single&#8208;agent efficacy in heavily pretreated patients, leading to formal development termination in November 2023 and complete trial closure in Q1 2024 [<xref rid="mco270401-bib-0327" ref-type="bibr">327</xref>]. FHD&#8208;609 experienced a Grade 4 QTc prolongation serious cardiac toxicity event in a synovial sarcoma patient at the second&#8208;highest dose in its Phase I clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04965753">NCT04965753</ext-link>), leading US FDA to implement partial clinical hold in April 2023 [<xref rid="mco270401-bib-0385" ref-type="bibr">385</xref>]. Subsequently, no plans to independently advance dose expansion studies were made, effectively terminating further development. These two cases fully demonstrate the significant challenges faced in balancing safety and efficacy in TPD drug development.</p></sec><sec id="mco270401-sec-0480"><label>5.9</label><title>SMARCA2 Targeting Twin Stars: PRT3789 and PRT7732</title><p>PRT3789 [<xref rid="mco270401-bib-0386" ref-type="bibr">386</xref>] is the first highly selective intravenous SMARCA2 degrader entering clinical trials, while PRT7732 is a potent oral SMARCA2 degrader. Both drugs&#8217; development is based on the same scientific principle: SMARCA4 is frequently mutated in multiple cancers, including up to 10% of NSCLC [<xref rid="mco270401-bib-0387" ref-type="bibr">387</xref>, <xref rid="mco270401-bib-0388" ref-type="bibr">388</xref>]. SMARCA4&#8208;deficient cancer cells are highly dependent on SMARCA2 for survival, and targeting SMARCA2 in SMARCA4&#8208;deficient cancers is expected to produce strong synthetic lethal effects [<xref rid="mco270401-bib-0232" ref-type="bibr">232</xref>].</p><p>In a Phase I (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05639751">NCT05639751</ext-link>) study investigating the novel SMARCA2 degrader PRT3789, patients with advanced cancers harboring SMARCA4 deficiency were treated to evaluate safety and efficacy [<xref rid="mco270401-bib-0389" ref-type="bibr">389</xref>]. The trial population included individuals with various tumor types, with NSCLC being the predominant diagnosis, followed by pancreatic and breast malignancies. Treatment&#8208;emergent adverse events of Grade 3 or higher occurred in about half of the patients; however, only a minority of these events were linked to the drug itself. Common side effects reported included nausea, appetite loss, and fatigue. Among those patients whose responses could be evaluated, encouraging tumor shrinkage was primarily seen in NSCLC and esophageal cancer cases, while patients with other tumor types did not exhibit measurable tumor regression.</p></sec><sec id="mco270401-sec-0490"><label>5.10</label><title>STAT3 and STAT6 Targeting</title><p>KT&#8208;333 is a STAT3&#8208;targeting PROTAC degrader using VHL&#8208;dependent mechanisms, currently in Phase Ia/1b clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05225584">NCT05225584</ext-link>) for indications including relapsed/refractory B&#8208;cell and T&#8208;cell lymphomas, classical Hodgkin lymphoma, solid tumors, and large granular lymphocytic leukemia/T&#8208;cell prolymphocytic leukemia, showing 31.4% ORR among 51 enrolled patients [<xref rid="mco270401-bib-0390" ref-type="bibr">390</xref>].</p><p>KT&#8208;621 is the world's first STAT6&#8208;targeting PROTAC drug, showing good pharmacokinetic characteristics in healthy subjects with rapid degradation of STAT6 protein in blood immune cells [<xref rid="mco270401-bib-0391" ref-type="bibr">391</xref>]. Doses of 12.5&#160;mg once daily and above achieved rapid degradation effects. While STAT6 protein degradation in skin tissue required longer time to reach &gt;90%, the drug showed good safety, with ideal metabolic and activity data and oral administration advantages. Currently in Phase I clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06945458">NCT06945458</ext-link>) evaluating atopic dermatitis patients, awaiting further clinical data validation of efficacy in patient populations.</p></sec><sec id="mco270401-sec-0500"><label>5.11</label><title>PROTAC Drugs Targeting Other Protein Targets Under Clinical Evaluation</title><p>As PROTAC technology continues developing, new PROTAC drugs keep emerging, providing new strategies for cancer treatment through protein degradation mechanisms. DT&#8208;2216 [<xref rid="mco270401-bib-0392" ref-type="bibr">392</xref>], as a BCL&#8208;X&#8208;targeting protein degrader, is currently in Phase I clinical trials in T&#8208;cell lymphoma patients evaluating safety and preliminary efficacy (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04886622">NCT04886622</ext-link>). EZH2&#8208;targeting drug AXT&#8208;1003 [<xref rid="mco270401-bib-0339" ref-type="bibr">339</xref>, <xref rid="mco270401-bib-0393" ref-type="bibr">393</xref>] was originally designed for treating relapsed or refractory non&#8208;Hodgkin lymphoma, but its Phase I clinical trial was terminated early (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05965505">NCT05965505</ext-link>), with specific termination reasons undisclosed.</p><p>In hematologic malignancy treatment, AUTX&#8208;703 [<xref rid="mco270401-bib-0394" ref-type="bibr">394</xref>] targets KAT2A and KAT2B, currently in Phase I studies in myelodysplastic syndromes and acute myeloid leukemia patients (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06846606">NCT06846606</ext-link>), while KT&#8208;253 [<xref rid="mco270401-bib-0395" ref-type="bibr">395</xref>], as an MDM2 protein degrader, restores p53 tumor suppressor function by inducing selective MDM2 protein degradation, currently in Phase I clinical evaluation in multiple blood cancers (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05775406">NCT05775406</ext-link>).</p><p>In solid tumor treatment, CFT&#8208;1946 represents an important technological breakthrough as a novel bifunctional degradation activating compound (BIDAC) that simultaneously inhibits and degrades mutant BRAF V600 protein. Compared with traditional BRAF inhibitors, CFT&#8208;1946's unique advantage lies in avoiding paradoxical RAF activation phenomena, since degraded BRAF V600 mutant protein cannot form dimeric signaling complexes. This drug is selective for mutant protein without affecting wild&#8208;type BRAF, currently in Phase I/II clinical studies for multiple BRAF V600&#8208;mutated solid tumors including melanoma [<xref rid="mco270401-bib-0396" ref-type="bibr">396</xref>], NSCLC, colorectal cancer, and anaplastic thyroid cancer, with both monotherapy and combination therapy with MEK inhibitor trametinib (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05668585">NCT05668585</ext-link>).</p><p>Additionally, BTX&#8208;9341 [<xref rid="mco270401-bib-0397" ref-type="bibr">397</xref>] targets CDK4/6, currently in Phase I trials in breast cancer patients (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06515470">NCT06515470</ext-link>), while <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="CG001419">CG001419</ext-link>, as an NTRK&#8208;targeting drug specifically for treating advanced solid tumors carrying NTRK alterations, is in Phase I/II clinical studies (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06636500">NCT06636500</ext-link>).</p></sec><sec id="mco270401-sec-0510"><label>5.12</label><title>Clinical Challenges and Future Development Directions for PROTAC Drugs</title><p>Despite remarkable progress in recent years, with vepdegestrant and other candidates entering Phase III trials and even submitting NDAs, this revolutionary technology still faces severe challenges on the path to commercialization [<xref rid="mco270401-bib-0181" ref-type="bibr">181</xref>]. PROTAC drugs consist of heterobifunctional molecules comprising target protein ligands, linkers, and E3 ubiquitin ligase ligands. While peptide PROTACs exist in research, all PROTACs in current clinical trials are composed of small molecules, yet their molecular weights far exceed traditional &#8220;small molecule&#8221; drug concepts.</p><p>Oral bioavailability represents the largest technical bottleneck for PROTAC drugs. Since PROTAC molecular weights typically exceed 800&#160;Da, far beyond ideal ranges for oral drugs, they universally possess unfavorable oral absorption characteristics including high molecular weight, multiple hydrogen bond donors/acceptors, and high polar surface area. For example, ARV&#8208;110's recommended Phase II dose is 420&#160;mg once daily, with only 23.8% oral bioavailability in rats [<xref rid="mco270401-bib-0398" ref-type="bibr">398</xref>]. This low bioavailability not only requires higher doses, increasing patient burden, but also raises &#8220;hook effect&#8221; concerns, where excessive concentrations form nonproductive binary complexes rather than ternary complexes, actually reducing target protein degradation efficiency.</p><p>Safety challenges are equally concerning, with recent terminations of multiple PROTAC programs due to serious safety issues serving as warnings for the entire field. FHD&#8208;609 [<xref rid="mco270401-bib-0328" ref-type="bibr">328</xref>], a BRD9 degrader, experienced Grade 4 QTc prolongation and syncope in Phase I trials, ultimately leading to US FDA clinical hold. CFT&#8208;8634 [<xref rid="mco270401-bib-0327" ref-type="bibr">327</xref>], despite achieving high&#8208;level BRD9 degradation, failed to produce sufficient efficacy in heavily pretreated patients and was discontinued. These cases suggest PROTAC drugs may have issues including off&#8208;target protein degradation, inadvertent degradation of essential cardiomyocyte proteins, and complex balancing of efficacy versus safety.</p><p>Facing these challenges, future PROTAC technology development requires multidimensional innovative breakthroughs. At the molecular design level, researchers are working on developing shorter, more rigid linkers to reduce molecular flexibility, exploring novel E3 ligase ligands for smaller, more stable alternatives, and introducing prodrug strategies to improve bioavailability through in vivo activation. Delivery technology innovation is also becoming important, including using lipid nanoparticles (LNPs) for enhanced stability, developing ADCs for precise targeting, and local administration strategies following GT20029's [<xref rid="mco270401-bib-0355" ref-type="bibr">355</xref>] successful dermatological application.</p><p>For safety assessment, establishing more comprehensive cardiac toxicity evaluation models, developing PROTAC&#8208;specific safety assessment indicators, utilizing humanized organ&#8208;on&#8208;chip technology for toxicity prediction, and constructing AI&#8208;based toxicity prediction models are current research focuses. Next&#8208;generation PROTAC technology development is also anticipated, including reversible PROTAC molecular design, multitarget PROTAC strategies, and novel E3 ligase development beyond traditional VHL, CRBN, and IAP systems [<xref rid="mco270401-bib-0399" ref-type="bibr">399</xref>, <xref rid="mco270401-bib-0400" ref-type="bibr">400</xref>, <xref rid="mco270401-bib-0401" ref-type="bibr">401</xref>]. Long&#8208;term, PROTAC technology success depends not only on individual drug approvals but on establishing a sustainable technology platform. As a completely new drug mechanism, PROTACs face unprecedented regulatory challenges, requiring new assessment standards covering target protein degradation quantitative evaluation, long&#8208;term safety monitoring, and special population safety assessment. Commercially, high development costs and relatively high failure rates require pharmaceutical companies to develop precise market positioning, reasonable pricing strategies, and comprehensive pharmacoeconomic data within limited patent protection periods.</p><p>Despite current multiple challenges, with advancing science and technology and accumulating clinical experience, issues including oral bioavailability, safety, and mechanistic understanding are expected to be gradually resolved.</p></sec></sec><sec id="mco270401-sec-0520"><label>6</label><title>Delivery Systems for PROTACs: Challenges and Strategic Solutions</title><p>PROTACs, as an emerging class of targeted protein degraders, have demonstrated immense therapeutic potential surpassing traditional inhibitors in a series of clinical trials. However, effectively delivering PROTACs to intracellular targets and ensuring their stability and bioavailability in complex biological environments remain core challenges that must be overcome to fully unleash their pharmacological activity. PROTAC molecules are often larger and more complex than traditional small molecule drugs, which leads to difficulties in crossing biological membranes, evading biological barriers, and avoiding nonspecific binding. To overcome these delivery hurdles, researchers have developed a variety of innovative strategies, which can be broadly categorized into two main approaches: structural optimization of the PROTAC molecule itself to enhance its cell permeability, and the use of various advanced delivery systems for its encapsulation or conjugation (Figure&#160;<xref rid="mco270401-fig-0003" ref-type="fig">3</xref>).</p><fig position="float" fig-type="FIGURE" id="mco270401-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Advanced delivery strategies for PROTACs. Delivery platforms, including exosomes, liposomes, antibodies, aptamers, and polymeric/nonorganic nanoparticles, have been developed to enhance the stability, bioavailability, tissue specificity, and cellular uptake of PROTACs.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="MCO2-6-e70401-g005.jpg"/></fig><sec id="mco270401-sec-0530"><label>6.1</label><title>Optimizing PROTAC Molecules for Enhanced Cell Permeability</title><p>The passive diffusion of traditional small molecule drugs into cells generally adheres to the Ro5, where parameters such as molecular weight, lipophilicity, and the number of hydrogen bond donors and acceptors should fall within specific ranges to ensure good oral bioavailability and cell permeability. However, many PROTAC molecules, particularly chimeras linking two or more functional domains, often have molecular weights that exceed the Ro5 limits, falling into the eRo5 or even bRo5 categories [<xref rid="mco270401-bib-0402" ref-type="bibr">402</xref>]. Such molecules typically exhibit lower passive membrane permeability, leading to insufficient intracellular concentrations and, consequently, limiting their in vivo efficacy.</p><p>To address this issue, a &#8220;chemical endocytic medicinal chemistry&#8221; strategy has been proposed, aiming to actively promote PROTAC entry into cells via endocytic pathways through structural modifications [<xref rid="mco270401-bib-0402" ref-type="bibr">402</xref>]. This approach no longer solely relies on passive diffusion but instead leverages the cell's intrinsic membrane transport mechanisms. For instance, a key study identified CD36, a fatty acid transporter, as a membrane receptor for PROTACs, especially eRo5/bRo5 molecules, mediating their cellular uptake [<xref rid="mco270401-bib-0402" ref-type="bibr">402</xref>]. By optimizing the structure of PROTACs to enhance their binding affinity to CD36, their intracellular internalization efficiency and pharmacological activity can be significantly improved, without compromising their solubility or stability. This strategy of finely tuning PROTAC structures to adapt to cellular endocytosis mechanisms offers a promising avenue for overcoming the permeability bottleneck of large PROTAC molecules. By identifying and exploiting specific receptor&#8208;mediated endocytosis, more efficient and targeted intracellular delivery of PROTACs can be achieved, which is crucial for improving their bioavailability and targeting.</p></sec><sec id="mco270401-sec-0540"><label>6.2</label><title>Advanced Delivery Systems: Constructing Multifunctional Vehicles</title><p>In addition to structural optimization of the PROTAC molecule itself, encapsulating or conjugating PROTACs into various advanced delivery systems is another major category of strategies for addressing their delivery challenges. These systems aim to protect PROTACs from enzymatic degradation, improve their solubility, prolong their systemic circulation time, and achieve targeted delivery to specific cells or tissues (Figure&#160;<xref rid="mco270401-fig-0003" ref-type="fig">3</xref>).</p><sec id="mco270401-sec-0550"><label>6.2.1</label><title>Conjugate&#8208;Based Delivery Systems</title><p>Conjugate delivery strategies achieve precise targeting and efficient delivery by covalently linking PROTAC molecules to biomolecules with specific delivery functions.</p><sec id="mco270401-sec-0560"><label>6.2.1.1</label><title>Antibody&#8211;PROTAC Conjugates</title><p>Drawing on the successful experience of ADCs, DACs leverage the high specificity of antibodies to recognize specific cell surface antigens. Antibodies can precisely bind to receptors on the surface of target cells and mediate the internalization of the conjugated PROTACs into cells via receptor&#8208;mediated endocytosis. The advantage of this strategy lies in its excellent cell and tissue specificity, which can effectively reduce the accumulation of PROTACs in nontarget cells, thereby lowering systemic toxicity, while enhancing PROTAC enrichment at target sites to improve efficacy. DACs represent a powerful platform for achieving precise tumor&#8208;targeted delivery of PROTACs. Maneiro et&#160;al. [<xref rid="mco270401-bib-0003" ref-type="bibr">3</xref>] demonstrated the successful development of trastuzumab&#8211;PROTAC conjugates that selectively degrade BRD4 only in HER2&#8208;positive breast cancer cells while sparing HER2&#8208;negative cells, achieving stable drug&#8208;to&#8208;antibody ratios of 4 with excellent serum stability. Similarly, Wang et&#160;al. [<xref rid="mco270401-bib-0403" ref-type="bibr">403</xref>] developed ROR1&#8208;targeting DACs that showed enhanced tumor&#8208;specific BRD4 degradation and improved antitumor efficacy in PC3 and MDA&#8211;MB&#8208;231 xenograft models, with superior pharmacokinetic profiles including extended half&#8208;life compared with unconjugated PROTACs. The conjugation strategy employed click chemistry and site&#8208;specific cysteine engineering to ensure controlled PROTAC release while maintaining antibody binding specificity. Notably, combination therapy with immune checkpoint inhibitors demonstrated enhanced therapeutic outcomes through tumor microenvironment modulation and increased T cell infiltration [<xref rid="mco270401-bib-0403" ref-type="bibr">403</xref>]. These studies establish DACs as promising candidates for overcoming traditional limitations of PROTAC selectivity and pharmacokinetics in cancer therapy.</p></sec><sec id="mco270401-sec-0570"><label>6.2.1.2</label><title>Aptamer&#8211;PROTAC Conjugates</title><p>This emerging conjugation strategy utilizes nucleic acid molecules, such as aptamers or engineered oligonucleotides, as PROTAC delivery vehicles. Aptamers are nucleic acid molecules obtained through in vitro selection that can bind to specific target molecules with high affinity and specificity [<xref rid="mco270401-bib-0404" ref-type="bibr">404</xref>]. By conjugating PROTACs to aptamers that target cell surface receptors, receptor&#8208;mediated endocytosis of PROTACs can be achieved, thereby specifically delivering them to target cells. This strategy combines the high specificity recognition capabilities of nucleic acids with the degradation function of PROTACs, offering new possibilities for precision medicine. Recent advances have demonstrated the feasibility of APCs for tumor&#8208;selective protein degradation. Zhang et&#160;al. [<xref rid="mco270401-bib-0405" ref-type="bibr">405</xref>] developed ZL216, a novel PROTAC using nucleic acid aptamer AS1411 as a targeting ligand for nucleolin, which showed excellent serum stability and water solubility while achieving potent nucleolin degradation in breast cancer cells both in vitro and in vivo. Similarly, Sun et&#160;al. [<xref rid="mco270401-bib-0406" ref-type="bibr">406</xref>] reported conjugated polyelectrolyte/ssDNA hybrid polyplexes that combined cationic conjugated polyelectrolytes with aptamer sequences, demonstrating enhanced cellular uptake efficiency and nuclease resistance for targeted ER&#945; degradation. These studies demonstrate that nucleic acid aptamers can effectively construct PROTACs, broadening the PROTAC toolbox and providing promising strategies for developing tumor&#8208;selective protein degraders with improved delivery efficiency and reduced off&#8208;target effects.</p></sec></sec><sec id="mco270401-sec-0580"><label>6.2.2</label><title>Nanoparticle&#8208;Based Delivery Systems</title><p>Nanoparticles, as versatile drug delivery platforms, have garnered significant attention due to their nanoscale size, high drug loading capacity, and modifiability. They can effectively encapsulate PROTACs, protecting them from enzymatic degradation and rapid clearance, while promoting cellular uptake and targeted delivery through various mechanisms.</p><sec id="mco270401-sec-0590"><label>6.2.2.1</label><title>Liposomes</title><p>Liposomes, versatile vesicles composed of one or more lipid bilayers surrounding an aqueous core, are highly effective carriers for delivering PROTACs due to their ability to encapsulate both hydrophilic and hydrophobic molecules. For PROTACs, which often suffer from poor water solubility, low bioavailability, and limited cell permeability due to their large molecular weight (&gt;800&#160;Da) and polar surfaces, liposomes offer a promising solution by encapsulating these molecules within the lipid bilayer or aqueous compartment. This encapsulation enhances in vivo stability, protects PROTACs from premature degradation, and minimizes nonspecific interactions with biological systems, thereby reducing off&#8208;target effects and toxicity [<xref rid="mco270401-bib-0404" ref-type="bibr">404</xref>]. Recent studies have demonstrated significant improvements in PROTAC pharmacokinetic properties through liposomal delivery. For GNE&#8208;01 and GNE&#8208;02, PROTAC&#8208;in&#8208;cyclodextrin liposome formulations showed 80&#8208;fold and 23&#8208;fold enhancements in AUC, respectively, compared with solution formulations [<xref rid="mco270401-bib-0407" ref-type="bibr">407</xref>]. Additionally, innovative codelivery approaches have been developed, such as DTX/ARV&#8208;lip systems that coencapsulate BRD4&#8211;PROTAC ARV825 with docetaxel, demonstrating enhanced antitumor effects through dual mechanisms of protein degradation and chemotherapy with tumor inhibition rates reaching 57.4% [<xref rid="mco270401-bib-0408" ref-type="bibr">408</xref>]. The biocompatibility, high loading capacity, and tunable physicochemical properties of lipid&#8208;based nanoparticles make them ideal for improving the pharmacokinetic profiles of PROTACs, facilitating their clinical translation. A notable example of liposome&#8208;based PROTAC delivery is the development of LARPC, a nanoliposome coloading the protein kinase C inhibitor palmitoyl&#8208;dl&#8208;carnitine chloride (PC) and the BRD4&#8208;targeting PROTAC ARV&#8208;825 [<xref rid="mco270401-bib-0409" ref-type="bibr">409</xref>]. Furthermore, engineered bioPROTAC formats capable of complexing with cationic and ionizable lipids via electrostatic interactions have shown remarkable efficacy, with near&#8208;complete elimination (up to 95% clearance) of targets within hours of treatment when delivered by biocompatible LNPs, demonstrating successful degradation of proteins localized to various subcellular compartments including the mitochondria, nucleus, cytosol, and membrane [<xref rid="mco270401-bib-0075" ref-type="bibr">75</xref>]. In this system, the hydrophobic ARV&#8208;825 resides within the lipid bilayer alongside the palmitoyl chain of PC, forming nanoparticles with a size of approximately 105.25&#160;&#177;&#160;2.76&#160;nm and a positive surface charge of 26.6&#160;mV. These properties enable selective tumor accumulation via the EPR effect and enhance internalization into cancer cells, resulting in potent inhibition of melanoma cell lines. This demonstrates the potential of liposomes to maximize anticancer efficacy while minimizing side effects through targeted delivery. Liposomes can be engineered to further optimize PROTAC delivery. Surface modifications, such as PEGylation, extend circulation time by reducing clearance, while conjugation with targeting ligands&#8212;such as antibodies, peptides, or small molecules&#8212;enables active targeting of specific cell types, such as cancer cells overexpressing FOLR1 or HER2 [<xref rid="mco270401-bib-0404" ref-type="bibr">404</xref>].</p></sec><sec id="mco270401-sec-0600"><label>6.2.2.2</label><title>Polymer&#8208;Based Nanostructures</title><p>These nanoparticles are fabricated from biodegradable polymers (e.g., PLGA, PLA), possessing good biocompatibility and controlled release characteristics. Polymeric NPs can encapsulate PROTACs in the form of micelles, nanospheres, or nanocapsules, providing drug protection and sustained release effects. Their surfaces are easily functionalized, allowing for attachment of targeting ligands to achieve specific cellular uptake, or to trigger PROTAC release in response to the tumor microenvironment. Recent advances demonstrate that stereocomplexation of P(LLA&#8208;stat&#8208;EtGly) and P(DLA&#8208;stat&#8208;EtGly) can tune melting temperature and crystallinity of polymers, directly impacting mechanical properties and drug release behavior without affecting hydrophilic/hydrophobic balance [<xref rid="mco270401-bib-0410" ref-type="bibr">410</xref>]. The formation of stereocomplexes leads to stronger polymer chain interactions, increased thermal stability, and higher Young's modulus compared with homochiral crystals [<xref rid="mco270401-bib-0410" ref-type="bibr">410</xref>]. MZ1&#8208;loaded polymeric nanoparticles using US FDA&#8208;approved PLA and PEI demonstrated excellent properties with particle sizes of 114&#8211;124&#160;nm, encapsulation efficiency of 55.7%, and high stability over 7 days [<xref rid="mco270401-bib-0411" ref-type="bibr">411</xref>]. These nanoparticles exhibited biphasic release patterns with controlled diffusion, while stereocomplexation kinetics showed that 7&#8208;day formation time optimized nanoparticle crystallinity and mechanical properties [<xref rid="mco270401-bib-0410" ref-type="bibr">410</xref>, <xref rid="mco270401-bib-0411" ref-type="bibr">411</xref>]. Trastuzumab&#8208;conjugated MZ1 nanoparticles (MZ1&#8211;ACNPs) showed significantly enhanced cytotoxic effects in HER2+ breast cancer cells and overcame natural MZ1 resistance in resistant cell lines, while antibody conjugation prevented protein corona formation and maintained delivery specificity [<xref rid="mco270401-bib-0411" ref-type="bibr">411</xref>].</p></sec><sec id="mco270401-sec-0610"><label>6.2.2.3</label><title>Exosome&#8208;Based Nanoparticles</title><p>Exosome&#8208;mediated PROTAC delivery systems represent a revolutionary drug delivery paradigm that demonstrates tremendous potential in the field of antiviral therapeutics. PROTACs constitute a class of bifunctional molecules capable of harnessing the cellular UPS for selective degradation of target proteins, while exosomes serve as naturally occurring nanoscale extracellular vesicles that possess excellent biocompatibility, stability, and the capacity to traverse biological barriers, thereby providing an optimal carrier platform for targeted PROTAC delivery [<xref rid="mco270401-bib-0040" ref-type="bibr">40</xref>, <xref rid="mco270401-bib-0412" ref-type="bibr">412</xref>]. Exosome&#8208;mediated PROTAC delivery significantly enhances drug bioavailability, enables cell&#8208;specific targeting, and minimizes off&#8208;target effects to the greatest extent possible. Through engineered modification of exosomal surface ligands, such as expression of cancer&#8208;specific surface receptors like EGFR, precise delivery to specific cell populations can be achieved, including HIV&#8208;infected cells and viral reservoirs [<xref rid="mco270401-bib-0413" ref-type="bibr">413</xref>]. Methods for loading PROTACs into exosomes encompass coincubation, electroporation, and sonication techniques, with electroporation demonstrating superior loading efficiency while preserving exosomal structural integrity [<xref rid="mco270401-bib-0414" ref-type="bibr">414</xref>]. This delivery system is particularly well&#8208;suited for targeting the degradation of critical HIV proteins including Tat, p24, and viral proteases, thereby disrupting viral replication and assembly processes. Exosomes possess the remarkable ability to penetrate immune&#8208;privileged sites, enabling access to and clearance of latent HIV reservoirs that are typically refractory to existing therapeutic modalities. As next&#8208;generation PROTAC technologies continue to advance, exosome&#8208;mediated delivery systems hold considerable promise for playing increasingly important roles in the treatment of HIV and other viral diseases.</p></sec><sec id="mco270401-sec-0620"><label>6.2.2.4</label><title>Nonorganic Nanoparticles</title><p>Inorganic NPs, such as gold NPs, silica NPs, and magnetic NPs, have also been explored for PROTAC delivery. These inorganic nanomaterials generally possess good biocompatibility, ease of surface modification, and controllable physicochemical properties. By modifying the surface of NPs with amino or thiol groups, PROTACs can be conjugated and enter cells via endocytosis. A notable example is the development of NIR&#8208;activatable PROTAC nanocages using UCNPs&#8208;based MSNs. In this system, a photocaged PROTAC targeting BRD4 was loaded into UMSNs to construct NIR light&#8208;activatable nanocages that could be activated upon 980&#160;nm laser irradiation to release active PROTAC for TPD and cancer cell apoptosis [<xref rid="mco270401-bib-0415" ref-type="bibr">415</xref>]. This approach addresses the limitations of UV&#8211;visible light&#8208;controlled PROTACs by utilizing NIR light, which offers better tissue penetration and reduced phototoxicity. The nanocages demonstrated effective BRD4 degradation and successfully suppressed tumor growth with 58.7% tumor growth inhibition in vivo. Another innovative approach involves injectable thermosensitive nanocomposite hydrogels that integrate multiple therapeutic modalities. Wu et al. [<xref rid="mco270401-bib-0416" ref-type="bibr">416</xref>] developed a system comprising CCM&#8208;coated MSNs containing both a peptide&#8208;based BMI1 PROTAC and paclitaxel, combined with imiquimod&#8208;encapsulated CaCO3 NPs within a PLGA&#8211;PEG&#8211;PLGA polymer framework. This system exploits the immunosuppressive TME by simultaneously targeting BMI1 degradation while modulating immune cell populations through pH&#8208;responsive release of immunoadjuvants. Upon injection, the hydrogel undergoes in situ gelation and gradually degrades in the acidic TME, releasing therapeutic NPs in a sustained manner. The CaCO3 NPs decompose under acidic conditions, neutralizing tumor pH and releasing imiquimod to promote M2&#8208;to&#8208;M1 macrophage polarization and DC maturation, thereby enhancing antitumor immune responses. This approach demonstrated superior therapeutic efficacy in HNSCC models, effectively suppressing both primary tumor growth and metastasis. Inorganic NPs may also offer additional functionalities, such as imaging or photothermal therapy, enabling integrated diagnosis and treatment.</p><p>PROTAC delivery research is advancing toward multifunctional, intelligent, and targeted approaches. From the structural optimization of PROTAC molecules themselves to a diverse array of advanced delivery systems, each strategy offers a unique solution to the specific challenges faced in PROTAC delivery. Future research will likely combine the advantages of multiple strategies to develop more efficient and safer PROTAC delivery platforms, ultimately propelling these revolutionary drugs toward clinical application.</p></sec></sec><sec id="mco270401-sec-0630"><label>6.2.3</label><title>Key Challenges and Future Perspectives: Critical Insights on PROTAC Delivery Systems</title><p>After thoroughly examining the current landscape of PROTAC technology, it is become clear that the field has reached a pivotal juncture. The ability to solve delivery challenges will ultimately determine whether these promising molecules can achieve their transformative potential. In our view, the delivery system puzzle represents both the most formidable barrier and the most exciting opportunity for innovation in the PROTAC arena. The fundamental challenge arises from an inherent paradox: PROTACs need to be large enough to simultaneously engage both the target protein and E3 ligase, yet must retain sufficient drug&#8208;like properties for effective delivery. When molecular weights routinely exceed 1000&#160;Da, conventional small molecule delivery principles simply fall short [<xref rid="mco270401-bib-0417" ref-type="bibr">417</xref>]. We have seen numerous elegantly designed PROTACs that demonstrate exceptional potency in vitro fail to progress clinically due to poor bioavailability and inadequate tissue penetration. This disconnect between laboratory promise and clinical reality demands a paradigm shift in how we approach PROTAC delivery.</p><p>Among the various delivery strategies explored, each presents distinct advantages and limitations that require careful consideration. Nanoparticle&#8208;based systems, particularly LNPs, offer excellent protection against enzymatic degradation and enable targeted delivery through surface modifications [<xref rid="mco270401-bib-0418" ref-type="bibr">418</xref>]. However, these systems often suffer from rapid clearance in vivo, and their size constrains tumor penetration. Manufacturing complexity and batch&#8208;to&#8208;batch variability also pose significant hurdles for clinical translation and regulatory approval. AOCs represent an elegant approach for achieving cell&#8208;specific delivery, leveraging the exquisite selectivity of antibodies. Yet in practice, conjugating an already complex PROTAC molecule to a 150&#160;kDa antibody creates an unwieldy construct. The resulting conjugates face formulation challenges, potential immunogenicity concerns, and remain limited to targets accessible from the extracellular space. Moreover, the heterogeneous nature of these conjugates complicates quality control and pharmacokinetic optimization. Prodrug strategies offer another compelling approach, enabling PROTACs to traverse biological barriers in an inactive form before activation at the target site [<xref rid="mco270401-bib-0419" ref-type="bibr">419</xref>]. We find enzyme&#8208;cleavable and pH&#8208;responsive prodrugs that exploit the tumor microenvironment particularly intriguing [<xref rid="mco270401-bib-0420" ref-type="bibr">420</xref>]. Nevertheless, the additional molecular complexity introduced by prodrug moieties can push already large PROTACs beyond practical limits for oral administration. The kinetics of prodrug activation must also be carefully balanced to avoid premature activation or excessive stability.</p><p>Looking ahead, several key developments could revolutionize PROTAC delivery. First, integrating artificial intelligence and machine learning could enable prediction of optimal delivery strategies based on PROTAC structure and target tissue characteristics [<xref rid="mco270401-bib-0243" ref-type="bibr">243</xref>]. The potential for AI to identify novel cell surface receptors that mediate PROTAC uptake in specific tissues or disease states is particularly exciting. Second, combination delivery approaches will likely prove more successful than single&#8208;strategy solutions. For instance, incorporating a prodrug&#8211;PROTAC into targeted nanoparticles could leverage multiple mechanisms for enhanced delivery. The key lies in maintaining the right balance between complexity and practicality. Third, tissue&#8208;specific delivery will become increasingly important as PROTACs expand beyond oncology. Developing brain&#8208;penetrant PROTACs for neurodegenerative diseases will require fundamentally different approaches than those used for solid tumors. Similarly, achieving selective delivery to inflamed tissues for autoimmune applications will demand innovative targeting strategies.</p><p>Solving the delivery challenge will require unprecedented collaboration between medicinal chemists, formulation scientists, clinicians, and regulatory experts. Based on the rapid progress we have witnessed and the creative solutions emerging from laboratories worldwide, we remain optimistic that while the delivery challenges facing PROTACs are formidable, they are ultimately surmountable.</p></sec></sec></sec><sec id="mco270401-sec-0640"><label>7</label><title>Future Directions and Improvement Strategies for PROTAC Technology</title><p>As PROTAC technology transitions from the proof&#8208;of&#8208;concept stage to the critical juncture of clinical application, the field is confronting unprecedented opportunities and challenges. While multiple PROTAC molecules have successfully entered clinical trials and demonstrated encouraging therapeutic efficacy, realizing their full potential as next&#8208;generation precision medicine tools requires systematic optimization across multiple dimensions, including molecular design, delivery strategies, and clinical translation. Based on current technical bottlenecks and clinical needs, the future development of PROTAC technology can be categorized into six core directions. These developmental pathways will collectively propel TPD technology from laboratory settings toward broader clinical applications (Figure&#160;<xref rid="mco270401-fig-0004" ref-type="fig">4</xref>).</p><fig position="float" fig-type="FIGURE" id="mco270401-fig-0004" orientation="portrait"><label>FIGURE 4</label><caption><p>Future directions and improvement strategies for PROTAC technology. Emerging areas of development are highlighted, such as the expansion of the E3 ligase toolbox, organ&#8208;specific targeting, advanced molecular designs, prodrug strategies, and combination therapies. These innovations aim to overcome current limitations and broaden the therapeutic applicability of PROTACs.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-9" orientation="portrait" xlink:href="MCO2-6-e70401-g002.jpg"/></fig><sec id="mco270401-sec-0650"><label>7.1</label><title>Molecular Design and Pharmacokinetic Optimization</title><sec id="mco270401-sec-0660"><label>7.1.1</label><title>Strategies for Enhancing Ternary Complex Stability</title><p>The core mechanism of PROTAC molecules relies on forming stable ternary complexes (POI&#8211;PROTAC&#8211;E3 ligase), but most current PROTAC molecules form ternary complexes with limited stability, directly impacting protein degradation efficiency [<xref rid="mco270401-bib-0421" ref-type="bibr">421</xref>]. Future molecular design will focus on enhancing ternary complex stability through computational modeling and structural optimization. Emerging artificial intelligence&#8208;assisted design methods, such as deep learning&#8208;based protein&#8211;protein interaction prediction models, are providing powerful tools for rational PROTAC design. By accurately predicting spatial conformational relationships between POI, PROTAC, and E3 ligase, researchers can design linker structures with superior geometric compatibility, significantly improving ternary complex formation efficiency and stability.</p></sec><sec id="mco270401-sec-0670"><label>7.1.2</label><title>Improvement of Cellular Permeability and Oral Bioavailability</title><p>Traditional PROTAC molecules, due to their large molecular weight (typically exceeding 800&#160;Da) and multiple hydrogen bond donors and acceptors, often face challenges of poor cell membrane permeability and low oral bioavailability [<xref rid="mco270401-bib-0422" ref-type="bibr">422</xref>]. This challenge is particularly pronounced in treating central nervous system diseases. To address this issue, researchers are exploring multiple innovative strategies. Among these, prodrug design represents one of the most promising approaches. By introducing modifying groups that can be cleaved by specific enzyme systems onto PROTAC molecules, this strategy not only improves drug ADME properties but also enables tissue&#8208;specific drug activation [<xref rid="mco270401-bib-0252" ref-type="bibr">252</xref>]. Additionally, novel delivery technologies such as LNPs and cyclodextrin inclusion complexes provide new solutions for enhancing PROTAC molecule bioavailability.</p></sec><sec id="mco270401-sec-0680"><label>7.1.3</label><title>Mechanistic Elucidation and Circumvention of the &#8220;Hook Effect&#8221;</title><p>The &#8220;hook effect&#8221; represents a unique challenge for PROTAC technology, referring to the phenomenon where PROTAC molecules paradoxically exhibit decreased degradation efficiency at high concentrations [<xref rid="mco270401-bib-0423" ref-type="bibr">423</xref>]. The mechanism underlying this effect involves competitive formation of binary complexes (POI&#8211;PROTAC or PROTAC&#8211;E3), which cannot promote protein degradation and instead hinder effective ternary complex formation. Understanding the molecular mechanisms of the hook effect is crucial for PROTAC optimization design. Recent studies indicate that by precisely modulating the binding affinity ratio between POI ligands and E3 ligands, as well as optimizing linker length and flexibility, the effective concentration window of PROTAC molecules can be effectively expanded while reducing hook effect occurrence [<xref rid="mco270401-bib-0424" ref-type="bibr">424</xref>].</p></sec></sec><sec id="mco270401-sec-0690"><label>7.2</label><title>Expansion of E3 Ligase Toolbox</title><sec id="mco270401-sec-0700"><label>7.2.1</label><title>Development of Novel E3 Ligase Ligands</title><p>Although the human genome encodes over 600 E3 ubiquitin ligases, current PROTAC design primarily relies on a few E3 ligases, such as CRBN, VHL, IAP, and MDM2. This limited E3 ligase selection significantly restricts the application scope and optimization space of PROTAC technology [<xref rid="mco270401-bib-0425" ref-type="bibr">425</xref>]. Future research priorities include discovering and developing small molecule ligands targeting novel E3 ligases. Through high&#8208;throughput screening, fragment&#8208;based drug discovery, and computer&#8208;aided drug design, researchers are working to expand the E3 ligase toolbox available for PROTAC design. Development of novel E3 ligands not only provides new solutions for difficult&#8208;to&#8208;degrade target proteins but also enables more precise tissue&#8208;specific protein degradation.</p></sec><sec id="mco270401-sec-0710"><label>7.2.2</label><title>Utilization of Tissue&#8208;Specific E3 Ligases</title><p>Different tissues and cell types exhibit significant variations in E3 ligase expression patterns, providing a natural foundation for achieving tissue&#8208;specific protein degradation. For example, certain E3 ligases are highly expressed in the nervous system while showing low expression in peripheral tissues [<xref rid="mco270401-bib-0426" ref-type="bibr">426</xref>]. PROTAC molecules designed using such E3 ligases hold promise for achieving brain&#8208;specific protein degradation [<xref rid="mco270401-bib-0427" ref-type="bibr">427</xref>]. Similarly, aberrant expression patterns of certain E3 ligases in tumor cells provide opportunities for cancer&#8208;specific therapy. Through systematic analysis of E3 ligase expression profile changes under different pathological conditions, researchers can identify disease&#8208;specific E3 ligase targets, thereby designing PROTAC molecules with higher selectivity and lower toxicity.</p></sec><sec id="mco270401-sec-0720"><label>7.2.3</label><title>Implementation of Tumor&#8208;Selective Applications</title><p>Tumor cells and normal cells exhibit systematic differences in E3 ligase expression, proteasome activity, cell cycle status, and other aspects [<xref rid="mco270401-bib-0428" ref-type="bibr">428</xref>]. These differences provide biological foundations for designing tumor&#8208;selective PROTACs. For instance, overexpression of specific E3 ligases in certain tumor cells makes them more sensitive to corresponding PROTAC molecules, while normal cells remain relatively unaffected due to lower E3 ligase expression levels. Furthermore, unique characteristics of the tumor microenvironment (such as hypoxia, acidic pH, specific enzyme activities) can be utilized to design environment&#8208;responsive PROTAC molecules, achieving selective protein degradation at tumor sites.</p></sec></sec><sec id="mco270401-sec-0730"><label>7.3</label><title>Development of Advanced Delivery Strategies</title><sec id="mco270401-sec-0740"><label>7.3.1</label><title>Application of Nanocarrier Systems</title><p>Nanocarrier technology provides innovative solutions for addressing PROTAC molecule delivery challenges. Various nanodelivery systems, including LNPs, polymeric nanoparticles, and inorganic nanocarriers, are being utilized for PROTAC molecule encapsulation and delivery [<xref rid="mco270401-bib-0429" ref-type="bibr">429</xref>, <xref rid="mco270401-bib-0430" ref-type="bibr">430</xref>]. These nanocarriers not only protect PROTAC molecules from enzymatic degradation in biological environments but also enable targeted delivery through surface modification. For example, by modifying nanocarrier surfaces with specific targeting ligands, PROTAC molecule enrichment in particular tissues or cell types can be achieved, thereby improving therapeutic efficacy while reducing systemic toxicity.</p></sec><sec id="mco270401-sec-0750"><label>7.3.2</label><title>Innovation in AOCs</title><p>AOCs represent an important developmental direction for TPD technology. By conjugating PROTAC molecules with specific antibodies, AOCs can achieve highly specific cellular targeted delivery [<xref rid="mco270401-bib-0431" ref-type="bibr">431</xref>]. When AOCs bind to cell surfaces expressing specific antigens, PROTAC molecules are delivered intracellularly through endocytosis, where they are released and exert protein degradation functions. This strategy is particularly suitable for treating cancer cells expressing specific surface markers, significantly improving treatment selectivity and efficacy.</p></sec><sec id="mco270401-sec-0760"><label>7.3.3</label><title>Refinement of Prodrug Design</title><p>Prodrug design holds unique value in PROTAC technology, not only improving drug physicochemical properties but also enabling conditional activation and targeted release [<xref rid="mco270401-bib-0432" ref-type="bibr">432</xref>]. Enzyme&#8208;activated prodrugs utilize differences in specific enzyme activities between particular tissues or pathological states to achieve selective PROTAC molecule activation. Photo&#8208;activated prodrugs enable spatiotemporally specific protein degradation through external light control. pH&#8208;responsive prodrugs utilize acidic characteristics of tumor microenvironments to achieve tumor&#8208;specific drug release. Development of these prodrug strategies provides powerful tools for precise PROTAC technology applications in complex biological systems.</p></sec></sec><sec id="mco270401-sec-0770"><label>7.4</label><title>Development of Organ&#8208;Specific PROTACs</title><sec id="mco270401-sec-0780"><label>7.4.1</label><title>Design of Blood&#8211;Brain Barrier Penetrating PROTACs</title><p>Treatment of central nervous system diseases has consistently been a major challenge for PROTAC technology, primarily due to strict blood&#8211;brain barrier (BBB) restrictions on macromolecular drugs [<xref rid="mco270401-bib-0433" ref-type="bibr">433</xref>]. To address this issue, researchers are exploring solutions from multiple angles. First is molecular design optimization, improving PROTAC molecule BBB penetration ability by reducing molecular weight, decreasing polar surface area, and optimizing hydrogen bond donor/acceptor ratios [<xref rid="mco270401-bib-0434" ref-type="bibr">434</xref>]. Second is utilizing carrier&#8208;mediated transport systems, such as glucose transporters and amino acid transporters, achieving active transport by conjugating PROTAC molecules with substrates of these transporters. Additionally, nanodelivery systems and physical methods (such as focused ultrasound) provide new possibilities for PROTAC molecules to cross the BBB.</p></sec><sec id="mco270401-sec-0790"><label>7.4.2</label><title>Development of Kidney/Liver&#8208;Targeted PROTACs</title><p>The kidneys and liver, as major metabolic and excretory organs, play crucial roles in the development and progression of numerous diseases. Developing organ&#8208;specific PROTAC molecules holds significant importance for treating kidney diseases (such as renal fibrosis, glomerular diseases) and liver diseases (such as hepatic fibrosis, fatty liver disease) [<xref rid="mco270401-bib-0435" ref-type="bibr">435</xref>, <xref rid="mco270401-bib-0436" ref-type="bibr">436</xref>]. Kidney targeting can utilize glomerular filtration characteristics and proximal tubule reabsorption mechanisms, achieving renal enrichment by modulating PROTAC molecule physicochemical properties such as molecular weight and charge distribution. Liver targeting can utilize specific receptors on hepatocyte surfaces (such as asialoglycoprotein receptors) or abundant hepatic blood flow characteristics.</p></sec><sec id="mco270401-sec-0800"><label>7.4.3</label><title>Application of Inhaled Formulations in Pulmonary Diseases</title><p>Treatment of pulmonary diseases such as pulmonary fibrosis, asthma, and lung cancer can achieve local high&#8208;concentration drug exposure through inhalation administration while reducing systemic side effects [<xref rid="mco270401-bib-0437" ref-type="bibr">437</xref>]. PROTAC molecule inhaled formulation development requires consideration of drug aerosol properties, pulmonary deposition patterns, local clearance mechanisms, and other factors. By optimizing carrier systems (such as liposomes, microspheres) and delivery devices, effective PROTAC molecule delivery and sustained release in the lungs can be achieved. This administration route is particularly suitable for treating lung&#8208;specific pathogenic proteins, such as fibrosis&#8208;related proteins playing key roles in pulmonary fibrosis.</p></sec></sec><sec id="mco270401-sec-0810"><label>7.5</label><title>Overcoming Clinical Translation Barriers</title><sec id="mco270401-sec-0820"><label>7.5.1</label><title>In&#8208;Depth Study of Resistance Mechanisms</title><p>Compared with traditional small molecule inhibitors, PROTAC molecules face unique resistance challenges. PROTAC resistance may arise from multiple levels: target protein mutations leading to decreased PROTAC binding ability, E3 ligase expression or functional abnormalities, proteasome system dysfunction, insufficient intracellular PROTAC concentrations, and others [<xref rid="mco270401-bib-0438" ref-type="bibr">438</xref>, <xref rid="mco270401-bib-0439" ref-type="bibr">439</xref>]. Understanding these resistance mechanisms is crucial for designing next&#8208;generation PROTAC molecules and developing rational combination treatment strategies. By establishing resistant cell models and conducting genomic and proteomic analyses, researchers can identify key resistance drivers, providing molecular targets for overcoming resistance.</p></sec><sec id="mco270401-sec-0830"><label>7.5.2</label><title>Establishment of Predictive Biomarkers</title><p>Personalized PROTAC therapy requires establishment of effective predictive biomarker systems. These biomarkers should predict patient responsiveness to specific PROTAC treatments, including both efficacy and toxicity [<xref rid="mco270401-bib-0440" ref-type="bibr">440</xref>]. Candidate biomarkers include target protein expression levels, E3 ligase expression profiles, proteasome activity, genomic variations, and others. Through multiomics data integration analysis and machine learning methods, comprehensive predictive models can be constructed, providing scientific foundations for precision medicine applications of PROTAC therapy.</p></sec><sec id="mco270401-sec-0840"><label>7.5.3</label><title>Optimization of Combination Treatment Strategies</title><p>Combined application of PROTAC molecules with other therapeutic modalities holds tremendous potential. PROTACs can be combined with traditional chemotherapy drugs, targeted therapy drugs, immunotherapy drugs, radiotherapy, and others, improving therapeutic efficacy through synergistic actions of different mechanisms. For example, PROTAC degradation of antiapoptotic proteins can enhance chemotherapy sensitivity [<xref rid="mco270401-bib-0441" ref-type="bibr">441</xref>]; PROTAC degradation of immunosuppressive proteins can enhance immunotherapy efficacy [<xref rid="mco270401-bib-0442" ref-type="bibr">442</xref>]. Combination treatment strategy design requires consideration of drug interactions, administration timing, dose optimization, and other factors, necessitating validation through systematic preclinical studies and early clinical trials.</p></sec></sec><sec id="mco270401-sec-0850"><label>7.6</label><title>Expansion of Therapeutic Areas</title><sec id="mco270401-sec-0860"><label>7.6.1</label><title>Targeted Treatment of Inflammatory Diseases</title><p>Inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and systemic lupus erythematosus involve complex inflammatory signaling networks, with many key regulatory proteins difficult to target with traditional drugs [<xref rid="mco270401-bib-0443" ref-type="bibr">443</xref>]. PROTAC technology provides new intervention approaches for these &#8220;undruggable&#8221; inflammatory regulatory proteins [<xref rid="mco270401-bib-0159" ref-type="bibr">159</xref>]. For example, transcription factor NF&#8208;&#954;B, STAT family proteins, inflammation&#8208;related kinases, and others can serve as potential PROTAC targets. By degrading these key inflammatory regulatory proteins, PROTACs hold promise for achieving more precise and durable anti&#8208;inflammatory effects.</p></sec><sec id="mco270401-sec-0870"><label>7.6.2</label><title>Protein Homeostasis Regulation in Age&#8208;Related Diseases</title><p>The aging process is accompanied by functional decline of protein homeostasis systems, leading to accumulation of harmful proteins and loss of key functional proteins. PROTAC technology can exert antiaging effects by selectively degrading aging&#8208;related harmful proteins (such as key proteins in senescent cell antiapoptotic pathways). For example, PROTAC degraders of antiapoptotic proteins BCL&#8208;XL and BCL&#8208;2 have demonstrated significant antiaging effects [<xref rid="mco270401-bib-0444" ref-type="bibr">444</xref>]. Additionally, PROTACs may be used to degrade aging&#8208;related transcriptional regulators, metabolic enzymes, and others, providing new pharmacological intervention strategies for healthy aging and lifespan extension.</p></sec><sec id="mco270401-sec-0880"><label>7.6.3</label><title>Conquering Undruggable Targets in Metabolic Diseases</title><p>Metabolic diseases such as diabetes, obesity, and lipid metabolism disorders involve numerous metabolic regulatory proteins [<xref rid="mco270401-bib-0445" ref-type="bibr">445</xref>, <xref rid="mco270401-bib-0446" ref-type="bibr">446</xref>], many of which lack suitable small molecule binding pockets and are considered &#8220;undruggable&#8221; targets. PROTAC technology provides entirely new intervention strategies for these targets through protein degradation mechanisms. For example, transcription factor SREBP, metabolic enzyme HMGCR, nuclear receptors, and others can be targeted for degradation through PROTAC technology [<xref rid="mco270401-bib-0447" ref-type="bibr">447</xref>, <xref rid="mco270401-bib-0448" ref-type="bibr">448</xref>]. This approach not only effectively regulates metabolic pathways but may also avoid compensatory responses potentially generated by traditional inhibitors.</p><p>Future development of PROTAC technology will advance simultaneously along multiple dimensions, from fundamental molecular design optimization to complex clinical translation applications. Each developmental direction contains tremendous innovative potential. With continuous integration of cutting&#8208;edge technologies such as artificial intelligence, nanotechnology, and precision medicine, PROTACs are poised to become core technological platforms for next&#8208;generation precision therapy. However, realizing this vision requires close collaboration among academia, industry, and regulatory agencies to collectively propel PROTAC technology from laboratory to clinic, ultimately benefiting patients worldwide. The next decade will be a critical period for PROTAC technology development, and we have reason to believe that this revolutionary technology will bring unprecedented breakthroughs to human health endeavors.</p></sec></sec></sec><sec id="mco270401-sec-0890"><label>8</label><title>Conclusion and Prospects</title><sec id="mco270401-sec-0900"><label>8.1</label><title>Transformative Impact and Current Achievements</title><p>The development of PROTACs represents a paradigmatic shift in drug discovery, fundamentally altering our approach to therapeutic intervention from traditional occupancy&#8208;driven inhibition to event&#8208;driven protein degradation. This comprehensive analysis reveals that PROTAC technology has successfully transitioned from academic curiosity to clinical reality within just two decades, achieving unprecedented milestones that validate its revolutionary potential. The successful progression of multiple PROTAC candidates through clinical trials, with vepdegestrant (ARV&#8208;471) becoming the first to submit for US FDA approval based on Phase III data [<xref rid="mco270401-bib-0181" ref-type="bibr">181</xref>], demonstrates the technology's maturation and commercial viability. Across diverse therapeutic areas, from hormone&#8208;dependent cancers and hematologic malignancies to inflammatory diseases and neurodegenerative conditions, PROTACs have consistently demonstrated their unique ability to target previously &#8220;undruggable&#8221; proteins, including transcription factors like STAT3 and MYC [<xref rid="mco270401-bib-0449" ref-type="bibr">449</xref>], mutant oncoproteins such as KRAS G12C and BRAF V600E, and scaffolding proteins that lack conventional binding pockets [<xref rid="mco270401-bib-0450" ref-type="bibr">450</xref>]. The clinical landscape analysis reveals remarkable progress, with over 50 PROTAC candidates currently under evaluation across various phases, spanning critical targets including AR, ER, BTK, and numerous kinases and epigenetic modulators [<xref rid="mco270401-bib-0385" ref-type="bibr">385</xref>]. The breakthrough discovery of CD36&#8208;mediated [<xref rid="mco270401-bib-0402" ref-type="bibr">402</xref>] endocytic transport mechanisms has fundamentally resolved one of the field's most persistent challenges, cellular uptake of large, polar PROTAC molecules, opening new avenues for rational design and optimization. Furthermore, the development of innovative delivery strategies, including AOCs, tissue&#8208;specific formulations, and prodrug approaches, has significantly expanded the therapeutic window and reduced systemic toxicity concerns that initially limited clinical translation.</p></sec><sec id="mco270401-sec-0910"><label>8.2</label><title>Addressing Current Limitations and Emerging Solutions</title><p>Despite these remarkable achievements, PROTAC technology continues to face significant challenges that require systematic resolution for broader clinical adoption. The molecular weight and polarity constraints that limit oral bioavailability remain formidable obstacles, as evidenced by the relatively high doses required for many clinical candidates and the associated manufacturing complexities. The &#8220;hook effect&#8221; phenomenon, where excessive concentrations paradoxically reduce degradation efficiency, necessitates careful dose optimization and represents a unique pharmacological challenge not encountered with traditional therapeutics [<xref rid="mco270401-bib-0451" ref-type="bibr">451</xref>]. Additionally, the emergence of resistance mechanisms, while less common than with conventional inhibitors, poses long&#8208;term sustainability concerns that demand proactive investigation and mitigation strategies. However, the field is actively addressing these limitations through multiple innovative approaches. The integration of artificial intelligence and machine learning in PROTAC design is revolutionizing our ability to predict ternary complex stability, optimize linker geometry, and enhance target selectivity. The expansion of the E3 ligase toolbox beyond traditional CRBN and VHL systems is providing new opportunities for tissue&#8208;specific degradation and overcoming resistance mechanisms. Novel delivery technologies, including the chemical endocytic medicinal chemistry strategy based on CD36 transport, are systematically improving bioavailability while maintaining drug stability and potency. The development of reversible PROTACs, multitarget degraders, and conditional activation systems represents the next generation of sophisticated molecular tools that will further enhance therapeutic precision and safety profiles.</p></sec><sec id="mco270401-sec-0920"><label>8.3</label><title>Future Directions and Transformative Potential</title><p>Looking ahead, PROTAC technology stands poised to expand into entirely new therapeutic territories that were previously considered intractable. The successful targeting of cellular senescence pathways through selective degradation of antiapoptotic proteins opens unprecedented opportunities for addressing age&#8208;related diseases and extending healthspan. The development of brain&#8208;penetrant PROTACs promises to revolutionize treatment of neurodegenerative diseases, where protein aggregation and misfolding represent central pathological mechanisms. In autoimmune and inflammatory diseases, the ability to selectively degrade key regulatory proteins like IRAK4 and STAT6 offers more precise intervention strategies compared with broad immunosuppression [<xref rid="mco270401-bib-0452" ref-type="bibr">452</xref>, <xref rid="mco270401-bib-0453" ref-type="bibr">453</xref>]. The technological convergence of PROTAC platforms with emerging therapeutic modalities presents extraordinary synergistic potential. Combination strategies with immunotherapy, particularly through degradation of immunosuppressive proteins and immune checkpoint modulators, could fundamentally reshape cancer treatment paradigms. The integration of PROTAC technology with gene therapy and cell therapy approaches may enable unprecedented precision in therapeutic protein modulation. Furthermore, the development of organ&#8208;specific and disease&#8208;context&#8208;selective PROTACs will likely enable personalized medicine approaches based on individual E3 ligase expression profiles and proteasome activity patterns.</p></sec><sec id="mco270401-sec-0930"><label>8.4</label><title>Transforming Modern Medicine</title><p>The ultimate impact of PROTAC technology extends far beyond individual therapeutic applications, it represents a fundamental expansion of the druggable proteome and a new paradigm for addressing complex diseases. By enabling therapeutic intervention against proteins that have resisted conventional drug discovery efforts for decades, PROTACs are democratizing access to previously privileged targets and opening new avenues for treating rare diseases, cancer subtypes, and complex genetic disorders. The technology's unique ability to achieve catalytic, sub&#8208;stoichiometric effects while potentially reducing off&#8208;target toxicity positions it as a cornerstone of next&#8208;generation precision medicine.</p><p>As we stand at the threshold of the first PROTAC drug approvals, the field faces the exciting challenge of translating this revolutionary technology into broad clinical benefit. The successful resolution of current technical limitations, combined with continued innovation in molecular design, delivery strategies, and clinical application, will determine whether PROTACs fulfill their transformative potential. The convergence of advancing scientific understanding, technological sophistication, and clinical validation suggests that TPD will become an indispensable tool in the modern therapeutic arsenal, offering hope for patients with currently intractable diseases and fundamentally changing how we approach drug discovery and development in the decades to come. The journey from the first PROTAC entering clinical trials in 2019 to potential approval in 2025 represents not merely a technological achievement, but the dawn of a new era in medicine where the impossible becomes possible through the elegant manipulation of cellular protein homeostasis.</p></sec></sec><sec id="mco270401-sec-0940"><title>Author Contributions</title><p>M.L., Z.H.T., and J.Y. designed this study. G.F., S.L.C, Q.P.Z, N.Y. and Z.Y.S. collected related articles. G.F., S.L.C., Q.P.Z., N.Y., Z.Y.S., Z.J.L, and W.M.G. wrote the manuscript and completed the figures. M.L., Z.H.T., J.Y., and G.F. revised manuscripts and completed tables. G.F., Z.H.T. and J.Y. provided funding support. All authors reviewed and approved the final manuscript.</p></sec><sec id="mco270401-sec-0960"><title>Ethics Statement</title><p>The authors have nothing to report.</p></sec><sec sec-type="COI-statement" id="mco270401-sec-0970"><title>Conflicts of Interest</title><p>The authors disclose no conflicts of interest.</p></sec></body><back><ack id="mco270401-sec-0950"><title>Acknowledgments</title><p>This work is supported by the National Natural Science Foundation of China (82471623), Guangdong Natural Science Foundation (2025A1515010482), Shenzhen Medical Research Fund (A2403066), Shenzhen Natural Science Foundation (JCYJ20240813114423031), Shenzhen Nanshan District Science and Technology Plan Project (NSZD2023041), and the Key Project of the Hunan Provincial Natural Science Foundation University Joint Fund (2025JJ90128). We acknowledge BioRender.com for assisting in the creation of graphical figures.</p></ack><sec sec-type="data-availability" id="mco270401-sec-0990"><title>Data Availability Statement</title><p>No data were used for the research described in the article.</p></sec><ref-list id="mco270401-bibl-0001"><title>References</title><ref id="mco270401-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="mco270401-cit-0001"><string-name name-style="western"><given-names>J.</given-names><surname>Jin</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Wu</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Zhao</surname></string-name>, et&#160;al., &#8220;<article-title>Small&#8208;molecule PROTAC mediates targeted protein degradation to treat STAT3&#8208;dependent epithelial cancer</article-title>,&#8221; <source>JCI Insight</source><volume>7</volume>, no. <issue>22</issue> (<year>2022</year>): <elocation-id>e160606</elocation-id>.<pub-id pub-id-type="pmid">36509291</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/jci.insight.160606</pub-id><pub-id pub-id-type="pmcid">PMC9746828</pub-id></mixed-citation></ref><ref id="mco270401-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="mco270401-cit-0002"><string-name name-style="western"><given-names>A. A.</given-names><surname>Azad</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Gurney</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Underhill</surname></string-name>, et&#160;al., &#8220;<article-title>Phase 1 study of HP518, a PROTAC AR degrader in patients With mCRPC: Results on safety, pharmacokinetics, and anti&#8208;tumor activity</article-title>,&#8221; <source>Investigational New Drugs</source><volume>43</volume>, no. <issue>2</issue> (<year>2025</year>): <fpage>435</fpage>&#8211;<lpage>445</lpage>.<pub-id pub-id-type="pmid">40289067</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10637-025-01533-8</pub-id></mixed-citation></ref><ref id="mco270401-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="mco270401-cit-0003"><string-name name-style="western"><given-names>M. A.</given-names><surname>Maneiro</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Forte</surname></string-name>, <string-name name-style="western"><given-names>M. M.</given-names><surname>Shchepinova</surname></string-name>, et&#160;al., &#8220;<article-title>Antibody&#8211;PROTAC conjugates enable HER2&#8208;dependent targeted protein degradation of BRD4</article-title>,&#8221; <source>ACS Chemical Biology</source><volume>15</volume>, no. <issue>6</issue> (<year>2020</year>): <fpage>1306</fpage>&#8211;<lpage>1312</lpage>.<pub-id pub-id-type="pmid">32338867</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acschembio.0c00285</pub-id><pub-id pub-id-type="pmcid">PMC7309268</pub-id></mixed-citation></ref><ref id="mco270401-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="mco270401-cit-0004"><string-name name-style="western"><given-names>S. J.</given-names><surname>Heidorn</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Milagre</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Whittaker</surname></string-name>, et&#160;al., &#8220;<article-title>Kinase&#8208;dead BRAF and oncogenic RAS cooperate to drive tumor progression Through CRAF</article-title>,&#8221; <source>Cell</source><volume>140</volume>, no. <issue>2</issue> (<year>2010</year>): <fpage>209</fpage>&#8211;<lpage>221</lpage>.<pub-id pub-id-type="pmid">20141835</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2009.12.040</pub-id><pub-id pub-id-type="pmcid">PMC2872605</pub-id></mixed-citation></ref><ref id="mco270401-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="mco270401-cit-0005"><string-name name-style="western"><given-names>J. H.</given-names><surname>Bushweller</surname></string-name>, &#8220;<article-title>Targeting transcription factors in cancer&#8212;From undruggable to reality</article-title>,&#8221; <source>Nature Reviews Cancer</source><volume>19</volume>, no. <issue>11</issue> (<year>2019</year>): <fpage>611</fpage>&#8211;<lpage>624</lpage>.<pub-id pub-id-type="pmid">31511663</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41568-019-0196-7</pub-id><pub-id pub-id-type="pmcid">PMC8820243</pub-id></mixed-citation></ref><ref id="mco270401-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="mco270401-cit-0006"><string-name name-style="western"><given-names>M. J.</given-names><surname>Henley</surname></string-name> and <string-name name-style="western"><given-names>A. N.</given-names><surname>Koehler</surname></string-name>, &#8220;<article-title>Advances in targeting &#8216;undruggable&#8217;transcription factors With small molecules</article-title>,&#8221; <source>Nature Reviews Drug Discovery</source><volume>20</volume>, no. <issue>9</issue> (<year>2021</year>): <fpage>669</fpage>&#8211;<lpage>688</lpage>.<pub-id pub-id-type="pmid">34006959</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41573-021-00199-0</pub-id></mixed-citation></ref><ref id="mco270401-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="mco270401-cit-0007"><string-name name-style="western"><given-names>L.</given-names><surname>Shu</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Li</surname></string-name>, et&#160;al., &#8220;<article-title>NRG1 regulates Fra&#8208;1 transcription and metastasis of triple&#8208;negative breast cancer cells via the c&#8208;Myc ubiquitination as manipulated by ERK1/2&#8208;mediated Fbxw7 phosphorylation</article-title>,&#8221; <source>Oncogene</source><volume>41</volume>, no. <issue>6</issue> (<year>2022</year>): <fpage>907</fpage>&#8211;<lpage>919</lpage>.<pub-id pub-id-type="pmid">34992218</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41388-021-02142-4</pub-id></mixed-citation></ref><ref id="mco270401-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="mco270401-cit-0008"><string-name name-style="western"><given-names>A. L.</given-names><surname>Hopkins</surname></string-name> and <string-name name-style="western"><given-names>C. R.</given-names><surname>Groom</surname></string-name>, &#8220;<article-title>The druggable genome</article-title>,&#8221; <source>Nature Reviews Drug Discovery</source><volume>1</volume>, no. <issue>9</issue> (<year>2002</year>): <fpage>727</fpage>&#8211;<lpage>730</lpage>.<pub-id pub-id-type="pmid">12209152</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd892</pub-id></mixed-citation></ref><ref id="mco270401-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="mco270401-cit-0009"><string-name name-style="western"><given-names>A. D.</given-names><surname>Buhimschi</surname></string-name>, <string-name name-style="western"><given-names>H. A.</given-names><surname>Armstrong</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Toure</surname></string-name>, et&#160;al., &#8220;<article-title>Targeting the C481S ibrutinib&#8208;resistance mutation in Bruton's tyrosine kinase using PROTAC&#8208;mediated degradation</article-title>,&#8221; <source>Biochemistry</source><volume>57</volume>, no. <issue>26</issue> (<year>2018</year>): <fpage>3564</fpage>&#8211;<lpage>3575</lpage>.<pub-id pub-id-type="pmid">29851337</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.biochem.8b00391</pub-id></mixed-citation></ref><ref id="mco270401-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="mco270401-cit-0010"><string-name name-style="western"><given-names>Y.</given-names><surname>Sun</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Ding</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Song</surname></string-name>, et&#160;al., &#8220;<article-title>Degradation of Bruton's tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib&#8208;resistant non&#8208;Hodgkin lymphomas</article-title>,&#8221; <source>Leukemia</source><volume>33</volume>, no. <issue>8</issue> (<year>2019</year>): <fpage>2105</fpage>&#8211;<lpage>2110</lpage>.<pub-id pub-id-type="pmid">30858551</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41375-019-0440-x</pub-id></mixed-citation></ref><ref id="mco270401-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="mco270401-cit-0011"><string-name name-style="western"><given-names>Y. S.</given-names><surname>Arbel</surname></string-name>, <string-name name-style="western"><given-names>B.&#8208;Z.</given-names><surname>Katz</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Gabizon</surname></string-name>, et&#160;al., &#8220;<article-title>Proteolysis targeting chimeras for BTK efficiently inhibit B&#8208;cell receptor signaling and can overcome ibrutinib resistance in CLL cells</article-title>,&#8221; <source>Frontiers in Oncology</source><volume>11</volume> (<year>2021</year>): <elocation-id>646971</elocation-id>.<pub-id pub-id-type="pmid">34055615</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2021.646971</pub-id><pub-id pub-id-type="pmcid">PMC8159153</pub-id></mixed-citation></ref><ref id="mco270401-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="mco270401-cit-0012"><string-name name-style="western"><given-names>S.</given-names><surname>Cao</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Ma</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Liu</surname></string-name>, et&#160;al., &#8220;<article-title>Proteolysis&#8208;targeting chimera (PROTAC) modification of dovitinib enhances the antiproliferative effect Against FLT3&#8208;ITD&#8208;positive acute myeloid leukemia cells</article-title>,&#8221; <source>Journal of Medicinal Chemistry</source><volume>64</volume>, no. <issue>22</issue> (<year>2021</year>): <fpage>16497</fpage>&#8211;<lpage>16511</lpage>.<pub-id pub-id-type="pmid">34694800</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.1c00996</pub-id></mixed-citation></ref><ref id="mco270401-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="mco270401-cit-0013"><string-name name-style="western"><given-names>K. M.</given-names><surname>Sakamoto</surname></string-name>, <string-name name-style="western"><given-names>K. B.</given-names><surname>Kim</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Kumagai</surname></string-name>, et&#160;al., &#8220;<article-title>Protacs: Chimeric molecules that target proteins to the Skp1&#8211;Cullin&#8211;F box complex for ubiquitination and degradation</article-title>,&#8221; <source>Proceedings of the National Academy of Sciences of the United States of America</source><volume>98</volume>, no. <issue>15</issue> (<year>2001</year>): <fpage>8554</fpage>&#8211;<lpage>8559</lpage>.<pub-id pub-id-type="pmid">11438690</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.141230798</pub-id><pub-id pub-id-type="pmcid">PMC37474</pub-id></mixed-citation></ref><ref id="mco270401-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="mco270401-cit-0014"><string-name name-style="western"><given-names>D. P.</given-names><surname>Petrylak</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Gao</surname></string-name>, <string-name name-style="western"><given-names>N. J.</given-names><surname>Vogelzang</surname></string-name>, et&#160;al., &#8220;<article-title>First&#8208;in&#8208;human phase I study of ARV&#8208;110, an androgen receptor (AR) PROTAC degrader in patients (pts) With metastatic castrate&#8208;resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI)[Z]</article-title>,&#8221; <source>American Society of Clinical Oncology</source><volume>157</volume> (<year>2020</year>): <fpage>259</fpage>&#8211;<lpage>267</lpage>.</mixed-citation></ref><ref id="mco270401-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="mco270401-cit-0015"><string-name name-style="western"><given-names>C.</given-names><surname>Arnold</surname></string-name>, &#8220;<article-title>PROTAC protein degraders to drug the undruggable enter phase 3 trials</article-title>,&#8221; <source>Nature Medicine</source><volume>30</volume>, no. <issue>11</issue> (<year>2024</year>): <fpage>3030</fpage>&#8211;<lpage>3031</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/d41591-024-00072-8</pub-id><pub-id pub-id-type="pmid">39379566</pub-id></mixed-citation></ref><ref id="mco270401-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="mco270401-cit-0016"><string-name name-style="western"><given-names>S.</given-names><surname>Ha</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Luo</surname></string-name>, and <string-name name-style="western"><given-names>H.</given-names><surname>Xiang</surname></string-name>, &#8220;<article-title>A Comprehensive Overview of Small&#8208;Molecule Androgen Receptor Degraders: Recent Progress and Future Perspectives</article-title>,&#8221; <source>Journal of Medicinal Chemistry</source><volume>65</volume>, no. <issue>24</issue> (<year>2022</year>): <fpage>16128</fpage>&#8211;<lpage>16154</lpage>.<pub-id pub-id-type="pmid">36459083</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.2c01487</pub-id></mixed-citation></ref><ref id="mco270401-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="mco270401-cit-0017"><string-name name-style="western"><given-names>C.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Wang</surname></string-name>, and <string-name name-style="western"><given-names>D.</given-names><surname>Xing</surname></string-name>, &#8220;<article-title>VHL&#8208;based PROTACs as potential therapeutic agents: Recent progress and perspectives</article-title>,&#8221; <source>European Journal of Medicinal Chemistry</source><volume>227</volume> (<year>2022</year>): <elocation-id>113906</elocation-id>.<pub-id pub-id-type="pmid">34656901</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2021.113906</pub-id></mixed-citation></ref><ref id="mco270401-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="mco270401-cit-0018"><string-name name-style="western"><given-names>M.</given-names><surname>Hay</surname></string-name>, <string-name name-style="western"><given-names>D. W.</given-names><surname>Thomas</surname></string-name>, <string-name name-style="western"><given-names>J. L.</given-names><surname>Craighead</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Economides</surname></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Rosenthal</surname></string-name>, &#8220;<article-title>Clinical development success rates for investigational drugs</article-title>,&#8221; <source>Nature Biotechnology</source><volume>32</volume>, no. <issue>1</issue> (<year>2014</year>): <fpage>40</fpage>&#8211;<lpage>51</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nbt.2786</pub-id><pub-id pub-id-type="pmid">24406927</pub-id></mixed-citation></ref><ref id="mco270401-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="mco270401-cit-0019"><string-name name-style="western"><given-names>Y.&#8208;L.</given-names><surname>Tseng</surname></string-name>, <string-name name-style="western"><given-names>P.&#8208;C.</given-names><surname>Lu</surname></string-name>, <string-name name-style="western"><given-names>C.&#8208;C.</given-names><surname>Lee</surname></string-name>, et&#160;al., &#8220;<article-title>Degradation of neurodegenerative disease&#8208;associated TDP&#8208;43 aggregates and oligomers via a proteolysis&#8208;targeting chimera</article-title>,&#8221; <source>Journal of Biomedical Science</source><volume>30</volume>, no. <issue>1</issue> (<year>2023</year>): <fpage>27</fpage>.<pub-id pub-id-type="pmid">37101169</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12929-023-00921-7</pub-id><pub-id pub-id-type="pmcid">PMC10131537</pub-id></mixed-citation></ref><ref id="mco270401-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="mco270401-cit-0020"><string-name name-style="western"><given-names>X.</given-names><surname>Jiang</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Zhou</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Wang</surname></string-name>, et&#160;al., &#8220;<article-title>PROTACs suppression of GSK&#8208;3&#946;, a crucial kinase in neurodegenerative diseases</article-title>,&#8221; <source>European Journal of Medicinal Chemistry</source><volume>210</volume> (<year>2021</year>): <elocation-id>112949</elocation-id>.<pub-id pub-id-type="pmid">33097303</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2020.112949</pub-id></mixed-citation></ref><ref id="mco270401-bib-0021"><label>21</label><mixed-citation publication-type="miscellaneous" id="mco270401-cit-0021"><string-name name-style="western"><given-names>M.</given-names><surname>Peyman</surname></string-name>, <article-title>Study of new strategies for steatotic liver disease: SIRT1&#8208;mediated modulation of VLDLR levels and evaluation of a soluble epoxyde hydrolase&#8208;targeted PROTAC</article-title>. (<year>2024</year>).</mixed-citation></ref><ref id="mco270401-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="mco270401-cit-0022"><string-name name-style="western"><given-names>J.</given-names><surname>Huang</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Ma</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Yang</surname></string-name>, et&#160;al., &#8220;<article-title>Discovery of Ibrutinib&#8208;based BTK PROTACs With in vivo anti&#8208;inflammatory efficacy by inhibiting NF&#8208;&#954;B activation</article-title>,&#8221; <source>European Journal of Medicinal Chemistry</source><volume>259</volume> (<year>2023</year>): <elocation-id>115664</elocation-id>.<pub-id pub-id-type="pmid">37487306</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2023.115664</pub-id></mixed-citation></ref><ref id="mco270401-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="mco270401-cit-0023"><string-name name-style="western"><given-names>H.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Yuan</surname></string-name>, <string-name name-style="western"><given-names>Q.</given-names><surname>Zheng</surname></string-name>, et&#160;al., &#8220;<article-title>Dual inhibition of CDK4/6 and XPO1 induces senescence With acquired vulnerability to CRBN&#8208;based PROTAC drugs</article-title>,&#8221; <source>Gastroenterology</source><volume>166</volume>, no. <issue>6</issue> (<year>2024</year>): <fpage>1130</fpage>&#8211;<lpage>1144</lpage>. e1138.<pub-id pub-id-type="pmid">38262581</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2024.01.025</pub-id></mixed-citation></ref><ref id="mco270401-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="mco270401-cit-0024"><string-name name-style="western"><given-names>Y.</given-names><surname>Yang</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Jn&#8208;Simon</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>He</surname></string-name>, et&#160;al., &#8220;<article-title>A BCL&#8208;xL/BCL&#8208;2 PROTAC effectively clears senescent cells in the liver and reduces MASH&#8208;driven hepatocellular carcinoma in mice</article-title>,&#8221; <source>Nature Aging</source><volume>5</volume>, no. <issue>3</issue> (<year>2025</year>): <fpage>386</fpage>&#8211;<lpage>400</lpage>.<pub-id pub-id-type="pmid">39890936</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43587-025-00811-7</pub-id></mixed-citation></ref><ref id="mco270401-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="mco270401-cit-0025"><string-name name-style="western"><given-names>V.</given-names><surname>Reen</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>D'Ambrosio</surname></string-name>, and <string-name name-style="western"><given-names>P. P.</given-names><surname>S&#248;gaard</surname></string-name>, &#8220;<article-title>SMARCA4 regulates the NK&#8208;mediated killing of senescent cells</article-title>,&#8221; <source>Science Advances</source><volume>11</volume>, no. <issue>3</issue> (<year>2025</year>): <elocation-id>eadn2811</elocation-id>.<pub-id pub-id-type="pmid">39813356</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.adn2811</pub-id><pub-id pub-id-type="pmcid">PMC11734740</pub-id></mixed-citation></ref><ref id="mco270401-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="mco270401-cit-0026"><string-name name-style="western"><given-names>M.</given-names><surname>Chang</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Gao</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Gnawali</surname></string-name>, et&#160;al., &#8220;<article-title>Selective elimination of senescent cancer cells by galacto&#8208;modified PROTACs</article-title>,&#8221; <source>Journal of Medicinal Chemistry</source><volume>67</volume>, no. <issue>9</issue> (<year>2024</year>): <fpage>7301</fpage>&#8211;<lpage>7311</lpage>.<pub-id pub-id-type="pmid">38635879</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.4c00152</pub-id><pub-id pub-id-type="pmcid">PMC11227109</pub-id></mixed-citation></ref><ref id="mco270401-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="mco270401-cit-0027"><string-name name-style="western"><given-names>N. Y.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>D. Y.</given-names><surname>Hou</surname></string-name>, <string-name name-style="western"><given-names>X. J.</given-names><surname>Hu</surname></string-name>, et&#160;al., &#8220;<article-title>Nano proteolysis targeting chimeras (PROTACs) With anti&#8208;hook effect for tumor therapy</article-title>,&#8221; <source>Angewandte Chemie International Edition</source><volume>62</volume>, no. <issue>37</issue> (<year>2023</year>): <elocation-id>e202308049</elocation-id>.<pub-id pub-id-type="pmid">37486792</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/anie.202308049</pub-id></mixed-citation></ref><ref id="mco270401-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="mco270401-cit-0028"><string-name name-style="western"><given-names>K.</given-names><surname>Moreau</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Coen</surname></string-name>, <string-name name-style="western"><given-names>A. X.</given-names><surname>Zhang</surname></string-name>, et&#160;al., &#8220;<article-title>Proteolysis&#8208;targeting chimeras in drug development: A safety perspective</article-title>,&#8221; <source>British Journal of Pharmacology</source><volume>177</volume>, no. <issue>8</issue> (<year>2020</year>): <fpage>1709</fpage>&#8211;<lpage>1718</lpage>.<pub-id pub-id-type="pmid">32022252</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bph.15014</pub-id><pub-id pub-id-type="pmcid">PMC7070175</pub-id></mixed-citation></ref><ref id="mco270401-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="mco270401-cit-0029"><string-name name-style="western"><given-names>K.</given-names><surname>Li</surname></string-name> and <string-name name-style="western"><given-names>C. M.</given-names><surname>Crews</surname></string-name>, &#8220;<article-title>PROTACs: Past, present and future</article-title>,&#8221; <source>Chemical Society Reviews</source><volume>51</volume>, no. <issue>12</issue> (<year>2022</year>): <fpage>5214</fpage>&#8211;<lpage>5236</lpage>.<pub-id pub-id-type="pmid">35671157</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/d2cs00193d</pub-id><pub-id pub-id-type="pmcid">PMC10237031</pub-id></mixed-citation></ref><ref id="mco270401-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="mco270401-cit-0030"><string-name name-style="western"><given-names>L. M.</given-names><surname>Simpson</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Glennie</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Brewer</surname></string-name>, et&#160;al., &#8220;<article-title>Target protein localization and its impact on PROTAC&#8208;mediated degradation</article-title>,&#8221; <source>Cell Chemical Biology</source><volume>29</volume>, no. <issue>10</issue> (<year>2022</year>): <fpage>1482</fpage>&#8211;<lpage>1504</lpage>. e1487.<pub-id pub-id-type="pmid">36075213</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chembiol.2022.08.004</pub-id></mixed-citation></ref><ref id="mco270401-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="mco270401-cit-0031"><string-name name-style="western"><given-names>D. C.</given-names><surname>Scott</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Dharuman</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Griffith</surname></string-name>, et&#160;al., &#8220;<article-title>Principles of paralog&#8208;specific targeted protein degradation engaging the C&#8208;degron E3 KLHDC2</article-title>,&#8221; <source>Nature Communications</source><volume>15</volume>, no. <issue>1</issue> (<year>2024</year>): <fpage>8829</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-024-52966-3</pub-id><pub-id pub-id-type="pmcid">PMC11470957</pub-id><pub-id pub-id-type="pmid">39396041</pub-id></mixed-citation></ref><ref id="mco270401-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="mco270401-cit-0032"><string-name name-style="western"><given-names>R.</given-names><surname>Beveridge</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Kessler</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Rumpel</surname></string-name>, et&#160;al., &#8220;<article-title>Native Mass Spectrometry Can Effectively Predict PROTAC Efficacy</article-title>,&#8221; <source>ACS Central Science</source><volume>6</volume>, no. <issue>7</issue> (<year>2020</year>): <fpage>1223</fpage>&#8211;<lpage>1230</lpage>.<pub-id pub-id-type="pmid">32724856</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acscentsci.0c00049</pub-id><pub-id pub-id-type="pmcid">PMC7379389</pub-id></mixed-citation></ref><ref id="mco270401-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="mco270401-cit-0033"><string-name name-style="western"><given-names>M. S.</given-names><surname>Gadd</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Testa</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Lucas</surname></string-name>, et&#160;al., &#8220;<article-title>Structural basis of PROTAC cooperative recognition for selective protein degradation</article-title>,&#8221; <source>Nature Chemical Biology</source><volume>13</volume>, no. <issue>5</issue> (<year>2017</year>): <fpage>514</fpage>&#8211;<lpage>521</lpage>.<pub-id pub-id-type="pmid">28288108</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nchembio.2329</pub-id><pub-id pub-id-type="pmcid">PMC5392356</pub-id></mixed-citation></ref><ref id="mco270401-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="mco270401-cit-0034"><string-name name-style="western"><given-names>V.</given-names><surname>Haridas</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Dutta</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Munjal</surname></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Singh</surname></string-name>, &#8220;<article-title>Inhibitors to degraders: Changing paradigm in drug discovery</article-title>,&#8221; <source>Iscience</source><volume>27</volume>, no. <issue>5</issue> (<year>2024</year>): <elocation-id>109574</elocation-id>.<pub-id pub-id-type="pmid">38646175</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.isci.2024.109574</pub-id><pub-id pub-id-type="pmcid">PMC11031827</pub-id></mixed-citation></ref><ref id="mco270401-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="mco270401-cit-0035"><string-name name-style="western"><given-names>X.</given-names><surname>Teng</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Zhao</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Dai</surname></string-name>, et&#160;al., &#8220;<article-title>ClickRNA&#8208;PROTAC for Tumor&#8208;Selective Protein Degradation and Targeted Cancer Therapy</article-title>,&#8221; <source>Journal of the American Chemical Society</source><volume>146</volume>, no. <issue>40</issue> (<year>2024</year>): <fpage>27382</fpage>&#8211;<lpage>27391</lpage>.<pub-id pub-id-type="pmid">39320981</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jacs.4c06402</pub-id></mixed-citation></ref><ref id="mco270401-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="mco270401-cit-0036"><string-name name-style="western"><given-names>Y. Y.</given-names><surname>Shi</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Fan</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Tan</surname></string-name>, et&#160;al., &#8220;<article-title>Treating ICB&#8208;resistant cancer by inhibiting PD&#8208;L1 via DHHC3 degradation induced by cell penetrating peptide&#8208;induced chimera conjugates</article-title>,&#8221; <source>Cell Death and Disease</source><volume>15</volume>, no. <issue>9</issue> (<year>2024</year>): <fpage>701</fpage>.<pub-id pub-id-type="pmid">39349454</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-024-07073-y</pub-id><pub-id pub-id-type="pmcid">PMC11442653</pub-id></mixed-citation></ref><ref id="mco270401-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="mco270401-cit-0037"><string-name name-style="western"><given-names>Y.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Xia</surname></string-name>, <string-name name-style="western"><given-names>U.</given-names><surname>Suwal</surname></string-name>, et&#160;al., &#8220;<article-title>Dual&#8208;ligand PROTACS mediate superior target protein degradation in vitro and therapeutic efficacy in vivo</article-title>,&#8221; <source>Chemical Science</source><volume>15</volume>, no. <issue>42</issue> (<year>2024</year>): <fpage>17691</fpage>&#8211;<lpage>17701</lpage>.<pub-id pub-id-type="pmid">39391379</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/d4sc03555k</pub-id><pub-id pub-id-type="pmcid">PMC11462456</pub-id></mixed-citation></ref><ref id="mco270401-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="mco270401-cit-0038"><string-name name-style="western"><given-names>D.</given-names><surname>Park</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Izaguirre</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Coffey</surname></string-name>, and <string-name name-style="western"><given-names>H.</given-names><surname>Xu</surname></string-name>, &#8220;<article-title>Modeling the Effect of Cooperativity in Ternary Complex Formation and Targeted Protein Degradation Mediated by Heterobifunctional Degraders</article-title>,&#8221; <source>ACS Bio Med Chem Au</source><volume>3</volume>, no. <issue>1</issue> (<year>2023</year>): <fpage>74</fpage>&#8211;<lpage>86</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsbiomedchemau.2c00037</pub-id><pub-id pub-id-type="pmcid">PMC10125322</pub-id><pub-id pub-id-type="pmid">37101604</pub-id></mixed-citation></ref><ref id="mco270401-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="mco270401-cit-0039"><string-name name-style="western"><given-names>S.</given-names><surname>Shi</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Du</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Zou</surname></string-name>, et&#160;al., &#8220;<article-title>Rational Design for Nitroreductase (NTR)&#8208;Responsive Proteolysis Targeting Chimeras (PROTACs) Selectively Targeting Tumor Tissues</article-title>,&#8221; <source>Journal of Medicinal Chemistry</source><volume>65</volume>, no. <issue>6</issue> (<year>2022</year>): <fpage>5057</fpage>&#8211;<lpage>5071</lpage>.<pub-id pub-id-type="pmid">35175763</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.1c02221</pub-id></mixed-citation></ref><ref id="mco270401-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="mco270401-cit-0040"><string-name name-style="western"><given-names>D. P.</given-names><surname>Bondeson</surname></string-name>, <string-name name-style="western"><given-names>B. E.</given-names><surname>Smith</surname></string-name>, <string-name name-style="western"><given-names>G. M.</given-names><surname>Burslem</surname></string-name>, et&#160;al., &#8220;<article-title>Lessons in PROTAC Design From Selective Degradation With a Promiscuous Warhead</article-title>,&#8221; <source>Cell Chemical Biology</source><volume>25</volume>, no. <issue>1</issue> (<year>2018</year>): <fpage>78</fpage>&#8211;<lpage>87</lpage>. e75.<pub-id pub-id-type="pmid">29129718</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chembiol.2017.09.010</pub-id><pub-id pub-id-type="pmcid">PMC5777153</pub-id></mixed-citation></ref><ref id="mco270401-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="mco270401-cit-0041"><string-name name-style="western"><given-names>M.</given-names><surname>Ignatov</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Jindal</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Kotelnikov</surname></string-name>, et&#160;al., &#8220;<article-title>High Accuracy Prediction of PROTAC Complex Structures</article-title>,&#8221; <source>Journal of the American Chemical Society</source><volume>145</volume>, no. <issue>13</issue> (<year>2023</year>): <fpage>7123</fpage>&#8211;<lpage>7135</lpage>.<pub-id pub-id-type="pmid">36961978</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jacs.2c09387</pub-id><pub-id pub-id-type="pmcid">PMC10240388</pub-id></mixed-citation></ref><ref id="mco270401-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="mco270401-cit-0042"><string-name name-style="western"><given-names>H.</given-names><surname>Nassar</surname></string-name>, <string-name name-style="western"><given-names>A. C.</given-names><surname>Sarnow</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Celik</surname></string-name>, et&#160;al., &#8220;<article-title>Ternary Complex Modeling, Induced Fit Docking and Molecular Dynamics Simulations as a Successful Approach for the Design of VHL&#8208;Mediated PROTACs Targeting the Kinase FLT3</article-title>,&#8221; <source>Archiv der Pharmazie &#8208; Chemistry in Life Sciences</source><volume>358</volume>, no. <issue>4</issue> (<year>2025</year>): <elocation-id>e3126</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ardp.202500102</pub-id><pub-id pub-id-type="pmcid">PMC11995253</pub-id><pub-id pub-id-type="pmid">40223615</pub-id></mixed-citation></ref><ref id="mco270401-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="mco270401-cit-0043"><string-name name-style="western"><given-names>D.</given-names><surname>Weerakoon</surname></string-name>, <string-name name-style="western"><given-names>R. J.</given-names><surname>Carbajo</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>De Maria</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Tyrchan</surname></string-name>, and <string-name name-style="western"><given-names>H.</given-names><surname>Zhao</surname></string-name>, &#8220;<article-title>Impact of PROTAC Linker Plasticity on the Solution Conformations and Dissociation of the Ternary Complex</article-title>,&#8221; <source>Journal of Chemical Information and Modeling</source><volume>62</volume>, no. <issue>2</issue> (<year>2022</year>): <fpage>340</fpage>&#8211;<lpage>349</lpage>.<pub-id pub-id-type="pmid">35018781</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jcim.1c01036</pub-id></mixed-citation></ref><ref id="mco270401-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="mco270401-cit-0044"><string-name name-style="western"><given-names>J. S.</given-names><surname>Schneekloth</surname><suffix>Jr.</suffix></string-name>, <string-name name-style="western"><given-names>F. N.</given-names><surname>Fonseca</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Koldobskiy</surname></string-name>, et&#160;al., &#8220;<article-title>Chemical genetic control of protein levels: Selective in vivo targeted degradation</article-title>,&#8221; <source>Journal of the American Chemical Society</source><volume>126</volume>, no. <issue>12</issue> (<year>2004</year>): <fpage>3748</fpage>&#8211;<lpage>3754</lpage>.<pub-id pub-id-type="pmid">15038727</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/ja039025z</pub-id></mixed-citation></ref><ref id="mco270401-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="mco270401-cit-0045"><string-name name-style="western"><given-names>G. E.</given-names><surname>Winter</surname></string-name>, <string-name name-style="western"><given-names>D. L.</given-names><surname>Buckley</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Paulk</surname></string-name>, et&#160;al., &#8220;<article-title>Drug Development. Phthalimide conjugation as a strategy for in vivo target protein degradation</article-title>,&#8221; <source>Science</source><volume>348</volume>, no. <issue>6241</issue> (<year>2015</year>): <fpage>1376</fpage>&#8211;<lpage>1381</lpage>.<pub-id pub-id-type="pmid">25999370</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aab1433</pub-id><pub-id pub-id-type="pmcid">PMC4937790</pub-id></mixed-citation></ref><ref id="mco270401-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="mco270401-cit-0046"><string-name name-style="western"><given-names>K.</given-names><surname>Raina</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Lu</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Qian</surname></string-name>, et&#160;al., &#8220;<article-title>PROTAC&#8208;induced BET protein degradation as a therapy for castration&#8208;resistant prostate cancer</article-title>,&#8221; <source>Proceedings of the National Academy of Sciences of the United States of America</source><volume>113</volume>, no. <issue>26</issue> (<year>2016</year>): <fpage>7124</fpage>&#8211;<lpage>7129</lpage>.<pub-id pub-id-type="pmid">27274052</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1521738113</pub-id><pub-id pub-id-type="pmcid">PMC4932933</pub-id></mixed-citation></ref><ref id="mco270401-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="mco270401-cit-0047"><string-name name-style="western"><given-names>X.</given-names><surname>Han</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Qin</surname></string-name>, et&#160;al., &#8220;<article-title>Discovery of ARD&#8208;69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer</article-title>,&#8221; <source>Journal of Medicinal Chemistry</source><volume>62</volume>, no. <issue>2</issue> (<year>2019</year>): <fpage>941</fpage>&#8211;<lpage>964</lpage>.<pub-id pub-id-type="pmid">30629437</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.8b01631</pub-id></mixed-citation></ref><ref id="mco270401-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="mco270401-cit-0048"><string-name name-style="western"><given-names>R. G.</given-names><surname>Guenette</surname></string-name>, <string-name name-style="western"><given-names>S. W.</given-names><surname>Yang</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Min</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Pei</surname></string-name>, and <string-name name-style="western"><given-names>P. R.</given-names><surname>Potts</surname></string-name>, &#8220;<article-title>Target and tissue selectivity of PROTAC degraders</article-title>,&#8221; <source>Chemical Society Reviews</source><volume>51</volume>, no. <issue>14</issue> (<year>2022</year>): <fpage>5740</fpage>&#8211;<lpage>5756</lpage>.<pub-id pub-id-type="pmid">35587208</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/d2cs00200k</pub-id></mixed-citation></ref><ref id="mco270401-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="mco270401-cit-0049"><string-name name-style="western"><given-names>S.</given-names><surname>Park</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Kim</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Lee</surname></string-name>, et&#160;al., &#8220;<article-title>Discovery of pan&#8208;IAP degraders via a CRBN recruiting mechanism</article-title>,&#8221; <source>European Journal of Medicinal Chemistry</source><volume>245</volume>, no. <issue>Pt 2</issue> (<year>2023</year>): <elocation-id>114910</elocation-id>.<pub-id pub-id-type="pmid">36410083</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2022.114910</pub-id></mixed-citation></ref><ref id="mco270401-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="mco270401-cit-0050"><string-name name-style="western"><given-names>J.</given-names><surname>Hines</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Lartigue</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Dong</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Qian</surname></string-name>, and <string-name name-style="western"><given-names>C. M.</given-names><surname>Crews</surname></string-name>, &#8220;<article-title>MDM2&#8208;Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53</article-title>,&#8221; <source>Cancer Research</source><volume>79</volume>, no. <issue>1</issue> (<year>2019</year>): <fpage>251</fpage>&#8211;<lpage>262</lpage>.<pub-id pub-id-type="pmid">30385614</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-18-2918</pub-id><pub-id pub-id-type="pmcid">PMC6318015</pub-id></mixed-citation></ref><ref id="mco270401-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="mco270401-cit-0051"><string-name name-style="western"><given-names>X.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>V. M.</given-names><surname>Crowley</surname></string-name>, <string-name name-style="western"><given-names>T. G.</given-names><surname>Wucherpfennig</surname></string-name>, <string-name name-style="western"><given-names>M. M.</given-names><surname>Dix</surname></string-name>, and <string-name name-style="western"><given-names>B. F.</given-names><surname>Cravatt</surname></string-name>, &#8220;<article-title>Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16</article-title>,&#8221; <source>Nature Chemical Biology</source><volume>15</volume>, no. <issue>7</issue> (<year>2019</year>): <fpage>737</fpage>&#8211;<lpage>746</lpage>.<pub-id pub-id-type="pmid">31209349</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41589-019-0279-5</pub-id><pub-id pub-id-type="pmcid">PMC6592777</pub-id></mixed-citation></ref><ref id="mco270401-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="mco270401-cit-0052"><string-name name-style="western"><given-names>S.</given-names><surname>He</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Ma</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Fang</surname></string-name>, et&#160;al., &#8220;<article-title>Homo&#8208;PROTAC mediated suicide of MDM2 to treat non&#8208;small cell lung cancer</article-title>,&#8221; <source>Acta Pharmaceutica Sinica B</source><volume>11</volume>, no. <issue>6</issue> (<year>2021</year>): <fpage>1617</fpage>&#8211;<lpage>1628</lpage>.<pub-id pub-id-type="pmid">34221872</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2020.11.022</pub-id><pub-id pub-id-type="pmcid">PMC8245912</pub-id></mixed-citation></ref><ref id="mco270401-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="mco270401-cit-0053"><string-name name-style="western"><given-names>G. M.</given-names><surname>Burslem</surname></string-name>, <string-name name-style="western"><given-names>B. E.</given-names><surname>Smith</surname></string-name>, <string-name name-style="western"><given-names>A. C.</given-names><surname>Lai</surname></string-name>, et&#160;al., &#8220;<article-title>The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study</article-title>,&#8221; <source>Cell Chemical Biology</source><volume>25</volume>, no. <issue>1</issue> (<year>2018</year>): <fpage>67</fpage>&#8211;<lpage>77</lpage>. e63.<pub-id pub-id-type="pmid">29129716</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chembiol.2017.09.009</pub-id><pub-id pub-id-type="pmcid">PMC5831399</pub-id></mixed-citation></ref><ref id="mco270401-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="mco270401-cit-0054"><string-name name-style="western"><given-names>M.</given-names><surname>B&#233;k&#233;s</surname></string-name>, <string-name name-style="western"><given-names>D. R.</given-names><surname>Langley</surname></string-name>, and <string-name name-style="western"><given-names>C. M.</given-names><surname>Crews</surname></string-name>, &#8220;<article-title>PROTAC targeted protein degraders: The Past is prologue</article-title>,&#8221; <source>Nature Reviews Drug Discovery</source><volume>21</volume>, no. <issue>3</issue> (<year>2022</year>): <fpage>181</fpage>&#8211;<lpage>200</lpage>.<pub-id pub-id-type="pmid">35042991</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41573-021-00371-6</pub-id><pub-id pub-id-type="pmcid">PMC8765495</pub-id></mixed-citation></ref><ref id="mco270401-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="mco270401-cit-0055"><string-name name-style="western"><given-names>D.</given-names><surname>Antermite</surname></string-name>, <string-name name-style="western"><given-names>S. D.</given-names><surname>Friis</surname></string-name>, <string-name name-style="western"><given-names>J. R.</given-names><surname>Johansson</surname></string-name>, et&#160;al., &#8220;<article-title>Late&#8208;stage synthesis of heterobifunctional molecules for PROTAC applications via ruthenium&#8208;catalysed C&#8210;H amidation</article-title>,&#8221; <source>Nature Communications</source><volume>14</volume>, no. <issue>1</issue> (<year>2023</year>): <fpage>8222</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-43789-9</pub-id><pub-id pub-id-type="pmcid">PMC10716378</pub-id><pub-id pub-id-type="pmid">38086825</pub-id></mixed-citation></ref><ref id="mco270401-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="mco270401-cit-0056"><string-name name-style="western"><given-names>M.</given-names><surname>Surowka</surname></string-name> and <string-name name-style="western"><given-names>C.</given-names><surname>Klein</surname></string-name>, &#8220;<article-title>A pivotal decade for bispecific antibodies?</article-title>,&#8221; <source>Mabs</source><volume>16</volume>, no. <issue>1</issue> (<year>2024</year>): <elocation-id>2321635</elocation-id>.<pub-id pub-id-type="pmid">38465614</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/19420862.2024.2321635</pub-id><pub-id pub-id-type="pmcid">PMC10936642</pub-id></mixed-citation></ref><ref id="mco270401-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="mco270401-cit-0057"><string-name name-style="western"><given-names>Z.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Hu</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Yang</surname></string-name>, et&#160;al., &#8220;<article-title>An overview of PROTACs: A promising drug discovery paradigm</article-title>,&#8221; <source>Molecular Biomedicine</source><volume>3</volume>, no. <issue>1</issue> (<year>2022</year>): <fpage>46</fpage>.<pub-id pub-id-type="pmid">36536188</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s43556-022-00112-0</pub-id><pub-id pub-id-type="pmcid">PMC9763089</pub-id></mixed-citation></ref><ref id="mco270401-bib-0058"><label>58</label><mixed-citation publication-type="journal" id="mco270401-cit-0058"><string-name name-style="western"><given-names>W.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>Q.</given-names><surname>Zhou</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Jiang</surname></string-name>, et&#160;al., &#8220;<article-title>A novel small&#8208;molecule PROTAC selectively promotes tau clearance to improve cognitive functions in Alzheimer&#8208;Like models</article-title>,&#8221; <source>Theranostics</source><volume>11</volume>, no. <issue>11</issue> (<year>2021</year>): <fpage>5279</fpage>&#8211;<lpage>5295</lpage>.<pub-id pub-id-type="pmid">33859747</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.55680</pub-id><pub-id pub-id-type="pmcid">PMC8039949</pub-id></mixed-citation></ref><ref id="mco270401-bib-0059"><label>59</label><mixed-citation publication-type="journal" id="mco270401-cit-0059"><string-name name-style="western"><given-names>P.</given-names><surname>Pfaff</surname></string-name>, <string-name name-style="western"><given-names>K. T. G.</given-names><surname>Samarasinghe</surname></string-name>, <string-name name-style="western"><given-names>C. M.</given-names><surname>Crews</surname></string-name>, and <string-name name-style="western"><given-names>E. M.</given-names><surname>Carreira</surname></string-name>, &#8220;<article-title>Reversible Spatiotemporal Control of Induced Protein Degradation by Bistable PhotoPROTACs</article-title>,&#8221; <source>ACS Central Science</source><volume>5</volume>, no. <issue>10</issue> (<year>2019</year>): <fpage>1682</fpage>&#8211;<lpage>1690</lpage>.<pub-id pub-id-type="pmid">31660436</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acscentsci.9b00713</pub-id><pub-id pub-id-type="pmcid">PMC6813558</pub-id></mixed-citation></ref><ref id="mco270401-bib-0060"><label>60</label><mixed-citation publication-type="journal" id="mco270401-cit-0060"><string-name name-style="western"><given-names>X.</given-names><surname>Sun</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Gao</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Yang</surname></string-name>, et&#160;al., &#8220;<article-title>PROTACs: Great opportunities for academia and industry</article-title>,&#8221; <source>Signal Transduction and Targeted Therapy</source><volume>4</volume> (<year>2019</year>): <fpage>64</fpage>.<pub-id pub-id-type="pmid">31885879</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-019-0101-6</pub-id><pub-id pub-id-type="pmcid">PMC6927964</pub-id></mixed-citation></ref><ref id="mco270401-bib-0061"><label>61</label><mixed-citation publication-type="journal" id="mco270401-cit-0061"><string-name name-style="western"><given-names>H.</given-names><surname>Zhou</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Zhou</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Yu</surname></string-name>, et&#160;al., &#8220;<article-title>Targeted Protein Degradation by KLHDC2 Ligands Identified by High Throughput Screening</article-title>,&#8221; <source>BioRxiv</source> (<year>2025</year>).<pub-id pub-id-type="doi" assigning-authority="pmc">10.7554/eLife.106844</pub-id><pub-id pub-id-type="pmcid">PMC12169847</pub-id><pub-id pub-id-type="pmid">40522120</pub-id></mixed-citation></ref><ref id="mco270401-bib-0062"><label>62</label><mixed-citation publication-type="journal" id="mco270401-cit-0062"><string-name name-style="western"><given-names>J.</given-names><surname>Gao</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Yang</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Lei</surname></string-name>, et&#160;al., &#8220;<article-title>Stimuli&#8208;activatable PROTACs for precise protein degradation and cancer therapy</article-title>,&#8221; <source>Science Bulletin (Beijing)</source><volume>68</volume>, no. <issue>10</issue> (<year>2023</year>): <fpage>1069</fpage>&#8211;<lpage>1085</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.scib.2023.04.028</pub-id><pub-id pub-id-type="pmid">37169612</pub-id></mixed-citation></ref><ref id="mco270401-bib-0063"><label>63</label><mixed-citation publication-type="journal" id="mco270401-cit-0063"><string-name name-style="western"><given-names>T. A.</given-names><surname>Lee</surname></string-name>, <string-name name-style="western"><given-names>E. Y.</given-names><surname>Tsai</surname></string-name>, <string-name name-style="western"><given-names>S. H.</given-names><surname>Liu</surname></string-name>, et&#160;al., &#8220;<article-title>Post&#8208;translational Modification of PD&#8208;1: Potential Targets for Cancer Immunotherapy</article-title>,&#8221; <source>Cancer Research</source><volume>84</volume>, no. <issue>6</issue> (<year>2024</year>): <fpage>800</fpage>&#8211;<lpage>807</lpage>.<pub-id pub-id-type="pmid">38231470</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-23-2664</pub-id><pub-id pub-id-type="pmcid">PMC10940856</pub-id></mixed-citation></ref><ref id="mco270401-bib-0064"><label>64</label><mixed-citation publication-type="journal" id="mco270401-cit-0064"><string-name name-style="western"><given-names>L.</given-names><surname>Mittal</surname></string-name>, <string-name name-style="western"><given-names>R. K.</given-names><surname>Tonk</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Awasthi</surname></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Asthana</surname></string-name>, &#8220;<article-title>Targeting cryptic&#8208;orthosteric site of PD&#8208;L1 for inhibitor identification using structure&#8208;guided approach</article-title>,&#8221; <source>Archives of Biochemistry and Biophysics</source><volume>713</volume> (<year>2021</year>): <elocation-id>109059</elocation-id>.<pub-id pub-id-type="pmid">34673001</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.abb.2021.109059</pub-id></mixed-citation></ref><ref id="mco270401-bib-0065"><label>65</label><mixed-citation publication-type="journal" id="mco270401-cit-0065"><string-name name-style="western"><given-names>R. V.</given-names><surname>Mancuso</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Welzenbach</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Steinberger</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Kr&#228;henb&#252;hl</surname></string-name>, and <string-name name-style="western"><given-names>G.</given-names><surname>Weitz&#8208;Schmidt</surname></string-name>, &#8220;<article-title>Downstream effect profiles discern different mechanisms of integrin &#945;L&#946;2 inhibition</article-title>,&#8221; <source>Biochemical Pharmacology</source><volume>119</volume> (<year>2016</year>): <fpage>42</fpage>&#8211;<lpage>55</lpage>.<pub-id pub-id-type="pmid">27613223</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bcp.2016.09.002</pub-id></mixed-citation></ref><ref id="mco270401-bib-0066"><label>66</label><mixed-citation publication-type="journal" id="mco270401-cit-0066"><string-name name-style="western"><given-names>P. S.</given-names><surname>Dragovich</surname></string-name>, <string-name name-style="western"><given-names>T. H.</given-names><surname>Pillow</surname></string-name>, <string-name name-style="western"><given-names>R. A.</given-names><surname>Blake</surname></string-name>, et&#160;al., &#8220;<article-title>Antibody&#8208;Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy</article-title>,&#8221; <source>Journal of Medicinal Chemistry</source><volume>64</volume>, no. <issue>5</issue> (<year>2021</year>): <fpage>2576</fpage>&#8211;<lpage>2607</lpage>.<pub-id pub-id-type="pmid">33596073</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.0c01846</pub-id></mixed-citation></ref><ref id="mco270401-bib-0067"><label>67</label><mixed-citation publication-type="journal" id="mco270401-cit-0067"><string-name name-style="western"><given-names>A.</given-names><surname>Ikeuchi</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Nakano</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Kamiya</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Yamane</surname></string-name>, and <string-name name-style="western"><given-names>Y.</given-names><surname>Kawarasaki</surname></string-name>, &#8220;<article-title>A method for reverse interactome analysis: High&#8208;resolution mapping of interdomain interaction network in Dam1 complex and its specific disorganization based on the interaction domain expression</article-title>,&#8221; <source>Biotechnology Progress</source><volume>26</volume>, no. <issue>4</issue> (<year>2010</year>): <fpage>945</fpage>&#8211;<lpage>953</lpage>.<pub-id pub-id-type="pmid">20730753</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/btpr.403</pub-id></mixed-citation></ref><ref id="mco270401-bib-0068"><label>68</label><mixed-citation publication-type="journal" id="mco270401-cit-0068"><string-name name-style="western"><given-names>H.</given-names><surname>Oh</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Lee</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Oh</surname></string-name>, et&#160;al., &#8220;<article-title>Kv7/KCNQ potassium channels in cortical hyperexcitability and juvenile seizure&#8208;related death in Ank2&#8208;mutant mice</article-title>,&#8221; <source>Nature Communications</source><volume>14</volume>, no. <issue>1</issue> (<year>2023</year>): <fpage>3547</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-39203-z</pub-id><pub-id pub-id-type="pmcid">PMC10272139</pub-id><pub-id pub-id-type="pmid">37321992</pub-id></mixed-citation></ref><ref id="mco270401-bib-0069"><label>69</label><mixed-citation publication-type="journal" id="mco270401-cit-0069"><string-name name-style="western"><given-names>N. H.</given-names><surname>Murray</surname></string-name>, <string-name name-style="western"><given-names>C. R. M.</given-names><surname>Asquith</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Fang</surname></string-name>, et&#160;al., &#8220;<article-title>Small&#8208;molecule inhibition of the archetypal UbiB protein COQ8</article-title>,&#8221; <source>Nature Chemical Biology</source><volume>19</volume>, no. <issue>2</issue> (<year>2023</year>): <fpage>230</fpage>&#8211;<lpage>238</lpage>.<pub-id pub-id-type="pmid">36302899</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41589-022-01168-3</pub-id><pub-id pub-id-type="pmcid">PMC9898131</pub-id></mixed-citation></ref><ref id="mco270401-bib-0070"><label>70</label><mixed-citation publication-type="journal" id="mco270401-cit-0070"><string-name name-style="western"><given-names>S.</given-names><surname>Zeng</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Jin</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Xia</surname></string-name>, et&#160;al., &#8220;<article-title>Discovery of highly efficient CRBN&#8208;recruiting HPK1&#8208;PROTAC as a potential chemical tool for investigation of scaffolding roles in TCR signaling</article-title>,&#8221; <source>Bioorganic Chemistry</source><volume>143</volume> (<year>2024</year>): <elocation-id>107016</elocation-id>.<pub-id pub-id-type="pmid">38086239</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bioorg.2023.107016</pub-id></mixed-citation></ref><ref id="mco270401-bib-0071"><label>71</label><mixed-citation publication-type="journal" id="mco270401-cit-0071"><string-name name-style="western"><given-names>M.</given-names><surname>Gazorpak</surname></string-name>, <string-name name-style="western"><given-names>K. M.</given-names><surname>Hugentobler</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Paul</surname></string-name>, et&#160;al., &#8220;<article-title>Harnessing PROTAC technology to combat stress hormone receptor activation</article-title>,&#8221; <source>Nature Communications</source><volume>14</volume>, no. <issue>1</issue> (<year>2023</year>): <fpage>8177</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-44031-2</pub-id><pub-id pub-id-type="pmcid">PMC10710461</pub-id><pub-id pub-id-type="pmid">38071198</pub-id></mixed-citation></ref><ref id="mco270401-bib-0072"><label>72</label><mixed-citation publication-type="journal" id="mco270401-cit-0072"><string-name name-style="western"><given-names>C. P.</given-names><surname>Tinworth</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Lithgow</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Dittus</surname></string-name>, et&#160;al., &#8220;<article-title>PROTAC&#8208;Mediated Degradation of Bruton's Tyrosine Kinase Is Inhibited by Covalent Binding</article-title>,&#8221; <source>ACS Chemical Biology</source><volume>14</volume>, no. <issue>3</issue> (<year>2019</year>): <fpage>342</fpage>&#8211;<lpage>347</lpage>.<pub-id pub-id-type="pmid">30807093</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acschembio.8b01094</pub-id></mixed-citation></ref><ref id="mco270401-bib-0073"><label>73</label><mixed-citation publication-type="journal" id="mco270401-cit-0073"><string-name name-style="western"><given-names>L. M.</given-names><surname>Gockel</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Pfeifer</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Baltes</surname></string-name>, et&#160;al., &#8220;<article-title>Design, synthesis, and characterization of PROTACs targeting the androgen receptor in prostate and lung cancer models</article-title>,&#8221; <source>Archiv Der Pharmazie</source><volume>355</volume>, no. <issue>5</issue> (<year>2022</year>): <elocation-id>e2100467</elocation-id>.<pub-id pub-id-type="pmid">35128717</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ardp.202100467</pub-id></mixed-citation></ref><ref id="mco270401-bib-0074"><label>74</label><mixed-citation publication-type="journal" id="mco270401-cit-0074"><string-name name-style="western"><given-names>Y.</given-names><surname>Xiong</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Zhong</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Yim</surname></string-name>, et&#160;al., &#8220;<article-title>Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets</article-title>,&#8221; <source>Journal of the American Chemical Society</source><volume>144</volume>, no. <issue>49</issue> (<year>2022</year>): <fpage>22622</fpage>&#8211;<lpage>22632</lpage>.<pub-id pub-id-type="pmid">36448571</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jacs.2c09255</pub-id><pub-id pub-id-type="pmcid">PMC9772293</pub-id></mixed-citation></ref><ref id="mco270401-bib-0075"><label>75</label><mixed-citation publication-type="journal" id="mco270401-cit-0075"><string-name name-style="western"><given-names>A.</given-names><surname>Chan</surname></string-name>, <string-name name-style="western"><given-names>R. M.</given-names><surname>Haley</surname></string-name>, <string-name name-style="western"><given-names>M. A.</given-names><surname>Najar</surname></string-name>, et&#160;al., &#8220;<article-title>Lipid&#8208;mediated intracellular delivery of recombinant bioPROTACs for the rapid degradation of undruggable proteins</article-title>,&#8221; <source>Nature Communications</source><volume>15</volume>, no. <issue>1</issue> (<year>2024</year>): <fpage>5808</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-024-50235-x</pub-id><pub-id pub-id-type="pmcid">PMC11237011</pub-id><pub-id pub-id-type="pmid">38987546</pub-id></mixed-citation></ref><ref id="mco270401-bib-0076"><label>76</label><mixed-citation publication-type="journal" id="mco270401-cit-0076"><string-name name-style="western"><given-names>S. F.</given-names><surname>Bakhoum</surname></string-name>, &#8220;<article-title>Targeting the undruggable</article-title>,&#8221; <source>Science</source><volume>380</volume>, no. <issue>6640</issue> (<year>2023</year>): <fpage>47</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.adg7671</pub-id><pub-id pub-id-type="pmid">37023189</pub-id></mixed-citation></ref><ref id="mco270401-bib-0077"><label>77</label><mixed-citation publication-type="journal" id="mco270401-cit-0077"><string-name name-style="western"><given-names>S.</given-names><surname>Imaide</surname></string-name>, <string-name name-style="western"><given-names>K. M.</given-names><surname>Riching</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Makukhin</surname></string-name>, et&#160;al., &#8220;<article-title>Trivalent PROTACs enhance protein degradation via combined avidity and cooperativity</article-title>,&#8221; <source>Nature Chemical Biology</source><volume>17</volume>, no. <issue>11</issue> (<year>2021</year>): <fpage>1157</fpage>&#8211;<lpage>1167</lpage>.<pub-id pub-id-type="pmid">34675414</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41589-021-00878-4</pub-id><pub-id pub-id-type="pmcid">PMC7611906</pub-id></mixed-citation></ref><ref id="mco270401-bib-0078"><label>78</label><mixed-citation publication-type="journal" id="mco270401-cit-0078"><string-name name-style="western"><given-names>Y.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Yang</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Zhang</surname></string-name>, et&#160;al., &#8220;<article-title>Antitumor Effect of Anti&#8208;c&#8208;Myc Aptamer&#8208;Based PROTAC for Degradation of the c&#8208;Myc Protein</article-title>,&#8221; <source>Advanced science (Weinheim)</source><volume>11</volume>, no. <issue>26</issue> (<year>2024</year>): <elocation-id>e2309639</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202309639</pub-id><pub-id pub-id-type="pmcid">PMC11234457</pub-id><pub-id pub-id-type="pmid">38682443</pub-id></mixed-citation></ref><ref id="mco270401-bib-0079"><label>79</label><mixed-citation publication-type="journal" id="mco270401-cit-0079"><string-name name-style="western"><given-names>Y.</given-names><surname>Jiang</surname></string-name>, <string-name name-style="western"><given-names>Q.</given-names><surname>Deng</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Zhao</surname></string-name>, et&#160;al., &#8220;<article-title>Development of Stabilized Peptide&#8208;Based PROTACs Against Estrogen Receptor &#945;</article-title>,&#8221; <source>ACS Chemical Biology</source><volume>13</volume>, no. <issue>3</issue> (<year>2018</year>): <fpage>628</fpage>&#8211;<lpage>635</lpage>.<pub-id pub-id-type="pmid">29271628</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acschembio.7b00985</pub-id></mixed-citation></ref><ref id="mco270401-bib-0080"><label>80</label><mixed-citation publication-type="journal" id="mco270401-cit-0080"><string-name name-style="western"><given-names>I.</given-names><surname>Cardoso</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Stamnaes</surname></string-name>, <string-name name-style="western"><given-names>J. T.</given-names><surname>Andersen</surname></string-name>, et&#160;al., &#8220;<article-title>Transglutaminase 2 interactions With extracellular matrix proteins as probed With celiac disease autoantibodies</article-title>,&#8221; <source>FEBS Journal</source><volume>282</volume>, no. <issue>11</issue> (<year>2015</year>): <fpage>2063</fpage>&#8211;<lpage>2075</lpage>.<pub-id pub-id-type="pmid">25808416</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/febs.13276</pub-id></mixed-citation></ref><ref id="mco270401-bib-0081"><label>81</label><mixed-citation publication-type="journal" id="mco270401-cit-0081"><string-name name-style="western"><given-names>N.</given-names><surname>Roehlen</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Muller</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Nehme</surname></string-name>, et&#160;al., &#8220;<article-title>Treatment of HCC With claudin&#8208;1&#8208;specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironment</article-title>,&#8221; <source>Journal of Hepatology</source><volume>78</volume>, no. <issue>2</issue> (<year>2023</year>): <fpage>343</fpage>&#8211;<lpage>355</lpage>.<pub-id pub-id-type="pmid">36309131</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2022.10.011</pub-id></mixed-citation></ref><ref id="mco270401-bib-0082"><label>82</label><mixed-citation publication-type="journal" id="mco270401-cit-0082"><string-name name-style="western"><given-names>T.</given-names><surname>Xu</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Chen</surname></string-name>, et&#160;al., &#8220;<article-title>Interrogating heterogeneity of cysteine&#8208;engineered antibody&#8208;drug conjugates and antibody&#8208;oligonucleotide conjugates by capillary zone electrophoresis&#8208;mass spectrometry</article-title>,&#8221; <source>Mabs</source><volume>15</volume>, no. <issue>1</issue> (<year>2023</year>): <elocation-id>2229102</elocation-id>.<pub-id pub-id-type="pmid">37381585</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/19420862.2023.2229102</pub-id><pub-id pub-id-type="pmcid">PMC10312020</pub-id></mixed-citation></ref><ref id="mco270401-bib-0083"><label>83</label><mixed-citation publication-type="journal" id="mco270401-cit-0083"><string-name name-style="western"><given-names>K. O.</given-names><surname>Nagornov</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Gasilova</surname></string-name>, <string-name name-style="western"><given-names>A. N.</given-names><surname>Kozhinov</surname></string-name>, et&#160;al., &#8220;<article-title>Drug&#8208;to&#8208;Antibody Ratio Estimation via Proteoform Peak Integration in the Analysis of Antibody&#8208;Oligonucleotide Conjugates With Orbitrap Fourier Transform Mass Spectrometry</article-title>,&#8221; <source>Analytical Chemistry</source><volume>93</volume>, no. <issue>38</issue> (<year>2021</year>): <fpage>12930</fpage>&#8211;<lpage>12937</lpage>.<pub-id pub-id-type="pmid">34519496</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.analchem.1c02247</pub-id></mixed-citation></ref><ref id="mco270401-bib-0084"><label>84</label><mixed-citation publication-type="journal" id="mco270401-cit-0084"><string-name name-style="western"><given-names>L.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Ke</surname></string-name>, <string-name name-style="western"><given-names>Q.</given-names><surname>He</surname></string-name>, et&#160;al., &#8220;<article-title>A novel ROR1&#8208;targeting antibody&#8208;PROTAC conjugate promotes BRD4 degradation for solid tumor treatment</article-title>,&#8221; <source>Theranostics</source><volume>15</volume>, no. <issue>4</issue> (<year>2025</year>): <fpage>1238</fpage>&#8211;<lpage>1254</lpage>.<pub-id pub-id-type="pmid">39816690</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.102531</pub-id><pub-id pub-id-type="pmcid">PMC11729552</pub-id></mixed-citation></ref><ref id="mco270401-bib-0085"><label>85</label><mixed-citation publication-type="journal" id="mco270401-cit-0085"><string-name name-style="western"><given-names>K.</given-names><surname>Chan</surname></string-name>, <string-name name-style="western"><given-names>P. S.</given-names><surname>Sathyamurthi</surname></string-name>, <string-name name-style="western"><given-names>M. A.</given-names><surname>Queisser</surname></string-name>, et&#160;al., &#8220;<article-title>Antibody&#8208;Proteolysis Targeting Chimera Conjugate Enables Selective Degradation of Receptor&#8208;Interacting Serine/Threonine&#8208;Protein Kinase 2 in HER2+ Cell Lines</article-title>,&#8221; <source>Bioconjugate Chemistry</source><volume>34</volume>, no. <issue>11</issue> (<year>2023</year>): <fpage>2049</fpage>&#8211;<lpage>2054</lpage>.<pub-id pub-id-type="pmid">37917829</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.bioconjchem.3c00366</pub-id><pub-id pub-id-type="pmcid">PMC10655034</pub-id></mixed-citation></ref><ref id="mco270401-bib-0086"><label>86</label><mixed-citation publication-type="journal" id="mco270401-cit-0086"><string-name name-style="western"><given-names>L.</given-names><surname>Yang</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Yang</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Zhang</surname></string-name>, et&#160;al., &#8220;<article-title>Sequential responsive nano&#8208;PROTACs for precise intracellular delivery and enhanced degradation efficacy in colorectal cancer therapy</article-title>,&#8221; <source>Signal Transduction and Targeted Therapy</source><volume>9</volume>, no. <issue>1</issue> (<year>2024</year>): <fpage>275</fpage>.<pub-id pub-id-type="pmid">39419977</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-024-01983-1</pub-id><pub-id pub-id-type="pmcid">PMC11486899</pub-id></mixed-citation></ref><ref id="mco270401-bib-0087"><label>87</label><mixed-citation publication-type="journal" id="mco270401-cit-0087"><string-name name-style="western"><given-names>Y.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Ding</surname></string-name>, et&#160;al., &#8220;<article-title>Ultrasound&#8208;Activated PROTAC Prodrugs Overcome Immunosuppression to Actuate Efficient Deep&#8208;Tissue Sono&#8208;Immunotherapy in Orthotopic Pancreatic Tumor Mouse Models</article-title>,&#8221; <source>Nano Letters</source><volume>24</volume>, no. <issue>28</issue> (<year>2024</year>): <fpage>8741</fpage>&#8211;<lpage>8751</lpage>.<pub-id pub-id-type="pmid">38953486</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.nanolett.4c02287</pub-id></mixed-citation></ref><ref id="mco270401-bib-0088"><label>88</label><mixed-citation publication-type="journal" id="mco270401-cit-0088"><string-name name-style="western"><given-names>Q.</given-names><surname>Xu</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Hu</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Ullah</surname></string-name>, et&#160;al., &#8220;<article-title>Biomimetic Hybrid PROTAC Nanovesicles Block Multiple DNA Repair Pathways to Overcome Temozolomide Resistance Against Orthotopic Glioblastoma</article-title>,&#8221; <source>Advanced Materials</source><volume>37</volume>, no. <issue>29</issue> (<year>2025</year>): <elocation-id>e2504253</elocation-id>.<pub-id pub-id-type="pmid">40347032</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.202504253</pub-id></mixed-citation></ref><ref id="mco270401-bib-0089"><label>89</label><mixed-citation publication-type="journal" id="mco270401-cit-0089"><string-name name-style="western"><given-names>V.</given-names><surname>Subbotin</surname></string-name> and <string-name name-style="western"><given-names>G.</given-names><surname>Fiksel</surname></string-name>, &#8220;<article-title>Modeling multi&#8208;needle injection Into solid tumor</article-title>,&#8221; <source>American Journal of Cancer Research</source><volume>9</volume>, no. <issue>10</issue> (<year>2019</year>): <fpage>2209</fpage>&#8211;<lpage>2215</lpage>.<pub-id pub-id-type="pmid">31720083</pub-id><pub-id pub-id-type="pmcid">PMC6834475</pub-id></mixed-citation></ref><ref id="mco270401-bib-0090"><label>90</label><mixed-citation publication-type="journal" id="mco270401-cit-0090"><string-name name-style="western"><given-names>H. M.</given-names><surname>Eltaher</surname></string-name>, <string-name name-style="western"><given-names>L. A.</given-names><surname>Blokpoel Ferreras</surname></string-name>, <string-name name-style="western"><given-names>A. R.</given-names><surname>Jalal</surname></string-name>, and <string-name name-style="western"><given-names>J. E.</given-names><surname>Dixon</surname></string-name>, &#8220;<article-title>Direct contact&#8208;mediated non&#8208;viral gene therapy using thermo&#8208;sensitive hydrogel&#8208;coated dressings</article-title>,&#8221; <source>Biomaterials Advances</source><volume>143</volume> (<year>2022</year>): <elocation-id>213177</elocation-id>.<pub-id pub-id-type="pmid">36371970</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bioadv.2022.213177</pub-id></mixed-citation></ref><ref id="mco270401-bib-0091"><label>91</label><mixed-citation publication-type="journal" id="mco270401-cit-0091"><string-name name-style="western"><given-names>N. W.</given-names><surname>Keiser</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Cant</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Sitaraman</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Shoemark</surname></string-name>, and <string-name name-style="western"><given-names>M. P.</given-names><surname>Limberis</surname></string-name>, &#8220;<article-title>Restoring Ciliary Function: Gene Therapeutics for Primary Ciliary Dyskinesia</article-title>,&#8221; <source>Human Gene Therapy</source><volume>34</volume>, no. <issue>17&#8211;18</issue> (<year>2023</year>): <fpage>821</fpage>&#8211;<lpage>835</lpage>.<pub-id pub-id-type="pmid">37624733</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/hum.2023.102</pub-id></mixed-citation></ref><ref id="mco270401-bib-0092"><label>92</label><mixed-citation publication-type="journal" id="mco270401-cit-0092"><string-name name-style="western"><given-names>M. M.</given-names><surname>Chang</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Gaidukov</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Jung</surname></string-name>, et&#160;al., &#8220;<article-title>Small&#8208;molecule control of antibody N&#8208;glycosylation in engineered mammalian cells</article-title>,&#8221; <source>Nature Chemical Biology</source><volume>15</volume>, no. <issue>7</issue> (<year>2019</year>): <fpage>730</fpage>&#8211;<lpage>736</lpage>.<pub-id pub-id-type="pmid">31110306</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41589-019-0288-4</pub-id></mixed-citation></ref><ref id="mco270401-bib-0093"><label>93</label><mixed-citation publication-type="journal" id="mco270401-cit-0093"><string-name name-style="western"><given-names>A.</given-names><surname>Greer&#8208;Short</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Greenwood</surname></string-name>, <string-name name-style="western"><given-names>E. C.</given-names><surname>Leon</surname></string-name>, et&#160;al., &#8220;<article-title>AAV9&#8208;mediated MYBPC3 gene therapy With optimized expression cassette enhances cardiac function and survival in MYBPC3 cardiomyopathy models</article-title>,&#8221; <source>Nature Communications</source><volume>16</volume>, no. <issue>1</issue> (<year>2025</year>): <fpage>2196</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-025-57481-7</pub-id><pub-id pub-id-type="pmcid">PMC11880196</pub-id><pub-id pub-id-type="pmid">40038304</pub-id></mixed-citation></ref><ref id="mco270401-bib-0094"><label>94</label><mixed-citation publication-type="journal" id="mco270401-cit-0094"><string-name name-style="western"><given-names>R. D.</given-names><surname>Koilkonda</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Yu</surname></string-name>, <string-name name-style="western"><given-names>T. H.</given-names><surname>Chou</surname></string-name>, et&#160;al., &#8220;<article-title>Safety and effects of the vector for the Leber hereditary optic neuropathy gene therapy clinical trial</article-title>,&#8221; <source>JAMA ophthalmology</source><volume>132</volume>, no. <issue>4</issue> (<year>2014</year>): <fpage>409</fpage>&#8211;<lpage>420</lpage>.<pub-id pub-id-type="pmid">24457989</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaophthalmol.2013.7630</pub-id><pub-id pub-id-type="pmcid">PMC4266107</pub-id></mixed-citation></ref><ref id="mco270401-bib-0095"><label>95</label><mixed-citation publication-type="journal" id="mco270401-cit-0095"><string-name name-style="western"><given-names>M.</given-names><surname>Kostic</surname></string-name> and <string-name name-style="western"><given-names>L. H.</given-names><surname>Jones</surname></string-name>, &#8220;<article-title>Critical Assessment of Targeted Protein Degradation as a Research Tool and Pharmacological Modality</article-title>,&#8221; <source>Trends in Pharmacological Sciences</source><volume>41</volume>, no. <issue>5</issue> (<year>2020</year>): <fpage>305</fpage>&#8211;<lpage>317</lpage>.<pub-id pub-id-type="pmid">32222318</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tips.2020.02.006</pub-id><pub-id pub-id-type="pmcid">PMC7202367</pub-id></mixed-citation></ref><ref id="mco270401-bib-0096"><label>96</label><mixed-citation publication-type="journal" id="mco270401-cit-0096"><string-name name-style="western"><given-names>W.</given-names><surname>He</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Zeng</surname></string-name>, and <string-name name-style="western"><given-names>C.</given-names><surname>Xu</surname></string-name>, &#8220;<article-title>Streamlined collaboration can boost CRISPR gene therapies for rare diseases</article-title>,&#8221; <source>Nature</source><volume>631</volume>, no. <issue>8019</issue> (<year>2024</year>): <fpage>28</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/d41586-024-02132-y</pub-id><pub-id pub-id-type="pmid">38956334</pub-id></mixed-citation></ref><ref id="mco270401-bib-0097"><label>97</label><mixed-citation publication-type="journal" id="mco270401-cit-0097"><string-name name-style="western"><given-names>F. A.</given-names><surname>Voza</surname></string-name>, <string-name name-style="western"><given-names>B. J.</given-names><surname>Byrne</surname></string-name>, <string-name name-style="western"><given-names>Y. Y.</given-names><surname>Ortiz</surname></string-name>, et&#160;al., &#8220;<article-title>Codon&#8208;Optimized and de novo&#8208;Synthesized E&#8208;Selectin/AAV2 Dose&#8208;Response Study for Vascular Regeneration Gene Therapy</article-title>,&#8221; <source>Annals of Surgery</source><volume>280</volume>, no. <issue>4</issue> (<year>2024</year>): <fpage>570</fpage>&#8211;<lpage>583</lpage>.<pub-id pub-id-type="pmid">38975668</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/SLA.0000000000006436</pub-id><pub-id pub-id-type="pmcid">PMC11379359</pub-id></mixed-citation></ref><ref id="mco270401-bib-0098"><label>98</label><mixed-citation publication-type="journal" id="mco270401-cit-0098"><string-name name-style="western"><given-names>G.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>S. S.</given-names><surname>Lin</surname></string-name>, <string-name name-style="western"><given-names>Z. L.</given-names><surname>Yu</surname></string-name>, et&#160;al., &#8220;<article-title>A PARP1 PROTAC as a novel strategy Against PARP inhibitor resistance via promotion of ferroptosis in p53&#8208;positive breast cancer</article-title>,&#8221; <source>Biochemical Pharmacology</source><volume>206</volume> (<year>2022</year>): <elocation-id>115329</elocation-id>.<pub-id pub-id-type="pmid">36309080</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bcp.2022.115329</pub-id></mixed-citation></ref><ref id="mco270401-bib-0099"><label>99</label><mixed-citation publication-type="journal" id="mco270401-cit-0099"><string-name name-style="western"><given-names>K.</given-names><surname>Salokas</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>&#214;hman</surname></string-name>, et&#160;al., &#8220;<article-title>Physical and functional interactome atlas of human receptor tyrosine kinases</article-title>,&#8221; <source>EMBO Reports</source><volume>23</volume>, no. <issue>6</issue> (<year>2022</year>): <elocation-id>e54041</elocation-id>.<pub-id pub-id-type="pmid">35384245</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/embr.202154041</pub-id><pub-id pub-id-type="pmcid">PMC9171411</pub-id></mixed-citation></ref><ref id="mco270401-bib-0100"><label>100</label><mixed-citation publication-type="journal" id="mco270401-cit-0100"><string-name name-style="western"><given-names>S.</given-names><surname>Solouki</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>August</surname></string-name>, and <string-name name-style="western"><given-names>W.</given-names><surname>Huang</surname></string-name>, &#8220;<article-title>Non&#8208;receptor tyrosine kinase signaling in autoimmunity and therapeutic implications</article-title>,&#8221; <source>Pharmacology &amp; Therapeutics</source><volume>201</volume> (<year>2019</year>): <fpage>39</fpage>&#8211;<lpage>50</lpage>.<pub-id pub-id-type="pmid">31082431</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pharmthera.2019.05.008</pub-id><pub-id pub-id-type="pmcid">PMC6738557</pub-id></mixed-citation></ref><ref id="mco270401-bib-0101"><label>101</label><mixed-citation publication-type="journal" id="mco270401-cit-0101"><string-name name-style="western"><given-names>A.</given-names><surname>Odelgard</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>H&#228;gglund</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Guy</surname></string-name>, and <string-name name-style="western"><given-names>S. G. E.</given-names><surname>Andersson</surname></string-name>, &#8220;<article-title>Phylogeny and Expansion of Serine/Threonine Kinases in Phagocytotic Bacteria in the Phylum Planctomycetota</article-title>,&#8221; <source>Genome Biology and Evolution</source><volume>16</volume>, no. <issue>4</issue> (<year>2024</year>): <elocation-id>evae068</elocation-id>.<pub-id pub-id-type="pmid">38547507</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/gbe/evae068</pub-id><pub-id pub-id-type="pmcid">PMC11032199</pub-id></mixed-citation></ref><ref id="mco270401-bib-0102"><label>102</label><mixed-citation publication-type="journal" id="mco270401-cit-0102"><string-name name-style="western"><given-names>Z.</given-names><surname>Du</surname></string-name> and <string-name name-style="western"><given-names>C. M.</given-names><surname>Lovly</surname></string-name>, &#8220;<article-title>Mechanisms of receptor tyrosine kinase activation in cancer</article-title>,&#8221; <source>Molecular Cancer</source><volume>17</volume>, no. <issue>1</issue> (<year>2018</year>): <fpage>58</fpage>.<pub-id pub-id-type="pmid">29455648</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-018-0782-4</pub-id><pub-id pub-id-type="pmcid">PMC5817791</pub-id></mixed-citation></ref><ref id="mco270401-bib-0103"><label>103</label><mixed-citation publication-type="journal" id="mco270401-cit-0103"><string-name name-style="western"><given-names>X.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Qin</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Qiu</surname></string-name>, et&#160;al., &#8220;<article-title>Novel EGFR inhibitors Against resistant L858R/T790M/C797S mutant for intervention of non&#8208;small cell lung cancer</article-title>,&#8221; <source>European Journal of Medicinal Chemistry</source><volume>277</volume> (<year>2024</year>): <elocation-id>116711</elocation-id>.<pub-id pub-id-type="pmid">39094277</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2024.116711</pub-id></mixed-citation></ref><ref id="mco270401-bib-0104"><label>104</label><mixed-citation publication-type="journal" id="mco270401-cit-0104"><string-name name-style="western"><given-names>R. B.</given-names><surname>Kargbo</surname></string-name>, &#8220;<article-title>Potent PROTACs Targeting EGFR Mutants in Drug Discovery</article-title>,&#8221; <source>Acs Medicinal Chemistry Letters</source><volume>13</volume>, no. <issue>12</issue> (<year>2022</year>): <fpage>1835</fpage>&#8211;<lpage>1836</lpage>.<pub-id pub-id-type="pmid">36518691</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsmedchemlett.2c00459</pub-id><pub-id pub-id-type="pmcid">PMC9743937</pub-id></mixed-citation></ref><ref id="mco270401-bib-0105"><label>105</label><mixed-citation publication-type="journal" id="mco270401-cit-0105"><string-name name-style="western"><given-names>H. Y.</given-names><surname>Zhao</surname></string-name>, <string-name name-style="western"><given-names>X. Y.</given-names><surname>Yang</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Lei</surname></string-name>, et&#160;al., &#8220;<article-title>Discovery of potent small molecule PROTACs targeting mutant EGFR</article-title>,&#8221; <source>European Journal of Medicinal Chemistry</source><volume>208</volume> (<year>2020</year>): <elocation-id>112781</elocation-id>.<pub-id pub-id-type="pmid">32883633</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2020.112781</pub-id></mixed-citation></ref><ref id="mco270401-bib-0106"><label>106</label><mixed-citation publication-type="journal" id="mco270401-cit-0106"><string-name name-style="western"><given-names>Y.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Han</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Liu</surname></string-name>, et&#160;al., &#8220;<article-title>Targeted degradation of anaplastic lymphoma kinase by gold nanoparticle&#8208;based multi&#8208;headed proteolysis targeting chimeras</article-title>,&#8221; <source>Colloids and Surfaces B, Biointerfaces</source><volume>188</volume> (<year>2020</year>): <elocation-id>110795</elocation-id>.<pub-id pub-id-type="pmid">31991291</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.colsurfb.2020.110795</pub-id></mixed-citation></ref><ref id="mco270401-bib-0107"><label>107</label><mixed-citation publication-type="journal" id="mco270401-cit-0107"><string-name name-style="western"><given-names>C.</given-names><surname>Ren</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Sun</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Kong</surname></string-name>, et&#160;al., &#8220;<article-title>Structure&#8208;based discovery of SIAIS001 as an oral bioavailability ALK degrader constructed From Alectinib</article-title>,&#8221; <source>European Journal of Medicinal Chemistry</source><volume>217</volume> (<year>2021</year>): <elocation-id>113335</elocation-id>.<pub-id pub-id-type="pmid">33751979</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2021.113335</pub-id></mixed-citation></ref><ref id="mco270401-bib-0108"><label>108</label><mixed-citation publication-type="journal" id="mco270401-cit-0108"><string-name name-style="western"><given-names>N.</given-names><surname>Sun</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Ren</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Kong</surname></string-name>, et&#160;al., &#8220;<article-title>Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance</article-title>,&#8221; <source>European Journal of Medicinal Chemistry</source><volume>193</volume> (<year>2020</year>): <elocation-id>112190</elocation-id>.<pub-id pub-id-type="pmid">32179332</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2020.112190</pub-id></mixed-citation></ref><ref id="mco270401-bib-0109"><label>109</label><mixed-citation publication-type="journal" id="mco270401-cit-0109"><string-name name-style="western"><given-names>C.</given-names><surname>Ren</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Sun</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Liu</surname></string-name>, et&#160;al., &#8220;<article-title>Discovery of a Brigatinib Degrader SIAIS164018 With Destroying Metastasis&#8208;Related Oncoproteins and a Reshuffling Kinome Profile</article-title>,&#8221; <source>Journal of Medicinal Chemistry</source><volume>64</volume>, no. <issue>13</issue> (<year>2021</year>): <fpage>9152</fpage>&#8211;<lpage>9165</lpage>.<pub-id pub-id-type="pmid">34138566</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.1c00373</pub-id></mixed-citation></ref><ref id="mco270401-bib-0110"><label>110</label><mixed-citation publication-type="journal" id="mco270401-cit-0110"><string-name name-style="western"><given-names>G.</given-names><surname>Du</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Jiang</surname></string-name>, <string-name name-style="western"><given-names>Q.</given-names><surname>Wu</surname></string-name>, et&#160;al., &#8220;<article-title>Discovery of a Potent Degrader for Fibroblast Growth Factor Receptor 1/2</article-title>,&#8221; <source>Angewandte Chemie International Edition in English</source><volume>60</volume>, no. <issue>29</issue> (<year>2021</year>): <fpage>15905</fpage>&#8211;<lpage>15911</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/anie.202101328</pub-id><pub-id pub-id-type="pmcid">PMC8324087</pub-id><pub-id pub-id-type="pmid">33915015</pub-id></mixed-citation></ref><ref id="mco270401-bib-0111"><label>111</label><mixed-citation publication-type="journal" id="mco270401-cit-0111"><string-name name-style="western"><given-names>Y.</given-names><surname>Uemoto</surname></string-name>, <string-name name-style="western"><given-names>C. A.</given-names><surname>Lin</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Wang</surname></string-name>, et&#160;al., &#8220;<article-title>Selective degradation of FGFR1/2 overcomes antiestrogen resistance in ER+ breast cancer With FGFR1/2 alterations</article-title>,&#8221; <source>Cancer Letters</source><volume>619</volume> (<year>2025</year>): <elocation-id>217668</elocation-id>.<pub-id pub-id-type="pmid">40127812</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.canlet.2025.217668</pub-id><pub-id pub-id-type="pmcid">PMC12143203</pub-id></mixed-citation></ref><ref id="mco270401-bib-0112"><label>112</label><mixed-citation publication-type="journal" id="mco270401-cit-0112"><string-name name-style="western"><given-names>M.</given-names><surname>Javle</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Roychowdhury</surname></string-name>, <string-name name-style="western"><given-names>R. K.</given-names><surname>Kelley</surname></string-name>, et&#160;al., &#8220;<article-title>Infigratinib (BGJ398) in previously treated patients With advanced or metastatic cholangiocarcinoma With FGFR2 fusions or rearrangements: Mature results From a multicentre, open&#8208;label, single&#8208;arm, phase 2 study</article-title>,&#8221; <source>Lancet Gastroenterol Hepatol</source><volume>6</volume>, no. <issue>10</issue> (<year>2021</year>): <fpage>803</fpage>&#8211;<lpage>815</lpage>.<pub-id pub-id-type="pmid">34358484</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2468-1253(21)00196-5</pub-id></mixed-citation></ref><ref id="mco270401-bib-0113"><label>113</label><mixed-citation publication-type="journal" id="mco270401-cit-0113"><string-name name-style="western"><given-names>M. M.</given-names><surname>Hurley</surname></string-name>, <string-name name-style="western"><given-names>J. D.</given-names><surname>Coffin</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Doetschman</surname></string-name>, et&#160;al., &#8220;<article-title>FGF receptor inhibitor BGJ398 partially rescues osteoarthritis&#8208;Like phenotype in older high molecular weight FGF2 transgenic mice via multiple mechanisms</article-title>,&#8221; <source>Scientific Reports</source><volume>12</volume>, no. <issue>1</issue> (<year>2022</year>): <elocation-id>15968</elocation-id>.<pub-id pub-id-type="pmid">36153352</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-022-20269-6</pub-id><pub-id pub-id-type="pmcid">PMC9509331</pub-id></mixed-citation></ref><ref id="mco270401-bib-0114"><label>114</label><mixed-citation publication-type="journal" id="mco270401-cit-0114"><string-name name-style="western"><given-names>G.</given-names><surname>Botrus</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Raman</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Oliver</surname></string-name>, and <string-name name-style="western"><given-names>T.</given-names><surname>Bekaii&#8208;Saab</surname></string-name>, &#8220;<article-title>Infigratinib (BGJ398): An investigational agent for the treatment of FGFR&#8208;altered intrahepatic cholangiocarcinoma</article-title>,&#8221; <source>Expert Opinion on Investigational Drugs</source><volume>30</volume>, no. <issue>4</issue> (<year>2021</year>): <fpage>309</fpage>&#8211;<lpage>316</lpage>.<pub-id pub-id-type="pmid">33307867</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13543784.2021.1864320</pub-id></mixed-citation></ref><ref id="mco270401-bib-0115"><label>115</label><mixed-citation publication-type="journal" id="mco270401-cit-0115"><string-name name-style="western"><given-names>Y.</given-names><surname>Shan</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Si</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Wang</surname></string-name>, et&#160;al., &#8220;<article-title>Discovery of novel anti&#8208;angiogenesis agents. Part 11: Development of PROTACs based on active molecules With potency of promoting vascular normalization</article-title>,&#8221; <source>European Journal of Medicinal Chemistry</source><volume>205</volume> (<year>2020</year>): <elocation-id>112654</elocation-id>.<pub-id pub-id-type="pmid">32750566</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2020.112654</pub-id></mixed-citation></ref><ref id="mco270401-bib-0116"><label>116</label><mixed-citation publication-type="journal" id="mco270401-cit-0116"><string-name name-style="western"><given-names>F. H.</given-names><surname>Shah</surname></string-name>, <string-name name-style="western"><given-names>Y. S.</given-names><surname>Nam</surname></string-name>, <string-name name-style="western"><given-names>J. Y.</given-names><surname>Bang</surname></string-name>, et&#160;al., &#8220;<article-title>Targeting vascular endothelial growth receptor&#8208;2 (VEGFR&#8208;2): Structural biology, functional insights, and therapeutic resistance</article-title>,&#8221; <source>Archives of Pharmacal Research</source><volume>48</volume>, no. <issue>5</issue> (<year>2025</year>): <fpage>404</fpage>&#8211;<lpage>425</lpage>.<pub-id pub-id-type="pmid">40341988</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12272-025-01545-1</pub-id><pub-id pub-id-type="pmcid">PMC12106596</pub-id></mixed-citation></ref><ref id="mco270401-bib-0117"><label>117</label><mixed-citation publication-type="journal" id="mco270401-cit-0117"><string-name name-style="western"><given-names>Z.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Xu</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Shi</surname></string-name>, et&#160;al., &#8220;<article-title>Natural Compound&#8208;Rhein and PROTACs Unleash Potent VEGFR&#8208;2 Degraders</article-title>,&#8221; <source>Chemistry and Biodiversity</source><volume>21</volume>, no. <issue>8</issue> (<year>2024</year>): <elocation-id>e202400753</elocation-id>.<pub-id pub-id-type="pmid">38818648</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cbdv.202400753</pub-id></mixed-citation></ref><ref id="mco270401-bib-0118"><label>118</label><mixed-citation publication-type="journal" id="mco270401-cit-0118"><string-name name-style="western"><given-names>R.</given-names><surname>Yerushalmi</surname></string-name>, <string-name name-style="western"><given-names>K. A.</given-names><surname>Gelmon</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Leung</surname></string-name>, et&#160;al., &#8220;<article-title>Insulin&#8208;Like growth factor receptor (IGF&#8208;1R) in breast cancer subtypes</article-title>,&#8221; <source>Breast Cancer Research and Treatment</source><volume>132</volume>, no. <issue>1</issue> (<year>2012</year>): <fpage>131</fpage>&#8211;<lpage>142</lpage>.<pub-id pub-id-type="pmid">21574055</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10549-011-1529-8</pub-id></mixed-citation></ref><ref id="mco270401-bib-0119"><label>119</label><mixed-citation publication-type="journal" id="mco270401-cit-0119"><string-name name-style="western"><given-names>Y.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Yuan</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Tang</surname></string-name>, et&#160;al., &#8220;<article-title>Degrading FLT3&#8208;ITD protein by proteolysis targeting chimera (PROTAC)</article-title>,&#8221; <source>Bioorganic Chemistry</source><volume>119</volume> (<year>2022</year>): <elocation-id>105508</elocation-id>.<pub-id pub-id-type="pmid">34959180</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bioorg.2021.105508</pub-id></mixed-citation></ref><ref id="mco270401-bib-0120"><label>120</label><mixed-citation publication-type="journal" id="mco270401-cit-0120"><string-name name-style="western"><given-names>W.</given-names><surname>Ye</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Wu</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Wang</surname></string-name>, et&#160;al., &#8220;<article-title>The proteolysis targeting chimera GMB&#8208;475 combined With dasatinib for the treatment of chronic myeloid leukemia With BCR::ABL1 mutants</article-title>,&#8221; <source>Frontiers in pharmacology</source><volume>13</volume> (<year>2022</year>): <elocation-id>931772</elocation-id>.<pub-id pub-id-type="pmid">36263131</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2022.931772</pub-id><pub-id pub-id-type="pmcid">PMC9574342</pub-id></mixed-citation></ref><ref id="mco270401-bib-0121"><label>121</label><mixed-citation publication-type="journal" id="mco270401-cit-0121"><string-name name-style="western"><given-names>X.</given-names><surname>Yu</surname></string-name>, <string-name name-style="western"><given-names>W. H.</given-names><surname>Guo</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Lin</surname></string-name>, et&#160;al., &#8220;<article-title>Discovery of a potent BTK and IKZF1/3 triple degrader Through reversible covalent BTK PROTAC development</article-title>,&#8221; <source>Current Research in Chemical Biology</source><volume>2</volume> (<year>2022</year>): <elocation-id>100029</elocation-id>.<pub-id pub-id-type="pmid">36712232</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.crchbi.2022.100029</pub-id><pub-id pub-id-type="pmcid">PMC9879287</pub-id></mixed-citation></ref><ref id="mco270401-bib-0122"><label>122</label><mixed-citation publication-type="journal" id="mco270401-cit-0122"><string-name name-style="western"><given-names>R.</given-names><surname>Gabizon</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Shraga</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Gehrtz</surname></string-name>, et&#160;al., &#8220;<article-title>Efficient Targeted Degradation via Reversible and Irreversible Covalent PROTACs</article-title>,&#8221; <source>Journal of the American Chemical Society</source><volume>142</volume>, no. <issue>27</issue> (<year>2020</year>): <fpage>11734</fpage>&#8211;<lpage>11742</lpage>.<pub-id pub-id-type="pmid">32369353</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jacs.9b13907</pub-id><pub-id pub-id-type="pmcid">PMC7349657</pub-id></mixed-citation></ref><ref id="mco270401-bib-0123"><label>123</label><mixed-citation publication-type="journal" id="mco270401-cit-0123"><string-name name-style="western"><given-names>G. M.</given-names><surname>Burslem</surname></string-name>, <string-name name-style="western"><given-names>D. P.</given-names><surname>Bondeson</surname></string-name>, and <string-name name-style="western"><given-names>C. M.</given-names><surname>Crews</surname></string-name>, &#8220;<article-title>Scaffold hopping enables direct access to more potent PROTACs With in vivo activity</article-title>,&#8221; <source>Chemical Communications</source><volume>56</volume>, no. <issue>50</issue> (<year>2020</year>): <fpage>6890</fpage>&#8211;<lpage>6892</lpage>.<pub-id pub-id-type="pmid">32519703</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/d0cc02201b</pub-id><pub-id pub-id-type="pmcid">PMC7404552</pub-id></mixed-citation></ref><ref id="mco270401-bib-0124"><label>124</label><mixed-citation publication-type="journal" id="mco270401-cit-0124"><string-name name-style="western"><given-names>Y.</given-names><surname>Yang</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Gao</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Sun</surname></string-name>, et&#160;al., &#8220;<article-title>Global PROTAC Toolbox for Degrading BCR&#8208;ABL Overcomes Drug&#8208;Resistant Mutants and Adverse Effects</article-title>,&#8221; <source>Journal of Medicinal Chemistry</source><volume>63</volume>, no. <issue>15</issue> (<year>2020</year>): <fpage>8567</fpage>&#8211;<lpage>8583</lpage>.<pub-id pub-id-type="pmid">32657579</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.0c00967</pub-id></mixed-citation></ref><ref id="mco270401-bib-0125"><label>125</label><mixed-citation publication-type="journal" id="mco270401-cit-0125"><string-name name-style="western"><given-names>T. S.</given-names><surname>Yu</surname></string-name>, <string-name name-style="western"><given-names>S. Q.</given-names><surname>Han</surname></string-name>, <string-name name-style="western"><given-names>L. J.</given-names><surname>Wang</surname></string-name>, et&#160;al., &#8220;<article-title>Effects of orelabrutinib, a BTK inhibitor, on antibody&#8208;mediated platelet destruction in primary immune thrombocytopenia</article-title>,&#8221; <source>British Journal of Haematology</source><volume>206</volume>, no. <issue>4</issue> (<year>2025</year>): <fpage>1186</fpage>&#8211;<lpage>1199</lpage>.<pub-id pub-id-type="pmid">40069128</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bjh.20045</pub-id></mixed-citation></ref><ref id="mco270401-bib-0126"><label>126</label><mixed-citation publication-type="journal" id="mco270401-cit-0126"><string-name name-style="western"><given-names>L. E.</given-names><surname>Nyhoff</surname></string-name>, <string-name name-style="western"><given-names>A. S.</given-names><surname>Griffith</surname></string-name>, <string-name name-style="western"><given-names>E. S.</given-names><surname>Clark</surname></string-name>, et&#160;al., &#8220;<article-title>Btk Supports Autoreactive B Cell Development and Protects Against Apoptosis but Is Expendable for Antigen Presentation</article-title>,&#8221; <source>Journal of Immunology</source><volume>207</volume>, no. <issue>12</issue> (<year>2021</year>): <fpage>2922</fpage>&#8211;<lpage>2932</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.2000558</pub-id><pub-id pub-id-type="pmcid">PMC9117567</pub-id><pub-id pub-id-type="pmid">34799428</pub-id></mixed-citation></ref><ref id="mco270401-bib-0127"><label>127</label><mixed-citation publication-type="journal" id="mco270401-cit-0127"><string-name name-style="western"><given-names>A. C.</given-names><surname>Lai</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Toure</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Hellerschmied</surname></string-name>, et&#160;al., &#8220;<article-title>Modular PROTAC Design for the Degradation of Oncogenic BCR&#8208;ABL</article-title>,&#8221; <source>Angewandte Chemie International Edition in English</source><volume>55</volume>, no. <issue>2</issue> (<year>2016</year>): <fpage>807</fpage>&#8211;<lpage>810</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/anie.201507634</pub-id><pub-id pub-id-type="pmcid">PMC4733637</pub-id><pub-id pub-id-type="pmid">26593377</pub-id></mixed-citation></ref><ref id="mco270401-bib-0128"><label>128</label><mixed-citation publication-type="journal" id="mco270401-cit-0128"><string-name name-style="western"><given-names>Q.</given-names><surname>Zhao</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Ren</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Liu</surname></string-name>, et&#160;al., &#8220;<article-title>Discovery of SIAIS178 as an Effective BCR&#8208;ABL Degrader by Recruiting Von Hippel&#8208;Lindau (VHL) E3 Ubiquitin Ligase</article-title>,&#8221; <source>Journal of Medicinal Chemistry</source><volume>62</volume>, no. <issue>20</issue> (<year>2019</year>): <fpage>9281</fpage>&#8211;<lpage>9298</lpage>.<pub-id pub-id-type="pmid">31539241</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.9b01264</pub-id></mixed-citation></ref><ref id="mco270401-bib-0129"><label>129</label><mixed-citation publication-type="journal" id="mco270401-cit-0129"><string-name name-style="western"><given-names>B.</given-names><surname>Tong</surname></string-name>, <string-name name-style="western"><given-names>J. N.</given-names><surname>Spradlin</surname></string-name>, <string-name name-style="western"><given-names>L. F. T.</given-names><surname>Novaes</surname></string-name>, et&#160;al., &#8220;<article-title>A Nimbolide&#8208;Based Kinase Degrader Preferentially Degrades Oncogenic BCR&#8208;ABL</article-title>,&#8221; <source>ACS Chemical Biology</source><volume>15</volume>, no. <issue>7</issue> (<year>2020</year>): <fpage>1788</fpage>&#8211;<lpage>1794</lpage>.<pub-id pub-id-type="pmid">32568522</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acschembio.0c00348</pub-id><pub-id pub-id-type="pmcid">PMC7891886</pub-id></mixed-citation></ref><ref id="mco270401-bib-0130"><label>130</label><mixed-citation publication-type="journal" id="mco270401-cit-0130"><string-name name-style="western"><given-names>Y. H.</given-names><surname>Jin</surname></string-name>, <string-name name-style="western"><given-names>M. C.</given-names><surname>Lu</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Wang</surname></string-name>, et&#160;al., &#8220;<article-title>Azo&#8208;PROTAC: Novel Light&#8208;Controlled Small&#8208;Molecule Tool for Protein Knockdown</article-title>,&#8221; <source>Journal of Medicinal Chemistry</source><volume>63</volume>, no. <issue>9</issue> (<year>2020</year>): <fpage>4644</fpage>&#8211;<lpage>4654</lpage>.<pub-id pub-id-type="pmid">32153174</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.9b02058</pub-id></mixed-citation></ref><ref id="mco270401-bib-0131"><label>131</label><mixed-citation publication-type="journal" id="mco270401-cit-0131"><string-name name-style="western"><given-names>H.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Ding</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Liu</surname></string-name>, et&#160;al., &#8220;<article-title>Discovery of novel BCR&#8208;ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation</article-title>,&#8221; <source>European Journal of Medicinal Chemistry</source><volume>223</volume> (<year>2021</year>): <elocation-id>113645</elocation-id>.<pub-id pub-id-type="pmid">34217059</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2021.113645</pub-id></mixed-citation></ref><ref id="mco270401-bib-0132"><label>132</label><mixed-citation publication-type="journal" id="mco270401-cit-0132"><string-name name-style="western"><given-names>H.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Sun</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Ren</surname></string-name>, et&#160;al., &#8220;<article-title>Construction of an IMiD&#8208;based azide library as a kit for PROTAC research</article-title>,&#8221; <source>Organic &amp; Biomolecular Chemistry</source><volume>19</volume>, no. <issue>1</issue> (<year>2021</year>): <fpage>166</fpage>&#8211;<lpage>170</lpage>.<pub-id pub-id-type="pmid">33226388</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/d0ob02120b</pub-id></mixed-citation></ref><ref id="mco270401-bib-0133"><label>133</label><mixed-citation publication-type="journal" id="mco270401-cit-0133"><string-name name-style="western"><given-names>M.</given-names><surname>He</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Cao</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Ni</surname></string-name>, et&#160;al., &#8220;<article-title>PROTACs: Great opportunities for academia and industry (an update From 2020 to 2021)</article-title>,&#8221; <source>Signal Transduction and Targeted Therapy</source><volume>7</volume>, no. <issue>1</issue> (<year>2022</year>): <fpage>181</fpage>.<pub-id pub-id-type="pmid">35680848</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-022-00999-9</pub-id><pub-id pub-id-type="pmcid">PMC9178337</pub-id></mixed-citation></ref><ref id="mco270401-bib-0134"><label>134</label><mixed-citation publication-type="journal" id="mco270401-cit-0134"><string-name name-style="western"><given-names>J. J.</given-names><surname>Lee</surname></string-name>, <string-name name-style="western"><given-names>R. A. H.</given-names><surname>van de Ven</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Zaganjor</surname></string-name>, et&#160;al., &#8220;<article-title>Inhibition of epithelial cell migration and Src/FAK signaling by SIRT3</article-title>,&#8221; <source>Proceedings of the National Academy of Sciences of the United States of America</source><volume>115</volume>, no. <issue>27</issue> (<year>2018</year>): <fpage>7057</fpage>&#8211;<lpage>7062</lpage>.<pub-id pub-id-type="pmid">29915029</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1800440115</pub-id><pub-id pub-id-type="pmcid">PMC6142214</pub-id></mixed-citation></ref><ref id="mco270401-bib-0135"><label>135</label><mixed-citation publication-type="journal" id="mco270401-cit-0135"><string-name name-style="western"><given-names>C. P.</given-names><surname>El Haibi</surname></string-name>, <string-name name-style="western"><given-names>P. K.</given-names><surname>Sharma</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Singh</surname></string-name>, et&#160;al., &#8220;<article-title>PI3Kp110&#8208;, Src&#8208;, FAK&#8208;dependent and DOCK2&#8208;independent migration and invasion of CXCL13&#8208;stimulated prostate cancer cells</article-title>,&#8221; <source>Molecular Cancer</source><volume>9</volume> (<year>2010</year>): <fpage>85</fpage>.<pub-id pub-id-type="pmid">20412587</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1476-4598-9-85</pub-id><pub-id pub-id-type="pmcid">PMC2873439</pub-id></mixed-citation></ref><ref id="mco270401-bib-0136"><label>136</label><mixed-citation publication-type="journal" id="mco270401-cit-0136"><string-name name-style="western"><given-names>R. P.</given-names><surname>Law</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Nunes</surname></string-name>, <string-name name-style="western"><given-names>C. W.</given-names><surname>Chung</surname></string-name>, et&#160;al., &#8220;<article-title>Discovery and Characterisation of Highly Cooperative FAK&#8208;Degrading PROTACs</article-title>,&#8221; <source>Angewandte Chemie International Edition in English</source><volume>60</volume>, no. <issue>43</issue> (<year>2021</year>): <fpage>23327</fpage>&#8211;<lpage>23334</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/anie.202109237</pub-id><pub-id pub-id-type="pmid">34416073</pub-id></mixed-citation></ref><ref id="mco270401-bib-0137"><label>137</label><mixed-citation publication-type="journal" id="mco270401-cit-0137"><string-name name-style="western"><given-names>I.</given-names><surname>Menzl</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Berger&#8208;Becvar</surname></string-name>, et&#160;al., &#8220;<article-title>A kinase&#8208;independent role for CDK8 in BCR&#8208;ABL1(+) leukemia</article-title>,&#8221; <source>Nature Communications</source><volume>10</volume>, no. <issue>1</issue> (<year>2019</year>): <fpage>4741</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-019-12656-x</pub-id><pub-id pub-id-type="pmcid">PMC6802219</pub-id><pub-id pub-id-type="pmid">31628323</pub-id></mixed-citation></ref><ref id="mco270401-bib-0138"><label>138</label><mixed-citation publication-type="journal" id="mco270401-cit-0138"><string-name name-style="western"><given-names>B.</given-names><surname>Jiang</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Gao</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Che</surname></string-name>, et&#160;al., &#8220;<article-title>Discovery and resistance mechanism of a selective CDK12 degrader</article-title>,&#8221; <source>Nature Chemical Biology</source><volume>17</volume>, no. <issue>6</issue> (<year>2021</year>): <fpage>675</fpage>&#8211;<lpage>683</lpage>.<pub-id pub-id-type="pmid">33753926</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41589-021-00765-y</pub-id><pub-id pub-id-type="pmcid">PMC8590456</pub-id></mixed-citation></ref><ref id="mco270401-bib-0139"><label>139</label><mixed-citation publication-type="journal" id="mco270401-cit-0139"><string-name name-style="western"><given-names>W.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Wu</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Yang</surname></string-name>, et&#160;al., &#8220;<article-title>CDK9 targeting PROTAC L055 inhibits ER&#945;&#8208;positive breast cancer</article-title>,&#8221; <source>Biomedicine &amp; Pharmacotherapy</source><volume>177</volume> (<year>2024</year>): <elocation-id>116972</elocation-id>.<pub-id pub-id-type="pmid">38906024</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2024.116972</pub-id></mixed-citation></ref><ref id="mco270401-bib-0140"><label>140</label><mixed-citation publication-type="journal" id="mco270401-cit-0140"><string-name name-style="western"><given-names>C.</given-names><surname>Yang</surname></string-name>, <string-name name-style="western"><given-names>C. A.</given-names><surname>Boyson</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Di Liberto</surname></string-name>, et&#160;al., &#8220;<article-title>CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine&#8208;Mediated Cytotoxicity</article-title>,&#8221; <source>Cancer Research</source><volume>75</volume>, no. <issue>9</issue> (<year>2015</year>): <fpage>1838</fpage>&#8211;<lpage>1845</lpage>.<pub-id pub-id-type="pmid">25744718</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-14-2486</pub-id><pub-id pub-id-type="pmcid">PMC4417369</pub-id></mixed-citation></ref><ref id="mco270401-bib-0141"><label>141</label><mixed-citation publication-type="journal" id="mco270401-cit-0141"><string-name name-style="western"><given-names>S.</given-names><surname>Hati</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Zallocchi</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Hazlitt</surname></string-name>, et&#160;al., &#8220;<article-title>AZD5438&#8208;PROTAC: A selective CDK2 degrader that protects Against cisplatin&#8208; and noise&#8208;induced hearing loss</article-title>,&#8221; <source>European Journal of Medicinal Chemistry</source><volume>226</volume> (<year>2021</year>): <elocation-id>113849</elocation-id>.<pub-id pub-id-type="pmid">34560429</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2021.113849</pub-id><pub-id pub-id-type="pmcid">PMC8608744</pub-id></mixed-citation></ref><ref id="mco270401-bib-0142"><label>142</label><mixed-citation publication-type="journal" id="mco270401-cit-0142"><string-name name-style="western"><given-names>M.</given-names><surname>Teng</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Jiang</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>He</surname></string-name>, et&#160;al., &#8220;<article-title>Development of CDK2 and CDK5 Dual Degrader TMX&#8208;2172</article-title>,&#8221; <source>Angewandte Chemie International Edition in English</source><volume>59</volume>, no. <issue>33</issue> (<year>2020</year>): <fpage>13865</fpage>&#8211;<lpage>13870</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/anie.202004087</pub-id><pub-id pub-id-type="pmcid">PMC7703486</pub-id><pub-id pub-id-type="pmid">32415712</pub-id></mixed-citation></ref><ref id="mco270401-bib-0143"><label>143</label><mixed-citation publication-type="journal" id="mco270401-cit-0143"><string-name name-style="western"><given-names>M.</given-names><surname>De Dominici</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Porazzi</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Xiao</surname></string-name>, et&#160;al., &#8220;<article-title>Selective inhibition of Ph&#8208;positive ALL cell growth Through kinase&#8208;dependent and &#8208;independent effects by CDK6&#8208;specific PROTACs</article-title>,&#8221; <source>Blood</source><volume>135</volume>, no. <issue>18</issue> (<year>2020</year>): <fpage>1560</fpage>&#8211;<lpage>1573</lpage>.<pub-id pub-id-type="pmid">32040545</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood.2019003604</pub-id><pub-id pub-id-type="pmcid">PMC7193186</pub-id></mixed-citation></ref><ref id="mco270401-bib-0144"><label>144</label><mixed-citation publication-type="journal" id="mco270401-cit-0144"><string-name name-style="western"><given-names>J.</given-names><surname>Hu</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Wei</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Yim</surname></string-name>, et&#160;al., &#8220;<article-title>Potent and Selective Mitogen&#8208;Activated Protein Kinase Kinase 1/2 (MEK1/2) Heterobifunctional Small&#8208;molecule Degraders</article-title>,&#8221; <source>Journal of Medicinal Chemistry</source><volume>63</volume>, no. <issue>24</issue> (<year>2020</year>): <fpage>15883</fpage>&#8211;<lpage>15905</lpage>.<pub-id pub-id-type="pmid">33284613</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.0c01609</pub-id><pub-id pub-id-type="pmcid">PMC7770057</pub-id></mixed-citation></ref><ref id="mco270401-bib-0145"><label>145</label><mixed-citation publication-type="journal" id="mco270401-cit-0145"><string-name name-style="western"><given-names>A.</given-names><surname>Prahallad</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Sun</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Huang</surname></string-name>, et&#160;al., &#8220;<article-title>Unresponsiveness of colon cancer to BRAF(V600E) inhibition Through feedback activation of EGFR</article-title>,&#8221; <source>Nature</source><volume>483</volume>, no. <issue>7387</issue> (<year>2012</year>): <fpage>100</fpage>&#8211;<lpage>103</lpage>.<pub-id pub-id-type="pmid">22281684</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature10868</pub-id></mixed-citation></ref><ref id="mco270401-bib-0146"><label>146</label><mixed-citation publication-type="journal" id="mco270401-cit-0146"><string-name name-style="western"><given-names>I.</given-names><surname>You</surname></string-name>, <string-name name-style="western"><given-names>E. C.</given-names><surname>Erickson</surname></string-name>, <string-name name-style="western"><given-names>K. A.</given-names><surname>Donovan</surname></string-name>, et&#160;al., &#8220;<article-title>Discovery of an AKT Degrader With Prolonged Inhibition of Downstream Signaling</article-title>,&#8221; <source>Cell Chemical Biology</source><volume>27</volume>, no. <issue>1</issue> (<year>2020</year>): <fpage>66</fpage>&#8211;<lpage>73</lpage>. e67.<pub-id pub-id-type="pmid">31859249</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chembiol.2019.11.014</pub-id><pub-id pub-id-type="pmcid">PMC6980747</pub-id></mixed-citation></ref><ref id="mco270401-bib-0147"><label>147</label><mixed-citation publication-type="journal" id="mco270401-cit-0147"><string-name name-style="western"><given-names>E. C.</given-names><surname>Erickson</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>You</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Perry</surname></string-name>, et&#160;al., &#8220;<article-title>Multiomic profiling of breast cancer cells uncovers stress MAPK&#8208;associated sensitivity to AKT degradation</article-title>,&#8221; <source>Science Signaling</source><volume>17</volume>, no. <issue>825</issue> (<year>2024</year>): <elocation-id>eadf2670</elocation-id>.<pub-id pub-id-type="pmid">38412255</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scisignal.adf2670</pub-id><pub-id pub-id-type="pmcid">PMC10949348</pub-id></mixed-citation></ref><ref id="mco270401-bib-0148"><label>148</label><mixed-citation publication-type="journal" id="mco270401-cit-0148"><string-name name-style="western"><given-names>X.</given-names><surname>Yu</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Xu</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Xie</surname></string-name>, et&#160;al., &#8220;<article-title>Design, Synthesis, and Evaluation of Potent, Selective, and Bioavailable AKT Kinase Degraders</article-title>,&#8221; <source>Journal of Medicinal Chemistry</source><volume>64</volume>, no. <issue>24</issue> (<year>2021</year>): <fpage>18054</fpage>&#8211;<lpage>18081</lpage>.<pub-id pub-id-type="pmid">34855399</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.1c01476</pub-id><pub-id pub-id-type="pmcid">PMC8819633</pub-id></mixed-citation></ref><ref id="mco270401-bib-0149"><label>149</label><mixed-citation publication-type="journal" id="mco270401-cit-0149"><string-name name-style="western"><given-names>X.</given-names><surname>Mu</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Bai</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Xu</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Wang</surname></string-name>, and <string-name name-style="western"><given-names>H.</given-names><surname>Lu</surname></string-name>, &#8220;<article-title>Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo&#8208;Like kinase 1 (PLK1) proteins in acute myeloid leukemia cells</article-title>,&#8221; <source>Biochemical and Biophysical Research Communications</source><volume>521</volume>, no. <issue>4</issue> (<year>2020</year>): <fpage>833</fpage>&#8211;<lpage>839</lpage>.<pub-id pub-id-type="pmid">31708096</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2019.11.007</pub-id></mixed-citation></ref><ref id="mco270401-bib-0150"><label>150</label><mixed-citation publication-type="journal" id="mco270401-cit-0150"><string-name name-style="western"><given-names>T.</given-names><surname>Niu</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Jiang</surname></string-name>, et&#160;al., &#8220;<article-title>Noncovalent CDK12/13 dual inhibitors&#8208;based PROTACs degrade CDK12&#8208;Cyclin K complex and induce synthetic lethality With PARP inhibitor</article-title>,&#8221; <source>European Journal of Medicinal Chemistry</source><volume>228</volume> (<year>2022</year>): <elocation-id>114012</elocation-id>.<pub-id pub-id-type="pmid">34864331</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2021.114012</pub-id></mixed-citation></ref><ref id="mco270401-bib-0151"><label>151</label><mixed-citation publication-type="journal" id="mco270401-cit-0151"><string-name name-style="western"><given-names>Z.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>B. J.</given-names><surname>Pinch</surname></string-name>, <string-name name-style="western"><given-names>C. M.</given-names><surname>Olson</surname></string-name>, et&#160;al., &#8220;<article-title>Development and Characterization of a Wee1 Kinase Degrader</article-title>,&#8221; <source>Cell Chemical Biology</source><volume>27</volume>, no. <issue>1</issue> (<year>2020</year>): <fpage>57</fpage>&#8211;<lpage>65</lpage>. e59.<pub-id pub-id-type="pmid">31735695</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chembiol.2019.10.013</pub-id><pub-id pub-id-type="pmcid">PMC6980656</pub-id></mixed-citation></ref><ref id="mco270401-bib-0152"><label>152</label><mixed-citation publication-type="journal" id="mco270401-cit-0152"><string-name name-style="western"><given-names>B.</given-names><surname>Adhikari</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Bozilovic</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Diebold</surname></string-name>, et&#160;al., &#8220;<article-title>PROTAC&#8208;mediated degradation reveals a non&#8208;catalytic function of AURORA&#8208;A kinase</article-title>,&#8221; <source>Nature Chemical Biology</source><volume>16</volume>, no. <issue>11</issue> (<year>2020</year>): <fpage>1179</fpage>&#8211;<lpage>1188</lpage>.<pub-id pub-id-type="pmid">32989298</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41589-020-00652-y</pub-id><pub-id pub-id-type="pmcid">PMC7610535</pub-id></mixed-citation></ref><ref id="mco270401-bib-0153"><label>153</label><mixed-citation publication-type="journal" id="mco270401-cit-0153"><string-name name-style="western"><given-names>X.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Wu</surname></string-name>, et&#160;al., &#8220;<article-title>Palmatine induces G2/M phase arrest and mitochondrial&#8208;associated pathway apoptosis in colon cancer cells by targeting AURKA</article-title>,&#8221; <source>Biochemical Pharmacology</source><volume>175</volume> (<year>2020</year>): <elocation-id>113933</elocation-id>.<pub-id pub-id-type="pmid">32224138</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bcp.2020.113933</pub-id></mixed-citation></ref><ref id="mco270401-bib-0154"><label>154</label><mixed-citation publication-type="journal" id="mco270401-cit-0154"><string-name name-style="western"><given-names>W.</given-names><surname>Yue</surname></string-name>, <string-name name-style="western"><given-names>H. Y.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Schatten</surname></string-name>, <string-name name-style="western"><given-names>T. G.</given-names><surname>Meng</surname></string-name>, and <string-name name-style="western"><given-names>Q. Y.</given-names><surname>Sun</surname></string-name>, &#8220;<article-title>CtIP regulates G2/M transition and bipolar spindle assembly During mouse oocyte meiosis</article-title>,&#8221; <source>Journal of Genetics and Genomics</source><volume>51</volume>, no. <issue>12</issue> (<year>2024</year>): <fpage>1435</fpage>&#8211;<lpage>1446</lpage>.<pub-id pub-id-type="pmid">39277031</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jgg.2024.09.005</pub-id></mixed-citation></ref><ref id="mco270401-bib-0155"><label>155</label><mixed-citation publication-type="journal" id="mco270401-cit-0155"><string-name name-style="western"><given-names>C.</given-names><surname>Donoghue</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Cubillos&#8208;Rojas</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Gutierrez&#8208;Prat</surname></string-name>, et&#160;al., &#8220;<article-title>Optimal linker length for small molecule PROTACs that selectively target p38&#945; and p38&#946; for degradation</article-title>,&#8221; <source>European Journal of Medicinal Chemistry</source><volume>201</volume> (<year>2020</year>): <elocation-id>112451</elocation-id>.<pub-id pub-id-type="pmid">32634680</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2020.112451</pub-id></mixed-citation></ref><ref id="mco270401-bib-0156"><label>156</label><mixed-citation publication-type="journal" id="mco270401-cit-0156"><string-name name-style="western"><given-names>D. R.</given-names><surname>McDonald</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Brown</surname></string-name>, <string-name name-style="western"><given-names>F. A.</given-names><surname>Bonilla</surname></string-name>, and <string-name name-style="western"><given-names>R. S.</given-names><surname>Geha</surname></string-name>, &#8220;<article-title>Interleukin receptor&#8208;associated kinase&#8208;4 deficiency impairs Toll&#8208;Like receptor&#8208;dependent innate antiviral immune responses</article-title>,&#8221; <source>Journal of Allergy and Clinical Immunology</source><volume>118</volume>, no. <issue>6</issue> (<year>2006</year>): <fpage>1357</fpage>&#8211;<lpage>1362</lpage>.<pub-id pub-id-type="pmid">17157666</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaci.2006.08.006</pub-id></mixed-citation></ref><ref id="mco270401-bib-0157"><label>157</label><mixed-citation publication-type="journal" id="mco270401-cit-0157"><string-name name-style="western"><given-names>L.</given-names><surname>Fu</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Shen</surname></string-name>, et&#160;al., &#8220;<article-title>Discovery of Highly Potent and Selective IRAK1 Degraders to Probe Scaffolding Functions of IRAK1 in ABC DLBCL</article-title>,&#8221; <source>Journal of Medicinal Chemistry</source><volume>64</volume>, no. <issue>15</issue> (<year>2021</year>): <fpage>10878</fpage>&#8211;<lpage>10889</lpage>.<pub-id pub-id-type="pmid">34279092</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.1c00103</pub-id></mixed-citation></ref><ref id="mco270401-bib-0158"><label>158</label><mixed-citation publication-type="journal" id="mco270401-cit-0158"><string-name name-style="western"><given-names>Z.</given-names><surname>Tao</surname></string-name> and <string-name name-style="western"><given-names>X.</given-names><surname>Wu</surname></string-name>, &#8220;<article-title>Targeting Transcription Factors in Cancer: From &#8221;Undruggable&#8220; to &#8220;Druggable&#8221;</article-title>,&#8221; <source>Methods in Molecular Biology</source><volume>2594</volume> (<year>2023</year>): <fpage>107</fpage>&#8211;<lpage>131</lpage>.<pub-id pub-id-type="pmid">36264492</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-1-0716-2815-7_9</pub-id><pub-id pub-id-type="pmcid">PMC9724592</pub-id></mixed-citation></ref><ref id="mco270401-bib-0159"><label>159</label><mixed-citation publication-type="journal" id="mco270401-cit-0159"><string-name name-style="western"><given-names>M.</given-names><surname>Dai</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Radhakrishnan</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Li</surname></string-name>, et&#160;al., &#8220;<article-title>Targeted Protein Degradation: An Important Tool for Drug Discovery for &#8221;Undruggable&#8220; Tumor Transcription Factors</article-title>,&#8221; <source>Technology in Cancer Research and Treatment</source><volume>21</volume> (<year>2022</year>): <elocation-id>15330338221095950</elocation-id>.<pub-id pub-id-type="pmid">35466792</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/15330338221095950</pub-id><pub-id pub-id-type="pmcid">PMC9047787</pub-id></mixed-citation></ref><ref id="mco270401-bib-0160"><label>160</label><mixed-citation publication-type="journal" id="mco270401-cit-0160"><string-name name-style="western"><given-names>F.</given-names><surname>Sias</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Zoroddu</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Migheli</surname></string-name>, and <string-name name-style="western"><given-names>L.</given-names><surname>Bagella</surname></string-name>, &#8220;<article-title>Untangling the Role of MYC in Sarcomas and Its Potential as a Promising Therapeutic Target</article-title>,&#8221; <source>International Journal of Molecular Sciences</source><volume>26</volume>, no. <issue>5</issue> (<year>2025</year>).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms26051973</pub-id><pub-id pub-id-type="pmcid">PMC11900228</pub-id><pub-id pub-id-type="pmid">40076599</pub-id></mixed-citation></ref><ref id="mco270401-bib-0161"><label>161</label><mixed-citation publication-type="journal" id="mco270401-cit-0161"><string-name name-style="western"><given-names>S.</given-names><surname>Lier</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Sellmer</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Orben</surname></string-name>, et&#160;al., &#8220;<article-title>A novel Cereblon E3 ligase modulator With antitumor activity in gastrointestinal cancer</article-title>,&#8221; <source>Bioorganic Chemistry</source><volume>119</volume> (<year>2022</year>): <elocation-id>105505</elocation-id>.<pub-id pub-id-type="pmid">34838332</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bioorg.2021.105505</pub-id></mixed-citation></ref><ref id="mco270401-bib-0162"><label>162</label><mixed-citation publication-type="journal" id="mco270401-cit-0162"><string-name name-style="western"><given-names>Y.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Zhang</surname></string-name>, et&#160;al., &#8220;<article-title>CCT5 induces epithelial&#8208;mesenchymal transition to promote gastric cancer lymph node metastasis by activating the Wnt/&#946;&#8208;catenin signalling pathway</article-title>,&#8221; <source>British Journal of Cancer</source><volume>126</volume>, no. <issue>12</issue> (<year>2022</year>): <fpage>1684</fpage>&#8211;<lpage>1694</lpage>.<pub-id pub-id-type="pmid">35194191</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41416-022-01747-0</pub-id><pub-id pub-id-type="pmcid">PMC9174209</pub-id></mixed-citation></ref><ref id="mco270401-bib-0163"><label>163</label><mixed-citation publication-type="journal" id="mco270401-cit-0163"><string-name name-style="western"><given-names>Q.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Guo</surname></string-name>, et&#160;al., &#8220;<article-title>CMTM6 promotes hepatocellular carcinoma progression Through stabilizing &#946;&#8208;catenin</article-title>,&#8221; <source>Cancer Letters</source><volume>583</volume> (<year>2024</year>): <elocation-id>216585</elocation-id>.<pub-id pub-id-type="pmid">38101607</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.canlet.2023.216585</pub-id></mixed-citation></ref><ref id="mco270401-bib-0164"><label>164</label><mixed-citation publication-type="journal" id="mco270401-cit-0164"><string-name name-style="western"><given-names>H.</given-names><surname>Liao</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Zhao</surname></string-name>, et&#160;al., &#8220;<article-title>A PROTAC peptide induces durable &#946;&#8208;catenin degradation and suppresses Wnt&#8208;dependent intestinal cancer</article-title>,&#8221; <source>Cell Discovery</source><volume>6</volume> (<year>2020</year>): <fpage>35</fpage>.<pub-id pub-id-type="pmid">32550000</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41421-020-0171-1</pub-id><pub-id pub-id-type="pmcid">PMC7280531</pub-id></mixed-citation></ref><ref id="mco270401-bib-0165"><label>165</label><mixed-citation publication-type="journal" id="mco270401-cit-0165"><string-name name-style="western"><given-names>E. P.</given-names><surname>Booy</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Howard</surname></string-name>, <string-name name-style="western"><given-names>O.</given-names><surname>Marushchak</surname></string-name>, et&#160;al., &#8220;<article-title>The RNA helicase RHAU (DHX36) suppresses expression of the transcription factor PITX1</article-title>,&#8221; <source>Nucleic Acids Research</source><volume>42</volume>, no. <issue>5</issue> (<year>2014</year>): <fpage>3346</fpage>&#8211;<lpage>3361</lpage>.<pub-id pub-id-type="pmid">24369427</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkt1340</pub-id><pub-id pub-id-type="pmcid">PMC3950718</pub-id></mixed-citation></ref><ref id="mco270401-bib-0166"><label>166</label><mixed-citation publication-type="journal" id="mco270401-cit-0166"><string-name name-style="western"><given-names>M.</given-names><surname>Hluch&#253;</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Gajdu&#353;kov&#225;</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Ruiz de Los Mozos</surname></string-name>, et&#160;al., &#8220;<article-title>CDK11 regulates pre&#8208;mRNA splicing by phosphorylation of SF3B1</article-title>,&#8221; <source>Nature</source><volume>609</volume>, no. <issue>7928</issue> (<year>2022</year>): <fpage>829</fpage>&#8211;<lpage>834</lpage>.<pub-id pub-id-type="pmid">36104565</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-022-05204-z</pub-id></mixed-citation></ref><ref id="mco270401-bib-0167"><label>167</label><mixed-citation publication-type="journal" id="mco270401-cit-0167"><string-name name-style="western"><given-names>R. A.</given-names><surname>Gama&#8208;Brambila</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Zhou</surname></string-name>, et&#160;al., &#8220;<article-title>A PROTAC targets splicing factor 3B1</article-title>,&#8221; <source>Cell Chemical Biology</source><volume>28</volume>, no. <issue>11</issue> (<year>2021</year>): <fpage>1616</fpage>&#8211;<lpage>1627</lpage>. e1618.<pub-id pub-id-type="pmid">34048672</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chembiol.2021.04.018</pub-id></mixed-citation></ref><ref id="mco270401-bib-0168"><label>168</label><mixed-citation publication-type="journal" id="mco270401-cit-0168"><string-name name-style="western"><given-names>J.</given-names><surname>Zhou</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Tison</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Zhou</surname></string-name>, et&#160;al., &#8220;<article-title>STAT5 and STAT3 balance shapes dendritic cell function and tumour immunity</article-title>,&#8221; <source>Nature</source><volume>643</volume>, no. <issue>8071</issue> (<year>2025</year>): <fpage>519</fpage>&#8211;<lpage>528</lpage>.<pub-id pub-id-type="pmid">40369063</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-025-09000-3</pub-id><pub-id pub-id-type="pmcid">PMC12240842</pub-id></mixed-citation></ref><ref id="mco270401-bib-0169"><label>169</label><mixed-citation publication-type="journal" id="mco270401-cit-0169"><string-name name-style="western"><given-names>X.</given-names><surname>Xie</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Yu</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Li</surname></string-name>, et&#160;al., &#8220;<article-title>Recent advances in targeting the &#8221;undruggable&#8220; proteins: From drug discovery to clinical trials</article-title>,&#8221; <source>Signal Transduction and Targeted Therapy</source><volume>8</volume>, no. <issue>1</issue> (<year>2023</year>): <fpage>335</fpage>.<pub-id pub-id-type="pmid">37669923</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-023-01589-z</pub-id><pub-id pub-id-type="pmcid">PMC10480221</pub-id></mixed-citation></ref><ref id="mco270401-bib-0170"><label>170</label><mixed-citation publication-type="journal" id="mco270401-cit-0170"><string-name name-style="western"><given-names>D. P.</given-names><surname>Petrylak</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Gao</surname></string-name>, <string-name name-style="western"><given-names>N. J.</given-names><surname>Vogelzang</surname></string-name>, et&#160;al., &#8220;<article-title>First&#8208;in&#8208;human phase I study of ARV&#8208;110, an androgen receptor (AR) PROTAC degrader in patients (pts) With metastatic castrate&#8208;resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI)</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>38</volume>, no. <issue>15</issue> suppl (<year>2020</year>): <fpage>3500</fpage>&#8211;<lpage>3500</lpage>.</mixed-citation></ref><ref id="mco270401-bib-0171"><label>171</label><mixed-citation publication-type="journal" id="mco270401-cit-0171"><string-name name-style="western"><given-names>L.</given-names><surname>Zhao</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Han</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Lu</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>McEachern</surname></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Wang</surname></string-name>, &#8220;<article-title>A highly potent PROTAC androgen receptor (AR) degrader ARD&#8208;61 effectively inhibits AR&#8208;positive breast cancer cell growth in vitro and tumor growth in vivo</article-title>,&#8221; <source>Neoplasia</source><volume>22</volume>, no. <issue>10</issue> (<year>2020</year>): <fpage>522</fpage>&#8211;<lpage>532</lpage>.<pub-id pub-id-type="pmid">32928363</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neo.2020.07.002</pub-id><pub-id pub-id-type="pmcid">PMC7498667</pub-id></mixed-citation></ref><ref id="mco270401-bib-0172"><label>172</label><mixed-citation publication-type="journal" id="mco270401-cit-0172"><string-name name-style="western"><given-names>X.</given-names><surname>Han</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Zhao</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Xiang</surname></string-name>, et&#160;al., &#8220;<article-title>Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands</article-title>,&#8221; <source>Journal of Medicinal Chemistry</source><volume>62</volume>, no. <issue>24</issue> (<year>2019</year>): <fpage>11218</fpage>&#8211;<lpage>11231</lpage>.<pub-id pub-id-type="pmid">31804827</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.9b01393</pub-id></mixed-citation></ref><ref id="mco270401-bib-0173"><label>173</label><mixed-citation publication-type="journal" id="mco270401-cit-0173"><string-name name-style="western"><given-names>X.</given-names><surname>Han</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Zhao</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Xiang</surname></string-name>, et&#160;al., &#8220;<article-title>Strategies Toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer</article-title>,&#8221; <source>Journal of Medicinal Chemistry</source><volume>64</volume>, no. <issue>17</issue> (<year>2021</year>): <fpage>12831</fpage>&#8211;<lpage>12854</lpage>.<pub-id pub-id-type="pmid">34431670</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.1c00882</pub-id><pub-id pub-id-type="pmcid">PMC8880306</pub-id></mixed-citation></ref><ref id="mco270401-bib-0174"><label>174</label><mixed-citation publication-type="journal" id="mco270401-cit-0174"><string-name name-style="western"><given-names>W.</given-names><surname>Xiang</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Zhao</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Han</surname></string-name>, et&#160;al., &#8220;<article-title>Discovery of ARD&#8208;2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer</article-title>,&#8221; <source>Journal of Medicinal Chemistry</source><volume>64</volume>, no. <issue>18</issue> (<year>2021</year>): <fpage>13487</fpage>&#8211;<lpage>13509</lpage>.<pub-id pub-id-type="pmid">34473519</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.1c00900</pub-id><pub-id pub-id-type="pmcid">PMC8855934</pub-id></mixed-citation></ref><ref id="mco270401-bib-0175"><label>175</label><mixed-citation publication-type="journal" id="mco270401-cit-0175"><string-name name-style="western"><given-names>A. D.</given-names><surname>Takwale</surname></string-name>, <string-name name-style="western"><given-names>S. H.</given-names><surname>Jo</surname></string-name>, <string-name name-style="western"><given-names>Y. U.</given-names><surname>Jeon</surname></string-name>, et&#160;al., &#8220;<article-title>Design and characterization of cereblon&#8208;mediated androgen receptor proteolysis&#8208;targeting chimeras</article-title>,&#8221; <source>European Journal of Medicinal Chemistry</source><volume>208</volume> (<year>2020</year>): <elocation-id>112769</elocation-id>.<pub-id pub-id-type="pmid">32961381</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2020.112769</pub-id></mixed-citation></ref><ref id="mco270401-bib-0176"><label>176</label><mixed-citation publication-type="journal" id="mco270401-cit-0176"><string-name name-style="western"><given-names>K.</given-names><surname>Dalal</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Roshan&#8208;Moniri</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Sharma</surname></string-name>, et&#160;al., &#8220;<article-title>Selectively targeting the DNA&#8208;binding domain of the androgen receptor as a prospective therapy for prostate cancer</article-title>,&#8221; <source>Journal of Biological Chemistry</source><volume>289</volume>, no. <issue>38</issue> (<year>2014</year>): <fpage>26417</fpage>&#8211;<lpage>26429</lpage>.<pub-id pub-id-type="pmid">25086042</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M114.553818</pub-id><pub-id pub-id-type="pmcid">PMC4176249</pub-id></mixed-citation></ref><ref id="mco270401-bib-0177"><label>177</label><mixed-citation publication-type="journal" id="mco270401-cit-0177"><string-name name-style="western"><given-names>K.</given-names><surname>Sienkiewicz</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Yang</surname></string-name>, <string-name name-style="western"><given-names>B. M.</given-names><surname>Paschal</surname></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>Ratan</surname></string-name>, &#8220;<article-title>Genomic analyses of the metastasis&#8208;derived prostate cancer cell lines LNCaP, VCaP, and PC3&#8208;AR</article-title>,&#8221; <source>Prostate</source><volume>82</volume>, no. <issue>4</issue> (<year>2022</year>): <fpage>442</fpage>&#8211;<lpage>451</lpage>.<pub-id pub-id-type="pmid">34951700</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/pros.24290</pub-id><pub-id pub-id-type="pmcid">PMC8792310</pub-id></mixed-citation></ref><ref id="mco270401-bib-0178"><label>178</label><mixed-citation publication-type="journal" id="mco270401-cit-0178"><string-name name-style="western"><given-names>G. T.</given-names><surname>Lee</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Nagaya</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Desantis</surname></string-name>, et&#160;al., &#8220;<article-title>Effects of MTX&#8208;23, a Novel PROTAC of Androgen Receptor Splice Variant&#8208;7 and Androgen Receptor, on CRPC Resistant to Second&#8208;Line Antiandrogen Therapy</article-title>,&#8221; <source>Molecular Cancer Therapeutics</source><volume>20</volume>, no. <issue>3</issue> (<year>2021</year>): <fpage>490</fpage>&#8211;<lpage>499</lpage>.<pub-id pub-id-type="pmid">33277442</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1535-7163.MCT-20-0417</pub-id></mixed-citation></ref><ref id="mco270401-bib-0179"><label>179</label><mixed-citation publication-type="journal" id="mco270401-cit-0179"><string-name name-style="western"><given-names>E. S.</given-names><surname>Antonarakis</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Lu</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Wang</surname></string-name>, et&#160;al., &#8220;<article-title>AR&#8208;V7 and resistance to enzalutamide and abiraterone in prostate cancer</article-title>,&#8221; <source>New England Journal of Medicine</source><volume>371</volume>, no. <issue>11</issue> (<year>2014</year>): <fpage>1028</fpage>&#8211;<lpage>1038</lpage>.<pub-id pub-id-type="pmid">25184630</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1315815</pub-id><pub-id pub-id-type="pmcid">PMC4201502</pub-id></mixed-citation></ref><ref id="mco270401-bib-0180"><label>180</label><mixed-citation publication-type="journal" id="mco270401-cit-0180"><string-name name-style="western"><given-names>M. M.</given-names><surname>Regan</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Viale</surname></string-name>, <string-name name-style="western"><given-names>M. G.</given-names><surname>Mastropasqua</surname></string-name>, et&#160;al., &#8220;<article-title>Re&#8208;evaluating adjuvant breast cancer trials: Assessing hormone receptor status by immunohistochemical versus extraction assays</article-title>,&#8221; <source>Journal of the National Cancer Institute</source><volume>98</volume>, no. <issue>21</issue> (<year>2006</year>): <fpage>1571</fpage>&#8211;<lpage>1581</lpage>.<pub-id pub-id-type="pmid">17077359</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djj415</pub-id></mixed-citation></ref><ref id="mco270401-bib-0181"><label>181</label><mixed-citation publication-type="journal" id="mco270401-cit-0181"><string-name name-style="western"><given-names>E. P.</given-names><surname>Hamilton</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Ma</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>De Laurentiis</surname></string-name>, et&#160;al., &#8220;<article-title>VERITAC&#8208;2: A Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2&#8208; advanced breast cancer</article-title>,&#8221; <source>Future Oncology</source><volume>20</volume>, no. <issue>32</issue> (<year>2024</year>): <fpage>2447</fpage>&#8211;<lpage>2455</lpage>.<pub-id pub-id-type="pmid">39072356</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/14796694.2024.2377530</pub-id><pub-id pub-id-type="pmcid">PMC11524203</pub-id></mixed-citation></ref><ref id="mco270401-bib-0182"><label>182</label><mixed-citation publication-type="journal" id="mco270401-cit-0182"><string-name name-style="western"><given-names>A. S.</given-names><surname>Lu</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Rouhimoghadam</surname></string-name>, <string-name name-style="western"><given-names>C. K.</given-names><surname>Arnatt</surname></string-name>, <string-name name-style="western"><given-names>E. J.</given-names><surname>Filardo</surname></string-name>, and <string-name name-style="western"><given-names>A. K.</given-names><surname>Salem</surname></string-name>, &#8220;<article-title>Proteolytic Targeting Chimeras With Specificity for Plasma Membrane and Intracellular Estrogen Receptors</article-title>,&#8221; <source>Molecular Pharmaceutics</source><volume>18</volume>, no. <issue>3</issue> (<year>2021</year>): <fpage>1455</fpage>&#8211;<lpage>1469</lpage>.<pub-id pub-id-type="pmid">33600191</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.molpharmaceut.1c00018</pub-id><pub-id pub-id-type="pmcid">PMC9671096</pub-id></mixed-citation></ref><ref id="mco270401-bib-0183"><label>183</label><mixed-citation publication-type="journal" id="mco270401-cit-0183"><string-name name-style="western"><given-names>B. L.</given-names><surname>Roberts</surname></string-name>, <string-name name-style="western"><given-names>Z. X.</given-names><surname>Ma</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Gao</surname></string-name>, et&#160;al., &#8220;<article-title>Two&#8208;Stage Strategy for Development of Proteolysis Targeting Chimeras and its Application for Estrogen Receptor Degraders</article-title>,&#8221; <source>ACS Chemical Biology</source><volume>15</volume>, no. <issue>6</issue> (<year>2020</year>): <fpage>1487</fpage>&#8211;<lpage>1496</lpage>.<pub-id pub-id-type="pmid">32255606</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acschembio.0c00140</pub-id></mixed-citation></ref><ref id="mco270401-bib-0184"><label>184</label><mixed-citation publication-type="journal" id="mco270401-cit-0184"><string-name name-style="western"><given-names>B.</given-names><surname>Hu</surname></string-name> and <string-name name-style="western"><given-names>J.</given-names><surname>Hu</surname></string-name>, &#8220;<article-title>Complete elimination of estrogen receptor &#945; by PROTAC estrogen receptor &#945; degrader ERD&#8208;148 in breast cancer cells</article-title>,&#8221; <source>Breast Cancer Research and Treatment</source><volume>203</volume>, no. <issue>2</issue> (<year>2024</year>): <fpage>383</fpage>&#8211;<lpage>396</lpage>.<pub-id pub-id-type="pmid">37847455</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10549-023-07136-2</pub-id></mixed-citation></ref><ref id="mco270401-bib-0185"><label>185</label><mixed-citation publication-type="journal" id="mco270401-cit-0185"><string-name name-style="western"><given-names>Y.</given-names><surname>Dai</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Yue</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Gong</surname></string-name>, et&#160;al., &#8220;<article-title>Development of cell&#8208;permeable peptide&#8208;based PROTACs targeting estrogen receptor &#945;</article-title>,&#8221; <source>European Journal of Medicinal Chemistry</source><volume>187</volume> (<year>2020</year>): <elocation-id>111967</elocation-id>.<pub-id pub-id-type="pmid">31865016</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2019.111967</pub-id></mixed-citation></ref><ref id="mco270401-bib-0186"><label>186</label><mixed-citation publication-type="journal" id="mco270401-cit-0186"><string-name name-style="western"><given-names>T. L.</given-names><surname>Gonzalez</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Hancock</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Sun</surname></string-name>, et&#160;al., &#8220;<article-title>Targeted degradation of activating estrogen receptor &#945; ligand&#8208;binding domain mutations in human breast cancer</article-title>,&#8221; <source>Breast Cancer Research and Treatment</source><volume>180</volume>, no. <issue>3</issue> (<year>2020</year>): <fpage>611</fpage>&#8211;<lpage>622</lpage>.<pub-id pub-id-type="pmid">32067153</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10549-020-05564-y</pub-id></mixed-citation></ref><ref id="mco270401-bib-0187"><label>187</label><mixed-citation publication-type="journal" id="mco270401-cit-0187"><string-name name-style="western"><given-names>D. R.</given-names><surname>Cochrane</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Bernales</surname></string-name>, <string-name name-style="western"><given-names>B. M.</given-names><surname>Jacobsen</surname></string-name>, et&#160;al., &#8220;<article-title>Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide</article-title>,&#8221; <source>Breast Cancer Research</source><volume>16</volume>, no. <issue>1</issue> (<year>2014</year>): <fpage>R7</fpage>.<pub-id pub-id-type="pmid">24451109</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/bcr3599</pub-id><pub-id pub-id-type="pmcid">PMC3978822</pub-id></mixed-citation></ref><ref id="mco270401-bib-0188"><label>188</label><mixed-citation publication-type="journal" id="mco270401-cit-0188"><string-name name-style="western"><given-names>R. R.</given-names><surname>Shah</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>De Vita</surname></string-name>, and <string-name name-style="western"><given-names>P. S.</given-names><surname>Sathyamurthi</surname></string-name>, &#8220;<article-title>Structure&#8208;Guided Design and Optimization of Covalent VHL&#8208;Targeted Sulfonyl Fluoride PROTACs</article-title>,&#8221; <source>Journal of Medicinal Chemistry</source><volume>67</volume>, no. <issue>6</issue> (<year>2024</year>): <fpage>4641</fpage>&#8211;<lpage>4654</lpage>.<pub-id pub-id-type="pmid">38478885</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.3c02123</pub-id><pub-id pub-id-type="pmcid">PMC10982999</pub-id></mixed-citation></ref><ref id="mco270401-bib-0189"><label>189</label><mixed-citation publication-type="journal" id="mco270401-cit-0189"><string-name name-style="western"><given-names>V.</given-names><surname>Ritter</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Krautter</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Klein</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Jendrossek</surname></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Rudner</surname></string-name>, &#8220;<article-title>Bcl&#8208;2/Bcl&#8208;xL inhibitor ABT&#8208;263 overcomes hypoxia&#8208;driven radioresistence and improves radiotherapy</article-title>,&#8221; <source>Cell Death and Disease</source><volume>12</volume>, no. <issue>7</issue> (<year>2021</year>): <fpage>694</fpage>.<pub-id pub-id-type="pmid">34257274</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-021-03971-7</pub-id><pub-id pub-id-type="pmcid">PMC8277842</pub-id></mixed-citation></ref><ref id="mco270401-bib-0190"><label>190</label><mixed-citation publication-type="journal" id="mco270401-cit-0190"><string-name name-style="western"><given-names>E.</given-names><surname>Gonz&#225;lez&#8208;Gualda</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>P&#224;ez&#8208;Ribes</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Lozano&#8208;Torres</surname></string-name>, et&#160;al., &#8220;<article-title>Galacto&#8208;conjugation of Navitoclax as an efficient strategy to increase senolytic specificity and reduce platelet toxicity</article-title>,&#8221; <source>Aging Cell</source><volume>19</volume>, no. <issue>4</issue> (<year>2020</year>): <elocation-id>e13142</elocation-id>.<pub-id pub-id-type="pmid">32233024</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/acel.13142</pub-id><pub-id pub-id-type="pmcid">PMC7189993</pub-id></mixed-citation></ref><ref id="mco270401-bib-0191"><label>191</label><mixed-citation publication-type="journal" id="mco270401-cit-0191"><string-name name-style="western"><given-names>Y.</given-names><surname>Jia</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Han</surname></string-name>, <string-name name-style="western"><given-names>C. L.</given-names><surname>Ramage</surname></string-name>, et&#160;al., &#8220;<article-title>Co&#8208;targeting BCL&#8208;XL and BCL&#8208;2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells</article-title>,&#8221; <source>Haematologica</source><volume>108</volume>, no. <issue>10</issue> (<year>2023</year>): <fpage>2626</fpage>.<pub-id pub-id-type="pmid">37078252</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3324/haematol.2022.281915</pub-id><pub-id pub-id-type="pmcid">PMC10542840</pub-id></mixed-citation></ref><ref id="mco270401-bib-0192"><label>192</label><mixed-citation publication-type="journal" id="mco270401-cit-0192"><string-name name-style="western"><given-names>Y.</given-names><surname>Jia</surname></string-name>, <string-name name-style="western"><given-names>Q.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Zhang</surname></string-name>, et&#160;al., &#8220;<article-title>Abstract CC09&#8208;01: Targeting BCL&#8208;XL/BCL&#8208;2 by PROTAC 753b effectively eliminates AML cells and enhances efficacy of chemotherapy by targeting senescent cells</article-title>,&#8221; <source>Molecular Cancer Therapeutics</source><volume>20</volume>, no. <issue>12</issue> Supplement (<year>2021</year>): CC09&#8211;01&#8211;CC09&#8211;01.</mixed-citation></ref><ref id="mco270401-bib-0193"><label>193</label><mixed-citation publication-type="journal" id="mco270401-cit-0193"><string-name name-style="western"><given-names>X.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Thummuri</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>He</surname></string-name>, et&#160;al., &#8220;<article-title>Utilizing PROTAC technology to address the on&#8208;target platelet toxicity associated With inhibition of BCL&#8208;X L</article-title>,&#8221; <source>Chemical Communications</source><volume>55</volume>, no. <issue>98</issue> (<year>2019</year>): <fpage>14765</fpage>&#8211;<lpage>14768</lpage>.<pub-id pub-id-type="pmid">31754664</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/c9cc07217a</pub-id><pub-id pub-id-type="pmcid">PMC7057339</pub-id></mixed-citation></ref><ref id="mco270401-bib-0194"><label>194</label><mixed-citation publication-type="journal" id="mco270401-cit-0194"><string-name name-style="western"><given-names>Y.</given-names><surname>Xu</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Lei</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Zhu</surname></string-name>, and <string-name name-style="western"><given-names>L.</given-names><surname>Wan</surname></string-name>, &#8220;<article-title>Mivebresib synergized With PZ703b, a novel Bcl&#8208;xl PROTAC degrader, induces apoptosis in bladder cancer cells via the mitochondrial pathway</article-title>,&#8221; <source>Biochemical and Biophysical Research Communications</source><volume>623</volume> (<year>2022</year>): <fpage>120</fpage>&#8211;<lpage>126</lpage>.<pub-id pub-id-type="pmid">35921705</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2022.07.045</pub-id></mixed-citation></ref><ref id="mco270401-bib-0195"><label>195</label><mixed-citation publication-type="journal" id="mco270401-cit-0195"><string-name name-style="western"><given-names>D.</given-names><surname>Lv</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Pal</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Liu</surname></string-name>, et&#160;al., &#8220;<article-title>Development of a BCL&#8208;xL and BCL&#8208;2 dual degrader With improved anti&#8208;leukemic activity</article-title>,&#8221; <source>Nature Communications</source><volume>12</volume>, no. <issue>1</issue> (<year>2021</year>): <fpage>6896</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-021-27210-x</pub-id><pub-id pub-id-type="pmcid">PMC8617031</pub-id><pub-id pub-id-type="pmid">34824248</pub-id></mixed-citation></ref><ref id="mco270401-bib-0196"><label>196</label><mixed-citation publication-type="journal" id="mco270401-cit-0196"><string-name name-style="western"><given-names>S.</given-names><surname>Khan</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Wiegand</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Zhang</surname></string-name>, et&#160;al., &#8220;<article-title>BCL&#8208;X(L) PROTAC degrader DT2216 synergizes With sotorasib in preclinical models of KRAS(G12C)&#8208;mutated cancers</article-title>,&#8221; <source>Journal of Hematology &amp; Oncology</source><volume>15</volume>, no. <issue>1</issue> (<year>2022</year>): <fpage>23</fpage>.<pub-id pub-id-type="pmid">35260176</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13045-022-01241-3</pub-id><pub-id pub-id-type="pmcid">PMC8905794</pub-id></mixed-citation></ref><ref id="mco270401-bib-0197"><label>197</label><mixed-citation publication-type="journal" id="mco270401-cit-0197"><string-name name-style="western"><given-names>S.</given-names><surname>Khan</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Lv</surname></string-name>, et&#160;al., &#8220;<article-title>A selective BCL&#8208;X(L) PROTAC degrader achieves safe and potent antitumor activity</article-title>,&#8221; <source>Nature Medicine</source><volume>25</volume>, no. <issue>12</issue> (<year>2019</year>): <fpage>1938</fpage>&#8211;<lpage>1947</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-019-0668-z</pub-id><pub-id pub-id-type="pmcid">PMC6898785</pub-id><pub-id pub-id-type="pmid">31792461</pub-id></mixed-citation></ref><ref id="mco270401-bib-0198"><label>198</label><mixed-citation publication-type="journal" id="mco270401-cit-0198"><string-name name-style="western"><given-names>C.</given-names><surname>Xu</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>C. J.</given-names><surname>Pirozzi</surname></string-name>, et&#160;al., &#8220;<article-title>TP53 wild&#8208;type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist</article-title>,&#8221; <source>Acta Neuropathol Commun</source><volume>9</volume>, no. <issue>1</issue> (<year>2021</year>): <fpage>178</fpage>.<pub-id pub-id-type="pmid">34732238</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40478-021-01270-y</pub-id><pub-id pub-id-type="pmcid">PMC8565061</pub-id></mixed-citation></ref><ref id="mco270401-bib-0199"><label>199</label><mixed-citation publication-type="journal" id="mco270401-cit-0199"><string-name name-style="western"><given-names>J.</given-names><surname>Yang</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Aguilar</surname></string-name>, et&#160;al., &#8220;<article-title>Simple Structural Modifications Converting a Bona fide MDM2 PROTAC Degrader Into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders</article-title>,&#8221; <source>Journal of Medicinal Chemistry</source><volume>62</volume>, no. <issue>21</issue> (<year>2019</year>): <fpage>9471</fpage>&#8211;<lpage>9487</lpage>.<pub-id pub-id-type="pmid">31560543</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.9b00846</pub-id><pub-id pub-id-type="pmcid">PMC7354697</pub-id></mixed-citation></ref><ref id="mco270401-bib-0200"><label>200</label><mixed-citation publication-type="journal" id="mco270401-cit-0200"><string-name name-style="western"><given-names>B.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Tandon</surname></string-name>, et&#160;al., &#8220;<article-title>Development of MDM2 degraders based on ligands derived From Ugi reactions: Lessons and discoveries</article-title>,&#8221; <source>European Journal of Medicinal Chemistry</source><volume>219</volume> (<year>2021</year>): <elocation-id>113425</elocation-id>.<pub-id pub-id-type="pmid">33862513</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2021.113425</pub-id><pub-id pub-id-type="pmcid">PMC8165035</pub-id></mixed-citation></ref><ref id="mco270401-bib-0201"><label>201</label><mixed-citation publication-type="journal" id="mco270401-cit-0201"><string-name name-style="western"><given-names>A.</given-names><surname>Goerg</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Piendl</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Albert</surname></string-name>, et&#160;al., &#8220;<article-title>Mdm2 targeting via PROteolysis TArgeting Chimeras (PROTAC) is efficient in p53 wildtype, p53&#8208;mutated, and abemaciclib&#8208;resistant estrogen receptor&#8208;positive cell lines and superior to mdm2 inhibition</article-title>,&#8221; <source>BMC cancer</source><volume>25</volume>, no. <issue>1</issue> (<year>2025</year>): <fpage>978</fpage>.<pub-id pub-id-type="pmid">40452017</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12885-025-14361-z</pub-id><pub-id pub-id-type="pmcid">PMC12128487</pub-id></mixed-citation></ref><ref id="mco270401-bib-0202"><label>202</label><mixed-citation publication-type="journal" id="mco270401-cit-0202"><string-name name-style="western"><given-names>J.</given-names><surname>Mart&#237;nez&#8208;Quintanilla</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Cabot</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Sabia</surname></string-name>, et&#160;al., &#8220;<article-title>Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei</article-title>,&#8221; <source>Clinical Cancer Research</source><volume>30</volume>, no. <issue>18</issue> (<year>2024</year>): <fpage>4082</fpage>&#8211;<lpage>4099</lpage>.<pub-id pub-id-type="pmid">39018564</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-23-4072</pub-id><pub-id pub-id-type="pmcid">PMC11393541</pub-id></mixed-citation></ref><ref id="mco270401-bib-0203"><label>203</label><mixed-citation publication-type="journal" id="mco270401-cit-0203"><string-name name-style="western"><given-names>A. G.</given-names><surname>Chapdelaine</surname></string-name>, <string-name name-style="western"><given-names>G. C.</given-names><surname>Ku</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Sun</surname></string-name>, and <string-name name-style="western"><given-names>M. K.</given-names><surname>Ayrapetov</surname></string-name>, &#8220;<article-title>The Targeted Degradation of BRAF V600E Reveals the Mechanisms of Resistance to BRAF&#8208;Targeted Treatments in Colorectal Cancer Cells</article-title>,&#8221; <source>Cancers (Basel)</source><volume>15</volume>, no. <issue>24</issue> (<year>2023</year>): <fpage>5805</fpage>.<pub-id pub-id-type="pmid">38136350</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers15245805</pub-id><pub-id pub-id-type="pmcid">PMC10741866</pub-id></mixed-citation></ref><ref id="mco270401-bib-0204"><label>204</label><mixed-citation publication-type="journal" id="mco270401-cit-0204"><string-name name-style="western"><given-names>G.</given-names><surname>Posternak</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Tang</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Maisonneuve</surname></string-name>, et&#160;al., &#8220;<article-title>Functional characterization of a PROTAC directed Against BRAF mutant V600E</article-title>,&#8221; <source>Nature Chemical Biology</source><volume>16</volume>, no. <issue>11</issue> (<year>2020</year>): <fpage>1170</fpage>&#8211;<lpage>1178</lpage>.<pub-id pub-id-type="pmid">32778845</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41589-020-0609-7</pub-id><pub-id pub-id-type="pmcid">PMC7862923</pub-id></mixed-citation></ref><ref id="mco270401-bib-0205"><label>205</label><mixed-citation publication-type="journal" id="mco270401-cit-0205"><string-name name-style="western"><given-names>R.</given-names><surname>Gutzmer</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Stroyakovskiy</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Gogas</surname></string-name>, et&#160;al., &#8220;<article-title>Atezolizumab, vemurafenib, and cobimetinib as first&#8208;line treatment for unresectable advanced BRAF(V600) mutation&#8208;positive melanoma (IMspire150): Primary analysis of the randomised, double&#8208;blind, placebo&#8208;controlled, phase 3 trial</article-title>,&#8221; <source>Lancet</source><volume>395</volume>, no. <issue>10240</issue> (<year>2020</year>): <fpage>1835</fpage>&#8211;<lpage>1844</lpage>.<pub-id pub-id-type="pmid">32534646</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)30934-X</pub-id></mixed-citation></ref><ref id="mco270401-bib-0206"><label>206</label><mixed-citation publication-type="journal" id="mco270401-cit-0206"><string-name name-style="western"><given-names>D. S.</given-names><surname>Hong</surname></string-name>, <string-name name-style="western"><given-names>M. G.</given-names><surname>Fakih</surname></string-name>, <string-name name-style="western"><given-names>J. H.</given-names><surname>Strickler</surname></string-name>, et&#160;al., &#8220;<article-title>KRAS(G12C) Inhibition With Sotorasib in Advanced Solid Tumors</article-title>,&#8221; <source>New England Journal of Medicine</source><volume>383</volume>, no. <issue>13</issue> (<year>2020</year>): <fpage>1207</fpage>&#8211;<lpage>1217</lpage>.<pub-id pub-id-type="pmid">32955176</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1917239</pub-id><pub-id pub-id-type="pmcid">PMC7571518</pub-id></mixed-citation></ref><ref id="mco270401-bib-0207"><label>207</label><mixed-citation publication-type="journal" id="mco270401-cit-0207"><string-name name-style="western"><given-names>S. I.</given-names><surname>Ou</surname></string-name>, <string-name name-style="western"><given-names>P. A.</given-names><surname>J&#228;nne</surname></string-name>, <string-name name-style="western"><given-names>T. A.</given-names><surname>Leal</surname></string-name>, et&#160;al., &#8220;<article-title>First&#8208;in&#8208;Human Phase I/IB Dose&#8208;Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS(G12C) Solid Tumors (KRYSTAL&#8208;1)</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>40</volume>, no. <issue>23</issue> (<year>2022</year>): <fpage>2530</fpage>&#8211;<lpage>2538</lpage>.<pub-id pub-id-type="pmid">35167329</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.21.02752</pub-id><pub-id pub-id-type="pmcid">PMC9362872</pub-id></mixed-citation></ref><ref id="mco270401-bib-0208"><label>208</label><mixed-citation publication-type="journal" id="mco270401-cit-0208"><string-name name-style="western"><given-names>M. J.</given-names><surname>Bond</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Chu</surname></string-name>, <string-name name-style="western"><given-names>D. A.</given-names><surname>Nalawansha</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Li</surname></string-name>, and <string-name name-style="western"><given-names>C. M.</given-names><surname>Crews</surname></string-name>, &#8220;<article-title>Targeted Degradation of Oncogenic KRAS(G12C) by VHL&#8208;Recruiting PROTACs</article-title>,&#8221; <source>ACS Central Science</source><volume>6</volume>, no. <issue>8</issue> (<year>2020</year>): <fpage>1367</fpage>&#8211;<lpage>1375</lpage>.<pub-id pub-id-type="pmid">32875077</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acscentsci.0c00411</pub-id><pub-id pub-id-type="pmcid">PMC7453568</pub-id></mixed-citation></ref><ref id="mco270401-bib-0209"><label>209</label><mixed-citation publication-type="journal" id="mco270401-cit-0209"><string-name name-style="western"><given-names>L.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Wu</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Yang</surname></string-name>, et&#160;al., &#8220;<article-title>Discovery of KRas G12C&#8208;IN&#8208;3 and Pomalidomide&#8208;based PROTACs as degraders of endogenous KRAS G12C With potent anticancer activity</article-title>,&#8221; <source>Bioorganic Chemistry</source><volume>117</volume> (<year>2021</year>): <elocation-id>105447</elocation-id>.<pub-id pub-id-type="pmid">34715575</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bioorg.2021.105447</pub-id></mixed-citation></ref><ref id="mco270401-bib-0210"><label>210</label><mixed-citation publication-type="journal" id="mco270401-cit-0210"><string-name name-style="western"><given-names>F.</given-names><surname>Yang</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Wen</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Wang</surname></string-name>, et&#160;al., &#8220;<article-title>Efficient targeted oncogenic KRAS(G12C) degradation via first reversible&#8208;covalent PROTAC</article-title>,&#8221; <source>European Journal of Medicinal Chemistry</source><volume>230</volume> (<year>2022</year>): <elocation-id>114088</elocation-id>.<pub-id pub-id-type="pmid">35007863</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2021.114088</pub-id></mixed-citation></ref><ref id="mco270401-bib-0211"><label>211</label><mixed-citation publication-type="journal" id="mco270401-cit-0211"><string-name name-style="western"><given-names>M.</given-names><surname>Yang</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Chen</surname></string-name>, et&#160;al., &#8220;<article-title>Bromodomain&#8208;containing protein 4 (BRD4) as an epigenetic regulator of fatty acid metabolism genes and ferroptosis</article-title>,&#8221; <source>Cell Death and Disease</source><volume>13</volume>, no. <issue>10</issue> (<year>2022</year>): <fpage>912</fpage>.<pub-id pub-id-type="pmid">36309482</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-022-05344-0</pub-id><pub-id pub-id-type="pmcid">PMC9617950</pub-id></mixed-citation></ref><ref id="mco270401-bib-0212"><label>212</label><mixed-citation publication-type="journal" id="mco270401-cit-0212"><string-name name-style="western"><given-names>L.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Yang</surname></string-name>, <string-name name-style="western"><given-names>B. P.</given-names><surname>Lavayen</surname></string-name>, et&#160;al., &#8220;<article-title>Targeted BRD4 protein degradation by dBET1 ameliorates acute ischemic brain injury and improves functional outcomes associated With reduced neuroinflammation and oxidative stress and preservation of blood&#8208;brain barrier integrity</article-title>,&#8221; <source>Journal of Neuroinflammation</source><volume>19</volume>, no. <issue>1</issue> (<year>2022</year>): <fpage>168</fpage>.<pub-id pub-id-type="pmid">35761277</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-022-02533-8</pub-id><pub-id pub-id-type="pmcid">PMC9237998</pub-id></mixed-citation></ref><ref id="mco270401-bib-0213"><label>213</label><mixed-citation publication-type="journal" id="mco270401-cit-0213"><string-name name-style="western"><given-names>G.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Ma</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Feng</surname></string-name>, et&#160;al., &#8220;<article-title>MZ1, a BRD4 inhibitor, exerted its anti&#8208;cancer effects by suppressing SDC1 in glioblastoma</article-title>,&#8221; <source>BMC cancer</source><volume>24</volume>, no. <issue>1</issue> (<year>2024</year>): <fpage>220</fpage>.<pub-id pub-id-type="pmid">38365636</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12885-024-11966-8</pub-id><pub-id pub-id-type="pmcid">PMC10870565</pub-id></mixed-citation></ref><ref id="mco270401-bib-0214"><label>214</label><mixed-citation publication-type="journal" id="mco270401-cit-0214"><string-name name-style="western"><given-names>L.</given-names><surname>He</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Gao</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Xu</surname></string-name>, and <string-name name-style="western"><given-names>Z.</given-names><surname>Ma</surname></string-name>, &#8220;<article-title>ARV&#8208;825&#8208;induced BRD4 protein degradation as a therapy for thyroid carcinoma</article-title>,&#8221; <source>Aging</source><volume>12</volume>, no. <issue>5</issue> (<year>2020</year>): <fpage>4547</fpage>&#8211;<lpage>4557</lpage>.<pub-id pub-id-type="pmid">32163373</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.102910</pub-id><pub-id pub-id-type="pmcid">PMC7093165</pub-id></mixed-citation></ref><ref id="mco270401-bib-0215"><label>215</label><mixed-citation publication-type="journal" id="mco270401-cit-0215"><string-name name-style="western"><given-names>X.</given-names><surname>Liao</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Qian</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Zhang</surname></string-name>, et&#160;al., &#8220;<article-title>ARV&#8208;825 Demonstrates Antitumor Activity in Gastric Cancer via MYC&#8208;Targets and G2M&#8208;Checkpoint Signaling Pathways</article-title>,&#8221; <source>Frontiers in oncology</source><volume>11</volume> (<year>2021</year>): <elocation-id>753119</elocation-id>.<pub-id pub-id-type="pmid">34733788</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2021.753119</pub-id><pub-id pub-id-type="pmcid">PMC8559897</pub-id></mixed-citation></ref><ref id="mco270401-bib-0216"><label>216</label><mixed-citation publication-type="journal" id="mco270401-cit-0216"><string-name name-style="western"><given-names>C.</given-names><surname>Qin</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Hu</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Zhou</surname></string-name>, et&#160;al., &#8220;<article-title>Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra&#8208;Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression</article-title>,&#8221; <source>Journal of Medicinal Chemistry</source><volume>61</volume>, no. <issue>15</issue> (<year>2018</year>): <fpage>6685</fpage>&#8211;<lpage>6704</lpage>.<pub-id pub-id-type="pmid">30019901</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.8b00506</pub-id><pub-id pub-id-type="pmcid">PMC6545111</pub-id></mixed-citation></ref><ref id="mco270401-bib-0217"><label>217</label><mixed-citation publication-type="journal" id="mco270401-cit-0217"><string-name name-style="western"><given-names>M.</given-names><surname>Actis</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Cresser&#8208;Brown</surname></string-name>, <string-name name-style="western"><given-names>E. A.</given-names><surname>Caine</surname></string-name>, et&#160;al., &#8220;<article-title>Evaluation of Cereblon&#8208;Directing Warheads for the Development of Orally Bioavailable PROTACs</article-title>,&#8221; <source>Journal of Medicinal Chemistry</source><volume>68</volume>, no. <issue>3</issue> (<year>2025</year>): <fpage>3591</fpage>&#8211;<lpage>3611</lpage>.<pub-id pub-id-type="pmid">39813384</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.4c02709</pub-id></mixed-citation></ref><ref id="mco270401-bib-0218"><label>218</label><mixed-citation publication-type="journal" id="mco270401-cit-0218"><string-name name-style="western"><given-names>R. P.</given-names><surname>Nowak</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Xiong</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Kirmani</surname></string-name>, et&#160;al., &#8220;<article-title>Structure&#8208;Guided Design of a &#8221;Bump&#8208;and&#8208;Hole&#8220; Bromodomain&#8208;Based Degradation Tag</article-title>,&#8221; <source>Journal of Medicinal Chemistry</source><volume>64</volume>, no. <issue>15</issue> (<year>2021</year>): <fpage>11637</fpage>&#8211;<lpage>11650</lpage>.<pub-id pub-id-type="pmid">34279939</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.1c00958</pub-id></mixed-citation></ref><ref id="mco270401-bib-0219"><label>219</label><mixed-citation publication-type="journal" id="mco270401-cit-0219"><string-name name-style="western"><given-names>K.</given-names><surname>Xu</surname></string-name>, <string-name name-style="western"><given-names>Z. J.</given-names><surname>Wu</surname></string-name>, <string-name name-style="western"><given-names>A. C.</given-names><surname>Groner</surname></string-name>, et&#160;al., &#8220;<article-title>EZH2 oncogenic activity in castration&#8208;resistant prostate cancer cells is Polycomb&#8208;independent</article-title>,&#8221; <source>Science</source><volume>338</volume>, no. <issue>6113</issue> (<year>2012</year>): <fpage>1465</fpage>&#8211;<lpage>1469</lpage>.<pub-id pub-id-type="pmid">23239736</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1227604</pub-id><pub-id pub-id-type="pmcid">PMC3625962</pub-id></mixed-citation></ref><ref id="mco270401-bib-0220"><label>220</label><mixed-citation publication-type="journal" id="mco270401-cit-0220"><string-name name-style="western"><given-names>D.</given-names><surname>Du</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Xu</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Zhu</surname></string-name>, et&#160;al., &#8220;<article-title>Structure&#8208;Guided Development of Small&#8208;Molecule PRC2 Inhibitors Targeting EZH2&#8208;EED Interaction</article-title>,&#8221; <source>Journal of Medicinal Chemistry</source><volume>64</volume>, no. <issue>12</issue> (<year>2021</year>): <fpage>8194</fpage>&#8211;<lpage>8207</lpage>.<pub-id pub-id-type="pmid">34077206</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.0c02261</pub-id></mixed-citation></ref><ref id="mco270401-bib-0221"><label>221</label><mixed-citation publication-type="journal" id="mco270401-cit-0221"><string-name name-style="western"><given-names>A.</given-names><surname>Testa</surname></string-name>, <string-name name-style="western"><given-names>S. J.</given-names><surname>Hughes</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Lucas</surname></string-name>, <string-name name-style="western"><given-names>J. E.</given-names><surname>Wright</surname></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>Ciulli</surname></string-name>, &#8220;<article-title>Structure&#8208;Based Design of a Macrocyclic PROTAC</article-title>,&#8221; <source>Angewandte Chemie International Edition in English</source><volume>59</volume>, no. <issue>4</issue> (<year>2020</year>): <fpage>1727</fpage>&#8211;<lpage>1734</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/anie.201914396</pub-id><pub-id pub-id-type="pmcid">PMC7004083</pub-id><pub-id pub-id-type="pmid">31746102</pub-id></mixed-citation></ref><ref id="mco270401-bib-0222"><label>222</label><mixed-citation publication-type="journal" id="mco270401-cit-0222"><string-name name-style="western"><given-names>G.</given-names><surname>Xue</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Zhou</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Zhong</surname></string-name>, and <string-name name-style="western"><given-names>Z.</given-names><surname>Pan</surname></string-name>, &#8220;<article-title>Light&#8208;Induced Protein Degradation With Photocaged PROTACs</article-title>,&#8221; <source>Journal of the American Chemical Society</source><volume>141</volume>, no. <issue>46</issue> (<year>2019</year>): <fpage>18370</fpage>&#8211;<lpage>18374</lpage>.<pub-id pub-id-type="pmid">31566962</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jacs.9b06422</pub-id></mixed-citation></ref><ref id="mco270401-bib-0223"><label>223</label><mixed-citation publication-type="journal" id="mco270401-cit-0223"><string-name name-style="western"><given-names>F.</given-names><surname>Potjewyd</surname></string-name>, <string-name name-style="western"><given-names>A. W.</given-names><surname>Turner</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Beri</surname></string-name>, et&#160;al., &#8220;<article-title>Degradation of Polycomb Repressive Complex 2 With an EED&#8208;Targeted Bivalent Chemical Degrader</article-title>,&#8221; <source>Cell Chemical Biology</source><volume>27</volume>, no. <issue>1</issue> (<year>2020</year>): <fpage>47</fpage>&#8211;<lpage>56</lpage>. e15.<pub-id pub-id-type="pmid">31831267</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chembiol.2019.11.006</pub-id><pub-id pub-id-type="pmcid">PMC7004250</pub-id></mixed-citation></ref><ref id="mco270401-bib-0224"><label>224</label><mixed-citation publication-type="journal" id="mco270401-cit-0224"><string-name name-style="western"><given-names>A.</given-names><surname>Ma</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Stratikopoulos</surname></string-name>, <string-name name-style="western"><given-names>K. S.</given-names><surname>Park</surname></string-name>, et&#160;al., &#8220;<article-title>Discovery of a first&#8208;in&#8208;class EZH2 selective degrader</article-title>,&#8221; <source>Nature Chemical Biology</source><volume>16</volume>, no. <issue>2</issue> (<year>2020</year>): <fpage>214</fpage>&#8211;<lpage>222</lpage>.<pub-id pub-id-type="pmid">31819273</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41589-019-0421-4</pub-id><pub-id pub-id-type="pmcid">PMC6982609</pub-id></mixed-citation></ref><ref id="mco270401-bib-0225"><label>225</label><mixed-citation publication-type="journal" id="mco270401-cit-0225"><string-name name-style="western"><given-names>Z.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Hu</surname></string-name>, <string-name name-style="western"><given-names>Q.</given-names><surname>Wang</surname></string-name>, et&#160;al., &#8220;<article-title>Design and Synthesis of EZH2&#8208;Based PROTACs to Degrade the PRC2 Complex for Targeting the Noncatalytic Activity of EZH2</article-title>,&#8221; <source>Journal of Medicinal Chemistry</source><volume>64</volume>, no. <issue>5</issue> (<year>2021</year>): <fpage>2829</fpage>&#8211;<lpage>2848</lpage>.<pub-id pub-id-type="pmid">33606537</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.0c02234</pub-id></mixed-citation></ref><ref id="mco270401-bib-0226"><label>226</label><mixed-citation publication-type="journal" id="mco270401-cit-0226"><string-name name-style="western"><given-names>Y.</given-names><surname>Tu</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Sun</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Qiao</surname></string-name>, et&#160;al., &#8220;<article-title>Design, Synthesis, and Evaluation of VHL&#8208;Based EZH2 Degraders to Enhance Therapeutic Activity Against Lymphoma</article-title>,&#8221; <source>Journal of Medicinal Chemistry</source><volume>64</volume>, no. <issue>14</issue> (<year>2021</year>): <fpage>10167</fpage>&#8211;<lpage>10184</lpage>.<pub-id pub-id-type="pmid">34196564</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.1c00460</pub-id></mixed-citation></ref><ref id="mco270401-bib-0227"><label>227</label><mixed-citation publication-type="journal" id="mco270401-cit-0227"><string-name name-style="western"><given-names>J. E.</given-names><surname>Thomas</surname><suffix>2nd</suffix></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Jiang</surname></string-name>, et&#160;al., &#8220;<article-title>Discovery of Exceptionally Potent, Selective, and Efficacious PROTAC Degraders of CBP and p300 Proteins</article-title>,&#8221; <source>Journal of Medicinal Chemistry</source><volume>66</volume>, no. <issue>12</issue> (<year>2023</year>): <fpage>8178</fpage>&#8211;<lpage>8199</lpage>.<pub-id pub-id-type="pmid">37276143</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.3c00492</pub-id></mixed-citation></ref><ref id="mco270401-bib-0228"><label>228</label><mixed-citation publication-type="journal" id="mco270401-cit-0228"><string-name name-style="western"><given-names>R.</given-names><surname>Vannam</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Sayilgan</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Ojeda</surname></string-name>, et&#160;al., &#8220;<article-title>Targeted degradation of the enhancer lysine acetyltransferases CBP and p300</article-title>,&#8221; <source>Cell Chemical Biology</source><volume>28</volume>, no. <issue>4</issue> (<year>2021</year>): <fpage>503</fpage>&#8211;<lpage>514</lpage>. e512.<pub-id pub-id-type="pmid">33400925</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chembiol.2020.12.004</pub-id></mixed-citation></ref><ref id="mco270401-bib-0229"><label>229</label><mixed-citation publication-type="journal" id="mco270401-cit-0229"><string-name name-style="western"><given-names>V.</given-names><surname>Tejwani</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Carroll</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Macartney</surname></string-name>, et&#160;al., &#8220;<article-title>PROTAC&#8208;mediated conditional degradation of the WRN helicase as a potential strategy for selective killing of cancer cells With microsatellite instability</article-title>,&#8221; <source>Scientific Reports</source><volume>14</volume>, no. <issue>1</issue> (<year>2024</year>): <elocation-id>20824</elocation-id>.<pub-id pub-id-type="pmid">39242638</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-024-71160-5</pub-id><pub-id pub-id-type="pmcid">PMC11379953</pub-id></mixed-citation></ref><ref id="mco270401-bib-0230"><label>230</label><mixed-citation publication-type="journal" id="mco270401-cit-0230"><string-name name-style="western"><given-names>X.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Yao</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Wu</surname></string-name>, and <string-name name-style="western"><given-names>Y.</given-names><surname>Song</surname></string-name>, &#8220;<article-title>A proteolysis&#8208;targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth</article-title>,&#8221; <source>Journal of Hematology &amp; Oncology</source><volume>15</volume>, no. <issue>1</issue> (<year>2022</year>): <fpage>41</fpage>.<pub-id pub-id-type="pmid">35395864</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13045-022-01258-8</pub-id><pub-id pub-id-type="pmcid">PMC8994274</pub-id></mixed-citation></ref><ref id="mco270401-bib-0231"><label>231</label><mixed-citation publication-type="journal" id="mco270401-cit-0231"><string-name name-style="western"><given-names>M. F.</given-names><surname>Mabanglo</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Wilson</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Noureldin</surname></string-name>, et&#160;al., &#8220;<article-title>Crystal structures of DCAF1&#8208;PROTAC&#8208;WDR5 ternary complexes provide insight Into DCAF1 substrate specificity</article-title>,&#8221; <source>Nature Communications</source><volume>15</volume>, no. <issue>1</issue> (<year>2024</year>): <elocation-id>10165</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-024-54500-x</pub-id><pub-id pub-id-type="pmcid">PMC11585590</pub-id><pub-id pub-id-type="pmid">39580491</pub-id></mixed-citation></ref><ref id="mco270401-bib-0232"><label>232</label><mixed-citation publication-type="journal" id="mco270401-cit-0232"><string-name name-style="western"><given-names>J.</given-names><surname>Cantley</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Ye</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Rousseau</surname></string-name>, et&#160;al., &#8220;<article-title>Selective PROTAC&#8208;mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers</article-title>,&#8221; <source>Nature Communications</source><volume>13</volume>, no. <issue>1</issue> (<year>2022</year>): <fpage>6814</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-022-34562-5</pub-id><pub-id pub-id-type="pmcid">PMC9649729</pub-id><pub-id pub-id-type="pmid">36357397</pub-id></mixed-citation></ref><ref id="mco270401-bib-0233"><label>233</label><mixed-citation publication-type="journal" id="mco270401-cit-0233"><string-name name-style="western"><given-names>X.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Shi</surname></string-name>, et&#160;al., &#8220;<article-title>PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities</article-title>,&#8221; <source>Molecules (Basel, Switzerland)</source><volume>28</volume>, no. <issue>3</issue> (<year>2023</year>): <fpage>1217</fpage>.<pub-id pub-id-type="pmid">36770884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules28031217</pub-id><pub-id pub-id-type="pmcid">PMC9919707</pub-id></mixed-citation></ref><ref id="mco270401-bib-0234"><label>234</label><mixed-citation publication-type="journal" id="mco270401-cit-0234"><string-name name-style="western"><given-names>L.</given-names><surname>Garnar&#8208;Wortzel</surname></string-name>, <string-name name-style="western"><given-names>T. R.</given-names><surname>Bishop</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Kitamura</surname></string-name>, et&#160;al., &#8220;<article-title>Chemical Inhibition of ENL/AF9 YEATS Domains in Acute Leukemia</article-title>,&#8221; <source>ACS Central Science</source><volume>7</volume>, no. <issue>5</issue> (<year>2021</year>): <fpage>815</fpage>&#8211;<lpage>830</lpage>.<pub-id pub-id-type="pmid">34079898</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acscentsci.0c01550</pub-id><pub-id pub-id-type="pmcid">PMC8161486</pub-id></mixed-citation></ref><ref id="mco270401-bib-0235"><label>235</label><mixed-citation publication-type="journal" id="mco270401-cit-0235"><string-name name-style="western"><given-names>X.</given-names><surname>Yu</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Kottur</surname></string-name>, et&#160;al., &#8220;<article-title>A selective WDR5 degrader inhibits acute myeloid leukemia in patient&#8208;derived mouse models</article-title>,&#8221; <source>Science Translational Medicine</source><volume>13</volume>, no. <issue>613</issue> (<year>2021</year>): <elocation-id>eabj1578</elocation-id>.<pub-id pub-id-type="pmid">34586829</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.abj1578</pub-id><pub-id pub-id-type="pmcid">PMC8500670</pub-id></mixed-citation></ref><ref id="mco270401-bib-0236"><label>236</label><mixed-citation publication-type="journal" id="mco270401-cit-0236"><string-name name-style="western"><given-names>M.</given-names><surname>Mota</surname></string-name>, <string-name name-style="western"><given-names>S. R.</given-names><surname>Sweha</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Pun</surname></string-name>, et&#160;al., &#8220;<article-title>Targeting SWI/SNF ATPases in H3.3K27M diffuse intrinsic pontine gliomas</article-title>,&#8221; <source>Proceedings of the National Academy of Sciences of the United States of America</source><volume>120</volume>, no. <issue>18</issue> (<year>2023</year>): <elocation-id>e2221175120</elocation-id>.<pub-id pub-id-type="pmid">37094128</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2221175120</pub-id><pub-id pub-id-type="pmcid">PMC10161095</pub-id></mixed-citation></ref><ref id="mco270401-bib-0237"><label>237</label><mixed-citation publication-type="journal" id="mco270401-cit-0237"><string-name name-style="western"><given-names>W.</given-names><surname>Farnaby</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Koegl</surname></string-name>, <string-name name-style="western"><given-names>M. J.</given-names><surname>Roy</surname></string-name>, et&#160;al., &#8220;<article-title>BAF complex vulnerabilities in cancer demonstrated via structure&#8208;based PROTAC design</article-title>,&#8221; <source>Nature Chemical Biology</source><volume>15</volume>, no. <issue>7</issue> (<year>2019</year>): <fpage>672</fpage>&#8211;<lpage>680</lpage>.<pub-id pub-id-type="pmid">31178587</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41589-019-0294-6</pub-id><pub-id pub-id-type="pmcid">PMC6600871</pub-id></mixed-citation></ref><ref id="mco270401-bib-0238"><label>238</label><mixed-citation publication-type="journal" id="mco270401-cit-0238"><string-name name-style="western"><given-names>P. D.</given-names><surname>Fischer</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Papadopoulos</surname></string-name>, <string-name name-style="western"><given-names>J. M.</given-names><surname>Dempersmier</surname></string-name>, et&#160;al., &#8220;<article-title>A biphenyl inhibitor of eIF4E targeting an internal binding site enables the design of cell&#8208;permeable PROTAC&#8208;degraders</article-title>,&#8221; <source>European Journal of Medicinal Chemistry</source><volume>219</volume> (<year>2021</year>): <elocation-id>113435</elocation-id>.<pub-id pub-id-type="pmid">33892272</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2021.113435</pub-id><pub-id pub-id-type="pmcid">PMC8846605</pub-id></mixed-citation></ref><ref id="mco270401-bib-0239"><label>239</label><mixed-citation publication-type="journal" id="mco270401-cit-0239"><string-name name-style="western"><given-names>Y.</given-names><surname>Sun</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Chen</surname></string-name>, et&#160;al., &#8220;<article-title>Discovery of a potent and selective proteolysis targeting chimera (PROTAC) degrader of NSD3 histone methyltransferase</article-title>,&#8221; <source>European Journal of Medicinal Chemistry</source><volume>239</volume> (<year>2022</year>): <elocation-id>114528</elocation-id>.<pub-id pub-id-type="pmid">35717870</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2022.114528</pub-id></mixed-citation></ref><ref id="mco270401-bib-0240"><label>240</label><mixed-citation publication-type="journal" id="mco270401-cit-0240"><string-name name-style="western"><given-names>X.</given-names><surname>Jiang</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Deng</surname></string-name>, et&#160;al., &#8220;<article-title>Role of the tumor microenvironment in PD&#8208;L1/PD&#8208;1&#8208;mediated tumor immune escape</article-title>,&#8221; <source>Molecular Cancer</source><volume>18</volume>, no. <issue>1</issue> (<year>2019</year>): <fpage>10</fpage>.<pub-id pub-id-type="pmid">30646912</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-018-0928-4</pub-id><pub-id pub-id-type="pmcid">PMC6332843</pub-id></mixed-citation></ref><ref id="mco270401-bib-0241"><label>241</label><mixed-citation publication-type="journal" id="mco270401-cit-0241"><string-name name-style="western"><given-names>M.</given-names><surname>He</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Cao</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Ni</surname></string-name>, et&#160;al., &#8220;<article-title>PROTACs: Great opportunities for academia and industry (an update From 2020 to 2021)</article-title>,&#8221; <source>Signal Transduction and Targeted Therapy</source><volume>7</volume>, no. <issue>1</issue> (<year>2022</year>): <fpage>181</fpage>.<pub-id pub-id-type="pmid">35680848</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-022-00999-9</pub-id><pub-id pub-id-type="pmcid">PMC9178337</pub-id></mixed-citation></ref><ref id="mco270401-bib-0242"><label>242</label><mixed-citation publication-type="journal" id="mco270401-cit-0242"><string-name name-style="western"><given-names>Q.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Yu</surname></string-name>, et&#160;al., &#8220;<article-title>Benzosceptrin C induces lysosomal degradation of PD&#8208;L1 and promotes antitumor immunity by targeting DHHC3</article-title>,&#8221; <source>Cell Reports Medicine</source><volume>5</volume>, no. <issue>2</issue> (<year>2024</year>): <elocation-id>101357</elocation-id>.<pub-id pub-id-type="pmid">38237597</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xcrm.2023.101357</pub-id><pub-id pub-id-type="pmcid">PMC10897506</pub-id></mixed-citation></ref><ref id="mco270401-bib-0243"><label>243</label><mixed-citation publication-type="journal" id="mco270401-cit-0243"><string-name name-style="western"><given-names>Y. Y.</given-names><surname>Shi</surname></string-name>, <string-name name-style="western"><given-names>D. R.</given-names><surname>Dong</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Fan</surname></string-name>, <string-name name-style="western"><given-names>M. Y.</given-names><surname>Dai</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Liu</surname></string-name>, &#8220;<article-title>A cyclic peptide&#8208;based PROTAC induces intracellular degradation of palmitoyltransferase and potently decreases PD&#8208;L1 expression in human cervical cancer cells</article-title>,&#8221; <source>Frontiers in immunology</source><volume>14</volume> (<year>2023</year>): <elocation-id>1237964</elocation-id>.<pub-id pub-id-type="pmid">37849747</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2023.1237964</pub-id><pub-id pub-id-type="pmcid">PMC10577221</pub-id></mixed-citation></ref><ref id="mco270401-bib-0244"><label>244</label><mixed-citation publication-type="journal" id="mco270401-cit-0244"><string-name name-style="western"><given-names>M. Y.</given-names><surname>Dai</surname></string-name>, <string-name name-style="western"><given-names>Y. Y.</given-names><surname>Shi</surname></string-name>, <string-name name-style="western"><given-names>A. J.</given-names><surname>Wang</surname></string-name>, et&#160;al., &#8220;<article-title>High&#8208;potency PD&#8208;1/PD&#8208;L1 degradation induced by Peptide&#8208;PROTAC in human cancer cells</article-title>,&#8221; <source>Cell Death and Disease</source><volume>13</volume>, no. <issue>11</issue> (<year>2022</year>): <fpage>924</fpage>.<pub-id pub-id-type="pmid">36333311</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-022-05375-7</pub-id><pub-id pub-id-type="pmcid">PMC9636179</pub-id></mixed-citation></ref><ref id="mco270401-bib-0245"><label>245</label><mixed-citation publication-type="journal" id="mco270401-cit-0245"><string-name name-style="western"><given-names>R.</given-names><surname>Xu</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Zhou</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Bai</surname></string-name>, et&#160;al., &#8220;<article-title>Discovery of SD&#8208;436: A Potent, Highly Selective and Efficacious STAT3 PROTAC Degrader Capable of Achieving Complete and Long&#8208;Lasting Tumor Regression</article-title>,&#8221; <source>Journal of Medicinal Chemistry</source><volume>67</volume>, no. <issue>22</issue> (<year>2024</year>): <fpage>20495</fpage>&#8211;<lpage>20513</lpage>.<pub-id pub-id-type="pmid">39509603</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.4c01946</pub-id></mixed-citation></ref><ref id="mco270401-bib-0246"><label>246</label><mixed-citation publication-type="journal" id="mco270401-cit-0246"><string-name name-style="western"><given-names>L.</given-names><surname>Schindler</surname></string-name>, <string-name name-style="western"><given-names>L. C. D.</given-names><surname>Smyth</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Bernhagen</surname></string-name>, <string-name name-style="western"><given-names>M. B.</given-names><surname>Hampton</surname></string-name>, and <string-name name-style="western"><given-names>N.</given-names><surname>Dickerhof</surname></string-name>, &#8220;<article-title>Macrophage migration inhibitory factor (MIF) enhances hypochlorous acid production in phagocytic neutrophils</article-title>,&#8221; <source>Redox Biology</source><volume>41</volume> (<year>2021</year>): <elocation-id>101946</elocation-id>.<pub-id pub-id-type="pmid">33823474</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.redox.2021.101946</pub-id><pub-id pub-id-type="pmcid">PMC8047225</pub-id></mixed-citation></ref><ref id="mco270401-bib-0247"><label>247</label><mixed-citation publication-type="journal" id="mco270401-cit-0247"><string-name name-style="western"><given-names>A.</given-names><surname>Majumdar</surname></string-name>, <string-name name-style="western"><given-names>A. D.</given-names><surname>Petrescu</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Xiong</surname></string-name>, and <string-name name-style="western"><given-names>N.</given-names><surname>Noy</surname></string-name>, &#8220;<article-title>Nuclear translocation of cellular retinoic acid&#8208;binding protein II is regulated by retinoic acid&#8208;controlled SUMOylation</article-title>,&#8221; <source>Journal of Biological Chemistry</source><volume>286</volume>, no. <issue>49</issue> (<year>2011</year>): <fpage>42749</fpage>&#8211;<lpage>42757</lpage>.<pub-id pub-id-type="pmid">21998312</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M111.293464</pub-id><pub-id pub-id-type="pmcid">PMC3234969</pub-id></mixed-citation></ref><ref id="mco270401-bib-0248"><label>248</label><mixed-citation publication-type="journal" id="mco270401-cit-0248"><string-name name-style="western"><given-names>N.</given-names><surname>Ohoka</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Tsuji</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Shoda</surname></string-name>, et&#160;al., &#8220;<article-title>Development of Small Molecule Chimeras That Recruit AhR E3 Ligase to Target Proteins</article-title>,&#8221; <source>ACS Chemical Biology</source><volume>14</volume>, no. <issue>12</issue> (<year>2019</year>): <fpage>2822</fpage>&#8211;<lpage>2832</lpage>.<pub-id pub-id-type="pmid">31580635</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acschembio.9b00704</pub-id></mixed-citation></ref><ref id="mco270401-bib-0249"><label>249</label><mixed-citation publication-type="journal" id="mco270401-cit-0249"><string-name name-style="western"><given-names>Y.</given-names><surname>Wu</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Pu</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Fu</surname></string-name>, et&#160;al., &#8220;<article-title>NAMPT&#8208;targeting PROTAC promotes antitumor immunity via suppressing myeloid&#8208;derived suppressor cell expansion</article-title>,&#8221; <source>Acta Pharmaceutica Sinica B</source><volume>12</volume>, no. <issue>6</issue> (<year>2022</year>): <fpage>2859</fpage>&#8211;<lpage>2868</lpage>.<pub-id pub-id-type="pmid">35755293</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2021.12.017</pub-id><pub-id pub-id-type="pmcid">PMC9214341</pub-id></mixed-citation></ref><ref id="mco270401-bib-0250"><label>250</label><mixed-citation publication-type="journal" id="mco270401-cit-0250"><string-name name-style="western"><given-names>J.</given-names><surname>Cheng</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>He</surname></string-name>, et&#160;al., &#8220;<article-title>Photoswitchable PROTACs for Reversible and Spatiotemporal Regulation of NAMPT and NAD()</article-title>,&#8221; <source>Angewandte Chemie International Edition in English</source><volume>63</volume>, no. <issue>12</issue> (<year>2024</year>): <elocation-id>e202315997</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/anie.202315997</pub-id><pub-id pub-id-type="pmid">38282119</pub-id></mixed-citation></ref><ref id="mco270401-bib-0251"><label>251</label><mixed-citation publication-type="journal" id="mco270401-cit-0251"><string-name name-style="western"><given-names>K.</given-names><surname>Bi</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Cheng</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>He</surname></string-name>, et&#160;al., &#8220;<article-title>Discovery of Highly Potent Nicotinamide Phosphoribosyltransferase Degraders for Efficient Treatment of Ovarian Cancer</article-title>,&#8221; <source>Journal of Medicinal Chemistry</source><volume>66</volume>, no. <issue>1</issue> (<year>2023</year>): <fpage>1048</fpage>&#8211;<lpage>1062</lpage>.<pub-id pub-id-type="pmid">36563407</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.2c01990</pub-id></mixed-citation></ref><ref id="mco270401-bib-0252"><label>252</label><mixed-citation publication-type="journal" id="mco270401-cit-0252"><string-name name-style="western"><given-names>H.</given-names><surname>Osawa</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Kurohara</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Ito</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Shibata</surname></string-name>, and <string-name name-style="western"><given-names>Y.</given-names><surname>Demizu</surname></string-name>, &#8220;<article-title>CRBN ligand expansion for hematopoietic prostaglandin D(2) synthase (H&#8208;PGDS) targeting PROTAC design and their in vitro ADME profiles</article-title>,&#8221; <source>Bioorganic &amp; Medicinal Chemistry</source><volume>84</volume> (<year>2023</year>): <elocation-id>117259</elocation-id>.<pub-id pub-id-type="pmid">37018877</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bmc.2023.117259</pub-id></mixed-citation></ref><ref id="mco270401-bib-0253"><label>253</label><mixed-citation publication-type="journal" id="mco270401-cit-0253"><string-name name-style="western"><given-names>Y.</given-names><surname>Murakami</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Osawa</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Kurohara</surname></string-name>, et&#160;al., &#8220;<article-title>Structure&#8208;activity relationship study of PROTACs Against hematopoietic prostaglandin D(2) synthase</article-title>,&#8221; <source>RSC Medicinal Chemistry</source><volume>13</volume>, no. <issue>12</issue> (<year>2022</year>): <fpage>1495</fpage>&#8211;<lpage>1503</lpage>.<pub-id pub-id-type="pmid">36561070</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/d2md00284a</pub-id><pub-id pub-id-type="pmcid">PMC9749925</pub-id></mixed-citation></ref><ref id="mco270401-bib-0254"><label>254</label><mixed-citation publication-type="journal" id="mco270401-cit-0254"><string-name name-style="western"><given-names>X.</given-names><surname>Wang</surname></string-name> and <string-name name-style="western"><given-names>D. T.</given-names><surname>Weaver</surname></string-name>, &#8220;<article-title>The ups and downs of DNA repair biomarkers for PARP inhibitor therapies</article-title>,&#8221; <source>American Journal of Cancer Research</source><volume>1</volume>, no. <issue>3</issue> (<year>2011</year>): <fpage>301</fpage>&#8211;<lpage>327</lpage>.<pub-id pub-id-type="pmid">21968427</pub-id><pub-id pub-id-type="pmcid">PMC3180060</pub-id></mixed-citation></ref><ref id="mco270401-bib-0255"><label>255</label><mixed-citation publication-type="journal" id="mco270401-cit-0255"><string-name name-style="western"><given-names>D.</given-names><surname>Fu</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Yuan</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Qin</surname></string-name>, et&#160;al., &#8220;<article-title>Design, synthesis and biological evaluation of tyrosinase&#8208;targeting PROTACs</article-title>,&#8221; <source>European Journal of Medicinal Chemistry</source><volume>226</volume> (<year>2021</year>): <elocation-id>113850</elocation-id>.<pub-id pub-id-type="pmid">34628235</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2021.113850</pub-id></mixed-citation></ref><ref id="mco270401-bib-0256"><label>256</label><mixed-citation publication-type="journal" id="mco270401-cit-0256"><string-name name-style="western"><given-names>L. C.</given-names><surname>Czuba</surname></string-name>, <string-name name-style="western"><given-names>K. M.</given-names><surname>Hillgren</surname></string-name>, and <string-name name-style="western"><given-names>P. W.</given-names><surname>Swaan</surname></string-name>, &#8220;<article-title>Post&#8208;translational modifications of transporters</article-title>,&#8221; <source>Pharmacology &amp; Therapeutics</source><volume>192</volume> (<year>2018</year>): <fpage>88</fpage>&#8211;<lpage>99</lpage>.<pub-id pub-id-type="pmid">29966598</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pharmthera.2018.06.013</pub-id><pub-id pub-id-type="pmcid">PMC6263853</pub-id></mixed-citation></ref><ref id="mco270401-bib-0257"><label>257</label><mixed-citation publication-type="journal" id="mco270401-cit-0257"><string-name name-style="western"><given-names>A.</given-names><surname>Bensimon</surname></string-name>, <string-name name-style="western"><given-names>M. D.</given-names><surname>Pizzagalli</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Kartnig</surname></string-name>, et&#160;al., &#8220;<article-title>Targeted Degradation of SLC Transporters Reveals Amenability of Multi&#8208;Pass Transmembrane Proteins to Ligand&#8208;Induced Proteolysis</article-title>,&#8221; <source>Cell Chemical Biology</source><volume>27</volume>, no. <issue>6</issue> (<year>2020</year>): <fpage>728</fpage>&#8211;<lpage>739</lpage>. e729.<pub-id pub-id-type="pmid">32386596</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chembiol.2020.04.003</pub-id><pub-id pub-id-type="pmcid">PMC7303955</pub-id></mixed-citation></ref><ref id="mco270401-bib-0258"><label>258</label><mixed-citation publication-type="journal" id="mco270401-cit-0258"><string-name name-style="western"><given-names>N.</given-names><surname>Park</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Marquez</surname></string-name>, <string-name name-style="western"><given-names>T. K.</given-names><surname>Pham</surname></string-name>, et&#160;al., &#8220;<article-title>Cereblon contributes to cardiac dysfunction by degrading Cav1.2&#945;</article-title>,&#8221; <source>European Heart Journal</source><volume>43</volume>, no. <issue>20</issue> (<year>2022</year>): <fpage>1973</fpage>&#8211;<lpage>1989</lpage>.<pub-id pub-id-type="pmid">35190817</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehac072</pub-id></mixed-citation></ref><ref id="mco270401-bib-0259"><label>259</label><mixed-citation publication-type="journal" id="mco270401-cit-0259"><string-name name-style="western"><given-names>C. E.</given-names><surname>Powell</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Du</surname></string-name>, <string-name name-style="western"><given-names>J. W.</given-names><surname>Bushman</surname></string-name>, et&#160;al., &#8220;<article-title>Selective degradation&#8208;inducing probes for studying cereblon (CRBN) biology</article-title>,&#8221; <source>RSC Medicinal Chemistry</source><volume>12</volume>, no. <issue>8</issue> (<year>2021</year>): <fpage>1381</fpage>&#8211;<lpage>1390</lpage>.<pub-id pub-id-type="pmid">34458741</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/d0md00382d</pub-id><pub-id pub-id-type="pmcid">PMC8372211</pub-id></mixed-citation></ref><ref id="mco270401-bib-0260"><label>260</label><mixed-citation publication-type="journal" id="mco270401-cit-0260"><string-name name-style="western"><given-names>C.</given-names><surname>Maniaci</surname></string-name>, <string-name name-style="western"><given-names>S. J.</given-names><surname>Hughes</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Testa</surname></string-name>, et&#160;al., &#8220;<article-title>Homo&#8208;PROTACs: Bivalent small&#8208;molecule dimerizers of the VHL E3 ubiquitin ligase to induce self&#8208;degradation</article-title>,&#8221; <source>Nature Communications</source><volume>8</volume>, no. <issue>1</issue> (<year>2017</year>): <fpage>830</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-017-00954-1</pub-id><pub-id pub-id-type="pmcid">PMC5635026</pub-id><pub-id pub-id-type="pmid">29018234</pub-id></mixed-citation></ref><ref id="mco270401-bib-0261"><label>261</label><mixed-citation publication-type="journal" id="mco270401-cit-0261"><string-name name-style="western"><given-names>M.</given-names><surname>Hanafi</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Chen</surname></string-name>, and <string-name name-style="western"><given-names>N.</given-names><surname>Neamati</surname></string-name>, &#8220;<article-title>Discovery of a Napabucasin PROTAC as an Effective Degrader of the E3 Ligase ZFP91</article-title>,&#8221; <source>Journal of Medicinal Chemistry</source><volume>64</volume>, no. <issue>3</issue> (<year>2021</year>): <fpage>1626</fpage>&#8211;<lpage>1648</lpage>.<pub-id pub-id-type="pmid">33506674</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.0c01897</pub-id><pub-id pub-id-type="pmcid">PMC8083113</pub-id></mixed-citation></ref><ref id="mco270401-bib-0262"><label>262</label><mixed-citation publication-type="journal" id="mco270401-cit-0262"><string-name name-style="western"><given-names>W.</given-names><surname>Bi</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Zhu</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Zeng</surname></string-name>, et&#160;al., &#8220;<article-title>Investigations Into the role of 26S proteasome non&#8208;ATPase regulatory subunit 13 in neuroinflammation</article-title>,&#8221; <source>Neuroimmunomodulation</source><volume>21</volume>, no. <issue>6</issue> (<year>2014</year>): <fpage>331</fpage>&#8211;<lpage>337</lpage>.<pub-id pub-id-type="pmid">24642793</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000357811</pub-id></mixed-citation></ref><ref id="mco270401-bib-0263"><label>263</label><mixed-citation publication-type="journal" id="mco270401-cit-0263"><string-name name-style="western"><given-names>J. J.</given-names><surname>Chi</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Zhou</surname></string-name>, et&#160;al., &#8220;<article-title>A novel strategy to block mitotic progression for targeted therapy</article-title>,&#8221; <source>EBioMedicine</source><volume>49</volume> (<year>2019</year>): <fpage>40</fpage>&#8211;<lpage>54</lpage>.<pub-id pub-id-type="pmid">31669221</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ebiom.2019.10.013</pub-id><pub-id pub-id-type="pmcid">PMC6945239</pub-id></mixed-citation></ref><ref id="mco270401-bib-0264"><label>264</label><mixed-citation publication-type="journal" id="mco270401-cit-0264"><string-name name-style="western"><given-names>B. K.</given-names><surname>Neilsen</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Chakraborty</surname></string-name>, <string-name name-style="western"><given-names>J. L.</given-names><surname>McCall</surname></string-name>, et&#160;al., &#8220;<article-title>WDR5 supports colon cancer cells by promoting methylation of H3K4 and suppressing DNA damage</article-title>,&#8221; <source>BMC cancer</source><volume>18</volume>, no. <issue>1</issue> (<year>2018</year>): <fpage>673</fpage>.<pub-id pub-id-type="pmid">29925347</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12885-018-4580-6</pub-id><pub-id pub-id-type="pmcid">PMC6011590</pub-id></mixed-citation></ref><ref id="mco270401-bib-0265"><label>265</label><mixed-citation publication-type="journal" id="mco270401-cit-0265"><string-name name-style="western"><given-names>C.</given-names><surname>R&#233;b&#233;</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Filomenko</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Raveneau</surname></string-name>, et&#160;al., &#8220;<article-title>Identification of biological markers of liver X receptor (LXR) activation at the cell surface of human monocytes</article-title>,&#8221; <source>PLoS ONE</source><volume>7</volume>, no. <issue>11</issue> (<year>2012</year>): <elocation-id>e48738</elocation-id>.<pub-id pub-id-type="pmid">23185273</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0048738</pub-id><pub-id pub-id-type="pmcid">PMC3504056</pub-id></mixed-citation></ref><ref id="mco270401-bib-0266"><label>266</label><mixed-citation publication-type="journal" id="mco270401-cit-0266"><string-name name-style="western"><given-names>H.</given-names><surname>Xu</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Ohoka</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Yokoo</surname></string-name>, et&#160;al., &#8220;<article-title>Development of Agonist&#8208;Based PROTACs Targeting Liver X Receptor</article-title>,&#8221; <source>Frontiers in Chemistry</source><volume>9</volume> (<year>2021</year>): <elocation-id>674967</elocation-id>.<pub-id pub-id-type="pmid">34124002</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fchem.2021.674967</pub-id><pub-id pub-id-type="pmcid">PMC8187946</pub-id></mixed-citation></ref><ref id="mco270401-bib-0267"><label>267</label><mixed-citation publication-type="journal" id="mco270401-cit-0267"><string-name name-style="western"><given-names>J.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Lu</surname></string-name>, and <string-name name-style="western"><given-names>C.</given-names><surname>Liang</surname></string-name>, &#8220;<article-title>Targeted protein degradation in cancers: Orthodox PROTACs and Beyond</article-title>,&#8221; <source>Innovation (Camb)</source><volume>4</volume>, no. <issue>3</issue> (<year>2023</year>): <elocation-id>100413</elocation-id>.<pub-id pub-id-type="pmid">37033156</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xinn.2023.100413</pub-id><pub-id pub-id-type="pmcid">PMC10074253</pub-id></mixed-citation></ref><ref id="mco270401-bib-0268"><label>268</label><mixed-citation publication-type="journal" id="mco270401-cit-0268"><string-name name-style="western"><given-names>J. A.</given-names><surname>Marteijn</surname></string-name>, <string-name name-style="western"><given-names>L. T.</given-names><surname>van der Meer</surname></string-name>, <string-name name-style="western"><given-names>J. J.</given-names><surname>Smit</surname></string-name>, et&#160;al., &#8220;<article-title>The ubiquitin ligase Triad1 inhibits myelopoiesis Through UbcH7 and Ubc13 interacting domains</article-title>,&#8221; <source>Leukemia</source><volume>23</volume>, no. <issue>8</issue> (<year>2009</year>): <fpage>1480</fpage>&#8211;<lpage>1489</lpage>.<pub-id pub-id-type="pmid">19340006</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/leu.2009.57</pub-id></mixed-citation></ref><ref id="mco270401-bib-0269"><label>269</label><mixed-citation publication-type="journal" id="mco270401-cit-0269"><string-name name-style="western"><given-names>V. M.</given-names><surname>Vergara</surname></string-name>, <string-name name-style="western"><given-names>A. R.</given-names><surname>Mayer</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Damaraju</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Hutchison</surname></string-name>, and <string-name name-style="western"><given-names>V. D.</given-names><surname>Calhoun</surname></string-name>, &#8220;<article-title>The effect of preprocessing pipelines in subject classification and detection of abnormal resting state functional network connectivity using group ICA</article-title>,&#8221; <source>Neuroimage</source><volume>145</volume> (<year>2017</year>): <fpage>365</fpage>&#8211;<lpage>376</lpage>.<pub-id pub-id-type="pmid">27033684</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2016.03.038</pub-id><pub-id pub-id-type="pmcid">PMC5035165</pub-id></mixed-citation></ref><ref id="mco270401-bib-0270"><label>270</label><mixed-citation publication-type="book" id="mco270401-cit-0270"><string-name name-style="western"><given-names>R. B.</given-names><surname>Kargbo</surname></string-name>, <source>PROTAC Degradation of IRAK4 for the Treatment of Neurodegenerative and Cardiovascular Diseases[Z]</source> (<publisher-name>ACS Publications</publisher-name>, <year>2019</year>): <fpage>1251</fpage>&#8211;<lpage>1252</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsmedchemlett.9b00385</pub-id><pub-id pub-id-type="pmcid">PMC6746078</pub-id><pub-id pub-id-type="pmid">31531192</pub-id></mixed-citation></ref><ref id="mco270401-bib-0271"><label>271</label><mixed-citation publication-type="journal" id="mco270401-cit-0271"><string-name name-style="western"><given-names>X.</given-names><surname>Yang</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Pei</surname></string-name>, et&#160;al., &#8220;<article-title>Discovery of thalidomide&#8208;based PROTAC small molecules as the highly efficient SHP2 degraders</article-title>,&#8221; <source>European Journal of Medicinal Chemistry</source><volume>218</volume> (<year>2021</year>): <elocation-id>113341</elocation-id>.<pub-id pub-id-type="pmid">33780898</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2021.113341</pub-id></mixed-citation></ref><ref id="mco270401-bib-0272"><label>272</label><mixed-citation publication-type="journal" id="mco270401-cit-0272"><string-name name-style="western"><given-names>X.</given-names><surname>Gao</surname></string-name>, <string-name name-style="western"><given-names>H. A.</given-names><surname>Burris</surname><suffix>III</suffix></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Vuky</surname></string-name>, &#8220;<article-title>Phase 1/2 study of ARV&#8208;110, an androgen receptor (AR) PROTAC degrader, in metastatic castration&#8208;resistant prostate cancer (mCRPC)[Z]</article-title>,&#8221; <source>American Society of Clinical Oncology</source><volume>40</volume>, no. <issue>6</issue> suppl (<year>2022</year>): <fpage>17</fpage>&#8211;<lpage>17</lpage>.</mixed-citation></ref><ref id="mco270401-bib-0273"><label>273</label><mixed-citation publication-type="journal" id="mco270401-cit-0273"><string-name name-style="western"><given-names>S. M.</given-names><surname>Gough</surname></string-name>, <string-name name-style="western"><given-names>J. J.</given-names><surname>Flanagan</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Teh</surname></string-name>, et&#160;al., &#8220;<article-title>Oral estrogen receptor PROTAC vepdegestrant (ARV&#8208;471) is highly efficacious as monotherapy and in combination With CDK4/6 or PI3K/mTOR pathway inhibitors in preclinical ER+ breast cancer models</article-title>,&#8221; <source>Clinical Cancer Research</source><volume>30</volume>, no. <issue>16</issue> (<year>2024</year>): <fpage>3549</fpage>&#8211;<lpage>3563</lpage>.<pub-id pub-id-type="pmid">38819400</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-23-3465</pub-id><pub-id pub-id-type="pmcid">PMC11325148</pub-id></mixed-citation></ref><ref id="mco270401-bib-0274"><label>274</label><mixed-citation publication-type="journal" id="mco270401-cit-0274"><string-name name-style="western"><given-names>S.</given-names><surname>Jaime&#8208;Figueroa</surname></string-name>, <string-name name-style="western"><given-names>A. D.</given-names><surname>Buhimschi</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Toure</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Hines</surname></string-name>, and <string-name name-style="western"><given-names>C. M.</given-names><surname>Crews</surname></string-name>, &#8220;<article-title>Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders With improved pharmacokinetic properties</article-title>,&#8221; <source>Bioorganic &amp; Medicinal Chemistry Letters</source><volume>30</volume>, no. <issue>3</issue> (<year>2020</year>): <elocation-id>126877</elocation-id>.<pub-id pub-id-type="pmid">31879210</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bmcl.2019.126877</pub-id><pub-id pub-id-type="pmcid">PMC7318425</pub-id></mixed-citation></ref><ref id="mco270401-bib-0275"><label>275</label><mixed-citation publication-type="journal" id="mco270401-cit-0275"><string-name name-style="western"><given-names>J. F.</given-names><surname>Seymour</surname></string-name>, <string-name name-style="western"><given-names>C. Y.</given-names><surname>Cheah</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Parrondo</surname></string-name>, et&#160;al., &#8220;<article-title>First results From a phase 1, first&#8208;in&#8208;human study of the Bruton's tyrosine kinase (BTK) degrader Bgb&#8208;16673 in patients (Pts) With relapsed or refractory (R/R) B&#8208;cell malignancies (BGB&#8208;16673&#8208;101)</article-title>,&#8221; <source>Blood</source><volume>142</volume> (<year>2023</year>): <fpage>4401</fpage>.</mixed-citation></ref><ref id="mco270401-bib-0276"><label>276</label><mixed-citation publication-type="journal" id="mco270401-cit-0276"><string-name name-style="western"><given-names>L.</given-names><surname>Zheng</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Cao</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Ma</surname></string-name>, et&#160;al., &#8220;<article-title>LC&#8208;MF&#8208;4, a Novel FGFR3 Degrader for Therapeutic Intervention in FGFR3&#8208;Altered Cancers</article-title>,&#8221; <source>Journal of Medicinal Chemistry</source><volume>68</volume>, no. <issue>13</issue> (<year>2025</year>): <fpage>13858</fpage>&#8211;<lpage>13871</lpage>.<pub-id pub-id-type="pmid">40575843</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.5c00731</pub-id></mixed-citation></ref><ref id="mco270401-bib-0277"><label>277</label><mixed-citation publication-type="journal" id="mco270401-cit-0277"><string-name name-style="western"><given-names>H.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>H.&#8208;Y.</given-names><surname>Zhao</surname></string-name>, <string-name name-style="western"><given-names>X.&#8208;X.</given-names><surname>Xi</surname></string-name>, et&#160;al., &#8220;<article-title>Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC)</article-title>,&#8221; <source>European Journal of Medicinal Chemistry</source><volume>189</volume> (<year>2020</year>): <elocation-id>112061</elocation-id>.<pub-id pub-id-type="pmid">31951960</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2020.112061</pub-id></mixed-citation></ref><ref id="mco270401-bib-0278"><label>278</label><mixed-citation publication-type="book" id="mco270401-cit-0278"><string-name name-style="western"><given-names>D. E.</given-names><surname>Rathkopf</surname></string-name>, <string-name name-style="western"><given-names>M. R.</given-names><surname>Patel</surname></string-name>, <string-name name-style="western"><given-names>A. D.</given-names><surname>Choudhury</surname></string-name>, et&#160;al., <source>First&#8208;in&#8208;human phase 1 study of CC&#8208;94676, a first&#8208;in&#8208;class androgen receptor (AR) ligand&#8208;directed degrader (LDD), in patients (pts) With metastatic castration&#8208;resistant prostate cancer (mCRPC)[Z]</source> (<publisher-name>American Society of Clinical Oncology</publisher-name>, <year>2024</year>).</mixed-citation></ref><ref id="mco270401-bib-0279"><label>279</label><mixed-citation publication-type="journal" id="mco270401-cit-0279"><string-name name-style="western"><given-names>E. P.</given-names><surname>Hamilton</surname></string-name>, <string-name name-style="western"><given-names>A. F.</given-names><surname>Schott</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Nanda</surname></string-name>, et&#160;al., &#8220;<article-title>ARV&#8208;471, an estrogen receptor (ER) PROTAC degrader, combined With palbociclib in advanced ER+/human epidermal growth factor receptor 2&#8211;negative (HER2&#8208;) breast cancer: Phase 1b cohort (part C) of a phase 1/2 study[Z]</article-title>,&#8221; <source>American Society of Clinical Oncology</source><volume>40</volume>, no. <issue>16</issue> suppl (<year>2022</year>): <fpage>TPS1120</fpage>&#8211;<lpage>TPS1120</lpage>.</mixed-citation></ref><ref id="mco270401-bib-0280"><label>280</label><mixed-citation publication-type="journal" id="mco270401-cit-0280"><string-name name-style="western"><given-names>T. H.</given-names><surname>Bae</surname></string-name>, <string-name name-style="western"><given-names>K. W.</given-names><surname>Sung</surname></string-name>, <string-name name-style="western"><given-names>T. M.</given-names><surname>Pham</surname></string-name>, et&#160;al., &#8220;<article-title>An Autophagy&#8208;Targeting Chimera Induces Degradation of Androgen Receptor Mutants and AR&#8208;v7 in Castration&#8208;Resistant Prostate Cancer</article-title>,&#8221; <source>Cancer Research</source><volume>85</volume>, no. <issue>2</issue> (<year>2025</year>): <fpage>342</fpage>&#8211;<lpage>359</lpage>.<pub-id pub-id-type="pmid">39531508</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-24-0591</pub-id><pub-id pub-id-type="pmcid">PMC11733533</pub-id></mixed-citation></ref><ref id="mco270401-bib-0281"><label>281</label><mixed-citation publication-type="journal" id="mco270401-cit-0281"><string-name name-style="western"><given-names>X.</given-names><surname>Han</surname></string-name> and <string-name name-style="western"><given-names>Y.</given-names><surname>Sun</surname></string-name>, &#8220;<article-title>Strategies for the discovery of oral PROTAC degraders aimed at cancer therapy</article-title>,&#8221; <source>Cell Reports Physical Science</source><volume>3</volume>, no. <issue>10</issue> (<year>2022</year>): <elocation-id>101062</elocation-id>.</mixed-citation></ref><ref id="mco270401-bib-0282"><label>282</label><mixed-citation publication-type="journal" id="mco270401-cit-0282"><string-name name-style="western"><given-names>S. R.</given-names><surname>Boyd</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Chamakuri</surname></string-name>, <string-name name-style="western"><given-names>A. J.</given-names><surname>Trostle</surname></string-name>, et&#160;al., &#8220;<article-title>MYC&#8208;targeting PROTACs lead to bimodal degradation and N&#8208;terminal truncation</article-title>,&#8221; <source>ACS Chemical Biology</source><volume>20</volume>, no. <issue>4</issue> (<year>2025</year>): <fpage>896</fpage>&#8211;<lpage>906</lpage>.<pub-id pub-id-type="pmid">40146931</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acschembio.4c00864</pub-id></mixed-citation></ref><ref id="mco270401-bib-0283"><label>283</label><mixed-citation publication-type="journal" id="mco270401-cit-0283"><string-name name-style="western"><given-names>S. U.</given-names><surname>Zaman</surname></string-name>, <string-name name-style="western"><given-names>P. P.</given-names><surname>Pagare</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Ma</surname></string-name>, et&#160;al., &#8220;<article-title>Novel PROTAC probes targeting KDM3 degradation to eliminate colorectal cancer stem cells Through inhibition of Wnt/&#946;&#8208;catenin signaling</article-title>,&#8221; <source>RSC Medicinal Chemistry</source><volume>15</volume>, no. <issue>11</issue> (<year>2024</year>): <fpage>3746</fpage>&#8211;<lpage>3758</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/d4md00122b</pub-id><pub-id pub-id-type="pmcid">PMC11393732</pub-id><pub-id pub-id-type="pmid">39281802</pub-id></mixed-citation></ref><ref id="mco270401-bib-0284"><label>284</label><mixed-citation publication-type="journal" id="mco270401-cit-0284"><string-name name-style="western"><given-names>H.</given-names><surname>Zhou</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Bai</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Xu</surname></string-name>, et&#160;al., &#8220;<article-title>Structure&#8208;based discovery of SD&#8208;36 as a potent, selective, and efficacious PROTAC degrader of STAT3 protein</article-title>,&#8221; <source>Journal of Medicinal Chemistry</source><volume>62</volume>, no. <issue>24</issue> (<year>2019</year>): <fpage>11280</fpage>&#8211;<lpage>11300</lpage>.<pub-id pub-id-type="pmid">31747516</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.9b01530</pub-id><pub-id pub-id-type="pmcid">PMC8848307</pub-id></mixed-citation></ref><ref id="mco270401-bib-0285"><label>285</label><mixed-citation publication-type="journal" id="mco270401-cit-0285"><string-name name-style="western"><given-names>P.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Liu</surname></string-name>, et&#160;al., &#8220;<article-title>PROTACs are effective in addressing the platelet toxicity associated With BCL&#8208;XL inhibitors</article-title>,&#8221; <source>Exploration of Targeted anti&#8208;tumor Therapy</source><volume>1</volume>, no. <issue>4</issue> (<year>2020</year>): <fpage>259</fpage>.<pub-id pub-id-type="pmid">34296214</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.37349/etat.2020.00017</pub-id><pub-id pub-id-type="pmcid">PMC8293695</pub-id></mixed-citation></ref><ref id="mco270401-bib-0286"><label>286</label><mixed-citation publication-type="journal" id="mco270401-cit-0286"><string-name name-style="western"><given-names>M. J.</given-names><surname>Bond</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Chu</surname></string-name>, <string-name name-style="western"><given-names>D. A.</given-names><surname>Nalawansha</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Li</surname></string-name>, and <string-name name-style="western"><given-names>C. M.</given-names><surname>Crews</surname></string-name>, &#8220;<article-title>Targeted degradation of oncogenic KRASG12C by VHL&#8208;recruiting PROTACs</article-title>,&#8221; <source>ACS Central Science</source><volume>6</volume>, no. <issue>8</issue> (<year>2020</year>): <fpage>1367</fpage>&#8211;<lpage>1375</lpage>.<pub-id pub-id-type="pmid">32875077</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acscentsci.0c00411</pub-id><pub-id pub-id-type="pmcid">PMC7453568</pub-id></mixed-citation></ref><ref id="mco270401-bib-0287"><label>287</label><mixed-citation publication-type="journal" id="mco270401-cit-0287"><string-name name-style="western"><given-names>E.</given-names><surname>Jeon</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Kim</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Ko</surname></string-name>, et&#160;al., &#8220;<article-title>KRASG12D selective VHL&#8208;PROTAC With sparing KRASWT and other KRAS mutants</article-title>,&#8221; <source>European Journal of Medicinal Chemistry</source><volume>297</volume> (<year>2025</year>): <elocation-id>117928</elocation-id>.<pub-id pub-id-type="pmid">40651134</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2025.117928</pub-id></mixed-citation></ref><ref id="mco270401-bib-0288"><label>288</label><mixed-citation publication-type="journal" id="mco270401-cit-0288"><string-name name-style="western"><given-names>C.</given-names><surname>Zhou</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Fan</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Gu</surname></string-name>, et&#160;al., &#8220;<article-title>Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRASG12D</article-title>,&#8221; <source>Journal of Medicinal Chemistry</source><volume>67</volume>, no. <issue>2</issue> (<year>2024</year>): <fpage>1147</fpage>&#8211;<lpage>1167</lpage>.<pub-id pub-id-type="pmid">38197882</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.3c01622</pub-id></mixed-citation></ref><ref id="mco270401-bib-0289"><label>289</label><mixed-citation publication-type="journal" id="mco270401-cit-0289"><string-name name-style="western"><given-names>M.</given-names><surname>Gonzales&#8208;Cope</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Sidoli</surname></string-name>, <string-name name-style="western"><given-names>N. V.</given-names><surname>Bhanu</surname></string-name>, <string-name name-style="western"><given-names>K.&#8208;J.</given-names><surname>Won</surname></string-name>, and <string-name name-style="western"><given-names>B. A.</given-names><surname>Garcia</surname></string-name>, &#8220;<article-title>Histone H4 acetylation and the epigenetic reader Brd4 are critical regulators of pluripotency in embryonic stem cells</article-title>,&#8221; <source>BMC Genomics [Electronic Resource]</source><volume>17</volume>, no. <issue>1</issue> (<year>2016</year>): <fpage>95</fpage>.<pub-id pub-id-type="pmid">26847871</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12864-016-2414-y</pub-id><pub-id pub-id-type="pmcid">PMC4740988</pub-id></mixed-citation></ref><ref id="mco270401-bib-0290"><label>290</label><mixed-citation publication-type="journal" id="mco270401-cit-0290"><string-name name-style="western"><given-names>R. A.</given-names><surname>Rao</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Dhele</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Cheemadan</surname></string-name>, et&#160;al., &#8220;<article-title>Ezh2 mediated H3K27me3 activity facilitates somatic transition During human pluripotent reprogramming</article-title>,&#8221; <source>Scientific Reports</source><volume>5</volume>, no. <issue>1</issue> (<year>2015</year>): <fpage>8229</fpage>.<pub-id pub-id-type="pmid">25648270</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep08229</pub-id><pub-id pub-id-type="pmcid">PMC4316165</pub-id></mixed-citation></ref><ref id="mco270401-bib-0291"><label>291</label><mixed-citation publication-type="journal" id="mco270401-cit-0291"><string-name name-style="western"><given-names>Q.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Yang</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Liu</surname></string-name>, et&#160;al., &#8220;<article-title>Histone acetyltransferases CBP/p300 in tumorigenesis and CBP/p300 inhibitors as promising novel anticancer agents</article-title>,&#8221; <source>Theranostics</source><volume>12</volume>, no. <issue>11</issue> (<year>2022</year>): <fpage>4935</fpage>.<pub-id pub-id-type="pmid">35836809</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.73223</pub-id><pub-id pub-id-type="pmcid">PMC9274749</pub-id></mixed-citation></ref><ref id="mco270401-bib-0292"><label>292</label><mixed-citation publication-type="journal" id="mco270401-cit-0292"><string-name name-style="western"><given-names>J.</given-names><surname>Guo</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Yu</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Zhang</surname></string-name>, et&#160;al., &#8220;<article-title>Beyond inhibition Against the PD&#8208;1/PD&#8208;L1 pathway: Development of PD&#8208;L1 inhibitors targeting internalization and degradation of PD&#8208;L1</article-title>,&#8221; <source>RSC Medicinal Chemistry</source><volume>15</volume>, no. <issue>4</issue> (<year>2024</year>): <fpage>1096</fpage>&#8211;<lpage>1108</lpage>.<pub-id pub-id-type="pmid">38665824</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/d3md00636k</pub-id><pub-id pub-id-type="pmcid">PMC11042118</pub-id></mixed-citation></ref><ref id="mco270401-bib-0293"><label>293</label><mixed-citation publication-type="journal" id="mco270401-cit-0293"><string-name name-style="western"><given-names>G.</given-names><surname>Zhong</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Chang</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Xie</surname></string-name>, and <string-name name-style="western"><given-names>X.</given-names><surname>Zhou</surname></string-name>, &#8220;<article-title>Targeted protein degradation: Advances in drug discovery and clinical practice</article-title>,&#8221; <source>Signal Transduction and Targeted Therapy</source><volume>9</volume>, no. <issue>1</issue> (<year>2024</year>): <fpage>308</fpage>.<pub-id pub-id-type="pmid">39500878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-024-02004-x</pub-id><pub-id pub-id-type="pmcid">PMC11539257</pub-id></mixed-citation></ref><ref id="mco270401-bib-0294"><label>294</label><mixed-citation publication-type="miscellaneous" id="mco270401-cit-0294"><string-name name-style="western"><given-names>L.</given-names><surname>Tran</surname></string-name>, <string-name name-style="western"><given-names>J. A.</given-names><surname>Winton</surname></string-name>, <string-name name-style="western"><given-names>K. T.</given-names><surname>Matschke</surname></string-name>, et&#160;al., &#8220;<article-title>The Effect of Itraconazole on the Pharmacokinetics of Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader in Healthy Adult Participants</article-title>,&#8221; (<year>2024</year>).</mixed-citation></ref><ref id="mco270401-bib-0295"><label>295</label><mixed-citation publication-type="journal" id="mco270401-cit-0295"><string-name name-style="western"><given-names>S.</given-names><surname>Hurvitz</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Schott</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Ma</surname></string-name>, et&#160;al., &#8220;<article-title>205P VERITAC update: Phase II study of ARV&#8208;471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader in ER+/human epidermal growth factor receptor 2 (HER2)&#8208;advanced breast cancer</article-title>,&#8221; <source>ESMO Open</source><volume>8</volume>, no. <issue>1</issue> (<year>2023</year>): <elocation-id>101394</elocation-id>.</mixed-citation></ref><ref id="mco270401-bib-0296"><label>296</label><mixed-citation publication-type="journal" id="mco270401-cit-0296"><string-name name-style="western"><given-names>A.</given-names><surname>Philipovskiy</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Schott</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Cort&#233;s</surname></string-name>, et&#160;al., &#8220;<article-title>256TiP TACTIVE&#8208;E: Phase Ib study of ARV&#8208;471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in combination With everolimus in ER+/human epidermal growth factor receptor 2 (HER2)&#8208;advanced breast cancer</article-title>,&#8221; <source>ESMO Open</source><volume>8</volume>, no. <issue>1</issue> (<year>2023</year>).</mixed-citation></ref><ref id="mco270401-bib-0297"><label>297</label><mixed-citation publication-type="journal" id="mco270401-cit-0297"><string-name name-style="western"><given-names>H.</given-names><surname>Iwata</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Hamilton</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Ma</surname></string-name>, et&#160;al., &#8220;<article-title>73TiP Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)&#8208;advanced breast cancer: VERITAC&#8208;2 and VERITAC&#8208;3</article-title>,&#8221; <source>Annals of Oncology</source><volume>34</volume> (<year>2023</year>): <elocation-id>S1493</elocation-id>.</mixed-citation></ref><ref id="mco270401-bib-0298"><label>298</label><mixed-citation publication-type="journal" id="mco270401-cit-0298"><string-name name-style="western"><given-names>P.</given-names><surname>Fasching</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Clifton</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Katashvili</surname></string-name>, et&#160;al., &#8220;<article-title>154TiP TACTIVE&#8208;N: Open&#8208;label, randomized, noncomparative neoadjuvant phase 2 study of ARV&#8208;471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, or anastrozole in postmenopausal women With ER+/human epidermal growth factor receptor 2 (HER2)&#8208;localized breast cancer</article-title>,&#8221; <source>ESMO Open</source><volume>8</volume>, no. <issue>1</issue> (<year>2023</year>).</mixed-citation></ref><ref id="mco270401-bib-0299"><label>299</label><mixed-citation publication-type="journal" id="mco270401-cit-0299"><string-name name-style="western"><given-names>J.</given-names><surname>Hilton</surname></string-name>, <string-name name-style="western"><given-names>K. J.</given-names><surname>Jerzak</surname></string-name>, <string-name name-style="western"><given-names>A. J.</given-names><surname>Chien</surname></string-name>, et&#160;al., &#8220;<article-title>Abstract P4&#8208;12&#8208;03: Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Plus Abemaciclib in ER&#8208;Pos/Human Epidermal Growth Factor Receptor 2 (HER2)&#8208;Negative Advanced or Metastatic Breast Cancer: TACTIVE&#8208;U Prelim Phase 1b Results</article-title>,&#8221; <source>Clinical Cancer Research</source><volume>31</volume>, no. <issue>12</issue> Supplement (<year>2025</year>): P4&#8211;12&#8211;03&#8211;P14&#8211;12&#8211;03.</mixed-citation></ref><ref id="mco270401-bib-0300"><label>300</label><mixed-citation publication-type="journal" id="mco270401-cit-0300"><string-name name-style="western"><given-names>D. Z.</given-names><surname>Yang</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Zhou</surname></string-name>, <string-name name-style="western"><given-names>J. A.</given-names><surname>Winton</surname></string-name>, et&#160;al., &#8220;<article-title>Effect of vepdegestrant, a PROTAC oestrogen receptor degrader, on dabigatran and rosuvastatin pharmacokinetics in healthy participants</article-title>,&#8221; <source>British Journal of Clinical Pharmacology</source> (<year>2025</year>).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/bcp.70198</pub-id><pub-id pub-id-type="pmid">40825714</pub-id></mixed-citation></ref><ref id="mco270401-bib-0301"><label>301</label><mixed-citation publication-type="journal" id="mco270401-cit-0301"><string-name name-style="western"><given-names>H.</given-names><surname>Iwata</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Naito</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Hattori</surname></string-name>, et&#160;al., &#8220;<article-title>58P Safety and pharmacokinetics (PK) of vepdegestrant in Japanese patients With estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)&#8208;advanced breast cancer: Results From a Japanese phase I study</article-title>,&#8221; <source>Annals of Oncology</source><volume>34</volume> (<year>2023</year>): <fpage>S1488</fpage>&#8211;<lpage>S1489</lpage>.</mixed-citation></ref><ref id="mco270401-bib-0302"><label>302</label><mixed-citation publication-type="journal" id="mco270401-cit-0302"><string-name name-style="western"><given-names>M.</given-names><surname>Campone</surname></string-name>, <string-name name-style="western"><given-names>C. X.</given-names><surname>Ma</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>De Laurentiis</surname></string-name>, et&#160;al., &#8220;<article-title>VERITAC&#8208;2: A global, randomized phase 3 study of ARV&#8208;471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, vs fulvestrant in ER+/human epidermal growth factor receptor 2 (HER2)&#8208;advanced breast cancer</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>41</volume>, no. <issue>16</issue> Suppl (<year>2023</year>).</mixed-citation></ref><ref id="mco270401-bib-0303"><label>303</label><mixed-citation publication-type="journal" id="mco270401-cit-0303"><string-name name-style="western"><given-names>S.</given-names><surname>Drescher</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Tan</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Zhang</surname></string-name>, and <string-name name-style="western"><given-names>J. P.</given-names><surname>Smith</surname></string-name>, &#8220;<article-title>Abstract P4&#8208;08&#8208;13: Evaluating CYP3A4&#8208;Mediated Drug Interaction Risks for Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in Combination With Cyclin&#8208;Dependent Kinase (CDK) 4/6 Inhibitors and Everolimus</article-title>,&#8221; <source>Clinical Cancer Research</source><volume>31</volume>, no. <issue>12</issue> Supplement (<year>2025</year>): P4&#8211;08&#8211;13&#8211;P04&#8211;08&#8211;13.</mixed-citation></ref><ref id="mco270401-bib-0304"><label>304</label><mixed-citation publication-type="journal" id="mco270401-cit-0304"><string-name name-style="western"><given-names>M.</given-names><surname>Telli</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Gawryletz</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Wei</surname></string-name>, et&#160;al., &#8220;<article-title>264TiP TACTIVE&#8208;K: Phase Ib/II study of vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in combination With PF&#8208;07220060, a cyclin&#8208;dependent kinase (CDK) 4 inhibitor, in ER+/human epidermal growth factor receptor 2 (HER2)&#8208;advanced breast cancer</article-title>,&#8221; <source>ESMO Open</source><volume>9</volume> (<year>2024</year>): <elocation-id>103285</elocation-id>.</mixed-citation></ref><ref id="mco270401-bib-0305"><label>305</label><mixed-citation publication-type="journal" id="mco270401-cit-0305"><string-name name-style="western"><given-names>H.</given-names><surname>Yokoo</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Naito</surname></string-name>, and <string-name name-style="western"><given-names>Y.</given-names><surname>Demizu</surname></string-name>, &#8220;<article-title>Investigating the cell permeability of proteolysis&#8208;targeting chimeras (PROTACs)</article-title>,&#8221; <source>Expert Opinion on Drug Discovery</source><volume>18</volume>, no. <issue>4</issue> (<year>2023</year>): <fpage>357</fpage>&#8211;<lpage>361</lpage>.<pub-id pub-id-type="pmid">36908022</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/17460441.2023.2187047</pub-id></mixed-citation></ref><ref id="mco270401-bib-0306"><label>306</label><mixed-citation publication-type="journal" id="mco270401-cit-0306"><string-name name-style="western"><given-names>W.</given-names><surname>Zhao</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Jiang</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Li</surname></string-name>, and <string-name name-style="western"><given-names>H.</given-names><surname>Wang</surname></string-name>, &#8220;<article-title>Nanotechnology&#8208;Enabled Targeted Protein Degradation for Cancer Therapeutics</article-title>,&#8221; <source>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</source><volume>16</volume>, no. <issue>6</issue> (<year>2024</year>): <elocation-id>e2020</elocation-id>.<pub-id pub-id-type="pmid">39663650</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/wnan.2020</pub-id></mixed-citation></ref><ref id="mco270401-bib-0307"><label>307</label><mixed-citation publication-type="journal" id="mco270401-cit-0307"><string-name name-style="western"><given-names>D. P.</given-names><surname>Petrylak</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>McKean</surname></string-name>, <string-name name-style="western"><given-names>J. M.</given-names><surname>Lang</surname></string-name>, et&#160;al., &#8220;<article-title>ARV&#8208;766, a PROteolysis TArgeting Chimera (PROTAC) Androgen Receptor Degrader, in Metastatic Castration&#8208;Resistant Prostate Cancer: Initial Results of a Phase 1/2 Study</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>42</volume>, no. <issue>16</issue> (<year>2024</year>).</mixed-citation></ref><ref id="mco270401-bib-0308"><label>308</label><mixed-citation publication-type="book" id="mco270401-cit-0308"><string-name name-style="western"><given-names>K. N.</given-names><surname>Chi</surname></string-name>, <string-name name-style="western"><given-names>R. R.</given-names><surname>McKay</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Sandhu</surname></string-name>, et&#160;al., <source>A phase 3 trial of the androgen receptor ligand&#8208;directed degrader, BMS&#8208;986365, versus investigator's choice in patients With metastatic castration&#8208;resistant prostate cancer (CA071&#8208;1000&#8208;rechARge)[Z]</source> (<publisher-name>American Society of Clinical Oncology</publisher-name>, <year>2025</year>).</mixed-citation></ref><ref id="mco270401-bib-0309"><label>309</label><mixed-citation publication-type="journal" id="mco270401-cit-0309"><string-name name-style="western"><given-names>D.</given-names><surname>Rathkopf</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Patel</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Choudhury</surname></string-name>, et&#160;al., &#8220;<article-title>1597MO Clinical activity of BMS&#8208;986365 (CC&#8208;94676), a dual androgen receptor (AR) ligand&#8208;directed degrader and antagonist, in heavily pretreated patients (pts) With metastatic castration&#8208;resistant prostate cancer (mCRPC)</article-title>,&#8221; <source>Annals of Oncology</source><volume>35</volume> (<year>2024</year>): <fpage>S962</fpage>&#8211;<lpage>S963</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annonc.2024.09.005</pub-id><pub-id pub-id-type="pmcid">PMC12094577</pub-id><pub-id pub-id-type="pmid">39293515</pub-id></mixed-citation></ref><ref id="mco270401-bib-0310"><label>310</label><mixed-citation publication-type="journal" id="mco270401-cit-0310"><string-name name-style="western"><given-names>M. M.</given-names><surname>Koralewicz</surname></string-name> and <string-name name-style="western"><given-names>O. A.</given-names><surname>Szatkowska</surname></string-name>, &#8220;<article-title>Topical solutions for androgenetic alopecia: Evaluating efficacy and safety</article-title>,&#8221; <source>Forum Dermatologicum</source><volume>10</volume>, no. <issue>3</issue> (<year>2024</year>): <fpage>71</fpage>&#8211;<lpage>78</lpage>.</mixed-citation></ref><ref id="mco270401-bib-0311"><label>311</label><mixed-citation publication-type="journal" id="mco270401-cit-0311"><string-name name-style="western"><given-names>H. A.</given-names><surname>Patel</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Guo</surname></string-name>, and <string-name name-style="western"><given-names>S. R.</given-names><surname>Feldman</surname></string-name>, &#8220;<article-title>The impact of current investigational drugs for acne on future treatment strategies</article-title>,&#8221; <source>Expert Opinion on Investigational Drugs</source><volume>33</volume>, no. <issue>2</issue> (<year>2024</year>): <fpage>127</fpage>&#8211;<lpage>132</lpage>.<pub-id pub-id-type="pmid">38369920</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13543784.2024.2313091</pub-id></mixed-citation></ref><ref id="mco270401-bib-0312"><label>312</label><mixed-citation publication-type="journal" id="mco270401-cit-0312"><string-name name-style="western"><given-names>A.</given-names><surname>Philippidis</surname></string-name>, &#8220;<article-title>Up&#8208;to&#8208;$2 B Sanofi Collaboration Pays Off for Kymera: Targeted protein degradation therapy developer generates $55 M in milestone payments From partnership to develop lead candidate in atopic dermatitis, hidradenitis suppurativa</article-title>,&#8221; <source>GEN Edge</source><volume>5</volume>, no. <issue>1</issue> (<year>2023</year>): <fpage>898</fpage>&#8211;<lpage>903</lpage>.</mixed-citation></ref><ref id="mco270401-bib-0313"><label>313</label><mixed-citation publication-type="journal" id="mco270401-cit-0313"><string-name name-style="western"><given-names>S.</given-names><surname>Agarwal</surname></string-name>, <string-name name-style="western"><given-names>A. A.</given-names><surname>McDonald</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Campbell</surname></string-name>, et&#160;al., &#8220;<article-title>Pharmacokinetics and Pharmacodynamics of KT&#8208;474, a Novel Selective Interleukin&#8208;1 Receptor&#8211;Associated Kinase 4 (IRAK4) Degrader, in Healthy Adults</article-title>,&#8221; <source>Clinical and Translational Science</source><volume>18</volume>, no. <issue>3</issue> (<year>2025</year>): <elocation-id>e70181</elocation-id>.<pub-id pub-id-type="pmid">40055981</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cts.70181</pub-id><pub-id pub-id-type="pmcid">PMC11889407</pub-id></mixed-citation></ref><ref id="mco270401-bib-0314"><label>314</label><mixed-citation publication-type="journal" id="mco270401-cit-0314"><string-name name-style="western"><given-names>L.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Luo</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Ma</surname></string-name>, et&#160;al., &#8220;<article-title>Discovery of LC&#8208;MI&#8208;3: A Potent and Orally Bioavailable Degrader of Interleukin&#8208;1 Receptor&#8208;Associated Kinase 4 for the Treatment of Inflammatory Diseases</article-title>,&#8221; <source>Journal of Medicinal Chemistry</source><volume>67</volume>, no. <issue>10</issue> (<year>2024</year>): <fpage>8060</fpage>&#8211;<lpage>8076</lpage>.<pub-id pub-id-type="pmid">38722184</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.4c00181</pub-id></mixed-citation></ref><ref id="mco270401-bib-0315"><label>315</label><mixed-citation publication-type="book" id="mco270401-cit-0315"><string-name name-style="western"><given-names>J. K.</given-names><surname>Lue</surname></string-name>, <string-name name-style="western"><given-names>D. A.</given-names><surname>Stevens</surname></string-name>, <string-name name-style="western"><given-names>M. E.</given-names><surname>Williams</surname></string-name>, et&#160;al., <source>Phase 1 study of KT&#8208;413, a targeted protein degrader of IRAK4 and IMiD substrates, in adult patients With relapsed or refractory B&#8208;cell non&#8208;Hodgkin lymphoma[Z]</source> (<publisher-loc>Washington, DC</publisher-loc>: <publisher-name>American Society of Hematology</publisher-name>, <year>2022</year>).</mixed-citation></ref><ref id="mco270401-bib-0316"><label>316</label><mixed-citation publication-type="journal" id="mco270401-cit-0316"><string-name name-style="western"><given-names>S.</given-names><surname>Chakraborty</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Morganti</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Dey</surname></string-name>, et&#160;al., &#8220;<article-title>A STAT3 degrader demonstrates pre&#8208;clinical efficacy in Venetoclax resistant Acute Myeloid Leukemia</article-title>,&#8221; <source>Blood</source><volume>142</volume> (<year>2023</year>): <fpage>2787</fpage>.</mixed-citation></ref><ref id="mco270401-bib-0317"><label>317</label><mixed-citation publication-type="journal" id="mco270401-cit-0317"><string-name name-style="western"><given-names>G.</given-names><surname>Nitulescu</surname></string-name>, <string-name name-style="western"><given-names>O. T.</given-names><surname>Olaru</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Andrei</surname></string-name>, <string-name name-style="western"><given-names>G. M.</given-names><surname>Nitulescu</surname></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>Zanfirescu</surname></string-name>, &#8220;<article-title>Targeting Intracellular Pathways in Atopic Dermatitis With Small Molecule Therapeutics</article-title>,&#8221; <source>Current Issues in Molecular Biology</source><volume>47</volume>, no. <issue>8</issue> (<year>2025</year>): <fpage>659</fpage>.<pub-id pub-id-type="pmid">40864813</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cimb47080659</pub-id><pub-id pub-id-type="pmcid">PMC12384770</pub-id></mixed-citation></ref><ref id="mco270401-bib-0318"><label>318</label><mixed-citation publication-type="journal" id="mco270401-cit-0318"><string-name name-style="western"><given-names>A. M.</given-names><surname>Shahid</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Vainchenker</surname></string-name>, and <string-name name-style="western"><given-names>S. N.</given-names><surname>Constantinescu</surname></string-name>, &#8220;<article-title>JCMM Annual Review on Advances in Biotechnology for the Treatment of Haematological Malignancies: A Review of the Latest In&#8208;Patient Developments 2024&#8211;2025</article-title>,&#8221; <source>Journal of Cellular and Molecular Medicine</source><volume>29</volume>, no. <issue>13</issue> (<year>2025</year>): <elocation-id>e70700</elocation-id>.<pub-id pub-id-type="pmid">40619749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jcmm.70700</pub-id><pub-id pub-id-type="pmcid">PMC12230202</pub-id></mixed-citation></ref><ref id="mco270401-bib-0319"><label>319</label><mixed-citation publication-type="journal" id="mco270401-cit-0319"><string-name name-style="western"><given-names>R.</given-names><surname>Lokaj</surname></string-name>, &#8220;<article-title>FDA Places Partial Hold on NX&#8208;2127 Phase 1 Trial in B&#8208;Cell Malignancies</article-title>,&#8221; <source>Cancer Network</source> (<year>2023</year>). NA&#8208;NA.</mixed-citation></ref><ref id="mco270401-bib-0320"><label>320</label><mixed-citation publication-type="journal" id="mco270401-cit-0320"><string-name name-style="western"><given-names>K.</given-names><surname>Linton</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Forconi</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Lewis</surname></string-name>, et&#160;al., &#8220;<article-title>PB2296: ROBUST BRUTON'S TYROSINE KINASE (BTK) DEGRADATION WITH NX&#8208;5948, AN ORAL BTK DEGRADER, IN A FIRST&#8208;IN&#8208;HUMAN PHASE 1A TRIAL IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES</article-title>,&#8221; <source>HemaSphere</source><volume>7</volume>, no. <issue>S3</issue> (<year>2023</year>): <elocation-id>e593178d</elocation-id>.</mixed-citation></ref><ref id="mco270401-bib-0321"><label>321</label><mixed-citation publication-type="journal" id="mco270401-cit-0321"><string-name name-style="western"><given-names>J.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Xu</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Yan</surname></string-name>, et&#160;al., &#8220;<article-title>Abstract CT128: Phase 1 study of HSK29116, a Bruton tyrosine kinase (BTK) proteolysis&#8208;targeting chimera (PROTAC) agent, in patients With relapsed or refractory B&#8208;cell malignancies</article-title>,&#8221; <source>Cancer Research</source><volume>83</volume>, no. <issue>8</issue> Supplement (<year>2023</year>): <fpage>CT128</fpage>&#8211;<lpage>CT128</lpage>.</mixed-citation></ref><ref id="mco270401-bib-0322"><label>322</label><mixed-citation publication-type="journal" id="mco270401-cit-0322"><string-name name-style="western"><given-names>R. T.</given-names><surname>Salvaris</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Brennan</surname></string-name>, and <string-name name-style="western"><given-names>K. L.</given-names><surname>Lewis</surname></string-name>, &#8220;<article-title>BTK is the target that keeps on giving: A review of BTK&#8208;degrader drug development, clinical data, and future directions in CLL</article-title>,&#8221; <source>Cancers</source><volume>17</volume>, no. <issue>3</issue> (<year>2025</year>): <fpage>557</fpage>.<pub-id pub-id-type="pmid">39941922</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers17030557</pub-id><pub-id pub-id-type="pmcid">PMC11817010</pub-id></mixed-citation></ref><ref id="mco270401-bib-0323"><label>323</label><mixed-citation publication-type="journal" id="mco270401-cit-0323"><string-name name-style="western"><given-names>M. C.</given-names><surname>Thompson</surname></string-name>, <string-name name-style="western"><given-names>R. D.</given-names><surname>Parrondo</surname></string-name>, <string-name name-style="western"><given-names>A. M.</given-names><surname>Frustaci</surname></string-name>, et&#160;al., &#8220;<article-title>Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB&#8208;16673 in patients With relapsed or refractory chronic lymphocytic Leukemia/Small lymphocytic lymphoma: Results From the phase 1 CaDAnCe&#8208;101 study</article-title>,&#8221; <source>Blood</source><volume>144</volume> (<year>2024</year>): <fpage>885</fpage>.</mixed-citation></ref><ref id="mco270401-bib-0324"><label>324</label><mixed-citation publication-type="journal" id="mco270401-cit-0324"><string-name name-style="western"><given-names>X.</given-names><surname>Feng</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Long</surname></string-name>, et&#160;al., &#8220;<article-title>P1239: Bruton Tyrosine Kinase (Btk) Protein Degrader Bgb&#8208;16673 Is less apt to cause, and able to overcome variable BTK resistance mutations compared to other BTK inhibitors (BTKi)</article-title>,&#8221; <source>HemaSphere</source><volume>7</volume>, no. <issue>S3</issue> (<year>2023</year>): <elocation-id>e368855c</elocation-id>.</mixed-citation></ref><ref id="mco270401-bib-0325"><label>325</label><mixed-citation publication-type="journal" id="mco270401-cit-0325"><string-name name-style="western"><given-names>D.</given-names><surname>Mahadevan</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Barve</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Mahalingam</surname></string-name>, et&#160;al., &#8220;<article-title>Abstract CT063: First in human phase 1 study of DT2216, a selective BCL&#8208;xL degrader, in patients With relapsed/refractory solid malignancies (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04886622">NCT04886622</ext-link>)</article-title>,&#8221; <source>Cancer Research</source><volume>85</volume>, no. <issue>8</issue> Supplement_2 (<year>2025</year>): <fpage>CT063</fpage>&#8211;<lpage>CT063</lpage>.</mixed-citation></ref><ref id="mco270401-bib-0326"><label>326</label><mixed-citation publication-type="journal" id="mco270401-cit-0326"><string-name name-style="western"><given-names>X.</given-names><surname>Qin</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Presser</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Johnson</surname></string-name>, et&#160;al., &#8220;<article-title>Paclitaxel&#8208;induced mitotic arrest results in a convergence of apoptotic dependencies that can be safely exploited by BCL&#8208;XL degradation to overcome cancer chemoresistance</article-title>,&#8221; <source>BioRxiv</source> (<year>2025</year>). 2025.2006. 2024.661170.</mixed-citation></ref><ref id="mco270401-bib-0327"><label>327</label><mixed-citation publication-type="journal" id="mco270401-cit-0327"><string-name name-style="western"><given-names>L. L.</given-names><surname>Poling</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Cocozziello</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>He</surname></string-name>, et&#160;al., &#8220;<article-title>CFT8634, a Clinical Stage BRD9 Bi DAC&#8482; Degrader, Is Active in a Subset of Multiple Myeloma Cell Line Models and Synergistic When Combined With Pomalidomide</article-title>,&#8221; <source>Blood</source><volume>142</volume> (<year>2023</year>): <fpage>6594</fpage>.</mixed-citation></ref><ref id="mco270401-bib-0328"><label>328</label><mixed-citation publication-type="journal" id="mco270401-cit-0328"><string-name name-style="western"><given-names>J. A.</given-names><surname>Livingston</surname></string-name>, <string-name name-style="western"><given-names>J.&#8208;Y.</given-names><surname>Blay</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Trent</surname></string-name>, et&#160;al., &#8220;<article-title>A phase I study of FHD&#8208;609, a heterobifunctional degrader of bromodomain&#8208;containing protein 9, in patients With advanced synovial sarcoma or SMARCB1&#8208;deficient tumors</article-title>,&#8221; <source>Clinical Cancer Research</source><volume>31</volume>, no. <issue>4</issue> (<year>2025</year>): <fpage>628</fpage>&#8211;<lpage>638</lpage>.<pub-id pub-id-type="pmid">39660994</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-24-2583</pub-id></mixed-citation></ref><ref id="mco270401-bib-0329"><label>329</label><mixed-citation publication-type="book" id="mco270401-cit-0329"><string-name name-style="western"><given-names>M.</given-names><surname>McKean</surname></string-name>, <string-name name-style="western"><given-names>A. I.</given-names><surname>Spira</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Rosen</surname></string-name>, et&#160;al., <source>A phase 1/2 study of CFT1946, a novel, bifunctional degradation activating compound (BIDAC) degrader, of mutant BRAF V600 as monotherapy and in combination With trametinib, in mutant BRAF V600 solid tumors[Z]</source> (<publisher-name>American Society of Clinical Oncology</publisher-name>, <year>2023</year>).</mixed-citation></ref><ref id="mco270401-bib-0330"><label>330</label><mixed-citation publication-type="book" id="mco270401-cit-0330"><string-name name-style="western"><given-names>T. A.</given-names><surname>Yap</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Gutierrez</surname></string-name>, <string-name name-style="western"><given-names>W. T.</given-names><surname>Iams</surname></string-name>, et&#160;al., <source>A phase 2 safety and efficacy study of PRT3789 in combination With pembrolizumab in patients With advanced or metastatic solid tumors and a SMARCA4 mutation[Z]</source> (<publisher-name>American Society of Clinical Oncology</publisher-name>, <year>2025</year>).</mixed-citation></ref><ref id="mco270401-bib-0331"><label>331</label><mixed-citation publication-type="journal" id="mco270401-cit-0331"><string-name name-style="western"><given-names>M.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Moore</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Grego</surname></string-name>, et&#160;al., &#8220;<article-title>Abstract C013: Clinical biomarkers based on PK/PD modeling to guide the development for a first&#8208;in&#8208;class, highly selective SMARCA2 (BRM) degrader, PRT3789</article-title>,&#8221; <source>Molecular Cancer Therapeutics</source><volume>22</volume>, no. <issue>12</issue> Supplement (<year>2023</year>): <fpage>C013</fpage>&#8211;<lpage>C013</lpage>.</mixed-citation></ref><ref id="mco270401-bib-0332"><label>332</label><mixed-citation publication-type="journal" id="mco270401-cit-0332"><string-name name-style="western"><given-names>T. S.</given-names><surname>Wilson</surname></string-name> and <string-name name-style="western"><given-names>P.</given-names><surname>Scaffidi</surname></string-name>, &#8220;<article-title>Compromised epigenetic robustness in cancer: Fueling evolution, exposing weakness</article-title>,&#8221; <source>Trends in Cancer</source><volume>11</volume>, no. <issue>6</issue> (<year>2025</year>): <fpage>575</fpage>&#8211;<lpage>590</lpage>.<pub-id pub-id-type="pmid">40055120</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trecan.2025.02.001</pub-id></mixed-citation></ref><ref id="mco270401-bib-0333"><label>333</label><mixed-citation publication-type="journal" id="mco270401-cit-0333"><string-name name-style="western"><given-names>J.</given-names><surname>Ren</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Xu</surname></string-name>, et&#160;al., &#8220;<article-title>Preclinical development of TQB3019: A potent and selective oral BTK degrader leveraging the OAPD&#174; platform to overcome acquired resistance mutations</article-title>,&#8221; <source>Cancer Research</source><volume>85</volume>, no. <issue>8</issue> Supplement_1 (<year>2025</year>): <fpage>400</fpage>&#8211;<lpage>400</lpage>.39810589
</mixed-citation></ref><ref id="mco270401-bib-0334"><label>334</label><mixed-citation publication-type="book" id="mco270401-cit-0334"><string-name name-style="western"><given-names>N. C.</given-names><surname>Rallabandi</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Panpatil</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Gahtory</surname></string-name>, <string-name name-style="western"><given-names>U.</given-names><surname>Navik</surname></string-name>, and <string-name name-style="western"><given-names>R.</given-names><surname>Kumar</surname></string-name>, <source>EGFR molecular degraders: Preclinical successes and the road ahead[Z]</source> (<publisher-name>Taylor &amp; Francis</publisher-name>, <year>2025</year>): <fpage>633</fpage>&#8211;<lpage>636</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/17568919.2025.2463871</pub-id><pub-id pub-id-type="pmcid">PMC11938961</pub-id><pub-id pub-id-type="pmid">39928493</pub-id></mixed-citation></ref><ref id="mco270401-bib-0335"><label>335</label><mixed-citation publication-type="journal" id="mco270401-cit-0335"><string-name name-style="western"><given-names>A.</given-names><surname>Van Acker</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>DeCarr</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Eaton</surname></string-name>, et&#160;al., &#8220;<article-title>ARV&#8208;393, a PROTAC B&#8208;cell lymphoma 6 (BCL6) degrader, combined With biologics or small molecule inhibitors (SMIs) induces tumor regressions in diffuse large B&#8208;cell lymphoma (DLBCL) models</article-title>,&#8221; <source>Cancer Research</source><volume>85</volume>, no. <issue>8</issue> Supplement_1 (<year>2025</year>): <fpage>1655</fpage>&#8211;<lpage>1655</lpage>.</mixed-citation></ref><ref id="mco270401-bib-0336"><label>336</label><mixed-citation publication-type="book" id="mco270401-cit-0336"><string-name name-style="western"><given-names>S.</given-names><surname>Sen</surname></string-name>, <string-name name-style="western"><given-names>A. F.</given-names><surname>Hezel</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Kasi</surname></string-name>, et&#160;al., <source>Trial in progress: Phase 1 study of the selective protein degrader ASP4396 in patients With locally advanced or metastatic solid tumors With KRAS G12D mutations[Z]</source> (<publisher-name>American Society of Clinical Oncology</publisher-name>, <year>2025</year>).</mixed-citation></ref><ref id="mco270401-bib-0337"><label>337</label><mixed-citation publication-type="journal" id="mco270401-cit-0337"><string-name name-style="western"><given-names>T.</given-names><surname>Nagashima</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Yoshinari</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Nishizono</surname></string-name>, et&#160;al., &#8220;<article-title>Novel KRAS G12D degrader ASP3082 demonstrates in vivo, dose&#8208;dependent KRAS degradation, KRAS pathway inhibition, and antitumor efficacy in multiple KRAS G12D&#8208;mutated cancer models</article-title>,&#8221; <source>Cancer Research</source><volume>83</volume>, no. <issue>7</issue> Supplement (<year>2023</year>): <fpage>5735</fpage>&#8211;<lpage>5735</lpage>.</mixed-citation></ref><ref id="mco270401-bib-0338"><label>338</label><mixed-citation publication-type="journal" id="mco270401-cit-0338"><string-name name-style="western"><given-names>L.</given-names><surname>Groocock</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Deb</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Zhu</surname></string-name>, et&#160;al., &#8220;<article-title>BMS&#8208;986458 a potential first&#8208;in&#8208;class, highly selective, potent and well tolerated BCL6 ligand directed degrader (LDD) demonstrates multi&#8208;modal anti&#8208;tumor efficacy for the treatment of B&#8208;cell non&#8208;Hodgkin's lymphoma</article-title>,&#8221; <source>Blood</source><volume>144</volume> (<year>2024</year>): <fpage>957</fpage>.</mixed-citation></ref><ref id="mco270401-bib-0339"><label>339</label><mixed-citation publication-type="journal" id="mco270401-cit-0339"><string-name name-style="western"><given-names>Y.</given-names><surname>Guo</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Cheng</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Wang</surname></string-name>, et&#160;al., &#8220;<article-title>Regulation of EZH2 protein stability: New mechanisms, roles in tumorigenesis, and roads to the clinic</article-title>,&#8221; <source>EBioMedicine</source><volume>100</volume> (<year>2024</year>): <elocation-id>104972</elocation-id>.<pub-id pub-id-type="pmid">38244292</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ebiom.2024.104972</pub-id><pub-id pub-id-type="pmcid">PMC10835131</pub-id></mixed-citation></ref><ref id="mco270401-bib-0340"><label>340</label><mixed-citation publication-type="journal" id="mco270401-cit-0340"><string-name name-style="western"><given-names>D.</given-names><surname>Romaniello</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Morselli</surname></string-name>, and <string-name name-style="western"><given-names>I.</given-names><surname>Marrocco</surname></string-name>, &#8220;<article-title>Strategies to Overcome Resistance to Osimertinib in EGFR&#8208;Mutated Lung Cancer</article-title>,&#8221; <source>International Journal of Molecular Sciences</source><volume>26</volume>, no. <issue>7</issue> (<year>2025</year>): <fpage>2957</fpage>.<pub-id pub-id-type="pmid">40243603</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms26072957</pub-id><pub-id pub-id-type="pmcid">PMC11988377</pub-id></mixed-citation></ref><ref id="mco270401-bib-0341"><label>341</label><mixed-citation publication-type="journal" id="mco270401-cit-0341"><string-name name-style="western"><given-names>M. R.</given-names><surname>Patel</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Tees</surname></string-name>, <string-name name-style="western"><given-names>F. T.</given-names><surname>Awan</surname></string-name>, et&#160;al., &#8220;<article-title>Abstract PO&#8208;009: AC676 a BTK chimeric degrader: Phase 1 study in patients With b&#8208;cell malignancies</article-title>,&#8221; <source>Blood Cancer Discovery</source><volume>5</volume>, no. <issue>3</issue> Supplement (<year>2024</year>): <elocation-id>PO&#8211;009&#8211;PO&#8211;009</elocation-id>.</mixed-citation></ref><ref id="mco270401-bib-0342"><label>342</label><mixed-citation publication-type="journal" id="mco270401-cit-0342"><string-name name-style="western"><given-names>J.</given-names><surname>Min</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Peng</surname></string-name>, et&#160;al., &#8220;<article-title>New generation estrogen receptor&#8208;targeted agents in breast cancer: Present situation and future prospectives</article-title>,&#8221; <source>Acta Materia Medica</source><volume>3</volume>, no. <issue>1</issue> (<year>2024</year>): <fpage>57</fpage>.<pub-id pub-id-type="pmid">39373009</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15212/amm-2024-0006</pub-id><pub-id pub-id-type="pmcid">PMC11450757</pub-id></mixed-citation></ref><ref id="mco270401-bib-0343"><label>343</label><mixed-citation publication-type="journal" id="mco270401-cit-0343"><string-name name-style="western"><given-names>Y.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Jiang</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Feng</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Liu</surname></string-name>, and <string-name name-style="western"><given-names>H.</given-names><surname>Sun</surname></string-name>, &#8220;<article-title>Degradation of proteins by PROTACs and other strategies</article-title>,&#8221; <source>Acta Pharmaceutica Sinica B</source><volume>10</volume>, no. <issue>2</issue> (<year>2020</year>): <fpage>207</fpage>&#8211;<lpage>238</lpage>.<pub-id pub-id-type="pmid">32082969</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2019.08.001</pub-id><pub-id pub-id-type="pmcid">PMC7016280</pub-id></mixed-citation></ref><ref id="mco270401-bib-0344"><label>344</label><mixed-citation publication-type="journal" id="mco270401-cit-0344"><string-name name-style="western"><given-names>X.</given-names><surname>Gao</surname></string-name>, <string-name name-style="western"><given-names>H. A.</given-names><surname>Burris</surname><suffix>III</suffix></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Vuky</surname></string-name>, et&#160;al., &#8220;<article-title>Phase 1/2 study of ARV&#8208;110, an androgen receptor (AR) PROTAC degrader, in metastatic castration&#8208;resistant prostate cancer (mCRPC)</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>40</volume>, no. <issue>6</issue> suppl (<year>2022</year>): <fpage>17</fpage>&#8211;<lpage>17</lpage>.</mixed-citation></ref><ref id="mco270401-bib-0345"><label>345</label><mixed-citation publication-type="journal" id="mco270401-cit-0345"><string-name name-style="western"><given-names>K. N.</given-names><surname>Chi</surname></string-name>, <string-name name-style="western"><given-names>R. R.</given-names><surname>McKay</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Sandhu</surname></string-name>, et&#160;al., &#8220;<article-title>rechARge: A randomized phase III trial of the androgen receptor ligand&#8208;directed degrader, BMS&#8208;986365, vs investigator's choice in patients With mCRPC</article-title>,&#8221; <source>Future oncology</source><volume>21</volume>, no. <issue>14</issue> (<year>2025</year>): <fpage>1</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">40455815</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/14796694.2025.2502318</pub-id><pub-id pub-id-type="pmcid">PMC12150650</pub-id></mixed-citation></ref><ref id="mco270401-bib-0346"><label>346</label><mixed-citation publication-type="journal" id="mco270401-cit-0346"><string-name name-style="western"><given-names>M.</given-names><surname>Campone</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>De Laurentiis</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Jhaveri</surname></string-name>, et&#160;al., &#8220;<article-title>Vepdegestrant, a PROTAC estrogen receptor degrader, in advanced breast cancer</article-title>,&#8221; <source>New England Journal of Medicine</source><volume>393</volume>, no. <issue>6</issue> (<year>2025</year>): <fpage>556</fpage>&#8211;<lpage>568</lpage>.<pub-id pub-id-type="pmid">40454645</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2505725</pub-id></mixed-citation></ref><ref id="mco270401-bib-0347"><label>347</label><mixed-citation publication-type="journal" id="mco270401-cit-0347"><string-name name-style="western"><given-names>R. L.</given-names><surname>Siegel</surname></string-name>, <string-name name-style="western"><given-names>A. N.</given-names><surname>Giaquinto</surname></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>Jemal</surname></string-name>, &#8220;<article-title>Cancer statistics, 2024</article-title>,&#8221; <source>CA: A Cancer Journal for Clinicians</source><volume>74</volume>, no. <issue>1</issue> (<year>2024</year>): <fpage>12</fpage>&#8211;<lpage>49</lpage>.<pub-id pub-id-type="pmid">38230766</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21820</pub-id></mixed-citation></ref><ref id="mco270401-bib-0348"><label>348</label><mixed-citation publication-type="journal" id="mco270401-cit-0348"><string-name name-style="western"><given-names>S. K.</given-names><surname>Bagal</surname></string-name>, <string-name name-style="western"><given-names>P. C.</given-names><surname>Astles</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Di&#232;ne</surname></string-name>, et&#160;al., &#8220;<article-title>Discovery of a Series of Orally Bioavailable Androgen Receptor Degraders for the Treatment of Prostate Cancer</article-title>,&#8221; <source>Journal of Medicinal Chemistry</source><volume>67</volume>, no. <issue>14</issue> (<year>2024</year>): <fpage>11732</fpage>&#8211;<lpage>11750</lpage>.<pub-id pub-id-type="pmid">38991141</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.4c00269</pub-id></mixed-citation></ref><ref id="mco270401-bib-0349"><label>349</label><mixed-citation publication-type="journal" id="mco270401-cit-0349"><string-name name-style="western"><given-names>X.</given-names><surname>Gao</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Iii</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Vuky</surname></string-name>, et&#160;al., &#8220;<article-title>Phase 1/2 study of ARV&#8208;110, an androgen receptor (AR) PROTAC degrader, in metastatic castration&#8208;resistant prostate cancer (mCRPC)</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>40</volume> (<year>2022</year>): <fpage>17</fpage>&#8211;<lpage>17</lpage>.</mixed-citation></ref><ref id="mco270401-bib-0350"><label>350</label><mixed-citation publication-type="journal" id="mco270401-cit-0350"><string-name name-style="western"><given-names>L.</given-names><surname>Ma</surname></string-name> and <string-name name-style="western"><given-names>X.</given-names><surname>Han</surname></string-name>, &#8220;<article-title>Bavdegalutamide (ARV&#8208;110): A potent PROTAC androgen receptor degrader for the treatment of metastatic&#8208;castration resistant prostate cancer</article-title>,&#8221; <source>Drug Discovery Stories</source> (<year>2025</year>): <fpage>357</fpage>&#8211;<lpage>378</lpage>.</mixed-citation></ref><ref id="mco270401-bib-0351"><label>351</label><mixed-citation publication-type="journal" id="mco270401-cit-0351"><string-name name-style="western"><given-names>K. N.</given-names><surname>Chi</surname></string-name>, <string-name name-style="western"><given-names>R. R.</given-names><surname>McKay</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Sandhu</surname></string-name>, et&#160;al., &#8220;<article-title>rechARge: A randomized phase III trial of the androgen receptor ligand&#8208;directed degrader, BMS&#8208;986365, vs investigator's choice in patients With mCRPC</article-title>,&#8221; <source>Future Oncology</source><volume>21</volume>, no. <issue>14</issue> (<year>2025</year>): <fpage>1771</fpage>&#8211;<lpage>1777</lpage>.<pub-id pub-id-type="pmid">40455815</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/14796694.2025.2502318</pub-id><pub-id pub-id-type="pmcid">PMC12150650</pub-id></mixed-citation></ref><ref id="mco270401-bib-0352"><label>352</label><mixed-citation publication-type="journal" id="mco270401-cit-0352"><string-name name-style="western"><given-names>P. A.</given-names><surname>Watson</surname></string-name>, <string-name name-style="western"><given-names>V. K.</given-names><surname>Arora</surname></string-name>, and <string-name name-style="western"><given-names>C. L.</given-names><surname>Sawyers</surname></string-name>, &#8220;<article-title>Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer</article-title>,&#8221; <source>Nature Reviews Cancer</source><volume>15</volume>, no. <issue>12</issue> (<year>2015</year>): <fpage>701</fpage>&#8211;<lpage>711</lpage>.<pub-id pub-id-type="pmid">26563462</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrc4016</pub-id><pub-id pub-id-type="pmcid">PMC4771416</pub-id></mixed-citation></ref><ref id="mco270401-bib-0353"><label>353</label><mixed-citation publication-type="journal" id="mco270401-cit-0353"><string-name name-style="western"><given-names>D. P.</given-names><surname>Petrylak</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>McKean</surname></string-name>, <string-name name-style="western"><given-names>J. M.</given-names><surname>Lang</surname></string-name>, et&#160;al., &#8220;<article-title>ARV&#8208;766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration&#8208;resistant prostate cancer (mCRPC): Initial results of a phase 1/2 study</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>42</volume>, no. <issue>16</issue> suppl (<year>2024</year>): <fpage>5011</fpage>&#8211;<lpage>5011</lpage>.</mixed-citation></ref><ref id="mco270401-bib-0354"><label>354</label><mixed-citation publication-type="journal" id="mco270401-cit-0354"><string-name name-style="western"><given-names>Q. H.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Munoz</surname></string-name>, and <string-name name-style="western"><given-names>D.</given-names><surname>Ashong</surname></string-name>, &#8220;<article-title>Insight Into Recent Advances in Degrading Androgen Receptor for Castration&#8208;Resistant Prostate Cancer</article-title>,&#8221; <source>Cancers (Basel)</source><volume>16</volume>, no. <issue>3</issue> (<year>2024</year>): <fpage>663</fpage>.<pub-id pub-id-type="pmid">38339414</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers16030663</pub-id><pub-id pub-id-type="pmcid">PMC10854644</pub-id></mixed-citation></ref><ref id="mco270401-bib-0355"><label>355</label><mixed-citation publication-type="journal" id="mco270401-cit-0355"><string-name name-style="western"><given-names>D.</given-names><surname>Saceda&#8208;Corralo</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Dom&#237;nguez&#8208;Santas</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Va&#241;&#243;&#8208;Galv&#225;n</surname></string-name>, and <string-name name-style="western"><given-names>R.</given-names><surname>Grimalt</surname></string-name>, &#8220;<article-title>What's new in therapy for male androgenetic alopecia?</article-title>,&#8221; <source>American Journal of Clinical Dermatology</source><volume>24</volume>, no. <issue>1</issue> (<year>2023</year>): <fpage>15</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="pmid">36169916</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40257-022-00730-y</pub-id></mixed-citation></ref><ref id="mco270401-bib-0356"><label>356</label><mixed-citation publication-type="journal" id="mco270401-cit-0356"><string-name name-style="western"><given-names>C.&#8208;C.</given-names><surname>Chou</surname></string-name>, <string-name name-style="western"><given-names>P.&#8208;C.</given-names><surname>Cheng</surname></string-name>, <string-name name-style="western"><given-names>H.&#8208;C.</given-names><surname>Chen</surname></string-name>, et&#160;al., &#8220;<article-title>52243 AH&#8208;001: An Emerging Androgen Receptor Degrader Showing Therapeutic Potential in Addressing Androgenetic Alopecia (AGA)</article-title>,&#8221; <source>Journal of the American Academy of Dermatology</source><volume>91</volume>, no. <issue>3</issue> (<year>2024</year>): <elocation-id>AB119</elocation-id>.</mixed-citation></ref><ref id="mco270401-bib-0357"><label>357</label><mixed-citation publication-type="journal" id="mco270401-cit-0357"><string-name name-style="western"><given-names>A.</given-names><surname>Grinshpun</surname></string-name>, &#8220;<article-title>Clinician's guide to targeted estrogen receptor degradation using PROTAC in patients With estrogen receptor&#8208;positive metastatic breast cancer</article-title>,&#8221; <source>Current Opinion in Oncology</source><volume>35</volume>, no. <issue>6</issue> (<year>2023</year>): <fpage>472</fpage>&#8211;<lpage>478</lpage>.<pub-id pub-id-type="pmid">37427531</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CCO.0000000000000972</pub-id><pub-id pub-id-type="pmcid">PMC10566586</pub-id></mixed-citation></ref><ref id="mco270401-bib-0358"><label>358</label><mixed-citation publication-type="journal" id="mco270401-cit-0358"><string-name name-style="western"><given-names>M.</given-names><surname>Campone</surname></string-name>, <string-name name-style="western"><given-names>M. D.</given-names><surname>Laurentiis</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Jhaveri</surname></string-name>, et&#160;al., &#8220;<article-title>Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer</article-title>,&#8221; <source>New England Journal of Medicine</source><volume>393</volume>, no. <issue>6</issue> (<year>2025</year>): <fpage>556</fpage>&#8211;<lpage>568</lpage>.<pub-id pub-id-type="pmid">40454645</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2505725</pub-id></mixed-citation></ref><ref id="mco270401-bib-0359"><label>359</label><mixed-citation publication-type="journal" id="mco270401-cit-0359"><string-name name-style="western"><given-names>H.</given-names><surname>Iwata</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Naito</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Hattori</surname></string-name>, et&#160;al., &#8220;<article-title>Safety and pharmacokinetics of vepdegestrant in Japanese patients With ER+&#8201;advanced breast cancer: A phase 1 study</article-title>,&#8221; <source>International Journal of Clinical Oncology</source><volume>30</volume>, no. <issue>1</issue> (<year>2025</year>): <fpage>72</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="pmid">39565495</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10147-024-02648-3</pub-id><pub-id pub-id-type="pmcid">PMC11700046</pub-id></mixed-citation></ref><ref id="mco270401-bib-0360"><label>360</label><mixed-citation publication-type="journal" id="mco270401-cit-0360"><string-name name-style="western"><given-names>J.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Lu</surname></string-name>, and <string-name name-style="western"><given-names>C.</given-names><surname>Liang</surname></string-name>, &#8220;<article-title>Targeted protein degradation in cancers: Orthodox PROTACs and Beyond</article-title>,&#8221; <source>The Innovation</source><volume>4</volume>, no. <issue>3</issue> (<year>2023</year>): <elocation-id>100413</elocation-id>.<pub-id pub-id-type="pmid">37033156</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xinn.2023.100413</pub-id><pub-id pub-id-type="pmcid">PMC10074253</pub-id></mixed-citation></ref><ref id="mco270401-bib-0361"><label>361</label><mixed-citation publication-type="journal" id="mco270401-cit-0361"><string-name name-style="western"><given-names>S.</given-names><surname>Montoya</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Bourcier</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Noviski</surname></string-name>, et&#160;al., &#8220;<article-title>Kinase&#8208;impaired BTK mutations are susceptible to clinical&#8208;stage BTK and IKZF1/3 degrader NX&#8208;2127</article-title>,&#8221; <source>Science</source><volume>383</volume>, no. <issue>6682</issue> (<year>2024</year>): <elocation-id>eadi5798</elocation-id>.<pub-id pub-id-type="pmid">38301010</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.adi5798</pub-id><pub-id pub-id-type="pmcid">PMC11103405</pub-id></mixed-citation></ref><ref id="mco270401-bib-0362"><label>362</label><mixed-citation publication-type="journal" id="mco270401-cit-0362"><string-name name-style="western"><given-names>D. W.</given-names><surname>Robbins</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Noviski</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Rountree</surname></string-name>, et&#160;al., &#8220;<article-title>Nx&#8208;5948, a Selective Degrader of BTK With Activity in Preclinical Models of Hematologic and Brain Malignancies</article-title>,&#8221; <source>Blood</source><volume>138</volume> (<year>2021</year>): <fpage>2251</fpage>.</mixed-citation></ref><ref id="mco270401-bib-0363"><label>363</label><mixed-citation publication-type="journal" id="mco270401-cit-0363"><string-name name-style="western"><given-names>M.</given-names><surname>Patel</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Tees</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Khan</surname></string-name>, et&#160;al., &#8220;<article-title>IBCL&#8208;147 AC676, an Orally Bioavailable BTK Chimeric Degrader in Patients With B&#8208;cell Malignancies</article-title>,&#8221; <source>Clinical Lymphoma Myeloma and Leukemia</source><volume>24</volume> (<year>2024</year>): <fpage>S494</fpage>.</mixed-citation></ref><ref id="mco270401-bib-0364"><label>364</label><mixed-citation publication-type="journal" id="mco270401-cit-0364"><string-name name-style="western"><given-names>M. T.</given-names><surname>Tees</surname></string-name>, <string-name name-style="western"><given-names>D. A.</given-names><surname>Bond</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Khan</surname></string-name>, et&#160;al., &#8220;<article-title>A Phase 1 Study of AC676, a Novel BTK Chimeric Degrader, in Patients With B&#8208;Cell Malignancies</article-title>,&#8221; <source>Blood</source><volume>144</volume>, no. Supplement <issue>1</issue> (<year>2024</year>): <fpage>4422.4421</fpage>&#8211;<lpage>4422.4421</lpage>.</mixed-citation></ref><ref id="mco270401-bib-0365"><label>365</label><mixed-citation publication-type="journal" id="mco270401-cit-0365"><string-name name-style="western"><given-names>J. K.</given-names><surname>Lue</surname></string-name>, <string-name name-style="western"><given-names>D. A.</given-names><surname>Stevens</surname></string-name>, <string-name name-style="western"><given-names>M. E.</given-names><surname>Williams</surname></string-name>, et&#160;al., &#8220;<article-title>Phase 1 Study of KT&#8208;413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates, in Adult Patients With Relapsed or Refractory B&#8208;Cell Non&#8208;Hodgkin Lymphoma</article-title>,&#8221; <source>Blood</source><volume>140</volume>, no. Supplement <issue>1</issue> (<year>2022</year>): <fpage>12143</fpage>&#8211;<lpage>12144</lpage>.</mixed-citation></ref><ref id="mco270401-bib-0366"><label>366</label><mixed-citation publication-type="journal" id="mco270401-cit-0366"><string-name name-style="western"><given-names>M. M.</given-names><surname>Weiss</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Zheng</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Ji</surname></string-name>, et&#160;al., &#8220;<article-title>Discovery of KT&#8208;413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates Targeting MYD88 Mutant Diffuse Large B&#8208;Cell Lymphoma</article-title>,&#8221; <source>Journal of Medicinal Chemistry</source><volume>67</volume>, no. <issue>13</issue> (<year>2024</year>): <fpage>10548</fpage>&#8211;<lpage>10566</lpage>.<pub-id pub-id-type="pmid">38920289</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.3c01823</pub-id></mixed-citation></ref><ref id="mco270401-bib-0367"><label>367</label><mixed-citation publication-type="journal" id="mco270401-cit-0367"><string-name name-style="western"><given-names>S. D.</given-names><surname>Edmondson</surname></string-name>, &#8220;<article-title>Discovery of the First Clinical Protein Degrader for the Treatment of Autoimmune Indications: Orally Bioavailable and Selective IRAK4 Degrader KT&#8208;474</article-title>,&#8221; <source>Journal of Medicinal Chemistry</source><volume>67</volume>, no. <issue>20</issue> (<year>2024</year>): <fpage>18017</fpage>&#8211;<lpage>18021</lpage>.<pub-id pub-id-type="pmid">39376047</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.4c02264</pub-id></mixed-citation></ref><ref id="mco270401-bib-0368"><label>368</label><mixed-citation publication-type="journal" id="mco270401-cit-0368"><string-name name-style="western"><given-names>J. J.</given-names><surname>Harvey</surname></string-name>, &#8220;<article-title>An unidentified virus which causes the rapid production of tumours in mice</article-title>,&#8221; <source>Nature</source><volume>204</volume> (<year>1964</year>): <fpage>1104</fpage>&#8211;<lpage>1105</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/2041104b0</pub-id><pub-id pub-id-type="pmid">14243400</pub-id></mixed-citation></ref><ref id="mco270401-bib-0369"><label>369</label><mixed-citation publication-type="journal" id="mco270401-cit-0369"><string-name name-style="western"><given-names>W. H.</given-names><surname>Kirsten</surname></string-name> and <string-name name-style="western"><given-names>L. A.</given-names><surname>Mayer</surname></string-name>, &#8220;<article-title>Morphologic responses to a murine erythroblastosis virus</article-title>,&#8221; <source>Journal of the National Cancer Institute</source><volume>39</volume>, no. <issue>2</issue> (<year>1967</year>): <fpage>311</fpage>&#8211;<lpage>335</lpage>.<pub-id pub-id-type="pmid">18623947</pub-id></mixed-citation></ref><ref id="mco270401-bib-0370"><label>370</label><mixed-citation publication-type="journal" id="mco270401-cit-0370"><string-name name-style="western"><given-names>M.</given-names><surname>Malumbres</surname></string-name> and <string-name name-style="western"><given-names>M.</given-names><surname>Barbacid</surname></string-name>, &#8220;<article-title>RAS oncogenes: The first 30 years</article-title>,&#8221; <source>Nature Reviews Cancer</source><volume>3</volume>, no. <issue>6</issue> (<year>2003</year>): <fpage>459</fpage>&#8211;<lpage>465</lpage>.<pub-id pub-id-type="pmid">12778136</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrc1097</pub-id></mixed-citation></ref><ref id="mco270401-bib-0371"><label>371</label><mixed-citation publication-type="journal" id="mco270401-cit-0371"><string-name name-style="western"><given-names>J. M.</given-names><surname>Ostrem</surname></string-name>, <string-name name-style="western"><given-names>U.</given-names><surname>Peters</surname></string-name>, <string-name name-style="western"><given-names>M. L.</given-names><surname>Sos</surname></string-name>, <string-name name-style="western"><given-names>J. A.</given-names><surname>Wells</surname></string-name>, and <string-name name-style="western"><given-names>K. M.</given-names><surname>Shokat</surname></string-name>, &#8220;<article-title>K&#8208;Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions</article-title>,&#8221; <source>Nature</source><volume>503</volume>, no. <issue>7477</issue> (<year>2013</year>): <fpage>548</fpage>&#8211;<lpage>551</lpage>.<pub-id pub-id-type="pmid">24256730</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature12796</pub-id><pub-id pub-id-type="pmcid">PMC4274051</pub-id></mixed-citation></ref><ref id="mco270401-bib-0372"><label>372</label><mixed-citation publication-type="journal" id="mco270401-cit-0372"><string-name name-style="western"><given-names>E. C.</given-names><surname>Nakajima</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Drezner</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Li</surname></string-name>, et&#160;al., &#8220;<article-title>FDA Approval Summary: Sotorasib for KRAS G12C&#8208;Mutated Metastatic NSCLC</article-title>,&#8221; <source>Clinical Cancer Research</source><volume>28</volume>, no. <issue>8</issue> (<year>2022</year>): <fpage>1482</fpage>&#8211;<lpage>1486</lpage>.<pub-id pub-id-type="pmid">34903582</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-21-3074</pub-id><pub-id pub-id-type="pmcid">PMC9012672</pub-id></mixed-citation></ref><ref id="mco270401-bib-0373"><label>373</label><mixed-citation publication-type="journal" id="mco270401-cit-0373"><string-name name-style="western"><given-names>S. S.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Lee</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Nagasaka</surname></string-name>, &#8220;<article-title>CodeBreak 200: Sotorasib Has Not Broken the KRAS(G12C) Enigma Code</article-title>,&#8221; <source>Lung Cancer (Auckl)</source><volume>14</volume> (<year>2023</year>): <fpage>27</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="pmid">37101895</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/LCTT.S403461</pub-id><pub-id pub-id-type="pmcid">PMC10123019</pub-id></mixed-citation></ref><ref id="mco270401-bib-0374"><label>374</label><mixed-citation publication-type="journal" id="mco270401-cit-0374"><string-name name-style="western"><given-names>H.</given-names><surname>Shen</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Lundy</surname></string-name>, <string-name name-style="western"><given-names>A. H.</given-names><surname>Strickland</surname></string-name>, et&#160;al., &#8220;<article-title>KRAS G12D Mutation Subtype in Pancreatic Ductal Adenocarcinoma: Does It Influence Prognosis or Stage of Disease at Presentation?</article-title>,&#8221; <source>Cells</source><volume>11</volume>, no. <issue>19</issue> (<year>2022</year>): <fpage>3175</fpage>.<pub-id pub-id-type="pmid">36231137</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells11193175</pub-id><pub-id pub-id-type="pmcid">PMC9562007</pub-id></mixed-citation></ref><ref id="mco270401-bib-0375"><label>375</label><mixed-citation publication-type="journal" id="mco270401-cit-0375"><string-name name-style="western"><given-names>S.</given-names><surname>Ramalingam</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Skoulidis</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Govindan</surname></string-name>, et&#160;al., &#8220;<article-title>P52.03 Efficacy of Sotorasib in &lt;em&gt;KRAS&lt;/em&gt;p.G12C&#8208;Mutated NSCLC With Stable Brain Metastases: A Post&#8208;Hoc Analysis of CodeBreaK 100</article-title>,&#8221; <source>Journal of Thoracic Oncology</source><volume>16</volume>, no. <issue>10</issue> (<year>2021</year>): <elocation-id>S1123</elocation-id>.</mixed-citation></ref><ref id="mco270401-bib-0376"><label>376</label><mixed-citation publication-type="journal" id="mco270401-cit-0376"><string-name name-style="western"><given-names>A. W.</given-names><surname>Tolcher</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Park</surname></string-name>, <string-name name-style="western"><given-names>J. S.</given-names><surname>Wang</surname></string-name>, et&#160;al., &#8220;<article-title>Trial in progress: A phase 1, first&#8208;in&#8208;human, open&#8208;label, multicenter, dose&#8208;escalation and dose&#8208;expansion study of ASP3082 in patients With previously treated advanced solid tumors and KRAS G12D mutations</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>41</volume>, no. <issue>4</issue> suppl (<year>2023</year>): <fpage>TPS764</fpage>&#8211;<lpage>TPS764</lpage>.</mixed-citation></ref><ref id="mco270401-bib-0377"><label>377</label><mixed-citation publication-type="journal" id="mco270401-cit-0377"><string-name name-style="western"><given-names>M.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Wang</surname></string-name>, et&#160;al., &#8220;<article-title>Recent Advance of KRAS&#8208;G12C Inhibitors for Cancer Therapy</article-title>,&#8221; <source>European Journal of Medicinal Chemistry</source> (<year>2025</year>): <elocation-id>117878</elocation-id>.<pub-id pub-id-type="pmid">40554983</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2025.117878</pub-id></mixed-citation></ref><ref id="mco270401-bib-0378"><label>378</label><mixed-citation publication-type="journal" id="mco270401-cit-0378"><string-name name-style="western"><given-names>D.</given-names><surname>Rangachari</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>To</surname></string-name>, <string-name name-style="western"><given-names>J. E.</given-names><surname>Shpilsky</surname></string-name>, et&#160;al., &#8220;<article-title>EGFR&#8208;Mutated Lung Cancers Resistant to Osimertinib Through EGFR C797S Respond to First&#8208;Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples</article-title>,&#8221; <source>Journal of Thoracic Oncology</source><volume>14</volume>, no. <issue>11</issue> (<year>2019</year>): <fpage>1995</fpage>&#8211;<lpage>2002</lpage>.<pub-id pub-id-type="pmid">31377341</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jtho.2019.07.016</pub-id><pub-id pub-id-type="pmcid">PMC6823139</pub-id></mixed-citation></ref><ref id="mco270401-bib-0379"><label>379</label><mixed-citation publication-type="journal" id="mco270401-cit-0379"><string-name name-style="western"><given-names>J. W.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Zheng</surname></string-name>, <string-name name-style="western"><given-names>F. J.</given-names><surname>Kaye</surname></string-name>, and <string-name name-style="western"><given-names>L.</given-names><surname>Wu</surname></string-name>, &#8220;<article-title>PROTAC therapy as a new targeted therapy for lung cancer</article-title>,&#8221; <source>Molecular Therapy</source><volume>31</volume>, no. <issue>3</issue> (<year>2023</year>): <fpage>647</fpage>&#8211;<lpage>656</lpage>.<pub-id pub-id-type="pmid">36415148</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ymthe.2022.11.011</pub-id><pub-id pub-id-type="pmcid">PMC10014230</pub-id></mixed-citation></ref><ref id="mco270401-bib-0380"><label>380</label><mixed-citation publication-type="book" id="mco270401-cit-0380"><string-name name-style="western"><given-names>N. C.</given-names><surname>Rallabandi</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Panpatil</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Gahtory</surname></string-name>, <string-name name-style="western"><given-names>U.</given-names><surname>Navik</surname></string-name>, and <string-name name-style="western"><given-names>R. J. F. M. C.</given-names><surname>Kumar</surname></string-name>, <source>EGFR molecular degraders: Preclinical successes and the road ahead[Z]</source> (<publisher-name>Taylor &amp; Francis</publisher-name>, <year>2025</year>): <fpage>1</fpage>&#8211;<lpage>4</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/17568919.2025.2463871</pub-id><pub-id pub-id-type="pmcid">PMC11938961</pub-id><pub-id pub-id-type="pmid">39928493</pub-id></mixed-citation></ref><ref id="mco270401-bib-0381"><label>381</label><mixed-citation publication-type="journal" id="mco270401-cit-0381"><string-name name-style="western"><given-names>X.</given-names><surname>Zhou</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Zeng</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Huang</surname></string-name>, et&#160;al., &#8220;<article-title>Strategies Beyond 3rd EGFR&#8208;TKI Acquired Resistance: Opportunities and Challenges</article-title>,&#8221; <source>Cancer medicine</source><volume>14</volume>, no. <issue>9</issue> (<year>2025</year>): <elocation-id>e70921</elocation-id>.<pub-id pub-id-type="pmid">40322930</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cam4.70921</pub-id><pub-id pub-id-type="pmcid">PMC12051098</pub-id></mixed-citation></ref><ref id="mco270401-bib-0382"><label>382</label><mixed-citation publication-type="journal" id="mco270401-cit-0382"><string-name name-style="western"><given-names>L.</given-names><surname>Groocock</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Deb</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Zhu</surname></string-name>, et&#160;al., &#8220;<article-title>BMS&#8208;986458 a Potential First&#8208;in&#8208;Class, Highly Selective, Potent and Well Tolerated BCL6 Ligand Directed Degrader (LDD) Demonstrates Multi&#8208;Modal Anti&#8208;Tumor Efficacy for the Treatment of B&#8208;Cell Non&#8208;Hodgkin's Lymphoma</article-title>,&#8221; <source>Blood</source><volume>144</volume>, no. Supplement <issue>1</issue> (<year>2024</year>): <fpage>957</fpage>&#8211;<lpage>957</lpage>.</mixed-citation></ref><ref id="mco270401-bib-0383"><label>383</label><mixed-citation publication-type="journal" id="mco270401-cit-0383"><string-name name-style="western"><given-names>P. F.</given-names><surname>Caimi</surname></string-name>, <string-name name-style="western"><given-names>S. F.</given-names><surname>Huntington</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Landrette</surname></string-name>, et&#160;al., &#8220;<article-title>Phase 1 Study of ARV&#8208;393, a PROTAC BCL6 Degrader, in Advanced Non&#8208;Hodgkin Lymphoma</article-title>,&#8221; <source>Blood</source><volume>144</volume> (<year>2024</year>): <fpage>6505</fpage>.</mixed-citation></ref><ref id="mco270401-bib-0384"><label>384</label><mixed-citation publication-type="journal" id="mco270401-cit-0384"><string-name name-style="western"><given-names>G. L.</given-names><surname>Brien</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Remillard</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Shi</surname></string-name>, et&#160;al., &#8220;<article-title>Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma</article-title>,&#8221; <source>Elife</source><volume>7</volume> (<year>2018</year>): <elocation-id>e41305</elocation-id>.<pub-id pub-id-type="pmid">30431433</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7554/eLife.41305</pub-id><pub-id pub-id-type="pmcid">PMC6277197</pub-id></mixed-citation></ref><ref id="mco270401-bib-0385"><label>385</label><mixed-citation publication-type="journal" id="mco270401-cit-0385"><string-name name-style="western"><given-names>V.</given-names><surname>Vetma</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>O'Connor</surname></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>Ciulli</surname></string-name>, &#8220;<article-title>Development of PROTAC degrader drugs for cancer</article-title>,&#8221; <source>Annual Review of Cancer Biology</source><volume>9</volume> (<year>2024</year>): <fpage>119</fpage>&#8211;<lpage>140</lpage>.</mixed-citation></ref><ref id="mco270401-bib-0386"><label>386</label><mixed-citation publication-type="journal" id="mco270401-cit-0386"><string-name name-style="western"><given-names>R.</given-names><surname>Guo</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Dowlati</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Dagogo&#8208;Jack</surname></string-name>, et&#160;al., &#8220;<article-title>603O First clinical results From a phase I trial of PRT3789: A first&#8208;in&#8208;class intravenous SMARCA2 degrader, in patients With advanced solid tumors With a SMARCA4 mutation</article-title>,&#8221; <source>Annals of Oncology</source><volume>35</volume> (<year>2024</year>): <fpage>S483</fpage>&#8211;<lpage>S484</lpage>.</mixed-citation></ref><ref id="mco270401-bib-0387"><label>387</label><mixed-citation publication-type="journal" id="mco270401-cit-0387"><string-name name-style="western"><given-names>J. H.</given-names><surname>Kim</surname></string-name>, <string-name name-style="western"><given-names>J. H.</given-names><surname>Woo</surname></string-name>, <string-name name-style="western"><given-names>C. Y.</given-names><surname>Lim</surname></string-name>, et&#160;al., &#8220;<article-title>SMARCA4&#8208;deficient non&#8208;small cell lung carcinoma: Clinicodemographic, computed tomography, and positron emission tomography&#8208;computed tomography features</article-title>,&#8221; <source>Journal of thoracic disease</source><volume>16</volume>, no. <issue>3</issue> (<year>2024</year>): <fpage>1753</fpage>&#8211;<lpage>1764</lpage>.<pub-id pub-id-type="pmid">38617754</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/jtd-23-1606</pub-id><pub-id pub-id-type="pmcid">PMC11009581</pub-id></mixed-citation></ref><ref id="mco270401-bib-0388"><label>388</label><mixed-citation publication-type="journal" id="mco270401-cit-0388"><string-name name-style="western"><given-names>X.</given-names><surname>Liang</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Gao</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Wang</surname></string-name>, et&#160;al., &#8220;<article-title>Clinical characteristics and prognostic analysis of SMARCA4&#8208;deficient non&#8208;small cell lung cancer</article-title>,&#8221; <source>Cancer medicine</source><volume>12</volume>, no. <issue>13</issue> (<year>2023</year>): <fpage>14171</fpage>&#8211;<lpage>14182</lpage>.<pub-id pub-id-type="pmid">37184108</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cam4.6083</pub-id><pub-id pub-id-type="pmcid">PMC10358186</pub-id></mixed-citation></ref><ref id="mco270401-bib-0389"><label>389</label><mixed-citation publication-type="journal" id="mco270401-cit-0389"><string-name name-style="western"><given-names>T.</given-names><surname>F&#252;reder</surname></string-name>, &#8220;<article-title>Best of ESMO: Pan&#8208;tumor highlights</article-title>,&#8221; <source>Memo&#8212;Magazine of European Medical Oncology</source><volume>18</volume>, no. <issue>2</issue> (<year>2025</year>): <fpage>1</fpage>&#8211;<lpage>4</lpage>.</mixed-citation></ref><ref id="mco270401-bib-0390"><label>390</label><mixed-citation publication-type="journal" id="mco270401-cit-0390"><string-name name-style="western"><given-names>N.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Sheng</surname></string-name>, and <string-name name-style="western"><given-names>H.&#8208;H.</given-names><surname>Zhu</surname></string-name>, &#8220;<article-title>Breakthroughs in treatment for hematological malignancies: Latest updates on molecular glue, PROTACs and RNA degraders From ASH 2024</article-title>,&#8221; <source>Journal of Hematology &amp; Oncology</source><volume>18</volume>, no. <issue>1</issue> (<year>2025</year>): <fpage>26</fpage>.<pub-id pub-id-type="pmid">40045307</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13045-025-01674-6</pub-id><pub-id pub-id-type="pmcid">PMC11884154</pub-id></mixed-citation></ref><ref id="mco270401-bib-0391"><label>391</label><mixed-citation publication-type="journal" id="mco270401-cit-0391"><string-name name-style="western"><given-names>A.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Yang</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Hossain</surname></string-name>, et&#160;al., &#8220;<article-title>Potent and Selective Oral Stat6 Degrader KT&#8208;621 Inhibits IL&#8208;4/IL&#8208;13 in Mouse Models of Asthma</article-title>,&#8221; <source>Annals of Allergy, Asthma &amp; Immunology</source><volume>133</volume>, no. <issue>6</issue> (<year>2024</year>): <fpage>S57</fpage>.</mixed-citation></ref><ref id="mco270401-bib-0392"><label>392</label><mixed-citation publication-type="journal" id="mco270401-cit-0392"><string-name name-style="western"><given-names>Y.</given-names><surname>He</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Koch</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Budamagunta</surname></string-name>, et&#160;al., &#8220;<article-title>DT2216&#8212;a Bcl&#8208;xL&#8208;specific degrader is highly active Against Bcl&#8208;xL&#8208;dependent T cell lymphomas</article-title>,&#8221; <source>Journal of Hematology &amp; Oncology</source><volume>13</volume>, no. <issue>1</issue> (<year>2020</year>): <fpage>95</fpage>.<pub-id pub-id-type="pmid">32677976</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13045-020-00928-9</pub-id><pub-id pub-id-type="pmcid">PMC7364785</pub-id></mixed-citation></ref><ref id="mco270401-bib-0393"><label>393</label><mixed-citation publication-type="journal" id="mco270401-cit-0393"><string-name name-style="western"><given-names>W.</given-names><surname>Dai</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Qiao</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Fang</surname></string-name>, et&#160;al., &#8220;<article-title>Epigenetics&#8208;targeted drugs: Current paradigms and future challenges</article-title>,&#8221; <source>Signal Transduction and Targeted Therapy</source><volume>9</volume>, no. <issue>1</issue> (<year>2024</year>): <fpage>332</fpage>.<pub-id pub-id-type="pmid">39592582</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-024-02039-0</pub-id><pub-id pub-id-type="pmcid">PMC11627502</pub-id></mixed-citation></ref><ref id="mco270401-bib-0394"><label>394</label><mixed-citation publication-type="journal" id="mco270401-cit-0394"><string-name name-style="western"><given-names>H.</given-names><surname>Duparc</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Neef</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Kandiah</surname></string-name>, et&#160;al., &#8220;<article-title>AUTX703, a Novel and Potent KAT2A and KAT2B Protein Degrader, Induces Differentiation and Offers Survival Advantage in a Primary Human AML Xenograft Model</article-title>,&#8221; <source>Blood</source><volume>144</volume> (<year>2024</year>): <fpage>3585</fpage>.</mixed-citation></ref><ref id="mco270401-bib-0395"><label>395</label><mixed-citation publication-type="journal" id="mco270401-cit-0395"><string-name name-style="western"><given-names>Y. K.</given-names><surname>Chutake</surname></string-name>, <string-name name-style="western"><given-names>M. F.</given-names><surname>Mayo</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Dumont</surname></string-name>, et&#160;al., &#8220;<article-title>KT&#8208;253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy Than MDM2 Small&#8208;Molecule Inhibitors</article-title>,&#8221; <source>Molecular Cancer Therapeutics</source><volume>24</volume>, no. <issue>4</issue> (<year>2025</year>): <fpage>497</fpage>&#8211;<lpage>510</lpage>.<pub-id pub-id-type="pmid">39648478</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1535-7163.MCT-24-0306</pub-id><pub-id pub-id-type="pmcid">PMC11962396</pub-id></mixed-citation></ref><ref id="mco270401-bib-0396"><label>396</label><mixed-citation publication-type="journal" id="mco270401-cit-0396"><string-name name-style="western"><given-names>M.</given-names><surname>McKean</surname></string-name>, <string-name name-style="western"><given-names>A. I.</given-names><surname>Spira</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Rosen</surname></string-name>, et&#160;al., &#8220;<article-title>A phase 1/2 study of CFT1946, a novel, bifunctional degradation activating compound (BIDAC) degrader, of mutant BRAF V600 as monotherapy and in combination With trametinib, in mutant BRAF V600 solid tumors</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>41</volume>, no. <issue>16</issue> suppl (<year>2023</year>): <fpage>TPS3163</fpage>&#8211;<lpage>TPS3163</lpage>.</mixed-citation></ref><ref id="mco270401-bib-0397"><label>397</label><mixed-citation publication-type="journal" id="mco270401-cit-0397"><string-name name-style="western"><given-names>H.</given-names><surname>Majeski</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Chahal</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Pasis</surname></string-name>, et&#160;al., &#8220;<article-title>Characterization of BTX&#8208;9341, a bifunctional degrader of CDK4 and CDK6 for HR+/HER2&#8208; breast cancer and glioblastoma multiforme</article-title>,&#8221; <source>Journal of Clinical Oncology</source><volume>42</volume>, no. <issue>16</issue> suppl (<year>2024</year>): <fpage>3111</fpage>&#8211;<lpage>3111</lpage>.</mixed-citation></ref><ref id="mco270401-bib-0398"><label>398</label><mixed-citation publication-type="journal" id="mco270401-cit-0398"><string-name name-style="western"><given-names>Y.</given-names><surname>He</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Zheng</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Zhu</surname></string-name>, et&#160;al., &#8220;<article-title>Radioactive ADME Demonstrates ARV&#8208;110's High Druggability Despite Low Oral Bioavailability</article-title>,&#8221; <source>Journal of Medicinal Chemistry</source><volume>67</volume>, no. <issue>16</issue> (<year>2024</year>): <fpage>14277</fpage>&#8211;<lpage>14291</lpage>.<pub-id pub-id-type="pmid">39072617</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.4c01104</pub-id></mixed-citation></ref><ref id="mco270401-bib-0399"><label>399</label><mixed-citation publication-type="journal" id="mco270401-cit-0399"><string-name name-style="western"><given-names>T.</given-names><surname>Ishida</surname></string-name> and <string-name name-style="western"><given-names>A.</given-names><surname>Ciulli</surname></string-name>, &#8220;<article-title>E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones</article-title>,&#8221; <source>SLAS Discovery</source><volume>26</volume>, no. <issue>4</issue> (<year>2021</year>): <fpage>484</fpage>&#8211;<lpage>502</lpage>.<pub-id pub-id-type="pmid">33143537</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2472555220965528</pub-id><pub-id pub-id-type="pmcid">PMC8013866</pub-id></mixed-citation></ref><ref id="mco270401-bib-0400"><label>400</label><mixed-citation publication-type="journal" id="mco270401-cit-0400"><string-name name-style="western"><given-names>T.</given-names><surname>Sobierajski</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Ma&#322;olepsza</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Pichlak</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Gendaszewska&#8208;Darmach</surname></string-name>, and <string-name name-style="western"><given-names>K. M.</given-names><surname>B&#322;a&#380;ewska</surname></string-name>, &#8220;<article-title>The impact of E3 ligase choice on PROTAC effectiveness in protein kinase degradation</article-title>,&#8221; <source>Drug Discovery Today</source><volume>29</volume>, no. <issue>7</issue> (<year>2024</year>): <elocation-id>104032</elocation-id>.<pub-id pub-id-type="pmid">38789027</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drudis.2024.104032</pub-id></mixed-citation></ref><ref id="mco270401-bib-0401"><label>401</label><mixed-citation publication-type="journal" id="mco270401-cit-0401"><string-name name-style="western"><given-names>J.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Tang</surname></string-name>, et&#160;al., &#8220;<article-title>Recent advances in dual PROTACs degrader strategies for disease treatment</article-title>,&#8221; <source>European Journal of Medicinal Chemistry</source><volume>279</volume> (<year>2024</year>): <elocation-id>116901</elocation-id>.<pub-id pub-id-type="pmid">39341095</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2024.116901</pub-id></mixed-citation></ref><ref id="mco270401-bib-0402"><label>402</label><mixed-citation publication-type="journal" id="mco270401-cit-0402"><string-name name-style="western"><given-names>Z.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>B. S.</given-names><surname>Pan</surname></string-name>, <string-name name-style="western"><given-names>R. K.</given-names><surname>Manne</surname></string-name>, et&#160;al., &#8220;<article-title>CD36&#8208;mediated endocytosis of proteolysis&#8208;targeting chimeras</article-title>,&#8221; <source>Cell</source><volume>188</volume>, no. <issue>12</issue> (<year>2025</year>): <fpage>3219</fpage>&#8211;<lpage>3237</lpage>.<pub-id pub-id-type="pmid">40250420</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2025.03.036</pub-id><pub-id pub-id-type="pmcid">PMC12167158</pub-id></mixed-citation></ref><ref id="mco270401-bib-0403"><label>403</label><mixed-citation publication-type="journal" id="mco270401-cit-0403"><string-name name-style="western"><given-names>L.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Ke</surname></string-name>, <string-name name-style="western"><given-names>Q.</given-names><surname>He</surname></string-name>, et&#160;al., &#8220;<article-title>A novel ROR1&#8208;targeting antibody&#8208;PROTAC conjugate promotes BRD4 degradation for solid tumor treatment</article-title>,&#8221; <source>Theranostics</source><volume>15</volume>, no. <issue>4</issue> (<year>2025</year>): <fpage>1238</fpage>.<pub-id pub-id-type="pmid">39816690</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.102531</pub-id><pub-id pub-id-type="pmcid">PMC11729552</pub-id></mixed-citation></ref><ref id="mco270401-bib-0404"><label>404</label><mixed-citation publication-type="journal" id="mco270401-cit-0404"><string-name name-style="western"><given-names>Y.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Tandon</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Heelan</surname></string-name>, et&#160;al., &#8220;<article-title>Proteolysis&#8208;targeting chimera (PROTAC) delivery system: Advancing protein degraders towards clinical translation</article-title>,&#8221; <source>Chemical Society Reviews</source><volume>51</volume>, no. <issue>13</issue> (<year>2022</year>): <fpage>5330</fpage>&#8211;<lpage>5350</lpage>.<pub-id pub-id-type="pmid">35713468</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/d1cs00762a</pub-id><pub-id pub-id-type="pmcid">PMC9382890</pub-id></mixed-citation></ref><ref id="mco270401-bib-0405"><label>405</label><mixed-citation publication-type="journal" id="mco270401-cit-0405"><string-name name-style="western"><given-names>L.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Wang</surname></string-name>, et&#160;al., &#8220;<article-title>Development of a novel PROTAC using the nucleic acid aptamer as a targeting ligand for tumor selective degradation of nucleolin</article-title>,&#8221; <source>Molecular Therapy Nucleic Acids</source><volume>30</volume> (<year>2022</year>): <fpage>66</fpage>&#8211;<lpage>79</lpage>.<pub-id pub-id-type="pmid">36250201</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.omtn.2022.09.008</pub-id><pub-id pub-id-type="pmcid">PMC9535278</pub-id></mixed-citation></ref><ref id="mco270401-bib-0406"><label>406</label><mixed-citation publication-type="journal" id="mco270401-cit-0406"><string-name name-style="western"><given-names>Y.</given-names><surname>Sun</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Jiang</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Zhang</surname></string-name>, et&#160;al., &#8220;<article-title>Conjugated Polyelectrolyte/Single Strand DNA Hybrid Polyplexes for Efficient Nucleic Acid Delivery and Targeted Protein Degradation</article-title>,&#8221; <source>ACS Appl Mater Interfaces</source><volume>16</volume>, no. <issue>16</issue> (<year>2023</year>): <fpage>19987</fpage>&#8211;<lpage>19994</lpage>.<pub-id pub-id-type="pmid">38108633</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsami.3c14640</pub-id></mixed-citation></ref><ref id="mco270401-bib-0407"><label>407</label><mixed-citation publication-type="journal" id="mco270401-cit-0407"><string-name name-style="western"><given-names>P.</given-names><surname>Kou</surname></string-name>, <string-name name-style="western"><given-names>E. S.</given-names><surname>Levy</surname></string-name>, <string-name name-style="western"><given-names>A. D.</given-names><surname>Nguyen</surname></string-name>, et&#160;al., &#8220;<article-title>Development of liposome systems for enhancing the PK properties of bivalent PROTACs</article-title>,&#8221; <source>Pharmaceutics</source><volume>15</volume>, no. <issue>8</issue> (<year>2023</year>): <fpage>2098</fpage>.<pub-id pub-id-type="pmid">37631312</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics15082098</pub-id><pub-id pub-id-type="pmcid">PMC10458015</pub-id></mixed-citation></ref><ref id="mco270401-bib-0408"><label>408</label><mixed-citation publication-type="journal" id="mco270401-cit-0408"><string-name name-style="western"><given-names>X.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Cui</surname></string-name>, et&#160;al., &#8220;<article-title>Liposomes&#8208;mediated enhanced antitumor effect of docetaxel With BRD4&#8208;PROTAC as synergist for breast cancer chemotherapy/immunotherapy</article-title>,&#8221; <source>International Journal of Pharmaceutics</source><volume>668</volume> (<year>2025</year>): <elocation-id>124973</elocation-id>.<pub-id pub-id-type="pmid">39566696</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijpharm.2024.124973</pub-id></mixed-citation></ref><ref id="mco270401-bib-0409"><label>409</label><mixed-citation publication-type="journal" id="mco270401-cit-0409"><string-name name-style="western"><given-names>Y.</given-names><surname>Fu</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Rathod</surname></string-name>, and <string-name name-style="western"><given-names>K.</given-names><surname>Patel</surname></string-name>, &#8220;<article-title>Protein kinase C inhibitor anchored BRD4 PROTAC PEGylated nanoliposomes for the treatment of vemurafenib&#8208;resistant melanoma</article-title>,&#8221; <source>Experimental Cell Research</source><volume>396</volume>, no. <issue>1</issue> (<year>2020</year>): <elocation-id>112275</elocation-id>.<pub-id pub-id-type="pmid">32898554</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.yexcr.2020.112275</pub-id><pub-id pub-id-type="pmcid">PMC12045034</pub-id></mixed-citation></ref><ref id="mco270401-bib-0410"><label>410</label><mixed-citation publication-type="journal" id="mco270401-cit-0410"><string-name name-style="western"><given-names>K.</given-names><surname>Scheuer</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Bandelli</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Helbing</surname></string-name>, et&#160;al., &#8220;<article-title>Self&#8208;assembly of copolyesters Into stereocomplex crystallites tunes the properties of polyester nanoparticles</article-title>,&#8221; <source>Macromolecules</source><volume>53</volume>, no. <issue>19</issue> (<year>2020</year>): <fpage>8340</fpage>&#8211;<lpage>8351</lpage>.</mixed-citation></ref><ref id="mco270401-bib-0411"><label>411</label><mixed-citation publication-type="journal" id="mco270401-cit-0411"><string-name name-style="western"><given-names>F. J.</given-names><surname>Cimas</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Niza</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Juan</surname></string-name>, et&#160;al., &#8220;<article-title>Controlled Delivery of BET&#8208;PROTACs: In vitro evaluation of MZ1&#8208;loaded polymeric antibody conjugated nanoparticles in breast cancer</article-title>,&#8221; <source>Pharmaceutics</source><volume>12</volume>, no. <issue>10</issue> (<year>2020</year>): <fpage>986</fpage>.<pub-id pub-id-type="pmid">33086530</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics12100986</pub-id><pub-id pub-id-type="pmcid">PMC7589709</pub-id></mixed-citation></ref><ref id="mco270401-bib-0412"><label>412</label><mixed-citation publication-type="journal" id="mco270401-cit-0412"><string-name name-style="western"><given-names>N.</given-names><surname>Mukerjee</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Maitra</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Ghosh</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Subramaniyan</surname></string-name>, and <string-name name-style="western"><given-names>R.</given-names><surname>Sharma</surname></string-name>, &#8220;<article-title>Exosome&#8208;mediated PROTACs delivery to target viral infections</article-title>,&#8221; <source>Drug Development Research</source><volume>84</volume>, no. <issue>6</issue> (<year>2023</year>): <fpage>1031</fpage>&#8211;<lpage>1036</lpage>.<pub-id pub-id-type="pmid">37391892</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ddr.22091</pub-id></mixed-citation></ref><ref id="mco270401-bib-0413"><label>413</label><mixed-citation publication-type="journal" id="mco270401-cit-0413"><string-name name-style="western"><given-names>N.</given-names><surname>Mukerjee</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Maitra</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Ghosh</surname></string-name>, et&#160;al., &#8220;<article-title>Synergizing proteolysis&#8208;targeting chimeras and nanoscale exosome&#8208;based delivery mechanisms for HIV and antiviral therapeutics</article-title>,&#8221; <source>ACS Applied Nano Materials</source><volume>7</volume>, no. <issue>4</issue> (<year>2024</year>): <fpage>3499</fpage>&#8211;<lpage>3514</lpage>.</mixed-citation></ref><ref id="mco270401-bib-0414"><label>414</label><mixed-citation publication-type="journal" id="mco270401-cit-0414"><string-name name-style="western"><given-names>R.</given-names><surname>Kojima</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Bojar</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Rizzi</surname></string-name>, et&#160;al., &#8220;<article-title>Designer exosomes produced by implanted cells intracerebrally deliver therapeutic cargo for Parkinson's disease treatment</article-title>,&#8221; <source>Nature Communications</source><volume>9</volume>, no. <issue>1</issue> (<year>2018</year>): <fpage>1305</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-018-03733-8</pub-id><pub-id pub-id-type="pmcid">PMC5880805</pub-id><pub-id pub-id-type="pmid">29610454</pub-id></mixed-citation></ref><ref id="mco270401-bib-0415"><label>415</label><mixed-citation publication-type="miscellaneous" id="mco270401-cit-0415">Q. He, L. Zhou, D. Yu, et al., "Near&#8208;Infrared&#8208;Activatable PROTAC Nanocages for Controllable Target Protein Degradation and On&#8208;Demand Antitumor Therapy," Journal of Medicinal Chemistry 66, no. 15 (2023): 10458&#8208;10472.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.3c00587</pub-id><pub-id pub-id-type="pmid">37279091</pub-id></mixed-citation></ref><ref id="mco270401-bib-0416"><label>416</label><mixed-citation publication-type="miscellaneous" id="mco270401-cit-0416">Y. Wu, X. Chang, G. Yang, et al., "A Physiologically Responsive Nanocomposite Hydrogel for Treatment of Head and Neck Squamous Cell Carcinoma via Proteolysis&#8208;Targeting Chimeras Enhanced Immunotherapy," Advanced Materials 35, no. 12 (2023): e2210787.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.202210787</pub-id><pub-id pub-id-type="pmid">36656993</pub-id></mixed-citation></ref><ref id="mco270401-bib-0417"><label>417</label><mixed-citation publication-type="journal" id="mco270401-cit-0417"><string-name name-style="western"><given-names>G.</given-names><surname>Fan</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Lu</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Tan</surname></string-name>, et&#160;al., &#8220;<article-title>Potent Efficacy of Computer&#8208;Aided Designed Peptide Degrader Drug on PCSK9&#8208;Mediated Hypercholesterolemia</article-title>,&#8221; <source>BioRxiv</source> (<year>2025</year>). 2025.2006. 2025.661251.</mixed-citation></ref><ref id="mco270401-bib-0418"><label>418</label><mixed-citation publication-type="journal" id="mco270401-cit-0418"><string-name name-style="western"><given-names>J.</given-names><surname>Chang</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Glass</surname></string-name>, et&#160;al., &#8220;<article-title>Integrating combinatorial lipid nanoparticle and chemically modified protein for intracellular delivery and genome editing</article-title>,&#8221; <source>Accounts of Chemical Research</source><volume>52</volume>, no. <issue>3</issue> (<year>2018</year>): <fpage>665</fpage>&#8211;<lpage>675</lpage>.<pub-id pub-id-type="pmid">30586281</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.accounts.8b00493</pub-id><pub-id pub-id-type="pmcid">PMC6513672</pub-id></mixed-citation></ref><ref id="mco270401-bib-0419"><label>419</label><mixed-citation publication-type="journal" id="mco270401-cit-0419"><string-name name-style="western"><given-names>J.</given-names><surname>Huang</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Yao</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Li</surname></string-name>, and <string-name name-style="western"><given-names>Y.</given-names><surname>Ping</surname></string-name>, &#8220;<article-title>Targeted delivery of PROTAC&#8208;based prodrug activated by bond&#8208;cleavage bioorthogonal chemistry for microneedle&#8208;assisted cancer therapy</article-title>,&#8221; <source>Journal of Controlled Release</source><volume>361</volume> (<year>2023</year>): <fpage>270</fpage>&#8211;<lpage>279</lpage>.<pub-id pub-id-type="pmid">37541594</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2023.07.062</pub-id></mixed-citation></ref><ref id="mco270401-bib-0420"><label>420</label><mixed-citation publication-type="journal" id="mco270401-cit-0420"><string-name name-style="western"><given-names>R.</given-names><surname>Bargakshatriya</surname></string-name> and <string-name name-style="western"><given-names>S. K.</given-names><surname>Pramanik</surname></string-name>, &#8220;<article-title>Leading prodrug strategies for targeted and specific release</article-title>,&#8221; <source>Future Medicinal Chemistry</source><volume>17</volume>, no. <issue>8</issue> (<year>2025</year>): <fpage>865</fpage>&#8211;<lpage>868</lpage>.<pub-id pub-id-type="pmid">40085509</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/17568919.2025.2479412</pub-id></mixed-citation></ref><ref id="mco270401-bib-0421"><label>421</label><mixed-citation publication-type="journal" id="mco270401-cit-0421"><string-name name-style="western"><given-names>X.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Song</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Zhang</surname></string-name>, et&#160;al., &#8220;<article-title>Unconventional PROTACs for Targeted Protein Degradation in Cancer Therapy</article-title>,&#8221; <source>Angewandte Chemie (International ed in English)</source><volume>64</volume>, no. <issue>31</issue> (<year>2025</year>): <elocation-id>e202507702</elocation-id>.<pub-id pub-id-type="pmid">40492592</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/anie.202507702</pub-id></mixed-citation></ref><ref id="mco270401-bib-0422"><label>422</label><mixed-citation publication-type="journal" id="mco270401-cit-0422"><string-name name-style="western"><given-names>R. K.</given-names><surname>Rej</surname></string-name>, <string-name name-style="western"><given-names>S. R.</given-names><surname>Allu</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Roy</surname></string-name>, et&#160;al., &#8220;<article-title>Orally Bioavailable Proteolysis&#8208;Targeting Chimeras: An Innovative Approach in the Golden Era of Discovering Small&#8208;Molecule Cancer Drugs</article-title>,&#8221; <source>Pharmaceuticals (Basel)</source><volume>17</volume>, no. <issue>4</issue> (<year>2024</year>).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ph17040494</pub-id><pub-id pub-id-type="pmcid">PMC11054475</pub-id><pub-id pub-id-type="pmid">38675453</pub-id></mixed-citation></ref><ref id="mco270401-bib-0423"><label>423</label><mixed-citation publication-type="journal" id="mco270401-cit-0423"><string-name name-style="western"><given-names>J.</given-names><surname>Tate</surname></string-name> and <string-name name-style="western"><given-names>G.</given-names><surname>Ward</surname></string-name>, &#8220;<article-title>Interferences in immunoassay</article-title>,&#8221; <source>Clinical Biochemist Reviews</source><volume>25</volume>, no. <issue>2</issue> (<year>2004</year>): <fpage>105</fpage>&#8211;<lpage>120</lpage>.<pub-id pub-id-type="pmid">18458713</pub-id><pub-id pub-id-type="pmcid">PMC1904417</pub-id></mixed-citation></ref><ref id="mco270401-bib-0424"><label>424</label><mixed-citation publication-type="journal" id="mco270401-cit-0424"><string-name name-style="western"><given-names>M.</given-names><surname>Schr&#246;der</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Renatus</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Liang</surname></string-name>, et&#160;al., &#8220;<article-title>DCAF1&#8208;based PROTACs With activity Against clinically validated targets overcoming intrinsic&#8208;and acquired&#8208;degrader resistance</article-title>,&#8221; <source>Nature Communications</source><volume>15</volume>, no. <issue>1</issue> (<year>2024</year>): <fpage>275</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-44237-4</pub-id><pub-id pub-id-type="pmcid">PMC10766610</pub-id><pub-id pub-id-type="pmid">38177131</pub-id></mixed-citation></ref><ref id="mco270401-bib-0425"><label>425</label><mixed-citation publication-type="journal" id="mco270401-cit-0425"><string-name name-style="western"><given-names>I.</given-names><surname>Sosi&#269;</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Bricelj</surname></string-name>, and <string-name name-style="western"><given-names>C.</given-names><surname>Steinebach</surname></string-name>, &#8220;<article-title>E3 ligase ligand chemistries: From building blocks to protein degraders</article-title>,&#8221; <source>Chemical Society Reviews</source><volume>51</volume>, no. <issue>9</issue> (<year>2022</year>): <fpage>3487</fpage>&#8211;<lpage>3534</lpage>.<pub-id pub-id-type="pmid">35393989</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/d2cs00148a</pub-id></mixed-citation></ref><ref id="mco270401-bib-0426"><label>426</label><mixed-citation publication-type="journal" id="mco270401-cit-0426"><string-name name-style="western"><given-names>L.</given-names><surname>Lescouz&#232;res</surname></string-name> and <string-name name-style="western"><given-names>P.</given-names><surname>Bomont</surname></string-name>, &#8220;<article-title>E3 Ubiquitin Ligases in Neurological Diseases: Focus on Gigaxonin and Autophagy</article-title>,&#8221; <source>Front in Physiology</source><volume>11</volume> (<year>2020</year>): <fpage>1022</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphys.2020.01022</pub-id><pub-id pub-id-type="pmcid">PMC7642974</pub-id><pub-id pub-id-type="pmid">33192535</pub-id></mixed-citation></ref><ref id="mco270401-bib-0427"><label>427</label><mixed-citation publication-type="journal" id="mco270401-cit-0427"><string-name name-style="western"><given-names>P.</given-names><surname>Lu</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Cheng</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Xue</surname></string-name>, et&#160;al., &#8220;<article-title>Selective degradation of multimeric proteins by TRIM21&#8208;based molecular glue and PROTAC degraders</article-title>,&#8221; <source>Cell</source><volume>187</volume>, no. <issue>25</issue> (<year>2024</year>): <fpage>7126</fpage>&#8211;<lpage>7142</lpage>. e7120.<pub-id pub-id-type="pmid">39488207</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2024.10.015</pub-id></mixed-citation></ref><ref id="mco270401-bib-0428"><label>428</label><mixed-citation publication-type="journal" id="mco270401-cit-0428"><string-name name-style="western"><given-names>Y.</given-names><surname>Sun</surname></string-name>, &#8220;<article-title>E3 ubiquitin ligases as cancer targets and biomarkers</article-title>,&#8221; <source>Neoplasia</source><volume>8</volume>, no. <issue>8</issue> (<year>2006</year>): <fpage>645</fpage>&#8211;<lpage>654</lpage>.<pub-id pub-id-type="pmid">16925947</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1593/neo.06376</pub-id><pub-id pub-id-type="pmcid">PMC1601942</pub-id></mixed-citation></ref><ref id="mco270401-bib-0429"><label>429</label><mixed-citation publication-type="journal" id="mco270401-cit-0429"><string-name name-style="western"><given-names>S.</given-names><surname>Datta</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Verma</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Dhara</surname></string-name>, et&#160;al., &#8220;<article-title>Interplay of precision therapeutics and MD study: Calocybe indica's potentials Against cervical cancer and its interaction With VEGF via octadecanoic acid</article-title>,&#8221; <source>Journal of Cellular and Molecular Medicine</source><volume>28</volume>, no. <issue>8</issue> (<year>2024</year>): <elocation-id>e18302</elocation-id>.<pub-id pub-id-type="pmid">38652115</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jcmm.18302</pub-id><pub-id pub-id-type="pmcid">PMC11037404</pub-id></mixed-citation></ref><ref id="mco270401-bib-0430"><label>430</label><mixed-citation publication-type="journal" id="mco270401-cit-0430"><string-name name-style="western"><given-names>O.</given-names><surname>Koshkina</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Rheinberger</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Flocke</surname></string-name>, et&#160;al., &#8220;<article-title>Biodegradable polyphosphoester micelles act as both background&#8208;free (31)P magnetic resonance imaging agents and drug nanocarriers</article-title>,&#8221; <source>Nature Communications</source><volume>14</volume>, no. <issue>1</issue> (<year>2023</year>): <fpage>4351</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-40089-0</pub-id><pub-id pub-id-type="pmcid">PMC10356825</pub-id><pub-id pub-id-type="pmid">37468502</pub-id></mixed-citation></ref><ref id="mco270401-bib-0431"><label>431</label><mixed-citation publication-type="journal" id="mco270401-cit-0431"><string-name name-style="western"><given-names>J.</given-names><surname>Dugal&#8208;Tessier</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Thirumalairajan</surname></string-name>, and <string-name name-style="western"><given-names>N.</given-names><surname>Jain</surname></string-name>, &#8220;<article-title>Antibody&#8208;oligonucleotide conjugates: A twist to antibody&#8208;drug conjugates</article-title>,&#8221; <source>Journal of Clinical Medicine</source><volume>10</volume>, no. <issue>4</issue> (<year>2021</year>): <fpage>838</fpage>.<pub-id pub-id-type="pmid">33670689</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm10040838</pub-id><pub-id pub-id-type="pmcid">PMC7922418</pub-id></mixed-citation></ref><ref id="mco270401-bib-0432"><label>432</label><mixed-citation publication-type="journal" id="mco270401-cit-0432"><string-name name-style="western"><given-names>C.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Wu</surname></string-name>, and <string-name name-style="western"><given-names>D.</given-names><surname>Xing</surname></string-name>, &#8220;<article-title>New&#8208;generation advanced PROTACs as potential therapeutic agents in cancer therapy</article-title>,&#8221; <source>Molecular Cancer</source><volume>23</volume>, no. <issue>1</issue> (<year>2024</year>): <fpage>110</fpage>.<pub-id pub-id-type="pmid">38773495</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-024-02024-9</pub-id><pub-id pub-id-type="pmcid">PMC11107062</pub-id></mixed-citation></ref><ref id="mco270401-bib-0433"><label>433</label><mixed-citation publication-type="journal" id="mco270401-cit-0433"><string-name name-style="western"><given-names>K.</given-names><surname>Farrell</surname></string-name> and <string-name name-style="western"><given-names>T. J.</given-names><surname>Jarome</surname></string-name>, &#8220;<article-title>Is PROTAC technology really a game changer for central nervous system drug discovery?</article-title>,&#8221; <source>Expert Opinion on Drug Discovery</source><volume>16</volume>, no. <issue>8</issue> (<year>2021</year>): <fpage>833</fpage>&#8211;<lpage>840</lpage>.<pub-id pub-id-type="pmid">33870803</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/17460441.2021.1915979</pub-id><pub-id pub-id-type="pmcid">PMC8298267</pub-id></mixed-citation></ref><ref id="mco270401-bib-0434"><label>434</label><mixed-citation publication-type="journal" id="mco270401-cit-0434"><string-name name-style="western"><given-names>K. R.</given-names><surname>Mittal</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Pharasi</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Sarna</surname></string-name>, et&#160;al., &#8220;<article-title>Nanotechnology&#8208;based drug delivery for the treatment of CNS disorders</article-title>,&#8221; <source>Translational Neuroscience</source><volume>13</volume>, no. <issue>1</issue> (<year>2022</year>): <fpage>527</fpage>&#8211;<lpage>546</lpage>.<pub-id pub-id-type="pmid">36741545</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1515/tnsci-2022-0258</pub-id><pub-id pub-id-type="pmcid">PMC9883694</pub-id></mixed-citation></ref><ref id="mco270401-bib-0435"><label>435</label><mixed-citation publication-type="journal" id="mco270401-cit-0435"><string-name name-style="western"><given-names>A.</given-names><surname>Suzuki</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Henao</surname></string-name>, <string-name name-style="western"><given-names>M. C.</given-names><surname>Reed</surname></string-name>, et&#160;al., &#8220;<article-title>Lower hepatic CBS and PEMT expression in advanced NAFLD: Inferencing strategies to lower homocysteine With a mathematical model</article-title>,&#8221; <source>Metabolism and Target Organ Damage</source><volume>4</volume>, no. <issue>3</issue> (<year>2024</year>). <elocation-id>N/A&#8208;N/A</elocation-id>.</mixed-citation></ref><ref id="mco270401-bib-0436"><label>436</label><mixed-citation publication-type="journal" id="mco270401-cit-0436"><string-name name-style="western"><given-names>A.</given-names><surname>Mantovani</surname></string-name> and <string-name name-style="western"><given-names>G.</given-names><surname>Targher</surname></string-name>, &#8220;<article-title>PNPLA3 rs738409 polymorphism and kidney dysfunction: An association Beyond nonalcoholic fatty liver disease?</article-title>,&#8221; <source>Metabolism and Target Organ Damage</source><volume>3</volume>, no. <issue>4</issue> (<year>2023</year>). <elocation-id>N/A&#8208;N/A</elocation-id>.</mixed-citation></ref><ref id="mco270401-bib-0437"><label>437</label><mixed-citation publication-type="journal" id="mco270401-cit-0437"><string-name name-style="western"><given-names>B.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>Q.</given-names><surname>Yang</surname></string-name>, et&#160;al., &#8220;<article-title>Pulmonary inhalation for disease treatment: Basic research and clinical translations</article-title>,&#8221; <source>Materials Today Bio</source><volume>25</volume> (<year>2024</year>): <elocation-id>100966</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mtbio.2024.100966</pub-id><pub-id pub-id-type="pmcid">PMC10840005</pub-id><pub-id pub-id-type="pmid">38318475</pub-id></mixed-citation></ref><ref id="mco270401-bib-0438"><label>438</label><mixed-citation publication-type="journal" id="mco270401-cit-0438"><string-name name-style="western"><given-names>S.&#8208;M.</given-names><surname>Qi</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Dong</surname></string-name>, <string-name name-style="western"><given-names>Z.&#8208;Y.</given-names><surname>Xu</surname></string-name>, et&#160;al., &#8220;<article-title>PROTAC: An effective targeted protein degradation strategy for cancer therapy</article-title>,&#8221; <source>Frontiers in pharmacology</source><volume>12</volume> (<year>2021</year>): <elocation-id>692574</elocation-id>.<pub-id pub-id-type="pmid">34025443</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2021.692574</pub-id><pub-id pub-id-type="pmcid">PMC8138175</pub-id></mixed-citation></ref><ref id="mco270401-bib-0439"><label>439</label><mixed-citation publication-type="journal" id="mco270401-cit-0439"><string-name name-style="western"><given-names>S.</given-names><surname>Zeng</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Huang</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Zheng</surname></string-name>, et&#160;al., &#8220;<article-title>Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges</article-title>,&#8221; <source>European Journal of Medicinal Chemistry</source><volume>210</volume> (<year>2021</year>): <elocation-id>112981</elocation-id>.<pub-id pub-id-type="pmid">33160761</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2020.112981</pub-id></mixed-citation></ref><ref id="mco270401-bib-0440"><label>440</label><mixed-citation publication-type="journal" id="mco270401-cit-0440"><string-name name-style="western"><given-names>R. G.</given-names><surname>Guenette</surname></string-name>, <string-name name-style="western"><given-names>S. W.</given-names><surname>Yang</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Min</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Pei</surname></string-name>, and <string-name name-style="western"><given-names>P. R.</given-names><surname>Potts</surname></string-name>, &#8220;<article-title>Target and tissue selectivity of PROTAC degraders</article-title>,&#8221; <source>Chemical Society Reviews</source><volume>51</volume>, no. <issue>14</issue> (<year>2022</year>): <fpage>5740</fpage>&#8211;<lpage>5756</lpage>.<pub-id pub-id-type="pmid">35587208</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/d2cs00200k</pub-id></mixed-citation></ref><ref id="mco270401-bib-0441"><label>441</label><mixed-citation publication-type="journal" id="mco270401-cit-0441"><string-name name-style="western"><given-names>C.</given-names><surname>Shi</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Wang</surname></string-name>, et&#160;al., &#8220;<article-title>PROTAC induced&#8208;BET protein degradation exhibits potent anti&#8208;osteosarcoma activity by triggering apoptosis</article-title>,&#8221; <source>Cell Death &amp; Disease</source><volume>10</volume>, no. <issue>11</issue> (<year>2019</year>): <fpage>815</fpage>.<pub-id pub-id-type="pmid">31653826</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-019-2022-2</pub-id><pub-id pub-id-type="pmcid">PMC6814818</pub-id></mixed-citation></ref><ref id="mco270401-bib-0442"><label>442</label><mixed-citation publication-type="journal" id="mco270401-cit-0442"><string-name name-style="western"><given-names>R.</given-names><surname>Kamaraj</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Ghosh</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Das</surname></string-name>, et&#160;al., &#8220;<article-title>Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera&#8208;Driven Ubiquitin&#8208;Proteasome Interactions</article-title>,&#8221; <source>Bioconjugate Chemistry</source><volume>35</volume>, no. <issue>8</issue> (<year>2024</year>): <fpage>1089</fpage>&#8211;<lpage>1115</lpage>.<pub-id pub-id-type="pmid">38990186</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.bioconjchem.4c00253</pub-id><pub-id pub-id-type="pmcid">PMC11342303</pub-id></mixed-citation></ref><ref id="mco270401-bib-0443"><label>443</label><mixed-citation publication-type="journal" id="mco270401-cit-0443"><string-name name-style="western"><given-names>Y.</given-names><surname>Xiang</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Jiang</surname></string-name>, <string-name name-style="western"><given-names>Q.</given-names><surname>Su</surname></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Shi</surname></string-name>, &#8220;<article-title>The role of inflammation in autoimmune disease: A therapeutic target</article-title>,&#8221; <source>Frontiers in immunology</source><volume>14</volume> (<year>2023</year>): <elocation-id>1267091</elocation-id>.<pub-id pub-id-type="pmid">37859999</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2023.1267091</pub-id><pub-id pub-id-type="pmcid">PMC10584158</pub-id></mixed-citation></ref><ref id="mco270401-bib-0444"><label>444</label><mixed-citation publication-type="journal" id="mco270401-cit-0444"><string-name name-style="western"><given-names>Y.</given-names><surname>He</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Chang</surname></string-name>, et&#160;al., &#8220;<article-title>Using proteolysis&#8208;targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity</article-title>,&#8221; <source>Nature Communications</source><volume>11</volume>, no. <issue>1</issue> (<year>2020</year>): <fpage>1996</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-15838-0</pub-id><pub-id pub-id-type="pmcid">PMC7181703</pub-id><pub-id pub-id-type="pmid">32332723</pub-id></mixed-citation></ref><ref id="mco270401-bib-0445"><label>445</label><mixed-citation publication-type="journal" id="mco270401-cit-0445"><string-name name-style="western"><given-names>A.</given-names><surname>Di Vincenzo</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Crescenzi</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Granzotto</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Vettor</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Rossato</surname></string-name>, &#8220;<article-title>Relationship Between sex hormones, markers of adiposity and inflammation in male patients With severe obesity undergoing bariatric surgery</article-title>,&#8221; <source>Metabolism and Target Organ Damage</source><volume>3</volume>, no. <issue>3</issue> (<year>2023</year>): <elocation-id>N/A&#8211;N/A</elocation-id>.</mixed-citation></ref><ref id="mco270401-bib-0446"><label>446</label><mixed-citation publication-type="journal" id="mco270401-cit-0446"><string-name name-style="western"><given-names>D.</given-names><surname>Ricciardi</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Galiero</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Todisco</surname></string-name>, et&#160;al., &#8220;<article-title>Neurophysiological assessment of peripheral neuropathy Through whole plantar nerve conduction in type 2 diabetes mellitus and healthy control subjects</article-title>,&#8221; <source>Metabolism and Target Organ Damage</source><volume>4</volume>, no. <issue>3</issue> (<year>2024</year>): <elocation-id>N/A&#8211;N/A</elocation-id>.</mixed-citation></ref><ref id="mco270401-bib-0447"><label>447</label><mixed-citation publication-type="journal" id="mco270401-cit-0447"><string-name name-style="western"><given-names>G.</given-names><surname>Luo</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Lin</surname></string-name>, et&#160;al., &#8220;<article-title>Discovery of an orally active VHL&#8208;recruiting PROTAC that achieves robust HMGCR degradation and potent hypolipidemic activity in vivo</article-title>,&#8221; <source>Acta Pharmaceutica Sinica B</source><volume>11</volume>, no. <issue>5</issue> (<year>2021</year>): <fpage>1300</fpage>&#8211;<lpage>1314</lpage>.<pub-id pub-id-type="pmid">34094835</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2020.11.001</pub-id><pub-id pub-id-type="pmcid">PMC8148065</pub-id></mixed-citation></ref><ref id="mco270401-bib-0448"><label>448</label><mixed-citation publication-type="journal" id="mco270401-cit-0448"><string-name name-style="western"><given-names>M.&#8208;X.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Yang</surname></string-name>, <string-name name-style="western"><given-names>Q.</given-names><surname>Zhao</surname></string-name>, et&#160;al., &#8220;<article-title>Degradation versus inhibition: Development of proteolysis&#8208;targeting chimeras for overcoming statin&#8208;induced compensatory upregulation of 3&#8208;hydroxy&#8208;3&#8208;methylglutaryl coenzyme A reductase</article-title>,&#8221; <source>Journal of Medicinal Chemistry</source><volume>63</volume>, no. <issue>9</issue> (<year>2020</year>): <fpage>4908</fpage>&#8211;<lpage>4928</lpage>.<pub-id pub-id-type="pmid">32321253</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.0c00339</pub-id></mixed-citation></ref><ref id="mco270401-bib-0449"><label>449</label><mixed-citation publication-type="journal" id="mco270401-cit-0449"><string-name name-style="western"><given-names>S.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Huang</surname></string-name>, et&#160;al., &#8220;<article-title>Decoy&#8208;PROTAC for specific degradation of &#8220;Undruggable&#8221; STAT3 transcription factor</article-title>,&#8221; <source>Cell death &amp; disease</source><volume>16</volume>, no. <issue>1</issue> (<year>2025</year>): <fpage>197</fpage>.<pub-id pub-id-type="pmid">40118821</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-025-07535-x</pub-id><pub-id pub-id-type="pmcid">PMC11928565</pub-id></mixed-citation></ref><ref id="mco270401-bib-0450"><label>450</label><mixed-citation publication-type="journal" id="mco270401-cit-0450"><string-name name-style="western"><given-names>X.</given-names><surname>Wu</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Pan</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Tang</surname></string-name>, and <string-name name-style="western"><given-names>Y. J. B.</given-names><surname>Shen</surname></string-name>, &#8220;<article-title>Targeting the&#8221; undruggable&#8220; cancer driver genes: Ras, myc, and tp53</article-title>,&#8221; <source>International Journal of Cancer</source><volume>47</volume>, no. <issue>7</issue> (<year>2023</year>).</mixed-citation></ref><ref id="mco270401-bib-0451"><label>451</label><mixed-citation publication-type="journal" id="mco270401-cit-0451"><string-name name-style="western"><given-names>N.</given-names><surname>Cruz&#8208;Rodriguez</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Tang</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Bateman</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Tang</surname></string-name>, and <string-name name-style="western"><given-names>M. J. L.</given-names><surname>Deininger</surname></string-name>, &#8220;<article-title>BCR: ABL1 Proteolysis&#8208;targeting chimeras (PROTACs): The new frontier in the treatment of Ph+ leukemias?</article-title>,&#8221; <source>Leukemia</source><volume>38</volume>, no. <issue>9</issue> (<year>2024</year>): <fpage>1885</fpage>&#8211;<lpage>1893</lpage>.<pub-id pub-id-type="pmid">39098922</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41375-024-02365-w</pub-id><pub-id pub-id-type="pmcid">PMC11569815</pub-id></mixed-citation></ref><ref id="mco270401-bib-0452"><label>452</label><mixed-citation publication-type="journal" id="mco270401-cit-0452"><string-name name-style="western"><given-names>H.</given-names><surname>Yadav</surname></string-name> and <string-name name-style="western"><given-names>R. K.</given-names><surname>Shirumalla</surname></string-name>, &#8220;<article-title>Emerging trends in IRAK&#8208;4 kinase research</article-title>,&#8221; <source>Molecular Biology Reports</source><volume>50</volume>, no. <issue>9</issue> (<year>2023</year>): <fpage>7825</fpage>&#8211;<lpage>7837</lpage>.<pub-id pub-id-type="pmid">37490192</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11033-023-08438-w</pub-id></mixed-citation></ref><ref id="mco270401-bib-0453"><label>453</label><mixed-citation publication-type="journal" id="mco270401-cit-0453"><string-name name-style="western"><given-names>S.</given-names><surname>Banerjee</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Biehl</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Gadina</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Hasni</surname></string-name>, and <string-name name-style="western"><given-names>D. M.</given-names><surname>Schwartz</surname></string-name>, &#8220;<article-title>JAK&#8211;STAT signaling as a target for inflammatory and autoimmune diseases: Current and future prospects</article-title>,&#8221; <source>Drugs</source><volume>77</volume> (<year>2017</year>): <fpage>521</fpage>&#8211;<lpage>546</lpage>.<pub-id pub-id-type="pmid">28255960</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40265-017-0701-9</pub-id><pub-id pub-id-type="pmcid">PMC7102286</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Neuroinflammation</journal-id><journal-id journal-id-type="iso-abbrev">J Neuroinflammation</journal-id><journal-id journal-id-type="pmc-domain-id">249</journal-id><journal-id journal-id-type="pmc-domain">jneuro</journal-id><journal-title-group><journal-title>Journal of Neuroinflammation</journal-title></journal-title-group><issn pub-type="epub">1742-2094</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12492848</article-id><article-id pub-id-type="pmcid-ver">PMC12492848.1</article-id><article-id pub-id-type="pmcaid">12492848</article-id><article-id pub-id-type="pmcaiid">12492848</article-id><article-id pub-id-type="pmid">41039439</article-id><article-id pub-id-type="doi">10.1186/s12974-025-03545-w</article-id><article-id pub-id-type="publisher-id">3545</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Cerebrospinal fluid neuronal pentraxin levels are associated with tau pathology via microglia&#8211;astrocyte signaling in alzheimer&#8217;s disease</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Zhang</surname><given-names initials="Z">Zihao</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Chen</surname><given-names initials="X">Xin</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sheng</surname><given-names initials="Z">Zehu</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Jiang</surname><given-names initials="N">Na</given-names></name><address><email>jianglucky_1983@163.com</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Zou</surname><given-names initials="WQ">Wen-Quan</given-names></name><address><email>wenquanzou@ncu.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/042v6xz23</institution-id><institution-id institution-id-type="GRID">grid.260463.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 2182 8825</institution-id><institution>Institute of Neurology, Jiangxi Academy of Clinical Medical Sciences, The First Affiliated Hospital, </institution><institution>Jiangxi Medical College, Nanchang University, </institution></institution-wrap>Nanchang, 330006 China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0056pyw12</institution-id><institution-id institution-id-type="GRID">grid.412543.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 0033 4148</institution-id><institution>School of athletic performance, </institution><institution>Shanghai University of Sport, </institution></institution-wrap>Shanghai, 200438 China </aff><aff id="Aff3"><label>3</label>Chongming District Sports School, Shanghai, 202150 China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/017z00e58</institution-id><institution-id institution-id-type="GRID">grid.203458.8</institution-id><institution-id institution-id-type="ISNI">0000 0000 8653 0555</institution-id><institution>Department of Geriatrics, </institution><institution>The First Affiliated Hospital of Chongqing Medical University, Chongqing Medical University, </institution></institution-wrap>Chongqing, 400016 China </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00g2ypp58</institution-id><institution-id institution-id-type="GRID">grid.440706.1</institution-id><institution-id institution-id-type="ISNI">0000 0001 0175 8217</institution-id><institution>Medicine and sports health promotion, Medical College, </institution><institution>Dalian University, </institution></institution-wrap>Dalian, 116622 China </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>22</volume><issue-id pub-id-type="pmc-issue-id">478515</issue-id><elocation-id>221</elocation-id><history><date date-type="received"><day>11</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>21</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-04 10:26:05.627"><day>04</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="12974_2025_Article_3545.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Recent studies have reported that Neuronal Pentraxin 2 (NPTX2), a synapse-associated protein, can significantly predict the progression of cognitive decline. However, the role of the NPTX protein family in the pathological progression of Alzheimer&#8217;s Disease (AD) in humans remains unclear.</p></sec><sec><title>Methods</title><p id="Par2">This study included 263 participants from the Alzheimer&#8217;s Disease Neuroimaging Initiative, including cognitively normal, mild cognitive impairment, and AD individuals, with a mean age of 73.99&#8201;&#177;&#8201;7.43 years. Cerebrospinal fluid (CSF) NPTX proteins and Glial Fibrillary Acidic Protein (GFAP) were quantified by Mass spectrometry, Soluble Triggering Receptor Expressed on Myeloid Cells 2 (sTREM2) by a Meso Scale Discovery-based multiplex immunoassay, and amyloid-beta 42 (A&#946;42), phosphorylated tau (P-tau), and total tau (T-tau) by Roche Elecsys immunoassays. We systematically evaluated the associations between NPTX proteins and baseline CSF AD biomarkers, as well as their relationships with longitudinal biomarker changes. Mediation models were applied to explore whether GFAP and sTREM2 mediate the associations between NPTX proteins and T-tau pathology. Additionally, subgroup analyses based on A/T/(N) classification were conducted to assess stage-specific effects, and sensitivity analyses were performed using 18&#160;F-fluorodeoxyglucose Positron Emission Tomography in place of CSF AD biomarkers.</p></sec><sec><title>Results</title><p id="Par3">We found that CSF NPTX proteins were significantly associated with CSF sTREM2 (<italic toggle="yes">&#946;</italic><sub><italic toggle="yes">NPTX1</italic></sub>&#8201;<italic toggle="yes">=&#8201;0.293</italic>, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; <italic toggle="yes">&#946;</italic><sub><italic toggle="yes">NPTX2</italic></sub>&#8201;<italic toggle="yes">=&#8201;0.387</italic>, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; <italic toggle="yes">&#946;</italic><sub><italic toggle="yes">NPR</italic></sub>&#8201;<italic toggle="yes">=&#8201;0.382</italic>, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), GFAP (<italic toggle="yes">&#946;</italic><sub><italic toggle="yes">NPTX1</italic></sub>&#8201;<italic toggle="yes">=&#8201;0.274</italic>, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; <italic toggle="yes">&#946;</italic><sub><italic toggle="yes">NPTX2</italic></sub>&#8201;<italic toggle="yes">=&#8201;0.472</italic>, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; <italic toggle="yes">&#946;</italic><sub><italic toggle="yes">NPR</italic></sub>&#8201;<italic toggle="yes">=&#8201;0.444</italic>, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), and core AD biomarkers at baseline. The association between NPTX2 and T-tau levels was significant and independent of A&#946;42 (<italic toggle="yes">&#946;&#8201;=&#8201;0.619</italic>, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). Mediation analyses indicated that sTREM2 and GFAP, individually or sequentially, partially mediated the associations between NPTX and T-tau pathology, with stronger effects observed in the suspected non-AD pathology and Stage 2 groups. Pathway analysis suggested that NPTX may influence tau pathology and cognitive function through the sequential sTREM2&#8594;GFAP&#8594;T-tau or P-tau pathway.</p></sec><sec><title>Conclusions</title><p id="Par4">NPTX proteins are associated with tau-related pathology in AD, and CSF GFAP and sTREM2 may mediate these associations, with their roles potentially differing across stages of disease progression.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12974-025-03545-w.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Alzheimer&#8217;s disease</kwd><kwd>Cerebrospinal fluid</kwd><kwd>T-tau</kwd><kwd>Microglia</kwd><kwd>Astrocyte</kwd></kwd-group><funding-group><award-group><funding-source><institution>National Natural Science Foundation</institution></funding-source><award-id>82471499</award-id><principal-award-recipient><name name-style="western"><surname>Zou</surname><given-names>Wen-Quan</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Jiangxi Key Laboratory of Neurological Diseases</institution></funding-source><award-id>2024SSY06072</award-id><principal-award-recipient><name name-style="western"><surname>Zou</surname><given-names>Wen-Quan</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>the startup package and developmental funds of the First Affiliated Hospital of Nanchang University</institution></funding-source><award-id>500021001 and 500021002</award-id><principal-award-recipient><name name-style="western"><surname>Zou</surname><given-names>Wen-Quan</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Alzheimer&#8217;s disease (AD) is a progressive neurodegenerative disorder pathologically characterized by the accumulation of &#946;-amyloid (A&#946;), tau hyperphosphorylation, and synaptic loss in the brain [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Among these, synaptic pathology is closely associated with cognitive impairment and is considered one of the earliest detectable pathological changes [<xref ref-type="bibr" rid="CR3">3</xref>]. Thus, identifying early molecular markers reflecting synaptic dysfunction is crucial for the early diagnosis and intervention of AD.</p><p id="Par6">Recently, increasing attention has been paid to the roles of neuronal pentraxin (NPTX) family members&#8212;NPTX1, NPTX2, and Neuronal Pentraxin Receptor (NPR)&#8212;in regulating synaptic homeostasis [<xref ref-type="bibr" rid="CR4">4</xref>]. NPTX2, an immediate early gene product secreted by excitatory neurons, is critical for maintaining excitatory synaptic connectivity, especially between pyramidal neurons and parvalbumin (PV) -positive interneurons [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. Multiple studies have demonstrated that cerebrospinal fluid (CSF) NPTX2 levels decline in AD patients and correlate with cognitive performance and hippocampal volume [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Moreover, the CSF YWHAG: NPTX2 ratio has been proposed as a predictive biomarker for conversion from normal cognition to mild cognitive impairment (MCI) or dementia, outperforming traditional A&#946; and T-tau [<xref ref-type="bibr" rid="CR9">9</xref>]. </p><p id="Par7">Although the link between NPTX proteins, synaptic function, and cognition has been extensively reported, the downstream pathways by which they affect tau pathology remain underexplored [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Recent studies have found that NPTX2 binds to complement component C1q and regulates complement activation, thereby limiting microglia-mediated synaptic engulfment and preserving excitatory synapses. In NPTX2-deficient mouse models, increased C1q levels and exaggerated synaptic loss have been observed [<xref ref-type="bibr" rid="CR11">11</xref>]. Although the microglial mechanisms involved remain incompletely defined, these findings suggest that NPTX2 may regulate neuroimmune interactions relevant to tau-mediated neurodegeneration. Additionally, NPTX proteins are structurally homologous to short pentraxins in the immune system (e.g., C-reactive protein), suggesting potential signaling roles in glial activation [<xref ref-type="bibr" rid="CR12">12</xref>]. Glial Fibrillary Acidic Protein (GFAP) and Soluble Triggering Receptor Expressed on Myeloid Cells 2 (sTREM2), widely used markers of glial activation [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>], have been shown to be involved in tau pathology and cognitive decline [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Based on these lines of evidence, we hypothesize that NPTX proteins may influence tau-related neurodegeneration and cognition through a glia-mediated signaling cascade involving sTREM2 and GFAP.</p><p id="Par8">In this study, we systematically investigated the associations of CSF NPTX proteins with AD pathological biomarkers, glial markers (sTREM2, GFAP), and cognitive performance in participants from the Alzheimer&#8217;s Disease Neuroimaging Initiative (ADNI) cohort, using the A/T/(N) classification framework [<xref ref-type="bibr" rid="CR17">17</xref>]. We further applied mediation and path analyses to test whether NPTX proteins affect cognition via the proposed &#8220;sTREM2 &#8594; GFAP &#8594; T-tau or P-tau&#8221; axis.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study participants</title><p id="Par9">A total of 263 participants were selected from the ADNI, including individuals from the ADNI-1, ADNI-GO, ADNI-2 and ADNI-3 cohorts (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://adni.loni.usc.edu">https://adni.loni.usc.edu</ext-link>).</p><p id="Par10">Participants were selected based on the availability of baseline CSF measurements for NPTX1, NPTX2, NPR, GFAP, sTREM2, A&#946;42, T-tau, and P-tau, as well as cognitive assessments, diagnostic classification, and key covariates including age, sex, education, and <italic toggle="yes">APOE &#949;4</italic> genotype. Individuals were excluded if they had missing data on any key variables (exposure, mediator, outcome, or covariates), a diagnosis of non-AD neurological conditions (e.g., Parkinson&#8217;s disease, stroke, traumatic brain injury), or significant medical comorbidities that could confound CSF biomarkers or cognition, consistent with ADNI exclusion criteria. During the 17-year follow-up period, the availability of cognitive assessments and AD biomarker data gradually decreased over time (sTable <xref rid="Tab1" ref-type="table">1</xref>). Written informed consent was obtained from all participants prior to enrollment, in accordance with the Declaration of Helsinki. The ADNI study was approved by the Institutional Review Boards of all participating centers.</p></sec><sec id="Sec4"><title>CSF biomarkers</title><p id="Par11">CSF levels of NPTX1, NPTX2, NPR, and GFAP were quantified using mass spectrometry with multiple reaction monitoring and normalized prior to analysis [<xref ref-type="bibr" rid="CR18">18</xref>]. CSF sTREM2 concentrations were measured using a multiplex immunoassay based on the Meso Scale Discovery platform. All measurements followed standard ADNI protocols for sample processing and quality control [<xref ref-type="bibr" rid="CR19">19</xref>]. </p><p id="Par12">CSF concentrations of A&#946;42, P-tau and T-tau were measured using electrochemiluminescence immunoassays (Elecsys) on a Roche cobas 601 analyzer. Detailed procedures for CSF collection, processing, and quality control are described in the ADNI protocol manual (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://adni.loni.usc.edu">https://adni.loni.usc.edu</ext-link>) [<xref ref-type="bibr" rid="CR20">20</xref>]. </p></sec><sec id="Sec5"><title>A/T/(N) classification</title><p id="Par13">According to the National Institute on Aging&#8211;Alzheimer&#8217;s Association (NIA-AA) criteria, abnormal CSF AD biomarkers were defined using the following thresholds: A&#946;42&#8201;&lt;&#8201;622.33 pg/ml (lower tertile), P-tau&#8201;&gt;&#8201;20.54 pg/ml (upper tertile), and total T-tau&#8201;&gt;&#8201;222.20 pg/ml (upper tertile). These cut-offs were derived from the tertile distribution of baseline CSF biomarker values in our study population [<xref ref-type="bibr" rid="CR17">17</xref>]. Participants with normal levels of all three markers (A&#8211;T&#8211;N&#8211;) were classified as Stage 0. Subsequent classifications included Stage 1 (A&#8201;+&#8201;T&#8211;N&#8211;), Stage 2 (A&#8201;+&#8201;T&#8201;+&#8201;N+), and suspected non-AD pathology (SNAP) (A-TN+) [<xref ref-type="bibr" rid="CR17">17</xref>]. </p></sec><sec id="Sec6"><title>18&#160;F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET)</title><p id="Par14">FDG-PET acquisition and preprocessing followed standard ADNI procedures [<xref ref-type="bibr" rid="CR21">21</xref>]. Briefly, after intravenous injection of 185 MBq [18&#160;F]-FDG, six 5-minute frames were acquired 30&#160;min post-injection. Images were coregistered, averaged, spatially normalized to MNI space, and smoothed with an 8&#160;mm FWHM kernel. FDG-PET was included as a supplementary neurodegeneration marker to test the specificity of NPTX associations beyond amyloid and tau pathology.</p></sec><sec id="Sec7"><title>Global cognition</title><p id="Par15">Global cognition was assessed in ADNI using the Mini-Mental State Examination (MMSE) and the Alzheimer&#8217;s Disease Assessment Scale (ADAS) [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Higher MMSE scores and lower ADAS scores indicate better cognitive performance.</p></sec><sec id="Sec8"><title>Statistical analyses</title><p id="Par16">Continuous variables were presented as means&#8201;&#177;&#8201;standard deviations (SD), and categorical variables as counts (percentages). Participants were categorized into four groups based on the A/T/(N) framework described earlier. In addition, we additionally applied the AT framework (A-T-, A&#8201;+&#8201;T-, A-T+, A&#8201;+&#8201;T+) for analyses of NPTX proteins. If overall group differences were significant, post hoc pairwise comparisons were performed using Tukey&#8217;s or Dunn&#8217;s with Bonferroni correction. Group comparisons for continuous variables were conducted using one-way ANOVA or the Kruskal&#8211;Wallis test, depending on data distribution. Categorical variables were compared using the chi-square test.</p><p id="Par17">All CSF biomarkers were log-transformed and subsequently standardized using z-scale to approximate normal distributions. Associations between NPTX proteins and sTREM2, GFAP, and core AD biomarkers were assessed using multivariable linear regression models, adjusting for age, sex, years of education, apolipoprotein E (APOE) &#949;4 genotype, and cognitive diagnosis. In addition, stratified and subgroup analyses were conducted to explore potential effect modification by covariates. Interaction terms (e.g., Age group &#215; NPTX1) were incorporated into regression models to formally test whether associations between NPTX proteins and outcomes varied across age groups, sex groups, education groups, or <italic toggle="yes">APOE &#949;4</italic> carrier status. To control for multiple comparisons, <italic toggle="yes">p</italic>-values were adjusted using the False Discovery Rate (FDR) correction method. To assess longitudinal changes, linear mixed-effects models were used to examine associations between baseline CSF NPTX levels and both cognitive trajectories and AD biomarker changes over time.</p><p id="Par18">We also conducted mediation analyses. First, based on the classical approach proposed by Baron and Kenny [<xref ref-type="bibr" rid="CR24">24</xref>], we examined whether CSF GFAP or sTREM2 individually mediated the relationship between NPTX proteins and AD biomarkers. Subsequently, we performed a serial mediation analysis to evaluate whether GFAP and sTREM2 served as sequential mediators in the association between NPTX proteins and CSF AD biomarkers. The structural equation model specified the following pathway: NPTX &#8594; sTREM2 &#8594; GFAP &#8594; AD biomarkers, capturing the potential glial signaling cascade underlying this relationship. All analyses were conducted using the &#8220;lavaan&#8221; package in R, and the statistical significance of indirect effects was estimated using bootstrapping with 1,000 resamples. Models were adjusted for age, sex, years of education, <italic toggle="yes">APOE&#949;4</italic> carrier status, and cognitive diagnosis. Additionally, we constructed an extended mediation model to explore a biologically plausible sequence in which NPTX may be associated with cognitive function through sTREM2, GFAP, and AD biomarkers (NPTX &#8594; sTREM2 &#8594; GFAP &#8594; AD biomarkers &#8594; cognition) [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. </p><p id="Par19">To assess the robustness of our findings, we conducted two sensitivity analyses:</p><p id="Par20">
<list list-type="order"><list-item><p id="Par21">We replaced T-tau with PET-FDG to determine whether sTREM2 or GFAP mediated the association between NPTX proteins and cerebral glucose metabolism; (2) We excluded participants diagnosed with AD to examine whether the observed associations remained consistent in non-demented individuals.</p></list-item></list>
</p><p id="Par22">All statistical analyses were conducted using R version 4.4.2, with statistical significance set at <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 for all analyses.</p></sec></sec><sec id="Sec9"><title>Results</title><sec id="Sec10"><title>Characteristics of participants</title><p id="Par23">Table&#160;<xref rid="Tab1" ref-type="table">1</xref> summarizes the demographic, clinical, and biomarker characteristics of the study population (<italic toggle="yes">n</italic>&#8201;=&#8201;263), including 106 SNAP, 69 Stage 0, 14 Stage 1, and 74 Stage 2 participants. The mean age was 73.99&#8201;&#177;&#8201;7.43 years, with 41.4% being female. Additionally, 55.1% of participants carried at least one copy of the <italic toggle="yes">APOE&#949;4</italic> allele.</p><p id="Par24">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>The demographic and clinical characteristics of participants</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Variance</th><th align="left" colspan="1" rowspan="1">Overall</th><th align="left" colspan="1" rowspan="1">SNAP</th><th align="left" colspan="1" rowspan="1">Stage0</th><th align="left" colspan="1" rowspan="1">Stage1</th><th align="left" colspan="1" rowspan="1">Stage2</th><th align="left" colspan="1" rowspan="1">
<italic toggle="yes">P</italic>
</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Number</td><td align="left" colspan="1" rowspan="1">263</td><td align="left" colspan="1" rowspan="1">106</td><td align="left" colspan="1" rowspan="1">69</td><td align="left" colspan="1" rowspan="1">14</td><td align="left" colspan="1" rowspan="1">74</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Age (years)</td><td align="left" colspan="1" rowspan="1">73.99 (7.43)</td><td align="left" colspan="1" rowspan="1">75.53 (7.54)</td><td align="left" colspan="1" rowspan="1">73.09 (7.25)</td><td align="left" colspan="1" rowspan="1">73.74 (4.73)</td><td align="left" colspan="1" rowspan="1">72.66 (7.57)</td><td align="left" colspan="1" rowspan="1">0.046</td></tr><tr><td align="left" colspan="1" rowspan="1">APOE&#949;4 (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">APOE&#949;4 (-)</td><td align="left" colspan="1" rowspan="1">118 (44.9)</td><td align="left" colspan="1" rowspan="1">43 (40.6)</td><td align="left" colspan="1" rowspan="1">58 (84.1)</td><td align="left" colspan="1" rowspan="1">3 (21.4)</td><td align="left" colspan="1" rowspan="1">14 (18.9)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">APOE&#949;4 (+)</td><td align="left" colspan="1" rowspan="1">145 (55.1)</td><td align="left" colspan="1" rowspan="1">63 (59.4)</td><td align="left" colspan="1" rowspan="1">11 (15.9)</td><td align="left" colspan="1" rowspan="1">11 (78.6)</td><td align="left" colspan="1" rowspan="1">60 (81.1)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Sex (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.575</td></tr><tr><td align="left" colspan="1" rowspan="1">Female</td><td align="left" colspan="1" rowspan="1">109 (41.4)</td><td align="left" colspan="1" rowspan="1">49 (46.2)</td><td align="left" colspan="1" rowspan="1">25 (36.2)</td><td align="left" colspan="1" rowspan="1">5 (35.7)</td><td align="left" colspan="1" rowspan="1">30 (40.5)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Male</td><td align="left" colspan="1" rowspan="1">154 (58.6)</td><td align="left" colspan="1" rowspan="1">57 (53.8)</td><td align="left" colspan="1" rowspan="1">44 (63.8)</td><td align="left" colspan="1" rowspan="1">9 (64.3)</td><td align="left" colspan="1" rowspan="1">44 (59.5)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Diagnosis (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">AD</td><td align="left" colspan="1" rowspan="1">61 (23.2)</td><td align="left" colspan="1" rowspan="1">24 (22.6)</td><td align="left" colspan="1" rowspan="1">4 (5.8)</td><td align="left" colspan="1" rowspan="1">4 (28.6)</td><td align="left" colspan="1" rowspan="1">29 (39.2)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">CN</td><td align="left" colspan="1" rowspan="1">46 (17.5)</td><td align="left" colspan="1" rowspan="1">17 (16.0)</td><td align="left" colspan="1" rowspan="1">24 (34.8)</td><td align="left" colspan="1" rowspan="1">2 (14.3)</td><td align="left" colspan="1" rowspan="1">3 (4.1)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">MCI</td><td align="left" colspan="1" rowspan="1">156 (59.3)</td><td align="left" colspan="1" rowspan="1">65 (61.3)</td><td align="left" colspan="1" rowspan="1">41 (59.4)</td><td align="left" colspan="1" rowspan="1">8 (57.1)</td><td align="left" colspan="1" rowspan="1">42 (56.8)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Education (years)</td><td align="left" colspan="1" rowspan="1">15.58 (2.96)</td><td align="left" colspan="1" rowspan="1">15.26 (3.18)</td><td align="left" colspan="1" rowspan="1">16.29 (2.64)</td><td align="left" colspan="1" rowspan="1">14.71 (3.27)</td><td align="left" colspan="1" rowspan="1">15.54 (2.80)</td><td align="left" colspan="1" rowspan="1">0.094</td></tr><tr><td align="left" colspan="1" rowspan="1">NPTX1 (pg/ml)</td><td align="left" colspan="1" rowspan="1">80802.69 (13697.08)</td><td align="left" colspan="1" rowspan="1">85240.13 (13208.79)</td><td align="left" colspan="1" rowspan="1">76295.64 (11801.60)</td><td align="left" colspan="1" rowspan="1">69925.79 (7183.96)</td><td align="left" colspan="1" rowspan="1">80706.66 (14593.41)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">NPTX2 (pg/ml)</td><td align="left" colspan="1" rowspan="1">12816.20 (4785.73)</td><td align="left" colspan="1" rowspan="1">14974.49 (4852.31)</td><td align="left" colspan="1" rowspan="1">10650.01 (2670.94)</td><td align="left" colspan="1" rowspan="1">8501.60 (3344.07)</td><td align="left" colspan="1" rowspan="1">12560.69 (4986.20)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">NPR (pg/ml)</td><td align="left" colspan="1" rowspan="1">53108.61 (13048.06)</td><td align="left" colspan="1" rowspan="1">59477.38 (12295.36)</td><td align="left" colspan="1" rowspan="1">47050.02 (9879.52)</td><td align="left" colspan="1" rowspan="1">40137.76 (8213.03)</td><td align="left" colspan="1" rowspan="1">52088.94 (12796.57)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">sTREM2 (pg/ml)</td><td align="left" colspan="1" rowspan="1">4314.45 (2385.25)</td><td align="left" colspan="1" rowspan="1">5197.82 (2175.07)</td><td align="left" colspan="1" rowspan="1">3303.69 (1613.86)</td><td align="left" colspan="1" rowspan="1">2872.44 (1483.94)</td><td align="left" colspan="1" rowspan="1">4264.36 (2880.34)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">GFAP (pg/ml)</td><td align="left" colspan="1" rowspan="1">1583.36 (456.69)</td><td align="left" colspan="1" rowspan="1">1773.40 (473.17)</td><td align="left" colspan="1" rowspan="1">1360.34 (342.87)</td><td align="left" colspan="1" rowspan="1">1366.92 (290.94)</td><td align="left" colspan="1" rowspan="1">1560.05 (439.25)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">A&#946;42 (pg/ml)</td><td align="left" colspan="1" rowspan="1">832.68 (359.60)</td><td align="left" colspan="1" rowspan="1">922.38 (296.88)</td><td align="left" colspan="1" rowspan="1">1139.55 (294.05)</td><td align="left" colspan="1" rowspan="1">453.35 (84.67)</td><td align="left" colspan="1" rowspan="1">489.83 (89.84)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">T-tau (pg/ml)</td><td align="left" colspan="1" rowspan="1">300.65 (135.92)</td><td align="left" colspan="1" rowspan="1">376.69 (122.75)</td><td align="left" colspan="1" rowspan="1">161.62 (28.30)</td><td align="left" colspan="1" rowspan="1">178.19 (25.19)</td><td align="left" colspan="1" rowspan="1">344.52 (110.83)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">P-tau (pg/ml)</td><td align="left" colspan="1" rowspan="1">29.72 (15.42)</td><td align="left" colspan="1" rowspan="1">37.83 (14.62)</td><td align="left" colspan="1" rowspan="1">14.16 (2.57)</td><td align="left" colspan="1" rowspan="1">16.21 (2.82)</td><td align="left" colspan="1" rowspan="1">35.16 (12.20)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">MMSE score</td><td align="left" colspan="1" rowspan="1">26.86 (2.51)</td><td align="left" colspan="1" rowspan="1">26.87 (2.54)</td><td align="left" colspan="1" rowspan="1">27.97 (1.99)</td><td align="left" colspan="1" rowspan="1">26.21 (2.42)</td><td align="left" colspan="1" rowspan="1">25.95 (2.54)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">ADAS score</td><td align="left" colspan="1" rowspan="1">11.24 (5.63)</td><td align="left" colspan="1" rowspan="1">11.36 (5.33)</td><td align="left" colspan="1" rowspan="1">8.06 (4.15)</td><td align="left" colspan="1" rowspan="1">11.24 (4.05)</td><td align="left" colspan="1" rowspan="1">14.03 (6.03)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr></tbody></table><table-wrap-foot><p>Data are mean (SD), n (%), or median (IQR)</p><p><italic toggle="yes">AD</italic>, Alzheimer&#8217;s Disease; <italic toggle="yes">A&#946;42</italic>, amyloid-&#946;42; <italic toggle="yes">P-tau</italic>, phosphorylated-tau; <italic toggle="yes">T-tau</italic>, total-tau; <italic toggle="yes">APOE&#949;4</italic>, Apolipoprotein E4; <italic toggle="yes">CN,</italic>&#160;Cognitively Normal; MCI&#3866;Mild Cognitive Impairment; <italic toggle="yes">GFAP</italic>, glial fibrillary acidic protein; <italic toggle="yes">sTREM2</italic>, soluble triggering receptor expressed on myeloid cells 2; <italic toggle="yes">NPTX1</italic>, neuronal pentraxin 1; <italic toggle="yes">NPTX2</italic>, neuronal pentraxin 2; <italic toggle="yes">NPR</italic>, neuronal pentraxin receptor; <italic toggle="yes">SNAP</italic>, suspected non-Alzheimer&#8217;s pathophysiology; <italic toggle="yes">MMSE</italic>, Mini-Mental State Examination; <italic toggle="yes">ADAS</italic>, Alzheimer&#8217;s Disease Assessment Scale</p></table-wrap-foot></table-wrap>
</p><p id="Par25">Group comparisons revealed statistically significant differences across the four A/T/(N) groups in CSF NPTX proteins (NPTX1, NPTX2, NPR), sTREM2, GFAP, AD biomarkers (A&#946;42, T-tau, P-tau), as well as cognitive scores including MMSE and ADAS (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001).</p><p id="Par26">In the A/T(N)-based stratification, participants in the SNAP group exhibited significantly higher NPTX1 levels compared to those in Stage 0&#8211;2, and these differences remained significant after Bonferroni correction (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05). Moreover, a significant difference was also observed between Stage 1 and Stage 2. Similar distribution patterns were observed for NPTX2 and NPR, with Stage 1 consistently showing the lowest levels across all three NPTX Markers, while Stage 2 and SNAP groups exhibited relatively higher levels (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>, sTable 2).</p><p id="Par27">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Transformed baseline NPTX in participants classified according to the NIA-AA criteria. Bold lines indicate statistically significant (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) differences between overall components; thin lines indicate significant differences between specific pairwise comparisons. <italic toggle="yes">P</italic>-values were adjusted using the Bonferroni correction *<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01 and ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001.&#160;Abbreviations: NPTX1, neuronal pentraxin 1; NPTX2, neuronal pentraxin 2; NPR, Neuronal Pentraxin Receptor; NIA-AA, National Institute on Aging- Alzheimer&#8217;s Association; A, amyloidosis; T, tau pathology; N, neurodegeneration; SNAP, suspected non-Alzheimer&#8217;s pathophysiology</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e966" position="float" orientation="portrait" xlink:href="12974_2025_3545_Fig1_HTML.jpg"/></fig>
</p><p id="Par28">Further stratified comparisons revealed that individuals in the T&#8201;+&#8201;and N&#8201;+&#8201;groups showed significantly elevated levels of NPTX1, NPTX2, and NPR compared to those in the T- and N- groups (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). Although the differences between A&#8201;+&#8201;and A- groups were more modest, NPTX protein levels were still slightly higher in the A&#8201;+&#8201;group, reaching statistical significance (NPTX1: <italic toggle="yes">p</italic>&#8201;=&#8201;0.044; NPTX2: <italic toggle="yes">p</italic>&#8201;=&#8201;0.005; NPR: <italic toggle="yes">p</italic>&#8201;=&#8201;0.006) (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). These findings suggest that the expression of NPTX proteins may be more strongly associated with tau pathology and neurodegeneration, whereas their association with amyloid pathology appears comparatively weaker. In the AT grouping results, three NPTX proteins showed significant differences between the A-T&#8201;+&#8201;group and the A-T- and A&#8201;+&#8201;T- groups (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) (sTable 3).</p></sec><sec id="Sec11"><title>Associations between baseline NPTX and baseline AD biomarkers</title><p id="Par29">Multiple linear regression analyses revealed that levels of NPTX1 (<italic toggle="yes">&#946;&#8201;=&#8201;0.365</italic>, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), NPTX2 (<italic toggle="yes">&#946;&#8201;=&#8201;0.586</italic>, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), and NPR (<italic toggle="yes">&#946;&#8201;=&#8201;0.558</italic>, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) were significantly positively associated with T-tau concentrations. Similarly, higher levels of NPTX1 (<italic toggle="yes">&#946;&#8201;=&#8201;0.346</italic>, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), NPTX2 (<italic toggle="yes">&#946;&#8201;=&#8201;0.554</italic>, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), and NPR (<italic toggle="yes">&#946;&#8201;=&#8201;0.531</italic>, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) were associated with increased P-tau levels (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). In the Stage 0, Stage 2, and SNAP groups, all three NPTX proteins were positively associated with T-tau and P-tau levels (sTable 4). Additionally, in the Stage 0 group, NPTX proteins also showed positive associations with A&#946;42 levels (sTable 4).</p><p id="Par30">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>The scatter plots illustrate the association between CSF NPTX and AD pathology. The normalized regression coefficients (&#946;) and <italic toggle="yes">P</italic>-values shown in the scatter plots are derived from multiple linear regression analyses. <italic toggle="yes">P</italic>-values were adjusted using the FDR correction. The models were adjusted for age, sex, education level, Apolipoprotein E4 status, and cognitive diagnosis.&#160;Abbreviations: NPTX1, neuronal pentraxin 1; NPTX2, neuronal pentraxin 2; NPR, neuronal pentraxin receptor; sTREM2, soluble triggering receptor expressed on myeloid cells 2; GFAP, glial fibrillary acidic protein; A&#946;42, amyloid-&#946;42; P-tau, phosphorylated-tau; Tau, total-tau</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1049" position="float" orientation="portrait" xlink:href="12974_2025_3545_Fig2_HTML.jpg"/></fig>
</p><p id="Par31">Interaction analyses revealed no significant moderating effects of covariates on the associations between NPTX1 and AD biomarkers (sTable 5). In contrast, significant interactions were observed between age and NPTX2 or NPR in relation to AD biomarkers (sTable 6&#8211;7). Stratified analyses showed that positive associations between NPTX proteins and T-tau or P-tau were significant in the late-life group (&#8805;&#8201;65 years) but not in the mid-life group (&lt;&#8201;65 years). Consistent positive associations were observed across subgroups stratified by sex, education level, <italic toggle="yes">APOE&#949;4</italic> carrier status, and cognitive diagnosis, with no substantial group differences (sTable 5&#8211;7). In addition, all NPTX proteins were significantly positively associated with GFAP and sTREM2 levels. Consistent with findings in the overall population, similar associations between NPTX2 or NPR and sTREM2 were observed in the stage 2 and SNAP groups (sTable 8).</p></sec><sec id="Sec12"><title>Associations between baseline NPTX and baseline cognition</title><p id="Par32">NPTX2 (<italic toggle="yes">&#946;&#8201;=&#8201;0.338</italic>, <italic toggle="yes">p</italic>&#8201;=&#8201;0.004) and NPR (<italic toggle="yes">&#946;&#8201;=&#8201;0.312</italic>, <italic toggle="yes">p</italic>&#8201;=&#8201;0.008) were positively associated with MMSE scores, while NPTX2 (<italic toggle="yes">&#946; = &#8722;0.391</italic>, <italic toggle="yes">p</italic>&#8201;=&#8201;0.001) and NPR (<italic toggle="yes">&#946; = &#8722;0.735</italic>, <italic toggle="yes">p</italic>&#8201;=&#8201;0.010) showed significant negative associations with ADAS scores (sTable 9). No significant associations were observed between NPTX1 and cognitive outcomes. These associations remained consistent in the SNAP group: NPTX2 (<italic toggle="yes">&#946;&#8201;=&#8201;0.548</italic>, <italic toggle="yes">p</italic>&#8201;=&#8201;0.013) was positively associated with MMSE scores, whereas NPTX2 (<italic toggle="yes">&#946; = &#8722;&#8201;1.655</italic>, <italic toggle="yes">p</italic>&#8201;=&#8201;0.001) and NPR (<italic toggle="yes">&#946; = &#8722;&#8201;1.660</italic>, <italic toggle="yes">p</italic>&#8201;=&#8201;0.001) were negatively associated with ADAS scores (sTable 9).</p></sec><sec id="Sec13"><title>Baseline NPTX and longitudinal changes in AD biomarkers and cognition</title><p id="Par33">Linear mixed-effects models revealed that NPTX2 was significantly associated with MMSE scores <italic toggle="yes">(&#946;&#8201;=&#8201;0.246</italic>, <italic toggle="yes">p</italic>&#8201;=&#8201;0.007) and ADAS scores <italic toggle="yes">(&#946; = &#8722;&#8201;0.425</italic>, <italic toggle="yes">p</italic>&#8201;=&#8201;0.015), while NPR showed a positive association with MMSE <italic toggle="yes">(&#946;&#8201;=&#8201;0.187</italic>, <italic toggle="yes">p</italic>&#8201;=&#8201;0.044) (sTable 10). However, no significant associations were observed between any of the three NPTX proteins and AD biomarkers.</p></sec><sec id="Sec14"><title>Association of NPTX with AD biomarkers mediated by CSF sTREM2 or GFAP</title><p id="Par34">Mediation analyses suggested that sTREM2 partially mediated the associations between NPTX1 (Proportion<sub>T&#8722;tau</sub> = 30.3%, IE&#8201;=&#8201;0.112, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; Proportion<sub>P&#8722;tau</sub> = 30.1%, IE&#8201;=&#8201;0.105, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), NPTX2 (Proportion<sub>T&#8722;tau</sub> = 17.6%, IE&#8201;=&#8201;0.104, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; Proportion<sub>P&#8722;tau</sub> = 17.4%, IE&#8201;=&#8201;0.097, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), and NPR (Proportion<sub>T&#8722;tau</sub> = 19.2%, IE&#8201;=&#8201;0.108, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; Proportion<sub>P&#8722;tau</sub> = 18.7%, IE&#8201;=&#8201;0.101, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) with T-tau and P-tau levels (sTable 11). Similarly, GFAP also appeared to mediate part of the associations between NPTX1 (Proportion<sub>T&#8722;tau</sub> = 31.6%, IE&#8201;=&#8201;0.116, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; Proportion<sub>P&#8722;tau</sub> = 31.2%, IE&#8201;=&#8201;0.109, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), NPTX2 (Proportion<sub>T&#8722;tau</sub> = 21.5%, IE&#8201;=&#8201;0.127, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; Proportion<sub>P&#8722;tau</sub> = 20.7%, IE&#8201;=&#8201;0.115, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), and NPR (Proportion<sub>T&#8722;tau</sub> = 23.6%, IE&#8201;=&#8201;0.132, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; Proportion<sub>P&#8722;tau</sub> = 22.4%, IE&#8201;=&#8201;0.120, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) with T-tau and P-tau levels (sTable 12). In addition to the cross-sectional mediation analyses, we conducted sensitivity analyses using longitudinal AD biomarkers. The results showed that both GFAP and sTREM2 were significantly associated with the statistical pathways linking NPTX1, NPTX2, and NPR to subsequent T-tau and P-tau levels (sTable 13&#8211;14). Additionally, sTREM2 was also involved in the statistical associations between NPTX proteins and A&#946; levels (sTable 14).</p><p id="Par35">In the SNAP group, sTREM2 partially mediated the associations between NPTX2 and NPR with T-tau or P-tau (sTable 15), while GFAP partially mediated the associations between NPTX2 and NPR with T-tau (sTable 16). In contrast, no similar mediation effects were observed in the Stage 0 group (sTable 17&#8211;18). In the Stage 2 group, both GFAP and sTREM2 partially mediated the associations between NPTX2 and NPR with T-tau or P-tau (sTable 19&#8211;20).</p><p id="Par36">Interaction and subgroup analyses revealed that the associations between NPTX proteins and T-tau or P-tau were stronger in the late-life group; therefore, we further conducted age-stratified mediation analyses to validate the robustness of this finding. In the late-life group, sTREM2 and GFAP mediated the associations between NPTX1, NPTX2, and NPR with T-tau and P-tau, consistent with the findings in the overall population (sTable 21&#8211;22); however, no such mediation effects were observed in the mid-life group (sTable 23&#8211;24).</p></sec><sec id="Sec15"><title>Independence of NPTX-tau associations from amyloid pathology</title><p id="Par37">Given the critical role of A&#946;42 in AD, we further evaluated whether the associations between NPTX proteins and T-tau or P-tau levels were independent of A&#946; status. Linear regression analyses showed that the positive associations between NPTX proteins and T-tau or P-tau remained significant after adjusting for A&#946;42 levels (sTable 25). Moreover, interaction analyses did not reveal significant moderating effects of A&#946; status on these associations (sTable 26). Mediation analyses indicated that A&#946;42 did not significantly mediate the associations between NPTX proteins and T-tau levels, although small but statistically significant indirect effects were observed for P-tau (all proportions&#8201;&#8804;&#8201;10.1%) (sTable 27).</p></sec><sec id="Sec16"><title>Mediation of the association between CSF NPTX and AD biomarkers by sTREM2 and GFAP</title><p id="Par38">We further explored whether sTREM2 and GFAP mediate the effects of NPTX proteins on AD pathology. Regardless of whether covariates were adjusted, three significant pathways were consistently observed: (1) CSF NPTX1 &#8594; sTREM2 &#8594; GFAP &#8594; T-tau or P-tau; (2) CSF NPTX2 &#8594; sTREM2 &#8594; GFAP &#8594; T-tau or P-tau; and (3) CSF NPR &#8594; sTREM2 &#8594; GFAP &#8594;T-tau or P-tau. All three NPTX proteins were positively associated with both sTREM2 and GFAP levels, and in turn, sTREM2 and GFAP levels were positively associated with T-tau and P-tau levels. However, the mediation pathways linking NPTX proteins to A&#946;42 via sTREM2 and GFAP were not statistically significant (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>; sFigure <xref rid="Fig1" ref-type="fig">1</xref>). Similar mediation patterns were observed in the late-life group, where sTREM2 and GFAP mediated the associations between NPTX proteins and T-tau or P-tau (sFigure <xref rid="Fig2" ref-type="fig">2</xref>). We next replaced baseline T-tau or P-tau with their longitudinal measures and found that the mediation paths of NPTX2 and NPR through sTREM2 and GFAP remained significant (sFigure <xref rid="Fig3" ref-type="fig">3</xref>).</p><p id="Par39">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Mediation analysis. These three pathways are presented using yellow, blue, and red lines. All mediation paths are adjusted by covariates (age, sex, education, Apolipoprotein E4 and cognitive diagnosis). Three mediation pathways were conducted between NPTX and AD biomarkers: (1) NPTX&#8594;sTREM2&#8594;GFAP&#8594;AD biomarkers; (2) NPTX&#8594;sTREM2&#8594;AD biomarkers; (3) NPTX&#8594;GFAP&#8594;AD biomarkers. The &#946; coefficients in each path and <italic toggle="yes">P</italic>-values for mediation effects were calculated by a bootstrap test with 10,000 resampling iterations. The dotted line indicates that the indirect effect is not significant (<italic toggle="yes">p</italic>&#8201;&#8805;&#8201;0.05), and the solid line indicates that the indirect effect is significant (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05). *<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01, ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001.&#160;Abbreviations: NPTX1, neuronal pentraxin 1; NPTX2, neuronal pentraxin 2; NPR, neuronal pentraxin receptor; sTREM2, soluble triggering receptor expressed on myeloid cells 2; GFAP, glial fibrillary acidic protein; A&#946;42, amyloid-&#946;42; P-tau, phosphorylated-tau; T-tau, total-tau</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1247" position="float" orientation="portrait" xlink:href="12974_2025_3545_Fig3_HTML.jpg"/></fig>
</p><p id="Par40">Building upon the above findings, we constructed a path model to evaluate the potential mechanism by which NPTX proteins influence cognitive change (as reflected by changes in ADAS scores) through sequential mediation by sTREM2 and GFAP leading to tau pathology. Path analysis revealed the pathway of NPTX &#8594; sTREM2 &#8594; GFAP &#8594; T-tau or P-tau &#8594; ADAS. Among the three proteins, NPTX2 exhibited the largest indirect effect (IE<sub>T&#8722;tau</sub> = 0.052; IE<sub>P&#8722;tau</sub> = 0.048), suggesting that NPTX2 may play a more prominent role in glia-mediated tau progression and cognitive change (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>; sFigure <xref rid="Fig4" ref-type="fig">4</xref>).</p><p id="Par41">
<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Schematic interlinking of the effect of neuronal pentraxin based microglia-astrocyte communication on Tau pathology</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1269" position="float" orientation="portrait" xlink:href="12974_2025_3545_Fig4_HTML.jpg"/></fig>
</p></sec><sec id="Sec17"><title>Sensitivity analysis</title><p id="Par42">We used PET-FDG as an alternative to tau pathology and found that NPTX2 (<italic toggle="yes">&#946;&#8201;=&#8201;0.256</italic>, <italic toggle="yes">p</italic>&#8201;=&#8201;0.002) and NPR (<italic toggle="yes">&#946;&#8201;=&#8201;0.200</italic>, <italic toggle="yes">p</italic>&#8201;=&#8201;0.026) remained significantly positively associated with FDG uptake (sTable 28). Furthermore, sTREM2 significantly mediated the associations between all three NPTX proteins and FDG, whereas GFAP did not show a significant mediating effect (sTable 29).</p><p id="Par43">In non-AD participants, the associations of the three NPTX proteins with CSF biomarkers and cognitive outcomes were similar to those observed in the overall population (sTable 4, 8, 10). Furthermore, sTREM2 and GFAP also mediated the associations between NPTX2 or NPR and T-tau or P-tau levels (sTable 30&#8211;31). Path analysis revealed the pathway of NPTX &#8594; sTREM2 &#8594; GFAP &#8594; T-tau or P-tau &#8594; ADAS (sFigure 5).</p></sec></sec><sec id="Sec18"><title>Discussion</title><p id="Par44">In this observational study based on data from the ADNI cohort (mean age&#8201;=&#8201;73.99 years), we investigated the associations between CSF neuronal pentraxins (NPTX1, NPTX2, NPR) and AD-related pathology. We found that baseline CSF NPTX levels were significantly associated with T-tau, independent of A&#946;42. Further mediation analyses indicated that sTREM2 and GFAP partially mediated the associations between NPTX proteins and T-tau or P-tau. Pathway analyses suggested that NPTX2 and NPR may be linked to cognitive changes via a potential pathway involving sTREM2, GFAP, and tau (sTREM2 &#8594; GFAP &#8594; T-tau or P-tau. These findings suggest that CSF NPTX2 and NPR may act as upstream regulators of tau-related neurodegeneration via microglia&#8211;astrocyte signaling pathways. Similar mediation patterns were observed in the late-life subgroup and in the non-AD population, further supporting the robustness of our results.</p><p id="Par45">Consistent with previous findings, accumulating evidence suggests that neuronal pentraxin proteins, especially NPTX2, play a crucial role in synaptic regulation and as indicators of cognitive function in AD [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. Studies using the ADNI cohort have similarly shown that CSF NPTX2 levels are significantly associated with various cognitive measures (such as ADAS and MMSE) and outperform traditional A&#946; and tau in predicting progression from MCI to dementia [<xref ref-type="bibr" rid="CR7">7</xref>]. NPTX2 is associated with cross-sectional cognitive performance, structural MRI, and FDG-PET metabolism, and can also predict the rate of cognitive decline, suggesting its potential as a dynamic biomarker [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. In addition, Bolsewig et al. reported that the combination of NPTX2 with neurofilament light chain (NfL) and GFAP could distinguish between different dementia subtypes more effectively than individual biomarkers alone [<xref ref-type="bibr" rid="CR31">31</xref>]. These findings underscore the utility of NPTX proteins in reflecting early synaptic damage and cognitive deterioration in AD.</p><p id="Par46">Our results also demonstrated positive associations between NPTX1, NPTX2, and NPR with T-tau and P-tau levels, and further suggested that these associations may be partially mediated by glial activation markers sTREM2 and GFAP. This is consistent with findings by Das et al., who reported strong correlations between NPTX2 and T-tau or P-tau, but weaker associations with NfL and A&#946; [<xref ref-type="bibr" rid="CR32">32</xref>], suggesting that NPTX2 may selectively reflect tau-related synaptic pathology rather than axonal degeneration or amyloid burden. Supporting this, animal studies have shown that NPTX2 suppresses complement-mediated synaptic pruning, thereby mitigating microglia-driven synaptic pathology [<xref ref-type="bibr" rid="CR33">33</xref>]. Several studies support a sequential biological link between synaptic protein regulation, glial activation, and tau pathology. At the synaptic level, neuronal pentraxins such as NPTX2 modulate complement activity and limit microglial synaptic pruning. Loss of NPTX2 enhances C1q deposition, leading to excessive synaptic engulfment and cognitive decline, while its overexpression provides protective effects [<xref ref-type="bibr" rid="CR33">33</xref>]. In parallel, microglia can induce neurotoxic A1 astrocytes via inflammatory signaling, forming a synergistic glial response that amplifies tau pathology [<xref ref-type="bibr" rid="CR34">34</xref>]. Building on these insights, we hypothesize that elevated NPTX levels are associated with glial activation and tau pathology, potentially positioning NPTX as an upstream regulator in the cascade of tau-related neurodegeneration.</p><p id="Par47">Importantly, the associations between NPTX proteins and T-tau or P-tau remained significant even after adjusting for A&#946;42 levels, and A&#946; status did not significantly moderate these relationships. Mediation analysis showed that A&#946;42 did not significantly mediate the association between NPTX and T-tau, and only a modest indirect effect observed in the P-tau pathway. This suggests that NPTX may influence tau phosphorylation-related pathology through A&#946;-independent mechanisms. We further speculate that this could involve signaling pathways related to kinases such as GSK3&#946; and CDK5, which are known to mediate tau phosphorylation independently of A&#946; signaling [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. Moreover, sTREM2 has been reported to be more strongly associated with P-tau than T-tau, possibly reflecting that under neuroinflammatory conditions, glial responses are more engaged with abnormal phosphorylated tau than with overall tau burden [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. Therefore, we propose that NPTX may modulate cognitive function by activating the microglia&#8211;astrocyte signaling axis and promoting pathological tau phosphorylation, rather than directly influencing T-tau levels.</p><p id="Par48">Based on these findings, NPTX, as a synapse-associated secreted protein, may promote the reactive activation of microglia (sTREM2) and astrocytes (GFAP) by modulating neuron&#8211;glia interactions, thereby contributing to the amplification of tau pathology [<xref ref-type="bibr" rid="CR38">38</xref>]. This mediating effect appears to be stage-dependent, showing stronger effects in the SNAP and Stage 2 groups, while being insignificant in Stage 0 or individuals with a lower pathological burden. This is consistent with the classical model of AD progression, where microglial activation marked by elevated sTREM2 typically reflects the transition of microglia from a homeostatic to a reactive state [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. This transition is closely associated with tau hyperphosphorylation, aggregation, and extracellular release. Previous studies have shown that activated microglia recognize, engulf, and clear abnormal tau through the TREM2 signaling pathway [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. However, when clearance capacity is compromised or microglia become dysfunctional, they may instead promote tau spreading and neuronal injury by releasing pro-inflammatory cytokines such as IL-1&#946;, TNF-&#945;, and reactive oxygen species [<xref ref-type="bibr" rid="CR43">43</xref>]. Unlike A&#946;, elevated sTREM2 levels are more commonly observed during increased tau burden or in the neurodegenerative stages, possibly reflecting microglial activation in response to tau-related stress rather than early A&#946; deposition.</p><p id="Par49">In addition, increased GFAP reflects the shift of astrocytes from supporting neuronal functions to a reactive, proliferative, or hypertrophic state. During the progression of tau pathology, reactive astrocytes can disrupt synaptic homeostasis by releasing inflammatory factors and reactive oxygen species, and by activating tau-related kinases such as GSK3&#946; and CDK5, thereby directly contributing to tau hyperphosphorylation and aggregation [<xref ref-type="bibr" rid="CR44">44</xref>&#8211;<xref ref-type="bibr" rid="CR46">46</xref>]. Moreover, astrocytes may serve as structural or signaling &#8220;bridges&#8221; that facilitate the spatial propagation of tau pathology across brain regions. Their reactive activation is closely linked to increased neuroinflammation, particularly in A/T/(N) Stage 2 or SNAP subtypes, suggesting their role in accelerating tau-related neuronal damage in the later stages of neurodegeneration.</p><p id="Par50">Based on the above findings, further dual mediation analyses revealed that NPTX may drive tau pathology through the combined action of sTREM2 and GFAP. Although sTREM2 and GFAP represent the distinct reactive profiles of microglia and astrocytes, respectively, previous studies suggest that these glial responses may not operate in isolation but rather form an interconnected, cascade-amplifying glial network [<xref ref-type="bibr" rid="CR47">47</xref>]. For example, studies in multiple sclerosis have shown that sTREM2 and GFAP are not only individually associated with various inflammatory markers but also exhibit a strong positive correlation with each other [<xref ref-type="bibr" rid="CR48">48</xref>]. This suggests that in the context of central nervous system inflammation or neurodegenerative conditions, microglial activation may precede and promote astrocytic reactivity, indicating the possibility of signal amplification and functional synergy between these two glial cell types [<xref ref-type="bibr" rid="CR41">41</xref>]. Such a mechanism is equally relevant in AD, particularly in the context of NPTX involvement. Microglia may serve as the primary responders to NPTX signaling, initiating local inflammation and synaptic stress via the TREM2 pathway, which subsequently spreads to the astrocytic network, creating a broader neuroglial pathological environment. This hypothesis is supported by our findings, where the dual mediation pathway exhibited a greater effect size compared to either sTREM2 or GFAP alone, suggesting that these two glial responses may synergistically amplify the impact of NPTX on tau pathology. Moreover, this microglia&#8211;astrocyte synergistic mechanism appears to be disease-specific. Previous studies in patients with delirium did not observe any significant interaction among NPTX, sTREM2, and GFAP, suggesting that the NPTX&#8211;glial&#8211;tau axis may not be a general feature across all central nervous system pathologies but rather a mechanism that is particularly relevant to AD [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. </p><p id="Par51">This study offers several strengths. First, we systematically reveal the role of NPTX in promoting tau pathology through the coordinated mediation of microglia (sTREM2) and astrocytes (GFAP), illustrating a dual mediation framework. This represents a novel mechanistic insight that has not been fully explored in previous NPTX research. Second, we conducted multi-level sensitivity analyses across different pathological stages (A/T/(N) classification) and population subgroups (such as older adults and non-AD participants), supporting the robustness and broader applicability of these associations, and enriching the understanding of the stage- and age-specific characteristics of the NPTX&#8211;glial&#8211;tau axis. However, this study also has several limitations. The cross-sectional design prevents us from establishing causal relationships between NPTX, glial activation, and tau pathology, and precludes inference on the directionality of the observed associations. Moreover, although sTREM2 and GFAP are widely used fluid biomarkers, they may not comprehensively capture the full spectrum of microglial and astrocytic activity, particularly in terms of metabolic and spatial heterogeneity. This study also lacks supporting evidence from brain tissue or neuroimaging, which restricts our understanding of the region-specific roles of NPTX proteins in the brain. Finally, although we applied multiple correction methods, some of the corrected <italic toggle="yes">p</italic>-values appeared extremely low given the relatively small sample size, which may limit the stability of the statistical inferences. Future studies should incorporate multi-modal data and longitudinal analyses to further refine and validate the mechanistic model proposed in this work.</p></sec><sec id="Sec19"><title>Conclusions</title><p id="Par52">Our findings suggest that the association between NPTX and T-tau pathology may be sequentially mediated by microglia (sTREM2) and astrocytes (GFAP), independently of amyloid-&#946; pathology. This highlights NPTX as a key factor linking glial activation, T-tau pathology progression, and cognitive impairment. These findings have important clinical implications, suggesting that modulating NPTX levels may represent a potential therapeutic strategy to slow the progression of Ad pathology and cognitive decline.</p></sec><sec id="Sec20" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12974_2025_3545_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Material 1.</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Zihao Zhang and Xin Chen contributed equally to this work.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Data collection and sharing for this project was funded by the Alzheimer&#8217;s Disease Neuroimaging Initiative (ADNI).</p></ack><notes notes-type="author-contribution"><title>Authors&#8217; contributions</title><p>WQ-Z contributed to the conception or design of the work. All authors were responsible for the acquisition, analysis and interpretation of data. ZH-Z X-C, ZH-S, N-J and WQ-Z drafted the manuscript. Critical revision of the manuscript for important intellectual content were performed by all authors. All author agreed with the content of the article to be submitted. All authors reviewed and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was partially supported by the startup package and developmental funds of the First Affiliated Hospital of Nanchang University (#500021001, #500021002), National Natural Science Foundation (NSFC) (82471499), and Jiangxi Key Laboratory of Neurological Diseases (2024SSY06072) to WQZ.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Raw data supporting the obtained results are available at the corresponding author.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par53">The entire approval for this study was obtained from the Eisai Ethics Committee (2017&#8201;&#8722;&#8201;0433). Following the Declaration of Helsinki, written informed consent was obtained from all participants or their guardians.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par54">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par55">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Long</surname><given-names>JM</given-names></name><name name-style="western"><surname>Holtzman</surname><given-names>DM</given-names></name></person-group><article-title>Alzheimer disease: an update on pathobiology and treatment strategies</article-title><source>Cell</source><year>2019</year><volume>179</volume><issue>2</issue><fpage>312</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.09.001</pub-id><pub-id pub-id-type="pmid">31564456</pub-id><pub-id pub-id-type="pmcid">PMC6778042</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment strategies. Cell. 2019;179(2):312&#8211;39.<pub-id pub-id-type="pmid">31564456</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2019.09.001</pub-id><pub-id pub-id-type="pmcid">PMC6778042</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodriguez-Jimenez</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Ure&#241;a-Peralta</surname><given-names>J</given-names></name><name name-style="western"><surname>Jendelova</surname><given-names>P</given-names></name><name name-style="western"><surname>Erceg</surname><given-names>S</given-names></name></person-group><article-title>Alzheimer&#8217;s disease and synapse loss: what can we learn from induced pluripotent stem cells??</article-title><source>J Adv Res</source><year>2023</year><volume>54</volume><fpage>105</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/j.jare.2023.01.006</pub-id><pub-id pub-id-type="pmid">36646419</pub-id><pub-id pub-id-type="pmcid">PMC10703628</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Rodriguez-Jimenez FJ, Ure&#241;a-Peralta J, Jendelova P, Erceg S. Alzheimer&#8217;s disease and synapse loss: what can we learn from induced pluripotent stem cells?? J Adv Res. 2023;54:105&#8211;18.<pub-id pub-id-type="pmid">36646419</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jare.2023.01.006</pub-id><pub-id pub-id-type="pmcid">PMC10703628</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mart&#237;nez-Serra</surname><given-names>R</given-names></name><name name-style="western"><surname>Alonso-Nanclares</surname><given-names>L</given-names></name><name name-style="western"><surname>Cho</surname><given-names>K</given-names></name><name name-style="western"><surname>Giese</surname><given-names>KP</given-names></name></person-group><article-title>Emerging insights into synapse dysregulation in alzheimer&#8217;s disease</article-title><source>Brain Commun</source><year>2022</year><volume>4</volume><issue>2</issue><fpage>fcac083</fpage><pub-id pub-id-type="doi">10.1093/braincomms/fcac083</pub-id><pub-id pub-id-type="pmid">35652120</pub-id><pub-id pub-id-type="pmcid">PMC9149787</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Mart&#237;nez-Serra R, Alonso-Nanclares L, Cho K, Giese KP. Emerging insights into synapse dysregulation in alzheimer&#8217;s disease. Brain Commun. 2022;4(2):fcac083.<pub-id pub-id-type="pmid">35652120</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/braincomms/fcac083</pub-id><pub-id pub-id-type="pmcid">PMC9149787</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de G&#243;mez</surname><given-names>N</given-names></name><name name-style="western"><surname>Massa</surname><given-names>F</given-names></name><name name-style="western"><surname>Halbgebauer</surname><given-names>S</given-names></name><name name-style="western"><surname>Oeckl</surname><given-names>P</given-names></name><name name-style="western"><surname>Steinacker</surname><given-names>P</given-names></name><name name-style="western"><surname>Otto</surname><given-names>M</given-names></name></person-group><article-title>Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration</article-title><source>J Neural Transm</source><year>2021</year><volume>129</volume><issue>2</issue><fpage>207</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1007/s00702-021-02411-2</pub-id><pub-id pub-id-type="pmid">34460014</pub-id><pub-id pub-id-type="pmcid">PMC8866268</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">de G&#243;mez N, Massa F, Halbgebauer S, Oeckl P, Steinacker P, Otto M. Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration. J Neural Transm. 2021;129(2):207&#8211;30.<pub-id pub-id-type="pmid">34460014</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00702-021-02411-2</pub-id><pub-id pub-id-type="pmcid">PMC8866268</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de G&#243;mez</surname><given-names>N</given-names></name><name name-style="western"><surname>Massa</surname><given-names>F</given-names></name><name name-style="western"><surname>Halbgebauer</surname><given-names>S</given-names></name><name name-style="western"><surname>Oeckl</surname><given-names>P</given-names></name><name name-style="western"><surname>Steinacker</surname><given-names>P</given-names></name><name name-style="western"><surname>Otto</surname><given-names>M</given-names></name></person-group><article-title>Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration</article-title><source>J Neural Transm (Vienna)</source><year>2022</year><volume>129</volume><issue>2</issue><fpage>207</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1007/s00702-021-02411-2</pub-id><pub-id pub-id-type="pmid">34460014</pub-id><pub-id pub-id-type="pmcid">PMC8866268</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">de G&#243;mez N, Massa F, Halbgebauer S, Oeckl P, Steinacker P, Otto M. Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration. J Neural Transm (Vienna). 2022;129(2):207&#8211;30.<pub-id pub-id-type="pmid">34460014</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00702-021-02411-2</pub-id><pub-id pub-id-type="pmcid">PMC8866268</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Ende</surname><given-names>EL</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>M</given-names></name><name name-style="western"><surname>Xu</surname><given-names>D</given-names></name><name name-style="western"><surname>Poos</surname><given-names>JM</given-names></name><name name-style="western"><surname>Panman</surname><given-names>JL</given-names></name><name name-style="western"><surname>Jiskoot</surname><given-names>LC</given-names></name><name name-style="western"><surname>Meeter</surname><given-names>LH</given-names></name><name name-style="western"><surname>Dopper</surname><given-names>EG</given-names></name><name name-style="western"><surname>Papma</surname><given-names>JM</given-names></name><name name-style="western"><surname>Heller</surname><given-names>C</given-names></name><etal/></person-group><article-title>Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2020</year><volume>91</volume><issue>6</issue><fpage>612</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1136/jnnp-2019-322493</pub-id><pub-id pub-id-type="pmid">32273328</pub-id><pub-id pub-id-type="pmcid">PMC7279197</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">van der Ende EL, Xiao M, Xu D, Poos JM, Panman JL, Jiskoot LC, Meeter LH, Dopper EG, Papma JM, Heller C, et al. Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2020;91(6):612&#8211;21.<pub-id pub-id-type="pmid">32273328</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp-2019-322493</pub-id><pub-id pub-id-type="pmcid">PMC7279197</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">Xiao MF, Xu D, Craig MT, Pelkey KA, Chien CC, Shi Y, Zhang J, Resnick S, Pletnikova O, Salmon D et al: NPTX2 and cognitive dysfunction in Alzheimer's Disease. Elife. 2017;6:e23798.<pub-id pub-id-type="doi" assigning-authority="pmc">10.7554/eLife.23798</pub-id><pub-id pub-id-type="pmcid">PMC5404919</pub-id><pub-id pub-id-type="pmid">28440221</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soldan</surname><given-names>A</given-names></name><name name-style="western"><surname>Oh</surname><given-names>S</given-names></name><name name-style="western"><surname>Ryu</surname><given-names>T</given-names></name><name name-style="western"><surname>Pettigrew</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Moghekar</surname><given-names>A</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>MF</given-names></name><name name-style="western"><surname>Pontone</surname><given-names>GM</given-names></name><name name-style="western"><surname>Albert</surname><given-names>M</given-names></name><name name-style="western"><surname>Na</surname><given-names>CH</given-names></name><etal/></person-group><article-title>NPTX2 in cerebrospinal fluid predicts the progression from normal cognition to mild cognitive impairment</article-title><source>Ann Neurol</source><year>2023</year><volume>94</volume><issue>4</issue><fpage>620</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1002/ana.26725</pub-id><pub-id pub-id-type="pmid">37345460</pub-id><pub-id pub-id-type="pmcid">PMC10543570</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Soldan A, Oh S, Ryu T, Pettigrew C, Zhu Y, Moghekar A, Xiao MF, Pontone GM, Albert M, Na CH, et al. NPTX2 in cerebrospinal fluid predicts the progression from normal cognition to mild cognitive impairment. Ann Neurol. 2023;94(4):620&#8211;31.<pub-id pub-id-type="pmid">37345460</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.26725</pub-id><pub-id pub-id-type="pmcid">PMC10543570</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">Oh HS, Urey DY, Karlsson L, Zhu Z, Shen Y, Farinas A, Timsina J, Duggan MR, Chen J, Guldner IH et al: A cerebrospinal fluid synaptic protein biomarker for prediction of cognitive resilience versus decline in Alzheimer's disease. Nat Med. 2025;31(5):1592&#8211;1603.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-025-03565-2</pub-id><pub-id pub-id-type="pmcid">PMC12092275</pub-id><pub-id pub-id-type="pmid">40164724</pub-id></mixed-citation></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abad</surname><given-names>MA</given-names></name><name name-style="western"><surname>Enguita</surname><given-names>M</given-names></name><name name-style="western"><surname>DeGregorio-Rocasolano</surname><given-names>N</given-names></name><name name-style="western"><surname>Ferrer</surname><given-names>I</given-names></name><name name-style="western"><surname>Trullas</surname><given-names>R</given-names></name></person-group><article-title>Neuronal pentraxin 1 contributes to the neuronal damage evoked by amyloid-beta and is overexpressed in dystrophic neurites in alzheimer&#8217;s brain</article-title><source>J Neurosci</source><year>2006</year><volume>26</volume><issue>49</issue><fpage>12735</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0575-06.2006</pub-id><pub-id pub-id-type="pmid">17151277</pub-id><pub-id pub-id-type="pmcid">PMC6674827</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Abad MA, Enguita M, DeGregorio-Rocasolano N, Ferrer I, Trullas R. Neuronal pentraxin 1 contributes to the neuronal damage evoked by amyloid-beta and is overexpressed in dystrophic neurites in alzheimer&#8217;s brain. J Neurosci. 2006;26(49):12735&#8211;47.<pub-id pub-id-type="pmid">17151277</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.0575-06.2006</pub-id><pub-id pub-id-type="pmcid">PMC6674827</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Zhou J, Wade SD, Graykowski D, Xiao MF, Zhao B, Giannini LAA, Hanson JE, van Swieten JC, Sheng M, Worley PF et al: The neuronal pentraxin Nptx2 regulates complement activity and restrains microglia-mediated synapse loss in neurodegeneration. Sci Transl Med. 2023;15(689):eadf0141.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.adf0141</pub-id><pub-id pub-id-type="pmcid">PMC10467038</pub-id><pub-id pub-id-type="pmid">36989373</pub-id></mixed-citation></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zou</surname><given-names>H</given-names></name><name name-style="western"><surname>Dai</surname><given-names>Z</given-names></name><name name-style="western"><surname>Feng</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>G</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Q</given-names></name></person-group><article-title>The basic characteristics of the pentraxin family and their functions in tumor progression</article-title><source>Front Immunol</source><year>2020</year><volume>11</volume><fpage>1757</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.01757</pub-id><pub-id pub-id-type="pmid">33013829</pub-id><pub-id pub-id-type="pmcid">PMC7461825</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Wang Z, Wang X, Zou H, Dai Z, Feng S, Zhang M, Xiao G, Liu Z, Cheng Q. The basic characteristics of the pentraxin family and their functions in tumor progression. Front Immunol. 2020;11:1757.<pub-id pub-id-type="pmid">33013829</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2020.01757</pub-id><pub-id pub-id-type="pmcid">PMC7461825</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wood</surname><given-names>H</given-names></name></person-group><article-title>Alzheimer disease: soluble TREM2 in CSF sheds light on microglial activation in AD</article-title><source>Nat Rev Neurol</source><year>2017</year><volume>13</volume><issue>2</issue><fpage>65</fpage><pub-id pub-id-type="doi">10.1038/nrneurol.2016.203</pub-id><pub-id pub-id-type="pmid">28084325</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Wood H. Alzheimer disease: soluble TREM2 in CSF sheds light on microglial activation in AD. Nat Rev Neurol. 2017;13(2):65.<pub-id pub-id-type="pmid">28084325</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrneurol.2016.203</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>T</given-names></name><name name-style="western"><surname>Zuo</surname><given-names>H</given-names></name><name name-style="western"><surname>Ma</surname><given-names>D</given-names></name><name name-style="western"><surname>Song</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>O</given-names></name></person-group><article-title>Cerebrospinal fluid GFAP is a predictive biomarker for conversion to dementia and alzheimer&#8217;s disease-associated biomarkers alterations among de Novo parkinson&#8217;s disease patients: a prospective cohort study</article-title><source>J Neuroinflammation</source><year>2023</year><volume>20</volume><issue>1</issue><fpage>167</fpage><pub-id pub-id-type="doi">10.1186/s12974-023-02843-5</pub-id><pub-id pub-id-type="pmid">37475029</pub-id><pub-id pub-id-type="pmcid">PMC10357612</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Liu T, Zuo H, Ma D, Song D, Zhao Y, Cheng O. Cerebrospinal fluid GFAP is a predictive biomarker for conversion to dementia and alzheimer&#8217;s disease-associated biomarkers alterations among de Novo parkinson&#8217;s disease patients: a prospective cohort study. J Neuroinflammation. 2023;20(1):167.<pub-id pub-id-type="pmid">37475029</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-023-02843-5</pub-id><pub-id pub-id-type="pmcid">PMC10357612</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>SH</given-names></name><name name-style="western"><surname>Meilandt</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Xie</surname><given-names>L</given-names></name><name name-style="western"><surname>Gandham</surname><given-names>VD</given-names></name><name name-style="western"><surname>Ngu</surname><given-names>H</given-names></name><name name-style="western"><surname>Barck</surname><given-names>KH</given-names></name><name name-style="western"><surname>Rezzonico</surname><given-names>MG</given-names></name><name name-style="western"><surname>Imperio</surname><given-names>J</given-names></name><name name-style="western"><surname>Lalehzadeh</surname><given-names>G</given-names></name><name name-style="western"><surname>Huntley</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Trem2 restrains the enhancement of Tau accumulation and neurodegeneration by &#946;-amyloid pathology</article-title><source>Neuron</source><year>2021</year><volume>109</volume><issue>8</issue><fpage>1283</fpage><lpage>e13011286</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2021.02.010</pub-id><pub-id pub-id-type="pmid">33675684</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Lee SH, Meilandt WJ, Xie L, Gandham VD, Ngu H, Barck KH, Rezzonico MG, Imperio J, Lalehzadeh G, Huntley MA, et al. Trem2 restrains the enhancement of Tau accumulation and neurodegeneration by &#946;-amyloid pathology. Neuron. 2021;109(8):1283&#8211;e13011286.<pub-id pub-id-type="pmid">33675684</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2021.02.010</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>YH</given-names></name><name name-style="western"><surname>Lin</surname><given-names>RR</given-names></name><name name-style="western"><surname>Huang</surname><given-names>HF</given-names></name><name name-style="western"><surname>Xue</surname><given-names>YY</given-names></name><name name-style="western"><surname>Tao</surname><given-names>QQ</given-names></name></person-group><article-title>Microglial activation, Tau pathology, and neurodegeneration biomarkers predict longitudinal cognitive decline in alzheimer&#8217;s disease continuum</article-title><source>Front Aging Neurosci</source><year>2022</year><volume>14</volume><fpage>848180</fpage><pub-id pub-id-type="doi">10.3389/fnagi.2022.848180</pub-id><pub-id pub-id-type="pmid">35847667</pub-id><pub-id pub-id-type="pmcid">PMC9280990</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Chen YH, Lin RR, Huang HF, Xue YY, Tao QQ. Microglial activation, Tau pathology, and neurodegeneration biomarkers predict longitudinal cognitive decline in alzheimer&#8217;s disease continuum. Front Aging Neurosci. 2022;14:848180.<pub-id pub-id-type="pmid">35847667</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2022.848180</pub-id><pub-id pub-id-type="pmcid">PMC9280990</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K</given-names></name><name name-style="western"><surname>Carrillo</surname><given-names>MC</given-names></name><name name-style="western"><surname>Dunn</surname><given-names>B</given-names></name><name name-style="western"><surname>Haeberlein</surname><given-names>SB</given-names></name><name name-style="western"><surname>Holtzman</surname><given-names>DM</given-names></name><name name-style="western"><surname>Jagust</surname><given-names>W</given-names></name><name name-style="western"><surname>Jessen</surname><given-names>F</given-names></name><name name-style="western"><surname>Karlawish</surname><given-names>J</given-names></name><etal/></person-group><article-title>NIA-AA research framework: toward a biological definition of alzheimer&#8217;s disease</article-title><source>Alzheimers Dement</source><year>2018</year><volume>14</volume><issue>4</issue><fpage>535</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2018.02.018</pub-id><pub-id pub-id-type="pmid">29653606</pub-id><pub-id pub-id-type="pmcid">PMC5958625</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Jack CR Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, et al. NIA-AA research framework: toward a biological definition of alzheimer&#8217;s disease. Alzheimers Dement. 2018;14(4):535&#8211;62.<pub-id pub-id-type="pmid">29653606</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2018.02.018</pub-id><pub-id pub-id-type="pmcid">PMC5958625</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spellman</surname><given-names>DS</given-names></name><name name-style="western"><surname>Wildsmith</surname><given-names>KR</given-names></name><name name-style="western"><surname>Honigberg</surname><given-names>LA</given-names></name><name name-style="western"><surname>Tuefferd</surname><given-names>M</given-names></name><name name-style="western"><surname>Baker</surname><given-names>D</given-names></name><name name-style="western"><surname>Raghavan</surname><given-names>N</given-names></name><name name-style="western"><surname>Nairn</surname><given-names>AC</given-names></name><name name-style="western"><surname>Croteau</surname><given-names>P</given-names></name><name name-style="western"><surname>Schirm</surname><given-names>M</given-names></name><name name-style="western"><surname>Allard</surname><given-names>R</given-names></name><etal/></person-group><article-title>Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in alzheimer&#8217;s disease neuroimaging initiative (ADNI) CSF</article-title><source>Proteom Clin Appl</source><year>2015</year><volume>9</volume><issue>7&#8211;8</issue><fpage>715</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1002/prca.201400178</pub-id><pub-id pub-id-type="pmcid">PMC4739636</pub-id><pub-id pub-id-type="pmid">25676562</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Spellman DS, Wildsmith KR, Honigberg LA, Tuefferd M, Baker D, Raghavan N, Nairn AC, Croteau P, Schirm M, Allard R, et al. Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in alzheimer&#8217;s disease neuroimaging initiative (ADNI) CSF. Proteom Clin Appl. 2015;9(7&#8211;8):715&#8211;31.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/prca.201400178</pub-id><pub-id pub-id-type="pmcid">PMC4739636</pub-id><pub-id pub-id-type="pmid">25676562</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaw</surname><given-names>LM</given-names></name><name name-style="western"><surname>Vanderstichele</surname><given-names>H</given-names></name><name name-style="western"><surname>Knapik-Czajka</surname><given-names>M</given-names></name><name name-style="western"><surname>Clark</surname><given-names>CM</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>PS</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>RC</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K</given-names></name><name name-style="western"><surname>Soares</surname><given-names>H</given-names></name><name name-style="western"><surname>Simon</surname><given-names>A</given-names></name><name name-style="western"><surname>Lewczuk</surname><given-names>P</given-names></name><etal/></person-group><article-title>Cerebrospinal fluid biomarker signature in alzheimer&#8217;s disease neuroimaging initiative subjects</article-title><source>Ann Neurol</source><year>2009</year><volume>65</volume><issue>4</issue><fpage>403</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1002/ana.21610</pub-id><pub-id pub-id-type="pmid">19296504</pub-id><pub-id pub-id-type="pmcid">PMC2696350</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, et al. Cerebrospinal fluid biomarker signature in alzheimer&#8217;s disease neuroimaging initiative subjects. Ann Neurol. 2009;65(4):403&#8211;13.<pub-id pub-id-type="pmid">19296504</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.21610</pub-id><pub-id pub-id-type="pmcid">PMC2696350</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bittner</surname><given-names>T</given-names></name><name name-style="western"><surname>Zetterberg</surname><given-names>H</given-names></name><name name-style="western"><surname>Teunissen</surname><given-names>CE</given-names></name><name name-style="western"><surname>Ostlund</surname><given-names>RE</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Militello</surname><given-names>M</given-names></name><name name-style="western"><surname>Andreasson</surname><given-names>U</given-names></name><name name-style="western"><surname>Hubeek</surname><given-names>I</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>D</given-names></name><name name-style="western"><surname>Chu</surname><given-names>DC</given-names></name><name name-style="western"><surname>Eichenlaub</surname><given-names>U</given-names></name><etal/></person-group><article-title>Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of &#946;-amyloid (1&#8211;42) in human cerebrospinal fluid</article-title><source>Alzheimers Dement</source><year>2016</year><volume>12</volume><issue>5</issue><fpage>517</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2015.09.009</pub-id><pub-id pub-id-type="pmid">26555316</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Bittner T, Zetterberg H, Teunissen CE, Ostlund RE Jr., Militello M, Andreasson U, Hubeek I, Gibson D, Chu DC, Eichenlaub U, et al. Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of &#946;-amyloid (1&#8211;42) in human cerebrospinal fluid. Alzheimers Dement. 2016;12(5):517&#8211;26.<pub-id pub-id-type="pmid">26555316</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2015.09.009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jagust</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Bandy</surname><given-names>D</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K</given-names></name><name name-style="western"><surname>Foster</surname><given-names>NL</given-names></name><name name-style="western"><surname>Landau</surname><given-names>SM</given-names></name><name name-style="western"><surname>Mathis</surname><given-names>CA</given-names></name><name name-style="western"><surname>Price</surname><given-names>JC</given-names></name><name name-style="western"><surname>Reiman</surname><given-names>EM</given-names></name><name name-style="western"><surname>Skovronsky</surname><given-names>D</given-names></name><name name-style="western"><surname>Koeppe</surname><given-names>RA</given-names></name></person-group><article-title>The alzheimer&#8217;s disease neuroimaging initiative positron emission tomography core</article-title><source>Alzheimers Dement</source><year>2010</year><volume>6</volume><issue>3</issue><fpage>221</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2010.03.003</pub-id><pub-id pub-id-type="pmid">20451870</pub-id><pub-id pub-id-type="pmcid">PMC2920531</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Jagust WJ, Bandy D, Chen K, Foster NL, Landau SM, Mathis CA, Price JC, Reiman EM, Skovronsky D, Koeppe RA. The alzheimer&#8217;s disease neuroimaging initiative positron emission tomography core. Alzheimers Dement. 2010;6(3):221&#8211;9.<pub-id pub-id-type="pmid">20451870</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2010.03.003</pub-id><pub-id pub-id-type="pmcid">PMC2920531</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>Z</given-names></name></person-group><article-title>Association of triglyceride glucose-body mass index with alzheimer&#8217;s disease pathology, cognition and brain structure in non-demented people</article-title><source>Sci Rep</source><year>2024</year><volume>14</volume><issue>1</issue><fpage>16097</fpage><pub-id pub-id-type="doi">10.1038/s41598-024-67052-3</pub-id><pub-id pub-id-type="pmid">38997334</pub-id><pub-id pub-id-type="pmcid">PMC11245502</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Zhang Z, Chen X, Sheng Z. Association of triglyceride glucose-body mass index with alzheimer&#8217;s disease pathology, cognition and brain structure in non-demented people. Sci Rep. 2024;14(1):16097.<pub-id pub-id-type="pmid">38997334</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-024-67052-3</pub-id><pub-id pub-id-type="pmcid">PMC11245502</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crane</surname><given-names>PK</given-names></name><name name-style="western"><surname>Carle</surname><given-names>A</given-names></name><name name-style="western"><surname>Gibbons</surname><given-names>LE</given-names></name><name name-style="western"><surname>Insel</surname><given-names>P</given-names></name><name name-style="western"><surname>Mackin</surname><given-names>RS</given-names></name><name name-style="western"><surname>Gross</surname><given-names>A</given-names></name><name name-style="western"><surname>Jones</surname><given-names>RN</given-names></name><name name-style="western"><surname>Mukherjee</surname><given-names>S</given-names></name><name name-style="western"><surname>Curtis</surname><given-names>SM</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>D</given-names></name><etal/></person-group><article-title>Development and assessment of a composite score for memory in the alzheimer&#8217;s disease neuroimaging initiative (ADNI)</article-title><source>Brain Imaging Behav</source><year>2012</year><volume>6</volume><issue>4</issue><fpage>502</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1007/s11682-012-9186-z</pub-id><pub-id pub-id-type="pmid">22782295</pub-id><pub-id pub-id-type="pmcid">PMC3806057</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Crane PK, Carle A, Gibbons LE, Insel P, Mackin RS, Gross A, Jones RN, Mukherjee S, Curtis SM, Harvey D, et al. Development and assessment of a composite score for memory in the alzheimer&#8217;s disease neuroimaging initiative (ADNI). Brain Imaging Behav. 2012;6(4):502&#8211;16.<pub-id pub-id-type="pmid">22782295</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11682-012-9186-z</pub-id><pub-id pub-id-type="pmcid">PMC3806057</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baron</surname><given-names>RM</given-names></name><name name-style="western"><surname>Kenny</surname><given-names>DA</given-names></name></person-group><article-title>The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations</article-title><source>J Pers Soc Psychol</source><year>1986</year><volume>51</volume><issue>6</issue><fpage>1173</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1037/0022-3514.51.6.1173</pub-id><pub-id pub-id-type="pmid">3806354</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol. 1986;51(6):1173&#8211;82.<pub-id pub-id-type="pmid">3806354</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1037//0022-3514.51.6.1173</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Habib</surname><given-names>N</given-names></name><name name-style="western"><surname>McCabe</surname><given-names>C</given-names></name><name name-style="western"><surname>Medina</surname><given-names>S</given-names></name><name name-style="western"><surname>Varshavsky</surname><given-names>M</given-names></name><name name-style="western"><surname>Kitsberg</surname><given-names>D</given-names></name><name name-style="western"><surname>Dvir-Szternfeld</surname><given-names>R</given-names></name><name name-style="western"><surname>Green</surname><given-names>G</given-names></name><name name-style="western"><surname>Dionne</surname><given-names>D</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>L</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Disease-associated astrocytes in alzheimer&#8217;s disease and aging</article-title><source>Nat Neurosci</source><year>2020</year><volume>23</volume><issue>6</issue><fpage>701</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1038/s41593-020-0624-8</pub-id><pub-id pub-id-type="pmid">32341542</pub-id><pub-id pub-id-type="pmcid">PMC9262034</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Habib N, McCabe C, Medina S, Varshavsky M, Kitsberg D, Dvir-Szternfeld R, Green G, Dionne D, Nguyen L, Marshall JL, et al. Disease-associated astrocytes in alzheimer&#8217;s disease and aging. Nat Neurosci. 2020;23(6):701&#8211;6.<pub-id pub-id-type="pmid">32341542</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41593-020-0624-8</pub-id><pub-id pub-id-type="pmcid">PMC9262034</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Song</surname><given-names>WM</given-names></name><name name-style="western"><surname>Andhey</surname><given-names>PS</given-names></name><name name-style="western"><surname>Swain</surname><given-names>A</given-names></name><name name-style="western"><surname>Levy</surname><given-names>T</given-names></name><name name-style="western"><surname>Miller</surname><given-names>KR</given-names></name><name name-style="western"><surname>Poliani</surname><given-names>PL</given-names></name><name name-style="western"><surname>Cominelli</surname><given-names>M</given-names></name><name name-style="western"><surname>Grover</surname><given-names>S</given-names></name><name name-style="western"><surname>Gilfillan</surname><given-names>S</given-names></name><etal/></person-group><article-title>Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in alzheimer&#8217;s disease</article-title><source>Nat Med</source><year>2020</year><volume>26</volume><issue>1</issue><fpage>131</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1038/s41591-019-0695-9</pub-id><pub-id pub-id-type="pmid">31932797</pub-id><pub-id pub-id-type="pmcid">PMC6980793</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Zhou Y, Song WM, Andhey PS, Swain A, Levy T, Miller KR, Poliani PL, Cominelli M, Grover S, Gilfillan S, et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in alzheimer&#8217;s disease. Nat Med. 2020;26(1):131&#8211;42.<pub-id pub-id-type="pmid">31932797</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-019-0695-9</pub-id><pub-id pub-id-type="pmcid">PMC6980793</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="other">Dulewicz M, Kulczy&#324;ska-Przybik A, S&#322;owik A, Borawska R, Mroczko B. Neurogranin and Neuronal Pentraxin Receptor as Synaptic Dysfunction Biomarkers in Alzheimer&#8217;s Disease. J Clin Med 2021;10(19).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm10194575</pub-id><pub-id pub-id-type="pmcid">PMC8509697</pub-id><pub-id pub-id-type="pmid">34640593</pub-id></mixed-citation></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>QL</given-names></name><name name-style="western"><surname>Teng</surname><given-names>E</given-names></name><name name-style="western"><surname>Zuo</surname><given-names>X</given-names></name><name name-style="western"><surname>Jones</surname><given-names>M</given-names></name><name name-style="western"><surname>Teter</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>EY</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>C</given-names></name><name name-style="western"><surname>Bilousova</surname><given-names>T</given-names></name><name name-style="western"><surname>Gylys</surname><given-names>KH</given-names></name><name name-style="western"><surname>Apostolova</surname><given-names>LG</given-names></name><etal/></person-group><article-title>Neuronal pentraxin 1: A synaptic-derived plasma biomarker in alzheimer&#8217;s disease</article-title><source>Neurobiol Dis</source><year>2018</year><volume>114</volume><fpage>120</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2018.02.014</pub-id><pub-id pub-id-type="pmid">29501530</pub-id><pub-id pub-id-type="pmcid">PMC8092920</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Ma QL, Teng E, Zuo X, Jones M, Teter B, Zhao EY, Zhu C, Bilousova T, Gylys KH, Apostolova LG, et al. Neuronal pentraxin 1: A synaptic-derived plasma biomarker in alzheimer&#8217;s disease. Neurobiol Dis. 2018;114:120&#8211;8.<pub-id pub-id-type="pmid">29501530</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nbd.2018.02.014</pub-id><pub-id pub-id-type="pmcid">PMC8092920</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belbin</surname><given-names>O</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>MF</given-names></name><name name-style="western"><surname>Xu</surname><given-names>D</given-names></name><name name-style="western"><surname>Carmona-Iragui</surname><given-names>M</given-names></name><name name-style="western"><surname>Pegueroles</surname><given-names>J</given-names></name><name name-style="western"><surname>Benejam</surname><given-names>B</given-names></name><name name-style="western"><surname>Videla</surname><given-names>L</given-names></name><name name-style="western"><surname>Fern&#225;ndez</surname><given-names>S</given-names></name><name name-style="western"><surname>Barroeta</surname><given-names>I</given-names></name><name name-style="western"><surname>Nu&#241;ez-Llaves</surname><given-names>R</given-names></name><etal/></person-group><article-title>Cerebrospinal fluid profile of NPTX2 supports role of alzheimer&#8217;s disease-related inhibitory circuit dysfunction in adults with down syndrome</article-title><source>Mol Neurodegener</source><year>2020</year><volume>15</volume><issue>1</issue><fpage>46</fpage><pub-id pub-id-type="doi">10.1186/s13024-020-00398-0</pub-id><pub-id pub-id-type="pmid">32807227</pub-id><pub-id pub-id-type="pmcid">PMC7433053</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Belbin O, Xiao MF, Xu D, Carmona-Iragui M, Pegueroles J, Benejam B, Videla L, Fern&#225;ndez S, Barroeta I, Nu&#241;ez-Llaves R, et al. Cerebrospinal fluid profile of NPTX2 supports role of alzheimer&#8217;s disease-related inhibitory circuit dysfunction in adults with down syndrome. Mol Neurodegener. 2020;15(1):46.<pub-id pub-id-type="pmid">32807227</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-020-00398-0</pub-id><pub-id pub-id-type="pmcid">PMC7433053</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galasko</surname><given-names>D</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>M</given-names></name><name name-style="western"><surname>Xu</surname><given-names>D</given-names></name><name name-style="western"><surname>Smirnov</surname><given-names>D</given-names></name><name name-style="western"><surname>Salmon</surname><given-names>DP</given-names></name><name name-style="western"><surname>Dewit</surname><given-names>N</given-names></name><name name-style="western"><surname>Vanbrabant</surname><given-names>J</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>D</given-names></name><name name-style="western"><surname>Vanderstichele</surname><given-names>H</given-names></name><name name-style="western"><surname>Vanmechelen</surname><given-names>E</given-names></name><etal/></person-group><article-title>Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and alzheimer&#8217;s disease</article-title><source>Alzheimers Dement (N Y)</source><year>2019</year><volume>5</volume><fpage>871</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.trci.2019.11.002</pub-id><pub-id pub-id-type="pmid">31853477</pub-id><pub-id pub-id-type="pmcid">PMC6911971</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Galasko D, Xiao M, Xu D, Smirnov D, Salmon DP, Dewit N, Vanbrabant J, Jacobs D, Vanderstichele H, Vanmechelen E, et al. Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and alzheimer&#8217;s disease. Alzheimers Dement (N Y). 2019;5:871&#8211;82.<pub-id pub-id-type="pmid">31853477</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trci.2019.11.002</pub-id><pub-id pub-id-type="pmcid">PMC6911971</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bolsewig</surname><given-names>K</given-names></name><name name-style="western"><surname>Hok-A-Hin</surname><given-names>YS</given-names></name><name name-style="western"><surname>Sepe</surname><given-names>FN</given-names></name><name name-style="western"><surname>Boonkamp</surname><given-names>L</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>D</given-names></name><name name-style="western"><surname>Bellomo</surname><given-names>G</given-names></name><name name-style="western"><surname>Paoletti</surname><given-names>FP</given-names></name><name name-style="western"><surname>Vanmechelen</surname><given-names>E</given-names></name><name name-style="western"><surname>Teunissen</surname><given-names>CE</given-names></name><name name-style="western"><surname>Parnetti</surname><given-names>L</given-names></name><etal/></person-group><article-title>A combination of neurofilament light, glial fibrillary acidic protein, and neuronal Pentraxin-2 discriminates between frontotemporal dementia and other dementias</article-title><source>J Alzheimers Dis</source><year>2022</year><volume>90</volume><issue>1</issue><fpage>363</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.3233/JAD-220318</pub-id><pub-id pub-id-type="pmid">36120776</pub-id><pub-id pub-id-type="pmcid">PMC9661338</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Bolsewig K, Hok-A-Hin YS, Sepe FN, Boonkamp L, Jacobs D, Bellomo G, Paoletti FP, Vanmechelen E, Teunissen CE, Parnetti L, et al. A combination of neurofilament light, glial fibrillary acidic protein, and neuronal Pentraxin-2 discriminates between frontotemporal dementia and other dementias. J Alzheimers Dis. 2022;90(1):363&#8211;80.<pub-id pub-id-type="pmid">36120776</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-220318</pub-id><pub-id pub-id-type="pmcid">PMC9661338</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="other">Das S, Goossens J, Jacobs D, Dewit N, Pijnenburg YAL, In 't Veld S, Teunissen CE, Vanmechelen E: Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer's disease and frontotemporal dementia. Alzheimers Res Ther. 2023;15(1):62.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-023-01212-x</pub-id><pub-id pub-id-type="pmcid">PMC10037899</pub-id><pub-id pub-id-type="pmid">36964594</pub-id></mixed-citation></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name><name name-style="western"><surname>Wade</surname><given-names>SD</given-names></name><name name-style="western"><surname>Graykowski</surname><given-names>D</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>MF</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>B</given-names></name><name name-style="western"><surname>Giannini</surname><given-names>LAA</given-names></name><name name-style="western"><surname>Hanson</surname><given-names>JE</given-names></name><name name-style="western"><surname>van Swieten</surname><given-names>JC</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>M</given-names></name><name name-style="western"><surname>Worley</surname><given-names>PF</given-names></name><etal/></person-group><article-title>The neuronal pentraxin Nptx2 regulates complement activity and restrains microglia-mediated synapse loss in neurodegeneration</article-title><source>Sci Transl Med</source><year>2023</year><volume>15</volume><issue>689</issue><fpage>eadf0141</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.adf0141</pub-id><pub-id pub-id-type="pmid">36989373</pub-id><pub-id pub-id-type="pmcid">PMC10467038</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Zhou J, Wade SD, Graykowski D, Xiao MF, Zhao B, Giannini LAA, Hanson JE, van Swieten JC, Sheng M, Worley PF, et al. The neuronal pentraxin Nptx2 regulates complement activity and restrains microglia-mediated synapse loss in neurodegeneration. Sci Transl Med. 2023;15(689):eadf0141.<pub-id pub-id-type="pmid">36989373</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.adf0141</pub-id><pub-id pub-id-type="pmcid">PMC10467038</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Friedman</surname><given-names>BA</given-names></name><name name-style="western"><surname>Srinivasan</surname><given-names>K</given-names></name><name name-style="western"><surname>Ayalon</surname><given-names>G</given-names></name><name name-style="western"><surname>Meilandt</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Lin</surname><given-names>H</given-names></name><name name-style="western"><surname>Huntley</surname><given-names>MA</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SH</given-names></name><name name-style="western"><surname>Haddick</surname><given-names>PCG</given-names></name><name name-style="western"><surname>Ngu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Diverse brain myeloid expression profiles reveal distinct microglial activation States and aspects of alzheimer&#8217;s disease not evident in mouse models</article-title><source>Cell Rep</source><year>2018</year><volume>22</volume><issue>3</issue><fpage>832</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.12.066</pub-id><pub-id pub-id-type="pmid">29346778</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Friedman BA, Srinivasan K, Ayalon G, Meilandt WJ, Lin H, Huntley MA, Cao Y, Lee SH, Haddick PCG, Ngu H, et al. Diverse brain myeloid expression profiles reveal distinct microglial activation States and aspects of alzheimer&#8217;s disease not evident in mouse models. Cell Rep. 2018;22(3):832&#8211;47.<pub-id pub-id-type="pmid">29346778</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2017.12.066</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hooper</surname><given-names>C</given-names></name><name name-style="western"><surname>Killick</surname><given-names>R</given-names></name><name name-style="western"><surname>Lovestone</surname><given-names>S</given-names></name></person-group><article-title>The GSK3 hypothesis of alzheimer&#8217;s disease</article-title><source>J Neurochem</source><year>2008</year><volume>104</volume><issue>6</issue><fpage>1433</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2007.05194.x</pub-id><pub-id pub-id-type="pmid">18088381</pub-id><pub-id pub-id-type="pmcid">PMC3073119</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of alzheimer&#8217;s disease. J Neurochem. 2008;104(6):1433&#8211;9.<pub-id pub-id-type="pmid">18088381</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1471-4159.2007.05194.x</pub-id><pub-id pub-id-type="pmcid">PMC3073119</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jembrek</surname><given-names>M</given-names></name><name name-style="western"><surname>Babi&#263;</surname><given-names>M</given-names></name><name name-style="western"><surname>Pivac</surname><given-names>N</given-names></name><name name-style="western"><surname>Hof</surname><given-names>P</given-names></name><name name-style="western"><surname>&#352;imi&#263;</surname><given-names>G</given-names></name></person-group><article-title>Hyperphosphorylation of Tau by GSK-3&#946; in alzheimer&#8217;s disease: the interaction of A&#946; and sphingolipid mediators as a therapeutic target</article-title><source>Translational Neurosci</source><year>2013</year><volume>4</volume><issue>4</issue><fpage>466</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.2478/s13380-013-0144-z</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Jembrek M, Babi&#263; M, Pivac N, Hof P, &#352;imi&#263; G. Hyperphosphorylation of Tau by GSK-3&#946; in alzheimer&#8217;s disease: the interaction of A&#946; and sphingolipid mediators as a therapeutic target. Translational Neurosci. 2013;4(4):466&#8211;76.</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su&#225;rez-Calvet</surname><given-names>M</given-names></name><name name-style="western"><surname>Kleinberger</surname><given-names>G</given-names></name><name name-style="western"><surname>Araque Caballero</surname><given-names>M</given-names></name><name name-style="western"><surname>Brendel</surname><given-names>M</given-names></name><name name-style="western"><surname>Rominger</surname><given-names>A</given-names></name><name name-style="western"><surname>Alcolea</surname><given-names>D</given-names></name><name name-style="western"><surname>Fortea</surname><given-names>J</given-names></name><name name-style="western"><surname>Lle&#243;</surname><given-names>A</given-names></name><name name-style="western"><surname>Blesa</surname><given-names>R</given-names></name><name name-style="western"><surname>Gispert</surname><given-names>JD</given-names></name><etal/></person-group><article-title>sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage alzheimer&#8217;s disease and associate with neuronal injury markers</article-title><source>EMBO Mol Med</source><year>2016</year><volume>8</volume><issue>5</issue><fpage>466</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.15252/emmm.201506123</pub-id><pub-id pub-id-type="pmid">26941262</pub-id><pub-id pub-id-type="pmcid">PMC5120370</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Su&#225;rez-Calvet M, Kleinberger G, Araque Caballero M, Brendel M, Rominger A, Alcolea D, Fortea J, Lle&#243; A, Blesa R, Gispert JD, et al. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage alzheimer&#8217;s disease and associate with neuronal injury markers. EMBO Mol Med. 2016;8(5):466&#8211;76.<pub-id pub-id-type="pmid">26941262</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/emmm.201506123</pub-id><pub-id pub-id-type="pmcid">PMC5120370</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liddelow</surname><given-names>SA</given-names></name><name name-style="western"><surname>Guttenplan</surname><given-names>KA</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>LE</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>FC</given-names></name><name name-style="western"><surname>Bohlen</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Schirmer</surname><given-names>L</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>ML</given-names></name><name name-style="western"><surname>M&#252;nch</surname><given-names>AE</given-names></name><name name-style="western"><surname>Chung</surname><given-names>WS</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>TC</given-names></name><etal/></person-group><article-title>Neurotoxic reactive astrocytes are induced by activated microglia</article-title><source>Nature</source><year>2017</year><volume>541</volume><issue>7638</issue><fpage>481</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1038/nature21029</pub-id><pub-id pub-id-type="pmid">28099414</pub-id><pub-id pub-id-type="pmcid">PMC5404890</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, Bennett ML, M&#252;nch AE, Chung WS, Peterson TC, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541(7638):481&#8211;7.<pub-id pub-id-type="pmid">28099414</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature21029</pub-id><pub-id pub-id-type="pmcid">PMC5404890</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nabizadeh</surname><given-names>F</given-names></name></person-group><article-title>sTREM2 is associated with attenuated Tau aggregate accumulation in the presence of amyloid-&#946; pathology</article-title><source>Brain Commun</source><year>2023</year><volume>5</volume><issue>6</issue><fpage>fcad286</fpage><pub-id pub-id-type="doi">10.1093/braincomms/fcad286</pub-id><pub-id pub-id-type="pmid">37942087</pub-id><pub-id pub-id-type="pmcid">PMC10629471</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Nabizadeh F. sTREM2 is associated with attenuated Tau aggregate accumulation in the presence of amyloid-&#946; pathology. Brain Commun. 2023;5(6):fcad286.<pub-id pub-id-type="pmid">37942087</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/braincomms/fcad286</pub-id><pub-id pub-id-type="pmcid">PMC10629471</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nabizadeh</surname><given-names>F</given-names></name><name name-style="western"><surname>Seyedmirzaei</surname><given-names>H</given-names></name><name name-style="western"><surname>Karami</surname><given-names>S</given-names></name></person-group><article-title>Neuroimaging biomarkers and CSF sTREM2 levels in alzheimer&#8217;s disease: a longitudinal study</article-title><source>Sci Rep</source><year>2024</year><volume>14</volume><issue>1</issue><fpage>15318</fpage><pub-id pub-id-type="doi">10.1038/s41598-024-66211-w</pub-id><pub-id pub-id-type="pmid">38961148</pub-id><pub-id pub-id-type="pmcid">PMC11222555</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Nabizadeh F, Seyedmirzaei H, Karami S. Neuroimaging biomarkers and CSF sTREM2 levels in alzheimer&#8217;s disease: a longitudinal study. Sci Rep. 2024;14(1):15318.<pub-id pub-id-type="pmid">38961148</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-024-66211-w</pub-id><pub-id pub-id-type="pmcid">PMC11222555</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>C</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>J</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name></person-group><article-title>Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets</article-title><source>Signal Transduct Target Ther</source><year>2023</year><volume>8</volume><issue>1</issue><fpage>359</fpage><pub-id pub-id-type="doi">10.1038/s41392-023-01588-0</pub-id><pub-id pub-id-type="pmid">37735487</pub-id><pub-id pub-id-type="pmcid">PMC10514343</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Gao C, Jiang J, Tan Y, Chen S. Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets. Signal Transduct Target Ther. 2023;8(1):359.<pub-id pub-id-type="pmid">37735487</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-023-01588-0</pub-id><pub-id pub-id-type="pmcid">PMC10514343</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Tang</surname><given-names>L</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Meng</surname><given-names>L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name></person-group><article-title>Soluble TREM2 ameliorates Tau phosphorylation and cognitive deficits through activating transgelin-2 in alzheimer&#8217;s disease</article-title><source>Nat Commun</source><year>2023</year><volume>14</volume><issue>1</issue><fpage>6670</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-42505-x</pub-id><pub-id pub-id-type="pmid">37865646</pub-id><pub-id pub-id-type="pmcid">PMC10590452</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Zhang X, Tang L, Yang J, Meng L, Chen J, Zhou L, Wang J, Xiong M, Zhang Z. Soluble TREM2 ameliorates Tau phosphorylation and cognitive deficits through activating transgelin-2 in alzheimer&#8217;s disease. Nat Commun. 2023;14(1):6670.<pub-id pub-id-type="pmid">37865646</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-42505-x</pub-id><pub-id pub-id-type="pmcid">PMC10590452</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><mixed-citation publication-type="other">Wu Q, Zou C. Microglial dysfunction in neurodegenerative diseases via RIPK1 and ROS. Antioxid (Basel) 2022, 11(11).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/antiox11112201</pub-id><pub-id pub-id-type="pmcid">PMC9686917</pub-id><pub-id pub-id-type="pmid">36358573</pub-id></mixed-citation></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leyns</surname><given-names>CEG</given-names></name><name name-style="western"><surname>Holtzman</surname><given-names>DM</given-names></name></person-group><article-title>Glial contributions to neurodegeneration in tauopathies</article-title><source>Mol Neurodegener</source><year>2017</year><volume>12</volume><issue>1</issue><fpage>50</fpage><pub-id pub-id-type="doi">10.1186/s13024-017-0192-x</pub-id><pub-id pub-id-type="pmid">28662669</pub-id><pub-id pub-id-type="pmcid">PMC5492997</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Leyns CEG, Holtzman DM. Glial contributions to neurodegeneration in tauopathies. Mol Neurodegener. 2017;12(1):50.<pub-id pub-id-type="pmid">28662669</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-017-0192-x</pub-id><pub-id pub-id-type="pmcid">PMC5492997</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><mixed-citation publication-type="other">Han J, Zhang Z, Zhang P, Yu Q, Cheng Q, Lu Z, Zong S. The roles of microglia and astrocytes in neuroinflammation of alzheimer&#8217;s disease. Front NeuroSci 2025, 19.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2025.1575453</pub-id><pub-id pub-id-type="pmcid">PMC12092354</pub-id><pub-id pub-id-type="pmid">40400619</pub-id></mixed-citation></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwon</surname><given-names>HS</given-names></name><name name-style="western"><surname>Koh</surname><given-names>SH</given-names></name></person-group><article-title>Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes</article-title><source>Transl Neurodegener</source><year>2020</year><volume>9</volume><issue>1</issue><fpage>42</fpage><pub-id pub-id-type="doi">10.1186/s40035-020-00221-2</pub-id><pub-id pub-id-type="pmid">33239064</pub-id><pub-id pub-id-type="pmcid">PMC7689983</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Kwon HS, Koh SH. Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Transl Neurodegener. 2020;9(1):42.<pub-id pub-id-type="pmid">33239064</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40035-020-00221-2</pub-id><pub-id pub-id-type="pmcid">PMC7689983</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Warmenhoven</surname><given-names>N</given-names></name><name name-style="western"><surname>S&#225;nchez-Benavides</surname><given-names>G</given-names></name><name name-style="western"><surname>Gonz&#225;lez&#8208;Escalante</surname><given-names>A</given-names></name><name name-style="western"><surname>Mil&#224;&#8208;Alom&#224;</surname><given-names>M</given-names></name><name name-style="western"><surname>Shekari</surname><given-names>M</given-names></name><name name-style="western"><surname>L&#243;pez&#8208;Martos</surname><given-names>D</given-names></name><name name-style="western"><surname>Ortiz&#8208;Romero</surname><given-names>P</given-names></name><name name-style="western"><surname>Kollmorgen</surname><given-names>G</given-names></name><name name-style="western"><surname>Quijano&#8208;Rubio</surname><given-names>C</given-names></name><name name-style="western"><surname>Minguill&#243;n</surname><given-names>C</given-names></name><etal/></person-group><article-title>CSF glial biomarkers are associated with cognition in individuals at risk of alzheimer&#8217;s disease</article-title><source>Alzheimer&#8217;s Dement</source><year>2024</year><volume>20</volume><issue>9</issue><fpage>5819</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1002/alz.13862</pub-id><pub-id pub-id-type="pmid">39032119</pub-id><pub-id pub-id-type="pmcid">PMC11497712</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Warmenhoven N, S&#225;nchez-Benavides G, Gonz&#225;lez&#8208;Escalante A, Mil&#224;&#8208;Alom&#224; M, Shekari M, L&#243;pez&#8208;Martos D, Ortiz&#8208;Romero P, Kollmorgen G, Quijano&#8208;Rubio C, Minguill&#243;n C, et al. CSF glial biomarkers are associated with cognition in individuals at risk of alzheimer&#8217;s disease. Alzheimer&#8217;s Dement. 2024;20(9):5819&#8211;32.<pub-id pub-id-type="pmid">39032119</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13862</pub-id><pub-id pub-id-type="pmcid">PMC11497712</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><mixed-citation publication-type="other">Azzolini F, Gilio L, Pavone L, Iezzi E, Dolcetti E, Bruno A, Buttari F, Musella A, Mandolesi G, Guadalupi L et al: Neuroinflammation Is Associated with GFAP and sTREM2 Levels in Multiple Sclerosis. Biomolecules 2022;12(2):222.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biom12020222</pub-id><pub-id pub-id-type="pmcid">PMC8961656</pub-id><pub-id pub-id-type="pmid">35204724</pub-id></mixed-citation></ref><ref id="CR49"><label>49.</label><mixed-citation publication-type="other">Piel JHA, Bargemann L, Leypoldt F, Wandinger KP, Dargvainiene J: Serum NFL and tau, but not serum UCHL-1 and GFAP or CSF SNAP-25, NPTX2, or sTREM2, correlate with delirium in a 3-year retrospective analysis. Front Neurol. 2024;15:1356575.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2024.1356575</pub-id><pub-id pub-id-type="pmcid">PMC10985356</pub-id><pub-id pub-id-type="pmid">38566855</pub-id></mixed-citation></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Eisel</surname><given-names>ULM</given-names></name></person-group><article-title>Microglia-Astrocyte communication in alzheimer&#8217;s disease</article-title><source>J Alzheimer&#8217;s Disease</source><year>2023</year><volume>95</volume><issue>3</issue><fpage>785</fpage><lpage>803</lpage><pub-id pub-id-type="doi">10.3233/JAD-230199</pub-id><pub-id pub-id-type="pmid">37638434</pub-id><pub-id pub-id-type="pmcid">PMC10578295</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Wu Y, Eisel ULM. Microglia-Astrocyte communication in alzheimer&#8217;s disease. J Alzheimer&#8217;s Disease. 2023;95(3):785&#8211;803.<pub-id pub-id-type="pmid">37638434</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-230199</pub-id><pub-id pub-id-type="pmcid">PMC10578295</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="pcn13869" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Psychiatry Clin Neurosci</journal-id><journal-id journal-id-type="iso-abbrev">Psychiatry Clin Neurosci</journal-id><journal-id journal-id-type="pmc-domain-id">379</journal-id><journal-id journal-id-type="pmc-domain">blackwellopen</journal-id><journal-id journal-id-type="publisher-id">PCN</journal-id><journal-title-group><journal-title>Psychiatry and Clinical Neurosciences</journal-title></journal-title-group><issn pub-type="ppub">1323-1316</issn><issn pub-type="epub">1440-1819</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Wiley Open Access Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12498121</article-id><article-id pub-id-type="pmcid-ver">PMC12498121.1</article-id><article-id pub-id-type="pmcaid">12498121</article-id><article-id pub-id-type="pmcaiid">12498121</article-id><article-id pub-id-type="pmid">40658049</article-id><article-id pub-id-type="doi">10.1111/pcn.13869</article-id><article-id pub-id-type="publisher-id">PCN13869</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Regular Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Plasma circulating microRNAs and symptoms of depression: Results from a population&#8208;based study</article-title><alt-title alt-title-type="right-running-head">microRNAs and symptoms of depression</alt-title></title-group><contrib-group><contrib id="pcn13869-cr-0001" contrib-type="author"><name name-style="western"><surname>Kuilman</surname><given-names initials="MM">Midas M.</given-names></name><degrees>MSc</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0000-1562-7541</contrib-id><xref rid="pcn13869-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="pcn13869-cr-0002" contrib-type="author"><name name-style="western"><surname>Finke</surname><given-names initials="T">Tim</given-names></name><degrees>MSc</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0000-1796-6133</contrib-id><xref rid="pcn13869-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="pcn13869-cr-0003" contrib-type="author"><name name-style="western"><surname>Ikram</surname><given-names initials="MA">M. Arfan</given-names></name><degrees>MD, PhD</degrees><xref rid="pcn13869-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="pcn13869-cr-0004" contrib-type="author"><name name-style="western"><surname>Luik</surname><given-names initials="AI">Annemarie I.</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7517-197X</contrib-id><xref rid="pcn13869-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="pcn13869-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="pcn13869-cr-0005" contrib-type="author"><name name-style="western"><surname>Neumann</surname><given-names initials="A">Alexander</given-names></name><degrees>PhD</degrees><xref rid="pcn13869-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="pcn13869-cr-0006" contrib-type="author"><name name-style="western"><surname>Cecil</surname><given-names initials="CAM">Charlotte A.M.</given-names></name><degrees>PhD</degrees><xref rid="pcn13869-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="pcn13869-cr-0007" contrib-type="author" corresp="yes"><name name-style="western"><surname>Ghanbari</surname><given-names initials="M">Mohsen</given-names></name><degrees>MD, PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9476-7143</contrib-id><xref rid="pcn13869-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>m.ghanbari@erasmusmc.nl</email></address></contrib></contrib-group><aff id="pcn13869-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Epidemiology</named-content>
<institution>Erasmus University Medical Center</institution>
<city>Rotterdam</city>
<country country="NL">The Netherlands</country>
</aff><aff id="pcn13869-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Child and Adolescent Psychiatry</named-content>
<institution>Erasmus University Medical Center</institution>
<city>Rotterdam</city>
<country country="NL">The Netherlands</country>
</aff><aff id="pcn13869-aff-0003">
<label>
<sup>3</sup>
</label>
<institution>Trimbos Institute &#8211; Netherlands Institute for Mental Health and Addiction</institution>
<city>Utrecht</city>
<country country="NL">The Netherlands</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label>
Correspondence: Email: <email>m.ghanbari@erasmusmc.nl</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>14</day><month>7</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>10</month><year>2025</year></pub-date><volume>79</volume><issue seq="80">10</issue><issue-id pub-id-type="pmc-issue-id">498353</issue-id><issue-id pub-id-type="doi">10.1111/pcn.v79.10</issue-id><fpage>636</fpage><lpage>644</lpage><history><date date-type="rev-recd"><day>28</day><month>5</month><year>2025</year></date><date date-type="received"><day>25</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>26</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>06</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>07</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-07 00:25:38.680"><day>07</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Psychiatry and Clinical Neurosciences</italic> published by John Wiley &amp; Sons Australia, Ltd on behalf of Japanese Society of Psychiatry and Neurology.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="PCN-79-636.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:PCN-79-636.pdf"/><abstract><sec id="pcn13869-sec-0001"><title>Background</title><p>Depression is a complex mental disorder with a multifactorial etiology. Recent research has highlighted the potential of microRNAs (miRNAs) as novel biomarkers and their involvement in the molecular pathways underlying depression; yet, these studies often focus on limited clinical samples and specific subsets of miRNAs. Here we aimed to explore plasma miRNA expression profiles associated with depressive symptoms in a population&#8208;based study of middle&#8208;aged and older adults.</p></sec><sec id="pcn13869-sec-0002"><title>Methods</title><p>We analyzed the levels of 591 circulating miRNAs well&#8208;expressed in plasma samples of 2,703 participants of the Rotterdam Study. The Center for Epidemiologic Studies Depression Scale was used to assess depressive symptoms in these participants. Negative&#8208;binomial regression models were employed to explore the relationship between individual miRNA levels and depressive symptoms, adjusting for potential confounders including age, sex, BMI, and other factors.</p></sec><sec id="pcn13869-sec-0003"><title>Results</title><p>Our analysis suggests 38 circulating miRNAs to be potentially associated with depressive symptoms (<italic toggle="no">P</italic>&#8201;&lt;&#8201;0.05). Although these miRNAs did not survive multiple testing correction, our subsequent <italic toggle="no">in silico</italic> analysis of their target genes suggests involvement in neural and psychiatric pathways, as well as enrichment for associations with depressive symptoms based on previous genome&#8208;wide association studies.</p></sec><sec id="pcn13869-sec-0004"><title>Conclusions</title><p>This study proposes several circulating miRNAs that may be associated with depressive symptoms within the general population. Our follow&#8208;up analyses indicate that the miRNAs with the largest effect estimates were potentially involved in neurological and psychiatric processes, warranting further investigation into their potential role in the biological mechanisms of depression. These results provide preliminary insights and should be considered exploratory and hypothesis&#8208;generating, warranting validation in future studies with larger and independent cohorts.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="pcn13869-kwd-0001">biomarkers</kwd><kwd id="pcn13869-kwd-0002">depression</kwd><kwd id="pcn13869-kwd-0003">MicroRNAs</kwd><kwd id="pcn13869-kwd-0004">population&#8208;based study</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Erasmus MC Fellowship</institution></institution-wrap></funding-source><award-id>EMCF20213</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>European Union's Horizon Europe Research and Innovation Programme</institution></institution-wrap></funding-source><award-id>101057529</award-id></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>Alzheimer Nederland</institution><institution-id institution-id-type="doi">10.13039/501100010969</institution-id></institution-wrap></funding-source><award-id>WE.03&#8208;2021&#8208;10</award-id></award-group><award-group id="funding-0004"><funding-source><institution-wrap><institution>European Research Council</institution><institution-id institution-id-type="doi">10.13039/100010663</institution-id></institution-wrap></funding-source><award-id>101039672</award-id></award-group><award-group id="funding-0005"><funding-source><institution-wrap><institution>European Union's Horizon 2020 Research and Innovation Programme</institution></institution-wrap></funding-source><award-id>848158</award-id></award-group></funding-group><counts><fig-count count="3"/><table-count count="2"/><page-count count="9"/><word-count count="6800"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:06.10.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="pcn13869-ntgp-0001"><fn id="pcn13869-note-0001"><p>Midas M. Kuilman and Tim Finke share first authorship.</p></fn></fn-group></notes></front><body id="pcn13869-body-0001"><p>Major depressive disorder is a prevalent and debilitating mental disorder that affects millions of individuals worldwide, imposing a substantial burden on both individuals and society.<xref rid="pcn13869-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> The underlying molecular mechanisms and biomarkers associated with depression, including the full scope of depressive disorders and depressive symptoms, remain poorly understood. Recent advances in molecular biology have shed light on microRNAs (miRNAs), small non&#8208;coding RNA molecules that play crucial roles in the post&#8208;transcriptional regulation of gene expression. MiRNAs can cross the blood&#8211;brain barrier, allowing them to serve as potential indicators of neural processes associated with mental disorders.<xref rid="pcn13869-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> MiRNAs may therefore act as promising candidates for understanding the pathophysiology of depression or as potential biomarkers, not only due to their involvement in neural processes,<xref rid="pcn13869-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="pcn13869-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="pcn13869-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> but also because of their detectability in peripheral biological fluids, like plasma.</p><p>Previous studies have identified a variety of miRNAs as potential biomarkers for depression, with findings indicating both upregulated and downregulated miRNAs in depressed individuals compared to healthy controls. A systematic review of circulatory miRNAs in major depressive disorder reported that 20 circulating miRNAs have been identified in two independent studies, and 10 in three or more. Most of these miRNAs are highly expressed in brain tissues and regulate neuronal and major depressive disorder associated processes.<xref rid="pcn13869-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> For example, upregulation of miR&#8208;132 serves as an important regulator of neurotropic action, mainly through the activation of hippocampal BDNF&#8208;ERK&#8208;CREB signaling pathways.<xref rid="pcn13869-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> Likewise, miR&#8208;124&#8208;3p is expressed in the brain of individuals with major depressive disorder<xref rid="pcn13869-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="pcn13869-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> and was proposed as a therapeutic target for anti&#8208;depressants<xref rid="pcn13869-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> or dysregulation of the let&#8208;7 family miRNAs has been identified as candidate biomarkers for major depressive disorder.<xref rid="pcn13869-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="pcn13869-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="pcn13869-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>
</p><p>Despite these promising findings, several key gaps remain to be addressed. First, many studies to date have been based on small, selected clinical samples using a case&#8211;control design.<xref rid="pcn13869-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> As such, little is known about how miRNA expression levels may associate with depressive symptoms in the general population.<xref rid="pcn13869-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> This is important given that depressive symptoms manifest along a continuum, and that individuals with subclinical scores on depression measures may still show dysregulated expression levels of circulating miRNAs. Second, studies have varied widely in the methods used for detecting miRNAs levels, mainly utilizing qRT&#8208;PCR to measure specific candidate miRNAs, which limits comparability between findings and also means that other miRNAs relevant to depression may remain undetected, as they were not tested.<xref rid="pcn13869-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> Third, studies to date have primarily focused on individuals during early and mid&#8208;adulthood. Yet, models of genetic and environmental influences on depression suggest that depression may have a heterogeneous pathophysiology over the lifespan,<xref rid="pcn13869-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> indicating that miRNA profiles associated with depression may also change in older age.</p><p>To address these gaps, we aimed to explore associations between plasma&#8208;derived extracellular miRNA profiles and depressive symptoms using data from the population&#8208;based Rotterdam Study cohort,<xref rid="pcn13869-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> in order to identify potential biomarkers and molecular pathways regulated by miRNAs linked to depression. To this end, we generated data from over 2700 participants using a next&#8208;generation RNA&#8208;sequencing platform, allowing for simultaneous, quantitative detection of 2083 miRNAs.<xref rid="pcn13869-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="pcn13869-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> This enabled testing for associations with a large set of potential miRNA biomarkers, and establishing the potential functional relevance of late life depression&#8208;associated miRNAs using a range of <italic toggle="yes">in silico</italic> studies. Though the Rotterdam Study primarily includes middle&#8208;aged and elderly individuals of European ancestry, the generalizability to younger or more diverse populations might be limited, so studying this cohort offers valuable insights into depressive symptoms later in life. Such insights may ultimately contribute to the development of more accurate diagnostic tools and deeper understanding of the biological mechanisms underlying this complex mental disorder.</p><sec sec-type="materials-and-methods" id="pcn13869-sec-0006"><title>Materials and Methods</title><sec id="pcn13869-sec-0007"><title>Study population</title><p>This study was conducted utilizing data from the Rotterdam Study, a prospective population&#8208;based cohort in the Netherlands ongoing since 1990.<xref rid="pcn13869-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> Detailed information about the Rotterdam Study has been previously published and is available in the Methods in the supporting information; Data&#160;<xref rid="pcn13869-supitem-0003" ref-type="supplementary-material">S3</xref>.</p><p>The baseline data for the current study were collected during inclusion rounds between 2002&#8211;2005 and 2017&#8211;2018. During this period, participants visited the research center for blood sampling and underwent extensive assessments. A random subset, for whom miRNA expression in plasma was determined, was included in this study. This included 1000 participants from the fourth visit of the first cohort (RS&#8208;I&#8208;4), 1000 participants from the second visit of the second cohort (RS&#8208;II&#8208;2), who visited the center between 2002 and 2005. Moreover, we included 754 participants from the first visit of the fourth cohort (RS&#8208;IV&#8208;1), where miRNA expression were measured from blood samples collected in 2017&#8211;2018. One participant had insufficient miRNA data quality, and 50 participants had insufficient data on depressive symptoms. Therefore, our study population consisted of 2703 participants.</p><p>The Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus MC (registration number MEC 02.1015) and by the Dutch Ministry of Health, Welfare and Sport (Population Screening Act WBO, license number 1071272&#8208;159521&#8208;PG). The study was conducted in accordance with the principles of the Declaration of Helsinki. The Rotterdam Study Personal Registration Data collection is filed with the Erasmus MC Data Protection Officer under registration number EMC1712001. The Rotterdam Study project persistent identifier is <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ror.org/02ac58f22" ext-link-type="uri">https://ror.org/02ac58f22</ext-link>. All participants provided written informed consent to participate in the study and to have their information obtained from treating physicians.<xref rid="pcn13869-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>
</p></sec><sec id="pcn13869-sec-0009"><title>
<styled-content style="fixed-case" toggle="no">MiRNA</styled-content> expression profiling</title><p>Expression levels of 2083 miRNAs in plasma were analyzed using the HTG EdgeSeq miRNA Whole Transcriptome Assay developed by HTG Molecular Diagnostics. The sequencing was performed on an Illumina NextSeq 500 sequencer (Illumina). The counts per million values of miRNA expression levels were first adjusted for total reads within each sample and subsequently log2 transformed. MiRNAs with lg2 counts per million &lt;1.0 were indicated as not expressed in the samples.</p><p>Out of the 2083 miRNAs initially profiled, 591 miRNAs were previously identified as well&#8208;expressed in plasma and were selected for subsequent analyses.<xref rid="pcn13869-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> For a comprehensive description of the methods employed for miRNA expression profiling, we refer to the Methods in the supporting information; Data&#160;<xref rid="pcn13869-supitem-0003" ref-type="supplementary-material">S3</xref>.</p></sec><sec id="pcn13869-sec-0010"><title>Depressive symptoms</title><p>Depressive symptoms were assessed with the Center for Epidemiologic Studies Depression (CES&#8208;D) scale, a 20&#8208;item scale covering cover a range of emotional, cognitive, and physical symptoms.<xref rid="pcn13869-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="pcn13869-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> The total score ranges between 0 and 60, where a higher score indicates more depressive symptoms.</p><p>A weighted CESD sum score was used for participants who had answered with a maximum of five questions missing, see Methods in the supporting information; Data&#160;<xref rid="pcn13869-supitem-0003" ref-type="supplementary-material">S3</xref>. However, if participants had more than five missing questions, CES&#8208;D scores were not calculated and assumed missing.</p></sec><sec id="pcn13869-sec-0011"><title>Statistical analysis</title><p>We investigated the association of each miRNA with depressive symptoms scores individually. To this end, we regressed depressive symptoms on each miRNA using negative&#8208;binomial linear models, from which we derived mean differences and their corresponding 95% confidence intervals (95% CI). We selected miRNA with <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 that also met a threshold for effect size with an absolute estimate greater than 0.1. We opted for a Negative Binomial Regression due to the nature of the CES&#8208;D scores showing signs of over&#8208;dispersion, with a greater variance than the mean, and skewness towards the lower scores, see Fig.&#160;<xref rid="pcn13869-supitem-0003" ref-type="supplementary-material">S1</xref>.</p><p>We accounted for BMI, white blood cells, red blood cells, education, smoking, Plate number, and well positioning. For a more detailed description of the used confounders, see Model building section in the supporting information; Data&#160;<xref rid="pcn13869-supitem-0003" ref-type="supplementary-material">S3</xref>. A Benjamini&#8208;Hochberg (False Discovery Rate, FDR) correction was applied to adjust for multiple testing.</p></sec><sec id="pcn13869-sec-0012"><title>Post hoc analysis of identified <styled-content style="fixed-case" toggle="no">miRNAs</styled-content> and target genes</title><p>We conducted a comprehensive set of <italic toggle="yes">in silico</italic> studies to explore the potential involvement of the identified miRNAs in underlying depression disease pathways.</p></sec><sec id="pcn13869-sec-0013"><title>Step 1: <styled-content style="fixed-case" toggle="no">miRNA</styled-content> target prediction</title><p>We first utilized two databases for miRNA target prediction, namely miRTarBase<xref rid="pcn13869-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> and miRDB.<xref rid="pcn13869-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> Predicted target genes for the identified miRNAs were extracted, with consideration given to targets having a score above 80 in miRDB and being functionally approved targets in miRTarBase.</p></sec><sec id="pcn13869-sec-0014"><title>Step 2: Functional enrichment analysis</title><p>We evaluated whether these putative target genes collectively contributed to specific biological pathways. This was carried out using the STRING<xref rid="pcn13869-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> database for association networks and functional enrichment analyses. It integrates data from scientific literature, experimental data, computational prediction methods, and public databases to facilitate the analysis of interaction networks and biological processes. In our approach, we specifically modified the default settings for active interaction sources by selecting only experiments, databases, and gene fusion as our evidence types.</p></sec><sec id="pcn13869-sec-0015"><title>Step 3: Brain expression examination</title><p>We looked up the expression of identified miRNAs in the brain. The objective was to elucidate potential links between plasma miRNA profiles and miRNAs expressed within the brain, specifically focusing on their relevance to depressive symptoms. We accessed brain expression data for miRNAs, which provided information on miRNA expression patterns within various brain regions, from the miRNATissueAtlas2.<xref rid="pcn13869-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>
</p></sec><sec id="pcn13869-sec-0016"><title>Step 4: <styled-content style="fixed-case" toggle="no">SNP</styled-content> analysis</title><p>We investigated whether single nucleotide polymorphisms (SNPs) are located within the corresponding sequences of identified miRNAs or their putative target genes, and then looked up their associations with depression. To achieve this, we made use of the genome&#8208;wide summary statistics obtained from a prior meta&#8208;analysis of PGC<xref rid="pcn13869-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> and UK Biobank<xref rid="pcn13869-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> focused on depression.<xref rid="pcn13869-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> We employed the Bonferroni correction to adjust our test statistics for the total number of miRNA and target genes combined.</p></sec><sec id="pcn13869-sec-0017"><title>Step 5: Gene based tests</title><p>We hypothesized that target genes of the top&#8208;associated miRNAs are more likely to be associated with depression than non&#8208;target genes. Specifically, we tested whether target gene sets are enriched for association with depression based on GWAS summary statistics of major depressive disorder.<xref rid="pcn13869-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> These subsets of genes are defined as the subset of target genes of upregulated miRNAs (1), target genes of downregulated miRNAs (2), or the combination of both subsets (3). We utilized MAGMA, a tool for gene&#8208;set analysis of GWAS summary data, which performs enrichment analyses using two steps. First, the joint effect of all SNPs within a gene is computed providing a gene&#8208;based <italic toggle="yes">P</italic>&#8208;value. Then, a multiple regression model is used to examine enrichment testing while accounting for linkage disequilibrium.<xref rid="pcn13869-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>, <xref rid="pcn13869-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>
</p></sec><sec id="pcn13869-sec-0018"><title>Step 6: Functional mapping and annotation</title><p>Finally, we utilized FUMA<xref rid="pcn13869-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> to annotate the top&#8208;associated miRNA target genes to a biological pathway. For both up&#8208; and down&#8208;regulated target genes, we examined enrichment by tissue type through studying overrepresentation in sets of differentially expressed genes for 30 general tissue types and 53 tissue types as based on tissue&#8208;specific expression patterns derived from GTEx RNA&#8208;seq v8.<xref rid="pcn13869-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> This results in an overview of biological functions of up&#8208; and downregulated target genes.</p></sec></sec><sec sec-type="results" id="pcn13869-sec-0019"><title>Results</title><sec id="pcn13869-sec-0020"><title>Participant characteristics</title><p>An overview of baseline participant characteristics and their relationship with depressive symptoms are shown in Table&#160;<xref rid="pcn13869-tbl-0001" ref-type="table">1</xref>. Female participants, on average, had stronger depressive symptoms compared to males.</p><table-wrap position="float" id="pcn13869-tbl-0001" content-type="Table" orientation="portrait"><label>Table 1</label><caption><p>Demographic characteristics and distribution of depressive symptoms (CES&#8208;D scale) for the study population</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Characteristics</th><th align="left" valign="bottom" rowspan="1" colspan="1">Count</th><th align="left" valign="bottom" rowspan="1" colspan="1">Mean (SD)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Median [25th&#8211;75th]</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="4" valign="top" rowspan="1">Age<xref rid="pcn13869-note-0003" ref-type="table-fn">
<sup>&#8224;</sup>
</xref>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&lt;60</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1158</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">6.62 (8.18)</td><td align="char" char="[" valign="top" rowspan="1" colspan="1">4 [1&#8211;9]</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">60&#8211;70</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1065</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">5.86 (7.39)</td><td align="char" char="[" valign="top" rowspan="1" colspan="1">3 [1&#8211;8]</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">70&#8211;80</td><td align="char" char="." valign="top" rowspan="1" colspan="1">398</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">5.43 (6.66)</td><td align="char" char="[" valign="top" rowspan="1" colspan="1">3 [1&#8211;7]</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&gt;80</td><td align="char" char="." valign="top" rowspan="1" colspan="1">82</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">5.7 (7.78)</td><td align="char" char="[" valign="top" rowspan="1" colspan="1">4 [1&#8211;7]</td></tr><tr><td align="left" colspan="4" valign="top" rowspan="1">Sex, n (%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Male</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1160</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">5.55 (7.09)</td><td align="char" char="[" valign="top" rowspan="1" colspan="1">3 [1&#8211;7]</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Female</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1543</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">6.62 (8.18)</td><td align="char" char="[" valign="top" rowspan="1" colspan="1">4 [1&#8211;9]</td></tr><tr><td align="left" colspan="4" valign="top" rowspan="1">Education</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Primary school</td><td align="char" char="." valign="top" rowspan="1" colspan="1">268</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">6.85 (9.01)</td><td align="char" char="[" valign="top" rowspan="1" colspan="1">4 [1&#8211;9]</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Lower</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1021</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">6.10 (7.65)</td><td align="char" char="[" valign="top" rowspan="1" colspan="1">3 [1&#8211;8]</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Intermediate</td><td align="char" char="." valign="top" rowspan="1" colspan="1">879</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">6.19 (7.86)</td><td align="char" char="[" valign="top" rowspan="1" colspan="1">3 [1&#8211;8]</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Higher</td><td align="char" char="." valign="top" rowspan="1" colspan="1">535</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">5.87 (7.04)</td><td align="char" char="[" valign="top" rowspan="1" colspan="1">4 [1&#8211;8]</td></tr><tr><td align="left" colspan="4" valign="top" rowspan="1">Smoking</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Never</td><td align="char" char="." valign="top" rowspan="1" colspan="1">923</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">5.90 (7.13)</td><td align="char" char="[" valign="top" rowspan="1" colspan="1">4 [1&#8211;8]</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Former</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1398</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">6.03 (7.51)</td><td align="char" char="[" valign="top" rowspan="1" colspan="1">3 [1&#8211;8]</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Current</td><td align="char" char="." valign="top" rowspan="1" colspan="1">382</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">7.27 (9.72)</td><td align="char" char="[" valign="top" rowspan="1" colspan="1">4 [1&#8211;9]</td></tr><tr><td align="left" colspan="4" valign="top" rowspan="1">BMI</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Below 18.5</td><td align="char" char="." valign="top" rowspan="1" colspan="1">17</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">9.76 (10.28)</td><td align="char" char="[" valign="top" rowspan="1" colspan="1">5 [1&#8211;17]</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">18.5&#8211;24.9</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1237</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">5.86 (7.43)</td><td align="char" char="[" valign="top" rowspan="1" colspan="1">3 [1&#8211;8]</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">25.0&#8211;29.9</td><td align="char" char="." valign="top" rowspan="1" colspan="1">696</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">6.24 (7.71)</td><td align="char" char="[" valign="top" rowspan="1" colspan="1">3 [1&#8211;8]</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">30.0 and Above</td><td align="char" char="." valign="top" rowspan="1" colspan="1">50</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">8.32 (9.94)</td><td align="char" char="[" valign="top" rowspan="1" colspan="1">4 [1&#8211;12]</td></tr></tbody></table><table-wrap-foot id="pcn13869-ntgp-0002"><fn id="pcn13869-note-0002"><p>The data are categorized by age, sex, education, and smoking status, and BMI. The count, mean (standard deviation), and median (the 25th&#8211;75th percentile range) for each category are reported.</p></fn><fn id="pcn13869-note-0003"><label>
<sup>&#8224;</sup>
</label><p>Age is in years.</p></fn></table-wrap-foot></table-wrap></sec><sec id="pcn13869-sec-0021"><title>Differential <styled-content style="fixed-case" toggle="no">miRNAs</styled-content> associated with depressive symptoms</title><p>We employed fully adjusted negative&#8208;binomial linear regression models to investigate the association between the expression levels of 591 miRNAs and the depressive symptoms scores (Fig.&#160;<xref rid="pcn13869-fig-0001" ref-type="fig">1a</xref>, Supplementary Material&#160;<xref rid="pcn13869-supitem-0001" ref-type="supplementary-material">1</xref>). Our exploratory analysis identified 38 miRNAs showing nominal associations with depressive symptoms (<italic toggle="yes">P</italic>&#8208;value &lt;0.05 and absolute effect estimate &gt;&#8201;=&#8201;0.1). For an estimate of 0.1, a one&#8208;unit increase in the log&#8208;transformed expression is associated with a 10.5% increase in the expected score on depressive symptoms, holding other variables constant. Of note, none of these associations remained significant after applying FDR multiple testing correction. The top associated miRNA was miR&#8208;6810&#8208;3p (<italic toggle="yes">P</italic>&#8208;value~0.001, beta&#8201;=&#8201;0.25, SE&#8201;=&#8201;0.08). Among the 38 nominally associated miRNAs, 23 were found to be upregulated (Fig.&#160;<xref rid="pcn13869-fig-0001" ref-type="fig">1b</xref>) and 15 miRNAs displayed downregulated expression (Fig.&#160;<xref rid="pcn13869-fig-0001" ref-type="fig">1c</xref>) in participants with higher scores on depressive symptoms.</p><fig position="float" fig-type="Fig." id="pcn13869-fig-0001" orientation="portrait"><label>Fig. 1</label><caption><p>Association of miRNAs with depressive symptoms. Panel (a) presents a volcano plot displaying the relationship between miRNAs and depressive symptom (CES&#8208;D) scores, highlighting miRNAs with significant <italic toggle="yes">P</italic>&#8208;values (y&#8208;axis) and regression coefficients (x&#8208;axis). Panels (b) and (c) show forest plots of the top upregulated (b) and downregulated (c) miRNAs with corresponding 95% confidence intervals.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="PCN-79-636-g002.jpg"/></fig><p>We next conducted some additional downstream analyses in order to assess the potential functional significance of the 38 identified miRNAs in depression by delving into their brain expression, putative target genes and relevant pathways. Despite our lack of miRNAs passing FDR correction; exploring the downstream enrichment, tissue&#8208;specific expression, and genetic overlap of these miRNAs may still prove informative. Taking the overlap in results between target genes from miRDB and miRTarBase led to the identification of 456 unique putative target genes, for which 241 were targets of upregulated miRNAs (Fig.&#160;<xref rid="pcn13869-supitem-0003" ref-type="supplementary-material">S2</xref>) and 246 were targets of downregulated miRNAs (Fig.&#160;<xref rid="pcn13869-supitem-0003" ref-type="supplementary-material">S3</xref>). The enrichment <italic toggle="yes">P</italic>&#8208;values for the targets of upregulated miRNAs and downregulated miRNAs, compared to the expected number of gene interactions at random versus the observed interactions in our results, are 2.33e<sup>&#8722;10</sup> and &lt;1.0e<sup>&#8722;16</sup>, respectively. A full list of the 38 miRNAs and their target genes is added as Supplementary Material&#160;<xref rid="pcn13869-supitem-0002" ref-type="supplementary-material">2</xref>.</p></sec><sec id="pcn13869-sec-0022"><title>Enrichment analysis</title><p>To further investigate the retrieved miRNA target genes, we proceeded with a functional enrichment analysis using STRING.<xref rid="pcn13869-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> This analysis was performed separately for the targets of up&#8208; and down&#8208;regulated miRNAs. Notably, both showed significant enrichment of head, brain, and (central) nervous system pathways. For the targets of upregulated miRNA, key associations emerged with terms like &#8216;Neuron to neuron synapse&#8217; and &#8216;Postsynaptic density&#8217;, as shown in Table&#160;<xref rid="pcn13869-tbl-0002" ref-type="table">2a</xref>. The targets of downregulated miRNA on the other hand provide terms as &#8216;Negative regulation of neurotransmitter secretion&#8217; and pathways related to EGFR and TGF&#8208;B, as shown in Table&#160;<xref rid="pcn13869-tbl-0002" ref-type="table">2b</xref>.</p><table-wrap position="float" id="pcn13869-tbl-0002" content-type="Table" orientation="portrait"><label>Table 2</label><caption><p>This table lists the pathways targeted by upregulated miRNAs</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Database</th><th align="center" valign="bottom" rowspan="1" colspan="1">Description</th><th align="center" valign="bottom" rowspan="1" colspan="1">Count in network</th><th align="center" valign="bottom" rowspan="1" colspan="1">Strength</th><th align="center" valign="bottom" rowspan="1" colspan="1">FDR</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="5" valign="top" rowspan="1">a. For 23 upregulated miRNAs</td></tr><tr><td align="left" style="padding-left:10%" rowspan="4" valign="top" colspan="1">Cellular Components (Gene Ontology)</td><td align="left" valign="top" rowspan="1" colspan="1">Neuron to neuron synapse</td><td align="center" valign="top" rowspan="1" colspan="1">18 of 355</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.63</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.0011</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Postsynaptic density</td><td align="center" valign="top" rowspan="1" colspan="1">15 of 324</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.59</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.0056</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anchoring junction</td><td align="center" valign="top" rowspan="1" colspan="1">36 of 1325</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.36</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.0032</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Synapse</td><td align="center" valign="top" rowspan="1" colspan="1">36 of 1350</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.35</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.0036</td></tr><tr><td align="left" style="padding-left:10%" rowspan="4" valign="top" colspan="1">Tissue expression</td><td align="left" valign="top" rowspan="1" colspan="1">Brain</td><td align="center" valign="top" rowspan="1" colspan="1">108 of 5733</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.2</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.0001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Nervous System</td><td align="center" valign="top" rowspan="1" colspan="1">112 of 6016</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.19</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.0001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Central Nervous System</td><td align="center" valign="top" rowspan="1" colspan="1">109 of 5825</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.19</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.0001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Head</td><td align="center" valign="top" rowspan="1" colspan="1">114 of 6642</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.16</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.0012</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">WikiPaths (UniProt)</td><td align="left" valign="top" rowspan="1" colspan="1">ErbB signaling pathway</td><td align="center" valign="top" rowspan="1" colspan="1">8 of 89</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.88</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.0156</td></tr><tr><td align="left" colspan="5" valign="top" rowspan="1">b. For 15 downregulated miRNAs</td></tr><tr><td align="left" style="padding-left:10%" rowspan="3" valign="top" colspan="1">Biological Process (Gene Ontology)</td><td align="left" valign="top" rowspan="1" colspan="1">ERBB2&#8208;ERBB4 signaling pathway</td><td align="center" valign="top" rowspan="1" colspan="1">3 of 5</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1.71</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.0071</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Negative regulation of neurotransmitter secretion</td><td align="center" valign="top" rowspan="1" colspan="1">3 of 11</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1.36</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.0308</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Epidermal growth factor receptor signaling pathway</td><td align="center" valign="top" rowspan="1" colspan="1">6 of 49</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1.02</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.0041</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Molecular Functioning (Gene Ontology)</td><td align="left" valign="top" rowspan="1" colspan="1">SMAD binding</td><td align="center" valign="top" rowspan="1" colspan="1">7 of 78</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.88</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.0370</td></tr><tr><td align="left" style="padding-left:10%" rowspan="3" valign="top" colspan="1">Tissue Expression</td><td align="left" valign="top" rowspan="1" colspan="1">Brain</td><td align="center" valign="top" rowspan="1" colspan="1">121 of 5733</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.25</td><td align="char" char="." valign="top" rowspan="1" colspan="1">8.51e&#8208;10</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Nervous system</td><td align="center" valign="top" rowspan="1" colspan="1">123 of 6016</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.24</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1.16e&#8208;09</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Head</td><td align="center" valign="top" rowspan="1" colspan="1">126 of 6642</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.21</td><td align="char" char="." valign="top" rowspan="1" colspan="1">6.05e&#8208;08</td></tr></tbody></table><table-wrap-foot id="pcn13869-ntgp-0003"><fn id="pcn13869-note-0004"><p>The &#8216;Count in Network&#8217; column shows the number of miRNAs involved in each pathway out of the total considered, while &#8216;Strength&#8217; indicates the pathway's relevance to the network of upregulated miRNAs. The &#8216;False Discovery Rate (FDR)&#8217; provides the adjusted <italic toggle="yes">P</italic>&#8208;value, indicating the significance of the pathway's association with the upregulated miRNAs.</p></fn></table-wrap-foot></table-wrap></sec><sec id="pcn13869-sec-0023"><title>Brain expression</title><p>We looked up the miRNATissueAtlas2<xref rid="pcn13869-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> to explore the expression patterns of 38 top&#8208;ranking miRNAs. We aimed to ascertain if these miRNAs displayed higher expression in the brain regions commonly affected in depression, such as the frontal lobe and hippocampus. MiRNAs nominally associated with depression displayed heightened expression in the brain, but the difference to non&#8208;associated miRNA was not statistically significant, albeit suggestive (<italic toggle="yes">P</italic>&#8201;=&#8201;0.054) (Fig.&#160;<xref rid="pcn13869-fig-0002" ref-type="fig">2</xref>).</p><fig position="float" fig-type="Fig." id="pcn13869-fig-0002" orientation="portrait"><label>Fig. 2</label><caption><p>Box plots illustrating the differential expression of 38 miRNAs associated with depressive symptoms across various brain regions. The comparison is between cases where the miRNA is associated with a high CES&#8208;D score (green) and non&#8208;associated cases (purple). The expression levels are log&#8208;transformed for normalization. Statistical significance is indicated by <italic toggle="yes">P</italic>&#8208;values from a Wilcoxon Signed Rank test.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="PCN-79-636-g001.jpg"/></fig></sec><sec id="pcn13869-sec-0024"><title>Genetic association study</title><p>We identified common SNPs located within the sequences of 38 miRNAs and their target genes, as described in the methods section. We then investigated these SNPs for significant associations with depression using previous genetic data.<xref rid="pcn13869-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> Given the number of tests we applied a significance threshold, adjusting for multiple testing with a corrected <italic toggle="yes">P</italic>&#8208;value of &lt;0.0001.</p><p>Five of the SNPs present in the summary statistics of the GWAS<xref rid="pcn13869-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> were found to be within the pre&#8208;miRNA base pairs of the identified miRNAs, but none of them were significantly associated. Further investigation revealed that 765 significantly associated unique SNPs (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.0001) were located within the miRNA target genes Fig.&#160;<xref rid="pcn13869-fig-0003" ref-type="fig">3</xref>. Of those, 682 were in the 14 gene targets of upregulated miRNAs (Fig.&#160;<xref rid="pcn13869-fig-0003" ref-type="fig">3a</xref>) and 454 were in 16 gene targets of downregulated miRNAs (Fig.&#160;<xref rid="pcn13869-fig-0003" ref-type="fig">3b</xref>). <italic toggle="yes">ERBB4</italic> was found to be a target of both upregulated and downregulated miRNAs.</p><fig position="float" fig-type="Fig." id="pcn13869-fig-0003" orientation="portrait"><label>Fig. 3</label><caption><p>Genomic Distribution of SNPs in miRNA Target Genes Associated with depressive symptoms. Panel (a) displays a Manhattan plot illustrating the significance of SNPs within genes targeted by upregulated miRNAs across chromosomes, with highlighted genes surpassing the threshold for suggestive significance. Panel (b) shows a similar distribution for SNPs in genes targeted by downregulated miRNAs, with key genes annotated above the line indicating the level of statistical significance against the backdrop of the genomic landscape. The genetic data presented in this figure were obtained from a combined GWAS conducted by Howard <italic toggle="yes">et al</italic>. in 2019.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="PCN-79-636-g003.jpg"/></fig></sec><sec id="pcn13869-sec-0025"><title>Gene based tests</title><p>We tested whether any of our three subsets of target genes (all, up&#8208;, and down&#8208;regulated) were enriched for association with depression based on GWAS summary statistics. For the target genes of upregulated miRNAs, this failed to yield a significant result (<italic toggle="yes">P</italic>&#8201;=&#8201;0.177), however, the selection targets of both up&#8208; and downregulated miRNAs (<italic toggle="yes">P</italic>&#8201;=&#8201;0.045) as well as the selection of exclusively targets of downregulated miRNAs (<italic toggle="yes">P</italic>&#8201;=&#8201;0.031) did show significantly enriched association statistics. This suggests that the positive finding for the combined set may be driven especially by the target genes of downregulated miRNAs. When we consider the selection of genes in our targets of downregulated miRNAs, the gene with the strongest association with depression was <italic toggle="yes">ERBB4</italic> (<italic toggle="yes">P</italic>&#8201;=&#8201;1.18&#8201;&#215;&#8201;10<sup>&#8722;</sup>
<sup>12</sup>). This finding suggests that not only <italic toggle="yes">ERBB4</italic> is involved in depression when examining on a SNP&#8208;level, as per our finding in the previous section, it is involved on a gene&#8208;level as well.</p></sec><sec id="pcn13869-sec-0026"><title>Functional mapping and annotation</title><p>We examined enrichment by tissue type through overrepresentation in pre&#8208;defined sets of differentially expressed genes for 30 general tissue types and 53 tissue types derived from GTEx RNA&#8208;seq v8.<xref rid="pcn13869-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> Notably we found that general brain tissue (Fig.&#160;<xref rid="pcn13869-supitem-0003" ref-type="supplementary-material">S4</xref>) as well as specific brain areas (Fig.&#160;<xref rid="pcn13869-supitem-0003" ref-type="supplementary-material">S5</xref>) including the nucleus accumbens, caudate nucleus, amygdala, cingulate cortex BA24, frontal cortex BA9, basal ganglia, hippocampus, hypothalamus, substantia nigra, and brain cortex were differentially expressed in our upregulated target genes. With the exception of the brain cortex, all these brain areas were both up&#8208; and downregulated themselves by our set of upregulated target genes. This may indicate that target genes of the miRNAs that were positively associated with depression were found to have a mixed effect on regulation in these brain areas. For the target genes of negatively associated miRNAs, we found the general brain tissue to be downregulated by these genes (Fig.&#160;<xref rid="pcn13869-supitem-0003" ref-type="supplementary-material">S6</xref>). This effect persisted when performing two&#8208;sided testing but not when testing for upregulation, suggesting a dilution of the signal in the two&#8208;sided test relative to the test for downregulation. Specific brain areas that showed downregulation by the target genes of our negatively associated miRNAs were the amygdala, putamen, caudate nucleus, brain cortex, hippocampus, anterior cingulate cortex BA24, substantia nigra, nucleus accumbens, frontal cortex BA9, hypothalamus, cerebellar hemisphere, and the cerebellum (Fig.&#160;<xref rid="pcn13869-supitem-0003" ref-type="supplementary-material">S7</xref>). For these specific brain areas, the target genes of our negatively associated miRNAs showed a downregulated effect. Only the cervical spinal cord showed significance in both up&#8208; and downregulated differentially expressed genes, suggesting a mixed signal deriving from the set of target genes of our negatively associated miRNAs.</p></sec></sec><sec sec-type="discussion" id="pcn13869-sec-0027"><title>Discussion</title><p>In this study, we examined plasma circulatory miRNAs profiles associated with depressive symptoms based on cohort data from over 2700 individuals from the general elderly population. We identified 38 miRNAs that were suggestively associated with depressive symptoms, including 23 upregulated and 15 downregulated miRNAs. Although these associations did not survive multiple testing correction, our down&#8208;stream <italic toggle="yes">in silico</italic> analyses of the indicative miRNAs and their putative target genes revealed enrichment for relevant molecular pathways, supporting their potential role in the pathophysiology of depression. These results provide preliminary insights, are exploratory and hypothesis&#8208;generating in nature, and warrant validation in future studies with larger and independent cohorts.</p><p>Several of the identified miRNAs in this study are in line with existing literature suggesting a role of these miRNAs in elderly age&#8208;related neural processes and mental disorders.<xref rid="pcn13869-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="pcn13869-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="pcn13869-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> Among the suggestive miRNAs identified as upregulated, miR&#8208;6810&#8208;3p is implicated in counteracting age&#8208;related macular degeneration and neurodegenerative processes.<xref rid="pcn13869-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> Moreover, miR&#8208;1202 has been shown to be upregulated in post&#8208;mortem brain tissue of people with Alzheimer's disease.<xref rid="pcn13869-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref> MiR&#8208;4505 expression in peripheral blood mononuclear cells was also negatively correlated with symptom severity in patients with general anxiety disorder.<xref rid="pcn13869-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> Furthermore, the 3p strand of miR&#8208;4505 is linked to Parkinson's disease, which plays a role in early neurodegeneration,<xref rid="pcn13869-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> a possible comorbidity suggesting a heterogeneous pathophysiology of depression over the lifespan. MiR&#8208;187&#8208;3p has been linked to anxiety disorders through downregulation after contextual fear conditioning in mice, modulating contextual fear memory in the hippocampus.<xref rid="pcn13869-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> Geaghan <italic toggle="yes">et al</italic>. found an enrichment of miRNA binding site variants among miR&#8208;31&#8208;5p targets in individuals with major depressive disorder, supporting its potential role in depression.<xref rid="pcn13869-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref> Elevated plasma levels of miR&#8208;193a&#8208;3p were found in schizophrenia patients. Given the high prevalence of depressive symptoms in schizophrenia, this finding may suggest a role of miR&#8208;193a&#8208;3p in mood regulation and warrants further investigation into the potential for shared molecular mechanisms across psychiatric disorders.<xref rid="pcn13869-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref>
</p><p>In the downregulated miRNAs group, miR&#8208;1249's anti&#8208;inflammatory properties suggest broader implications in stress and depression&#8208;related inflammation.<xref rid="pcn13869-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref> Let&#8208;7d has been associated with multiple psychiatric disorders, regulating dopamine D3 receptors and influencing neuropsychiatric pathways and showed improvement of depression&#8208; and anxiety&#8208;like behavior in mice.<xref rid="pcn13869-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> MiR&#8208;484 in plasma has been found to be downregulated in relation to bipolar disorder.<xref rid="pcn13869-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref> Furthermore, downregulation of miR&#8208;484 has been reported in association with late&#8208;life depression and elevated risk for dementia through synaptic plasticity, synaptic transmission, and mitochondrial fission.<xref rid="pcn13869-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref> Higher levels of miR&#8208;652&#8208;3p related to higher probabilities of bipolar disease when comparing euthymic bipolar patients under lithium treatment and healthy controls.<xref rid="pcn13869-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref> MiR&#8208;128&#8208;3p, implicated in Alzheimer's disease, suppresses tau phosphorylation and reduces amyloid&#8208;beta accumulation, potentially positioning it as a significant player in neurodegenerative processes.<xref rid="pcn13869-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref> Additionally, <italic toggle="yes">ERBB4</italic> was found to be one of the target genes of the downregulated group and contains rs11693031, which is related to depression.<xref rid="pcn13869-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref> Other than depression, ERBB4 was found to be related to Alzheimer's disease,<xref rid="pcn13869-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref> loneliness day,<xref rid="pcn13869-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref>, <xref rid="pcn13869-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref> and household income.<xref rid="pcn13869-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref>
</p><p>Among our findings were negative associations between depression and miRNAs identified in prior studies, such as let&#8208;7d&#8208;3p. This miRNA was identified in the context of depression before, although the direction of effect does not seem to be consistent with our findings. Let&#8208;7d&#8208;3p was found upregulated for major depressive disorder in both CSF (<italic toggle="yes">n</italic>&#8201;=&#8201;12) and serum (<italic toggle="yes">n</italic>&#8201;=&#8201;53), albeit in smaller sample sizes than the current study.<xref rid="pcn13869-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref> Although there is a chance of a false positive finding in either previous or current studies, this observation may also reflect an effect depending on study contexts such as age and population examined. For example, mean ages ranged between 32&#8201;years for cases and controls in CSF&#8208;samples, and 34&#8201;years in serum&#8208;samples, whereas our sample's mean age was 62&#8201;years.</p><p>Overall, our findings are suggestive and should therefore be interpreted with caution. Nevertheless, the identified miRNAs may represent interesting targets for future research and if replicated, could help in designing novel diagnostic tools. Currently, the diagnosis of depression relies heavily on clinical assessment, which is subjective.<xref rid="pcn13869-bib-0051" ref-type="bibr">
<sup>51</sup>
</xref>, <xref rid="pcn13869-bib-0052" ref-type="bibr">
<sup>52</sup>
</xref> The identified miRNAs in our study may represent candidate biomarkers which may eventually contribute to more precise and early diagnosis. Furthermore, understanding the target genes and pathways regulated by these miRNAs could open new avenues for therapeutic interventions, potentially leading to the development of miRNA&#8208;based therapies.</p><p>Our study has several strengths, which are outlined here. First, we leverage a large cohort, enhancing the statistical power and representativeness of findings relative to a middle&#8208;aged and elderly population. Second, our use of a targeted RNA&#8208;sequencing based method ensures high sensitivity and reproducibility, addressing limitations related to methodological inconsistencies in measurement noted in earlier research and covering a large number of human miRNAs.<xref rid="pcn13869-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="pcn13869-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> Third, we adjusted rigorously for multiple testing, which has been unevenly applied in many existing studies on miRNAs and behavioral outcomes. Additionally, as a population&#8208;based study, our work encompasses a broad, elderly demographic, extending our understanding of the relationship between miRNAs and dimensional depressive symptoms at an older age. Our study is also not without limitations. The cross&#8208;sectional and observational nature of our analysis limits our ability to infer causality. Longitudinal studies are needed to determine whether changes in plasma miRNA expression precede the onset of depressive symptoms or are a consequence of the disorder. Furthermore, while our sample size was relatively large compared to previous studies, it may still have limited power to detect small effect sizes after correction for multiple testing. This limitation could have contributed to the absence of significant findings after multiple testing correction. Based on our sample size, detectable associations are likely limited to miRNAs with moderate to large effect sizes. Mendelian Randomization may help assess potential causal links between identified miRNAs and depressive symptoms, strengthening biological interpretation beyond observational findings in future studies. However, this approach requires strong and valid genetic instruments for the miRNAs, which are currently lacking. Additionally, our study population is an elderly population of predominantly European descent, which may limit the generalizability of our findings to other age cohorts, such as adolescents, or to different ethnicities. Future studies should include more ethnically diverse populations to enhance the generalizability of the results. Finally, we highlighted target genes and pathways for suggestive miRNAs in our downstream analyses. These downstream analyses were based on nominally significant results, and permutation&#8208;based validation was not feasible due to limitations of the STRING tool, which restricts large&#8208;scale automated querying. Exploring the functional roles of these miRNAs in gene regulation in relevant cell or animal models could provide direct evidence of their involvement in depression&#8208;related pathways. Investigating interactions between these miRNAs and environmental factors, such as stress or trauma, could offer insights into the etiology of depression.</p><p>Collectively, we examined plasma circulatory miRNA profiles associated with depressive symptoms based on data from the general elderly population. Our findings suggest associations between several circulating miRNAs and depressive symptoms. Our follow&#8208;up <italic toggle="yes">in silico</italic> analyses highlight that miRNAs with the largest effect estimates did appear to be involved in important neurological and psychiatric processes, suggesting a possible role in the biological mechanisms of depression that warrant further validation.</p></sec><sec id="pcn13869-sec-0030"><title>Disclosure statement</title><p>The authors declare no conflict of interest.</p></sec><sec id="pcn13869-sec-0031"><title>Funding Information</title><p>The Rotterdam Study is supported by the Erasmus Medical Center and the Erasmus University Rotterdam, the Netherlands Organization for Scientific Research (NWO), the Netherlands Organization for Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture, and Science, the Ministry of Health, Welfare and Sports, the European Commission (DG XII), and the municipality of Rotterdam. MiRNA expression profiling was funded by the Janssen Prevention Center of Janssen Vaccines and Prevention BV, part of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson. The work of MK and MG was partly supported by the Erasmus MC Fellowship (EMCF20213) and Alzheimer Nederland (WE.03&#8208;2021&#8208;10) grants. The work of TF, AN and CAMC was supported the European Union's Horizon Europe Research and Innovation Programme (FAMILY, grant agreement No 101057529). AN and CAMC are supported by the European Research Council (TEMPO; grant agreement No 101039672). The work of CAMC is further supported by the European Union's Horizon 2020 Research and Innovation. Programme (EarlyCause, grant agreement No 848158). This research was conducted while CAMC was a Hevolution/AFAR New Investigator Awardee in Aging Biology and Geroscience Research. The mentioned funders had no role in the design and conduct of the study, nor in the decision to submit the manuscript for publication.</p></sec><sec id="pcn13869-sec-0032"><title>Author contributions</title><p>Conceptualization: MG. Data curation: MG, AIL. Formal analysis: MMK, TF. Funding acquisition: MG, CAMC. Investigation: MG, AIL. Methodology: MG, AN, CAMC. Project administration: MG. Resources: MG, AIL, MAI. Software: MMK, TF. Supervision: MG, AN, CAMC. Validation: MG, AN, CAMC. Visualization: MMK, TF. Writing &#8211; original draft: MMK, TF. Writing &#8211; review and editing: All authors.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="pcn13869-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Data S1.</bold> Supporting information.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PCN-79-636-s003.csv" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="pcn13869-supitem-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Data S2.</bold> Supporting information.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PCN-79-636-s002.csv" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="pcn13869-supitem-0003" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Data S3.</bold> Supporting information.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PCN-79-636-s001.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="pcn13869-sec-0033"><title>Acknowledgments</title><p>We are grateful to the study participants residing in Ommoord, their general practitioners, the staff at the research center, and the data management team for their invaluable efforts in contributing to the Rotterdam Study during all these years.</p></ack><sec sec-type="data-availability" id="pcn13869-sec-0029"><title>Data availability statement</title><p>The Rotterdam Study data can be made available to interested researchers upon request. Requests can be directed to data manager Frank J. A. van Rooij (<email>f.vanrooij@erasmusmc.nl</email>) or visit the following website for more information: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ergo-onderzoek.nl/contact" ext-link-type="uri" specific-use="software is-supplemented-by">https://www.ergo-onderzoek.nl/contact</ext-link>. We are unable to place data in a public repository due to the confidential nature of the data collected and legal and ethical constraints. The summary of the results from our miRNA projects are available through <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mirnomics.com/" ext-link-type="uri" specific-use="software is-supplemented-by">https://www.mirnomics.com/</ext-link>.</p></sec><ref-list content-type="cited-references" id="pcn13869-bibl-0001"><title>References</title><ref id="pcn13869-bib-0001"><label>1</label><mixed-citation publication-type="miscellaneous" id="pcn13869-cit-0001"><collab collab-type="authors">World&#8208;Health&#8208;Organisation</collab>
. <article-title>
Depressive disorder (depression)
</article-title>. <year>2023</year>.</mixed-citation></ref><ref id="pcn13869-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="pcn13869-cit-0002"><string-name name-style="western"><surname>Miao</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>J</given-names></string-name>. <article-title>The important roles of microRNAs in depression: New research progress and future prospects</article-title>. <source>J. Mol. Med. (Berl)</source><year>2021</year>; <volume>99</volume>: <fpage>619</fpage>&#8211;<lpage>636</lpage>.<pub-id pub-id-type="pmid">33641067</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00109-021-02052-8</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="pcn13869-cit-0003"><string-name name-style="western"><surname>Ding</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Su</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>Q</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>The role of microRNAs in depression</article-title>. <source>Front. Pharmacol.</source><year>2023</year>; <volume>14</volume>: <elocation-id>1129186</elocation-id>.<pub-id pub-id-type="pmid">37063278</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2023.1129186</pub-id><pub-id pub-id-type="pmcid">PMC10090555</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="pcn13869-cit-0004"><string-name name-style="western"><surname>Gao</surname><given-names>YN</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>YQ</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>YL</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>NM</given-names></string-name>. <article-title>A new player in depression: MiRNAs as modulators of altered synaptic plasticity</article-title>. <source>Int. J. Mol. Sci.</source><year>2022</year>; <volume>23</volume>: <fpage>4555</fpage>.<pub-id pub-id-type="pmid">35562946</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms23094555</pub-id><pub-id pub-id-type="pmcid">PMC9101307</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="pcn13869-cit-0005"><string-name name-style="western"><surname>Hassan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Amir</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Shahzadi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kloczkowski</surname><given-names>A</given-names></string-name>. <article-title>Therapeutic implications of microRNAs in depressive disorders: A review</article-title>. <source>Int. J. Mol. Sci.</source><year>2022</year>; <volume>23</volume>: <fpage>13530</fpage>.<pub-id pub-id-type="pmid">36362315</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms232113530</pub-id><pub-id pub-id-type="pmcid">PMC9658840</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="pcn13869-cit-0006"><string-name name-style="western"><surname>Rasheed</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Asghar</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Firdoos</surname><given-names>S</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>A systematic review of circulatory microRNAs in major depressive disorder: Potential biomarkers for disease prognosis</article-title>. <source>Int. J. Mol. Sci.</source><year>2022</year>; <volume>23</volume>: <fpage>1294</fpage>.<pub-id pub-id-type="pmid">35163214</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms23031294</pub-id><pub-id pub-id-type="pmcid">PMC8835958</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="pcn13869-cit-0007"><string-name name-style="western"><surname>Yi</surname><given-names>LT</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>BB</given-names></string-name>, <string-name name-style="western"><surname>Luo</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Geng</surname><given-names>D</given-names></string-name>. <article-title>BDNF&#8208;ERK&#8208;CREB signalling mediates the role of miR&#8208;132 in the regulation of the effects of oleanolic acid in male mice</article-title>. <source>J. Psychiatry Neurosci.</source><year>2014</year>; <volume>39</volume>: <fpage>348</fpage>&#8211;<lpage>359</lpage>.<pub-id pub-id-type="pmid">25079084</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1503/jpn.130169</pub-id><pub-id pub-id-type="pmcid">PMC4160364</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="pcn13869-cit-0008"><string-name name-style="western"><surname>Dwivedi</surname><given-names>Y</given-names></string-name>. <article-title>microRNA&#8208;124: A putative therapeutic target and biomarker for major depression</article-title>. <source>Expert Opin. Ther. Targets</source><year>2017</year>; <volume>21</volume>: <fpage>653</fpage>&#8211;<lpage>656</lpage>.<pub-id pub-id-type="pmid">28490207</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/14728222.2017.1328501</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="pcn13869-cit-0009"><string-name name-style="western"><surname>Gu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Pan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>L</given-names></string-name>. <article-title>MiR&#8208;124 suppression in the prefrontal cortex reduces depression&#8208;like behavior in mice</article-title>. <source>Biosci. Rep.</source><year>2019</year>; <volume>39</volume>: <elocation-id>BSR20190186</elocation-id>.<pub-id pub-id-type="pmid">31431514</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/BSR20190186</pub-id><pub-id pub-id-type="pmcid">PMC6744582</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="pcn13869-cit-0010"><string-name name-style="western"><surname>Roy</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Dunbar</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Shelton</surname><given-names>RC</given-names></string-name>, <string-name name-style="western"><surname>Dwivedi</surname><given-names>Y</given-names></string-name>. <article-title>Identification of MicroRNA&#8208;124&#8208;3p as a putative epigenetic signature of major depressive disorder</article-title>. <source>Neuropsychopharmacology</source><year>2017</year>; <volume>42</volume>: <fpage>864</fpage>&#8211;<lpage>875</lpage>.<pub-id pub-id-type="pmid">27577603</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/npp.2016.175</pub-id><pub-id pub-id-type="pmcid">PMC5312059</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="pcn13869-cit-0011"><string-name name-style="western"><surname>Gururajan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Naughton</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Scott</surname><given-names>KA</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>MicroRNAs as biomarkers for major depression: A role for let&#8208;7b and let&#8208;7c</article-title>. <source>Transl. Psychiatry</source><year>2016</year>; <volume>6</volume>: <elocation-id>e862</elocation-id>.<pub-id pub-id-type="pmid">27483380</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/tp.2016.131</pub-id><pub-id pub-id-type="pmcid">PMC5022079</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="pcn13869-cit-0012"><string-name name-style="western"><surname>Maffioletti</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Cattaneo</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rosso</surname><given-names>G</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Peripheral whole blood microRNA alterations in major depression and bipolar disorder</article-title>. <source>J. Affect. Disord.</source><year>2016</year>; <volume>200</volume>: <fpage>250</fpage>&#8211;<lpage>258</lpage>.<pub-id pub-id-type="pmid">27152760</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jad.2016.04.021</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="pcn13869-cit-0013"><string-name name-style="western"><surname>Scott</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Hoban</surname><given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>Clarke</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Moloney</surname><given-names>GM</given-names></string-name>, <string-name name-style="western"><surname>Dinan</surname><given-names>TG</given-names></string-name>, <string-name name-style="western"><surname>Cryan</surname><given-names>JF</given-names></string-name>. <article-title>Thinking small: Towards microRNA&#8208;based therapeutics for anxiety disorders</article-title>. <source>Expert Opin. Investig. Drugs</source><year>2015</year>; <volume>24</volume>: <fpage>529</fpage>&#8211;<lpage>542</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/13543784.2014.997873</pub-id><pub-id pub-id-type="pmid">25566796</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="pcn13869-cit-0014"><string-name name-style="western"><surname>Issler</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>A</given-names></string-name>. <article-title>Determining the role of microRNAs in psychiatric disorders</article-title>. <source>Nat. Rev. Neurosci.</source><year>2015</year>; <volume>16</volume>: <fpage>201</fpage>&#8211;<lpage>212</lpage>.<pub-id pub-id-type="pmid">25790865</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrn3879</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="pcn13869-cit-0015"><string-name name-style="western"><surname>Gillespie</surname><given-names>NA</given-names></string-name>, <string-name name-style="western"><surname>Kirk</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Evans</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Heath</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Hickie</surname><given-names>IB</given-names></string-name>, <string-name name-style="western"><surname>Martin</surname><given-names>NG</given-names></string-name>. <article-title>Do the genetic or environmental determinants of anxiety and depression change with age? A longitudinal study of Australian twins</article-title>. <source>Twin Res.</source><year>2004</year>; <volume>7</volume>: <fpage>39</fpage>&#8211;<lpage>53</lpage>.<pub-id pub-id-type="pmid">15053853</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1375/13690520460741435</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="pcn13869-cit-0016"><string-name name-style="western"><surname>Ikram</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Brusselle</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Ghanbari</surname><given-names>M</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Objectives, design and main findings until 2020 from the Rotterdam study</article-title>. <source>Eur. J. Epidemiol.</source><year>2020</year>; <volume>35</volume>: <fpage>483</fpage>&#8211;<lpage>517</lpage>.<pub-id pub-id-type="pmid">32367290</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10654-020-00640-5</pub-id><pub-id pub-id-type="pmcid">PMC7250962</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="pcn13869-cit-0017"><string-name name-style="western"><surname>Brown</surname><given-names>RAM</given-names></string-name>, <string-name name-style="western"><surname>Epis</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Horsham</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Kabir</surname><given-names>TD</given-names></string-name>, <string-name name-style="western"><surname>Richardson</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Leedman</surname><given-names>PJ</given-names></string-name>. <article-title>Total RNA extraction from tissues for microRNA and target gene expression analysis: Not all kits are created equal</article-title>. <source>BMC Biotechnol.</source><year>2018</year>; <volume>18</volume>: <fpage>16</fpage>.<pub-id pub-id-type="pmid">29548320</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12896-018-0421-6</pub-id><pub-id pub-id-type="pmcid">PMC5857145</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="pcn13869-cit-0018"><string-name name-style="western"><surname>Godoy</surname><given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>Barczak</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>DeHoff</surname><given-names>P</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Comparison of reproducibility, accuracy, sensitivity, and specificity of miRNA quantification platforms</article-title>. <source>Cell Rep.</source><year>2019</year>; <volume>29</volume>: <fpage>4212</fpage>&#8211;<lpage>4222 e5</lpage>.<pub-id pub-id-type="pmid">31851944</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2019.11.078</pub-id><pub-id pub-id-type="pmcid">PMC7499898</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="pcn13869-cit-0019"><string-name name-style="western"><surname>Yaqub</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mens</surname><given-names>MMJ</given-names></string-name>, <string-name name-style="western"><surname>Klap</surname><given-names>JM</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Genome&#8208;wide profiling of circulatory microRNAs associated with cognition and dementia</article-title>. <source>Alzheimers Dement.</source><year>2023</year>; <volume>19</volume>: <fpage>1194</fpage>&#8211;<lpage>1203</lpage>.<pub-id pub-id-type="pmid">35946915</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12752</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="pcn13869-cit-0020"><string-name name-style="western"><surname>Radloff</surname><given-names>LS</given-names></string-name>. <article-title>The CES&#8208;D scale: A self&#8208;report depression scale for research in the general population</article-title>. <source>Appl. Psychol. Measur.</source><year>1977</year>; <volume>1</volume>: <fpage>385</fpage>&#8211;<lpage>401</lpage>.</mixed-citation></ref><ref id="pcn13869-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="pcn13869-cit-0021"><string-name name-style="western"><surname>Beekman</surname><given-names>AT</given-names></string-name>, <string-name name-style="western"><surname>Deeg</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Van Limbeek</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Braam</surname><given-names>AW</given-names></string-name>, <string-name name-style="western"><surname>De Vries</surname><given-names>MZ</given-names></string-name>, <string-name name-style="western"><surname>Van Tilburg</surname><given-names>W</given-names></string-name>. <article-title>Criterion validity of the Center for Epidemiologic Studies Depression scale (CES&#8208;D): Results from a community&#8208;based sample of older subjects in The Netherlands</article-title>. <source>Psychol. Med.</source><year>1997</year>; <volume>27</volume>: <fpage>231</fpage>&#8211;<lpage>235</lpage>.<pub-id pub-id-type="pmid">9122304</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/s0033291796003510</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="pcn13869-cit-0022"><string-name name-style="western"><surname>Huang</surname><given-names>HY</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>YCD</given-names></string-name>, <string-name name-style="western"><surname>Cui</surname><given-names>S</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>miRTarBase update 2022: An informative resource for experimentally validated miRNA&#8208;target interactions</article-title>. <source>Nucleic Acids Res.</source><year>2022</year>; <volume>50</volume>: <fpage>D222</fpage>&#8211;<lpage>D230</lpage>.<pub-id pub-id-type="pmid">34850920</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkab1079</pub-id><pub-id pub-id-type="pmcid">PMC8728135</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="pcn13869-cit-0023"><string-name name-style="western"><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>. <article-title>miRDB: An online database for prediction of functional microRNA targets</article-title>. <source>Nucleic Acids Res.</source><year>2020</year>; <volume>48</volume>: <fpage>D127</fpage>&#8211;<lpage>D131</lpage>.<pub-id pub-id-type="pmid">31504780</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkz757</pub-id><pub-id pub-id-type="pmcid">PMC6943051</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="pcn13869-cit-0024"><string-name name-style="western"><surname>Szklarczyk</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Kirsch</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Koutrouli</surname><given-names>M</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>The STRING database in 2023: Protein&#8208;protein association networks and functional enrichment analyses for any sequenced genome of interest</article-title>. <source>Nucleic Acids Res.</source><year>2023</year>; <volume>51</volume>: <fpage>D638</fpage>&#8211;<lpage>D646</lpage>.<pub-id pub-id-type="pmid">36370105</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkac1000</pub-id><pub-id pub-id-type="pmcid">PMC9825434</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="pcn13869-cit-0025"><string-name name-style="western"><surname>Keller</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gr&#246;ger</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Tschernig</surname><given-names>T</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>miRNATissueAtlas2: An update to the human miRNA tissue atlas</article-title>. <source>Nucleic Acids Res.</source><year>2022</year>; <volume>50</volume>: <fpage>D211</fpage>&#8211;<lpage>D221</lpage>.<pub-id pub-id-type="pmid">34570238</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkab808</pub-id><pub-id pub-id-type="pmcid">PMC8728130</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="pcn13869-cit-0026"><string-name name-style="western"><surname>Wray</surname><given-names>NR</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Genome&#8208;wide association analyses identify 44 risk variants and refine the genetic architecture of major depression</article-title>. <source>Nat. Genet.</source><year>2018</year>; <volume>50</volume>: <fpage>668</fpage>&#8211;<lpage>681</lpage>.<pub-id pub-id-type="pmid">29700475</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-018-0090-3</pub-id><pub-id pub-id-type="pmcid">PMC5934326</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="pcn13869-cit-0027"><string-name name-style="western"><surname>Howard</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Adams</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Shirali</surname><given-names>M</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Genome&#8208;wide association study of depression phenotypes in UK biobank identifies variants in excitatory synaptic pathways</article-title>. <source>Nat. Commun.</source><year>2018</year>; <volume>9</volume>: <fpage>1470</fpage>.<pub-id pub-id-type="pmid">29662059</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-018-03819-3</pub-id><pub-id pub-id-type="pmcid">PMC5902628</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="pcn13869-cit-0028"><string-name name-style="western"><surname>Howard</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Adams</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Clarke</surname><given-names>TK</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Genome&#8208;wide meta&#8208;analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions</article-title>. <source>Nat. Neurosci.</source><year>2019</year>; <volume>22</volume>: <fpage>343</fpage>&#8211;<lpage>352</lpage>.<pub-id pub-id-type="pmid">30718901</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41593-018-0326-7</pub-id><pub-id pub-id-type="pmcid">PMC6522363</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="pcn13869-cit-0029"><string-name name-style="western"><surname>de Leeuw</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Mooij</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Heskes</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Posthuma</surname><given-names>D</given-names></string-name>. <article-title>MAGMA: Generalized gene&#8208;set analysis of GWAS data</article-title>. <source>PLoS Comput. Biol.</source><year>2015</year>; <volume>11</volume>: <elocation-id>e1004219</elocation-id>.<pub-id pub-id-type="pmid">25885710</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pcbi.1004219</pub-id><pub-id pub-id-type="pmcid">PMC4401657</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="pcn13869-cit-0030"><string-name name-style="western"><surname>Watanabe</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Taskesen</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>van Bochoven</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Posthuma</surname><given-names>D</given-names></string-name>. <article-title>Functional mapping and annotation of genetic associations with FUMA</article-title>. <source>Nat. Commun.</source><year>2017</year>; <volume>8</volume>: <fpage>1826</fpage>.<pub-id pub-id-type="pmid">29184056</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-017-01261-5</pub-id><pub-id pub-id-type="pmcid">PMC5705698</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="pcn13869-cit-0031"><collab collab-type="authors">GTEx Consortium</collab>
. <article-title>The GTEx consortium atlas of genetic regulatory effects across human tissues</article-title>. <source>Science</source><year>2020</year>; <volume>369</volume>: <fpage>1318</fpage>&#8211;<lpage>1330</lpage>.<pub-id pub-id-type="pmid">32913098</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aaz1776</pub-id><pub-id pub-id-type="pmcid">PMC7737656</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="pcn13869-cit-0032"><string-name name-style="western"><surname>Strafella</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Caputo</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Termine</surname><given-names>A</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Genetic determinants highlight the existence of shared etiopathogenetic mechanisms characterizing age&#8208;related macular degeneration and neurodegenerative disorders</article-title>. <source>Front. Neurol.</source><year>2021</year>; <volume>12</volume>: <elocation-id>626066</elocation-id>.<pub-id pub-id-type="pmid">34135841</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2021.626066</pub-id><pub-id pub-id-type="pmcid">PMC8200556</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="pcn13869-cit-0033"><string-name name-style="western"><surname>Henriques</surname><given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Machado&#8208;Silva</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Leite</surname><given-names>REP</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Genome&#8208;wide profiling and predicted significance of post&#8208;mortem brain microRNA in Alzheimer's disease</article-title>. <source>Mech. Ageing Dev.</source><year>2020</year>; <volume>191</volume>: <elocation-id>111352</elocation-id>.<pub-id pub-id-type="pmid">32920076</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mad.2020.111352</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="pcn13869-cit-0034"><string-name name-style="western"><surname>Chen</surname><given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>XY</given-names></string-name>, <string-name name-style="western"><surname>Niu</surname><given-names>W</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Correlation between the level of microRNA expression in peripheral blood mononuclear cells and symptomatology in patients with generalized anxiety disorder</article-title>. <source>Compr. Psychiatry</source><year>2016</year>; <volume>69</volume>: <fpage>216</fpage>&#8211;<lpage>224</lpage>.<pub-id pub-id-type="pmid">27423364</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.comppsych.2016.05.006</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="pcn13869-cit-0035"><string-name name-style="western"><surname>Soto</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Fern&#225;ndez</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bravo</surname><given-names>P</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Differential serum microRNAs in premotor LRRK2 G2019S carriers from Parkinson's disease</article-title>. <source>NPJ Parkinsons Dis.</source><year>2023</year>; <volume>9</volume>: <fpage>15</fpage>.<pub-id pub-id-type="pmid">36732514</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41531-023-00451-x</pub-id><pub-id pub-id-type="pmcid">PMC9894906</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="pcn13869-cit-0036"><string-name name-style="western"><surname>Zhao</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Cao</surname><given-names>J</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>miR&#8208;187&#8208;3p participates in contextual fear memory formation through modulating SATB2 expression in the hippocampus</article-title>. <source>Neuroreport</source><year>2020</year>; <volume>31</volume>: <fpage>909</fpage>&#8211;<lpage>917</lpage>.<pub-id pub-id-type="pmid">32568775</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/WNR.0000000000001484</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="pcn13869-cit-0037"><string-name name-style="western"><surname>Geaghan</surname><given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Reay</surname><given-names>WR</given-names></string-name>, <string-name name-style="western"><surname>Cairns</surname><given-names>MJ</given-names></string-name>. <article-title>MicroRNA binding site variation is enriched in psychiatric disorders</article-title>. <source>Hum. Mutat.</source><year>2022</year>; <volume>43</volume>: <fpage>2153</fpage>&#8211;<lpage>2169</lpage>.<pub-id pub-id-type="pmid">36217923</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/humu.24481</pub-id><pub-id pub-id-type="pmcid">PMC10947041</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="pcn13869-cit-0038"><string-name name-style="western"><surname>Wei</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yuan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>S</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Detection of circulating miRNA levels in schizophrenia</article-title>. <source>Am. J. Psychiatry</source><year>2015</year>; <volume>172</volume>: <fpage>1141</fpage>&#8211;<lpage>1147</lpage>.<pub-id pub-id-type="pmid">26183697</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1176/appi.ajp.2015.14030273</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="pcn13869-cit-0039"><string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>L</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Natural killer cell&#8208;derived exosomal miR&#8208;1249&#8208;3p attenuates insulin resistance and inflammation in mouse models of type 2 diabetes</article-title>. <source>Signal Transduct. Target. Ther.</source><year>2021</year>; <volume>6</volume>: <fpage>409</fpage>.<pub-id pub-id-type="pmid">34848693</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-021-00805-y</pub-id><pub-id pub-id-type="pmcid">PMC8632983</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="pcn13869-cit-0040"><string-name name-style="western"><surname>Bahi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Dreyer</surname><given-names>JL</given-names></string-name>. <article-title>Lentiviral&#8208;mediated up&#8208;regulation of let&#8208;7d microRNA decreases alcohol intake through down&#8208;regulating the dopamine D3 receptor</article-title>. <source>Eur. Neuropsychopharmacol.</source><year>2020</year>; <volume>37</volume>: <fpage>70</fpage>&#8211;<lpage>81</lpage>.<pub-id pub-id-type="pmid">32646740</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.euroneuro.2020.06.011</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="pcn13869-cit-0041"><string-name name-style="western"><surname>Ceylan</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Tufekci</surname><given-names>KU</given-names></string-name>, <string-name name-style="western"><surname>Keskinoglu</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Genc</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>&#214;zerdem</surname><given-names>A</given-names></string-name>. <article-title>Circulating exosomal microRNAs in bipolar disorder</article-title>. <source>J. Affect. Disord.</source><year>2020</year>; <volume>262</volume>: <fpage>99</fpage>&#8211;<lpage>107</lpage>.<pub-id pub-id-type="pmid">31726266</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jad.2019.10.038</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="pcn13869-cit-0042"><string-name name-style="western"><surname>Wingo</surname><given-names>TS</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Fan</surname><given-names>W</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Brain microRNAs associated with late&#8208;life depressive symptoms are also associated with cognitive trajectory and dementia</article-title>. <source>NPJ Genom. Med.</source><year>2020</year>; <volume>5</volume>: <fpage>6</fpage>.<pub-id pub-id-type="pmid">32047652</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41525-019-0113-8</pub-id><pub-id pub-id-type="pmcid">PMC7004995</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="pcn13869-cit-0043"><string-name name-style="western"><surname>Tekdemir</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Selvi</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Alt&#305;nba&#351;</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Ko&#231;ak</surname><given-names>N</given-names></string-name>. <article-title>Decreased miR&#8208;15b&#8208;5p/miR&#8208;155&#8208;5p levels and increased miR&#8208;134&#8208;5p/miR&#8208;652&#8208;3p levels among BD patients under lithium treatment</article-title>. <source>J. Affect. Disord.</source><year>2022</year>; <volume>317</volume>: <fpage>6</fpage>&#8211;<lpage>14</lpage>.<pub-id pub-id-type="pmid">36028011</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jad.2022.08.034</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="pcn13869-cit-0044"><string-name name-style="western"><surname>Li</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Poon</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>MicroRNA&#8208;128 suppresses tau phosphorylation and reduces amyloid&#8208;beta accumulation by inhibiting the expression of GSK3beta, APPBP2, and mTOR in Alzheimer's disease</article-title>. <source>CNS Neurosci. Ther.</source><year>2023</year>; <volume>29</volume>: <fpage>1848</fpage>&#8211;<lpage>1864</lpage>.<pub-id pub-id-type="pmid">36880288</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cns.14143</pub-id><pub-id pub-id-type="pmcid">PMC10324361</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="pcn13869-cit-0045"><string-name name-style="western"><surname>Thorp</surname><given-names>JG</given-names></string-name>, <string-name name-style="western"><surname>Campos</surname><given-names>AI</given-names></string-name>, <string-name name-style="western"><surname>Grotzinger</surname><given-names>AD</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Symptom&#8208;level modelling unravels the shared genetic architecture of anxiety and depression</article-title>. <source>Nat. Hum. Behav.</source><year>2021</year>; <volume>5</volume>: <fpage>1432</fpage>&#8211;<lpage>1442</lpage>.<pub-id pub-id-type="pmid">33859377</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41562-021-01094-9</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="pcn13869-cit-0046"><string-name name-style="western"><surname>Li</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wetten</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>L</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Candidate single&#8208;nucleotide polymorphisms from a genomewide association study of Alzheimer disease</article-title>. <source>Arch. Neurol.</source><year>2008</year>; <volume>65</volume>: <fpage>45</fpage>&#8211;<lpage>53</lpage>.<pub-id pub-id-type="pmid">17998437</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archneurol.2007.3</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="pcn13869-cit-0047"><string-name name-style="western"><surname>Day</surname><given-names>FR</given-names></string-name>, <string-name name-style="western"><surname>Ong</surname><given-names>KK</given-names></string-name>, <string-name name-style="western"><surname>Perry</surname><given-names>JRB</given-names></string-name>. <article-title>Elucidating the genetic basis of social interaction and isolation</article-title>. <source>Nat. Commun.</source><year>2018</year>; <volume>9</volume>: <fpage>2457</fpage>.<pub-id pub-id-type="pmid">29970889</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-018-04930-1</pub-id><pub-id pub-id-type="pmcid">PMC6030100</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="pcn13869-cit-0048"><string-name name-style="western"><surname>Nagel</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Watanabe</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Stringer</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Posthuma</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>van der Sluis</surname><given-names>S</given-names></string-name>. <article-title>Item&#8208;level analyses reveal genetic heterogeneity in neuroticism</article-title>. <source>Nat. Commun.</source><year>2018</year>; <volume>9</volume>: <fpage>905</fpage>.<pub-id pub-id-type="pmid">29500382</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-018-03242-8</pub-id><pub-id pub-id-type="pmcid">PMC5834468</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="pcn13869-cit-0049"><string-name name-style="western"><surname>Hill</surname><given-names>WD</given-names></string-name>, <string-name name-style="western"><surname>Davies</surname><given-names>NM</given-names></string-name>, <string-name name-style="western"><surname>Ritchie</surname><given-names>SJ</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Genome&#8208;wide analysis identifies molecular systems and 149 genetic loci associated with income</article-title>. <source>Nat. Commun.</source><year>2019</year>; <volume>10</volume>: <fpage>5741</fpage>.<pub-id pub-id-type="pmid">31844048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-019-13585-5</pub-id><pub-id pub-id-type="pmcid">PMC6915786</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="pcn13869-cit-0050"><string-name name-style="western"><surname>Wan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Identification of differential microRNAs in cerebrospinal fluid and serum of patients with major depressive disorder</article-title>. <source>PLoS One</source><year>2015</year>; <volume>10</volume>: <elocation-id>e0121975</elocation-id>.<pub-id pub-id-type="pmid">25763923</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0121975</pub-id><pub-id pub-id-type="pmcid">PMC4357380</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="pcn13869-cit-0051"><string-name name-style="western"><surname>Bilello</surname><given-names>JA</given-names></string-name>. <article-title>Seeking an objective diagnosis of depression</article-title>. <source>Biomark. Med.</source><year>2016</year>; <volume>10</volume>: <fpage>861</fpage>&#8211;<lpage>875</lpage>.<pub-id pub-id-type="pmid">27415130</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/bmm-2016-0076</pub-id></mixed-citation></ref><ref id="pcn13869-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="pcn13869-cit-0052"><string-name name-style="western"><surname>Smith</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Renshaw</surname><given-names>PF</given-names></string-name>, <string-name name-style="western"><surname>Bilello</surname><given-names>J</given-names></string-name>. <article-title>The diagnosis of depression: Current and emerging methods</article-title>. <source>Compr. Psychiatry</source><year>2013</year>; <volume>54</volume>: <fpage>1</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">22901834</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.comppsych.2012.06.006</pub-id><pub-id pub-id-type="pmcid">PMC5502713</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Brain Commun</journal-id><journal-id journal-id-type="iso-abbrev">Brain Commun</journal-id><journal-id journal-id-type="pmc-domain-id">3915</journal-id><journal-id journal-id-type="pmc-domain">braincomms</journal-id><journal-id journal-id-type="publisher-id">braincomms</journal-id><journal-title-group><journal-title>Brain Communications</journal-title></journal-title-group><issn pub-type="epub">2632-1297</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12492488</article-id><article-id pub-id-type="pmcid-ver">PMC12492488.1</article-id><article-id pub-id-type="pmcaid">12492488</article-id><article-id pub-id-type="pmcaiid">12492488</article-id><article-id pub-id-type="pmid">41048544</article-id><article-id pub-id-type="doi">10.1093/braincomms/fcaf345</article-id><article-id pub-id-type="publisher-id">fcaf345</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00310</subject><subject>AcademicSubjects/SCI01870</subject></subj-group></article-categories><title-group><article-title>Sulcal morphology in former American football players</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0004-2125-5923</contrib-id><name name-style="western"><surname>Jung</surname><given-names initials="LB">Leonard B</given-names></name><aff>
<institution>Department of Rehabilitation Medicine, NYU Grossman School of Medicine</institution>, <addr-line>New York, NY 10016</addr-line>, <country country="US">USA</country></aff><aff>
<institution>Psychiatry Neuroimaging Laboratory, Brigham and Women&#8217;s Hospital, Harvard Medical School</institution>, <addr-line>Boston, MA 02145</addr-line>, <country country="US">USA</country></aff><aff>
<institution>cBRAIN, Department of Child and Adolescent Psychiatry, Psychosomatics, and Psychotherapy, University Hospital, Ludwig-Maximilians-Universit&#228;t</institution>, <addr-line>Munich, Bavaria 80336</addr-line>, <country country="DE">Germany</country></aff><aff>
<institution>Department of Neurosurgery, University Hospital, Ludwig-Maximilians-Universit&#228;t</institution>, <addr-line>Munich, Bavaria 80336</addr-line>, <country country="DE">Germany</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mirmajlesi</surname><given-names initials="AS">Anya S</given-names></name><aff>
<institution>Department of Rehabilitation Medicine, NYU Grossman School of Medicine</institution>, <addr-line>New York, NY 10016</addr-line>, <country country="US">USA</country></aff><aff>
<institution>NYU Langone Concussion Center, NYU Langone Health</institution>, <addr-line>New York, NY 10016</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0002-5326-2090</contrib-id><name name-style="western"><surname>Stearns</surname><given-names initials="J">Jared</given-names></name><aff>
<institution>Department of Rehabilitation Medicine, NYU Grossman School of Medicine</institution>, <addr-line>New York, NY 10016</addr-line>, <country country="US">USA</country></aff><aff>
<institution>NYU Langone Concussion Center, NYU Langone Health</institution>, <addr-line>New York, NY 10016</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4408-3728</contrib-id><name name-style="western"><surname>Breedlove</surname><given-names initials="K">Katherine</given-names></name><aff>
<institution>Center for Clinical Spectroscopy, Department of Radiology, Brigham and Women&#8217;s Hospital, Harvard Medical School</institution>, <addr-line>Boston, MA 02115</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0008-3745-7270</contrib-id><name name-style="western"><surname>John</surname><given-names initials="O">Omar</given-names></name><aff>
<institution>Department of Rehabilitation Medicine, NYU Grossman School of Medicine</institution>, <addr-line>New York, NY 10016</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kim</surname><given-names initials="N">Nicholas</given-names></name><aff>
<institution>Psychiatry Neuroimaging Laboratory, Brigham and Women&#8217;s Hospital, Harvard Medical School</institution>, <addr-line>Boston, MA 02145</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wickham</surname><given-names initials="A">Alana</given-names></name><aff>
<institution>Psychiatry Neuroimaging Laboratory, Brigham and Women&#8217;s Hospital, Harvard Medical School</institution>, <addr-line>Boston, MA 02145</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Su</surname><given-names initials="Y">Yi</given-names></name><aff>
<institution>Banner Alzheimer's Institute, Arizona State University, and Arizona Alzheimer's Consortium</institution>, <addr-line>Phoenix, AZ 85006</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Protas</surname><given-names initials="H">Hillary</given-names></name><aff>
<institution>Banner Alzheimer's Institute, Arizona State University, and Arizona Alzheimer's Consortium</institution>, <addr-line>Phoenix, AZ 85006</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Baucom</surname><given-names initials="ZH">Zachary H</given-names></name><aff>
<institution>Department of Biostatistics, Boston University School of Public Health</institution>, <addr-line>Boston, MA 02118</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tuz-Zahra</surname><given-names initials="F">Fatima</given-names></name><aff>
<institution>Department of Biostatistics, Boston University School of Public Health</institution>, <addr-line>Boston, MA 02118</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2190-7608</contrib-id><name name-style="western"><surname>Tripodis</surname><given-names initials="Y">Yorghos</given-names></name><aff>
<institution>Department of Biostatistics, Boston University School of Public Health</institution>, <addr-line>Boston, MA 02118</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Daneshvar</surname><given-names initials="DH">Daniel H</given-names></name><aff>
<institution>Department of Physical Medicine and Rehabilitation, Harvard Medical School</institution>, <addr-line>Boston, MA 02115</addr-line>, <country country="US">USA</country></aff><aff>
<institution>Department of Physical Medicine and Rehabilitation, Massachusetts General Hospital</institution>, <addr-line>Boston, MA 02114</addr-line>, <country country="US">USA</country></aff><aff>
<institution>Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital</institution>, <addr-line>Boston, MA 02129</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wiegand</surname><given-names initials="TLT">Tim L T</given-names></name><aff>
<institution>Psychiatry Neuroimaging Laboratory, Brigham and Women&#8217;s Hospital, Harvard Medical School</institution>, <addr-line>Boston, MA 02145</addr-line>, <country country="US">USA</country></aff><aff>
<institution>cBRAIN, Department of Child and Adolescent Psychiatry, Psychosomatics, and Psychotherapy, University Hospital, Ludwig-Maximilians-Universit&#228;t</institution>, <addr-line>Munich, Bavaria 80336</addr-line>, <country country="DE">Germany</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Billah</surname><given-names initials="T">Tashrif</given-names></name><aff>
<institution>Psychiatry Neuroimaging Laboratory, Brigham and Women&#8217;s Hospital, Harvard Medical School</institution>, <addr-line>Boston, MA 02145</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pasternak</surname><given-names initials="O">Ofer</given-names></name><aff>
<institution>Psychiatry Neuroimaging Laboratory, Brigham and Women&#8217;s Hospital, Harvard Medical School</institution>, <addr-line>Boston, MA 02145</addr-line>, <country country="US">USA</country></aff><aff>
<institution>Department of Radiology, Brigham and Women&#8217;s Hospital, Harvard Medical School</institution>, <addr-line>Boston, MA 02115</addr-line>, <country country="US">USA</country></aff><aff>
<institution>Department of Psychiatry, Massachusetts General Hospital</institution>, <addr-line>Boston, MA 02114</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Heller</surname><given-names initials="C">Carina</given-names></name><aff>
<institution>Masonic Institute for the Developing Brain, University of Minnesota, Minneapolis, MN</institution>, <country country="US">USA</country></aff><aff>
<institution>Department of Pediatrics, University of Minnesota, Minneapolis, MN</institution>, <country country="US">USA</country></aff><aff>
<institution>Department of Psychological and Brain Sciences, University of California, Santa Barbara, CA</institution>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Im</surname><given-names initials="BS">Brian S</given-names></name><aff>
<institution>Department of Rehabilitation Medicine, NYU Grossman School of Medicine</institution>, <addr-line>New York, NY 10016</addr-line>, <country country="US">USA</country></aff><aff>
<institution>NYU Langone Concussion Center, NYU Langone Health</institution>, <addr-line>New York, NY 10016</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Datta</surname><given-names initials="S">Shae</given-names></name><aff>
<institution>NYU Langone Concussion Center, NYU Langone Health</institution>, <addr-line>New York, NY 10016</addr-line>, <country country="US">USA</country></aff><aff>
<institution>Department of Neurology, NYU Grossman School of Medicine</institution>, <addr-line>New York, NY 10016</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Coleman</surname><given-names initials="MJ">Michael J</given-names></name><aff>
<institution>Psychiatry Neuroimaging Laboratory, Brigham and Women&#8217;s Hospital, Harvard Medical School</institution>, <addr-line>Boston, MA 02145</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1045-2743</contrib-id><name name-style="western"><surname>Adler</surname><given-names initials="CH">Charles H</given-names></name><aff>
<institution>Department of Neurology, Mayo Clinic College of Medicine, Mayo Clinic Arizona</institution>, <addr-line>Scottsdale, AZ 85259</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bernick</surname><given-names initials="C">Charles</given-names></name><aff>
<institution>Cleveland Clinic Lou Ruvo Center for Brain Health</institution>, <addr-line>Las Vegas, NV 89106</addr-line>, <country country="US">USA</country></aff><aff>
<institution>Department of Neurology, University of Washington</institution>, <addr-line>Seattle, WA 98195</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Balcer</surname><given-names initials="LJ">Laura J</given-names></name><aff>
<institution>Department of Neurology, NYU Grossman School of Medicine</institution>, <addr-line>New York, NY 10016</addr-line>, <country country="US">USA</country></aff><aff>
<institution>Department of Population Health, NYU Grossman School of Medicine</institution>, <addr-line>New York, NY 10017</addr-line>, <country country="US">USA</country></aff><aff>
<institution>Department of Ophthalmology, NYU Grossman School of Medicine</institution>, <addr-line>New York, NY 10017</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8113-8428</contrib-id><name name-style="western"><surname>Alosco</surname><given-names initials="ML">Michael L</given-names></name><aff>
<institution>Department of Neurology, Boston University Alzheimer&#8217;s Disease Research Center and CTE Center, Boston University Chobanian &amp; Avedisian School of Medicine</institution>, <addr-line>Boston, MA 02118</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lin</surname><given-names initials="AP">Alexander P</given-names></name><aff>
<institution>Center for Clinical Spectroscopy, Department of Radiology, Brigham and Women&#8217;s Hospital, Harvard Medical School</institution>, <addr-line>Boston, MA 02115</addr-line>, <country country="US">USA</country></aff><aff>
<institution>Department of Radiology, Brigham and Women&#8217;s Hospital, Harvard Medical School</institution>, <addr-line>Boston, MA 02115</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cummings</surname><given-names initials="JL">Jeffrey L</given-names></name><aff>
<institution>Chambers-Grundy Center for Transformative Neuroscience, Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada</institution>, <addr-line>Las Vegas, Las Vegas, NV 89154</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Reiman</surname><given-names initials="EM">Eric M</given-names></name><aff>
<institution>Banner Alzheimer's Institute, Arizona State University, and Arizona Alzheimer's Consortium</institution>, <addr-line>Phoenix, AZ 85006</addr-line>, <country country="US">USA</country></aff><aff>
<institution>Department of Psychiatry, University of Arizona</institution>, <addr-line>Phoenix, AZ 85004</addr-line>, <country country="US">USA</country></aff><aff>
<institution>Department of Psychiatry, Arizona State University</institution>, <addr-line>Phoenix, AZ 85008</addr-line>, <country country="US">USA</country></aff><aff>
<institution>Neurogenomics Division, Translational Genomics Research Institute and Alzheimer&#8217;s Consortium</institution>, <addr-line>Phoenix, AZ 85004</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Stern</surname><given-names initials="RA">Robert A</given-names></name><aff>
<institution>Department of Neurology, Boston University Alzheimer&#8217;s Disease Research Center and CTE Center, Boston University Chobanian &amp; Avedisian School of Medicine</institution>, <addr-line>Boston, MA 02118</addr-line>, <country country="US">USA</country></aff><aff>
<institution>Department of Anatomy and Neurobiology, Boston University Chobanian &amp; Avedisian School of Medicine</institution>, <addr-line>Boston, MA 02118</addr-line>, <country country="US">USA</country></aff><aff>
<institution>Department of Neurosurgery, Boston University Chobanian &amp; Avedisian School of Medicine</institution>, <addr-line>Boston, MA 02118</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shenton</surname><given-names initials="ME">Martha E</given-names></name><aff>
<institution>Psychiatry Neuroimaging Laboratory, Brigham and Women&#8217;s Hospital, Harvard Medical School</institution>, <addr-line>Boston, MA 02145</addr-line>, <country country="US">USA</country></aff><aff>
<institution>Department of Radiology, Brigham and Women&#8217;s Hospital, Harvard Medical School</institution>, <addr-line>Boston, MA 02115</addr-line>, <country country="US">USA</country></aff><aff>
<institution>Department of Psychiatry, Massachusetts General Hospital</institution>, <addr-line>Boston, MA 02114</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bouix</surname><given-names initials="S">Sylvain</given-names></name><aff>
<institution>Department of Software Engineering and Information Technology, &#201;cole de Technologie Sup&#233;rieure, Universit&#233; du Qu&#233;bec</institution>, <addr-line>Montr&#233;al, QC H3C 1K3</addr-line>, <country country="CA">Canada</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1281-9286</contrib-id><name name-style="western"><surname>Koerte</surname><given-names initials="IK">Inga K</given-names></name><aff>
<institution>Psychiatry Neuroimaging Laboratory, Brigham and Women&#8217;s Hospital, Harvard Medical School</institution>, <addr-line>Boston, MA 02145</addr-line>, <country country="US">USA</country></aff><aff>
<institution>cBRAIN, Department of Child and Adolescent Psychiatry, Psychosomatics, and Psychotherapy, University Hospital, Ludwig-Maximilians-Universit&#228;t</institution>, <addr-line>Munich, Bavaria 80336</addr-line>, <country country="DE">Germany</country></aff><aff>
<institution>Department of Radiology, Brigham and Women&#8217;s Hospital, Harvard Medical School</institution>, <addr-line>Boston, MA 02115</addr-line>, <country country="US">USA</country></aff><aff>
<institution>Graduate School of Systemic Neurosciences, Ludwig-Maximilians-Universit&#228;t</institution>, <addr-line>Munich, Bavaria 82152</addr-line>, <country country="DE">Germany</country></aff><aff>
<institution>German Center for Child and Adolescent Health (DZKJ), Partner Site Munich</institution>, <addr-line>Munich, Bavaria 82152</addr-line>, <country country="DE">Germany</country></aff><xref rid="FM1" ref-type="author-notes"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5565-9633</contrib-id><name name-style="western"><surname>Arciniega</surname><given-names initials="H">Hector</given-names></name><aff>
<institution>Department of Rehabilitation Medicine, NYU Grossman School of Medicine</institution>, <addr-line>New York, NY 10016</addr-line>, <country country="US">USA</country></aff><aff>
<institution>NYU Langone Concussion Center, NYU Langone Health</institution>, <addr-line>New York, NY 10016</addr-line>, <country country="US">USA</country></aff><xref rid="fcaf345-cor1" ref-type="corresp"/><xref rid="FM1" ref-type="author-notes"/></contrib><contrib contrib-type="author"><collab>for the DIAGNOSE CTE Research Project
<contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Reiman</surname><given-names initials="E">Eric</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Su</surname><given-names initials="Y">Yi</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="K">Kewei</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Protas</surname><given-names initials="H">Hillary</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Boker</surname><given-names initials="C">Connie</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Alosco</surname><given-names initials="ML">Michael L</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Au</surname><given-names initials="R">Rhoda</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cantu</surname><given-names initials="RC">Robert C</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Farrer</surname><given-names initials="L">Lindsay</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Helm</surname><given-names initials="R">Robert</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Katz</surname><given-names initials="DI">Douglas I</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kowall</surname><given-names initials="N">Neil</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mez</surname><given-names initials="J">Jesse</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mercier</surname><given-names initials="G">Gustavo</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Otis</surname><given-names initials="J">James</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Stern</surname><given-names initials="RA">Robert A</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Weller</surname><given-names initials="J">Jason</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Simkin</surname><given-names initials="I">Irene</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Andino</surname><given-names initials="A">Alondra</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Conneely</surname><given-names initials="S">Shannon</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Diamond</surname><given-names initials="C">Courtney</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fagle</surname><given-names initials="T">Tessa</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Haller</surname><given-names initials="O">Olivia</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hunt</surname><given-names initials="T">Tennyson</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gullotti</surname><given-names initials="N">Nicole</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mariani</surname><given-names initials="M">Megan</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mayville</surname><given-names initials="B">Brian</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>McLaughlin</surname><given-names initials="K">Kathleen</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nanna</surname><given-names initials="M">Mary</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Platt</surname><given-names initials="T">Taylor</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pulukuri</surname><given-names initials="S">Surya</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rice</surname><given-names initials="F">Fiona</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sestak</surname><given-names initials="M">Madison</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>McClean</surname><given-names initials="M">Michael</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tripodis</surname><given-names initials="Y">Yorghos</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Annis</surname><given-names initials="D">Douglas</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chaisson</surname><given-names initials="C">Christine</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dixon</surname><given-names initials="DB">Diane B</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Finney</surname><given-names initials="C">Carolyn</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gallagher</surname><given-names initials="K">Kerrin</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hartlage</surname><given-names initials="K">Kaitlin</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lu</surname><given-names initials="J">Jun</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Martin</surname><given-names initials="B">Brett</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ojo</surname><given-names initials="E">Emmanuel</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Palmisano</surname><given-names initials="JN">Joseph N</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pine</surname><given-names initials="B">Brittany</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ramachandran</surname><given-names initials="J">Janani</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bouix</surname><given-names initials="S">Sylvain</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fitzsimmons</surname><given-names initials="J">Jennifer</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lin</surname><given-names initials="AP">Alexander P</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Koerte</surname><given-names initials="IK">Inga K</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pasternak</surname><given-names initials="O">Ofer</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shenton</surname><given-names initials="ME">Martha E</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Arcinieago</surname><given-names initials="H">Hector</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Billah</surname><given-names initials="T">Tashrif</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bonke</surname><given-names initials="E">Elena</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Breedlove</surname><given-names initials="K">Katherine</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Coello</surname><given-names initials="E">Eduardo</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Coleman</surname><given-names initials="MJ">Michael J</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jung</surname><given-names initials="L">Leonhard</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liao</surname><given-names initials="H">Huijun</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Loy</surname><given-names initials="M">Maria</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rizzoni</surname><given-names initials="E">Elizabeth</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schultz</surname><given-names initials="V">Vivian</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Silva</surname><given-names initials="A">Annelise</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Vessey</surname><given-names initials="B">Brynn</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wiegand</surname><given-names initials="TLT">Tim L T</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Banks</surname><given-names initials="S">Sarah</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bernick</surname><given-names initials="C">Charles</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Miller</surname><given-names initials="J">Jason</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ritter</surname><given-names initials="A">Aaron</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sabbagh</surname><given-names initials="M">Marwan</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>de la Cruz</surname><given-names initials="R">Raelynn</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Durant</surname><given-names initials="J">Jan</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Golceker</surname><given-names initials="M">Morgan</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Harmon</surname><given-names initials="N">Nicolette</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kaylegian</surname><given-names initials="K">Kaeson</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Long</surname><given-names initials="R">Rachelle</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nance</surname><given-names initials="C">Christin</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sandoval</surname><given-names initials="P">Priscilla</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Turner</surname><given-names initials="RW">Robert W</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Marek</surname><given-names initials="KL">Kenneth L</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Serrano</surname><given-names initials="A">Andrew</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Adler</surname><given-names initials="CH">Charles H</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dodick</surname><given-names initials="DW">David W</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Geda</surname><given-names initials="Y">Yonas</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wethe</surname><given-names initials="JV">Jennifer V</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Falk</surname><given-names initials="B">Bryce</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Duffy</surname><given-names initials="A">Amy</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Howard</surname><given-names initials="M">Marci</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Montague</surname><given-names initials="M">Michelle</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Osgood</surname><given-names initials="T">Thomas</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Babcock</surname><given-names initials="D">Debra</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bellgowan</surname><given-names initials="P">Patrick</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Balcer</surname><given-names initials="L">Laura</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Barr</surname><given-names initials="W">William</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Goldberg</surname><given-names initials="J">Judith</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wisniewski</surname><given-names initials="T">Thomas</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kirov</surname><given-names initials="I">Ivan</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lui</surname><given-names initials="Y">Yvonne</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Marmar</surname><given-names initials="C">Charles</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hasanaj</surname><given-names initials="L">Lisena</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Serrano</surname><given-names initials="L">Liliana</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Al-Kharafi</surname><given-names initials="A">Alhassan</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>George</surname><given-names initials="A">Allan</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Martin</surname><given-names initials="S">Sammie</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Riley</surname><given-names initials="E">Edward</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Runge</surname><given-names initials="W">William</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cummings</surname><given-names initials="JL">Jeffrey L</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Peskind</surname><given-names initials="ER">Elaine R</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Colasurdo</surname><given-names initials="E">Elizabeth</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Marcus</surname><given-names initials="DS">Daniel S</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gurney</surname><given-names initials="J">Jenny</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Greenwald</surname><given-names initials="R">Richard</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Johnson</surname><given-names initials="KA">Keith A</given-names></name></contrib></contrib-group></collab></contrib></contrib-group><author-notes><corresp id="fcaf345-cor1">Correspondence to: Hector Arciniega, PhD, Department of Rehabilitation Medicine, NYU Grossman School of Medicine, 240 East 38th Street, 17th Floor, New York, NY 10016, USA E-mail: <email>hector.arciniega@nyulangone.org</email></corresp><fn id="FM1"><p>Inga K Koerte and Hector Arciniega contributed equally to this work.</p></fn></author-notes><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub" iso-8601-date="2025-09-11"><day>11</day><month>9</month><year>2025</year></pub-date><volume>7</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">495905</issue-id><elocation-id>fcaf345</elocation-id><history><date date-type="received"><day>18</day><month>3</month><year>2025</year></date><date date-type="rev-recd"><day>06</day><month>8</month><year>2025</year></date><date date-type="accepted"><day>09</day><month>9</month><year>2025</year></date><date date-type="corrected-typeset"><day>03</day><month>10</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>11</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-06 17:25:22.027"><day>06</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025. Published by Oxford University Press on behalf of the Guarantors of Brain.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fcaf345.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fcaf345.pdf"/><abstract><title>Abstract</title><p>Repetitive head impacts are associated with structural brain changes and an increased risk for chronic traumatic encephalopathy, a progressive neurodegenerative disease that can only be diagnosed after death. Chronic traumatic encephalopathy is defined by the abnormal accumulation of phosphorylated tau protein, particularly at the depths of the superior frontal sulci, suggesting that sulcal morphology may serve as a relevant structural biomarker. Contact sport athletes, such as former football players, are at elevated risk due to their prolonged exposure to repetitive head impacts. Cortical atrophy linked to underlying tau accumulation may result in shallower and wider sulci, potentially making sulcal morphology an imaging marker for identifying individuals at risk for this disease. This study investigated sulcal morphological differences in former football players and examined associations with age, football-related exposure, clinical diagnosis of traumatic encephalopathy syndrome, levels of certainty for chronic traumatic encephalopathy pathology, neuropsychological performance, and positron emission tomography imaging using flortaucipir. We analysed structural magnetic resonance imaging data from 169 male former football players (mean age 57.2 (8.2) years, range 45&#8211;74) and 54 age-matched, unexposed asymptomatic male controls (mean age 59.4 (8.5) years, range 45&#8211;74). Sulcal depth and width were quantified using the CalcSulc, focusing on two regions in each hemisphere commonly affected by chronic traumatic encephalopathy pathology: the superior frontal and occipitotemporal sulci. Generalized least squares models were used to assess group differences and interactions with age and football exposure variables, including age of first exposure, total years played, and cumulative head impact exposure. An analysis of covariance evaluated relationships between sulcal morphology, clinical measures, and flortaucipir uptake, adjusting for age, race, body mass index, education, imaging site, apolipoprotein E4 status, and total intracranial volume. Former football players demonstrated significantly shallower sulcal depth in the left superior frontal sulcus compared to unexposed controls. Earlier age of first exposure and longer football careers were associated with greater widening of the left occipitotemporal sulcus. Higher cumulative head impact exposure was linked to reduced sulcal depth in the left superior frontal region. However, sulcal morphology was not associated with clinical diagnosis, levels of certainty, neuropsychological test performance, or flortaucipir imaging. These findings suggest that sulcal morphology may reflect cumulative exposure to repetitive head impacts, particularly in brain regions vulnerable to chronic traumatic encephalopathy pathology. Future ante- and post-mortem validation studies are needed to determine whether sulcal morphology can serve as a reliable <italic toggle="yes">in vivo</italic> biomarker of risk.</p></abstract><abstract abstract-type="teaser"><p>This study demonstrates that former football players show altered sulcal morphology in brain regions vulnerable to repetitive head impacts. Shallower and wider sulci were associated with earlier age of first exposure and longer play duration. Findings suggest sulcal morphology may serve as a structural marker of cumulative head impact exposure.</p></abstract><abstract abstract-type="graphical"><title>Graphical Abstract</title><p>
<fig position="anchor" id="fcaf345-fcaf345_ga" orientation="portrait"><label>Graphical Abstract</label><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcaf345_ga.jpg"/></fig>
</p></abstract><kwd-group><kwd>neuroimaging</kwd><kwd>structural MRI</kwd><kwd>sports-related head injury</kwd><kwd>repetitive head impact</kwd><kwd>former American football players</kwd></kwd-group><funding-group><award-group award-type="grant"><funding-source><institution-wrap><institution>National Institute of Neurological Disorders and Stroke</institution><institution-id institution-id-type="DOI">10.13039/100000065</institution-id></institution-wrap></funding-source><award-id>U01NS093334</award-id><award-id>R01NS100952</award-id><award-id>K00 NS113419</award-id><award-id>R21 NS140565</award-id></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Alzheimer&#8217;s Association</institution><institution-id institution-id-type="DOI">10.13039/100000957</institution-id></institution-wrap></funding-source><award-id>25AARG-NTF-1377286</award-id></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>National Institute on Minority Health and Health Disparities Loan Repayment Program</institution><institution-id institution-id-type="DOI">10.13039/100006545</institution-id></institution-wrap></funding-source><award-id>L32 MD016519</award-id></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Harvard&#8217;s Mind Brain and Behavior Young Investigator Award</institution></institution-wrap></funding-source></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Rainwater Charitable Foundation Tau Leadership Fellows Award</institution><institution-id institution-id-type="DOI">10.13039/100016608</institution-id></institution-wrap></funding-source></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Burroughs Wellcome Fund Postdoctoral Diversity Enrichment Program</institution><institution-id institution-id-type="DOI">10.13039/100000861</institution-id></institution-wrap></funding-source></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Black Men&#8217;s Brain Health Emerging Scholars Fellowship</institution></institution-wrap></funding-source></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Grass Foundations Henry Grass</institution></institution-wrap></funding-source></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>M.D. Rising Star in Neuroscience Award</institution></institution-wrap></funding-source></award-group></funding-group><counts><page-count count="16"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="fcaf345-s1"><title>Introduction</title><p>Repetitive head impacts (RHI) are associated with cognitive, functional and behavioural impairments and increase the risk of developing neurodegenerative diseases, including chronic traumatic encephalopathy (CTE).<sup><xref rid="fcaf345-B1" ref-type="bibr">1-3</xref></sup> CTE has been linked to participation in contact and collision sports, such as American football, where RHI is frequent.<sup><xref rid="fcaf345-B4" ref-type="bibr">4-9</xref></sup> Understanding the long-term consequences of RHI and identifying clinical and biomarker features indicative of CTE <italic toggle="yes">in vivo</italic> is critical for advancing early detection, refining diagnostic criteria and developing targeted interventions to mitigate disease progression.</p><p>Currently, one approach aimed at identifying CTE in living individuals relies on the clinical classification of symptoms outlined in the 2021 National Institute of Neurological Disorders and Stroke (NINDS) consensus diagnostic criteria for Traumatic Encephalopathy Syndrome (TES).<sup><xref rid="fcaf345-B10" ref-type="bibr">10</xref></sup> Following a TES diagnosis, a level of certainty for CTE pathology (suggestive, possible, probable or definite CTE with TES) can be assigned. However, this classification relies solely on the progression of clinical symptoms and supportive clinical features without the incorporation of objective biomarkers.<sup><xref rid="fcaf345-B10" ref-type="bibr">10</xref></sup> Identifying and validating supportive biomarkers, such as neuroimaging and blood-based markers, may improve the accuracy of CTE diagnosis and further elucidate the pathological consequences of RHI. Among potential neuroimaging biomarkers, positron emission tomography (PET) has emerged as a promising tool for detecting pathological changes associated with CTE. Preliminary evidence suggests that flortaucipir PET binding is associated with CTE pathology, but its specificity for tau aggregation in CTE remains under investigation.<sup><xref rid="fcaf345-B11" ref-type="bibr">11</xref>,<xref rid="fcaf345-B12" ref-type="bibr">12</xref></sup> Further research is required to determine the relationship between flortaucipir retention and structural brain changes in regions known to be affected by CTE pathology.</p><p>One possible approach for identifying <italic toggle="yes">in vivo</italic> biomarkers of RHI and CTE involves examining neuroanatomical alterations in individuals at increased risk, such as former American football players.<sup><xref rid="fcaf345-B1" ref-type="bibr">1-3</xref>,<xref rid="fcaf345-B13" ref-type="bibr">13-15</xref></sup> Structural magnetic resonance imaging (MRI) provides an opportunity to investigate cortical features that may serve as surrogate markers of neurodegeneration in CTE. Notably, postmortem studies have demonstrated that phosphorylated tau (p-tau) aggregates in CTE are predominantly localized to the depths of the frontal and temporal sulci.<sup><xref rid="fcaf345-B2" ref-type="bibr">2</xref>,<xref rid="fcaf345-B3" ref-type="bibr">3</xref>,<xref rid="fcaf345-B16" ref-type="bibr">16</xref>,<xref rid="fcaf345-B17" ref-type="bibr">17</xref></sup> As the disease progresses, the accumulation of tau pathology and neurodegeneration leads to cortical atrophy, potentially resulting in sulcal widening and shallowing where such structural alterations may serve as quantifiable markers of disease progression.<sup><xref rid="fcaf345-B4" ref-type="bibr">4</xref>,<xref rid="fcaf345-B6" ref-type="bibr">6</xref>,<xref rid="fcaf345-B18" ref-type="bibr">18</xref></sup> Unlike traditional morphometric metrics such as cortical thickness, volume, or surface area, sulcal measures may provide enhanced sensitivity to these focal pathological changes, particularly given the preferential accumulation of tau in sulcal depths. Sulcal widening and shallowing have also been observed in other neurodegenerative conditions, including Alzheimer's disease, where these morphological changes are frequently detected in medial temporal regions.<sup><xref rid="fcaf345-B19" ref-type="bibr">19-22</xref></sup> Given the distinct localization of tau pathology in CTE, it is plausible that sulcal morphological alterations, specifically, shallower and wider sulci in the frontal and temporal cortices, may serve as indicators of CTE risk in individuals with a history of RHI.<sup><xref rid="fcaf345-B2" ref-type="bibr">2</xref>,<xref rid="fcaf345-B3" ref-type="bibr">3</xref>,<xref rid="fcaf345-B18" ref-type="bibr">18</xref>,<xref rid="fcaf345-B23" ref-type="bibr">23</xref>,<xref rid="fcaf345-B24" ref-type="bibr">24</xref></sup> These structural changes may reflect underlying neurodegenerative processes, including tau-mediated neurotoxicity, neuroinflammation and cortical atrophy, which are hypothesized to contribute to disease onset and progression.<sup><xref rid="fcaf345-B2" ref-type="bibr">2-5</xref>,<xref rid="fcaf345-B18" ref-type="bibr">18</xref>,<xref rid="fcaf345-B23" ref-type="bibr">23</xref>,<xref rid="fcaf345-B25" ref-type="bibr">25</xref>,<xref rid="fcaf345-B26" ref-type="bibr">26</xref></sup> Investigating sulcal morphology in at-risk populations may provide critical insights into the detection and staging of CTE, ultimately informing biomarker development and potential intervention strategies.</p><p>In this study, we investigated four main hypotheses. First, we assess <italic toggle="yes">in vivo</italic> sulcal morphometric changes in former American football players, focusing on the superior frontal and temporal lobes&#8212;regions implicated in postmortem CTE pathology.<sup><xref rid="fcaf345-B3" ref-type="bibr">3</xref>,<xref rid="fcaf345-B4" ref-type="bibr">4</xref>,<xref rid="fcaf345-B16" ref-type="bibr">16</xref>,<xref rid="fcaf345-B26" ref-type="bibr">26</xref>,<xref rid="fcaf345-B27" ref-type="bibr">27</xref></sup> We hypothesize that these individuals will exhibit shallower sulcal depth and wider sulci compared to unexposed asymptomatic controls. Second, we investigate the relationship between sulcal morphology, age and RHI-related exposure factors [age of first exposure, total years in football, cumulative head impact index (CHII) measures, including frequency, linear acceleration and rotational force]. We hypothesize that greater age and RHI exposure will be associated with increased sulcal widening and shallowing, suggesting a dose&#8211;response relationship contributing to the development of CTE pathology. Third, we hypothesize that former American football players with TES will exhibit distinct sulcal morphological differences compared to those without TES. Additionally, we expect that football players with higher levels of certainty for CTE pathology will show increased sulcal widening and shallowing, further linking clinical symptoms and diagnosis to underlying neuroanatomical changes associated with CTE. Finally, we hypothesize that these sulcal alterations will correlate with higher flortaucipir uptake on PET imaging, suggesting a potential relationship between structural changes and tau pathology in CTE.</p></sec><sec sec-type="materials|methods" id="fcaf345-s2"><title>Materials and methods</title><sec id="fcaf345-s2.1"><title>Study design and participants</title><p>This study is part of the Diagnostics, Imaging, And Genetics Network for the Objective Study and Evaluation of Chronic Traumatic Encephalopathy (DIAGNOSE CTE) Research Project.<sup><xref rid="fcaf345-B28" ref-type="bibr">28</xref></sup> Data were collected from September 2016 to February 2020 at Boston University Chobanian &amp; Avedisian School of Medicine (MRI data collection at Brigham and Women&#8217;s Hospital), New York University Langone Medical Center, Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas and the Mayo Clinic in Arizona (PET data collection at Banner Alzheimer&#8217;s Institute). All study sites received approval from their Institutional Review Board, and all participants provided written informed consent before enrolment. The DIAGNOSE CTE Research Project employed an open recruitment strategy to ensure an unbiased approach to recruitment.<sup><xref rid="fcaf345-B28" ref-type="bibr">28</xref></sup> The college football group includes individuals who played &#8805;6 years of organized football, including &#8805;3 years at the collegiate varsity level, and did not participate in contact or collision sports after college. The professional football group includes individuals with &#8805;12 years of organized play, including &#8805;3 years in both college and the National Football League (NFL). Only those who played high-exposure positions (offensive/defensive linemen, linebackers, running backs, receivers or defensive backs) are eligible; quarterbacks and kickers are excluded due to their lower exposure risk. All football-exposed participants must be English-speaking males aged 45&#8211;74 and meet general health and safety criteria for imaging and biomarker procedures. The unexposed asymptomatic control group comprises individuals with no history of participation in organized contact/collision sports and military combat. They must be asymptomatic at screening (no current mood, behavioural, cognitive or functional complaints), have no history of traumatic brain injury (TBI), psychiatric illness or cognitive impairment, and possess at least 2 years of post-secondary education. We provide detailed study inclusion criteria in <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig 1</xref> and <xref rid="sup1" ref-type="supplementary-material">Supplementary Table 1</xref>. This transparent approach helped mitigate potential biases in participant selection and ensured a more representative sample for the study.</p><p>A total of 240 participants were enrolled in the study, including 180 former American football players (120 professional football players, 60 former college players) and 60 unexposed asymptomatic control participants with no history of RHI, TBI or prior participation in organized sports. Data from 11 former American football players and two unexposed asymptomatic controls were excluded from the analyses because of poor quality and/or incomplete structural MRIs. Furthermore, at follow-up, four controls reported prior RHI exposure/head injury or long-standing psychiatric illness and were therefore excluded from the analyses. The final sample consisted of 169 former American football players (114 former professional and 55 former college players) and 54 unexposed asymptomatic controls who had no history of RHI exposure, TBI, or long-standing psychiatric illness.</p></sec><sec id="fcaf345-s2.2"><title>Sample characteristics</title><p>Semi-structured interviews and online questionnaires were used to acquire information about demographics (e.g. age, education, race and ethnicity), clinical history, athletic history, military involvement and TBI history [number, type, severity and timing of injuries, as well as exposure to RHI across different contexts (e.g. sports, military, occupational)]. Age was analysed as a continuous variable. Education was defined by total years in school (e.g. high school graduate = 12 years). Race and ethnicity were coded using the Office of Management and Budget Directive 15 definitions of racial and ethnic categories, and participants could select more than one race or ethnicity. Body mass index (BMI) was calculated using the participant's height and weight. Apolipoprotein E <italic toggle="yes">&#949;</italic>4 (APOE4) genotyping was performed for each participant. See <xref rid="fcaf345-T1" ref-type="table">Table 1</xref> for all cohort characteristics and <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig 1</xref> and <xref rid="sup1" ref-type="supplementary-material">Supplementary Table 1</xref> for recruitment information.</p><table-wrap position="float" id="fcaf345-T1" orientation="portrait"><label>Table 1</label><caption><p>Cohort demographics</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Former football players<break/>(<italic toggle="yes">n</italic> = 169)</th><th align="center" rowspan="1" colspan="1">Unexposed asymptomatic controls<break/>(<italic toggle="yes">n</italic> = 54)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Primary demographics</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Age</td><td rowspan="1" colspan="1">57.2 y (8.2), [45&#8211;74 y]</td><td rowspan="1" colspan="1">59.4 y (8.5), [45&#8211;74 y]</td></tr><tr><td rowspan="1" colspan="1">BMI kg/m<sup>2</sup></td><td rowspan="1" colspan="1">32.7 (4.7), [22.8&#8211;47.4]</td><td rowspan="1" colspan="1">31 (4.6), [23.7&#8211;43.5]</td></tr><tr><td rowspan="1" colspan="1">Education</td><td rowspan="1" colspan="1">16.7 y (1.5), [15&#8211;27 y]</td><td rowspan="1" colspan="1">17.2 y (3.4), [13&#8211;30 y]</td></tr><tr><td rowspan="1" colspan="1">Apolipoprotein 4 carriers<sup><xref rid="tblfn3" ref-type="table-fn">a</xref></sup></td><td rowspan="1" colspan="1">47 (28%)</td><td rowspan="1" colspan="1">10 (18.5%)</td></tr><tr><td rowspan="1" colspan="1">Race</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;White</td><td rowspan="1" colspan="1">108 (64%)</td><td rowspan="1" colspan="1">34 (63%)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Black/African American</td><td rowspan="1" colspan="1">58 (34%)</td><td rowspan="1" colspan="1">19 (35.2%)</td></tr><tr><td rowspan="1" colspan="1">&#8195;American Indian/Alaska Native</td><td rowspan="1" colspan="1">0 (0%)</td><td rowspan="1" colspan="1">0 (0%)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Asian</td><td rowspan="1" colspan="1">0 (0%)</td><td rowspan="1" colspan="1">0 (0%)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Native Hawaiian/Other Pacific Islander</td><td rowspan="1" colspan="1">0 (0%)</td><td rowspan="1" colspan="1">1 (1.8%)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Multiple Races</td><td rowspan="1" colspan="1">3 (2%)</td><td rowspan="1" colspan="1">0 (0%)</td></tr><tr><td rowspan="1" colspan="1">Exposure to RHIs</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Total years in Football</td><td rowspan="1" colspan="1">16y (4.3), [6&#8211;25 y]</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Age of first exposure</td><td rowspan="1" colspan="1">11.1 y (2.8), [4&#8211;18 y]</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Cumulative head impact index seasons</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Frequency</td><td rowspan="1" colspan="1">10 895 (4691), [3560&#8211;28 020]</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Linear acceleration (g)</td><td rowspan="1" colspan="1">228 327 (73 362), [79 212&#8211;446 257]</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Rotational force (rad/s<sup>2</sup>)</td><td rowspan="1" colspan="1">18 302 568 (6 448 603), [6 053 874&#8211;44 072 194]</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">PET SUVR</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Superior frontal</td><td rowspan="1" colspan="1">1.1(0.09)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Superior temporal</td><td rowspan="1" colspan="1">1.02 (0.06)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Traumatic encephalopathy syndrome</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Traumatic encephalopathy Syndrome diagnosis (%)<sup><xref rid="tblfn4" ref-type="table-fn">b</xref></sup></td><td rowspan="1" colspan="1">107 (63%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Neuropsychological evaluations</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;MoCA</td><td rowspan="1" colspan="1">24.7 (3.4) [11&#8211;30]</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;NAB list learning<sup><xref rid="tblfn5" ref-type="table-fn">c</xref></sup></td><td rowspan="1" colspan="1">5.1 (3.0) [0&#8211;11]</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Trails A</td><td rowspan="1" colspan="1">31.3 (13.3) [12.2&#8211;118]</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Trails B</td><td rowspan="1" colspan="1">82.1 (47.2) [29&#8211;300]</td><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><p>Overview of cohort characteristics including demographics of 169 former football players and 54 unexposed asymptomatic control participants. Values represent mean, (standard deviation) [range].</p></fn><fn id="tblfn2"><p>RHI, repetitive head impacts; y, years.</p></fn><fn id="tblfn3"><p>
<sup>a</sup>Apolipoprotein 4 carrier analysis was only available for 210 participants.</p></fn><fn id="tblfn4"><p>
<sup>b</sup>Traumatic Encephalopathy Syndrome diagnosis is missing for one participant.</p></fn><fn id="tblfn5"><p>
<sup>c</sup>One participant is missing the NAB List Learning Long Delay, and one other participant was missing all neuropsychological evaluations.</p></fn></table-wrap-foot></table-wrap></sec><sec id="fcaf345-s2.3"><title>MRI acquisition</title><p>All study participants underwent a head MRI scan at one of the four sites or their corresponding imaging centres. All scans followed the same imaging acquisition protocol, with total acquisition time lasting approximately 50&#8211;60&#8197;min, as part of a multi-sequence neuroimaging protocol and used the same 3T scanner model (Siemens Magnetom Skyra, Erlangen, Germany; software version VE11) with a 20-channel head coil across the four sites. The protocol included structural, diffusion and functional MRI scans. Relevant to this study is the high resolution (1 &#215; 1 &#215; 1&#8197;mm<sup>3</sup>) 3D T1-weighted (T1w) magnetization-prepared-rapid-gradient-echo (MPRAGE) sequence (inversion time = 1100&#8197;ms, TR = 2530&#8197;ms, TE = 3.36&#8197;ms, 7-degree flip angle, 256 FOV) and the high resolution (1 &#215; 1 &#215; 1&#8197;mm<sup>3</sup>) and the 3D T2-weighted (T2w) Sampling-Perfection-with-Application-optimized-Contrasts-by-using-flip-angle-Evolution (SPACE) sequence (TR = 3200&#8197;ms, TE = 412&#8197;ms, 256 FOV).</p></sec><sec id="fcaf345-s2.4"><title>MRI processing and calculation of sulcal morphology</title><p>The raw images were visually inspected for completeness, distortion and motion artefacts using 3D Slicer (version 4.10, Surgical Planning Laboratory, Brigham and Women&#8217;s Hospital, Boston, MA, USA). Brain masking was performed for all T1w and T2w scans using custom tools developed by the Psychiatry Neuroimaging Laboratory<sup><xref rid="fcaf345-B29" ref-type="bibr">29</xref>,<xref rid="fcaf345-B30" ref-type="bibr">30</xref></sup> and further processed with FreeSurfer v7.1. to generate volumetric segmentations and parcellations of cortical and subcortical structures according to the Destrieux atlas.<sup><xref rid="fcaf345-B31" ref-type="bibr">31-37</xref></sup> All FreeSurfer segmentations were quality controlled by blinded raters. Following this, we calculated the local gyrification index using FreeSurfer.<sup><xref rid="fcaf345-B38" ref-type="bibr">38</xref></sup> Calculations of sulcal width and depth were then extracted using the CalcSulc toolbox in MATLAB (The MathWorks, Natick, MA).<sup><xref rid="fcaf345-B39" ref-type="bibr">39</xref></sup> Sulcal morphology measures were extracted from the CalcSulc output, encompassing eight regions of interest in both the left and right hemispheres, resulting in 16 regions. However, six of the eight regions are not usually affected by CTE neuropathology. Thus, to investigate the regions implicated in CTE pathology, our analysis focused a priori on two anatomical regions, the superior frontal and the medial occipitotemporal and lingual sulcus (closest approximation to the temporal lobe) regions in both the left and right hemispheres resulting in a total of four regions of interest; see <xref rid="fcaf345-F1" ref-type="fig">Fig. 1</xref> for region locations; image was created using <italic toggle="yes">fsbrain.</italic><sup><xref rid="fcaf345-B40" ref-type="bibr">40</xref></sup> In <xref rid="sup1" ref-type="supplementary-material">Supplementary Tables 2</xref> and <xref rid="sup1" ref-type="supplementary-material">3</xref>, we provide estimates and confidence intervals for the depth and width of sulci across a total of 16 regions as calculated using CalcSulc.</p><fig position="float" id="fcaf345-F1" fig-type="figure" orientation="portrait"><label>Figure 1</label><caption><p>
<bold>Illustration of the sulcal morphological regions with depictions of width and depth.</bold> The superior frontal area is highlighted in the top panel, while the occipitotemporal areas are shaded in the bottom panel. The image on the right provides a concise overview of how CalcSulc calculates depth and width.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcaf345f1.jpg"/></fig></sec><sec id="fcaf345-s2.5"><title>PET acquisition</title><p>Participants underwent a PET scan utilizing a flortaucipir tracer (18F-AV-1451). The tracer dose was obtained from Avid Radiopharmaceuticals (Philadelphia, PA, USA). Readers are directed to the methods paper from the DIAGNOSE CTE Research Project<sup><xref rid="fcaf345-B28" ref-type="bibr">28</xref></sup> for a comprehensive overview of PET imaging details. In this study, the application of flortaucipir was conducted under an Investigational New Drug (IND #131391) obtained from the U.S. Food and Drug Administration. The flortaucipir protocol involved a 370 MBq (10 mCi) bolus injection, and 80&#8197;min later, the participant underwent a continuous dynamic 20-min brain scan, consisting of four frames with a duration of 5&#8197;min each.</p></sec><sec id="fcaf345-s2.6"><title>PET processing</title><p>Flortaucipir PET images were processed using the PET Unified Pipeline, involving scanner harmonization, motion correction, frame summation, PET to MRI co-registration and standard uptake value ratio (SUVR) estimation with the cerebellum cortex as the reference region.<sup><xref rid="fcaf345-B41" ref-type="bibr">41</xref>,<xref rid="fcaf345-B42" ref-type="bibr">42</xref></sup> Regional SUVR values were provided for each FreeSurfer-defined volume using the Desikan&#8211;Killiany Atlas. The process included partial volume correction using the regional spread function. Spatial normalization was achieved using Statistical Parametric Mapping 12 (SPM12) with T1w images, transforming flortaucipir PET images to the MNI template space.<sup><xref rid="fcaf345-B41" ref-type="bibr">41</xref></sup> Due to variations between the atlas outputs from CalcSulc and PET images, we opted for the closest approximations from the PET Desikan&#8211;Killiany atlas to the CalcSulc Destrieux Atlas. Accordingly, we chose the SUVR of the superior frontal and superior temporal regions of the Desikan&#8211;Killiany Atlas for analysis. All analyses evaluating PET data only included the sample of former American football players. Exclusion criteria for PET analyses were missing data. Consequently, 10 participants from our sample lacked PET imaging, and these 10 participants were excluded from any analysis involving flortaucipir PET.</p></sec><sec id="fcaf345-s2.7"><title>Exposure to RHI</title><p>Exposure to American football was evaluated based on self-reported age at first exposure to tackle football as well as the total years of active football play. Additionally, we calculated CHII scores for the former American football player group. The rationale behind utilizing CHII is to account for the variability in head impact patterns over a career in American football. CHII scores are calculated using the total seasons of active football play, the playing positions at each career level, and the estimated head impact profile of the playing position at each level, based on previous studies of helmet accelerometry.<sup><xref rid="fcaf345-B9" ref-type="bibr">9</xref></sup> The scores are used to estimate the frequency (CHII), linear acceleration (CHII-G) and rotational force (CHII-R) endured over a career in American football.<sup><xref rid="fcaf345-B9" ref-type="bibr">9</xref></sup> Higher CHII scores reflect greater exposure to RHI.</p></sec><sec id="fcaf345-s2.8"><title>Evaluation of TES and provisional levels of certainty for CTE pathology</title><p>All participants were evaluated for a diagnosis of TES based on a multidisciplinary diagnostic consensus conference using the 2021 NINDS Consensus Diagnostic Criteria.<sup><xref rid="fcaf345-B10" ref-type="bibr">10</xref></sup> The DIAGNOSE CTE consensus panel evaluated the participant&#8217;s medical history; RHI exposure; self- and informant-reported complaints of cognitive, mood and/or behaviour problems, as well as functional dependence status; neurological/motor evaluation findings; and standardized neuropsychological and neuropsychiatric test results. A diagnosis of TES (yes/no) was then adjudicated based on: (i) substantial exposure to RHI; (ii) core clinical features involving <italic toggle="yes">cognitive impairment</italic> (yes/no) and/or <italic toggle="yes">neurobehavioural dysregulation</italic> (yes/no), (iii) evidence of <italic toggle="yes">progressive worsening</italic> of clinical symptoms (yes/no) and (iv) absence of another disease or condition that could account for core clinical features. See <xref rid="fcaf345-T1" ref-type="table">Table 1</xref> for details.</p><p>Provisional levels of certainty for CTE pathology (suggestive, possible, probable, definite CTE with TES) were then determined through a stepwise evaluation alongside a TES diagnosis. This evaluation considers RHI exposure, distinct clinical characteristics and a collection of supportive features.<sup><xref rid="fcaf345-B10" ref-type="bibr">10</xref></sup> Of note, none of our football players had a provisional level of certainty for CTE pathology that was classified as definite CTE with TES, as this would require postmortem evaluation. See <xref rid="fcaf345-T1" ref-type="table">Table 1</xref> for a breakdown of levels of certainty for CTE pathology among our football players.</p></sec><sec id="fcaf345-s2.9"><title>Objective neuropsychological evaluation</title><p>As a post-hoc analysis, we examined objective neuropsychological test performance exclusively in our former American football players. Each participant completed an in-person baseline neuropsychological assessment, which included a standardized battery of paper-and-pencil tests administered by a trained examiner.<sup><xref rid="fcaf345-B28" ref-type="bibr">28</xref></sup> A comprehensive list of the cognitive domains assessed, specific tests administered, and individual performance metrics can be found in Alosco <italic toggle="yes">et al</italic>.<sup><xref rid="fcaf345-B43" ref-type="bibr">43</xref></sup> Our analysis cantered on the three most affected cognitive domains&#8212;learning and memory, attention and psychomotor speed and executive function. To evaluate performance, we extracted raw scores from four key measures: the Montreal Cognitive Assessment (MoCA), the Neuropsychological Assessment Battery (NAB) List Learning Long Delay,<sup><xref rid="fcaf345-B44" ref-type="bibr">44</xref></sup> Trail Making Test Part A<sup><xref rid="fcaf345-B45" ref-type="bibr">45</xref></sup> and Trail Making Test Part B.<sup><xref rid="fcaf345-B45" ref-type="bibr">45</xref></sup> A summary of the raw data is provided in <xref rid="fcaf345-T1" ref-type="table">Table 1</xref>.</p></sec><sec id="fcaf345-s2.10"><title>Statistical analysis</title><sec id="fcaf345-s2.10.1"><title>Group level differences and interactions</title><p>To examine group-level differences in demographic variables between former American football players and unexposed asymptomatic control participants, we conducted an independent Welch&#8217;s <italic toggle="yes">t</italic>-test for continuous variables (age, BMI and education) and applied a chi-square test for categorical variables (race and APOE4 gene status).</p><p>We used a generalized least squares model with sulcal width and depth as respective outcome variables to compare group-level differences using customized code in R Studio. In this model and the ANCOVA, we controlled for age,<sup><xref rid="fcaf345-B46" ref-type="bibr">46-48</xref></sup> BMI,<sup><xref rid="fcaf345-B49" ref-type="bibr">49-51</xref></sup> race,<sup><xref rid="fcaf345-B48" ref-type="bibr">48</xref>,<xref rid="fcaf345-B52" ref-type="bibr">52</xref></sup> education in years,<sup><xref rid="fcaf345-B53" ref-type="bibr">53-56</xref></sup> imaging site, total intracranial volume<sup><xref rid="fcaf345-B57" ref-type="bibr">57</xref>,<xref rid="fcaf345-B58" ref-type="bibr">58</xref></sup> and APOE4 allele status (presence or absence).<sup><xref rid="fcaf345-B59" ref-type="bibr">59</xref>,<xref rid="fcaf345-B60" ref-type="bibr">60</xref></sup> We carefully selected these covariates as they have either been shown to affect neurodegenerative processes and/or MRI-based imaging analyses. Throughout our analyses, we report 95% confidence intervals (CIs), and all <italic toggle="yes">P</italic>-values were corrected for multiple comparisons across the full set of regions of interest and outcome variables. Specifically, for each family of tests (i.e. all regions of interest analysed for a given outcome), we controlled the false discovery rate (FDR) using the Benjamini &amp; Hochberg method. Only FDR-adjusted <italic toggle="yes">P</italic>-values less than 0.05 were considered statistically significant. This approach ensures that the correction was applied across all ROIs within each outcome, not just within individual regions. Using the generalized least square model, we also tested interactions with age and exposure factors (age of first exposure, total years of football played, CHII frequency, linear acceleration and rotational forces) and sulcal width and depth as respective outcome variables. We corrected for total years in football as an additional covariate when testing interactions between the age of first exposure and sulcal morphology.</p></sec><sec id="fcaf345-s2.10.2"><title>Group-level differences in TES</title><p>We compared sulcal morphology in former American football players with and without a diagnosis of TES using the generalized least squares model, correcting for the same covariates listed above. Furthermore, we compared sulcal morphology in former American football players across the different levels of certainty for CTE pathology using an ANCOVA.</p></sec><sec id="fcaf345-s2.10.3"><title>Associations with neuropsychological evaluations</title><p>To investigate the relationship between our regions of interest linked to CTE pathology in postmortem studies and individual neuropsychological performance, we conducted a linear regression analysis. This analysis examined scores from the MoCA, NAB List Learning Long Delay, Trail Making Test Part A and Trail Making Test Part B while accounting for key covariates, including age, race, BMI, education, imaging site, APOE4 gene status and total intracranial volume. To control for multiple comparisons, we applied the Benjamini &amp; Hochberg correction. The analysis was restricted to former American football players, with two participants excluded due to missing data.</p></sec><sec id="fcaf345-s2.10.4"><title>Flortaucipir-PET</title><p>For assessing the relationship between sulcal width and depth with flortaucipir SUVR values, we conducted a linear regression while controlling for the aforementioned covariates: age, BMI, race, education in years, imaging site, total intracranial volume and APOE4 allele status. The resulting <italic toggle="yes">P</italic>-values were adjusted for multiple comparisons using the Benjamini &amp; Hochberg method. For the analysis of exposure factors, TES, and flortaucipir, we evaluated only the former American football player group.</p></sec></sec></sec><sec sec-type="results" id="fcaf345-s3"><title>Results</title><sec id="fcaf345-s3.1"><title>Demographics</title><p>Using a Welch two-sample <italic toggle="yes">t</italic>-test, we detected differences in BMI between our former American football players and unexposed asymptomatic controls (<italic toggle="yes">t</italic>(102) = 2.6, mean difference = 1.8, 95% CI [0.5, 3.2], <italic toggle="yes">P</italic> = 0.01), signifying a higher BMI in the football player group. No additional group differences were evident.</p></sec><sec id="fcaf345-s3.2"><title>Group differences in sulcal morphology</title><p>Using the generalized least squares model, we tested for differences in sulcal width and depth of the superior frontal and occipitotemporal areas between former American football players and the unexposed asymptomatic control group. This model identified shallower sulcal depth in former American football players in the left hemisphere superior frontal region (95% CI [&#8722;0.96, &#8722;0.07], <italic toggle="yes">P</italic> = 0.04). No other main effects reached significance; all <italic toggle="yes">P</italic>&#8217;s &gt; 0.2; see <xref rid="fcaf345-T2" ref-type="table">Table 2</xref>, and <xref rid="sup1" ref-type="supplementary-material">Supplementary Tables 2</xref> and <xref rid="sup1" ref-type="supplementary-material">3</xref> for a summary of all findings.</p><table-wrap position="float" id="fcaf345-T2" orientation="portrait"><label>Table 2</label><caption><p>Group-level differences for sulcal morphology</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="center" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="center" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><th align="center" colspan="4" rowspan="1">Left</th><th align="center" colspan="4" rowspan="1">Right</th></tr><tr><th align="left" colspan="2" rowspan="1">Region of interest</th><th align="center" rowspan="1" colspan="1">Estimate</th><th align="center" rowspan="1" colspan="1">SD</th><th align="center" rowspan="1" colspan="1">95% CI</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic> Value</th><th align="center" rowspan="1" colspan="1">Estimate</th><th align="center" rowspan="1" colspan="1">SD</th><th align="center" rowspan="1" colspan="1">95% CI</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic> Value</th></tr></thead><tbody><tr><td colspan="10" rowspan="1">
<bold>Group-Level (Football &#215; Control)</bold>
</td></tr><tr><td rowspan="2" colspan="1">
<bold>Depth</bold>
</td><td rowspan="1" colspan="1">Superior frontal</td><td rowspan="1" colspan="1">&#8722;0.5</td><td rowspan="1" colspan="1">0.2</td><td rowspan="1" colspan="1">[&#8722;0.9, &#8722;0.07]</td><td rowspan="1" colspan="1">
<bold>0.04</bold>
</td><td rowspan="1" colspan="1">0.1</td><td rowspan="1" colspan="1">0.2</td><td rowspan="1" colspan="1">[&#8722;0.4, 0.5]</td><td rowspan="1" colspan="1">0.3</td></tr><tr><td rowspan="1" colspan="1">Occipitotemporal</td><td rowspan="1" colspan="1">0.2</td><td rowspan="1" colspan="1">0.2</td><td rowspan="1" colspan="1">[&#8722;0.3, 0.7]</td><td rowspan="1" colspan="1">0.4</td><td rowspan="1" colspan="1">0.3</td><td rowspan="1" colspan="1">0.2</td><td rowspan="1" colspan="1">[&#8722;0.1, 0.8]</td><td rowspan="1" colspan="1">0.7</td></tr><tr><td rowspan="2" colspan="1">
<bold>Width</bold>
</td><td rowspan="1" colspan="1">Superior frontal</td><td rowspan="1" colspan="1">&#8722;0.1</td><td rowspan="1" colspan="1">0.2</td><td rowspan="1" colspan="1">[&#8722;0.5, 0.1]</td><td rowspan="1" colspan="1">0.3</td><td rowspan="1" colspan="1">0.1</td><td rowspan="1" colspan="1">0.1</td><td rowspan="1" colspan="1">[&#8722;0.2, 0.4]</td><td rowspan="1" colspan="1">0.5</td></tr><tr><td rowspan="1" colspan="1">Occipitotemporal</td><td rowspan="1" colspan="1">0.1</td><td rowspan="1" colspan="1">0.1</td><td rowspan="1" colspan="1">[&#8722;0.1, &#8722;0.3]</td><td rowspan="1" colspan="1">0.3</td><td rowspan="1" colspan="1">&#8722;0.07</td><td rowspan="1" colspan="1">0.1</td><td rowspan="1" colspan="1">[&#8722;0.3, 0.1]</td><td rowspan="1" colspan="1">0.5</td></tr><tr><td colspan="10" rowspan="1">
<bold>Age interaction</bold>
</td></tr><tr><td rowspan="2" colspan="1">
<bold>Depth</bold>
</td><td rowspan="1" colspan="1">Superior frontal</td><td rowspan="1" colspan="1">&#8722;0.02</td><td rowspan="1" colspan="1">0.03</td><td rowspan="1" colspan="1">[&#8722;0.07, 0.03]</td><td rowspan="1" colspan="1">0.5</td><td rowspan="1" colspan="1">&#8722;0.01</td><td rowspan="1" colspan="1">0.03</td><td rowspan="1" colspan="1">[&#8722;0.08, 0.05]</td><td rowspan="1" colspan="1">0.6</td></tr><tr><td rowspan="1" colspan="1">Occipitotemporal</td><td rowspan="1" colspan="1">&#8722;0.07</td><td rowspan="1" colspan="1">0.03</td><td rowspan="1" colspan="1">[&#8722;0.1, &#8722;0.006]</td><td rowspan="1" colspan="1">0.08</td><td rowspan="1" colspan="1">&#8722;0.05</td><td rowspan="1" colspan="1">0.03</td><td rowspan="1" colspan="1">[&#8722;0.1, &#8722;0.002]</td><td rowspan="1" colspan="1">0.1</td></tr><tr><td rowspan="2" colspan="1">
<bold>Width</bold>
</td><td rowspan="1" colspan="1">Superior frontal</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">0.02</td><td rowspan="1" colspan="1">[&#8722;0.03, 0.05]</td><td rowspan="1" colspan="1">0.6</td><td rowspan="1" colspan="1">&#8722;0.03</td><td rowspan="1" colspan="1">0.02</td><td rowspan="1" colspan="1">[&#8722;0.06, 0.004]</td><td rowspan="1" colspan="1">0.2</td></tr><tr><td rowspan="1" colspan="1">Occipitotemporal</td><td rowspan="1" colspan="1">0.03</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">[.003, 0.06]</td><td rowspan="1" colspan="1">0.058</td><td rowspan="1" colspan="1">0.008</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">[&#8722;0.02, 0.03]</td><td rowspan="1" colspan="1">0.5</td></tr><tr><td colspan="10" rowspan="1">
<bold>Age of first exposure</bold>
</td></tr><tr><td rowspan="2" colspan="1">
<bold>Depth</bold>
</td><td rowspan="1" colspan="1">Superior frontal</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">0.04</td><td rowspan="1" colspan="1">[&#8722;0.08, 0.1]</td><td rowspan="1" colspan="1">0.8</td><td rowspan="1" colspan="1">&#8722;0.02</td><td rowspan="1" colspan="1">0.06</td><td rowspan="1" colspan="1">[&#8722;0.1, 0.09]</td><td rowspan="1" colspan="1">0.8</td></tr><tr><td rowspan="1" colspan="1">Occipitotemporal</td><td rowspan="1" colspan="1">0.05</td><td rowspan="1" colspan="1">0.05</td><td rowspan="1" colspan="1">[&#8722;0.04, 0.1]</td><td rowspan="1" colspan="1">0.6</td><td rowspan="1" colspan="1">0.06</td><td rowspan="1" colspan="1">0.04</td><td rowspan="1" colspan="1">[&#8722;0.02, 0.1]</td><td rowspan="1" colspan="1">0.3</td></tr><tr><td rowspan="2" colspan="1">
<bold>Width</bold>
</td><td rowspan="1" colspan="1">Superior frontal</td><td rowspan="1" colspan="1">0.03</td><td rowspan="1" colspan="1">0.03</td><td rowspan="1" colspan="1">[&#8722;0.02, 0.09]</td><td rowspan="1" colspan="1">0.2</td><td rowspan="1" colspan="1">&#8722;0.04</td><td rowspan="1" colspan="1">0.03</td><td rowspan="1" colspan="1">[&#8722;0.09, 0.02]</td><td rowspan="1" colspan="1">0.3</td></tr><tr><td rowspan="1" colspan="1">Occipitotemporal</td><td rowspan="1" colspan="1">&#8722;0.05</td><td rowspan="1" colspan="1">0.02</td><td rowspan="1" colspan="1">[&#8722;0.09, &#8722;0.01]</td><td rowspan="1" colspan="1">
<bold>0.03</bold>
</td><td rowspan="1" colspan="1">&#8722;0.02</td><td rowspan="1" colspan="1">0.02</td><td rowspan="1" colspan="1">[&#8722;0.05, 0.02]</td><td rowspan="1" colspan="1">0.3</td></tr><tr><td colspan="10" rowspan="1">
<bold>Total years in football</bold>
</td></tr><tr><td rowspan="2" colspan="1">
<bold>Depth</bold>
</td><td rowspan="1" colspan="1">Superior frontal</td><td rowspan="1" colspan="1">&#8722;0.01</td><td rowspan="1" colspan="1">0.03</td><td rowspan="1" colspan="1">[&#8722;0.06, 0.05]</td><td rowspan="1" colspan="1">0.7</td><td rowspan="1" colspan="1">0.009</td><td rowspan="1" colspan="1">0.03</td><td rowspan="1" colspan="1">[&#8722;0.06, 0.07]</td><td rowspan="1" colspan="1">0.8</td></tr><tr><td rowspan="1" colspan="1">Occipitotemporal</td><td rowspan="1" colspan="1">&#8722;0.04</td><td rowspan="1" colspan="1">0.03</td><td rowspan="1" colspan="1">[&#8722;0.09, 0.02]</td><td rowspan="1" colspan="1">0.4</td><td rowspan="1" colspan="1">&#8722;0.01</td><td rowspan="1" colspan="1">0.03</td><td rowspan="1" colspan="1">[&#8722;0.07, 0.04]</td><td rowspan="1" colspan="1">0.8</td></tr><tr><td rowspan="2" colspan="1">
<bold>Width</bold>
</td><td rowspan="1" colspan="1">Superior frontal</td><td rowspan="1" colspan="1">0.003</td><td rowspan="1" colspan="1">0.02</td><td rowspan="1" colspan="1">[&#8722;0.03, 0.04]</td><td rowspan="1" colspan="1">0.9</td><td rowspan="1" colspan="1">0.03</td><td rowspan="1" colspan="1">0.02</td><td rowspan="1" colspan="1">[&#8722;0.01, 0.08]</td><td rowspan="1" colspan="1">0.3</td></tr><tr><td rowspan="1" colspan="1">Occipitotemporal</td><td rowspan="1" colspan="1">&#8722;0.03</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">[&#8722;0.06, &#8722;0.003]</td><td rowspan="1" colspan="1">
<bold>0.047</bold>
</td><td rowspan="1" colspan="1">&#8722;0.01</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">[&#8722;0.04, 0.01]</td><td rowspan="1" colspan="1">0.3</td></tr><tr><td colspan="10" rowspan="1">
<bold>CHII-Frequency (CHII)</bold>
</td></tr><tr><td rowspan="2" colspan="1">
<bold>Depth</bold>
</td><td rowspan="1" colspan="1">Superior frontal</td><td rowspan="1" colspan="1">&#8722;0.000007</td><td rowspan="1" colspan="1">0.00003</td><td rowspan="1" colspan="1">[&#8722;0.00007, 000005]</td><td rowspan="1" colspan="1">0.8</td><td rowspan="1" colspan="1">&#8722;0.00004</td><td rowspan="1" colspan="1">0.00004</td><td rowspan="1" colspan="1">[&#8722;0.0001, 0.00003]</td><td rowspan="1" colspan="1">0.5</td></tr><tr><td rowspan="1" colspan="1">Occipitotemporal</td><td rowspan="1" colspan="1">&#8722;0.00003</td><td rowspan="1" colspan="1">0.00003</td><td rowspan="1" colspan="1">[&#8722;0.00009, 0.00003]</td><td rowspan="1" colspan="1">0.5</td><td rowspan="1" colspan="1">0.00002</td><td rowspan="1" colspan="1">0.00003</td><td rowspan="1" colspan="1">[&#8722;0.00003, 0.00007]</td><td rowspan="1" colspan="1">0.5</td></tr><tr><td rowspan="2" colspan="1">
<bold>Width</bold>
</td><td rowspan="1" colspan="1">Superior frontal</td><td rowspan="1" colspan="1">0.00003</td><td rowspan="1" colspan="1">0.00002</td><td rowspan="1" colspan="1">[&#8722;0.00002, 0.00007]</td><td rowspan="1" colspan="1">0.5</td><td rowspan="1" colspan="1">&#8722;0.00002</td><td rowspan="1" colspan="1">0.00002</td><td rowspan="1" colspan="1">[.00007, 0.00002]</td><td rowspan="1" colspan="1">0.5</td></tr><tr><td rowspan="1" colspan="1">Occipitotemporal</td><td rowspan="1" colspan="1">0.000001</td><td rowspan="1" colspan="1">0.00002</td><td rowspan="1" colspan="1">[&#8722;0.00003, 0.00004]</td><td rowspan="1" colspan="1">0.9</td><td rowspan="1" colspan="1">&#8722;0.0000002</td><td rowspan="1" colspan="1">0.00001</td><td rowspan="1" colspan="1">[&#8722;0.00003, 0.00003]</td><td rowspan="1" colspan="1">0.9</td></tr><tr><td colspan="10" rowspan="1">
<bold>CHII-Linear Acceleration (CHII-G)</bold>
</td></tr><tr><td rowspan="2" colspan="1">
<bold>Depth</bold>
</td><td rowspan="1" colspan="1">Superior frontal</td><td rowspan="1" colspan="1">&#8722;0.000003</td><td rowspan="1" colspan="1">0.000001</td><td rowspan="1" colspan="1">[&#8722;0.000006, &#8722;0.0000007]</td><td rowspan="1" colspan="1">
<bold>0.03</bold>
</td><td rowspan="1" colspan="1">&#8722;0.000004</td><td rowspan="1" colspan="1">0.000002</td><td rowspan="1" colspan="1">[&#8722;0.000008, &#8722;0.0000002]</td><td rowspan="1" colspan="1">0.08</td></tr><tr><td rowspan="1" colspan="1">Occipitotemporal</td><td rowspan="1" colspan="1">&#8722;0.000002</td><td rowspan="1" colspan="1">0.000002</td><td rowspan="1" colspan="1">[&#8722;0.000005, 0.000002]</td><td rowspan="1" colspan="1">0.4</td><td rowspan="1" colspan="1">&#8722;0.000001</td><td rowspan="1" colspan="1">0.000001</td><td rowspan="1" colspan="1">[&#8722;0.000004, 0.000002]</td><td rowspan="1" colspan="1">0.4</td></tr><tr><td rowspan="2" colspan="1">
<bold>Width</bold>
</td><td rowspan="1" colspan="1">Superior frontal</td><td rowspan="1" colspan="1">0.0000004</td><td rowspan="1" colspan="1">0.000001</td><td rowspan="1" colspan="1">[&#8722;0.000002, 0.000003]</td><td rowspan="1" colspan="1">0.7</td><td rowspan="1" colspan="1">0.0000002</td><td rowspan="1" colspan="1">0.000001</td><td rowspan="1" colspan="1">[&#8722;0.000002, 0.000002]</td><td rowspan="1" colspan="1">0.9</td></tr><tr><td rowspan="1" colspan="1">Occipitotemporal</td><td rowspan="1" colspan="1">&#8722;0.0000004</td><td rowspan="1" colspan="1">0.0000009</td><td rowspan="1" colspan="1">[&#8722;0.000002, 0.000001]</td><td rowspan="1" colspan="1">0.7</td><td rowspan="1" colspan="1">&#8722;0.000001</td><td rowspan="1" colspan="1">0.0000006</td><td rowspan="1" colspan="1">[&#8722;0.000002, 0.0000003]</td><td rowspan="1" colspan="1">0.2</td></tr><tr><td colspan="10" rowspan="1">
<bold>CHII-Rotational Force (CHII-R)</bold>
</td></tr><tr><td rowspan="2" colspan="1">
<bold>Depth</bold>
</td><td rowspan="1" colspan="1">Superior frontal</td><td rowspan="1" colspan="1">&#8722;0.00000003</td><td rowspan="1" colspan="1">0.00000002</td><td rowspan="1" colspan="1">[&#8722;0.00000007, 0.0000000004]</td><td rowspan="1" colspan="1">0.1</td><td rowspan="1" colspan="1">&#8722;0.00000005</td><td rowspan="1" colspan="1">0.00000002</td><td rowspan="1" colspan="1">[&#8722;0.00000009, &#8722;0.000000002]</td><td rowspan="1" colspan="1">0.09</td></tr><tr><td rowspan="1" colspan="1">Occipitotemporal</td><td rowspan="1" colspan="1">&#8722;0.000000006</td><td rowspan="1" colspan="1">0.00000002</td><td rowspan="1" colspan="1">[&#8722;0.00000005, 0.00000003]</td><td rowspan="1" colspan="1">0.8</td><td rowspan="1" colspan="1">&#8722;0.000000001</td><td rowspan="1" colspan="1">0.00000002</td><td rowspan="1" colspan="1">[&#8722;0.00000004, 0.00000004]</td><td rowspan="1" colspan="1">0.9</td></tr><tr><td rowspan="2" colspan="1">
<bold>Width</bold>
</td><td rowspan="1" colspan="1">Superior frontal</td><td rowspan="1" colspan="1">0.00000000008</td><td rowspan="1" colspan="1">0.00000001</td><td rowspan="1" colspan="1">[&#8722;0.00000003, 0.00000003]</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0.000000001</td><td rowspan="1" colspan="1">0.00000001</td><td rowspan="1" colspan="1">[&#8722;0.00000003, 0.00000003]</td><td rowspan="1" colspan="1">0.9</td></tr><tr><td rowspan="1" colspan="1">Occipitotemporal</td><td rowspan="1" colspan="1">&#8722;0.000000006</td><td rowspan="1" colspan="1">0.00000001</td><td rowspan="1" colspan="1">[&#8722;0.00000003, 0.00000001]</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#8722;0.00000001</td><td rowspan="1" colspan="1">0.000000007</td><td rowspan="1" colspan="1">[&#8722;0.00000002, 0.000000006]</td><td rowspan="1" colspan="1">0.4</td></tr><tr><td colspan="10" rowspan="1">
<bold>TES</bold>
</td></tr><tr><td rowspan="1" colspan="1">
<bold>Depth</bold>
</td><td rowspan="1" colspan="1">Superior frontal</td><td rowspan="1" colspan="1">&#8722;0.3</td><td rowspan="1" colspan="1">0.2</td><td rowspan="1" colspan="1">[&#8722;0.06, &#8722;0.003]</td><td rowspan="1" colspan="1">0.4</td><td rowspan="1" colspan="1">&#8722;0.2</td><td rowspan="1" colspan="1">0.3</td><td rowspan="1" colspan="1">[&#8722;0.8, 0.3]</td><td rowspan="1" colspan="1">0.8</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Occipitotemporal</td><td rowspan="1" colspan="1">&#8722;0.06</td><td rowspan="1" colspan="1">0.2</td><td rowspan="1" colspan="1">[&#8722;0.7, 0.2]</td><td rowspan="1" colspan="1">0.8</td><td rowspan="1" colspan="1">&#8722;0.06</td><td rowspan="1" colspan="1">0.2</td><td rowspan="1" colspan="1">[&#8722;0.5, 0.4]</td><td rowspan="1" colspan="1">0.8</td></tr><tr><td rowspan="1" colspan="1">
<bold>Width</bold>
</td><td rowspan="1" colspan="1">Superior frontal</td><td rowspan="1" colspan="1">&#8722;0.2</td><td rowspan="1" colspan="1">0.1</td><td rowspan="1" colspan="1">[&#8722;0.5, 0.1]</td><td rowspan="1" colspan="1">0.5</td><td rowspan="1" colspan="1">0.2</td><td rowspan="1" colspan="1">0.2</td><td rowspan="1" colspan="1">[&#8722;0.2, 0.5]</td><td rowspan="1" colspan="1">0.3</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Occipitotemporal</td><td rowspan="1" colspan="1">0.03</td><td rowspan="1" colspan="1">0.1</td><td rowspan="1" colspan="1">[&#8722;0.2, 0.3]</td><td rowspan="1" colspan="1">0.8</td><td rowspan="1" colspan="1">&#8722;0.2</td><td rowspan="1" colspan="1">0.1</td><td rowspan="1" colspan="1">[&#8722;0.4, 0.01]</td><td rowspan="1" colspan="1">0.1</td></tr></tbody></table><table-wrap-foot><fn id="tblfn6"><p>Estimates, 95% CI, and <italic toggle="yes">P</italic> values for regions of interest for group-level differences and interactions. All <italic toggle="yes">P</italic> values are corrected for multiple comparisons. All significant values at <italic toggle="yes">P</italic> &lt; 0.05 are bolded.</p></fn></table-wrap-foot></table-wrap></sec><sec id="fcaf345-s3.3"><title>Exposure to RHI and sulcal morphology</title><p>We identified a significant association between the age of first exposure to tackle football and left hemisphere occipitotemporal sulcal width (95% CI [&#8722;0.09, &#8722;0.01], <italic toggle="yes">P</italic> = 0.03), which showed wider sulcal width in those who participated in football at earlier ages; see <xref rid="fcaf345-T2" ref-type="table">Table 2</xref>. Additionally, we observed an association between the left hemisphere occipitotemporal sulcal width and total years in football (95% CI [&#8722;0.06, &#8722;0.003], <italic toggle="yes">P</italic> = 0.047), showing wider sulci the longer a football player participated in football. Moreover, we showed an association between left hemisphere superior frontal sulcal depth and CHII-G (95% CI [&#8722;0.000006, &#8722;0.0000007], <italic toggle="yes">P</italic> = 0.03), with shallower sulcal depth associated with increased estimates of linear acceleration throughout a football career; see <xref rid="fcaf345-T2" ref-type="table">Table 2</xref>. No other associations, including group-level associations with age, reached significance; all <italic toggle="yes">P</italic>&#8217;s &gt; 0.058; see <xref rid="fcaf345-T2" ref-type="table">Table 2</xref>.</p></sec><sec id="fcaf345-s3.4"><title>Group-level differences in TES and provisional levels of certainty for CTE pathology</title><p>There were no differences in sulcal width (all <italic toggle="yes">P</italic>&#8217;s &gt; 0.1) or sulcal depth (all <italic toggle="yes">P</italic>&#8217;s &gt; 0.7) between our former American football players with or without a diagnosis of TES. Furthermore, there were no significant differences in sulcal width (all <italic toggle="yes">P</italic>&#8217;s &gt; 0.5) or sulcal depth (all <italic toggle="yes">P</italic>&#8217;s &gt; 0.07) across the levels of certainty for CTE pathology.</p></sec><sec id="fcaf345-s3.5"><title>Associations with neuropsychological evaluations</title><p>There was no significant association between the neuropsychological evaluations and sulcal width (all <italic toggle="yes">P</italic>&#8217;s &gt; 0.5) or depth (all <italic toggle="yes">P</italic>&#8217;s &gt; 0.6).</p></sec><sec id="fcaf345-s3.6"><title>Flortaucipir-PET</title><p>There was no significant association between flortaucipir SUVR values and sulcal width (all <italic toggle="yes">P</italic>&#8217;s &gt; 0.1) or depth (all <italic toggle="yes">P</italic>&#8217;s &gt; 0.4).</p></sec></sec><sec sec-type="discussion" id="fcaf345-s4"><title>Discussion</title><p>This study aimed to characterize <italic toggle="yes">in vivo</italic> sulcal morphometric changes in former American football players, focusing on the superior frontal and occipitotemporal regions associated with postmortem CTE neuropathology. We found that former players exhibited shallower sulcal depth in the left superior frontal region compared to controls. Additionally, earlier age of first exposure to tackle football and longer football participation were associated with wider occipitotemporal sulci, while greater cumulative head impact exposure correlated with shallower superior frontal sulci. Sulcal morphology was neither associated with age, TES, levels of certainty for CTE pathology, neuropsychological test performance, nor flortaucipir PET. We review the details of these findings below.</p><sec id="fcaf345-s4.1"><title>Sulcal morphological changes in former American football players</title><p>Our results show evidence of shallower sulcal depth in the left hemisphere superior frontal region among former American football players compared to unexposed controls, suggesting a potential relationship between RHI and cerebral morphology.<sup><xref rid="fcaf345-B61" ref-type="bibr">61</xref></sup> A hallmark feature of CTE is the accumulation of p-tau at the depths of the cortical sulci. The sulci appear to be particularly susceptible to RHI, a vulnerability supported by computational and physical models of brain biomechanics.<sup><xref rid="fcaf345-B62" ref-type="bibr">62</xref>,<xref rid="fcaf345-B63" ref-type="bibr">63</xref></sup> These models demonstrate that the gyral architecture of the brain concentrates mechanical strain at the crests of gyri and, most notably, at the depths of sulci, regions also prone to the formation of cavitation vapor bubbles.<sup><xref rid="fcaf345-B64" ref-type="bibr">64</xref>,<xref rid="fcaf345-B65" ref-type="bibr">65</xref></sup> This elevated strain may disrupt axonal integrity and contribute to the focal initiation of tau pathology. Over time, the accumulation of p-tau in these regions can promote neuroinflammation, neuronal loss and cortical atrophy, potentially resulting in measurable structural changes such as sulcal widening and shallowing. Thus, alterations in sulcal morphology may serve as an indirect <italic toggle="yes">in vivo</italic> marker of underlying p-tau deposition and associated neurodegenerative processes in individuals exposed to RHI.</p><p>This hypothesis is further supported by prior research demonstrating volume loss in CTE-associated brain regions in former American football players, particularly within the superior frontal region.<sup><xref rid="fcaf345-B66" ref-type="bibr">66</xref></sup> These findings suggest that sulcal widening and shallowing may possibly reflect neurodegenerative processes linked to tau pathology, providing a potential structural biomarker for early detection and disease progression monitoring in individuals at risk for CTE. Yet, our findings highlight shallower sulcal depth in the left hemisphere superior frontal region but no differences in sulcal width. While most cases of CTE present with cortical p-tau accumulation, there are individuals exposed to RHI who develop CTE that show a low overall cortical burden of p-tau pathology, which is classified as cortical-sparing CTE.<sup><xref rid="fcaf345-B23" ref-type="bibr">23</xref></sup> Therefore, it may be the case that if a sub-group of former American football players have CTE, some may have cortical-sparing CTE, making it even more difficult to detect robust findings in cortical areas. Importantly, since we do not have pathological confirmation of CTE in our sample, it is also possible that some of the athletes included in the study may not have CTE, which adds to the variability of our findings. Yet, our findings support the notion that shallower sulci are primarily a result of cortical atrophy, a phenomenon we have previously observed in this sample.<sup><xref rid="fcaf345-B66" ref-type="bibr">66</xref></sup> This atrophy contributes to a reduction in sulcal depth, which we hypothesize is driven by the shrinkage of the adjacent gyri. As the gyri shrink, the sulci appear broader, thereby altering their apparent depth. This mechanism aligns with our previous reports, offering further insight into the relationship between cortical changes and now sulcal morphology. It is also important to note that the observed differences may be associated with the consequences of RHI and not necessarily indicative of CTE, as not everyone exposed to RHI will develop CTE. Therefore, these group-level differences observed in the sulci of our cohort of former American football players may be consequences of their exposure to RHI and unrelated to the neuropathology of CTE. These findings stress the need for further research to disentangle the specific effects of RHI from CTE neuropathology, as not all exposed individuals develop CTE.</p></sec><sec id="fcaf345-s4.2"><title>Associations between sulcal morphology and age</title><p>We did not observe an age-by-group interaction in sulcal width or depth in the superior frontal and occipitotemporal regions. This is noteworthy as alterations in sulcal morphology have been identified in several neurodegenerative diseases, particularly Alzheimer&#8217;s disease. Prior studies have consistently shown that sulcal widening and shallower depths are common in areas of the brain affected by Alzheimer&#8217;s pathology, such as the temporal lobe, and these changes are thought to reflect underlying cortical atrophy associated with disease progression.<sup><xref rid="fcaf345-B19" ref-type="bibr">19-22</xref></sup> Specifically, wider sulci and reduced sulcal depth in Alzheimer&#8217;s disease may serve as indirect markers of neurodegeneration, with these structural alterations potentially linked to loss of grey matter volume in affected regions. Therefore, our findings, or lack thereof, in the superior frontal and occipitotemporal areas, may suggest that sulcal morphology changes in former American football players may follow a distinct pattern compared to what has been observed in Alzheimer&#8217;s disease. The absence of age-related interactions in sulcal morphology could indicate that the structural changes in football players are driven more by cumulative head trauma rather than age-related neurodegenerative processes, as seen in the Alzheimer&#8217;s disease literature. Future research is necessary to explore sulcal morphology across different neurodegenerative diseases which could provide valuable insights into the pathophysiological differences between possible CTE and Alzheimer&#8217;s disease, especially in cohorts with varying ages and brain injury histories.</p></sec><sec id="fcaf345-s4.3"><title>Associations between sulcal morphology and exposure factors</title><p>Our findings revealed an association between a younger age of first exposure to American football and sulcal widening in the left hemisphere occipitotemporal region. This change underscores the potential influence of early-life RHI on cerebral morphology later in life. The link between the age of first exposure to football and subsequent changes in brain structure and cognition has been previously documented.<sup><xref rid="fcaf345-B67" ref-type="bibr">67-72</xref></sup> Taken together, structural neuroimaging markers could serve as valuable additions to existing imaging biomarkers for detecting neurodegenerative processes in athletes with a history of RHI exposure. Our study adds to this body of literature by identifying more cortical sulcal morphological changes associated with early exposure to RHI. However, it is important to acknowledge that some studies indicate a younger age of first exposure to American football does not correlate with post-career health outcomes.<sup><xref rid="fcaf345-B73" ref-type="bibr">73-79</xref></sup> However, our findings are supported by the association between total years of football play and the left hemisphere occipitotemporal region, which indicates that more years of play leads to wider sulcal width in our football players. Yet, we acknowledge that further research is essential to elucidate the full extent of the relationship between early and longer exposure to American football and overall brain morphometry.</p><p>An association between CHII-linear acceleration over a career in American football and shallower superior frontal sulcal depth was also observed. This highlights the potential impact of biomechanics and linear forces of RHI on sulcal morphology. Biomechanical studies suggest that head impacts in American football strain the cortical grey matter/white matter boundary near the cerebral sulci, potentially triggering a harmful cascade of pathological changes in these areas.<sup><xref rid="fcaf345-B63" ref-type="bibr">63</xref></sup> We hypothesize that this could result in the accumulation of p-tau in the depths of cortical sulci, as observed in CTE neuropathology, subsequently leading to alterations in sulcal morphology. Previous research from our team has also revealed that CHII metrics are associated with alterations in subcortical structures. For example, the relative length of a cavum septum pellucidum, a non-specific biomarker of CTE, tends to increase as estimates of CHII-rotational forces are experienced during play.<sup><xref rid="fcaf345-B80" ref-type="bibr">80</xref></sup> These findings provide insights into the factors associated with non-specific biomarkers of CTE. However, additional research is needed to unravel the complex relationship between different RHI exposure factors and specific sulcal morphological changes. The borderline associations with total years in football and CHII-rotation forces suggest potential trends that warrant further exploration with larger sample sizes and larger distributions in exposure metrics. Therefore, prospective studies using accelerometer data should be considered.</p><p>This regional dissociation, where sulcal widening in the left occipitotemporal region is associated with age of first exposure and years of play, while sulcal depth in the left superior frontal sulcus is linked only to cumulative head impact burden, may reflect distinct patterns of vulnerability across cortical regions. One possibility is that the occipitotemporal cortex, which matures earlier during neurodevelopment, may be more sensitive to early-life and prolonged exposure to RHI. In contrast, the superior frontal region, involved in higher-order executive functions, may be more susceptible to cumulative biomechanical strain sustained over time. These divergent associations could also reflect region-specific trajectories of atrophy or compensatory mechanisms in response to different types of exposure. While speculative, such findings underscore the importance of examining multiple structural markers across brain regions to capture the heterogeneous effects of RHI. Future longitudinal studies are needed to clarify whether these regionally specific patterns represent true biological distinctions or are influenced by measurement variability or sample characteristics.</p></sec><sec id="fcaf345-s4.4"><title>Associations between sulcal morphology and TES diagnosis</title><p>While our study highlights structural changes, the absence of significant group-level differences in sulcal morphology between former American football players with or without TES underscores the need for comprehensive diagnostic criteria that include possible biomarkers. Reliance on patient history and clinical symptoms alone for TES diagnosis is a significant limitation. Efforts should continue to integrate biomarkers and supportive features into diagnostic criteria to enhance accuracy and reliability. This is particularly important because the clinical symptoms associated with TES diagnoses are not exclusive to possible CTE or RHI exposure; these symptoms also appear in the general population, especially among adults experiencing chronic pain, idiopathic mental health issues, or both.<sup><xref rid="fcaf345-B81" ref-type="bibr">81</xref></sup> Additionally, cognitive and neurobehavioural symptoms are common among those who participate in contact and collision sports, but these symptoms are not always distinct between individuals with and without confirmed CTE.<sup><xref rid="fcaf345-B24" ref-type="bibr">24</xref>,<xref rid="fcaf345-B82" ref-type="bibr">82</xref></sup> Our investigation indicates that further studies examining the relationship between TES and other potential <italic toggle="yes">in vivo</italic> biomarkers of CTE, as well as changes associated with RHI exposure, are warranted. This finding was further corroborated by the absence of any significant differences between our football players across varying levels of certainty for CTE pathology. Despite the use of criteria specifically designed to reflect increased clinical severity potentially linked to underlying p-tau pathology, this approach did not effectively differentiate between our groups. This suggests that the criteria intended to capture subtle variations in pathology did not yield the expected distinctions, highlighting the complexity of using clinical indicators to distinguish between varying levels of neurodegenerative progression.</p></sec><sec id="fcaf345-s4.5"><title>Associations between sulcal morphology and neuropsychological evaluation</title><p>Given the absence of group-level differences in TES diagnosis or the levels of certainty for CTE pathology, we performed a post-hoc investigation of how sulcal morphological changes may be associated with neuropsychological evaluations. It is also important to highlight that the superior frontal and occipitotemporal regions, selected a priori, are critically linked to cognitive domains such as executive function, working memory, and attention&#8212;key components of TES diagnosis and common cognitive complaints among former contact&#8211;collision sports athletes. By focusing on these regions, we sought to capture more relevant, quantifiable cognitive impairments that may better reflect the sulcal morphometric differences we observed, providing a more comprehensive understanding of the underlying structural changes. However, we did not find any significant associations between sulcal morphology and performance on neuropsychological assessments. This suggests that variations in these structural features may not directly influence cognitive function, at least within the scope of our study. The relationship between sulcal morphology and cognitive outcomes remains complex and challenging to pinpoint, as sulcal changes may reflect broader neuroanatomical processes that interact with multiple structural and functional brain networks. Additionally, cognitive function is influenced by a multitude of factors, including white matter integrity, cortical thickness and connectivity patterns, which may play a more direct role than sulcal morphology alone.<sup><xref rid="fcaf345-B20" ref-type="bibr">20</xref>,<xref rid="fcaf345-B83" ref-type="bibr">83-88</xref></sup> Further research incorporating multimodal imaging and longitudinal analyses is needed to understand better how sulcal characteristics contribute to cognitive aging and disease progression in individuals at higher risk of developing CTE.</p></sec><sec id="fcaf345-s4.6"><title>Associations between sulcal morphology and flortaucipir-PET</title><p>Lastly, our study also explored the association between sulcal morphology and flortaucipir accumulation detected via PET, and no significant associations were observed between sulcal morphology and flortaucipir SUVR values. Previous findings using the same sample of former American football players found significantly elevated flortaucipir uptake in former American football players bilaterally in the superior frontal, bilateral medial temporal and left parietal regions.<sup><xref rid="fcaf345-B11" ref-type="bibr">11</xref></sup> This study also reported no differences in flortaucipir SUVR values in football players with or without a TES diagnosis.<sup><xref rid="fcaf345-B11" ref-type="bibr">11</xref></sup> Sulcal morphology may represent a late-stage indicator of cortical damage following the accumulation of p-tau. Given this hypothesized difference in timing, a significant association may not be observed in this cross-sectional analysis. Future longitudinal studies should explore the relationship between cortical flortaucipir uptake and the development of alterations in sulcal morphology. Additionally, in this study, it may be the case that sulcal morphology detected via structural MRI may not be sufficiently sensitive to show a significant correlation with PET data. This lack of association suggests that structural changes in the sulci assessed may not directly mirror tau deposition, but rather the consequences of tau accumulation like aging or atrophy, potentially highlighting the complexity of the relationship between structural alterations and molecular biomarkers.</p></sec><sec id="fcaf345-s4.7"><title>Limitations</title><p>Some limitations need to be considered. First, the cross-sectional design restricts causal inferences, emphasizing the need for longitudinal studies to clarify the temporal dynamics of sulcal changes. Second, the absence of postmortem data prevents us from directly linking our findings to the underlying pathology. Third, the inclusion of only male former American football players who participated between 1952 and 2007 affects the generalizability of the findings. This time span also limits our scope, given the evolution of football in terms of play intensity and health protocols. Future studies should aim to include larger cohorts that include participants from other sports, gender identities, and participation timeframes. Fourth, our unexposed control participants were asymptomatic at the time of screening, which could influence group-level comparisons as it limits our comparison to those who do not show cognitive deficits either as a sign of natural aging or other neurodegenerative diseases, like Alzheimer&#8217;s disease. Fifth, although a substantial number of our football players and unexposed controls identify as Black, mirroring the demographics of former NFL players from 1967 to 1996, future studies should attempt to recruit a more diverse sample of participants to reflect the current demographical breakdown of the NFL. Sixth, our methodology is limited by the regions assessed using CalcSulc, as this measurement tool restricts the examination of other brain regions implicated in CTE neuropathology. Furthermore, our analysis of the association between sulcal morphology and flortaucipir-PET employs two distinct segmentation atlases (Destrieux for CalcSulc and Desikan&#8211;Killiany for flortaucipir SUVR calculations). This methodological complexity might explain the lack of observed associations, as the two regions do not fully overlap. Nonetheless, we used the closest matching brain regions from each atlas for the best possible correspondence. Lastly, and seventh, the lack of helmet accelerometer data from professional football players for deriving CHII scores introduces not only variability, but it is important to note that the scores were estimated from self-reported data on seasons played, player positions and accelerometer data from youth, high school and collegiate athletes. Thus, they are estimates of head impact exposure and do not capture the individual variability in head impact exposure. Thus, future studies are needed that incorporate long-term helmet accelerometer data.</p></sec></sec><sec id="fcaf345-s5"><title>Conclusion</title><p>In summary, this study reports shallower sulcal depths in former American football players in the superior frontal region, a brain region commonly affected in the initial stages of CTE, compared to unexposed asymptomatic controls. We also observed interactions between sulcal morphometric measures (depth and width) and RHI exposure metrics (age of first exposure to football, total years in football and career-long estimates of linear acceleration). However, contrary to our hypotheses, we did not find significant group-level differences between football players with and without a TES diagnosis or varying levels of certainty for CTE pathology. Additionally, we found no significant associations between sulcal morphology measures and age, neuropsychological assessments, and flortaucipir-PET uptake. Overall, our findings could indicate that exposure to RHI impacts the morphometric properties of the sulci, with earlier and greater exposure associated with more pronounced brain alterations later in life.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sup1" position="float" content-type="local-data" orientation="portrait"><label>fcaf345_Supplementary_Data</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fcaf345_supplementary_data.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="ack1"><title>Acknowledgements</title><p>We thank all study participants of the DIAGNOSE CTE Research Project for contributing to this research.</p></ack><sec id="fcaf345-s6"><title>Supplementary material</title><p>Supplementary material is available at <italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">Brain Communications</xref></italic> online.</p></sec><sec id="fcaf345-s7"><title>Funding</title><p>This study was supported by the National Institute of Neurological Disorders and Stroke U01NS093334 (J.L.C., E.M.R., M.E.S., R.A.S.), R01NS100952 (I.K.K.), K00 NS113419 (H.A.), R21 NS140565 (H.A.); Alzheimer&#8217;s Association Grant-25AARG-NTF-1377286 (H.A.), National Institute on Minority Health and Health Disparities Loan Repayment Program L32 MD016519 (H.A.), Harvard&#8217;s Mind Brain and Behavior Young Investigator Award (H.A.), Rainwater Charitable Foundation Tau Leadership Fellows Award (H.A.), Burroughs Wellcome Fund Postdoctoral Diversity Enrichment Program (H.A.), Black Men&#8217;s Brain Health Emerging Scholars Fellowship (H.A.) and the Grass Foundations Henry Grass M.D. Rising Star in Neuroscience Award (H.A.).</p></sec><sec sec-type="COI-statement" id="fcaf345-s8"><title>Competing interests</title><p>Dr. Laura Balcer is the Editor-in-Chief of the Journal of Neuro-Ophthalmology. Dr. Charles Bernick receives research support from the Ultimate Fighting Championship, Top Rank promotions, and Haymon Boxing. Dr. Alexander P. Lin has an ownership interest as a Co-founder of BrainSpec and consults for Agios Pharmaceuticals, Biomarin Pharmaceuticals, DesignTx, and Moncon MRI. Dr. Jeffrey L. Cummings has provided consultation to Acadia, Actinogen, Acumen, AlphaCognition, Aprinoia, AriBio, Artery, Biogen, BioVie, Bristol-Myers Squib, Cassava, Cerecin, Diadem, EIP Pharma, Eisai, GemVax, Genentech, GAP Innovations, Janssen, Jocasta, Karuna, Lighthouse, Lilly, Lundbeck, LSP/EQT, Merck, NervGen, Novo Nordisk, Oligomerix, Optoceutics, Ono, Otsuka, PRODEO, Prothena, ReMYND, Roche, Sage Therapeutics, Signant Health, Simcere, Suven, SynapseBio, TrueBinding, Vaxxinity, and Wren pharmaceutical, assessment, and investment companies. He owns the copyright of the Neuropsychiatric Inventory. Dr. Eric M. Reiman is a compensated scientific advisor for Alkahest, Alzheon, Aural Analytics, Denali, Green Valley, Retromer Therapeutics, and Vaxxinity, and a co-founder of ALZPath. Dr. Robert A. Stern is a member of the Board of Directors of King-Devick Technologies, Inc. (Chicago, IL, USA), and he receives royalties for published neuropsychological tests from Psychological Assessment Resources, Inc. (Lutz, FL, USA). IKK receives funding for a collaborative project from Abbott Inc. She receives royalties for book chapters. Her spouse is an employee at Siemens AG and a stockholder of Siemens AG and Siemens Healthineers.</p></sec><sec sec-type="data-availability" id="fcaf345-s9"><title>Data availability</title><p>Data from the DIAGNOSE CTE Research Project will be available to qualified investigators through the Federal Interagency Traumatic Brain Injury Research (FITBIR) Informatics System, through the National Institutes of Health (NIH) Center for Information Technology: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://fitbir.nih.gov/content/access-data" ext-link-type="uri">https://fitbir.nih.gov/content/access-data</ext-link>. DIAGNOSE CTE Research Project data, including those reported in this study, will also be available to qualified investigators through a project-specific data-sharing portal. The data and research tools utilized in this manuscript were obtained and analysed from controlled access datasets provided by the DOD- and NIH-supported Informatics Systems. Established by the Department of Defense and the National Institutes of Health, this Informatics System serves as a national resource to advance research in TBI and trauma. Dataset identifier: DOI. The views expressed in this manuscript are those of the authors and do not necessarily represent the opinions or perspectives of the DOD, NIH, or the original data submitters to the Informatics System. For specific questions regarding the data presented in this manuscript, interested investigators should contact Dr. Hector Arciniega at <email>Hector.Arciniega@nyulangone.org</email>.</p></sec><app-group><app id="app1"><title>Appendix</title><sec><title>DIAGNOSE CTE Research Project Team</title><p>Eric Reiman, M.D., Yi Su, Ph.D., Kewei Chen, Ph.D., Hillary Protas, Ph.D., Connie Boker, M.B.A., Michael L. Alosco, Ph.D., Rhoda Au, Ph.D., Robert C. Cantu, Ph.D., Lindsay Farrer, Ph.D., Robert Helm, M.D., Douglas I. Katz, M.D., Neil Kowall, M.D., Jesse Mez, M.D., Gustavo Mercier, M.D., Ph.D., James Otis, M.D., Robert A. Stern, Ph.D., Jason Weller, M.D., Irene Simkin, M.S., Alondra Andino, B.A., Shannon Conneely, B.A., Courtney Diamond, M.B.A., Tessa Fagle, B.A., Olivia Haller, B.A., Tennyson Hunt, M.B.A., Nicole Gullotti, M.B.A., Megan Mariani, B.S., B.A., Brian Mayville, B.S., Kathleen McLaughlin, B.A., Mary Nanna, B.A., Taylor Platt, M.P.H., Surya Pulukuri, B.A., Fiona Rice, M.P.H., Madison Sestak, B.S., Michael McClean, Sc.D., Yorghos Tripodis, Ph.D., Douglas Annis, M.S., Christine Chaisson, M.P.H., Diane B. Dixon, Carolyn Finney, B.A., Kerrin Gallagher, M.P.H., Kaitlin Hartlage, M.P.H., Jun Lu, M.S., Brett Martin, M.S., Emmanuel Ojo, M.P.H., Joseph N. Palmisano, M.A., M.P.H., Brittany Pine, B.A., B.S., Janani Ramachandran, M.S., Sylvain Bouix, Ph.D., Jennifer Fitzsimmons, M.D., Alexander P. Lin, Ph.D., Inga K. Koerte, M.D., Ph.D., Ofer Pasternak, Ph.D., Martha E. Shenton, Ph.D., Hector Arcinieago, Ph.D., Tashrif Billah, M.S., Elena Bonke, M.S., Katherine Breedlove, Ph.D., Eduardo Coello, Ph.D., Michael J. Coleman, M.A., Leonhard Jung, Huijun Liao, B.S., Maria Loy, M.B.A., M.P.H., Elizabeth Rizzoni, B.A., Vivian Schultz, M.D., Annelise Silva, B.S., Brynn Vessey, B.S., Tim L.T. Wiegand, Sarah Banks, Ph.D., Charles Bernick, M.D., Jason Miller, Ph.D., Aaron Ritter, M.D., Marwan Sabbagh, M.D., Raelynn de la Cruz, Jan Durant, Morgan Golceker, Nicolette Harmon, Kaeson Kaylegian, Rachelle Long, Christin Nance, Priscilla Sandoval, Robert W. Turner, Ph.D., Kenneth L. Marek, M.D., Andrew Serrano, M.B.A., Charles H. Adler, M.D., Ph.D., David W. Dodick, M.D., Yonas Geda, M.D., MSc, Jennifer V. Wethe, Ph.D., Bryce Falk, R.N., Amy Duffy, Marci Howard, Michelle Montague, Thomas Osgood, Debra Babcock, M.D., Ph.D., Patrick Bellgowan, Ph.D., Laura Balcer, M.D., M.S.C.E., William Barr, PhD., Judith Goldberg, Sc.D., Thomas Wisniewski, M.D., Ivan Kirov, Ph.D., Yvonne Lui, M.D., Charles Marmar, M.D., Lisena Hasanaj, Liliana Serrano, Alhassan Al-Kharafi, Allan George, Sammie Martin, Edward Riley, William Runge, Jeffrey L. Cummings, M.D., ScD, Elaine R. Peskind, M.D., Elizabeth Colasurdo, Daniel S. Marcus, Ph.D., Jenny Gurney, M.S., Richard Greenwald, Ph.D. and Keith A. Johnson, M.D.</p></sec></app></app-group><ref-list id="ref1"><title>References</title><ref id="fcaf345-B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nowinski</surname> &#160;<given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Bureau</surname> &#160;<given-names>SC</given-names></string-name>, <string-name name-style="western"><surname>Buckland</surname> &#160;<given-names>ME</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Applying the Bradford Hill criteria for causation to repetitive head impacts and chronic traumatic encephalopathy</article-title>. <source>Front Neurol</source>. <year>2022</year>;<volume>13</volume>:<fpage>938163</fpage>.<pub-id pub-id-type="pmid">35937061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2022.938163</pub-id><pub-id pub-id-type="pmcid">PMC9355594</pub-id></mixed-citation></ref><ref id="fcaf345-B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>McKee</surname> &#160;<given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Stein</surname> &#160;<given-names>TD</given-names></string-name>, <string-name name-style="western"><surname>Huber</surname> &#160;<given-names>BR</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Chronic traumatic encephalopathy (CTE): Criteria for neuropathological diagnosis and relationship to repetitive head impacts</article-title>. <source>Acta Neuropathol</source>. <year>2023</year>;<volume>145</volume>(<issue>4</issue>):<fpage>371</fpage>&#8211;<lpage>394</lpage>.<pub-id pub-id-type="pmid">36759368</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-023-02540-w</pub-id><pub-id pub-id-type="pmcid">PMC10020327</pub-id></mixed-citation></ref><ref id="fcaf345-B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bieniek</surname> &#160;<given-names>KF</given-names></string-name>, <string-name name-style="western"><surname>Cairns</surname> &#160;<given-names>NJ</given-names></string-name>, <string-name name-style="western"><surname>Crary</surname> &#160;<given-names>JF</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>The second NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy</article-title>. <source>J Neuropathol Exp Neurol</source>. <year>2021</year>;<volume>80</volume>(<issue>3</issue>):<fpage>210</fpage>&#8211;<lpage>219</lpage>.<pub-id pub-id-type="pmid">33611507</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnen/nlab001</pub-id><pub-id pub-id-type="pmcid">PMC7899277</pub-id></mixed-citation></ref><ref id="fcaf345-B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>McKee</surname> &#160;<given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Stern</surname> &#160;<given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Nowinski</surname> &#160;<given-names>CJ</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>The spectrum of disease in chronic traumatic encephalopathy</article-title>. <source>Brain</source>. <year>2013</year>;<volume>136</volume>(<issue>Pt 1</issue>):<fpage>43</fpage>&#8211;<lpage>64</lpage>.<pub-id pub-id-type="pmid">23208308</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/aws307</pub-id><pub-id pub-id-type="pmcid">PMC3624697</pub-id></mixed-citation></ref><ref id="fcaf345-B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bieniek</surname> &#160;<given-names>KF</given-names></string-name>, <string-name name-style="western"><surname>Ross</surname> &#160;<given-names>OA</given-names></string-name>, <string-name name-style="western"><surname>Cormier</surname> &#160;<given-names>KA</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Chronic traumatic encephalopathy pathology in a neurodegenerative disorders brain bank</article-title>. <source>Acta Neuropathol</source>. <year>2015</year>;<volume>130</volume>(<issue>6</issue>):<fpage>877</fpage>&#8211;<lpage>889</lpage>.<pub-id pub-id-type="pmid">26518018</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-015-1502-4</pub-id><pub-id pub-id-type="pmcid">PMC4655127</pub-id></mixed-citation></ref><ref id="fcaf345-B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mez</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Daneshvar</surname> &#160;<given-names>DH</given-names></string-name>, <string-name name-style="western"><surname>Kiernan</surname> &#160;<given-names>PT</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Clinicopathological evaluation of chronic traumatic encephalopathy in players of American football</article-title>. <source>JAMA</source>. <year>2017</year>;<volume>318</volume>(<issue>4</issue>):<fpage>360</fpage>&#8211;<lpage>370</lpage>.<pub-id pub-id-type="pmid">28742910</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2017.8334</pub-id><pub-id pub-id-type="pmcid">PMC5807097</pub-id></mixed-citation></ref><ref id="fcaf345-B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ling</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Morris</surname> &#160;<given-names>HR</given-names></string-name>, <string-name name-style="western"><surname>Neal</surname> &#160;<given-names>JW</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Mixed pathologies including chronic traumatic encephalopathy account for dementia in retired association football (soccer) players</article-title>. <source>Acta Neuropathol</source>. <year>2017</year>;<volume>133</volume>(<issue>3</issue>):<fpage>337</fpage>&#8211;<lpage>352</lpage>.<pub-id pub-id-type="pmid">28205009</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-017-1680-3</pub-id><pub-id pub-id-type="pmcid">PMC5325836</pub-id></mixed-citation></ref><ref id="fcaf345-B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Corsellis</surname> &#160;<given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Bruton</surname> &#160;<given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Freeman-Browne</surname> &#160;<given-names>D</given-names></string-name></person-group>. <article-title>The aftermath of boxing</article-title>. <source>Psychol Med</source>. <year>1973</year>;<volume>3</volume>(<issue>3</issue>):<fpage>270</fpage>&#8211;<lpage>303</lpage>.<pub-id pub-id-type="pmid">4729191</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/s0033291700049588</pub-id></mixed-citation></ref><ref id="fcaf345-B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Daneshvar</surname> &#160;<given-names>DH</given-names></string-name>, <string-name name-style="western"><surname>Nair</surname> &#160;<given-names>ES</given-names></string-name>, <string-name name-style="western"><surname>Baucom</surname> &#160;<given-names>ZH</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Leveraging football accelerometer data to quantify associations between repetitive head impacts and chronic traumatic encephalopathy in males</article-title>. <source>Nat Commun</source>. <year>2023</year>;<volume>14</volume>(<issue>1</issue>):<fpage>3470</fpage>.<pub-id pub-id-type="pmid">37340004</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-39183-0</pub-id><pub-id pub-id-type="pmcid">PMC10281995</pub-id></mixed-citation></ref><ref id="fcaf345-B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Katz</surname> &#160;<given-names>DI</given-names></string-name>, <string-name name-style="western"><surname>Bernick</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Dodick</surname> &#160;<given-names>DW</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for traumatic encephalopathy syndrome</article-title>. <source>Neurology</source>. <year>2021</year>;<volume>96</volume>(<issue>18</issue>):<fpage>848</fpage>&#8211;<lpage>863</lpage>.<pub-id pub-id-type="pmid">33722990</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000011850</pub-id><pub-id pub-id-type="pmcid">PMC8166432</pub-id></mixed-citation></ref><ref id="fcaf345-B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Su</surname> &#160;<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Protas</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Luo</surname> &#160;<given-names>J</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Flortaucipir tau PET findings from former professional and college American football players in the DIAGNOSE CTE research project</article-title>. <source>Alzheimers Dement</source>. <year>2024</year>;<volume>20</volume>(<issue>3</issue>):<fpage>1827</fpage>&#8211;<lpage>1838</lpage>.<pub-id pub-id-type="pmid">38134231</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13602</pub-id><pub-id pub-id-type="pmcid">PMC10984430</pub-id></mixed-citation></ref><ref id="fcaf345-B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Stern</surname> &#160;<given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Adler</surname> &#160;<given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname> &#160;<given-names>K</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Tau positron-emission tomography in former national football league players</article-title>. <source>N Engl J Med</source>. <year>2019</year>;<volume>380</volume>(<issue>18</issue>):<fpage>1716</fpage>&#8211;<lpage>1725</lpage>.<pub-id pub-id-type="pmid">30969506</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1900757</pub-id><pub-id pub-id-type="pmcid">PMC6636818</pub-id></mixed-citation></ref><ref id="fcaf345-B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tharmaratnam</surname> &#160;<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Iskandar</surname> &#160;<given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Tabobondung</surname> &#160;<given-names>TC</given-names></string-name>, <string-name name-style="western"><surname>Tobbia</surname> &#160;<given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Gopee-Ramanan</surname> &#160;<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Tabobondung</surname> &#160;<given-names>TA</given-names></string-name></person-group>. <article-title>Chronic traumatic encephalopathy in professional American football players: Where are we now?</article-title> &#160;<source>Front Neurol</source>. <year>2018</year>;<volume>9</volume>:<fpage>445</fpage>.<pub-id pub-id-type="pmid">29971037</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2018.00445</pub-id><pub-id pub-id-type="pmcid">PMC6018081</pub-id></mixed-citation></ref><ref id="fcaf345-B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mez</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Daneshvar</surname> &#160;<given-names>DH</given-names></string-name>, <string-name name-style="western"><surname>Abdolmohammadi</surname> &#160;<given-names>B</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Duration of American football play and chronic traumatic encephalopathy</article-title>. <source>Ann Neurol</source>. <year>2020</year>;<volume>87</volume>(<issue>1</issue>):<fpage>116</fpage>&#8211;<lpage>131</lpage>.<pub-id pub-id-type="pmid">31589352</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.25611</pub-id><pub-id pub-id-type="pmcid">PMC6973077</pub-id></mixed-citation></ref><ref id="fcaf345-B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Buckland</surname> &#160;<given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Affleck</surname> &#160;<given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Pearce</surname> &#160;<given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Suter</surname> &#160;<given-names>CM</given-names></string-name></person-group>. <article-title>Chronic traumatic encephalopathy as a preventable environmental disease</article-title>. <source>Front Neurol</source>. <year>2022</year>;<volume>13</volume>:<fpage>880905</fpage>.<pub-id pub-id-type="pmid">35769361</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2022.880905</pub-id><pub-id pub-id-type="pmcid">PMC9234108</pub-id></mixed-citation></ref><ref id="fcaf345-B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>McKee</surname> &#160;<given-names>AC</given-names></string-name></person-group>. <article-title>The neuropathology of chronic traumatic encephalopathy: The status of the literature</article-title>. <source>Semin Neurol</source>. <year>2020</year>;<volume>40</volume>(<issue>4</issue>):<fpage>359</fpage>&#8211;<lpage>369</lpage>.<pub-id pub-id-type="pmid">32712946</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/s-0040-1713632</pub-id></mixed-citation></ref><ref id="fcaf345-B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Arena</surname> &#160;<given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Johnson</surname> &#160;<given-names>VE</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname> &#160;<given-names>EB</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Astroglial tau pathology alone preferentially concentrates at sulcal depths in chronic traumatic encephalopathy neuropathologic change</article-title>. <source>Brain Commun</source>. <year>2020</year>;<volume>2</volume>(<issue>2</issue>):<fpage>fcaa210</fpage>.<pub-id pub-id-type="pmid">33426528</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/braincomms/fcaa210</pub-id><pub-id pub-id-type="pmcid">PMC7784042</pub-id></mixed-citation></ref><ref id="fcaf345-B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Alosco</surname> &#160;<given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Cherry</surname> &#160;<given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Huber</surname> &#160;<given-names>BR</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Characterizing tau deposition in chronic traumatic encephalopathy (CTE): Utility of the McKee CTE staging scheme</article-title>. <source>Acta Neuropathol</source>. <year>2020</year>;<volume>140</volume>(<issue>4</issue>):<fpage>495</fpage>&#8211;<lpage>512</lpage>.<pub-id pub-id-type="pmid">32778942</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-020-02197-9</pub-id><pub-id pub-id-type="pmcid">PMC7914059</pub-id></mixed-citation></ref><ref id="fcaf345-B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Im</surname> &#160;<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname> &#160;<given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Seo</surname> &#160;<given-names>SW</given-names></string-name>, <string-name name-style="western"><surname>Hyung Kim</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname> &#160;<given-names>SI</given-names></string-name>, <string-name name-style="western"><surname>Na</surname> &#160;<given-names>DL</given-names></string-name></person-group>. <article-title>Sulcal morphology changes and their relationship with cortical thickness and gyral white matter volume in mild cognitive impairment and Alzheimer's disease</article-title>. <source>Neuroimage</source>. <year>2008</year>;<volume>43</volume>(<issue>1</issue>):<fpage>103</fpage>&#8211;<lpage>113</lpage>.<pub-id pub-id-type="pmid">18691657</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2008.07.016</pub-id></mixed-citation></ref><ref id="fcaf345-B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bertoux</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lagarde</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Corlier</surname> &#160;<given-names>F</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Sulcal morphology in Alzheimer's disease: An effective marker of diagnosis and cognition</article-title>. <source>Neurobiol Aging</source>. <year>2019</year>;<volume>84</volume>:<fpage>41</fpage>&#8211;<lpage>49</lpage>.<pub-id pub-id-type="pmid">31491594</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2019.07.015</pub-id></mixed-citation></ref><ref id="fcaf345-B21"><label>21</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Andersen</surname> &#160;<given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Jakobsen</surname> &#160;<given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Pedersen</surname> &#160;<given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Rasmussen</surname> &#160;<given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Plocharski</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>&#216;stergaard</surname> &#160;<given-names>LR</given-names></string-name></person-group>. <source>Classification of Alzheimer&#8217;s disease from MRI using sulcal morphology</source>. <publisher-name>Springer International Publishing</publisher-name>; <year>2015</year>:<fpage>103</fpage>&#8211;<lpage>113</lpage>.</mixed-citation></ref><ref id="fcaf345-B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Reiner</surname> &#160;<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Jouvent</surname> &#160;<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Duchesnay</surname> &#160;<given-names>E</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Sulcal span in Azheimer's disease, amnestic mild cognitive impairment, and healthy controls</article-title>. <source>J Alzheimers Dis</source>. <year>2012</year>;<volume>29</volume>(<issue>3</issue>):<fpage>605</fpage>&#8211;<lpage>613</lpage>.<pub-id pub-id-type="pmid">22297645</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-2012-111622</pub-id></mixed-citation></ref><ref id="fcaf345-B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Alexander</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Alvarez</surname> &#160;<given-names>VE</given-names></string-name>, <string-name name-style="western"><surname>Huber</surname> &#160;<given-names>BR</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Cortical-sparing chronic traumatic encephalopathy (CSCTE): A distinct subtype of CTE</article-title>. <source>Acta Neuropathol</source>. <year>2024</year>;<volume>147</volume>(<issue>1</issue>):<fpage>45</fpage>.<pub-id pub-id-type="pmid">38407651</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-024-02690-5</pub-id><pub-id pub-id-type="pmcid">PMC11348287</pub-id></mixed-citation></ref><ref id="fcaf345-B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>McKee</surname> &#160;<given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Mez</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Abdolmohammadi</surname> &#160;<given-names>B</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Neuropathologic and clinical findings in young contact sport athletes exposed to repetitive head impacts</article-title>. <source>JAMA Neurol</source>. <year>2023</year>;<volume>80</volume>:<fpage>1037</fpage>&#8211;<lpage>1050</lpage>.<pub-id pub-id-type="pmid">37639244</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2023.2907</pub-id><pub-id pub-id-type="pmcid">PMC10463175</pub-id></mixed-citation></ref><ref id="fcaf345-B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>McKee</surname> &#160;<given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Alosco</surname> &#160;<given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Huber</surname> &#160;<given-names>BR</given-names></string-name></person-group>. <article-title>Repetitive head impacts and chronic traumatic encephalopathy</article-title>. <source>Neurosurg Clin N Am</source>. <year>2016</year>;<volume>27</volume>(<issue>4</issue>):<fpage>529</fpage>&#8211;<lpage>535</lpage>.<pub-id pub-id-type="pmid">27637402</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nec.2016.05.009</pub-id><pub-id pub-id-type="pmcid">PMC5028120</pub-id></mixed-citation></ref><ref id="fcaf345-B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>McKee</surname> &#160;<given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Stein</surname> &#160;<given-names>TD</given-names></string-name>, <string-name name-style="western"><surname>Kiernan</surname> &#160;<given-names>PT</given-names></string-name>, <string-name name-style="western"><surname>Alvarez</surname> &#160;<given-names>VE</given-names></string-name></person-group>. <article-title>The neuropathology of chronic traumatic encephalopathy</article-title>. <source>Brain Pathol</source>. <year>2015</year>;<volume>25</volume>(<issue>3</issue>):<fpage>350</fpage>&#8211;<lpage>364</lpage>.<pub-id pub-id-type="pmid">25904048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bpa.12248</pub-id><pub-id pub-id-type="pmcid">PMC4526170</pub-id></mixed-citation></ref><ref id="fcaf345-B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Stein</surname> &#160;<given-names>TD</given-names></string-name>, <string-name name-style="western"><surname>Alvarez</surname> &#160;<given-names>VE</given-names></string-name>, <string-name name-style="western"><surname>McKee</surname> &#160;<given-names>AC</given-names></string-name></person-group>. <article-title>Chronic traumatic encephalopathy: A spectrum of neuropathological changes following repetitive brain trauma in athletes and military personnel</article-title>. <source>Alzheimers Res Ther</source>. <year>2014</year>;<volume>6</volume>(<issue>1</issue>):<fpage>4</fpage>.<pub-id pub-id-type="pmid">24423082</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/alzrt234</pub-id><pub-id pub-id-type="pmcid">PMC3979082</pub-id></mixed-citation></ref><ref id="fcaf345-B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Alosco</surname> &#160;<given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Mariani</surname> &#160;<given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Adler</surname> &#160;<given-names>CH</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Developing methods to detect and diagnose chronic traumatic encephalopathy during life: Rationale, design, and methodology for the DIAGNOSE CTE research project</article-title>. <source>Alzheimers Res Ther</source>. <year>2021</year>;<volume>13</volume>(<issue>1</issue>):<fpage>136</fpage>.<pub-id pub-id-type="pmid">34384490</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-021-00872-x</pub-id><pub-id pub-id-type="pmcid">PMC8357968</pub-id></mixed-citation></ref><ref id="fcaf345-B29"><label>29</label><mixed-citation publication-type="data"><person-group person-group-type="curator"><string-name name-style="western"><surname>Billah</surname> &#160;<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Bouix</surname> &#160;<given-names>S.</given-names></string-name></person-group> A Luigi workflow joining individual modules of an MRI processing pipeline (Version 0.0) [Computer software]. <data-title>Zenodo</data-title>. 2020. doi:<pub-id pub-id-type="doi">10.5281/zenodo.3666802</pub-id></mixed-citation></ref><ref id="fcaf345-B30"><label>30</label><mixed-citation publication-type="data"><person-group person-group-type="curator"><string-name name-style="western"><surname>Billah</surname> &#160;<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Bouix</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Rathi</surname> &#160;<given-names>Y</given-names></string-name></person-group>. <data-title>NIFTI MRI processing pipeline</data-title>. <year>2019</year>. doi:<pub-id pub-id-type="doi">10.5281/zenodo.3258854</pub-id></mixed-citation></ref><ref id="fcaf345-B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Del Re</surname> &#160;<given-names>EC</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname> &#160;<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Eckbo</surname> &#160;<given-names>R</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>A new MRI masking technique based on multi-atlas brain segmentation in controls and schizophrenia: A rapid and viable alternative to manual masking</article-title>. <source>J Neuroimaging</source>. <year>2016</year>;<volume>26</volume>(<issue>1</issue>):<fpage>28</fpage>&#8211;<lpage>36</lpage>.<pub-id pub-id-type="pmid">26585545</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jon.12313</pub-id><pub-id pub-id-type="pmcid">PMC5356023</pub-id></mixed-citation></ref><ref id="fcaf345-B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dale</surname> &#160;<given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Fischl</surname> &#160;<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Sereno</surname> &#160;<given-names>MI</given-names></string-name></person-group>. <article-title>Cortical surface-based analysis: I. Segmentation and surface reconstruction</article-title>. <source>Neuroimage</source>. <year>1999</year>;<volume>9</volume>(<issue>2</issue>):<fpage>179</fpage>&#8211;<lpage>194</lpage>.<pub-id pub-id-type="pmid">9931268</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/nimg.1998.0395</pub-id></mixed-citation></ref><ref id="fcaf345-B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fischl</surname> &#160;<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Salat</surname> &#160;<given-names>DH</given-names></string-name>, <string-name name-style="western"><surname>Busa</surname> &#160;<given-names>E</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Whole brain segmentation: Automated labeling of neuroanatomical structures in the human brain</article-title>. <source>Neuron</source>. <year>2002</year>;<volume>33</volume>(<issue>3</issue>):<fpage>341</fpage>&#8211;<lpage>355</lpage>.<pub-id pub-id-type="pmid">11832223</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0896-6273(02)00569-x</pub-id></mixed-citation></ref><ref id="fcaf345-B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fischl</surname> &#160;<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Sereno</surname> &#160;<given-names>MI</given-names></string-name>, <string-name name-style="western"><surname>Dale</surname> &#160;<given-names>AM</given-names></string-name></person-group>. <article-title>Cortical surface-based analysis. II: Inflation, flattening, and a surface-based coordinate system</article-title>. <source>Neuroimage</source>. <year>1999</year>;<volume>9</volume>(<issue>2</issue>):<fpage>195</fpage>&#8211;<lpage>207</lpage>.<pub-id pub-id-type="pmid">9931269</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/nimg.1998.0396</pub-id></mixed-citation></ref><ref id="fcaf345-B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fischl</surname> &#160;<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Sereno</surname> &#160;<given-names>MI</given-names></string-name>, <string-name name-style="western"><surname>Tootell</surname> &#160;<given-names>RB</given-names></string-name>, <string-name name-style="western"><surname>Dale</surname> &#160;<given-names>AM</given-names></string-name></person-group>. <article-title>High-resolution intersubject averaging and a coordinate system for the cortical surface</article-title>. <source>Hum Brain Mapp</source>. <year>1999</year>;<volume>8</volume>(<issue>4</issue>):<fpage>272</fpage>&#8211;<lpage>284</lpage>.<pub-id pub-id-type="pmid">10619420</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(SICI)1097-0193(1999)8:4&amp;#x0003c;272::AID-HBM10&amp;#x0003e;3.0.CO;2-4</pub-id><pub-id pub-id-type="pmcid">PMC6873338</pub-id></mixed-citation></ref><ref id="fcaf345-B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Destrieux</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Fischl</surname> &#160;<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Dale</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Halgren</surname> &#160;<given-names>E</given-names></string-name></person-group>. <article-title>Automatic parcellation of human cortical gyri and sulci using standard anatomical nomenclature</article-title>. <source>Neuroimage</source>. <year>2010</year>;<volume>53</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>15</lpage>.<pub-id pub-id-type="pmid">20547229</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2010.06.010</pub-id><pub-id pub-id-type="pmcid">PMC2937159</pub-id></mixed-citation></ref><ref id="fcaf345-B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fischl</surname> &#160;<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>van der Kouwe</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Destrieux</surname> &#160;<given-names>C</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Automatically parcellating the human cerebral cortex</article-title>. <source>Cereb Cortex</source>. <year>2004</year>;<volume>14</volume>(<issue>1</issue>):<fpage>11</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="pmid">14654453</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cercor/bhg087</pub-id></mixed-citation></ref><ref id="fcaf345-B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schaer</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Cuadra</surname> &#160;<given-names>MB</given-names></string-name>, <string-name name-style="western"><surname>Schmansky</surname> &#160;<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Fischl</surname> &#160;<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Thiran</surname> &#160;<given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Eliez</surname> &#160;<given-names>S</given-names></string-name></person-group>. <article-title>How to measure cortical folding from MR images: A step-by-step tutorial to compute local gyrification index</article-title>. <source>J Vis Exp</source>. <year>2012</year>;<volume>59</volume>:<fpage>e3417</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3791/3417</pub-id><pub-id pub-id-type="pmcid">PMC3369773</pub-id><pub-id pub-id-type="pmid">22230945</pub-id></mixed-citation></ref><ref id="fcaf345-B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Madan</surname> &#160;<given-names>CR</given-names></string-name></person-group>. <article-title>Robust estimation of sulcal morphology</article-title>. <source>Brain Inform</source>. <year>2019</year>;<volume>6</volume>(<issue>1</issue>):<fpage>5</fpage>.<pub-id pub-id-type="pmid">31187294</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40708-019-0098-1</pub-id><pub-id pub-id-type="pmcid">PMC6560124</pub-id></mixed-citation></ref><ref id="fcaf345-B40"><label>40</label><mixed-citation publication-type="other"><person-group person-group-type="author"><string-name name-style="western"><surname>Sch&#228;fer</surname> &#160;<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Ecker</surname> &#160;<given-names>C</given-names></string-name></person-group>. fsbrain: an R package for the visualization of structural neuroimaging data. <italic toggle="yes">bioRxiv</italic>. [Preprint] doi:<pub-id pub-id-type="doi">10.1101/2020.09.18.302935</pub-id></mixed-citation></ref><ref id="fcaf345-B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Su</surname> &#160;<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Blazey</surname> &#160;<given-names>TM</given-names></string-name>, <string-name name-style="western"><surname>Snyder</surname> &#160;<given-names>AZ</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Partial volume correction in quantitative amyloid imaging</article-title>. <source>Neuroimage</source> &#160;<year>2015</year>;<volume>107</volume>:<fpage>55</fpage>&#8211;<lpage>64</lpage>.<pub-id pub-id-type="pmid">25485714</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2014.11.058</pub-id><pub-id pub-id-type="pmcid">PMC4300252</pub-id></mixed-citation></ref><ref id="fcaf345-B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Su</surname> &#160;<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>D'Angelo</surname> &#160;<given-names>GM</given-names></string-name>, <string-name name-style="western"><surname>Vlassenko</surname> &#160;<given-names>AG</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Quantitative analysis of PiB-PET with FreeSurfer ROIs</article-title>. <source>PLoS One</source>. <year>2013</year>;<volume>8</volume>(<issue>11</issue>):<fpage>e73377</fpage>.<pub-id pub-id-type="pmid">24223109</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0073377</pub-id><pub-id pub-id-type="pmcid">PMC3819320</pub-id></mixed-citation></ref><ref id="fcaf345-B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Alosco</surname> &#160;<given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Barr</surname> &#160;<given-names>WB</given-names></string-name>, <string-name name-style="western"><surname>Banks</surname> &#160;<given-names>SJ</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Neuropsychological test performance of former American football players</article-title>. <source>Alzheimers Res Ther</source>. <year>2023</year>;<volume>15</volume>(<issue>1</issue>):<fpage>1</fpage>.<pub-id pub-id-type="pmid">36597138</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-022-01147-9</pub-id><pub-id pub-id-type="pmcid">PMC9808953</pub-id></mixed-citation></ref><ref id="fcaf345-B44"><label>44</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Stern</surname> &#160;<given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>White</surname> &#160;<given-names>T</given-names></string-name></person-group>. <source>NAB, neuropsychological assessment battery: Administration, scoring, and interpretation manual</source>. <publisher-name>Psychological Assessment Resources Lutz</publisher-name>; <year>2003</year>.</mixed-citation></ref><ref id="fcaf345-B45"><label>45</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Reitan</surname> &#160;<given-names>RM</given-names></string-name></person-group>. <source>Trail making test: Manual for administration and scoring</source>. <publisher-name>Reitan Neuropsychology Laboratory</publisher-name>; <year>1992</year>.</mixed-citation></ref><ref id="fcaf345-B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fotenos</surname> &#160;<given-names>AF</given-names></string-name>, <string-name name-style="western"><surname>Mintun</surname> &#160;<given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Snyder</surname> &#160;<given-names>AZ</given-names></string-name>, <string-name name-style="western"><surname>Morris</surname> &#160;<given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Buckner</surname> &#160;<given-names>RL</given-names></string-name></person-group>. <article-title>Brain volume decline in aging: Evidence for a relation between socioeconomic status, preclinical Alzheimer disease, and reserve</article-title>. <source>Arch Neurol</source>. <year>2008</year>;<volume>65</volume>(<issue>1</issue>):<fpage>113</fpage>&#8211;<lpage>120</lpage>.<pub-id pub-id-type="pmid">18195148</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archneurol.2007.27</pub-id></mixed-citation></ref><ref id="fcaf345-B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fujita</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mori</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Onda</surname> &#160;<given-names>K</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Characterization of brain volume changes in aging individuals with normal cognition using serial magnetic resonance imaging</article-title>. <source>JAMA Netw Open</source>. <year>2023</year>;<volume>6</volume>(<issue>6</issue>):<fpage>e2318153</fpage>.<pub-id pub-id-type="pmid">37378985</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2023.18153</pub-id><pub-id pub-id-type="pmcid">PMC10308250</pub-id></mixed-citation></ref><ref id="fcaf345-B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Turney</surname> &#160;<given-names>IC</given-names></string-name>, <string-name name-style="western"><surname>Lao</surname> &#160;<given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Renter&#237;a</surname> &#160;<given-names>MA</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Brain aging among racially and ethnically diverse middle-aged and older adults</article-title>. <source>JAMA Neurol</source>. <year>2023</year>;<volume>80</volume>(<issue>1</issue>):<fpage>73</fpage>&#8211;<lpage>81</lpage>.<pub-id pub-id-type="pmid">36374494</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2022.3919</pub-id><pub-id pub-id-type="pmcid">PMC9664371</pub-id></mixed-citation></ref><ref id="fcaf345-B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ward</surname> &#160;<given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Carlsson</surname> &#160;<given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Trivedi</surname> &#160;<given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Sager</surname> &#160;<given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Johnson</surname> &#160;<given-names>SC</given-names></string-name></person-group>. <article-title>The effect of body mass index on global brain volume in middle-aged adults: A cross sectional study</article-title>. <source>BMC Neurol</source>. <year>2005</year>;<volume>5</volume>(<issue>1</issue>):<fpage>23</fpage>.<pub-id pub-id-type="pmid">16321166</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-2377-5-23</pub-id><pub-id pub-id-type="pmcid">PMC1325254</pub-id></mixed-citation></ref><ref id="fcaf345-B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Herrmann</surname> &#160;<given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Tesar</surname> &#160;<given-names>A-K</given-names></string-name>, <string-name name-style="western"><surname>Beier</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Berg</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Warrings</surname> &#160;<given-names>B</given-names></string-name></person-group>. <article-title>Grey matter alterations in obesity: A meta-analysis of whole-brain studies</article-title>. <source>Obes Rev</source>. <year>2019</year>;<volume>20</volume>(<issue>3</issue>):<fpage>464</fpage>&#8211;<lpage>471</lpage>.<pub-id pub-id-type="pmid">30537231</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/obr.12799</pub-id></mixed-citation></ref><ref id="fcaf345-B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>G&#243;mez-Apo</surname> &#160;<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Mondrag&#243;n-Maya</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ferrari-D&#237;az</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Silva-Pereyra</surname> &#160;<given-names>J</given-names></string-name></person-group>. <article-title>Structural brain changes associated with overweight and obesity</article-title>. <source>J Obes</source>. <year>2021</year>;<volume>2021</volume>(<issue>1</issue>):<fpage>6613385</fpage>.<pub-id pub-id-type="pmid">34327017</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2021/6613385</pub-id><pub-id pub-id-type="pmcid">PMC8302366</pub-id></mixed-citation></ref><ref id="fcaf345-B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Brickman</surname> &#160;<given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Schupf</surname> &#160;<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Manly</surname> &#160;<given-names>JJ</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Brain morphology in older African Americans, Caribbean Hispanics, and whites from northern Manhattan</article-title>. <source>Arch Neurol</source>. <year>2008</year>;<volume>65</volume>(<issue>8</issue>):<fpage>1053</fpage>&#8211;<lpage>1061</lpage>.<pub-id pub-id-type="pmid">18695055</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archneur.65.8.1053</pub-id><pub-id pub-id-type="pmcid">PMC2692286</pub-id></mixed-citation></ref><ref id="fcaf345-B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Coffey</surname> &#160;<given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Saxton</surname> &#160;<given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Ratcliff</surname> &#160;<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Bryan</surname> &#160;<given-names>RN</given-names></string-name>, <string-name name-style="western"><surname>Lucke</surname> &#160;<given-names>JF</given-names></string-name></person-group>. <article-title>Relation of education to brain size in normal aging: Implications for the reserve hypothesis</article-title>. <source>Neurology</source>. <year>1999</year>;<volume>53</volume>(<issue>1</issue>):<fpage>189</fpage>&#8211;<lpage>189</lpage>.<pub-id pub-id-type="pmid">10408558</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.53.1.189</pub-id></mixed-citation></ref><ref id="fcaf345-B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Foubert-Samier</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Catheline</surname> &#160;<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Amieva</surname> &#160;<given-names>H</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Education, occupation, leisure activities, and brain reserve: A population-based study</article-title>. <source>Neurobiol Aging</source>. <year>2012</year>;<volume>2</volume>:<fpage>423.e15</fpage>&#8211;<lpage>423.e25</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2010.09.023</pub-id><pub-id pub-id-type="pmid">21074901</pub-id></mixed-citation></ref><ref id="fcaf345-B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Arenaza-Urquijo</surname> &#160;<given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Landeau</surname> &#160;<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>La Joie</surname> &#160;<given-names>R</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Relationships between years of education and gray matter volume, metabolism and functional connectivity in healthy elders</article-title>. <source>Neuroimage</source>. <year>2013</year>;<volume>83</volume>:<fpage>450</fpage>&#8211;<lpage>457</lpage>.<pub-id pub-id-type="pmid">23796547</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2013.06.053</pub-id></mixed-citation></ref><ref id="fcaf345-B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kim</surname> &#160;<given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Seo</surname> &#160;<given-names>SW</given-names></string-name>, <string-name name-style="western"><surname>Shin</surname> &#160;<given-names>HY</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Effects of education on aging-related cortical thinning among cognitively normal individuals</article-title>. <source>Neurology</source>. <year>2015</year>;<volume>85</volume>:<fpage>806</fpage>&#8211;<lpage>812</lpage>.<pub-id pub-id-type="pmid">26231257</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000001884</pub-id></mixed-citation></ref><ref id="fcaf345-B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jenkins</surname> &#160;<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Fox</surname> &#160;<given-names>NC</given-names></string-name>, <string-name name-style="western"><surname>Rossor</surname> &#160;<given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Harvey</surname> &#160;<given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Rossor</surname> &#160;<given-names>MN</given-names></string-name></person-group>. <article-title>Intracranial volume and Alzheimer disease: Evidence against the cerebral reserve hypothesis</article-title>. <source>Arch Neurol</source>. <year>2000</year>;<volume>57</volume>(<issue>2</issue>):<fpage>220</fpage>&#8211;<lpage>224</lpage>.<pub-id pub-id-type="pmid">10681081</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archneur.57.2.220</pub-id></mixed-citation></ref><ref id="fcaf345-B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Whitwell</surname> &#160;<given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Crum</surname> &#160;<given-names>WR</given-names></string-name>, <string-name name-style="western"><surname>Watt</surname> &#160;<given-names>HC</given-names></string-name>, <string-name name-style="western"><surname>Fox</surname> &#160;<given-names>NC</given-names></string-name></person-group>. <article-title>Normalization of cerebral volumes by use of intracranial volume: Implications for longitudinal quantitative MR imaging</article-title>. <source>AJNR Am J Neuroradiol</source>. <year>2001</year>;<volume>22</volume>(<issue>8</issue>):<fpage>1483</fpage>&#8211;<lpage>1489</lpage>.<pub-id pub-id-type="pmid">11559495</pub-id><pub-id pub-id-type="pmcid">PMC7974589</pub-id></mixed-citation></ref><ref id="fcaf345-B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Heise</surname> &#160;<given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Offer</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Whiteley</surname> &#160;<given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Mackay</surname> &#160;<given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Armitage</surname> &#160;<given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Parish</surname> &#160;<given-names>S</given-names></string-name></person-group>. <article-title>A comprehensive analysis of APOE genotype effects on human brain structure in the UK Biobank</article-title>. <source>Transl Psychiatry</source>. <year>2024</year>;<volume>14</volume>(<issue>1</issue>):<fpage>143</fpage>.<pub-id pub-id-type="pmid">38472178</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41398-024-02848-5</pub-id><pub-id pub-id-type="pmcid">PMC10933274</pub-id></mixed-citation></ref><ref id="fcaf345-B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>R&#233;gy</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Dugravot</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sabia</surname> &#160;<given-names>S</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Association of APOE &#949;4 with cerebral gray matter volumes in non-demented older adults: The MEMENTO cohort study</article-title>. <source>Neuroimage</source>. <year>2022</year>;<volume>250</volume>:<fpage>118966</fpage>.<pub-id pub-id-type="pmid">35122970</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2022.118966</pub-id></mixed-citation></ref><ref id="fcaf345-B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nicks</surname> &#160;<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Shah</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Stathas</surname> &#160;<given-names>SA</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Neurodegeneration in the cortical sulcus is a feature of chronic traumatic encephalopathy and associated with repetitive head impacts</article-title>. <source>Acta Neuropathol</source>. <year>2024</year>;<volume>148</volume>(<issue>1</issue>):<fpage>79</fpage>.<pub-id pub-id-type="pmid">39643767</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-024-02833-8</pub-id><pub-id pub-id-type="pmcid">PMC11624223</pub-id></mixed-citation></ref><ref id="fcaf345-B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Adler</surname> &#160;<given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>DelBello</surname> &#160;<given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Weber</surname> &#160;<given-names>W</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>MRI evidence of neuropathic changes in former college football players</article-title>. <source>Clin J Sport Med</source>. <year>2018</year>;<volume>28</volume>(<issue>2</issue>):<fpage>100</fpage>&#8211;<lpage>105</lpage>.<pub-id pub-id-type="pmid">27755011</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/JSM.0000000000000391</pub-id></mixed-citation></ref><ref id="fcaf345-B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ghajari</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hellyer</surname> &#160;<given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Sharp</surname> &#160;<given-names>DJ</given-names></string-name></person-group>. <article-title>Computational modelling of traumatic brain injury predicts the location of chronic traumatic encephalopathy pathology</article-title>. <source>Brain</source>. <year>2017</year>;<volume>140</volume>(<issue>2</issue>):<fpage>333</fpage>&#8211;<lpage>343</lpage>.<pub-id pub-id-type="pmid">28043957</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/aww317</pub-id><pub-id pub-id-type="pmcid">PMC5278309</pub-id></mixed-citation></ref><ref id="fcaf345-B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kerwin</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Y&#252;cesoy</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Vidhate</surname> &#160;<given-names>S</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Sulcal cavitation in linear head acceleration: Possible correlation with chronic traumatic encephalopathy</article-title>. <source>Front Neurol</source>. <year>2022</year>;<volume>13</volume>:<fpage>832370</fpage>.<pub-id pub-id-type="pmid">35295830</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2022.832370</pub-id><pub-id pub-id-type="pmcid">PMC8918564</pub-id></mixed-citation></ref><ref id="fcaf345-B65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Butler</surname> &#160;<given-names>MLMD</given-names></string-name>, <string-name name-style="western"><surname>Dixon</surname> &#160;<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Stein</surname> &#160;<given-names>TD</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Tau pathology in chronic traumatic encephalopathy is primarily neuronal</article-title>. <source>J Neuropathol Exp Neurol</source>. <year>2022</year>;<volume>81</volume>(<issue>10</issue>):<fpage>773</fpage>&#8211;<lpage>780</lpage>.<pub-id pub-id-type="pmid">35903039</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnen/nlac065</pub-id><pub-id pub-id-type="pmcid">PMC9487650</pub-id></mixed-citation></ref><ref id="fcaf345-B66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Arciniega</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Baucom</surname> &#160;<given-names>ZH</given-names></string-name>, <string-name name-style="western"><surname>Tuz-Zahra</surname> &#160;<given-names>F</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Brain morphometry in former American football players: Findings from the DIAGNOSE CTE research project</article-title>. <source>Brain</source>. <year>2024</year>;<volume>147</volume>(<issue>10</issue>):<fpage>3596</fpage>&#8211;<lpage>3610</lpage>.<pub-id pub-id-type="pmid">38533783</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awae098</pub-id><pub-id pub-id-type="pmcid">PMC11449133</pub-id></mixed-citation></ref><ref id="fcaf345-B67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kaufmann</surname> &#160;<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Sollmann</surname> &#160;<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Kaufmann</surname> &#160;<given-names>E</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Age at first exposure to tackle football is associated with cortical thickness in former professional American football players</article-title>. <source>Cereb Cortex</source>. <year>2021</year>;<volume>31</volume>(<issue>7</issue>):<fpage>3426</fpage>&#8211;<lpage>3434</lpage>.<pub-id pub-id-type="pmid">33676369</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cercor/bhab021</pub-id><pub-id pub-id-type="pmcid">PMC8196248</pub-id></mixed-citation></ref><ref id="fcaf345-B68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Alosco</surname> &#160;<given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Stern</surname> &#160;<given-names>RA</given-names></string-name></person-group>. <article-title>Youth exposure to repetitive head impacts from tackle football and long-term neurologic outcomes: A review of the literature, knowledge gaps and future directions, and societal and clinical implications</article-title>. <source>Semin Pediatr Neurol</source>. <year>2019</year>;<volume>30</volume>:<fpage>107</fpage>&#8211;<lpage>116</lpage>.<pub-id pub-id-type="pmid">31235012</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.spen.2019.03.016</pub-id></mixed-citation></ref><ref id="fcaf345-B69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Alosco</surname> &#160;<given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Kasimis</surname> &#160;<given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>Stamm</surname> &#160;<given-names>JM</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Age of first exposure to American football and long-term neuropsychiatric and cognitive outcomes</article-title>. <source>Transl Psychiatry</source>. <year>2017</year>;<volume>7</volume>(<issue>9</issue>):<fpage>e1236</fpage>.<pub-id pub-id-type="pmid">28926003</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/tp.2017.197</pub-id><pub-id pub-id-type="pmcid">PMC5639242</pub-id></mixed-citation></ref><ref id="fcaf345-B70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Deshpande</surname> &#160;<given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Hasegawa</surname> &#160;<given-names>RB</given-names></string-name>, <string-name name-style="western"><surname>Rabinowitz</surname> &#160;<given-names>AR</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Association of playing high school football with cognition and mental health later in life</article-title>. <source>JAMA Neurol</source>. <year>2017</year>;<volume>74</volume>(<issue>8</issue>):<fpage>909</fpage>&#8211;<lpage>918</lpage>.<pub-id pub-id-type="pmid">28672325</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2017.1317</pub-id><pub-id pub-id-type="pmcid">PMC5710329</pub-id></mixed-citation></ref><ref id="fcaf345-B71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Stamm</surname> &#160;<given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Koerte</surname> &#160;<given-names>IK</given-names></string-name>, <string-name name-style="western"><surname>Muehlmann</surname> &#160;<given-names>M</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Age at first exposure to football is associated with altered corpus callosum white matter microstructure in former professional football players</article-title>. <source>J Neurotrauma</source>. <year>2015</year>;<volume>32</volume>(<issue>22</issue>):<fpage>1768</fpage>&#8211;<lpage>1776</lpage>.<pub-id pub-id-type="pmid">26200068</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/neu.2014.3822</pub-id><pub-id pub-id-type="pmcid">PMC4651044</pub-id></mixed-citation></ref><ref id="fcaf345-B72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Stamm</surname> &#160;<given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Bourlas</surname> &#160;<given-names>AP</given-names></string-name>, <string-name name-style="western"><surname>Baugh</surname> &#160;<given-names>CM</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Age of first exposure to football and later-life cognitive impairment in former NFL players</article-title>. <source>Neurology</source>. <year>2015</year>;<volume>84</volume>(<issue>11</issue>):<fpage>1114</fpage>&#8211;<lpage>1120</lpage>.<pub-id pub-id-type="pmid">25632088</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000001358</pub-id><pub-id pub-id-type="pmcid">PMC4371403</pub-id></mixed-citation></ref><ref id="fcaf345-B73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Terry</surname> &#160;<given-names>DP</given-names></string-name>, <string-name name-style="western"><surname>Grashow</surname> &#160;<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Iverson</surname> &#160;<given-names>GL</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Age of first exposure does not relate to post-career health in former professional American-style football players</article-title>. <source>Sports Med</source>. <year>2024</year>;<volume>54</volume>:<fpage>2675</fpage>&#8211;<lpage>2684</lpage>.<pub-id pub-id-type="pmid">38918303</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40279-024-02062-9</pub-id><pub-id pub-id-type="pmcid">PMC11467122</pub-id></mixed-citation></ref><ref id="fcaf345-B74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Iverson</surname> &#160;<given-names>GL</given-names></string-name>, <string-name name-style="western"><surname>Caccese</surname> &#160;<given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Merz</surname> &#160;<given-names>ZC</given-names></string-name>, <string-name name-style="western"><surname>B&#252;ttner</surname> &#160;<given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Terry</surname> &#160;<given-names>DP</given-names></string-name></person-group>. <article-title>Age of first exposure to football is not associated with later-in-life cognitive or mental health problems</article-title>. <source>Front Neurol</source>. <year>2021</year>;<volume>12</volume>:<fpage>647314</fpage>.<pub-id pub-id-type="pmid">34025554</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2021.647314</pub-id><pub-id pub-id-type="pmcid">PMC8131846</pub-id></mixed-citation></ref><ref id="fcaf345-B75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Iverson</surname> &#160;<given-names>GL</given-names></string-name>, <string-name name-style="western"><surname>Terry</surname> &#160;<given-names>DP</given-names></string-name>, <string-name name-style="western"><surname>Caccese</surname> &#160;<given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>B&#252;ttner</surname> &#160;<given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Merz</surname> &#160;<given-names>ZC</given-names></string-name></person-group>. <article-title>Age of first exposure to football is not associated with midlife brain health problems</article-title>. <source>J Neurotrauma</source>. <year>2021</year>;<volume>38</volume>(<issue>5</issue>):<fpage>538</fpage>&#8211;<lpage>545</lpage>.<pub-id pub-id-type="pmid">33126834</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/neu.2020.7041</pub-id></mixed-citation></ref><ref id="fcaf345-B76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Caccese</surname> &#160;<given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>DeWolf</surname> &#160;<given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Kaminski</surname> &#160;<given-names>TW</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Estimated age of first exposure to American football and neurocognitive performance amongst NCAA male student-athletes: A cohort study</article-title>. <source>Sports Med</source>. <year>2019</year>;<volume>49</volume>(<issue>3</issue>):<fpage>477</fpage>&#8211;<lpage>487</lpage>.<pub-id pub-id-type="pmid">30747378</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40279-019-01069-x</pub-id></mixed-citation></ref><ref id="fcaf345-B77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Caccese</surname> &#160;<given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Bodt</surname> &#160;<given-names>BA</given-names></string-name>, <string-name name-style="western"><surname>Iverson</surname> &#160;<given-names>GL</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Estimated age of first exposure to contact sports and neurocognitive, psychological, and physical outcomes in healthy NCAA collegiate athletes: A cohort study</article-title>. <source>Sports Med</source>. <year>2020</year>;<volume>50</volume>(<issue>7</issue>):<fpage>1377</fpage>&#8211;<lpage>1392</lpage>.<pub-id pub-id-type="pmid">32002824</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40279-020-01261-4</pub-id></mixed-citation></ref><ref id="fcaf345-B78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Solomon</surname> &#160;<given-names>GS</given-names></string-name>, <string-name name-style="western"><surname>Kuhn</surname> &#160;<given-names>AW</given-names></string-name>, <string-name name-style="western"><surname>Zuckerman</surname> &#160;<given-names>SL</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Participation in pre-high school football and neurological, neuroradiological, and neuropsychological findings in later life: A study of 45 retired national football league players</article-title>. <source>Am J Sports Med</source>. <year>2016</year>;<volume>5</volume>:<fpage>1106</fpage>&#8211;<lpage>1115</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0363546515626164</pub-id><pub-id pub-id-type="pmid">26888877</pub-id></mixed-citation></ref><ref id="fcaf345-B79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Roberts</surname> &#160;<given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Pascual-Leone</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Speizer</surname> &#160;<given-names>FE</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Exposure to American football and neuropsychiatric health in former national football league players: Findings from the football players health study</article-title>. <source>Am J Sports Med</source>. <year>2019</year>;<volume>47</volume>(<issue>12</issue>):<fpage>2871</fpage>&#8211;<lpage>2880</lpage>.<pub-id pub-id-type="pmid">31468987</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0363546519868989</pub-id><pub-id pub-id-type="pmcid">PMC7163246</pub-id></mixed-citation></ref><ref id="fcaf345-B80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Arciniega</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Jung</surname> &#160;<given-names>LB</given-names></string-name>, <string-name name-style="western"><surname>Tuz-Zahra</surname> &#160;<given-names>F</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Cavum septum pellucidum in former American football players: Findings from the DIAGNOSE CTE research project</article-title>. <source>Neurol Clin Pract</source>. <year>2024</year>;<volume>14</volume>(<issue>5</issue>):<fpage>e200324</fpage>.<pub-id pub-id-type="pmid">39161749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/CPJ.0000000000200324</pub-id><pub-id pub-id-type="pmcid">PMC11332980</pub-id></mixed-citation></ref><ref id="fcaf345-B81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Iverson</surname> &#160;<given-names>GL</given-names></string-name>, <string-name name-style="western"><surname>Gardner</surname> &#160;<given-names>AJ</given-names></string-name></person-group>. <article-title>Symptoms of traumatic encephalopathy syndrome are common in the US general population</article-title>. <source>Brain Commun</source>. <year>2021</year>;<volume>3</volume>(<issue>1</issue>):<fpage>fcab001</fpage>.<pub-id pub-id-type="pmid">33842882</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/braincomms/fcab001</pub-id><pub-id pub-id-type="pmcid">PMC8023423</pub-id></mixed-citation></ref><ref id="fcaf345-B82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mez</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Alosco</surname> &#160;<given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Daneshvar</surname> &#160;<given-names>DH</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Validity of the 2014 traumatic encephalopathy syndrome criteria for CTE pathology</article-title>. <source>Alzheimers Dement</source>. <year>2021</year>;<volume>17</volume>(<issue>10</issue>):<fpage>1709</fpage>&#8211;<lpage>1724</lpage>.<pub-id pub-id-type="pmid">33826224</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12338</pub-id><pub-id pub-id-type="pmcid">PMC8596795</pub-id></mixed-citation></ref><ref id="fcaf345-B83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Subotic</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>McCreary</surname> &#160;<given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Saad</surname> &#160;<given-names>F</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Cortical thickness and its association with clinical cognitive and neuroimaging markers in cerebral amyloid angiopathy</article-title>. <source>J Alzheimers Dis</source>. <year>2021</year>;<volume>81</volume>(<issue>4</issue>):<fpage>1663</fpage>&#8211;<lpage>1671</lpage>.<pub-id pub-id-type="pmid">33998545</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-210138</pub-id><pub-id pub-id-type="pmcid">PMC8293635</pub-id></mixed-citation></ref><ref id="fcaf345-B84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Veselinovi&#263;</surname> &#160;<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Rajkumar</surname> &#160;<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Amort</surname> &#160;<given-names>L</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Connectivity patterns in the core resting-state networks and their influence on cognition</article-title>. <source>Brain Connect</source>. <year>2022</year>;<volume>12</volume>(<issue>4</issue>):<fpage>334</fpage>&#8211;<lpage>347</lpage>.<pub-id pub-id-type="pmid">34182786</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/brain.2020.0943</pub-id></mixed-citation></ref><ref id="fcaf345-B85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Madden</surname> &#160;<given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Bennett</surname> &#160;<given-names>IJ</given-names></string-name>, <string-name name-style="western"><surname>Song</surname> &#160;<given-names>AW</given-names></string-name></person-group>. <article-title>Cerebral white matter integrity and cognitive aging: Contributions from diffusion tensor imaging</article-title>. <source>Neuropsychol Rev</source>. <year>2009</year>;<volume>19</volume>(<issue>4</issue>):<fpage>415</fpage>&#8211;<lpage>435</lpage>.<pub-id pub-id-type="pmid">19705281</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11065-009-9113-2</pub-id><pub-id pub-id-type="pmcid">PMC2787975</pub-id></mixed-citation></ref><ref id="fcaf345-B86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Janssen</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Alloza</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>D&#237;az-Caneja</surname> &#160;<given-names>CM</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Longitudinal allometry of sulcal morphology in health and schizophrenia</article-title>. <source>J Neurosci</source>. <year>2022</year>;<volume>42</volume>(<issue>18</issue>):<fpage>3704</fpage>&#8211;<lpage>3715</lpage>.<pub-id pub-id-type="pmid">35318286</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.0606-21.2022</pub-id><pub-id pub-id-type="pmcid">PMC9087719</pub-id></mixed-citation></ref><ref id="fcaf345-B87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Amiez</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wilson</surname> &#160;<given-names>CRE</given-names></string-name>, <string-name name-style="western"><surname>Procyk</surname> &#160;<given-names>E</given-names></string-name></person-group>. <article-title>Variations of cingulate sulcal organization and link with cognitive performance</article-title>. <source>Sci Rep</source>. <year>2018</year>;<volume>8</volume>(<issue>1</issue>):<fpage>13988</fpage>.<pub-id pub-id-type="pmid">30228357</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-018-32088-9</pub-id><pub-id pub-id-type="pmcid">PMC6143647</pub-id></mixed-citation></ref><ref id="fcaf345-B88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mortamais</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gutierrez</surname> &#160;<given-names>L-A</given-names></string-name>, <string-name name-style="western"><surname>Balem</surname> &#160;<given-names>M</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Sulcal morphology as cognitive decline predictor in older adults with memory complaints</article-title>. <source>Neurobiol Aging</source>. <year>2022</year>;<volume>113</volume>:<fpage>84</fpage>&#8211;<lpage>94</lpage>.<pub-id pub-id-type="pmid">35325814</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2022.02.003</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">eLife</journal-id><journal-id journal-id-type="iso-abbrev">Elife</journal-id><journal-id journal-id-type="pmc-domain-id">1894</journal-id><journal-id journal-id-type="pmc-domain">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12494380</article-id><article-id pub-id-type="pmcid-ver">PMC12494380.1</article-id><article-id pub-id-type="pmcaid">12494380</article-id><article-id pub-id-type="pmcaiid">12494380</article-id><article-id pub-id-type="pmid">41042139</article-id><article-id pub-id-type="doi">10.7554/eLife.102449</article-id><article-id pub-id-type="publisher-id">102449</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version article-version-type="publication-state">version of record</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Chromosomes and Gene Expression</subject></subj-group><subj-group subj-group-type="heading"><subject>Computational and Systems Biology</subject></subj-group></article-categories><title-group><article-title>Pan-tissue transcriptome analysis reveals sex-dimorphic human aging</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Wang</surname><given-names initials="S">Siqi</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1491-2962</contrib-id><email>siqiwang@ucla.edu</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="con1" ref-type="fn"/><xref rid="conf1" ref-type="fn"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dong</surname><given-names initials="D">Danyue</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="con2" ref-type="fn"/><xref rid="conf1" ref-type="fn"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="X">Xin</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="fund6" ref-type="other"/><xref rid="fund8" ref-type="other"/><xref rid="fund7" ref-type="other"/><xref rid="con3" ref-type="fn"/><xref rid="conf1" ref-type="fn"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Wang</surname><given-names initials="Z">Zefeng</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6605-3637</contrib-id><email>wangzf@sustech.edu.cn</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff3" ref-type="aff">3</xref><xref rid="fund1" ref-type="other"/><xref rid="fund5" ref-type="other"/><xref rid="fund3" ref-type="other"/><xref rid="fund4" ref-type="other"/><xref rid="con4" ref-type="fn"/><xref rid="conf1" ref-type="fn"/></contrib><aff id="aff1">
<label>1</label>
<institution-wrap><institution-id institution-id-type="ror">https://ror.org/00rytkh49</institution-id><institution>Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences</institution></institution-wrap>
<addr-line>Shanghai</addr-line>
<country>China</country>
</aff><aff id="aff2">
<label>2</label>
<institution-wrap><institution-id institution-id-type="ror">https://ror.org/046rm7j60</institution-id><institution>University of California, Los Angeles</institution></institution-wrap>
<addr-line>Los Angeles</addr-line>
<country>United States</country>
</aff><aff id="aff3">
<label>3</label>
<institution-wrap><institution-id institution-id-type="ror">https://ror.org/049tv2d57</institution-id><institution>School of Life Science, Southern University of Science and Technology</institution></institution-wrap>
<addr-line>Shenzhen</addr-line>
<country>China</country>
</aff></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Gurkar</surname><given-names initials="AU">Aditi U</given-names></name><role>Reviewing Editor</role><aff>
<institution-wrap><institution-id institution-id-type="ror">https://ror.org/01an3r305</institution-id><institution>University of Pittsburgh</institution></institution-wrap>
<country>United States</country>
</aff></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Kapahi</surname><given-names initials="P">Pankaj</given-names></name><role>Senior Editor</role><aff>
<institution-wrap><institution-id institution-id-type="ror">https://ror.org/050sv4x28</institution-id><institution>Buck Institute for Research on Aging</institution></institution-wrap>
<country>United States</country>
</aff></contrib></contrib-group><pub-date date-type="pub" publication-format="electronic"><day>03</day><month>10</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2025</year></pub-date><volume>13</volume><issue-id pub-id-type="pmc-issue-id">452381</issue-id><elocation-id>RP102449</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-09-21"><day>21</day><month>9</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-04 17:26:04.457"><day>04</day><month>10</month><year>2025</year></date></event><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-09-25"><day>25</day><month>9</month><year>2024</year></date><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="preprint" xlink:href="https://doi.org/10.1101/2023.05.26.542373"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-12-03"><day>03</day><month>12</month><year>2024</year></date><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.102449.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-07-09"><day>09</day><month>7</month><year>2025</year></date><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.102449.2"/></event></pub-history><permissions><copyright-statement>&#169; 2024, Wang et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Wang et al</copyright-holder><ali:free_to_read/><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="elife-102449.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="elife-102449.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="figures-pdf" xlink:href="elife-102449-figures.pdf"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="preprint" xml:lang="en" ext-link-type="doi" xlink:href="10.1101/2023.05.26.542373"><pub-id pub-id-type="doi">10.1101/2023.05.26.542373</pub-id></related-article><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="preprint" xml:lang="en" ext-link-type="doi" xlink:href="10.7554/eLife.102449.1"><pub-id pub-id-type="doi">10.7554/eLife.102449.1</pub-id></related-article><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="preprint" xml:lang="en" ext-link-type="doi" xlink:href="10.7554/eLife.102449.2"><pub-id pub-id-type="doi">10.7554/eLife.102449.2</pub-id></related-article><abstract><p>Complex diseases often exhibit sex dimorphism in morbidity and prognosis, many of which are age-related. However, the underlying mechanisms of sex-dimorphic aging remain foggy, with limited studies across multiple tissues. We systematically analyzed ~17,000 transcriptomes from 35 human tissues to quantitatively evaluate the individual and combined contributions of sex and age to transcriptomic variations. We discovered extensive sex dimorphisms during aging with distinct patterns of change in gene expression and alternative splicing (AS). Intriguingly, the male-biased age-associated AS events have a stronger association with Alzheimer&#8217;s disease, and the female-biased events are often regulated by several sex-biased splicing factors that may be controlled by estrogen receptors. Breakpoint analysis showed that sex-dimorphic aging rates are significantly associated with decline of sex hormones, with males having a larger and earlier transcriptome change. Collectively, this study uncovered an essential role of sex during aging at the molecular and multi-tissue levels, providing insight into sex-dimorphic regulatory patterns.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>sex dimorphism</kwd><kwd>aging</kwd><kwd>alternative splicing</kwd><kwd>AS regulatory network</kwd><kwd>time series</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>Strategic Priority Research Program of CAS</institution></institution-wrap></funding-source><award-id>XDB38040100</award-id><principal-award-recipient><name name-style="western"><surname>Wang</surname><given-names>Zefeng</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>91940303</award-id><principal-award-recipient><name name-style="western"><surname>Wang</surname><given-names>Zefeng</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01h0zpd94</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>32030064</award-id><principal-award-recipient><name name-style="western"><surname>Wang</surname><given-names>Zefeng</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01h0zpd94</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>31730110</award-id><principal-award-recipient><name name-style="western"><surname>Wang</surname><given-names>Zefeng</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution>National Key Research and Development Program of China</institution></institution-wrap></funding-source><award-id>2018YFA0107602</award-id><principal-award-recipient><name name-style="western"><surname>Wang</surname><given-names>Zefeng</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution>National Key Research and Development Program of China</institution></institution-wrap></funding-source><award-id>2021YFA0805200</award-id><principal-award-recipient><name name-style="western"><surname>Li</surname><given-names>Xin</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution>National Key Research and Development Program of China</institution></institution-wrap></funding-source><award-id>2019YFC1315804</award-id><principal-award-recipient><name name-style="western"><surname>Li</surname><given-names>Xin</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>31970554</award-id><principal-award-recipient><name name-style="western"><surname>Li</surname><given-names>Xin</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Widespread sex-dimorphic transcriptomic changes during human aging in pan-tissues scale reveal distinct molecular aging trajectories and potential links to age-related disease vulnerability.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Human diseases often exhibit differences between females and males, including sex-differential morbidity, prognosis, and mortality (<xref rid="bib80" ref-type="bibr">Westergaard et al., 2019</xref>; <xref rid="bib42" ref-type="bibr">Khramtsova et al., 2019</xref>; <xref rid="bib65" ref-type="bibr">Regitz-Zagrosek, 2012</xref>). The sex dimorphism has been widely reported in neurological disorders (<xref rid="bib24" ref-type="bibr">Ferretti et al., 2018</xref>; <xref rid="bib37" ref-type="bibr">Jazin and Cahill, 2010</xref>), cardiovascular diseases (<xref rid="bib16" ref-type="bibr">Colafella and Denton, 2018</xref>), immunological defects (<xref rid="bib43" ref-type="bibr">Klein and Flanagan, 2016</xref>), and cancers (<xref rid="bib48" ref-type="bibr">Li et al., 2018b</xref>). Accordingly, the life expectancy shows substantial variability between females and males. The evidence on sex-differential mortality was recently reported during the COVID-19 pandemic, mainly affected by different immune responses between females and males (<xref rid="bib62" ref-type="bibr">Park, 2020</xref>; <xref rid="bib73" ref-type="bibr">Takahashi et al., 2020</xref>). The known molecular mechanisms mostly revolved around sex-differential genetic variants, epigenetics, transcriptomes, and sex-differential responses to environmental exposures (<xref rid="bib42" ref-type="bibr">Khramtsova et al., 2019</xref>). It is worth noting that many diseases with sex dimorphism are also age-related, especially in neurodegenerative disorders, cardiovascular diseases, and cancers (<xref rid="bib67" ref-type="bibr">Sampathkumar et al., 2020</xref>). Such sex-differential susceptibility contributes substantially to different life expectancies between females and males, and the related underlying mechanisms are thought to be hormone-driven, mitochondria-related, and sex-chromosome-linked (<xref rid="bib67" ref-type="bibr">Sampathkumar et al., 2020</xref>; <xref rid="bib30" ref-type="bibr">H&#228;gg and Jylh&#228;v&#228;, 2021</xref>; <xref rid="bib5" ref-type="bibr">Austad and Fischer, 2016</xref>; <xref rid="bib17" ref-type="bibr">Davis et al., 2021</xref>; <xref rid="bib25" ref-type="bibr">Ferretti and Santuccione Chadha, 2021</xref>). Previously, sex-differential aging signatures, including chronological trends and gene networks, have been studied in the whole blood and brain regions of healthy donors (<xref rid="bib52" ref-type="bibr">M&#225;rquez et al., 2020</xref>), revealing the sex differences of disease vulnerabilities during aging (<xref rid="bib9" ref-type="bibr">Berchtold et al., 2008</xref>; <xref rid="bib91" ref-type="bibr">Zhou et al., 2023</xref>). Sex differences regarding the composition and inflammatory signaling of immunocytes in blood were also analyzed in single-cell resolution, which suggested sex-differential aging in the immune response (<xref rid="bib36" ref-type="bibr">Huang et al., 2021</xref>). Moreover, at the proteogenomic level, sex-biased genes play key roles in several important cellular processes during cardiac aging, such as mitochondrial metabolism, RNA splicing, and translation, implying sex dimorphism in cardiac diseases (<xref rid="bib31" ref-type="bibr">Han et al., 2022</xref>). However, a systematic analysis across multiple tissues on the sex-differential aging and underlying molecular mechanisms is currently lacking.</p><p>The Genotype-Tissue Expression (GTEx) project contains a large set of high-throughput sequencing data from postmortem donors across 54 human tissues (<xref rid="bib1" ref-type="bibr">Aguet et al., 2020</xref>; <xref rid="bib61" ref-type="bibr">Oliva et al., 2020</xref>). Previous studies have uncovered many sex-biased genes or expression quantitative trait loci (eQTLs) (<xref rid="bib61" ref-type="bibr">Oliva et al., 2020</xref>; <xref rid="bib41" ref-type="bibr">Khodursky et al., 2022</xref>) across different tissues that could affect several critical cellular signal pathways related to human diseases. Since the GTEx donors have a wide age range of 20&#8211;70 years, it is possible to identify genes and molecular pathways significantly changed during the aging process (<xref rid="bib89" ref-type="bibr">Zeng et al., 2020</xref>; <xref rid="bib38" ref-type="bibr">Jia et al., 2018</xref>). However, the relationship between sex-differential regulation and aging has not been thoroughly studied on a transcriptome or pan-tissue level scale. Therefore, the GTEx data could also provide an integrated resource for a comprehensive study of this topic.</p><p>In addition to transcriptional regulation, most human genes undergo alternative splicing (AS) to produce different isoforms with distinct activities (<xref rid="bib29" ref-type="bibr">Gallego-Paez et al., 2017</xref>). AS is tightly regulated in various tissues or developmental stages by multiple <italic toggle="yes">cis</italic>-acting elements and <italic toggle="yes">trans</italic>-acting factors (<xref rid="bib75" ref-type="bibr">Wang and Burge, 2008</xref>; <xref rid="bib8" ref-type="bibr">Baralle and Giudice, 2017</xref>). Dysregulation of AS is closely related to many age-related diseases, such as neurodegenerative diseases (<xref rid="bib57" ref-type="bibr">Nikom and Zheng, 2023</xref>) and cancers (<xref rid="bib78" ref-type="bibr">Wang et al., 2020</xref>). Since most introns are co-transcriptionally spliced, AS is also affected by various factors that regulate transcription, such as promoter activity, Pol II elongation, and chromatin modification/remodeling (<xref rid="bib8" ref-type="bibr">Baralle and Giudice, 2017</xref>). Recent studies reported that AS regulation is closely associated with sex (<xref rid="bib40" ref-type="bibr">Karlebach et al., 2020</xref>) and age (<xref rid="bib77" ref-type="bibr">Wang et al., 2018</xref>; <xref rid="bib11" ref-type="bibr">Bhadra et al., 2020</xref>; <xref rid="bib4" ref-type="bibr">Angarola and Anczuk&#243;w, 2021</xref>) thus, it is intriguing to further explore the AS regulation during aging stages in different sexes.</p><p>In this study, we initiated an integrated analysis of pan-tissue transcriptome data in GTEx and systematically determined how sex and age contributed to the global variations of gene expression (GE) and AS (<xref rid="fig1" ref-type="fig">Figure 1</xref>). We further focused on the sex-biased AS changes during aging and found that these AS events are significantly associated with neurodegenerative diseases in a sex-biased fashion. We further examined the chronological changes of age-associated genes and found a sex-dimorphic transcriptome aging, with males showing an earlier onset of aging and a faster aging rate in most tissues. Collectively, this study clarified the sex and age effects on the transcriptomic changes, revealing the sex-dimorphic aging at a multi-tissue level and their potential mechanisms.</p><fig position="float" id="fig1" orientation="portrait"><label>Figure 1.</label><caption><title>Schematic overview of our study.</title><p>RNA-seq datasets from 54 human tissues (including 13 brain regions) were downloaded from GTEx Portal. Gene expression (GE) and alternative splicing (AS) quantifications were performed by Paean. The individual sex or age and age-by-sex effects on global transcriptomic variation were evaluated by designing a principal component-based signal-to-variation <underline>r</underline>atio (pcSVR) value, and the age-differential genes/AS events were subsequently identified in each sex. Sex-biased age-associated AS events were used to find the sex-specific associations with certain diseases. We also constructed AS regulatory networks to find the regulatory age-associated splicing factors (SFs) and explored the transcriptional regulation of sex hormones via nuclear receptors. Moreover, we focused on age-associated GE and then evaluated the aging rate and their modulated genes in different sexes.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="elife-102449-fig1.jpg"/><p content-type="supplemental-figure"><fig position="anchor" id="fig1s1" specific-use="child-fig" orientation="portrait"><label>Figure 1&#8212;figure supplement 1.</label><caption><title>Principal component analysis (PCA) on gene expression (GE) and alternative splicing (AS) profiles.</title><p>PCA is performed using GE and AS profiles, respectively. The <italic toggle="yes">X</italic>- and <italic toggle="yes">Y</italic>-axis indicate scores of the top 2 PCs. Female and male samples are labeled with the red and blue dots, while samples with continuous ages are labeled in a gradient palette. The percentage of explained variation by each PC is labeled nearby each axis.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="elife-102449-fig1-figsupp1.jpg"/></fig></p></fig></sec><sec sec-type="results" id="s2"><title>Results</title><sec id="s2-1"><title>Sex and age are critical drivers to the global transcriptome variation</title><p>To systematically study how sex and age affect transcriptome complexity, we conducted a thorough analysis of RNA-seq data from the GTEx project (<xref rid="bib1" ref-type="bibr">Aguet et al., 2020</xref>) to quantify the GE and AS patterns of all genes from 54 tissues (<xref rid="fig1" ref-type="fig">Figure 1</xref>). Due to data sparseness, the brain tissues were recombined into four functional regions (<xref rid="supp1" ref-type="supplementary-material">Supplementary file 1</xref>), including hormone- or emotion-related region, movement-related region, memory-related region, and decision-related region (see Methods). We performed the principal component analysis (PCA) on GE and AS data and observed the sex and age differences in several tissues (<xref rid="fig1s1" ref-type="fig">Figure 1&#8212;figure supplement 1</xref>). Based on a previous study (<xref rid="bib51" ref-type="bibr">Lopes-Ramos et al., 2020</xref>), we designed a method called <underline>p</underline>rincipal <underline>c</underline>omponent-based <underline>s</underline>ignal-to-<underline>v</underline>ariation <underline>r</underline>atio (pcSVR) to measure the adjusted Euclidean distance in higher dimensions. The pcSVR quantified the distance between different sex or age groups divided by the data dispersion within each group (intrinsic differences between groups will result in a pcSVR value significantly larger than 1), serving as a reliable measurement for the sex or age effects on transcriptomic variations (<xref rid="fig2s1" ref-type="fig">Figure 2&#8212;figure supplement 1A</xref>, see Materials and methods, <xref rid="equ1 equ2 equ3" ref-type="disp-formula">Equations 1&#8211;3</xref>). Compared with the direct identification of differentially expressed genes or AS events, pcSVR provides a global measurement by considering variations from all genes and AS events between different groups.</p><p>We grouped the samples into male vs. female and young vs. old and calculated the sex-pcSVR and age-pcSVR in multiple tissues (<xref rid="fig2" ref-type="fig">Figure 2A, B</xref>). Due to a large variation of menopause ages among different individuals and a continuous decline of sexual steroid levels between ages 40 and 60 (<xref rid="bib15" ref-type="bibr">Chan et al., 2020</xref>; <xref rid="bib59" ref-type="bibr">Ober et al., 2008</xref>), we grouped the samples into young (age &lt;40) vs. old (age &gt;60) with an age gap instead of a specific age cutoff to reduce the data noise. We found that the breast tissue showed the largest sex-pcSVR, while the adipose and cardiovascular tissues showed larger age-pcSVR (i.e., differences between age groups). The tissues with significant sex differences were similar to those reported in a previous study of sex-differential GE using transcriptomic signal-to-noise ratio (SNR) (<xref rid="bib51" ref-type="bibr">Lopes-Ramos et al., 2020</xref>), including breast, thyroid, skin, and adipose. Using the permutation test for pcSVRs, we found that age showed substantially larger effects than sex to human transcriptome in most tissues as judged by both GE and AS (<xref rid="fig2" ref-type="fig">Figure 2A, B</xref>, <xref rid="supp2" ref-type="supplementary-material">Supplementary file 2</xref>). Moreover, AS was significantly affected by both sex and age across most tissues, while GE was affected by sex in a much smaller number of tissues as compared to AS profiles (i.e., comparing the orange triangles in <xref rid="fig2" ref-type="fig">Figure 2A vs. B</xref>). For example, the coronary artery and adrenal gland are significantly affected by sex and age in their AS profile, but their GE profiles are not affected by sex or age (<xref rid="fig2" ref-type="fig">Figure 2A, B</xref>). Similar results were found even when removing the genes and AS events encoded by sex chromosomes (<xref rid="fig2s1" ref-type="fig">Figure 2&#8212;figure supplement 1B, C</xref>), selecting a range of PC cutoffs to capture different global variance (<xref rid="fig2s1" ref-type="fig">Figure 2&#8212;figure supplement 1D, E</xref>), or using other approaches for p-value estimation (e.g., bootstrapping with replacement, see Materials and methods, <xref rid="fig2s1" ref-type="fig">Figure 2&#8212;figure supplement 1F, G</xref>).</p><fig position="float" id="fig2" orientation="portrait"><label>Figure 2.</label><caption><title>Individual sex or age effects and combined age-by-sex effects on global transcriptome variation.</title><p>Principal component-based signal-to-variation ratio (pcSVR) between different sex or age groups calculated by gene expression (GE) (<bold>A</bold>) and alternative splicing (AS) (<bold>B</bold>). The yellow triangles show the significant sex-pcSVR calculated between females and males, while black triangles show the significant age-pcSVR calculated between young (i.e., 20&#8211;40 years old) and old (i.e.,&gt;60 years old) using the empirical p-value cutoff 0.1. Insignificant data points are labeled in gray. (<bold>C</bold>) The age effect on transcriptome variation as calculated by GE vs. AS. The <italic toggle="yes">X</italic>-axis of the scatter plot shows the log<sub>2</sub> transformed age-pcSVR between young and old calculated by GE, while the <italic toggle="yes">Y</italic>-axis shows the values calculated by AS. Blue dots indicate the tissues with significant pcSVR specific in AS, while green dots indicate the tissues with significant pcSVR specific in GE. Tissue names in each class are labeled under the scatter plot. (<bold>D</bold>) The sex effect on transcriptome variation as calculated by GE vs. AS. The analyses and labels are similar to panel <bold>C</bold> except the sex-pcSVR is used in all calculations. Scatter plots of the age effect between females <italic toggle="yes">vs</italic>. males calculated by GE (<bold>E</bold>) and AS (<bold>F</bold>). The <italic toggle="yes">X</italic>-axis shows log<sub>2</sub> transformed age-pcSVR calculated in females, while the <italic toggle="yes">Y</italic>-axis shows the age effect calculated in males. Dashed lines showed equal age-pcSVR in females and males. Dark red and blue dots indicate the tissues with female- and male-specific age effects.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="elife-102449-fig2.jpg"/><p content-type="supplemental-figure"><fig position="anchor" id="fig2s1" specific-use="child-fig" orientation="portrait"><label>Figure 2&#8212;figure supplement 1.</label><caption><title>Principal component-based signal-to-variation ratio (pcSVR) calculation and robustness.</title><p>(<bold>A</bold>) Schematic diagram of pcSVR calculation. pcSVR higher than 1 indicates that the differences between groups are higher than the noise within groups (left). pcSVR no more than 1 indicates that the differences between groups are smaller than the noise within groups (right). Two spheres represent two groups (females vs. males or young vs. old). Only three dimensions are shown. pcSVR between different sex or age groups calculated by gene expression (GE) (<bold>B</bold>) and alternative splicing (AS) (<bold>C</bold>) without genes and AS events on sex chromosomes. The yellow triangles show significant pcSVR calculated between females and males, while the black triangles show significant pcSVR calculated between young (i.e., 20&#8211;40 years old) and old (i.e., &gt;60 years old) groups using permutation p-value &lt;0.1. Insignificant values are labeled in gray. Bar plot of the age- and sex-pcSVR values (<bold>D</bold>) and corresponding empirical p-values (<bold>E</bold>) calculated using different numbers of PCs capturing 50&#8211;90% of the variance. The dashed lines indicate the thresholds for significant sex/age effects judged by the pcSVR analysis, and the mean and s.d. (standard deviation) are plotted here. s. D. are plotted here. (<bold>F</bold>) Correlations of pcSVRs calculated by the bootstrap and sub-sampling approaches as shown in scatter plots of sex-pcSVR and age-pcSVR values. The <italic toggle="yes">X</italic>-axis shows the results from the bootstrap approach, while the <italic toggle="yes">Y</italic>-axis shows the results from permutation analysis using 50% sub-sampling. Each point indicates a tissue. (<bold>G</bold>) Correlations of empirical p-values calculated by the bootstrap and sub-sampling approaches as shown in scatter plots of &#8722;log<sub>10</sub> transformed empirical p-values. The label of the <italic toggle="yes">X</italic>- and <italic toggle="yes">Y</italic>-axis is similar to panel <bold>F</bold>. The dots at the right margin indicate the empirical p-values equal to 0, with infinite &#8722;log<sub>10</sub> transformed values.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="elife-102449-fig2-figsupp1.jpg"/></fig></p></fig><p>We further compared the age and sex effects calculated by GE vs. AS (<xref rid="supp2" ref-type="supplementary-material">Supplementary file 2</xref>) and found a significant correlation between the age-pcSVR of GE and AS in most tissues (<italic toggle="yes">R</italic> = 0.67, p &lt; 0.05, <xref rid="fig2" ref-type="fig">Figure 2C</xref>), suggesting the age contribution to transcriptome variation is largely consistent regardless of the input data types (i.e., GE or AS). However, the sex effects on GE and AS showed a much weaker correlation (<italic toggle="yes">R</italic> = 0.21, <xref rid="fig2" ref-type="fig">Figure 2D</xref>), consistent with our earlier results (<xref rid="fig2" ref-type="fig">Figure 2A, B</xref>). We also found that age was a more vital driver of AS variation than GE in specific tissues like coronary artery and stomach, whereas sex contributed more to AS variations in whole blood, skeletal muscle, and most brain regions.</p><p>To further examine the sex-differential age effect, we compared the age-pcSVR between females and males (<xref rid="fig2" ref-type="fig">Figure 2E, F</xref>; GE and AS, respectively). Consistent with earlier findings (<xref rid="fig2" ref-type="fig">Figure 2C</xref>), we found significant age effects in both sexes across most tissues. Moreover, the age effects in both GE and AS were apparently larger in males than in females (<xref rid="fig2" ref-type="fig">Figure 2E, F</xref>). These results suggested that age and sex contributed significantly to transcriptome variation in various tissues with certain degrees of heterogeneity for different data types.</p></sec><sec id="s2-2"><title>Differential GE and AS analyses reveal general interactions of age-by-sex</title><p>We next identified specific genes or AS events responsible for sex or age effect on transcriptomic variations via a linear regression model containing an age-by-sex coefficient term (see Materials and methods, <xref rid="equ4 equ5" ref-type="disp-formula">Equations 4 and 5</xref>). In each tissue, we identified the sex- or age-differential genes and AS events (<xref rid="fig3s1" ref-type="fig">Figure 3&#8212;figure supplement 1A, B</xref>). Consistent with previous reports (<xref rid="bib51" ref-type="bibr">Lopes-Ramos et al., 2020</xref>; <xref rid="bib54" ref-type="bibr">Mel&#233; et al., 2015</xref>; <xref rid="bib69" ref-type="bibr">Seidler et al., 2010</xref>), the breast tissue contains the largest amount of sex-differentially expressed genes, while the age-biased genes were widely discovered in brain regions and artery-related tissues. Interestingly, in most tissues, there were no significant overlaps between age-differential genes and AS events (<xref rid="fig3s1" ref-type="fig">Figure 3&#8212;figure supplement 1A</xref>, hypergeometric test p-value &lt;0.01). In contrast, we found significant overlaps between sex-differential genes and AS events in most tissues (<xref rid="fig3s1" ref-type="fig">Figure 3&#8212;figure supplement 1B</xref>).</p><p>As a control, we constructed a separate regression model to evaluate the contribution of sampling biases, including sample sizes and the total number of genes or AS events detected in each tissue (<xref rid="equ7" ref-type="disp-formula">Equation 6</xref>). We found that the sample size did not significantly affect the number of identified sex- or age-differential genes/AS events (<xref rid="fig3s1" ref-type="fig">Figure 3&#8212;figure supplement 1C, D</xref>), suggesting our analyses are not affected by sampling biases. Furthermore, using the coefficient of the age-by-sex term in this model allowed us to identify thousands of genes and AS events affected by the functional interactions between sex and age (i.e., the sex effects on GE/AS depend on the age, or vice versa) (<xref rid="fig3s1" ref-type="fig">Figure 3&#8212;figure supplement 1E</xref>), suggesting extensive sex-dimorphic changes of the transcriptome during aging.</p><p>A recent study reported the environmental effect on human genetic background during aging (<xref rid="bib7" ref-type="bibr">Balliu et al., 2019</xref>), which should be considered when analyzing large datasets from different populations. In the linear regression model, we included the surrogate variables (SVs) as confounders to control for the effect of genetic backgrounds (<xref rid="equ4 equ5" ref-type="disp-formula">Equations 4 and 5</xref>). Using the differential GE analysis in whole blood as an example (other tissues have the same trend), we evaluated the correlation between SVs with donors&#8217; ethnicity using Point Biserial Correlation and found that many SVs showed significant correlations with the donors&#8217; ethnical background (<xref rid="fig3s2" ref-type="fig">Figure 3&#8212;figure supplement 2A</xref>), suggesting that these SVs could effectively reflect the variables of genetic background. Additionally, we calculated the correlation between SVs with the top 5 principal components as judged by whole-genome sequencing (WGS) data (<xref rid="fig3s2" ref-type="fig">Figure 3&#8212;figure supplement 2B</xref>), and found roughly the same set of SVs also showed a significant correlation with PC1.</p><p>Moreover, recent studies demonstrated the powerful impacts of post-mortem interval (PMI) and time of death (TOD), which included the death seasons and day times on GE (<xref rid="bib23" ref-type="bibr">Ferreira et al., 2018</xref>; <xref rid="bib81" ref-type="bibr">Wucher et al., 2023</xref>). Thus, we carefully evaluated whether both factors are controlled as potential confounders in our linear model. Our results showed that PMI and TOD significantly correlate with covariates in most tissues (<xref rid="fig3s2" ref-type="fig">Figure 3&#8212;figure supplement 2C&#8211;E</xref>), suggesting that their effects could be effectively regressed in our model. Together, the SVs in the linear regression models could effectively control the confounders of human genetic regulation.</p><p>To further evaluate the robustness of the differential analyses, we performed detailed assessments of the linear regression models and the selection of GE/AS cutoffs using the decision-related brain region as an example. We calculated the fraction of original differential genes/AS events identified in each permutation iteration and the false discovery rate (FDR) for each gene/AS event using the permutation analysis in the linear regression model (see Materials and methods). Briefly, we generated the permuted data 1000 times by randomly shuffling the group labels (sex and age) with the same sample sizes as the original labels. The distribution of the p-values of sex/age-differential genes/AS events identified based on the original and each shuffled phenotype data was evaluated (<xref rid="fig3s3" ref-type="fig">Figure 3&#8212;figure supplement 3A, D</xref>). We first observed low fractions of sex/age-differential genes/AS events in most iterations under our cutoffs (<xref rid="fig3s3" ref-type="fig">Figure 3&#8212;figure supplement 3</xref>). We found that FDRs of most sex/age-differential genes/AS events were not more than 5% using the linear regression model (<xref rid="fig3s2" ref-type="fig">Figure 3&#8212;figure supplement 2C, F</xref>), which is much lower than the FDR of DESeq2 and edgeR (<xref rid="bib49" ref-type="bibr">Li et al., 2022</xref>). As a result, this approach could justifiably control the false discovery for differential analysis. Furthermore, the TPMs of most sex- or age-differential genes were higher than 1, and the junction read counts (JC) of most differential AS events were higher than 10 (<xref rid="fig3s4" ref-type="fig">Figure 3&#8212;figure supplement 4A, B</xref>), suggesting that our cutoffs (TPM &gt;1 or JC &gt;10) preserved most of the differential GE and AS events. In addition, we found a low overlap between the genes with age-differential GE and AS under most combinations of TPM and JC cutoffs in the decision-related brain region (<xref rid="fig3s4" ref-type="fig">Figure 3&#8212;figure supplement 4C</xref>), which is consistent with our earlier findings (<xref rid="fig3s1" ref-type="fig">Figure 3&#8212;figure supplement 1A</xref>). Collectively, these controls confirmed the reliability of our differential analyses.</p></sec><sec id="s2-3"><title>AS regulation shows a stronger sex dimorphism during aging than GE across all tissues</title><p>We further studied the transcriptomic changes during the aging process in different sexes by identifying age-associated genes or AS events separately in females and males (<xref rid="supp3" ref-type="supplementary-material">Supplementary file 3</xref>). We found that the age-associated genes significantly overlapped between females and males in most tissues (p-values &lt;0.01 by hypergeometric tests, <xref rid="fig3" ref-type="fig">Figure 3A</xref>), whereas the overlaps of the age-associated AS events were much smaller (<xref rid="fig3" ref-type="fig">Figure 3B</xref>). Consistently, in most tissues, the age effect on GE was more correlated between females and males (Spearman&#8217;s correlation between <italic toggle="yes">&#946;</italic><sub>F</sub> and <italic toggle="yes">&#946;</italic><sub>M</sub>, <xref rid="equ8" ref-type="disp-formula">Equation 7</xref> than the age effect on AS <xref rid="fig3" ref-type="fig">Figure 3C</xref>), regardless of different GE/AS filters used in such analysis (<xref rid="fig3s4" ref-type="fig">Figure 3&#8212;figure supplement 4D</xref>). Taken together, these observations suggested that the age effect on GE is more consistent in both sexes, while age-associated AS showed a stronger discrepancy between two sexes, implying that splicing regulation had a stronger sex dimorphism during aging.</p><fig position="float" id="fig3" orientation="portrait"><label>Figure 3.</label><caption><title>Sex-stratified age-associated genes and alternative splicing (AS) events across tissues.</title><p>The numbers of age-associated genes (<bold>A</bold>, left) and AS events (<bold>B</bold>, left) in each sex. The red bars indicate the numbers of age-associated genes or AS events in females, while blue bars indicate those in males. The numbers of age-associated genes and AS events common in both sexes are shown in bars with relatively lighter colors. The significance of the overlapped age-associated genes (<bold>A</bold>, right) or AS events (<bold>B</bold>, right) between sexes is estimated using the hypergeometric test. Tissues with significant overlapped p-values are labeled by dark red dots. (<bold>C</bold>) Correlation between the age effects on genes (green) or AS events (blue) in females vs. males. The <italic toggle="yes">Y</italic>-axis represents the correlations of the effect sizes of age (<italic toggle="yes">&#946;</italic><sub>F</sub>, <italic toggle="yes">&#946;</italic><sub>M</sub>) between two sexes across all genes/AS events (Spearman&#8217;s correlation). Gray lines link a pair of tissue in gene expression (GE) and AS, and the median &#177;1.5xIQR are plotted in box plot. The p-values are estimated using the Wilcoxon signed-rank test.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="elife-102449-fig3.jpg"/><p content-type="supplemental-figure"><fig position="anchor" id="fig3s1" specific-use="child-fig" orientation="portrait"><label>Figure 3&#8212;figure supplement 1.</label><caption><title>Differential gene expression (GE) and alternative splicing (AS) analysis to identify sex/age-differential genes and AS events.</title><p>The numbers of age-differential (<bold>A</bold>) and sex-differential (<bold>B</bold>) genes (left) and AS events (right). The color bar between the two bar plots represents the overlapped significance between sex/age-differential genes and spliced genes calculated using hypergeometric test. The dashed lines separate the tissues with significant or non-significant overlaps using the p-value &lt;0.01. The sex/age-differential genes and AS events are defined with coefficient p-value &lt;0.05 and fold change &gt;1.5 for GE or &#916;PSI &gt;0.05 for AS. Correlation between the sample sizes and the numbers of age/sex-differential genes (<bold>C</bold>) or AS events (<bold>D</bold>). The <italic toggle="yes">X</italic>-axis indicates the total sample sizes. The <italic toggle="yes">Y</italic>-axis shows the numbers of age-differential genes/AS events (left) and sex-differential genes/AS events (right). The p-values of the coefficient of the sample sizes are calculated by linear regression as the formula on the bottom. (<bold>E</bold>) The numbers of genes (left) and AS events (right) with significant age-by-sex interactions. The color bar between two bar plots represents the overlapped significance between genes and spliced genes calculated using the hypergeometric test. The dashed lines separate the tissues with significant or non-significant overlaps.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="elife-102449-fig3-figsupp1.jpg"/></fig></p><p content-type="supplemental-figure"><fig position="anchor" id="fig3s2" specific-use="child-fig" orientation="portrait"><label>Figure 3&#8212;figure supplement 2.</label><caption><title>The evaluation of the confounding factors in the linear regression model.</title><p>Correlation between the surrogate variables and human genetic background, including the donor ethnicity (<bold>A</bold>) and the principal components from whole-genome sequencing (WGS) data (<bold>B</bold>). The highest correlation <italic toggle="yes">r</italic> between surrogate variables vs. post-mortem interval (PMI) (<bold>C</bold>), season of death (<bold>D</bold>), and time of death (<bold>E</bold>). Each bar represents those correlations in each human tissue. The bars are color-coded according to a &#8722;log<sub>10</sub>(p-value) scale shown on the right.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="elife-102449-fig3-figsupp2.jpg"/></fig></p><p content-type="supplemental-figure"><fig position="anchor" id="fig3s3" specific-use="child-fig" orientation="portrait"><label>Figure 3&#8212;figure supplement 3.</label><caption><title>Permutation analysis of the linear regression model in differential analysis.</title><p>Distribution of the p-values across sex/age-differential genes (<bold>A</bold>) or alternative splicing (AS) events (<bold>D</bold>) identified from original groups or shuffled groups in 1000 permutated iterations. Fractions of original sex/age-differential genes (<bold>B</bold>) or AS events (<bold>E</bold>) that are detected in each permutation. Each data point indicates the result from one shuffled permutation, and the median &#177;1.5xIQR are plotted as box plot. False discovery rate (FDR) of each age/sex-differential gene (<bold>C</bold>) and AS event (<bold>F</bold>) calculated across 1000 permutations. Each data point indicates the result of one age/sex-differential gene (<bold>C</bold>) and AS event (<bold>F</bold>), and the median &#177;1.5xIQR are plotted as box plot.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="elife-102449-fig3-figsupp3.jpg"/></fig></p><p content-type="supplemental-figure"><fig position="anchor" id="fig3s4" specific-use="child-fig" orientation="portrait"><label>Figure 3&#8212;figure supplement 4.</label><caption><title>Robustness of gene expression (GE) and alternative splicing (AS) cutoffs.</title><p>The distribution of junction reads counts (<bold>A</bold>) and TPMs (<bold>B</bold>) of age/sex-differential genes/AS events in multiple tissues. The <italic toggle="yes">X</italic>-axis indicates the average TPMs or JCs across the samples in certain tissue. The <italic toggle="yes">X</italic>-axis indicates the average TPMs or JCs across the samples in certain tissue. (<bold>C</bold>) Overlap between the age/sex-differential genes and AS genes in decision-related brain region. The overlapped p-values calculated by hypergeometric test are shown with the color bar. (<bold>D</bold>) Correlation of the age effects between females and males on GE (green) or AS (blue) using decision-related brain regions as example. <italic toggle="yes">Y</italic>-axis represents the correlations of the effect sizes of age (<italic toggle="yes">&#946;</italic><sub>F</sub>, <italic toggle="yes">&#946;</italic><sub>M</sub>) between two sexes across all genes/AS events (Spearman&#8217;s correlation). Each jitter indicates the correlation under each single cutoff, with the median &#177;1.5xIQR plotted. The p-values are estimated using the Wilcoxon signed-rank test.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="elife-102449-fig3-figsupp4.jpg"/></fig></p></fig></sec><sec id="s2-4"><title>AS changes show a male-biased association with Alzheimer&#8217;s disease in human brain</title><p>Because most age-associated AS events were sex-specific, we defined the AS events significantly affected by age in only one sex as the <underline>s</underline>ex-<underline>b</underline>iased <underline>a</underline>ge-associated A<underline>S e</underline>vents (sBASEs), and further examined their functional impacts on human health using Gene Ontology and Disease Ontology analyses. The functional association of sBASEs varied considerably in different tissues and sexes (<xref rid="fig4s1" ref-type="fig">Figure 4&#8212;figure supplement 1</xref>, <xref rid="supp4" ref-type="supplementary-material">Supplementary file 4</xref>). Having established patterns across all tissues, we next focused on tissue-specific AS changes in the brain that is highly affected by age-related processes. Since many neurological conditions show sex differences, the sex-biased splicing events in the brain could be helpful to explain differential susceptibility to age-related cognitive decline and neurodegeneration. Notably, the sBASEs in brain regions were significantly enriched in pathways such as amyloid-beta formation and cytoskeleton (<xref rid="fig4" ref-type="fig">Figure 4A</xref>), with the male decision-related brain region being particularly associated with cognitive and psychotic disorders (<xref rid="fig4s2" ref-type="fig">Figure 4&#8212;figure supplement 2A</xref>). Because previous studies suggested that the disease manifestations of Alzheimer&#8217;s disease (AD) showed sex differences in cognitive decline and brain atrophy (<xref rid="bib24" ref-type="bibr">Ferretti et al., 2018</xref>), we next focused on sBASEs in brain to explore their contribution to the sex-dimorphic risks of neurodegenerative diseases. This question was addressed by an integrative analysis of the large datasets from other independent AD studies, which is a common strategy (and strength) of computational biology in the big data era.</p><fig position="float" id="fig4" orientation="portrait"><label>Figure 4.</label><caption><title>Male-biased associations between the alternative splicing (AS) changes during aging and Alzheimer&#8217;s disease (AD).</title><p>(<bold>A</bold>) GO analysis of the sex-biased age-associated AS events (sBASEs) in each sex and brain region. The heatmap shows the sex-specific pathways that are significantly enriched in more than three brain regions. Clustering is conducted by default parameters in <italic toggle="yes">pheatmap</italic> functions. The &#8722;log<sub>10</sub> transformed enrichment p-values are shown in the color scale. (<bold>B</bold>) Venn diagram between the sBASEs in females and males with AD-related AS events. The p-values are calculated using the hypergeometric test. (<bold>C</bold>) Correlation between AD- and age-associated AS changes in females and males. The <italic toggle="yes">X</italic>-axis indicates the PSI<sub>Old</sub> &#8722; PSI<sub>Young</sub>, while the <italic toggle="yes">Y</italic>-axis indicates PSI<sub>AD</sub> &#8722; PSI<sub>Control</sub>. sBASEs in females are labeled in red, while sBASEs in males are in deep blue. The estimated Rho and p-value by Spearman&#8217;s correlation test in each sex are labeled on the top. (<bold>D</bold>) Model for AD prediction and feature importance evaluation. sBASEs are used for predicting AD in females and males, respectively. 90% of samples are randomly selected as training sets for 100 iterations. The recursive feature elimination approach is used for feature selection. Feature importance is evaluated by the averaged mean decrease accuracy (MDA) across 100 iterations. (<bold>E</bold>) AS levels of the skipped exon 10 on SLC43A2 during plaque stages in males and females. (<bold>F</bold>) AS levels of the skipped exons 3 and 4 on FAM107A during tangles stages in males and females. Mean &#177; standard error is shown in the error bar. (<bold>G</bold>) Performances of sex-stratified and merge-sexes models predicted by sBASEs or randomly selected AS events for 100 iterations. The control models (i.e., the sex-stratified model trained by randomly selected AS events and the merge-sexes model trained by sBASEs in each sex) are highlighted with dashed lines. The median &#177; 1.5xIQR of area under the curve (AUC) across 100 iterations is shown in the boxplot.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="elife-102449-fig4.jpg"/><p content-type="supplemental-figure"><fig position="anchor" id="fig4s1" specific-use="child-fig" orientation="portrait"><label>Figure 4&#8212;figure supplement 1.</label><caption><title>Functional enrichment of sex-biased age-associated alternative splicing events (sBASEs) across tissues.</title><p>GO enrichment of the sBASEs in females or males across all tissues. Sex-specific GO terms significantly in at least 15 tissues were shown.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="elife-102449-fig4-figsupp1.jpg"/></fig></p><p content-type="supplemental-figure"><fig position="anchor" id="fig4s2" specific-use="child-fig" orientation="portrait"><label>Figure 4&#8212;figure supplement 2.</label><caption><title>Sex-biased associations between sex-biased age-associated alternative splicing events (sBASEs) and diseases in decision-related brain region.</title><p>(<bold>A</bold>) DO analysis of the sBASEs in females or males in decision-related brain region. Sex-specific DO terms with top 10 &#8722;log<sub>10</sub> transformed enrichment p-values in each sex were shown. (<bold>B</bold>) Venn diagram between sex-biased age-associated genes and Alzheimer&#8217;s disease (AD)-related genes. The p-values are calculated using the hypergeometric test. (<bold>C</bold>) Correlation between AD- and age-associated AS changes across the sBASEs in females and males from the ROSMAP dataset. The <italic toggle="yes">X</italic>-axis indicates the age-associated AS changes (PSI<sub>Old</sub> &#8722; PSI<sub>Young</sub>), while <italic toggle="yes">Y</italic>-axis indicates AD-associated AS changes (PSI<sub>AD</sub> &#8722; PSI<sub>Control</sub>). (<bold>D</bold>) Performances of sex-stratified and merge-sexes models predicted by sBASEs and randomly selected AS events for 100 iterations using support vector machine (SVM) classifier. The control models (i.e., the sex-stratified model trained by randomly selected AS events and the merge-sexes model trained by sBASEs in each sex) are highlighted with dashed lines. The m median &#177; 1.5xIQR of area under the curve (AUC) in 100 iterations is shown in the boxplot.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="elife-102449-fig4-figsupp2.jpg"/></fig></p></fig><p>We analyzed the RNA-seq dataset of the brain prefrontal cortex with a dataset of 91 AD patients and healthy controls manually curated to match the sex and disease ratio (Female:Male &#8776; 1:1; AD:Control &#8776; 1:1, see Materials and methods). Surprisingly, although the number of sBASEs in males was smaller compared with that in females, we found that the AD-related AS events significantly overlapped with the sBASEs in males (p = 0.037) but not in females (p = 0.425) (<xref rid="fig4" ref-type="fig">Figure 4B</xref>). In addition, the magnitude of AD-associated AS changes across the male-specific sBASEs (i.e., <inline-formula><alternatives><mml:math id="inf1"><mml:mstyle><mml:mrow><mml:mstyle displaystyle="false"><mml:mi>P</mml:mi><mml:mi>S</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>A</mml:mi><mml:mi>D</mml:mi></mml:mrow></mml:msub><mml:mo>&#8722;</mml:mo><mml:mi>P</mml:mi><mml:mi>S</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>t</mml:mi><mml:mi>r</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="inft1">\begin{document}$PSI_{AD}- PSI_{Ctrl}$\end{document}</tex-math></alternatives></inline-formula>) was significantly correlated with the age-associated AS changes in males (i.e., <inline-formula><alternatives><mml:math id="inf2"><mml:mstyle><mml:mrow><mml:mstyle displaystyle="false"><mml:mi>P</mml:mi><mml:mi>S</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>O</mml:mi><mml:mi>l</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msub><mml:mo>&#8722;</mml:mo><mml:mi>P</mml:mi><mml:mi>S</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>Y</mml:mi><mml:mi>o</mml:mi><mml:mi>u</mml:mi><mml:mi>n</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="inft2">\begin{document}$PSI_{Old}- PSI_{Young}$\end{document}</tex-math></alternatives></inline-formula>) (Pearson&#8217;s product-moment correlation, <italic toggle="yes">R</italic> = 0.27, p = 6.6 &#215; 10<sup>&#8211;5</sup>), and such correlation was significantly higher than that in a separate analysis in females using the female-specific sBASEs (<italic toggle="yes">R</italic> = 0.11, p = 0.04; <xref rid="fig4" ref-type="fig">Figure 4C</xref>; see Materials and methods). In contrast, we found a significant overlap between the AD-related genes and the sex-biased age-associated GE changes in females (p = 0.031) but not in males (p = 0.60) (<xref rid="fig4s2" ref-type="fig">Figure 4&#8212;figure supplement 2B</xref>), supporting a recent finding that females are more vulnerable to AD during aging due to the post-menopause activation of C/EBP&#946;&#8211;AEP/&#948;-secretase pathway by sex hormone changes (<xref rid="bib83" ref-type="bibr">Xiong et al., 2022</xref>).</p><p>In addition, we performed similar analyses using an independent dataset from ROSMAP containing 271 filtered RNA-seq samples from dorsolateral prefrontal cortex (DLPFC) with matched age distribution between AD and control samples. As expected, we found that the AD-associated AS changes of sBASEs in males showed a significantly stronger positive correlation with the age-associated changes (<italic toggle="yes">R</italic> = 0.509, p &lt; 2.2 &#215; 10<sup>&#8211;16</sup>) than such correlation across the sBASEs in females (<italic toggle="yes">R</italic> = 0.371, p &lt; 2.2 &#215; 10<sup>&#8211;16</sup>) (<xref rid="fig4s2" ref-type="fig">Figure 4&#8212;figure supplement 2C</xref>), which is largely consistent with the earlier finding using a smaller dataset (<xref rid="fig4" ref-type="fig">Figure 4C</xref>). This male-biased association indicated that the AS changes during aging could contribute more to the AD in males than females, suggesting additional molecular complexity in the sex effect of AD.</p><p>To further examine the contribution of individual sBASE to AD risk, we constructed a sex-stratified random forest classifier using a subset of sBASEs that were also detected in ROSMAP data for AD prediction. For each sex, we randomly divided the datasets of AD patients and controls into separate training and test sets and repeated the prediction 100 times (<xref rid="fig4" ref-type="fig">Figure 4D</xref>). For each selected sBASE, we also evaluated its averaged feature importance (i.e., mean decrease accuracy, MDA) across 100 iterations and the association with the classic AD neuropathology (such as tangles and plaques), resulting in the identification of a series of key sBASEs significantly associated with AD in a sex-specific manner. For example, the skipping of exon 10 in SLC43A2 negatively correlated with the neuritic plaques stage in males but not in females (<xref rid="fig4" ref-type="fig">Figure 4E</xref>). Meanwhile, skipping of exons 3 and 4 in FAM107A, a gene related to synaptic and cognitive functions, showed a male-specific negative association with neurofibrillary tangle stages (<xref rid="fig4" ref-type="fig">Figure 4F</xref>). In addition, the prediction models based on sBASEs performed significantly better in males than females (<xref rid="fig4" ref-type="fig">Figure 4G</xref>, <xref rid="fig4s2" ref-type="fig">Figure 4&#8212;figure supplement 2D</xref>, left panel), suggesting that age-associated AS events could serve as a better predictor for AD risk in male patients. As negative controls, we performed the same analysis to predict male and female patients separately using randomly selected AS events (sex-stratified model; <xref rid="fig4" ref-type="fig">Figure 4G</xref>, middle panel), and predict all patients with male- or female-specific sBASEs (merge-sexes model; <xref rid="fig4" ref-type="fig">Figure 4G</xref>, right panel). We found that both control models showed no differences in males and females, indicating the crucial roles of sBASEs in AD during male aging. Collectively, our analyses of human brains revealed a surprising sex-biased association between RNA splicing and AD, suggesting that regulation of AS may play a critical role in the sex-dimorphisms of age-related diseases such as AD.</p></sec><sec id="s2-5"><title>sBASEs are regulated by splicing factors with sex-dimorphic expression during aging</title><p>AS is generally regulated by splicing regulatory <italic toggle="yes">cis</italic>-elements that specifically recruit various <italic toggle="yes">trans</italic>-acting splicing factors (SFs) to promote or inhibit splicing of adjacent exons (<xref rid="bib75" ref-type="bibr">Wang and Burge, 2008</xref>; <xref rid="bib53" ref-type="bibr">Matera and Wang, 2014</xref>). Dysfunction of the SFs has been reported as a hallmark of aging, presumably by regulating the genes in cellular senescence during the aging process (<xref rid="bib11" ref-type="bibr">Bhadra et al., 2020</xref>). Consistently, our analyses identified a large number of age-associated SFs in human brain (<xref rid="supp5" ref-type="supplementary-material">Supplementary file 5</xref>). To further examine the sex-dimorphic regulation through age-associated SFs, we constructed an SF&#8211;RNA regulatory network between age-associated SFs and sBASEs in each sex. This process integrated the correlations between the SF levels and PSI of sBASEs, the significant changes of sBASEs upon SF knockdown, and the existence of SF-binding motifs around sBASEs (<xref rid="fig5" ref-type="fig">Figure 5A</xref>, left panel). We required the regulatory connections between the SFs and AS events that pass all these three criteria. Such regulatory networks can be generated in different tissues, and we focused on the brain due to its association with age-related diseases such as cognitive disorders and synaptic diseases.</p><fig position="float" id="fig5" orientation="portrait"><label>Figure 5.</label><caption><title>Sex-dimorphic alternative splicing (AS) regulation during aging in decision-related brain region.</title><p>(<bold>A</bold>) Schematic diagram for constructing AS regulatory networks (left) and the networks of the decision-related brain region (right). The blue and red lines indicate the regulations in males and females. Hub genes in octagons are splicing factors (SFs). The red ones are female-specific age-associated SFs, while the age-associated SFs common in both sexes are labeled in yellow. The color of the ellipse indicates the significance of sex-biased age-associated AS events (sBASEs) during aging, and the thickness of the line shows &#8722;log<sub>10</sub> Spearman&#8217;s correlation p-values between the TPMs of SFs and PSIs of AS events during aging. (<bold>B</bold>) Examples of female-specific age-associated SFs (left) and age-associated SFs common in both sexes (right) during aging. Median &#177;1.5xIQR is shown in the boxplot. The grey triangles indicate averaged expression level. The p-value and fold change between old and young are labeled at the bottom. (<bold>C</bold>) Percentages of the sBASEs regulated by the sex-specific age-associated SFs in four brain regions. (<bold>D</bold>) Functional enrichment of sBASEs regulated by female-specific age-associated SFs based on MsigDB. (<bold>E</bold>) Schematic diagram for the transcriptional regulation on age-associated SFs via nuclear receptors (left). The boxplot shows the ESR1-binding scores on age-associated SFs (right). The <italic toggle="yes">Y</italic>-axis indicates the ratio of ESR1-binding scores of each SF divided by the median binding score of age-associated SFs common in both sexes. (<bold>F</bold>) Expression levels of ESR1 during aging. The legends of each group are the same as those in B. (<bold>G</bold>) Expression levels of SRSF1 and SRSF7 treated by estrogen receptor agonist (PPT) vs. DMSO in MCF-7 cell line (<italic toggle="yes">N</italic> = 3). (<bold>H</bold>) Expression levels of SRSF1 and SRSF7 treated by 1 nM estradiol (E2) vs. vehicle control (veh) in ESR1 wild-type, Y537S, and D538G mutant MCF-7 cells (<italic toggle="yes">N</italic> = 4). The error bars indicate the mean &#177; s.d. (<bold>I</bold>) Expression levels of SRSF1 and SRSF7 during aging. <italic toggle="yes">Y</italic>-axis indicates the normalized TPM values. The p-value and fold change between old and young groups in each sex are labeled at the bottom. The legends of each group are the same as those in <bold>B</bold>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="elife-102449-fig5.jpg"/><p content-type="supplemental-figure"><fig position="anchor" id="fig5s1" specific-use="child-fig" orientation="portrait"><label>Figure 5&#8212;figure supplement 1.</label><caption><title>Gene expression regulation of sex-biased age-associated splicing factors by estrogen via ESR1 in multiple datasets.</title><p>(<bold>A</bold>) Expression levels of HNRNPA2B1 and HNRNPC treated by 1 nM estradiol (E2) vs. vehicle control (veh) in ESR1 wild-type, Y537S, and D538G mutant MCF-7 cell lines. <italic toggle="yes">Y</italic>-axis indicates the TPM values (N=3); the p-value is labeled on the top. (<bold>B</bold>) Expression levels of Hnrnpa2b1, Hnrnpc, Srsf1, and Srsf7 treated by estradiol (E2) vs. vehicle control (Oil) of ER&#945; wild-type and knockout ARCs in female mice. <italic toggle="yes">Y</italic>-axis indicates the FPKM values. (<bold>C</bold>) ESR1 ChIP-seq reads coverages around Srsf1 and Srsf7 treated by estradiol (E2) vs. vehicle control (Oil) of ER&#945; wild-type (WT, top panel) and knock-out (KO, bottom panel) in female mice. <italic toggle="yes">Y</italic>-axis of each track indicates the read counts at each position from ChIP-seq. mean &#177; s.d. is plotted.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="elife-102449-fig5-figsupp1.jpg"/></fig></p></fig><p>We identified several key age-associated SFs that regulate multiple sBASEs in decision-related brain regions (<xref rid="fig5" ref-type="fig">Figure 5A</xref>, right panel). Interestingly, several SFs showed significant age association only in females (e.g., TIA1 in <xref rid="fig5" ref-type="fig">Figure 5B</xref>, left panel), while others were associated with age in both sexes (e.g., FXR2 in <xref rid="fig5" ref-type="fig">Figure 5B</xref>, right panel). This finding is consistent with our earlier observation that more sex-specific age-associated AS events were identified in decision-related brain regions of females than males (<xref rid="fig4" ref-type="fig">Figure 4B</xref>). Most of the sBASEs were regulated by sex-specific age-associated SFs rather than the SFs associated with aging in both sexes (<xref rid="fig5" ref-type="fig">Figure 5C</xref>). Functional enrichment analysis showed that these sBASEs regulated by female-specific age-associated SFs were significantly enriched in glial cells and oligodendrocyte development (<xref rid="fig5" ref-type="fig">Figure 5D</xref>), which participated in the myelin generation of aging brain and neurodegenerative diseases in central nervous system (<xref rid="bib10" ref-type="bibr">Bergles and Richardson, 2016</xref>). These results indicated that the SFs with sex-dimorphic expression during aging, especially the female-specific changes of SFs, were one of the main factors in regulating sBASEs with important biological functions.</p><p>Furthermore, we studied the potential mechanism that controls the female-specific changes of SFs during aging in decision-related brain regions. It was previously reported that the female sex hormone estrogen consistently decreases during lifespan (<xref rid="bib59" ref-type="bibr">Ober et al., 2008</xref>; <xref rid="bib34" ref-type="bibr">Horstman et al., 2012</xref>) thus, we speculated that estrogen may play roles in controlling transcription of SFs during aging through activation of nuclear receptors. To this end, we analyzed the public ChIP-Atlas data to examine the binding of canonical estrogen receptor ESR1 to the promoter region. We found that the ESR1-binding ratios on the female-specific age-associated SFs were significantly higher than the median value of the age-associated SFs common in both sexes (<xref rid="fig5" ref-type="fig">Figure 5E</xref>; p = 0.032), suggesting that ESR1 was more likely to bind the promoters of the female-specific age-associated SFs. In addition, the age-associated decline of ESR1 was more substantial in females than males (<xref rid="fig5" ref-type="fig">Figure 5F</xref>), and some of the female-specific age-associated SFs (e.g., SRSF1 and SRSF7) could be stimulated by propyl pyrazole triol, an agonist of ER&#945; (<xref rid="fig5" ref-type="fig">Figure 5G</xref>; <xref rid="bib13" ref-type="bibr">Cao et al., 2024</xref>).</p><p>These observations were further confirmed by an independent experiment where the wild-type and two constitutively active mutants (Y537S and D538G) of ESR1 were engineered into MCF-7 cells using CRISPR&#8211;Cas technology (<xref rid="bib6" ref-type="bibr">Bahreini et al., 2017</xref>). The resulting cells were treated with estradiol or vehicle controls and subjected to transcriptome profiling by RNA-seq, and the data were reanalyzed using the same pipeline. We found that the basal levels of SRSF1 and SRSF7 were significantly higher in the cells with constitutively active ESR1 (<xref rid="fig5" ref-type="fig">Figure 5H</xref>, comparing samples treated with vehicle controls), and SRSF1 and SRSF7 were further induced by the estradiol treatment only in cells with wild-type ESR1 but not in cells with mutated ESR1 (<xref rid="fig5" ref-type="fig">Figure 5H</xref>, compare the samples treated with estradiol vs. control in different cells), indicating that the activation of the ESR1 pathway can promote expression of SRSF1 and SRSF7. The similar changes were also found in other SFs including HNRNPA2B1 and HNRNPC (<xref rid="fig5s1" ref-type="fig">Figure 5&#8212;figure supplement 1A</xref>). As expected, the expression levels of SRSF1 and SRSF7 showed an obvious decrease during female aging (<xref rid="fig5" ref-type="fig">Figure 5I</xref>).</p><p>To further confirm our findings in different tissues, we analyzed the RNA-seq data with ER knockout and estrogen treatments in mouse brain arcuate nucleus (ARCs) (<xref rid="bib84" ref-type="bibr">Yang et al., 2017</xref>) and found a consistent trend in the expression changes for SFs Srsf1, Srsf7, and Hnrnpa2b1 under estradiol (E2) regulation (<xref rid="fig5s1" ref-type="fig">Figure 5&#8212;figure supplement 1B</xref>). Specifically, these SFs were activated by estrogen in wild-type mice but exhibited reduced expression in ER knock-out mice. The direct binding of estrogen was also examined through integrating the ESR1 ChIP-seq data (<xref rid="bib33" ref-type="bibr">Hewitt et al., 2014</xref>). As expected, a major ESR1-binding peak was found in the promoter regions of Srsf7, which was increased by estrogen treatment (<xref rid="fig5s1" ref-type="fig">Figure 5&#8212;figure supplement 1C</xref>).</p><p>Collectively, these analyses across multiple datatypes suggested that the female-specific SFs (such as SRSF1 and SRSF7) are more sensitive to the estrogen changes via ESR1-mediated pathway, leading to extended sex-biased AS regulations during aging.</p></sec><sec id="s2-6"><title>The aging rates of GE show sex dimorphism during aging across multiple tissues</title><p>In the earlier results (<xref rid="fig3" ref-type="fig">Figure 3A</xref>), we found a large proportion of age-associated genes are common in both sexes. Therefore, we asked whether the levels of GE change at the same pace during aging in females and males. The age-associated genes ubiquitously changed in both sexes were analyzed for consistency. We first used the Autoregressive Integrated Moving Average (ARIMA) model (<xref rid="bib12" ref-type="bibr">Brockwell et al., 2016</xref>) to capture the age-associated genes with significant chronological changes beyond random fluctuations, which are the main contributors to transcriptome dynamics during aging. We further quantified the GE changes between adjacent age windows using breakpoint analysis (<xref rid="bib52" ref-type="bibr">M&#225;rquez et al., 2020</xref>; <xref rid="fig6" ref-type="fig">Figure 6</xref> see Materials and methods). Such analyses were conducted across all tissues in both sexes (<xref rid="fig6s1" ref-type="fig">Figure 6&#8212;figure supplement 1A</xref>), with two tissues shown in (<xref rid="fig6" ref-type="fig">Figure 6</xref>). A higher value on the <italic toggle="yes">Y</italic>-axis (mean &#8722;log <italic toggle="yes">P</italic>) indicated a larger GE change at the given age, and thus the peaks were regarded as aging &#8216;breakpoints&#8217; that represent the key time point of transcriptome aging. Compared to females, males showed significantly larger GE changes during aging in most tissues (<xref rid="fig6s1" ref-type="fig">Figure 6&#8212;figure supplement 1A</xref>), except transverse colon, fibroblast cells, and whole blood (<xref rid="fig6s1" ref-type="fig">Figure 6&#8212;figure supplement 1B</xref>). The number of breakpoints also showed sex-dimorphism in several tissues. For example, in sun-exposed skin and colon, males showed two main breakpoints around ages 35 and 50, whereas females only have one breakpoint at age ~45 (<xref rid="fig6s1" ref-type="fig">Figure 6&#8212;figure supplement 1A</xref>).</p><fig position="float" id="fig6" orientation="portrait"><label>Figure 6.</label><caption><title>Sex-dimorphic aging rate of gene expression (GE) during aging process.</title><p>(<bold>A</bold>) Workflow of time series and breakpoint analysis of GE in each sex. (<bold>B</bold>) Aging rates and breakpoints in the aorta (left) and transverse colon (right). The <italic toggle="yes">Y</italic>-axis shows the estimated aging rate (see Materials and methods). The p-values are calculated using the Wilcoxon signed-rank test. (<bold>C</bold>) Characteristics of the major breakpoints across tissues in each sex. The left panel shows the distribution of the major breakpoints across multiple tissues. The right panel shows the aging rate at the major breakpoints. The p-values are calculated using the Wilcoxon signed-rank test. (<bold>D</bold>) Pipelines for identifying aging-modulated <underline>g</underline>enes (AMGs) in each sex and tissue (see Method). (<bold>E</bold>) AMGs in different sexes and tissues. The numbers of AMGs in females (red) and males (blue) are shown in the bar plot (left). Tissues are ordered by the number of AMGs common in both sexes, which are shown in lighter colors. Significances of the overlapped AMGs are calculated using hypergeometric test and colored in a gradient palette (right). GO analysis of male-biased AMGs (<bold>F</bold>) and female-biased AMGs (<bold>G</bold>). Sex-specific GO terms with top 10 &#8722;log<sub>10</sub> transformed enrichment p-values are plotted. GO terms are labeled by purple dots, the size of which indicates the significance of the enrichment analysis. The larger the dots, the more significant enrichment scores of the biological pathways. AMGs are labeled by blue dots, the color of which indicates the number of GO terms associated with those genes. (<bold>H</bold>) The binding scores of AR (top) and ESR1 (bottom) on male-specific AMGs, female-specific AMGs, and randomly selected AR/ESR1 target genes. The p-values are calculated by the Wilcoxon rank-sum test. The error bars indicate median &#177;1.5xIQR.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="elife-102449-fig6.jpg"/><p content-type="supplemental-figure"><fig position="anchor" id="fig6s1" specific-use="child-fig" orientation="portrait"><label>Figure 6&#8212;figure supplement 1.</label><caption><title>Breakpoint analysis across multiple tissues.</title><p>Tissues with faster aging rates in males (<bold>A</bold>) and females (<bold>B</bold>). The p-values are calculated using the Wilcoxon signed-rank test and are labeled at the bottom. (<bold>C</bold>) Characteristics of the major breakpoints calculated by all chronological genes in females and males. The left panel shows the distribution of the major breakpoints across multiple tissues. The right panel shows the aging rate at the major breakpoints. The p-values are both calculated using the Wilcoxon signed-rank test. Characteristics of the major breakpoints calculated by chronological sex-biased age-associated alternative splicing events (sBASEs) (<bold>D</bold>) and all chronological alternative splicing (AS) events (<bold>E</bold>) in females and males. The left panel shows the distribution of the major breakpoints across multiple tissues. The right panel shows the aging rate at the major breakpoints. p-values are both calculated using the Wilcoxon signed-rank test. The error bars indicate median &#177;1.5xIQR.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="elife-102449-fig6-figsupp1.jpg"/></fig></p><p content-type="supplemental-figure"><fig position="anchor" id="fig6s2" specific-use="child-fig" orientation="portrait"><label>Figure 6&#8212;figure supplement 2.</label><caption><title>Gene expression (GE) patterns of the aging-modulated <underline>g</underline>enes (AMGs) in whole blood tissue.</title><p>(<bold>A</bold>) GE patterns of AMGs common in both sexes (counts = 82) during aging. The values represent the <italic toggle="yes">z</italic>-score of fitted TPM from Autoregressive Integrated Moving Average (ARIMA) models. (<bold>B</bold>) Examples of AMGs common in both sexes with specific GE patterns. The dots indicate the ARIMA-fitted expression levels at each age point. The solid lines indicate the fitted values from LOESS regression for displaying the GE trends during aging. (<bold>C</bold>) GO analysis of the AMGs common in both sexes with specific GE patterns during aging. GE patterns of male-biased (<bold>D</bold>, counts = 83) and female-biased (<bold>E</bold>, counts = 61) AMGs during aging. AMGs in dotted circles indicate the cluster of AMGs with increasing expression levels during aging in males.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="elife-102449-fig6-figsupp2.jpg"/></fig></p></fig><p>Moreover, we found that the major aging breakpoints (i.e., breakpoints with the largest GE changes) occurred earlier in males than females across most tissues, and the magnitudes of changes were also more prominent in males (<xref rid="fig6" ref-type="fig">Figure 6C</xref>), suggesting that males may age faster with a larger age-associated GE change. In addition, we conducted breakpoint analysis with all chronological genes in both sexes and found similar results when comparing the breakpoints in males and females (<xref rid="fig6s1" ref-type="fig">Figure 6&#8212;figure supplement 1C</xref>). We also performed a similar analysis using chronological sBASEs and all chronological AS events in females and males separately, and again found an earlier and more obvious breakpoint (<xref rid="fig6s1" ref-type="fig">Figure 6&#8212;figure supplement 1D, E</xref>). In summary, these results uncovered an earlier aging and a higher aging rate in males at molecular levels, again implying that males could be surprisingly more vulnerable to aging.</p></sec><sec id="s2-7"><title>Aging contributors in separate sexes show distinct functions</title><p>To further examine how the individual gene affected aging rates, we designed a disturbance analysis to identify <underline>a</underline>ging-modulated <underline>g</underline>enes (AMGs) (<xref rid="fig6" ref-type="fig">Figure 6</xref>). Specifically, we randomly removed 20% of chronological genes and repeated the breakpoint analysis with the remaining genes to test if the breakpoints were significantly altered (see Materials and methods). This process was repeated 200 times, and the genes enriched in the 200 random samplings (judged by Fisher&#8217;s exact test p &lt; 0.05) were defined as AMGs that serve as the key contributors to molecular aging.</p><p>We identified a total of 1035 AMGs across different tissues (<xref rid="supp6" ref-type="supplementary-material">Supplementary file 6</xref>), around 70% of which (723 in 1035) were sex-specific (<xref rid="fig6" ref-type="fig">Figure 6</xref>). Functional enrichment analysis suggested that the female-specific AMGs were significantly enriched in cellular respiration and NADH dehydrogenase pathways (<xref rid="fig6" ref-type="fig">Figure 6F</xref>), which is consistent with an earlier report of their roles in human aging and longevity (<xref rid="bib22" ref-type="bibr">Durieux et al., 2011</xref>). Such functional enrichment was not found in the male-specific AMGs (<xref rid="fig6" ref-type="fig">Figure 6G</xref>), implying that female aging may be more sensitive to mitochondrial and oxidative functions. Intriguingly, we also found many male-specific AMGs relevant to myeloid leukocyte differentiation, phagocytosis, and macrophage apoptotic processes, implying a sex-differential role of the immune system during aging.</p><p>To determine the potential mechanism of the sex-dimorphic aging rate, we focused on sex hormones that are critical for transcriptional regulation. We found that the androgen receptor (AR) tends to bind the promoters of male-specific AMGs (p = 0.007), suggesting potential regulations by androgen during male aging (<xref rid="fig6" ref-type="fig">Figure 6G</xref>, top panel). On the other hand, female-specific AMGs were more likely to be bound and regulated by estrogen receptor ESR1 (<xref rid="fig6" ref-type="fig">Figure 6H</xref>, bottom panel), suggesting the potential regulation by distinct sex hormones.</p><p>Furthermore, we examined the detailed expression profile of AMGs from the whole blood that is commonly used for health surveillance. The AMGs common to both sexes can be grouped into three clusters based on age-associated expression profiles. GE of the largest cluster increased at young ages and abruptly decreased in mid-ages in males, but monotonically decreased in females (<xref rid="fig6s2" ref-type="fig">Figure 6&#8212;figure supplement 2A, B</xref>). These genes were functionally enriched in neutrophil and granulocyte migration and RNA splicing (<xref rid="fig6s2" ref-type="fig">Figure 6&#8212;figure supplement 2C</xref>). Moreover, we also examined sex-specific AMGs and found very distinct expression patterns (<xref rid="fig6s2" ref-type="fig">Figure 6&#8212;figure supplement 2D, E</xref>). Interestingly, while most of these genes showed decreased expression at old ages, the expression of some male-specific AMGs gradually increased during aging (<xref rid="fig6s2" ref-type="fig">Figure 6&#8212;figure supplement 2D</xref>, dotted box). Taken together, these results suggested that these age-associated genes modulating the transcriptome aging rate showed different functional impacts in females and males.</p></sec></sec><sec sec-type="discussion" id="s3"><title>Discussion</title><p>Previous studies in selected tissues suggested that sex is a key factor in affecting human aging and age-related diseases (<xref rid="bib67" ref-type="bibr">Sampathkumar et al., 2020</xref>; <xref rid="bib30" ref-type="bibr">H&#228;gg and Jylh&#228;v&#228;, 2021</xref>), which may contribute to different life expectancies between two sexes. However, few pan-tissue investigations on age-by-sex effect were conducted at the transcriptome level, especially in the resolution of AS isoforms. By comprehensively analyzing ~17,000 samples across 54 tissues, we uncovered individual sex or age effect on global transcriptome variations, as well as the combined age-by-sex effects. Using a sex-stratified differential analysis, we found that AS changes showed a stronger discrepancy between females and males during aging. We further identified the regulatory SFs for sBASEs and explored the underlying mechanism of sex-differential AS regulation during aging. Conversely, we found the change of age-associated GE was consistent between two sexes, with a faster aging rate in males. Our analysis provided a comprehensive landscape of how sex and age affect human transcriptome, revealing the sex-dimorphic aging at a multi-tissue level.</p><p>Multiple mRNA isoforms can be produced from a single gene through AS, increasing the transcriptomic and proteomic complexity in different cells (<xref rid="bib19" ref-type="bibr">Djebali et al., 2012</xref>; <xref rid="bib76" ref-type="bibr">Wang et al., 2008</xref>). Therefore, analyses of AS changes during aging of each sex may provide additional information beyond the GE profile. Interestingly, we observed different patterns when analyzing the profiles of GE vs. AS. For example, judged by the AS changes, we observed more tissues with a significant sex or age effect on transcriptome and a higher discrepancy between females and males from the combinatorial effects of age-by-sex (<xref rid="fig3" ref-type="fig">Figure 3</xref>), highlighting the contribution of splicing in sex dimorphism during human aging at an isoform-specific resolution.</p><p>The sex-dimorphic patterns of AS and GE not only illuminate aging-related transcriptomic changes but also reveal intriguing connections to age-related diseases, such as AD. Most studies showed that females have a higher risk of AD due to the post-menopause changes of sex hormones (<xref rid="bib83" ref-type="bibr">Xiong et al., 2022</xref>) however, a higher incidence rate of mild cognitive impairment in males is also reported (<xref rid="bib66" ref-type="bibr">Roberts et al., 2012</xref>). Additionally, based on an early study on a large cohort of 17,127 participants from UK Biobank, age-related cognitive risk factors are more widely discovered in males, suggesting a potential vulnerability of males to cognitive decline with age (<xref rid="bib26" ref-type="bibr">Foo et al., 2021</xref>). We further validated our findings using the Alzheimer&#8217;s disease dataset, ROSMAP, where the consistent correlations between aging-related splicing changes and AD-related changes were observed, providing additional evidence for the robustness of our results. At the splicing level, we surprisingly observed a male-biased association between age-associated AS changes and AD (<xref rid="fig4" ref-type="fig">Figure 4</xref>). Such associations could not be detected by analyzing GE, suggesting that analysis at isoform resolution can provide different information into sex-dimorphic aging. We also designed a sex-stratified random forest classifier to predict AD in males and identify several key AS events contributing to such prediction. Due to the limited sample size, large variations were observed between different training/testing iterations during the sex-stratified AD prediction. However, we still observed a higher performance of the classifier in males compared to the control model, which is in concordance with that the AS changes during aging may contribute more to AD in males than females. Our findings suggest that male-biased age-associated AS changes may contribute to the increased vulnerability of males to cognitive decline, providing a complementary perspective to existing research. We expect that future investigations using bigger datasets will further identify the sex differences in AD.</p><p>Using a pan-tissues analysis, we discovered that transcriptomic aging happened earlier in males than in females (<xref rid="fig6" ref-type="fig">Figure 6D</xref>), consistent with the reported shorter life expectancy in males (<xref rid="bib30" ref-type="bibr">H&#228;gg and Jylh&#228;v&#228;, 2021</xref>). Furthermore, we identified many sex-specific AMGs with different biological functions, such as the macrophage and mitochondria functions (<xref rid="fig6" ref-type="fig">Figure 6F, G</xref>). These genes tend to be regulated by the dominant sex hormones in each sex. The investigation of the aging rate provided insights into the intervention of the aging process or age-related diseases and, to some extent, made available for identifying therapeutic targets at specific age points. It is worth noting that our analysis of the aging rate in this section does not include the data from brain tissues due to the sample sparsity in selecting parameters.</p><p>Our analyses also have some technical limitations, the biggest of which may be caused by the cell type and sample heterogeneity between different donors of GTEx datasets. Since the GTEx dataset is the most comprehensive dataset with both transcriptome and WGS data, it is a good public resource for sex, age, and age-by-sex interaction analysis within a healthy context. Compared with the earlier studies that used either microarray or other RNA-seq data to analyze the effect of age or sex on brain transcriptome, our main findings supported the main conclusion of these reports, including the diverse gene profiles across brain regions during aging, as well as more vulnerability in males on a global scale (<xref rid="bib9" ref-type="bibr">Berchtold et al., 2008</xref>; <xref rid="bib91" ref-type="bibr">Zhou et al., 2023</xref>). In addition, GTEx has a very strict selection of healthy donors to reduce biases from different diseases (<xref rid="bib14" ref-type="bibr">Carithers et al., 2015</xref>), which is a unique feature compared to other cohorts that often contain patients of various diseases that may affect the analyses at the molecular level. In particular, the large-scale brain samples provide a unique opportunity to analyze transcriptomic changes in sex-dimorphic aging. However, several technical challenges could limit the generalizability due to dataset-specific biases, including cell type heterogeneity, postmortem artifacts, as well as sequencing biases. For example, GTEx data is bulk RNA-seq, which does not capture cell-type-specific transcriptomic changes. Given the cellular complexity of the brain tissues, the observed differences in GE and splicing may be influenced by shifts in cellular composition rather than intrinsic transcriptional regulation.</p><p>The second limitation is the existence of potential confounding factors (like batch effect, genetic background, etc.) that are often associated with big data analyses. However, when such batch effects are entangled with the effect from distinct sex/age groups, it becomes technically challenging to effectively remove such factors without canceling out the contribution of sex/age, which is a common technical difficulty reported also in other analyses (<xref rid="bib58" ref-type="bibr">Nygaard et al., 2016</xref>). We take several measurements to reduce the effect of confounding factors. First, we utilized the original TPM/PSI data to aggregate sex/age effects and conducted a permutation analysis to assign an empirical p-value to each pcSVR. This approach provided a robust statistical framework for evaluating the significance of sex/age effects while accounting for potential batch effects. Secondly, in the context of the differential analysis, we preserved all possible confounders and identified changes that were more obvious than the effects of these confounders, a strategy that reduces false positive discoveries originating from potential batch effects. Another technical limitation is related to the small number of samples in some tissues, and thus we either omitted them from aging analyses (like pituitary, bladder, and kidney) or combined similar tissues (like brain regions) for detailed analyses.</p><p>Moreover, we derived the AS regulatory networks using the multi-dimensional large-scale data from highly proliferative and easily cultivable cancer cell lines, which may not be an ideal model for the post-mitotic cells in human tissues. However, we dissected the RBP&#8211;RNA regulatory network by integrating multi-dimensional data obtained through several orthogonal state-of-the-art approaches (<xref rid="fig5" ref-type="fig">Figure 5A</xref>), including the eCLIP-seq, in vitro RNA affinity evaluation, RNA-seq with RBP depletion, and chromatin association (<xref rid="bib74" ref-type="bibr">Van Nostrand et al., 2020</xref>). In addition, the RBP&#8211;RNA-binding relationships seem to be universal, and the distinct splicing outcomes are mainly determined by the tissue-specific expression and activity of different splicing regulatory factors. Therefore, it is possible to use the data in cancer cells to derive a connectivity map of RBP&#8211;RNA, and then use the tissue-specific expression of RBPs to refine the regulatory map.</p><p>It was reported that there is only a moderate correlation between mRNA and protein abundances for many human genes, mainly because of the variation in translation efficiency of different mRNAs and the additional regulation in protein degradation. Here we constructed the SF&#8211;RNA regulation network with the shRNA-seq data that represents the reduction of specific SFs in both RNA and protein levels. Such data is more reliable than the correlation of cell-specific expression of RNA and protein, and thus it is feasible to evaluate the consequences of gene silencing by looking at the RNA level. To minimize tissue biases in the RBP&#8211;RNA regulation network, we incorporated three-step processes (see Materials and methods) including the restrictions of the correlations between RBP expression and AS events within each tissue. Additional large-scale experiments are needed in the future to globally profile the physical and functional interactions between RNA and RBP with a higher accuracy from different tissues.</p><p>Mechanistically, we found a prominent role of sex hormones in regulating sex-dimorphic aging or age-related diseases. Using a range of RNA-seq and ChIP-seq data, we uncovered a type of female-specific age-associated AS regulation (<xref rid="fig5" ref-type="fig">Figure 5A</xref>), which may be achieved partially through the estrogen-mediated regulation of female-specific SFs (<xref rid="fig5" ref-type="fig">Figure 5E, I</xref>). We further quantified chronological changes of transcriptome dynamics using breakpoint analysis and observed the sex-dimorphic aging rates across multiple tissues. Our analysis observed the non-linear aging patterns with two breakpoints, which is consistent with recent findings, with some differences in specific age points due to sex differences as well as tissue diversities (<xref rid="bib71" ref-type="bibr">Shen et al., 2024</xref>). In addition, our aging breakpoints are largely consistent with the changes in circulating sex hormones during aging. The level of testosterone starts to decrease at the age of 35&#8211;40 in males, while in females, estrogen level starts to decrease at a later age (i.e., ~50 years old) (<xref rid="bib59" ref-type="bibr">Ober et al., 2008</xref>; <xref rid="bib34" ref-type="bibr">Horstman et al., 2012</xref>). These breakpoints could represent key junctures in the aging process that align with the non-linear patterns of aging and disease progression. Furthermore, we identified a series of female- and male-specific AMGs, whose functions are consistent with the reported roles of sex hormones. For example, estrogen was reported to participate in the antioxidant system via NADPH (<xref rid="bib59" ref-type="bibr">Ober et al., 2008</xref>; <xref rid="bib34" ref-type="bibr">Horstman et al., 2012</xref>), which is functionally enriched in female-specific AMGs (<xref rid="fig6" ref-type="fig">Figure 6</xref>). Conversely, androgen was reported to affect the inflammation in immune response (<xref rid="bib59" ref-type="bibr">Ober et al., 2008</xref>; <xref rid="bib34" ref-type="bibr">Horstman et al., 2012</xref>), which is enriched in the male-specific AMGs (<xref rid="fig6" ref-type="fig">Figure 6G</xref>). Consistently, we found that the sex-specific AMGs were more likely to be regulated by androgen receptor in males or estrogen receptor in females (<xref rid="fig6" ref-type="fig">Figure 6H</xref>). However, the regulation of sex-biased aging is probably more complicated. Other factors, including mitochondrial functions, genes encoded by sex chromosomes, non-coding RNAs, and transposable elements, may also contribute to the sex-dimorphism during aging (<xref rid="bib30" ref-type="bibr">H&#228;gg and Jylh&#228;v&#228;, 2021</xref>; <xref rid="bib17" ref-type="bibr">Davis et al., 2021</xref>; <xref rid="bib64" ref-type="bibr">Ramanujan et al., 2021</xref>; <xref rid="bib85" ref-type="bibr">Yoshida and Apte, 2022</xref>). In addition, it is possible that the genetic variants, including expression QTL (eQTLs) and splicing QTLs (sQTL), can affect GE or AS in a sex-biased or age-associated fashion (<xref rid="bib61" ref-type="bibr">Oliva et al., 2020</xref>; <xref rid="bib7" ref-type="bibr">Balliu et al., 2019</xref>; <xref rid="bib82" ref-type="bibr">Xiong et al., 2021</xref>). Future studies of these factors will improve our understanding of the intricate regulation of transcriptome dynamics, providing us a broader horizon at a multi-omics scale.</p><p>Various biological aging clocks had previously been constructed based on different molecular markers, including DNA methylome (<xref rid="bib39" ref-type="bibr">Jylh&#228;v&#228; et al., 2017</xref>; <xref rid="bib35" ref-type="bibr">Horvath and Raj, 2018</xref>; <xref rid="bib28" ref-type="bibr">Galkin et al., 2021</xref>), transcriptome (<xref rid="bib56" ref-type="bibr">Meyer and Schumacher, 2021</xref>), circulating immune proteins (<xref rid="bib68" ref-type="bibr">Sayed et al., 2021</xref>), human gut microbiome (<xref rid="bib27" ref-type="bibr">Galkin et al., 2020</xref>), and multi-omics features (<xref rid="bib50" ref-type="bibr">Li et al., 2023</xref>). Such aging clocks generally pay little attention to the difference between females and males. However, our results advocate for a sex-specific age model. In addition, certain age-related diseases may accelerate the aging process, as tumors aged 40% faster than matched normal tissues based on DNA methylome (<xref rid="bib32" ref-type="bibr">Hannum et al., 2013</xref>). Therefore, we speculate that constructing separate aging clocks in distinct sexes will help model the progression of age-related diseases accurately.</p></sec><sec sec-type="materials|methods" id="s4"><title>Materials and methods</title><sec id="s4-1"><title>Transcriptome quantifications and data processing</title><p>We used the transcriptome data from the Genotype-Tissues Expression (GTEx) project version 8.0, which contains 17,382 samples in 54 tissues (including 13 brain regions and two cell lines). We downloaded the RNA-seq bam files and the phenotype information from dbGaP (study accession: phs000424.v8.p2; table accession: pht002743.v8.p2.c1). The tissues with a small number of samples and specific to only a single sex (such as ovary and testis) were removed for a better comparison. In addition, for each donor, we combined 13 brain regions into 4 main functional regions, including hormone- or emotion-related region (amygdala, anterior cingulate cortex, and hypothalamus), movement-related region (cerebellar hemisphere, cerebellum, and spinal cord), memory-related region (caudate, hippocampus, nucleus accumbens, putamen, and substantia nigra) and decision-related region (cortex and frontal cortex). As a result, for the N donors that each have 13 brain regions (<italic toggle="yes">N</italic> &#215; 13 sample matrix), we merged the data into 4 functional regions to generate an <italic toggle="yes">N</italic> &#215; 4 sample matrix in the downstream analyses. In total, 16,202 samples in 35 tissues or brain regions (31 tissues and 13 brain regions) from 948 donors passed these filters for further analysis. The numbers of samples in each tissue are shown in <xref rid="supp1" ref-type="supplementary-material">Supplementary file 1</xref>.</p><p>GE and AS quantifications were performed by Paean (<xref rid="bib47" ref-type="bibr">Li et al., 2018a</xref>), a parallel computing system on the GPU&#8211;CPU platform with high computational efficiency for super-large datasets. We calculated TPM (transcripts per million) for protein-coding genes and PSI (percent of spliced-in) values for AS events, including skipped exon (SE), alternative 5&#8242; splice site (A5SS), alternative 3&#8242; splice site (A3SS), and retained intron (RI). Genes with low expression (average TPM &lt;1) were removed. We also filtered the AS events by first removing the samples with missing PSI values in more than 50% of AS events (16,182 samples left), and then filtered the AS events using the following criteria: (1) percentage of the missing PSI values in &lt;5% samples; (2) averaged total reads counts in spliced junctions (i.e., spliced in counts + spliced out counts) &gt;10; (3) non-constant PSI values across samples; (4) max(PSI) &#8211; min(PSI) &gt;0.05; (5) standard deviation &gt;0.01; (6) averaged PSI value in the range from 0.05 to 0.95; (7) TPM of the spliced genes &gt;1. We focused on the AS events in protein-coding genes. In different tissues, the average numbers of genes and AS events for downstream analysis were 12,144 and 13,939, respectively.</p><p>Even after removing the AS events with too many missing values, the remaining AS data were still too sparse in some samples for a reliable statistical analysis. On average, there are about 0.17% AS events missing from the RNA-seq samples in different tissues. For a single RNA-seq sample in certain tissues, there were up to 15% AS events still missing (i.e., below the detecting limit). Several imputation techniques (reference-based and reference-free) have been widely used and easily implemented in multi-omics datasets (<xref rid="bib72" ref-type="bibr">Song et al., 2020</xref>), and we used the <italic toggle="yes">k</italic>-nearest neighbors algorithm for missing PSI value imputation in this analysis.</p></sec><sec id="s4-2"><title>Principal component-based signal-to-variation ratio</title><p>To evaluate the sex/age effect on human transcriptome, we designed a pcSVR based on PCA and SNR. The PCA process could maximize the global transcriptomic variations, and SNR could calculate the distances between sex/age groups divided by the noises within each group (<xref rid="equ1 equ2 equ3" ref-type="disp-formula">Equations 1&#8211;3</xref>, female vs. male and young vs. old). We selected the principal components that captured more than 80% of the global variation (other PC cutoffs capturing 50&#8211;90% of variations were also tested as controls). The SNR of the principal component score was calculated according to the following formula:<disp-formula id="equ1"><label>(1)</label><alternatives><mml:math id="m1"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>p</mml:mi><mml:mi>c</mml:mi><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:mi>R</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>X</mml:mi><mml:mo>,</mml:mo><mml:mi>Y</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:msub><mml:mrow><mml:mo symmetric="true">&#8214;</mml:mo><mml:mrow><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">&#175;</mml:mo></mml:mover></mml:mrow><mml:mo>&#8722;</mml:mo><mml:mrow><mml:mover><mml:mi>Y</mml:mi><mml:mo stretchy="false">&#175;</mml:mo></mml:mover></mml:mrow></mml:mrow><mml:mo symmetric="true">&#8214;</mml:mo></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msqrt><mml:mfrac><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>y</mml:mi></mml:mrow></mml:msub></mml:mfrac></mml:msqrt></mml:mfrac></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="t1">\begin{document}$$\displaystyle pcSVR\left (X,Y\right)=\frac{\left \| \bar{X}- \bar{Y}\right \| _{2}}{\sqrt{\frac{\sigma _{X}^{2}}{N_{x}}+\frac{\sigma _{Y}^{2}}{N_{y}}}}$$\end{document}</tex-math></alternatives></disp-formula><disp-formula id="equ2"><label>(2)</label><alternatives><mml:math id="m2"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:munderover><mml:mo>&#8721;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:munderover><mml:msubsup><mml:mrow><mml:mo symmetric="true">&#8214;</mml:mo><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>&#8722;</mml:mo><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">&#175;</mml:mo></mml:mover></mml:mrow></mml:mrow><mml:mo symmetric="true">&#8214;</mml:mo></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>&#8722;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfrac></mml:mstyle></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="t2">\begin{document}$$\displaystyle  \sigma _{X}^{2}=\frac{\sum _{i=1}^{N_{x}}\left \| x_{i}- \bar{X}\right \| _{2}^{2}}{N_{x}- 1}$$\end{document}</tex-math></alternatives></disp-formula><disp-formula id="equ3"><label>(3)</label><alternatives><mml:math id="m3"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:munderover><mml:mo>&#8721;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>y</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:munderover><mml:msubsup><mml:mrow><mml:mo symmetric="true">&#8214;</mml:mo><mml:mrow><mml:msub><mml:mi>y</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>&#8722;</mml:mo><mml:mrow><mml:mover><mml:mi>Y</mml:mi><mml:mo stretchy="false">&#175;</mml:mo></mml:mover></mml:mrow></mml:mrow><mml:mo symmetric="true">&#8214;</mml:mo></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>y</mml:mi></mml:mrow></mml:msub><mml:mo>&#8722;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfrac></mml:mstyle></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="t3">\begin{document}$$\displaystyle  \sigma _{Y}^{2}=\frac{\sum _{i=1}^{N_{y}}\left \| y_{i}- \bar{Y}\right \| _{2}^{2}}{N_{y}- 1}$$\end{document}</tex-math></alternatives></disp-formula></p><p>where <inline-formula><alternatives><mml:math id="inf3"><mml:mi>X</mml:mi></mml:math><tex-math id="inft3">\begin{document}$X$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf4"><mml:mi>Y</mml:mi></mml:math><tex-math id="inft4">\begin{document}$Y$\end{document}</tex-math></alternatives></inline-formula> label two groups with sample sizes <inline-formula><alternatives><mml:math id="inf5"><mml:mstyle><mml:mrow><mml:mstyle displaystyle="false"><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="inft5">\begin{document}$N_{x}$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf6"><mml:mstyle><mml:mrow><mml:mstyle displaystyle="false"><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>y</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="inft6">\begin{document}$N_{y}$\end{document}</tex-math></alternatives></inline-formula> (females and males; young and old); <inline-formula><alternatives><mml:math id="inf7"><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:math><tex-math id="inft7">\begin{document}$x_{i}$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf8"><mml:msub><mml:mrow><mml:mi>y</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:math><tex-math id="inft8">\begin{document}$y_{i}$\end{document}</tex-math></alternatives></inline-formula> are the PC scores in sample <inline-formula><alternatives><mml:math id="inf9"><mml:mi>i</mml:mi></mml:math><tex-math id="inft9">\begin{document}$i$\end{document}</tex-math></alternatives></inline-formula>; and <inline-formula><alternatives><mml:math id="inf10"><mml:mstyle><mml:mrow><mml:mstyle displaystyle="false"><mml:mrow><mml:mover><mml:mi>X</mml:mi><mml:mo stretchy="false">&#175;</mml:mo></mml:mover></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="inft10">\begin{document}$\bar{X}$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf11"><mml:mover accent="false"><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mo>&#175;</mml:mo></mml:mover></mml:math><tex-math id="inft11">\begin{document}$\bar{Y}$\end{document}</tex-math></alternatives></inline-formula> are average PC scores across samples in each group calculated by GE or AS.</p><p>Here, to figure out whether the pcSVR is statistically significant enough, we conducted the permutation analysis and derived empirical p-values of the pcSVR. We first randomly selected subsamples (50% numbers of the minimum sample sizes of two groups) 10,000 times in each sex/age group and computed the averaged pcSVR. Then, we also randomly selected the same number of subsamples 10,000 times in each tissue regardless of the sex/age labels. The empirical p-values were calculated by the percentage of tested 10,000 pcSVR values (i.e., calculated using 50% sub-sampling irrespective of the group labels for 10,000 repeats) higher than the average pcSVR (i.e., calculated using 50% sub-sampling with the group labels for 10,000 repeats). The null hypothesis is that the two sets of pcSVR values are drawn from the same distribution. We performed all of the random sampling approaches using even probabilities in the R function &#8216;sample&#8217; with the parameter prob = NULL. The tissues with more than three samples in each age group in females or males are included for this analysis (total 29 tissues and 4 brain regions).</p><p>To compare different approaches for empirical p-value estimation, a bootstrap with the replacement approach was also performed for null distributions. The process was repeated 10,000 times to minimize the biases of random sampling to construct a proper null distribution. Compared with the bootstrapping approach with replacement, the sub-sampling approach could also evaluate the robustness of pcSVR values to the sample size. Genes and AS events encoded by the protein-coding genes with averaged TPM &gt;1 were considered. To evaluate the contribution of sex chromosomes to pcSVR, we also removed the genes and AS events encoded by sex chromosomes and recalculated the pcSVR with corresponding p-values in each tissue.</p></sec><sec id="s4-3"><title>Identification of differentially expressed genes and AS events</title><p>A recent study reported that DESeq2 and edgeR have unexpectedly high FDR in analyzing large-scale datasets, as well as the inconsistency between differentially expressed genes identified by these two approaches (<xref rid="bib49" ref-type="bibr">Li et al., 2022</xref>). Linear regression models have been widely used for transcriptomic and genomic differential analysis in recent studies (<xref rid="bib61" ref-type="bibr">Oliva et al., 2020</xref>; <xref rid="bib77" ref-type="bibr">Wang et al., 2018</xref>; <xref rid="bib51" ref-type="bibr">Lopes-Ramos et al., 2020</xref>; <xref rid="bib90" ref-type="bibr">Zhang et al., 2020</xref>), which have the advantages of controlling all known (e.g., sex, age, race, etc.) and unknown variables (e.g., confounders and other batch effects, etc.). In each tissue, we fitted a linear regression model including age, sex, and age-by-sex interactions as covariates, as well as other confounding factors. The following linear regression was used:<disp-formula id="equ4"><label>(4)</label><alternatives><mml:math id="m4"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>P</mml:mi><mml:mi>S</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mspace width="thinmathspace"/><mml:mo>&#8764;</mml:mo><mml:msub><mml:mi>&#956;</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>&#945;</mml:mi><mml:mi>S</mml:mi><mml:mi>E</mml:mi><mml:msub><mml:mi>X</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>&#946;</mml:mi><mml:mi>A</mml:mi><mml:mi>G</mml:mi><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>&#947;</mml:mi><mml:mi>S</mml:mi><mml:mi>E</mml:mi><mml:msub><mml:mi>X</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>&#215;</mml:mo><mml:mi>A</mml:mi><mml:mi>G</mml:mi><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mo>&#8721;</mml:mo></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>N</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mi>&#948;</mml:mi><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mi>S</mml:mi><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mi>k</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#949;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="t4">\begin{document}$$\displaystyle  PSI_{ij}\,\sim \mu _{i}+\alpha SEX_{j}+\beta AGE_{j}+\gamma SEX_{j}\times AGE_{j}+{\sum} _{k=1}^{N}\delta _{k}SV_{kj}+\varepsilon _{ij}$$\end{document}</tex-math></alternatives></disp-formula><disp-formula id="equ5"><label>(5)</label><alternatives><mml:math id="m5"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>T</mml:mi><mml:mi>P</mml:mi><mml:msub><mml:mi>M</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>&#8764;</mml:mo><mml:msub><mml:mi>&#956;</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>&#945;</mml:mi><mml:mi>S</mml:mi><mml:mi>E</mml:mi><mml:msub><mml:mi>X</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>&#946;</mml:mi><mml:mi>A</mml:mi><mml:mi>G</mml:mi><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>&#947;</mml:mi><mml:mi>S</mml:mi><mml:mi>E</mml:mi><mml:msub><mml:mi>X</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>&#215;</mml:mo><mml:mi>A</mml:mi><mml:mi>G</mml:mi><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mo>&#8721;</mml:mo></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>N</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mi>&#948;</mml:mi><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mi>S</mml:mi><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mi>k</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#949;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="t5">\begin{document}$$\displaystyle  TPM_{ij}\sim \mu _{i}+\alpha SEX_{j}+\beta AGE_{j}+\gamma SEX_{j}\times AGE_{j}+{\sum}_{k=1}^{N}\delta _{k}SV_{kj}+\varepsilon _{ij}$$\end{document}</tex-math></alternatives></disp-formula></p><p>where <inline-formula><alternatives><mml:math id="inf12"><mml:msub><mml:mrow><mml:mi>P</mml:mi><mml:mi>S</mml:mi><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:math><tex-math id="inft12">\begin{document}$PSI_{ij}$\end{document}</tex-math></alternatives></inline-formula> is the normalized PSI value for AS event <inline-formula><alternatives><mml:math id="inf13"><mml:mi>i</mml:mi></mml:math><tex-math id="inft13">\begin{document}$i$\end{document}</tex-math></alternatives></inline-formula> in sample <inline-formula><alternatives><mml:math id="inf14"><mml:mi>j</mml:mi></mml:math><tex-math id="inft14">\begin{document}$j$\end{document}</tex-math></alternatives></inline-formula>; <inline-formula><alternatives><mml:math id="inf15"><mml:mi>&#945;</mml:mi><mml:mo>,</mml:mo><mml:mi>&#946;</mml:mi><mml:mo>,</mml:mo><mml:mi>&#947;</mml:mi></mml:math><tex-math id="inft15">\begin{document}$\alpha ,\beta ,\gamma $\end{document}</tex-math></alternatives></inline-formula> are the coefficients of sex, age, and age-by-sex interactions, respectively; <inline-formula><alternatives><mml:math id="inf16"><mml:msub><mml:mrow><mml:mi>&#956;</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:math><tex-math id="inft16">\begin{document}$\mu _{i}$\end{document}</tex-math></alternatives></inline-formula> is the regression intercept; <inline-formula><alternatives><mml:math id="inf17"><mml:mstyle><mml:mrow><mml:mstyle displaystyle="false"><mml:msub><mml:mi>&#949;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="inft17">\begin{document}$\varepsilon_{ij}$\end{document}</tex-math></alternatives></inline-formula> is the error term; and <inline-formula><alternatives><mml:math id="inf18"><mml:mstyle><mml:mrow><mml:mstyle displaystyle="false"><mml:mi>k</mml:mi></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="inft18">\begin{document}$k$\end{document}</tex-math></alternatives></inline-formula> is the number of SVs in <inline-formula><alternatives><mml:math id="inf19"><mml:mstyle><mml:mrow><mml:mstyle displaystyle="false"><mml:mi>N</mml:mi></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="inft19">\begin{document}$N$\end{document}</tex-math></alternatives></inline-formula> total SVs for sample <inline-formula><alternatives><mml:math id="inf20"><mml:mi>j</mml:mi></mml:math><tex-math id="inft20">\begin{document}$j$\end{document}</tex-math></alternatives></inline-formula> with the coefficients <inline-formula><alternatives><mml:math id="inf21"><mml:msub><mml:mrow><mml:mi>&#948;</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:math><tex-math id="inft21">\begin{document}$\delta _{k}$\end{document}</tex-math></alternatives></inline-formula>. SVs are estimated using SVA (surrogate variable analysis) (<xref rid="bib46" ref-type="bibr">Leek et al., 2012</xref>). For differential GE analysis, we used the same linear regression model for analyzing differential GE by replacing PSI with TPM in the formula (<xref rid="equ5" ref-type="disp-formula">Equation 5</xref>). To deal with the different orders of magnitude between PSI and TPM values, we normalized the PSI/TPM of each gene/AS event across samples using a scaling method to normalize the distance from the mean PSI/TPM across all samples.<disp-formula id="equ6"><alternatives><mml:math id="m6"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>n</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>m</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>&#8722;</mml:mo><mml:mi>m</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mi>D</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>;</mml:mo><mml:mi>A</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mi>D</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:munderover><mml:mo>&#8721;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:munderover><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>&#8722;</mml:mo><mml:mi>m</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow></mml:mrow><mml:mi>n</mml:mi></mml:mfrac></mml:mstyle></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="t6">\begin{document}$$\displaystyle  norm\left (Y_{ij}\right)=\frac{Y_{ij}- mean\left (Y_{j}\right)}{AveDis\left (Y_{j}\right)};AveDis\left (Y_{j}\right)=\frac{\sum _{i=1}^{n}|Y_{ij}- mean\left (Y_{j}\right)|}{n}$$\end{document}</tex-math></alternatives></disp-formula></p><p>Here, <inline-formula><alternatives><mml:math id="inf22"><mml:msub><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:math><tex-math id="inft22">\begin{document}$Y_{ij}$\end{document}</tex-math></alternatives></inline-formula> indicates the PSI or TPM of the gene/AS event <italic toggle="yes">i</italic> in sample <italic toggle="yes">j</italic>, and the <inline-formula><alternatives><mml:math id="inf23"><mml:mi>A</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mi>D</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:math><tex-math id="inft23">\begin{document}$AveDis\left (Y_{j}\right)$\end{document}</tex-math></alternatives></inline-formula> indicates the average distance from the mean PSI/TPM across all samples.</p><p>We defined sex- or age-differential genes with the cutoffs of p-value &lt;0.05 for the <italic toggle="yes">a</italic> or <italic toggle="yes">b</italic> coefficients, and fold change &gt;1.5. Sex- or age-differential AS events were defined with the cutoffs of p-value &lt;0.05 for the a or b coefficients, and |&#916;PSI| &gt;0.05. We performed the differential analysis in each gene or AS event independently. The <inline-formula><alternatives><mml:math id="inf24"><mml:mi>&#947;</mml:mi></mml:math><tex-math id="inft24">\begin{document}$\gamma $\end{document}</tex-math></alternatives></inline-formula> significantly larger or smaller than 0 indicates significant age-by-sex interaction, which suggests that the values of TPM and PSI are not only determined by sex or age independently but also affected by the age at a specific sex or sex at a specific age.</p><p>To evaluate whether the genetic effects could be controlled by SVs, we calculated the correlation between SVs and donors&#8217; ethnicity using Point Biserial Correlation which measures the association between continuous variables and dichotomous variables. Also, the Spearman&#8217;s correlation was used to calculate the correlation between SVs and the top 5 principal components as judged by WGS data. The ethnicity information was extracted from phenotype data. The results of principal components calculated by the WGS dataset were downloaded from the GTEx portal.</p><p>Permutation analysis was used to address the false discovery issue of this linear regression model in the differential analysis. We first generated the permuted data by randomly shuffling the group labels (sex or age) with the same sample sizes as the original group labels. The differential genes/AS events (DEGs/DASs) were identified based on each generated permuted phenotype data. This process was performed 1,000 times and we used two strategies to examine the robustness of our cutoffs. We first defined the fractions of original DEGs/DASs which are also identified in each permutation iteration. Meanwhile, the FDR is defined as how many permutations incorrectly identified the specific DEG/DAS across 1,000 permutations.</p></sec><sec id="s4-4"><title>Evaluation of the effect of the sample sizes in differential GE and AS analysis</title><p>The effects of GTEx sample sizes on the numbers of differential genes/AS events were evaluated by a linear regression model by the following formula:<disp-formula id="equ7"><label>(6)</label><alternatives><mml:math id="m7"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>&#8764;</mml:mo><mml:mi>&#956;</mml:mi><mml:mo>+</mml:mo><mml:mi>&#945;</mml:mi><mml:mi>S</mml:mi><mml:mi>i</mml:mi><mml:mi>z</mml:mi><mml:msub><mml:mi>e</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>&#946;</mml:mi><mml:mi>D</mml:mi><mml:mi>e</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>&#949;</mml:mi></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="t7">\begin{document}$$\displaystyle N_{i}\sim \mu +\alpha Size_{i}+\beta Detected_{i}+\varepsilon $$\end{document}</tex-math></alternatives></disp-formula></p><p>where <inline-formula><alternatives><mml:math id="inf25"><mml:mi>N</mml:mi></mml:math><tex-math id="inft25">\begin{document}$N$\end{document}</tex-math></alternatives></inline-formula> is the number of sex- or age-differential genes/AS events in tissue <inline-formula><alternatives><mml:math id="inf26"><mml:mi>i</mml:mi></mml:math><tex-math id="inft26">\begin{document}$i$\end{document}</tex-math></alternatives></inline-formula>; is the number of selected samples; <inline-formula><alternatives><mml:math id="inf27"><mml:mi>D</mml:mi><mml:mi>e</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi></mml:math><tex-math id="inft27">\begin{document}$Detected$\end{document}</tex-math></alternatives></inline-formula> is the detected numbers of genes/AS events after filtering in preprocessing procedures; <inline-formula><alternatives><mml:math id="inf28"><mml:mi>&#945;</mml:mi><mml:mo>,</mml:mo><mml:mi>&#946;</mml:mi></mml:math><tex-math id="inft28">\begin{document}$\alpha ,\beta $\end{document}</tex-math></alternatives></inline-formula> are the coefficients of the sample sizes and numbers of detected genes/AS events, respectively; <italic toggle="yes">&#181;</italic> is the regression intercept; and <inline-formula><alternatives><mml:math id="inf29"><mml:mi>&#949;</mml:mi></mml:math><tex-math id="inft29">\begin{document}$\varepsilon $\end{document}</tex-math></alternatives></inline-formula> is the error term.</p></sec><sec id="s4-5"><title>Identification of sex-stratified age-associated genes/AS events</title><p>To identify the genes/AS events affected by age in separate sexes, we also conducted differential analysis by fitting the following linear regression model in females and males, respectively:<disp-formula id="equ8"><label>(7)</label><alternatives><mml:math id="m8"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>&#8764;</mml:mo><mml:msub><mml:mi>&#946;</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#946;</mml:mi><mml:mrow><mml:mi>F</mml:mi><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mi>M</mml:mi></mml:mrow></mml:msub><mml:mi>A</mml:mi><mml:mi>G</mml:mi><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mo>&#8721;</mml:mo></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>N</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mi>&#948;</mml:mi><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mi>S</mml:mi><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mi>k</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#949;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="t8">\begin{document}$$\displaystyle  Y_{ij}\sim \beta _{0}+\beta _{F/M}AGE_{j}+{\sum}_{k=1}^{N}\delta _{k}SV_{kj}+\varepsilon _{ij}$$\end{document}</tex-math></alternatives></disp-formula></p><p>where <inline-formula><alternatives><mml:math id="inf30"><mml:msub><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:math><tex-math id="inft30">\begin{document}$Y_{ij}$\end{document}</tex-math></alternatives></inline-formula> is the normalized TPM or PSI values of gene/AS event <inline-formula><alternatives><mml:math id="inf31"><mml:mi>i</mml:mi></mml:math><tex-math id="inft31">\begin{document}$i$\end{document}</tex-math></alternatives></inline-formula> in sample <inline-formula><alternatives><mml:math id="inf32"><mml:mi>j</mml:mi></mml:math><tex-math id="inft32">\begin{document}$j$\end{document}</tex-math></alternatives></inline-formula>; <inline-formula><alternatives><mml:math id="inf33"><mml:msub><mml:mrow><mml:mi>&#946;</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mo>/</mml:mo><mml:mrow><mml:mi>M</mml:mi></mml:mrow></mml:mrow></mml:mrow></mml:msub></mml:math><tex-math id="inft33">\begin{document}$\beta _{F/M}$\end{document}</tex-math></alternatives></inline-formula> is the coefficient of age in females or males; <inline-formula><alternatives><mml:math id="inf34"><mml:msub><mml:mrow><mml:mi>&#946;</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:math><tex-math id="inft34">\begin{document}$\beta _{0}$\end{document}</tex-math></alternatives></inline-formula> is the regression intercept; <inline-formula><alternatives><mml:math id="inf35"><mml:msub><mml:mrow><mml:mi>&#949;</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:math><tex-math id="inft35">\begin{document}$\varepsilon _{ij}$\end{document}</tex-math></alternatives></inline-formula> is the error term; and <inline-formula><alternatives><mml:math id="inf36"><mml:mi>k</mml:mi></mml:math><tex-math id="inft36">\begin{document}$k$\end{document}</tex-math></alternatives></inline-formula> is the number of SVs in <inline-formula><alternatives><mml:math id="inf37"><mml:mi>N</mml:mi></mml:math><tex-math id="inft37">\begin{document}$N$\end{document}</tex-math></alternatives></inline-formula> total SVs for sample <inline-formula><alternatives><mml:math id="inf38"><mml:mi>j</mml:mi></mml:math><tex-math id="inft38">\begin{document}$j$\end{document}</tex-math></alternatives></inline-formula> with the coefficients <inline-formula><alternatives><mml:math id="inf39"><mml:msub><mml:mrow><mml:mi>&#948;</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:math><tex-math id="inft39">\begin{document}$\delta _{k}$\end{document}</tex-math></alternatives></inline-formula> evaluated in each sex. Age-associated genes or AS events were defined according to a significant age effect in different sexes (<italic toggle="yes">&#946;</italic><sub>M</sub>, <italic toggle="yes">&#946;</italic><sub>F</sub>, with cutoffs of p &lt; 0.05; GE fold change &gt;1.5 or AS |&#916;PSI| &gt;0.05). The biases in different sexes also reflected the functional interactions between sex and age. This approach not only could indicate whether there is a sex-by-age interaction, but also define the direction of sex-by-age interaction, that is, how females/males affect GE/AS during aging differently. In addition, &#916;PSI and Fold change have also been used for filtering, which are the important thresholds to evaluate the degree of changes. Thus, we further defined the female- or male-specific age-associated genes/AS events using this sex-stratified analysis and classified these age-associated genes/AS events into sex-biased age-associated genes/AS events (i.e., age-associated genes or AS events specific to one sex) or sex-ubiquitous age-associated genes/AS events (i.e., age-associated genes or AS events in both sexes).</p></sec><sec id="s4-6"><title>Functional enrichment and disease ontology analysis</title><p>Potential functions of sBASEs were expounded based on C5 collections (ontology gene sets) in Molecular Signatures Database (MSigDB) and Disease Ontology. We carried out these processes using Bioconductor R packages <italic toggle="yes">msigdbr</italic> (<xref rid="bib21" ref-type="bibr">Dolgalev, 2020</xref>), <italic toggle="yes">clusterProfiler</italic> (<xref rid="bib86" ref-type="bibr">Yu et al., 2012</xref>), and <italic toggle="yes">DOSE</italic> (<xref rid="bib88" ref-type="bibr">Yu et al., 2015b</xref>), with the significance threshold p-value &lt;0.05. The GO terms with the significances specific to only one sex per tissue were selected for downstream analysis. In the enrichment heatmap of brain regions (<xref rid="fig4" ref-type="fig">Figure 4A</xref>), we plotted the GO terms with significance in at least 3 brain regions. Because the enrichment heatmap across all tissues is unrealistically large, we plotted the terms within at least 15 tissues and the tissues/sex with significance in at least 9 significant GO terms (<xref rid="fig3s4" ref-type="fig">Figure 3&#8212;figure supplement 4</xref>). The entire results of the enrichment analysis are shown in <xref rid="supp4" ref-type="supplementary-material">Supplementary file 4</xref>.</p></sec><sec id="s4-7"><title>Processing of Alzheimer&#8217;s disease datasets and construction of AD prediction model</title><p>The AD samples of human prefrontal cortex were selected from GEO datasets (ID: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE174367">GSE174367</ext-link>) containing 375 samples of single-nucleus RNA-seq, single-nucleus ATAC-seq, and bulk RNA-seq. We filtered the datasets by selecting the RNA-seq samples from the Frontal Cortex brain region (Library Source: &#8216;TRANSCRIPTOMIC&#8217;; Brain region: &#8216;FC&#8217;). Next, we selected the samples with the isolation approach &#8216;total RNA isolation&#8217;. Due to the sequencing depth on the splicing junction, we filtered out the samples lower than 1 Gb Bytes (SRR14514282, SRR14514349, SRR14514308, and SRR14514275). The remaining 91 samples were selected for GE and AS quantification, including 45 AD samples and 46 control samples from 47 male and 44 female donors (Female:Male &#8776; 1:1; AD:Control &#8776; 1:1) with similar age distribution between AD and control groups. Quality control and adaptor trimming were performed using FastQC (<xref rid="bib3" ref-type="bibr">Andrews, 2010</xref>) (version 0.11.9) and Trim Galore (version 0.6.6). Bowtie2 (<xref rid="bib45" ref-type="bibr">Langmead and Salzberg, 2012</xref>) (version 2.4.2) was used to remove reads mapping to ribosomal RNA. Then, clean reads were mapped to human reference (GRCh38) using STAR (<xref rid="bib20" ref-type="bibr">Dobin et al., 2013</xref>) (version 2.7.6). We also used pre-mapped RNA-seq data from ROSMAP containing the RNA-seq samples from the bulk sequencing of DLPFC. We further filtered the data to match the number of both sexes and the age distribution between AD and control groups, resulting in the 215 AD and 56 control samples. The quantifications of GE and AS were performed by Paean (<xref rid="bib47" ref-type="bibr">Li et al., 2018a</xref>).</p><p>To identify AD-related genes/AS events, we fitted a linear regression model with AD diagnosis (categorical outcomes) and SVs calculated by SVA (<xref rid="bib46" ref-type="bibr">Leek et al., 2012</xref>). AD-related genes/AS events were defined whose coefficients of the &#8216;diagnosis&#8217; term significantly deviated to zero. To compare the correlation coefficients that evaluated the correlation between AD- and age-associated AS changes in males and females independently, we performed Fisher&#8217;s <italic toggle="yes">z</italic>-transformation on Pearson correlation coefficients using R packages <italic toggle="yes">cocor</italic> (<xref rid="bib18" ref-type="bibr">Diedenhofen and Musch, 2015</xref>).</p><p>To capture the key age-associated splicing changes in males and females that were particularly involved in AD pathogenesis, we focused on the frontal cortex that was relevant to AD and further used the sBASEs for AD prediction. We randomly divided 90% samples for training sets and 10% for test sets and repeated this for 100 iterations. In each iteration, we performed a fivefold cross-validation with the feature selection approach called Recursive Feature Elimination via R packages <italic toggle="yes">caret</italic> (<xref rid="bib44" ref-type="bibr">Kuhn and Johnson, 2013</xref>). Model performance was evaluated by the area under the curve. Random forest and support vector machine with a linear kernel were used for classification (<xref rid="fig4" ref-type="fig">Figure 4D</xref> and <xref rid="fig4s2" ref-type="fig">Figure 4&#8212;figure supplement 2D</xref>)<italic toggle="yes">.</italic> To evaluate the final selected features that crucially contributed to AD prediction, we calculated the importance of each feature in each iteration (i.e., MDA) and then ranked the features by the averaged MDAs across 100 iterations. As negative controls, the sex-stratified model predicted AD patients in females and males separately using randomly selected AS events, and the merge-sexes model predicted AD patients in all samples regardless of sex labels using sBASEs<italic toggle="yes">.</italic></p></sec><sec id="s4-8"><title>Transcriptome-wide association analysis with AD pathology</title><p>We used a linear regression model to identify the associations between AS events and AD pathology. The pathology includes tangles and plaque stages with continuous outcomes. Age was included as one of the covariates. This association analysis was performed for each sex.</p></sec><sec id="s4-9"><title>Construction of AS regulatory network</title><p>Splicing-related genes were extracted from the GO_RNA_SPLICING term based on MsigDB (c5.all.v7.4.symbols.gmt). Networks between age-associated SFs and sBASEs in each sex were constructed with the following three steps.</p><p>First, we examined the significant correlations between the expression of SFs and splicing of AS events during aging. We conducted Spearman&#8217;s correlation test between TPMs of SFs and PSIs of AS events during aging using the threshold p-value &lt;0.05.</p><p>Second, we chose the AS events significantly perturbed by RBP knockdown for downstream analysis. RBP shRNA RNA-seq bam files of 200 RBPs in HepG2 and K562 were downloaded from ENCODE Consortium. The TPM and PSI values were also quantified by Paean (<xref rid="bib47" ref-type="bibr">Li et al., 2018a</xref>). Differential analysis between control and shRNA groups was performed by a linear regression model:<disp-formula id="equ9"><label>(8)</label><alternatives><mml:math id="m9"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>P</mml:mi><mml:mi>S</mml:mi><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>&#8764;</mml:mo><mml:msub><mml:mi>&#956;</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#946;</mml:mi><mml:mrow><mml:mi>G</mml:mi></mml:mrow></mml:msub><mml:mi>G</mml:mi><mml:mi>r</mml:mi><mml:mi>o</mml:mi><mml:mi>u</mml:mi><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#949;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="t9">\begin{document}$$\displaystyle PSI_{ij}\sim \mu _{i}+\beta _{G}Group_{j}+\varepsilon _{ij}$$\end{document}</tex-math></alternatives></disp-formula></p><p>where <inline-formula><alternatives><mml:math id="inf40"><mml:msub><mml:mrow><mml:mi>G</mml:mi><mml:mi>r</mml:mi><mml:mi>o</mml:mi><mml:mi>u</mml:mi><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:math><tex-math id="inft40">\begin{document}$Group_{j}$\end{document}</tex-math></alternatives></inline-formula> represents a categorical variable labeled by &#8216;Control&#8217; or &#8216;shRNA&#8217;. AS events significantly perturbed by RBP knockdown were defined by the estimated coefficient <inline-formula><alternatives><mml:math id="inf41"><mml:msub><mml:mrow><mml:mi>&#946;</mml:mi></mml:mrow><mml:mrow><mml:mi>G</mml:mi></mml:mrow></mml:msub></mml:math><tex-math id="inft41">\begin{document}$\beta _{G}$\end{document}</tex-math></alternatives></inline-formula> significantly deviating from zero.</p><p>Thirdly, we identified the AS events with SF-binding motifs around the alternative splice sites (SS). We used DeepBind (<xref rid="bib2" ref-type="bibr">Alipanahi et al., 2015</xref>) to predict the specific binding scores of RBPs within the upstream to downstream region adjacent to the alternative SS. BEDTools getfasta (<xref rid="bib63" ref-type="bibr">Quinlan and Hall, 2010</xref>) extracted sequences from specific genomic regions in a.bed6 file. We first subdivided the sequences into multiple subsequences (window = 40 nt; step = 1 nt) and calculated the binding scores with the parameter &#8216;average&#8217; of each subsequence. To identify whether there were binding signals in the upstream to downstream 300-nt region adjacent to the alternative splice sites, we rearranged the binding scores in each region into small bins (width = 20) and tested the median differences between the bins with maximum and minimum averaged binding scores by Wilcoxon rank-sum test. The AS events whose maximum binding scores &gt;1 and p-value &lt;0.05 were reserved. Taken together, we required the regulatory connections between the RBPs and AS events that pass all the individual criteria as judged by all three types of experiments with different techniques. The networks between age-associated SFs and sBASEs were constructed and figured by Cytoscape (<xref rid="bib70" ref-type="bibr">Shannon et al., 2003</xref>).</p></sec><sec id="s4-10"><title>Regulation of hormone receptors to the target genes</title><p>To examine the estrogen regulation using the RNA-seq dataset, we downloaded the RNA-seq datasets from MCF-7 cell line stimulated by estrogen receptor agonist (propyl pyrazole triol) in three biological replicates (GEO ID: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE203058">GSE203058</ext-link>) (<xref rid="bib13" ref-type="bibr">Cao et al., 2024</xref>). Additional datasets (ID: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE89888">GSE89888</ext-link>) are downloaded to confirm our findings in engineered MCF-7 cell lines (<xref rid="bib6" ref-type="bibr">Bahreini et al., 2017</xref>) with wild-type and two constitutively active mutants (Y537S and D538G) of ESR1. These cells were treated with 1 nM estradiol (E2) or vehicle control (veh) for 24 hr before collecting the total RNAs and subjected to transcriptome profiling by RNA-seq. We analyzed these data using the same pipelines in earlier Alzheimer&#8217;s disease datasets (<xref rid="fig4" ref-type="fig">Figure 4</xref>). The GE changes under estrogen treatments were evaluated in a linear regression model using the p-values of the coefficients deviated from zero. To confirm the expression changes of SFs in other cells or tissues, we downloaded the FPKM table from <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE86609">GSE86609</ext-link> that analyzed the ER knockout mice with estrogen treatments in mouse brain arcuate nucleus (ARCs) (<xref rid="bib84" ref-type="bibr">Yang et al., 2017</xref>).</p><p>To further identify the regulation of the estrogen and androgen using ChIP-seq dataset (<xref rid="fig5" ref-type="fig">Figures 5E</xref> and <xref rid="fig6" ref-type="fig">6H</xref>), we evaluated the binding scores of ESR1 and AR to the promoter regions of the target genes (i.e., &#177;1 kb of the transcription start sites, TSS). The binding score of each target gene (i.e., &#8211;10*log<sub>10</sub>[MACS Q-value] from ChIP-seq analysis) was calculated by the ChIP-Atlas (<xref rid="bib60" ref-type="bibr">Oki et al., 2018</xref>), an integrative database of public ChIP-seq data. The ratios in <xref rid="fig5" ref-type="fig">Figure 5E</xref> were calculated by the binding scores of each SF divided by the median binding score of age-associated SFs common in both sexes. Additionally, the ESR1 ChIP-seq peak files in WT mice treated by estrogen were also downloaded from the Gene Expression Omnibus (ID: GSE3645) (<xref rid="bib33" ref-type="bibr">Hewitt et al., 2014</xref>). The peaks were annotated using ChIPSeeker (<xref rid="bib87" ref-type="bibr">Yu et al., 2015a</xref>).</p></sec><sec id="s4-11"><title>Time series and breakpoint analysis</title><p>ARIMA model is one of the linear models for forecasting chronological trends. For non-stationary data, the <italic toggle="yes">auto.arima</italic>() function from the R package <italic toggle="yes">forecast</italic> conducts a stepwise procedure to search for the best model using the smallest Akaike Information Criterion (AIC). This procedure is a variation of the Hyndman&#8211;Khandakar algorithm (<xref rid="bib12" ref-type="bibr">Brockwell et al., 2016</xref>).</p><p>We first corrected the TPM/PSI values for each gene/AS event by removing the unknown confounding factors except for the sex and age effect via R package <italic toggle="yes">limma</italic> and averaged the values of the samples with the same sex and age. Then, we applied ARIMA models to figure out genes with potential chronological trends during aging in each sex. In brief, the input data was first transformed into <italic toggle="yes">z</italic>-ordered objects (R package <italic toggle="yes">zoo</italic>) and the best model was stepwise optimized by AIC (<italic toggle="yes">auto.arima</italic> function from R package <italic toggle="yes">Forecast</italic>). We filtered out the genes/AS events with the significant trend for further analysis by non-seasonal difference order higher than zero (<italic toggle="yes">D</italic> &gt; 0) and the sum of AR or MA coefficient higher than zero (AR +MA &gt; 0).</p><p>Furthermore, we calculated the rate of change at each age point and estimated the breakpoints during aging. The rate of change at each age <inline-formula><alternatives><mml:math id="inf42"><mml:mi>i</mml:mi></mml:math><tex-math id="inft42">\begin{document}$i$\end{document}</tex-math></alternatives></inline-formula> was evaluated by the differences between bins in <inline-formula><alternatives><mml:math id="inf43"><mml:mstyle><mml:mrow><mml:mstyle displaystyle="false"><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>&#8722;</mml:mo><mml:mi>w</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>i</mml:mi></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="inft43">\begin{document}$\left (i- w\right)i$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf44"><mml:mstyle><mml:mrow><mml:mstyle displaystyle="false"><mml:mi>i</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mi>w</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="inft44">\begin{document}$i\left (i+w\right)$\end{document}</tex-math></alternatives></inline-formula> in the following steps. <inline-formula><alternatives><mml:math id="inf45"><mml:mstyle><mml:mrow><mml:mstyle displaystyle="false"><mml:mi>w</mml:mi></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="inft45">\begin{document}$w$\end{document}</tex-math></alternatives></inline-formula> indicated a series of window spans from 5 to 15 years old. The p-values were first tested by MANOVA of three PCs after reducing dimensionality in the PCA process and then smoothed by LOESS regression with the smoothing bandwidth in the range from 0.25 to 0.75 (with interval 0.05). The p-values of each window span were integrated by average &#8722;log<sub>10</sub> transformed p-values and smoothed by LOESS regressions with bandwidth = 0.5. The final rate of changes at each age point was defined by the averaged values through all window spans calculated in the previous step. Moreover, we determined the breakpoints as the age points at the global maximums, as well as the local maximums whose distance to the nearest minimum relative to the global maximum was more than 10%. This model was conducted based on the approach from a previously published study (<xref rid="bib52" ref-type="bibr">M&#225;rquez et al., 2020</xref>; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/UcarLab/SexDimorphismNatureCommunications" ext-link-type="uri">https://github.com/UcarLab/SexDimorphismNatureCommunications</ext-link>, <xref rid="bib55" ref-type="bibr">Mellert and Ucar, 2019</xref>).</p></sec><sec id="s4-12"><title>Identification of AMGs</title><p>We performed the following steps to identify the AMGs that serve as the key contributors to molecular aging (<xref rid="fig6" ref-type="fig">Figure 6</xref>). We randomly trimmed 20% of chronological genes 200 times and repeated breakpoint analysis in each iteration. The Wilcoxon signed-rank test was used to compare the changing rate after removal with that calculated before removal. Using a p-value &lt;0.05, we obtained the set of genes that could significantly alter the aging rate. The AMGs were defined as the set of genes that were significantly enriched from the 200 random samplings (as judged by the Fisher exact test using a p-value &lt;0.05). The tissues with more than 10 chronological genes were selected for AMG identification process. Functional enrichment of sex-biased AMGs was based on MSigDB, and the network between GO terms and genes was constructed by Cytoscape (<xref rid="bib70" ref-type="bibr">Shannon et al., 2003</xref>). GE patterns during aging were shown by the R package <italic toggle="yes">pheatmap</italic>.</p><p>Our results observed clusters of AMGs common in both sexes in whole blood tissue with sex-specific changing patterns (i.e., some genes increased first at young ages and then decreased during male aging, whereas these genes monotonically decreased during female aging). To identify AMGs with this expression pattern, we divided the age points into 9 age windows (e.g., 20&#8211;25, 26&#8211;30, 31&#8211;35, etc.) and averaged the ARIMA-fitted expression levels of the samples within each age window. The AMGs increased at young ages were defined by the mean of fitted expression levels at 31&#8211;40 larger than at 20&#8211;30.</p></sec></sec></body><back><sec sec-type="funding-information"><title>Funding Information</title><p>This paper was supported by the following grants:</p><list list-type="bullet"><list-item><p><funding-source><institution-wrap><institution>Strategic Priority Research Program of CAS</institution></institution-wrap></funding-source>
<award-id>XDB38040100</award-id> to Zefeng Wang.</p></list-item><list-item><p><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source>
<award-id>91940303</award-id> to Zefeng Wang.</p></list-item><list-item><p><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01h0zpd94</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source>
<award-id>32030064</award-id> to Zefeng Wang.</p></list-item><list-item><p><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01h0zpd94</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source>
<award-id>31730110</award-id> to Zefeng Wang.</p></list-item><list-item><p><funding-source><institution-wrap><institution>National Key Research and Development Program of China</institution></institution-wrap></funding-source>
<award-id>2018YFA0107602</award-id> to Zefeng Wang.</p></list-item><list-item><p><funding-source><institution-wrap><institution>National Key Research and Development Program of China</institution></institution-wrap></funding-source>
<award-id>2021YFA0805200</award-id> to Xin Li.</p></list-item><list-item><p><funding-source><institution-wrap><institution>National Key Research and Development Program of China</institution></institution-wrap></funding-source>
<award-id>2019YFC1315804</award-id> to Xin Li.</p></list-item><list-item><p><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source>
<award-id>31970554</award-id> to Xin Li.</p></list-item></list></sec><ack id="ack"><title>Acknowledgements</title><p>The authors want to thank Dr. Yue Hu and Jiefu Li in Wang Lab for their discussions and comments. We also thank Prof. Guoqing Zhang in SINH for his assistance with public data access and Ruijie Yao for helping download RBP shRNA-seq bam files from ENCODE Consortium and providing Paean scripts for multi-processing on the CPU&#8211;GPU platform. This work is supported by the Strategic Priority Research Program of CAS (XDB38040100), the Natural Science Foundation of China (91940303, 32030064, and 31730110), and the National Key Research and Development Program of China (2018YFA0107602) to ZW. ZW is supported by the type A CAS Pioneer 100-Talent program. This work is also supported by the National Key Research and Development Program of China to XL (2021YFA0805200 and 2019YFC1315804), and the National Natural Science Foundation of China to XL (31970554).</p></ack><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Software, Formal analysis, Supervision, Validation, Visualization, Methodology, Writing &#8211; original draft, Project administration, Writing &#8211; review and editing.</p></fn><fn fn-type="con" id="con2"><p>Resources, Data curation, Methodology, Writing &#8211; review and editing.</p></fn><fn fn-type="con" id="con3"><p>Resources, Data curation, Supervision, Methodology, Writing &#8211; review and editing.</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Supervision, Funding acquisition, Investigation, Methodology, Writing &#8211; original draft, Project administration, Writing &#8211; review and editing.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar" position="float" content-type="local-data" orientation="portrait"><label>MDAR checklist</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="elife-102449-mdarchecklist1.pdf" id="d67e3596" position="anchor" orientation="portrait"/></supplementary-material><supplementary-material id="supp1" position="float" content-type="local-data" orientation="portrait"><label>Supplementary file 1.</label><caption><title>Summary for sample sizes of each group in multiple tissues.</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="elife-102449-supp1.xlsx" id="d67e3601" position="anchor" orientation="portrait"/></supplementary-material><supplementary-material id="supp2" position="float" content-type="local-data" orientation="portrait"><label>Supplementary file 2.</label><caption><title>Principal component-based signal-to-variation ratio (pcSVR) values and corresponding permutation p-values between different age or sex groups as judged by gene expression (GE) and alternative splicing (AS).</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="elife-102449-supp2.xlsx" id="d67e3606" position="anchor" orientation="portrait"/></supplementary-material><supplementary-material id="supp3" position="float" content-type="local-data" orientation="portrait"><label>Supplementary file 3.</label><caption><title>Lists of sex-stratified age-associated genes and alternative splicing (AS) events in 35 human tissues and brain regions.</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="elife-102449-supp3.xlsx" id="d67e3611" position="anchor" orientation="portrait"/></supplementary-material><supplementary-material id="supp4" position="float" content-type="local-data" orientation="portrait"><label>Supplementary file 4.</label><caption><title>p-values of GO analysis for sex-biased age-associated alternative splicing events (sBASEs) across multiple tissues.</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="elife-102449-supp4.xlsx" id="d67e3616" position="anchor" orientation="portrait"/></supplementary-material><supplementary-material id="supp5" position="float" content-type="local-data" orientation="portrait"><label>Supplementary file 5.</label><caption><title>AS regulatory networks between sex-biased age-associated alternative splicing events (sBASEs) and age-associated splicing factors in four functional brain regions.</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="elife-102449-supp5.xlsx" id="d67e3621" position="anchor" orientation="portrait"/></supplementary-material><supplementary-material id="supp6" position="float" content-type="local-data" orientation="portrait"><label>Supplementary file 6.</label><caption><title>Aging-modulated genes (AMGs) and enriched p-values across multiple tissues.</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="elife-102449-supp6.xlsx" id="d67e3626" position="anchor" orientation="portrait"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The current manuscript is a computational study, so no data have been generated for this manuscript. GTEx data were obtained through dbGaP (accession number phs000424.v8.p2). The source RNA-seq data (*.fastq) of AD and control samples were obtained from Gene Expression Omnibus (accession number <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE174367">GSE174367</ext-link>). The RNA-seq and ChIP-seq data with estrogen treatment in ER mutant and wild -type cells were downloaded from Gene Expression Omnibus (accession number <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE203058">GSE203058</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE89888">GSE89888</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE86609">GSE86609</ext-link>, and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE36455">GSE36455</ext-link>). Pre-mapped RNA-seq data (*.bam) of AD and control samples were obtained from ROSMAP (accession number syn8540863). shRNA-seq data of 200 RBPs in HepG2 and K562 cell lines were downloaded from ENCODE consortium (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.encodeproject.org" ext-link-type="uri">https://www.encodeproject.org</ext-link>). Molecular Signatures Database, (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://software.broadinstitute.org/gsea/msigdb/collections.jsp" ext-link-type="uri">http://software.broadinstitute.org/gsea/msigdb/collections.jsp</ext-link>). The source code is available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/rnasys/Sex-dimorphic-aging" ext-link-type="uri">GitHub</ext-link> (copy archived at <xref rid="bib79" ref-type="bibr">Wang, 2025</xref>) and from <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.5281/zenodo.10970995" ext-link-type="uri">Zenodo</ext-link>.</p><p>The following previously published datasets were used:</p><p>
<element-citation publication-type="data" id="dataset1"><person-group person-group-type="author"><collab>GTEx Consortium</collab></person-group><year iso-8601-date="2020">2020</year><data-title>Common Fund (CF) Genotype-Tissue Expression Project (GTEx)</data-title><source>dbGaP</source><pub-id xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000424.v8.p2">phs000424.v8.p2</pub-id></element-citation>
</p><p>
<element-citation publication-type="data" id="dataset2"><person-group person-group-type="author"><name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></name><name name-style="western"><surname>Buchman</surname><given-names>AS</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>PA</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>LL</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>RS</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>The Religious Orders Study and Memory and Aging Project (ROSMAP) Study</data-title><source>AD Knowledge Portal</source><pub-id xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="accession" xlink:href="https://adknowledgeportal.synapse.org/Explore/Studies/DetailsPage/StudyDetails?Study=syn3219045">syn8540863</pub-id></element-citation>
</p><p>
<element-citation publication-type="data" id="dataset3"><person-group person-group-type="author"><name name-style="western"><surname>Morabito</surname><given-names>S</given-names></name><name name-style="western"><surname>Miyoshi</surname><given-names>E</given-names></name><name name-style="western"><surname>Swarup</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Single-nucleus chromatin accessibility and transcriptomic characterization of Alzheimer&#8217;s Disease</data-title><source>NCBI Gene Expression Omnibus</source><pub-id xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE174367">GSE174367</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-021-00894-z</pub-id><pub-id pub-id-type="pmcid">PMC8766217</pub-id><pub-id pub-id-type="pmid">34239132</pub-id></element-citation>
</p><p>
<element-citation publication-type="data" id="dataset4"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>L</given-names></name><name name-style="western"><surname>Ruan</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N</given-names></name><name name-style="western"><surname>Gao</surname><given-names>C</given-names></name><name name-style="western"><surname>Cai</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Hu</surname><given-names>M</given-names></name><name name-style="western"><surname>Shu</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Estrogen receptor &#945;-mediated signaling inhibits type I interferon response to promote breast cancer</data-title><source>NCBI Gene Expression Omnibus</source><pub-id xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE203058">GSE203058</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jmcb/mjad047</pub-id><pub-id pub-id-type="pmcid">PMC11066933</pub-id><pub-id pub-id-type="pmid">37442610</pub-id></element-citation>
</p><p>
<element-citation publication-type="data" id="dataset5"><person-group person-group-type="author"><name name-style="western"><surname>Bahreini</surname><given-names>A</given-names></name><name name-style="western"><surname>Oesterreich</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><data-title>RNA-seq analysis of ESR1 mutations in T47D and MCF7 cell lines</data-title><source>NCBI Gene Expression Omnibus</source><pub-id xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE89888">GSE89888</pub-id></element-citation>
</p><p>
<element-citation publication-type="data" id="dataset6"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>JA</given-names></name><name name-style="western"><surname>Stires</surname><given-names>H</given-names></name><name name-style="western"><surname>Belden</surname><given-names>W</given-names></name><name name-style="western"><surname>Roepke</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="2017">2017</year><data-title>The Arcuate Estrogenome: Estrogen Response Element-dependent and -independent Signaling of ER&#945;</data-title><source>NCBI Gene Expression Omnibus</source><pub-id xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE86609">GSE86609</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/en.2016-1663</pub-id><pub-id pub-id-type="pmcid">PMC5460777</pub-id><pub-id pub-id-type="pmid">28359086</pub-id></element-citation>
</p><p>
<element-citation publication-type="data" id="dataset7"><person-group person-group-type="author"><name name-style="western"><surname>Hewitt</surname><given-names>SC</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Grimm</surname><given-names>SA</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bushel</surname><given-names>PR</given-names></name><name name-style="western"><surname>Fargo</surname><given-names>D</given-names></name><name name-style="western"><surname>Korach</surname><given-names>KS</given-names></name></person-group><year iso-8601-date="2012">2012</year><data-title>ER&#945; and PolII ChIP seq from Mouse Uterus</data-title><source>NCBI Gene Expression Omnibus</source><pub-id xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE36455">GSE36455</pub-id></element-citation>
</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aguet</surname><given-names>F</given-names></name><name name-style="western"><surname>Anand</surname><given-names>S</given-names></name><name name-style="western"><surname>Ardlie</surname><given-names>KG</given-names></name><name name-style="western"><surname>Gabriel</surname><given-names>S</given-names></name><name name-style="western"><surname>Getz</surname><given-names>GA</given-names></name><name name-style="western"><surname>Graubert</surname><given-names>A</given-names></name><name name-style="western"><surname>Hadley</surname><given-names>K</given-names></name><name name-style="western"><surname>Handsaker</surname><given-names>RE</given-names></name><name name-style="western"><surname>Huang</surname><given-names>KH</given-names></name><name name-style="western"><surname>Kashin</surname><given-names>S</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>MacArthur</surname><given-names>DG</given-names></name><name name-style="western"><surname>Meier</surname><given-names>SR</given-names></name><name name-style="western"><surname>Nedzel</surname><given-names>JL</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>DT</given-names></name><name name-style="western"><surname>Segr&#232;</surname><given-names>AV</given-names></name><name name-style="western"><surname>Todres</surname><given-names>E</given-names></name><name name-style="western"><surname>Balliu</surname><given-names>B</given-names></name><name name-style="western"><surname>Barbeira</surname><given-names>AN</given-names></name><name name-style="western"><surname>Battle</surname><given-names>A</given-names></name><name name-style="western"><surname>Bonazzola</surname><given-names>R</given-names></name><name name-style="western"><surname>Brown</surname><given-names>A</given-names></name><name name-style="western"><surname>Brown</surname><given-names>CD</given-names></name><name name-style="western"><surname>Castel</surname><given-names>SE</given-names></name><name name-style="western"><surname>Conrad</surname><given-names>DF</given-names></name><name name-style="western"><surname>Cotter</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Cox</surname><given-names>N</given-names></name><name name-style="western"><surname>Das</surname><given-names>S</given-names></name><name name-style="western"><surname>de Goede</surname><given-names>OM</given-names></name><name name-style="western"><surname>Dermitzakis</surname><given-names>ET</given-names></name><name name-style="western"><surname>Einson</surname><given-names>J</given-names></name><name name-style="western"><surname>Engelhardt</surname><given-names>BE</given-names></name><name name-style="western"><surname>Eskin</surname><given-names>E</given-names></name><name name-style="western"><surname>Eulalio</surname><given-names>TY</given-names></name><name name-style="western"><surname>Ferraro</surname><given-names>NM</given-names></name><name name-style="western"><surname>Flynn</surname><given-names>ED</given-names></name><name name-style="western"><surname>Fresard</surname><given-names>L</given-names></name><name name-style="western"><surname>Gamazon</surname><given-names>ER</given-names></name><name name-style="western"><surname>Garrido-Mart&#237;n</surname><given-names>D</given-names></name><name name-style="western"><surname>Gay</surname><given-names>NR</given-names></name><name name-style="western"><surname>Gloudemans</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Guig&#243;</surname><given-names>R</given-names></name><name name-style="western"><surname>Hame</surname><given-names>AR</given-names></name><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hoffman</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Hormozdiari</surname><given-names>F</given-names></name><name name-style="western"><surname>Hou</surname><given-names>L</given-names></name><name name-style="western"><surname>Im</surname><given-names>HK</given-names></name><name name-style="western"><surname>Jo</surname><given-names>B</given-names></name><name name-style="western"><surname>Kasela</surname><given-names>S</given-names></name><name name-style="western"><surname>Kellis</surname><given-names>M</given-names></name><name name-style="western"><surname>Kim-Hellmuth</surname><given-names>S</given-names></name><name name-style="western"><surname>Kwong</surname><given-names>A</given-names></name><name name-style="western"><surname>Lappalainen</surname><given-names>T</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Mangul</surname><given-names>S</given-names></name><name name-style="western"><surname>Mohammadi</surname><given-names>P</given-names></name><name name-style="western"><surname>Montgomery</surname><given-names>SB</given-names></name><name name-style="western"><surname>Mu&#241;oz-Aguirre</surname><given-names>M</given-names></name><name name-style="western"><surname>Nachun</surname><given-names>DC</given-names></name><name name-style="western"><surname>Nobel</surname><given-names>AB</given-names></name><name name-style="western"><surname>Oliva</surname><given-names>M</given-names></name><name name-style="western"><surname>Park</surname><given-names>Y</given-names></name><name name-style="western"><surname>Park</surname><given-names>Y</given-names></name><name name-style="western"><surname>Parsana</surname><given-names>P</given-names></name><name name-style="western"><surname>Rao</surname><given-names>AS</given-names></name><name name-style="western"><surname>Reverter</surname><given-names>F</given-names></name><name name-style="western"><surname>Rouhana</surname><given-names>JM</given-names></name><name name-style="western"><surname>Sabatti</surname><given-names>C</given-names></name><name name-style="western"><surname>Saha</surname><given-names>A</given-names></name><name name-style="western"><surname>Stephens</surname><given-names>M</given-names></name><name name-style="western"><surname>Stranger</surname><given-names>BE</given-names></name><name name-style="western"><surname>Strober</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Teran</surname><given-names>NA</given-names></name><name name-style="western"><surname>Vi&#241;uela</surname><given-names>A</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G</given-names></name><name name-style="western"><surname>Wen</surname><given-names>X</given-names></name><name name-style="western"><surname>Wright</surname><given-names>F</given-names></name><name name-style="western"><surname>Wucher</surname><given-names>V</given-names></name><name name-style="western"><surname>Zou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>PG</given-names></name><name name-style="western"><surname>Li</surname><given-names>G</given-names></name><name name-style="western"><surname>Mel&#233;</surname><given-names>M</given-names></name><name name-style="western"><surname>Yeger-Lotem</surname><given-names>E</given-names></name><name name-style="western"><surname>Barcus</surname><given-names>ME</given-names></name><name name-style="western"><surname>Bradbury</surname><given-names>D</given-names></name><name name-style="western"><surname>Krubit</surname><given-names>T</given-names></name><name name-style="western"><surname>McLean</surname><given-names>JA</given-names></name><name name-style="western"><surname>Qi</surname><given-names>L</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>K</given-names></name><name name-style="western"><surname>Roche</surname><given-names>NV</given-names></name><name name-style="western"><surname>Smith</surname><given-names>AM</given-names></name><name name-style="western"><surname>Sobin</surname><given-names>L</given-names></name><name name-style="western"><surname>Tabor</surname><given-names>DE</given-names></name><name name-style="western"><surname>Undale</surname><given-names>A</given-names></name><name name-style="western"><surname>Bridge</surname><given-names>J</given-names></name><name name-style="western"><surname>Brigham</surname><given-names>LE</given-names></name><name name-style="western"><surname>Foster</surname><given-names>BA</given-names></name><name name-style="western"><surname>Gillard</surname><given-names>BM</given-names></name><name name-style="western"><surname>Hasz</surname><given-names>R</given-names></name><name name-style="western"><surname>Hunter</surname><given-names>M</given-names></name><name name-style="western"><surname>Johns</surname><given-names>C</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>M</given-names></name><name name-style="western"><surname>Karasik</surname><given-names>E</given-names></name><name name-style="western"><surname>Kopen</surname><given-names>G</given-names></name><name name-style="western"><surname>Leinweber</surname><given-names>WF</given-names></name><name name-style="western"><surname>McDonald</surname><given-names>A</given-names></name><name name-style="western"><surname>Moser</surname><given-names>MT</given-names></name><name name-style="western"><surname>Myer</surname><given-names>K</given-names></name><name name-style="western"><surname>Ramsey</surname><given-names>KD</given-names></name><name name-style="western"><surname>Roe</surname><given-names>B</given-names></name><name name-style="western"><surname>Shad</surname><given-names>S</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>JA</given-names></name><name name-style="western"><surname>Walters</surname><given-names>G</given-names></name><name name-style="western"><surname>Washington</surname><given-names>M</given-names></name><name name-style="western"><surname>Wheeler</surname><given-names>J</given-names></name><name name-style="western"><surname>Jewell</surname><given-names>SD</given-names></name><name name-style="western"><surname>Rohrer</surname><given-names>DC</given-names></name><name name-style="western"><surname>Valley</surname><given-names>DR</given-names></name><name name-style="western"><surname>Davis</surname><given-names>DA</given-names></name><name name-style="western"><surname>Mash</surname><given-names>DC</given-names></name><name name-style="western"><surname>Branton</surname><given-names>PA</given-names></name><name name-style="western"><surname>Barker</surname><given-names>LK</given-names></name><name name-style="western"><surname>Gardiner</surname><given-names>HM</given-names></name><name name-style="western"><surname>Mosavel</surname><given-names>M</given-names></name><name name-style="western"><surname>Siminoff</surname><given-names>LA</given-names></name><name name-style="western"><surname>Flicek</surname><given-names>P</given-names></name><name name-style="western"><surname>Haeussler</surname><given-names>M</given-names></name><name name-style="western"><surname>Juettemann</surname><given-names>T</given-names></name><name name-style="western"><surname>Kent</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Lee</surname><given-names>CM</given-names></name><name name-style="western"><surname>Powell</surname><given-names>CC</given-names></name><name name-style="western"><surname>Rosenbloom</surname><given-names>KR</given-names></name><name name-style="western"><surname>Ruffier</surname><given-names>M</given-names></name><name name-style="western"><surname>Sheppard</surname><given-names>D</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>K</given-names></name><name name-style="western"><surname>Trevanion</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Zerbino</surname><given-names>DR</given-names></name><name name-style="western"><surname>Abell</surname><given-names>NS</given-names></name><name name-style="western"><surname>Akey</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Demanelis</surname><given-names>K</given-names></name><name name-style="western"><surname>Doherty</surname><given-names>JA</given-names></name><name name-style="western"><surname>Feinberg</surname><given-names>AP</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>KD</given-names></name><name name-style="western"><surname>Hickey</surname><given-names>PF</given-names></name><name name-style="western"><surname>Jasmine</surname><given-names>F</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>L</given-names></name><name name-style="western"><surname>Kaul</surname><given-names>R</given-names></name><name name-style="western"><surname>Kibriya</surname><given-names>MG</given-names></name><name name-style="western"><surname>Li</surname><given-names>JB</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S</given-names></name><name name-style="western"><surname>Linder</surname><given-names>SE</given-names></name><name name-style="western"><surname>Pierce</surname><given-names>BL</given-names></name><name name-style="western"><surname>Rizzardi</surname><given-names>LF</given-names></name><name name-style="western"><surname>Skol</surname><given-names>AD</given-names></name><name name-style="western"><surname>Smith</surname><given-names>KS</given-names></name><name name-style="western"><surname>Snyder</surname><given-names>M</given-names></name><name name-style="western"><surname>Stamatoyannopoulos</surname><given-names>J</given-names></name><name name-style="western"><surname>Tang</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Carithers</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Guan</surname><given-names>P</given-names></name><name name-style="western"><surname>Koester</surname><given-names>SE</given-names></name><name name-style="western"><surname>Little</surname><given-names>AR</given-names></name><name name-style="western"><surname>Moore</surname><given-names>HM</given-names></name><name name-style="western"><surname>Nierras</surname><given-names>CR</given-names></name><name name-style="western"><surname>Rao</surname><given-names>AK</given-names></name><name name-style="western"><surname>Vaught</surname><given-names>JB</given-names></name><name name-style="western"><surname>Volpi</surname><given-names>S</given-names></name><collab>The GTEx Consortium</collab></person-group><year iso-8601-date="2020">2020</year><article-title>The GTEx Consortium atlas of genetic regulatory effects across human tissues</article-title><source>Science</source><volume>369</volume><fpage>1318</fpage><lpage>1330</lpage><pub-id pub-id-type="doi">10.1126/science.aaz1776</pub-id><pub-id pub-id-type="pmid">32913098</pub-id><pub-id pub-id-type="pmcid">PMC7737656</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alipanahi</surname><given-names>B</given-names></name><name name-style="western"><surname>Delong</surname><given-names>A</given-names></name><name name-style="western"><surname>Weirauch</surname><given-names>MT</given-names></name><name name-style="western"><surname>Frey</surname><given-names>BJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Predicting the sequence specificities of DNA- and RNA-binding proteins by deep learning</article-title><source>Nature Biotechnology</source><volume>33</volume><fpage>831</fpage><lpage>838</lpage><pub-id pub-id-type="doi">10.1038/nbt.3300</pub-id><pub-id pub-id-type="pmid">26213851</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="software"><person-group person-group-type="author"><name name-style="western"><surname>Andrews</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2010">2010</year><data-title>FastQC: a quality control tool for high throughput sequence data</data-title><source>Babraham Institute</source><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.bioinformatics.babraham.ac.uk/projects/fastqc/" ext-link-type="uri">https://www.bioinformatics.babraham.ac.uk/projects/fastqc/</ext-link></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Angarola</surname><given-names>BL</given-names></name><name name-style="western"><surname>Anczuk&#243;w</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Splicing alterations in healthy aging and disease</article-title><source>Wiley Interdisciplinary Reviews. RNA</source><volume>12</volume><elocation-id>e1643</elocation-id><pub-id pub-id-type="doi">10.1002/wrna.1643</pub-id><pub-id pub-id-type="pmid">33565261</pub-id><pub-id pub-id-type="pmcid">PMC8195850</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Austad</surname><given-names>SN</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>KE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Sex differences in lifespan</article-title><source>Cell Metabolism</source><volume>23</volume><fpage>1022</fpage><lpage>1033</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2016.05.019</pub-id><pub-id pub-id-type="pmid">27304504</pub-id><pub-id pub-id-type="pmcid">PMC4932837</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bahreini</surname><given-names>A</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P</given-names></name><name name-style="western"><surname>Levine</surname><given-names>KM</given-names></name><name name-style="western"><surname>Tasdemir</surname><given-names>N</given-names></name><name name-style="western"><surname>Cao</surname><given-names>L</given-names></name><name name-style="western"><surname>Weir</surname><given-names>HM</given-names></name><name name-style="western"><surname>Puhalla</surname><given-names>SL</given-names></name><name name-style="western"><surname>Davidson</surname><given-names>NE</given-names></name><name name-style="western"><surname>Stern</surname><given-names>AM</given-names></name><name name-style="western"><surname>Chu</surname><given-names>D</given-names></name><name name-style="western"><surname>Park</surname><given-names>BH</given-names></name><name name-style="western"><surname>Lee</surname><given-names>AV</given-names></name><name name-style="western"><surname>Oesterreich</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models</article-title><source>Breast Cancer Research</source><volume>19</volume><elocation-id>60</elocation-id><pub-id pub-id-type="doi">10.1186/s13058-017-0851-4</pub-id><pub-id pub-id-type="pmid">28535794</pub-id><pub-id pub-id-type="pmcid">PMC5442865</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balliu</surname><given-names>B</given-names></name><name name-style="western"><surname>Durrant</surname><given-names>M</given-names></name><name name-style="western"><surname>de Goede</surname><given-names>O</given-names></name><name name-style="western"><surname>Abell</surname><given-names>N</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name><name name-style="western"><surname>Gloudemans</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Cook</surname><given-names>NL</given-names></name><name name-style="western"><surname>Smith</surname><given-names>KS</given-names></name><name name-style="western"><surname>Knowles</surname><given-names>DA</given-names></name><name name-style="western"><surname>Pala</surname><given-names>M</given-names></name><name name-style="western"><surname>Cucca</surname><given-names>F</given-names></name><name name-style="western"><surname>Schlessinger</surname><given-names>D</given-names></name><name name-style="western"><surname>Jaiswal</surname><given-names>S</given-names></name><name name-style="western"><surname>Sabatti</surname><given-names>C</given-names></name><name name-style="western"><surname>Lind</surname><given-names>L</given-names></name><name name-style="western"><surname>Ingelsson</surname><given-names>E</given-names></name><name name-style="western"><surname>Montgomery</surname><given-names>SB</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Genetic regulation of gene expression and splicing during a 10-year period of human aging</article-title><source>Genome Biology</source><volume>20</volume><elocation-id>230</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-019-1840-y</pub-id><pub-id pub-id-type="pmid">31684996</pub-id><pub-id pub-id-type="pmcid">PMC6827221</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baralle</surname><given-names>FE</given-names></name><name name-style="western"><surname>Giudice</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Alternative splicing as a regulator of development and tissue identity</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>18</volume><fpage>437</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1038/nrm.2017.27</pub-id><pub-id pub-id-type="pmid">28488700</pub-id><pub-id pub-id-type="pmcid">PMC6839889</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berchtold</surname><given-names>NC</given-names></name><name name-style="western"><surname>Cribbs</surname><given-names>DH</given-names></name><name name-style="western"><surname>Coleman</surname><given-names>PD</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>J</given-names></name><name name-style="western"><surname>Head</surname><given-names>E</given-names></name><name name-style="western"><surname>Kim</surname><given-names>R</given-names></name><name name-style="western"><surname>Beach</surname><given-names>T</given-names></name><name name-style="western"><surname>Miller</surname><given-names>C</given-names></name><name name-style="western"><surname>Troncoso</surname><given-names>J</given-names></name><name name-style="western"><surname>Trojanowski</surname><given-names>JQ</given-names></name><name name-style="western"><surname>Zielke</surname><given-names>HR</given-names></name><name name-style="western"><surname>Cotman</surname><given-names>CW</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Gene expression changes in the course of normal brain aging are sexually dimorphic</article-title><source>PNAS</source><volume>105</volume><fpage>15605</fpage><lpage>15610</lpage><pub-id pub-id-type="doi">10.1073/pnas.0806883105</pub-id><pub-id pub-id-type="pmid">18832152</pub-id><pub-id pub-id-type="pmcid">PMC2563070</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bergles</surname><given-names>DE</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>WD</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Oligodendrocyte development and plasticity</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>8</volume><elocation-id>a020453</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a020453</pub-id><pub-id pub-id-type="pmcid">PMC4743079</pub-id><pub-id pub-id-type="pmid">26492571</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhadra</surname><given-names>M</given-names></name><name name-style="western"><surname>Howell</surname><given-names>P</given-names></name><name name-style="western"><surname>Dutta</surname><given-names>S</given-names></name><name name-style="western"><surname>Heintz</surname><given-names>C</given-names></name><name name-style="western"><surname>Mair</surname><given-names>WB</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Alternative splicing in aging and longevity</article-title><source>Human Genetics</source><volume>139</volume><fpage>357</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1007/s00439-019-02094-6</pub-id><pub-id pub-id-type="pmid">31834493</pub-id><pub-id pub-id-type="pmcid">PMC8176884</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Brockwell</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Brockwell</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Davis</surname><given-names>RA</given-names></name><name name-style="western"><surname>Davis</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><source>Introduction to Time Series and Forecasting</source><publisher-name>Springer</publisher-name><pub-id pub-id-type="doi">10.1007/978-3-319-29854-2</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>LB</given-names></name><name name-style="western"><surname>Ruan</surname><given-names>ZL</given-names></name><name name-style="western"><surname>Yang</surname><given-names>YL</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>NC</given-names></name><name name-style="western"><surname>Gao</surname><given-names>C</given-names></name><name name-style="western"><surname>Cai</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Hu</surname><given-names>MM</given-names></name><name name-style="western"><surname>Shu</surname><given-names>HB</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Estrogen receptor &#945;-mediated signaling inhibits type I interferon response to promote breast carcinogenesis</article-title><source>Journal of Molecular Cell Biology</source><volume>15</volume><elocation-id>mjad047</elocation-id><pub-id pub-id-type="doi">10.1093/jmcb/mjad047</pub-id><pub-id pub-id-type="pmid">37442610</pub-id><pub-id pub-id-type="pmcid">PMC11066933</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carithers</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Ardlie</surname><given-names>K</given-names></name><name name-style="western"><surname>Barcus</surname><given-names>M</given-names></name><name name-style="western"><surname>Branton</surname><given-names>PA</given-names></name><name name-style="western"><surname>Britton</surname><given-names>A</given-names></name><name name-style="western"><surname>Buia</surname><given-names>SA</given-names></name><name name-style="western"><surname>Compton</surname><given-names>CC</given-names></name><name name-style="western"><surname>DeLuca</surname><given-names>DS</given-names></name><name name-style="western"><surname>Peter-Demchok</surname><given-names>J</given-names></name><name name-style="western"><surname>Gelfand</surname><given-names>ET</given-names></name><name name-style="western"><surname>Guan</surname><given-names>P</given-names></name><name name-style="western"><surname>Korzeniewski</surname><given-names>GE</given-names></name><name name-style="western"><surname>Lockhart</surname><given-names>NC</given-names></name><name name-style="western"><surname>Rabiner</surname><given-names>CA</given-names></name><name name-style="western"><surname>Rao</surname><given-names>AK</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>KL</given-names></name><name name-style="western"><surname>Roche</surname><given-names>NV</given-names></name><name name-style="western"><surname>Sawyer</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Segr&#232;</surname><given-names>AV</given-names></name><name name-style="western"><surname>Shive</surname><given-names>CE</given-names></name><name name-style="western"><surname>Smith</surname><given-names>AM</given-names></name><name name-style="western"><surname>Sobin</surname><given-names>LH</given-names></name><name name-style="western"><surname>Undale</surname><given-names>AH</given-names></name><name name-style="western"><surname>Valentino</surname><given-names>KM</given-names></name><name name-style="western"><surname>Vaught</surname><given-names>J</given-names></name><name name-style="western"><surname>Young</surname><given-names>TR</given-names></name><name name-style="western"><surname>Moore</surname><given-names>HM</given-names></name><collab>GTEx Consortium</collab></person-group><year iso-8601-date="2015">2015</year><article-title>A novel approach to high-quality postmortem tissue procurement: the GTEx project</article-title><source>Biopreservation and Biobanking</source><volume>13</volume><fpage>311</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1089/bio.2015.0032</pub-id><pub-id pub-id-type="pmid">26484571</pub-id><pub-id pub-id-type="pmcid">PMC4675181</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>S</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>A</given-names></name><name name-style="western"><surname>Singh</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Is menopause still evolving? Evidence from a longitudinal study of multiethnic populations and its relevance to women&#8217;s health</article-title><source>BMC Women&#8217;s Health</source><volume>20</volume><elocation-id>74</elocation-id><pub-id pub-id-type="doi">10.1186/s12905-020-00932-8</pub-id><pub-id pub-id-type="pmid">32307019</pub-id><pub-id pub-id-type="pmcid">PMC7168978</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Colafella</surname><given-names>KMM</given-names></name><name name-style="western"><surname>Denton</surname><given-names>KM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Sex-specific differences in hypertension and associated cardiovascular disease</article-title><source>Nature Reviews. Nephrology</source><volume>14</volume><fpage>185</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1038/nrneph.2017.189</pub-id><pub-id pub-id-type="pmid">29380817</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davis</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Solsberg</surname><given-names>CW</given-names></name><name name-style="western"><surname>White</surname><given-names>CC</given-names></name><name name-style="western"><surname>Mi&#241;ones-Moyano</surname><given-names>E</given-names></name><name name-style="western"><surname>Sirota</surname><given-names>M</given-names></name><name name-style="western"><surname>Chibnik</surname><given-names>L</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></name><name name-style="western"><surname>De Jager</surname><given-names>PL</given-names></name><name name-style="western"><surname>Yokoyama</surname><given-names>JS</given-names></name><name name-style="western"><surname>Dubal</surname><given-names>DB</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Sex-specific association of the X chromosome with cognitive change and tau pathology in aging and alzheimer disease</article-title><source>JAMA Neurology</source><volume>78</volume><fpage>1249</fpage><lpage>1254</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2021.2806</pub-id><pub-id pub-id-type="pmid">34424272</pub-id><pub-id pub-id-type="pmcid">PMC8383157</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diedenhofen</surname><given-names>B</given-names></name><name name-style="western"><surname>Musch</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>cocor: a comprehensive solution for the statistical comparison of correlations</article-title><source>PLOS ONE</source><volume>10</volume><elocation-id>e0121945</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0121945</pub-id><pub-id pub-id-type="pmid">25835001</pub-id><pub-id pub-id-type="pmcid">PMC4383486</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Djebali</surname><given-names>S</given-names></name><name name-style="western"><surname>Davis</surname><given-names>CA</given-names></name><name name-style="western"><surname>Merkel</surname><given-names>A</given-names></name><name name-style="western"><surname>Dobin</surname><given-names>A</given-names></name><name name-style="western"><surname>Lassmann</surname><given-names>T</given-names></name><name name-style="western"><surname>Mortazavi</surname><given-names>A</given-names></name><name name-style="western"><surname>Tanzer</surname><given-names>A</given-names></name><name name-style="western"><surname>Lagarde</surname><given-names>J</given-names></name><name name-style="western"><surname>Lin</surname><given-names>W</given-names></name><name name-style="western"><surname>Schlesinger</surname><given-names>F</given-names></name><name name-style="western"><surname>Xue</surname><given-names>C</given-names></name><name name-style="western"><surname>Marinov</surname><given-names>GK</given-names></name><name name-style="western"><surname>Khatun</surname><given-names>J</given-names></name><name name-style="western"><surname>Williams</surname><given-names>BA</given-names></name><name name-style="western"><surname>Zaleski</surname><given-names>C</given-names></name><name name-style="western"><surname>Rozowsky</surname><given-names>J</given-names></name><name name-style="western"><surname>R&#246;der</surname><given-names>M</given-names></name><name name-style="western"><surname>Kokocinski</surname><given-names>F</given-names></name><name name-style="western"><surname>Abdelhamid</surname><given-names>RF</given-names></name><name name-style="western"><surname>Alioto</surname><given-names>T</given-names></name><name name-style="western"><surname>Antoshechkin</surname><given-names>I</given-names></name><name name-style="western"><surname>Baer</surname><given-names>MT</given-names></name><name name-style="western"><surname>Bar</surname><given-names>NS</given-names></name><name name-style="western"><surname>Batut</surname><given-names>P</given-names></name><name name-style="western"><surname>Bell</surname><given-names>K</given-names></name><name name-style="western"><surname>Bell</surname><given-names>I</given-names></name><name name-style="western"><surname>Chakrabortty</surname><given-names>S</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Chrast</surname><given-names>J</given-names></name><name name-style="western"><surname>Curado</surname><given-names>J</given-names></name><name name-style="western"><surname>Derrien</surname><given-names>T</given-names></name><name name-style="western"><surname>Drenkow</surname><given-names>J</given-names></name><name name-style="western"><surname>Dumais</surname><given-names>E</given-names></name><name name-style="western"><surname>Dumais</surname><given-names>J</given-names></name><name name-style="western"><surname>Duttagupta</surname><given-names>R</given-names></name><name name-style="western"><surname>Falconnet</surname><given-names>E</given-names></name><name name-style="western"><surname>Fastuca</surname><given-names>M</given-names></name><name name-style="western"><surname>Fejes-Toth</surname><given-names>K</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>P</given-names></name><name name-style="western"><surname>Foissac</surname><given-names>S</given-names></name><name name-style="western"><surname>Fullwood</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Gao</surname><given-names>H</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>D</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>A</given-names></name><name name-style="western"><surname>Gunawardena</surname><given-names>H</given-names></name><name name-style="western"><surname>Howald</surname><given-names>C</given-names></name><name name-style="western"><surname>Jha</surname><given-names>S</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>R</given-names></name><name name-style="western"><surname>Kapranov</surname><given-names>P</given-names></name><name name-style="western"><surname>King</surname><given-names>B</given-names></name><name name-style="western"><surname>Kingswood</surname><given-names>C</given-names></name><name name-style="western"><surname>Luo</surname><given-names>OJ</given-names></name><name name-style="western"><surname>Park</surname><given-names>E</given-names></name><name name-style="western"><surname>Persaud</surname><given-names>K</given-names></name><name name-style="western"><surname>Preall</surname><given-names>JB</given-names></name><name name-style="western"><surname>Ribeca</surname><given-names>P</given-names></name><name name-style="western"><surname>Risk</surname><given-names>B</given-names></name><name name-style="western"><surname>Robyr</surname><given-names>D</given-names></name><name name-style="western"><surname>Sammeth</surname><given-names>M</given-names></name><name name-style="western"><surname>Schaffer</surname><given-names>L</given-names></name><name name-style="western"><surname>See</surname><given-names>LH</given-names></name><name name-style="western"><surname>Shahab</surname><given-names>A</given-names></name><name name-style="western"><surname>Skancke</surname><given-names>J</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>AM</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>H</given-names></name><name name-style="western"><surname>Tilgner</surname><given-names>H</given-names></name><name name-style="western"><surname>Trout</surname><given-names>D</given-names></name><name name-style="western"><surname>Walters</surname><given-names>N</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Wrobel</surname><given-names>J</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ruan</surname><given-names>X</given-names></name><name name-style="western"><surname>Hayashizaki</surname><given-names>Y</given-names></name><name name-style="western"><surname>Harrow</surname><given-names>J</given-names></name><name name-style="western"><surname>Gerstein</surname><given-names>M</given-names></name><name name-style="western"><surname>Hubbard</surname><given-names>T</given-names></name><name name-style="western"><surname>Reymond</surname><given-names>A</given-names></name><name name-style="western"><surname>Antonarakis</surname><given-names>SE</given-names></name><name name-style="western"><surname>Hannon</surname><given-names>G</given-names></name><name name-style="western"><surname>Giddings</surname><given-names>MC</given-names></name><name name-style="western"><surname>Ruan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wold</surname><given-names>B</given-names></name><name name-style="western"><surname>Carninci</surname><given-names>P</given-names></name><name name-style="western"><surname>Guig&#243;</surname><given-names>R</given-names></name><name name-style="western"><surname>Gingeras</surname><given-names>TR</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Landscape of transcription in human cells</article-title><source>Nature</source><volume>489</volume><fpage>101</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1038/nature11233</pub-id><pub-id pub-id-type="pmid">22955620</pub-id><pub-id pub-id-type="pmcid">PMC3684276</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dobin</surname><given-names>A</given-names></name><name name-style="western"><surname>Davis</surname><given-names>CA</given-names></name><name name-style="western"><surname>Schlesinger</surname><given-names>F</given-names></name><name name-style="western"><surname>Drenkow</surname><given-names>J</given-names></name><name name-style="western"><surname>Zaleski</surname><given-names>C</given-names></name><name name-style="western"><surname>Jha</surname><given-names>S</given-names></name><name name-style="western"><surname>Batut</surname><given-names>P</given-names></name><name name-style="western"><surname>Chaisson</surname><given-names>M</given-names></name><name name-style="western"><surname>Gingeras</surname><given-names>TR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>STAR: ultrafast universal RNA-seq aligner</article-title><source>Bioinformatics</source><volume>29</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id><pub-id pub-id-type="pmid">23104886</pub-id><pub-id pub-id-type="pmcid">PMC3530905</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="software"><person-group person-group-type="author"><name name-style="western"><surname>Dolgalev</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>Msigdbr: msigdb gene sets for multiple organisms in a tidy data format</data-title><version designator="7.1.1">7.1.1</version><source>CRAN</source><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cran.r-project.org/package=msigdbr" ext-link-type="uri">https://cran.r-project.org/package=msigdbr</ext-link></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Durieux</surname><given-names>J</given-names></name><name name-style="western"><surname>Wolff</surname><given-names>S</given-names></name><name name-style="western"><surname>Dillin</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The cell-non-autonomous nature of electron transport chain-mediated longevity</article-title><source>Cell</source><volume>144</volume><fpage>79</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.12.016</pub-id><pub-id pub-id-type="pmid">21215371</pub-id><pub-id pub-id-type="pmcid">PMC3062502</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferreira</surname><given-names>PG</given-names></name><name name-style="western"><surname>Mu&#241;oz-Aguirre</surname><given-names>M</given-names></name><name name-style="western"><surname>Reverter</surname><given-names>F</given-names></name><name name-style="western"><surname>S&#225; Godinho</surname><given-names>CP</given-names></name><name name-style="western"><surname>Sousa</surname><given-names>A</given-names></name><name name-style="western"><surname>Amadoz</surname><given-names>A</given-names></name><name name-style="western"><surname>Sodaei</surname><given-names>R</given-names></name><name name-style="western"><surname>Hidalgo</surname><given-names>MR</given-names></name><name name-style="western"><surname>Pervouchine</surname><given-names>D</given-names></name><name name-style="western"><surname>Carbonell-Caballero</surname><given-names>J</given-names></name><name name-style="western"><surname>Nurtdinov</surname><given-names>R</given-names></name><name name-style="western"><surname>Breschi</surname><given-names>A</given-names></name><name name-style="western"><surname>Amador</surname><given-names>R</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>P</given-names></name><name name-style="western"><surname>&#199;ubuk</surname><given-names>C</given-names></name><name name-style="western"><surname>Curado</surname><given-names>J</given-names></name><name name-style="western"><surname>Aguet</surname><given-names>F</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>C</given-names></name><name name-style="western"><surname>Dopazo</surname><given-names>J</given-names></name><name name-style="western"><surname>Sammeth</surname><given-names>M</given-names></name><name name-style="western"><surname>Ardlie</surname><given-names>KG</given-names></name><name name-style="western"><surname>Guig&#243;</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The effects of death and post-mortem cold ischemia on human tissue transcriptomes</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>490</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-017-02772-x</pub-id><pub-id pub-id-type="pmid">29440659</pub-id><pub-id pub-id-type="pmcid">PMC5811508</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferretti</surname><given-names>MT</given-names></name><name name-style="western"><surname>Iulita</surname><given-names>MF</given-names></name><name name-style="western"><surname>Cavedo</surname><given-names>E</given-names></name><name name-style="western"><surname>Chiesa</surname><given-names>PA</given-names></name><name name-style="western"><surname>Schumacher Dimech</surname><given-names>A</given-names></name><name name-style="western"><surname>Santuccione Chadha</surname><given-names>A</given-names></name><name name-style="western"><surname>Baracchi</surname><given-names>F</given-names></name><name name-style="western"><surname>Girouard</surname><given-names>H</given-names></name><name name-style="western"><surname>Misoch</surname><given-names>S</given-names></name><name name-style="western"><surname>Giacobini</surname><given-names>E</given-names></name><name name-style="western"><surname>Depypere</surname><given-names>H</given-names></name><name name-style="western"><surname>Hampel</surname><given-names>H</given-names></name><collab>Women&#8217;s Brain Project and the Alzheimer Precision Medicine Initiative</collab></person-group><year iso-8601-date="2018">2018</year><article-title>Sex differences in Alzheimer disease - the gateway to precision medicine</article-title><source>Nature Reviews. Neurology</source><volume>14</volume><fpage>457</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1038/s41582-018-0032-9</pub-id><pub-id pub-id-type="pmid">29985474</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferretti</surname><given-names>MT</given-names></name><name name-style="western"><surname>Santuccione Chadha</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The missing X factor in Alzheimer disease</article-title><source>Nature Reviews. Neurology</source><volume>17</volume><fpage>727</fpage><lpage>728</lpage><pub-id pub-id-type="doi">10.1038/s41582-021-00573-x</pub-id><pub-id pub-id-type="pmid">34635841</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foo</surname><given-names>H</given-names></name><name name-style="western"><surname>Thalamuthu</surname><given-names>A</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>J</given-names></name><name name-style="western"><surname>Koch</surname><given-names>F</given-names></name><name name-style="western"><surname>Mather</surname><given-names>KA</given-names></name><name name-style="western"><surname>Wen</surname><given-names>W</given-names></name><name name-style="western"><surname>Sachdev</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Age- and sex-related topological organization of human brain functional networks and their relationship to cognition</article-title><source>Frontiers in Aging Neuroscience</source><volume>13</volume><elocation-id>758817</elocation-id><pub-id pub-id-type="doi">10.3389/fnagi.2021.758817</pub-id><pub-id pub-id-type="pmid">34975453</pub-id><pub-id pub-id-type="pmcid">PMC8718995</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galkin</surname><given-names>F</given-names></name><name name-style="western"><surname>Mamoshina</surname><given-names>P</given-names></name><name name-style="western"><surname>Aliper</surname><given-names>A</given-names></name><name name-style="western"><surname>Putin</surname><given-names>E</given-names></name><name name-style="western"><surname>Moskalev</surname><given-names>V</given-names></name><name name-style="western"><surname>Gladyshev</surname><given-names>VN</given-names></name><name name-style="western"><surname>Zhavoronkov</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Human gut microbiome aging clock based on taxonomic profiling and deep learning</article-title><source>iScience</source><volume>23</volume><elocation-id>101199</elocation-id><pub-id pub-id-type="doi">10.1016/j.isci.2020.101199</pub-id><pub-id pub-id-type="pmid">32534441</pub-id><pub-id pub-id-type="pmcid">PMC7298543</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galkin</surname><given-names>F</given-names></name><name name-style="western"><surname>Mamoshina</surname><given-names>P</given-names></name><name name-style="western"><surname>Kochetov</surname><given-names>K</given-names></name><name name-style="western"><surname>Sidorenko</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhavoronkov</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>DeepMAge: a methylation aging clock developed with deep learning</article-title><source>Aging and Disease</source><volume>12</volume><fpage>1252</fpage><lpage>1262</lpage><pub-id pub-id-type="doi">10.14336/AD.2020.1202</pub-id><pub-id pub-id-type="pmid">34341706</pub-id><pub-id pub-id-type="pmcid">PMC8279523</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gallego-Paez</surname><given-names>LM</given-names></name><name name-style="western"><surname>Bordone</surname><given-names>MC</given-names></name><name name-style="western"><surname>Leote</surname><given-names>AC</given-names></name><name name-style="western"><surname>Saraiva-Agostinho</surname><given-names>N</given-names></name><name name-style="western"><surname>Ascens&#227;o-Ferreira</surname><given-names>M</given-names></name><name name-style="western"><surname>Barbosa-Morais</surname><given-names>NL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Alternative splicing: the pledge, the turn, and the prestige</article-title><source>Human Genetics</source><volume>136</volume><fpage>1015</fpage><lpage>1042</lpage><pub-id pub-id-type="doi">10.1007/s00439-017-1790-y</pub-id><pub-id pub-id-type="pmid">28374191</pub-id><pub-id pub-id-type="pmcid">PMC5602094</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>H&#228;gg</surname><given-names>S</given-names></name><name name-style="western"><surname>Jylh&#228;v&#228;</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Sex differences in biological aging with a focus on human studies</article-title><source>eLife</source><volume>10</volume><elocation-id>e63425</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.63425</pub-id><pub-id pub-id-type="pmid">33982659</pub-id><pub-id pub-id-type="pmcid">PMC8118651</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wennersten</surname><given-names>SA</given-names></name><name name-style="western"><surname>Wright</surname><given-names>JM</given-names></name><name name-style="western"><surname>Ludwig</surname><given-names>RW</given-names></name><name name-style="western"><surname>Lau</surname><given-names>E</given-names></name><name name-style="western"><surname>Lam</surname><given-names>MPY</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Proteogenomics reveals sex-biased aging genes and coordinated splicing in cardiac aging</article-title><source>American Journal of Physiology. Heart and Circulatory Physiology</source><volume>323</volume><fpage>H538</fpage><lpage>H558</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00244.2022</pub-id><pub-id pub-id-type="pmid">35930447</pub-id><pub-id pub-id-type="pmcid">PMC9448281</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hannum</surname><given-names>G</given-names></name><name name-style="western"><surname>Guinney</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>G</given-names></name><name name-style="western"><surname>Sadda</surname><given-names>S</given-names></name><name name-style="western"><surname>Klotzle</surname><given-names>B</given-names></name><name name-style="western"><surname>Bibikova</surname><given-names>M</given-names></name><name name-style="western"><surname>Fan</surname><given-names>J-B</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Deconde</surname><given-names>R</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name><name name-style="western"><surname>Rajapakse</surname><given-names>I</given-names></name><name name-style="western"><surname>Friend</surname><given-names>S</given-names></name><name name-style="western"><surname>Ideker</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Genome-wide methylation profiles reveal quantitative views of human aging rates</article-title><source>Molecular Cell</source><volume>49</volume><fpage>359</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2012.10.016</pub-id><pub-id pub-id-type="pmid">23177740</pub-id><pub-id pub-id-type="pmcid">PMC3780611</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hewitt</surname><given-names>SC</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Grimm</surname><given-names>SA</given-names></name><name name-style="western"><surname>Winuthayanon</surname><given-names>W</given-names></name><name name-style="western"><surname>Hamilton</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Pockette</surname><given-names>B</given-names></name><name name-style="western"><surname>Rubel</surname><given-names>CA</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>LC</given-names></name><name name-style="western"><surname>Fargo</surname><given-names>D</given-names></name><name name-style="western"><surname>Lanz</surname><given-names>RB</given-names></name><name name-style="western"><surname>DeMayo</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Sch&#252;tz</surname><given-names>G</given-names></name><name name-style="western"><surname>Korach</surname><given-names>KS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Novel DNA motif binding activity observed in vivo with an estrogen receptor &#945; mutant mouse</article-title><source>Molecular Endocrinology</source><volume>28</volume><fpage>899</fpage><lpage>911</lpage><pub-id pub-id-type="doi">10.1210/me.2014-1051</pub-id><pub-id pub-id-type="pmid">24713037</pub-id><pub-id pub-id-type="pmcid">PMC4042070</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horstman</surname><given-names>AM</given-names></name><name name-style="western"><surname>Dillon</surname><given-names>EL</given-names></name><name name-style="western"><surname>Urban</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Sheffield-Moore</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The role of androgens and estrogens on healthy aging and longevity</article-title><source>The Journals of Gerontology Series A</source><volume>67</volume><fpage>1140</fpage><lpage>1152</lpage><pub-id pub-id-type="doi">10.1093/gerona/gls068</pub-id><pub-id pub-id-type="pmcid">PMC3636678</pub-id><pub-id pub-id-type="pmid">22451474</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horvath</surname><given-names>S</given-names></name><name name-style="western"><surname>Raj</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>DNA methylation-based biomarkers and the epigenetic clock theory of ageing</article-title><source>Nature Reviews. Genetics</source><volume>19</volume><fpage>371</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1038/s41576-018-0004-3</pub-id><pub-id pub-id-type="pmid">29643443</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chen</surname><given-names>B</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Xie</surname><given-names>L</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Duan</surname><given-names>R</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Su</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Effects of sex and aging on the immune cell landscape as assessed by single-cell transcriptomic analysis</article-title><source>PNAS</source><volume>118</volume><elocation-id>e16118</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2023216118</pub-id><pub-id pub-id-type="pmcid">PMC8379935</pub-id><pub-id pub-id-type="pmid">34385315</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jazin</surname><given-names>E</given-names></name><name name-style="western"><surname>Cahill</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Sex differences in molecular neuroscience: from fruit flies to humans</article-title><source>Nature Reviews. Neuroscience</source><volume>11</volume><fpage>9</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1038/nrn2754</pub-id><pub-id pub-id-type="pmid">20019686</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jia</surname><given-names>K</given-names></name><name name-style="western"><surname>Cui</surname><given-names>C</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>An analysis of aging-related genes derived from the Genotype-Tissue Expression project (GTEx)</article-title><source>Cell Death Discovery</source><volume>4</volume><elocation-id>26</elocation-id><pub-id pub-id-type="doi">10.1038/s41420-018-0093-y</pub-id><pub-id pub-id-type="pmid">30155276</pub-id><pub-id pub-id-type="pmcid">PMC6102484</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jylh&#228;v&#228;</surname><given-names>J</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>NL</given-names></name><name name-style="western"><surname>H&#228;gg</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Biological age predictors</article-title><source>EBioMedicine</source><volume>21</volume><fpage>29</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2017.03.046</pub-id><pub-id pub-id-type="pmid">28396265</pub-id><pub-id pub-id-type="pmcid">PMC5514388</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="preprint"><person-group person-group-type="author"><name name-style="western"><surname>Karlebach</surname><given-names>G</given-names></name><name name-style="western"><surname>Veiga</surname><given-names>DFT</given-names></name><name name-style="western"><surname>Chatzipantsiou</surname><given-names>C</given-names></name><name name-style="western"><surname>Barja</surname><given-names>PP</given-names></name><name name-style="western"><surname>Chatzou</surname><given-names>M</given-names></name><name name-style="western"><surname>Kesarwani</surname><given-names>AK</given-names></name><name name-style="western"><surname>Danis</surname><given-names>D</given-names></name><name name-style="western"><surname>Kararigas</surname><given-names>G</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>XA</given-names></name><name name-style="western"><surname>George</surname><given-names>J</given-names></name><name name-style="western"><surname>Steinhaus</surname><given-names>R</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The impact of biological sex on alternative splicing</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/490904</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khodursky</surname><given-names>S</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>CS</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>EB</given-names></name><name name-style="western"><surname>Vaughan</surname><given-names>R</given-names></name><name name-style="western"><surname>Schrider</surname><given-names>DR</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Sex differences in interindividual gene expression variability across human tissues</article-title><source>PNAS Nexus</source><volume>1</volume><elocation-id>gac243</elocation-id><pub-id pub-id-type="doi">10.1093/pnasnexus/pgac243</pub-id><pub-id pub-id-type="pmid">36712323</pub-id><pub-id pub-id-type="pmcid">PMC9802459</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khramtsova</surname><given-names>EA</given-names></name><name name-style="western"><surname>Davis</surname><given-names>LK</given-names></name><name name-style="western"><surname>Stranger</surname><given-names>BE</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The role of sex in the genomics of human complex traits</article-title><source>Nature Reviews. Genetics</source><volume>20</volume><fpage>173</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1038/s41576-018-0083-1</pub-id><pub-id pub-id-type="pmid">30581192</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klein</surname><given-names>SL</given-names></name><name name-style="western"><surname>Flanagan</surname><given-names>KL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Sex differences in immune responses</article-title><source>Nature Reviews. Immunology</source><volume>16</volume><fpage>626</fpage><lpage>638</lpage><pub-id pub-id-type="doi">10.1038/nri.2016.90</pub-id><pub-id pub-id-type="pmid">27546235</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Kuhn</surname><given-names>M</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2013">2013</year><source>Applied Predictive Modeling</source><publisher-name>Springer</publisher-name><pub-id pub-id-type="doi">10.1007/978-1-4614-6849-3</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Langmead</surname><given-names>B</given-names></name><name name-style="western"><surname>Salzberg</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fast gapped-read alignment with Bowtie 2</article-title><source>Nature Methods</source><volume>9</volume><fpage>357</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1923</pub-id><pub-id pub-id-type="pmid">22388286</pub-id><pub-id pub-id-type="pmcid">PMC3322381</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leek</surname><given-names>JT</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>WE</given-names></name><name name-style="western"><surname>Parker</surname><given-names>HS</given-names></name><name name-style="western"><surname>Jaffe</surname><given-names>AE</given-names></name><name name-style="western"><surname>Storey</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The sva package for removing batch effects and other unwanted variation in high-throughput experiments</article-title><source>Bioinformatics</source><volume>28</volume><fpage>882</fpage><lpage>883</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts034</pub-id><pub-id pub-id-type="pmid">22257669</pub-id><pub-id pub-id-type="pmcid">PMC3307112</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Guan</surname><given-names>J</given-names></name><name name-style="western"><surname>Qian</surname><given-names>J</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2018">2018a</year><source>2018 IEEE International Conference on Bioinformatics and Biomedicine (BIBM)</source><publisher-name>IEEE</publisher-name><pub-id pub-id-type="doi">10.1109/BIBM.2018.8621118</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>CH</given-names></name><name name-style="western"><surname>Haider</surname><given-names>S</given-names></name><name name-style="western"><surname>Shiah</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Thai</surname><given-names>K</given-names></name><name name-style="western"><surname>Boutros</surname><given-names>PC</given-names></name></person-group><year iso-8601-date="2018">2018b</year><article-title>Sex differences in cancer driver genes and biomarkers</article-title><source>Cancer Research</source><volume>78</volume><fpage>5527</fpage><lpage>5537</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-18-0362</pub-id><pub-id pub-id-type="pmid">30275052</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ge</surname><given-names>X</given-names></name><name name-style="western"><surname>Peng</surname><given-names>F</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Li</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Exaggerated false positives by popular differential expression methods when analyzing human population samples</article-title><source>Genome Biology</source><volume>23</volume><elocation-id>79</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-022-02648-4</pub-id><pub-id pub-id-type="pmid">35292087</pub-id><pub-id pub-id-type="pmcid">PMC8922736</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>M</given-names></name><name name-style="western"><surname>Fu</surname><given-names>XH</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Dong</surname><given-names>C</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>F</given-names></name><name name-style="western"><surname>Wang</surname><given-names>SW</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Ping</surname><given-names>J</given-names></name><name name-style="western"><surname>Che</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Yang</surname><given-names>K</given-names></name><name name-style="western"><surname>Zuo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lu</surname><given-names>X</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Lan</surname><given-names>T</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Ma</surname><given-names>S</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CS</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>KY</given-names></name><name name-style="western"><surname>Ye</surname><given-names>J</given-names></name><name name-style="western"><surname>Qu</surname><given-names>J</given-names></name><name name-style="western"><surname>Xue</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>YG</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Liu</surname><given-names>GH</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Determining a multimodal aging clock in a cohort of Chinese women</article-title><source>Med</source><volume>4</volume><fpage>825</fpage><lpage>848</lpage><pub-id pub-id-type="doi">10.1016/j.medj.2023.06.010</pub-id><pub-id pub-id-type="pmid">37516104</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopes-Ramos</surname><given-names>CM</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CY</given-names></name><name name-style="western"><surname>Kuijjer</surname><given-names>ML</given-names></name><name name-style="western"><surname>Paulson</surname><given-names>JN</given-names></name><name name-style="western"><surname>Sonawane</surname><given-names>AR</given-names></name><name name-style="western"><surname>Fagny</surname><given-names>M</given-names></name><name name-style="western"><surname>Platig</surname><given-names>J</given-names></name><name name-style="western"><surname>Glass</surname><given-names>K</given-names></name><name name-style="western"><surname>Quackenbush</surname><given-names>J</given-names></name><name name-style="western"><surname>DeMeo</surname><given-names>DL</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Sex differences in gene expression and regulatory networks across 29 human tissues</article-title><source>Cell Reports</source><volume>31</volume><elocation-id>107795</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2020.107795</pub-id><pub-id pub-id-type="pmid">32579922</pub-id><pub-id pub-id-type="pmcid">PMC7898458</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#225;rquez</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Chung</surname><given-names>CH</given-names></name><name name-style="western"><surname>Marches</surname><given-names>R</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Nehar-Belaid</surname><given-names>D</given-names></name><name name-style="western"><surname>Eroglu</surname><given-names>A</given-names></name><name name-style="western"><surname>Mellert</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Kuchel</surname><given-names>GA</given-names></name><name name-style="western"><surname>Banchereau</surname><given-names>J</given-names></name><name name-style="western"><surname>Ucar</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Sexual-dimorphism in human immune system aging</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>751</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-14396-9</pub-id><pub-id pub-id-type="pmid">32029736</pub-id><pub-id pub-id-type="pmcid">PMC7005316</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matera</surname><given-names>AG</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A day in the life of the spliceosome</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>15</volume><fpage>108</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1038/nrm3742</pub-id><pub-id pub-id-type="pmid">24452469</pub-id><pub-id pub-id-type="pmcid">PMC4060434</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mel&#233;</surname><given-names>M</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>PG</given-names></name><name name-style="western"><surname>Reverter</surname><given-names>F</given-names></name><name name-style="western"><surname>DeLuca</surname><given-names>DS</given-names></name><name name-style="western"><surname>Monlong</surname><given-names>J</given-names></name><name name-style="western"><surname>Sammeth</surname><given-names>M</given-names></name><name name-style="western"><surname>Young</surname><given-names>TR</given-names></name><name name-style="western"><surname>Goldmann</surname><given-names>JM</given-names></name><name name-style="western"><surname>Pervouchine</surname><given-names>DD</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>R</given-names></name><name name-style="western"><surname>Segr&#232;</surname><given-names>AV</given-names></name><name name-style="western"><surname>Djebali</surname><given-names>S</given-names></name><name name-style="western"><surname>Niarchou</surname><given-names>A</given-names></name><name name-style="western"><surname>Wright</surname><given-names>FA</given-names></name><name name-style="western"><surname>Lappalainen</surname><given-names>T</given-names></name><name name-style="western"><surname>Calvo</surname><given-names>M</given-names></name><name name-style="western"><surname>Getz</surname><given-names>G</given-names></name><name name-style="western"><surname>Dermitzakis</surname><given-names>ET</given-names></name><name name-style="western"><surname>Ardlie</surname><given-names>KG</given-names></name><name name-style="western"><surname>Guig&#243;</surname><given-names>R</given-names></name><collab>GTEx Consortium</collab></person-group><year iso-8601-date="2015">2015</year><article-title>Human genomics. The human transcriptome across tissues and individuals</article-title><source>Science</source><volume>348</volume><fpage>660</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1126/science.aaa0355</pub-id><pub-id pub-id-type="pmid">25954002</pub-id><pub-id pub-id-type="pmcid">PMC4547472</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="software"><person-group person-group-type="author"><name name-style="western"><surname>Mellert</surname><given-names>D</given-names></name><name name-style="western"><surname>Ucar</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>Sex dimorphism nature communications</data-title><version designator="24c78e8">24c78e8</version><source>GitHub</source><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/UcarLab/SexDimorphismNatureCommunications" ext-link-type="uri">https://github.com/UcarLab/SexDimorphismNatureCommunications</ext-link></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meyer</surname><given-names>DH</given-names></name><name name-style="western"><surname>Schumacher</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>BiT age: A transcriptome-based aging clock near the theoretical limit of accuracy</article-title><source>Aging Cell</source><volume>20</volume><elocation-id>e13320</elocation-id><pub-id pub-id-type="doi">10.1111/acel.13320</pub-id><pub-id pub-id-type="pmid">33656257</pub-id><pub-id pub-id-type="pmcid">PMC7963339</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nikom</surname><given-names>D</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Alternative splicing in neurodegenerative disease and the promise of RNA therapies</article-title><source>Nature Reviews. Neuroscience</source><volume>24</volume><fpage>457</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1038/s41583-023-00717-6</pub-id><pub-id pub-id-type="pmid">37336982</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nygaard</surname><given-names>V</given-names></name><name name-style="western"><surname>R&#248;dland</surname><given-names>EA</given-names></name><name name-style="western"><surname>Hovig</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Methods that remove batch effects while retaining group differences may lead to exaggerated confidence in downstream analyses</article-title><source>Biostatistics</source><volume>17</volume><fpage>29</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1093/biostatistics/kxv027</pub-id><pub-id pub-id-type="pmid">26272994</pub-id><pub-id pub-id-type="pmcid">PMC4679072</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ober</surname><given-names>C</given-names></name><name name-style="western"><surname>Loisel</surname><given-names>DA</given-names></name><name name-style="western"><surname>Gilad</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Sex-specific genetic architecture of human disease</article-title><source>Nature Reviews. Genetics</source><volume>9</volume><fpage>911</fpage><lpage>922</lpage><pub-id pub-id-type="doi">10.1038/nrg2415</pub-id><pub-id pub-id-type="pmid">19002143</pub-id><pub-id pub-id-type="pmcid">PMC2694620</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oki</surname><given-names>S</given-names></name><name name-style="western"><surname>Ohta</surname><given-names>T</given-names></name><name name-style="western"><surname>Shioi</surname><given-names>G</given-names></name><name name-style="western"><surname>Hatanaka</surname><given-names>H</given-names></name><name name-style="western"><surname>Ogasawara</surname><given-names>O</given-names></name><name name-style="western"><surname>Okuda</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kawaji</surname><given-names>H</given-names></name><name name-style="western"><surname>Nakaki</surname><given-names>R</given-names></name><name name-style="western"><surname>Sese</surname><given-names>J</given-names></name><name name-style="western"><surname>Meno</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>ChIP-Atlas: a data-mining suite powered by full integration of public ChIP-seq data</article-title><source>EMBO Reports</source><volume>19</volume><elocation-id>e46255</elocation-id><pub-id pub-id-type="doi">10.15252/embr.201846255</pub-id><pub-id pub-id-type="pmid">30413482</pub-id><pub-id pub-id-type="pmcid">PMC6280645</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oliva</surname><given-names>M</given-names></name><name name-style="western"><surname>Mu&#241;oz-Aguirre</surname><given-names>M</given-names></name><name name-style="western"><surname>Kim-Hellmuth</surname><given-names>S</given-names></name><name name-style="western"><surname>Wucher</surname><given-names>V</given-names></name><name name-style="western"><surname>Gewirtz</surname><given-names>ADH</given-names></name><name name-style="western"><surname>Cotter</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Parsana</surname><given-names>P</given-names></name><name name-style="western"><surname>Kasela</surname><given-names>S</given-names></name><name name-style="western"><surname>Balliu</surname><given-names>B</given-names></name><name name-style="western"><surname>Vi&#241;uela</surname><given-names>A</given-names></name><name name-style="western"><surname>Castel</surname><given-names>SE</given-names></name><name name-style="western"><surname>Mohammadi</surname><given-names>P</given-names></name><name name-style="western"><surname>Aguet</surname><given-names>F</given-names></name><name name-style="western"><surname>Zou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Khramtsova</surname><given-names>EA</given-names></name><name name-style="western"><surname>Skol</surname><given-names>AD</given-names></name><name name-style="western"><surname>Garrido-Mart&#237;n</surname><given-names>D</given-names></name><name name-style="western"><surname>Reverter</surname><given-names>F</given-names></name><name name-style="western"><surname>Brown</surname><given-names>A</given-names></name><name name-style="western"><surname>Evans</surname><given-names>P</given-names></name><name name-style="western"><surname>Gamazon</surname><given-names>ER</given-names></name><name name-style="western"><surname>Payne</surname><given-names>A</given-names></name><name name-style="western"><surname>Bonazzola</surname><given-names>R</given-names></name><name name-style="western"><surname>Barbeira</surname><given-names>AN</given-names></name><name name-style="western"><surname>Hamel</surname><given-names>AR</given-names></name><name name-style="western"><surname>Martinez-Perez</surname><given-names>A</given-names></name><name name-style="western"><surname>Soria</surname><given-names>JM</given-names></name><name name-style="western"><surname>Pierce</surname><given-names>BL</given-names></name><name name-style="western"><surname>Stephens</surname><given-names>M</given-names></name><name name-style="western"><surname>Eskin</surname><given-names>E</given-names></name><name name-style="western"><surname>Dermitzakis</surname><given-names>ET</given-names></name><name name-style="western"><surname>Segr&#232;</surname><given-names>AV</given-names></name><name name-style="western"><surname>Im</surname><given-names>HK</given-names></name><name name-style="western"><surname>Engelhardt</surname><given-names>BE</given-names></name><name name-style="western"><surname>Ardlie</surname><given-names>KG</given-names></name><name name-style="western"><surname>Montgomery</surname><given-names>SB</given-names></name><name name-style="western"><surname>Battle</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Lappalainen</surname><given-names>T</given-names></name><name name-style="western"><surname>Guig&#243;</surname><given-names>R</given-names></name><name name-style="western"><surname>Stranger</surname><given-names>BE</given-names></name><collab>GTEx Consortium</collab></person-group><year iso-8601-date="2020">2020</year><article-title>The impact of sex on gene expression across human tissues</article-title><source>Science</source><volume>369</volume><elocation-id>eaba3066</elocation-id><pub-id pub-id-type="doi">10.1126/science.aba3066</pub-id><pub-id pub-id-type="pmid">32913072</pub-id><pub-id pub-id-type="pmcid">PMC8136152</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>MD</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Sex differences in immune responses in COVID-19</article-title><source>Nature Reviews. Immunology</source><volume>20</volume><elocation-id>461</elocation-id><pub-id pub-id-type="doi">10.1038/s41577-020-0378-2</pub-id><pub-id pub-id-type="pmid">32572247</pub-id><pub-id pub-id-type="pmcid">PMC7306659</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quinlan</surname><given-names>AR</given-names></name><name name-style="western"><surname>Hall</surname><given-names>IM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>BEDTools: a flexible suite of utilities for comparing genomic features</article-title><source>Bioinformatics</source><volume>26</volume><fpage>841</fpage><lpage>842</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btq033</pub-id><pub-id pub-id-type="pmid">20110278</pub-id><pub-id pub-id-type="pmcid">PMC2832824</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramanujan</surname><given-names>SA</given-names></name><name name-style="western"><surname>Cravens</surname><given-names>EN</given-names></name><name name-style="western"><surname>Krishfield</surname><given-names>SM</given-names></name><name name-style="western"><surname>Kyttaris</surname><given-names>VC</given-names></name><name name-style="western"><surname>Moulton</surname><given-names>VR</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Estrogen&#8208;Induced hsa&#8208;miR&#8208;10b&#8208;5p is elevated in T cells from patients with systemic lupus erythematosus and down&#8208;regulates serine/arginine&#8208;rich splicing factor 1</article-title><source>Arthritis &amp; Rheumatology</source><volume>73</volume><fpage>2052</fpage><lpage>2058</lpage><pub-id pub-id-type="doi">10.1002/art.41787</pub-id><pub-id pub-id-type="pmid">33982889</pub-id><pub-id pub-id-type="pmcid">PMC8568617</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Regitz-Zagrosek</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Sex and gender differences in health. Science &amp; society series on sex and science</article-title><source>EMBO Reports</source><volume>13</volume><fpage>596</fpage><lpage>603</lpage><pub-id pub-id-type="doi">10.1038/embor.2012.87</pub-id><pub-id pub-id-type="pmid">22699937</pub-id><pub-id pub-id-type="pmcid">PMC3388783</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>RO</given-names></name><name name-style="western"><surname>Geda</surname><given-names>YE</given-names></name><name name-style="western"><surname>Knopman</surname><given-names>DS</given-names></name><name name-style="western"><surname>Cha</surname><given-names>RH</given-names></name><name name-style="western"><surname>Pankratz</surname><given-names>VS</given-names></name><name name-style="western"><surname>Boeve</surname><given-names>BF</given-names></name><name name-style="western"><surname>Tangalos</surname><given-names>EG</given-names></name><name name-style="western"><surname>Ivnik</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Rocca</surname><given-names>WA</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>RC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The incidence of MCI differs by subtype and is higher in men: the mayo clinic study of aging</article-title><source>Neurology</source><volume>78</volume><fpage>342</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3182452862</pub-id><pub-id pub-id-type="pmid">22282647</pub-id><pub-id pub-id-type="pmcid">PMC3280046</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sampathkumar</surname><given-names>NK</given-names></name><name name-style="western"><surname>Bravo</surname><given-names>JI</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Danthi</surname><given-names>PS</given-names></name><name name-style="western"><surname>Donahue</surname><given-names>EK</given-names></name><name name-style="western"><surname>Lai</surname><given-names>RW</given-names></name><name name-style="western"><surname>Lu</surname><given-names>R</given-names></name><name name-style="western"><surname>Randall</surname><given-names>LT</given-names></name><name name-style="western"><surname>Vinson</surname><given-names>N</given-names></name><name name-style="western"><surname>Benayoun</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Widespread sex dimorphism in aging and age-related diseases</article-title><source>Human Genetics</source><volume>139</volume><fpage>333</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1007/s00439-019-02082-w</pub-id><pub-id pub-id-type="pmid">31677133</pub-id><pub-id pub-id-type="pmcid">PMC7031050</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sayed</surname><given-names>N</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>K</given-names></name><name name-style="western"><surname>Krejciova-Rajaniemi</surname><given-names>Z</given-names></name><name name-style="western"><surname>Grawe</surname><given-names>AP</given-names></name><name name-style="western"><surname>Gao</surname><given-names>T</given-names></name><name name-style="western"><surname>Tibshirani</surname><given-names>R</given-names></name><name name-style="western"><surname>Hastie</surname><given-names>T</given-names></name><name name-style="western"><surname>Alpert</surname><given-names>A</given-names></name><name name-style="western"><surname>Cui</surname><given-names>L</given-names></name><name name-style="western"><surname>Kuznetsova</surname><given-names>T</given-names></name><name name-style="western"><surname>Rosenberg-Hasson</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ostan</surname><given-names>R</given-names></name><name name-style="western"><surname>Monti</surname><given-names>D</given-names></name><name name-style="western"><surname>Lehallier</surname><given-names>B</given-names></name><name name-style="western"><surname>Shen-Orr</surname><given-names>SS</given-names></name><name name-style="western"><surname>Maecker</surname><given-names>HT</given-names></name><name name-style="western"><surname>Dekker</surname><given-names>CL</given-names></name><name name-style="western"><surname>Wyss-Coray</surname><given-names>T</given-names></name><name name-style="western"><surname>Franceschi</surname><given-names>C</given-names></name><name name-style="western"><surname>Jojic</surname><given-names>V</given-names></name><name name-style="western"><surname>Haddad</surname><given-names>F</given-names></name><name name-style="western"><surname>Montoya</surname><given-names>JG</given-names></name><name name-style="western"><surname>Wu</surname><given-names>JC</given-names></name><name name-style="western"><surname>Davis</surname><given-names>MM</given-names></name><name name-style="western"><surname>Furman</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>An inflammatory aging clock (iAge) based on deep learning tracks multimorbidity, immunosenescence, frailty and cardiovascular aging</article-title><source>Nature Aging</source><volume>1</volume><fpage>598</fpage><lpage>615</lpage><pub-id pub-id-type="doi">10.1038/s43587-021-00082-y</pub-id><pub-id pub-id-type="pmid">34888528</pub-id><pub-id pub-id-type="pmcid">PMC8654267</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seidler</surname><given-names>RD</given-names></name><name name-style="western"><surname>Bernard</surname><given-names>JA</given-names></name><name name-style="western"><surname>Burutolu</surname><given-names>TB</given-names></name><name name-style="western"><surname>Fling</surname><given-names>BW</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>MT</given-names></name><name name-style="western"><surname>Gwin</surname><given-names>JT</given-names></name><name name-style="western"><surname>Kwak</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lipps</surname><given-names>DB</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Motor control and aging: Links to age-related brain structural, functional, and biochemical effects</article-title><source>Neuroscience &amp; Biobehavioral Reviews</source><volume>34</volume><fpage>721</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.1016/j.neubiorev.2009.10.005</pub-id><pub-id pub-id-type="pmid">19850077</pub-id><pub-id pub-id-type="pmcid">PMC2838968</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shannon</surname><given-names>P</given-names></name><name name-style="western"><surname>Markiel</surname><given-names>A</given-names></name><name name-style="western"><surname>Ozier</surname><given-names>O</given-names></name><name name-style="western"><surname>Baliga</surname><given-names>NS</given-names></name><name name-style="western"><surname>Wang</surname><given-names>JT</given-names></name><name name-style="western"><surname>Ramage</surname><given-names>D</given-names></name><name name-style="western"><surname>Amin</surname><given-names>N</given-names></name><name name-style="western"><surname>Schwikowski</surname><given-names>B</given-names></name><name name-style="western"><surname>Ideker</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Cytoscape: a software environment for integrated models of biomolecular interaction networks</article-title><source>Genome Research</source><volume>13</volume><fpage>2498</fpage><lpage>2504</lpage><pub-id pub-id-type="doi">10.1101/gr.1239303</pub-id><pub-id pub-id-type="pmid">14597658</pub-id><pub-id pub-id-type="pmcid">PMC403769</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>W</given-names></name><name name-style="western"><surname>Hornburg</surname><given-names>D</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S</given-names></name><name name-style="western"><surname>Snyder</surname><given-names>MP</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Nonlinear dynamics of multi-omics profiles during human aging</article-title><source>Nature Aging</source><volume>4</volume><fpage>1619</fpage><lpage>1634</lpage><pub-id pub-id-type="doi">10.1038/s43587-024-00692-2</pub-id><pub-id pub-id-type="pmid">39143318</pub-id><pub-id pub-id-type="pmcid">PMC11564093</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>M</given-names></name><name name-style="western"><surname>Greenbaum</surname><given-names>J</given-names></name><name name-style="western"><surname>Luttrell</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>W</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C</given-names></name><name name-style="western"><surname>Shen</surname><given-names>H</given-names></name><name name-style="western"><surname>Gong</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Deng</surname><given-names>HW</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A review of integrative imputation for multi-omics datasets</article-title><source>Frontiers in Genetics</source><volume>11</volume><elocation-id>570255</elocation-id><pub-id pub-id-type="doi">10.3389/fgene.2020.570255</pub-id><pub-id pub-id-type="pmid">33193667</pub-id><pub-id pub-id-type="pmcid">PMC7594632</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takahashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Ellingson</surname><given-names>MK</given-names></name><name name-style="western"><surname>Wong</surname><given-names>P</given-names></name><name name-style="western"><surname>Israelow</surname><given-names>B</given-names></name><name name-style="western"><surname>Lucas</surname><given-names>C</given-names></name><name name-style="western"><surname>Klein</surname><given-names>J</given-names></name><name name-style="western"><surname>Silva</surname><given-names>J</given-names></name><name name-style="western"><surname>Mao</surname><given-names>T</given-names></name><name name-style="western"><surname>Oh</surname><given-names>JE</given-names></name><name name-style="western"><surname>Tokuyama</surname><given-names>M</given-names></name><name name-style="western"><surname>Lu</surname><given-names>P</given-names></name><name name-style="western"><surname>Venkataraman</surname><given-names>A</given-names></name><name name-style="western"><surname>Park</surname><given-names>A</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F</given-names></name><name name-style="western"><surname>Meir</surname><given-names>A</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>EY</given-names></name><name name-style="western"><surname>Casanovas-Massana</surname><given-names>A</given-names></name><name name-style="western"><surname>Wyllie</surname><given-names>AL</given-names></name><name name-style="western"><surname>Vogels</surname><given-names>CBF</given-names></name><name name-style="western"><surname>Earnest</surname><given-names>R</given-names></name><name name-style="western"><surname>Lapidus</surname><given-names>S</given-names></name><name name-style="western"><surname>Ott</surname><given-names>IM</given-names></name><name name-style="western"><surname>Moore</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>A</given-names></name><name name-style="western"><surname>Fournier</surname><given-names>JB</given-names></name><name name-style="western"><surname>Odio</surname><given-names>CD</given-names></name><name name-style="western"><surname>Farhadian</surname><given-names>S</given-names></name><name name-style="western"><surname>Dela Cruz</surname><given-names>C</given-names></name><name name-style="western"><surname>Grubaugh</surname><given-names>ND</given-names></name><name name-style="western"><surname>Schulz</surname><given-names>WL</given-names></name><name name-style="western"><surname>Ring</surname><given-names>AM</given-names></name><name name-style="western"><surname>Ko</surname><given-names>AI</given-names></name><name name-style="western"><surname>Omer</surname><given-names>SB</given-names></name><name name-style="western"><surname>Iwasaki</surname><given-names>A</given-names></name><collab>Yale IMPACT Research Team</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Sex differences in immune responses that underlie COVID-19 disease outcomes</article-title><source>Nature</source><volume>588</volume><fpage>315</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2700-3</pub-id><pub-id pub-id-type="pmid">32846427</pub-id><pub-id pub-id-type="pmcid">PMC7725931</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Nostrand</surname><given-names>EL</given-names></name><name name-style="western"><surname>Freese</surname><given-names>P</given-names></name><name name-style="western"><surname>Pratt</surname><given-names>GA</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>R</given-names></name><name name-style="western"><surname>Blue</surname><given-names>SM</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J-Y</given-names></name><name name-style="western"><surname>Cody</surname><given-names>NAL</given-names></name><name name-style="western"><surname>Dominguez</surname><given-names>D</given-names></name><name name-style="western"><surname>Olson</surname><given-names>S</given-names></name><name name-style="western"><surname>Sundararaman</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>L</given-names></name><name name-style="western"><surname>Bazile</surname><given-names>C</given-names></name><name name-style="western"><surname>Bouvrette</surname><given-names>LPB</given-names></name><name name-style="western"><surname>Bergalet</surname><given-names>J</given-names></name><name name-style="western"><surname>Duff</surname><given-names>MO</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>KE</given-names></name><name name-style="western"><surname>Gelboin-Burkhart</surname><given-names>C</given-names></name><name name-style="western"><surname>Hochman</surname><given-names>M</given-names></name><name name-style="western"><surname>Lambert</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>McGurk</surname><given-names>MP</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>TB</given-names></name><name name-style="western"><surname>Palden</surname><given-names>T</given-names></name><name name-style="western"><surname>Rabano</surname><given-names>I</given-names></name><name name-style="western"><surname>Sathe</surname><given-names>S</given-names></name><name name-style="western"><surname>Stanton</surname><given-names>R</given-names></name><name name-style="western"><surname>Su</surname><given-names>A</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R</given-names></name><name name-style="western"><surname>Yee</surname><given-names>BA</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>B</given-names></name><name name-style="western"><surname>Louie</surname><given-names>AL</given-names></name><name name-style="western"><surname>Aigner</surname><given-names>S</given-names></name><name name-style="western"><surname>Fu</surname><given-names>X-D</given-names></name><name name-style="western"><surname>L&#233;cuyer</surname><given-names>E</given-names></name><name name-style="western"><surname>Burge</surname><given-names>CB</given-names></name><name name-style="western"><surname>Graveley</surname><given-names>BR</given-names></name><name name-style="western"><surname>Yeo</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A large-scale binding and functional map of human RNA-binding proteins</article-title><source>Nature</source><volume>583</volume><fpage>711</fpage><lpage>719</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2077-3</pub-id><pub-id pub-id-type="pmid">32728246</pub-id><pub-id pub-id-type="pmcid">PMC7410833</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Burge</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Splicing regulation: from a parts list of regulatory elements to an integrated splicing code</article-title><source>RNA</source><volume>14</volume><fpage>802</fpage><lpage>813</lpage><pub-id pub-id-type="doi">10.1261/rna.876308</pub-id><pub-id pub-id-type="pmid">18369186</pub-id><pub-id pub-id-type="pmcid">PMC2327353</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>ET</given-names></name><name name-style="western"><surname>Sandberg</surname><given-names>R</given-names></name><name name-style="western"><surname>Luo</surname><given-names>S</given-names></name><name name-style="western"><surname>Khrebtukova</surname><given-names>I</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Mayr</surname><given-names>C</given-names></name><name name-style="western"><surname>Kingsmore</surname><given-names>SF</given-names></name><name name-style="western"><surname>Schroth</surname><given-names>GP</given-names></name><name name-style="western"><surname>Burge</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Alternative isoform regulation in human tissue transcriptomes</article-title><source>Nature</source><volume>456</volume><fpage>470</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1038/nature07509</pub-id><pub-id pub-id-type="pmid">18978772</pub-id><pub-id pub-id-type="pmcid">PMC2593745</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>K</given-names></name><name name-style="western"><surname>Wu</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Das</surname><given-names>A</given-names></name><name name-style="western"><surname>Basu</surname><given-names>M</given-names></name><name name-style="western"><surname>Malin</surname><given-names>J</given-names></name><name name-style="western"><surname>Cao</surname><given-names>K</given-names></name><name name-style="western"><surname>Hannenhalli</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Comprehensive map of age-associated splicing changes across human tissues and their contributions to age-associated diseases</article-title><source>Scientific Reports</source><volume>8</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1038/s41598-018-29086-2</pub-id><pub-id pub-id-type="pmid">30026530</pub-id><pub-id pub-id-type="pmcid">PMC6053367</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Splicing dysregulation in cancer: from mechanistic understanding to a new class of therapeutic targets</article-title><source>Science China Life Sciences</source><volume>63</volume><fpage>469</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1007/s11427-019-1605-0</pub-id><pub-id pub-id-type="pmid">32086672</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="software"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2025">2025</year><data-title>Sex-dimorphic-aging</data-title><version designator="swh:1:rev:4837f1b8596b1b920cfd349a4650e519d2d74b5d">swh:1:rev:4837f1b8596b1b920cfd349a4650e519d2d74b5d</version><source>Software Heritage</source><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://archive.softwareheritage.org/swh:1:dir:405cf7c0c87195b2ecb36296f2c746c5caa7ffc5;origin=https://github.com/rnasys/Sex-dimorphic-aging;visit=swh:1:snp:712b49f0fa17038f84e8422559d94565d165b7f7;anchor=swh:1:rev:4837f1b8596b1b920cfd349a4650e519d2d74b5d" ext-link-type="uri">https://archive.softwareheritage.org/swh:1:dir:405cf7c0c87195b2ecb36296f2c746c5caa7ffc5;origin=https://github.com/rnasys/Sex-dimorphic-aging;visit=swh:1:snp:712b49f0fa17038f84e8422559d94565d165b7f7;anchor=swh:1:rev:4837f1b8596b1b920cfd349a4650e519d2d74b5d</ext-link></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Westergaard</surname><given-names>D</given-names></name><name name-style="western"><surname>Moseley</surname><given-names>P</given-names></name><name name-style="western"><surname>S&#248;rup</surname><given-names>FKH</given-names></name><name name-style="western"><surname>Baldi</surname><given-names>P</given-names></name><name name-style="western"><surname>Brunak</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Population-wide analysis of differences in disease progression patterns in men and women</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>666</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-08475-9</pub-id><pub-id pub-id-type="pmid">30737381</pub-id><pub-id pub-id-type="pmcid">PMC6368599</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wucher</surname><given-names>V</given-names></name><name name-style="western"><surname>Sodaei</surname><given-names>R</given-names></name><name name-style="western"><surname>Amador</surname><given-names>R</given-names></name><name name-style="western"><surname>Irimia</surname><given-names>M</given-names></name><name name-style="western"><surname>Guig&#243;</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Day-night and seasonal variation of human gene expression across tissues</article-title><source>PLOS Biology</source><volume>21</volume><elocation-id>e3001986</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.3001986</pub-id><pub-id pub-id-type="pmid">36745672</pub-id><pub-id pub-id-type="pmcid">PMC9934459</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiong</surname><given-names>X</given-names></name><name name-style="western"><surname>Hou</surname><given-names>L</given-names></name><name name-style="western"><surname>Park</surname><given-names>YP</given-names></name><name name-style="western"><surname>Molinie</surname><given-names>B</given-names></name><collab>GTEx Consortium</collab><name name-style="western"><surname>Gregory</surname><given-names>RI</given-names></name><name name-style="western"><surname>Kellis</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Genetic drivers of m<sup>6</sup>A methylation in human brain, lung, heart and muscle</article-title><source>Nature Genetics</source><volume>53</volume><fpage>1156</fpage><lpage>1165</lpage><pub-id pub-id-type="doi">10.1038/s41588-021-00890-3</pub-id><pub-id pub-id-type="pmid">34211177</pub-id><pub-id pub-id-type="pmcid">PMC9112289</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiong</surname><given-names>J</given-names></name><name name-style="western"><surname>Kang</surname><given-names>SS</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>T-C</given-names></name><name name-style="western"><surname>Korkmaz</surname><given-names>F</given-names></name><name name-style="western"><surname>Padilla</surname><given-names>A</given-names></name><name name-style="western"><surname>Miyashita</surname><given-names>S</given-names></name><name name-style="western"><surname>Chan</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Katsel</surname><given-names>P</given-names></name><name name-style="western"><surname>Burgess</surname><given-names>J</given-names></name><name name-style="western"><surname>Gumerova</surname><given-names>A</given-names></name><name name-style="western"><surname>Ievleva</surname><given-names>K</given-names></name><name name-style="western"><surname>Sant</surname><given-names>D</given-names></name><name name-style="western"><surname>Yu</surname><given-names>S-P</given-names></name><name name-style="western"><surname>Muradova</surname><given-names>V</given-names></name><name name-style="western"><surname>Frolinger</surname><given-names>T</given-names></name><name name-style="western"><surname>Lizneva</surname><given-names>D</given-names></name><name name-style="western"><surname>Iqbal</surname><given-names>J</given-names></name><name name-style="western"><surname>Goosens</surname><given-names>KA</given-names></name><name name-style="western"><surname>Gera</surname><given-names>S</given-names></name><name name-style="western"><surname>Rosen</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Haroutunian</surname><given-names>V</given-names></name><name name-style="western"><surname>Ryu</surname><given-names>V</given-names></name><name name-style="western"><surname>Yuen</surname><given-names>T</given-names></name><name name-style="western"><surname>Zaidi</surname><given-names>M</given-names></name><name name-style="western"><surname>Ye</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>FSH blockade improves cognition in mice with Alzheimer&#8217;s disease</article-title><source>Nature</source><volume>603</volume><fpage>470</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-04463-0</pub-id><pub-id pub-id-type="pmid">35236988</pub-id><pub-id pub-id-type="pmcid">PMC9940301</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>JA</given-names></name><name name-style="western"><surname>Stires</surname><given-names>H</given-names></name><name name-style="western"><surname>Belden</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Roepke</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The arcuate estrogen-regulated transcriptome: estrogen response element-dependent and -independent signaling of ER&#945; in Female Mice</article-title><source>Endocrinology</source><volume>158</volume><fpage>612</fpage><lpage>626</lpage><pub-id pub-id-type="doi">10.1210/en.2016-1663</pub-id><pub-id pub-id-type="pmid">28359086</pub-id><pub-id pub-id-type="pmcid">PMC5460777</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoshida</surname><given-names>M</given-names></name><name name-style="western"><surname>Apte</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>NAD+ boosting brings tears to aging eyes</article-title><source>Nature Aging</source><volume>2</volume><fpage>97</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1038/s43587-022-00172-5</pub-id><pub-id pub-id-type="pmid">37117757</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>G</given-names></name><name name-style="western"><surname>Wang</surname><given-names>LG</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y</given-names></name><name name-style="western"><surname>He</surname><given-names>QY</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>clusterProfiler: an R package for comparing biological themes among gene clusters</article-title><source>Omics</source><volume>16</volume><fpage>284</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1089/omi.2011.0118</pub-id><pub-id pub-id-type="pmid">22455463</pub-id><pub-id pub-id-type="pmcid">PMC3339379</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>G</given-names></name><name name-style="western"><surname>Wang</surname><given-names>LG</given-names></name><name name-style="western"><surname>He</surname><given-names>QY</given-names></name></person-group><year iso-8601-date="2015">2015a</year><article-title>ChIPseeker: an R/Bioconductor package for ChIP peak annotation, comparison and visualization</article-title><source>Bioinformatics</source><volume>31</volume><fpage>2382</fpage><lpage>2383</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btv145</pub-id><pub-id pub-id-type="pmid">25765347</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>G</given-names></name><name name-style="western"><surname>Wang</surname><given-names>LG</given-names></name><name name-style="western"><surname>Yan</surname><given-names>GR</given-names></name><name name-style="western"><surname>He</surname><given-names>QY</given-names></name></person-group><year iso-8601-date="2015">2015b</year><article-title>DOSE: an R/Bioconductor package for disease ontology semantic and enrichment analysis</article-title><source>Bioinformatics</source><volume>31</volume><fpage>608</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu684</pub-id><pub-id pub-id-type="pmid">25677125</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>L</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Peng</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name><name name-style="western"><surname>Suh</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tu</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Transcriptome analysis reveals the difference between &#8220;healthy&#8221; and &#8220;common&#8221; aging and their connection with age-related diseases</article-title><source>Aging Cell</source><volume>19</volume><elocation-id>e13121</elocation-id><pub-id pub-id-type="doi">10.1111/acel.13121</pub-id><pub-id pub-id-type="pmid">32077223</pub-id><pub-id pub-id-type="pmcid">PMC7059150</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>HT</given-names></name><name name-style="western"><surname>Kadash-Edmondson</surname><given-names>K</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Z</given-names></name><name name-style="western"><surname>Davidson</surname><given-names>BL</given-names></name><name name-style="western"><surname>Xing</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Regional variation of splicing QTLs in human brain</article-title><source>American Journal of Human Genetics</source><volume>107</volume><fpage>196</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2020.06.002</pub-id><pub-id pub-id-type="pmid">32589925</pub-id><pub-id pub-id-type="pmcid">PMC7413857</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name><name name-style="western"><surname>Cao</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L</given-names></name><name name-style="western"><surname>Farrell</surname><given-names>K</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Guo</surname><given-names>L</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>McKenzie</surname><given-names>A</given-names></name><name name-style="western"><surname>Crary</surname><given-names>JF</given-names></name><name name-style="western"><surname>Cai</surname><given-names>D</given-names></name><name name-style="western"><surname>Tu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Molecular differences in brain regional vulnerability to aging between males and females</article-title><source>Frontiers in Aging Neuroscience</source><volume>15</volume><elocation-id>1153251</elocation-id><pub-id pub-id-type="doi">10.3389/fnagi.2023.1153251</pub-id><pub-id pub-id-type="pmid">37284017</pub-id><pub-id pub-id-type="pmcid">PMC10239962</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.102449.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Gurkar</surname><given-names initials="AU">Aditi U</given-names></name><role specific-use="editor">Reviewing Editor</role><aff>
<institution>University of Pittsburgh</institution>
<country>United States</country>
</aff></contrib></contrib-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group><kwd-group kwd-group-type="evidence-strength"><kwd>Solid</kwd></kwd-group></front-stub><body><p>In this study Wang et. al. mined publicly available RNA-seq data from The Genotype-Tissue Expression (GTEx) database spanning multiple tissues to ask the question of how transcriptomes are changed with age and in both sexes. The authors provide <bold>solid</bold> evidence reporting widespread gene expression changes and alternative splicing events that vary in an age- and sex-dependent manner. An <bold>important</bold> finding is that many of these changes coincide with the time sex hormones begin to decline; additionally, the rate of aging is faster in males than in females.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.102449.3.sa1</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>In this manuscript, Wang et al analyze ~17,000 transcriptomes from 35 human tissues from the GTEx database and address transcriptomic variations due to age and sex. They identified both gene expression changes as well as alternative splicing events that differ among sexes. Using breakpoint analysis, the authors find sex dimorphic shifts begin with declining sex hormone levels with males being affected more than females. This is an important pan-tissue transcriptomic study exploring age and sex-dependent changes although not the first one.</p><p>Strengths:</p><p>(1) The authors use sophisticated modeling and statistics for differential, correlational and predictive analysis.</p><p>(2) The authors consider important variables such as genetic background, ethnicity, sampling bias, sample sizes, detected genes etc.</p><p>(3) This is likely the first study to evaluate alternative splicing changes with age and sex at a pan-tissue scale.</p><p>(4) Sex dimorphism with age is an important topic and is thoroughly analyzed in this study.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.102449.3.sa2</article-id><title-group><article-title>Reviewer #3 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>In this study, Wang et al utilized the available GTEx data to compile a comprehensive analysis that attempt to reveal aging-related sex-dimorphic gene expression as well as alternative splicing changes in human. The key conclusions based upon their analysis are that (1) extensive sex-dimorphisms during aging with distinct patterns of change in gene expression and alternative splicing (AS), and (2) the male-biased age-associated AS events have a stronger association with Alzheimer's disease, and (3) the females-biased events are often regulated by several sex-biased splicing factors that may be controlled by estrogen receptors. They further performed break-point analysis and reveal in males there are two main breakpoints around ages 35 and 50, while in female only one breakpoint at 45.</p><p>Strengths:</p><p>This study sets an ambitious goal, leveraging the extensive GTEx dataset to investigate aging-related, sex-dimorphic gene expression and alternative splicing changes in humans. The research addresses a significant question, as our understanding of sex-dimorphic gene expression in the context of human aging is still in its early stages. Advancing our knowledge of these molecular changes is vital for identifying therapeutic targets for age-related diseases and extending human healthspan. The study is highly comprehensive, and the authors are commendable for their attempted thorough analysis of both gene expression and alternative splicing-an area often overlooked in similar studies.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.102449.3.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="S">Siqi</given-names></name><role specific-use="author">Author</role><aff>
<institution>Shanghai Institute of Nutrition and Health</institution>
<addr-line>Shanghai</addr-line>
<country>China</country>
</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dong</surname><given-names initials="D">Danyue</given-names></name><role specific-use="author">Author</role><aff>
<institution>Shanghai Institute of Nutrition and Health</institution>
<addr-line>Shanghai</addr-line>
<country>China</country>
</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="X">Xin</given-names></name><role specific-use="author">Author</role><aff>
<institution>Shanghai Institute of Nutrition and Health</institution>
<addr-line>Shanghai</addr-line>
<country>China</country>
</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="Z">Zefeng</given-names></name><role specific-use="author">Author</role><aff>
<institution>Southern University of Science and Technology</institution>
<addr-line>Shenzhen</addr-line>
<country>China</country>
</aff></contrib></contrib-group></front-stub><body><p>The following is the authors&#8217; response to the original reviews</p><disp-quote content-type="editor-comment"><p>
<bold>Public Reviews:</bold>
</p><p>
<bold>Reviewer #1 (Public review):</bold>
</p><p>Summary:</p><p>Wang et al. investigate sexual dimorphic changes in the transcriptome of aged humans. This study relies upon analysis of the Genotype-Tissue Expression dataset that includes 54 tissues from human donors. The authors investigate 17,000 transcriptomes from 35 tissues to investigate the effect of age and sex on transcriptomic variation, including the analysis of alternative splicing. Alternative splicing is becoming more appreciated as an influence in the aging process, but how it is affected by sexual dimorphism is still largely unclear. The authors investigated multiple tissues but ended up distilling brain tissue down to four separate regions: decision, hormone, memory, and movement. Building upon prior work, the authors used an analysis method called principal component-based signal-to-variation ratio (pcSVR) to quantify differences between sex or age by considering data dispersion. This method also considers differentially expressed genes and alternative splicing events.</p><p>Strengths:</p><p>(1) The authors investigate sexual dimorphism on gene expression and alternative splicing events with age in multiple tissues from a large publicly available data set that allows for reanalysis.</p><p>(2) Furthermore, the authors take into account the ethnic background of donors. Identification of agingmodulating genes could be useful for the reanalysis of prior data sets.</p><p>Weaknesses:</p><p>The models built off of the GTEx dataset should be tested in another data set (ex. Alzheimer's disease) where there are functional changes that can be correlated. Gene-length-dependent transcription decline, which occurs with age and disease, should also be investigated in this data set for potential sexual dimorphism.</p></disp-quote><p>We appreciate the reviewer&#8217;s constructive feedback and acknowledgment of the strengths of our study. The detailed results are included in the &#8216;Recommendations for the authors&#8217; from the editorial office. Below we summarize our feedback that address the concerns of this reviewer:</p><p>(1) Independent Alzheimer&#8217;s disease (AD) datasets:</p><p>We acknowledge the importance of validating our models beyond GTEx to assess their generalizability aging to Alzheimer&#8217;s disease. While GTEx provides valuable transcriptomic data across multiple tissues, it lacks direct functional assessments linked to disease states. We have already analyzed RNA-seq data from ROSMAP and GEO in Figure 4, focusing on sex-biased gene expression and splicing changes between aging and AD. The results showed a male-biased association with Alzheimer&#8217;s disease at AS resolution, indicating that the AS changes during aging could contribute more to AD in males than females. We added a highlight to this analysis in the manuscript (Pages 6-7).</p><p>(2) Sexual dimorphism in Gene-Length-Dependent Transcription Decline (GLTD)</p><p>We appreciate the reviewer&#8217;s suggestion to explore gene-length-dependent transcription decline (GLTD), which has been implicated in both aging and disease. As the reviewer suggested, our analysis revealed that GLTD exhibits sex-biased patterns in different tissues, aligning with recent literature on sex-dimorphic transcriptional aging. Our findings also revealed that longer genes with greater transcriptional decline are enriched in AD-related pathways. We have incorporated this new analysis in the &#8216;Recommendations for the authors&#8217; in Author response image 5-6 and expanded the discussion of the biological relevance.</p><disp-quote content-type="editor-comment"><p>
<bold>Reviewer #2 (Public review):</bold>
</p><p>Summary:</p><p>In this manuscript, Wang et al analyze ~17,000 transcriptomes from 35 human tissues from the GTEx database and address transcriptomic variations due to age and sex. They identified both gene expression changes as well as alternative splicing events that differ among sexes. Using breakpoint analysis, the authors find sex dimorphic shifts begin with declining sex hormone levels with males being affected more than females. This is an important pan-tissue transcriptomic study exploring age and sex-dependent changes although not the first one.</p><p>Strengths:</p><p>(1) The authors use sophisticated modeling and statistics for differential, correlational, and predictive analysis.</p><p>(2) The authors consider important variables such as genetic background, ethnicity, sampling bias, sample sizes, detected genes, etc.</p><p>(3) This is likely the first study to evaluate alternative splicing changes with age and sex at a pan-tissue scale.</p><p>(4) Sex dimorphism with age is an important topic and is thoroughly analyzed in this study. Weaknesses:</p><p>(1) The findings have not been independently validated in a separate cohort or through experiments. Only selective splicing factor regulation has been verified in other studies.</p><p>(2) It seems the authors have not considered PMI or manner of death as a variable in their analysis.</p><p>(3) The manuscript is very dense and sometimes difficult to follow due to many different types of analyses and correlations.</p><p>(4) Short-read data can detect and quantify alternative splicing events with only moderate confidence and therefore the generalizability of these findings remains to be experimentally validated.</p></disp-quote><p>We appreciate the thorough review and thoughtful feedback. We have addressed the reviewer&#8217;s concerns and added clarification. The detailed results are included in Recommendations for the authors. Here are the summaries.</p><p>(1) Challenge of independent validation in separate cohorts</p><p>&#8226; The GTEx dataset includes the most comprehensive transcriptome resource for studying population-level differences in age and sex across tissues, particularly including large-scale brain samples. This provides a unique opportunity to analyze sex-dimorphic aging and the relevance of age-associated diseases. Several technical issues, including cell type heterogeneity, postmortem artifacts, as well as sequencing biases, lead to technical challenges in different cohorts.</p><p>&#8226; As the reviewer mentioned, we analyzed transcriptomic data from Shen et al. (2024) and compared them with GTEx results (Author response image 2). Limited overlap in differentially expressed genes again highlighted the challenges in cross-dataset validation due to the differences in cell composition and data processing (peripheral blood mononuclear cells (PBMCs) vs whole blood).</p><p>&#8226; Due to the limited human brain transcriptome data covering different age and sex groups, we found mouse hippocampus datasets from Mass spectrometry (MS), including young and old, as well as female and male groups. The results validated the expression of splicing factors in brain (Author response image 9). This cross-species consistency supports the robustness of our findings in human brain aging.</p><p>(2) Effects of Postmortem Interval, Manner of Death, and Time of Death</p><p>&#8226; We agree that the sample collections could introduce confounding effects. To address this, we calculated the correlations between the confounding factors with Postmortem Interval (PMI), Manner of Death (DTHMNNR), or Time of Death (DTHTIME and DTHSEASON). We observed strong correlations in some surrogate variables in most tissues, indicating that those factors could be well-regressed during our analysis (Recommendations for the authors, Figure S4 and R8).</p><p>&#8226; In addition, we re-evaluated our analyses while incorporating PMI as a covariate in our models. Our results align with our initial findings (Author response image 1), suggesting that age- and sex-dependent transcriptomic changes are not strongly confounded by PMI and confirming that our model has controlled PMI. These results are detailed in &#8216;Recommendations for the authors&#8217; and included in Figure S4C-E with the description in text, Page 5.</p><p>(3) Readability of manuscript and flow of analyses</p><p>&#8226; In summary, our study first examined global alternative splicing (AS) and gene expression (GE) across all tissues before focusing on specific regions for deeper insights. To improve clarity, we have made the following revisions:</p><p>&#8226; Add clearer statements when transitioning between all-tissue and brain-specific analyses (Page 6-7).</p><p>&#8226; Modify the subtitle of Results to highlight all-tissue vs. brain analyses (Page 6).</p><p>&#8226; These refinements could enhance the manuscript&#8217;s structure, making the flow of analysis and conclusions more intuitive for readers.</p><p>(4) Limitations of short-read RNA-seq for splicing analysis</p><p>&#8226; Short-read RNA-seq provides only moderate confidence in detecting and quantifying full-length isoforms. However, its higher sequencing depth makes it more suitable for quantifying changes in alternative splicing (AS) events.</p><p>&#8226; Our analysis focused on splicing event-level quantification, applying stringent filters and using our GPU-based tool, which showed strong concordance with RT-PCR and other pipelines. Therefore, we also cited and included the updated Paean manuscript that benchmarks its performance in AS analysis.</p><disp-quote content-type="editor-comment"><p>
<bold>Reviewer #3 (Public review):</bold>
</p><p>Summary:</p><p>In this study, Wang et al utilized the available GTEx data to compile a comprehensive analysis that attempt to reveal aging-related sex-dimorphic gene expression as well as alternative splicing changes in humans.</p><p>The key conclusions based on their analysis are that.</p><p>(1) extensive sex-dimorphisms during aging with distinct patterns of change in gene expression and alternative splicing (AS), and</p><p>(2) the male-biased age-associated AS events have a stronger association with Alzheimer's disease, and (3) the female-biased events are often regulated by several sex-biased splicing factors that may be controlled by estrogen receptors. They further performed break-point analysis and revealed that in males there are two main breakpoints around ages 35 and 50, while in females, there is only one breakpoint at 45.</p><p>Strengths:</p><p>This study sets an ambitious goal, leveraging the extensive GTEx dataset to investigate aging-related, sexdimorphic gene expression and alternative splicing changes in humans. The research addresses a significant question, as our understanding of sex-dimorphic gene expression in the context of human aging is still in its early stages. Advancing our knowledge of these molecular changes is vital for identifying therapeutic targets for age-related diseases and extending the human health span. The study is highly comprehensive, and the authors are commendable for their attempted thorough analysis of both gene expression and alternative splicing - an area often overlooked in similar studies.</p></disp-quote><p>We thank this reviewer for the insightful review and recognition of our study's significance. We agree with the reviewer on how to examine sex-dimorphic gene expression and alternative splicing in aging by using the GTEx dataset. This is indeed an essential aspect of developing potential therapeutic targets for agerelated diseases to promote human health span.</p><disp-quote content-type="editor-comment"><p>Weaknesses:</p><p>Due to the inherent noise within the GTEx dataset - which includes numerous variables beyond aging and sex - there are significant technical concerns surrounding this study. Additionally, the lack of crossvalidation with independent, existing data raises questions about whether the observed gene expression changes genuinely reflect those associated with human aging. For instance, the break-point analysis in this study identifies two major breakpoints in males around ages 35 and 50, and one breakpoint in females at age 45; however, these findings contradict a recent multi-omics longitudinal study involving 108 participants aged 25 to 75 years, where breakpoint at 44 and 60 years was observed in both male and females (Shen et al, 2024). These issues cast doubt on the robustness of the study's conclusions. Specific concerns are outlined below:</p><p>References:</p><p>Ferreira PG, Mu&#241;oz-Aguirre M, Reverter F, S&#225; Godinho CP, Sousa A, Amadoz A, Sodaei R, Hidalgo MR, Pervouchine D, Carbonell-Caballero J et al (2018) The effects of death and post-mortem cold ischemia on human tissue transcriptomes. Nature Communications 9: 490.</p><p>Shen X, Wang C, Zhou X, Zhou W, Hornburg D, Wu S, Snyder MP (2024) Nonlinear dynamics of multiomics profiles during human aging. Nature Aging.</p><p>Wucher V, Sodaei R, Amador R, Irimia M, Guig&#243; R (2023) Day-night and seasonal variation of human gene expression across tissues. PLOS Biology 21: e3001986.</p><p>(1) The primary method used in this study is linear regression, incorporating age, sex, and age-by-sex interactions as covariates, alongside other confounding factors (such as ethnicity) as unknown variables. However, the analysis overlooks two critical known variables in the GTEx dataset: time of death (TOD) and postmortem interval (PMI). Both TOD and PMI are recorded for each sample and account for substantial variance in gene expression profiles. A recent study by Wucher et al.(Wucher et al, 2023) demonstrated the powerful impact of TOD on gene expression by using it to reconstruct human circadian and even circannual datasets. Similarly, Ferreira et al. (Ferreira et al, 2018) highlighted PMI's influence on gene expression patterns. Without properly adjusting for these two variables, confidence in the study's conclusions remains limited at best.</p></disp-quote><p>We appreciate the reviewer for raising this important point regarding the impact of post-mortem interval (PMI) and time of death (TOD) on gene expression, including the death seasons (DTHSEASON) and daytime (DTHTIME). To address this point, we carefully evaluated whether our linear model controlled for these factors as potential confounders.</p><p>Our results showed that PMI and TOD significantly correlated with the estimated covariates in most tissues, suggesting that their effects could be effectively regressed out using our model (Figure S4). As the reviewers and editors suggested, we have now included this correlation analysis in the updated Figure S4C-E and the text in the Results section, citing relevant literature [1,2] (Page 5).</p><fig position="float" id="sa3fig1" orientation="portrait"><label>Author response image 1.</label><caption><title>The results of differential gene expression analysis with vs without the inclusion of PMI correction as a known covariate.</title><p>The scatter plots show the correlations of significance levels (pvalues, left panel) and effect sizes (coefficients, right panel) of sex (A) and age (B). Whole-blood tissue is used as an example.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="elife-102449-sa3-fig1.jpg"/></fig><p>In addition, we did the differential analysis that incorporated PMI as a covariate in the regression models and re-evaluated the age- and sex-related transcriptomic changes. Using WholeBlood gene expression as an example, our revised analysis shows that the inclusion of PMI in the covariates has minimal impact on the significance levels and effects of sex and age (i.e., p-values and coefficients, respectively), indicating that our findings are robust using confounding factors (Author response image 1).</p><disp-quote content-type="editor-comment"><p>(2) To demonstrate that their analysis is robust and that the covariates TOD and PMI are otherwise negligible - the authors should cross-validate their findings with independent datasets to confirm that the identified gene expression changes are reproducible for some tissues. For instance, the recent study by Shen et al. (Shen et al., 2024) in Nature Aging offers an excellent dataset for cross-validation, particularly for blood samples. Comparing the GTEx-derived results with this longitudinal transcriptome dataset would enable verification of gene expression changes at both the individual gene and pathway levels. Without such validation, confidence in the study's conclusions remains limited.</p></disp-quote><p>We thank the reviewer for the insightful suggestion regarding cross-validation with independent datasets. We understand that validating findings across datasets is crucial for ensuring robustness. As the reviewers suggested, we see whether there are some shared findings in the GTEx data with the study by Shen et al. (2024) in Nature Aging. However, after performing comparisons with our GTEx results in whole blood tissue, we found that the overlaps of differentially expressed genes are limited (Fig. 3). In our results, we found a large proportion of age-associated genes in the GTEx data, whereas just 54 genes are age-associated from Shen et al.&#8217;s PBMC data. 3 in 7 genes are differentially expressed in both datasets (Fig. 3A). Additionally, we performed the functional enrichment analysis on the GTEx-specific age-associated genes.</p><p>We observed a strong enrichment in the biological pathways related to neutrophil functions and innate immune responses, which are specific to the cell compositions in whole blood rather than PBMC (Fig. 3B).</p><fig position="float" id="sa3fig2" orientation="portrait"><label>Author response image 2.</label><caption><title>The comparison between the gene expression of whole blood tissue from GTEx and PBMCs from Shen et al.</title><p>(A) The bar plot shows the number of age (left panel) or sex-associated (right panel) genes in the two datasets. The grey bars highlight the proportion of overlapped genes in both datasets. (B) The top 10 significantly enriched biological processes in the GTEx-specific age-associated genes. The color bar shows the number of age-associated genes in specific pathways.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="elife-102449-sa3-fig2.jpg"/></fig><p>These discrepancies highlighted the crucial factors in cross-dataset comparison:</p><p>&#8226; Cell compositions: GTEx used whole blood, which contains all blood components, including neutrophils and erythrocytes, whereas PBMCs contain lymphocytes and monocytes. Under the influence of granulocytes and red blood cells in whole blood, the gene expression profiles between these two datasets are different.</p><p>&#8226; Biological functions: Whole blood includes both innate and adaptive immune components; thus, aging-related gene expression changes in whole blood may include a broader systemic response than those in PBMCs. This difference in biological context contributes to the observed variation in the differentially expressed genes, as demonstrated by our functional enrichment analysis (Fig. 3B).</p><p>&#8226; Sequencing biases and data processing: The two datasets were generated using different RNAseq processing pipelines, including distinct normalization, batch correction, and quantification methodologies. These technical differences may introduce systematic variations that complicate direct cross-validation.</p><p>Due to these fundamental problems, a direct one-to-one validation between the two datasets is challenging. We understand the importance of independent dataset validation and appreciate the reviewer&#8217;s suggestion. However, future studies could be performed more precisely if comparable whole-blood-based datasets are available. In addition, GTEx data provides nearly thousands of samples in whole blood, which is a largescale, comprehensive, and clinically relevant dataset for studying aging-related changes, particularly in innate immunity and inflammation, which are not well captured in PBMCs.</p><disp-quote content-type="editor-comment"><p>(3) As a demonstration of the lack of such validation, in the Shen et al. study (Shen et al., 2024), breakpoints at 44 and 60 years were observed in both males and females, while this study identifies two major breakpoints in males around ages 35 and 50, and one breakpoint in females at age 45. What caused this discrepancy?</p></disp-quote><p>We thank the reviewer and the editors for both coming up with the non-linear multi-omic aging patterns observed by Shen et al. They observed two prominent crests around the ages of 45 and 60 from omics data.</p><p>Similarly, we also identified two breakpoints in our analysis, with some differences in specific age breakpoints. These could be the result of sample preparation methods and breakpoint definition. These responses are also included in the editor&#8217;s recommendations.</p><p>Definition of breakpoints vs crests:</p><p>&#8226; Crests represent age-related molecular changes at each time point across the human lifespan. They indicate the number of molecules that are differentially expressed during aging (q &lt; 0.05), without considering individual expression levels.</p><p>&#8226; Our breakpoints, in contrast, are identified after filtering the chronological trends using the Autoregressive Integrated Moving Average (ARIMA) model. We calculated the rate of change at each age point using the smooth approach and sliding windows. Breakpoints are defined as local maxima where the distance to the nearest minimum, relative to the global maximum. We indeed found some local wide peaks around 60 in some tissues, shown in Figure S10, however, we excluded these due to our strict cutoffs to remove noise.</p><p>Differences and similarities between sequenced tissues:</p><p>&#8226; Whole-blood vs PBMC: In the GTEx RNA-seq data used in our study, whole blood samples from donors were sequenced, whereas their study used PBMCs. Whole blood contains all blood components, including red blood cells, platelets, granulocytes (e.g., neutrophils), lymphocytes, and monocytes, while PBMCs represent a subset of white blood cells, primarily consisting of lymphocytes (T cells, B cells, NK cells) and monocytes, excluding granulocytes and erythrocytes. As we mentioned in the previous responses, the gene expression changes observed in whole blood capture the contributions of neutrophils and other granulocytes, which are neglected in the PBMC profile (also shown in Figure S11C).</p><p>&#8226; For the shared tissues in two studies &#8211; skin, we looked at the non-linear changes during aging and found the same two breakpoints: 43 and 58.</p><p>Novelties in our study:</p><p>&#8226; Whole blood can serve as a readily accessible resource for testing age-related disease biomarkers without cell separation, making it more practical for clinical applications.</p><p>&#8226; Our analysis was performed on females and males, respectively. The main object of our analysis is to compare the differences in aging rates between sexes. Our results reveal clear sex-specific differences across multiple human tissues. Therefore, the identified breakpoints may differ when sex effects are not taken into account, highlighting the specificity of our analysis.</p><p>&#8226; Additionally, our breakpoints are integrated across multiple tissues. Our results showed that there is a large diversity of aging patterns in different tissues.</p><p>As the reviewers and editors suggested, we have added the following statements to clarify this distinction in the Discussion section: &#8216;Our analysis observed the non-linear aging patterns with two breakpoints, which is consistent with recent findings, with differences in specific age points due to sex differences as well as tissue diversities 3.&#8217; (Page 14), and &#8216;These breakpoints could represent key junctures in the aging process that align with the non-linear patterns of aging and disease progression.&#8217; (Page 15)</p><disp-quote content-type="editor-comment"><p>(4) Although the alternative splicing analysis is intriguing, the authors did not differentiate between splicing events that alter the protein-coding sequence and those that do not. Many splicing changes occurring in the 5' UTR and 3' UTR regions do not impact protein coding, so it is essential to filter these out and focus specifically on alternative splicing events that can modify protein-coding sequences.</p></disp-quote><p>The reviewer raises an important point. In our study, we included the AS events in protein-coding genes to gain a comprehensive understanding of sex-biased age-associated splicing. As the reviewer suggested, focusing on coding-sequence-altering events is particularly relevant to protein function. To address this, we performed an additional analysis to specifically annotate sBASEs occurring within the coding sequence (defeined as CDS-altering sBASEs) and reanalyzed their functional pathways and AD-associations (Author response image 3).</p><p>Our analysis revealed that most of the sBASEs are relevant to protein-coding sequences (CDS) across multiple tissues (Author response image 3A). We then confirmed our findings using CDS-altering sBASEs. We found that those sBASEs in brain regions were significantly enriched in pathways related to amyloid-beta formation and actin filament organization (Author response image 3B). Notably, male-biased sBASEs in decision-related brain regions were particularly associated with dendrite development and regulation of cell morphogenesis, highlighting the sex-specific roles of sBASEs in brain functions. Additionally, we performed a random forest classification using only CDS-altering sBASEs in AD datasets (Author response image 3C-D), again confirming the malebiased association between aging and AD.</p><p>Overall, we found that most of the identified sBASEs could modify protein-coding sequences, and our main conclusions remain consistent even after filtering out non-coding events.</p><p>Nevertheless, in addition to AS events that impact protein sequences, alternative splicing in untranslated regions (UTRs) also plays a critical regulatory role. Splicing events in the 5&#8242; UTR can influence translation efficiency by modifying upstream open reading frames (uORFs) or RNA secondary structures, while splicing in the 3&#8242;UTR can affect mRNA stability, localization, and translation by altering microRNA binding sites and RNA-binding protein interactions. Given these functional implications, we believe that UTR-targeted AS events should also be considered to supplement the understanding of post-transcriptional gene regulation in future research.</p><fig position="float" id="sa3fig3" orientation="portrait"><label>Author response image 3.</label><caption><title>The distribution and functional relevance of sBASEs with coding effects.</title><p>(A) The number of sBASEs and CDS-altering sBASEs across multiple tissues. The deeper bars show the number of sBASEs whose alternative splice sites are located at protein-coding regions. (B) GO biological pathways in each sex and brain region. Heatmap shows the sex-specific pathways that are significantly enriched by CDS-altering sBASEs in more than 2 brain regions and sex. (C) Correlation between ADassociated and age-associated AS changes across the CDS-altering sBASEs that alter protein-coding sequences in females and males. (D) Performances of sex-stratified models predicted by CDS-altering sBASEs in 100 iterations using the random forest approach</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="elife-102449-sa3-fig3.jpg"/></fig><disp-quote content-type="editor-comment"><p>(5) One of the study's main conclusions - that "male-biased age-associated AS events have a stronger association with Alzheimer's disease" - is not supported by the data presented in Figure 4A, which shows an association with "regulation of amyloid precursor formation" only in female, not male, alternative splicing genes. Additionally, the gene ontology term "Alzheimer's disease" is absent from the unbiased GO analysis in Figure S6. These discrepancies suggest that the focus on Alzheimer's disease may reflect selective data interpretation rather than results driven by an unbiased analysis.</p></disp-quote><p>We thank the reviewer for this point. In our functional analysis, we identified distinct biological processes enriched in female- and male-biased AS genes, such as the regulation of amyloid precursor formation in females and structural constituents of the cytoskeleton in males. However, Alzheimer&#8217;s disease (AD) is a complex neurodegenerative disorder with multiple pathological mechanisms beyond amyloid-beta (A&#946;) formation, many of which are strongly age-related in both sexes. This complexity motivates us to explore novel relationships between splicing and AD in distinct sexes.</p><p>Although Figure 4A shows the enrichment of &#8220;regulation of amyloid precursor formation&#8221; in female-biased AS events, this does not contradict the broader enrichment of AD-related processes in male-biased AS events. Our disease ontology analysis supports this finding, as male-biased age-associated AS events are enriched in neurodegenerative diseases, including cognitive disorders. Additionally, we considered not only individual GO terms but also the disease-associated transcriptomic signatures from AD-related datasets, which collectively indicate a stronger association in males.</p><p>Regarding Figure S6 mentioned by the reviewer, the GO term &#8220;Alzheimer&#8217;s disease&#8221; is not explicitly listed in the heatmap because we filtered the pathways that are consistently enriched in multiple tissues. As noted in the figure legend, we only displayed sex-specific GO terms that were significant in at least 15 tissues. Then, since the brain is highly affected by age-related processes and neurological conditions show sex differences, the sex-biased AS events could help explain differential susceptibility to age-related cognitive decline and neurodegeneration. That&#8217;s why we chose the brain data for detailed analysis.</p><p>To improve clarity, we have revised the text to describe the purpose of our analysis in brain rather than other tissues (Page 6-7). We appreciate the reviewer&#8217;s feedback, and we will consider additional analyses to further explore the sex-biased AS as well as disease risk in other tissues.</p><disp-quote content-type="editor-comment"><p>(6) The experimental data presented in Figures 5E - I merely demonstrate that estrogen receptor regulates the expression of two splicing factors, SRSF1 and SRSF7, in an estradiol-dependent manner. However, this finding does not support the notion that this regulation actually contributes to sex-dimorphic alternative splicing changes during human aging. Notably, the authors do not provide evidence that SRSF1 and SRSF7 expression changes actually occur in a sex-dependent manner with human aging (in a manner similar to TIA1). As such, this experimental dataset is disconnected from the main focus of the study and does not substantiate the conclusions on sex-dimorphic splicing during human aging. The authors performed RNAseq in wild-type and ER mutant cells, and they should perform a comprehensive analysis of ER-dependent alternative splicing and compare the results with the GTEx data. It should be straightforward.</p></disp-quote><p>Thanks for the reviewer&#8217;s feedback. The main purpose of the analyses in Figures 5E-I was to explore which factors affect the sex-biased expression of splicing factors during aging and substantially regulate alternative splicing (AS). To address the reviewer&#8217;s concerns, we have included additional analysis and explained the challenge of linking estrogen receptor (ER)-regulated splicing factors to sex-dimorphic AS changes during human aging in specific human cell types.</p><p>&#8226; As suggested by the reviewer, we first examined the expression changes of SRSF1 and SRSF7 during aging in males and females, like TIA1 in decision-related brain regions (Fig. 5I).</p><p>&#8226; Secondly, the regulation is based on a highly complex regulatory network involving multiple splicing factors and cell heterogeneity. Due to these complexities, we did not overlap ER-dependent AS changes with sBASEs from GTEx datasets directly. As far as the reviewer is concerned, we supplemented the AS analysis in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE89888">GSE89888</ext-link> dataset (Fig. 5H) and identified the estrogenregulated AS events mediated by ESR1. We found that ~6% (26/396) of female-specific ageassociated AS events were regulated by ESR1, of which 6 sBASEs can be regulated by femalebiased splicing factors. The low overlaps could be represented by the limited coverage of different RNA-seq datasets and cell types used across these analyses. Notably, the results indicated that only a fraction of AS could be directly accounted for by estrogen via ESR1, suggesting the complexity of transcriptional and splicing regulatory networks during aging.</p><p>&#8226; Meanwhile, we downloaded independent experimental datasets to discover the regulation by our candidate splicing factors. Due to SRSF1 is identified as a potential regulator of sex-biased splicing, we analyzed RNA-seq data with SRSF1 knock-down (KD) glioblastoma cell lines (U87MG and U251), a type of brain cancer formed from astrocytes that support nerve cells 4. As a result, we indeed found that some sBASEs are regulated by SRSF1 during aging through this experiment using brain cell lines (Author response image 4). Together, these results suggested that some of the SF-RNA regulatory relationships can be observed in another cellular system, further supporting our findings.</p><p>Due to the limitations of cell-based models and the complexity in the splicing regulatory network, it is challenging to directly validate aging regulation, particularly between different sexes, based on ER treatments in vivo. However, our findings still provide valuable mechanistic insights into ER-regulated splicing factors, implying their potential role in sex-biased aging.</p><fig position="float" id="sa3fig4" orientation="portrait"><label>Author response image 4.</label><caption><title>SRSF1 regulations on specific sBASEs using SRSF1 knock-down RNA-seq data in GBM cells.</title><p>Three examples are shown to be regulated during aging with significant changes between SRSF1 KD vs control in U251 and U87MG cell lines. The splicing diagrams are shown below.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="elife-102449-sa3-fig4.jpg"/></fig><disp-quote content-type="editor-comment"><p>
<bold>Recommendations for the authors:</bold>
</p><p>
<bold>Reviewer #1 (Recommendations for the authors):</bold>
</p><p>The authors found that alternative splicing was affected by both sex and age across many tissues, with gene expression differences affected by both parameters only present in some tissues. This trend was consistent when the effects of sex chromosomes were subtracted from the analysis. The effect of aging on differential gene expression and alternative splicing was more prevalent in male than female samples. For analysis purposes, young subjects were deemed to be anyone under 40, and old subjects were over 60 years old. The authors then investigated if specific genes or alternative splicing events were responsible for these effects. Some candidate genes or splicing events were identified but there was little overlap between tissues, suggesting no universal gene or event as a driver of aging. Surrogate variables like the ethnic backgrounds of donors were also investigated. Ultimately the authors found that alternative splicing events showed a stronger sexual dimorphic effect with age than did differential gene expression and that at least for the brain, alternative splicing changes showed a bias for Alzheimer's disease in male samples. This was highlighted by examples of exon skipping in SCL43A2 and FAM107A in males that were associated respectively with plaques and tangles.</p><p>The authors go on to identify sexual dimorphic differences in splicing factors in particular brain regions during age. Finally, the authors performed analysis for aging-modulated genes, identifying nearly 1000 across the tissues, nearly 70% of which are sex-specific. Their work suggests that further analysis of these aging-modulated genes could be differentially modulating the transcriptome based on sex. The work is novel and interesting, especially investigating sexual dimorphism in alternative splicing. However, the work is still preliminary, and these assumptions need to be applied to other data sets beyond GTEx for validation as well as some other phenomena that need to be considered. I recommend major revisions to address the points below.</p><p>(1) At the beginning of the results section, the authors state that the brain is stratified into four functional regions. It would be useful to explicitly state those four regions in the text at that point.</p></disp-quote><p>We agree that specifying these regions early in the text will improve clarity and provide the reader with a clear understanding of the analysis. As the reviewer&#8217;s suggestion, we revised the Results section (Page 3) to explicitly state the four functional brain regions as follows: &#8216;Due to data sparseness, the brain tissues were recombined into four functional regions (table S1), including hormone- or emotion-related region, movement-related region, memory-related region, and decision-related region (See Methods).&#8217;. This ensures that the regions are clearly defined before the subsequent analysis is presented.</p><disp-quote content-type="editor-comment"><p>(2) The manuscript becomes a bit confusing when the authors shift from all the tissues as a whole specifically to the brain and then back to the larger tissue set to make assumptions. This can be a bit confusing and should be better delineated.</p></disp-quote><p>We thank the reviewer and editor for the feedback regarding the transitions between the analysis of all tissues and the brain-specific analysis. In our study, we first conducted a broad analysis of alternative splicing (AS) and gene expression (GE) across all tissues. For the AS analyses, we did sBASEs analysis in all tissues and then focused on specific tissue (i.e., brain) whose splicing changes are functionally enriched with age-related diseases. For the GE analyses, we also analyzed the aging rate across tissues and identified the tissue-specific/shared patterns.</p><p>We agree that the shifts of the tissues for AS and GE may cause some confusion, and have made the following revisions to delineate why we focused on different tissues for distinct analyses:</p><p>&#8226; We have added clear statements to better delineate when we shift focus from the analysis of all tissues to the region-specific analysis and vice versa. For instance, in the Results section (Page 67), we include a transitional phrase: &#8216;Having established patterns across all tissues, we now turn to a more focused analysis to investigate tissue-specific alternative splicing changes.&#8217;</p><p>&#8226; To improve the overall structure, we have reorganized the Results section, adding distinct subheadings for the analysis of all tissues and the brain (Page 6), which should make the transition between these sections smoother and more intuitive for the reader.</p><p>We believe that these revisions will make the manuscript&#8217;s structure clearer and allow the reader to better follow the flow of the analysis and the subsequent conclusions.</p><disp-quote content-type="editor-comment"><p>(3) Gene-length-dependent transcription decline (GLTD) is another phenomenon that occurs with aging and is known to be associated with Alzheimer's disease [PMID38519330]. The authors should make some statement if this is present in their dataset and if any sexual dimorphism in tissues is present.</p></disp-quote><p>We thank the editors and reviewers for bringing up the possible connection of gene-length-dependent transcription decline (GLTD), which was reported to be associated with both aging and Alzheimer&#8217;s disease (AD). We appreciate the reviewer&#8217;s suggestion and have addressed whether GLTD is present in our dataset and whether any sex differences are observed in this context.</p><p>We evaluated GLTD using the correlation between gene length with age-associated changes (i.e., the coefficients of the &#8216;age&#8217; term in the linear regression model) in GTEx data. We did observe strong evidence of GLTD, particularly in the brain, heart, muscle, pancreas, spleen, skin, muscle, etc (Author response image 5A). In brain, we performed the functional enrichment analysis on the genes with Foldchange &gt; 2 and length &gt; 10<sup>5</sup> bp (Author response image 5B). We found that these extremely long genes are significantly relevant to synapse and neuron functions. These findings align with previous studies showing that GLTD can occur with aging in the tissues that are relevant to Alzheimer&#8217;s disease, cardiovascular diseases, and common failures of metabolism (e.g., diabetes) [5,6]. Additionally, it was not a ubiquitous phenomenon across all tissues. The correlations could be positive in tissues like adipose and artery. These findings suggested the GLTD could be varied and tissuespecific in its manifestation during aging.</p><fig position="float" id="sa3fig5" orientation="portrait"><label>Author response image 5.</label><caption><p>(A) The correlation between gene length and age-associated changes across GTEx tissues in human samples. The correlation tests are evaluated using Spearman&#8217;s approach. The color bar indicates the -log10 transformed p-values in the correlation test. (B) The results of GO enrichment analysis using the genes with Foldchange &gt; 2 and length &gt; 10<sup>5</sup> bp. The parent terms calculated by &#8216;rrvgo&#8217; with a similarity threshold of 0.9 are shown.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="elife-102449-sa3-fig5.jpg"/></fig><p>Regarding sexual dimorphism, we conducted this analysis in females and males, respectively (Author response image 6). We found GLTD exists in both females and males in most tissues, such as brain, whole blood, muscle, etc, consistent with the previous results without considering the sex groups. Interestingly, we observed sexbiased patterns in certain tissues. In particular, the left ventricle, pancreas, and hippocampus showed notable male-biased patterns in the degree of transcriptional decline with gene length, whereas skin, liver, small intestine, and esophagus showed that in females. These findings suggest that GLTD could be relevant to aging and age-related diseases; the levels of expression and sexual dimorphism may vary depending on the tissue type. We hope this clarification addresses the reviewer&#8217;s concern and provides a more comprehensive understanding of the GLTD and sex differences observed in our dataset.</p><fig position="float" id="sa3fig6" orientation="portrait"><label>Author response image 6.</label><caption><title>The correlation between gene length and age-associated changes across tissues in females and males, respectively.</title><p>The correlation tests are evaluated using the Spearman&#8217;s approach. The red dots indicate the significant correlations in females, while the navy dots show those in males.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="elife-102449-sa3-fig6.jpg"/></fig><disp-quote content-type="editor-comment"><p>(4) Because the majority of this work has been performed in the GTEx dataset, applying this analysis to another publicly available dataset would be useful validation. For instance, the authors have interesting findings in the brain and correlations to Alzheimer's disease. Analysis of an existing RNAseq dataset from Alzheimer's disease patients and controls (with functional outcomes) would provide more evidence beyond the preliminary findings from GTEx.</p></disp-quote><p>We appreciate the reviewer&#8217;s suggestion on the validation of our findings by applying our analysis to independent RNA-seq datasets from Alzheimer&#8217;s disease patients.</p><p>&#8226; We have used two Alzheimer&#8217;s disease datasets, GEO and ROSMAP, to investigate the correlation between aging and Alzheimer&#8217;s disease (AD) and included these analyses in our study (Fig. 4B-C and Figure S8C).</p><p>&#8226; In the Results section (Page 7), we have presented the results of this validation, where we identified correlations between sex-biased aging-related splicing changes and AD-related changes. These findings support the conclusions from the GTEx dataset and further strengthen the relevance of our results to AD.</p><p>As suggested, we have updated the manuscript to more explicitly highlight this validation in the Discussion section (Page 12), noting: &#8216;We further validated our findings using Alzheimer&#8217;s disease dataset, ROSMAP, where we observed consistent correlations between aging-related splicing changes and Alzheimer&#8217;s disease-related changes, providing additional evidence for the robustness of our results.&#8217;</p><disp-quote content-type="editor-comment"><p>
<bold>Reviewer #2 (Recommendations for the authors):</bold>
</p><p>(1) In the text (Introduction and Discussion), the authors mention analyzing 54 tissues, the abstract states 35 tissues, Table S1 lists 48, and Figure 2A-B shows 33. Could the authors please clarify exactly how many tissues they used? I am also confused by the sample numbers in Table S1. For example: for adiposesubcutaneous tissue, the total number of females is listed as 218 but the sum of young and old females is only 110. Does this mean some samples were excluded? What is the exclusion criterion?</p></disp-quote><p>We thank the reviewers and editors for pointing out the discrepancies regarding the number of tissues analyzed and the sample numbers in Table S1. We appreciate the opportunity to clarify these points:</p><p>Number of tissues analyzed:</p><p>&#8226; We downloaded and analyzed 17,382 samples in 54 tissues from GTEx in total (31 tissues and 13 brain regions), as mentioned in the Results, Methods, and Discussion sections. Table S1 lists 48 tissues (31 tissues, 13 brain regions, and 4 merged brain regions), which include a refined classification of the tissues we analyzed, accounting for the variations in brain region categorization in the dataset.</p><p>&#8226; The discrepancy also arises from the different sample size cutoffs in specific analyses. For pcSVR analysis (Figure 2A-B), we did the subsampling for the permutation analysis for certain key findings, so we filtered a subset of 33 tissues (29 tissues and 4 merged brain regions), which included at least 3 samples in each age group in females or males.</p><p>&#8226; To resolve this, we have clarified the total number of tissues analyzed and aligned the numbers across the manuscript. In the revised manuscript, we now explicitly state in both the Abstract and Methods sections that 54 tissues were analyzed in the context of this study. We added a note in Methods to clarify that 35 tissues are 31 tissues and 4 merged brain regions (Page 16). In Figure 2A-B, we clarified that the 33 tissues are filtered due to the usage in this analysis (Page 17).</p><p>Sample numbers in Table S1:</p><p>&#8226; Regarding the sample sizes of age groups, the discrepancy occurred due to the classification of the age groups. We classify the samples into three: Young, Middle, and Old, as mentioned in the Results section (Page 4).</p><p>&#8226; Additionally, we excluded the sample sizes in 13 single brain regions. We aligned the total tissue number to 35 with our texts.</p><p>We hope this resolves the confusion regarding the number of tissues and the sample sizes used in the analysis. These clarifications have been incorporated into the revised manuscript to ensure consistency.</p><disp-quote content-type="editor-comment"><p>(2) Was post-mortem interval (PMI) or manner of death considered in the model? For example, traumatic death may have major consequences on gene expression. Similarly, a few tissues have low sample numbers, for example, kidney cortex and brain. The pooling of brain samples is explained and the kidney cortex is excluded, so why is it listed in Table S1?</p></disp-quote><p>Thank you for raising this important point regarding the potential impact of post-mortem interval (PMI) and manner of death (DTHMNNR) on gene expression. We carefully considered both factors as potential confounders in our analysis.</p><p>Specifically, to evaluate their impacts, we calculated the correlations between the coefficients of PMI or manner of death, with the confounding factors. Our results showed that PMI and DTHMNNR are significantly correlated with the covariates in most tissues, suggesting that their effects could be effectively regressed in our model (Figure S4). As we have mentioned in Figure S4 and Author response image 1, we conducted a differential analysis that incorporated PMI as a covariate in the regression models and re-evaluated the age- and sex-related transcriptomic changes to address this concern. The high correlations showed the minor effect size of PMI when including the covariates in the model. As suggested by the reviewers and editors, we have now included this correlation analysis in Figure S4C-E and updated the text in the results section (Page 5).</p><p>Additionally, as the responses above, Table S1 provides the general sample sizes of all GTEx tissues without filtering. We have modified the table to include a total of 35 tissues, including 31 non-brain tissues and 4 brain regions.</p><disp-quote content-type="editor-comment"><p>(3) It might be important to show a simple visual of cohort details such as age ranges, sexes, ethnicities, PMIs, etc.</p></disp-quote><p>To address this, we added summary figures to illustrate the distributions of key demographic variables, including age, sex, BMI, ethnicity, post-mortem intervals (PMIs), and manner of death (DTHMNNR) (Author response image 7 and Author response image 8). This will provide readers with a clearer overview of the dataset composition and potential covariates affecting the analysis.</p><fig position="float" id="sa3fig7" orientation="portrait"><label>Author response image 7.</label><caption><title>Age (left panel), BMI (Body Mass Index) (middle panel), and PMI (Post-Mortem Interval) (right panel) distribution in GTEx v8 cohort.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="elife-102449-sa3-fig7.jpg"/></fig><fig position="float" id="sa3fig8" orientation="portrait"><label>Author response image 8.</label><caption><title>Sex (left panel), ethnicity (middle panel), and manner of death (DTHMNNR) (right panel) distribution in GTEx v8 cohort.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="elife-102449-sa3-fig8.jpg"/></fig><disp-quote content-type="editor-comment"><p>(4) Since this study is highly correlative, it is impossible to determine if the findings hold true without an independent cohort validation or experimental validation. They used the ROSMAP cohort for AD samples, and some splicing factors regulation but the generalizability to the age and sex effects have not been independently tested.</p></disp-quote><p>The reviewer raises an important point regarding the independent validation of sex- and age-associated splicing changes associated with AD. We used GTEx primarily because it includes approximately 17,000 RNA-seq samples across multiple human tissues, making it the most comprehensive public resource for studying population-level differences in age and sex. In particular, its large-scale brain samples provide a unique opportunity to analyze transcriptomic changes in sex-dimorphic aging.</p><p>We understand the reviewer&#8217;s concern that our findings are mainly supported by correlative evidence, which could be affected by dataset-specific biases. However, there are several technical issues in crossvalidation with transcriptomes across different datasets, including limited comparability due to cell type heterogeneity, postmortem artifacts, and sequencing biases.</p><p>Specifically, GTEx data is bulk RNA-seq that does not capture cell-type-specific transcriptomic changes. Given the cellular complexity of the brain and other tissues, observed differences in gene expression and splicing may be influenced by shifts in cellular composition rather than intrinsic transcriptional regulation. For example, we compared our results from GTEx whole blood with the analysis using an external dataset from Peripheral Blood Mononuclear Cells (PBMCs) provided by Shen et al. (2024) [3] (Author response image 2). We observed limited overlap in differentially expressed genes between these datasets (probably because the whole blood contains diverse immune cell populations), highlighting the challenges in cross-dataset validation due to differences in tissue composition and sample processing.</p><p>Therefore, we applied surrogate variable analysis (SVA) to minimize technical and biological confounders. This approach helped reduce biases from genetic background to hidden batch effects, including postmortem artifacts, sequencing biases (Figure S4), and other covariates. This approach could help us identify whether sex-biased splicing events are biologically meaningful rather than technical artifacts.</p><p>In addition, to address the reviewer&#8217;s concern on the splicing factor regulation, we managed to find a dataset in decision-related brain regions. Due to the limitation of human brain data covering different age and sex groups, we used mouse hippocampus datasets, including young and old, as well as female and male groups [7]. The analysis of protein levels from MS data identified sex-biased age-associated splicing factors, including Srsf1 and Srsf7. We found that the changes are consistent with the findings from GTEx (Author response image 9), aligning with our sex-biased splicing factor expression during aging in the same region of the human brain. This cross-species consistency supports the robustness of our findings in human brain aging.</p><fig position="float" id="sa3fig9" orientation="portrait"><label>Author response image 9.</label><caption><title>Protein levels of some male-specific splicing factors in human hippocampus quantified using MS data.</title><p>The Y-axis shows the protein intensity. Different facets mean different sample batch sets. The yellow boxes indicate the protein levels in the young group, while the brown boxes indicate those in the old group.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="elife-102449-sa3-fig9.jpg"/></fig><p>In summary, despite the inherent limitations of RNA-seq studies in sex- and age-related transcriptomics, we have made our best efforts to address these concerns through comparisons with external datasets, statistical corrections, and validation using proteomic data. We appreciate the reviewer&#8217;s feedback and include additional discussion on these points (Page 13).</p><disp-quote content-type="editor-comment"><p>(5) Are AS predictions from short-read data accurate enough to make the predictions the authors report?</p></disp-quote><p>The reviewer is correct that the short-read sequencing has inherent limitations in reconstructing full-length isoforms. However, the higher sequencing depth for short reads makes it a better choice in quantifying the relative change of each AS event across different conditions. As a result, short-read data are extensively used in the splicing field to quantitatively measure the AS changes. For this reason, we focused on the levels of alternative splicing events, rather than the quantification of full-length isoforms. We used a series of stringent filters in our analyses to increase the reliability of our results.</p><p>Specifically, we filtered the read counts of the junction read counts (JC) of most differential AS events that were higher than 10, as mentioned in the Methods section. Also, we used our GPU-based gene expression quantification tool, Paean, which performed better in cross-validation with quantitative RT-PCR results. The results of Paean are consistent with other pipelines. We cited an updated version of Paean that included the comparison with other tools in analyzing AS for consistency. The manuscript on the new Paean version is being reviewed in another journal, and we included the PDF of that manuscript (Fig. 3 in the Paean manuscript) in the revised documents.</p><disp-quote content-type="editor-comment"><p>(6) Along the same lines, the finding that male age-related AS events are linked to Alzheimer's disease somewhat contradicts epidemiological studies that show that even after adjusting for age, women still have a greater risk of developing Alzheimer's than men. The authors show a significant overlap with AD GE events in females but don't explain the discrepancy.</p></disp-quote><p>We appreciate the editor&#8217;s comment regarding these discrepancies with the epidemiological studies. Previous studies suggested that the disease manifestations of Alzheimer&#8217;s Disease (AD) showed sex differences in AD phenotypes, including cognitive decline and brain atrophy [8]. The analyses on the sex/age effect of AD are indeed pretty complex, depending on the molecular criteria (GE or AS vs epidemiological data) in distinct studies, probably due to the difficulty in capturing how environmental exposures interact with biological pathways. We hope to bring up three related points regarding this concern, which were also discussed in the revised manuscript.</p><p>&#8226; As we have mentioned in the Discussion section, an early study investigated the relationship between age, sex, and cognitive function in a large cohort of 17,127 UK Biobank participants [9]. Their study highlighted more apparent age-related changes in cognitive function among men, suggesting a potential vulnerability of men to cognitive decline with age. Their main conclusion is consistent with our findings.</p><p>&#8226; While men and women can both suffer from Alzheimer's disease, women are more likely to be diagnosed, possibly due to longer lifespans and potential differences in brain structure or other factors. Although women exhibit a higher overall risk of AD, they may also have distinct molecular compensatory mechanisms that influence disease progression.</p><p>&#8226; To avoid the age effect, in our AD datasets, including ROSMAP, we filtered the samples over 90 years old to match the number of both sexes and the age distribution between the AD and control groups. Our analysis avoided the age biases in comparing AD and control, suggesting the crucial roles of sBASEs in AD during male aging.</p><p>Moreover, for gene expression (GE), we showed distinct patterns of AD-related genes in females with AS. These two molecular processes do not necessarily have the same functional impact. AS changes may precede or contribute to disease onset in different ways compared to GE alterations. Our study came up with the underlying mechanisms linking cognitive disorders and alternative splicing (AS) at a higher molecular resolution.</p><disp-quote content-type="editor-comment"><p>(7) Could the authors explain which sBASE subset they used for their random forest prediction model and what was the rationale?</p></disp-quote><p>We are sorry for missing the details in selecting sBASEs (sex-biased age-associated splicing events) for the random forest prediction model. We specifically used sBASEs that exhibited specific sex-biased changes in splicing associated with aging. This subset of sBASEs was chosen in terms of those that could also be detected in the ROSMAP AD dataset due to different sequencing depths or technical biases across datasets. These sBASEs were further input to a prediction model with the feature selection algorithm RFE, and then evaluated their contributions. In the revised manuscript, we added the details of this selection in the Methods (Page 7).</p><disp-quote content-type="editor-comment"><p>(8) The breakpoint analysis is particularly interesting. Can this be speculated to correlate with the recent non-linear multi-omic aging patterns observed by Shen et al in Nature Aging?</p></disp-quote><p>Thank you for highlighting the interesting aspects of our breakpoint analysis and suggesting its potential correlation with the non-linear aging patterns observed by Shen et al.</p><p>Shen et al. observed two prominent crests around the ages of 45 and 60 using omics data. Similarly, we also identified the non-linear aging patterns with two breakpoints in our analysis. However, there are some notable differences in specific breakpoints between these two studies, resulting from the breakpoint definition, as well as the sample preparations. According to the response in Author response image 2, the differences come from the following aspects:</p><p>The definition of breakpoints vs crests:</p><p>&#8226; Crests represent age-related molecular changes at each time point across the human lifespan. They indicate the number of molecules that are differentially expressed during aging (q &lt; 0.05), without considering individual expression levels.</p><p>&#8226; Our breakpoints, in contrast, are identified after filtering the chronological trends based on the expression levels and calculating the rate of change at each age point using sliding windows. Breakpoints are defined as local maxima where the distance to the nearest minimum, relative to the global maximum, exceeds 10%. We indeed found some local wide peaks around 60 in some tissues, shown in Figure S10, however, we excluded these due to our strict cutoffs.</p><p>The sequenced biosamples:</p><p>&#8226; Whole-blood vs Peripheral Blood Mononuclear Cells (PBMC): As mentioned in previous responses, in GTEx, whole blood samples from donors were sequenced, whereas their study used PBMCs. Whole blood contains all blood components, including red blood cells, platelets, granulocytes (e.g., neutrophils), lymphocytes, and monocytes, while PBMCs only represent a subset of white blood cells, primarily consisting of lymphocytes (T cells, B cells, NK cells) and monocytes, excluding granulocytes and erythrocytes. Gene expression changes observed in whole blood capture the contributions from neutrophils and other granulocytes, which are absent in PBMC analyses (as shown in Figure S11C and Author response image 2). Additionally, whole blood can serve as a readily accessible biomarker source for testing age-related diseases without the need for cell separation, making it a more practical option for clinical applications.</p><p>&#8226; For both studies, we share a tissue, which is skin, we looked at the non-linear changes during aging and found the same two breakpoints: 43 and 58.</p><p>Sex-specific analysis in females and males:</p><p>&#8226; The main object of our analysis is to compare the differences in aging rates between sexes. Notably, the identified breakpoints may differ when sex effects are not taken into account, highlighting the importance of analyzing males and females separately.</p><p>We have added the following statements to further clarify this connection: &#8216;Our analysis observed the nonlinear aging patterns with two breakpoints, which is consistent with recent findings (Nature Aging, 2024), with differences in specific age points due to the sex differences as well as tissue diversities.&#8217; (Page 14), and &#8216;These breakpoints could represent key junctures in the aging process that align with the non-linear patterns of aging and disease progression.&#8217; (Page 15)</p><disp-quote content-type="editor-comment"><p>(9) Minor - the authors should refer to figures in the Discussion. They do so in some cases but this needs to be more extensive.</p></disp-quote><p>Thank you for pointing this out. In response, we have reviewed the Discussion section and added references to relevant figures where appropriate. In the section discussing the discrepancies between the profiles of GE vs. AS, we now refer to Figure 3 to highlight the earlier onset of different transcriptomic resolutions (Page 12); When describing the sex-specific age-associated AS changes and their associations with Alzheimer&#8217;s disease, we have added references to Figure 4 (Page 12); In the discussion of estrogen-mediated regulation of splicing factors, we have referred to Figure 5A, which detail the construction of RBP-RNA regulatory network integrating muti-dimensional data obtained through several orthogonal state-of-the-art approaches (Page 14).</p><p>Reference:</p><p>(1) Ferreira, P.G. et al. The effects of death and post-mortem cold ischemia on human tissue transcriptomes. Nature communications 9, 490 (2018).</p><p>(2) Wucher, V., Sodaei, R., Amador, R., Irimia, M. &amp; Guig&#243;, R. Day-night and seasonal variation of human gene expression across tissues. PLoS Biology 21, e3001986 (2023).</p><p>(3) Shen, X. et al. Nonlinear dynamics of multi-omics profiles during human aging. Nature aging, 116 (2024).</p><p>(4) Zhou, X. et al. Splicing factor SRSF1 promotes gliomagenesis via oncogenic splice-switching of MYO1B. The Journal of clinical investigation 129, 676-693 (2019).</p><p>(5) Soheili-Nezhad, S., Ib&#225;&#241;ez-Sol&#233;, O., Izeta, A., Hoeijmakers, J.H. &amp; Stoeger, T. Time is ticking faster for long genes in aging. Trends in Genetics 40, 299-312 (2024).</p><p>(6) Brouillette, M. Gene length could be a critical factor in the aging of the genome. Proceedings of the National Academy of Sciences 121, e2416630121 (2024).</p><p>(7) Keele, G.R. et al. Global and tissue-specific aging effects on murine proteomes. Cell reports 42(2023).</p><p>(8) Ferretti, M.T. et al. Sex differences in Alzheimer disease&#8212;the gateway to precision medicine. Nature Reviews Neurology 14, 457-469 (2018).</p><p>(9) Foo, H. et al. Age-and sex-related topological organization of human brain functional networks and their relationship to cognition. Frontiers in aging neuroscience 13, 758817 (2021).</p></body></sub-article></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="alz70592" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Dement</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Dement</journal-id><journal-id journal-id-type="pmc-domain-id">4549</journal-id><journal-id journal-id-type="pmc-domain">alzdem</journal-id><journal-id journal-id-type="publisher-id">ALZ</journal-id><journal-title-group><journal-title>Alzheimer's &amp; Dementia</journal-title></journal-title-group><issn pub-type="ppub">1552-5260</issn><issn pub-type="epub">1552-5279</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12497512</article-id><article-id pub-id-type="pmcid-ver">PMC12497512.1</article-id><article-id pub-id-type="pmcaid">12497512</article-id><article-id pub-id-type="pmcaiid">12497512</article-id><article-id pub-id-type="pmid">41047467</article-id><article-id pub-id-type="doi">10.1002/alz.70592</article-id><article-id pub-id-type="publisher-id">ALZ70592</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Decoding amyloid beta clearance systems at inner blood&#8211;retina barrier using three&#8208;dimensional ex vivo retinal imaging in Alzheimer's disease</article-title><alt-title alt-title-type="left-running-head">WIJESINGHE <sc>et&#160;al.</sc></alt-title></title-group><contrib-group><contrib id="alz70592-cr-0001" contrib-type="author"><name name-style="western"><surname>Wijesinghe</surname><given-names initials="P">Printha</given-names></name><xref rid="alz70592-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70592-cr-0002" contrib-type="author"><name name-style="western"><surname>Hosseini</surname><given-names initials="A">Amir</given-names></name><xref rid="alz70592-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70592-cr-0003" contrib-type="author"><name name-style="western"><surname>Campbell</surname><given-names initials="M">Matthew</given-names></name><xref rid="alz70592-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70592-cr-0004" contrib-type="author"><name name-style="western"><surname>Tejpal</surname><given-names initials="S">Shivani</given-names></name><xref rid="alz70592-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70592-cr-0005" contrib-type="author"><name name-style="western"><surname>Haynes</surname><given-names initials="J">Justin</given-names></name><xref rid="alz70592-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="alz70592-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="alz70592-cr-0006" contrib-type="author"><name name-style="western"><surname>Xi</surname><given-names initials="J">Jeanne</given-names></name><xref rid="alz70592-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70592-cr-0007" contrib-type="author"><name name-style="western"><surname>Mackenzie</surname><given-names initials="IR">Ian R.</given-names></name><xref rid="alz70592-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="alz70592-cr-0008" contrib-type="author"><name name-style="western"><surname>Hirsch&#8208;Reinshagen</surname><given-names initials="V">Veronica</given-names></name><xref rid="alz70592-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="alz70592-cr-0009" contrib-type="author"><name name-style="western"><surname>Hsiung</surname><given-names initials="GYR">Ging&#8208;Yuek Robin</given-names></name><xref rid="alz70592-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="alz70592-cr-0010" contrib-type="author"><name name-style="western"><surname>Spiller</surname><given-names initials="BW">Benjamin W.</given-names></name><xref rid="alz70592-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="alz70592-cr-0011" contrib-type="author"><name name-style="western"><surname>Wadzinski</surname><given-names initials="BE">Brian E.</given-names></name><xref rid="alz70592-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="alz70592-cr-0012" contrib-type="author"><name name-style="western"><surname>Pham</surname><given-names initials="W">Wellington</given-names></name><xref rid="alz70592-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="alz70592-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="alz70592-cr-0013" contrib-type="author" corresp="yes"><name name-style="western"><surname>Matsubara</surname><given-names initials="JA">Joanne A.</given-names></name><xref rid="alz70592-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70592-aff-0007" ref-type="aff">
<sup>7</sup>
</xref><address><email>jms@mail.ubc.ca</email></address></contrib></contrib-group><aff id="alz70592-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Ophthalmology &amp; Visual Sciences</named-content>
<named-content content-type="organisation-division">Faculty of Medicine</named-content>
<institution>The University of British Columbia, Eye Care Centre</institution>
<city>Vancouver</city>
<named-content content-type="country-part">BC</named-content>
<country country="CA">Canada</country>
</aff><aff id="alz70592-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Radiology and Radiological Sciences</named-content>
<institution>Vanderbilt University Medical Center</institution>
<city>Nashville</city>
<named-content content-type="country-part">Tennessee</named-content>
<country country="US">USA</country>
</aff><aff id="alz70592-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Vanderbilt University Institute of Imaging Science</named-content>
<institution>Vanderbilt University Medical Center</institution>
<city>Nashville</city>
<named-content content-type="country-part">Tennessee</named-content>
<country country="US">USA</country>
</aff><aff id="alz70592-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology and Laboratory Medicine, Faculty of Medicine</named-content>
<institution>The University of British Columbia</institution>
<city>Vancouver</city>
<named-content content-type="country-part">BC</named-content>
<country country="CA">Canada</country>
</aff><aff id="alz70592-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Division of Neurology, Faculty of Medicine</named-content>
<institution>The University of British Columbia</institution>
<city>Vancouver</city>
<named-content content-type="country-part">BC</named-content>
<country country="CA">Canada</country>
</aff><aff id="alz70592-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Department of Pharmacology</named-content>
<institution>Vanderbilt University</institution>
<city>Nashville</city>
<named-content content-type="country-part">Tennessee</named-content>
<country country="US">USA</country>
</aff><aff id="alz70592-aff-0007">
<label>
<sup>7</sup>
</label>
<named-content content-type="organisation-division">Djavad Mowafaghian Centre for Brain Health</named-content>
<institution>The University of British Columbia</institution>
<city>Vancouver</city>
<named-content content-type="country-part">BC</named-content>
<country country="CA">Canada</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>Joanne A. Matsubara, Department of Ophthalmology &amp; Visual Sciences, Eye Care Centre, 2550 Willow Street, Vancouver,&#160;BC,&#160;V5Z 3N9, Canada.<break/> Email: <email>jms@mail.ubc.ca</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>05</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><volume>21</volume><issue seq="1040">9</issue><issue-id pub-id-type="pmc-issue-id">495846</issue-id><issue-id pub-id-type="doi">10.1002/alz.v21.9</issue-id><elocation-id>e70592</elocation-id><history><date date-type="rev-recd"><day>24</day><month>6</month><year>2025</year></date><date date-type="received"><day>12</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>26</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>05</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>07</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-07 04:25:35.700"><day>07</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Alzheimer's &amp; Dementia</italic> published by Wiley Periodicals LLC on behalf of Alzheimer's Association.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ALZ-21-e70592.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:ALZ-21-e70592.pdf"/><abstract><title>Abstract</title><sec id="alz70592-sec-0010"><title>INTRODUCTION</title><p>Impaired amyloid beta (A&#946;) clearance contributes to sporadic Alzheimer's disease (AD). This study investigated retinal A&#946; clearance involving neuronal, glial, and vascular interactions at the inner blood&#8211;retina barrier (iBRB), a functional analog of the blood&#8211;brain barrier (BBB).</p></sec><sec id="alz70592-sec-0020"><title>METHODS</title><p>Retinal wholemounts from AD donors and controls were analyzed alongside transgenic amyloid precursor protein/presenilin 1 (APP&#8208;PS1) and non&#8208;carrier control mouse retinal cross&#8208;sections using three&#8208; and two&#8208;dimensional ex vivo imaging.</p></sec><sec id="alz70592-sec-0030"><title>RESULTS</title><p>AD neuroretinas displayed increased larger A&#946;42 deposits, microglial elongation, and substantial reductions in macroglial support and water channel expression. The uptake of soluble A&#946; oligomers (SA&#946;Os) by peripheral macrophage&#8208;like, A&#946;&#8208;binding myeloid lineage cells was also diminished. In APP&#8208;PS1 mice, elevated glia levels, alongside increased APP/A&#946; expression, suggest gliosis and failures in clearance processes with disease progression.</p></sec><sec id="alz70592-sec-0040"><title>DISCUSSION</title><p>Ex vivo three&#8208;dimensional retinal imaging at the iBRB provides novel insights into A&#946; clearance in AD, which is difficult to replicate in ex vivo brain studies at the BBB.</p></sec><sec id="alz70592-sec-0050"><title>Highlights</title><p>
<list list-type="bullet" id="alz70592-list-0001"><list-item><p>Impaired clearance mechanisms play a key role in sporadic AD.</p></list-item><list-item><p>The iBRB serves as a functional analog to the BBB.</p></list-item><list-item><p>At the iBRB, the glymphatic system and microglial phagocytosis help mitigate A&#946; burden.</p></list-item><list-item><p>Peripheral macrophage&#8208;like myeloid lineage cells may aid SA&#946;O clearance.</p></list-item><list-item><p>The imaging plane (surface vs cross&#8208;section) may affect AD pathogenesis findings.</p></list-item></list>
</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="alz70592-kwd-0001">Alzheimer's retina</kwd><kwd id="alz70592-kwd-0002">glymphatic structures</kwd><kwd id="alz70592-kwd-0003">inner blood&#8211;retina barrier</kwd><kwd id="alz70592-kwd-0004">microglia</kwd><kwd id="alz70592-kwd-0005">soluble A&#946; oligomer</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Alzheimer Society of Canada and Brain Canada</institution></institution-wrap></funding-source></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>Canadian Institute of Health Research</institution></institution-wrap></funding-source></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>National Sciences and Engineering Research Council of Canada</institution></institution-wrap></funding-source></award-group><award-group id="funding-0004"><funding-source><institution-wrap><institution>National Institutes of Health</institution><institution-id institution-id-type="doi">10.13039/100000002</institution-id></institution-wrap></funding-source><award-id>NIA R01 AG061138</award-id></award-group><award-group id="funding-0005"><funding-source><institution-wrap><institution>Vanderbilt CTSA Grant</institution></institution-wrap></funding-source><award-id>UL1TR002243</award-id></award-group><award-group id="funding-0006"><funding-source><institution-wrap><institution>NCATS/NIH</institution></institution-wrap></funding-source></award-group><award-group id="funding-0007"><funding-source><institution-wrap><institution>Vanderbilt&#8208;Ingram Cancer Center Shared Resource Scholarship</institution></institution-wrap></funding-source></award-group></funding-group><counts><fig-count count="8"/><table-count count="0"/><page-count count="24"/><word-count count="14867"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>September 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:05.10.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="alz70592-cite-0001"><string-name name-style="western"><surname>Wijesinghe</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Hosseini</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Campbell</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Decoding amyloid beta clearance systems at inner blood&#8211;retina barrier using three&#8208;dimensional ex vivo retinal imaging in Alzheimer's disease</article-title>. <source>Alzheimer's Dement</source>. <year>2025</year>;<volume>21</volume>:<elocation-id>e70592</elocation-id>. <pub-id pub-id-type="doi">10.1002/alz.70592</pub-id><pub-id pub-id-type="pmid">41047467</pub-id></mixed-citation>
</p></notes></front><body><sec id="alz70592-sec-0060"><label>1</label><title>BACKGROUND</title><p>Amyloid beta (A&#946;) is produced through the sequential cleavage of amyloid precursor protein (APP) by &#946;&#8208; and &#947;&#8208;secretases, primarily in neurons, followed by brain endothelial cells and astrocytes.<xref rid="alz70592-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="alz70592-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="alz70592-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> A&#946; peptides vary in length, with A&#946;1&#8208;40 and A&#946;1&#8208;42 being the most common isoforms found in senile plaques.<xref rid="alz70592-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="alz70592-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> A&#946;1&#8208;40, which is soluble and less toxic, constitutes about 90% of A&#946; in healthy brains, while A&#946;1&#8208;42, comprising less than 10%, is highly neurotoxic and predominant in Alzheimer's disease (AD) brains.<xref rid="alz70592-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="alz70592-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> In AD brains, A&#946; exists in various forms, including monomers, oligomers, and fibrils. Numerous studies have demonstrated that soluble A&#946; oligomers (SA&#946;Os) are the primary agents responsible for synaptic dysfunction and neurodegeneration in AD.<xref rid="alz70592-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="alz70592-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="alz70592-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="alz70592-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> Furthermore, recent research suggests that SA&#946;Os accumulate early in the disease and impair memory prior to plaque formation and that reducing their levels may reverse cognitive deficits. These findings identify SA&#946;Os as one of the earliest pathogenic factors in AD.<xref rid="alz70592-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="alz70592-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="alz70592-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>
</p><p>It has been suggested that even minor impairments in A&#946; clearance from the brain can lead to its accumulation, as effective clearance is crucial for maintaining A&#946; homeostasis and preventing the toxic buildup of misfolded assemblies resulting from ongoing APP processing and A&#946; generation.<xref rid="alz70592-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> Similar to other brain metabolites, A&#946; turnover partly relies on bulk flow through cerebrospinal fluid, crossing the BBB, perivascular circulation, and the glia&#8211;lymphatic (glymphatic) system.<xref rid="alz70592-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="alz70592-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> Approximately 40% to 60% of A&#946; produced in the brain diffuses into the bloodstream and is cleared through the peripheral system.<xref rid="alz70592-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="alz70592-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="alz70592-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> A&#946; transport across the BBB is regulated by various transporters, whose expression is altered in AD. The low&#8208;density lipoprotein receptor&#8208;related protein 1 (LRP1), present in the endothelial cells and pericytes of the BBB, plays a key role in removing A&#946; from the brain into the peripheral circulation.<xref rid="alz70592-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="alz70592-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="alz70592-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> Conversely, A&#946; can enter the brain from the periphery via receptors like the receptor for advanced glycation end products (RAGE), which facilitate its transport across the BBB.<xref rid="alz70592-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="alz70592-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="alz70592-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> Additionally, innate immune cells are vital for defending the brain against toxic molecules such as A&#946;, though their mechanisms appear inadequate in AD.<xref rid="alz70592-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> Circulating and infiltrating monocytes, which help clear A&#946; deposits, are effective in the vascular system and parenchyma, respectively. Recent studies on AD and mild cognitive impairment (MCI) patients highlight that macrophage&#8208;like A&#946;&#8208;binding monocytes with high phagocytic potential, both in the periphery and central nervous system (CNS), play a significant role in A&#946; clearance.<xref rid="alz70592-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="alz70592-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="alz70592-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> Microglia, the brain's resident immune cells, help maintain homeostasis and eliminate neurotoxic elements, but their efficiency in clearing A&#946; declines with age.</p><p>The retina, an extension of the CNS, shares embryological origins and vasculature with the brain, utilizing similar molecules, growth factors, neurotransmitters, and cellular structures.<xref rid="alz70592-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="alz70592-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> In both the retina and the brain, glial cells support neurons in a mutually beneficial relationship.<xref rid="alz70592-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> Several retinal biomarkers for AD have been identified. For example, retinal thinning of the nerve fiber layer (NFL), which involves the axons of retinal ganglion cells, astrocytes, and M&#252;ller cells, has been consistently observed in AD patients using optical coherence tomography.<xref rid="alz70592-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="alz70592-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> This NFL thinning correlates with disease severity and cognitive decline and can even be detected before cognitive symptoms manifest.<xref rid="alz70592-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>, <xref rid="alz70592-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> Moreover, retinal A&#946; plaques have been found in both AD patients and animal models, suggesting their potential use for differential diagnosis.<xref rid="alz70592-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>, <xref rid="alz70592-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>, <xref rid="alz70592-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>, <xref rid="alz70592-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>, <xref rid="alz70592-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> Retinal vascular changes, such as reduced vessel density, decreased perfusion, and increased vascular A&#946; deposition, have also been noted in AD, potentially reflecting underlying cerebrovascular pathology and impaired A&#946; clearance.<xref rid="alz70592-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>, <xref rid="alz70592-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref>
</p><p>This study aimed to investigate impaired A&#946; clearance systems involved in the pathogenesis of sporadic AD by examining the interactions among neuronal cells, glial cells, and retinal vasculature, particularly at the iBRB, using wholemount neuroretinas and three&#8208;dimensional (3D) ex vivo imaging. These interactions cannot be effectively studied in brain tissues ex vivo, particularly at the BBB, because of the complex structure.</p></sec><sec id="alz70592-sec-0070"><label>2</label><title>METHODS</title><sec id="alz70592-sec-0080"><label>2.1</label><title>Human donors</title><p>This study was approved by the Clinical Ethics Research Board of the University of British Columbia (H20&#8208;02944) and strictly adhered to the Declaration of Helsinki and its later amendments or comparable ethical standards. Ten donor eyes from individuals diagnosed with AD were obtained from the Department of Pathology at Vancouver General Hospital, British Columbia, Canada. The severity of AD was confirmed neuropathologically at <italic toggle="yes">post mortem</italic> according to the National Institute on Aging&#8208;Alzheimer's Association (NIA&#8208;AA, 2012) criteria.<xref rid="alz70592-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> Ten age&#8208;matched donor eyes, provided for research purposes by the Eye Bank of British Columbia, were used as controls. Additionally, two donor eyes from male individuals under the age of 60 were included to assess age&#8208;related structural or morphological alterations.</p><sec id="alz70592-sec-0090"><label>2.1.1</label><title>Neuroretina dissection</title><p>The posterior eyecup was prepared by careful dissection, with the cornea, lens, and iris being removed. The eyecup was then divided into four major quadrants (superior, temporal, inferior, and nasal) (Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S1A</xref>), allowing most of the liquefied vitreous humor to drain. Each quadrant was further divided into three pie&#8208;shaped sections, and the neuroretina was separated from the retinal pigment epithelium (RPE) and choroid. Any vitreous remnants were carefully removed using forceps. Next, 3.5&#8208;mm&#8208;diameter punches were taken from the mid&#8208;peripheral and peripheral regions of the neuroretina, specifically from the temporal and superior quadrants, under a dissection microscope, ensuring no mechanical damage or tissue loss. The neuroretina punches were then washed in phosphate&#8208;buffered saline (1&#215; PBS, pH 7.2&#8211;7.4) before undergoing double or triple fluorescence staining.</p></sec><sec id="alz70592-sec-0100"><label>2.1.2</label><title>Localization of selected protein markers in human neuroretina wholemounts</title><p>The primary antibodies used in various combinations included 12F4, specific to the 1&#8208;42 amino acid residues of A&#946; species; macroglial markers such as glial fibrillary acidic protein (GFAP), a type III intermediate filament protein characteristic of differentiated and mature astrocytes, and glutamine synthetase (GS), an enzyme expressed predominantly in M&#252;ller glia; aquaporin 4 (AQP4), a major CNS water channel; microglia/macrophage markers such as ionized calcium&#8208;binding adapter molecule 1 (IBA1) and cluster of differentiation 68 (CD68); and the vascular endothelium marker <italic toggle="yes">Ulex europaeus</italic> agglutinin (UEA&#8208;l). For the validation&#160;&#8211; such as distinguishing blood&#8208;derived monocytes/macrophages from resident tissue microglia/macrophages&#160;&#8211; CD45 was used in combination with IBA1 and UEA&#8208;l markers. To assess lysosomal activity, lysosomal&#8208;associated membrane protein 1 (LAMP1) was used together with IBA1 and UEA&#8208;l. As validations were based on a small sample size (<italic toggle="yes">N</italic>&#160;=&#160;1 or 2 per group) from the same cohort, only qualitative assessments were performed. Table&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S1</xref> summarizes the primary and secondary antibodies and their dilutions used for double and triple immunofluorescence staining. Negative control tissues were processed alongside experimental tissues, with primary antibodies omitted during treatment. All other reagents, including blocking solutions and secondary antibodies, were applied identically to ensure consistency.</p><boxed-text position="float" content-type="box" orientation="portrait"><sec id="alz70592-sec-0110"><title>RESEARCH IN CONTEXT</title><p>
<list list-type="order" id="alz70592-list-0002"><list-item><p>
<bold>Systematic review</bold>: The authors conducted a literature search in PubMed and Web of Science. No studies have examined clearance impairments leading to pathological protein buildup at the iBRB&#160;&#8211; a functional analog of the BBB&#160;&#8211; in transgenic models or <italic toggle="yes">post mortem</italic> human retinas.</p></list-item><list-item><p>
<bold>Interpretation</bold>: Wholemount neuroretina analyses suggested that the glymphatic system and microglia/macrophage phagocytosis serve as compensatory mechanisms for mitigating A&#946; accumulation at the iBRB. Peripheral macrophage&#8208;like myeloid lineage cells appeared to uptake SA&#946;Os within the retinal vasculature. These mechanisms were largely disrupted in AD donors.</p></list-item><list-item><p>
<bold>Future directions</bold>: Researchers should consider the plane of view, as demonstrated in wholemount neuroretinas and retinal cross&#8208;sections, in the context of AD pathogenesis. Ex vivo 3D retinal imaging offers novel insights into retinal and BBB&#8208;analog processes in AD. Future studies should include a larger sample size of both sexes and a diverse group of donors to explore the translational potential for diagnostic applications.</p></list-item></list>
</p></sec></boxed-text><p>Neuroretinas were carefully placed in 24&#8208;well plates containing 1&#215; PBS and rinsed three times for 5 min each with gentle shaking. To detect A&#946;, an 88% formic acid pretreatment was applied, followed by a 5&#8208;min incubation at room temperature (RT). The samples were then rinsed three more times in 1&#215; PBS (5 min each, with gentle shaking). Antigen retrieval was performed using one of two methods: either a 10&#8208;min treatment with 0.05% proteinase K in Tris&#8208;EDTA buffer (pH 8.0) at RT or heat&#8208;induced retrieval in preheated citrate buffer (pH 6.0) for 4 min, followed by an additional 10 min at power level 800. Afterward, the samples underwent three additional 5&#8208;min washes in 1&#215; PBS with gentle shaking. Blocking was carried out by incubating the samples in blocking buffer (3% to 5% normal goat serum [NGS] in 0.3% Triton X&#8208;100 in 1&#215; PBS) for 20 to 30 min at RT. Primary antibodies, diluted in either 3% NGS blocking buffer or 1% bovine serum albumin (BSA), were applied for a 2&#8208;h incubation at RT on a shaker, followed by an additional 48&#8208;h incubation at 4&#176;C with gentle agitation.</p><p>Following primary antibody incubation, the wholemounts were rinsed four times in 1&#215; PBS (5 min each, with gentle shaking). Secondary antibodies, including Alexa Fluor 546 IgG1, Alexa Fluor 546 IgG2a, Alexa Fluor 488, and DyLight 649, were diluted in 1&#215; PBS in various combinations, added to each well, and incubated at RT for 45 min. The wholemounts were then washed 3 to 4 times in 1&#215; PBS (10&#8211;15 min each, with gentle shaking). Nuclei were stained with 4&#8242;,6&#8208;diamidino&#8208;2&#8208;phenylindole dihydrochloride (DAPI) (1:500) for 15 min, followed by four additional washes in 1&#215; PBS (10&#8211;15 min each, with gentle shaking). Neuroretinas were then mounted onto glass slides with the inner limiting membrane (ILM) facing upward, using ProLong Antifade or Mowiol 4&#8208;88 mounting medium, coverslipped with No. 1.5 thickness coverglass, and sealed for confocal microscopy.</p><p>Additionally, 6&#8208;&#181;m retinal cross&#8208;sections from a different cohort of AD and age&#8208;matched control cases (AD#11, AD#12, Control#11, and Control#12; Table&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S2</xref>) were examined using various markers to compare wholemount and cross&#8208;sectional morphological and pathological changes associated with sporadic AD. The panel included markers for A&#946; species (12F4, 6E10), macroglia (GFAP, GS), the AQP4 water channel, microglia/macrophages (IBA1), and the vascular marker UEA&#8208;l (Table&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S1</xref>). Standard double and triple immunofluorescence staining, combined with confocal microscopy, was used for qualitative assessment.</p></sec><sec id="alz70592-sec-0120"><label>2.1.3</label><title>Localization of SA&#946;Os in human wholemount neuroretinas</title><p>A novel anti&#8208;SA&#946;O (E3) nanobody, generated from an alpaca immunized with solubilized human A&#946;1&#8208;42 peptide, was used for this purpose.<xref rid="alz70592-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> The E3 nanobody can traverse the BBB and has shown a distinct spatial distribution: SA&#946;Os are primarily associated with neurons, while A&#946; plaques are found in the extracellular matrix.<xref rid="alz70592-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>
</p><p>Wholemount neuroretinas from AD and control groups were used for nanobody&#8208;antibody staining, utilizing Fluorescein (FAM)&#8208;labeled E3 and 12F4, as well as near&#8208;infrared (NIR)&#8208;conjugated E3 and 12F4. A modified nanobody staining protocol was adapted to localize the nanoparticles (SA&#946;Os) in the wholemount retinas.<xref rid="alz70592-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> The original protocol, developed by Fang et&#160;al. (2018), enables a correlative light and electron microscopy approach that preserves tissue ultrastructure while allowing for the location of multiple molecular moieties, even deep within tissues.</p><p>Briefly, neuroretina punches were rinsed in 0.1&#160;M PBS three times for 5&#160;min each. Antigen retrieval was performed using 88% formic acid for 5&#160;min at RT, followed by three 5&#8208;min rinses in 0.1&#160;M PBS. A glycine&#8208;blocking buffer consisting of 0.1&#160;M PBS, 0.1&#160;M glycine, and 0.05% sodium azide was added to each sample and incubated for 20 min at RT. The primary antibody 12F4 (1:500) and nanobody E3 (1:100) were diluted in the glycine&#8208;blocking buffer to co&#8208;localize the 12F4<sup>+</sup>A&#946;42 in the wholemount retinas. After adding the primary antibodies, the samples were light&#8208;protected and incubated at 4&#176;C for 48&#160;h with gentle shaking. The samples were then rinsed in 0.1&#160;M PBS three times for 5&#160;min each. To visualize the 12F4<sup>+</sup>A&#946;42, Alexa Fluor 546 IgG1 secondary antibody (diluted 1:400 in 0.1&#160;M PBS) was added and incubated at RT for 45&#160;min with gentle shaking. The samples were rinsed again in 0.1&#160;M PBS three times for 5&#160;min each. Hoechst nuclear dye (1:500 in 0.1&#160;M PBS) was added and incubated at RT for 15&#160;min, followed by three additional 5&#8208;min PBS rinses. Finally, each retinal punch was mounted with the ILM facing up, using ProLong Antifade or Mowiol 4&#8208;88 mounting medium, and covered with No. 1.5 thickness coverglass for confocal microscopy.</p></sec></sec><sec id="alz70592-sec-0130"><label>2.2</label><title>Animals</title><p>All animal experiments followed the guidelines and received approval from the University of British Columbia Animal Care Committee (A24&#8208;0098) and the Biosafety Committee (B20&#8208;0074). APP/PS1 double transgenic (Tg) mice (B6;C3&#8208;Tg, strain 034829&#8208;JAX), which express a chimeric mouse/human amyloid precursor protein (Mo/HuAPP695swe) and a mutant human presenilin 1 (PS1&#8208;dE9), along with their non&#8208;transgenic (NTg) siblings, were studied. These mutations are linked to early&#8208;onset AD and amyloid plaque formation.<xref rid="alz70592-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref> Brain and eye samples were obtained from two groups of mice at two different age ranges: 3 to 4 months (younger) and 9 to 10 months (older). In total, 16 female mice were used, distributed across four groups (<italic toggle="yes">n</italic>&#160;=&#160;4 mice per group) (Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S1B</xref>).</p><sec id="alz70592-sec-0140"><label>2.2.1</label><title>Sample collection and preparation</title><p>Animals were euthanized, and brain and eye samples were collected as previously described.<xref rid="alz70592-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref>, <xref rid="alz70592-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref> The left hemisphere of the brain and the left eye were allocated for gene expression analysis, whereas the right hemisphere and the right eye were designated for protein expression studies.</p></sec><sec id="alz70592-sec-0150"><label>2.2.2</label><title>Differentially expressed genes</title><p>As previously described,<xref rid="alz70592-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref>, <xref rid="alz70592-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref> total RNA was isolated from pooled neocortex&#8208;hippocampus tissues and eye tissues (<italic toggle="yes">n</italic>&#160;=&#160;4 per age group and model), followed by cDNA synthesis. Each reaction utilized approximately 10&#160;ng cDNA. Gene expression analysis was performed for 22 target genes, with a minimum of three technical replicates per sample. RT&#8208;qPCR, widely regarded as the gold standard for gene expression studies, was conducted using the 7500 Fast Real&#8208;Time PCR System (Applied Biosystems). Glyceraldehyde&#8208;3&#8208;phosphate dehydrogenase (<italic toggle="yes">Gapdh</italic>) served as the reference gene for data normalization, and optimized primer pairs were selected for the experiments (Table&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S3</xref>).</p></sec><sec id="alz70592-sec-0160"><label>2.2.3</label><title>Localization of selected protein markers in mouse brain sagittal and retinal cross&#8208;sections</title><p>Mid&#8208;sagittal brain and eye cross&#8208;sections, 6 &#181;m thick, were stained using double immunofluorescence protocols based on our previous studies.<xref rid="alz70592-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> Both APP&#8208;PS1 mice and their non&#8208;carrier sibling controls (<italic toggle="yes">n</italic>&#160;=&#160;4 per age group) were evaluated. Primary antibodies included 6E10, targeting APP and the 1 to 16 amino acid residues of A&#946; species, as well as AQP4 (water channel); GFAP and GS (macroglia markers); and IBA1 (microglia/macrophage marker). To detect APP/A&#946; peptides, an 88% formic acid pretreatment was applied, alongside standard antigen retrieval methods using either 0.05% proteinase K in Tris&#8208;EDTA buffer (pH 8.0) or heat&#8208;induced citrate buffer (pH 6.0). To validate 6E10<sup>+</sup> APP labeling, we used a knockout&#8208;validated APP antibody (rabbit monoclonal, Catalogue No. A17911) on brain and eye cross&#8208;sections. The presence of SA&#946;Os was also screened in brain and eye cross&#8208;sections using an NIR&#8208;conjugated E3 nanobody and a standard immunostaining protocol. As validations were based on a small sample size (<italic toggle="yes">N</italic>&#160;=&#160;1 to 2 per group) from the same cohort, only qualitative assessments were performed. Table&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S1</xref> summarizes the primary and secondary antibodies and their dilutions used for single or double immunofluorescence staining. Negative controls were processed in parallel, omitting the primary antibodies.</p></sec></sec><sec id="alz70592-sec-0170"><label>2.3</label><title>Fluorescence confocal microscopy and image analysis</title><p>All fluorescent images were captured using a Zeiss LSM 800 confocal microscope with ZEN 3.7 (Blue edition) software.</p><sec id="alz70592-sec-0180"><label>2.3.1</label><title>Imaging parameters</title><p>Various fluorophores, including Alexa Fluor 546 IgG1, Alexa Fluor 546 IgG2a, Alexa Fluor 488, DyLight 649, FAM, and NIR dyes, were used. Each fluorophore was imaged at its corresponding excitation and emission wavelengths. Confocal settings (e.g., laser wavelength, pinhole, master gain, scaling) were kept constant for each marker and its negative controls across all samples to ensure consistency and minimize variability. Regions with tissue damage, tearing, or other artifacts were excluded during imaging.</p></sec><sec id="alz70592-sec-0190"><label>2.3.2</label><title>Magnifications and regions of interest</title><p>Z&#8208;stack images (1&#8208;&#181;m slices) of human wholemount neuroretinas were taken at 200&#215; magnification across five non&#8208;overlapping fields (Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S1A</xref>), focusing on the retinal ganglion cell layer (GCL). The GCL was identified by sequential imaging from the ILM/NFL through to the outer nuclear layer (ONL). The density and size of the DAPI&#8208;labeled nuclei in the GCL, inner nuclear layer (INL), and ONL served as identifiers for these layers, while the inner and outer plexiform layers (IPL and OPL) were identified as DAPI&#8208; (e.g., cell) free zones. The Z&#8208;stack images confirmed antibody penetration through the full thickness of the wholemounts, with labeling observed as deep as the ONL.</p><p>Mouse brain sagittal sections were imaged at 100&#215; and 200&#215; magnifications to analyze double&#8208;labeling of 6E10&#8208;GFAP and 6E10&#8208;IBA1 markers, respectively. Non&#8208;overlapping regions&#160;&#8211; four from the hippocampus (dentate gyrus [DG], cornu Ammonis 4 [CA4], CA3&#8208;CA2, and CA1) and four from the neocortex (prefrontal, frontal, parietal, and occipital regions)&#160;&#8211; were captured. Mouse retinal cross&#8208;sections were imaged at 200&#215; magnification for double labeling of GFAP&#8208;GS and 6E10&#8208;AQP4, as well as single labeling of IBA1. For each retina, two central, two mid&#8208;peripheral, and two peripheral regions were captured.</p></sec><sec id="alz70592-sec-0200"><label>2.3.3</label><title>Semi&#8208;quantitative analysis</title><p>The numbers of 6E10<sup>+</sup> A&#946; plaques (including diffuse&#8208;type) and IBA1<sup>+</sup> microglial cells were counted semi&#8208;quantitatively in brain samples from APP&#8208;PS1 and non&#8208;carrier sibling mice. NIR&#8208;E3<sup>+</sup> macrophage&#8208;like A&#946;&#8208;binding myeloid lineage cells were counted semi&#8208;quantitatively in wholemount neuroretinas from AD and control donors. In addition, IBA1<sup>+</sup> and CD68<sup>+</sup> co&#8208;localized microglial circular processes were counted in wholemount neuroretinas from AD and control donors. Cell counting was performed by two or more independent investigators who were masked to the group assignments.</p></sec><sec id="alz70592-sec-0210"><label>2.3.4</label><title>Image analysis</title><p>It was performed using ImageJ software with appropriate plugins. High&#8208;resolution TIFF files were used for both mouse brain samples (eight images per marker per mouse) and retina samples (six images per marker per mouse) and human wholemount neuroretinas (five orthogonal projections per marker per donor). Immunoreactivity was evaluated by two or more independent investigators, who were masked to the sample identities.</p><p>Briefly, individual channel TIFF files (preclinical data and FAM&#8208;E3/12F4 nanobody staining) were opened in ImageJ. Although the mouse sagittal brain and human wholemount retina areas remained constant, the freehand selection tool was used to define the mouse retinal cross&#8208;sectional area from the ILM to the outer limiting membrane. Areas outside this region were cleared using <italic toggle="yes">Edit&gt;Clear Outside</italic>, and the selected area was recorded using the <italic toggle="yes">Analyze&gt;Measure</italic> command. Next, images (brain or retina) were converted to black and white using <italic toggle="yes">Image&gt;Color&gt;Split Channels</italic> and duplicated using <italic toggle="yes">Image&gt;Duplicate</italic>. The duplicated image was processed using <italic toggle="yes">Process&gt;Noise&gt;Remove Outliers</italic>, applying a constant radius (range: 10 to 15) and threshold setting (range: 30 to 50), depending on marker morphology or labeling pattern. The processed duplicate was then subtracted from the original black&#8208;and&#8208;white image using <italic toggle="yes">Process&gt;Image Calculator</italic>, and the resulting image was converted into a binary format via <italic toggle="yes">Process&gt;Binary&gt;Make Binary</italic>. Finally, pixel values were recorded using <italic toggle="yes">Analyze&gt;Histogram&gt;List</italic> and normalized by dividing by the measured area to obtain standardized pixel values for each marker.</p><p>For human wholemount studies, the area (field of view) was kept constant across comparison groups. Protein markers&#160;&#8211; GFAP, GS, AQP4, and IBA1&#160;&#8211; were evaluated using orthogonal projections to capture the optimized signals across the layers. TIFF orthogonal projection images were opened in ImageJ and converted to black and white using <italic toggle="yes">Image&gt;Color&gt;Split Channels</italic>. The threshold was manually adjusted for each image using <italic toggle="yes">Image&gt;Adjust&gt;Threshold</italic> to accurately capture the morphology. Pixel values were then obtained using the <italic toggle="yes">Analyze&gt;Histogram&gt;List</italic> command.</p><p>For 12F4<sup>+</sup>A&#946;42 depositions appearing as clumps in human wholemounts, a different protocol was applied. A representative Z&#8208;stack slice image was selected at the GCL level, excluding surface&#8208;level 12F4<sup>+</sup>A&#946;42 signals that might reflect clearance processes. The selected image was opened in ImageJ and converted to black and white using <italic toggle="yes">Image&gt;Color&gt;Split Channels</italic>. The threshold was manually adjusted using <italic toggle="yes">Image&gt;Adjust&gt;Threshold</italic> to accurately capture 12F4<sup>+</sup>A&#946;42 clump&#8208;like depositions. Clump size was then defined using <italic toggle="yes">Analyze&gt;Analyze Particles</italic>, and the number and area of clumps (in pixel units) were recorded by applying a constant size and circularity range across all samples.</p></sec></sec><sec id="alz70592-sec-0220"><label>2.4</label><title>Statistical analysis</title><sec id="alz70592-sec-0230"><label>2.4.1</label><title>Differential gene expression in mouse samples</title><p>Relative expression levels were determined using the comparative cycle threshold (Ct) method.<xref rid="alz70592-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref> Ct values were obtained using constant threshold and baseline settings across all samples and target genes. Normalized Ct values were compared across animal groups and time points. The Shapiro&#8211;Wilk test was initially used to assess normality. As a result of pooling, Ct values were normally distributed for each target gene. Therefore, a two&#8208;way ANOVA (two factors: model and age group) with Bonferroni correction for multiple comparisons was performed to analyze differences among the comparison groups. Target genes were considered differentially expressed if they exhibited a statistically significant (<italic toggle="yes">p</italic>&#160;&lt;&#160;0.05) &#8805;2&#8208;fold intergroup difference.</p></sec><sec id="alz70592-sec-0240"><label>2.4.2</label><title>Protein expression analysis in mouse samples</title><p>Pixel data, normalized to area, were screened for outliers using the ROUT method (<italic toggle="yes">Q</italic>&#160;=&#160;1%) across the four comparison groups: Tg younger, Tg older, NTg younger, and NTg older. The Shapiro&#8211;Wilk test was performed to assess normality in the cleaned dataset and to determine whether the data followed a normal or non&#8208;normal distribution within each group. Immunoreactivity was analyzed using either the Brown&#8211;Forsythe and Welch ANOVA with Dunnett's T3 multiple comparisons test or the Kruskal&#8211;Wallis test with Dunn's multiple comparisons test, as appropriate. For subgroup analysis (central vs peripheral), two central and two peripheral regions were analyzed, excluding two mid&#8208;region pixel values for each retina.</p></sec><sec id="alz70592-sec-0250"><label>2.4.3</label><title>Protein expression analysis in human wholemounts</title><p>Pixel data were screened for outliers using the ROUT method (<italic toggle="yes">Q</italic>&#160;=&#160;1%) for AD and control groups. The Shapiro&#8211;Wilk test was performed to assess normality in the cleaned data. Differences in wholemount neuroretina findings between AD and control donors were compared using an unpaired <italic toggle="yes">t</italic>&#8208;test (Student's or Welch's corrected <italic toggle="yes">t</italic>&#8208;test depending on variance equality) or a Mann&#8211;Whitney U test for non&#8208;normally distributed data.</p><p>All statistical analyses and graph generations were performed using GraphPad Prism 10.3.0 (GraphPad Software Inc., San Diego, CA, USA).</p></sec></sec></sec><sec id="alz70592-sec-0260"><label>3</label><title>RESULTS</title><sec id="alz70592-sec-0270"><label>3.1</label><title>Evidence from retrospective human post&#8208;mortem samples</title><sec id="alz70592-sec-0280"><label>3.1.1</label><title>Demographics of the human samples studied for wholemount neuroretinas</title><p>The demographic details of the samples used are summarized in Table&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S2</xref>. Eight out of 10 AD cases had a high likelihood of dementia. Only two had pure, severe AD neuropathology at the time of death, which occurred in their 60s. The remaining cases had one or more coexisting primary or additional pathologies alongside AD, including Lewy body dementia, frontotemporal lobar degeneration, cerebrovascular disease, cerebral amyloid angiopathy, and others. Most of the control eyes were obtained from donors who died of cancer, and none showed evidence of neurodegenerative diseases.</p><p>The specific wholemount neuroretina regions, protein markers used for double and triple staining, number of Z&#8208;stack images analyzed for each combination, sample sizes, mean ages (in years), and gender distributions for the AD and control groups are summarized in Table&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S4</xref>. A total of 70 Z&#8208;stacks for 12F4<sup>+</sup>A&#946;42, 65 Z&#8208;stacks for IBA1<sup>+</sup> microglia/macrophages, 70 Z&#8208;stacks for GFAP<sup>+</sup> astroglia, 35 Z&#8208;stacks for GS<sup>+</sup> M&#252;ller glia, 55 Z&#8208;stacks for AQP<sup>+</sup> water channels, and 15 Z&#8208;stacks for CD68<sup>+</sup> lysosomal compartments&#160;&#8211; spanning from the ILM to the ONL&#160;&#8211; were investigated for each group. An unpaired <italic toggle="yes">t</italic>&#8208;test revealed no statistically significant difference in mean ages between the AD and control groups for each experimental comparison. This lack of significant age difference confirms that the groups were appropriately age&#8208;matched, reducing the potential for age&#8208;related confounding and ensuring that observed effects are more likely attributable to disease&#8208;specific factors rather than age.</p></sec><sec id="alz70592-sec-0290"><label>3.1.2</label><title>A&#946; expression pattern in neuroretinas of AD and control subjects from superficial perspective</title><p>The imaging planes (surface vs cross&#8208;section) of a control neuroretina (Figure&#160;<xref rid="alz70592-fig-0001" ref-type="fig">1A</xref>) were used to illustrate the spatial differences in UEA&#8208;I<sup>+</sup> vasculature, demonstrating how wholemount neuroretina preparations allow for detailed visualization of morphological and pathological changes at the iBRB. Additionally, it is important to consider that in the wholemount neuroretina, labeling patterns varied across layers (e.g., 12F4<sup>+</sup>A&#946;42, AQP4<sup>+</sup> water channels) depending on spatial distribution, as well as the localization of glial cells and associated vascular structures.</p><fig position="float" fig-type="FIGURE" id="alz70592-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Differences in 12F4<sup>+</sup>A&#946;42 expression between AD and control neuroretinas. (A) Imaging planes: surface versus cross&#8208;section showing differences in UEA&#8208;l<sup>+</sup> vasculature in a control retina. (B) Superficial lower&#8208;magnification (10&#215; objective) views of 12F4<sup>+</sup> A&#946;42 expression in a control and an AD donor, respectively. White arrowheads in control retina suggest drainage path&#8208;like patterns. (C) A younger control neuroretina showing weaker 12F4<sup>+</sup>A&#946;42 labeling and polarized AQP4<sup>+</sup> water channels at ILM, above superficial vascular plexus. (D,&#160;E)&#160;Co&#8208;localization of 12F4<sup>+</sup>A&#946;42 with AQP4<sup>+</sup> water channels and UEA&#8208;l<sup>+</sup> vessels in control and AD neuroretinas, respectively. White arrowheads in control neuroretina suggest 12F4<sup>+</sup>A&#946;42 drainage path&#8208;like patterns; white dashed circle in AD neuroretina suggests 12F4<sup>+</sup>A&#946;42 deposition in clumps. (F, G) Co&#8208;localization of 12F4<sup>+</sup>A&#946;42 with IBA1<sup>+</sup> microglia/macrophages (indicated by white arrowheads and zoomed&#8208;in white dashed boxes) in control and AD neuroretinas, respectively. In the control retina, white dashed lines outline blood vessels, suggesting A&#946; drainage path&#8208;like patterns through peri&#8208; and paravascular spaces. In contrast, in the AD retina, white dashed lines outline blood vessels, suggesting defective A&#946; drainage around blood vessels, resulting in A&#946; clump formation (Video&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S9</xref>). (H, I) Three&#8208;dimensional views of A&#946; expression around larger retinal blood vessels (white dashed lines) in control and AD neuroretinas, respectively. White stars in panels (F) and (H) suggest powder&#8208;like soluble forms of 12F4<sup>+</sup>A&#946;42, while white arrowheads in panel (I) show neuritic type&#8208;like 12F4<sup>+</sup>A&#946;42 plaques. (J, K) The number of 12F4<sup>+</sup>A&#946;42 clumps and the clump area, measured in pixel units, were compared between AD and control groups. Mean pixel values for individual donors are overlaid on the violin plots. (L) Retinal cross&#8208;sections from control and AD donor eyes showing intraneuronal inclusions of 6E10<sup>+</sup> APP/A&#946; peptides in both groups, with 6E10<sup>+</sup> A&#946; plaques found only in AD. Statistical comparisons were performed using an unpaired <italic toggle="yes">t</italic>&#8208;test; <italic toggle="yes">p</italic> values&#160;&lt;&#160;0.05 were considered statistically significant and are indicated. (Scale bar: 20&#160;&#181;m; sample size: <italic toggle="yes">N</italic>&#160;=&#160;10 per group for 12F4 and IBA1 double labeling, and <italic toggle="yes">N</italic>&#160;=&#160;4 per group for 12F4, AQP4, and UEA&#8208;I triple labeling). A&#946;, amyloid beta; AD, Alzheimer's disease; APP, amyloid precursor protein; AQP4, aquaporin 4; ILM, inner limiting membrane; UEA, <italic toggle="yes">Ulex europaeus</italic> agglutinin.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="ALZ-21-e70592-g003.jpg"/></fig><p>All samples were analyzed for A&#946; expression. A low&#8208;magnification view (10&#215; objective) of the superficial layers revealed differences in 12F4 labeling patterns between control and AD neuroretinas (Figure&#160;<xref rid="alz70592-fig-0001" ref-type="fig">1B</xref>). In the AD neuroretina, 12F4<sup>+</sup>A&#946;42 appeared as clump&#8208;like deposits, whereas the matched control neuroretina showed 12F4<sup>+</sup>A&#946;42 localization along drainage path&#8208;like patterns (indicated by white arrowheads). In contrast, the neuroretina of a younger control exhibited comparatively weaker 12F4<sup>+</sup>A&#946;42 signals (Figure&#160;<xref rid="alz70592-fig-0001" ref-type="fig">1C</xref>), suggesting more effective clearance systems in the younger group compared to both the AD retina and the age&#8208;matched control.</p><p>In the younger control neuroretina, co&#8208;localization of AQP4 with 12F4 and UEA&#8208;l markers revealed that AQP4<sup>+</sup> water channels were primarily localized at the ILM, facing the vitreous humor (Figure&#160;<xref rid="alz70592-fig-0001" ref-type="fig">1C</xref>; Video&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S1</xref>). Co&#8208;localization of 12F4 with AQP4 and UEA&#8208;I markers in the ILM and superficial layers is shown in Figure&#160;<xref rid="alz70592-fig-0001" ref-type="fig">1D,E</xref> for control and AD neuroretinas, respectively. In control tissue, AQP4<sup>+</sup> water channels were distributed at the ILM&#8211;NFL, alongside 12F4<sup>+</sup>A&#946;42 displaying drainage&#8208;path&#8208;like patterns (indicated by white arrowheads). In contrast, the AD retina exhibited marked degeneration of AQP4<sup>+</sup> water channels at the ILM&#8211;NFL, co&#8208;localizing with clump&#8208;like 12F4<sup>+</sup>A&#946;42 deposits (indicated by a white dashed circle).</p><p>Figure&#160;<xref rid="alz70592-fig-0001" ref-type="fig">1F,G</xref> illustrate the co&#8208;localization of 12F4 with IBA1 in both control and AD neuroretinas, focusing on the level of the GCL and deeper layers. A 3D view of 12F4<sup>+</sup>A&#946;42 deposition in control and AD neuroretinas is shown in Figure&#160;<xref rid="alz70592-fig-0001" ref-type="fig">1H,I</xref>, respectively. In controls, 12F4<sup>+</sup>A&#946;42 frequently colocalized within IBA1<sup>+</sup> microglia/macrophages encasing large retinal blood vessels&#8212;a pattern largely diminished in AD (white arrowheads and zoomed&#8208;in dashed white boxes in Figure&#160;<xref rid="alz70592-fig-0001" ref-type="fig">1F,G</xref>, respectively). Additionally, 12F4<sup>+</sup>A&#946;42 deposits were observed within the peri&#8208; and paravascular spaces of large blood vessels in controls (white dashed lines outline the blood vessels in Figure&#160;<xref rid="alz70592-fig-0001" ref-type="fig">1F,H</xref>). These deposits appeared as a fine, powder&#8208;like distribution, likely representing soluble A&#946; forms (white stars in Figure&#160;<xref rid="alz70592-fig-0001" ref-type="fig">1F,H</xref>), suggesting the involvement of the peri&#8208; and paravascular clearance system. In contrast, 12F4 labeling in AD neuroretinas appeared as unevenly distributed clumps, possibly corresponding to insoluble A&#946; forms, clustered around blood vessels in the GCL and deeper layers (Figure&#160;<xref rid="alz70592-fig-0001" ref-type="fig">1</xref>G,I; white dashed lines outline the vessels). The number of 12F4<sup>+</sup>A&#946;42 clumps (Figure&#160;<xref rid="alz70592-fig-0001" ref-type="fig">1J</xref>; mean&#160;&#177;&#160;SD: 24.46&#160;&#177;&#160;19.7 for AD and 5.61&#160;&#177;&#160;7.8 for controls) and the clump area in pixel units (Figure&#160;<xref rid="alz70592-fig-0001" ref-type="fig">1K</xref>; 0.824&#160;&#177;&#160;0.69 for AD and 0.098&#160;&#177;&#160;0.11 for controls) were significantly higher in AD samples compared to controls (<italic toggle="yes">p</italic>&#160;&lt;&#160;0.0001 for both comparisons, unpaired <italic toggle="yes">t</italic>&#8208;test).</p><p>We have included videos featuring Z&#8208;stack flythroughs to illustrate the drainage path&#8208;like patterns of 12F4&#8314;A&#946;42 in relation to AQP4&#8314; water channels and UEA&#8208;I&#8314; vessels (Video&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S2</xref> for control; Video&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S3</xref>, and additionally Video&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S4</xref> for AD), as well as the peri&#8208; and paravascular localization of 12F4&#8314; A&#946;42 peptides with IBA1&#8314; microglia/macrophages across retinal layers in both control and AD neuroretinas (Videos <xref rid="alz70592-supinfo-0001" ref-type="">S5, S6</xref>, and additionally Video&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S7</xref> for controls; Videos <xref rid="alz70592-supinfo-0001" ref-type="">S8, S9</xref>, and additionally Video&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S10</xref> for AD cases).</p><p>Additionally, we used retinal cross&#8208;sections to see differences in imaging planes for localizing A&#946; species across retinal layers. Using the 12F4 antibody, we did not detect intraneuronal inclusions in retinal cross&#8208;sections from either group. In contrast, a few 12F4&#8314;A&#946;42 plaques were found in the AD retina, particularly within the IPL&#8211;ONL regions (data not shown). Conversely, 6E10&#8314; APP/A&#946; peptides appeared as intraneuronal inclusions, predominantly within the GCL and INL, in both control and AD retinas (Figure&#160;<xref rid="alz70592-fig-0001" ref-type="fig">1L</xref>), consistent with findings in APP&#8208;PS1 and control mice (Section&#160;<xref rid="alz70592-sec-0350" ref-type="sec">3.2.1</xref>). In addition, a few 6E10&#8314;A&#946; plaques were observed only in AD retinas (yellow arrowhead).</p></sec><sec id="alz70592-sec-0300"><label>3.1.3</label><title>Disrupted SA&#946;O clearance in Alzheimer's eye</title><p>We utilized a novel anti&#8208;SA&#946;O E3 nanobody in conjunction with a modified nanobody staining protocol to visualize SA&#946;O distribution. The expression patterns of the E3 nanobody, along with the 12F4 antibody, are shown in Figure&#160;<xref rid="alz70592-fig-0002" ref-type="fig">2</xref>. SA&#946;O<sup>+</sup> signals, detected by the NIR&#8208;E3 nanobody, were predominantly localized within retinal blood vessels, demonstrating the nanobody's ability to cross the iBRB and bind macrophage&#8208;like, A&#946;&#8208;binding myeloid lineage cells&#160;&#8211; a capability not observed with the 12F4 antibody (Figure&#160;<xref rid="alz70592-fig-0002" ref-type="fig">2A&#8211;E</xref>; Videos <xref rid="alz70592-supinfo-0001" ref-type="">S11&#8211;S14</xref>). Video&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S11</xref> demonstrates E3 nanobody labeling within blood vessels using the vascular marker UEA&#8208;l. Labeling of NIR&#8208;E3<sup>+</sup> SA&#946;Os across the retinal vasculature is illustrated alongside a schematic diagram (Figure&#160;<xref rid="alz70592-fig-0002" ref-type="fig">2B</xref>). A significant difference was observed between control (mean&#160;&#177;&#160;SD: 6.08&#160;&#177;&#160;3.7) and AD (1.71&#160;&#177;&#160;2.1) samples, with counts of NIR&#8208;E3<sup>+</sup> macrophage&#8208;like, A&#946;&#8208;binding myeloid lineage cells (yellow arrowheads) significantly higher in controls (<italic toggle="yes">p</italic>&#160;&lt;&#160;0.0001, unpaired <italic toggle="yes">t</italic>&#8208;test) (Figure&#160;<xref rid="alz70592-fig-0002" ref-type="fig">2C</xref>). Erythrocytes (pink arrowheads), identified by their biconcave disk shape and lack of nuclear staining, did not exhibit any positive signal for the NIR&#8208;E3 nanobody.</p><fig position="float" fig-type="FIGURE" id="alz70592-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Localization of SA&#946;Os in human wholemount neuroretinas. An E3 nanobody conjugated with NIR (655&#160;nm, yellow) and FAM (495&#160;nm, green) dyes was used alongside the 12F4 antibody (546&#160;nm, red) to stain wholemount peripheral retinas from human AD and control donor eyes, following an ex vivo nanobody staining protocol. (A) Two&#8208;dimensional images of control and AD retinas stained for NIR&#8208;E3 and 12F4 markers demonstrate NIR&#8208;E3<sup>+</sup> SA&#946;O uptake by macrophage&#8208;like, A&#946;&#8208;binding myeloid lineage cells (yellow arrowheads) within retinal blood vessels in superficial vascular plexus. In contrast, erythrocytes (pink arrowheads, identified by their biconcave disk shape) did not show SA&#946;Os uptake. (B)&#160;SA&#946;Os were detected throughout the retinal vasculature (a schematic of the retinal vasculature is included), regardless of vessel size. (C)&#160;Differences in NIR&#8208;E3<sup>+</sup> cell counts between control and AD retinas were analyzed using an unpaired <italic toggle="yes">t</italic>&#8208;test, with mean counts for individual donors superimposed on the violin plots. (D, E) Three&#8208;dimensional visualization of SA&#946;Os within retinal blood vessels in control and AD retinas, respectively. (F) A&#946; species at the retina&#8211;vitreous humor interface stained positive for FAM&#8208;E3 and 12F4 markers. (G) Immunoreactivity, measured in pixels for the FAM&#8208;E3 nanobody and 12F4 antibody, was compared between AD and control groups using the Mann&#8211;Whiteny U test. <italic toggle="yes">P</italic> values&#160;&lt;&#160;0.05 were considered statistically significant and are indicated. (Scale bar: 20&#160;&#181;m; sample size: <italic toggle="yes">N</italic>&#160;=&#160;7 per group for NIR&#8208;E3 and 12F4 double labeling, and <italic toggle="yes">N</italic>&#160;=&#160;3 per group for FAM&#8208;E3 and 12F4 double labeling). A&#946;, amyloid&#8208;beta; AD, Alzheimer's disease; FAM, fluorescein; NIR, near&#8208;infrared; SA&#946;O, soluble A&#946; oligomer.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="ALZ-21-e70592-g001.jpg"/></fig><p>Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S2</xref> illustrates the presence of NIR&#8208;E3<sup>+</sup> SA&#946;Os within both the superficial (Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S2A</xref>) and deep (Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S2B</xref>) retinal vascular plexuses. Higher&#8208;magnification 2D images (Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S2C&#8211;E</xref>) further demonstrate the uptake of NIR&#8208;E3<sup>+</sup> SA&#946;Os, possibly by peripheral monocytes (indicated by white dashed circles), based on their size, nuclear morphology, and intravascular localization. A corresponding 3D image and Video&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S13</xref> are provided alongside schematic cartoons (Figure&#160;<xref rid="alz70592-fig-0002" ref-type="fig">2SF</xref>; white arrowheads and dashed circles). Due to the lack of commercially available nanobodies capable of penetrating the BRB to specifically label peripheral monocytes, we were unable to confirm their identity using a definitive marker. However, our findings suggest a potential role for peripheral monocytes in the recruitment of SA&#946;Os&#160;&#8211; a process that appears to be significantly diminished in AD neuroretinas.</p><p>A small subset of samples (<italic toggle="yes">N</italic>&#160;=&#160;3 per group) was used for double staining with FAM&#8208;labeled E3 nanobody and Alexa Fluor 546&#8208;labeled 12F4 antibody. Both markers confirmed their localization at the retina&#8211;vitreous humor interface (Figure&#160;<xref rid="alz70592-fig-0002" ref-type="fig">2F</xref>; Videos <xref rid="alz70592-supinfo-0001" ref-type="">S15</xref> and <xref rid="alz70592-supinfo-0001" ref-type="">S16</xref>). In control samples, a flow&#8208;like nanoparticle distribution was observed at this interface. In contrast, these patterns were either diminished or disrupted in AD retinas, resulting in a significant reduction in the FAM&#8208;E3 signal (<italic toggle="yes">p</italic>&#160;=&#160;0.0186, Mann&#8211;Whitney U test) (Figure&#160;<xref rid="alz70592-fig-0002" ref-type="fig">2G</xref>). Similar results were obtained using the Alexa Fluor 546&#8208;labeled 12F4 antibody, with a comparable signal reduction in AD retinas (<italic toggle="yes">p</italic>&#160;=&#160;0.0408, Mann&#8211;Whitney U test) (Figure&#160;<xref rid="alz70592-fig-0002" ref-type="fig">2G</xref>). However, quantitative analysis was limited to three AD and three control neuroretinas due to technical challenges in preserving the retina&#8211;vitreous interface from dissection through mounting.</p><p>Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S3</xref> provides additional evidence of SA&#946;O labeling within retinal blood vessels, illustrating differences among a negative control (Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S3A</xref>), a younger control (Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S3B</xref>), and an age&#8208;matched control (Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S3C</xref>). Three&#8208;dimensional views of SA&#946;Os<sup>+</sup> cells within retinal blood vessels revealed no discernible differences in the staining patterns of NIR&#8208; (Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S3D</xref>) and FAM&#8208; (Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S3E</xref>) dye&#8208;conjugated to E3 nanobodies between control and AD neuroretinas. A&#946;42, labeled by both the E3 nanobody and the 12F4 antibody, was detected at the retina&#8211;vitreous humor interface in both control and AD retinas (Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S3F,G</xref>), with larger A&#946;42 species prominently observed in AD neuroretinas (Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S3G</xref>).</p></sec><sec id="alz70592-sec-0310"><label>3.1.4</label><title>Microglia morphology in neuroretinas of AD and control donors</title><p>Differences in A&#946; expression patterns between AD and control neuroretinas suggest potential differences in A&#946; clearance between the two groups. Microglia, the resident macrophages of the CNS, serve as the first line of defense against pathogens and injury in the brain. Reduced A&#946; uptake capacity by microglia has been proposed as a major contributor to AD pathogenesis.<xref rid="alz70592-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref>, <xref rid="alz70592-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref> To explore this possibility, we analyzed all samples to compare microglial expression patterns between AD and control neuroretinas (Figures&#160;<xref rid="alz70592-fig-0003" ref-type="fig">3</xref> and <xref rid="alz70592-supinfo-0001" ref-type="">S4</xref>).</p><fig position="float" fig-type="FIGURE" id="alz70592-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Differences in microglia morphology between AD and control neuroretinas. (A) Low&#8208;magnification (10&#215; objective) superficial views of IBA1<sup>+</sup> microglia/macrophages in control and AD neuroretinas (infiltrated IBA<sup>+</sup> cells are indicated by white arrowheads). (B) Co&#8208;localization of 12F4<sup>+</sup>A&#946;42 with IBA1<sup>+</sup> cells (yellow arrowheads) in an AD neuroretina suggests hyalocyte infiltration, based on their spatial localization at ILM. (C) Three&#8208;dimensional renderings of microglial expression in control and AD neuroretinas. White arrowheads in control retina indicate microglia processes containing circular structures, while yellow arrowheads in AD retina indicate rod&#8208;shaped or elongated morphology. (D) IBA1&#8208;CD68 double labeling is shown for a younger control, an age&#8208;matched control, and an AD donor. Yellow arrowheads indicate IBA1 and CD68 co&#8208;localization in both control and AD retinas. (E) The immunoreactivity of IBA1<sup>+</sup> cells, quantified in pixels, was compared between AD and control groups using an unpaired <italic toggle="yes">t</italic>&#8208;test. Mean pixel values for individual donors are overlaid on violin plots. (F) The total number of IBA1<sup>+</sup>CD68<sup>+</sup> co&#8208;localized circular structures was compared between AD and control groups using the Mann&#8211;Whiteny U test. (G) Triple labeling of IBA1, LAMP1, and UEA&#8208;l markers is shown for a control and an AD donor, with no colorization observed between IBA1 and LAMP1. (H) Triple labeling of IBA1, CD45, and UEA&#8208;I markers shows sparse IBA1&#8314; cells with CD45&#8314; cytoplasmic tail labeling (yellow arrowheads) in both control and AD retinas. (I) Retinal cross&#8208;sections from AD and control donors stained for IBA1 and UEA&#8208;l show microglial processes with rounded structures in controls, predominantly spanning from the NFL to the IPL. In AD retinas, microglia exhibit a rod&#8208;shaped or elongated morphology within the NFL&#8211;GCL, IPL, and OPL. A <italic toggle="yes">p</italic> value&#160;&lt;&#160;0.05 was considered statistically significant and is indicated. (Scale bar: 20&#160;&#181;m; sample size: <italic toggle="yes">N</italic>&#160;=&#160;10 per group for 12F4 and IBA1 double labeling, and <italic toggle="yes">N</italic>&#160;=&#160;3 per group for IBA1 and CD68 double labeling). A&#946;, amyloid beta; AD, Alzheimer's disease; GCL, ganglion cell layer; ILM, inner limiting membrane; IPL, inner plexiform layer; NFL, nerve fiber layer; OPL, outer plexiform layer; UEA, <italic toggle="yes">Ulex europaeus</italic> agglutinin.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="ALZ-21-e70592-g002.jpg"/></fig><p>Low&#8208;power images of the superficial layers in wholemount neuroretinas revealed notable differences in microglial distribution and morphology (Figure&#160;<xref rid="alz70592-fig-0003" ref-type="fig">3A</xref>, 10&#215; objective; Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S4A,B</xref>, 2.5&#215; objective). Specifically, in AD neuroretinas, infiltration of IBA1<sup>+</sup> cells was detected in the ILM&#8211;NFL region, as indicated by white arrowheads in Figure&#160;<xref rid="alz70592-fig-0003" ref-type="fig">3A</xref>. Some of these infiltrated IBA1<sup>+</sup> cells, possibly hyalocytes&#160;&#8211; vitreous&#8208;resident macrophages&#160;&#8211; also showed positive signals for 12F4<sup>+</sup>A&#946;42, suggesting their involvement in A&#946; phagocytosis (Figure&#160;<xref rid="alz70592-fig-0003" ref-type="fig">3B</xref>, yellow arrowheads). Video&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S17</xref> further supports the notion that these infiltrating IBA1<sup>+</sup> cells are most likely hyalocytes based on their spatial localization.</p><p>High&#8208;magnification 3D views revealed distinct microglial morphologies between AD and control neuroretinas (Figure&#160;<xref rid="alz70592-fig-0003" ref-type="fig">3C</xref>). In control samples, microglial processes were predominantly rounded, resembling phagocytic cup&#8208;like structures (white arrowheads), and were concentrated in the NFL&#8211;IPL, particularly around larger retinal vessels (Videos <xref rid="alz70592-supinfo-0001" ref-type="">S5&#8211;S7</xref>). In contrast, microglia in AD neuroretinas appeared rod&#8208;shaped or elongated (yellow arrowheads), with retracted or absent phagocytic processes, suggesting dystrophic morphologies within the NFL&#8211;IPL (Videos <xref rid="alz70592-supinfo-0001" ref-type="">S8&#8211;S10</xref>). Quantitative analysis of immunoreactivity, measured as normalized pixel counts, revealed significantly higher labeling in AD neuroretinas compared with controls (<italic toggle="yes">p</italic>&#160;=&#160;0.0036, unpaired <italic toggle="yes">t</italic>&#8208;test) (Figure&#160;<xref rid="alz70592-fig-0003" ref-type="fig">3E</xref>). This increase is attributed to resident microglia/macrophages and infiltrating IBA1<sup>+</sup> cells.</p><p>To further investigate phagocytic activity, a subset of samples (<italic toggle="yes">N</italic>&#160;=&#160;3 per group) was analyzed using CD68, a marker for lysosomal/endosomal compartments of microglia/macrophages (Figures&#160;<xref rid="alz70592-fig-0003" ref-type="fig">3D</xref> and <xref rid="alz70592-supinfo-0001" ref-type="">S4C,D</xref>). Representative images include a younger control, an age&#8208;matched control, and an AD donor (yellow arrowheads denote IBA1<sup>+</sup>CD68<sup>+</sup> cells). The number of co&#8208;labeled microglial processes&#160;&#8211; potentially suggestive of phagocytic activity&#160;&#8211; was assessed semi&#8208;quantitatively and yielded no significant difference between AD and control retinas (<italic toggle="yes">p</italic>&#160;=&#160;0.5969, Mann&#8211;Whitney U test; Figure&#160;<xref rid="alz70592-fig-0003" ref-type="fig">3F</xref>). Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S4</xref> illustrates CD68 and IBA1 co&#8208;localization in the ILM and superficial layers (Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S4C</xref>), where yellow arrowheads denote IBA1&#8314;CD68&#8314; cells and white dashed circles indicate IBA1&#8314;CD68<sup>&#8722;</sup> cells, as well as around blood vessels (Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S4D</xref>), with white dashed lines outlining vessels and yellow arrowheads indicating co&#8208;localization. These findings suggest that co&#8208;labeling is particularly prominent around large vessels, regardless of disease status. Videos <xref rid="alz70592-supinfo-0001" ref-type="">S18</xref> and <xref rid="alz70592-supinfo-0001" ref-type="">S19</xref> illustrate the IBA1 and CD68 co&#8208;localization across retinal layers in control and AD neuroretinas, respectively. In AD samples, most infiltrating IBA1<sup>+</sup> cells were negative for CD68, further supporting their identity as hyalocytes, consistent with prior literature.<xref rid="alz70592-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref>, <xref rid="alz70592-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref>
</p><p>For additional validation, we used IBA1, LAMP1, and UEA&#8208;l markers to assess lysosomal activity (Figures&#160;<xref rid="alz70592-fig-0003" ref-type="fig">3G</xref> and <xref rid="alz70592-supinfo-0001" ref-type="">S4E</xref>) and IBA1, CD45, and UEA&#8208;l markers to evaluate the presence of blood&#8208;derived macrophages (Figures&#160;<xref rid="alz70592-fig-0003" ref-type="fig">3H</xref> and <xref rid="alz70592-supinfo-0001" ref-type="">S4F</xref>) in both groups. Minimal co&#8208;localization of LAMP1 and IBA1 was observed in control neuroretina, but not in the AD sample. Interestingly, co&#8208;localization of LAMP1 and UEA&#8208;1 was detected in the superficial vascular plexus of the control neuroretina, suggesting lysosomal activity in UEA&#8208;l<sup>+</sup> vascular endothelial cells (Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S4E</xref>, yellow arrowheads; Video&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S20</xref>). CD45, a surface marker of hematopoietic cells, was not detected in the wholemount neuroretinas of either group. However, a few IBA1&#8314; cells encasing vessel walls exhibited cytoplasmic CD45 labeling, possibly resulting from cleavage of the CD45 cytoplasmic tail during phagocyte activation (yellow arrowheads in Figures&#160;<xref rid="alz70592-fig-0003" ref-type="fig">3H</xref> and <xref rid="alz70592-supinfo-0001" ref-type="">S4F</xref>).<xref rid="alz70592-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref>, <xref rid="alz70592-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref> Videos <xref rid="alz70592-supinfo-0001" ref-type="">S21</xref> and <xref rid="alz70592-supinfo-0001" ref-type="">S22</xref> show resident microglial morphology and lack of CD45 labeling, along with UEA&#8208;1&#8314; vessel labeling, in control and AD retinas, respectively.</p><p>In addition to wholemounts, retinal cross&#8208;sections were examined to assess microglial morphology. In control retinas, IBA1&#8314; microglial processes appeared mostly rounded, spanning from the NFL to the IPL (Figure&#160;<xref rid="alz70592-fig-0003" ref-type="fig">3I</xref>). In contrast, microglia in AD retinas exhibited rod&#8208;shaped or elongated morphology, primarily localized to the NFL&#8211;GCL, IPL, and OPL (Figure&#160;<xref rid="alz70592-fig-0003" ref-type="fig">3I</xref>).</p><p>Additionally, in control neuroretinas, beyond the prominent co&#8208;localization of 12F4&#8314;A&#946;42 with IBA1&#8314; signals along blood vessel walls (Figure&#160;<xref rid="alz70592-fig-0001" ref-type="fig">1F</xref>), co&#8208;localization of 12F4&#8314;A&#946;42 with IBA1&#8314; phagosome&#8208;like structures was also observed at the superficial layers (Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S4G</xref>). However, some 12F4&#8314;A&#946;42 signals did not co&#8208;localize with IBA1<sup>+</sup> cells (Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S4H</xref>), suggesting that lysosomal activity may also originate from the superficial vasculature, as illustrated in Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S4E</xref> and Video&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S20</xref> for the control neuroretina. These A&#946; clearance processes are not readily captured in brain or eye cross&#8208;sectional studies. In our previous work comparing wholemounts with cross&#8208;sections, we identified IBA1&#8314; blood&#8208;derived phagosome&#8208;like structures co&#8208;labeled with 6E10&#8314; APP/A&#946; peptides in ergothioneine&#8208;treated 5XFAD mice, in contrast to untreated 5XFAD mice.<xref rid="alz70592-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref>
</p></sec><sec id="alz70592-sec-0320"><label>3.1.5</label><title>Macroglia morphology in AD and control neuroretinas</title><p>Macroglial (GFAP<sup>+</sup> and GS<sup>+</sup>) morphology in the wholemounts is illustrated in relation to retinal blood vessels (Figure&#160;<xref rid="alz70592-fig-0004" ref-type="fig">4A&#8211;E</xref>). According to the literature, GFAP labels astrocytes and reactive M&#252;ller cells; however, under normal conditions, GFAP expression in M&#252;ller cells is restricted to their endfeet. In contrast, GS is a robust marker for M&#252;ller glia and is expressed throughout the entire cell. UEA&#8208;l labels the endothelial cells of retinal blood vessels.</p><fig position="float" fig-type="FIGURE" id="alz70592-fig-0004" orientation="portrait"><label>FIGURE 4</label><caption><p>Differences in macroglia morphology between AD and control neuroretinas. (A&#8211;C) Macroglia (GFAP<sup>+</sup> and GS<sup>+</sup>) associated with retinal blood vessels (UEA&#8208;1<sup>+</sup>) in ILM superficial layers are illustrated for a younger control, an age&#8208;matched control, and an AD donor, respectively. (D, E) Three&#8208;dimensional views of macroglial morphology and blood vessels are presented for control and AD neuroretinas, respectively. (F, G) To illustrate differences in imaging planes, retinal cross&#8208;sections from AD and control donors stained with GFAP, GS, and UEA&#8208;l markers are shown. (H) An artery and a vein, along with associated macroglia located between the ILM and GCL of a control eye, are distinguished by their round and flattened lumens, respectively. (I, J) Immunoreactivity, measured in pixels, is shown for both GFAP and GS markers. An unpaired <italic toggle="yes">t</italic>&#8208;test was used for the comparisons. Mean pixel values for individual donors are superimposed on the violin plots. <italic toggle="yes">P</italic> values&#160;&lt;&#160;0.05 were considered statistically significant and are indicated (scale bar: 20&#160;&#181;m; sample size: <italic toggle="yes">N</italic>&#160;=&#160;7 per group for GFAP, GS, and UEA&#8208;I triple labeling). AD, Alzheimer's disease; GCL, ganglion cell layer; GFAP, glial fibrillary acidic protein; GS, glutamine synthetase; ILM, inner limiting membrane; UEA, <italic toggle="yes">Ulex europaeus</italic> agglutinin.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="ALZ-21-e70592-g005.jpg"/></fig><p>Our comprehensive assessment of wholemount Z&#8208;stacks from control and AD neuroretinas revealed a range of differences in the superficial macroglial structures. Like younger controls (Figure&#160;<xref rid="alz70592-fig-0004" ref-type="fig">4A</xref>; Video&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S23</xref>), age&#8208;matched controls showed preserved macroglial structures (Figure&#160;<xref rid="alz70592-fig-0004" ref-type="fig">4B,D</xref>; Video&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S24</xref>), whereas AD neuroretinas exhibited prominent degenerative changes (Figure&#160;<xref rid="alz70592-fig-0004" ref-type="fig">4C,E</xref>; Video&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S25</xref>). M&#252;ller glial endfeet were tightly attached to larger blood vessels in controls, similar to those observed in younger controls (merged images in Figure&#160;<xref rid="alz70592-fig-0004" ref-type="fig">4A,B,D</xref>), whereas these attachments appeared degraded in AD neuroretinas (merged images in Figure&#160;<xref rid="alz70592-fig-0004" ref-type="fig">4C,E</xref>). Importantly, AD retinas displayed a wide spectrum of degenerative changes, ranging from bead&#8208;like formations or clasmatodendrosis to a near&#8208;complete absence of macroglia (Videos <xref rid="alz70592-supinfo-0001" ref-type="">S25</xref> and <xref rid="alz70592-supinfo-0001" ref-type="">S26</xref>).</p><p>Additionally, to assess differences in imaging planes, retinal cross&#8208;sections from human AD donors and age&#8208;matched controls were examined using GFAP, GS, and UEA&#8208;I markers (Figure&#160;<xref rid="alz70592-fig-0004" ref-type="fig">4F,G</xref>, respectively). Similar to the wholemounts, control samples exhibited intact macroglial morphology, with UEA&#8208;I&#8314; blood vessels prominently within ILM&#8211;GCL. In contrast, GS&#8314; M&#252;ller glia and UEA&#8208;I&#8314; endothelial cells showed marked degenerative changes, and GFAP<sup>+</sup> astroglia showed relatively reduced expression in AD&#160;&#8211; supporting the wholemount findings that macroglial degeneration is a prominent feature of AD.</p><p>Figure&#160;<xref rid="alz70592-fig-0004" ref-type="fig">4H</xref> illustrates the labeling patterns of GFAP, GS, and UEA&#8208;I markers around an artery with a rounded lumen and a vein with a flattened lumen in a retinal cross&#8208;section from an older control, based on their characteristic appearances as described in the literature.</p><p>Pixel intensity measurements of immunoreactivity revealed a significant reduction in GFAP (<italic toggle="yes">p</italic>&#160;=&#160;0.0025, unpaired <italic toggle="yes">t</italic>&#8208;test) and GS (<italic toggle="yes">p</italic>&#160;=&#160;0.0015, unpaired <italic toggle="yes">t</italic>&#8208;test) expression in AD neuroretinas (Figure&#160;<xref rid="alz70592-fig-0004" ref-type="fig">4I,J</xref>, respectively), consistent with our qualitative assessment of human retinal cross&#8208;sections. This suggests degeneration of both astrocytes and M&#252;ller glia, potentially linked to ocular glymphatic dysfunction. Although reports on wholemount GFAP expression in human AD versus control neuroretinas are limited, our earlier study similarly demonstrated significant depletion of GFAP expression in 5xFAD mice wholemounts compared with matched C57BL/6J controls, further supporting ocular glymphatic dysfunction.<xref rid="alz70592-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref>
</p></sec><sec id="alz70592-sec-0330"><label>3.1.6</label><title>Membrane distribution of AQP4 water channels along with GFAP<sup>+</sup> astroglia</title><p>AQP4 is the principal water channel in the neuropil of the CNS, primarily expressed in astrocytes but also found in endothelial cells.<xref rid="alz70592-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref>, <xref rid="alz70592-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref> It exhibits a polarized distribution in brain astrocytes and retinal M&#252;ller cells, with enrichment in the endfeet membrane that contacts brain microvessels, the subarachnoid space, or the vitreous humor and retinal blood vessels. A lower but significant presence is also observed in non&#8208;endfeet membrane, including astrocytic processes that ensheath glutamatergic synapses.<xref rid="alz70592-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref>, <xref rid="alz70592-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref>
</p><p>Since AQP4 water channels contribute to glymphatic A&#946; clearance,<xref rid="alz70592-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref>, <xref rid="alz70592-bib-0051" ref-type="bibr">
<sup>51</sup>
</xref> we investigated their distribution in AD and control wholemount neuroretinas, along with GFAP<sup>+</sup> astroglia and UEA&#8208;l<sup>+</sup> vessels, using 3D imaging. Co&#8208;localization of GFAP<sup>+</sup> astroglia and AQP4<sup>+</sup> water channels was primarily observed in the ILM and superficial layers of both control and AD donor neuroretinas (Figure&#160;<xref rid="alz70592-fig-0005" ref-type="fig">5A&#8211;E</xref>, indicated by white dashed circles and Videos <xref rid="alz70592-supinfo-0001" ref-type="">S27</xref> and <xref rid="alz70592-supinfo-0001" ref-type="">S28</xref>). The non&#8208;endfeet distribution of AQP4<sup>+</sup> water channels was largely preserved in age&#8208;matched controls (Figure&#160;<xref rid="alz70592-fig-0005" ref-type="fig">5B,D</xref>), resembling that of younger controls (Figures&#160;<xref rid="alz70592-fig-0005" ref-type="fig">5A</xref> and <xref rid="alz70592-supinfo-0001" ref-type="">S5A</xref>), but was notably degenerated in AD retinas (Figure&#160;<xref rid="alz70592-fig-0005" ref-type="fig">5C,E</xref>). The densest expression of AQP4<sup>+</sup> water channels at the endfeet of M&#252;ller glia, which are tightly attached to the blood vessel wall, was confirmed by AQP4, GS, and UEA&#8208;l, as well as GS, GFAP, and UEA&#8208;l triple staining in a young control neuroretina (white dashed circles, Figure&#160;<xref rid="alz70592-fig-0005" ref-type="fig">5F,G</xref>, respectively). Quantification of immunoreactivity, measured in pixels for AQP4 and GFAP, revealed significantly higher values in controls compared to AD retinas (<italic toggle="yes">p</italic>&#160;&lt;&#160;0.0001 and <italic toggle="yes">p</italic>&#160;=&#160;0.0013, respectively, unpaired <italic toggle="yes">t</italic>&#8208;test) (Figure&#160;<xref rid="alz70592-fig-0005" ref-type="fig">5H,I</xref>, respectively).</p><fig position="float" fig-type="FIGURE" id="alz70592-fig-0005" orientation="portrait"><label>FIGURE 5</label><caption><p>Distribution of AQP4 water channels along with GFAP<sup>+</sup> astroglia between AD and control neuroretinas. (A&#8211;C) The expression patterns of AQP4<sup>+</sup> water channels, GFAP<sup>+</sup> astroglia, and UEA&#8208;l<sup>+</sup> vessels are shown at the ILM superficial layers for a younger control, an age&#8208;matched control, and an AD, respectively. (D, E) Three&#8208;dimensional views of control and AD neuroretinas, respectively. (F, G) Densest expression of AQP4<sup>+</sup> water channels at endfeet of M&#252;ller cells, particularly at the vessel wall, was confirmed using the M&#252;ller cell&#8208;specific marker GS, along with GFAP and UEA&#8208;l, in a younger control retina. This arrangement resembled a &#8220;sewer top&#8221; structure facilitating water movement (white dashed circles). (H, I) Immunoreactivity, measured in pixels, is shown for both AQP4 and GFAP, respectively. An unpaired <italic toggle="yes">t</italic>&#8208;test was used for statistical analysis. Mean pixel values for individual donors are superimposed on the violin plots. (J, K) Retinal cross&#8208;sections from a control and an AD donor, respectively, illustrate AQP4<sup>+</sup> water channel distribution, suggesting a polarized arrangement at the M&#252;ller glia endfeet&#8208;like structures in controls and degeneration with loss of polarity in the AD retina. (L) An older control wholemount neuroretina at the ILM level shows the peri&#8208; and paravascular localization of 12F4<sup>+</sup>A&#946;42 along with the densest AQP4<sup>+</sup> water channels. White dashed lines outline an adjacent artery and vein, indicated within the white dashed box at the GCL level based on the lumen size. White arrows suggest possible direction of 12F4<sup>+</sup>A&#946;42 drainage from an artery to a vein. <italic toggle="yes">P</italic> values&#160;&lt;&#160;0.05 were considered statistically significant and are indicated. (Scale bar: 20&#160;&#181;m; sample size: <italic toggle="yes">N</italic>&#160;=&#160;7 per group for AQP4, GFAP, and UEA&#8208;I triple labeling). A&#946;, amyloid beta; AD, Alzheimer's disease; AQP4, aquaporin 4; GCL, ganglion cell layer; GFAP, glial fibrillary acidic protein; GS, glutamine synthetase; ILM, inner limiting membrane; UEA, <italic toggle="yes">Ulex europaeus</italic> agglutinin.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-9" orientation="portrait" xlink:href="ALZ-21-e70592-g006.jpg"/></fig><p>Additionally, retinal cross&#8208;sections from AD and control neuroretinas were examined for AQP4, GFAP, and UEA&#8208;I markers to validate differences observed across imaging planes. In controls, AQP4<sup>+</sup> water channels exhibited a polarized appearance, possibly localized to M&#252;ller cell endfeet&#8208;like structures within the ILM&#8211;NFL region (Figures&#160;<xref rid="alz70592-fig-0005" ref-type="fig">5J</xref> and <xref rid="alz70592-supinfo-0001" ref-type="">S5B</xref>). In contrast, AD retinal cross&#8208;sections exhibited both a depolarized arrangement and degeneration of AQP4<sup>+</sup> channels in the same region (Figures&#160;<xref rid="alz70592-fig-0005" ref-type="fig">5K</xref> and <xref rid="alz70592-supinfo-0001" ref-type="">S5B</xref>). Such AQP4<sup>+</sup> water channel appearance was not observed in any of our preclinical data, despite a relatively larger sample size (Section&#160;<xref rid="alz70592-sec-0350" ref-type="sec">3.2.1</xref>).</p><p>Ex vivo imaging of a control wholemount neuroretina illustrated the peri&#8208; and paravascular localization of 12F4<sup>+</sup>A&#946;42 in both an artery and a vein at the ILM (Figure&#160;<xref rid="alz70592-fig-0005" ref-type="fig">5L</xref>; white dashed lines outline the adjacent vessels, and white arrows suggest the possible direction of the flow path). 12F4<sup>+</sup>A&#946;42 was particularly localized along vessel walls, where glial cell endfeet are tightly attached and enriched with AQP4<sup>+</sup> water channels, as illustrated in Figure&#160;<xref rid="alz70592-fig-0005" ref-type="fig">5F,G</xref>. The distinction between artery and vein was based on lumen size, as shown at the GCL level (white dashed box). Videos <xref rid="alz70592-supinfo-0001" ref-type="">S29</xref> and <xref rid="alz70592-supinfo-0001" ref-type="">S30</xref> provide a layer&#8208;by&#8208;layer fly&#8208;through of the staining patterns described earlier.</p><p>Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S5</xref> further illustrates a spectrum of morphological changes in GFAP and AQP4 labeling across control cases (Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S5C&#8211;E</xref>) and AD cases (Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S5F&#8211;J</xref>). A 70&#8208;year&#8208;old female control showed some GFAP<sup>+</sup> reactive astrocytes and reduced non&#8208;endfeet AQP4<sup>+</sup> water channels (Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S5E</xref>), while two female AD cases in their 80s exhibited GFAP<sup>+</sup> severe reactive astrogliosis and markedly depolarized or degenerated AQP4<sup>+</sup> water channels (Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S5I,J</xref>). Notably, two sporadic AD cases in their 60s&#160;&#8211; both presenting severe AD neuropathology without other comorbidities&#160;&#8211; exhibited marked degeneration of both endfeet and non&#8208;endfeet AQP4<sup>+</sup> water channels, along with GFAP<sup>+</sup> astroglia degeneration (Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S5H</xref>), suggesting a potential link between early&#8208;onset sporadic AD and glymphatic system dysfunction.</p></sec></sec><sec id="alz70592-sec-0340"><label>3.2</label><title>Evidence from preclinical transgenic mouse models</title><sec id="alz70592-sec-0350"><label>3.2.1</label><title>Localization of APP/A&#946; peptides and glial cells in the retina of 9&#8208;month&#8208;old APP&#8208;PS1 mice</title><p>The localization of APP/A&#946; peptides and AQP4<sup>+</sup> water channels across central and peripheral retinal cross&#8208;sections from 9&#8208;month&#8208;old APP&#8208;PS1 mice is shown in Figure&#160;<xref rid="alz70592-fig-0006" ref-type="fig">6A</xref>. Intraneuronal inclusion was predominantly observed in the GCL, followed by the INL, as indicated by the yellow dashed regions. The co&#8208;localization of the macroglial markers GFAP and GS in central and peripheral retinal cross&#8208;sections of 9&#8208;month&#8208;old APP&#8208;PS1 mice is shown in Figure&#160;<xref rid="alz70592-fig-0006" ref-type="fig">6C</xref>. The endfeet of GS<sup>+</sup> M&#252;ller cells, along with GFAP<sup>+</sup> astrocytes, were primarily localized to the ILM and NFL. Regarding IBA1<sup>+</sup> microglia, staining appeared relatively weak in the retinal cross&#8208;sections regardless of mouse model; however, their processes were detectable in the NFL&#8211;GCL, IPL, and OPL as illustrated in Figure&#160;<xref rid="alz70592-fig-0006" ref-type="fig">6E</xref> for 9&#8208;month&#8208;old APP&#8208;PS1 mice.</p><fig position="float" fig-type="FIGURE" id="alz70592-fig-0006" orientation="portrait"><label>FIGURE 6</label><caption><p>Localization of APP/A&#946; peptides and glial cells in retina of 9&#8208;month&#8208;old APP&#8208;PS1 mice. (A) Co&#8208;localization of 6E10<sup>+</sup> APP/A&#946; peptides with AQP4<sup>+</sup> membrane water channels, (C) co&#8208;localization of macroglia markers GFAP<sup>+</sup> astrocytes and GS<sup>+</sup> M&#252;ller cells, and (E) IBA1<sup>+</sup> microglia were demonstrated across central and peripheral regions of retina of 9&#8208;month&#8208;old APP&#8208;PS1 mice. (B, D, F) Quantification of immunoreactivity (measured in normalized pixels) was performed for 6E10<sup>+</sup> APP/A&#946; peptides, AQP4<sup>+</sup> water channels, GFAP<sup>+</sup> astrocytes, GS<sup>+</sup> M&#252;ller cells, and IBA1<sup>+</sup> microglia across the entire retina. Data are presented as violin plots comparing 3&#8208; and 9&#8208;month&#8208;old APP&#8208;PS1 mice and controls. Statistical significance was assessed using the non&#8208;parametric Kruskal&#8211;Wallis test followed by Dunn's multiple comparisons test. (G) A knockout&#8208;validated rabbit monoclonal APP antibody confirmed the intraneuronal inclusions of APP peptides in both the central and peripheral retinal regions (indicated by yellow dashed boxes) in 9&#8208;month&#8208;old APP&#8208;PS1 mice. (H) Double immunostaining with 6E10 and AQP4 shows the distribution of AQP4<sup>+</sup> water channels in the hippocampus and neocortex, illustrating similarities in the imaging planes between retinal cross&#8208;sections and brain sagittal sections, particularly regarding AQP4<sup>+</sup> water channels (yellow arrowheads) in 9&#8208;month&#8208;old APP&#8208;PS1 mice. White arrowheads indicate 6E10<sup>+</sup> A&#946; plaques. (I) NIR&#8208;E3<sup>+</sup> SA&#946;Os were detected in a 3&#8208;month&#8208;old APP&#8208;PS1 mouse along the endothelial cell layer of blood vessel lumens near the optic nerve (white arrowheads), with some oligomers taken up by peripheral myeloid lineage cells, possibly monocytes, based on their characteristic horseshoe&#8208;shaped nuclei (zoomed&#8208;in images shown in white dashed boxes and arrowheads). (J) Co&#8208;localization of 6E10<sup>+</sup> APP/A&#946; peptides with IBA1<sup>+</sup> macrophages in the superficial retinal layers suggests the presence of phagosome&#8208;like structures in a 3&#8208;month&#8208;old APP&#8208;PS1 mouse (yellow arrowheads). (K) A heatmap illustrates differential gene expression in pooled eye tissues comparing APP&#8208;PS1 and control mice at 3 and 9 months of age, including age&#8208;related changes within each group. Significantly upregulated genes are shown with corresponding <italic toggle="yes">p</italic> values and fold changes. Two&#8208;way ANOVA with Bonferroni&#8208;corrected multiple comparisons was used for statistical analysis. <italic toggle="yes">P</italic> values&#160;&lt;&#160;0.05 were considered statistically significant. (Scale bar: 20&#160;&#181;m; sample size: <italic toggle="yes">N</italic>&#160;=&#160;4 per age group and model for 6E10 and AQP4 double labeling, GFAP and GS double labeling, and IBA1 single staining). A&#946;, amyloid beta; APP, amyloid precursor protein; AQP4, aquaporin 4; GFAP, glial fibrillary acidic protein; GS, glutamine synthetase; NIR, near&#8208;infrared; SA&#946;O, soluble A&#946; oligomer.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-11" orientation="portrait" xlink:href="ALZ-21-e70592-g008.jpg"/></fig><p>Pixel quantification was performed using six regions of interest per retinal cross&#8208;section to represent the entire retina. Table&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S5</xref> summarizes the immunoreactivity of each marker, measured in normalized pixel values. Expression of 6E10<sup>+</sup> APP/A&#946; peptide was significantly elevated in the retinas of 9&#8208;month&#8208;old APP&#8208;PS1 mice compared to both age&#8208;matched control mice (<italic toggle="yes">p</italic>&#160;&lt;&#160;0.0001) and their younger counterparts (<italic toggle="yes">p</italic>&#160;&lt;&#160;0.0001). In contrast, 9&#8208;month&#8208;old control mice exhibited a significant decrease in APP/A&#946; levels compared to 3&#8208;month&#8208;old controls (<italic toggle="yes">p</italic>&#160;=&#160;0.0032) (Figure&#160;<xref rid="alz70592-fig-0006" ref-type="fig">6B</xref>). Interestingly, AQP4 expression significantly increased with aging in the retinas of both APP&#8208;PS1 (<italic toggle="yes">p</italic>&#160;&lt;&#160;0.0001) and control mice (<italic toggle="yes">p</italic>&#160;=&#160;0.0019) (Figure&#160;<xref rid="alz70592-fig-0006" ref-type="fig">6B</xref>). GFAP expression was significantly lower in 3&#8208;month&#8208;old APP&#8208;PS1 mice compared to their age&#8208;matched controls (<italic toggle="yes">p</italic>&#160;=&#160;0.041) (Figure&#160;<xref rid="alz70592-fig-0006" ref-type="fig">6D</xref>). However, GFAP immunoreactivity showed a significant increase in 9&#8208;month&#8208;old APP&#8208;PS1 mice (<italic toggle="yes">p</italic>&#160;=&#160;0.0003), whereas GS immunoreactivity significantly decreased in 9&#8208;month&#8208;old control mice compared to their 3&#8208;month&#8208;old counterparts (<italic toggle="yes">p</italic>&#160;=&#160;0.0007) (Figure&#160;<xref rid="alz70592-fig-0006" ref-type="fig">6D</xref>). Additionally, IBA1 expression significantly increased with aging in the retinas of both APP&#8208;PS1 mice (<italic toggle="yes">p</italic>&#160;&lt;&#160;0.0001) and control mice (<italic toggle="yes">p</italic>&#160;&lt;&#160;0.0001) (Figure&#160;<xref rid="alz70592-fig-0006" ref-type="fig">6F</xref>).</p><p>To validate 6E10&#8314; APP peptide presence in mouse tissues, we repeated staining with a rabbit monoclonal, knockout&#8208;validated APP antibody, revealing a similar expression pattern in retinal cross&#8208;sections of both APP&#8208;PS1 (Figure&#160;<xref rid="alz70592-fig-0006" ref-type="fig">6G</xref>, yellow dashed regions) and control (Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S6C</xref>, white dashed regions) mice. AQP4&#8314; water channel localization in the hippocampus and neocortex of a 9&#8208;month&#8208;old APP&#8208;PS1 mouse, alongside 6E10&#8314; A&#946; plaques (Figure&#160;<xref rid="alz70592-fig-0006" ref-type="fig">6H</xref>, white arrowheads), displaying similar AQP4 expression patterns in both retinal and brain cross&#8208;sections (yellow arrowheads, Figure&#160;<xref rid="alz70592-fig-0006" ref-type="fig">6A,H</xref>). We further examined the presence of SA&#946;Os in the retinal cross&#8208;sections using the NIR&#8208;E3 nanobody (Figure&#160;<xref rid="alz70592-fig-0006" ref-type="fig">6I</xref>). SA&#946;Os were primarily observed in endothelial cells lining the blood vessel lumens surrounding the optic nerve (white arrowheads, left), with some also taken up by myeloid lineage cells (white arrowheads, right). The horseshoe&#8208;shaped nucleus (indicated in the zoomed&#8208;in white dashed box) suggests monocyte involvement in SA&#946;O uptake, consistent with findings from human neuroretina wholemounts (Figures&#160;<xref rid="alz70592-fig-0002" ref-type="fig">2</xref> and <xref rid="alz70592-supinfo-0001" ref-type="">S2</xref>). Notably, SA&#946;Os were not observed as intraneuronal inclusions; tiny puncta were sparsely scattered across the retinal layers. NIR&#8208;E3<sup>+</sup> labeling is relatively weak in 9&#8208;month&#8208;old APP&#8208;PS1 mice compared to the other three groups.</p><p>Furthermore, wholemount neuroretina from a 3&#8208;month&#8208;old APP&#8208;PS1 mouse revealed IBA1&#8314; phagosome&#8208;like structures co&#8208;labeled with 6E10&#8314; APP/A&#946; peptides in the superficial ILM&#8211;NFL region (Figure&#160;<xref rid="alz70592-fig-0006" ref-type="fig">6J</xref>). These structures are not discernible in cross&#8208;sectional imaging, as previously demonstrated in our view&#8208;plane comparison of 5xFAD and C57BL/6J mice.<xref rid="alz70592-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> The lack of wholemount preparations for the respective animals&#160;&#8211; due to one eye being used for cross&#8208;sectional studies and the other for gene expression analyses&#160;&#8211; precluded confirmation of these phagosome&#8208;like structures across all groups using markers CD68 or LAMP1.</p><p>Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S6</xref> summarizes the 6E10 and AQP4 labeling across the four comparison groups for central (Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S6A</xref>) and peripheral (Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S6B</xref>) retinas, respectively. Pixel quantification of 6E10 and AQP4 expression was conducted separately for central (Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S6D</xref>) and peripheral (Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S6E</xref>) regions, excluding the mid&#8208;retinal region. This subgroup analysis revealed a significant increase in 6E10&#8314; APP/A&#946; peptide levels in the central retina of 9&#8208;month&#8208;old APP&#8208;PS1 mice compared to their younger counterparts (<italic toggle="yes">p</italic>&#160;=&#160;0.0018). In the peripheral retina, 6E10&#8314; APP/A&#946; peptide levels were significantly higher in 9&#8208;month&#8208;old APP&#8208;PS1 mice compared to age&#8208;matched controls (<italic toggle="yes">p</italic>&#160;=&#160;0.0186). Other comparisons&#160;&#8211; either between models or across age groups&#160;&#8211; were not statistically significant. In contrast, AQP4 expression showed a significant age&#8208;related increase in 9&#8208;month&#8208;old APP&#8208;PS1 mice in both the central (<italic toggle="yes">p</italic>&#160;=&#160;0.0348) and peripheral (<italic toggle="yes">p</italic>&#160;=&#160;0.0006) retinas. For control mice, AQP4 expression significantly increased only in the peripheral retina at 9 months of age (<italic toggle="yes">p</italic>&#160;=&#160;0.0146).</p><p>Co&#8208;localization of GFAP and GS across the comparison groups for the central and peripheral retinas is shown in Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S6F,G</xref>, respectively. Pixel quantification for these regions is presented in Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S6H,I</xref>. In the central retina, aging was associated with a significant increase in GFAP expression in APP&#8208;PS1 mice (<italic toggle="yes">p</italic>&#160;=&#160;0.0442) and a significant decrease in GS expression in control mice (<italic toggle="yes">p</italic>&#160;=&#160;0.0285) compared to their younger counterparts. No significant changes were observed for either marker in the peripheral retina.</p><p>IBA1 staining patterns in the central and peripheral retinas are shown in Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S6J,K</xref>, respectively, with pixel quantification provided in Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S6L</xref>. Both APP&#8208;PS1 and control mice exhibited significant age&#8208;related increases in IBA1 expression in both the central (<italic toggle="yes">p</italic>&#160;=&#160;0.0258 and <italic toggle="yes">p</italic>&#160;=&#160;0.0221, respectively) and peripheral (<italic toggle="yes">p</italic>&#160;=&#160;0.0035 and <italic toggle="yes">p</italic>&#160;=&#160;0.0043, respectively) retinas compared to their younger counterparts.</p><p>Table&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S6</xref> summarizes the relative expression levels of 22 target mRNAs based on RT&#8208;qPCR data. Both mouse <italic toggle="yes">App</italic> and human <italic toggle="yes">PSEN1</italic> mRNA levels were significantly upregulated in pooled eye tissues from both 3&#8208; and 9&#8208;month&#8208;old APP&#8208;PS1 mice compared to age&#8208;matched controls. A heatmap (Figure&#160;<xref rid="alz70592-fig-0006" ref-type="fig">6K</xref>) illustrates the differential gene expression patterns between APP&#8208;PS1 and control mice at 3 and 9 months of age, as well as age&#8208;related differences within each group. Notably, the microglial markers <italic toggle="yes">Aif1</italic> (2.4&#8208;fold, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.0001) and <italic toggle="yes">Trem2</italic> (2.3&#8208;fold, <italic toggle="yes">p</italic>&#160;=&#160;0.0016) were significantly upregulated in 9&#8208;month&#8208;old APP&#8208;PS1 mice compared to 3&#8208;month&#8208;old counterparts.</p></sec><sec id="alz70592-sec-0360"><label>3.2.2</label><title>Localization of APP/A&#946; peptides and glial cells in neocortex&#8208;hippocampus of 9&#8208;month&#8208;old APP&#8208;PS1 mice</title><p>The distribution of A&#946; plaques and co&#8208;localization with astroglia and microglia in the hippocampus and neocortex of 9&#8208;month&#8208;old APP&#8208;PS1 mice are shown in Figure&#160;<xref rid="alz70592-fig-0007" ref-type="fig">7A,B</xref>, respectively. The number of 6E10<sup>+</sup> A&#946; plaques significantly increased (<italic toggle="yes">p</italic>&#160;&lt;&#160;0.0001) in both regions of 9&#8208;month&#8208;old APP&#8208;PS1 mice compared to 3&#8208;month&#8208;old counterparts and age&#8208;matched controls (Figure&#160;<xref rid="alz70592-fig-0007" ref-type="fig">7F</xref>; Tables <xref rid="alz70592-supinfo-0001" ref-type="">S7</xref> and <xref rid="alz70592-supinfo-0001" ref-type="">S8</xref>). In the hippocampus, 3&#8208;month&#8208;old APP&#8208;PS1 mice showed a significantly higher GFAP expression than their age&#8208;matched counterparts (<italic toggle="yes">p</italic>&#160;=&#160;0.0022). However, with aging, GFAP<sup>+</sup> astroglia showed a significant reduction in the hippocampus of 9&#8208;month&#8208;old APP&#8208;PS1 mice (<italic toggle="yes">p</italic>&#160;=&#160;0.0004) (Figure&#160;<xref rid="alz70592-fig-0007" ref-type="fig">7H</xref>; Table&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S7</xref>). In contrast, IBA1<sup>+</sup> microglial cell counts (<italic toggle="yes">p</italic>&#160;=&#160;0.0099) (Figure&#160;<xref rid="alz70592-fig-0007" ref-type="fig">7G</xref>; Table&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S7</xref>) and pixel counts (<italic toggle="yes">p</italic>&#160;=&#160;0.0374) (Figure&#160;<xref rid="alz70592-fig-0007" ref-type="fig">7I</xref>; Table&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S7</xref>) were significantly increased in the hippocampus of 9&#8208;month&#8208;old controls compared to 3&#8208;month&#8208;old controls, suggesting a role for microglia in mitigating APP/A&#946; peptide buildup, similar to findings observed in the aging control retina (Figure&#160;<xref rid="alz70592-fig-0006" ref-type="fig">6F</xref>). Aside from the 6E10<sup>+</sup> A&#946; plaques, astroglial and microglial expression in the neocortex showed no significant differences between APP&#8208;PS1 mice and controls at either time point (Table&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S8</xref>).</p><fig position="float" fig-type="FIGURE" id="alz70592-fig-0007" orientation="portrait"><label>FIGURE 7</label><caption><p>Localization of APP/A&#946; peptides and glial cells in the neocortex&#8208;hippocampus of 9&#8208;month&#8208;old APP&#8208;PS1 mice. Co&#8208;localization of 6E10<sup>+</sup> A&#946; plaques (yellow arrowheads) with (A) GFAP<sup>+</sup> astroglia and (B) IBA1<sup>+</sup> microglia was observed exclusively in the hippocampus and neocortex regions of 9&#8208;month&#8208;old APP&#8208;PS1 mice. (C) A rabbit monoclonal knockout&#8208;validated APP antibody confirmed intraneuronal inclusions of APP peptides (white arrows), predominantly in the neocortex, with minimal or no APP inclusions observed in the hippocampal CA regions. APP<sup>+</sup> dystrophic neurites (green arrows) were uniquely identified in 9&#8208;month&#8208;old APP&#8208;PS1 mice. (D) NIR&#8208;E3<sup>+</sup> SA&#946;Os in a 3&#8208;month&#8208;old APP&#8208;PS1 mouse were primarily detected within the endothelial cell layers of blood vessel lumens at meninges and appeared as small deposits within parenchyma (white arrowheads). (E) Intraneuronal inclusions of 6E10<sup>+</sup> APP peptides (white arrows) were observed in neocortex of 9&#8208;month&#8208;old APP&#8208;PS1 mice. (F&#8211;I) Semi&#8208;quantification of 6E10<sup>+</sup> A&#946; plaques (including diffuse&#8208;type) and IBA1<sup>+</sup> microglia, along with immunoreactivity quantified in pixels for GFAP<sup>+</sup> astroglia and IBA1<sup>+</sup> microglia, is presented as violin plots comparing 3&#8208; and 9&#8208;month&#8208;old APP&#8208;PS1 mice and controls in both the hippocampus and neocortex. Statistical significance was assessed using either the Brown&#8211;Forsythe and Welch ANOVA tests with Dunnett's T3 multiple comparisons or the Kruskal&#8211;Wallis test with Dunn's multiple comparisons, as appropriate. (J) A heatmap illustrates differential gene expression in pooled neocortex&#8208;hippocampus tissues, comparing APP&#8208;PS1 and control mice at 3 and 9 months of age, including age&#8208;related changes within each group. Significantly upregulated genes are shown with corresponding <italic toggle="yes">p</italic> values and fold changes. Two&#8208;way ANOVA with Bonferroni&#8208;corrected multiple comparisons was used for statistical analysis. <italic toggle="yes">P</italic> values&#160;&lt;&#160;0.05 were considered statistically significant. (Scale bar: 20&#160;&#181;m; sample size: <italic toggle="yes">N</italic>&#160;=&#160;4 per age group and model for 6E10 and GFAP, and 6E10 and IBA1 double labeling). A&#946;, amyloid beta; APP, amyloid precursor protein; GFAP, glial fibrillary acidic protein; NIR, near&#8208;infrared; SA&#946;O, soluble A&#946; oligomer.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-13" orientation="portrait" xlink:href="ALZ-21-e70592-g007.jpg"/></fig><p>Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S7</xref> summarizes the double labeling of 6E10 and GFAP or IBA1 across comparison groups in the hippocampus and neocortex. Co&#8208;localization of 6E10&#8314; A&#946; plaques with GFAP&#8314; astrocytes (yellow arrowheads) was observed exclusively in 9&#8208;month&#8208;old APP&#8208;PS1 mice (Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S7A</xref>). Similarly, co&#8208;localization of 6E10&#8314; A&#946; plaques with IBA1&#8314; microglia (yellow arrowheads) was detected only in the hippocampus (Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S7B</xref>) and neocortex (Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S7C</xref>) of 9&#8208;month&#8208;old APP&#8208;PS1 mice. To a lesser extent, diffuse&#8208;type 6E10&#8314; A&#946; plaques were also found in 3&#8208;month&#8208;old APP&#8208;PS1 mice (white arrowhead in Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S7B</xref>).</p><p>Although we focused solely on 6E10<sup>+</sup> A&#946; plaques for quantification, intraneuronal inclusions of 6E10<sup>+</sup> APP/A&#946; peptides were also identified within cortical neurons (Figure&#160;<xref rid="alz70592-fig-0007" ref-type="fig">7E</xref>, white arrows), consistent with the intraneuronal inclusions observed in retinal cross&#8208;sections (Figure&#160;<xref rid="alz70592-fig-0006" ref-type="fig">6A</xref>). To ensure that the observed signals were not due to background staining or cross&#8208;reactivity from mouse antibodies, we employed a knockout&#8208;validated rabbit monoclonal APP antibody. Intraneuronal APP&#8314; inclusions were detected in the neocortex of all animal groups but were absent in the hippocampus (Figures&#160;<xref rid="alz70592-fig-0007" ref-type="fig">7C</xref> and <xref rid="alz70592-supinfo-0001" ref-type="">S7D,E</xref>). Strong APP&#8314; intraneuronal inclusions were detected in 3&#8208;month&#8208;old APP&#8208;PS1 mice, while APP&#8314; dystrophic neurites were observed in the neocortex of 9&#8208;month&#8208;old APP&#8208;PS1 mice. In control mice, APP immunoreactivity decreased with age. This is noteworthy, as AD is characterized by neuritic plaques containing dystrophic neurites,<xref rid="alz70592-bib-0052" ref-type="bibr">
<sup>52</sup>
</xref> likely resulting from impaired clearance of intraneuronal APP peptides, as demonstrated in the neocortex of 9&#8208;month&#8208;old APP&#8208;PS1 mice (Figures&#160;<xref rid="alz70592-fig-0007" ref-type="fig">7C</xref> and <xref rid="alz70592-supinfo-0001" ref-type="">S7E</xref>). Interestingly, our recent work in 9&#8208;month&#8208;old apolipoprotein E (<italic toggle="yes">ApoE</italic>) knockout mice also showed strong immunoreactivity for APP&#8314; intraneuronal inclusions in both the hippocampus and cortex, supporting the role of <italic toggle="yes">ApoE</italic> in APP clearance.<xref rid="alz70592-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref>
</p><p>Additionally, we used the NIR&#8208;E3 nanobody to detect SA&#946;Os in the neocortex and hippocampus. NIR&#8208;E3 labeling was predominantly observed in endothelial cells lining blood vessel lumens, particularly in the leptomeninges, while small, dot&#8208;like, and sparsely distributed NIR&#8208;E3<sup>+</sup> SA&#946;Os were detected throughout the parenchyma (Figure&#160;<xref rid="alz70592-fig-0007" ref-type="fig">7D</xref>). Similar to the retina, NIR&#8208;E3&#8314; labeling in the leptomeninges of 9&#8208;month&#8208;old APP&#8208;PS1 mice was relatively weak compared to other groups.</p><p>Supplementary Table&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S9</xref> summarizes the relative expression levels of 22 target genes screened in pooled neocortex&#8208;hippocampus tissue using RT&#8208;qPCR. Both mouse <italic toggle="yes">App</italic> and human <italic toggle="yes">PSEN1</italic> mRNA levels were significantly upregulated in 3&#8208; and 9&#8208;month&#8208;old APP&#8208;PS1 mice compared to age&#8208;matched controls (Table&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S9</xref>). A heatmap (Figure&#160;<xref rid="alz70592-fig-0007" ref-type="fig">7J</xref>) illustrates the differential expression patterns between APP&#8208;PS1 and control mice at both ages, as well as age&#8208;related differences within each group. Notably, Trem2 (3.2&#8208;fold, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.0001) and Aqp4 (2&#8208;fold, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.0001) were significantly upregulated in 9&#8208;month&#8208;old APP&#8208;PS1 mice compared to their 3&#8208;month&#8208;old counterparts (Figure&#160;<xref rid="alz70592-fig-0007" ref-type="fig">7J</xref>).</p><p>APP&#8208;PS1 mice express chimeric mouse/human <italic toggle="yes">APP</italic> (<italic toggle="yes">Mo/HuAPP695swe</italic>) and mutant human <italic toggle="yes">PSEN1</italic> (<italic toggle="yes">PS1&#8208;dE9</italic>) genes, which drive A&#946; overproduction. We confirmed the upregulation of these gene transcripts in both neocortex&#8208;hippocampus and eye tissues at both time points compared to age&#8208;matched control mice (Tables <xref rid="alz70592-supinfo-0001" ref-type="">S6</xref> and <xref rid="alz70592-supinfo-0001" ref-type="">S9</xref>). The expression patterns of the remaining genes were comprehensively summarized in heatmaps for both the neocortex&#8208;hippocampus and eye tissues (Figures&#160;<xref rid="alz70592-fig-0006" ref-type="fig">6K</xref> and&#160;<xref rid="alz70592-fig-0007" ref-type="fig">7J</xref>, respectively). Apart from the transgenes, we observed a significant upregulation of <italic toggle="yes">Trem2</italic> mRNA in both brain and eye tissues of APP/PS1 mice as the disease progressed. <italic toggle="yes">Trem2</italic> is a key regulator of microglial adaptation to neurodegeneration, mediating the balance between protective phagocytosis and pro&#8208;inflammatory responses.<xref rid="alz70592-bib-0053" ref-type="bibr">
<sup>53</sup>
</xref> Downregulation of <italic toggle="yes">Trem2</italic> in microglia has been shown to markedly exacerbate AD&#8208;related neuropathology in APP/PS1 mice, including increased A&#946; deposition, gliosis, neuroinflammation, and neuronal and synaptic loss, which are accompanied by cognitive decline.<xref rid="alz70592-bib-0054" ref-type="bibr">
<sup>54</sup>
</xref> Authors<xref rid="alz70592-bib-0054" ref-type="bibr">
<sup>54</sup>
</xref> state that <italic toggle="yes">Trem2</italic> expression is elevated in APP/PS1 mice as early as 3 months of age and continues to increase with aging, supporting its proposed neuroprotective role.</p><p>While differentially expressed mRNAs correlate significantly better with their protein products than non&#8208;differentially expressed mRNAs,<xref rid="alz70592-bib-0055" ref-type="bibr">
<sup>55</sup>
</xref> as we have shown between <italic toggle="yes">Aif1</italic> mRNA levels and IBA1<sup>+</sup> immunoreactivity in eye tissue of aging APP&#8208;PS1 mice, discordance between mRNA and protein abundance can still occur, as demonstrated by the mismatch between <italic toggle="yes">GFAP</italic> mRNA levels and GFAP<sup>+</sup> immunoreactivity in the same tissue. Such discrepancies are often attributed to post&#8208;transcriptional and translational regulation (e.g., microRNAs), temporal decoupling, compensatory evolutionary mechanisms, and measurement limitations.<xref rid="alz70592-bib-0056" ref-type="bibr">
<sup>56</sup>
</xref>, <xref rid="alz70592-bib-0057" ref-type="bibr">
<sup>57</sup>
</xref>
</p></sec></sec></sec><sec id="alz70592-sec-0370"><label>4</label><title>DISCUSSION</title><p>An imbalance between the production and clearance of pathological proteins is a key contributor to AD, particularly in sporadic form. In familial AD, mutations in <italic toggle="yes">APP</italic>, <italic toggle="yes">PSEN1</italic>, and <italic toggle="yes">PSEN2</italic> drive disease progression by increasing A&#946; production.<xref rid="alz70592-bib-0058" ref-type="bibr">
<sup>58</sup>
</xref> Conversely, sporadic AD is strongly associated with risk genes like <italic toggle="yes">APOE</italic> and <italic toggle="yes">TREM2</italic>, which affect clearance and promote pathological protein accumulation.<xref rid="alz70592-bib-0058" ref-type="bibr">
<sup>58</sup>
</xref> Wholemount neuroretinas offer a valuable model to study interactions among neurons, glial cells, and the vasculature, particularly at the iBRB&#8211;interactions that cannot be effectively demonstrated at the BBB in brain cross&#8208;sections ex vivo.</p><p>In this study, we observed 12F4<sup>+</sup>A&#946;42 drainage path&#8208;like patterns in control neuroretinas that were largely disrupted in AD, suggesting the formation of 12F4<sup>+</sup>A&#946;42 aggregates, primarily around retinal blood vessels. Over the past decade, retinal A&#946; deposition in human AD and control neuroretinas has been reported using various antibodies targeting A&#946; oligomers, fibrils, plaques, and non&#8208;invasive imaging probes.<xref rid="alz70592-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="alz70592-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref>, <xref rid="alz70592-bib-0059" ref-type="bibr">
<sup>59</sup>
</xref>, <xref rid="alz70592-bib-0060" ref-type="bibr">
<sup>60</sup>
</xref>, <xref rid="alz70592-bib-0061" ref-type="bibr">
<sup>61</sup>
</xref> Recent in vivo mouse studies have revealed substantial peri&#8208; and para&#8208;vascular spaces surrounding pial arteries and penetrating arterioles,<xref rid="alz70592-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref>, <xref rid="alz70592-bib-0051" ref-type="bibr">
<sup>51</sup>
</xref>, <xref rid="alz70592-bib-0062" ref-type="bibr">
<sup>62</sup>
</xref>, <xref rid="alz70592-bib-0063" ref-type="bibr">
<sup>63</sup>
</xref>, <xref rid="alz70592-bib-0064" ref-type="bibr">
<sup>64</sup>
</xref> which were largely unrecognized before the advent of high&#8208;resolution imaging, as they are not visible in fixed tissues. To our knowledge, this is the first ex vivo study to demonstrate a defective 12F4<sup>+</sup>A&#946;42 clearance system at the iBRB, marked by increased 124<sup>+</sup>A&#946;42 clump&#8208;like deposition around blood vessels in AD (Figure&#160;<xref rid="alz70592-fig-0001" ref-type="fig">1</xref>), along with reduced SA&#946;O uptake (Figure&#160;<xref rid="alz70592-fig-0002" ref-type="fig">2</xref>), microglial elongation (Figure&#160;<xref rid="alz70592-fig-0003" ref-type="fig">3</xref>), macroglial degeneration (Figure&#160;<xref rid="alz70592-fig-0004" ref-type="fig">4</xref>), and AQP4 depletion (Figure&#160;<xref rid="alz70592-fig-0005" ref-type="fig">5</xref>). In contrast, control neuroretinas showed 12F4<sup>+</sup>A&#946;42 drainage path&#8208;like patterns at the ILM&#8211;NFL and along peri&#8208; and para&#8208;vascular spaces, where glymphatic structures were preserved and microglia displayed rounded processes. These findings are supported by 2D and 3D imaging of wholemount neuroretinas (Figure&#160;<xref rid="alz70592-fig-0001" ref-type="fig">1</xref>; Videos <xref rid="alz70592-supinfo-0001" ref-type="">S2&#8211;S10</xref>). Due to the limitations of ex vivo 3D imaging, both &#8220;peri&#8221; and &#8220;para&#8208;vascular&#8221; terms were used to describe 12F4<sup>+</sup>A&#946;42 peptide localization around blood vessels.</p><p>Compared to insoluble A&#946; deposits, A&#946; oligomers are considered the most toxic components in AD.<xref rid="alz70592-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="alz70592-bib-0065" ref-type="bibr">
<sup>65</sup>
</xref> We demonstrated SA&#946;O<sup>+</sup> labeling within the retinal vasculature in controls, which was significantly diminished in AD cases (Figure&#160;<xref rid="alz70592-fig-0002" ref-type="fig">2</xref>; Videos <xref rid="alz70592-supinfo-0001" ref-type="">S11&#8211;S14</xref>). The SA&#946;O antibody was developed against human A&#946;1&#8208;42 residues. Extensive in vitro and in vivo characterization has confirmed that the E3 nanobody crosses the BBB and binds selectively to SA&#946;Os and A&#946; plaques in a preclinical AD mouse model.<xref rid="alz70592-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> The NIR&#8208; and FAM&#8208;labeled E3 nanobody, approximately 10 times smaller than conventional antibodies, effectively penetrates the iBRB, suggesting SA&#946;O uptake by peripheral macrophage&#8208;like, A&#946;&#8208;binding myeloid lineage cells (Figure&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S2</xref>; Video&#160;<xref rid="alz70592-supinfo-0001" ref-type="">S13</xref>).</p><p>A recent study of 359 plasma samples reported lower concentrations of A&#946; oligomers in individuals with subjective cognitive decline and AD compared to healthy controls, linking impaired clearance to <italic toggle="yes">APOE4</italic> status.<xref rid="alz70592-bib-0066" ref-type="bibr">
<sup>66</sup>
</xref> Growing evidence supports a role for A&#946;&#8208;binding monocytes in A&#946; clearance,<xref rid="alz70592-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="alz70592-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> with reduced A&#946; uptake by blood monocytes observed during aging and more prominently in AD.<xref rid="alz70592-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> Huang et&#160;al.<xref rid="alz70592-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> developed a flow cytometry assay to identify CD14<sup>+</sup>CD16<sup>+</sup> monocytes that bind to A&#946; in the blood, revealing their macrophage&#8208;like phenotype with high A&#946; phagocytic potential. Using confocal microscopy, they localized A&#946; peptides on the cell surface and within the cytoplasm. Notably, surface A&#946; levels on monocytes were significantly lower in patients with MCI and AD, indicating impaired brain A&#946; clearance and suggesting these cells as potential biomarkers for AD diagnosis and therapeutic monitoring.</p><p>In our study, employing the E3 nanobody combined with a modified nanobody staining protocol<xref rid="alz70592-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> and confocal microscopy, we similarly demonstrated reduced uptake of SA&#946;Os by macrophage&#8208;like, A&#946;&#8208;binding myeloid lineage cells within the retinal vasculature of AD wholemount neuroretinas. The retina&#8208;vitreous humor interface, where flow&#8208;like nanoparticles are typically observed, appeared intact in controls but showed larger A&#946;42 species or reduced flow&#8208;like patterns in AD neuroretinas (Figures&#160;<xref rid="alz70592-fig-0002" ref-type="fig">2F</xref> and <xref rid="alz70592-supinfo-0001" ref-type="">S3F,G</xref>; Videos <xref rid="alz70592-supinfo-0001" ref-type="">S15</xref> and <xref rid="alz70592-supinfo-0001" ref-type="">S16</xref>). This aligns with our prior study showing enhanced APP/A&#946; efflux at the wholemount surface in ergothioneine&#8208;treated versus untreated 5xFAD mice.<xref rid="alz70592-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref>
</p><p>Microglia respond to brain tissue damage from aging and neurodegeneration by altering their morphology and transcriptome to clear debris and restore homeostasis.<xref rid="alz70592-bib-0053" ref-type="bibr">
<sup>53</sup>
</xref> While microglial phenotypes have been extensively studied in rodent AD models and human AD brain tissue, research on retinal microglia in AD&#160;&#8211; particularly in humans&#160;&#8211; remains limited.<xref rid="alz70592-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="alz70592-bib-0060" ref-type="bibr">
<sup>60</sup>
</xref>, <xref rid="alz70592-bib-0067" ref-type="bibr">
<sup>67</sup>
</xref>, <xref rid="alz70592-bib-0068" ref-type="bibr">
<sup>68</sup>
</xref>, <xref rid="alz70592-bib-0069" ref-type="bibr">
<sup>69</sup>
</xref>, <xref rid="alz70592-bib-0070" ref-type="bibr">
<sup>70</sup>
</xref> In our recent study using 3D imaging and machine learning, we found significantly fewer but larger microglia in human AD wholemounts.<xref rid="alz70592-bib-0067" ref-type="bibr">
<sup>67</sup>
</xref> Building on these findings with a larger sample, we observed significantly higher IBA1 expression in AD mid&#8208;peripheral regions, likely due to infiltrating IBA1&#8314; cells (Figures&#160;<xref rid="alz70592-fig-0003" ref-type="fig">3</xref> and <xref rid="alz70592-supinfo-0001" ref-type="">S4</xref>; Videos <xref rid="alz70592-supinfo-0001" ref-type="">S17</xref> and <xref rid="alz70592-supinfo-0001" ref-type="">S19</xref>). Despite some infiltrating or amoeboid&#8208;shaped IBA1&#8314; cells in the ILM and superficial layers and a few resting IBA1&#8314; microglia in deeper layers (OPL), 2D and 3D analyses revealed predominantly rod&#8208;shaped or elongated microglia with dystrophic features in AD, mainly from the NFL to OPL. Similar morphologies were reported in <italic toggle="yes">post mortem</italic> AD cases in the 1900s and have re&#8208;emerged in recent brain injury models.<xref rid="alz70592-bib-0071" ref-type="bibr">
<sup>71</sup>
</xref> In contrast, IBA1&#8314; microglia/macrophages in controls exhibited rounded processes, mainly located in the NFL to IPL. Limited CD68 or LAMP1 co&#8208;localization with IBA1<sup>+</sup> cells in small subgroup analyses underscores the need for larger cohorts or alternative markers to assess phagocytic activity at the iBRB.</p><p>Neuroimaging and fluid transport studies emphasize the glymphatic&#8211;lymphatic system's role in clearing A&#946; and other proteins.<xref rid="alz70592-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref>, <xref rid="alz70592-bib-0051" ref-type="bibr">
<sup>51</sup>
</xref>, <xref rid="alz70592-bib-0072" ref-type="bibr">
<sup>72</sup>
</xref> As anti&#8208;A&#946; trials falter, targeting waste clearance provides a broad, transporter&#8208;independent approach to mitigating protein aggregation. Evidence suggests that A&#946; initiates&#160;&#8211; but does not directly cause&#160;&#8211; neuronal loss and cognitive decline in AD. Using a rodent model, Wang et&#160;al.<xref rid="alz70592-bib-0072" ref-type="bibr">
<sup>72</sup>
</xref> demonstrated that the ocular glymphatic pathway, reliant on the glial water channel AQP4, removes metabolites and A&#946; tracers from the retina and vitreous humor via an ocular&#8208;cranial pressure gradient through the optic nerve and meningeal lymphatics. The iBRB, structurally and functionally similar to the BBB,<xref rid="alz70592-bib-0073" ref-type="bibr">
<sup>73</sup>
</xref>, <xref rid="alz70592-bib-0074" ref-type="bibr">
<sup>74</sup>
</xref>, <xref rid="alz70592-bib-0075" ref-type="bibr">
<sup>75</sup>
</xref> consists of non&#8208;fenestrated endothelial cells, pericytes, and astroglial/M&#252;ller cell endfeet enriched with AQP4. Loss of perivascular AQP4 contributes to age&#8208;related vulnerability to protein misaggregation, such as A&#946;, in AD.<xref rid="alz70592-bib-0076" ref-type="bibr">
<sup>76</sup>
</xref> While in vitro and transgenic models have advanced AD research, their relevance to humans remains uncertain, as demonstrated by structural differences in the ILM&#8211;GCL region between human and mouse retinas observed in this study. Notably, AD neuroretinas exhibited marked degeneration of macroglia (GFAP&#8314; astrocytes and GS&#8314; M&#252;ller cells) and AQP4&#8314; water channels, in contrast to their preservation in controls, as seen in wholemounts and supported by human retinal cross&#8208;sections.<xref rid="alz70592-fig-0008" ref-type="fig">&#8195;</xref>
</p><p>In our preclinical 2D analyses, intraneuronal inclusion of 6E10&#8314; APP/A&#946; peptides, along with elevated GFAP, AQP4, and IBA1 expression, was observed in the retinas (all regions) of aging APP&#8208;PS1 mice&#160;&#8211; consistent with findings from human AD retinal cross&#8208;sections.<xref rid="alz70592-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="alz70592-bib-0060" ref-type="bibr">
<sup>60</sup>
</xref> Koronyo et&#160;al.<xref rid="alz70592-bib-0060" ref-type="bibr">
<sup>60</sup>
</xref> reported increased IBA1&#8314; microgliosis and GFAP&#8314; or S100&#946;&#8314; macrogliosis&#160;&#8211; markers of astrocytes and M&#252;ller glia&#160;&#8211; surrounding retinal A&#946; deposits in MCI and AD patients. These glial responses correlated with A&#946; burden, implicating A&#946;&#8208;induced glial activation.<xref rid="alz70592-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="alz70592-bib-0060" ref-type="bibr">
<sup>60</sup>
</xref> In contrast, non&#8208;carrier sibling controls showed reduced 6E10&#8314; APP/A&#946; and increased IBA1&#8314; microglia, consistent with our previous findings in age&#8208;matched C57BL/6J mice.<xref rid="alz70592-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref> APP&#8208;specific antibody validation confirmed lower APP in cortical neurons of non&#8208;carrier sibling controls, unlike APP&#8314; dystrophic neurites in aging APP&#8208;PS1 mice, suggesting failures in APP/A&#946; peptide clearance.</p><p>We acknowledge the limitations of our study. As it relied on ex vivo imaging, we could not assess A&#946; clearance or drainage through functional assays with A&#946; tracers or evaluate the effects of AQP4 inhibition&#160;&#8211; approaches typically used in in vivo imaging, mainly in animal models. We also lacked vessel markers to distinguish veins from arteries in adult wholemounts using fluorescence microscopy. Additionally, due to the limited sample size, we did not analyze the findings concerning comorbidities in AD donors. Age&#8208;matched control donor eyes were obtained through an eye bank, with no documented history of AD or related dementias. The small sample size also prevented us from addressing diversity, equity, and inclusion (DEI) in the study's design, execution, and interpretation.</p><p>For the animal studies, limitations included a small sample size, a focus on female mice, and analysis at only two time points (3 and 9&#160;months). The sample size was determined using the resource equation method. Beyond age and genetic predisposition, female sex is a non&#8208;modifiable risk factor for AD; thus, we focused on female mice. We analyzed 3&#8208; and 9&#8208;month time points to assess early disease changes; however, this was not a true longitudinal study, as different mouse cohorts were used.</p><p>Overall, our schematic illustration (Figure&#160;<xref rid="alz70592-fig-0008" ref-type="fig">8</xref>) succinctly depicts a proposed model of multiple A&#946; clearance pathways at the iBRB. The imaging view plane (surface vs cross&#8208;section) may significantly influence findings, as demonstrated by differences observed in human wholemounts and mouse retinal cross&#8208;sections in the context of AD. Wholemounts revealed layer&#8208;specific labeling and notable variability, especially within the AD group. Nevertheless, our comprehensive wholemount investigations identified compensatory interactions between the glymphatic system and microglia/macrophage phagocytosis in mitigating A&#946; deposition, as well as the involvement of peripheral macrophage&#8208;like A&#946;&#8208;binding myeloid lineage cells in SA&#946;O uptake in controls. These processes appeared largely disrupted in AD donors. These findings were revealed through ex vivo 3D retinal imaging, employed for the first time to study this process, particularly at the iBRB, a functional analog of the BBB.</p><fig position="float" fig-type="FIGURE" id="alz70592-fig-0008" orientation="portrait"><label>FIGURE 8</label><caption><p>Schematic illustration depicting a proposed model of multiple A&#946; clearance pathways, potentially incorporating findings observed through ex vivo 3D imaging at iBRB. (A) Illustration of connection between eye and brain via optic nerve. (B, C) Flat&#8208;mounted neuroretina, illustrating retinal vasculature at superficial plexus. (D) Vascular transport of soluble A&#946; as bulk flow. (E) Ocular glymphatic drainage pathway for soluble A&#946; bulk flow. (F) Uptake and degradation of SA&#946;O by peripheral monocytes, and phagocytosis of insoluble A&#946; deposits by resident microglia/macrophages. This figure was created in BioRender (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://BioRender.com/b64q914" ext-link-type="uri">https://BioRender.com/b64q914</ext-link>). A&#946;, amyloid beta; iBRB, inner blood&#8211;retina barrier; SA&#946;O, soluble A&#946; oligomer; LRP1, low&#8208;density lipoprotein receptor&#8208;related protein 1; RAGE, receptor for advanced glycation end products.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-15" orientation="portrait" xlink:href="ALZ-21-e70592-g004.jpg"/></fig></sec><sec id="alz70592-sec-0380"><title>AUTHOR CONTRIBUTIONS</title><p>
<italic toggle="yes">Conceptualization</italic>: Printha Wijesinghe and Joanne A. Matsubara. <italic toggle="yes">Project administration</italic>: Printha Wijesinghe and Joanne A. Matsubara. <italic toggle="yes">Funding acquisition</italic>: Printha Wijesinghe, Wellington Pham, and Joanne A. Matsubara. <italic toggle="yes">Data curation</italic>: Printha Wijesinghe, Jeanne Xi, Ian R. Mackenzie, Veronica Hirsch&#8208;Reinshagen, and Ging&#8208;Yuek Robin Hsiung <italic toggle="yes">Formal analysis</italic>: Printha Wijesinghe. <italic toggle="yes">Investigation</italic>: Printha Wijesinghe, Amir Hosseini, Matthew Campbell, Shivani Tejpal, Justin Haynes, Jeanne Xi, Ian R. Mackenzie, Veronica Hirsch&#8208;Reinshagen, Ging&#8208;Yuek Robin Hsiung, Benjamin W. Spiller, and Brian E. Wadzinski. <italic toggle="yes">Methodology</italic>: Printha Wijesinghe, Amir Hosseini, Matthew Campbell, Shivani Tejpal, Justin Haynes, Jeanne Xi, Ian R. Mackenzie, Veronica Hirsch&#8208;Reinshagen, Ging&#8208;Yuek Robin Hsiung, Benjamin W. Spiller, and Brian E. Wadzinski. <italic toggle="yes">Validation</italic>: Ian R. Mackenzie, Veronica Hirsch&#8208;Reinshagen, Ging&#8208;Yuek Robin Hsiung, Benjamin W. Spiller, Brian E. Wadzinski, Wellington Pham, and Joanne A. Matsubara. <italic toggle="yes">Visualization</italic>: Printha Wijesinghe, Amir Hosseini, and Matthew Campbell. <italic toggle="yes">Writing&#160;&#8211; original draft and major revision</italic>: Printha Wijesinghe. Writing&#160;&#8211; review and editing: Amir Hosseini, Matthew Campbell, Shivani Tejpal, Justin Haynes, Jeanne Xi, Ian R. Mackenzie, Veronica Hirsch&#8208;Reinshagen, Ging&#8208;Yuek Robin Hsiung, Benjamin W. Spiller, Brian E. Wadzinski, Wellington Pham, and Joanne A. Matsubara. <italic toggle="yes">Resources</italic>: Wellington Pham and Joanne A. Matsubara. <italic toggle="yes">Supervision</italic>: Printha Wijesinghe and Joanne A. Matsubara.</p></sec><sec sec-type="COI-statement" id="alz70592-sec-0400"><title>CONFLICT OF INTEREST STATEMENT</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationship that could be construed as a potential conflict of interest. BWS and BEW are co&#8208;founders and owners of Turkey Creek Biotechnology (TCB). TCB was not involved in this work.</p></sec><sec id="alz70592-sec-0430"><title>CONSENT STATEMENT</title><p>We confirm that informed consent was obtained from all human subjects.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="alz70592-supinfo-0001" position="float" content-type="local-data" orientation="portrait"/><supplementary-material id="alz70592-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s015.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s008.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0003" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s045.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0004" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s044.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0005" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s023.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0006" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s035.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0007" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s028.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0008" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s024.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0009" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s039.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0010" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s036.tif" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0011" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s046.tif" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0012" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s007.tif" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0013" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s041.tif" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0014" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s047.tif" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0015" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s029.tif" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0016" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s013.tif" position="float" orientation="portrait"/></supplementary-material><supplementary-material position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s042.mov" mimetype="video" mime-subtype="quicktime" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0017" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s009.mov" mimetype="video" mime-subtype="quicktime" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0018" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s032.mov" mimetype="video" mime-subtype="quicktime" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0019" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s040.mov" mimetype="video" mime-subtype="quicktime" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0020" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s033.mov" mimetype="video" mime-subtype="quicktime" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0021" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s031.mov" mimetype="video" mime-subtype="quicktime" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0022" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s010.mov" mimetype="video" mime-subtype="quicktime" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0023" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s012.mov" mimetype="video" mime-subtype="quicktime" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0024" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s048.mov" mimetype="video" mime-subtype="quicktime" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0025" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s011.mov" mimetype="video" mime-subtype="quicktime" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0026" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s016.mov" mimetype="video" mime-subtype="quicktime" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0027" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s037.mov" mimetype="video" mime-subtype="quicktime" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0028" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s025.mov" mimetype="video" mime-subtype="quicktime" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0029" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s026.mov" mimetype="video" mime-subtype="quicktime" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0030" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s004.mov" mimetype="video" mime-subtype="quicktime" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0031" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s018.mov" mimetype="video" mime-subtype="quicktime" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0032" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s001.mov" mimetype="video" mime-subtype="quicktime" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0033" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s019.mov" mimetype="video" mime-subtype="quicktime" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0034" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s002.mov" mimetype="video" mime-subtype="quicktime" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0035" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s006.mov" mimetype="video" mime-subtype="quicktime" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0036" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s014.mov" mimetype="video" mime-subtype="quicktime" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0037" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s034.mov" mimetype="video" mime-subtype="quicktime" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0038" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s021.mov" mimetype="video" mime-subtype="quicktime" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0039" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s005.mov" mimetype="video" mime-subtype="quicktime" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0040" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s027.mov" mimetype="video" mime-subtype="quicktime" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0041" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s038.mov" mimetype="video" mime-subtype="quicktime" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0042" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s017.mov" mimetype="video" mime-subtype="quicktime" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0043" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s003.mov" mimetype="video" mime-subtype="quicktime" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0044" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s020.mov" mimetype="video" mime-subtype="quicktime" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0045" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s030.mov" mimetype="video" mime-subtype="quicktime" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0047" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s043.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70592-supitem-0048" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70592-s022.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="alz70592-sec-0390"><title>ACKNOWLEDGMENTS</title><p>The authors would like to thank our past lab manager, Eleanor To, and our current lab manager, Chuan&#8208;Hui&#160;Kuo, for their timely assistance in placing orders during the experimental processes. The authors greatly appreciate Dr. Jing Cui for facilitating the collection of human donor eyes, as well as medical students Hao Ran Li, Khola Bilal, and Jean Oh and undergraduate students Zhengyuan Ai and Si Xuan Chen, for their support in independent image analysis, including pixel counting and manual semi&#8208;quantitative assessments. Alzheimer Society of Canada and Brain Canada, Canadian Institute of Health Research, National Sciences and Engineering Research Council of Canada, and National Institutes of Health&#8208;NIA R01 AG061138, Vanderbilt CTSA Grant UL1TR002243 from NCATS/NIH, Vanderbilt Brain Institute TIPS Funding, and the Vanderbilt Ingram Cancer Center Shared Resource Scholarships.</p></ack><sec sec-type="data-availability" id="alz70592-sec-0420"><title>DATA AVAILABILITY STATEMENT</title><p>The raw data supporting the conclusions of this manuscript will be made available by the authors upon request.</p></sec><ref-list id="alz70592-bibl-0001"><title>REFERENCES</title><ref id="alz70592-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="alz70592-cite-0002"><string-name name-style="western"><surname>Hampel</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Hardy</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Blennow</surname><given-names>K</given-names></string-name>, et&#160;al. <article-title>The amyloid&#8208;&#946; pathway in Alzheimer's disease</article-title>. <source>Mol Psychiatry</source>. <year>2021</year>;<volume>26</volume>:<fpage>5481</fpage>&#8208;<lpage>5503</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41380-021-01249-0</pub-id><pub-id pub-id-type="pmid">34456336</pub-id><pub-id pub-id-type="pmcid">PMC8758495</pub-id></mixed-citation></ref><ref id="alz70592-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="alz70592-cite-0003"><string-name name-style="western"><surname>Wang</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Yin</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Ge</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Lei</surname><given-names>P</given-names></string-name>. <article-title>Relationship between amyloid&#8208;&#946; deposition and blood&#8208;brain barrier dysfunction in Alzheimer's disease</article-title>. <source>Front Cell Neurosci</source>. <year>2021</year>;<volume>15</volume>:<elocation-id>695479</elocation-id>. doi:<pub-id pub-id-type="doi">10.3389/fncel.2021.695479</pub-id><pub-id pub-id-type="pmid">34349624</pub-id><pub-id pub-id-type="pmcid">PMC8326917</pub-id></mixed-citation></ref><ref id="alz70592-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="alz70592-cite-0004"><string-name name-style="western"><surname>Roselli</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Satir</surname><given-names>TM</given-names></string-name>, <string-name name-style="western"><surname>Camacho</surname><given-names>R</given-names></string-name>, et&#160;al. <article-title>APP&#8208;BACE1 interaction and intracellular localization regulate A&#946; production in iPSC&#8208;derived cortical neurons</article-title>. <source>Cell Mol Neurobiol</source>. <year>2023</year>;<volume>43</volume>:<fpage>3653</fpage>&#8208;<lpage>3668</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10571-023-01374-0</pub-id><pub-id pub-id-type="pmid">37355492</pub-id><pub-id pub-id-type="pmcid">PMC10477112</pub-id></mixed-citation></ref><ref id="alz70592-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="alz70592-cite-0005"><string-name name-style="western"><surname>Walsh</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Klyubin</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Fadeeva</surname><given-names>JV</given-names></string-name>, et&#160;al. <article-title>Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long&#8208;term potentiation in vivo</article-title>. <source>Nature</source>. <year>2002</year>;<volume>416</volume>:<fpage>535</fpage>&#8208;<lpage>539</lpage>. doi:<pub-id pub-id-type="doi">10.1038/416535a</pub-id><pub-id pub-id-type="pmid">11932745</pub-id></mixed-citation></ref><ref id="alz70592-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="alz70592-cite-0006"><string-name name-style="western"><surname>Shankar</surname><given-names>GM</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mehta</surname><given-names>TH</given-names></string-name>, et&#160;al. <article-title>Amyloid&#8208;beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory</article-title>. <source>Nat Med</source>. <year>2008</year>;<volume>14</volume>:<fpage>837</fpage>&#8208;<lpage>842</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nm1782</pub-id><pub-id pub-id-type="pmid">18568035</pub-id><pub-id pub-id-type="pmcid">PMC2772133</pub-id></mixed-citation></ref><ref id="alz70592-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="alz70592-cite-0007"><string-name name-style="western"><surname>Esparza</surname><given-names>TJ</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Cirrito</surname><given-names>JR</given-names></string-name>, et&#160;al. <article-title>Amyloid&#8208;&#946; oligomerization in Alzheimer dementia versus high&#8208;pathology controls</article-title>. <source>Ann Neurol</source>. <year>2013</year>;<volume>73</volume>:<fpage>104</fpage>&#8208;<lpage>119</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ana.23748</pub-id><pub-id pub-id-type="pmid">23225543</pub-id><pub-id pub-id-type="pmcid">PMC3563737</pub-id></mixed-citation></ref><ref id="alz70592-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="alz70592-cite-0008"><string-name name-style="western"><surname>Fukumoto</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Tokuda</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Kasai</surname><given-names>T</given-names></string-name>, et&#160;al. <article-title>High&#8208;molecular&#8208;weight beta&#8208;amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients</article-title>. <source>FASEB J</source>. <year>2010</year>;<volume>24</volume>:<fpage>2716</fpage>&#8208;<lpage>2726</lpage>. doi:<pub-id pub-id-type="doi">10.1096/fj.09-150359</pub-id><pub-id pub-id-type="pmid">20339023</pub-id></mixed-citation></ref><ref id="alz70592-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="alz70592-cite-0009"><string-name name-style="western"><surname>Bilousova</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Miller</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Poon</surname><given-names>WW</given-names></string-name>, et&#160;al. <article-title>Synaptic amyloid&#8208;&#946; oligomers precede p&#8208;tau and differentiate high pathology control cases</article-title>. <source>Am J Pathol</source>. <year>2016</year>;<volume>186</volume>:<fpage>185</fpage>&#8208;<lpage>198</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ajpath.2015.09.018</pub-id><pub-id pub-id-type="pmid">26718979</pub-id><pub-id pub-id-type="pmcid">PMC4715217</pub-id></mixed-citation></ref><ref id="alz70592-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="alz70592-cite-0010"><string-name name-style="western"><surname>Haynes</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Whitmore</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Behof</surname><given-names>WJ</given-names></string-name>, et&#160;al. <article-title>Targeting soluble amyloid&#8208;beta oligomers with a novel nanobody</article-title>. <source>Sci Rep</source>. <year>2024</year>;<volume>14</volume>:<elocation-id>16086</elocation-id>. doi:<pub-id pub-id-type="doi">10.1038/s41598-024-66970-6</pub-id><pub-id pub-id-type="pmid">38992064</pub-id><pub-id pub-id-type="pmcid">PMC11239946</pub-id></mixed-citation></ref><ref id="alz70592-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="alz70592-cite-0011"><string-name name-style="western"><surname>Cleary</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Walsh</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Hofmeister</surname><given-names>JJ</given-names></string-name>, et&#160;al. <article-title>Natural oligomers of the amyloid&#8208;beta protein specifically disrupt cognitive function</article-title>. <source>Nat Neurosci</source>. <year>2005</year>;<volume>8</volume>:<fpage>79</fpage>&#8208;<lpage>84</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nn1372</pub-id><pub-id pub-id-type="pmid">15608634</pub-id></mixed-citation></ref><ref id="alz70592-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="alz70592-cite-0012"><string-name name-style="western"><surname>Bateman</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Munsell</surname><given-names>LY</given-names></string-name>, <string-name name-style="western"><surname>Morris</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Swarm</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Yarasheski</surname><given-names>KE</given-names></string-name>, <string-name name-style="western"><surname>Holtzman</surname><given-names>DM</given-names></string-name>. <article-title>Human amyloid&#8208;beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo</article-title>. <source>Nat Med</source>. <year>2006</year>;<volume>12</volume>:<fpage>856</fpage>&#8208;<lpage>861</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nm1438</pub-id><pub-id pub-id-type="pmid">16799555</pub-id><pub-id pub-id-type="pmcid">PMC2983090</pub-id></mixed-citation></ref><ref id="alz70592-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="alz70592-cite-0013"><string-name name-style="western"><surname>Engelhardt</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Carare</surname><given-names>RO</given-names></string-name>, <string-name name-style="western"><surname>Bechmann</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Fl&#252;gel</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Laman</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Weller</surname><given-names>RO</given-names></string-name>. <article-title>Vascular, glial, and lymphatic immune gateways of the central nervous system</article-title>. <source>Acta Neuropathol</source>. <year>2016</year>;<volume>132</volume>:<fpage>317</fpage>&#8208;<lpage>338</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00401-016-1606-5</pub-id><pub-id pub-id-type="pmid">27522506</pub-id><pub-id pub-id-type="pmcid">PMC4992028</pub-id></mixed-citation></ref><ref id="alz70592-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="alz70592-cite-0014"><string-name name-style="western"><surname>Qosa</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Abuasal</surname><given-names>BS</given-names></string-name>, <string-name name-style="western"><surname>Romero</surname><given-names>IA</given-names></string-name>, et&#160;al. <article-title>Differences in amyloid&#8208;&#946; clearance across mouse and human blood&#8208;brain barrier models: kinetic analysis and mechanistic modeling</article-title>. <source>Neuropharmacology</source>. <year>2014</year>;<volume>79</volume>:<fpage>668</fpage>&#8208;<lpage>678</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.neuropharm.2014.01.023</pub-id><pub-id pub-id-type="pmid">24467845</pub-id><pub-id pub-id-type="pmcid">PMC3965363</pub-id></mixed-citation></ref><ref id="alz70592-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="alz70592-cite-0015"><string-name name-style="western"><surname>Xiang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Bu</surname><given-names>X&#8208;L</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y&#8208;H</given-names></string-name>, et&#160;al. <article-title>Physiological amyloid&#8208;beta clearance in the periphery and its therapeutic potential for Alzheimer's disease</article-title>. <source>Acta Neuropathol</source>. <year>2015</year>;<volume>130</volume>:<fpage>487</fpage>&#8208;<lpage>499</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00401-015-1477-1</pub-id><pub-id pub-id-type="pmid">26363791</pub-id><pub-id pub-id-type="pmcid">PMC4575389</pub-id></mixed-citation></ref><ref id="alz70592-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="alz70592-cite-0016"><string-name name-style="western"><surname>Yuede</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Restivo</surname><given-names>JL</given-names></string-name>, et&#160;al. <article-title>Rapid in vivo measurement of &#946;&#8208;amyloid reveals biphasic clearance kinetics in an Alzheimer's mouse model</article-title>. <source>J Exp Med</source>. <year>2016</year>;<volume>213</volume>:<fpage>677</fpage>&#8208;<lpage>685</lpage>. doi:<pub-id pub-id-type="doi">10.1084/jem.20151428</pub-id><pub-id pub-id-type="pmid">27069115</pub-id><pub-id pub-id-type="pmcid">PMC4854730</pub-id></mixed-citation></ref><ref id="alz70592-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="alz70592-cite-0017"><string-name name-style="western"><surname>Kim</surname><given-names>DE</given-names></string-name>, <string-name name-style="western"><surname>Priefer</surname><given-names>R</given-names></string-name>. <article-title>Therapeutic potential of direct clearance of the amyloid&#8208;&#946; in Alzheimer's disease</article-title>. <source>Brain Sci</source>. <year>2020</year>;<volume>10</volume>:<fpage>93</fpage>. doi:<pub-id pub-id-type="doi">10.3390/brainsci10020093</pub-id><pub-id pub-id-type="pmid">32050618</pub-id><pub-id pub-id-type="pmcid">PMC7071829</pub-id></mixed-citation></ref><ref id="alz70592-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="alz70592-cite-0018"><string-name name-style="western"><surname>Th&#233;riault</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>ElAli</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rivest</surname><given-names>S</given-names></string-name>. <article-title>The dynamics of monocytes and microglia in Alzheimer's disease</article-title>. <source>Alzheimers Res Ther</source>. <year>2015</year>;<volume>7</volume>:<fpage>41</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13195-015-0125-2</pub-id><pub-id pub-id-type="pmid">25878730</pub-id><pub-id pub-id-type="pmcid">PMC4397873</pub-id></mixed-citation></ref><ref id="alz70592-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="alz70592-cite-0019"><string-name name-style="western"><surname>Chen</surname><given-names>S&#8208;H</given-names></string-name>, <string-name name-style="western"><surname>Tian</surname><given-names>D&#8208;Y</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>Y&#8208;Y</given-names></string-name>, et&#160;al. <article-title>Amyloid&#8208;beta uptake by blood monocytes is reduced with ageing and Alzheimer's disease</article-title>. <source>Transl Psychiatry</source>. <year>2020</year>;<volume>10</volume>:<fpage>423</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41398-020-01113-9</pub-id><pub-id pub-id-type="pmid">33293506</pub-id><pub-id pub-id-type="pmcid">PMC7722845</pub-id></mixed-citation></ref><ref id="alz70592-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="alz70592-cite-0020"><string-name name-style="western"><surname>Huang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Fowler</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, et&#160;al. <article-title>Clearance and transport of amyloid &#946; by peripheral monocytes correlate with Alzheimer's disease progression</article-title>. <source>Nat Commun</source>. <year>2024</year>;<volume>15</volume>:<fpage>7998</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41467-024-52396-1</pub-id><pub-id pub-id-type="pmid">39266542</pub-id><pub-id pub-id-type="pmcid">PMC11393069</pub-id></mixed-citation></ref><ref id="alz70592-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="alz70592-cite-0021"><string-name name-style="western"><surname>Juul&#8208;Madsen</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Parbo</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Ismail</surname><given-names>R</given-names></string-name>, et&#160;al. <article-title>Amyloid&#8208;&#946; aggregates activate peripheral monocytes in mild cognitive impairment</article-title>. <source>Nat Commun</source>. <year>2024</year>;<volume>15</volume>:<fpage>1224</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41467-024-45627-y</pub-id><pub-id pub-id-type="pmid">38336934</pub-id><pub-id pub-id-type="pmcid">PMC10858199</pub-id></mixed-citation></ref><ref id="alz70592-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="alz70592-cite-0022"><string-name name-style="western"><surname>Kashani</surname><given-names>AH</given-names></string-name>, <string-name name-style="western"><surname>Asanad</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Chan</surname><given-names>JW</given-names></string-name>, et&#160;al. <article-title>Past, present and future role of retinal imaging in neurodegenerative disease</article-title>. <source>Prog Retin Eye Res</source>. <year>2021</year>;<volume>83</volume>:<elocation-id>100938</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.preteyeres.2020.100938</pub-id><pub-id pub-id-type="pmid">33460813</pub-id><pub-id pub-id-type="pmcid">PMC8280255</pub-id></mixed-citation></ref><ref id="alz70592-bib-0022"><label>22</label><mixed-citation publication-type="book" id="alz70592-cite-0023"><string-name name-style="western"><surname>Purves</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Augustine</surname><given-names>GJ</given-names></string-name>, <string-name name-style="western"><surname>Fitzpatrick</surname><given-names>D</given-names></string-name>, et&#160;al. <article-title>The Retina. <italic toggle="yes">Neuroscience. 2nd edition</italic>
</article-title>. <publisher-name>Sinauer Associates</publisher-name>; <year>2001</year>.</mixed-citation></ref><ref id="alz70592-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="alz70592-cite-0024"><string-name name-style="western"><surname>Xu</surname><given-names>QA</given-names></string-name>, <string-name name-style="western"><surname>Boerkoel</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Hirsch&#8208;Reinshagen</surname><given-names>V</given-names></string-name>, et&#160;al. <article-title>M&#252;ller cell degeneration and microglial dysfunction in the Alzheimer's retina</article-title>. <source>Acta Neuropathol Commun</source>. <year>2022</year>;<volume>10</volume>:<fpage>145</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s40478-022-01448-y</pub-id><pub-id pub-id-type="pmid">36199154</pub-id><pub-id pub-id-type="pmcid">PMC9533552</pub-id></mixed-citation></ref><ref id="alz70592-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="alz70592-cite-0025"><string-name name-style="western"><surname>Kim</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>YJ</given-names></string-name>, <string-name name-style="western"><surname>Bae</surname><given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Woo</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>KW</given-names></string-name>. <article-title>Association between retinal layer thickness and cognitive decline in older adults</article-title>. <source>JAMA Ophthalmol</source>. <year>2022</year>;<volume>140</volume>:<fpage>683</fpage>&#8208;<lpage>690</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamaophthalmol.2022.1563</pub-id><pub-id pub-id-type="pmid">35616950</pub-id><pub-id pub-id-type="pmcid">PMC9136677</pub-id></mixed-citation></ref><ref id="alz70592-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="alz70592-cite-0026"><string-name name-style="western"><surname>Berisha</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Feke</surname><given-names>GT</given-names></string-name>, <string-name name-style="western"><surname>Trempe</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>McMeel</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Schepens</surname><given-names>CL</given-names></string-name>. <article-title>Retinal abnormalities in early Alzheimer's disease</article-title>. <source>Invest Ophthalmol Vis Sci</source>. <year>2007</year>;<volume>48</volume>:<fpage>2285</fpage>&#8208;<lpage>2289</lpage>. doi:<pub-id pub-id-type="doi">10.1167/iovs.06-1029</pub-id><pub-id pub-id-type="pmid">17460292</pub-id></mixed-citation></ref><ref id="alz70592-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="alz70592-cite-0027"><string-name name-style="western"><surname>Snyder</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Johnson</surname><given-names>LN</given-names></string-name>, <string-name name-style="western"><surname>Lim</surname><given-names>YY</given-names></string-name>, et&#160;al. <article-title>Nonvascular retinal imaging markers of preclinical Alzheimer's disease</article-title>. <source>Alzheimers Dement</source>. <year>2016</year>;<volume>4</volume>:<fpage>169</fpage>&#8208;<lpage>178</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.dadm.2016.09.001</pub-id><pub-id pub-id-type="pmcid">PMC5078641</pub-id><pub-id pub-id-type="pmid">27830174</pub-id></mixed-citation></ref><ref id="alz70592-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="alz70592-cite-0028"><string-name name-style="western"><surname>Marziani</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Pomati</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ramolfo</surname><given-names>P</given-names></string-name>, et&#160;al. <article-title>Evaluation of retinal nerve fiber layer and ganglion cell layer thickness in Alzheimer's disease using spectral&#8208;domain optical coherence tomography</article-title>. <source>Invest Ophthalmol Vis Sci</source>. <year>2013</year>;<volume>54</volume>:<fpage>5953</fpage>&#8208;<lpage>5958</lpage>. doi:<pub-id pub-id-type="doi">10.1167/iovs.13-12046</pub-id><pub-id pub-id-type="pmid">23920375</pub-id></mixed-citation></ref><ref id="alz70592-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="alz70592-cite-0029"><string-name name-style="western"><surname>Shi</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Koronyo</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Rentsendorj</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Identification of early pericyte loss and vascular amyloidosis in Alzheimer's disease retina</article-title>. <source>Acta Neuropathol</source>. <year>2020</year>;<volume>139</volume>:<fpage>813</fpage>&#8208;<lpage>836</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00401-020-02134-w</pub-id><pub-id pub-id-type="pmid">32043162</pub-id><pub-id pub-id-type="pmcid">PMC7181564</pub-id></mixed-citation></ref><ref id="alz70592-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="alz70592-cite-0030"><string-name name-style="western"><surname>Grimaldi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Pediconi</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Oieni</surname><given-names>F</given-names></string-name>, et&#160;al. <article-title>Neuroinflammatory processes, A1 astrocyte activation and protein aggregation in the retina of Alzheimer's disease patients, possible biomarkers for early diagnosis</article-title>. <source>Front Neurosci</source>. <year>2019</year>;<volume>13</volume>:<fpage>925</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fnins.2019.00925</pub-id><pub-id pub-id-type="pmid">31551688</pub-id><pub-id pub-id-type="pmcid">PMC6737046</pub-id></mixed-citation></ref><ref id="alz70592-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="alz70592-cite-0031"><string-name name-style="western"><surname>Koronyo&#8208;Hamaoui</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Koronyo</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ljubimov</surname><given-names>AV</given-names></string-name>, et&#160;al. <article-title>Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model</article-title>. <source>Neuroimage</source>. <year>2011</year>;<volume>54</volume>(Suppl <issue>1</issue>):<fpage>S204</fpage>&#8208;<lpage>217</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.neuroimage.2010.06.020</pub-id><pub-id pub-id-type="pmid">20550967</pub-id><pub-id pub-id-type="pmcid">PMC2991559</pub-id></mixed-citation></ref><ref id="alz70592-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="alz70592-cite-0032"><string-name name-style="western"><surname>Shi</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Koronyo</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Fuchs</surname><given-names>D&#8208;T</given-names></string-name>, et&#160;al. <article-title>Retinal arterial A&#946;40 deposition is linked with tight junction loss and cerebral amyloid angiopathy in MCI and AD patients</article-title>. <source>Alzheimers Dement</source>. <year>2023</year>;<volume>19</volume>:<fpage>5185</fpage>&#8208;<lpage>5197</lpage>. doi:<pub-id pub-id-type="doi">10.1002/alz.13086</pub-id><pub-id pub-id-type="pmid">37166032</pub-id><pub-id pub-id-type="pmcid">PMC10638467</pub-id></mixed-citation></ref><ref id="alz70592-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="alz70592-cite-0033"><string-name name-style="western"><surname>den Haan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Morrema</surname><given-names>THJ</given-names></string-name>, <string-name name-style="western"><surname>Verbraak</surname><given-names>FD</given-names></string-name>, et&#160;al. <article-title>Amyloid&#8208;beta and phosphorylated tau in post&#8208;mortem Alzheimer's disease retinas</article-title>. <source>Acta Neuropathol Commun</source>. <year>2018</year>;<volume>6</volume>:<fpage>147</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s40478-018-0650-x</pub-id><pub-id pub-id-type="pmid">30593285</pub-id><pub-id pub-id-type="pmcid">PMC6309096</pub-id></mixed-citation></ref><ref id="alz70592-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="alz70592-cite-0034"><string-name name-style="western"><surname>Querques</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Borrelli</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Sacconi</surname><given-names>R</given-names></string-name>, et&#160;al. <article-title>Functional and morphological changes of the retinal vessels in Alzheimer's disease and mild cognitive impairment</article-title>. <source>Sci Rep</source>. <year>2019</year>;<volume>9</volume>:<fpage>63</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-018-37271-6</pub-id><pub-id pub-id-type="pmid">30635610</pub-id><pub-id pub-id-type="pmcid">PMC6329813</pub-id></mixed-citation></ref><ref id="alz70592-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="alz70592-cite-0035"><string-name name-style="western"><surname>Gaire</surname><given-names>BP</given-names></string-name>, <string-name name-style="western"><surname>Koronyo</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Fuchs</surname><given-names>D&#8208;T</given-names></string-name>, et&#160;al. <article-title>Alzheimer's disease pathophysiology in the retina</article-title>. <source>Prog Retin Eye Res</source>. <year>2024</year>;<volume>101</volume>:<elocation-id>101273</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.preteyeres.2024.101273</pub-id><pub-id pub-id-type="pmid">38759947</pub-id><pub-id pub-id-type="pmcid">PMC11285518</pub-id></mixed-citation></ref><ref id="alz70592-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="alz70592-cite-0036"><string-name name-style="western"><surname>Hyman</surname><given-names>BT</given-names></string-name>, <string-name name-style="western"><surname>Phelps</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Beach</surname><given-names>TG</given-names></string-name>, et&#160;al. <article-title>National Institute on Aging&#8208;Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease</article-title>. <source>Alzheimers Dement</source>. <year>2012</year>;<volume>8</volume>:<fpage>1</fpage>&#8208;<lpage>13</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jalz.2011.10.007</pub-id><pub-id pub-id-type="pmid">22265587</pub-id><pub-id pub-id-type="pmcid">PMC3266529</pub-id></mixed-citation></ref><ref id="alz70592-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="alz70592-cite-0037"><string-name name-style="western"><surname>Fang</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Berger</surname><given-names>D</given-names></string-name>, et&#160;al. <article-title>Nanobody immunostaining for correlated light and electron microscopy with preservation of ultrastructure</article-title>. <source>Nat Methods</source>. <year>2018</year>;<volume>15</volume>:<fpage>1029</fpage>&#8208;<lpage>1032</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41592-018-0177-x</pub-id><pub-id pub-id-type="pmid">30397326</pub-id><pub-id pub-id-type="pmcid">PMC6405223</pub-id></mixed-citation></ref><ref id="alz70592-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="alz70592-cite-0038"><string-name name-style="western"><surname>Jankowsky</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Fadale</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Anderson</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Mutant presenilins specifically elevate the levels of the 42 residue beta&#8208;amyloid peptide in vivo: evidence for augmentation of a 42&#8208;specific gamma secretase</article-title>. <source>Hum Mol Genet</source>. <year>2004</year>;<volume>13</volume>:<fpage>159</fpage>&#8208;<lpage>170</lpage>. doi:<pub-id pub-id-type="doi">10.1093/hmg/ddh019</pub-id><pub-id pub-id-type="pmid">14645205</pub-id></mixed-citation></ref><ref id="alz70592-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="alz70592-cite-0039"><string-name name-style="western"><surname>Wijesinghe</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Xi</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Cui</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Campbell</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Pham</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Matsubara</surname><given-names>JA</given-names></string-name>. <article-title>MicroRNAs in tear fluids predict underlying molecular changes associated with Alzheimer's disease</article-title>. <source>Life Sci Alliance</source>. <year>2023</year>;<volume>6</volume>:<elocation-id>e202201757</elocation-id>. doi:<pub-id pub-id-type="doi">10.26508/lsa.202201757</pub-id><pub-id pub-id-type="pmid">36941055</pub-id><pub-id pub-id-type="pmcid">PMC10027899</pub-id></mixed-citation></ref><ref id="alz70592-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="alz70592-cite-0040"><string-name name-style="western"><surname>Wijesinghe</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>HR</given-names></string-name>, <string-name name-style="western"><surname>Ai</surname><given-names>Z</given-names></string-name>, et&#160;al. <article-title>Apolipoprotein E dysfunction in Alzheimer's disease: a study on miRNA regulation, glial markers, and amyloid pathology</article-title>. <source>Front Aging Neurosci</source>. <year>2024</year>;<volume>16</volume>:<elocation-id>1495615</elocation-id>. doi:<pub-id pub-id-type="doi">10.3389/fnagi.2024.1495615</pub-id><pub-id pub-id-type="pmid">39744521</pub-id><pub-id pub-id-type="pmcid">PMC11688329</pub-id></mixed-citation></ref><ref id="alz70592-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="alz70592-cite-0041"><string-name name-style="western"><surname>Wijesinghe</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Whitmore</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Campbell</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Ergothioneine, a dietary antioxidant improves amyloid beta clearance in the neuroretina of a mouse model of Alzheimer's disease</article-title>. <source>Front Neurosci</source>. <year>2023</year>;<volume>17</volume>:<elocation-id>1107436</elocation-id>. doi:<pub-id pub-id-type="doi">10.3389/fnins.2023.1107436</pub-id><pub-id pub-id-type="pmid">36998724</pub-id><pub-id pub-id-type="pmcid">PMC10043244</pub-id></mixed-citation></ref><ref id="alz70592-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="alz70592-cite-0042"><string-name name-style="western"><surname>Schmittgen</surname><given-names>TD</given-names></string-name>, <string-name name-style="western"><surname>Livak</surname><given-names>KJ</given-names></string-name>. <article-title>Analyzing real&#8208;time PCR data by the comparative C(T) method</article-title>. <source>Nat Protoc</source>. <year>2008</year>;<volume>3</volume>:<fpage>1101</fpage>&#8208;<lpage>1108</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nprot.2008.73</pub-id><pub-id pub-id-type="pmid">18546601</pub-id></mixed-citation></ref><ref id="alz70592-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="alz70592-cite-0043"><string-name name-style="western"><surname>Zhang</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>L</given-names></string-name>. <article-title>Microglia in Alzheimer's disease: a target for therapeutic intervention</article-title>. <source>Front Cell Neurosci</source>. <year>2021</year>;<volume>15</volume>:<elocation-id>749587</elocation-id>. doi:<pub-id pub-id-type="doi">10.3389/fncel.2021.749587</pub-id><pub-id pub-id-type="pmid">34899188</pub-id><pub-id pub-id-type="pmcid">PMC8651709</pub-id></mixed-citation></ref><ref id="alz70592-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="alz70592-cite-0044"><string-name name-style="western"><surname>Miao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>Y</given-names></string-name>, et&#160;al. <article-title>Microglia in Alzheimer's disease: pathogenesis, mechanisms, and therapeutic potentials</article-title>. <source>Front Aging Neurosci</source>. <year>2023</year>;<volume>15</volume>:<elocation-id>1201982</elocation-id>. doi:<pub-id pub-id-type="doi">10.3389/fnagi.2023.1201982</pub-id><pub-id pub-id-type="pmid">37396657</pub-id><pub-id pub-id-type="pmcid">PMC10309009</pub-id></mixed-citation></ref><ref id="alz70592-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="alz70592-cite-0045"><string-name name-style="western"><surname>Boneva</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Wolf</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Rosmus</surname><given-names>D&#8208;D</given-names></string-name>, et&#160;al. <article-title>Transcriptional profiling uncovers human hyalocytes as a unique innate immune cell population</article-title>. <source>Front Immunol</source>. <year>2020</year>;<volume>11</volume>:<elocation-id>567274</elocation-id>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2020.567274</pub-id><pub-id pub-id-type="pmid">33042148</pub-id><pub-id pub-id-type="pmcid">PMC7517040</pub-id></mixed-citation></ref><ref id="alz70592-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="alz70592-cite-0046"><string-name name-style="western"><surname>Lazarus</surname><given-names>HS</given-names></string-name>, <string-name name-style="western"><surname>Hageman</surname><given-names>GS</given-names></string-name>. <article-title>In situ characterization of the human hyalocyte</article-title>. <source>Arch Ophthalmol</source>. <year>1994</year>;<volume>112</volume>:<fpage>1356</fpage>&#8208;<lpage>1362</lpage>. doi:<pub-id pub-id-type="doi">10.1001/archopht.1994.01090220106031</pub-id><pub-id pub-id-type="pmid">7945040</pub-id></mixed-citation></ref><ref id="alz70592-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="alz70592-cite-0047"><string-name name-style="western"><surname>Kirchberger</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Majdic</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Bl&#252;ml</surname><given-names>S</given-names></string-name>, et&#160;al. <article-title>The cytoplasmic tail of CD45 is released from activated phagocytes and can act as an inhibitory messenger for T cells</article-title>. <source>Blood</source>. <year>2008</year>;<volume>112</volume>:<fpage>1240</fpage>&#8208;<lpage>1248</lpage>. doi:<pub-id pub-id-type="doi">10.1182/blood-2008-02-138131</pub-id><pub-id pub-id-type="pmid">18511809</pub-id></mixed-citation></ref><ref id="alz70592-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="alz70592-cite-0048"><string-name name-style="western"><surname>Puck</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>K&#252;nig</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Modak</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>The soluble cytoplasmic tail of CD45 regulates T&#8208;cell activation via TLR4 signaling</article-title>. <source>Eur J Immunol</source>. <year>2021</year>;<volume>51</volume>:<fpage>3176</fpage>&#8208;<lpage>3185</lpage>. doi:<pub-id pub-id-type="doi">10.1002/eji.202149227</pub-id><pub-id pub-id-type="pmid">34626426</pub-id></mixed-citation></ref><ref id="alz70592-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="alz70592-cite-0049"><string-name name-style="western"><surname>Nagelhus</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Ottersen</surname><given-names>OP</given-names></string-name>. <article-title>Physiological roles of aquaporin&#8208;4 in brain</article-title>. <source>Physiol Rev</source>. <year>2013</year>;<volume>93</volume>:<fpage>1543</fpage>&#8208;<lpage>1562</lpage>. doi:<pub-id pub-id-type="doi">10.1152/physrev.00011.2013</pub-id><pub-id pub-id-type="pmid">24137016</pub-id><pub-id pub-id-type="pmcid">PMC3858210</pub-id></mixed-citation></ref><ref id="alz70592-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="alz70592-cite-0050"><string-name name-style="western"><surname>Nagelhus</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Mathiisen</surname><given-names>TM</given-names></string-name>, <string-name name-style="western"><surname>Ottersen</surname><given-names>OP</given-names></string-name>. <article-title>Aquaporin&#8208;4 in the central nervous system: cellular and subcellular distribution and coexpression with KIR4.1</article-title>. <source>Neuroscience</source>. <year>2004</year>;<volume>129</volume>:<fpage>905</fpage>&#8208;<lpage>913</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.neuroscience.2004.08.053</pub-id><pub-id pub-id-type="pmid">15561407</pub-id></mixed-citation></ref><ref id="alz70592-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="alz70592-cite-0051"><string-name name-style="western"><surname>Iliff</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Liao</surname><given-names>Y</given-names></string-name>, et&#160;al. <article-title>A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid &#946;</article-title>. <source>Sci Transl Med</source>. <year>2012</year>;<volume>4</volume>:<elocation-id>147ra111</elocation-id>. doi:<pub-id pub-id-type="doi">10.1126/scitranslmed.3003748</pub-id><pub-id pub-id-type="pmcid">PMC3551275</pub-id><pub-id pub-id-type="pmid">22896675</pub-id></mixed-citation></ref><ref id="alz70592-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="alz70592-cite-0052"><string-name name-style="western"><surname>Iliff</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zeppenfeld</surname><given-names>DM</given-names></string-name>, et&#160;al. <article-title>Cerebral arterial pulsation drives paravascular CSF&#8208;interstitial fluid exchange in the murine brain</article-title>. <source>J Neurosci</source>. <year>2013</year>;<volume>33</volume>:<fpage>18190</fpage>&#8208;<lpage>18199</lpage>. doi:<pub-id pub-id-type="doi">10.1523/JNEUROSCI.1592-13.2013</pub-id><pub-id pub-id-type="pmid">24227727</pub-id><pub-id pub-id-type="pmcid">PMC3866416</pub-id></mixed-citation></ref><ref id="alz70592-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="alz70592-cite-0053"><string-name name-style="western"><surname>Sharoar</surname><given-names>MG</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>X&#8208;M</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>R</given-names></string-name>. <article-title>Sequential formation of different layers of dystrophic neurites in Alzheimer's brains</article-title>. <source>Mol Psychiatry</source>. <year>2019</year>;<volume>24</volume>:<fpage>1369</fpage>&#8208;<lpage>1382</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41380-019-0396-2</pub-id><pub-id pub-id-type="pmid">30899091</pub-id><pub-id pub-id-type="pmcid">PMC7204504</pub-id></mixed-citation></ref><ref id="alz70592-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="alz70592-cite-0054"><string-name name-style="western"><surname>Krasemann</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Madore</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Cialic</surname><given-names>R</given-names></string-name>, et&#160;al. <article-title>The TREM2&#8208;ApoE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases</article-title>. <source>Immunity</source>. <year>2017</year>;<volume>47</volume>:<fpage>566</fpage>&#8208;<lpage>581.e9</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.immuni.2017.08.008</pub-id><pub-id pub-id-type="pmid">28930663</pub-id><pub-id pub-id-type="pmcid">PMC5719893</pub-id></mixed-citation></ref><ref id="alz70592-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="alz70592-cite-0055"><string-name name-style="western"><surname>Ruganzu</surname><given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>Y</given-names></string-name>, et&#160;al. <article-title>Downregulation of TREM2 expression exacerbates neuroinflammatory responses through TLR4&#8208;mediated MAPK signaling pathway in a transgenic mouse model of Alzheimer's disease</article-title>. <source>Mol Immunol</source>. <year>2022</year>;<volume>142</volume>:<fpage>22</fpage>&#8208;<lpage>36</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.molimm.2021.12.018</pub-id><pub-id pub-id-type="pmid">34959070</pub-id></mixed-citation></ref><ref id="alz70592-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="alz70592-cite-0056"><string-name name-style="western"><surname>Koussounadis</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Langdon</surname><given-names>SP</given-names></string-name>, <string-name name-style="western"><surname>Um</surname><given-names>IH</given-names></string-name>, <string-name name-style="western"><surname>Harrison</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>VA</given-names></string-name>. <article-title>Relationship between differentially expressed mRNA and mRNA&#8208;protein correlations in a xenograft model system</article-title>. <source>Sci Rep</source>. <year>2015</year>;<volume>5</volume>:<elocation-id>10775</elocation-id>. doi:<pub-id pub-id-type="doi">10.1038/srep10775</pub-id><pub-id pub-id-type="pmid">26053859</pub-id><pub-id pub-id-type="pmcid">PMC4459080</pub-id></mixed-citation></ref><ref id="alz70592-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="alz70592-cite-0057"><string-name name-style="western"><surname>Tasaki</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Avey</surname><given-names>DR</given-names></string-name>, et&#160;al. <article-title>Inferring protein expression changes from mRNA in Alzheimer's dementia using deep neural networks</article-title>. <source>Nat Commun</source>. <year>2022</year>;<volume>13</volume>:<fpage>655</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41467-022-28280-1</pub-id><pub-id pub-id-type="pmid">35115553</pub-id><pub-id pub-id-type="pmcid">PMC8814036</pub-id></mixed-citation></ref><ref id="alz70592-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="alz70592-cite-0058"><string-name name-style="western"><surname>Wegler</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>&#214;lander</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wi&#347;niewski</surname><given-names>JR</given-names></string-name>, et&#160;al. <article-title>Global variability analysis of mRNA and protein concentrations across and within human tissues</article-title>. <source>NAR Genom Bioinform</source>. <year>2020</year>;<volume>2</volume>:<elocation-id>lqz010</elocation-id>. doi:<pub-id pub-id-type="doi">10.1093/nargab/lqz010</pub-id><pub-id pub-id-type="pmid">33575562</pub-id><pub-id pub-id-type="pmcid">PMC7671341</pub-id></mixed-citation></ref><ref id="alz70592-bib-0058"><label>58</label><mixed-citation publication-type="journal" id="alz70592-cite-0059"><string-name name-style="western"><surname>Guerreiro</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Br&#225;s</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hardy</surname><given-names>J</given-names></string-name>. <article-title>SnapShot: genetics of Alzheimer's disease</article-title>. <source>Cell</source>. <year>2013</year>;<volume>155</volume>:<fpage>968</fpage>&#8208;<lpage>968.e1</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cell.2013.10.037</pub-id><pub-id pub-id-type="pmid">24209629</pub-id></mixed-citation></ref><ref id="alz70592-bib-0059"><label>59</label><mixed-citation publication-type="journal" id="alz70592-cite-0060"><string-name name-style="western"><surname>Koronyo</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Biggs</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Barron</surname><given-names>E</given-names></string-name>, et&#160;al. <article-title>Retinal amyloid pathology and proof&#8208;of&#8208;concept imaging trial in Alzheimer's disease</article-title>. <source>JCI Insight</source>. <year>2017</year>;<volume>2</volume>:<elocation-id>e93621</elocation-id>. doi:<pub-id pub-id-type="doi">10.1172/jci.insight.93621</pub-id><pub-id pub-id-type="pmid">28814675</pub-id><pub-id pub-id-type="pmcid">PMC5621887</pub-id></mixed-citation></ref><ref id="alz70592-bib-0060"><label>60</label><mixed-citation publication-type="journal" id="alz70592-cite-0061"><string-name name-style="western"><surname>Koronyo</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Rentsendorj</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mirzaei</surname><given-names>N</given-names></string-name>, et&#160;al. <article-title>Retinal pathological features and proteome signatures of Alzheimer's disease</article-title>. <source>Acta Neuropathol</source>. <year>2023</year>;<volume>145</volume>:<fpage>409</fpage>&#8208;<lpage>438</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00401-023-02548-2</pub-id><pub-id pub-id-type="pmid">36773106</pub-id><pub-id pub-id-type="pmcid">PMC10020290</pub-id></mixed-citation></ref><ref id="alz70592-bib-0061"><label>61</label><mixed-citation publication-type="journal" id="alz70592-cite-0062"><string-name name-style="western"><surname>Lee</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>McIlmoyle</surname><given-names>B</given-names></string-name>, et&#160;al. <article-title>Amyloid beta immunoreactivity in the retinal ganglion cell layer of the Alzheimer's eye</article-title>. <source>Front Neurosci</source>. <year>2020</year>;<volume>14</volume>:<fpage>758</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fnins.2020.00758</pub-id><pub-id pub-id-type="pmid">32848548</pub-id><pub-id pub-id-type="pmcid">PMC7412634</pub-id></mixed-citation></ref><ref id="alz70592-bib-0062"><label>62</label><mixed-citation publication-type="journal" id="alz70592-cite-0063"><string-name name-style="western"><surname>Achariyar</surname><given-names>TM</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>W</given-names></string-name>, et&#160;al. <article-title>Glymphatic distribution of CSF&#8208;derived ApoE into brain is isoform specific and suppressed during sleep deprivation</article-title>. <source>Mol Neurodegener</source>. <year>2016</year>;<volume>11</volume>:<fpage>74</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13024-016-0138-8</pub-id><pub-id pub-id-type="pmid">27931262</pub-id><pub-id pub-id-type="pmcid">PMC5146863</pub-id></mixed-citation></ref><ref id="alz70592-bib-0063"><label>63</label><mixed-citation publication-type="journal" id="alz70592-cite-0064"><string-name name-style="western"><surname>Bakker</surname><given-names>ENTP</given-names></string-name>, <string-name name-style="western"><surname>Bacskai</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>Arbel&#8208;Ornath</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Lymphatic clearance of the brain: perivascular, paravascular and significance for neurodegenerative diseases</article-title>. <source>Cell Mol Neurobiol</source>. <year>2016</year>;<volume>36</volume>:<fpage>181</fpage>&#8208;<lpage>194</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10571-015-0273-8</pub-id><pub-id pub-id-type="pmid">26993512</pub-id><pub-id pub-id-type="pmcid">PMC4844641</pub-id></mixed-citation></ref><ref id="alz70592-bib-0064"><label>64</label><mixed-citation publication-type="journal" id="alz70592-cite-0065"><string-name name-style="western"><surname>Mestre</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Tithof</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Du</surname><given-names>T</given-names></string-name>, et&#160;al. <article-title>Flow of cerebrospinal fluid is driven by arterial pulsations and is reduced in hypertension</article-title>. <source>Nat Commun</source>. <year>2018</year>;<volume>9</volume>:<fpage>4878</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41467-018-07318-3</pub-id><pub-id pub-id-type="pmid">30451853</pub-id><pub-id pub-id-type="pmcid">PMC6242982</pub-id></mixed-citation></ref><ref id="alz70592-bib-0065"><label>65</label><mixed-citation publication-type="journal" id="alz70592-cite-0066"><string-name name-style="western"><surname>Cline</surname><given-names>EN</given-names></string-name>, <string-name name-style="western"><surname>Bicca</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Viola</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Klein</surname><given-names>WL</given-names></string-name>. <article-title>The amyloid&#8208;&#946; oligomer hypothesis: beginning of the third decade</article-title>. <source>J Alzheimers Dis</source>. <year>2018</year>;<volume>64</volume>:<fpage>S567</fpage>&#8208;<lpage>610</lpage>. doi:<pub-id pub-id-type="doi">10.3233/JAD-179941</pub-id><pub-id pub-id-type="pmid">29843241</pub-id><pub-id pub-id-type="pmcid">PMC6004937</pub-id></mixed-citation></ref><ref id="alz70592-bib-0066"><label>66</label><mixed-citation publication-type="journal" id="alz70592-cite-0067"><string-name name-style="western"><surname>Bl&#246;meke</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Rehn</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Pils</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Blood&#8208;based quantification of A&#946; oligomers indicates impaired clearance from brain in ApoE &#949;4 positive subjects</article-title>. <source>Commun Med</source>. <year>2024</year>;<volume>4</volume>:<fpage>1</fpage>&#8208;<lpage>13</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s43856-024-00690-w</pub-id><pub-id pub-id-type="pmid">39658587</pub-id><pub-id pub-id-type="pmcid">PMC11631981</pub-id></mixed-citation></ref><ref id="alz70592-bib-0067"><label>67</label><mixed-citation publication-type="journal" id="alz70592-cite-0068"><string-name name-style="western"><surname>Nassrallah</surname><given-names>WB</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>HR</given-names></string-name>, <string-name name-style="western"><surname>Irani</surname><given-names>L</given-names></string-name>, et&#160;al. <article-title>3&#8208;Dimensional morphological characterization of neuroretinal microglia in Alzheimer's disease via machine learning</article-title>. <source>Acta Neuropathol Commun</source>. <year>2024</year>;<volume>12</volume>:<fpage>202</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s40478-024-01898-6</pub-id><pub-id pub-id-type="pmid">39719599</pub-id><pub-id pub-id-type="pmcid">PMC11669245</pub-id></mixed-citation></ref><ref id="alz70592-bib-0068"><label>68</label><mixed-citation publication-type="journal" id="alz70592-cite-0069"><string-name name-style="western"><surname>Shi</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yin</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Koronyo</surname><given-names>Y</given-names></string-name>, et&#160;al. <article-title>Regulating microglial miR&#8208;155 transcriptional phenotype alleviates Alzheimer's&#8208;induced retinal vasculopathy by limiting Clec7a/Galectin&#8208;3+ neurodegenerative microglia</article-title>. <source>Acta Neuropathol Commun</source>. <year>2022</year>;<volume>10</volume>:<fpage>136</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s40478-022-01439-z</pub-id><pub-id pub-id-type="pmid">36076283</pub-id><pub-id pub-id-type="pmcid">PMC9461176</pub-id></mixed-citation></ref><ref id="alz70592-bib-0069"><label>69</label><mixed-citation publication-type="journal" id="alz70592-cite-0070"><string-name name-style="western"><surname>Grimaldi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Brighi</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Peruzzi</surname><given-names>G</given-names></string-name>, et&#160;al. <article-title>Inflammation, neurodegeneration and protein aggregation in the retina as ocular biomarkers for Alzheimer's disease in the 3xTg&#8208;AD mouse model</article-title>. <source>Cell Death Dis</source>. <year>2018</year>;<volume>9</volume>:<fpage>685</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41419-018-0740-5</pub-id><pub-id pub-id-type="pmid">29880901</pub-id><pub-id pub-id-type="pmcid">PMC5992214</pub-id></mixed-citation></ref><ref id="alz70592-bib-0070"><label>70</label><mixed-citation publication-type="journal" id="alz70592-cite-0071"><string-name name-style="western"><surname>Salobrar&#8208;Garc&#237;a</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Rodrigues&#8208;Neves</surname><given-names>AC</given-names></string-name>, et&#160;al. <article-title>Microglial activation in the retina of a triple&#8208;transgenic Alzheimer's disease mouse model (3xTg&#8208;AD)</article-title>. <source>Int J Mol Sci</source>. <year>2020</year>;<volume>21</volume>:<fpage>816</fpage>. doi:<pub-id pub-id-type="doi">10.3390/ijms21030816</pub-id><pub-id pub-id-type="pmid">32012676</pub-id><pub-id pub-id-type="pmcid">PMC7038053</pub-id></mixed-citation></ref><ref id="alz70592-bib-0071"><label>71</label><mixed-citation publication-type="journal" id="alz70592-cite-0072"><string-name name-style="western"><surname>Giordano</surname><given-names>KR</given-names></string-name>, <string-name name-style="western"><surname>Denman</surname><given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Dubisch</surname><given-names>PS</given-names></string-name>, <string-name name-style="western"><surname>Akhter</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lifshitz</surname><given-names>J</given-names></string-name>. <article-title>An update on the rod microglia variant in experimental and clinical brain injury and disease</article-title>. <source>Brain Commun</source>. <year>2021</year>;<volume>3</volume>:<elocation-id>fcaa227</elocation-id>. doi:<pub-id pub-id-type="doi">10.1093/braincomms/fcaa227</pub-id><pub-id pub-id-type="pmid">33501429</pub-id><pub-id pub-id-type="pmcid">PMC7811762</pub-id></mixed-citation></ref><ref id="alz70592-bib-0072"><label>72</label><mixed-citation publication-type="journal" id="alz70592-cite-0073"><string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Lou</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Eberhardt</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>An ocular glymphatic clearance system removes &#946;&#8208;amyloid from the rodent eye</article-title>. <source>Sci Transl Med</source>. <year>2020</year>;<volume>12</volume>:<elocation-id>eaaw3210</elocation-id>. doi:<pub-id pub-id-type="doi">10.1126/scitranslmed.aaw3210</pub-id><pub-id pub-id-type="pmid">32213628</pub-id><pub-id pub-id-type="pmcid">PMC7356596</pub-id></mixed-citation></ref><ref id="alz70592-bib-0073"><label>73</label><mixed-citation publication-type="journal" id="alz70592-cite-0074"><string-name name-style="western"><surname>London</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Benhar</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Schwartz</surname><given-names>M</given-names></string-name>. <article-title>The retina as a window to the brain&#8208;from eye research to CNS disorders</article-title>. <source>Nat Rev Neurol</source>. <year>2013</year>;<volume>9</volume>:<fpage>44</fpage>&#8208;<lpage>53</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrneurol.2012.227</pub-id><pub-id pub-id-type="pmid">23165340</pub-id></mixed-citation></ref><ref id="alz70592-bib-0074"><label>74</label><mixed-citation publication-type="journal" id="alz70592-cite-0075"><string-name name-style="western"><surname>Tarasoff&#8208;Conway</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Carare</surname><given-names>RO</given-names></string-name>, <string-name name-style="western"><surname>Osorio</surname><given-names>RS</given-names></string-name>, et&#160;al. <article-title>Clearance systems in the brain&#8208;implications for Alzheimer disease</article-title>. <source>Nat Rev Neurol</source>. <year>2015</year>;<volume>11</volume>:<fpage>457</fpage>&#8208;<lpage>470</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrneurol.2015.119</pub-id><pub-id pub-id-type="pmid">26195256</pub-id><pub-id pub-id-type="pmcid">PMC4694579</pub-id></mixed-citation></ref><ref id="alz70592-bib-0075"><label>75</label><mixed-citation publication-type="journal" id="alz70592-cite-0076"><string-name name-style="western"><surname>Andjelkovic</surname><given-names>AV</given-names></string-name>, <string-name name-style="western"><surname>Situ</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Citalan&#8208;Madrid</surname><given-names>AF</given-names></string-name>, <string-name name-style="western"><surname>Stamatovic</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Xiang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Keep</surname><given-names>RF</given-names></string-name>. <article-title>Blood&#8208;brain barrier dysfunction in normal aging and neurodegeneration: mechanisms, impact, and treatments</article-title>. <source>Stroke</source>. <year>2023</year>;<volume>54</volume>:<fpage>661</fpage>&#8208;<lpage>672</lpage>. doi:<pub-id pub-id-type="doi">10.1161/STROKEAHA.122.040578</pub-id><pub-id pub-id-type="pmid">36848419</pub-id><pub-id pub-id-type="pmcid">PMC9993074</pub-id></mixed-citation></ref><ref id="alz70592-bib-0076"><label>76</label><mixed-citation publication-type="journal" id="alz70592-cite-0077"><string-name name-style="western"><surname>Zeppenfeld</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Simon</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Haswell</surname><given-names>JD</given-names></string-name>, et&#160;al. <article-title>Association of perivascular localization of aquaporin&#8208;4 with cognition and Alzheimer disease in aging brains</article-title>. <source>JAMA Neurol</source>. <year>2017</year>;<volume>74</volume>:<fpage>91</fpage>&#8208;<lpage>99</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamaneurol.2016.4370</pub-id><pub-id pub-id-type="pmid">27893874</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>